ID AAPK2_HUMAN Reviewed; 552 AA. AC P54646; Q9H1E8; Q9UD43; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 16-APR-2002, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-2; DE Short=AMPK subunit alpha-2; DE EC=2.7.11.1 {ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:32029622, ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666}; DE AltName: Full=Acetyl-CoA carboxylase kinase; DE Short=ACACA kinase; DE AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase; DE Short=HMGCR kinase; DE EC=2.7.11.31 {ECO:0000250|UniProtKB:Q09137}; GN Name=PRKAA2 {ECO:0000312|HGNC:HGNC:9377}; Synonyms=AMPK, AMPK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RC TISSUE=Heart; RX PubMed=7959015; DOI=10.1016/0378-1119(94)90174-0; RA Aguan K., Scott J., See C.G., Sarkar N.H.; RT "Characterization and chromosomal localization of the human homologue of a RT rat AMP-activated protein kinase-encoding gene: a major regulator of lipid RT metabolism in mammals."; RL Gene 149:345-350(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Skeletal muscle; RX PubMed=7988703; DOI=10.1016/0014-5793(94)01247-4; RA Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D., RA Scott J., Carey F.; RT "Molecular cloning, expression and chromosomal localisation of human AMP- RT activated protein kinase."; RL FEBS Lett. 356:117-121(1994). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [6] RP FUNCTION IN PHOSPHORYLATION OF EP300. RX PubMed=11518699; DOI=10.1074/jbc.c100316200; RA Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.; RT "Regulation of transcription by AMP-activated protein kinase: RT phosphorylation of p300 blocks its interaction with nuclear receptors."; RL J. Biol. Chem. 276:38341-38344(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11602624; DOI=10.1172/jci13505; RA Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., RA Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., RA Moller D.E.; RT "Role of AMP-activated protein kinase in mechanism of metformin action."; RL J. Clin. Invest. 108:1167-1174(2001). RN [8] RP FUNCTION IN PHOSPHORYLATION OF CFTR. RX PubMed=12519745; DOI=10.1152/ajpcell.00227.2002; RA Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.; RT "Physiological modulation of CFTR activity by AMP-activated protein kinase RT in polarized T84 cells."; RL Am. J. Physiol. 284:C1297-C1308(2003). RN [9] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [10] RP PHOSPHORYLATION AT THR-172, AND ACTIVITY REGULATION. RX PubMed=15980064; DOI=10.1074/jbc.m503824200; RA Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., RA Witters L.A.; RT "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated RT protein kinase kinases."; RL J. Biol. Chem. 280:29060-29066(2005). RN [11] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [12] RP FUNCTION IN PHOSPHORYLATION OF FOXO3. RX PubMed=17711846; DOI=10.1074/jbc.m705325200; RA Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., RA Brunet A.; RT "The energy sensor AMP-activated protein kinase directly regulates the RT mammalian FOXO3 transcription factor."; RL J. Biol. Chem. 282:30107-30119(2007). RN [13] RP FUNCTION IN CELL POLARITY. RX PubMed=17486097; DOI=10.1038/nature05828; RA Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H., RA Shong M., Kim J.M., Kim J., Chung J.; RT "Energy-dependent regulation of cell structure by AMP-activated protein RT kinase."; RL Nature 447:1017-1020(2007). RN [14] RP FUNCTION IN PHOSPHORYLATION OF HDAC5. RX PubMed=18184930; DOI=10.2337/db07-0843; RA McGee S.L., van Denderen B.J., Howlett K.F., Mollica J., Schertzer J.D., RA Kemp B.E., Hargreaves M.; RT "AMP-activated protein kinase regulates GLUT4 transcription by RT phosphorylating histone deacetylase 5."; RL Diabetes 57:860-867(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KLC1. RX PubMed=20074060; DOI=10.1042/bst0380205; RA McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G., Rutter G.A.; RT "Cell-wide analysis of secretory granule dynamics in three dimensions in RT living pancreatic beta-cells: evidence against a role for AMPK-dependent RT phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin RT granule movement."; RL Biochem. Soc. Trans. 38:205-208(2010). RN [19] RP FUNCTION. RX PubMed=20160076; DOI=10.1073/pnas.0913860107; RA Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., RA Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B., RA Walker C.L.; RT "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to RT ROS."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010). RN [20] RP PHOSPHORYLATION BY ULK1. RX PubMed=21460634; DOI=10.4161/auto.7.7.15451; RA Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M., RA Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.; RT "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory RT feedback loop."; RL Autophagy 7:696-706(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP FUNCTION IN PHOSPHORYLATION OF ULK1. RX PubMed=21205641; DOI=10.1126/science.1196371; RA Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., RA Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., RA Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.; RT "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects RT energy sensing to mitophagy."; RL Science 331:456-461(2011). RN [23] RP REVIEW ON FUNCTION. RX PubMed=17307971; DOI=10.1161/01.res.0000256090.42690.05; RA Towler M.C., Hardie D.G.; RT "AMP-activated protein kinase in metabolic control and insulin signaling."; RL Circ. Res. 100:328-341(2007). RN [24] RP REVIEW ON FUNCTION. RX PubMed=17712357; DOI=10.1038/nrm2249; RA Hardie D.G.; RT "AMP-activated/SNF1 protein kinases: conserved guardians of cellular RT energy."; RL Nat. Rev. Mol. Cell Biol. 8:774-785(2007). RN [25] RP ACTIVITY REGULATION BY SALICYLATE. RX PubMed=22517326; DOI=10.1126/science.1215327; RA Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C., RA Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J., Kemp B.E., RA Sakamoto K., Steinberg G.R., Hardie D.G.; RT "The ancient drug salicylate directly activates AMP-activated protein RT kinase."; RL Science 336:918-922(2012). RN [26] RP DEPHOSPHORYLATION AT THR-172. RX PubMed=23088624; DOI=10.1042/bj20121201; RA Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y., Takano-Yamamoto T., RA Tamura S., Kobayashi T.; RT "N-Myristoylation is essential for protein phosphatases PPM1A and PPM1B to RT dephosphorylate their physiological substrates in cells."; RL Biochem. J. 449:741-749(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP PHOSPHORYLATION AT THR-172. RX PubMed=24767988; DOI=10.1016/j.celrep.2014.03.065; RA Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J., RA DeBerardinis R.J., MacKeigan J.P.; RT "A mitochondrial RNAi screen defines cellular bioenergetic determinants and RT identifies an adenylate kinase as a key regulator of ATP levels."; RL Cell Rep. 7:907-917(2014). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=25687571; DOI=10.1074/mcp.m114.047159; RA Boutchueng-Djidjou M., Collard-Simard G., Fortier S., Hebert S.S., RA Kelly I., Landry C.R., Faure R.L.; RT "The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole- RT 4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) RT plays a central role in insulin signaling and the Golgi/endosomes protein RT network."; RL Mol. Cell. Proteomics 14:1079-1092(2015). RN [30] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT THR-172, INTERACTION WITH RP ACSS2, AND MUTAGENESIS OF THR-172. RX PubMed=28552616; DOI=10.1016/j.molcel.2017.04.026; RA Li X., Yu W., Qian X., Xia Y., Zheng Y., Lee J.H., Li W., Lyu J., Rao G., RA Zhang X., Qian C.N., Rozen S.G., Jiang T., Lu Z.; RT "Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal RT Biogenesis and Autophagy."; RL Mol. Cell 66:684-697(2017). RN [31] RP FUNCTION. RX PubMed=28561066; DOI=10.1038/ncomms15637; RA Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M., RA Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B., RA Proikas-Cezanne T.; RT "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling RT circuits in the control of autophagy."; RL Nat. Commun. 8:15637-15637(2017). RN [32] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32029622; DOI=10.1126/science.aay0542; RA Zhao P., Sun X., Chaggan C., Liao Z., In Wong K., He F., Singh S., RA Loomba R., Karin M., Witztum J.L., Saltiel A.R.; RT "An AMPK-caspase-6 axis controls liver damage in nonalcoholic RT steatohepatitis."; RL Science 367:652-660(2020). RN [33] RP FUNCTION. RX PubMed=34077757; DOI=10.1016/j.molcel.2021.05.005; RA Liu R., Lee J.H., Li J., Yu R., Tan L., Xia Y., Zheng Y., Bian X.L., RA Lorenzi P.L., Chen Q., Lu Z.; RT "Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of RT lipid droplets."; RL Mol. Cell 81:2722-2735(2021). RN [34] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=36732624; DOI=10.1038/s42255-022-00732-4; RA Dai X., Jiang C., Jiang Q., Fang L., Yu H., Guo J., Yan P., Chi F., RA Zhang T., Inuzuka H., Asara J.M., Wang P., Guo J., Wei W.; RT "AMPK-dependent phosphorylation of the GATOR2 component WDR24 suppresses RT glucose-mediated mTORC1 activation."; RL Nat. Metab. 5:265-276(2023). RN [35] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37079666; DOI=10.1126/science.abj5559; RA Malik N., Ferreira B.I., Hollstein P.E., Curtis S.D., Trefts E., RA Weiser Novak S., Yu J., Gilson R., Hellberg K., Fang L., Sheridan A., RA Hah N., Shadel G.S., Manor U., Shaw R.J.; RT "Induction of lysosomal and mitochondrial biogenesis by AMPK RT phosphorylation of FNIP1."; RL Science 380:eabj5559-eabj5559(2023). RN [36] RP FUNCTION, INTERACTION WITH ARF6, AND MUTAGENESIS OF LYS-45 AND THR-172. RX PubMed=36017701; DOI=10.1242/jcs.259609; RA Chen K.J., Hsu J.W., Lee F.S.; RT "AMPK promotes Arf6 activation in a kinase-independent manner upon glucose RT starvation."; RL J. Cell Sci. 135:0-0(2022). RN [37] RP FUNCTION. RX PubMed=36367943; DOI=10.1126/sciadv.abo7956; RA Tilokani L., Russell F.M., Hamilton S., Virga D.M., Segawa M., Paupe V., RA Gruszczyk A.V., Protasoni M., Tabara L.C., Johnson M., Anand H., RA Murphy M.P., Hardie D.G., Polleux F., Prudent J.; RT "AMPK-dependent phosphorylation of MTFR1L regulates mitochondrial RT morphology."; RL Sci. Adv. 8:eabo7956-eabo7956(2022). RN [38] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279. RX PubMed=20124709; DOI=10.1107/s1744309109052543; RA Littler D.R., Walker J.R., Davis T., Wybenga-Groot L.E., Finerty P.J. Jr., RA Newman E., Mackenzie F., Dhe-Paganon S.; RT "A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP- RT binding site and catalytic loop refolding as a means of regulation."; RL Acta Crystallogr. F 66:143-151(2010). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN RP COMPLEX WITH COMPOUND C, ACTIVITY REGULATION, AND MUTAGENESIS OF THR-172. RX PubMed=21543851; DOI=10.1107/s0907444911010201; RA Handa N., Takagi T., Saijo S., Kishishita S., Takaya D., Toyama M., RA Terada T., Shirouzu M., Suzuki A., Lee S., Yamauchi T., Okada-Iwabu M., RA Iwabu M., Kadowaki T., Minokoshi Y., Yokoyama S.; RT "Structural basis for compound C inhibition of the human AMP-activated RT protein kinase alpha2 subunit kinase domain."; RL Acta Crystallogr. D 67:480-487(2011). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase (AMPK), an CC energy sensor protein kinase that plays a key role in regulating CC cellular energy metabolism (PubMed:17307971, PubMed:17712357). In CC response to reduction of intracellular ATP levels, AMPK activates CC energy-producing pathways and inhibits energy-consuming processes: CC inhibits protein, carbohydrate and lipid biosynthesis, as well as cell CC growth and proliferation (PubMed:17307971, PubMed:17712357). AMPK acts CC via direct phosphorylation of metabolic enzymes, and by longer-term CC effects via phosphorylation of transcription regulators CC (PubMed:17307971, PubMed:17712357). Regulates lipid synthesis by CC phosphorylating and inactivating lipid metabolic enzymes such as ACACA, CC ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol CC synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) CC and hormone-sensitive lipase (LIPE) enzymes, respectively CC (PubMed:7959015). Promotes lipolysis of lipid droplets by mediating CC phosphorylation of isoform 1 of CHKA (CHKalpha2) (PubMed:34077757). CC Regulates insulin-signaling and glycolysis by phosphorylating IRS1, CC PFKFB2 and PFKFB3 (By similarity). Involved in insulin receptor/INSR CC internalization (PubMed:25687571). AMPK stimulates glucose uptake in CC muscle by increasing the translocation of the glucose transporter CC SLC2A4/GLUT4 to the plasma membrane, possibly by mediating CC phosphorylation of TBC1D4/AS160 (By similarity). Regulates CC transcription and chromatin structure by phosphorylating transcription CC regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, CC histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, CC SREBF1, SREBF2 and PPARGC1A (PubMed:11518699, PubMed:11554766, CC PubMed:15866171, PubMed:17711846, PubMed:18184930). Acts as a key CC regulator of glucose homeostasis in liver by phosphorylating CC CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm (By CC similarity). In response to stress, phosphorylates 'Ser-36' of histone CC H2B (H2BS36ph), leading to promote transcription (By similarity). Acts CC as a key regulator of cell growth and proliferation by phosphorylating CC FNIP1, TSC2, RPTOR, WDR24 and ATG1/ULK1: in response to nutrient CC limitation, negatively regulates the mTORC1 complex by phosphorylating CC RPTOR component of the mTORC1 complex and by phosphorylating and CC activating TSC2 (PubMed:14651849, PubMed:20160076, PubMed:21205641). CC Also phosphorylates and inhibits GATOR2 subunit WDR24 in response to CC nutrient limitation, leading to suppress glucose-mediated mTORC1 CC activation (PubMed:36732624). In response to energetic stress, CC phosphorylates FNIP1, inactivating the non-canonical mTORC1 signaling, CC thereby promoting nuclear translocation of TFEB and TFE3, and inducing CC transcription of lysosomal or autophagy genes (PubMed:37079666). In CC response to nutrient limitation, promotes autophagy by phosphorylating CC and activating ATG1/ULK1 (PubMed:21205641). In that process, it also CC activates WDR45/WIPI4 (PubMed:28561066). Phosphorylates CASP6, thereby CC preventing its autoprocessing and subsequent activation CC (PubMed:32029622). AMPK also acts as a regulator of circadian rhythm by CC mediating phosphorylation of CRY1, leading to destabilize it (By CC similarity). May regulate the Wnt signaling pathway by phosphorylating CC CTNNB1, leading to stabilize it (By similarity). Also acts as a CC regulator of cellular polarity by remodeling the actin cytoskeleton; CC probably by indirectly activating myosin (PubMed:17486097). Also CC phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1 (PubMed:12519745, CC PubMed:20074060). Plays an important role in the differential CC regulation of pro-autophagy (composed of PIK3C3, BECN1, PIK3R4 and CC UVRAG or ATG14) and non-autophagy (composed of PIK3C3, BECN1 and CC PIK3R4) complexes, in response to glucose starvation (By similarity). CC Can inhibit the non-autophagy complex by phosphorylating PIK3C3 and can CC activate the pro-autophagy complex by phosphorylating BECN1 (By CC similarity). Upon glucose starvation, promotes ARF6 activation in a CC kinase-independent manner leading to cell migration (PubMed:36017701). CC Upon glucose deprivation mediates the phosphorylation of ACSS2 at 'Ser- CC 659', which exposes the nuclear localization signal of ACSS2, required CC for its interaction with KPNA1 and nuclear translocation CC (PubMed:28552616). Upon stress, regulates mitochondrial fragmentation CC through phosphorylation of MTFR1L (PubMed:36367943). CC {ECO:0000250|UniProtKB:Q09137, ECO:0000250|UniProtKB:Q8BRK8, CC ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17486097, CC ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:18184930, CC ECO:0000269|PubMed:20074060, ECO:0000269|PubMed:20160076, CC ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25687571, CC ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:28561066, CC ECO:0000269|PubMed:32029622, ECO:0000269|PubMed:34077757, CC ECO:0000269|PubMed:36017701, ECO:0000269|PubMed:36367943, CC ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666, CC ECO:0000269|PubMed:7959015, ECO:0000303|PubMed:17307971, CC ECO:0000303|PubMed:17712357}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:32029622, CC ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[acetyl-CoA carboxylase] + ATP = O-phospho-L-seryl- CC [acetyl-CoA carboxylase] + ADP + H(+); Xref=Rhea:RHEA:20333, CC Rhea:RHEA-COMP:13722, Rhea:RHEA-COMP:13723, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A reductase] + CC ATP = O-phospho-L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A CC reductase] + ADP + H(+); Xref=Rhea:RHEA:23172, Rhea:RHEA-COMP:13692, CC Rhea:RHEA-COMP:13693, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; CC EC=2.7.11.31; Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-172 CC (PubMed:15980064). Binding of AMP to non-catalytic gamma subunit CC (PRKAG1, PRKAG2 or PRKAG3) results in allosteric activation, inducing CC phosphorylation on Thr-172 (PubMed:15980064). AMP-binding to gamma CC subunit also sustains activity by preventing dephosphorylation of Thr- CC 172 (PubMed:15980064). ADP also stimulates Thr-172 phosphorylation, CC without stimulating already phosphorylated AMPK (PubMed:15980064). ATP CC promotes dephosphorylation of Thr-172, rendering the enzyme inactive CC (PubMed:15980064). Under physiological conditions AMPK mainly exists in CC its inactive form in complex with ATP, which is much more abundant than CC AMP. AMPK is activated by antihyperglycemic drug metformin, a drug CC prescribed to patients with type 2 diabetes: in vivo, metformin seems CC to mainly inhibit liver gluconeogenesis. However, metformin can be used CC to activate AMPK in muscle and other cells in culture or ex vivo CC (PubMed:11602624). Selectively inhibited by compound C (6-[4-(2- CC Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a] CC pyrimidine. Activated by resveratrol, a natural polyphenol present in CC red wine, and S17834, a synthetic polyphenol. Salicylate/aspirin CC directly activates kinase activity, primarily by inhibiting Thr-172 CC dephosphorylation. {ECO:0000269|PubMed:11602624, CC ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:21543851, CC ECO:0000269|PubMed:22517326}. CC -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit (PRKAA1 CC or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-catalytic CC subunits (PRKAG1, PRKAG2 or PRKAG3) (PubMed:21543851). Interacts with CC FNIP1 and FNIP2. Associates with internalized insulin receptor/INSR CC complexes on Golgi/endosomal membranes; PRKAA2/AMPK2 together with ATIC CC and HACD3/PTPLAD1 is proposed to be part of a signaling network CC regulating INSR autophosphorylation and endocytosis (PubMed:25687571). CC Interacts with ARF6 (PubMed:36017701). The phosphorylated form at Thr- CC 172 mediated by CamKK2 interacts with ACSS2 (PubMed:28552616). CC {ECO:0000269|PubMed:21543851, ECO:0000269|PubMed:25687571, CC ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:36017701}. CC -!- INTERACTION: CC P54646; Q8IZP0-5: ABI1; NbExp=3; IntAct=EBI-1383852, EBI-11743294; CC P54646; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-1383852, EBI-743598; CC P54646; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-1383852, EBI-11096309; CC P54646; Q13155: AIMP2; NbExp=3; IntAct=EBI-1383852, EBI-745226; CC P54646; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-1383852, EBI-357530; CC P54646; P31749: AKT1; NbExp=3; IntAct=EBI-1383852, EBI-296087; CC P54646; A2BDD9: AMOT; NbExp=3; IntAct=EBI-1383852, EBI-17286414; CC P54646; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-1383852, EBI-746752; CC P54646; Q9NYG5-2: ANAPC11; NbExp=3; IntAct=EBI-1383852, EBI-12224467; CC P54646; Q92624: APPBP2; NbExp=3; IntAct=EBI-1383852, EBI-743771; CC P54646; Q96B67: ARRDC3; NbExp=3; IntAct=EBI-1383852, EBI-2875665; CC P54646; Q5T686: AVPI1; NbExp=3; IntAct=EBI-1383852, EBI-8640233; CC P54646; Q9P1Z2: CALCOCO1; NbExp=3; IntAct=EBI-1383852, EBI-749920; CC P54646; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-1383852, EBI-739580; CC P54646; P0C7W6: CCDC172; NbExp=3; IntAct=EBI-1383852, EBI-2548868; CC P54646; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-1383852, EBI-745269; CC P54646; Q00587-2: CDC42EP1; NbExp=3; IntAct=EBI-1383852, EBI-11027409; CC P54646; Q01850: CDR2; NbExp=3; IntAct=EBI-1383852, EBI-1181367; CC P54646; O14627: CDX4; NbExp=3; IntAct=EBI-1383852, EBI-10181162; CC P54646; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-1383852, EBI-11523759; CC P54646; O75638-2: CTAG2; NbExp=3; IntAct=EBI-1383852, EBI-12265122; CC P54646; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-1383852, EBI-3867333; CC P54646; Q9NQM4: DNAAF6; NbExp=3; IntAct=EBI-1383852, EBI-10239299; CC P54646; P50570: DNM2; NbExp=3; IntAct=EBI-1383852, EBI-346547; CC P54646; Q92997: DVL3; NbExp=3; IntAct=EBI-1383852, EBI-739789; CC P54646; Q9Y6C2-2: EMILIN1; NbExp=3; IntAct=EBI-1383852, EBI-11748557; CC P54646; O95208-2: EPN2; NbExp=3; IntAct=EBI-1383852, EBI-12135243; CC P54646; Q53EP0-3: FNDC3B; NbExp=3; IntAct=EBI-1383852, EBI-10242151; CC P54646; Q6FG41: FOS; NbExp=3; IntAct=EBI-1383852, EBI-10198738; CC P54646; O75420: GIGYF1; NbExp=3; IntAct=EBI-1383852, EBI-947774; CC P54646; P08151: GLI1; NbExp=3; IntAct=EBI-1383852, EBI-308084; CC P54646; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1383852, EBI-618309; CC P54646; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-1383852, EBI-11163335; CC P54646; O75791: GRAP2; NbExp=3; IntAct=EBI-1383852, EBI-740418; CC P54646; P28799: GRN; NbExp=3; IntAct=EBI-1383852, EBI-747754; CC P54646; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-1383852, EBI-2549423; CC P54646; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-1383852, EBI-10172004; CC P54646; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-1383852, EBI-11522367; CC P54646; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383852, EBI-747204; CC P54646; Q719H9: KCTD1; NbExp=3; IntAct=EBI-1383852, EBI-9027502; CC P54646; Q7L273: KCTD9; NbExp=3; IntAct=EBI-1383852, EBI-4397613; CC P54646; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-1383852, EBI-3437878; CC P54646; Q96L93-6: KIF16B; NbExp=3; IntAct=EBI-1383852, EBI-10988217; CC P54646; Q5T7B8-2: KIF24; NbExp=3; IntAct=EBI-1383852, EBI-10213781; CC P54646; Q9BVG8: KIFC3; NbExp=4; IntAct=EBI-1383852, EBI-2125614; CC P54646; P08779: KRT16; NbExp=3; IntAct=EBI-1383852, EBI-356410; CC P54646; Q15323: KRT31; NbExp=3; IntAct=EBI-1383852, EBI-948001; CC P54646; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-1383852, EBI-11749135; CC P54646; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-1383852, EBI-10172052; CC P54646; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-2686809; CC P54646; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-11985629; CC P54646; P80188: LCN2; NbExp=3; IntAct=EBI-1383852, EBI-11911016; CC P54646; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1383852, EBI-741037; CC P54646; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383852, EBI-2340269; CC P54646; Q6PF18: MORN3; NbExp=3; IntAct=EBI-1383852, EBI-9675802; CC P54646; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-1383852, EBI-995714; CC P54646; Q5JR59-3: MTUS2; NbExp=4; IntAct=EBI-1383852, EBI-11522433; CC P54646; P12524-2: MYCL; NbExp=3; IntAct=EBI-1383852, EBI-18936665; CC P54646; Q15742: NAB2; NbExp=3; IntAct=EBI-1383852, EBI-8641936; CC P54646; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-1383852, EBI-10172876; CC P54646; Q15233-2: NONO; NbExp=3; IntAct=EBI-1383852, EBI-10203843; CC P54646; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-1383852, EBI-945833; CC P54646; Q96F24: NRBF2; NbExp=3; IntAct=EBI-1383852, EBI-2362014; CC P54646; Q86Y26: NUTM1; NbExp=3; IntAct=EBI-1383852, EBI-10178410; CC P54646; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-1383852, EBI-12014286; CC P54646; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383852, EBI-11320284; CC P54646; Q9Y478: PRKAB1; NbExp=10; IntAct=EBI-1383852, EBI-719769; CC P54646; O43741: PRKAB2; NbExp=18; IntAct=EBI-1383852, EBI-1053424; CC P54646; P54619: PRKAG1; NbExp=14; IntAct=EBI-1383852, EBI-1181439; CC P54646; P31321: PRKAR1B; NbExp=3; IntAct=EBI-1383852, EBI-2805516; CC P54646; P41219: PRPH; NbExp=3; IntAct=EBI-1383852, EBI-752074; CC P54646; Q86YV0: RASAL3; NbExp=3; IntAct=EBI-1383852, EBI-3437896; CC P54646; Q93062: RBPMS; NbExp=3; IntAct=EBI-1383852, EBI-740322; CC P54646; Q04864-2: REL; NbExp=4; IntAct=EBI-1383852, EBI-10829018; CC P54646; Q8HWS3: RFX6; NbExp=3; IntAct=EBI-1383852, EBI-746118; CC P54646; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-1383852, EBI-396669; CC P54646; Q7Z5V6-2: SAXO4; NbExp=3; IntAct=EBI-1383852, EBI-12000762; CC P54646; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-1383852, EBI-748621; CC P54646; Q15477: SKIC2; NbExp=3; IntAct=EBI-1383852, EBI-373226; CC P54646; Q9H6Q3: SLA2; NbExp=3; IntAct=EBI-1383852, EBI-1222854; CC P54646; Q5JUK2: SOHLH1; NbExp=3; IntAct=EBI-1383852, EBI-12288855; CC P54646; O43609: SPRY1; NbExp=3; IntAct=EBI-1383852, EBI-3866665; CC P54646; Q6ZMT1: STAC2; NbExp=3; IntAct=EBI-1383852, EBI-948802; CC P54646; Q15831: STK11; NbExp=3; IntAct=EBI-1383852, EBI-306838; CC P54646; P15884: TCF4; NbExp=3; IntAct=EBI-1383852, EBI-533224; CC P54646; Q96CG3: TIFA; NbExp=3; IntAct=EBI-1383852, EBI-740711; CC P54646; Q08117: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-717810; CC P54646; Q08117-2: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-11741437; CC P54646; Q15645: TRIP13; NbExp=3; IntAct=EBI-1383852, EBI-358993; CC P54646; Q15654: TRIP6; NbExp=3; IntAct=EBI-1383852, EBI-742327; CC P54646; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-1383852, EBI-739485; CC P54646; O75385: ULK1; NbExp=2; IntAct=EBI-1383852, EBI-908831; CC P54646; Q9Y6N9-4: USH1C; NbExp=3; IntAct=EBI-1383852, EBI-11523636; CC P54646; Q495M9: USH1G; NbExp=3; IntAct=EBI-1383852, EBI-8601749; CC P54646; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-1383852, EBI-739895; CC P54646; Q9UK41-2: VPS28; NbExp=3; IntAct=EBI-1383852, EBI-12146727; CC P54646; Q9H9H4: VPS37B; NbExp=3; IntAct=EBI-1383852, EBI-4400866; CC P54646; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-1383852, EBI-2799833; CC P54646; O76024: WFS1; NbExp=3; IntAct=EBI-1383852, EBI-720609; CC P54646; O00308: WWP2; NbExp=3; IntAct=EBI-1383852, EBI-743923; CC P54646; P62258: YWHAE; NbExp=2; IntAct=EBI-1383852, EBI-356498; CC P54646; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-1383852, EBI-742740; CC P54646; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-1383852, EBI-12030590; CC P54646; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-1383852, EBI-1640204; CC P54646; Q8NF99: ZNF397; NbExp=3; IntAct=EBI-1383852, EBI-10213894; CC P54646; Q3MJ62: ZSCAN23; NbExp=3; IntAct=EBI-1383852, EBI-5667532; CC P54646; Q9WTK7: Stk11; Xeno; NbExp=2; IntAct=EBI-1383852, EBI-8627450; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q8BRK8}. Nucleus CC {ECO:0000269|PubMed:15866171}. Note=In response to stress, recruited by CC p53/TP53 to specific promoters. {ECO:0000269|PubMed:15866171}. CC -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some sequence CC similarity with the ubiquitin-associated domains and represses kinase CC activity. {ECO:0000250|UniProtKB:Q13131}. CC -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q8BRK8}. CC -!- PTM: Phosphorylated at Thr-172 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Also CC phosphorylated at Thr-172 by CAMKK2; triggered by a rise in CC intracellular calcium ions, without detectable changes in the AMP/ATP CC ratio. CAMKK1 can also phosphorylate Thr-172, but at much lower level. CC Dephosphorylated by protein phosphatase 2A and 2C (PP2A and PP2C). CC Phosphorylated by ULK1; leading to negatively regulate AMPK activity CC and suggesting the existence of a regulatory feedback loop between ULK1 CC and AMPK. Dephosphorylated by PPM1A and PPM1B at Thr-172 (mediated by CC STK11/LKB1). {ECO:0000269|PubMed:15980064, CC ECO:0000269|PubMed:21460634}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U06454; AAA64745.1; -; mRNA. DR EMBL; AL035705; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC069680; AAH69680.1; -; mRNA. DR EMBL; BC069740; AAH69740.1; -; mRNA. DR EMBL; BC069823; AAH69823.1; -; mRNA. DR CCDS; CCDS605.1; -. DR PIR; S51025; S51025. DR RefSeq; NP_006243.2; NM_006252.3. DR PDB; 2H6D; X-ray; 1.85 A; A=6-279. DR PDB; 2LTU; NMR; -; A=282-339. DR PDB; 2YZA; X-ray; 3.02 A; A=6-279. DR PDB; 3AQV; X-ray; 2.08 A; A=6-279. DR PDB; 4CFE; X-ray; 3.02 A; A/C=1-552. DR PDB; 4CFF; X-ray; 3.92 A; A/C=1-552. DR PDB; 4ZHX; X-ray; 2.99 A; A/C=2-552. DR PDB; 5EZV; X-ray; 2.99 A; A/C=2-347, A/C=397-552. DR PDB; 5ISO; X-ray; 2.63 A; A/C=1-552. DR PDB; 6B1U; X-ray; 2.77 A; A/C=2-552. DR PDB; 6B2E; X-ray; 3.80 A; A=2-552. DR PDB; 6BX6; X-ray; 2.90 A; A=6-279. DR PDB; 7MYJ; X-ray; 2.95 A; A/C=2-552. DR PDB; 8BIK; X-ray; 2.50 A; A/D=1-552. DR PDB; 9IC2; X-ray; 2.50 A; A=6-280. DR PDBsum; 2H6D; -. DR PDBsum; 2LTU; -. DR PDBsum; 2YZA; -. DR PDBsum; 3AQV; -. DR PDBsum; 4CFE; -. DR PDBsum; 4CFF; -. DR PDBsum; 4ZHX; -. DR PDBsum; 5EZV; -. DR PDBsum; 5ISO; -. DR PDBsum; 6B1U; -. DR PDBsum; 6B2E; -. DR PDBsum; 6BX6; -. DR PDBsum; 7MYJ; -. DR PDBsum; 8BIK; -. DR PDBsum; 9IC2; -. DR AlphaFoldDB; P54646; -. DR BMRB; P54646; -. DR SMR; P54646; -. DR BioGRID; 111550; 239. DR ComplexPortal; CPX-5787; AMPK complex, alpha2-beta1-gamma1 variant. DR ComplexPortal; CPX-5790; AMPK complex, alpha2-beta2-gamma1 variant. DR ComplexPortal; CPX-5840; AMPK complex, alpha2-beta2-gamma3 variant. DR ComplexPortal; CPX-5843; AMPK complex, alpha2-beta1-gamma3 variant. DR ComplexPortal; CPX-5844; AMPK complex, alpha2-beta1-gamma2 variant. DR ComplexPortal; CPX-5845; AMPK complex, alpha2-beta2-gamma2 variant. DR CORUM; P54646; -. DR DIP; DIP-39796N; -. DR FunCoup; P54646; 2136. DR IntAct; P54646; 181. DR MINT; P54646; -. DR STRING; 9606.ENSP00000360290; -. DR BindingDB; P54646; -. DR ChEMBL; CHEMBL2116; -. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB00131; Adenosine phosphate. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00273; Topiramate. DR DrugCentral; P54646; -. DR TCDB; 8.A.104.1.1; the 5'-amp-activated protein kinase (ampk) family. DR GlyConnect; 985; 2 N-Linked glycans (1 site). DR GlyCosmos; P54646; 1 site, 3 glycans. DR GlyGen; P54646; 2 sites, 3 N-linked glycans (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P54646; -. DR PhosphoSitePlus; P54646; -. DR BioMuta; PRKAA2; -. DR DMDM; 20178276; -. DR jPOST; P54646; -. DR MassIVE; P54646; -. DR PaxDb; 9606-ENSP00000360290; -. DR PeptideAtlas; P54646; -. DR ProteomicsDB; 56689; -. DR Pumba; P54646; -. DR Antibodypedia; 3399; 836 antibodies from 45 providers. DR DNASU; 5563; -. DR Ensembl; ENST00000371244.9; ENSP00000360290.4; ENSG00000162409.13. DR GeneID; 5563; -. DR KEGG; hsa:5563; -. DR MANE-Select; ENST00000371244.9; ENSP00000360290.4; NM_006252.4; NP_006243.2. DR UCSC; uc001cyk.5; human. DR AGR; HGNC:9377; -. DR CIViC; 5563; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33745; -. DR CTD; 5563; -. DR DisGeNET; 5563; -. DR GeneCards; PRKAA2; -. DR HGNC; HGNC:9377; PRKAA2. DR HPA; ENSG00000162409; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MIM; 600497; gene. DR OpenTargets; ENSG00000162409; -. DR VEuPathDB; HostDB:ENSG00000162409; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000156945; -. DR HOGENOM; CLU_000288_59_3_1; -. DR InParanoid; P54646; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; P54646; 4 GO annotations based on evolutionary models. DR PhylomeDB; P54646; -. DR BRENDA; 2.7.11.1; 2681. DR BRENDA; 2.7.11.31; 2681. DR PathwayCommons; P54646; -. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-200425; Carnitine shuttle. DR Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9613354; Lipophagy. DR Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. DR Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2. DR SignaLink; P54646; -. DR SIGNOR; P54646; -. DR Agora; ENSG00000162409; -. DR BioGRID-ORCS; 5563; 16 hits in 1188 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PRKAA2; human. DR EvolutionaryTrace; P54646; -. DR GeneWiki; PRKAA2; -. DR GenomeRNAi; 5563; -. DR Pharos; P54646; Tchem. DR PRO; PR:P54646; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P54646; protein. DR Bgee; ENSG00000162409; Expressed in skeletal muscle tissue of rectus abdominis and 181 other cell types or tissues. DR ExpressionAtlas; P54646; baseline and differential. DR GO; GO:0030424; C:axon; ISS:ARUK-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0010494; C:cytoplasmic stress granule; ISS:ARUK-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:ARUK-UCL. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0031588; C:nucleotide-activated protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:ComplexPortal. DR GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; ISS:UniProtKB. DR GO; GO:0140823; F:histone H2BS36 kinase activity; ISS:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0071277; P:cellular response to calcium ion; ISS:ARUK-UCL. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:ARUK-UCL. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:ComplexPortal. DR GO; GO:0034599; P:cellular response to oxidative stress; ISS:ARUK-UCL. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB. DR GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:1905691; P:lipid droplet disassembly; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL. DR GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IDA:UniProt. DR GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904428; P:negative regulation of tubulin deacetylation; IEA:Ensembl. DR GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB. DR GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB. DR GO; GO:0016239; P:positive regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; ISS:ARUK-UCL. DR GO; GO:1990044; P:protein localization to lipid droplet; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; ISS:UniProtKB. DR GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; ISS:ARUK-UCL. DR GO; GO:0062028; P:regulation of stress granule assembly; IEA:Ensembl. DR GO; GO:0014850; P:response to muscle activity; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd12200; AMPKA2_C; 1. DR CDD; cd14079; STKc_AMPK_alpha; 1. DR CDD; cd14404; UBA_AID_AAPK2; 1. DR FunFam; 1.10.510.10:FF:000079; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000014; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000136; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00661; -. DR InterPro; IPR032270; AMPK_C. DR InterPro; IPR039148; AMPKA2_C. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049020; PRKAA1/2_AID. DR InterPro; IPR028783; PRKAA2. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346:SF104; 5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2; 1. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR Pfam; PF16579; AdenylateSensor; 1. DR Pfam; PF21147; AMPK_alpha_AID; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Autophagy; Biological rhythms; KW Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator; KW Cytoplasm; Fatty acid biosynthesis; Fatty acid metabolism; Kinase; KW Lipid biosynthesis; Lipid metabolism; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Steroid biosynthesis; KW Steroid metabolism; Sterol biosynthesis; Sterol metabolism; Transcription; KW Transcription regulation; Transferase; Ubl conjugation; KW Wnt signaling pathway. FT CHAIN 1..552 FT /note="5'-AMP-activated protein kinase catalytic subunit FT alpha-2" FT /id="PRO_0000085594" FT DOMAIN 16..268 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 291..376 FT /note="AIS" FT /evidence="ECO:0000250|UniProtKB:Q13131" FT REGION 477..521 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 480..490 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 501..510 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 511..521 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 22..30 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 45 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 172 FT /note="Phosphothreonine; by LKB1 and CaMKK2" FT /evidence="ECO:0000269|PubMed:15980064, FT ECO:0000269|PubMed:24767988, ECO:0000269|PubMed:28552616" FT MOD_RES 258 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q09137" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 491 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q09137" FT VARIANT 371 FT /note="P -> T (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035623" FT VARIANT 407 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040355" FT VARIANT 523 FT /note="S -> G (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035624" FT MUTAGEN 45 FT /note="K->R: Complete loss of kinase activity." FT /evidence="ECO:0000305|PubMed:36017701" FT MUTAGEN 172 FT /note="T->A: Loss of ARF6 activation. Loss of interaction FT with ACSS2." FT /evidence="ECO:0000269|PubMed:28552616, FT ECO:0000269|PubMed:36017701" FT MUTAGEN 172 FT /note="T->D: Phosphomimetic mutant." FT /evidence="ECO:0000269|PubMed:21543851" FT CONFLICT 180 FT /note="A -> T (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT CONFLICT 271 FT /note="D -> G (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT CONFLICT 403..404 FT /note="HL -> RQ (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT STRAND 16..24 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 26..35 FT /evidence="ECO:0007829|PDB:2H6D" FT TURN 36..38 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 41..48 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 49..54 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 58..69 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 113..133 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 192..209 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 219..228 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:6BX6" FT HELIX 239..248 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 253..255 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 259..264 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 266..269 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 274..276 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 290..299 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 304..312 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 319..335 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 338..341 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 412..425 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 429..434 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 437..443 FT /evidence="ECO:0007829|PDB:8BIK" FT TURN 445..447 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 450..461 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 464..471 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 535..549 FT /evidence="ECO:0007829|PDB:8BIK" SQ SEQUENCE 552 AA; 62320 MW; C46AAFC1D5104975 CRC64; MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ KIRSLDVVGK IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE LFDYICKHGR VEEMEARRLF QQILSAVDYC HRHMVVHRDL KPENVLLDAH MNAKIADFGL SNMMSDGEFL RTSCGSPNYA APEVISGRLY AGPEVDIWSC GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS VATLLMHMLQ VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPSGS FMDDSAMHIP PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA KWHLGIRSQS KPYDIMAEVY RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR SGSSTPQRSC SAAGLHRPRS SFDSTTAESH SLSGSLTGSL TGSTLSSVSP RLGSHTMDFF EMCASLITTL AR // ID ACK1_HUMAN Reviewed; 1038 AA. AC Q07912; Q6ZMQ0; Q8N6U7; Q96H59; DT 24-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 3. DT 28-JAN-2026, entry version 240. DE RecName: Full=Activated CDC42 kinase 1; DE Short=ACK-1; DE EC=2.7.10.2 {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297}; DE EC=2.7.11.1 {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; DE AltName: Full=Tyrosine kinase non-receptor protein 2; GN Name=TNK2; Synonyms=ACK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42. RC TISSUE=Hippocampus; RX PubMed=8497321; DOI=10.1038/363364a0; RA Manser E., Leung T., Salihuddin H., Tan L., Lim L.; RT "A non-receptor tyrosine kinase that inhibits the GTPase activity of RT p21cdc42."; RL Nature 363:364-367(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-725. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP INTERACTION WITH CSPG4. RX PubMed=10587647; DOI=10.1038/70302; RA Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L., RA Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.; RT "Melanoma chondroitin sulphate proteoglycan regulates cell spreading RT through Cdc42, Ack-1 and p130cas."; RL Nat. Cell Biol. 1:507-513(1999). RN [6] RP FUNCTION AS MCF2 KINASE, CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=10652228; DOI=10.1006/bbrc.2000.2106; RA Kato J., Kaziro Y., Satoh T.; RT "Activation of the guanine nucleotide exchange factor Dbl following ACK1- RT dependent tyrosine phosphorylation."; RL Biochem. Biophys. Res. Commun. 268:141-147(2000). RN [7] RP FUNCTION. RX PubMed=11278436; DOI=10.1074/jbc.m008795200; RA Teo M., Tan L., Lim L., Manser E.; RT "The tyrosine kinase ACK1 associates with clathrin-coated vesicles through RT a binding motif shared by arrestin and other adaptors."; RL J. Biol. Chem. 276:18392-18398(2001). RN [8] RP SUBCELLULAR LOCATION. RX PubMed=14733946; DOI=10.1016/j.bbrc.2003.12.137; RA Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E., RA Meiners S., Nur-E-Kamal A.; RT "Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, RT ACK."; RL Biochem. Biophys. Res. Commun. 314:571-579(2004). RN [9] RP AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND RP MUTAGENESIS OF LYS-158 AND LEU-487. RX PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127; RA Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.; RT "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of RT Ack1 in polyubiquitination of tumor suppressor Wwox."; RL Cancer Res. 65:10514-10523(2005). RN [10] RP INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION. RX PubMed=16137687; DOI=10.1016/j.febslet.2005.07.093; RA Yeow-Fong L., Lim L., Manser E.; RT "SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector RT ACK1."; RL FEBS Lett. 579:5040-5048(2005). RN [11] RP FUNCTION AS WAS KINASE, INTERACTION WITH WASL, CATALYTIC ACTIVITY, AND RP COFACTOR. RX PubMed=16257963; DOI=10.1074/jbc.m506996200; RA Yokoyama N., Lougheed J., Miller W.T.; RT "Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual RT hydroxyamino acid specificity in a tyrosine kinase."; RL J. Biol. Chem. 280:42219-42226(2005). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [13] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=16247015; DOI=10.1073/pnas.0508014102; RA van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L., RA Orf J., Rong M., Li S., See L.-H., Nguyen K.Q.C., Hoey T., Wesche H., RA Powers S.; RT "Metastatic properties and genomic amplification of the tyrosine kinase RT gene ACK1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15901-15906(2005). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK. RX PubMed=17038317; DOI=10.1074/jbc.m604342200; RA Modzelewska K., Newman L.P., Desai R., Keely P.J.; RT "Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas."; RL J. Biol. Chem. 281:37527-37535(2006). RN [16] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT TYR-284. RX PubMed=16472662; DOI=10.1016/s0076-6879(06)06018-6; RA Yokoyama N., Miller W.T.; RT "Purification and enzyme activity of ACK1."; RL Methods Enzymol. 406:250-260(2006). RN [17] RP INTERACTION WITH AR. RX PubMed=17494760; DOI=10.1073/pnas.0700420104; RA Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., RA Earp H.S., Whang Y.E.; RT "Activated Cdc42-associated kinase Ack1 promotes prostate cancer RT progression via androgen receptor tyrosine phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007). RN [18] RP INTERACTION WITH NPHP1. RX PubMed=18477472; DOI=10.1016/j.bbrc.2008.05.016; RA Eley L., Moochhala S.H., Simms R., Hildebrandt F., Sayer J.A.; RT "Nephrocystin-1 interacts directly with Ack1 and is expressed in human RT collecting duct."; RL Biochem. Biophys. Res. Commun. 371:877-882(2008). RN [19] RP FUNCTION. RX PubMed=18435854; DOI=10.1186/bcr2087; RA Howlin J., Rosenkvist J., Andersson T.; RT "TNK2 preserves epidermal growth factor receptor expression on the cell RT surface and enhances migration and invasion of human breast cancer cells."; RL Breast Cancer Res. 10:R36-R36(2008). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18262180; DOI=10.1016/j.yexcr.2007.12.017; RA Groevdal L.M., Johannessen L.E., Roedland M.S., Madshus I.H., Stang E.; RT "Dysregulation of Ack1 inhibits down-regulation of the EGF receptor."; RL Exp. Cell Res. 314:1292-1300(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP INTERACTION WITH NEDD4, AND UBIQUITINATION. RX PubMed=19144635; DOI=10.1074/jbc.m806877200; RA Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.; RT "Down-regulation of active ACK1 is mediated by association with the E3 RT ubiquitin ligase Nedd4-2."; RL J. Biol. Chem. 284:8185-8194(2009). RN [24] RP FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284 AND SER-724, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN RP SAM-LIKE. RX PubMed=20979614; DOI=10.1186/1471-2091-11-42; RA Prieto-Echaguee V., Gucwa A., Brown D.A., Miller W.T.; RT "Regulation of Ack1 localization and activity by the amino-terminal SAM RT domain."; RL BMC Biochem. 11:42-42(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, VARIANTS LEU-34; GLN-99; LYS-346 AND RP ILE-409, CHARACTERIZATION OF VARIANTS LEU-34; GLN-99; LYS-346 AND ILE-409, RP AND MUTAGENESIS OF LEU-120; LEU-197 AND VAL-365. RX PubMed=20110370; DOI=10.1074/jbc.m109.060459; RA Prieto-Echaguee V., Gucwa A., Craddock B.P., Brown D.A., Miller W.T.; RT "Cancer-associated mutations activate the nonreceptor tyrosine kinase RT Ack1."; RL J. Biol. Chem. 285:10605-10615(2010). RN [28] RP FUNCTION AS AR KINASE, AND ACTIVITY REGULATION. RX PubMed=20383201; DOI=10.1038/onc.2010.103; RA Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E.; RT "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen RT receptor by Ack1 and Src kinases."; RL Oncogene 29:3208-3216(2010). RN [29] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH AKT1, SUBCELLULAR RP LOCATION, CHARACTERIZATION OF VARIANT LYS-346, PHOSPHORYLATION AT TYR-284, RP AND TISSUE SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [30] RP PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ACTIVITY REGULATION. RX PubMed=20623637; DOI=10.1002/pros.21163; RA Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., RA Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.; RT "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen RT receptor activity."; RL Prostate 70:1274-1285(2010). RN [31] RP PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC. RX PubMed=21309750; DOI=10.1042/bj20102156; RA Chan W., Sit S.T., Manser E.; RT "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires Src RT for activation."; RL Biochem. J. 435:355-364(2011). RN [32] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518; TYR-827; RP TYR-859 AND TYR-872. RX PubMed=21169560; DOI=10.1091/mbc.e10-07-0637; RA Shen H., Ferguson S.M., Dephoure N., Park R., Yang Y., Volpicelli-Daley L., RA Gygi S., Schlessinger J., De Camilli P.; RT "Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at RT arrested endocytic clathrin-coated pits of cells that lack dynamin."; RL Mol. Biol. Cell 22:493-502(2011). RN [33] RP REVIEW ON TUMOR GROWTH. RX PubMed=20432460; DOI=10.1002/jcp.22162; RA Mahajan K., Mahajan N.P.; RT "Shepherding AKT and androgen receptor by Ack1 tyrosine kinase."; RL J. Cell. Physiol. 224:327-333(2010). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP STRUCTURE BY NMR OF 448-489. RX PubMed=10360579; DOI=10.1038/20732; RA Mott H.R., Owen D., Nietlispach D., Lowe P.N., Manser E., Lim L., RA Laue E.D.; RT "Structure of the small G protein Cdc42 bound to the GTPase-binding domain RT of ACK."; RL Nature 399:384-388(1999). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION AT RP TYR-284. RX PubMed=15308621; DOI=10.1074/jbc.m406703200; RA Lougheed J.C., Chen R.-H., Mak P., Stout T.J.; RT "Crystal structures of the phosphorylated and unphosphorylated kinase RT domains of the Cdc42-associated tyrosine kinase ACK1."; RL J. Biol. Chem. 279:44039-44045(2004). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH INHIBITOR, RP AND CATALYTIC ACTIVITY. RX PubMed=18993068; DOI=10.1016/j.bmcl.2008.10.092; RA Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C., Cardozo M.G., RA Liu J., Wang Z., Walker N.P., Wesche H., Li S., Farrelly E., Xiao S.H., RA Kayser F.; RT "Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4- RT d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors."; RL Bioorg. Med. Chem. Lett. 18:6352-6356(2008). RN [38] RP VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409; RP SER-507; LEU-725; GLN-748 AND HIS-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [39] RP VARIANT MET-638, INTERACTION WITH NEDD4 AND NEDD4L, AND CHARACTERIZATION OF RP VARIANT MET-638. RX PubMed=23686771; DOI=10.1002/ana.23934; RA Hitomi Y., Heinzen E.L., Donatello S., Dahl H.H., Damiano J.A., RA McMahon J.M., Berkovic S.F., Scheffer I.E., Legros B., Rai M., RA Weckhuysen S., Suls A., De Jonghe P., Pandolfo M., Goldstein D.B., RA Van Bogaert P., Depondt C.; RT "Mutations in TNK2 in severe autosomal recessive infantile onset RT epilepsy."; RL Ann. Neurol. 74:496-501(2013). CC -!- FUNCTION: Non-receptor tyrosine-protein and serine/threonine-protein CC kinase that is implicated in cell spreading and migration, cell CC survival, cell growth and proliferation. Transduces extracellular CC signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, CC MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated CC endocytosis through binding to epidermal growth factor receptor (EGFR) CC and clathrin. Binds to both poly- and mono-ubiquitin and regulates CC ligand-induced degradation of EGFR, thereby contributing to the CC accumulation of EGFR at the limiting membrane of early endosomes. CC Downstream effector of CDC42 which mediates CDC42-dependent cell CC migration via phosphorylation of BCAR1. May be involved both in adult CC synaptic function and plasticity and in brain development. Activates CC AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' CC and 'Tyr-363' thereby promoting its recruitment to androgen-responsive CC enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates CC MCF2, thereby enhancing its activity as a guanine nucleotide exchange CC factor (GEF) toward Rho family proteins. Contributes to the control of CC AXL receptor levels. Confers metastatic properties on cancer cells and CC promotes tumor growth by negatively regulating tumor suppressor such as CC WWOX and positively regulating pro-survival factors such as AKT1 and CC AR. Phosphorylates WASP (PubMed:20110370). CC {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:11278436, CC ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:18262180, ECO:0000269|PubMed:18435854, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20110370, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20383201}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, CC ECO:0000269|PubMed:20333297}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:20333297}; CC -!- ACTIVITY REGULATION: Inhibited by AIM-100 (4-amino-5,6-biaryl-furo[2,3- CC d]pyrimidine), which suppresses activating phosphorylation at Tyr-284. CC Repressed by dasatinib. {ECO:0000269|PubMed:20383201, CC ECO:0000269|PubMed:20623637}. CC -!- SUBUNIT: Interacts with NEDD4 (via WW3 domain). NEDD4L and EGF promote CC association with NEDD4 (By similarity). Homodimer. Interacts with AR, CC CDC42, WWASL and WWOX. Interacts with CSPG4 (activated). Interacts with CC MERTK (activated); stimulates autophosphorylation. May interact CC (phosphorylated) with HSP90AB1; maintains kinase activity. Interacts CC with NPHP1. Interacts with SNX9 (via SH3 domain). Interacts with SRC CC (via SH2 and SH3 domain). Interacts with EGFR, and this interaction is CC dependent on EGF stimulation and kinase activity of EGFR. Interacts CC (via kinase domain) with AKT1. Part of a collagen stimulated complex CC involved in cell migration composed of CDC42, CRK, TNK2 and CC BCAR1/p130cas. Interacts with BCAR1/p130cas via SH3 domains. Forms CC complexes with GRB2 and numerous receptor tyrosine kinases (RTK) CC including LTK, AXL or PDGFRL, in which GRB2 promotes RTK recruitment by CC TNK2. {ECO:0000250, ECO:0000269|PubMed:10587647, CC ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:18477472, CC ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:19144635, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21309750, CC ECO:0000269|PubMed:23686771, ECO:0000269|PubMed:8497321}. CC -!- INTERACTION: CC Q07912; P29972: AQP1; NbExp=3; IntAct=EBI-603457, EBI-745213; CC Q07912; P56945: BCAR1; NbExp=5; IntAct=EBI-603457, EBI-702093; CC Q07912; P60953-2: CDC42; NbExp=2; IntAct=EBI-603457, EBI-287394; CC Q07912; Q00610: CLTC; NbExp=3; IntAct=EBI-603457, EBI-354967; CC Q07912; P07902: GALT; NbExp=3; IntAct=EBI-603457, EBI-750827; CC Q07912; P62993: GRB2; NbExp=6; IntAct=EBI-603457, EBI-401755; CC Q07912; P08238: HSP90AB1; NbExp=3; IntAct=EBI-603457, EBI-352572; CC Q07912; P16333: NCK1; NbExp=4; IntAct=EBI-603457, EBI-389883; CC Q07912; Q9HC98: NEK6; NbExp=3; IntAct=EBI-603457, EBI-740364; CC Q07912; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-603457, EBI-945833; CC Q07912; O60880: SH2D1A; NbExp=3; IntAct=EBI-603457, EBI-6983382; CC Q07912; Q9Y5X1: SNX9; NbExp=4; IntAct=EBI-603457, EBI-77848; CC Q07912; Q07912: TNK2; NbExp=2; IntAct=EBI-603457, EBI-603457; CC Q07912-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11994780, EBI-3867333; CC Q07912-2; Q9BQC3: DPH2; NbExp=3; IntAct=EBI-11994780, EBI-10237931; CC Q07912-2; P07902: GALT; NbExp=3; IntAct=EBI-11994780, EBI-750827; CC Q07912-2; Q92569: PIK3R3; NbExp=3; IntAct=EBI-11994780, EBI-79893; CC Q07912-2; O60880: SH2D1A; NbExp=3; IntAct=EBI-11994780, EBI-6983382; CC Q07912-2; O14796: SH2D1B; NbExp=3; IntAct=EBI-11994780, EBI-3923013; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614}. Nucleus {ECO:0000269|PubMed:14733946, CC ECO:0000269|PubMed:20333297}. Endosome {ECO:0000250|UniProtKB:O54967}. CC Cell junction, adherens junction {ECO:0000305}. Cytoplasmic vesicle CC membrane; Peripheral membrane protein; Cytoplasmic side CC {ECO:0000269|PubMed:16137687}. Cytoplasmic vesicle, clathrin-coated CC vesicle {ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:18262180}. CC Membrane, clathrin-coated pit {ECO:0000269|PubMed:21169560}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:20110370}. Cytoplasm, cytosol CC {ECO:0000250|UniProtKB:O54967}. Note=The Tyr-284 phosphorylated form is CC found both in the membrane and nucleus (By similarity). Co-localizes CC with EGFR on endosomes (PubMed:20333297). Nuclear translocation is CC CDC42-dependent (By similarity). Detected in long filamentous cytosolic CC structures where it co-localizes with CTPS1 (By similarity). CC {ECO:0000250|UniProtKB:O54967, ECO:0000269|PubMed:20333297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q07912-1; Sequence=Displayed; CC Name=2; CC IsoId=Q07912-2; Sequence=VSP_008655, VSP_008656; CC Name=3; CC IsoId=Q07912-3; Sequence=VSP_037284, VSP_037285, VSP_037286; CC -!- TISSUE SPECIFICITY: The Tyr-284 phosphorylated form shows a significant CC increase in expression in breast cancers during the progressive stages CC i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), CC invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) CC stages. It also shows a significant increase in expression in prostate CC cancers during the progressive stages. {ECO:0000269|PubMed:16247015, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20623637}. CC -!- DOMAIN: The EBD (EGFR-binding domain) domain is necessary for CC interaction with EGFR. {ECO:0000250}. CC -!- DOMAIN: The SAM-like domain is necessary for NEDD4-mediated CC ubiquitination. Promotes membrane localization and dimerization to CC allow for autophosphorylation. {ECO:0000269|PubMed:20979614}. CC -!- DOMAIN: The UBA domain binds both poly- and mono-ubiquitin. CC {ECO:0000269|PubMed:20979614}. CC -!- PTM: Autophosphorylation regulates kinase activity. Phosphorylation on CC Tyr-518 is required for interaction with SRC and is observed during CC association with clathrin-coated pits. {ECO:0000269|PubMed:15308621, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, CC ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750}. CC -!- PTM: Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced CC by EGF and is lysosome-dependent (By similarity). {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08884.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305}; CC Sequence=BAD18675.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L13738; AAA53570.2; -; mRNA. DR EMBL; AK131539; BAD18675.1; ALT_INIT; mRNA. DR EMBL; AC124944; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008884; AAH08884.1; ALT_SEQ; mRNA. DR EMBL; BC028164; AAH28164.1; -; mRNA. DR CCDS; CCDS33927.2; -. [Q07912-3] DR CCDS; CCDS33928.1; -. [Q07912-1] DR PIR; S33596; S33596. DR RefSeq; NP_001010938.2; NM_001010938.2. [Q07912-3] DR RefSeq; NP_001294975.1; NM_001308046.1. DR RefSeq; NP_001374642.1; NM_001387713.1. [Q07912-1] DR RefSeq; NP_001374643.1; NM_001387714.1. [Q07912-1] DR RefSeq; NP_005772.3; NM_005781.4. [Q07912-1] DR RefSeq; XP_047303107.1; XM_047447151.1. [Q07912-1] DR RefSeq; XP_047303116.1; XM_047447160.1. [Q07912-1] DR RefSeq; XP_054200839.1; XM_054344864.1. [Q07912-1] DR RefSeq; XP_054200851.1; XM_054344876.1. [Q07912-1] DR PDB; 1CF4; NMR; -; B=448-489. DR PDB; 1U46; X-ray; 2.00 A; A/B=109-395. DR PDB; 1U4D; X-ray; 2.10 A; A/B=109-395. DR PDB; 1U54; X-ray; 2.80 A; A/B=109-395. DR PDB; 3EQP; X-ray; 2.30 A; A/B=117-392. DR PDB; 3EQR; X-ray; 2.00 A; A/B=117-392. DR PDB; 4EWH; X-ray; 2.50 A; A/B=117-391. DR PDB; 4HZR; X-ray; 1.31 A; A/B=115-389. DR PDB; 4HZS; X-ray; 3.23 A; A/B/C/D=115-453. DR PDB; 4ID7; X-ray; 3.00 A; A=117-389. DR PDB; 5ZXB; X-ray; 2.20 A; A/B=117-391. DR PDB; 6VQM; X-ray; 2.87 A; A/B=109-395. DR PDB; 7KP6; X-ray; 1.79 A; A/B=110-391. DR PDB; 8FE9; X-ray; 3.20 A; A=110-391. DR PDB; 8FZ3; X-ray; 2.78 A; A/B/C/D=958-1038. DR PDB; 8HMT; X-ray; 3.17 A; A/B/C/D=117-389. DR PDB; 8Q5P; X-ray; 1.81 A; B=508-519. DR PDB; 8THA; X-ray; 1.68 A; A=954-1038. DR PDBsum; 1CF4; -. DR PDBsum; 1U46; -. DR PDBsum; 1U4D; -. DR PDBsum; 1U54; -. DR PDBsum; 3EQP; -. DR PDBsum; 3EQR; -. DR PDBsum; 4EWH; -. DR PDBsum; 4HZR; -. DR PDBsum; 4HZS; -. DR PDBsum; 4ID7; -. DR PDBsum; 5ZXB; -. DR PDBsum; 6VQM; -. DR PDBsum; 7KP6; -. DR PDBsum; 8FE9; -. DR PDBsum; 8FZ3; -. DR PDBsum; 8HMT; -. DR PDBsum; 8Q5P; -. DR PDBsum; 8THA; -. DR AlphaFoldDB; Q07912; -. DR SMR; Q07912; -. DR BioGRID; 115485; 135. DR CORUM; Q07912; -. DR DIP; DIP-33858N; -. DR FunCoup; Q07912; 728. DR IntAct; Q07912; 73. DR MINT; Q07912; -. DR STRING; 9606.ENSP00000371341; -. DR BindingDB; Q07912; -. DR ChEMBL; CHEMBL4599; -. DR DrugBank; DB18236; (R)-9b. DR DrugBank; DB00171; ATP. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q07912; -. DR GuidetoPHARMACOLOGY; 2246; -. DR GlyCosmos; Q07912; 2 sites, 1 glycan. DR GlyGen; Q07912; 6 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q07912; -. DR PhosphoSitePlus; Q07912; -. DR BioMuta; TNK2; -. DR DMDM; 229462980; -. DR CPTAC; CPTAC-1779; -. DR CPTAC; CPTAC-2789; -. DR jPOST; Q07912; -. DR MassIVE; Q07912; -. DR PaxDb; 9606-ENSP00000371341; -. DR PeptideAtlas; Q07912; -. DR ProteomicsDB; 58556; -. [Q07912-1] DR ProteomicsDB; 58557; -. [Q07912-2] DR ProteomicsDB; 58558; -. [Q07912-3] DR Pumba; Q07912; -. DR Antibodypedia; 4095; 764 antibodies from 40 providers. DR CPTC; Q07912; 5 antibodies. DR DNASU; 10188; -. DR Ensembl; ENST00000333602.14; ENSP00000329425.6; ENSG00000061938.22. [Q07912-1] DR Ensembl; ENST00000439230.6; ENSP00000395588.1; ENSG00000061938.22. [Q07912-2] DR Ensembl; ENST00000671753.1; ENSP00000499858.1; ENSG00000061938.22. [Q07912-3] DR GeneID; 10188; -. DR KEGG; hsa:10188; -. DR UCSC; uc003fvt.2; human. [Q07912-1] DR AGR; HGNC:19297; -. DR ClinPGx; PA134909759; -. DR CTD; 10188; -. DR DisGeNET; 10188; -. DR GeneCards; TNK2; -. DR HGNC; HGNC:19297; TNK2. DR HPA; ENSG00000061938; Low tissue specificity. DR MalaCards; TNK2; -. DR MIM; 606994; gene. DR OpenTargets; ENSG00000061938; -. DR Orphanet; 391316; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression. DR VEuPathDB; HostDB:ENSG00000061938; -. DR eggNOG; KOG0199; Eukaryota. DR GeneTree; ENSGT00940000160853; -. DR HOGENOM; CLU_000288_7_39_1; -. DR InParanoid; Q07912; -. DR OrthoDB; 635774at2759; -. DR PAN-GO; Q07912; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q07912; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q07912; -. DR Reactome; R-HSA-9842663; Signaling by LTK. DR SignaLink; Q07912; -. DR SIGNOR; Q07912; -. DR Agora; ENSG00000061938; -. DR BioGRID-ORCS; 10188; 11 hits in 1191 CRISPR screens. DR ChiTaRS; TNK2; human. DR EvolutionaryTrace; Q07912; -. DR GeneWiki; TNK2; -. DR GenomeRNAi; 10188; -. DR Pharos; Q07912; Tclin. DR PRO; PR:Q07912; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q07912; protein. DR Bgee; ENSG00000061938; Expressed in right hemisphere of cerebellum and 192 other cell types or tissues. DR ExpressionAtlas; Q07912; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB. DR GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB. DR GO; GO:0097268; C:cytoophidium; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; ISS:UniProtKB. DR GO; GO:0070436; C:Grb2-EGFR complex; IDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0005095; F:GTPase inhibitor activity; TAS:ProtInc. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0050699; F:WW domain binding; ISS:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB. DR GO; GO:0007264; P:small GTPase-mediated signal transduction; TAS:ProtInc. DR CDD; cd05040; PTKc_Ack_like; 1. DR CDD; cd09539; SAM_TNK-like; 1. DR CDD; cd14274; UBA_ACK1; 1. DR CDD; cd14328; UBA_TNK1; 1. DR DisProt; DP01772; -. DR FunFam; 4.10.680.10:FF:000001; activated CDC42 kinase 1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000080; Putative activated CDC42 kinase 1; 1. DR FunFam; 3.30.200.20:FF:000107; Putative activated CDC42 kinase 1; 1. DR Gene3D; 4.10.680.10; Cdc42-like binding domain; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00276; -. DR InterPro; IPR055175; ACK/TNK-like_SAM. DR InterPro; IPR030220; Ack1_UBA_dom. DR InterPro; IPR015116; Cdc42-bd-like. DR InterPro; IPR037085; Cdc42-bd-like_dom_sf. DR InterPro; IPR052112; EGFR_SigReg_Kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR021619; Mig-6. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR049587; TNK-like_SAM. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR14254; GENE 33 POLYPEPTIDE; 1. DR PANTHER; PTHR14254:SF6; NON-SPECIFIC PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF09027; GTPase_binding; 1. DR Pfam; PF11555; Inhibitor_Mig-6; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF22931; SAM_TNK; 1. DR Pfam; PF14604; SH3_9; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell junction; KW Cell membrane; Coated pit; Cytoplasm; Cytoplasmic vesicle; Endocytosis; KW Endosome; Kinase; Magnesium; Membrane; Metal-binding; Methylation; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation. FT CHAIN 1..1038 FT /note="Activated CDC42 kinase 1" FT /id="PRO_0000088058" FT DOMAIN 126..385 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 388..448 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 454..466 FT /note="CRIB" FT DOMAIN 958..996 FT /note="UBA" FT REGION 1..110 FT /note="SAM-like domain" FT REGION 90..114 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 497..535 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 623..652 FT /note="Required for interaction with SRC" FT /evidence="ECO:0000269|PubMed:21309750" FT REGION 632..635 FT /note="Required for interaction with NEDD4" FT /evidence="ECO:0000250" FT REGION 659..702 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 718..840 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..876 FT /note="EBD domain" FT /evidence="ECO:0000250" FT REGION 917..957 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 738..749 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 772..783 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 794..805 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 252 FT /note="Proton acceptor" FT BINDING 132..140 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 284 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000269|PubMed:15308621, FT ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, FT ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750, FT ECO:0007744|PubMed:19369195" FT MOD_RES 518 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 827 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 839 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:O54967" FT MOD_RES 859 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 872 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT VAR_SEQ 1 FT /note="M -> MGERSAYQRLAGGEEGPQRLGGGRM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037284" FT VAR_SEQ 485..528 FT /note="LYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPL -> CPFS FT AFSPGHPPAETCGQVLWTGRREACASDPRLHPVSSRTKGL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008655" FT VAR_SEQ 514 FT /note="K -> KREPPPRPPQPAFFTQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037285" FT VAR_SEQ 529..1038 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008656" FT VAR_SEQ 965..994 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037286" FT VARIANT 34 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates; no FT effect on subcellular localization to perinuclear region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032792" FT VARIANT 71 FT /note="K -> R (in dbSNP:rs56036945)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032793" FT VARIANT 99 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; increased autophosphorylation at Y-284; FT increased function in phosphorylation of peptide substrates FT and WASP; no effect on subcellular localization to FT perinuclear region; dbSNP:rs113498671)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032794" FT VARIANT 99 FT /note="R -> W (in dbSNP:rs3747673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032795" FT VARIANT 152 FT /note="T -> M (in dbSNP:rs56161912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032796" FT VARIANT 346 FT /note="E -> K (in an ovarian endometrioid cancer sample; FT somatic mutation; undergoes autoactivation and causes FT phosphorylation on Y-284 leading to activation of AKT1; FT increased autophosphorylation at Y-284; increased function FT in phosphorylation of peptide substrates and WASP; no FT effect on catalytic activity itself as the purified kinase FT domain has activity in vitro comparable to wild-type FT protein; no effect on subcellular localization to FT perinuclear region; dbSNP:rs970946035)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370, ECO:0000269|PubMed:20333297" FT /id="VAR_032797" FT VARIANT 409 FT /note="M -> I (in a gastric adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates and WASP; FT no effect on subcellular localization to perinuclear FT region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032798" FT VARIANT 507 FT /note="P -> S (in dbSNP:rs35759128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032799" FT VARIANT 638 FT /note="V -> M (found in patients with childhood-onset FT epilepsy; uncertain significance; loss of interaction with FT NEDD4 and NEDD4L; increased protein abundance; FT dbSNP:rs201407161)" FT /evidence="ECO:0000269|PubMed:23686771" FT /id="VAR_076966" FT VARIANT 725 FT /note="P -> L (in dbSNP:rs56260729)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032800" FT VARIANT 748 FT /note="R -> Q (in dbSNP:rs57872314)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032801" FT VARIANT 802 FT /note="P -> L (in dbSNP:rs3749333)" FT /id="VAR_057115" FT VARIANT 1038 FT /note="R -> H (in dbSNP:rs13433937)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032802" FT MUTAGEN 120 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 158 FT /note="K->R: Loss of autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:16288044, FT ECO:0000269|PubMed:20110370" FT MUTAGEN 197 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 365 FT /note="V->R: Increased autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 487 FT /note="L->F: Constantly active kinase." FT /evidence="ECO:0000269|PubMed:16288044" FT CONFLICT 138 FT /note="G -> V (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 304..352 FT /note="TRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPR -> FT PPWRDISASSSTQFPHAVPCFPTSLLAKLLLRHSVPASSREIKLVSILC (in Ref. FT 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 353..1038 FT /note="Missing (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 586 FT /note="A -> P (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 722 FT /note="Missing (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 838..840 FT /note="PRA -> AG (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 123..125 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 126..133 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 140..146 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:3EQP" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 164..166 FT /evidence="ECO:0007829|PDB:3EQR" FT HELIX 171..181 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 192..196 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 209..212 FT /evidence="ECO:0007829|PDB:8FE9" FT HELIX 213..219 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 226..245 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 258..262 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 265..268 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 273..276 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:3EQP" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 299..304 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 306..308 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 309..324 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:4HZS" FT TURN 330..333 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 336..344 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 358..367 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 372..374 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 378..387 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 392..394 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 402..404 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 412..417 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 419..421 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 423..432 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 449..451 FT /evidence="ECO:0007829|PDB:1CF4" FT TURN 484..486 FT /evidence="ECO:0007829|PDB:1CF4" SQ SEQUENCE 1038 AA; 114569 MW; 74A1980665BC3E6B CRC64; MQPEEGTGWL LELLSEVQLQ QYFLRLRDDL NVTRLSHFEY VKNEDLEKIG MGRPGQRRLW EAVKRRKALC KRKSWMSKVF SGKRLEAEFP PHHSQSTFRK TSPAPGGPAG EGPLQSLTCL IGEKDLRLLE KLGDGSFGVV RRGEWDAPSG KTVSVAVKCL KPDVLSQPEA MDDFIREVNA MHSLDHRNLI RLYGVVLTPP MKMVTELAPL GSLLDRLRKH QGHFLLGTLS RYAVQVAEGM GYLESKRFIH RDLAARNLLL ATRDLVKIGD FGLMRALPQN DDHYVMQEHR KVPFAWCAPE SLKTRTFSHA SDTWMFGVTL WEMFTYGQEP WIGLNGSQIL HKIDKEGERL PRPEDCPQDI YNVMVQCWAH KPEDRPTFVA LRDFLLEAQP TDMRALQDFE EPDKLHIQMN DVITVIEGRA ENYWWRGQNT RTLCVGPFPR NVVTSVAGLS AQDISQPLQN SFIHTGHGDS DPRHCWGFPD RIDELYLGNP MDPPDLLSVE LSTSRPPQHL GGVKKPTYDP VSEDQDPLSS DFKRLGLRKP GLPRGLWLAK PSARVPGTKA SRGSGAEVTL IDFGEEPVVP ALRPCAPSLA QLAMDACSLL DETPPQSPTR ALPRPLHPTP VVDWDARPLP PPPAYDDVAQ DEDDFEICSI NSTLVGAGVP AGPSQGQTNY AFVPEQARPP PPLEDNLFLP PQGGGKPPSS AQTAEIFQAL QQECMRQLQA PAGSPAPSPS PGGDDKPQVP PRVPIPPRPT RPHVQLSPAP PGEEETSQWP GPASPPRVPP REPLSPQGSR TPSPLVPPGS SPLPPRLSSS PGKTMPTTQS FASDPKYATP QVIQAPGPRA GPCILPIVRD GKKVSSTHYY LLPERPSYLE RYQRFLREAQ SPEEPTPLPV PLLLPPPSTP APAAPTATVR PMPQAALDPK ANFSTNNSNP GARPPPPRAT ARLPQRGCPG DGPEAGRPAD KIQMAMVHGV TTEECQAALQ CHGWSVQRAA QYLKVEQLFG LGLRPRGECH KVLEMFDWNL EQAGCHLLGS WGPAHHKR // ID AFAP1_HUMAN Reviewed; 730 AA. AC Q8N556; A8K442; B4DMU2; E9PDT7; Q59EY5; Q9HBY1; DT 05-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 05-FEB-2008, sequence version 2. DT 28-JAN-2026, entry version 163. DE RecName: Full=Actin filament-associated protein 1; DE AltName: Full=110 kDa actin filament-associated protein; DE Short=AFAP-110; GN Name=AFAP1; Synonyms=AFAP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH SRC, PHOSPHORYLATION BY SRC, AND MUTAGENESIS OF PRO-71; RP PRO-77; TYR-93; TYR-94; TYR-125; TYR-451 AND TYR-453. RC TISSUE=Lung; RX PubMed=15485829; DOI=10.1074/jbc.m406880200; RA Han B., Bai X.H., Lodyga M., Xu J., Yang B.B., Keshavjee S., Post M., RA Liu M.; RT "Conversion of mechanical force into biochemical signaling."; RL J. Biol. Chem. 279:54793-54801(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT RP CYS-403. RC TISSUE=Brain, and Kidney; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT CYS-403. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 93-730 (ISOFORM 1), AND VARIANT RP MET-518. RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [7] RP TISSUE SPECIFICITY, AND KNOCKDOWN IN MDA-MB-231 CELLS. RX PubMed=17520695; DOI=10.1002/jcp.21143; RA Dorfleutner A., Stehlik C., Zhang J., Gallick G.E., Flynn D.C.; RT "AFAP-110 is required for actin stress fiber formation and cell adhesion in RT MDA-MB-231 breast cancer cells."; RL J. Cell. Physiol. 213:740-749(2007). RN [8] RP TISSUE SPECIFICITY, AND POSSIBLE FUNCTION IN PROSTATE CANCER PROGRESSION. RX PubMed=17885682; DOI=10.1172/jci30710; RA Zhang J., Park S.I., Artime M.C., Summy J.M., Shah A.N., Bomser J.A., RA Dorfleutner A., Flynn D.C., Gallick G.E.; RT "AFAP-110 is overexpressed in prostate cancer and contributes to RT tumorigenic growth by regulating focal contacts."; RL J. Clin. Invest. 117:2962-2973(2007). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-282; SER-283; SER-664; RP SER-665; SER-668; SER-679 AND SER-687, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548 AND SER-668, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-668, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [12] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-668, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-668, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Can cross-link actin filaments into both network and bundle CC structures (By similarity). May modulate changes in actin filament CC integrity and induce lamellipodia formation. May function as an adapter CC molecule that links other proteins, such as SRC and PKC to the actin CC cytoskeleton. Seems to play a role in the development and progression CC of prostate adenocarcinoma by regulating cell-matrix adhesions and CC migration in the cancer cells. {ECO:0000250, CC ECO:0000269|PubMed:15485829}. CC -!- SUBUNIT: Monomer and homomultimer. Interacts via its C-terminus with F- CC actin; probably involving AFAP1 multimers (By similarity). Interacts CC with activated SRC SH3-SH2 domains. Interacts via its PH 1 domain with CC PRKCA, PRKCB and PRKCI (By similarity). {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, stress fiber CC {ECO:0000269|PubMed:15485829}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8N556-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8N556-2; Sequence=VSP_044838; CC -!- TISSUE SPECIFICITY: Low expression in normal breast epithelial cell CC line MCF-10A and in tumorigenic breast cancer cell lines MCF-7, T-47D CC and ZR-75-1. Highly expressed in the invasive breast cancer cell lines CC MDA-MB-231 and MDA-MB-435. Overexpressed in prostate carcinoma. CC {ECO:0000269|PubMed:17520695, ECO:0000269|PubMed:17885682}. CC -!- PTM: Phosphorylated on tyrosine residues by SRC. CC {ECO:0000269|PubMed:15485829}. CC -!- MISCELLANEOUS: Knockdown in MDA-MB-231 cells resulted in loss of actin CC stress fibers, decreased adhesion and spreading on fibronectin. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF188700; AAG17055.1; -; mRNA. DR EMBL; AK290807; BAF83496.1; -; mRNA. DR EMBL; AK297631; BAG60004.1; -; mRNA. DR EMBL; AC004169; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC097381; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC112254; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC141931; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC144451; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032777; AAH32777.1; -; mRNA. DR EMBL; AB209676; BAD92913.1; -; mRNA. DR CCDS; CCDS3397.1; -. [Q8N556-1] DR CCDS; CCDS47010.1; -. [Q8N556-2] DR RefSeq; NP_001128119.1; NM_001134647.2. [Q8N556-2] DR RefSeq; NP_001358019.1; NM_001371090.1. [Q8N556-1] DR RefSeq; NP_001358020.1; NM_001371091.1. [Q8N556-1] DR RefSeq; NP_940997.1; NM_198595.3. [Q8N556-1] DR RefSeq; XP_011511846.1; XM_011513544.4. [Q8N556-2] DR RefSeq; XP_054206664.1; XM_054350689.1. [Q8N556-2] DR AlphaFoldDB; Q8N556; -. DR SMR; Q8N556; -. DR BioGRID; 121895; 78. DR FunCoup; Q8N556; 678. DR IntAct; Q8N556; 46. DR STRING; 9606.ENSP00000410689; -. DR GlyGen; Q8N556; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8N556; -. DR PhosphoSitePlus; Q8N556; -. DR BioMuta; AFAP1; -. DR DMDM; 166919564; -. DR jPOST; Q8N556; -. DR MassIVE; Q8N556; -. DR PeptideAtlas; Q8N556; -. DR ProteomicsDB; 19745; -. DR ProteomicsDB; 72004; -. [Q8N556-1] DR Pumba; Q8N556; -. DR Antibodypedia; 2882; 517 antibodies from 32 providers. DR DNASU; 60312; -. DR Ensembl; ENST00000358461.6; ENSP00000351245.2; ENSG00000196526.12. [Q8N556-1] DR Ensembl; ENST00000360265.9; ENSP00000353402.4; ENSG00000196526.12. [Q8N556-1] DR Ensembl; ENST00000382543.4; ENSP00000371983.3; ENSG00000196526.12. [Q8N556-2] DR Ensembl; ENST00000420658.6; ENSP00000410689.1; ENSG00000196526.12. [Q8N556-2] DR GeneID; 60312; -. DR KEGG; hsa:60312; -. DR MANE-Select; ENST00000420658.6; ENSP00000410689.1; NM_001134647.2; NP_001128119.1. [Q8N556-2] DR UCSC; uc003gkg.2; human. [Q8N556-1] DR AGR; HGNC:24017; -. DR ClinPGx; PA162375733; -. DR CTD; 60312; -. DR DisGeNET; 60312; -. DR GeneCards; AFAP1; -. DR HGNC; HGNC:24017; AFAP1. DR HPA; ENSG00000196526; Low tissue specificity. DR MalaCards; AFAP1; -. DR MIM; 608252; gene. DR OpenTargets; ENSG00000196526; -. DR VEuPathDB; HostDB:ENSG00000196526; -. DR eggNOG; ENOG502QQI1; Eukaryota. DR GeneTree; ENSGT00950000183067; -. DR HOGENOM; CLU_014418_2_0_1; -. DR InParanoid; Q8N556; -. DR OMA; THMASIP; -. DR OrthoDB; 5970758at2759; -. DR PAN-GO; Q8N556; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8N556; -. DR PathwayCommons; Q8N556; -. DR SignaLink; Q8N556; -. DR SIGNOR; Q8N556; -. DR Agora; ENSG00000196526; -. DR BioGRID-ORCS; 60312; 9 hits in 1141 CRISPR screens. DR ChiTaRS; AFAP1; human. DR GeneWiki; AFAP1; -. DR GenomeRNAi; 60312; -. DR Pharos; Q8N556; Tbio. DR PRO; PR:Q8N556; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q8N556; protein. DR Bgee; ENSG00000196526; Expressed in stromal cell of endometrium and 125 other cell types or tissues. DR ExpressionAtlas; Q8N556; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0005884; C:actin filament; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005925; C:focal adhesion; IDA:HPA. DR GO; GO:0001725; C:stress fiber; IEA:UniProtKB-SubCell. DR GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW. DR GO; GO:0009966; P:regulation of signal transduction; IBA:GO_Central. DR CDD; cd13306; PH1_AFAP; 1. DR CDD; cd13307; PH2_AFAP; 1. DR FunFam; 2.30.29.30:FF:000122; Actin filament associated protein 1; 1. DR FunFam; 2.30.29.30:FF:000020; Actin filament-associated protein 1-like 2 isoform 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 2. DR InterPro; IPR030113; AFAP. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR PANTHER; PTHR14338:SF8; ACTIN FILAMENT-ASSOCIATED PROTEIN 1; 1. DR PANTHER; PTHR14338; ACTIN FILAMENT-ASSOCIATED PROTEIN 1 FAMILY MEMBER; 1. DR Pfam; PF00169; PH; 2. DR SMART; SM00233; PH; 2. DR SUPFAM; SSF50729; PH domain-like; 2. DR PROSITE; PS50003; PH_DOMAIN; 2. PE 1: Evidence at protein level; KW Acetylation; Actin-binding; Alternative splicing; Coiled coil; Cytoplasm; KW Cytoskeleton; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT CHAIN 1..730 FT /note="Actin filament-associated protein 1" FT /id="PRO_0000317658" FT DOMAIN 153..249 FT /note="PH 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 347..441 FT /note="PH 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT REGION 47..91 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 119..140 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 252..292 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 512..537 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 594..637 FT /note="Interaction with F-actin" FT /evidence="ECO:0000250" FT COILED 557..648 FT /evidence="ECO:0000255" FT MOTIF 71..74 FT /note="SH3-binding" FT /evidence="ECO:0000250" FT MOTIF 94..97 FT /note="SH2-binding 1" FT /evidence="ECO:0000250" FT MOTIF 451..456 FT /note="SH2-binding 2" FT /evidence="ECO:0000250" FT COMPBIAS 60..85 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 268..283 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 282 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 283 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 548 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 665 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 668 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 675 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q80YS6" FT MOD_RES 679 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 687 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT VAR_SEQ 510 FT /note="S -> SWEPEDGFPASCSRGLGEEVLYDNAGLYDNLPPPHIFARYSPADRKA FT SRLSADKLSSNHYKYPASAQSVTNTSSVGRASLGLNSQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044838" FT VARIANT 403 FT /note="S -> C (in dbSNP:rs28406288)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334" FT /id="VAR_038578" FT VARIANT 518 FT /note="V -> M (in dbSNP:rs41264705)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_038579" FT MUTAGEN 71 FT /note="P->A: Decreased tyrosine phosphorylation." FT /evidence="ECO:0000269|PubMed:15485829" FT MUTAGEN 77 FT /note="P->A: No effect on tyrosine phosphorylation." FT /evidence="ECO:0000269|PubMed:15485829" FT MUTAGEN 93 FT /note="Y->F: Reduces phosphorylation and phosphorylation of FT SRC at Y-416; when associated with F-94; F-125; F-451 and FT F-453." FT /evidence="ECO:0000269|PubMed:15485829" FT MUTAGEN 94 FT /note="Y->F: Reduces phosphorylation and phosphorylation of FT SRC at Y-416; when associated with F-93; F-125; F-451 and FT F-453." FT /evidence="ECO:0000269|PubMed:15485829" FT MUTAGEN 125 FT /note="Y->F: Reduces phosphorylation and phosphorylation of FT SRC at Y-416; when associated with F-93; F-94; F-451 and F- FT 453." FT /evidence="ECO:0000269|PubMed:15485829" FT MUTAGEN 451 FT /note="Y->F: Reduces phosphorylation and phosphorylation of FT SRC at Y-416; when associated with F-93; F-94; F-125 and F- FT 453." FT /evidence="ECO:0000269|PubMed:15485829" FT MUTAGEN 453 FT /note="Y->F: Reduces phosphorylation and phosphorylation of FT SRC at Y-416; when associated with F-93; F-94; F-125 and F- FT 451." FT /evidence="ECO:0000269|PubMed:15485829" FT CONFLICT 197 FT /note="P -> L (in Ref. 1; AAG17055)" FT /evidence="ECO:0000305" FT CONFLICT 223 FT /note="G -> D (in Ref. 1; AAG17055)" FT /evidence="ECO:0000305" FT CONFLICT 238 FT /note="E -> G (in Ref. 1; AAG17055)" FT /evidence="ECO:0000305" FT CONFLICT 465 FT /note="T -> A (in Ref. 2; BAF83496)" FT /evidence="ECO:0000305" FT CONFLICT Q8N556-2:561 FT /note="A -> V (in Ref. 2; BAG60004)" FT /evidence="ECO:0000305" SQ SEQUENCE 730 AA; 80725 MW; 4E916BB4F82F5547 CRC64; MEELIVELRL FLELLDHEYL TSTVREKKAV ITNILLRIQS SKGFDVKDHA QKQETANSLP APPQMPLPEI PQPWLPPDSG PPPLPTSSLP EGYYEEAVPL SPGKAPEYIT SNYDSDAMSS SYESYDEEEE DGKGKKTRHQ WPSEEASMDL VKDAKICAFL LRKKRFGQWT KLLCVIKDTK LLCYKSSKDQ QPQMELPLQG CNITYIPKDS KKKKHELKIT QQGTDPLVLA VQSKEQAEQW LKVIKEAYSG CSGPVDSECP PPPSSPVHKA ELEKKLSSER PSSDGEGVVE NGITTCNGKE QVKRKKSSKS EAKGTVSKVT GKKITKIISL GKKKPSTDEQ TSSAEEDVPT CGYLNVLSNS RWRERWCRVK DNKLIFHKDR TDLKTHIVSI PLRGCEVIPG LDSKHPLTFR LLRNGQEVAV LEASSSEDMG RWIGILLAET GSSTDPEALH YDYIDVEMSA SVIQTAKQTF CFMNRRVISA NPYLGGTSNG YAHPSGTALH YDDVPCINGS LKGKKPPVAS NGVTGKGKTL SSQPKKADPA AVVKRTGSNA AQYKYGKNRV EADAKRLQTK EEELLKRKEA LRNRLAQLRK ERKDLRAAIE VNAGRKPQAI LEEKLKQLEE ECRQKEAERV SLELELTEVK ESLKKALAGG VTLGLAIEPK SGTSSPQSPV FRHRTLENSP ISSCDTSDTE GPVPVNSAAV LKKSQAAPGS SPCRGHVLRK AKEWELKNGT // ID AKT1_HUMAN Reviewed; 480 AA. AC P31749; B2RAM5; B7Z5R1; Q9BWB6; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 2. DT 28-JAN-2026, entry version 272. DE RecName: Full=RAC-alpha serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; DE AltName: Full=Protein kinase B; DE Short=PKB; DE AltName: Full=Protein kinase B alpha; DE Short=PKB alpha; DE AltName: Full=Proto-oncogene c-Akt; DE AltName: Full=RAC-PK-alpha; GN Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY. RX PubMed=1851997; DOI=10.1073/pnas.88.10.4171; RA Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.; RT "Molecular cloning and identification of a serine/threonine protein kinase RT of the second-messenger subfamily."; RL Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11508278; DOI=10.1007/s001250100577; RA Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B., RA Permutt M.A.; RT "Isolation and characterization of the human AKT1 gene, identification of RT 13 single nucleotide polymorphisms (SNPs), and their lack of association RT with Type II diabetes."; RL Diabetologia 44:910-913(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Adrenal gland; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC RP ACTIVITY, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin; RX PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x; RA Coffer P.J., Woodgett J.R.; RT "Molecular cloning and characterisation of a novel putative protein-serine RT kinase related to the cAMP-dependent and protein kinase C families."; RL Eur. J. Biochem. 201:475-481(1991). RN [8] RP ERRATUM OF PUBMED:1718748, AND SEQUENCE REVISION. RX PubMed=1533586; RA Coffer P.J., Woodgett J.R.; RL Eur. J. Biochem. 205:1217-1218(1992). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9829964; DOI=10.1074/jbc.273.49.32377; RA Du K., Montminy M.; RT "CREB is a regulatory target for the protein kinase Akt/PKB."; RL J. Biol. Chem. 273:32377-32379(1998). RN [10] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-473. RX PubMed=9736715; DOI=10.1073/pnas.95.19.11211; RA Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.; RT "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase RT kinase 3 and protein kinase B/AKT by the integrin-linked kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998). RN [11] RP MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND RP SER-473. RX PubMed=8978681; DOI=10.1002/j.1460-2075.1996.tb01045.x; RA Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P., RA Hemmings B.A.; RT "Mechanism of activation of protein kinase B by insulin and IGF-1."; RL EMBO J. 15:6541-6551(1996). RN [12] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1. RX PubMed=9512493; DOI=10.1042/bj3310299; RA Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.; RT "Activation of protein kinase B beta and gamma isoforms by insulin in vivo RT and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison RT with protein kinase B alpha."; RL Biochem. J. 331:299-308(1998). RN [13] RP FUNCTION IN PHOSPHORYLATION OF FOXO1. RX PubMed=10358075; DOI=10.1074/jbc.274.24.17179; RA Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.; RT "Phosphorylation of the transcription factor forkhead family member FKHR by RT protein kinase B."; RL J. Biol. Chem. 274:17179-17183(1999). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2. RX PubMed=10926925; DOI=10.1074/jbc.m001753200; RA Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.; RT "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis RT factor-induced protein kinase C-related kinase 2 (PRK2) cleavage."; RL J. Biol. Chem. 275:34451-34458(2000). RN [16] RP INTERACTION WITH MTCP1; TCL1A AND TCL1B. RX PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3; RA Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.; RT "The protooncogene TCL1 is an Akt kinase coactivator."; RL Mol. Cell 6:395-407(2000). RN [17] RP INTERACTION WITH TCL1A. RX PubMed=10716693; DOI=10.1073/pnas.97.7.3028; RA Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., RA Russo G., Tsichlis P., Croce C.M.; RT "Tcl1 enhances Akt kinase activity and mediates its nuclear RT translocation."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000). RN [18] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5. RX PubMed=11154276; DOI=10.1128/mcb.21.3.893-901.2001; RA Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.; RT "Akt phosphorylates and negatively regulates apoptosis signal-regulating RT kinase 1."; RL Mol. Cell. Biol. 21:893-901(2001). RN [19] RP INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION. RX PubMed=11598301; DOI=10.1126/science.1062030; RA Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., RA Hemmings B.A.; RT "Carboxyl-terminal modulator protein (CTMP), a negative regulator of RT PKB/Akt and v-Akt at the plasma membrane."; RL Science 294:374-380(2001). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TBC1D4. RX PubMed=11994271; DOI=10.1074/jbc.c200198200; RA Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., RA Lienhard G.E.; RT "A method to identify serine kinase substrates. Akt phosphorylates a novel RT adipocyte protein with a Rab GTPase-activating protein (GAP) domain."; RL J. Biol. Chem. 277:22115-22118(2002). RN [21] RP INTERACTION WITH CDKN1B, AND FUNCTION. RX PubMed=12042314; DOI=10.1074/jbc.m203668200; RA Fujita N., Sato S., Katayama K., Tsuruo T.; RT "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and RT cytoplasmic localization."; RL J. Biol. Chem. 277:28706-28713(2002). RN [22] RP PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474. RX PubMed=12149249; DOI=10.1074/jbc.m203387200; RA Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.; RT "Direct identification of tyrosine 474 as a regulatory phosphorylation site RT for the Akt protein kinase."; RL J. Biol. Chem. 277:38021-38028(2002). RN [23] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=12150915; DOI=10.1016/s1097-2765(02)00568-3; RA Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.; RT "Identification of the tuberous sclerosis complex-2 tumor suppressor gene RT product tuberin as a target of the phosphoinositide 3-kinase/akt pathway."; RL Mol. Cell 10:151-162(2002). RN [24] RP INTERACTION WITH TCL1A. RX PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002; RA Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., RA Roumestand C., Stern M.H., Noguchi M.; RT "Identification of Akt association and oligomerization domains of the Akt RT kinase coactivator TCL1."; RL Mol. Cell. Biol. 22:1513-1525(2002). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=12172553; DOI=10.1038/ncb839; RA Inoki K., Li Y., Zhu T., Wu J., Guan K.L.; RT "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR RT signalling."; RL Nat. Cell Biol. 4:648-657(2002). RN [26] RP INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473. RX PubMed=12244301; DOI=10.1038/nm759; RA Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., RA Arteaga C.L.; RT "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at RT threonine 157 and modulation of its cellular localization."; RL Nat. Med. 8:1145-1152(2002). RN [27] RP FUNCTION IN PARTICIPATION IN KIT SIGNALING. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [28] RP INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473. RX PubMed=14761976; DOI=10.1074/jbc.m312175200; RA Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.; RT "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt RT activity and mediates cellular invasion."; RL J. Biol. Chem. 279:16441-16451(2004). RN [29] RP PHOSPHORYLATION AT SER-473. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [30] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [31] RP PHOSPHORYLATION AT SER-473. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [32] RP INTERACTION WITH AKTIP. RX PubMed=14749367; DOI=10.1128/mcb.24.4.1493-1504.2004; RA Remy I., Michnick S.W.; RT "Regulation of apoptosis by the Ft1 protein, a new modulator of protein RT kinase B/Akt."; RL Mol. Cell. Biol. 24:1493-1504(2004). RN [33] RP INTERACTION WITH AGAP2. RX PubMed=15118108; DOI=10.1073/pnas.0400921101; RA Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.; RT "PIKE-A is amplified in human cancers and prevents apoptosis by up- RT regulating Akt."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004). RN [34] RP PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING. RX PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422; RA Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., RA Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., RA Serve H.; RT "Constitutive activation of Akt by Flt3 internal tandem duplications is RT necessary for increased survival, proliferation, and myeloid RT transformation."; RL Cancer Res. 65:9643-9650(2005). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001; RA Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K., RA Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.; RT "Akt/PKB regulates actin organization and cell motility via Girdin/APE."; RL Dev. Cell 9:389-402(2005). RN [36] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15861136; DOI=10.1038/sj.emboj.7600648; RA Cartlidge R.A., Knebel A., Peggie M., Alexandrov A., Phizicky E.M., RA Cohen P.; RT "The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK RT in vitro and in cells."; RL EMBO J. 24:1696-1705(2005). RN [37] RP PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [38] RP PHOSPHORYLATION AT SER-473. RX PubMed=17013611; DOI=10.1007/s00401-006-0128-y; RA Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E., RA Simon M., Knobbe C., Bluemcke I., Becker A.J.; RT "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene RT mutations in epilepsy-associated Taylor-type focal cortical dysplasias."; RL Acta Neuropathol. 112:715-725(2006). RN [39] RP INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [40] RP FUNCTION, AND INTERACTION WITH RARA. RX PubMed=16417524; DOI=10.1042/bj20051794; RA Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., RA Brown P.H., Kurie J.M.; RT "Akt phosphorylates and suppresses the transactivation of retinoic acid RT receptor alpha."; RL Biochem. J. 395:653-662(2006). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [42] RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=16540465; DOI=10.1074/jbc.m601384200; RA Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.; RT "Kinetic mechanism of AKT/PKB enzyme family."; RL J. Biol. Chem. 281:13949-13956(2006). RN [43] RP FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=16982699; DOI=10.1128/mcb.00201-06; RA Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., RA Hemmings B.A., Fernandez A., Lamb N.J.; RT "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle RT exit through p21 binding."; RL Mol. Cell. Biol. 26:8267-8280(2006). RN [44] RP INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17932490; DOI=10.1038/sj.emboj.7601872; RA Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N., RA Rubin M.A., Yelick P.C., Freeman M.R.; RT "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct RT inhibitors of Akt1."; RL EMBO J. 26:4523-4534(2007). RN [45] RP FUNCTION, AND INTERACTION WITH STK4/MST1. RX PubMed=17726016; DOI=10.1074/jbc.m704542200; RA Jang S.W., Yang S.J., Srinivasan S., Ye K.; RT "Akt phosphorylates MstI and prevents its proteolytic activation, blocking RT FOXO3 phosphorylation and nuclear translocation."; RL J. Biol. Chem. 282:30836-30844(2007). RN [46] RP FUNCTION IN PHOSPHORYLATION OF PROHIBITIN. RX PubMed=18507042; RA Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.; RT "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is RT an Akt substrate both in vitro and in cells."; RL Anticancer Res. 28:957-963(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP UBIQUITINATION BY TTC3. RX PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007; RA Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N., RA Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., RA Obata T., Noguchi M.; RT "The E3 ligase TTC3 facilitates ubiquitination and degradation of RT phosphorylated Akt."; RL Dev. Cell 17:800-810(2009). RN [49] RP FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2. RX PubMed=19592491; DOI=10.1074/jbc.m109.026237; RA Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.; RT "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle RT and cell death in neurons."; RL J. Biol. Chem. 284:24512-24525(2009). RN [50] RP FUNCTION. RX PubMed=19934221; DOI=10.1242/jcs.053728; RA Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.; RT "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin RT dynamics and thereby regulate cell migration."; RL J. Cell Sci. 122:4535-4546(2009). RN [51] RP UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, RP AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17. RX PubMed=19713527; DOI=10.1126/science.1175065; RA Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B., RA Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.; RT "The E3 ligase TRAF6 regulates Akt ubiquitination and activation."; RL Science 325:1134-1138(2009). RN [52] RP FUNCTION, AND INTERACTION WITH STK3/MST2. RX PubMed=20086174; DOI=10.1158/0008-5472.can-09-3147; RA Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.; RT "Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, RT Raf-1, and Akt."; RL Cancer Res. 70:1195-1203(2010). RN [53] RP RETRACTED PAPER. RX PubMed=19940129; DOI=10.1074/jbc.m109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RT "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic RT signaling through phosphorylation of threonine 120."; RL J. Biol. Chem. 285:3815-3824(2010). RN [54] RP RETRACTION NOTICE OF PUBMED:19940129. RX PubMed=27825096; DOI=10.1074/jbc.a109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RL J. Biol. Chem. 291:22858-22858(2016). RN [55] RP FUNCTION, AND INTERACTION WITH CLK2. RX PubMed=20682768; DOI=10.1074/jbc.m110.122044; RA Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S., RA Jeong M., Jin Y.W.; RT "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls RT cell survival after ionizing radiation."; RL J. Biol. Chem. 285:31157-31163(2010). RN [56] RP FUNCTION IN PHOSPHORYLATION OF PALLD. RX PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031; RA Chin Y.R., Toker A.; RT "The actin-bundling protein palladin is an Akt1-specific substrate that RT regulates breast cancer cell migration."; RL Mol. Cell 38:333-344(2010). RN [57] RP RETRACTED PAPER. RX PubMed=20231902; DOI=10.1371/journal.pone.0009616; RA Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.; RT "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1- RT Akt pathway."; RL PLoS ONE 5:E9616-E9616(2010). RN [58] RP CAUTION, AND RETRACTION NOTICE OF PUBMED:20231902. RX PubMed=37490513; DOI=10.1371/journal.pone.0289329; RG PLOS ONE Editors; RT "Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by RT the IGF1-Akt Pathway."; RL PLoS ONE 18:e0289329-e0289329(2023). RN [59] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND RP SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE RP SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [60] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [61] RP INTERACTION WITH TRIM13, AND UBIQUITINATION. RX PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001; RA Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., RA Kim H.S., Jeong M., An S., Jin Y.W.; RT "Ret finger protein 2 enhances ionizing radiation-induced apoptosis via RT degradation of AKT and MDM2."; RL Eur. J. Cell Biol. 90:420-431(2011). RN [62] RP INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION. RX PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007; RA Rodgers J.T., Vogel R.O., Puigserver P.; RT "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A RT phosphatase holoenzyme complex on Akt."; RL Mol. Cell 41:471-479(2011). RN [63] RP INTERACTION WITH FAM168A. RX PubMed=23251525; DOI=10.1371/journal.pone.0051413; RA Peng B., Gu Y., Xiong Y., Zheng G., He Z.; RT "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as RT mediators of TCRP1-associated resistance to cisplatin in oral squamous cell RT carcinoma."; RL PLoS ONE 7:E51413-E51413(2012). RN [64] RP PROTEOLYTIC CLEAVAGE. RX PubMed=23152800; DOI=10.1371/journal.pone.0048770; RA Sen T., Sen N., Noordhuis M.G., Ravi R., Wu T.C., Ha P.K., Sidransky D., RA Hoque M.O.; RT "OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function."; RL PLoS ONE 7:e48770-e48770(2012). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [66] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [67] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [68] RP REVIEW ON FUNCTION. RX PubMed=11882383; DOI=10.1016/s0898-6568(01)00271-6; RA Nicholson K.M., Anderson N.G.; RT "The protein kinase B/Akt signalling pathway in human malignancy."; RL Cell. Signal. 14:381-395(2002). RN [69] RP PHOSPHORYLATION AT SER-473. RX PubMed=20978158; DOI=10.1158/1535-7163.mct-10-0730; RA Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K., RA Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S., Sasaki R., RA Mizukami T.; RT "A novel human dynactin-associated protein, dynAP, promotes activation of RT Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of RT human cancer cells."; RL Mol. Cancer Ther. 9:2934-2942(2010). RN [70] RP REVIEW ON FUNCTION. RX PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004; RA Hers I., Vincent E.E., Tavare J.M.; RT "Akt signalling in health and disease."; RL Cell. Signal. 23:1515-1527(2011). RN [71] RP REVIEW ON FUNCTION. RX PubMed=21432781; DOI=10.14670/hh-26.651; RA Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.; RT "Akt1 and Akt2: differentiating the aktion."; RL Histol. Histopathol. 26:651-662(2011). RN [72] RP PHOSPHORYLATION AT THR-308 AND SER-473. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [73] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT RP LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20. RX PubMed=21775285; DOI=10.1126/scisignal.2001465; RA Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., RA Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.; RT "The deacetylase SIRT1 promotes membrane localization and activation of Akt RT and PDK1 during tumorigenesis and cardiac hypertrophy."; RL Sci. Signal. 4:RA46-RA46(2011). RN [74] RP UBIQUITINATION AT LYS-284. RX PubMed=22410793; DOI=10.1038/cr.2012.38; RA Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K., Kim J., RA An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y., Jin Y.W., RA Lee J.H., An S.; RT "Akt is negatively regulated by the MULAN E3 ligase."; RL Cell Res. 22:873-885(2012). RN [75] RP GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR RP LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312. RX PubMed=22629392; DOI=10.1371/journal.pone.0037427; RA Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C., RA Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.; RT "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates RT Akt signaling."; RL PLoS ONE 7:E37427-E37427(2012). RN [76] RP PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1. RX PubMed=23799035; DOI=10.1371/journal.pone.0065679; RA Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K., RA Mao Z.B.; RT "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell RT apoptosis, and suppresses tumor growth of bladder cancer by directly RT dephosphorylating Akt at Ser473 site."; RL PLoS ONE 8:E65679-E65679(2013). RN [77] RP FUNCTION. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [78] RP INTERACTION WITH SYAP1. RX PubMed=23300339; DOI=10.1126/scisignal.2003295; RA Yao Y., Suraokar M., Darnay B.G., Hollier B.G., Shaiken T.E., Asano T., RA Chen C.H., Chang B.H., Lu Y., Mills G.B., Sarbassov D., Mani S.A., RA Abbruzzese J.L., Reddy S.A.; RT "BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress RT expression of FoxC2 and stimulate adipocyte differentiation."; RL Sci. Signal. 6:RA2-RA2(2013). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP PHOSPHORYLATION AT SER-477 AND THR-479, AND MUTAGENESIS OF 76-ARG--LEU-78 RP AND 273-ARG--LEU-275. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26440888; DOI=10.1016/j.celrep.2015.09.007; RA Seo G.J., Yang A., Tan B., Kim S., Liang Q., Choi Y., Yuan W., Feng P., RA Park H.S., Jung J.U.; RT "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway."; RL Cell Rep. 13:440-449(2015). RN [82] RP INTERACTION WITH KIF14. RX PubMed=24784001; DOI=10.1016/j.neo.2014.03.008; RA Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., RA Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E., Lum L., RA Corson T.W., Shay J.W.; RT "KIF14 promotes AKT phosphorylation and contributes to chemoresistance in RT triple-negative breast cancer."; RL Neoplasia 16:247-256(2014). RN [83] RP PHOSPHORYLATION AT SER-473, DEPHOSPHORYLATION, AND INTERACTION WITH PHLPP1 RP AND FKBP5. RX PubMed=28147277; DOI=10.1016/j.celrep.2017.01.009; RA Yu J., Qin B., Wu F., Qin S., Nowsheen S., Shan S., Zayas J., Pei H., RA Lou Z., Wang L.; RT "Regulation of serine-threonine kinase Akt activation by NAD+-dependent RT deacetylase SIRT7."; RL Cell Rep. 18:1229-1240(2017). RN [84] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29343641; DOI=10.1073/pnas.1705954115; RA Choppara S., Malonia S.K., Sankaran G., Green M.R., Santra M.K.; RT "Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:998-1003(2018). RN [85] RP FUNCTION. RX PubMed=30504268; DOI=10.15252/embj.201899435; RA Marchi S., Corricelli M., Branchini A., Vitto V.A.M., Missiroli S., RA Morciano G., Perrone M., Ferrarese M., Giorgi C., Pinotti M., Galluzzi L., RA Kroemer G., Pinton P.; RT "Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels RT and tumor growth."; RL EMBO J. 38:0-0(2019). RN [86] RP FUNCTION. RX PubMed=31204173; DOI=10.1016/j.devcel.2019.05.022; RA Walia V., Cuenca A., Vetter M., Insinna C., Perera S., Lu Q., Ritt D.A., RA Semler E., Specht S., Stauffer J., Morrison D.K., Lorentzen E., RA Westlake C.J.; RT "Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis."; RL Dev. Cell 50:229-246(2019). RN [87] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [88] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32322062; DOI=10.1038/s41586-020-2183-2; RA Xu D., Wang Z., Xia Y., Shao F., Xia W., Wei Y., Li X., Qian X., Lee J.H., RA Du L., Zheng Y., Lv G., Leu J.S., Wang H., Xing D., Liang T., Hung M.C., RA Lu Z.; RT "The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis."; RL Nature 580:530-535(2020). RN [89] RP INTERACTION WITH TMEM175, AND FUNCTION. RX PubMed=32228865; DOI=10.7554/elife.53430; RA Oh S., Paknejad N., Hite R.K.; RT "Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175."; RL Elife 9:0-0(2020). RN [90] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=33594058; DOI=10.1038/s41467-021-21206-3; RA Li T., Wang X., Ju E., da Silva S.R., Chen L., Zhang X., Wei S., Gao S.J.; RT "RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 RT for ubiquitination and degradation."; RL Nat. Commun. 12:1055-1055(2021). RN [91] RP INTERACTION WITH SLC9D1, PHOSPHORYLATION AT THR-308 AND SER-473, AND RP SUBCELLULAR LOCATION. RX PubMed=40285646; DOI=10.1002/advs.202504187; RA Li X., Han M., Zhu H., Pan Y., Su C., Liu Y., Liao Z., Zhang B., Chen X.; RT "m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by RT Facilitating the Membrane Translocation and Activation of AKT."; RL Adv. Sci. 12:e2504187-e2504187(2025). RN [92] RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, FUNCTION, INTERACTION WITH RP PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, MUTAGENESIS OF LYS-14; ARG-25 AND RP ARG-86, AND CHARACTERIZATION OF VARIANT CWS6 CYS-25. RX PubMed=12176338; DOI=10.1016/s0960-9822(02)00972-7; RA Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.; RT "High-resolution structure of the pleckstrin homology domain of protein RT kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate."; RL Curr. Biol. 12:1256-1262(2002). RN [93] RP X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, FUNCTION, AND INTERACTION RP WITH PTDINS(1,3,4,5)P4. RX PubMed=12964941; DOI=10.1042/bj20031229; RA Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R., RA Van Aalten D.M.; RT "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin RT homology domain of protein kinase B induces a conformational change."; RL Biochem. J. 375:531-538(2003). RN [94] {ECO:0007744|PDB:3CQU, ECO:0007744|PDB:3CQW} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034; RA Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J., Robinson S., RA Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E., Barbacci-Tobin E.G., RA Vincent P., Troutman M., Baker D., Rajamohan F., Kakar S., Clark T., RA Morris J.; RT "Synthesis and structure based optimization of novel Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 18:3359-3363(2008). RN [95] {ECO:0007744|PDB:3OCB} RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053; RA Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., RA Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T., RA Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.; RT "Discovery of pyrrolopyrimidine inhibitors of Akt."; RL Bioorg. Med. Chem. Lett. 20:5607-5612(2010). RN [96] {ECO:0007744|PDB:3MV5, ECO:0007744|PDB:3MVH} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=20481595; DOI=10.1021/jm1003842; RA Freeman-Cook K.D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., RA Bernardo V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., RA Knauth E., Lippa B., Luzzio M.J., Mansour M., Martinelli G., Marx M., RA Nelson K., Pandit J., Rajamohan F., Robinson S., Subramanyam C., Wei L., RA Wythes M., Morris J.; RT "Design of selective, ATP-competitive inhibitors of Akt."; RL J. Med. Chem. 53:4615-4622(2010). RN [97] {ECO:0007744|PDB:3O96} RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND. RX PubMed=20886116; DOI=10.1371/journal.pone.0012913; RA Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P., RA Brandhuber B.J.; RT "Crystal structure of human AKT1 with an allosteric inhibitor reveals a new RT mode of kinase inhibition."; RL PLoS ONE 5:E12913-E12913(2010). RN [98] {ECO:0007744|PDB:3QKK, ECO:0007744|PDB:3QKL} RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073; RA Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R., RA Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D., RA Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.; RT "Discovery and SAR of spirochromane Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 21:2410-2414(2011). RN [99] RP VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER RP LYS-17. RX PubMed=17611497; DOI=10.1038/nature05933; RA Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., RA Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., RA Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., RA Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., RA Thomas J.E.; RT "A transforming mutation in the pleckstrin homology domain of AKT1 in RT cancer."; RL Nature 448:439-444(2007). RN [100] RP CHARACTERIZATION OF VARIANT PROTEUSS LYS-17. RX PubMed=18954143; DOI=10.1021/bi801683k; RA Landgraf K.E., Pilling C., Falke J.J.; RT "Molecular mechanism of an oncogenic mutation that alters membrane RT targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH RT domain."; RL Biochemistry 47:12260-12269(2008). RN [101] RP VARIANT PROTEUSS LYS-17. RX PubMed=21793738; DOI=10.1056/nejmoa1104017; RA Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., RA Turner J., Cannons J.L., Bick D., Blakemore L., Blumhorst C., Brockmann K., RA Calder P., Cherman N., Deardorff M.A., Everman D.B., Golas G., RA Greenstein R.M., Kato B.M., Keppler-Noreuil K.M., Kuznetsov S.A., RA Miyamoto R.T., Newman K., Ng D., O'Brien K., Rothenberg S., RA Schwartzentruber D.J., Singhal V., Tirabosco R., Upton J., Wientroub S., RA Zackai E.H., Hoag K., Whitewood-Neal T., Robey P.G., Schwartzberg P.L., RA Darling T.N., Tosi L.L., Mullikin J.C., Biesecker L.G.; RT "A mosaic activating mutation in AKT1 associated with the Proteus RT syndrome."; RL N. Engl. J. Med. 365:611-619(2011). RN [102] RP VARIANTS CWS6 CYS-25 AND PRO-435. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). CC -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein CC kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate CC many processes including metabolism, proliferation, cell survival, CC growth and angiogenesis (PubMed:11882383, PubMed:15526160, CC PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). CC This is mediated through serine and/or threonine phosphorylation of a CC range of downstream substrates (PubMed:11882383, PubMed:15526160, CC PubMed:21432781, PubMed:21620960, PubMed:29343641, PubMed:31204173). CC Over 100 substrate candidates have been reported so far, but for most CC of them, no isoform specificity has been reported (PubMed:11882383, CC PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible CC of the regulation of glucose uptake by mediating insulin-induced CC translocation of the SLC2A4/GLUT4 glucose transporter to the cell CC surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' CC negatively modulates its phosphatase activity preventing CC dephosphorylation of the insulin receptor and the attenuation of CC insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers CC the binding of this effector to inhibitory 14-3-3 proteins, which is CC required for insulin-stimulated glucose transport (PubMed:11994271). CC AKT also regulates the storage of glucose in the form of glycogen by CC phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in CC inhibition of its kinase activity (By similarity). Phosphorylation of CC GSK3 isoforms by AKT is also thought to be one mechanism by which cell CC proliferation is driven (By similarity). AKT also regulates cell CC survival via the phosphorylation of MAP3K5 (apoptosis signal-related CC kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 CC kinase activity stimulated by oxidative stress and thereby prevents CC apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein CC synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby CC activating the mTORC1 signaling pathway, and leading to both CC phosphorylation of 4E-BP1 and in activation of RPS6KB1 CC (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling CC pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 CC (PubMed:31548394, PubMed:33594058). AKT plays a role as key modulator CC of the AKT-mTOR signaling pathway controlling the tempo of the process CC of newborn neurons integration during adult neurogenesis, including CC correct neuron positioning, dendritic development and synapse formation CC (By similarity). Part of a positive feedback loop of mTORC2 signaling CC by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 CC activation (By similarity). AKT is involved in the phosphorylation of CC members of the FOXO factors (Forkhead family of transcription factors), CC leading to binding of 14-3-3 proteins and cytoplasmic localization CC (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', CC 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are CC phosphorylated on equivalent sites (PubMed:10358075). AKT has an CC important role in the regulation of NF-kappa-B-dependent gene CC transcription and positively regulates the activity of CREB1 (cyclic CC AMP (cAMP)-response element binding protein) (PubMed:9829964). The CC phosphorylation of CREB1 induces the binding of accessory proteins that CC are necessary for the transcription of pro-survival genes such as BCL2 CC and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate CC lyase (ACLY), thereby potentially regulating ACLY activity and fatty CC acid synthesis (By similarity). Activates the 3B isoform of cyclic CC nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', CC resulting in reduced cyclic AMP levels and inhibition of lipolysis (By CC similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in CC increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating CC protein DLC1 is another substrate and its phosphorylation is implicated CC in the regulation cell proliferation and cell growth (By similarity). CC Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate CC the effects of various growth factors such as platelet-derived growth CC factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like CC growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates CC the antiapoptotic effects of IGF1 (By similarity). Essential for the CC SPATA13-mediated regulation of cell migration and adhesion assembly and CC disassembly (PubMed:19934221). May be involved in the regulation of the CC placental development (By similarity). Phosphorylates STK4/MST1 at CC 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, CC nuclear translocation, autophosphorylation and ability to phosphorylate CC FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and CC 'Thr-384' leading to inhibition of its: cleavage, kinase activity, CC autophosphorylation at Thr-180, binding to RASSF1 and nuclear CC translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its CC kinase activity towards SRSF2 and ACIN1 and promotes its nuclear CC translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and CC negatively regulates its activity (PubMed:10576742). Phosphorylation of CC BAD stimulates its pro-apoptotic activity (PubMed:10926925). CC Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the CC interaction of KAT6A with PML and negatively regulates its acetylation CC activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin CC (PALLD), modulating cytoskeletal organization and cell motility CC (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an CC important role in cell metabolism and proliferation (PubMed:18507042). CC Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces CC its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). CC These recent findings indicate that the AKT1 isoform has a more CC specific role in cell motility and proliferation (PubMed:16139227). CC Phosphorylates CLK2 thereby controlling cell survival to ionizing CC radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing CC the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an CC atypical protein kinase activity using GTP as donor (PubMed:32322062). CC Also acts as an activator of TMEM175 potassium channel activity in CC response to growth factors: forms the lysoK(GF) complex together with CC TMEM175 and acts by promoting TMEM175 channel activation, independently CC of its protein kinase activity (PubMed:32228865). Acts as a regulator CC of mitochondrial calcium uptake by mediating phosphorylation of MICU1 CC in the mitochondrial intermembrane space, impairing MICU1 maturation CC (PubMed:30504268). Acts as an inhibitor of tRNA methylation by CC mediating phosphorylation of the N-terminus of METTL1, thereby CC inhibiting METTL1 methyltransferase activity (PubMed:15861136). In CC response to LPAR1 receptor pathway activation, phosphorylates CC Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which CC induces WDR44 binding to Rab11, thereby switching Rab11 vesicular CC function from preciliary trafficking to endocytic recycling CC (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, CC ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, CC ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, CC ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:30504268, CC ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, CC ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, CC ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, CC ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:1851997, ECO:0000269|PubMed:26440888, CC ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:1851997}; CC -!- ACTIVITY REGULATION: Three specific sites, one in the kinase domain CC (Thr-308) and the two other ones in the C-terminal regulatory region CC (Ser-473 and Tyr-474), need to be phosphorylated for its full CC activation (PubMed:15262962, PubMed:20481595, PubMed:21392984, CC PubMed:9512493, PubMed:9736715). Inhibited by pyrrolopyrimidine CC inhibitors like aniline triazole and spiroindoline (PubMed:18456494, CC PubMed:20810279). {ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20810279, ECO:0000269|PubMed:21392984, CC ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715, CC ECO:0000305|PubMed:20810279}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.8 uM for ATP (for purified and in vitro activated AKT1) CC {ECO:0000269|PubMed:16540465}; CC KM=0.5 uM for peptide substrate (for purified and in vitro activated CC AKT1) {ECO:0000269|PubMed:16540465}; CC KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and CC immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465}; CC KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 CC expressed and immunoprecipitated from Rat-1 cells) CC {ECO:0000269|PubMed:16540465}; CC -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20 CC (By similarity). Interacts (via the C-terminus) with CCDC88A (via its CC C-terminus). Interacts with GRB10; the interaction leads to GRB10 CC phosphorylation thus promoting YWHAE-binding (By similarity). Interacts CC with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence CC of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) CC with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction CC phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle CC progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, CC PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts CC with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. CC Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to CC its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts CC (via the C-terminus) with THEM4 (via its C-terminus). Interacts with CC and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). CC Interacts with KIF14; the interaction is detected in the plasma CC membrane upon INS stimulation and promotes AKT1 phosphorylation CC (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT CC signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 CC (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts CC with SYAP1 (via phosphorylated form and BSD domain); this interaction CC is enhanced in a mTORC2-mediated manner in response to epidermal growth CC factor (EGF) stimulation and activates AKT1 (PubMed:23300339). CC Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; CC promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing CC dephosphorylation and subsequent activation of Akt/AKT1 CC (PubMed:28147277). Interacts with TMEM175; leading to formation of the CC lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of CC the cGAS-STING pathway by mediating phosphorylation of CGAS during CC mitosis, leading to its inhibition (PubMed:26440888). Interacts with CC SLC9D1 (when phosphorylated); the interaction facilitates the membrane CC translocation and activation of AKT1 (PubMed:40285646). CC {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10716693, CC ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:10983986, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11598301, CC ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:12042314, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12244301, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:14749367, CC ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16417524, CC ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392, CC ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23300339, CC ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:24784001, CC ECO:0000269|PubMed:26440888, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:40285646}. CC -!- INTERACTION: CC P31749; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-296087, EBI-10173507; CC P31749; P31749: AKT1; NbExp=4; IntAct=EBI-296087, EBI-296087; CC P31749; P31751: AKT2; NbExp=3; IntAct=EBI-296087, EBI-296058; CC P31749; Q86V81: ALYREF; NbExp=5; IntAct=EBI-296087, EBI-347640; CC P31749; P32121: ARRB2; NbExp=5; IntAct=EBI-296087, EBI-714559; CC P31749; Q8IXJ9: ASXL1; NbExp=3; IntAct=EBI-296087, EBI-1646500; CC P31749; Q13315: ATM; NbExp=5; IntAct=EBI-296087, EBI-495465; CC P31749; P54253: ATXN1; NbExp=6; IntAct=EBI-296087, EBI-930964; CC P31749; Q99728: BARD1; NbExp=3; IntAct=EBI-296087, EBI-473181; CC P31749; O95999: BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922; CC P31749; Q6W2J9: BCOR; NbExp=3; IntAct=EBI-296087, EBI-950027; CC P31749; P15056: BRAF; NbExp=4; IntAct=EBI-296087, EBI-365980; CC P31749; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-296087, EBI-935503; CC P31749; P62324: BTG1; NbExp=4; IntAct=EBI-296087, EBI-742279; CC P31749; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-296087, EBI-1383687; CC P31749; P20248: CCNA2; NbExp=2; IntAct=EBI-296087, EBI-457097; CC P31749; P30281: CCND3; NbExp=3; IntAct=EBI-296087, EBI-375013; CC P31749; Q16543: CDC37; NbExp=5; IntAct=EBI-296087, EBI-295634; CC P31749; P46527: CDKN1B; NbExp=4; IntAct=EBI-296087, EBI-519280; CC P31749; Q8TAP6: CEP76; NbExp=4; IntAct=EBI-296087, EBI-742887; CC P31749; Q92793: CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215; CC P31749; Q15438: CYTH1; NbExp=3; IntAct=EBI-296087, EBI-997830; CC P31749; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-296087, EBI-742054; CC P31749; P26358: DNMT1; NbExp=6; IntAct=EBI-296087, EBI-719459; CC P31749; P00533: EGFR; NbExp=4; IntAct=EBI-296087, EBI-297353; CC P31749; Q9UJM3: ERRFI1; NbExp=3; IntAct=EBI-296087, EBI-2941912; CC P31749; Q15910: EZH2; NbExp=3; IntAct=EBI-296087, EBI-530054; CC P31749; Q1W6H9: FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563; CC P31749; Q00597: FANCC; NbExp=4; IntAct=EBI-296087, EBI-81625; CC P31749; Q9HB96: FANCE; NbExp=4; IntAct=EBI-296087, EBI-396803; CC P31749; Q969H0: FBXW7; NbExp=5; IntAct=EBI-296087, EBI-359574; CC P31749; Q12778: FOXO1; NbExp=2; IntAct=EBI-296087, EBI-1108782; CC P31749; O43524: FOXO3; NbExp=4; IntAct=EBI-296087, EBI-1644164; CC P31749; P06241: FYN; NbExp=3; IntAct=EBI-296087, EBI-515315; CC P31749; P22466: GAL; NbExp=3; IntAct=EBI-296087, EBI-6624768; CC P31749; P49841: GSK3B; NbExp=5; IntAct=EBI-296087, EBI-373586; CC P31749; P68431: H3C12; NbExp=4; IntAct=EBI-296087, EBI-79722; CC P31749; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-296087, EBI-25830912; CC P31749; P08238: HSP90AB1; NbExp=3; IntAct=EBI-296087, EBI-352572; CC P31749; P42858: HTT; NbExp=3; IntAct=EBI-296087, EBI-466029; CC P31749; P08476: INHBA; NbExp=3; IntAct=EBI-296087, EBI-8077140; CC P31749; Q8WZ60: KLHL6; NbExp=3; IntAct=EBI-296087, EBI-6426464; CC P31749; Q5S007: LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863; CC P31749; Q99683: MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; CC P31749; O15264: MAPK13; NbExp=4; IntAct=EBI-296087, EBI-2116951; CC P31749; Q8TD08: MAPK15; NbExp=3; IntAct=EBI-296087, EBI-1383794; CC P31749; Q9BPZ7: MAPKAP1; NbExp=3; IntAct=EBI-296087, EBI-749938; CC P31749; P10636: MAPT; NbExp=2; IntAct=EBI-296087, EBI-366182; CC P31749; Q07820: MCL1; NbExp=3; IntAct=EBI-296087, EBI-1003422; CC P31749; Q00987: MDM2; NbExp=6; IntAct=EBI-296087, EBI-389668; CC P31749; Q14696: MESD; NbExp=3; IntAct=EBI-296087, EBI-6165891; CC P31749; P42345: MTOR; NbExp=6; IntAct=EBI-296087, EBI-359260; CC P31749; P04198: MYCN; NbExp=3; IntAct=EBI-296087, EBI-878369; CC P31749; P25963: NFKBIA; NbExp=3; IntAct=EBI-296087, EBI-307386; CC P31749; Q9BZQ8: NIBAN1; NbExp=2; IntAct=EBI-296087, EBI-6916466; CC P31749; P04150: NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507; CC P31749; O15530: PDPK1; NbExp=5; IntAct=EBI-296087, EBI-717097; CC P31749; Q96S96: PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667; CC P31749; P19174: PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387; CC P31749; Q03181: PPARD; NbExp=3; IntAct=EBI-296087, EBI-6426768; CC P31749; O60437: PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; CC P31749; P62136: PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253; CC P31749; P67775: PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311; CC P31749; P30153: PPP2R1A; NbExp=3; IntAct=EBI-296087, EBI-302388; CC P31749; P54646: PRKAA2; NbExp=3; IntAct=EBI-296087, EBI-1383852; CC P31749; P17612: PRKACA; NbExp=3; IntAct=EBI-296087, EBI-476586; CC P31749; Q05513: PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351; CC P31749; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-296087, EBI-743880; CC P31749; Q06124: PTPN11; NbExp=3; IntAct=EBI-296087, EBI-297779; CC P31749; P04049: RAF1; NbExp=3; IntAct=EBI-296087, EBI-365996; CC P31749; P10276: RARA; NbExp=3; IntAct=EBI-296087, EBI-413374; CC P31749; Q9NS23: RASSF1; NbExp=3; IntAct=EBI-296087, EBI-367363; CC P31749; Q6R327: RICTOR; NbExp=3; IntAct=EBI-296087, EBI-1387196; CC P31749; P15880: RPS2; NbExp=3; IntAct=EBI-296087, EBI-443446; CC P31749; P23443: RPS6KB1; NbExp=3; IntAct=EBI-296087, EBI-1775921; CC P31749; Q15047: SETDB1; NbExp=10; IntAct=EBI-296087, EBI-79691; CC P31749; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; CC P31749; Q13309: SKP2; NbExp=4; IntAct=EBI-296087, EBI-456291; CC P31749; Q13485: SMAD4; NbExp=6; IntAct=EBI-296087, EBI-347263; CC P31749; Q8N3U4: STAG2; NbExp=3; IntAct=EBI-296087, EBI-1057252; CC P31749; Q14849: STARD3; NbExp=3; IntAct=EBI-296087, EBI-9819324; CC P31749; Q13043: STK4; NbExp=13; IntAct=EBI-296087, EBI-367376; CC P31749; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-296087, EBI-15687717; CC P31749; P56279: TCL1A; NbExp=8; IntAct=EBI-296087, EBI-749995; CC P31749; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109; CC P31749; Q5T1C6: THEM4; NbExp=4; IntAct=EBI-296087, EBI-7684443; CC P31749; Q92547: TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302; CC P31749; P53804: TTC3; NbExp=4; IntAct=EBI-296087, EBI-2681313; CC P31749; P10599: TXN; NbExp=3; IntAct=EBI-296087, EBI-594644; CC P31749; P08670: VIM; NbExp=29; IntAct=EBI-296087, EBI-353844; CC P31749; Q6GPH4: XAF1; NbExp=4; IntAct=EBI-296087, EBI-2815120; CC P31749; P17028: ZNF24; NbExp=3; IntAct=EBI-296087, EBI-707773; CC P31749; P29067: Arrb2; Xeno; NbExp=2; IntAct=EBI-296087, EBI-1636616; CC P31749; P06762: Hmox1; Xeno; NbExp=2; IntAct=EBI-296087, EBI-7410266; CC P31749; Q83730: m005R; Xeno; NbExp=3; IntAct=EBI-296087, EBI-6859930; CC P31749; P03165: X; Xeno; NbExp=3; IntAct=EBI-296087, EBI-7683985; CC P31749-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}. Nucleus CC {ECO:0000269|PubMed:20333297}. Cell membrane CC {ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:40285646}. CC Mitochondrion intermembrane space {ECO:0000250|UniProtKB:P31750}. CC Note=Nucleus after activation by integrin-linked protein kinase 1 CC (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. CC Phosphorylation on Tyr-176 by TNK2 results in its localization to the CC cell membrane where it is targeted for further phosphorylations on Thr- CC 308 and Ser-473 leading to its activation and the activated form CC translocates to the nucleus. Colocalizes with WDFY2 in intracellular CC vesicles (PubMed:16792529). Also localizes to mitochondrial CC intermembrane space in response to rapamycin treatment (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:16792529}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P31749-1; Sequence=Displayed; CC Name=2; CC IsoId=P31749-2; Sequence=VSP_056180; CC -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase CC from the normal to the malignant state (at protein level). Expressed in CC all human cell types so far analyzed. The Tyr-176 phosphorylated form CC shows a significant increase in expression in breast cancers during the CC progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma CC in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node CC metastatic (LNMM) stages. {ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- CC trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase CC alpha (PIK3CA) activity results in its targeting to the plasma membrane CC (PubMed:12176338, PubMed:12964941). PI(3,4,5)P3 is also required for CC phosphorylation at Thr-308 and subsequent activation (By similarity). CC The PH domain mediates interaction with TNK2 and Tyr-176 is also CC essential for this interaction (PubMed:20333297). CC {ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:12176338, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4. CC {ECO:0000269|PubMed:11598301}. CC -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating CC phosphorylation at Thr-308 via disrupting the interaction between AKT1 CC and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with CC phosphorylation at this site. {ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:17013611, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20978158, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for CC full activity (PubMed:12149249, PubMed:15047712, PubMed:15262962, CC PubMed:16266983, PubMed:18456494, PubMed:20481595, PubMed:20978158, CC PubMed:8978681, PubMed:9512493, PubMed:9736715). Phosphorylation of the CC activation loop at Thr-308 by PDPK1/PDK1 is a prerequisite for full CC activation (PubMed:9512493). Phosphorylation by mTORC2 in response to CC growth factors plays a key role in AKT1 activation: mTORC2 CC phosphorylates different sites depending on the context, such as Thr- CC 450, Ser-473, Ser-477 or Thr-479, thereby facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:15718470, CC PubMed:24670654). Phosphorylation at Ser-473 by mTORC2 promotes CC ubiquitination and degradation by the proteasome (By similarity). Also CC phosphorylated at Ser-477 and Thr-479 by CDK2, facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:24670654). CC Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to CC the anionic plasma membrane phospholipid PA (PubMed:20333297). This CC phosphorylated form localizes to the cell membrane, where it is CC targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and CC Ser-473 leading to its activation (PubMed:20333297). Phosphorylated at CC Thr-308 and Ser-473 by IKBKE and TBK1 (PubMed:21464307). Ser-473 CC phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE- CC A) (PubMed:14761976). Ser-473 phosphorylation is enhanced in focal CC cortical dysplasias with Taylor-type balloon cells (PubMed:17013611). CC Ser-473 phosphorylation is enhanced by signaling through activated FLT3 CC (PubMed:16266983). Ser-473 is dephosphorylated by PHLPP CC (PubMed:28147277). Dephosphorylated at Thr-308 and Ser-473 by PP2A CC phosphatase (PubMed:21329884). The phosphorylated form of PPP2R5B is CC required for bridging AKT1 with PP2A phosphatase (PubMed:21329884). CC Ser-473 is dephosphorylated by CPPED1, leading to termination of CC signaling (PubMed:23799035). AIM2 acts as an inhibitor of AKT1 by CC inhibiting phosphorylation Ser-473: AIM2 acts both by inhibiting the CC activity of PRKDC/DNA-PK kinase and promoting dephosphorylation by PP2A CC phosphatase (By similarity). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:12149249, ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, CC ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21329884, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked CC polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination CC is critical for phosphorylation and activation (PubMed:19713527). When CC ubiquitinated, it translocates to the plasma membrane, where it becomes CC phosphorylated (PubMed:20059950). When fully phosphorylated and CC translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination CC catalyzed by TTC3, leading to its degradation by the proteasome CC (PubMed:20059950). Also ubiquitinated by TRIM13 leading to its CC proteasomal degradation (PubMed:21333377). Phosphorylated, undergoes CC 'Lys-48'-linked polyubiquitination preferentially at Lys-284 catalyzed CC by MUL1, leading to its proteasomal degradation (PubMed:22410793). CC Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading CC to its degradation by the proteasome (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:19713527, CC ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:22410793}. CC -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases CC EP300 and KAT2B. Acetylation results in reduced phosphorylation and CC inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. CC SIRT1-mediated deacetylation relieves the inhibition. CC {ECO:0000269|PubMed:21775285}. CC -!- PTM: Cleavage by caspase-3/CASP3 (By similarity). Cleaved at the CC caspase-3 consensus site Asp-462 during apoptosis, resulting in down- CC regulation of the AKT signaling pathway and decreased cell survival CC (PubMed:23152800). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:23152800}. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:17611497}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- DISEASE: Note=Genetic variations in AKT1 may play a role in CC susceptibility to ovarian cancer. CC -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly variable, CC severe disorder of asymmetric and disproportionate overgrowth of body CC parts, connective tissue nevi, epidermal nevi, dysregulated adipose CC tissue, and vascular malformations. Many features of Proteus syndrome CC overlap with other overgrowth syndromes. {ECO:0000269|PubMed:18954143, CC ECO:0000269|PubMed:21793738}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:23246288}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. RAC subfamily. {ECO:0000305}. CC -!- CAUTION: PUBMED:20231902 has been retracted because there was evidence CC of data fabrication and/or falsification in multiple figure panels. CC {ECO:0000305|PubMed:20231902, ECO:0000305|PubMed:37490513}. CC -!- CAUTION: PUBMED:19940129 has been retracted because the same data were CC used to represent different experimental conditions. CC {ECO:0000305|PubMed:19940129, ECO:0000305|PubMed:27825096}. CC -!- CAUTION: In light of strong homologies in the primary amino acid CC sequence, the 3 AKT kinases were long surmised to play redundant and CC overlapping roles. More recent studies has brought into question the CC redundancy within AKT kinase isoforms and instead pointed to isoform CC specific functions in different cellular events and diseases. AKT1 is CC more specifically involved in cellular survival pathways, by inhibiting CC apoptotic processes; whereas AKT2 is more specific for the insulin CC receptor signaling pathway. Moreover, while AKT1 and AKT2 are often CC implicated in many aspects of cellular transformation, the 2 isoforms CC act in a complementary opposing manner. The role of AKT3 is less clear, CC though it appears to be predominantly expressed in brain. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/355/AKT1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63167; AAA36539.1; -; mRNA. DR EMBL; AF283830; AAL55732.1; -; Genomic_DNA. DR EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AK299310; BAH12997.1; -; mRNA. DR EMBL; AK314256; BAG36922.1; -; mRNA. DR EMBL; AB451242; BAG70056.1; -; mRNA. DR EMBL; AB451367; BAG70181.1; -; mRNA. DR EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000479; AAH00479.1; -; mRNA. DR EMBL; BC084538; AAH84538.1; -; mRNA. DR EMBL; X61037; CAA43372.1; -; mRNA. DR CCDS; CCDS9994.1; -. [P31749-1] DR PIR; A39360; A39360. DR RefSeq; NP_001014431.1; NM_001014431.2. [P31749-1] DR RefSeq; NP_001014432.1; NM_001014432.2. [P31749-1] DR RefSeq; NP_001369359.1; NM_001382430.1. [P31749-1] DR RefSeq; NP_001369360.1; NM_001382431.1. [P31749-1] DR RefSeq; NP_001369361.1; NM_001382432.1. [P31749-1] DR RefSeq; NP_001369362.1; NM_001382433.1. [P31749-1] DR RefSeq; NP_005154.2; NM_005163.2. [P31749-1] DR RefSeq; XP_047287025.1; XM_047431069.1. [P31749-1] DR RefSeq; XP_047287026.1; XM_047431070.1. [P31749-1] DR RefSeq; XP_047287027.1; XM_047431071.1. [P31749-1] DR RefSeq; XP_047287028.1; XM_047431072.1. [P31749-1] DR RefSeq; XP_047287029.1; XM_047431073.1. [P31749-1] DR RefSeq; XP_047287030.1; XM_047431074.1. [P31749-1] DR RefSeq; XP_047287031.1; XM_047431075.1. [P31749-1] DR RefSeq; XP_054231528.1; XM_054375553.1. [P31749-1] DR RefSeq; XP_054231529.1; XM_054375554.1. [P31749-1] DR RefSeq; XP_054231530.1; XM_054375555.1. [P31749-1] DR RefSeq; XP_054231531.1; XM_054375556.1. [P31749-1] DR RefSeq; XP_054231532.1; XM_054375557.1. [P31749-1] DR RefSeq; XP_054231533.1; XM_054375558.1. [P31749-1] DR PDB; 1H10; X-ray; 1.40 A; A=1-123. DR PDB; 1UNP; X-ray; 1.65 A; A=1-121. DR PDB; 1UNQ; X-ray; 0.98 A; A=1-123. DR PDB; 1UNR; X-ray; 1.25 A; A=1-123. DR PDB; 2UVM; X-ray; 1.94 A; A=1-123. DR PDB; 2UZR; X-ray; 1.94 A; A=1-123. DR PDB; 2UZS; X-ray; 2.46 A; A=1-123. DR PDB; 3CQU; X-ray; 2.20 A; A=144-480. DR PDB; 3CQW; X-ray; 2.00 A; A=144-480. DR PDB; 3MV5; X-ray; 2.47 A; A=144-480. DR PDB; 3MVH; X-ray; 2.01 A; A=144-480. DR PDB; 3O96; X-ray; 2.70 A; A=2-443. DR PDB; 3OCB; X-ray; 2.70 A; A/B=144-480. DR PDB; 3OW4; X-ray; 2.60 A; A/B=144-480. DR PDB; 3QKK; X-ray; 2.30 A; A=144-480. DR PDB; 3QKL; X-ray; 1.90 A; A=144-480. DR PDB; 3QKM; X-ray; 2.20 A; A=144-480. DR PDB; 4EJN; X-ray; 2.19 A; A=2-446. DR PDB; 4EKK; X-ray; 2.80 A; A/B=144-480. DR PDB; 4EKL; X-ray; 2.00 A; A=144-480. DR PDB; 4GV1; X-ray; 1.49 A; A=144-480. DR PDB; 5KCV; X-ray; 2.70 A; A=2-446. DR PDB; 6BUU; X-ray; 2.40 A; A/B=144-480. DR PDB; 6CCY; X-ray; 2.18 A; A=144-466. DR PDB; 6HHF; X-ray; 2.90 A; A=2-446. DR PDB; 6HHG; X-ray; 2.30 A; A=2-446. DR PDB; 6HHH; X-ray; 2.70 A; A=2-446. DR PDB; 6HHI; X-ray; 2.70 A; A=2-446. DR PDB; 6HHJ; X-ray; 2.30 A; A=2-446. DR PDB; 6NPZ; X-ray; 2.12 A; A/B=123-480, A/B=144-480. DR PDB; 6S9W; X-ray; 2.30 A; A=2-446. DR PDB; 6S9X; X-ray; 2.60 A; A=2-446. DR PDB; 7APJ; X-ray; 2.05 A; A=1-119, A=136-445. DR PDB; 7MYX; X-ray; 1.39 A; A=1-121. DR PDB; 7NH4; X-ray; 2.30 A; A=2-446. DR PDB; 7NH5; X-ray; 1.90 A; A=2-446. DR PDB; 8JOW; X-ray; 1.40 A; B/D=466-477. DR PDB; 8UVY; X-ray; 2.11 A; A=2-446. DR PDB; 8UW2; X-ray; 2.20 A; A=2-446. DR PDB; 8UW7; X-ray; 1.97 A; A=2-446. DR PDB; 8UW9; X-ray; 1.90 A; A=2-446. DR PDB; 8ZPU; X-ray; 2.80 A; C/D=466-477. DR PDBsum; 1H10; -. DR PDBsum; 1UNP; -. DR PDBsum; 1UNQ; -. DR PDBsum; 1UNR; -. DR PDBsum; 2UVM; -. DR PDBsum; 2UZR; -. DR PDBsum; 2UZS; -. DR PDBsum; 3CQU; -. DR PDBsum; 3CQW; -. DR PDBsum; 3MV5; -. DR PDBsum; 3MVH; -. DR PDBsum; 3O96; -. DR PDBsum; 3OCB; -. DR PDBsum; 3OW4; -. DR PDBsum; 3QKK; -. DR PDBsum; 3QKL; -. DR PDBsum; 3QKM; -. DR PDBsum; 4EJN; -. DR PDBsum; 4EKK; -. DR PDBsum; 4EKL; -. DR PDBsum; 4GV1; -. DR PDBsum; 5KCV; -. DR PDBsum; 6BUU; -. DR PDBsum; 6CCY; -. DR PDBsum; 6HHF; -. DR PDBsum; 6HHG; -. DR PDBsum; 6HHH; -. DR PDBsum; 6HHI; -. DR PDBsum; 6HHJ; -. DR PDBsum; 6NPZ; -. DR PDBsum; 6S9W; -. DR PDBsum; 6S9X; -. DR PDBsum; 7APJ; -. DR PDBsum; 7MYX; -. DR PDBsum; 7NH4; -. DR PDBsum; 7NH5; -. DR PDBsum; 8JOW; -. DR PDBsum; 8UVY; -. DR PDBsum; 8UW2; -. DR PDBsum; 8UW7; -. DR PDBsum; 8UW9; -. DR PDBsum; 8ZPU; -. DR AlphaFoldDB; P31749; -. DR SMR; P31749; -. DR BioGRID; 106710; 600. DR CORUM; P31749; -. DR DIP; DIP-24269N; -. DR ELM; P31749; -. DR FunCoup; P31749; 3098. DR IntAct; P31749; 602. DR MINT; P31749; -. DR STRING; 9606.ENSP00000451828; -. DR BindingDB; P31749; -. DR ChEMBL; CHEMBL4282; -. DR DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE. DR DrugBank; DB07585; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. DR DrugBank; DB08568; A-674563. DR DrugBank; DB11648; Afuresertib. DR DrugBank; DB05971; Archexin. DR DrugBank; DB01169; Arsenic trioxide. DR DrugBank; DB00171; ATP. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12218; Capivasertib. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB12795; CMX-2043. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01645; Genistein. DR DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate. DR DrugBank; DB11743; Ipatasertib. DR DrugBank; DB15431; M-2698. DR DrugBank; DB14982; Miransertib. DR DrugBank; DB07584; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB02709; Resveratrol. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugCentral; P31749; -. DR GuidetoPHARMACOLOGY; 1479; -. DR TCDB; 8.A.104.1.10; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; P31749; 6 sites, 1 glycan. DR GlyGen; P31749; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P31749; -. DR MetOSite; P31749; -. DR PhosphoSitePlus; P31749; -. DR BioMuta; AKT1; -. DR DMDM; 60391226; -. DR CPTAC; CPTAC-3162; -. DR CPTAC; CPTAC-3163; -. DR CPTAC; CPTAC-3164; -. DR CPTAC; CPTAC-3165; -. DR CPTAC; CPTAC-3166; -. DR CPTAC; CPTAC-3167; -. DR CPTAC; CPTAC-5758; -. DR CPTAC; CPTAC-5759; -. DR CPTAC; CPTAC-5805; -. DR CPTAC; CPTAC-5806; -. DR CPTAC; CPTAC-5807; -. DR CPTAC; CPTAC-5808; -. DR CPTAC; CPTAC-783; -. DR CPTAC; CPTAC-784; -. DR CPTAC; non-CPTAC-5328; -. DR CPTAC; non-CPTAC-5329; -. DR CPTAC; non-CPTAC-5332; -. DR CPTAC; non-CPTAC-5527; -. DR CPTAC; non-CPTAC-5528; -. DR CPTAC; non-CPTAC-5719; -. DR CPTAC; non-CPTAC-5720; -. DR jPOST; P31749; -. DR MassIVE; P31749; -. DR PaxDb; 9606-ENSP00000451828; -. DR PeptideAtlas; P31749; -. DR ProteomicsDB; 54800; -. [P31749-1] DR ProteomicsDB; 6712; -. DR Pumba; P31749; -. DR ABCD; P31749; 12 sequenced antibodies. DR Antibodypedia; 135; 5291 antibodies from 58 providers. DR CPTC; P31749; 6 antibodies. DR DNASU; 207; -. DR Ensembl; ENST00000349310.7; ENSP00000270202.4; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000402615.6; ENSP00000385326.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000407796.7; ENSP00000384293.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554581.5; ENSP00000451828.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554848.5; ENSP00000451166.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000555528.5; ENSP00000450688.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000649815.2; ENSP00000497822.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000683722.1; ENSP00000507879.1; ENSG00000142208.20. [P31749-1] DR GeneID; 207; -. DR KEGG; hsa:207; -. DR MANE-Select; ENST00000649815.2; ENSP00000497822.1; NM_001382430.1; NP_001369359.1. DR UCSC; uc001ypk.4; human. [P31749-1] DR AGR; HGNC:391; -. DR CIViC; 207; 18 evidence items across 19 molecular profiles. DR ClinPGx; PA24684; -. DR CTD; 207; -. DR DisGeNET; 207; -. DR GeneCards; AKT1; -. DR GeneReviews; AKT1; -. DR HGNC; HGNC:391; AKT1. DR HPA; ENSG00000142208; Low tissue specificity. DR MalaCards; AKT1; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 164730; gene. DR MIM; 176920; phenotype. DR MIM; 615109; phenotype. DR OpenTargets; ENSG00000142208; -. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 744; Proteus syndrome. DR VEuPathDB; HostDB:ENSG00000142208; -. DR eggNOG; KOG0690; Eukaryota. DR GeneTree; ENSGT00940000158752; -. DR HOGENOM; CLU_000288_11_0_1; -. DR InParanoid; P31749; -. DR OMA; MDMEIYL; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P31749; 3 GO annotations based on evolutionary models. DR PhylomeDB; P31749; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P31749; -. DR Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol. DR Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-203615; eNOS activation. DR Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma. DR Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt). DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856532; Mechanical load activates signaling by PIEZO1 and integrins in osteocytes. DR SABIO-RK; P31749; -. DR SignaLink; P31749; -. DR SIGNOR; P31749; -. DR Agora; ENSG00000142208; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 207; 54 hits in 1212 CRISPR screens. DR ChiTaRS; AKT1; human. DR EvolutionaryTrace; P31749; -. DR GeneWiki; AKT1; -. DR GenomeRNAi; 207; -. DR Pharos; P31749; Tchem. DR PRO; PR:P31749; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P31749; protein. DR Bgee; ENSG00000142208; Expressed in stromal cell of endometrium and 189 other cell types or tissues. DR ExpressionAtlas; P31749; baseline and differential. DR GO; GO:0005938; C:cell cortex; NAS:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; NAS:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProt. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0033011; C:perinuclear theca; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL. DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB. DR GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0099104; F:potassium channel activator activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:1904841; F:TORC2 complex binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0160213; P:beta-arrestin-dependent dopamine receptor signaling pathway; NAS:ParkinsonsUK-UCL. DR GO; GO:0030154; P:cell differentiation; TAS:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0036294; P:cellular response to decreased oxygen levels; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB. DR GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB. DR GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IMP:BHF-UCL. DR GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0072752; P:cellular response to rapamycin; ISS:UniProt. DR GO; GO:0033554; P:cellular response to stress; TAS:Reactome. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl. DR GO; GO:0002430; P:complement receptor mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl. DR GO; GO:0010761; P:fibroblast migration; NAS:BHF-UCL. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW. DR GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0022605; P:mammalian oogenesis stage; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB. DR GO; GO:0001893; P:maternal placenta development; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:1902018; P:negative regulation of cilium assembly; IDA:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL. DR GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL. DR GO; GO:2000402; P:negative regulation of lymphocyte migration; IMP:BHF-UCL. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; TAS:Reactome. DR GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; ISS:UniProt. DR GO; GO:0150033; P:negative regulation of protein localization to lysosome; IDA:UniProtKB. DR GO; GO:1903318; P:negative regulation of protein maturation; ISS:UniProt. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:ARUK-UCL. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc. DR GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:1905786; P:positive regulation of anaphase-promoting complex-dependent catabolic process; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProt. DR GO; GO:0046326; P:positive regulation of D-glucose import; IMP:BHF-UCL. DR GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:UniProtKB. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1905552; P:positive regulation of protein localization to endoplasmic reticulum; IDA:UniProt. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL. DR GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW. DR GO; GO:0110002; P:regulation of tRNA methylation; IDA:UniProt. DR GO; GO:2000074; P:regulation of type B pancreatic cell development; TAS:Reactome. DR GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL. DR GO; GO:0032094; P:response to food; IEA:Ensembl. DR GO; GO:0070848; P:response to growth factor; IDA:UniProtKB. DR GO; GO:0060416; P:response to growth hormone; ISS:AgBase. DR GO; GO:0009408; P:response to heat; TAS:ProtInc. DR GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase. DR GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR CDD; cd01241; PH_PKB; 1. DR CDD; cd05594; STKc_PKB_alpha; 1. DR DisProt; DP03300; -. DR FunFam; 1.10.510.10:FF:000033; Non-specific serine/threonine protein kinase; 1. DR FunFam; 2.30.29.30:FF:000027; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000838; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00412; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034676; Akt1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR039026; PH_PKB. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein; KW Disease variant; Disulfide bond; Glucose metabolism; Glycogen biosynthesis; KW Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane; KW Mitochondrion; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Sugar transport; Transferase; KW Translation regulation; Transport; Ubl conjugation. FT CHAIN 1..480 FT /note="RAC-alpha serine/threonine-protein kinase" FT /id="PRO_0000085605" FT DOMAIN 5..108 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 150..408 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 409..480 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 113..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 450..480 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 274 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 14..19 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 23..25 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 53 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 86 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 156..164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 462 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250|UniProtKB:P31750" FT MOD_RES 14 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 20 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 124 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 126 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 129 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 176 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:20333297" FT MOD_RES 308 FT /note="Phosphothreonine; by IKKE, PDPK1 and TBK1" FT /evidence="ECO:0000269|PubMed:15718470, FT ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:40285646, ECO:0000269|PubMed:8978681, FT ECO:0000269|PubMed:9512493" FT MOD_RES 448 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 450 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 473 FT /note="Phosphoserine; by IKKE, MTOR, PRKDC and TBK1; FT alternate" FT /evidence="ECO:0000269|PubMed:14761976, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, FT ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, FT ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:40285646, FT ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9736715" FT MOD_RES 474 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:12149249" FT MOD_RES 477 FT /note="Phosphoserine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT MOD_RES 479 FT /note="Phosphothreonine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT CARBOHYD 126 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 129 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 305 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 312 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 473 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000250|UniProtKB:P31750" FT DISULFID 60..77 FT /evidence="ECO:0000269|PubMed:20886116" FT DISULFID 296..310 FT /evidence="ECO:0000250|UniProtKB:P31751" FT CROSSLNK 284 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22410793" FT VAR_SEQ 1..62 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056180" FT VARIANT 17 FT /note="E -> K (in PROTEUSS and breast cancer; also detected FT in colorectal and ovarian cancer; somatic mutation; results FT in increased phosphorylation at T-308 and higher basal FT ubiquitination; the mutant protein is more efficiently FT recruited to the plasma membrane; alters FT phosphatidylinositiol phosphates lipid specificity of the FT AKT1 PH domain; dbSNP:rs121434592)" FT /evidence="ECO:0000269|PubMed:17611497, FT ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527, FT ECO:0000269|PubMed:21793738" FT /id="VAR_055422" FT VARIANT 25 FT /note="R -> C (in CWS6; impairs interaction with FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2; dbSNP:rs397514644)" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:23246288" FT /id="VAR_069791" FT VARIANT 167 FT /note="V -> A (in dbSNP:rs11555433)" FT /id="VAR_051617" FT VARIANT 435 FT /note="T -> P (in CWS6; dbSNP:rs397514645)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069792" FT MUTAGEN 8 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation as well FT as IGF1-induced membrane recruitment. Decrease in FT ubiquitination and phosphorylation at T-308 as well as FT impaired association with the membrane; when associated FT with K-17." FT /evidence="ECO:0000269|PubMed:19713527" FT MUTAGEN 14 FT /note="K->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, loss of AKT activation, and loss of binding FT to PIP3 as well as IGF1-induced membrane recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation, loss of FT binding to PIP3 as well as IGF1-induced membrane FT recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 17 FT /note="E->K: Loss of membrane localization; when associated FT with Q-20." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, reduced AKT activation, and reduced binding FT to PIP3 as well as IGF1-induced membrane recruitment. Loss FT of membrane localization; when associated with K-17." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->R: Slight increase of phosphorylation at T-308 FT and S-473." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 25 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 76..78 FT /note="RCL->ACA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 86 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 176 FT /note="Y->F: Significant loss of interaction with TNK2. FT Loss of membrane localization. Significant reduction in FT phosphorylation on Ser-473." FT /evidence="ECO:0000269|PubMed:20333297" FT MUTAGEN 179 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:12172553, FT ECO:0000269|PubMed:33594058" FT MUTAGEN 273..275 FT /note="RDL->ADA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 305 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-312." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 305 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 308 FT /note="T->D: 5-fold activation and 18-fold activation; when FT associated with D-473." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 312 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-305." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 312 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 473 FT /note="S->D: 7-fold activation and 25-fold activation; when FT associated with D-308." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 474 FT /note="Y->F: 55% inhibition of activation." FT /evidence="ECO:0000269|PubMed:12149249" FT CONFLICT 173..174 FT /note="GR -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="L -> Q (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="A -> R (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 246 FT /note="S -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 409 FT /note="A -> T (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="A -> P (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> S (in Ref. 1; AAA36539, 2; AAL55732, 3; FT BAG36922 and 4; BAG70056/BAG70181)" FT /evidence="ECO:0000305" FT HELIX 2..4 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 6..15 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 22..30 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 33..40 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:7APJ" FT HELIX 45..48 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 67..69 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 72..79 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 82..89 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 150..158 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 160..169 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 170..172 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 175..182 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 213..218 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 235..242 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 247..268 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:4EJN" FT STRAND 288..290 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:3MVH" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 318..322 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 330..344 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 374..383 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 396..398 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 399..403 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 406..408 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 413..417 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:3MVH" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:7NH5" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:4GV1" SQ SEQUENCE 480 AA; 55686 MW; 6EAFF4F8AD436714 CRC64; MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA // ID AMGO2_HUMAN Reviewed; 522 AA. AC Q86SJ2; Q4VBP6; Q7Z4A0; Q96CN8; DT 21-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=Amphoterin-induced protein 2; DE AltName: Full=AMIGO-2; DE AltName: Full=Alivin-1; DE AltName: Full=Differentially expressed in gastric adenocarcinomas; DE Short=DEGA; DE Flags: Precursor; GN Name=AMIGO2 {ECO:0000312|EMBL:AAH47595.1}; GN Synonyms=ALI1 {ECO:0000312|EMBL:BAC81189.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000312|EMBL:AAO48946.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fibrosarcoma {ECO:0000269|PubMed:12629050}; RX PubMed=12629050; DOI=10.1083/jcb.200209074; RA Kuja-Panula J., Kiiltomaeki M., Yamashiro T., Rouhiainen A., Rauvala H.; RT "AMIGO, a transmembrane protein implicated in axon tract development, RT defines a novel protein family with leucine-rich repeats."; RL J. Cell Biol. 160:963-973(2003). RN [2] {ECO:0000312|EMBL:BAC81189.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain {ECO:0000312|EMBL:BAC81189.1}; RX PubMed=12843293; DOI=10.1523/jneurosci.23-13-05887.2003; RA Ono T., Sekino-Suzuki N., Kikkawa Y., Yonekawa H., Kawashima S.; RT "Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and RT promotes survival of cerebellar granule neurons."; RL J. Neurosci. 23:5887-5896(2003). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAR83271.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=15107827; DOI=10.1038/sj.onc.1207681; RA Rabenau K.E., O'Toole J.M., Bassi R., Kotanides H., Witte L., Ludwig D.L., RA Pereira D.S.; RT "DEGA/AMIGO-2, a leucine-rich repeat family member, differentially RT expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal RT stability, cell adhesion/migration and tumorigenicity."; RL Oncogene 23:5056-5067(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Stomach; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] {ECO:0000312|EMBL:AAH47595.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis {ECO:0000312|EMBL:AAH47595.1}, and RC Uterus {ECO:0000312|EMBL:AAH14103.2}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). CC -!- FUNCTION: Required for depolarization-dependent survival of cultured CC cerebellar granule neurons. May mediate homophilic as well as CC heterophilic cell-cell interaction with AMIGO1 or AMIGO3. May CC contribute to signal transduction through its intracellular domain. May CC be required for tumorigenesis of a subset of gastric adenocarcinomas. CC -!- SUBUNIT: Binds itself as well as AMIGO1 and AMIGO3. {ECO:0000250}. CC -!- INTERACTION: CC Q86SJ2; O00555: CACNA1A; NbExp=2; IntAct=EBI-3866830, EBI-766279; CC Q86SJ2; Q6PL24: TMED8; NbExp=3; IntAct=EBI-3866830, EBI-11603430; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Nucleus {ECO:0000250}. Note=Associated CC with nucleus as well as plasma membrane. Restricted to somata of CC cerebellar as well as hippocampal neurons (By similarity). CC {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Highest levels in breast, ovary, cervix, and CC uterus. Lower levels in lung, colon, and rectum. Differentially CC expressed in 56% of thyroid, 57% of pancreatic and 45% of stomach CC cancers. {ECO:0000269|PubMed:15107827}. CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. AMIGO family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY237005; AAO48946.1; -; mRNA. DR EMBL; AB079074; BAC81188.1; -; mRNA. DR EMBL; AB080610; BAC81189.1; -; mRNA. DR EMBL; AY454159; AAR83271.1; -; mRNA. DR EMBL; AL833007; CAH56293.1; -; mRNA. DR EMBL; BC014103; AAH14103.2; -; mRNA. DR EMBL; BC047595; AAH47595.1; -; mRNA. DR EMBL; BC095477; AAH95477.1; -; mRNA. DR CCDS; CCDS8751.1; -. DR RefSeq; NP_001137140.1; NM_001143668.1. DR RefSeq; NP_001357228.1; NM_001370299.1. DR RefSeq; NP_862830.1; NM_181847.4. DR RefSeq; XP_047284741.1; XM_047428785.1. DR AlphaFoldDB; Q86SJ2; -. DR SMR; Q86SJ2; -. DR BioGRID; 131497; 48. DR FunCoup; Q86SJ2; 22. DR IntAct; Q86SJ2; 9. DR STRING; 9606.ENSP00000266581; -. DR GlyConnect; 1007; 4 N-Linked glycans (1 site). DR GlyCosmos; Q86SJ2; 8 sites, 4 glycans. DR GlyGen; Q86SJ2; 10 sites, 6 N-linked glycans (3 sites). DR iPTMnet; Q86SJ2; -. DR PhosphoSitePlus; Q86SJ2; -. DR SwissPalm; Q86SJ2; -. DR BioMuta; AMIGO2; -. DR DMDM; 68052338; -. DR jPOST; Q86SJ2; -. DR MassIVE; Q86SJ2; -. DR PaxDb; 9606-ENSP00000266581; -. DR PeptideAtlas; Q86SJ2; -. DR ProteomicsDB; 69596; -. DR Pumba; Q86SJ2; -. DR Antibodypedia; 13397; 235 antibodies from 31 providers. DR DNASU; 347902; -. DR Ensembl; ENST00000266581.4; ENSP00000266581.4; ENSG00000139211.8. DR Ensembl; ENST00000429635.1; ENSP00000406020.1; ENSG00000139211.8. DR Ensembl; ENST00000550413.2; ENSP00000449034.1; ENSG00000139211.8. DR GeneID; 347902; -. DR KEGG; hsa:347902; -. DR MANE-Select; ENST00000550413.2; ENSP00000449034.1; NM_001370299.1; NP_001357228.1. DR UCSC; uc001rpk.4; human. DR AGR; HGNC:24073; -. DR ClinPGx; PA142672626; -. DR CTD; 347902; -. DR DisGeNET; 347902; -. DR GeneCards; AMIGO2; -. DR HGNC; HGNC:24073; AMIGO2. DR HPA; ENSG00000139211; Low tissue specificity. DR MIM; 615690; gene. DR OpenTargets; ENSG00000139211; -. DR VEuPathDB; HostDB:ENSG00000139211; -. DR eggNOG; ENOG502R009; Eukaryota. DR GeneTree; ENSGT00950000183146; -. DR HOGENOM; CLU_030478_0_0_1; -. DR InParanoid; Q86SJ2; -. DR OMA; DFVWVGP; -. DR OrthoDB; 676979at2759; -. DR PAN-GO; Q86SJ2; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q86SJ2; -. DR PathwayCommons; Q86SJ2; -. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR SignaLink; Q86SJ2; -. DR Agora; ENSG00000139211; -. DR BioGRID-ORCS; 347902; 22 hits in 1166 CRISPR screens. DR GenomeRNAi; 347902; -. DR Pharos; Q86SJ2; Tbio. DR PRO; PR:Q86SJ2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q86SJ2; protein. DR Bgee; ENSG00000139211; Expressed in blood vessel layer and 190 other cell types or tissues. DR ExpressionAtlas; Q86SJ2; baseline and differential. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; ISS:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; ISS:UniProtKB. DR GO; GO:0043069; P:negative regulation of programmed cell death; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IBA:GO_Central. DR FunFam; 2.60.40.10:FF:001047; amphoterin-induced protein 2 isoform X1; 1. DR FunFam; 3.80.10.10:FF:000170; amphoterin-induced protein 2 isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR InterPro; IPR031283; AMIGO. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp. DR InterPro; IPR032675; LRR_dom_sf. DR PANTHER; PTHR24368; AMPHOTERIN-INDUCED PROTEIN; 1. DR PANTHER; PTHR24368:SF209; AMPHOTERIN-INDUCED PROTEIN 2; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF13855; LRR_8; 1. DR SMART; SM00409; IG; 1. DR SMART; SM00369; LRR_TYP; 5. DR SMART; SM00082; LRRCT; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 7. PE 1: Evidence at protein level; KW Cell adhesion; Cell membrane; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Leucine-rich repeat; Membrane; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..39 FT /evidence="ECO:0000255" FT CHAIN 40..522 FT /note="Amphoterin-induced protein 2" FT /evidence="ECO:0000255" FT /id="PRO_0000014509" FT TOPO_DOM 40..398 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 399..419 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 420..522 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 40..68 FT /note="LRRNT" FT REPEAT 69..90 FT /note="LRR 1" FT REPEAT 94..115 FT /note="LRR 2" FT REPEAT 118..139 FT /note="LRR 3" FT REPEAT 142..163 FT /note="LRR 4" FT REPEAT 166..187 FT /note="LRR 5" FT REPEAT 193..214 FT /note="LRR 6" FT DOMAIN 228..284 FT /note="LRRCT" FT DOMAIN 289..379 FT /note="Ig-like C2-type" FT /evidence="ECO:0000255" FT REGION 501..522 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 58 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 281 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 288 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 373 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 381 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 384 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 41..47 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 45..54 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 232..260 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 234..282 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 310..363 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" SQ SEQUENCE 522 AA; 57934 MW; 20A86E3D82C05B9B CRC64; MSLRVHTLPT LLGAVVRPGC RELLCLLMIT VTVGPGASGV CPTACICATD IVSCTNKNLS KVPGNLFRLI KRLDLSYNRI GLLDSEWIPV SFAKLNTLIL RHNNITSIST GSFSTTPNLK CLDLSSNKLK TVKNAVFQEL KVLEVLLLYN NHISYLDPSA FGGLSQLQKL YLSGNFLTQF PMDLYVGRFK LAELMFLDVS YNRIPSMPMH HINLVPGKQL RGIYLHGNPF VCDCSLYSLL VFWYRRHFSS VMDFKNDYTC RLWSDSRHSR QVLLLQDSFM NCSDSIINGS FRALGFIHEA QVGERLMVHC DSKTGNANTD FIWVGPDNRL LEPDKEMENF YVFHNGSLVI ESPRFEDAGV YSCIAMNKQR LLNETVDVTI NVSNFTVSRS HAHEAFNTAF TTLAACVASI VLVLLYLYLT PCPCKCKTKR QKNMLHQSNA HSSILSPGPA SDASADERKA GAGKRVVFLE PLKDTAAGQN GKVRLFPSEA VIAEGILKST RGKSDSDSVN SVFSDTPFVA ST // ID ANDR_HUMAN Reviewed; 920 AA. AC P10275; A0A0B4J1T2; A2RUN2; B1AKD7; C0JKD3; C0JKD4; E7EVX6; Q9UD95; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 16-MAR-2016, sequence version 3. DT 28-JAN-2026, entry version 308. DE RecName: Full=Androgen receptor; DE AltName: Full=Dihydrotestosterone receptor; DE AltName: Full=Nuclear receptor subfamily 3 group C member 4; GN Name=AR; Synonyms=DHTR, NR3C4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3216866; DOI=10.1210/mend-2-12-1265; RA Lubahn D.B., Joseph D.R., Sar M., Tan J., Higgs H.N., Larson R.E., RA French F.S., Wilson E.M.; RT "The human androgen receptor: complementary deoxyribonucleic acid cloning, RT sequence analysis and gene expression in prostate."; RL Mol. Endocrinol. 2:1265-1275(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Prostate; RX PubMed=3174628; DOI=10.1073/pnas.85.19.7211; RA Chang C., Kokontis J., Liao S.; RT "Structural analysis of complementary DNA and amino acid sequences of human RT and rat androgen receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 85:7211-7215(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Prostate; RX PubMed=2911578; DOI=10.1073/pnas.86.1.327; RA Tilley W.D., Marcelli M., Wilson J.D., McPhaul M.J.; RT "Characterization and expression of a cDNA encoding the human androgen RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 86:327-331(1989). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT AIS MET-867. RX PubMed=2594783; DOI=10.1073/pnas.86.23.9534; RA Lubahn D.B., Brown T.R., Simental J.A., Higgs H.N., Migeon C.J., RA Wilson E.M., French F.S.; RT "Sequence of the intron/exon junctions of the coding region of the human RT androgen receptor gene and identification of a point mutation in a family RT with complete androgen insensitivity."; RL Proc. Natl. Acad. Sci. U.S.A. 86:9534-9538(1989). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=2342476; DOI=10.1210/mend-4-3-417; RA Govindan M.V.; RT "Specific region in hormone binding domain is essential for hormone binding RT and trans-activation by human androgen receptor."; RL Mol. Endocrinol. 4:417-427(1990). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RP 1). RC TISSUE=Prostate; RX PubMed=2293020; DOI=10.1210/mend-4-8-1105; RA Marcelli M., Tilley W.D., Wilson C.M., Griffin J.E., Wilson J.D., RA McPhaul M.J.; RT "Definition of the human androgen receptor gene structure permits the RT identification of mutations that cause androgen resistance: premature RT termination of the receptor protein at amino acid residue 588 causes RT complete androgen resistance."; RL Mol. Endocrinol. 4:1105-1116(1990). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2), TISSUE RP SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15634333; DOI=10.1111/j.1742-4658.2004.04395.x; RA Ahrens-Fath I., Politz O., Geserick C., Haendler B.; RT "Androgen receptor function is modulated by the tissue-specific AR45 RT variant."; RL FEBS J. 272:74-84(2005). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), VARIANT GLN-57, FUNCTION RP (ISOFORMS 3 AND 4), AND SUBCELLULAR LOCATION (ISOFORM 3). RX PubMed=19244107; DOI=10.1158/0008-5472.can-08-3795; RA Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., RA Melamed J., Tepper C.G., Kung H.J., Brodie A.M., Edwards J., Qiu Y.; RT "A novel androgen receptor splice variant is up-regulated during prostate RT cancer progression and promotes androgen depletion-resistant growth."; RL Cancer Res. 69:2305-2313(2009). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-539. RX PubMed=2917688; DOI=10.1016/0303-7207(89)90137-8; RA Faber P.W., Kuiper G.G.J.M., van Rooij H.C.J., van der Korput J.A.G.M., RA Brinkmann A.O., Trapman J.; RT "The N-terminal domain of the human androgen receptor is encoded by one, RT large exon."; RL Mol. Cell. Endocrinol. 61:257-262(1989). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 191-920 (ISOFORM 1). RX PubMed=3353726; DOI=10.1126/science.3353726; RA Chang C., Kokontis J., Liao S.; RT "Molecular cloning of human and rat complementary DNA encoding androgen RT receptors."; RL Science 240:324-326(1988). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 448-476. RC TISSUE=Blood; RA Lu J., Danielsen M.; RL Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 470-920 (ISOFORM 1). RX PubMed=3377788; DOI=10.1016/s0006-291x(88)81214-2; RA Trapman J., Klaassen P., Kuiper G.G.J.M., van der Korput J.A.G.M., RA Faber P.W., van Rooij H.C.J., Geurts van Kessel A., Voorhorst M.M., RA Mulder E., Brinkmann A.O.; RT "Cloning, structure and expression of a cDNA encoding the human androgen RT receptor."; RL Biochem. Biophys. Res. Commun. 153:241-248(1988). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 537-541; 587-591; 626-630; 722-726; RP 770-774; 814-817 AND 866-870. RX PubMed=2546571; DOI=10.1677/jme.0.002r001; RA Kuiper G.G., Faber P.W., van Rooij H.C., van der Korput J.A., RA Ris-Stalpers C., Klaassen P., Trapman J., Brinkmann A.O.; RT "Structural organization of the human androgen receptor gene."; RL J. Mol. Endocrinol. 2:R1-R4(1989). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 558-625 (ISOFORMS 1/2), AND VARIANT AIS RP HIS-616. RC TISSUE=Fibroblast; RX PubMed=8413310; DOI=10.1210/mend.7.7.8413310; RA Mowszowicz I., Lee H.-J., Chen H.-T., Mestayer C., Portois M.-C., RA Cabrol S., Mauvais-Jarvis P., Chang C.; RT "A point mutation in the second zinc finger of the DNA-binding domain of RT the androgen receptor gene causes complete androgen insensitivity in two RT siblings with receptor-positive androgen resistance."; RL Mol. Endocrinol. 7:861-869(1993). RN [18] RP NUCLEOTIDE SEQUENCE [MRNA] OF 560-625 (ISOFORMS 1/2). RX PubMed=3353727; DOI=10.1126/science.3353727; RA Lubahn D.B., Joseph D.R., Sullivan P.M., Willard H.F., French F.S., RA Wilson E.M.; RT "Cloning of human androgen receptor complementary DNA and localization to RT the X chromosome."; RL Science 240:327-330(1988). RN [19] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 630-724, AND VARIANTS AIS ASN-696 AND RP HIS-696. RX PubMed=1775137; DOI=10.1210/mend-5-10-1562; RA Ris-Stalpers C., Trifiro M.A., Kuiper G.G.J.M., Jenster G., Romalo G., RA Sai T., van Rooij H.C.J., Kaufman M., Rosenfield R.L., Liao S., RA Schweikert H.-U., Trapman J., Pinsky L., Brinkmann A.O.; RT "Substitution of aspartic acid-686 by histidine or asparagine in the human RT androgen receptor leads to a functionally inactive protein with altered RT hormone-binding characteristics."; RL Mol. Endocrinol. 5:1562-1569(1991). RN [20] RP POLYMORPHISM OF POLY-GLN REGION. RX PubMed=1561105; DOI=10.1093/nar/20.6.1427-a; RA Sleddens H.F.B.M., Oostra B.A., Brinkmann A.O., Trapman J.; RT "Trinucleotide repeat polymorphism in the androgen receptor gene (AR)."; RL Nucleic Acids Res. 20:1427-1427(1992). RN [21] RP INTERACTION WITH NCOA4. RC TISSUE=Prostatic carcinoma; RX PubMed=8643607; DOI=10.1073/pnas.93.11.5517; RA Yeh S., Chang C.; RT "Cloning and characterization of a specific coactivator, ARA70, for the RT androgen receptor in human prostate cells."; RL Proc. Natl. Acad. Sci. U.S.A. 93:5517-5521(1996). RN [22] RP POLYMORPHISM OF POLY-GLN REGION. RX PubMed=9096391; DOI=10.1073/pnas.94.7.3320; RA Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., RA Talcott J., Hennekens C.H., Kantoff P.W.; RT "The CAG repeat within the androgen receptor gene and its relationship to RT prostate cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 94:3320-3323(1997). RN [23] RP ERRATUM OF PUBMED:9096391. RA Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., RA Talcott J., Hennekens C.H., Kantoff P.W.; RL Proc. Natl. Acad. Sci. U.S.A. 94:8272-8272(1997). RN [24] RP INTERACTION WITH PQBP1. RC TISSUE=Brain; RX PubMed=10332029; DOI=10.1093/hmg/8.6.977; RA Waragai M., Lammers C.-H., Takeuchi S., Imafuku I., Udagawa Y., RA Kanazawa I., Kawabata M., Mouradian M.M., Okazawa H.; RT "PQBP-1, a novel polyglutamine tract binding protein, inhibits RT transcription activation by Brn-2 and affects cell survival."; RL Hum. Mol. Genet. 8:977-987(1999). RN [25] RP INTERACTION WITH TGFB1I1. RX PubMed=10075738; DOI=10.1074/jbc.274.12.8316; RA Fujimoto N., Yeh S., Kang H.-Y., Inui S., Chang H.-C., Mizokami A., RA Chang C.; RT "Cloning and characterization of androgen receptor coactivator, ARA55, in RT human prostate."; RL J. Biol. Chem. 274:8316-8321(1999). RN [26] RP INTERACTION WITH UBE2I. RX PubMed=10383460; DOI=10.1074/jbc.274.27.19441; RA Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., Jaenne O.A.; RT "Ubc9 interacts with the androgen receptor and activates receptor-dependent RT transcription."; RL J. Biol. Chem. 274:19441-19446(1999). RN [27] RP INTERACTION WITH RAN. RX PubMed=10400640; DOI=10.1074/jbc.274.29.20229; RA Hsiao P.-W., Lin D.-L., Nakao R., Chang C.; RT "The linkage of Kennedy's neuron disease to ARA24, the first identified RT androgen receptor polyglutamine region-associated coactivator."; RL J. Biol. Chem. 274:20229-20234(1999). RN [28] RP INTERACTION WITH SPDEF. RX PubMed=10625666; DOI=10.1074/jbc.275.2.1216; RA Oettgen P., Finger E., Sun Z., Akbarali Y., Thamrongsak U., Boltax J., RA Grall F., Dube A., Weiss A., Brown L., Quinn G., Kas K., Endress G., RA Kunsch C., Libermann T.A.; RT "PDEF, a novel prostate epithelium-specific ets transcription factor, RT interacts with the androgen receptor and activates prostate-specific RT antigen gene expression."; RL J. Biol. Chem. 275:1216-1225(2000). RN [29] RP INTERACTION WITH KAT7. RX PubMed=10930412; DOI=10.1074/jbc.m004838200; RA Sharma M., Zarnegar M., Li X., Lim B., Sun Z.; RT "Androgen receptor interacts with a novel MYST protein, HBO1."; RL J. Biol. Chem. 275:35200-35208(2000). RN [30] RP SUMOYLATION AT LYS-388 AND LYS-521. RX PubMed=11121022; DOI=10.1073/pnas.97.26.14145; RA Poukka H., Karvonen U., Jaenne O.A., Palvimo J.J.; RT "Covalent modification of the androgen receptor by small ubiquitin-like RT modifier 1 (SUMO-1)."; RL Proc. Natl. Acad. Sci. U.S.A. 97:14145-14150(2000). RN [31] RP INTERACTION WITH RANBP9. RX PubMed=12361945; DOI=10.1074/jbc.m209741200; RA Rao M.A., Cheng H., Quayle A.N., Nishitani H., Nelson C.C., Rennie P.S.; RT "RanBPM, a nuclear protein that interacts with and regulates RT transcriptional activity of androgen receptor and glucocorticoid RT receptor."; RL J. Biol. Chem. 277:48020-48027(2002). RN [32] RP INTERACTION WITH PRPF6. RX PubMed=12039962; DOI=10.1074/jbc.m203811200; RA Zhao Y., Goto K., Saitoh M., Yanase T., Nomura M., Okabe T., Takayanagi R., RA Nawata H.; RT "Activation function-1 domain of androgen receptor contributes to the RT interaction between subnuclear splicing factor compartment and nuclear RT receptor compartment. Identification of the p102 U5 small nuclear RT ribonucleoprotein particle-binding protein as a coactivator for the RT receptor."; RL J. Biol. Chem. 277:30031-30039(2002). RN [33] RP RETRACTED PAPER. RX PubMed=12415108; DOI=10.1073/pnas.192569699; RA Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.; RT "Estrogen receptor-interacting protein that modulates its nongenomic RT activity-crosstalk with Src/Erk phosphorylation cascade."; RL Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002). RN [34] RP RETRACTION NOTICE OF PUBMED:12415108. RX PubMed=19666546; DOI=10.1073/pnas.0908685106; RA Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.; RL Proc. Natl. Acad. Sci. U.S.A. 106:14180-14180(2009). RN [35] RP INTERACTION WITH ZMIZ1. RX PubMed=14609956; DOI=10.1093/emboj/cdg585; RA Sharma M., Li X., Wang Y., Zarnegar M., Huang C.-Y., Palvimo J.J., Lim B., RA Sun Z.; RT "hZimp10 is an androgen receptor co-activator and forms a complex with RT SUMO-1 at replication foci."; RL EMBO J. 22:6101-6114(2003). RN [36] RP INTERACTION WITH RACK1, AND SUBCELLULAR LOCATION. RX PubMed=12958311; DOI=10.1074/jbc.m306219200; RA Rigas A.C., Ozanne D.M., Neal D.E., Robson C.N.; RT "The scaffolding protein RACK1 interacts with androgen receptor and RT promotes cross-talk through a protein kinase C signaling pathway."; RL J. Biol. Chem. 278:46087-46093(2003). RN [37] RP FUNCTION, AND INTERACTION WITH RBAK. RX PubMed=14664718; DOI=10.1677/jme.0.0310583; RA Hofman K., Swinnen J.V., Claessens F., Verhoeven G., Heyns W.; RT "The retinoblastoma protein-associated transcription repressor RBaK RT interacts with the androgen receptor and enhances its transcriptional RT activity."; RL J. Mol. Endocrinol. 31:583-596(2003). RN [38] RP INTERACTION WITH EFCAB6. RX PubMed=12612053; RA Niki T., Takahashi-Niki K., Taira T., Iguchi-Ariga S.M.M., Ariga H.; RT "DJBP: a novel DJ-1-binding protein, negatively regulates the androgen RT receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes RT this inhibition by abrogation of this complex."; RL Mol. Cancer Res. 1:247-261(2003). RN [39] RP PHOSPHORYLATION BY PAK6. RX PubMed=14573606; DOI=10.1074/jbc.m311145200; RA Schrantz N., da Silva Correia J., Fowler B., Ge Q., Sun Z., Bokoch G.M.; RT "Mechanism of p21-activated kinase 6-mediated inhibition of androgen RT receptor signaling."; RL J. Biol. Chem. 279:1922-1931(2004). RN [40] RP INTERACTION WITH HIP1. RX PubMed=16027218; DOI=10.1083/jcb.200503106; RA Mills I.G., Gaughan L., Robson C., Ross T., McCracken S., Kelly J., RA Neal D.E.; RT "Huntingtin interacting protein 1 modulates the transcriptional activity of RT nuclear hormone receptors."; RL J. Cell Biol. 170:191-200(2005). RN [41] RP INTERACTION WITH ZMIZ2. RX PubMed=16051670; DOI=10.1210/me.2005-0097; RA Huang C.-Y., Beliakoff J., Li X., Lee J., Li X., Sharma M., Lim B., Sun Z.; RT "hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated RT transcription and interacts with SWI/SNF-like BAF complexes."; RL Mol. Endocrinol. 19:2915-2929(2005). RN [42] RP PHOSPHORYLATION AT TYR-225; TYR-269; TYR-309; TYR-348; TYR-359; TYR-364; RP TYR-365; TYR-395; TYR-535; TYR-552 AND TYR-916, MUTAGENESIS OF TYR-225; RP TYR-269; TYR-309; TYR-348; TYR-359; TYR-364; TYR-365; TYR-395; TYR-535; RP TYR-552 AND TYR-916, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=17045208; DOI=10.1016/j.ccr.2006.08.021; RA Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., Nesheiwat I., Kong X., RA Melamed J., Handratta V.D., Njar V.C., Brodie A.M., Yu L.-R., RA Veenstra T.D., Chen H., Qiu Y.; RT "Regulation of androgen receptor activity by tyrosine phosphorylation."; RL Cancer Cell 10:309-319(2006). RN [43] RP ERRATUM OF PUBMED:17045208. RA Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., Nesheiwat I., Kong X., RA Melamed J., Handratta V.D., Njar V.C., Brodie A.M., Yu L.-R., RA Veenstra T.D., Chen H., Qiu Y.; RL Cancer Cell 11:97-97(2007). RN [44] RP INTERACTION WITH MAK, AND SUBUNIT. RX PubMed=16951154; DOI=10.1158/0008-5472.can-06-1636; RA Ma A.H., Xia L., Desai S.J., Boucher D.L., Guan Y., Shih H.M., Shi X.B., RA deVere White R.W., Chen H.W., Tepper C.G., Kung H.J.; RT "Male germ cell-associated kinase, a male-specific kinase regulated by RT androgen, is a coactivator of androgen receptor in prostate cancer cells."; RL Cancer Res. 66:8439-8447(2006). RN [45] RP INTERACTION WITH PRMT2, AND SUBCELLULAR LOCATION. RX PubMed=17587566; DOI=10.1016/j.jsbmb.2007.05.006; RA Meyer R., Wolf S.S., Obendorf M.; RT "PRMT2, a member of the protein arginine methyltransferase family, is a RT coactivator of the androgen receptor."; RL J. Steroid Biochem. Mol. Biol. 107:1-14(2007). RN [46] RP INTERACTION WITH RREB1. RX PubMed=17550981; DOI=10.1210/me.2006-0503; RA Mukhopadhyay N.K., Cinar B., Mukhopadhyay L., Lutchman M., Ferdinand A.S., RA Kim J., Chung L.W.K., Adam R.M., Ray S.K., Leiter A.B., Richie J.P., RA Liu B.C.-S., Freeman M.R.; RT "The zinc finger protein Ras-responsive element binding protein-1 is a RT coregulator of the androgen receptor: implications for the role of the Ras RT pathway in enhancing androgenic signaling in prostate cancer."; RL Mol. Endocrinol. 21:2056-2070(2007). RN [47] RP INTERACTION WITH RANBP10. RX PubMed=18222118; DOI=10.1016/j.bbrc.2008.01.072; RA Harada N., Yokoyama T., Yamaji R., Nakano Y., Inui H.; RT "RanBP10 acts as a novel coactivator for the androgen receptor."; RL Biochem. Biophys. Res. Commun. 368:121-125(2008). RN [48] RP INTERACTION WITH TNK2, PHOSPHORYLATION AT TYR-269 AND TYR-365 BY TNK2, AND RP MUTAGENESIS OF TYR-269 AND TYR-365. RX PubMed=17494760; DOI=10.1073/pnas.0700420104; RA Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., RA Earp H.S., Whang Y.E.; RT "Activated Cdc42-associated kinase Ack1 promotes prostate cancer RT progression via androgen receptor tyrosine phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007). RN [49] RP INTERACTION WITH TRIM68. RX PubMed=18451177; DOI=10.1158/0008-5472.can-07-6059; RA Miyajima N., Maruyama S., Bohgaki M., Kano S., Shigemura M., Shinohara N., RA Nonomura K., Hatakeyama S.; RT "TRIM68 regulates ligand-dependent transcription of androgen receptor in RT prostate cancer cells."; RL Cancer Res. 68:3486-3494(2008). RN [50] RP INTERACTION WITH LPXN. RX PubMed=18451096; DOI=10.1210/me.2006-0546; RA Kaulfuss S., Grzmil M., Hemmerlein B., Thelen P., Schweyer S., Neesen J., RA Bubendorf L., Glass A.G., Jarry H., Auber B., Burfeind P.; RT "Leupaxin, a novel coactivator of the androgen receptor, is expressed in RT prostate cancer and plays a role in adhesion and invasion of prostate RT carcinoma cells."; RL Mol. Endocrinol. 22:1606-1621(2008). RN [51] RP FUNCTION, AND INTERACTION WITH ZIPK/DAPK3. RX PubMed=18084323; DOI=10.1038/sj.onc.1210995; RA Leister P., Felten A., Chasan A.I., Scheidtmann K.H.; RT "ZIP kinase plays a crucial role in androgen receptor-mediated RT transcription."; RL Oncogene 27:3292-3300(2008). RN [52] RP INTERACTION WITH TRIM24. RX PubMed=19909775; DOI=10.1016/j.bbamcr.2009.11.001; RA Kikuchi M., Okumura F., Tsukiyama T., Watanabe M., Miyajima N., Tanaka J., RA Imamura M., Hatakeyama S.; RT "TRIM24 mediates ligand-dependent activation of androgen receptor and is RT repressed by a bromodomain-containing protein, BRD7, in prostate cancer RT cells."; RL Biochim. Biophys. Acta 1793:1828-1836(2009). RN [53] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, POLYUBIQUITINATION AT RP LYS-846 AND LYS-848 BY RNF6, MUTAGENESIS OF LYS-846 AND LYS-848, RP INTERACTION WITH RNF14 AND RNF6, AND SUBCELLULAR LOCATION. RX PubMed=19345326; DOI=10.1016/j.ccr.2009.02.021; RA Xu K., Shimelis H., Linn D.E., Jiang R., Yang X., Sun F., Guo Z., Chen H., RA Li W., Chen H., Kong X., Melamed J., Fang S., Xiao Z., Veenstra T.D., RA Qiu Y.; RT "Regulation of androgen receptor transcriptional activity and specificity RT by RNF6-induced ubiquitination."; RL Cancer Cell 15:270-282(2009). RN [54] RP FUNCTION, AND INTERACTION WITH MACROD1. RX PubMed=19022849; DOI=10.1677/erc-08-0150; RA Yang J., Zhao Y.-L., Wu Z.-Q., Si Y.-L., Meng Y.G., Fu X.B., Mu Y.-M., RA Han W.-D.; RT "The single-macro domain protein LRP16 is an essential cofactor of androgen RT receptor."; RL Endocr. Relat. Cancer 16:139-153(2009). RN [55] RP FUNCTION IN AR KINASE, PHOSPHORYLATION AT SER-83 BY CDK9, MUTAGENESIS OF RP SER-83, AND INTERACTION WITH CDK9. RX PubMed=20980437; DOI=10.1210/me.2010-0238; RA Gordon V., Bhadel S., Wunderlich W., Zhang J., Ficarro S.B., Mollah S.A., RA Shabanowitz J., Hunt D.F., Xenarios I., Hahn W.C., Conaway M., Carey M.F., RA Gioeli D.; RT "CDK9 regulates AR promoter selectivity and cell growth through serine 81 RT phosphorylation."; RL Mol. Endocrinol. 24:2267-2280(2010). RN [56] RP UBIQUITINATION, DEUBIQUITINATION, AND INTERACTION WITH USP26. RX PubMed=20501646; DOI=10.1158/1541-7786.mcr-09-0424; RA Dirac A.M., Bernards R.; RT "The deubiquitinating enzyme USP26 is a regulator of androgen receptor RT signaling."; RL Mol. Cancer Res. 8:844-854(2010). RN [57] RP PHOSPHORYLATION AT TYR-269, AND ACTIVITY REGULATION. RX PubMed=20623637; DOI=10.1002/pros.21163; RA Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., RA Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.; RT "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen RT receptor activity."; RL Prostate 70:1274-1285(2010). RN [58] RP PHOSPHORYLATION AT SER-651, AND INTERACTION WITH STK4/MST1. RX PubMed=21512132; DOI=10.1158/0008-5472.can-10-4532; RA Cinar B., Collak F.K., Lopez D., Akgul S., Mukhopadhyay N.K., RA Kilicarslan M., Gioeli D.G., Freeman M.R.; RT "MST1 is a multifunctional caspase-independent inhibitor of androgenic RT signaling."; RL Cancer Res. 71:4303-4313(2011). RN [59] RP FUNCTION, AND INTERACTION WITH NCOR1; NCOR2 AND ZBTB7A. RX PubMed=20812024; DOI=10.1007/s00018-010-0511-7; RA Cui J., Yang Y., Zhang C., Hu P., Kan W., Bai X., Liu X., Song H.; RT "FBI-1 functions as a novel AR co-repressor in prostate cancer cells."; RL Cell. Mol. Life Sci. 68:1091-1103(2011). RN [60] RP INTERACTION WITH CRY1. RX PubMed=22170608; DOI=10.1038/nature10700; RA Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W., RA Downes M., Evans R.M.; RT "Cryptochromes mediate rhythmic repression of the glucocorticoid RT receptor."; RL Nature 480:552-556(2011). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [62] RP PALMITOYLATION. RX PubMed=22031296; DOI=10.1091/mbc.e11-07-0638; RA Pedram A., Razandi M., Deschenes R.J., Levin E.R.; RT "DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors."; RL Mol. Biol. Cell 23:188-199(2012). RN [63] RP INTERACTION WITH RWDD1. RX PubMed=22406838; DOI=10.1016/j.mce.2012.02.020; RA Groetsch H., Kunert M., Mooslehner K.A., Gao Z., Struve D., Hughes I.A., RA Hiort O., Werner R.; RT "RWDD1 interacts with the ligand binding domain of the androgen receptor RT and acts as a coactivator of androgen-dependent transactivation."; RL Mol. Cell. Endocrinol. 358:53-62(2012). RN [64] RP INTERACTION WITH CCAR1 AND GATA2. RX PubMed=23887938; DOI=10.1093/nar/gkt644; RA Seo W.Y., Jeong B.C., Yu E.J., Kim H.J., Kim S.H., Lim J.E., Kwon G.Y., RA Lee H.M., Kim J.H.; RT "CCAR1 promotes chromatin loading of androgen receptor (AR) transcription RT complex by stabilizing the association between AR and GATA2."; RL Nucleic Acids Res. 41:8526-8536(2013). RN [65] RP INTERACTION WITH ARID4A. RX PubMed=23487765; DOI=10.1073/pnas.1218318110; RA Wu R.C., Jiang M., Beaudet A.L., Wu M.Y.; RT "ARID4A and ARID4B regulate male fertility, a functional link to the AR and RT RB pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 110:4616-4621(2013). RN [66] RP FUNCTIONAL CHARACTERIZATION OF ISOFORM 3. RX PubMed=25008967; DOI=10.1016/j.biocel.2014.06.013; RA Krause W.C., Shafi A.A., Nakka M., Weigel N.L.; RT "Androgen receptor and its splice variant, AR-V7, differentially regulate RT FOXA1 sensitive genes in LNCaP prostate cancer cells."; RL Int. J. Biochem. Cell Biol. 54:49-59(2014). RN [67] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96 AND SER-258, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 658-920. RX PubMed=10840043; DOI=10.1074/jbc.m004571200; RA Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., RA Otto N., Joschko S., Scholz P., Wegg A., Baesler S., Schaefer M., Egner U., RA Carrondo M.A.; RT "Structural evidence for ligand specificity in the binding domain of the RT human androgen receptor. Implications for pathogenic gene mutations."; RL J. Biol. Chem. 275:26164-26171(2000). RN [69] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 671-918. RX PubMed=11906285; DOI=10.1021/jm011072j; RA Matias P.M., Carrondo M.A., Coelho R., Thomaz M., Zhao X.Y., Wegg A., RA Crusius K., Egner U., Donner P.; RT "Structural basis for the glucocorticoid response in a mutant human RT androgen receptor (AR(ccr)) derived from an androgen-independent prostate RT cancer."; RL J. Med. Chem. 45:1439-1446(2002). RN [70] RP X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 672-920 IN COMPLEXES WITH RP N-TERMINAL MODULATING DOMAIN AND NCOA2, INTERACTION WITH NCOA1, AND RP CHARACTERIZATION OF VARIANT PROSTATE CANCER MET-731. RX PubMed=15525515; DOI=10.1016/j.molcel.2004.09.036; RA He B., Gampe R.T. Jr., Kole A.J., Hnat A.T., Stanley T.B., An G., RA Stewart E.L., Kalman R.I., Minges J.T., Wilson E.M.; RT "Structural basis for androgen receptor interdomain and coactivator RT interactions suggests a transition in nuclear receptor activation function RT dominance."; RL Mol. Cell 16:425-438(2004). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 670-920 IN COMPLEXES WITH RP DIHYDROTESTOSTERONE AND NCOA1; NCOA2; NCOA3 AND NCOA4, FUNCTION, RP INTERACTION WITH NCOA1; NCOA2; NCOA3 AND NCOA4, AND MUTAGENESIS OF LYS-721 RP AND GLU-898. RX PubMed=15563469; DOI=10.1074/jbc.m407046200; RA Estebanez-Perpina E., Moore J.M.R., Mar E., Delgado-Rodrigues E., RA Nguyen P., Baxter J.D., Buehrer B.M., Webb P., Fletterick R.J., Guy R.K.; RT "The molecular mechanisms of coactivator utilization in ligand-dependent RT transactivation by the androgen receptor."; RL J. Biol. Chem. 280:8060-8068(2005). RN [72] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 665-920 IN COMPLEXES WITH RP NONSTEROIDAL LIGANDS, MUTAGENESIS OF TRP-742, CHARACTERIZATION OF VARIANT RP PROSTATE CANCER ALA-878, AND CHARACTERIZATION OF VARIANT AIS THR-896. RX PubMed=16129672; DOI=10.1074/jbc.m507464200; RA Bohl C.E., Miller D.D., Chen J., Bell C.E., Dalton J.T.; RT "Structural basis for accommodation of nonsteroidal ligands in the androgen RT receptor."; RL J. Biol. Chem. 280:37747-37754(2005). RN [73] RP X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) OF 655-920 IN COMPLEXES WITH RP TESTOSTERONE; DIHYDROTESTOSTERONE AND TETRAHYDROGESTRINONE. RX PubMed=16641486; DOI=10.1110/ps.051905906; RA Pereira de Jesus-Tran K., Cote P.-L., Cantin L., Blanchet J., Labrie F., RA Breton R.; RT "Comparison of crystal structures of human androgen receptor ligand-binding RT domain complexed with various agonists reveals molecular determinants RT responsible for binding affinity."; RL Protein Sci. 15:987-999(2006). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 672-919 IN COMPLEX WITH NR0B2. RX PubMed=18007036; DOI=10.1107/s0907444907045702; RA Jouravel N., Sablin E., Arnold L.A., Guy R.K., Fletterick R.J.; RT "Interaction between the androgen receptor and a segment of its corepressor RT SHP."; RL Acta Crystallogr. D 63:1198-1200(2007). RN [75] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 671-919 OF MUTANT ALA-878 IN RP COMPLEX WITH THE ANTIANDROGEN CYPROTERONE ACETATE, CHARACTERIZATION OF RP VARIANT PROSTATE CANCER ALA-878, AND MUTAGENESIS OF LEU-702. RX PubMed=17311914; DOI=10.1074/jbc.m611711200; RA Bohl C.E., Wu Z., Miller D.D., Bell C.E., Dalton J.T.; RT "Crystal structure of the T877A human androgen receptor ligand-binding RT domain complexed to cyproterone acetate provides insight for ligand-induced RT conformational changes and structure-based drug design."; RL J. Biol. Chem. 282:13648-13655(2007). RN [76] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 663-919 OF WILD-TYPE AND MUTANT RP TYR-875 IN COMPLEX WITH TESTOSTERONE AND NCOA2, ACTIVATION BY THE RP N-TERMINAL MODULATING DOMAIN, INTERACTION WITH NCOA2 AND MAGEA11, FUNCTION, RP MUTAGENESIS OF LYS-721 AND GLU-898, AND CHARACTERIZATION OF VARIANT RP PROSTATE CANCER TYR-875. RX PubMed=17591767; DOI=10.1074/jbc.m703268200; RA Askew E.B., Gampe R.T. Jr., Stanley T.B., Faggart J.L., Wilson E.M.; RT "Modulation of androgen receptor activation function 2 by testosterone and RT dihydrotestosterone."; RL J. Biol. Chem. 282:25801-25816(2007). RN [77] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 655-920 IN COMPLEX WITH EM5744. RX PubMed=17711855; DOI=10.1074/jbc.m705524200; RA Cantin L., Faucher F., Couture J.-F., de Jesus-Tran K.P., Legrand P., RA Ciobanu L.C., Frechette Y., Labrecque R., Singh S.M., Labrie F., Breton R.; RT "Structural characterization of the human androgen receptor ligand-binding RT domain complexed with EM5744, a rationally designed steroidal ligand RT bearing a bulky chain directed toward helix 12."; RL J. Biol. Chem. 282:30910-30919(2007). RN [78] RP X-RAY CRYSTALLOGRAPHY (1.76 ANGSTROMS) OF 670-920 IN COMPLEXES WITH RP SYNTHETIC LIGANDS, FUNCTION, AND INTERACTION WITH NCOA2. RX PubMed=17911242; DOI=10.1073/pnas.0708036104; RA Estebanez-Perpina E., Arnold L.A., Nguyen P., Rodrigues E.D., Mar E., RA Bateman R., Pallai P., Shokat K.M., Baxter J.D., Guy R.K., Webb P., RA Fletterick R.J.; RT "A surface on the androgen receptor that allosterically regulates RT coactivator binding."; RL Proc. Natl. Acad. Sci. U.S.A. 104:16074-16079(2007). RN [79] {ECO:0007744|PDB:4OEA, ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, ECO:0007744|PDB:4OFU, ECO:0007744|PDB:4OGH, ECO:0007744|PDB:4OH5, ECO:0007744|PDB:4OHA, ECO:0007744|PDB:4OIL} RP X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 671-920 OF VARIANT PROSTATE RP CANCER ALA-878 AND WILD-TYPE IN COMPLEX WITH DIHYDROTESTOSTERONE AND BUD31 RP PEPTIDES, INTERACTION WITH BUD31, FUNCTION, SUBCELLULAR LOCATION, AND RP DOMAIN. RX PubMed=25091737; DOI=10.1016/j.molonc.2014.06.009; RA Hsu C.L., Liu J.S., Wu P.L., Guan H.H., Chen Y.L., Lin A.C., Ting H.J., RA Pang S.T., Yeh S.D., Ma W.L., Chen C.J., Wu W.G., Chang C.; RT "Identification of a new androgen receptor (AR) co-regulator BUD31 and RT related peptides to suppress wild-type and mutated AR-mediated prostate RT cancer growth via peptide screening and X-ray structure analysis."; RL Mol. Oncol. 8:1575-1587(2014). RN [80] RP VARIANT PAIS VAL-822, AND VARIANTS AIS ASN-665; TYR-733 AND ASN-815. RX PubMed=1458719; RA Pinsky L., Trifiro M.A., Kaufman M., Beitel L.K., Mhatre A., RA Kazemi-Esfarjani P., Sabbaghian N., Lumbroso R., Alvarado C., Vasiliou M., RA Gottlieb B.; RT "Androgen resistance due to mutation of the androgen receptor."; RL Clin. Invest. Med. 15:456-472(1992). RN [81] RP VARIANT PAIS TYR-807, AND VARIANT AIS LEU-857. RX PubMed=8339746; DOI=10.1007/bf02125442; RA Brown T.R., Scherer P.A., Chang Y.-T., Migeon C.J., Ghirri P., Murono K., RA Zhou Z.; RT "Molecular genetics of human androgen insensitivity."; RL Eur. J. Pediatr. 152 Suppl. 2:S62-S69(1993). RN [82] RP VARIANT AIS LYS-586. RX PubMed=8240973; DOI=10.1016/0960-0760(93)90178-y; RA Sultan C., Lumbroso S., Poujol N., Belon C., Boudon C., Lobaccaro J.-M.; RT "Mutations of androgen receptor gene in androgen insensitivity syndromes."; RL J. Steroid Biochem. Mol. Biol. 46:519-530(1993). RN [83] RP REVIEW ON VARIANTS. RX PubMed=7937057; RA Patterson M.N., Hughes I.A., Gottlieb B., Pinsky L.; RT "The androgen receptor gene mutations database."; RL Nucleic Acids Res. 22:3560-3562(1994). RN [84] RP VARIANTS AIS PHE-745 AND ARG-752. RX PubMed=7626493; DOI=10.1016/0960-0760(95)00090-m; RA Brinkmann A.O., Jenster G., Ris-Stalpers C., van der Korput J.A.G.M., RA Bruggenwirth H.T., Boehmer A.L.M., Trapman J.; RT "Androgen receptor mutations."; RL J. Steroid Biochem. Mol. Biol. 53:443-448(1995). RN [85] RP REVIEW ON VARIANTS. RX PubMed=9016528; DOI=10.1093/nar/25.1.158; RA Gottlieb B., Trifiro M.A., Lumbroso R., Vasiliou D.M., Pinsky L.; RT "The androgen receptor gene mutations database."; RL Nucleic Acids Res. 25:158-162(1997). RN [86] RP REVIEW ON VARIANTS. RX PubMed=22334387; DOI=10.1002/humu.22046; RA Gottlieb B., Beitel L.K., Nadarajah A., Paliouras M., Trifiro M.; RT "The androgen receptor gene mutations database: 2012 update."; RL Hum. Mutat. 33:887-894(2012). RN [87] RP VARIANT LNCAP ALA-878. RX PubMed=2260966; DOI=10.1016/s0006-291x(05)80067-1; RA Veldscholte J., Ris-Stalpers C., Kuiper G.G.J.M., Jenster G., RA Berrevoets C.A., Claassen E., van Rooij H.C.J., Trapman J., Brinkmann A.O., RA Mulder E.; RT "A mutation in the ligand binding domain of the androgen receptor of human RT LNCaP cells affects steroid binding characteristics and response to anti- RT androgens."; RL Biochem. Biophys. Res. Commun. 173:534-540(1990). RN [88] RP VARIANTS AIS CYS-775; GLN-832 AND MET-867. RX PubMed=2082179; DOI=10.1210/mend-4-12-1759; RA Brown T.R., Lubahn D.B., Wilson E.M., French F.S., Migeon C.J., RA Corfen J.L.; RT "Functional characterization of naturally occurring mutant androgen RT receptors from subjects with complete androgen insensitivity."; RL Mol. Endocrinol. 4:1759-1772(1990). RN [89] RP VARIANT CYS-775. RX PubMed=1856263; DOI=10.1210/jcem-73-2-318; RA Marcelli M., Tilley W.D., Zoppi S., Griffin J.E., Wilson J.D., RA McPhaul M.J.; RT "Androgen resistance associated with a mutation of the androgen receptor at RT amino acid 772 (Arg-->Cys) results from a combination of decreased RT messenger ribonucleic acid levels and impairment of receptor function."; RL J. Clin. Endocrinol. Metab. 73:318-325(1991). RN [90] RP VARIANTS AIS PRO-616 AND PRO-618. RX PubMed=1999491; DOI=10.1172/jci115076; RA Marcelli M., Zoppi S., Grino P.B., Griffin J.E., Wilson J.D., McPhaul M.J.; RT "A mutation in the DNA-binding domain of the androgen receptor gene causes RT complete testicular feminization in a patient with receptor-positive RT androgen resistance."; RL J. Clin. Invest. 87:1123-1126(1991). RN [91] RP VARIANT PAIS CYS-764. RX PubMed=2010552; DOI=10.1172/jci115147; RA McPhaul M.J., Marcelli M., Tilley W.D., Griffin J.E., RA Isidro-Gutierrez R.F., Wilson J.D.; RT "Molecular basis of androgen resistance in a family with a qualitative RT abnormality of the androgen receptor and responsive to high-dose androgen RT therapy."; RL J. Clin. Invest. 87:1413-1421(1991). RN [92] RP POLY-GLN REGION EXPANSION, AND INVOLVEMENT IN SPINAL AND BULBAR MUSCULAR RP ATROPHY. RX PubMed=2062380; DOI=10.1038/352077a0; RA la Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H.; RT "Androgen receptor gene mutations in X-linked spinal and bulbar muscular RT atrophy."; RL Nature 352:77-79(1991). RN [93] RP VARIANTS AIS CYS-775 AND HIS-775. RX PubMed=1609793; RA Prior L., Bordet S., Trifiro M.A., Mhatre A., Kaufman M., Pinsky L., RA Wrogemann K., Belsham D.D., Pereira F., Greenberg C.R., Trapman J., RA Brinkmann A.O., Chang C., Liao S.; RT "Replacement of arginine 773 by cysteine or histidine in the human androgen RT receptor causes complete androgen insensitivity with different receptor RT phenotypes."; RL Am. J. Hum. Genet. 51:143-155(1992). RN [94] RP VARIANTS PAIS LYS-609 AND LEU-867. RX PubMed=1424203; DOI=10.1111/j.1365-2265.1992.tb02313.x; RA Saunders P.T., Padayachi T., Tincello D.G., Shalet S.M., Wu F.C.; RT "Point mutations detected in the androgen receptor gene of three men with RT partial androgen insensitivity syndrome."; RL Clin. Endocrinol. (Oxf.) 37:214-220(1992). RN [95] RP VARIANT AIS THR-766. RX PubMed=1426313; DOI=10.1016/s0015-0282(16)55315-1; RA Sweet C.R., Behzadian M.A., McDonough P.G.; RT "A unique point mutation in the androgen receptor gene in a family with RT complete androgen insensitivity syndrome."; RL Fertil. Steril. 58:703-707(1992). RN [96] RP VARIANT AIS VAL-750. RX PubMed=1487249; DOI=10.1007/bf00220088; RA Jakubiczka S., Werder E.A., Wieacker P.; RT "Point mutation in the steroid-binding domain of the androgen receptor gene RT in a family with complete androgen insensitivity syndrome (CAIS)."; RL Hum. Genet. 90:311-312(1992). RN [97] RP VARIANTS AIS, AND VARIANTS PAIS. RX PubMed=1307250; DOI=10.1093/hmg/1.7.497; RA Batch J.A., Williams D.M., Davies H.R., Brown B.D., Evans B.A.J., RA Hughes I.A., Patterson M.N.; RT "Androgen receptor gene mutations identified by SSCP in fourteen subjects RT with androgen insensitivity syndrome."; RL Hum. Mol. Genet. 1:497-503(1992). RN [98] RP VARIANT AIS VAL-788. RX PubMed=1569163; DOI=10.1210/jcem.74.5.1569163; RA Nakao R., Haji M., Yanase T., Ogo A., Takayanagi R., Katsube T., RA Fukumaki Y., Nawata H.; RT "A single amino acid substitution (Met-786-->Val) in the steroid-binding RT domain of human androgen receptor leads to complete androgen insensitivity RT syndrome."; RL J. Clin. Endocrinol. Metab. 74:1152-1157(1992). RN [99] RP VARIANTS AIS ARG-742 AND CYS-835. RX PubMed=1464650; DOI=10.1210/jcem.75.6.1464650; RA Wilson C.M., Griffin J.E., Wilson J.D., Marcelli M., Zoppi S., RA McPhaul M.J.; RT "Immunoreactive androgen receptor expression in subjects with androgen RT resistance."; RL J. Clin. Endocrinol. Metab. 75:1474-1478(1992). RN [100] RP VARIANTS AIS, VARIANTS PAIS, VARIANTS AIS SER-767 AND HIS-905, AND VARIANTS RP PAIS LYS-855 AND MET-904. RX PubMed=1430233; DOI=10.1172/jci116093; RA McPhaul M.J., Marcelli M., Zoppi S., Wilson C.M., Griffin J.E., RA Wilson J.D.; RT "Mutations in the ligand-binding domain of the androgen receptor gene RT cluster in two regions of the gene."; RL J. Clin. Invest. 90:2097-2101(1992). RN [101] RP VARIANT PROSTATE CANCER ALA-878. RX PubMed=1562539; DOI=10.1016/0960-0760(92)90401-4; RA Veldscholte J., Berrevoets C.A., Ris-Stalpers C., Kuiper G.G.J.M., RA Jenster G., Trapman J., Brinkmann A.O., Mulder E.; RT "The androgen receptor in LNCaP cells contains a mutation in the ligand RT binding domain which affects steroid binding characteristics and response RT to antiandrogens."; RL J. Steroid Biochem. Mol. Biol. 41:665-669(1992). RN [102] RP VARIANTS AIS TYR-560 AND ARG-577, AND VARIANTS PAIS GLY-598 AND PRO-618. RX PubMed=1316540; DOI=10.1210/mend.6.3.1316540; RA Zoppi S., Marcelli M., Deslypere J.-P., Griffin J.E., Wilson J.D., RA McPhaul M.J.; RT "Amino acid substitutions in the DNA-binding domain of the human androgen RT receptor are a frequent cause of receptor-binding positive androgen RT resistance."; RL Mol. Endocrinol. 6:409-415(1992). RN [103] RP VARIANTS AIS SER-706; VAL-750; PHE-760; HIS-775; CYS-856 AND GLY-865. RX PubMed=1480178; DOI=10.1210/mend.6.11.1480178; RA De Bellis A., Quigley C.A., Cariello N.F., el-Awady M.K., Sar M., RA Lane M.V., Wilson E.M., French F.S.; RT "Single base mutations in the human androgen receptor gene causing complete RT androgen insensitivity: rapid detection by a modified denaturing gradient RT gel electrophoresis technique."; RL Mol. Endocrinol. 6:1909-1920(1992). RN [104] RP VARIANT PAIS/BREAST CANCER GLN-608. RX PubMed=1303262; DOI=10.1038/ng1092-132; RA Wooster R., Mangion J., Eeles R., Smith S., Dowsett M., Averill D., RA Barrett-Lee P., Easton D.F., Ponder B.A., Stratton M.R.; RT "A germline mutation in the androgen receptor gene in two brothers with RT breast cancer and Reifenstein syndrome."; RL Nat. Genet. 2:132-134(1992). RN [105] RP VARIANT MET-731. RX PubMed=1631125; DOI=10.1073/pnas.89.14.6319; RA Newmark J.R., Hardy D.O., Tonb D.C., Carter B.S., Epstein J.I., RA Isaacs W.B., Brown T.R., Barrack E.R.; RT "Androgen receptor gene mutations in human prostate cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6319-6323(1992). RN [106] RP VARIANTS ARG-207 AND ASP-794. RX PubMed=8213813; RA Macke J.P., Hu N., Hu S., Bailey M., King V.L., Brown T., Hamer D., RA Nathans J.; RT "Sequence variation in the androgen receptor gene is not a common RT determinant of male sexual orientation."; RL Am. J. Hum. Genet. 53:844-852(1993). RN [107] RP VARIANT AIS PHE-582. RX PubMed=8224266; DOI=10.1016/s0015-0282(16)56281-5; RA Lumbroso S., Lobaccaro J.-M., Belon C., Martin D., Chaussain J.-L., RA Sultan C.; RT "A new mutation within the deoxyribonucleic acid-binding domain of the RT androgen receptor gene in a family with complete androgen insensitivity RT syndrome."; RL Fertil. Steril. 60:814-819(1993). RN [108] RP VARIANT AIS VAL-755. RX PubMed=8103398; DOI=10.1093/hmg/2.7.1041; RA Lobaccaro J.-M., Lumbroso S., Ktari R., Dumas R., Sultan C.; RT "An exonic point mutation creates a MaeIII site in the androgen receptor RT gene of a family with complete androgen insensitivity syndrome."; RL Hum. Mol. Genet. 2:1041-1043(1993). RN [109] RP VARIANT PAIS/BREAST CANCER LYS-609. RX PubMed=8281139; DOI=10.1093/hmg/2.11.1799; RA Lobaccaro J.-M., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., RA Lesimple T., Namer M., Cutuli B.F., Pujol H., Sultan C.; RT "Androgen receptor gene mutation in male breast cancer."; RL Hum. Mol. Genet. 2:1799-1802(1993). RN [110] RP VARIANT AIS ARG-808. RX PubMed=8281140; DOI=10.1093/hmg/2.11.1809; RA Adeyemo O., Kallio P.J., Palvimo J.J., Kontula K., Jaenne O.A.; RT "A single-base substitution in exon 6 of the androgen receptor gene causing RT complete androgen insensitivity: the mutated receptor fails to RT transactivate but binds to DNA in vitro."; RL Hum. Mol. Genet. 2:1809-1812(1993). RN [111] RP VARIANT PAIS VAL-744. RX PubMed=8325932; DOI=10.1210/jcem.77.1.8325932; RA Nakao R., Yanase T., Sakai Y., Haji M., Nawata H.; RT "A single amino acid substitution (Gly743 --> Val) in the steroid-binding RT domain of the human androgen receptor leads to Reifenstein syndrome."; RL J. Clin. Endocrinol. Metab. 77:103-107(1993). RN [112] RP VARIANTS AIS LYS-682 AND THR-843, AND VARIANTS PAIS HIS-841 AND LEU-867. RX PubMed=8325950; DOI=10.1210/jcem.77.1.8325950; RA Hiort O., Huang Q., Sinnecker G.H., Sadeghi-Nejad A., Kruse K., Wolfe H.J., RA Yandell D.W.; RT "Single strand conformation polymorphism analysis of androgen receptor gene RT mutations in patients with androgen insensitivity syndromes: application RT for diagnosis, genetic counseling, and therapy."; RL J. Clin. Endocrinol. Metab. 77:262-266(1993). RN [113] RP INVOLVEMENT IN PAIS, INVOLVEMENT IN HYSP1, AND VARIANTS PAIS HIS-856 AND RP MET-870. RX PubMed=8097257; DOI=10.1136/jmg.30.3.198; RA Batch J.A., Evans B.A.J., Hughes I.A., Patterson M.N.; RT "Mutations of the androgen receptor gene identified in perineal RT hypospadias."; RL J. Med. Genet. 30:198-201(1993). RN [114] RP VARIANT AIS VAL-744. RX PubMed=8096390; DOI=10.1016/0960-0760(93)90081-7; RA Lobaccaro J.-M., Lumbroso S., Berta P., Chaussain J.-L., Sultan C.; RT "Complete androgen insensitivity syndrome associated with a de novo RT mutation of the androgen receptor gene detected by single strand RT conformation polymorphism."; RL J. Steroid Biochem. Mol. Biol. 44:211-216(1993). RN [115] RP VARIANTS HIS-702 AND ALA-878. RX PubMed=8274409; DOI=10.1016/0960-0760(93)90316-o; RA Suzuki H., Sato N., Watabe Y., Masai M., Seino S., Shimazaki J.; RT "Androgen receptor gene mutations in human prostate cancer."; RL J. Steroid Biochem. Mol. Biol. 46:759-765(1993). RN [116] RP VARIANT AIS MET-867, AND VARIANT PAIS LEU-867. RX PubMed=8446106; DOI=10.1210/mend.7.1.8446106; RA Kazemi-Esfarjani P., Beitel L.K., Trifiro M.A., Kaufman M., Rennie P., RA Sheppard P., Matusik R., Pinsky L.; RT "Substitution of valine-865 by methionine or leucine in the human androgen RT receptor causes complete or partial androgen insensitivity, respectively RT with distinct androgen receptor phenotypes."; RL Mol. Endocrinol. 7:37-46(1993). RN [117] RP VARIANT PROSTATE CANCER MET-716. RX PubMed=8145761; DOI=10.1210/mend.7.12.8145761; RA Culig Z., Hobisch A., Cronauer M.V., Cato A.C.B., Hittmair A., Radmayr C., RA Eberle J., Bartsch G., Klocker H.; RT "Mutant androgen receptor detected in an advanced-stage prostatic carcinoma RT is activated by adrenal androgens and progesterone."; RL Mol. Endocrinol. 7:1541-1550(1993). RN [118] RP VARIANTS AIS PHE-582; VAL-744; VAL-755; GLU-768 AND CYS-856. RA Lobaccaro J.-M., Lumbroso S., Belon C., Chaussain J.L., Toublanc J.E., RA Leheup B., Sultan C.; RT "Androgen receptor (AR) gene mutations in 6 families with androgen RT insensitivity syndrome (Abstract #114)."; RL Pediatr. Res. Suppl. 33:S22-S22(1993). RN [119] RP VARIANTS PROSTATE CANCER LEU-342 AND GLU-799. RX PubMed=7511268; RA Castagnaro M., Yandell D.W., Dockhorn-Dworniczak B., Wolfe H.J., RA Poremba C.; RT "Androgen receptor gene mutations and p53 gene analysis in advanced RT prostate cancer."; RL Verh. Dtsch. Ges. Pathol. 77:119-123(1993). RN [120] RP POLY-GLN REGION CONTRACTION, AND INVOLVEMENT IN PROSTATE CANCER. RX PubMed=8292051; DOI=10.1006/bbrc.1994.1011; RA Schoenberg M.P., Hakimi J.M., Wang S., Bova G.S., Epstein J.I., RA Fischbeck K.H., Isaacs W.B., Walsh P.C., Barrack E.R.; RT "Microsatellite mutation (CAG24-->18) in the androgen receptor gene in RT human prostate cancer."; RL Biochem. Biophys. Res. Commun. 198:74-80(1994). RN [121] RP VARIANT PROSTATE CANCER ALA-878. RX PubMed=8187068; RA Gaddipati J.P., McLeod D.G., Heidenberg H.B., Sesterhenn I.A., Finger M.J., RA Moul J.W., Srivastava S.; RT "Frequent detection of codon 877 mutation in the androgen receptor gene in RT advanced prostate cancers."; RL Cancer Res. 54:2861-2864(1994). RN [122] RP VARIANT PAIS TRP-569. RX PubMed=7910529; DOI=10.1111/j.1365-2265.1994.tb03922.x; RA Lobaccaro J.-M., Belon C., Lumbroso S., Olewniczack G., Carre-Pigeon F., RA Job J.C., Chaussain J.L., Toublanc J.E., Sultan C.; RT "Molecular prenatal diagnosis of partial androgen insensitivity syndrome RT based on the Hind III polymorphism of the androgen receptor gene."; RL Clin. Endocrinol. (Oxf.) 40:297-302(1994). RN [123] RP VARIANT PAIS HIS-841. RX PubMed=7909256; DOI=10.1530/eje.0.1300327; RA Lumbroso S., Lobaccaro J.-M., Belon C., Amram S., Bachelard B., RA Garandeau P., Sultan C.; RT "Molecular prenatal exclusion of familial partial androgen insensitivity RT (Reifenstein syndrome)."; RL Eur. J. Endocrinol. 130:327-332(1994). RN [124] RP VARIANT PAIS HIS-841. RX PubMed=8205256; DOI=10.1530/eje.0.1300569; RA Imasaki K., Hasegawa T., Okabe T., Sakai Y., Haji M., Takayanagi R., RA Nawata H.; RT "Single amino acid substitution (840Arg-->His) in the hormone-binding RT domain of the androgen receptor leads to incomplete androgen insensitivity RT syndrome associated with a thermolabile androgen receptor."; RL Eur. J. Endocrinol. 130:569-574(1994). RN [125] RP VARIANT PAIS VAL-871. RX PubMed=8033918; DOI=10.1007/bf01956409; RA Hiort O., Klauber G., Cendron M., Sinnecker G.H., Keim L., Schwinger E., RA Wolfe H.J., Yandell D.W.; RT "Molecular characterization of the androgen receptor gene in boys with RT hypospadias."; RL Eur. J. Pediatr. 153:317-321(1994). RN [126] RP VARIANT PAIS ASP-691 DEL. RA Schwartz M., Skovby F., Mueller J., Nielsen O., Skakkebaek N.E.; RT "Partial androgen insensitivity (PAIS) in a large eskimo kindred caused by RT a delD690 mutation in the androgen receptor (AR) gene (Abstract #244)."; RL Horm. Res. 41:117-117(1994). RN [127] RP VARIANTS AIS PHE-583 DEL; ARG-616 DEL AND HIS-616. RX PubMed=8162033; DOI=10.1093/hmg/3.1.21; RA Beitel L.K., Prior L., Vasiliou D.M., Gottlieb B., Kaufman M., Lumbroso R., RA Alvarado C., McGillivray B., Trifiro M.A., Pinsky L.; RT "Complete androgen insensitivity due to mutations in the probable alpha- RT helical segments of the DNA-binding domain in the human androgen RT receptor."; RL Hum. Mol. Genet. 3:21-27(1994). RN [128] RP VARIANTS PAIS SER-583; TYR-605; ALA-709; LEU-755 AND HIS-772, AND VARIANT RP AIS TRP-780. RX PubMed=7981687; DOI=10.1093/hmg/3.7.1163; RA Hiort O., Wodtke A., Struve D., Zoellner A., Sinnecker G.H.; RT "Detection of point mutations in the androgen receptor gene using non- RT isotopic single strand conformation polymorphism analysis."; RL Hum. Mol. Genet. 3:1163-1166(1994). RN [129] RP VARIANT AIS PHE-602. RX PubMed=7981689; DOI=10.1093/hmg/3.7.1169; RA Baldazzi L., Baroncini C., Pirazzoli P., Balsamo A., Capelli M., RA Marchetti G., Bernardi F., Cacciari E.; RT "Two mutations causing complete androgen insensitivity: a frame-shift in RT the steroid binding domain and a Cys-->Phe substitution in the second zinc RT finger of the androgen receptor."; RL Hum. Mol. Genet. 3:1169-1170(1994). RN [130] RP VARIANTS PAIS ARG-617; HIS-841 AND MET-890. RX PubMed=8126121; DOI=10.1210/jcem.78.3.8126121; RA De Bellis A., Quigley C.A., Marschke K.B., el-Awady M.K., Lane M.V., RA Smith E.P., Sar M., Wilson E.M., French F.S.; RT "Characterization of mutant androgen receptors causing partial androgen RT insensitivity syndrome."; RL J. Clin. Endocrinol. Metab. 78:513-522(1994). RN [131] RP VARIANT AIS PHE-791. RX PubMed=7962294; DOI=10.1210/jcem.79.4.7962294; RA Tsukada T., Inoue M., Tachibana S., Nakai Y., Takebe H.; RT "An androgen receptor mutation causing androgen resistance in RT undervirilized male syndrome."; RL J. Clin. Endocrinol. Metab. 79:1202-1207(1994). RN [132] RP VARIANTS AIS CYS-841 AND HIS-841. RX PubMed=8040309; DOI=10.1172/jci117368; RA Beitel L.K., Kazemi-Esfarjani P., Kaufman M., Lumbroso R., DiGeorge A.M., RA Killinger D.W., Trifiro M.A., Pinsky L.; RT "Substitution of arginine-839 by cysteine or histidine in the androgen RT receptor causes different receptor phenotypes in cultured cells and RT coordinate degrees of clinical androgen resistance."; RL J. Clin. Invest. 94:546-554(1994). RN [133] RP VARIANTS AIS, AND VARIANTS PAIS. RX PubMed=7929841; DOI=10.1172/jci117507; RA Marcelli M., Zoppi S., Wilson C.M., Griffin J.E., McPhaul M.J.; RT "Amino acid substitutions in the hormone-binding domain of the human RT androgen receptor alter the stability of the hormone receptor complex."; RL J. Clin. Invest. 94:1642-1650(1994). RN [134] RP VARIANT AIS LYS-728. RX PubMed=7993455; DOI=10.1016/s0140-6736(94)92385-x; RA Yong E.L., Ng S.C., Roy A.C., Yun G., Ratnam S.S.; RT "Pregnancy after hormonal correction of severe spermatogenic defect due to RT mutation in androgen receptor gene."; RL Lancet 344:826-827(1994). RN [135] RP VARIANTS AIS HIS-616 AND LEU-765, AND VARIANTS PAIS VAL-743 AND THR-746. RX PubMed=7970939; DOI=10.1203/00006450-199408000-00015; RA Ris-Stalpers C., Hoogenboezem T., Sleddens H.F.B.M., RA Verleun-Mooijman M.C.T., Degenhart H.J., Drop S.L.S., Halley D.J.J., RA Oosterwijk J.C., Hodgins M.B., Trapman J., Brinkmann A.O.; RT "A practical approach to the detection of androgen receptor gene mutations RT and pedigree analysis in families with X-linked androgen insensitivity."; RL Pediatr. Res. 36:227-234(1994). RN [136] RP VARIANT AIS HIS-841. RX PubMed=8830623; DOI=10.1177/000456329503200508; RA Imai A., Ohno T., Iida K., Ohsuye K., Okano Y., Tamaya T.; RT "A frame-shift mutation of the androgen receptor gene in a patient with RT receptor-negative complete testicular feminization: comparison with a RT single base substitution in a receptor-reduced incomplete form."; RL Ann. Clin. Biochem. 32:482-486(1995). RN [137] RP VARIANTS PROSTATE CANCER. RX PubMed=7712463; RA Takahashi H., Furusato M., Allsbrook W.C. Jr., Nishii H., Wakui S., RA Barrett J.C., Boyd J.; RT "Prevalence of androgen receptor gene mutations in latent prostatic RT carcinomas from Japanese men."; RL Cancer Res. 55:1621-1624(1995). RN [138] RP VARIANT AIS VAL-882. RX PubMed=7641413; DOI=10.1111/j.1365-2265.1995.tb01895.x; RA Davies H.R., Hughes I.A., Patterson M.N.; RT "Genetic counselling in complete androgen insensitivity syndrome: RT trinucleotide repeat polymorphisms, single-strand conformation polymorphism RT and direct detection of two novel mutations in the androgen receptor RT gene."; RL Clin. Endocrinol. (Oxf.) 43:69-77(1995). RN [139] RP VARIANTS AIS SER-706 AND HIS-764, AND VARIANTS PAIS LEU-726; THR-738; RP HIS-775 AND GLU-799. RX PubMed=7671849; DOI=10.1210/edrv-16-3-271; RA Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., RA French F.S.; RT "Androgen receptor defects: historical, clinical, and molecular RT perspectives."; RL Endocr. Rev. 16:271-321(1995). RN [140] RP ERRATUM OF PUBMED:7671849. RA Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., RA French F.S.; RL Endocr. Rev. 16:546-546(1995). RN [141] RP VARIANTS AIS LEU-832 AND GLN-832. RX PubMed=7633398; DOI=10.1093/hmg/4.4.515; RA Shkolny D.L., Brown T.R., Punnett H.H., Kaufman M., Trifiro M.A., RA Pinsky L.; RT "Characterization of alternative amino acid substitutions at arginine 830 RT of the androgen receptor that cause complete androgen insensitivity in RT three families."; RL Hum. Mol. Genet. 4:515-521(1995). RN [142] RP VARIANT AIS PRO-678. RX PubMed=7537149; DOI=10.1002/humu.1380050104; RA Belsham D.D., Pereira F., Greenberg C.R., Liao S., Wrogemann K.; RT "Leu-676-Pro mutation of the androgen receptor causes complete androgen RT insensitivity syndrome in a large Hutterite kindred."; RL Hum. Mutat. 5:28-33(1995). RN [143] RP VARIANT PAIS CYS-764, AND VARIANTS AIS TRP-780; VAL-808 AND CYS-856. RX PubMed=7581399; DOI=10.1002/humu.1380060208; RA Murono K., Mendonca B.B., Arnhold I.J.P., Rigon A.C.M.M., Migeon C.J., RA Brown T.R.; RT "Human androgen insensitivity due to point mutations encoding amino acid RT substitutions in the androgen receptor steroid-binding domain."; RL Hum. Mutat. 6:152-162(1995). RN [144] RP VARIANT PROSTATE CANCER MET-731. RX PubMed=7591265; DOI=10.1002/ijc.2910630415; RA Peterziel H., Culig Z., Stober J., Hobisch A., Radmayr C., Bartsch G., RA Klocker H., Cato A.C.B.; RT "Mutant androgen receptors in prostatic tumors distinguish between amino- RT acid-sequence requirements for transactivation and ligand binding."; RL Int. J. Cancer 63:544-550(1995). RN [145] RP VARIANT VAL-569. RX PubMed=7673412; DOI=10.1210/jcem.80.9.7673412; RA Allera A., Herbst M.A., Griffin J.E., Wilson J.D., Schweikert H.-U., RA McPhaul M.J.; RT "Mutations of the androgen receptor coding sequence are infrequent in RT patients with isolated hypospadias."; RL J. Clin. Endocrinol. Metab. 80:2697-2699(1995). RN [146] RP INVOLVEMENT IN HPCX3, AND VARIANT HPCX3 LEU-727. RX PubMed=8530589; DOI=10.1210/jcem.80.12.8530589; RA Elo J.P., Kvist L., Leinonen K., Isomaa V., Henttu P., Lukkarinen O., RA Vihko P.; RT "Mutated human androgen receptor gene detected in a prostatic cancer RT patient is also activated by estradiol."; RL J. Clin. Endocrinol. Metab. 80:3494-3500(1995). RN [147] RP VARIANT PAIS THR-597. RX PubMed=7649358; DOI=10.1016/0303-7207(95)03554-k; RA Gast A., Neuschmid-Kaspar F., Klocker H., Cato A.C.B.; RT "A single amino acid exchange abolishes dimerization of the androgen RT receptor and causes Reifenstein syndrome."; RL Mol. Cell. Endocrinol. 111:93-98(1995). RN [148] RP VARIANTS PROSTATE CANCER. RX PubMed=7723794; DOI=10.1056/nejm199505253322101; RA Taplin M.-E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., RA Ogata G.K., Keer H.N., Balk S.P.; RT "Mutation of the androgen-receptor gene in metastatic androgen-independent RT prostate cancer."; RL N. Engl. J. Med. 332:1393-1398(1995). RN [149] RP VARIANTS AIS AND PAIS, VARIANTS PAIS ARG-687; VAL-688; PHE-713; MET-747; RP SER-757 AND SER-842, AND VARIANTS AIS GLU-689; MET-747 AND THR-899. RX PubMed=8723113; RX DOI=10.1002/(sici)1096-8628(19960503)63:1<218::aid-ajmg38>3.0.co;2-p; RA Hiort O., Sinnecker G.H., Holterhus P.M., Nitsche E.M., Kruse K.; RT "The clinical and molecular spectrum of androgen insensitivity syndromes."; RL Am. J. Med. Genet. 63:218-222(1996). RN [150] RP VARIANTS PROSTATE CANCER. RX PubMed=9816170; RA Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M.; RT "Mutations in the androgen receptor gene are associated with progression of RT human prostate cancer to androgen independence."; RL Clin. Cancer Res. 2:277-285(1996). RN [151] RP VARIANTS PAIS GLN-608; THR-611; LEU-755; HIS-841; THR-843 AND HIS-856, AND RP VARIANT AIS MET-867. RX PubMed=9039340; DOI=10.1046/j.1365-2265.1996.8600869.x; RA Weidemann W., Linck B., Haupt H., Mentrup B., Romalo G., Stockklauser K., RA Brinkmann A.O., Schweikert H.-U., Spindler K.D.; RT "Clinical and biochemical investigations and molecular analysis of subjects RT with mutations in the androgen receptor gene."; RL Clin. Endocrinol. (Oxf.) 45:733-739(1996). RN [152] RP VARIANT AIS CYS-856. RX PubMed=9001799; DOI=10.1111/j.1399-0004.1996.tb02626.x; RA Malmgren H., Gustavsson J., Tuvemo T., Dahl N.; RT "Rapid detection of a mutation hot-spot in the human androgen receptor."; RL Clin. Genet. 50:202-205(1996). RN [153] RP VARIANTS PAIS ILE-743; ILE-781; GLU-799; CYS-841; HIS-856 AND MET-870. RX PubMed=8824883; DOI=10.1093/hmg/5.2.265; RA Bevan C.L., Brown B.B., Davies H.R., Evans B.A.J., Hughes I.A., RA Patterson M.N.; RT "Functional analysis of six androgen receptor mutations identified in RT patients with partial androgen insensitivity syndrome."; RL Hum. Mol. Genet. 5:265-273(1996). RN [154] RP VARIANT PAIS ARG-910. RX PubMed=8550758; DOI=10.1210/jcem.81.1.8550758; RA Choong C.S., Sturm M.J., Strophair J.A., McCulloch R.K., Tilley W.D., RA Leedman P.J., Hurley D.M.; RT "Partial androgen insensitivity caused by an androgen receptor mutation at RT amino acid 907 (Gly-->Arg) that results in decreased ligand binding RT affinity and reduced androgen receptor messenger ribonucleic acid levels."; RL J. Clin. Endocrinol. Metab. 81:236-243(1996). RN [155] RP VARIANT AIS ARG-708. RX PubMed=8626869; DOI=10.1210/jcem.81.5.8626869; RA Lumbroso S., Lobaccaro J.-M., Georget V., Leger J., Poujol N., RA Terouanne B., Evain-Brion D., Czernichow P., Sultan C.; RT "A novel substitution (Leu707Arg) in exon 4 of the androgen receptor gene RT causes complete androgen resistance."; RL J. Clin. Endocrinol. Metab. 81:1984-1988(1996). RN [156] RP VARIANT AIS ILE-781. RX PubMed=8768864; DOI=10.1210/jcem.81.8.8768864; RA Rodien P., Mebarki F., Mowszowicz I., Chaussain J.L., Young J., Morel Y., RA Schaison G.; RT "Different phenotypes in a family with androgen insensitivity caused by the RT same M780I point mutation in the androgen receptor gene."; RL J. Clin. Endocrinol. Metab. 81:2994-2998(1996). RN [157] RP VARIANT PAIS LYS-2. RX PubMed=8823308; DOI=10.1172/jci118930; RA Choong C.S., Quigley C.A., French F.S., Wilson E.M.; RT "A novel missense mutation in the amino-terminal domain of the human RT androgen receptor gene in a family with partial androgen insensitivity RT syndrome causes reduced efficiency of protein translation."; RL J. Clin. Invest. 98:1423-1431(1996). RN [158] RP VARIANT AIS ASP-574. RX PubMed=8918984; DOI=10.1016/0960-0760(96)00095-7; RA Bruggenwirth H.T., Boehmer A.L.M., Verleun-Mooijman M.C.T., RA Hoogenboezem T., Kleijer W.J., Otten B.J., Trapman J., Brinkmann A.O.; RT "Molecular basis of androgen insensitivity."; RL J. Steroid Biochem. Mol. Biol. 58:569-575(1996). RN [159] RP VARIANT AIS SER-549. RX PubMed=8683794; DOI=10.1097/00005392-199608001-00077; RA Sutherland R.W., Wiener J.S., Hicks J.P., Marcelli M., Gonzales E.T. Jr., RA Roth D.R., Lamb D.J.; RT "Androgen receptor gene mutations are rarely associated with isolated RT penile hypospadias."; RL J. Urol. 156:828-831(1996). RN [160] RP VARIANT AIS PRO-617. RX PubMed=8647313; DOI=10.1016/0303-7207(95)03709-8; RA Lobaccaro J.-M., Poujol N., Chiche L., Lumbroso S., Brown T.R., Sultan C.; RT "Molecular modeling and in vitro investigations of the human androgen RT receptor DNA-binding domain: application for the study of two mutations."; RL Mol. Cell. Endocrinol. 116:137-147(1996). RN [161] RP VARIANT AIS PHE-580, AND VARIANT PAIS TYR-583. RX PubMed=8809734; DOI=10.1016/0303-7207(96)03812-9; RA Imasaki K., Okabe T., Murakami H., Tanaka Y., Haji M., Takayanagi R., RA Nawata H.; RT "Androgen insensitivity syndrome due to new mutations in the DNA-binding RT domain of the androgen receptor."; RL Mol. Cell. Endocrinol. 120:15-24(1996). RN [162] RP VARIANT PROSTATE CANCER GLU-799. RX PubMed=8628719; RX DOI=10.1002/(sici)1097-0045(199603)28:3<162::aid-pros3>3.0.co;2-h; RA Evans B.A.J., Harper M.E., Daniells C.E., Watts C.E., Matenhelia S., RA Green J., Griffiths K.; RT "Low incidence of androgen receptor gene mutations in human prostatic RT tumors using single strand conformation polymorphism analysis."; RL Prostate 28:162-171(1996). RN [163] RP VARIANT PROSTATE CANCER ALA-878. RX PubMed=8827083; RX DOI=10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5; RA Suzuki H., Akakura K., Komiya A., Aida S., Akimoto S., Shimazaki J.; RT "Codon 877 mutation in the androgen receptor gene in advanced prostate RT cancer: relation to antiandrogen withdrawal syndrome."; RL Prostate 29:153-158(1996). RN [164] RP VARIANT AIS HIS-856. RX PubMed=9106550; RA Boehmer A.L.M., Brinkmann A.O., Niermeijer M.F., Bakker L., Halley D.J.J., RA Drop S.L.S.; RT "Germ-line and somatic mosaicism in the androgen insensitivity syndrome: RT implications for genetic counseling."; RL Am. J. Hum. Genet. 60:1003-1006(1997). RN [165] RP VARIANT PROSTATE CANCER ALA-684. RX PubMed=9000575; RA Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., RA Trapman J., Cleutjens K., Noordzij A., Visakorpi T., Kallioniemi O.-P.; RT "Androgen receptor gene amplification: a possible molecular mechanism for RT androgen deprivation therapy failure in prostate cancer."; RL Cancer Res. 57:314-319(1997). RN [166] RP VARIANTS PAIS LYS-609 AND GLY-773. RX PubMed=9196614; DOI=10.1046/j.1365-2265.1997.1140927.x; RA Tincello D.G., Saunders P.T., Hodgins M.B., Simpson N.B., Edwards C.R., RA Hargreaves T.B., Wu F.C.; RT "Correlation of clinical, endocrine and molecular abnormalities with in RT vivo responses to high-dose testosterone in patients with partial androgen RT insensitivity syndrome."; RL Clin. Endocrinol. (Oxf.) 46:497-506(1997). RN [167] RP VARIANT AIS MET-890. RX PubMed=9160185; RA Essawi M., Gad Y.Z., el-Rouby O., Temtamy S.A., Sabour Y.A., el-Awady M.K.; RT "Molecular analysis of androgen resistance syndromes in Egyptian RT patients."; RL Dis. Markers 13:99-105(1997). RN [168] RP VARIANT AIS TRP-780. RX PubMed=9007482; DOI=10.1007/s004310050542; RA Sinnecker G.H., Hiort O., Nitsche E.M., Holterhus P.M., Kruse K.; RT "Functional assessment and clinical classification of androgen sensitivity RT in patients with mutations of the androgen receptor gene."; RL Eur. J. Pediatr. 156:7-14(1997). RN [169] RP VARIANTS AIS VAL-750; CYS-775; ILE-781 AND SER-795. RX PubMed=8990010; RX DOI=10.1002/(sici)1098-1004(1997)9:1<57::aid-humu10>3.0.co;2-o; RA Jakubiczka S., Nedel S., Werder E.A., Schleiermacher E., Theile U., RA Wolff G., Wieacker P.; RT "Mutations of the androgen receptor gene in patients with complete androgen RT insensitivity."; RL Hum. Mutat. 9:57-61(1997). RN [170] RP VARIANTS HIS-702 AND ARG-911. RX PubMed=9438000; DOI=10.1093/jjco/27.6.389; RA Watanabe M., Ushijima T., Shiraishi T., Yatani R., Shimazaki J., Kotake T., RA Sugimura T., Nagao M.; RT "Genetic alterations of androgen receptor gene in Japanese human prostate RT cancer."; RL Jpn. J. Clin. Oncol. 27:389-393(1997). RN [171] RP VARIANT PROSTATE CANCER GLN-630. RX PubMed=9184448; DOI=10.5980/jpnjurol1989.88.550; RA Wang C., Uchida T.; RT "Androgen receptor gene mutations in prostate cancer."; RL Nihon Hinyokika Gakkai Zasshi 88:550-556(1997). RN [172] RP VARIANTS AIS ARG-196 AND CYS-856. RX PubMed=9255042; DOI=10.1111/j.1447-0756.1997.tb00845.x; RA Komori S., Sakata K., Tanaka H., Shima H., Koyama K.; RT "DNA analysis of the androgen receptor gene in two cases with complete RT androgen insensitivity syndrome."; RL J. Obstet. Gynaecol. Res. 23:277-281(1997). RN [173] RP VARIANTS PAIS ALA-709 AND GLY-871. RX PubMed=9329414; DOI=10.1016/s0022-3476(97)80063-7; RA Albers N., Ulrichs C., Gluer S., Hiort O., Sinnecker G.H., Mildenberger H., RA Brodehl J.; RT "Etiologic classification of severe hypospadias: implications for prognosis RT and management."; RL J. Pediatr. 131:386-392(1997). RN [174] RP VARIANTS AIS ASN-733 AND THR-766. RX PubMed=9252933; RA Ko T.M., Yang Y.S., Wu M.Y., Kao C.H., Hsu P.M., Chuang S.M., Lee T.Y.; RT "Complete androgen insensitivity syndrome. Molecular characterization in RT two Chinese women."; RL J. Reprod. Med. 42:424-428(1997). RN [175] RP VARIANTS AIS ASP-751; PHE-763; THR-766; ASN-865 AND PHE-908. RX PubMed=9328206; DOI=10.1016/s0960-0760(97)00001-0; RA Bevan C.L., Hughes I.A., Patterson M.N.; RT "Wide variation in androgen receptor dysfunction in complete androgen RT insensitivity syndrome."; RL J. Steroid Biochem. Mol. Biol. 61:19-26(1997). RN [176] RP VARIANT PAIS GLY-704, AND VARIANT AIS LEU-917. RX PubMed=9302173; DOI=10.1097/00005392-199710000-00075; RA Radmayr C., Culig Z., Glatzl J., Neuschmid-Kaspar F., Bartsch G., RA Klocker H.; RT "Androgen receptor point mutations as the underlying molecular defect in 2 RT patients with androgen insensitivity syndrome."; RL J. Urol. 158:1553-1556(1997). RN [177] RP VARIANTS AIS CYS-572; GLN-753 AND CYS-775. RX PubMed=9544375; DOI=10.1007/s004040050206; RA Komori S., Kasumi H., Sakata K., Tanaka H., Hamada K., Koyama K.; RT "Molecular analysis of the androgen receptor gene in 4 patients with RT complete androgen insensitivity."; RL Arch. Gynecol. Obstet. 261:95-100(1998). RN [178] RP VARIANTS AIS HIS-616 AND GLN-753. RX PubMed=9698822; DOI=10.1590/s0100-879x1998000600008; RA Cabral D.F., Maciel-Guerra A.T., Hackel C.; RT "Mutations of androgen receptor gene in Brazilian patients with male RT pseudohermaphroditism."; RL Braz. J. Med. Biol. Res. 31:775-778(1998). RN [179] RP VARIANT ARG-216, AND CHARACTERIZATION OF VARIANT ARG-216. RX PubMed=9788719; DOI=10.1111/j.1399-0004.1998.tb04282.x; RA Wang Q., Ghadessy F.J., Yong E.L.; RT "Analysis of the transactivation domain of the androgen receptor in RT patients with male infertility."; RL Clin. Genet. 54:185-192(1998). RN [180] RP VARIANT AIS ASP-574. RX PubMed=9421404; DOI=10.1210/endo.139.1.5696; RA Brueggenwirth H.T., Boehmer A.L., Lobaccaro J.M., Chiche L., Sultan C., RA Trapman J., Brinkmann A.O.; RT "Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic RT acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu RT exerts differential effects on DNA binding."; RL Endocrinology 139:103-110(1998). RN [181] RP VARIANTS AIS PRO-257 AND ALA-821. RX PubMed=9610419; DOI=10.3109/09513599809024954; RA Tanaka H., Komori S., Sakata K., Shima H., Koyama K.; RT "One additional mutation at exon A amplifies thermolability of androgen RT receptor in a case with complete androgen insensitivity syndrome."; RL Gynecol. Endocrinol. 12:75-82(1998). RN [182] RP VARIANTS AIS THR-766; TYR-785 AND THR-896, AND VARIANT PAIS GLY-841. RX PubMed=9856504; DOI=10.1007/s004390050864; RA Lundberg Giwercman Y., Nikoshkov A., Lindsten K., Bystroem B., Pousette A., RA Chibalin A.V., Arvidsson S., Tiulpakov A., Semitcheva T.V., Peterkova V., RA Hagenfeldt K., Ritzen E.M., Wedell A.; RT "Functional characterisation of mutations in the ligand-binding domain of RT the androgen receptor gene in patients with androgen insensitivity RT syndrome."; RL Hum. Genet. 103:529-531(1998). RN [183] RP VARIANT AIS VAL-696. RX PubMed=9554754; RA Doerk T., Schnieders F., Jakubiczka S., Wieacker P., Schroeder-Kurth T., RA Schmidtke J.; RT "A new missense substitution at a mutational hot spot of the androgen RT receptor in siblings with complete androgen insensitivity syndrome."; RL Hum. Mutat. 11:337-339(1998). RN [184] RP VARIANT ASP-646. RX PubMed=9554755; RA Nordenskjoeld A., Soederhaell S.; RT "An androgen receptor gene mutation (A645D) in a boy with a normal RT phenotype."; RL Hum. Mutat. 11:339-339(1998). RN [185] RP VARIANT AIS LEU-893. RA Knoke I., Jakubiczka S., Rohrer T., Hanimann B., Werder E.A., Wieacker P.; RT "Single amino acid substitution in the hormone-binding domain of the RT androgen receptor in a family with complete androgen insensitivity syndrome RT (CAIS)."; RL Hum. Mutat. 12:220-220(1998). RN [186] RP VARIANT PAIS GLN-608. RX PubMed=9543136; DOI=10.1210/jcem.83.4.4704; RA Weidemann W., Peters B., Romalo G., Spindler K.D., Schweikert H.-U.; RT "Response to androgen treatment in a patient with partial androgen RT insensitivity and a mutation in the deoxyribonucleic acid-binding domain of RT the androgen receptor."; RL J. Clin. Endocrinol. Metab. 83:1173-1176(1998). RN [187] RP VARIANTS PAIS VAL-744 AND CYS-841. RX PubMed=9768671; DOI=10.1210/jcem.83.10.5201; RA Georget V., Terouanne B., Lumbroso S., Nicolas J.C., Sultan C.; RT "Trafficking of androgen receptor mutants fused to green fluorescent RT protein: a new investigation of partial androgen insensitivity syndrome."; RL J. Clin. Endocrinol. Metab. 83:3597-3603(1998). RN [188] RP VARIANT AIS GLU-799. RX PubMed=9851768; DOI=10.1210/jcem.83.12.5358; RA Wang Q., Ghadessy F.J., Trounson A., de Kretser D., McLachlan R., Ng S.C., RA Yong E.L.; RT "Azoospermia associated with a mutation in the ligand-binding domain of an RT androgen receptor displaying normal ligand binding, but defective trans- RT activation."; RL J. Clin. Endocrinol. Metab. 83:4303-4309(1998). RN [189] RP VARIANTS AIS, VARIANT AIS PHE-723, AND VARIANT PAIS HIS-734. RX PubMed=9627582; DOI=10.1016/s0022-3476(98)70387-7; RA Hiort O., Sinnecker G.H., Holterhus P.M., Nitsche E.M., Kruse K.; RT "Inherited and de novo androgen receptor gene mutations: investigation of RT single-case families."; RL J. Pediatr. 132:939-943(1998). RN [190] RP VARIANT PAIS THR-759. RX PubMed=9607727; DOI=10.1016/s0303-7207(97)00229-3; RA Yong E.L., Tut T.G., Ghadessy F.J., Prins G., Ratnam S.S.; RT "Partial androgen insensitivity and correlations with the predicted three RT dimensional structure of the androgen receptor ligand-binding domain."; RL Mol. Cell. Endocrinol. 137:41-50(1998). RN [191] RP VARIANT PAIS LEU-912. RX PubMed=10470409; DOI=10.1046/j.1439-0272.1999.00278.x; RA Knoke I., Jakubiczka S., Lehnert H., Wieacker P.; RT "A new point mutation of the androgen receptor gene in a patient with RT partial androgen resistance and severe oligozoospermia."; RL Andrologia 31:199-201(1999). RN [192] RP VARIANTS PROSTATE CANCER ALA-878 AND ASN-891. RX PubMed=10363963; RA Taplin M.-E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., RA Balk S.P.; RT "Selection for androgen receptor mutations in prostate cancers treated with RT androgen antagonist."; RL Cancer Res. 59:2511-2515(1999). RN [193] RP VARIANTS AIS ILE-685 AND VAL-709. RX PubMed=10425033; RX DOI=10.1002/(sici)1098-1004(1999)14:2<103::aid-humu2>3.0.co;2-a; RA Gottlieb B., Beitel L.K., Lumbroso R., Pinsky L., Trifiro M.; RT "Update of the androgen receptor gene mutations database."; RL Hum. Mutat. 14:103-114(1999). RN [194] RP VARIANT PAIS SER-841. RX PubMed=10502786; RX DOI=10.1002/(sici)1098-1004(199910)14:4<353::aid-humu16>3.0.co;2-7; RA Melo K.F.S., Latronico A.C., Costa E.M.F., Billerbeck A.E.C., RA Mendonca B.B., Arnhold I.J.P.; RT "A novel point mutation (R840S) in the androgen receptor in a Brazilian RT family with partial androgen insensitivity syndrome."; RL Hum. Mutat. 14:353-353(1999). RN [195] RP VARIANTS AIS ARG-392 AND ARG-445. RX PubMed=10571951; RX DOI=10.1002/(sici)1098-1004(199912)14:6<527::aid-humu12>3.0.co;2-x; RA Gottlieb B., Vasiliou D.M., Lumbroso R., Beitel L.K., Pinsky L., RA Trifiro M.A.; RT "Analysis of exon 1 mutations in the androgen receptor gene."; RL Hum. Mutat. 14:527-539(1999). RN [196] RP VARIANT PAIS GLN-608, AND VARIANT AIS LYS-682. RX PubMed=10221692; DOI=10.1093/humrep/14.3.664; RA Chen C.P., Chern S.R., Wang T.Y., Wang W., Wang K.L., Jeng C.J.; RT "Androgen receptor gene mutations in 46,XY females with germ cell RT tumours."; RL Hum. Reprod. 14:664-670(1999). RN [197] RP VARIANT AIS LEU-893. RX PubMed=10404311; DOI=10.1046/j.1442-2042.1999.00065.x; RA Kanayama H., Naroda T., Inoue Y., Kurokawa Y., Kagawa S.; RT "A case of complete testicular feminization: laparoscopic orchiectomy and RT analysis of androgen receptor gene mutation."; RL Int. J. Urol. 6:327-330(1999). RN [198] RP VARIANT PAIS ALA-773, AND VARIANT AIS GLY-872. RX PubMed=10022458; DOI=10.1210/jcem.84.2.5453; RA Shkolny D.L., Beitel L.K., Ginsberg J., Pekeles G., Arbour L., Pinsky L., RA Trifiro M.A.; RT "Discordant measures of androgen-binding kinetics in two mutant androgen RT receptors causing mild or partial androgen insensitivity, respectively."; RL J. Clin. Endocrinol. Metab. 84:805-810(1999). RN [199] RP VARIANT AIS VAL-887. RX PubMed=10359561; DOI=10.1172/jci4289; RA Ghadessy F.J., Lim J., Abdullah A.A., Panet-Raymond V., Choo C.K., RA Lumbroso R., Tut T.G., Gottlieb B., Pinsky L., Trifiro M.A., Yong E.L.; RT "Oligospermic infertility associated with an androgen receptor mutation RT that disrupts interdomain and coactivator (TIF2) interactions."; RL J. Clin. Invest. 103:1517-1525(1999). RN [200] RP VARIANT ALA-684. RX PubMed=10629558; RX DOI=10.1002/(sici)1096-9896(199912)189:4<559::aid-path471>3.0.co;2-y; RA Wallen M.J., Linja M., Kaartinen K., Schleutker J., Visakorpi T.; RT "Androgen receptor gene mutations in hormone-refractory prostate cancer."; RL J. Pathol. 189:559-563(1999). RN [201] RP VARIANTS HIS-702 AND ALA-878. RX PubMed=10569618; DOI=10.1016/s0022-5347(05)68158-x; RA Zhao X.Y., Boyle B., Krishnan A.V., Navone N.M., Peehl D.M., Feldman D.; RT "Two mutations identified in the androgen receptor of the new human RT prostate cancer cell line MDA PCa 2a."; RL J. Urol. 162:2192-2199(1999). RN [202] RP VARIANT PAIS THR-808. RX PubMed=10543676; DOI=10.1016/s0140-6736(99)03205-5; RA Ong Y.C., Wong H.B., Adaikan G., Yong E.L.; RT "Directed pharmacological therapy of ambiguous genitalia due to an androgen RT receptor gene mutation."; RL Lancet 354:1444-1445(1999). RN [203] RP VARIANT AIS LEU-893. RX PubMed=10221770; DOI=10.1016/s0303-7207(98)00237-8; RA Peters I., Weidemann W., Romalo G., Knorr D., Schweikert H.-U., RA Spindler K.D.; RT "An androgen receptor mutation in the direct vicinity of the proposed C- RT terminal alpha-helix of the ligand binding domain containing the AF-2 RT transcriptional activating function core is associated with complete RT androgen insensitivity."; RL Mol. Cell. Endocrinol. 148:47-53(1999). RN [204] RP VARIANT PROSTATE CANCER TYR-620. RX PubMed=10598582; DOI=10.1210/mend.13.12.0382; RA Nazareth L.V., Stenoien D.L., Bingman W.E. III, James A.J., Wu C., RA Zhang Y., Edwards D.P., Mancini M., Marcelli M., Lamb D.J., Weigel N.L.; RT "A C619Y mutation in the human androgen receptor causes inactivation and RT mislocalization of the receptor with concomitant sequestration of SRC-1."; RL Mol. Endocrinol. 13:2065-2075(1999). RN [205] RP ERRATUM OF PUBMED:10598582. RA Nazareth L.V., Stenoien D.L., Bingman W.E. III, James A.J., Wu C., RA Zhang Y., Edwards D.P., Mancini M., Marcelli M., Lamb D.J., Weigel N.L.; RL Mol. Endocrinol. 14:544-544(2000). RN [206] RP VARIANT AIS THR-597. RX PubMed=10590024; DOI=10.1203/00006450-199912000-00009; RA Holterhus P.M., Wiebel J., Sinnecker G.H., Bruggenwirth H.T., Sippell W.G., RA Brinkmann A.O., Kruse K., Hiort O.; RT "Clinical and molecular spectrum of somatic mosaicism in androgen RT insensitivity syndrome."; RL Pediatr. Res. 46:684-690(1999). RN [207] RP VARIANTS AIS PHE-813 AND GLN-832. RX PubMed=10458483; DOI=10.1620/tjem.187.263; RA Yaegashi N., Uehara S., Senoo M., Sato J., Fujiwara J., Funato T., RA Sasaki T., Yajima A.; RT "Point mutations in the steroid-binding domain of the androgen receptor RT gene of five Japanese patients with androgen insensitivity syndrome."; RL Tohoku J. Exp. Med. 187:263-272(1999). RN [208] RP VARIANTS THR-598 AND LEU-726. RX PubMed=10092153; DOI=10.1007/s002400050088; RA Nordenskjoeld A., Friedman E., Tapper-Persson M., Soederhaell C., RA Leviav A., Svensson J., Anvret M.; RT "Screening for mutations in candidate genes for hypospadias."; RL Urol. Res. 27:49-55(1999). RN [209] RP VARIANTS PROSTATE CANCER ALA-576; ARG-581; VAL-587; TYR-620; ALA-758 AND RP GLY-847. RX PubMed=10706109; RA Marcelli M., Ittmann M., Mariani S., Sutherland R.W., Nigam R., Murthy L., RA Zhao Y., DiConcini D., Puxeddu E., Esen A., Eastham J., Weigel N.L., RA Lamb D.J.; RT "Androgen receptor mutations in prostate cancer."; RL Cancer Res. 60:944-949(2000). RN [210] RP VARIANTS AIS AND PAIS, AND VARIANTS AIS SER-492; MET-701; CYS-704; THR-711; RP SER-724; ASP-725; PRO-769; PRO-792; LEU-857; PRO-866 AND ARG-918. RX PubMed=10690872; DOI=10.1210/jcem.85.2.6337; RA Ahmed S.F., Cheng A., Dovey L., Hawkins J.R., Martin H., Rowland J., RA Shimura N., Tait A.D., Hughes I.A.; RT "Phenotypic features, androgen receptor binding, and mutational analysis in RT 278 clinical cases reported as androgen insensitivity syndrome."; RL J. Clin. Endocrinol. Metab. 85:658-665(2000). RN [211] RP VARIANT AIS SER-392. RX PubMed=10946887; DOI=10.1210/jcem.85.8.6713; RA Hiort O., Holterhus P.M., Horter T., Schulze W., Kremke B., RA Bals-Pratsch M., Sinnecker G.H., Kruse K.; RT "Significance of mutations in the androgen receptor gene in males with RT idiopathic infertility."; RL J. Clin. Endocrinol. Metab. 85:2810-2815(2000). RN [212] RP VARIANTS PAIS THR-683 AND GLU-712, AND VARIANTS AIS GLU-744; VAL-828; RP ARG-875 AND TYR-880. RX PubMed=11587068; DOI=10.1007/s100380170021; RA Chavez B., Mendez J.P., Ulloa-Aguirre A., Larrea F., Vilchis F.; RT "Eight novel mutations of the androgen receptor gene in patients with RT androgen insensitivity syndrome."; RL J. Hum. Genet. 46:560-565(2001). RN [213] RP INVOLVEMENT IN ANDROGENETIC ALOPECIA, AND POLYMORPHISM OF POLY-GLY REGION. RX PubMed=11231320; DOI=10.1046/j.1523-1747.2001.01261.x; RA Ellis J.A., Stebbing M., Harrap S.B.; RT "Polymorphism of the androgen receptor gene is associated with male pattern RT baldness."; RL J. Invest. Dermatol. 116:452-455(2001). RN [214] RP VARIANT AIS TYR-706. RX PubMed=11744994; RA Sills E.S., Sholes T.E., Perloe M., Kaplan C.R., Davis J.G., Tucker M.J.; RT "Characterization of a novel receptor mutation A->T at exon 4 in complete RT androgen insensitivity syndrome and a carrier sibling via bidirectional RT polymorphism sequence analysis."; RL Int. J. Mol. Med. 9:45-48(2002). RN [215] RP VARIANT PAIS PHE-548. RX PubMed=11788616; DOI=10.1210/jcem.87.1.7923; RA Bouvattier C., Carel J.C., Lecointre C., David A., Sultan C., RA Bertrand A.M., Morel Y., Chaussain J.L.; RT "Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the RT AR gene."; RL J. Clin. Endocrinol. Metab. 87:29-32(2002). RN [216] RP INVOLVEMENT IN ANDROGENETIC ALOPECIA, AND POLYMORPHISM OF POLY-GLY REGION. RX PubMed=15902657; DOI=10.1086/431425; RA Hillmer A.M., Hanneken S., Ritzmann S., Becker T., Freudenberg J., RA Brockschmidt F.F., Flaquer A., Freudenberg-Hua Y., Jamra R.A., Metzen C., RA Heyn U., Schweiger N., Betz R.C., Blaumeiser B., Hampe J., Schreiber S., RA Schulze T.G., Hennies H.C., Schumacher J., Propping P., Ruzicka T., RA Cichon S., Wienker T.F., Kruse R., Noethen M.M.; RT "Genetic variation in the human androgen receptor gene is the major RT determinant of common early-onset androgenetic alopecia."; RL Am. J. Hum. Genet. 77:140-148(2005). RN [217] RP INVOLVEMENT IN SMAX1. RX PubMed=15851746; DOI=10.1212/01.wnl.0000158617.41819.f3; RA Echaniz-Laguna A., Rousso E., Anheim M., Cossee M., Tranchant C.; RT "A family with early-onset and rapidly progressive X-linked spinal and RT bulbar muscular atrophy."; RL Neurology 64:1458-1460(2005). RN [218] RP VARIANT AIS PHE-577. RX PubMed=14756668; DOI=10.1111/j.0009-9163.2004.00197.x; RA Hooper H.T., Figueiredo B.C., Pavan-Senn C.C., De Lacerda L., Sandrini R., RA Mengarelli J.K., Japp K., Karaviti L.P.; RT "Concordance of phenotypic expression and gender identity in a large RT kindred with a mutation in the androgen receptor."; RL Clin. Genet. 65:183-190(2004). RN [219] RP CHARACTERIZATION OF VARIANTS AIS ASN-696; CYS-764; HIS-775; GLU-799; RP HIS-856 AND PHE-908. RX PubMed=16595706; DOI=10.1677/jme.1.01885; RA Jaeaeskelaeinen J., Deeb A., Schwabe J.W., Mongan N.P., Martin H., RA Hughes I.A.; RT "Human androgen receptor gene ligand-binding-domain mutations leading to RT disrupted interaction between the N- and C-terminal domains."; RL J. Mol. Endocrinol. 36:361-368(2006). RN [220] RP VARIANT AIS LEU-892. RX PubMed=24737579; DOI=10.1111/j.2047-2927.2014.00215.x; RA Akcay T., Fernandez-Cancio M., Turan S., Gueran T., Audi L., Bereket A.; RT "AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children RT with a clinical diagnosis of androgen insensitivity."; RL Andrology 2:572-578(2014). RN [221] RP VARIANT ARG-216. RX PubMed=27535533; DOI=10.1038/nature19057; RG Exome Aggregation Consortium; RA Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., RA O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., RA Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J., RA Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M., RA Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N., RA Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P., RA Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A., RA Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G., RA Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M., RA Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C., RA Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M., RA McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M., RA Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P., RA Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G., RA Daly M.J., MacArthur D.G.; RT "Analysis of protein-coding genetic variation in 60,706 humans."; RL Nature 536:285-291(2016). RN [222] RP POLYMORPHISM. RX PubMed=33647767; DOI=10.1016/j.ebiom.2021.103246; RG Spanish Covid HGE, GEN-COVID Multicenter Study; RA Baldassarri M., Picchiotti N., Fava F., Fallerini C., Benetti E., Daga S., RA Valentino F., Doddato G., Furini S., Giliberti A., Tita R., Amitrano S., RA Bruttini M., Croci S., Meloni I., Pinto A.M., Iuso N., Gabbi C., RA Sciarra F., Venneri M.A., Gori M., Sanarico M., Crawley F.P., Pagotto U., RA Fanelli F., Mezzullo M., Dominguez-Garrido E., Planas-Serra L., RA Schlueter A., Colobran R., Soler-Palacin P., Lapunzina P., Tenorio J., RA Pujol A., Castagna M.G., Marcelli M., Isidori A.M., Renieri A., RA Frullanti E., Mari F.; RT "Shorter androgen receptor polyQ alleles protect against life-threatening RT COVID-19 disease in European males."; RL EBioMedicine 65:103246-103246(2021). CC -!- FUNCTION: Steroid hormone receptors are ligand-activated transcription CC factors that regulate eukaryotic gene expression and affect cellular CC proliferation and differentiation in target tissues (PubMed:19022849). CC Transcription factor activity is modulated by bound coactivator and CC corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the CC androgen response elements/ARE on target genes, negatively regulating CC androgen receptor signaling and androgen-induced cell proliferation CC (PubMed:20812024). Transcription activation is also down-regulated by CC NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. CC {ECO:0000269|PubMed:14664718, ECO:0000269|PubMed:15563469, CC ECO:0000269|PubMed:17591767, ECO:0000269|PubMed:17911242, CC ECO:0000269|PubMed:18084323, ECO:0000269|PubMed:19022849, CC ECO:0000269|PubMed:19345326, ECO:0000269|PubMed:20812024, CC ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:25091737}. CC -!- FUNCTION: [Isoform 3]: Lacks the C-terminal ligand-binding domain and CC therefore constitutively regulates the transcription of a specific set CC of canonical AR-target genes, including PSA/KLK3 and TMPRSS2, CC independently of steroid hormones (PubMed:19244107, PubMed:25008967). CC However, some genes are differentially regulated by full-length AR CC (isoform 1) and isoform 3. Isoform 3-specific target genes may be CC regulated independently of FOXA1 expression (PubMed:25008967). CC {ECO:0000269|PubMed:19244107, ECO:0000269|PubMed:25008967}. CC -!- FUNCTION: [Isoform 4]: Lacks the C-terminal ligand-binding domain and CC may therefore constitutively activate the transcription of a specific CC set of genes independently of steroid hormones. CC {ECO:0000269|PubMed:19244107}. CC -!- ACTIVITY REGULATION: AIM-100 (4-amino-5,6-biaryl-furo[2,3-d]pyrimidine) CC suppresses TNK2-mediated phosphorylation at Tyr-269. Inhibits the CC binding of the Tyr-269 phosphorylated form to androgen-responsive CC enhancers (AREs) and its transcriptional activity. CC {ECO:0000269|PubMed:20623637}. CC -!- SUBUNIT: Binds DNA as a homodimer. Part of a ternary complex containing CC AR, EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the CC presence of androgen. The ligand binding domain interacts with CC KAT7/HBO1 in the presence of dihydrotestosterone. Interacts with CC EFCAB6/DJBP, PQBP1, RANBP9, RBAK, SPDEF, SRA1, TGFB1I1 and RREB1. CC Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance its CC transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4. CC Interacts with MACROD1 (via macro domain) (PubMed:19022849). Interacts CC via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1, CC NCOA2, NCOA3 and MAGEA11. Interacts (via nuclear receptor DNA binding CC domain and nuclear receptor ligand binding domain) with NCOA4 CC (PubMed:15563469, PubMed:8643607). The AR N-terminal poly-Gln region CC binds Ran resulting in enhancement of AR-mediated transactivation. Ran- CC binding decreases as the poly-Gln length increases. Interacts with HIP1 CC (via coiled coil domain). Interacts (via ligand-binding domain) with CC TRIM68. Interacts with TNK2. Interacts with USP26. Interacts with RNF6. CC Interacts (regulated by RNF6 probably through polyubiquitination) with CC RNF14; regulates AR transcriptional activity. Interacts with PRMT2 and CC TRIM24. Interacts with RACK1. Interacts with RANBP10; this interaction CC enhances dihydrotestosterone-induced AR transcriptional activity. CC Interacts with PRPF6 in a hormone-independent way; this interaction CC enhances dihydrotestosterone-induced AR transcriptional activity. CC Interacts with STK4/MST1. Interacts with ZIPK/DAPK3. Interacts with CC LPXN. Interacts with MAK. Part of a complex containing AR, MAK and CC NCOA3. Interacts with CRY1. Interacts with CCAR1 and GATA2. Interacts CC with ZNF318 (By similarity). Interacts with BUD31 (PubMed:25091737). CC Interacts with ARID4A (PubMed:23487765). Interacts with ARID4B (By CC similarity). Interacts (via NR LBD domain) with ZBTB7A; the interaction CC is direct and androgen-dependent (PubMed:20812024). Interacts with CC NCOR1 (PubMed:20812024). Interacts with NCOR2 (PubMed:20812024). CC Interacts with CRY2 in a ligand-dependent manner (By similarity). CC Interacts (via NR LBD domain) with RWDD1; the interaction is direct and CC may stimulate AR activity (PubMed:22406838). CC {ECO:0000250|UniProtKB:P15207, ECO:0000250|UniProtKB:P19091, CC ECO:0000269|PubMed:10075738, ECO:0000269|PubMed:10332029, CC ECO:0000269|PubMed:10383460, ECO:0000269|PubMed:10400640, CC ECO:0000269|PubMed:10625666, ECO:0000269|PubMed:10930412, CC ECO:0000269|PubMed:12039962, ECO:0000269|PubMed:12361945, CC ECO:0000269|PubMed:12612053, ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:14609956, ECO:0000269|PubMed:14664718, CC ECO:0000269|PubMed:15525515, ECO:0000269|PubMed:15563469, CC ECO:0000269|PubMed:16027218, ECO:0000269|PubMed:16051670, CC ECO:0000269|PubMed:16951154, ECO:0000269|PubMed:17311914, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:17550981, CC ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:17591767, CC ECO:0000269|PubMed:17711855, ECO:0000269|PubMed:17911242, CC ECO:0000269|PubMed:18007036, ECO:0000269|PubMed:18084323, CC ECO:0000269|PubMed:18222118, ECO:0000269|PubMed:18451096, CC ECO:0000269|PubMed:18451177, ECO:0000269|PubMed:19022849, CC ECO:0000269|PubMed:19345326, ECO:0000269|PubMed:19909775, CC ECO:0000269|PubMed:20501646, ECO:0000269|PubMed:20812024, CC ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21512132, CC ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:22406838, CC ECO:0000269|PubMed:23487765, ECO:0000269|PubMed:23887938, CC ECO:0000269|PubMed:25091737, ECO:0000269|PubMed:8643607}. CC -!- INTERACTION: CC P10275; P00519: ABL1; NbExp=2; IntAct=EBI-608057, EBI-375543; CC P10275; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-608057, EBI-540797; CC P10275; P51451: BLK; NbExp=3; IntAct=EBI-608057, EBI-2105445; CC P10275; Q8WV28: BLNK; NbExp=2; IntAct=EBI-608057, EBI-2623522; CC P10275; O60885-1: BRD4; NbExp=6; IntAct=EBI-608057, EBI-9345088; CC P10275; P78543: BTG2; NbExp=4; IntAct=EBI-608057, EBI-1047576; CC P10275; Q14790: CASP8; NbExp=3; IntAct=EBI-608057, EBI-78060; CC P10275; P24385: CCND1; NbExp=4; IntAct=EBI-608057, EBI-375001; CC P10275; Q92793: CREBBP; NbExp=3; IntAct=EBI-608057, EBI-81215; CC P10275; O14595: CTDSP2; NbExp=3; IntAct=EBI-608057, EBI-2802973; CC P10275; P35222: CTNNB1; NbExp=15; IntAct=EBI-608057, EBI-491549; CC P10275; Q9UER7: DAXX; NbExp=5; IntAct=EBI-608057, EBI-77321; CC P10275; P20711: DDC; NbExp=2; IntAct=EBI-608057, EBI-1632155; CC P10275; P11308: ERG; NbExp=4; IntAct=EBI-608057, EBI-79704; CC P10275; P07332: FES; NbExp=3; IntAct=EBI-608057, EBI-1055635; CC P10275; P09769: FGR; NbExp=3; IntAct=EBI-608057, EBI-1383732; CC P10275; Q14192: FHL2; NbExp=2; IntAct=EBI-608057, EBI-701903; CC P10275; Q02790: FKBP4; NbExp=2; IntAct=EBI-608057, EBI-1047444; CC P10275; P55317: FOXA1; NbExp=4; IntAct=EBI-608057, EBI-3918034; CC P10275; O75593: FOXH1; NbExp=3; IntAct=EBI-608057, EBI-1759806; CC P10275; Q14451: GRB7; NbExp=3; IntAct=EBI-608057, EBI-970191; CC P10275; P06396: GSN; NbExp=2; IntAct=EBI-608057, EBI-351506; CC P10275; P56524: HDAC4; NbExp=4; IntAct=EBI-608057, EBI-308629; CC P10275; Q16665: HIF1A; NbExp=2; IntAct=EBI-608057, EBI-447269; CC P10275; Q16666: IFI16; NbExp=3; IntAct=EBI-608057, EBI-2867186; CC P10275; O15357: INPPL1; NbExp=3; IntAct=EBI-608057, EBI-1384248; CC P10275; Q15652: JMJD1C; NbExp=4; IntAct=EBI-608057, EBI-1224969; CC P10275; Q92993: KAT5; NbExp=2; IntAct=EBI-608057, EBI-399080; CC P10275; O95251: KAT7; NbExp=5; IntAct=EBI-608057, EBI-473199; CC P10275; Q9BY66: KDM5D; NbExp=2; IntAct=EBI-608057, EBI-1246860; CC P10275; Q9BY66-3: KDM5D; NbExp=2; IntAct=EBI-608057, EBI-12559887; CC P10275; Q03164: KMT2A; NbExp=4; IntAct=EBI-608057, EBI-591370; CC P10275; O14686: KMT2D; NbExp=3; IntAct=EBI-608057, EBI-996065; CC P10275; P06239: LCK; NbExp=7; IntAct=EBI-608057, EBI-1348; CC P10275; P07948: LYN; NbExp=5; IntAct=EBI-608057, EBI-79452; CC P10275; P20794: MAK; NbExp=5; IntAct=EBI-608057, EBI-3911321; CC P10275; P42679: MATK; NbExp=4; IntAct=EBI-608057, EBI-751664; CC P10275; Q00987: MDM2; NbExp=2; IntAct=EBI-608057, EBI-389668; CC P10275; Q15596: NCOA2; NbExp=4; IntAct=EBI-608057, EBI-81236; CC P10275; Q14686: NCOA6; NbExp=3; IntAct=EBI-608057, EBI-78670; CC P10275; O96028: NSD2; NbExp=5; IntAct=EBI-608057, EBI-2693298; CC P10275; Q99497: PARK7; NbExp=6; IntAct=EBI-608057, EBI-1164361; CC P10275; P27986: PIK3R1; NbExp=5; IntAct=EBI-608057, EBI-79464; CC P10275; O00459: PIK3R2; NbExp=14; IntAct=EBI-608057, EBI-346930; CC P10275; Q92569: PIK3R3; NbExp=37; IntAct=EBI-608057, EBI-79893; CC P10275; P19174: PLCG1; NbExp=22; IntAct=EBI-608057, EBI-79387; CC P10275; P16885: PLCG2; NbExp=6; IntAct=EBI-608057, EBI-617403; CC P10275; Q06830: PRDX1; NbExp=3; IntAct=EBI-608057, EBI-353193; CC P10275; P78527: PRKDC; NbExp=3; IntAct=EBI-608057, EBI-352053; CC P10275; Q06124: PTPN11; NbExp=12; IntAct=EBI-608057, EBI-297779; CC P10275; P20936: RASA1; NbExp=16; IntAct=EBI-608057, EBI-1026476; CC P10275; Q9UBS8: RNF14; NbExp=2; IntAct=EBI-608057, EBI-2130308; CC P10275; Q9Y252: RNF6; NbExp=10; IntAct=EBI-608057, EBI-2341483; CC P10275; O14796: SH2D1B; NbExp=3; IntAct=EBI-608057, EBI-3923013; CC P10275; Q9NP31: SH2D2A; NbExp=6; IntAct=EBI-608057, EBI-490630; CC P10275; P29353: SHC1; NbExp=14; IntAct=EBI-608057, EBI-78835; CC P10275; Q6S5L8: SHC4; NbExp=3; IntAct=EBI-608057, EBI-9453524; CC P10275; Q5VZ18: SHE; NbExp=3; IntAct=EBI-608057, EBI-3956977; CC P10275; Q15797: SMAD1; NbExp=6; IntAct=EBI-608057, EBI-1567153; CC P10275; O14544: SOCS6; NbExp=4; IntAct=EBI-608057, EBI-3929549; CC P10275; P12931: SRC; NbExp=7; IntAct=EBI-608057, EBI-621482; CC P10275; Q9ULZ2: STAP1; NbExp=2; IntAct=EBI-608057, EBI-6083058; CC P10275; P63165: SUMO1; NbExp=7; IntAct=EBI-608057, EBI-80140; CC P10275; Q9HBL0: TNS1; NbExp=3; IntAct=EBI-608057, EBI-3389814; CC P10275; P07947: YES1; NbExp=5; IntAct=EBI-608057, EBI-515331; CC P10275; Q9R1E0: Foxo1; Xeno; NbExp=4; IntAct=EBI-608057, EBI-1371343; CC P10275; Q06986: Siah2; Xeno; NbExp=6; IntAct=EBI-608057, EBI-957413; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:15634333, ECO:0000269|PubMed:17587566, CC ECO:0000269|PubMed:19244107, ECO:0000269|PubMed:19345326, CC ECO:0000269|PubMed:25091737}. Cytoplasm {ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:19244107}. CC Note=Detected at the promoter of target genes (PubMed:25091737). CC Predominantly cytoplasmic in unligated form but translocates to the CC nucleus upon ligand-binding. Can also translocate to the nucleus in CC unligated form in the presence of RACK1. {ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:25091737}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=AR-B; CC IsoId=P10275-1; Sequence=Displayed; CC Name=2; Synonyms=AR-A, Variant AR45; CC IsoId=P10275-2; Sequence=VSP_036889, VSP_036890; CC Name=3; Synonyms=AR3, AR-V7 {ECO:0000303|PubMed:25008967}; CC IsoId=P10275-3; Sequence=VSP_058166, VSP_058168; CC Name=4; Synonyms=AR4; CC IsoId=P10275-4; Sequence=VSP_058167, VSP_058169; CC -!- TISSUE SPECIFICITY: [Isoform 2]: Mainly expressed in heart and skeletal CC muscle. {ECO:0000269|PubMed:15634333}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: Expressed in basal and stromal cells CC of the prostate (at protein level). {ECO:0000269|PubMed:19244107}. CC -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a CC DNA-binding domain and a C-terminal ligand-binding domain. In the CC presence of bound steroid the ligand-binding domain interacts with the CC N-terminal modulating domain, and thereby activates AR transcription CC factor activity. Agonist binding is required for dimerization and CC binding to target DNA. The transcription factor activity of the complex CC formed by ligand-activated AR and DNA is modulated by interactions with CC coactivator and corepressor proteins (PubMed:25091737). Interaction CC with RANBP9 is mediated by both the N-terminal domain and the DNA- CC binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA- CC binding domain. {ECO:0000269|PubMed:25091737}. CC -!- PTM: Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. CC Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked CC polyubiquitination by RNF6 modulates AR transcriptional activity and CC specificity. {ECO:0000269|PubMed:11121022, ECO:0000269|PubMed:19345326, CC ECO:0000269|PubMed:20501646}. CC -!- PTM: Phosphorylated in prostate cancer cells in response to several CC growth factors including EGF. Phosphorylation is induced by c-Src CC kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an CC increase in phosphorylation and Src kinase activity is associated with CC prostate cancer progression. Phosphorylation by TNK2 enhances the DNA- CC binding and transcriptional activity and may be responsible for CC androgen-independent progression of prostate cancer. Phosphorylation at CC Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. CC Phosphorylation by PAK6 leads to AR-mediated transcription inhibition. CC {ECO:0000269|PubMed:14573606, ECO:0000269|PubMed:17045208, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:20623637, CC ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21512132}. CC -!- PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required CC for plasma membrane targeting and for rapid intracellular signaling via CC ERK and AKT kinases and cAMP generation. {ECO:0000269|PubMed:22031296}. CC -!- POLYMORPHISM: The poly-Gln region of AR is highly polymorphic and the CC number of Gln varies in the population (from 17 to 26). A smaller size CC of the poly-Gln region may be associated with the development of CC prostate cancer. Long poly-Gln alleles (>23) may be associated with CC higher testosterone levels and severe clinical outcome in COVID-19 CC disease (PubMed:33647767). {ECO:0000269|PubMed:1561105, CC ECO:0000269|PubMed:2062380, ECO:0000269|PubMed:33647767, CC ECO:0000269|PubMed:8292051, ECO:0000269|PubMed:9096391}. CC -!- POLYMORPHISM: The poly-Gly region of AR is polymorphic and ranges from CC 24 to 31 Gly. A poly-Gly region shorter or equal to 23 may be CC associated with the development of androgenetic alopecia. CC {ECO:0000269|PubMed:11231320, ECO:0000269|PubMed:15902657}. CC -!- DISEASE: Androgen insensitivity syndrome (AIS) [MIM:300068]: An X- CC linked recessive form of pseudohermaphroditism due end-organ resistance CC to androgen. Affected males have female external genitalia, female CC breast development, blind vagina, absent uterus and female adnexa, and CC abdominal or inguinal testes, despite a normal 46,XY karyotype. CC {ECO:0000269|PubMed:10022458, ECO:0000269|PubMed:10221692, CC ECO:0000269|PubMed:10221770, ECO:0000269|PubMed:10359561, CC ECO:0000269|PubMed:10404311, ECO:0000269|PubMed:10425033, CC ECO:0000269|PubMed:10458483, ECO:0000269|PubMed:10571951, CC ECO:0000269|PubMed:10590024, ECO:0000269|PubMed:10690872, CC ECO:0000269|PubMed:10946887, ECO:0000269|PubMed:11587068, CC ECO:0000269|PubMed:11744994, ECO:0000269|PubMed:1307250, CC ECO:0000269|PubMed:1316540, ECO:0000269|PubMed:1426313, CC ECO:0000269|PubMed:1430233, ECO:0000269|PubMed:1458719, CC ECO:0000269|PubMed:1464650, ECO:0000269|PubMed:14756668, CC ECO:0000269|PubMed:1480178, ECO:0000269|PubMed:1487249, CC ECO:0000269|PubMed:1569163, ECO:0000269|PubMed:1609793, CC ECO:0000269|PubMed:16129672, ECO:0000269|PubMed:16595706, CC ECO:0000269|PubMed:1775137, ECO:0000269|PubMed:1999491, CC ECO:0000269|PubMed:2082179, ECO:0000269|PubMed:24737579, CC ECO:0000269|PubMed:2594783, ECO:0000269|PubMed:7537149, CC ECO:0000269|PubMed:7581399, ECO:0000269|PubMed:7626493, CC ECO:0000269|PubMed:7633398, ECO:0000269|PubMed:7641413, CC ECO:0000269|PubMed:7671849, ECO:0000269|PubMed:7929841, CC ECO:0000269|PubMed:7962294, ECO:0000269|PubMed:7970939, CC ECO:0000269|PubMed:7981687, ECO:0000269|PubMed:7981689, CC ECO:0000269|PubMed:7993455, ECO:0000269|PubMed:8040309, CC ECO:0000269|PubMed:8096390, ECO:0000269|PubMed:8103398, CC ECO:0000269|PubMed:8162033, ECO:0000269|PubMed:8224266, CC ECO:0000269|PubMed:8240973, ECO:0000269|PubMed:8281140, CC ECO:0000269|PubMed:8325950, ECO:0000269|PubMed:8339746, CC ECO:0000269|PubMed:8413310, ECO:0000269|PubMed:8446106, CC ECO:0000269|PubMed:8626869, ECO:0000269|PubMed:8647313, CC ECO:0000269|PubMed:8683794, ECO:0000269|PubMed:8723113, CC ECO:0000269|PubMed:8768864, ECO:0000269|PubMed:8809734, CC ECO:0000269|PubMed:8830623, ECO:0000269|PubMed:8918984, CC ECO:0000269|PubMed:8990010, ECO:0000269|PubMed:9001799, CC ECO:0000269|PubMed:9007482, ECO:0000269|PubMed:9039340, CC ECO:0000269|PubMed:9106550, ECO:0000269|PubMed:9160185, CC ECO:0000269|PubMed:9252933, ECO:0000269|PubMed:9255042, CC ECO:0000269|PubMed:9302173, ECO:0000269|PubMed:9328206, CC ECO:0000269|PubMed:9421404, ECO:0000269|PubMed:9544375, CC ECO:0000269|PubMed:9554754, ECO:0000269|PubMed:9610419, CC ECO:0000269|PubMed:9627582, ECO:0000269|PubMed:9698822, CC ECO:0000269|PubMed:9851768, ECO:0000269|PubMed:9856504, CC ECO:0000269|Ref.118, ECO:0000269|Ref.185}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Spinal and bulbar muscular atrophy X-linked 1 (SMAX1) CC [MIM:313200]: An X-linked recessive form of spinal muscular atrophy. CC Spinal muscular atrophy refers to a group of neuromuscular disorders CC characterized by degeneration of the anterior horn cells of the spinal CC cord, leading to symmetrical muscle weakness and atrophy. SMAX1 occurs CC only in men. Age at onset is usually in the third to fifth decade of CC life, but earlier involvement has been reported. It is characterized by CC slowly progressive limb and bulbar muscle weakness with fasciculations, CC muscle atrophy, and gynecomastia. The disorder is clinically similar to CC classic forms of autosomal spinal muscular atrophy. CC {ECO:0000269|PubMed:15851746}. Note=The disease is caused by variants CC affecting the gene represented in this entry. Caused by trinucleotide CC CAG repeat expansion. In SMAX1 patients the number of Gln ranges from CC 38 to 62. Longer expansions result in earlier onset and more severe CC clinical manifestations of the disease. CC -!- DISEASE: Prostate cancer, hereditary, X-linked 3 (HPCX3) [MIM:301120]: CC A condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:8530589}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Note=Defects in AR may play a role in metastatic prostate CC cancer. The mutated receptor stimulates prostate growth and metastases CC development despite of androgen ablation. This treatment can reduce CC primary and metastatic lesions probably by inducing apoptosis of tumor CC cells when they express the wild-type receptor. CC {ECO:0000269|PubMed:10363963, ECO:0000269|PubMed:10569618, CC ECO:0000269|PubMed:1562539, ECO:0000269|PubMed:16129672, CC ECO:0000269|PubMed:17311914, ECO:0000269|PubMed:2260966, CC ECO:0000269|PubMed:25091737, ECO:0000269|PubMed:8187068, CC ECO:0000269|PubMed:8274409, ECO:0000269|PubMed:8827083}. CC -!- DISEASE: Androgen insensitivity, partial (PAIS) [MIM:312300]: A CC disorder that is characterized by hypospadias, hypogonadism, CC gynecomastia, genital ambiguity, normal XY karyotype, and a pedigree CC pattern consistent with X-linked recessive inheritance. Some patients CC present azoospermia or severe oligospermia without other clinical CC manifestations. {ECO:0000269|PubMed:10022458, CC ECO:0000269|PubMed:10221692, ECO:0000269|PubMed:10470409, CC ECO:0000269|PubMed:10502786, ECO:0000269|PubMed:10543676, CC ECO:0000269|PubMed:10690872, ECO:0000269|PubMed:11587068, CC ECO:0000269|PubMed:11788616, ECO:0000269|PubMed:1303262, CC ECO:0000269|PubMed:1307250, ECO:0000269|PubMed:1316540, CC ECO:0000269|PubMed:1424203, ECO:0000269|PubMed:1430233, CC ECO:0000269|PubMed:1458719, ECO:0000269|PubMed:14756668, CC ECO:0000269|PubMed:2010552, ECO:0000269|PubMed:7581399, CC ECO:0000269|PubMed:7649358, ECO:0000269|PubMed:7671849, CC ECO:0000269|PubMed:7909256, ECO:0000269|PubMed:7910529, CC ECO:0000269|PubMed:7929841, ECO:0000269|PubMed:7970939, CC ECO:0000269|PubMed:7981687, ECO:0000269|PubMed:8033918, CC ECO:0000269|PubMed:8097257, ECO:0000269|PubMed:8126121, CC ECO:0000269|PubMed:8205256, ECO:0000269|PubMed:8281139, CC ECO:0000269|PubMed:8325932, ECO:0000269|PubMed:8325950, CC ECO:0000269|PubMed:8339746, ECO:0000269|PubMed:8446106, CC ECO:0000269|PubMed:8550758, ECO:0000269|PubMed:8723113, CC ECO:0000269|PubMed:8809734, ECO:0000269|PubMed:8823308, CC ECO:0000269|PubMed:8824883, ECO:0000269|PubMed:9039340, CC ECO:0000269|PubMed:9196614, ECO:0000269|PubMed:9302173, CC ECO:0000269|PubMed:9329414, ECO:0000269|PubMed:9543136, CC ECO:0000269|PubMed:9607727, ECO:0000269|PubMed:9627582, CC ECO:0000269|PubMed:9768671, ECO:0000269|PubMed:9856504, CC ECO:0000269|Ref.126}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Hypospadias 1, X-linked (HYSP1) [MIM:300633]: A common CC malformation in which the urethra opens on the ventral side of the CC penis, due to developmental arrest of urethral fusion. The opening can CC be located glandular, penile, or even more posterior in the scrotum or CC perineum. Hypospadias is a feature of several syndromic disorders, CC including the androgen insensitivity syndrome and Opitz syndrome. CC {ECO:0000269|PubMed:8097257}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In the absence of ligand, steroid hormone receptors are CC thought to be weakly associated with nuclear components; hormone CC binding greatly increases receptor affinity. The hormone-receptor CC complex appears to recognize discrete DNA sequences upstream of CC transcriptional start sites. CC -!- MISCELLANEOUS: Transcriptional activity is enhanced by binding to CC RANBP9. CC -!- MISCELLANEOUS: The level of tyrosine phosphorylation may serve as a CC diagnostic tool to predict patient outcome in response to hormone- CC ablation therapy. Inhibition of tyrosine phosphorylation may be an CC effective intervention target for hormone-refractory prostate cancer. CC -!- MISCELLANEOUS: [Isoform 3]: Minor isoform up-regulated in prostate CC cancer cells. {ECO:0000269|PubMed:19244107}. CC -!- MISCELLANEOUS: [Isoform 4]: Minor isoform identified in prostate cancer CC cells. {ECO:0000269|PubMed:19244107}. CC -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3 CC subfamily. {ECO:0000305}. CC -!- CAUTION: Had previously been shown to interact with PELP1. However this CC paper was retracted as cell-based data was viewed as unreliable. CC {ECO:0000305|PubMed:12415108, ECO:0000305|PubMed:19666546}. CC -!- WEB RESOURCE: Name=Androgen receptor gene mutations database; CC URL="https://androgendb.mcgill.ca"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/685/AR"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Androgen receptor entry; CC URL="https://en.wikipedia.org/wiki/Androgen_receptor"; CC -!- WEB RESOURCE: Name=X-chromosome gene database, androgen receptor (AR); CC Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/AR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M20132; AAA51729.1; -; mRNA. DR EMBL; M23263; AAA51775.1; -; mRNA. DR EMBL; M27430; AAA51886.1; -; Genomic_DNA. DR EMBL; M27423; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27424; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27425; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27426; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27427; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27428; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27429; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M34233; AAA51780.1; -; mRNA. DR EMBL; M21748; AAA51771.1; -; mRNA. DR EMBL; M35851; AAA51772.1; -; Genomic_DNA. DR EMBL; M35844; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35845; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35846; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35847; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35848; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35849; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35850; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; AX453758; -; NOT_ANNOTATED_CDS; Unassigned_DNA. DR EMBL; FJ235916; ACN39559.1; -; mRNA. DR EMBL; FJ235917; ACN39560.1; -; mRNA. DR EMBL; AL049564; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL158016; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL356358; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471132; EAX05380.1; -; Genomic_DNA. DR EMBL; BC132975; AAI32976.1; -; mRNA. DR EMBL; L29496; AAA51770.1; -; mRNA. DR EMBL; U16371; AAB60346.1; -; Genomic_DNA. DR EMBL; M20260; AAA51774.1; -; mRNA. DR EMBL; S79366; AAB21256.2; -; Genomic_DNA. DR EMBL; S79368; AAB21257.2; -; Genomic_DNA. DR CCDS; CCDS14387.1; -. [P10275-1] DR CCDS; CCDS87754.1; -. [P10275-3] DR PIR; A39248; A39248. DR RefSeq; NP_000035.2; NM_000044.4. [P10275-1] DR RefSeq; NP_001011645.1; NM_001011645.3. [P10275-2] DR RefSeq; NP_001334990.1; NM_001348061.1. [P10275-3] DR RefSeq; NP_001334992.1; NM_001348063.1. [P10275-4] DR RefSeq; NP_001334993.1; NM_001348064.1. DR PDB; 1E3G; X-ray; 2.40 A; A=658-920. DR PDB; 1GS4; X-ray; 1.95 A; A=671-918. DR PDB; 1T5Z; X-ray; 2.30 A; A=670-920. DR PDB; 1T63; X-ray; 2.07 A; A=670-919. DR PDB; 1T65; X-ray; 1.66 A; A=670-920. DR PDB; 1XJ7; X-ray; 2.70 A; A=664-920. DR PDB; 1XOW; X-ray; 1.80 A; A=672-920, B=20-30. DR PDB; 1XQ3; X-ray; 2.25 A; A=672-920. DR PDB; 1Z95; X-ray; 1.80 A; A=673-918. DR PDB; 2AM9; X-ray; 1.64 A; A=655-920. DR PDB; 2AMA; X-ray; 1.90 A; A=655-920. DR PDB; 2AMB; X-ray; 1.75 A; A=655-920. DR PDB; 2AO6; X-ray; 1.89 A; A=672-920. DR PDB; 2AX6; X-ray; 1.50 A; A=665-920. DR PDB; 2AX7; X-ray; 1.90 A; A=665-920. DR PDB; 2AX8; X-ray; 1.70 A; A=665-920. DR PDB; 2AX9; X-ray; 1.65 A; A=665-920. DR PDB; 2AXA; X-ray; 1.80 A; A=665-920. DR PDB; 2HVC; X-ray; 2.10 A; A=670-919. DR PDB; 2OZ7; X-ray; 1.80 A; A=672-920. DR PDB; 2PIO; X-ray; 2.03 A; A=670-920. DR PDB; 2PIP; X-ray; 1.80 A; L=670-920. DR PDB; 2PIQ; X-ray; 2.40 A; A=670-920. DR PDB; 2PIR; X-ray; 2.10 A; A=670-920. DR PDB; 2PIT; X-ray; 1.76 A; A=670-920. DR PDB; 2PIU; X-ray; 2.12 A; A=670-920. DR PDB; 2PIV; X-ray; 1.95 A; A=670-920. DR PDB; 2PIW; X-ray; 2.58 A; A=670-920. DR PDB; 2PIX; X-ray; 2.40 A; A=670-920. DR PDB; 2PKL; X-ray; 2.49 A; A=670-920. DR PDB; 2PNU; X-ray; 1.65 A; A=655-920. DR PDB; 2Q7I; X-ray; 1.87 A; A=664-920, B=20-30. DR PDB; 2Q7J; X-ray; 1.90 A; A=664-920. DR PDB; 2Q7K; X-ray; 1.80 A; A=664-920, B=20-30. DR PDB; 2Q7L; X-ray; 1.92 A; A=664-920. DR PDB; 2YHD; X-ray; 2.20 A; A=672-920. DR PDB; 2YLO; X-ray; 2.50 A; A=665-920. DR PDB; 2YLP; X-ray; 2.30 A; A=665-920. DR PDB; 2YLQ; X-ray; 2.40 A; A=665-920. DR PDB; 2Z4J; X-ray; 2.60 A; A=672-919. DR PDB; 3B5R; X-ray; 1.80 A; A=672-920. DR PDB; 3B65; X-ray; 1.80 A; A=672-920. DR PDB; 3B66; X-ray; 1.65 A; A=672-920. DR PDB; 3B67; X-ray; 1.90 A; A=672-920. DR PDB; 3B68; X-ray; 1.90 A; A=672-920. DR PDB; 3BTR; X-ray; 2.60 A; B=622-636. DR PDB; 3L3X; X-ray; 1.55 A; A=671-919. DR PDB; 3L3Z; X-ray; 2.00 A; A=671-919. DR PDB; 3RLJ; X-ray; 1.90 A; A=672-918. DR PDB; 3RLL; X-ray; 1.70 A; A=672-918. DR PDB; 3V49; X-ray; 1.70 A; A=655-920, B=21-31. DR PDB; 3V4A; X-ray; 1.95 A; A=672-920, B=21-31. DR PDB; 3ZQT; X-ray; 2.29 A; A=665-920. DR PDB; 4HLW; X-ray; 2.50 A; A=665-920. DR PDB; 4K7A; X-ray; 2.44 A; A=671-919. DR PDB; 4OEA; X-ray; 2.12 A; A=671-920. DR PDB; 4OED; X-ray; 2.79 A; A=671-920. DR PDB; 4OEY; X-ray; 1.83 A; A=671-920. DR PDB; 4OEZ; X-ray; 1.80 A; A=671-920. DR PDB; 4OFR; X-ray; 2.26 A; A=671-920. DR PDB; 4OFU; X-ray; 2.12 A; A=671-920. DR PDB; 4OGH; X-ray; 2.98 A; A=671-920. DR PDB; 4OH5; X-ray; 2.00 A; A=671-920. DR PDB; 4OH6; X-ray; 3.56 A; A=671-920. DR PDB; 4OHA; X-ray; 1.42 A; A=671-920. DR PDB; 4OIL; X-ray; 2.51 A; A=671-920. DR PDB; 4OIU; X-ray; 3.01 A; A=671-920. DR PDB; 4OJ9; X-ray; 3.31 A; A=671-920. DR PDB; 4OJB; X-ray; 2.00 A; A=671-920. DR PDB; 4OK1; X-ray; 2.09 A; A=671-920. DR PDB; 4OKB; X-ray; 2.95 A; A=671-920. DR PDB; 4OKT; X-ray; 2.50 A; A=671-920. DR PDB; 4OKW; X-ray; 2.00 A; A=671-920. DR PDB; 4OKX; X-ray; 2.10 A; A=671-920. DR PDB; 4OLM; X-ray; 2.80 A; A=671-920. DR PDB; 4QL8; X-ray; 2.10 A; A=663-920. DR PDB; 5CJ6; X-ray; 2.07 A; A=642-920, B=21-30. DR PDB; 5JJM; X-ray; 2.15 A; A/B/C/D=669-920. DR PDB; 5T8E; X-ray; 2.71 A; A=672-920. DR PDB; 5T8J; X-ray; 2.70 A; A=672-920. DR PDB; 5V8Q; X-ray; 1.44 A; A=672-920. DR PDB; 5VO4; X-ray; 2.35 A; A=671-920. DR PDB; 7ZTX; X-ray; 1.89 A; A=672-920. DR PDB; 7ZTZ; X-ray; 1.40 A; A=672-920. DR PDB; 7ZU1; X-ray; 1.68 A; A=672-920. DR PDB; 7ZU2; X-ray; 1.74 A; A=672-920. DR PDB; 8E1A; X-ray; 1.20 A; A=665-920. DR PDB; 8FGY; X-ray; 2.20 A; A=663-920. DR PDB; 8FGZ; X-ray; 1.61 A; A=663-920. DR PDB; 8FH0; X-ray; 1.59 A; A=663-920. DR PDB; 8FH1; X-ray; 1.69 A; A=663-920. DR PDB; 8FH2; X-ray; 1.59 A; A=663-920. DR PDB; 8RM6; X-ray; 2.05 A; A/B=557-629. DR PDB; 8RM7; X-ray; 2.25 A; A/B=557-629. DR PDBsum; 1E3G; -. DR PDBsum; 1GS4; -. DR PDBsum; 1T5Z; -. DR PDBsum; 1T63; -. DR PDBsum; 1T65; -. DR PDBsum; 1XJ7; -. DR PDBsum; 1XOW; -. DR PDBsum; 1XQ3; -. DR PDBsum; 1Z95; -. DR PDBsum; 2AM9; -. DR PDBsum; 2AMA; -. DR PDBsum; 2AMB; -. DR PDBsum; 2AO6; -. DR PDBsum; 2AX6; -. DR PDBsum; 2AX7; -. DR PDBsum; 2AX8; -. DR PDBsum; 2AX9; -. DR PDBsum; 2AXA; -. DR PDBsum; 2HVC; -. DR PDBsum; 2OZ7; -. DR PDBsum; 2PIO; -. DR PDBsum; 2PIP; -. DR PDBsum; 2PIQ; -. DR PDBsum; 2PIR; -. DR PDBsum; 2PIT; -. DR PDBsum; 2PIU; -. DR PDBsum; 2PIV; -. DR PDBsum; 2PIW; -. DR PDBsum; 2PIX; -. DR PDBsum; 2PKL; -. DR PDBsum; 2PNU; -. DR PDBsum; 2Q7I; -. DR PDBsum; 2Q7J; -. DR PDBsum; 2Q7K; -. DR PDBsum; 2Q7L; -. DR PDBsum; 2YHD; -. DR PDBsum; 2YLO; -. DR PDBsum; 2YLP; -. DR PDBsum; 2YLQ; -. DR PDBsum; 2Z4J; -. DR PDBsum; 3B5R; -. DR PDBsum; 3B65; -. DR PDBsum; 3B66; -. DR PDBsum; 3B67; -. DR PDBsum; 3B68; -. DR PDBsum; 3BTR; -. DR PDBsum; 3L3X; -. DR PDBsum; 3L3Z; -. DR PDBsum; 3RLJ; -. DR PDBsum; 3RLL; -. DR PDBsum; 3V49; -. DR PDBsum; 3V4A; -. DR PDBsum; 3ZQT; -. DR PDBsum; 4HLW; -. DR PDBsum; 4K7A; -. DR PDBsum; 4OEA; -. DR PDBsum; 4OED; -. DR PDBsum; 4OEY; -. DR PDBsum; 4OEZ; -. DR PDBsum; 4OFR; -. DR PDBsum; 4OFU; -. DR PDBsum; 4OGH; -. DR PDBsum; 4OH5; -. DR PDBsum; 4OH6; -. DR PDBsum; 4OHA; -. DR PDBsum; 4OIL; -. DR PDBsum; 4OIU; -. DR PDBsum; 4OJ9; -. DR PDBsum; 4OJB; -. DR PDBsum; 4OK1; -. DR PDBsum; 4OKB; -. DR PDBsum; 4OKT; -. DR PDBsum; 4OKW; -. DR PDBsum; 4OKX; -. DR PDBsum; 4OLM; -. DR PDBsum; 4QL8; -. DR PDBsum; 5CJ6; -. DR PDBsum; 5JJM; -. DR PDBsum; 5T8E; -. DR PDBsum; 5T8J; -. DR PDBsum; 5V8Q; -. DR PDBsum; 5VO4; -. DR PDBsum; 7ZTX; -. DR PDBsum; 7ZTZ; -. DR PDBsum; 7ZU1; -. DR PDBsum; 7ZU2; -. DR PDBsum; 8E1A; -. DR PDBsum; 8FGY; -. DR PDBsum; 8FGZ; -. DR PDBsum; 8FH0; -. DR PDBsum; 8FH1; -. DR PDBsum; 8FH2; -. DR PDBsum; 8RM6; -. DR PDBsum; 8RM7; -. DR AlphaFoldDB; P10275; -. DR PCDDB; P10275; -. DR SMR; P10275; -. DR BioGRID; 106862; 954. DR CORUM; P10275; -. DR DIP; DIP-125N; -. DR ELM; P10275; -. DR FunCoup; P10275; 1131. DR IntAct; P10275; 312. DR MINT; P10275; -. DR STRING; 9606.ENSP00000363822; -. DR BindingDB; P10275; -. DR ChEMBL; CHEMBL1871; -. DR DrugBank; DB07422; (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide. DR DrugBank; DB07039; (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide. DR DrugBank; DB04709; (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE. DR DrugBank; DB07717; (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE. DR DrugBank; DB07454; (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE. DR DrugBank; DB02932; (R)-Bicalutamide. DR DrugBank; DB08035; 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE. DR DrugBank; DB01481; 1-Testosterone. DR DrugBank; DB05107; 16-Bromoepiandrosterone. DR DrugBank; DB08088; 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile. DR DrugBank; DB08461; 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL. DR DrugBank; DB08087; 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE. DR DrugBank; DB07421; 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile. DR DrugBank; DB01063; Acetophenazine. DR DrugBank; DB07423; Andarine. DR DrugBank; DB11901; Apalutamide. DR DrugBank; DB07352; Apigenin. DR DrugBank; DB01128; Bicalutamide. DR DrugBank; DB06973; Bisphenol A. DR DrugBank; DB07286; BMS-564929. DR DrugBank; DB01541; Boldenone. DR DrugBank; DB14639; Boldenone undecylenate. DR DrugBank; DB01564; Calusterone. DR DrugBank; DB13111; Chromanol. DR DrugBank; DB12499; Clascoterone. DR DrugBank; DB04839; Cyproterone acetate. DR DrugBank; DB01406; Danazol. DR DrugBank; DB12941; Darolutamide. DR DrugBank; DB09123; Dienogest. DR DrugBank; DB00255; Diethylstilbestrol. DR DrugBank; DB06133; Dimethylcurcumin. DR DrugBank; DB01395; Drospirenone. DR DrugBank; DB00858; Drostanolone. DR DrugBank; DB15488; Echinacoside. DR DrugBank; DB11219; Enzacamene. DR DrugBank; DB08899; Enzalutamide. DR DrugBank; DB19123; Enzalutamide d3. DR DrugBank; DB13155; Esculin. DR DrugBank; DB00655; Estrone. DR DrugBank; DB01493; Ethylestrenol. DR DrugBank; DB09086; Eugenol. DR DrugBank; DB07776; Flavone. DR DrugBank; DB00687; Fludrocortisone. DR DrugBank; DB02266; Flufenamic acid. DR DrugBank; DB01185; Fluoxymesterone. DR DrugBank; DB00623; Fluphenazine. DR DrugBank; DB00499; Flutamide. DR DrugBank; DB12415; Galeterone. DR DrugBank; DB11619; Gestrinone. DR DrugBank; DB12461; GLPG-0492. DR DrugBank; DB11064; Homosalate. DR DrugBank; DB01852; Kaempherol. DR DrugBank; DB01026; Ketoconazole. DR DrugBank; DB15647; Ketodarolutamide. DR DrugBank; DB00367; Levonorgestrel. DR DrugBank; DB08089; LGD-2226. DR DrugBank; DB05234; LGD2941. DR DrugBank; DB13934; Ligandrol. DR DrugBank; DB16221; Lonaprisan. DR DrugBank; DB11425; Luprostiol. DR DrugBank; DB06710; Methyltestosterone. DR DrugBank; DB02998; Metribolone. DR DrugBank; DB11429; Mibolerone. DR DrugBank; DB00648; Mitotane. DR DrugBank; DB16244; MK-0773. DR DrugBank; DB13169; Nandrolone. DR DrugBank; DB08804; Nandrolone decanoate. DR DrugBank; DB00984; Nandrolone phenpropionate. DR DrugBank; DB00665; Nilutamide. DR DrugBank; DB06713; Norelgestromin. DR DrugBank; DB00717; Norethisterone. DR DrugBank; DB09371; Norethynodrel. DR DrugBank; DB00957; Norgestimate. DR DrugBank; DB09389; Norgestrel. DR DrugBank; DB00621; Oxandrolone. DR DrugBank; DB01428; Oxybenzone. DR DrugBank; DB06412; Oxymetholone. DR DrugBank; DB01608; Periciazine. DR DrugBank; DB15221; PF-06260414. DR DrugBank; DB11447; Phenothiazine. DR DrugBank; DB01708; Prasterone. DR DrugBank; DB00396; Progesterone. DR DrugBank; DB13939; RAD-140. DR DrugBank; DB07419; S-23. DR DrugBank; DB07769; S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE. DR DrugBank; DB14583; Segesterone acetate. DR DrugBank; DB00421; Spironolactone. DR DrugBank; DB02901; Stanolone. DR DrugBank; DB13951; Stanolone acetate. DR DrugBank; DB06718; Stanozolol. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB00624; Testosterone. DR DrugBank; DB13943; Testosterone cypionate. DR DrugBank; DB13944; Testosterone enanthate. DR DrugBank; DB01420; Testosterone propionate. DR DrugBank; DB13946; Testosterone undecanoate. DR DrugBank; DB06870; Tetrahydrogestrinone. DR DrugBank; DB08604; Triclosan. DR DrugBank; DB08867; Ulipristal. DR DrugCentral; P10275; -. DR GuidetoPHARMACOLOGY; 628; -. DR SwissLipids; SLP:000001553; -. DR MoonDB; P10275; Predicted. DR GlyGen; P10275; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P10275; -. DR PhosphoSitePlus; P10275; -. DR SwissPalm; P10275; -. DR BioMuta; AR; -. DR DMDM; 113830; -. DR jPOST; P10275; -. DR MassIVE; P10275; -. DR PaxDb; 9606-ENSP00000363822; -. DR PeptideAtlas; P10275; -. DR ProteomicsDB; 18721; -. DR ProteomicsDB; 52590; -. [P10275-1] DR ProteomicsDB; 52591; -. [P10275-2] DR TopDownProteomics; P10275-1; -. [P10275-1] DR Antibodypedia; 3489; 2587 antibodies from 51 providers. DR DNASU; 367; -. DR Ensembl; ENST00000374690.9; ENSP00000363822.3; ENSG00000169083.19. [P10275-1] DR Ensembl; ENST00000504326.5; ENSP00000421155.1; ENSG00000169083.19. [P10275-3] DR Ensembl; ENST00000612452.5; ENSP00000484033.2; ENSG00000169083.19. [P10275-1] DR GeneID; 367; -. DR KEGG; hsa:367; -. DR MANE-Select; ENST00000374690.9; ENSP00000363822.3; NM_000044.6; NP_000035.2. DR UCSC; uc004dwv.3; human. [P10275-1] DR UCSC; uc011mpf.2; human. DR AGR; HGNC:644; -. DR CIViC; 367; 1 clinical assertion and 47 evidence items across 34 molecular profiles. DR ClinPGx; PA57; -. DR CTD; 367; -. DR DisGeNET; 367; -. DR GeneCards; AR; -. DR GeneReviews; AR; -. DR HGNC; HGNC:644; AR. DR HPA; ENSG00000169083; Tissue enhanced (liver). DR MalaCards; AR; -. DR MIM; 300068; phenotype. DR MIM; 300633; phenotype. DR MIM; 301120; phenotype. DR MIM; 312300; phenotype. DR MIM; 313200; phenotype. DR MIM; 313700; gene. DR OpenTargets; ENSG00000169083; -. DR Orphanet; 99429; Complete androgen insensitivity syndrome. DR Orphanet; 481; Kennedy disease. DR Orphanet; 95706; Non-syndromic posterior hypospadias. DR Orphanet; 90797; Partial androgen insensitivity syndrome. DR VEuPathDB; HostDB:ENSG00000169083; -. DR eggNOG; KOG3575; Eukaryota. DR GeneTree; ENSGT00940000155516; -. DR HOGENOM; CLU_007368_15_0_1; -. DR InParanoid; P10275; -. DR OMA; SHMEGYE; -. DR OrthoDB; 10032732at2759; -. DR PAN-GO; P10275; 5 GO annotations based on evolutionary models. DR PhylomeDB; P10275; -. DR PathwayCommons; P10275; -. DR Reactome; R-HSA-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand. DR Reactome; R-HSA-383280; Nuclear Receptor transcription pathway. DR Reactome; R-HSA-4090294; SUMOylation of intracellular receptors. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation. DR SignaLink; P10275; -. DR SIGNOR; P10275; -. DR Agora; ENSG00000169083; -. DR BioGRID-ORCS; 367; 14 hits in 805 CRISPR screens. DR CD-CODE; DFB52F78; Synthetic Condensate 000129. DR CD-CODE; EEE9EDCA; Synthetic Condensate 000155. DR ChiTaRS; AR; human. DR EvolutionaryTrace; P10275; -. DR GeneWiki; Androgen_receptor; -. DR GenomeRNAi; 367; -. DR Pharos; P10275; Tclin. DR PRO; PR:P10275; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P10275; protein. DR Bgee; ENSG00000169083; Expressed in seminal vesicle and 180 other cell types or tissues. DR ExpressionAtlas; P10275; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:CAFA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:Ensembl. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005497; F:androgen binding; IDA:UniProtKB. DR GO; GO:0051117; F:ATPase binding; IDA:MGI. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0034056; F:estrogen response element binding; IBA:GO_Central. DR GO; GO:0060090; F:molecular adaptor activity; IDA:DisProt. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt. DR GO; GO:0004879; F:nuclear receptor activity; IDA:UniProtKB. DR GO; GO:0003707; F:nuclear steroid receptor activity; IDA:BHF-UCL. DR GO; GO:0070974; F:POU domain binding; IEA:Ensembl. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB. DR GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl. DR GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0001223; F:transcription coactivator binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030521; P:androgen receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0048645; P:animal organ formation; IEA:Ensembl. DR GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc. DR GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:ARUK-UCL. DR GO; GO:0071383; P:cellular response to steroid hormone stimulus; IMP:CAFA. DR GO; GO:0071394; P:cellular response to testosterone stimulus; IDA:ARUK-UCL. DR GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0003382; P:epithelial cell morphogenesis; IEA:Ensembl. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0030520; P:estrogen receptor signaling pathway; IDA:ARUK-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0030522; P:intracellular receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0060599; P:lateral sprouting involved in mammary gland duct morphogenesis; IEA:Ensembl. DR GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl. DR GO; GO:0048808; P:male genitalia morphogenesis; IEA:Ensembl. DR GO; GO:0008584; P:male gonad development; IBA:GO_Central. DR GO; GO:0019102; P:male somatic sex determination; IEA:Ensembl. DR GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:DisProt. DR GO; GO:0060571; P:morphogenesis of an epithelial fold; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:CAFA. DR GO; GO:0045597; P:positive regulation of cell differentiation; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB. DR GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045726; P:positive regulation of integrin biosynthetic process; IDA:BHF-UCL. DR GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IDA:BHF-UCL. DR GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl. DR GO; GO:0060736; P:prostate gland growth; IEA:Ensembl. DR GO; GO:0060514; P:prostate induction; IEA:Ensembl. DR GO; GO:0048638; P:regulation of developmental growth; IEA:Ensembl. DR GO; GO:1903076; P:regulation of protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0003073; P:regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007338; P:single fertilization; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IBA:GO_Central. DR GO; GO:0060748; P:tertiary branching involved in mammary gland duct morphogenesis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd07173; NR_DBD_AR; 1. DR CDD; cd07073; NR_LBD_AR; 1. DR DisProt; DP00492; -. DR FunFam; 3.30.50.10:FF:000024; Androgen receptor; 1. DR FunFam; 1.10.565.10:FF:000004; Androgen receptor variant; 1. DR Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1. DR Gene3D; 1.10.565.10; Retinoid X Receptor; 1. DR IDEAL; IID00020; -. DR InterPro; IPR001103; Andrgn_rcpt. DR InterPro; IPR035500; NHR-like_dom_sf. DR InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd. DR InterPro; IPR050200; Nuclear_hormone_rcpt_NR3. DR InterPro; IPR001628; Znf_hrmn_rcpt. DR InterPro; IPR013088; Znf_NHR/GATA. DR PANTHER; PTHR48092; KNIRPS-RELATED PROTEIN-RELATED; 1. DR Pfam; PF02166; Androgen_recep; 1. DR Pfam; PF00104; Hormone_recep; 1. DR Pfam; PF00105; zf-C4; 1. DR PRINTS; PR00521; ANDROGENR. DR PRINTS; PR00047; STROIDFINGER. DR SMART; SM00430; HOLI; 1. DR SMART; SM00399; ZnF_C4; 1. DR SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1. DR SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1. DR PROSITE; PS51843; NR_LBD; 1. DR PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1. DR PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Cytoplasm; Disease variant; KW DNA-binding; Isopeptide bond; Lipid-binding; Lipoprotein; Metal-binding; KW Neurodegeneration; Nucleus; Palmitate; Phosphoprotein; KW Proteomics identification; Pseudohermaphroditism; Receptor; KW Reference proteome; Steroid-binding; Transcription; KW Transcription regulation; Triplet repeat expansion; Ubl conjugation; Zinc; KW Zinc-finger. FT CHAIN 1..920 FT /note="Androgen receptor" FT /id="PRO_0000053704" FT DOMAIN 669..900 FT /note="NR LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01189" FT DNA_BIND 560..632 FT /note="Nuclear receptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 560..580 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 596..620 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT REGION 1..587 FT /note="Interaction with ZNF318" FT /evidence="ECO:0000250|UniProtKB:P19091" FT REGION 1..559 FT /note="Modulating" FT REGION 36..167 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 195..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 552..919 FT /note="Interaction with LPXN" FT /evidence="ECO:0000269|PubMed:18451096" FT REGION 572..662 FT /note="Interaction with HIPK3" FT /evidence="ECO:0000250|UniProtKB:P15207" FT REGION 592..919 FT /note="Interaction with CCAR1" FT /evidence="ECO:0000269|PubMed:23887938" FT REGION 625..919 FT /note="Interaction with KAT7" FT /evidence="ECO:0000269|PubMed:10930412" FT COMPBIAS 44..91 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 195..217 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 218..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 706 FT /ligand="17beta-hydroxy-5alpha-androstan-3-one" FT /ligand_id="ChEBI:CHEBI:16330" FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:16641486, ECO:0000269|PubMed:17591767, FT ECO:0000269|PubMed:25091737, ECO:0007744|PDB:1T5Z, FT ECO:0007744|PDB:1T63, ECO:0007744|PDB:1T65, FT ECO:0007744|PDB:1XJ7, ECO:0007744|PDB:2AM9, FT ECO:0007744|PDB:2AMA, ECO:0007744|PDB:2AMB, FT ECO:0007744|PDB:2PIO, ECO:0007744|PDB:2PIP, FT ECO:0007744|PDB:2PIR, ECO:0007744|PDB:2PIT, FT ECO:0007744|PDB:2PIU, ECO:0007744|PDB:2PIV, FT ECO:0007744|PDB:2PIW, ECO:0007744|PDB:2PIX, FT ECO:0007744|PDB:2PKL, ECO:0007744|PDB:2PNU, FT ECO:0007744|PDB:2Q7I, ECO:0007744|PDB:2Q7J, FT ECO:0007744|PDB:2Q7K, ECO:0007744|PDB:2Q7L, FT ECO:0007744|PDB:2YHD, ECO:0007744|PDB:2YLO, FT ECO:0007744|PDB:2YLP, ECO:0007744|PDB:2YLQ, FT ECO:0007744|PDB:3L3X, ECO:0007744|PDB:3L3Z, FT ECO:0007744|PDB:3ZQT, ECO:0007744|PDB:4HLW, FT ECO:0007744|PDB:4K7A, ECO:0007744|PDB:4OEA, FT ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, FT ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, FT ECO:0007744|PDB:4OFU, ECO:0007744|PDB:5JJM" FT BINDING 753 FT /ligand="17beta-hydroxy-5alpha-androstan-3-one" FT /ligand_id="ChEBI:CHEBI:16330" FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:16641486, ECO:0000269|PubMed:17591767, FT ECO:0000269|PubMed:25091737, ECO:0007744|PDB:1T5Z, FT ECO:0007744|PDB:1T63, ECO:0007744|PDB:1T65, FT ECO:0007744|PDB:1XJ7, ECO:0007744|PDB:2AM9, FT ECO:0007744|PDB:2AMA, ECO:0007744|PDB:2PIO, FT ECO:0007744|PDB:2PIP, ECO:0007744|PDB:2PIQ, FT ECO:0007744|PDB:2PIR, ECO:0007744|PDB:2PIT, FT ECO:0007744|PDB:2PIU, ECO:0007744|PDB:2PIV, FT ECO:0007744|PDB:2PIW, ECO:0007744|PDB:2PIX, FT ECO:0007744|PDB:2PKL, ECO:0007744|PDB:2Q7I, FT ECO:0007744|PDB:2Q7J, ECO:0007744|PDB:2Q7K, FT ECO:0007744|PDB:2Q7L, ECO:0007744|PDB:2YHD, FT ECO:0007744|PDB:2YLO, ECO:0007744|PDB:2YLP, FT ECO:0007744|PDB:2YLQ, ECO:0007744|PDB:2Z4J, FT ECO:0007744|PDB:3L3X, ECO:0007744|PDB:3L3Z, FT ECO:0007744|PDB:3ZQT, ECO:0007744|PDB:4HLW, FT ECO:0007744|PDB:4K7A, ECO:0007744|PDB:4OEA, FT ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, FT ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, FT ECO:0007744|PDB:4OFU, ECO:0007744|PDB:5JJM" FT BINDING 878 FT /ligand="17beta-hydroxy-5alpha-androstan-3-one" FT /ligand_id="ChEBI:CHEBI:16330" FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:16641486, ECO:0000269|PubMed:17591767, FT ECO:0000269|PubMed:25091737, ECO:0007744|PDB:1T5Z, FT ECO:0007744|PDB:1T63, ECO:0007744|PDB:1T65, FT ECO:0007744|PDB:1XJ7, ECO:0007744|PDB:2AM9, FT ECO:0007744|PDB:2AMA, ECO:0007744|PDB:2PIO, FT ECO:0007744|PDB:2PIP, ECO:0007744|PDB:2PIQ, FT ECO:0007744|PDB:2PIR, ECO:0007744|PDB:2PIT, FT ECO:0007744|PDB:2PIU, ECO:0007744|PDB:2PIV, FT ECO:0007744|PDB:2PIW, ECO:0007744|PDB:2PIX, FT ECO:0007744|PDB:2PKL, ECO:0007744|PDB:2Q7I, FT ECO:0007744|PDB:2Q7J, ECO:0007744|PDB:2Q7K, FT ECO:0007744|PDB:2Q7L, ECO:0007744|PDB:2YHD, FT ECO:0007744|PDB:2YLO, ECO:0007744|PDB:2YLP, FT ECO:0007744|PDB:2YLQ, ECO:0007744|PDB:2Z4J, FT ECO:0007744|PDB:3L3X, ECO:0007744|PDB:3L3Z, FT ECO:0007744|PDB:3ZQT, ECO:0007744|PDB:4HLW, FT ECO:0007744|PDB:4K7A, ECO:0007744|PDB:4OEA, FT ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, FT ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, FT ECO:0007744|PDB:4OFU, ECO:0007744|PDB:5JJM" FT SITE 721 FT /note="Interaction with coactivator LXXL and FXXFY motifs" FT /evidence="ECO:0000269|PubMed:25091737" FT SITE 898 FT /note="Interaction with coactivator FXXLF and FXXFY motifs" FT /evidence="ECO:0000269|PubMed:25091737" FT MOD_RES 83 FT /note="Phosphoserine; by CDK9" FT /evidence="ECO:0000269|PubMed:20980437" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 225 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 258 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 269 FT /note="Phosphotyrosine; by CSK and TNK2" FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:20623637" FT MOD_RES 309 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 348 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 359 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 364 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 365 FT /note="Phosphotyrosine; by CSK and TNK2" FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760" FT MOD_RES 395 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 535 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 552 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 651 FT /note="Phosphoserine; by STK4/MST1" FT /evidence="ECO:0000269|PubMed:21512132" FT MOD_RES 916 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT CROSSLNK 388 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11121022" FT CROSSLNK 521 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11121022" FT CROSSLNK 846 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19345326" FT CROSSLNK 848 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19345326" FT VAR_SEQ 1..532 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_036889" FT VAR_SEQ 533..539 FT /note="GPYGDMR -> MILWLHS (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_036890" FT VAR_SEQ 629..644 FT /note="ARKLKKLGNLKLQEEG -> EKFRVGNCKHLKMTRP (in isoform 3)" FT /id="VSP_058166" FT VAR_SEQ 630..648 FT /note="RKLKKLGNLKLQEEGEASS -> AVVVSERILRVFGVSEWLP (in FT isoform 4)" FT /id="VSP_058167" FT VAR_SEQ 645..920 FT /note="Missing (in isoform 3)" FT /id="VSP_058168" FT VAR_SEQ 649..920 FT /note="Missing (in isoform 4)" FT /id="VSP_058169" FT VARIANT 2 FT /note="E -> K (in PAIS; dbSNP:rs104894742)" FT /evidence="ECO:0000269|PubMed:8823308" FT /id="VAR_004679" FT VARIANT 54 FT /note="L -> S (in prostate cancer)" FT /id="VAR_004680" FT VARIANT 57 FT /note="L -> Q (in prostate cancer; dbSNP:rs78686797)" FT /evidence="ECO:0000269|PubMed:19244107" FT /id="VAR_004681" FT VARIANT 64 FT /note="Q -> R (in prostate cancer)" FT /id="VAR_009711" FT VARIANT 114 FT /note="Q -> H (in prostate cancer)" FT /id="VAR_009712" FT VARIANT 182 FT /note="K -> R (in prostate cancer)" FT /id="VAR_009713" FT VARIANT 196 FT /note="Q -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:9255042" FT /id="VAR_009224" FT VARIANT 207 FT /note="S -> R (in dbSNP:rs374549047)" FT /evidence="ECO:0000269|PubMed:8213813" FT /id="VAR_009714" FT VARIANT 216 FT /note="G -> R (20% lower transactivation capacity; FT dbSNP:rs199554641)" FT /evidence="ECO:0000269|PubMed:27535533, FT ECO:0000269|PubMed:9788719" FT /id="VAR_009715" FT VARIANT 257 FT /note="L -> P (in AIS)" FT /evidence="ECO:0000269|PubMed:9610419" FT /id="VAR_009225" FT VARIANT 268 FT /note="M -> T (in prostate cancer)" FT /id="VAR_009716" FT VARIANT 271 FT /note="P -> S (in prostate cancer)" FT /id="VAR_009717" FT VARIANT 342 FT /note="P -> L (in prostate cancer; dbSNP:rs138454018)" FT /evidence="ECO:0000269|PubMed:7511268" FT /id="VAR_009718" FT VARIANT 392 FT /note="P -> R (in AIS; dbSNP:rs773996740)" FT /evidence="ECO:0000269|PubMed:10571951" FT /id="VAR_009226" FT VARIANT 392 FT /note="P -> S (in AIS; dbSNP:rs201934623)" FT /evidence="ECO:0000269|PubMed:10946887" FT /id="VAR_009227" FT VARIANT 445 FT /note="Q -> R (in AIS; uncertain significance; FT dbSNP:rs1355285524)" FT /evidence="ECO:0000269|PubMed:10571951" FT /id="VAR_009228" FT VARIANT 492 FT /note="G -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009719" FT VARIANT 529 FT /note="D -> G (in prostate cancer)" FT /id="VAR_009720" FT VARIANT 548 FT /note="L -> F (in PAIS; dbSNP:rs139524801)" FT /evidence="ECO:0000269|PubMed:11788616" FT /id="VAR_009721" FT VARIANT 549 FT /note="P -> S (in AIS; dbSNP:rs137852588)" FT /evidence="ECO:0000269|PubMed:8683794" FT /id="VAR_009722" FT VARIANT 560 FT /note="C -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:1316540" FT /id="VAR_009723" FT VARIANT 569 FT /note="G -> V (in a patient with isolated hypospadias)" FT /evidence="ECO:0000269|PubMed:7673412" FT /id="VAR_009725" FT VARIANT 569 FT /note="G -> W (in PAIS; dbSNP:rs1555982864)" FT /evidence="ECO:0000269|PubMed:7910529" FT /id="VAR_009726" FT VARIANT 572 FT /note="Y -> C (in AIS)" FT /evidence="ECO:0000269|PubMed:9544375" FT /id="VAR_009727" FT VARIANT 574 FT /note="A -> D (in AIS)" FT /evidence="ECO:0000269|PubMed:9421404" FT /id="VAR_009728" FT VARIANT 575 FT /note="L -> P (in prostate cancer)" FT /id="VAR_009729" FT VARIANT 576 FT /note="T -> A (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009730" FT VARIANT 577 FT /note="C -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:14756668" FT /id="VAR_009731" FT VARIANT 577 FT /note="C -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:1316540" FT /id="VAR_009732" FT VARIANT 580 FT /note="C -> F (in AIS; reduced transcription and DNA FT binding; dbSNP:rs137852586)" FT /evidence="ECO:0000269|PubMed:8809734" FT /id="VAR_009733" FT VARIANT 580 FT /note="C -> Y (in AIS; dbSNP:rs137852586)" FT /id="VAR_009734" FT VARIANT 581 FT /note="K -> R (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009735" FT VARIANT 582 FT /note="V -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:8224266, ECO:0000269|Ref.118" FT /id="VAR_009736" FT VARIANT 583 FT /note="F -> S (in PAIS)" FT /evidence="ECO:0000269|PubMed:7981687" FT /id="VAR_009737" FT VARIANT 583 FT /note="F -> Y (in PAIS; dbSNP:rs137852587)" FT /evidence="ECO:0000269|PubMed:8809734" FT /id="VAR_009738" FT VARIANT 583 FT /note="Missing (in AIS)" FT /evidence="ECO:0000269|PubMed:8162033" FT /id="VAR_009739" FT VARIANT 586 FT /note="R -> K (in AIS)" FT /evidence="ECO:0000269|PubMed:8240973" FT /id="VAR_009740" FT VARIANT 587 FT /note="A -> V (in prostate cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009741" FT VARIANT 588 FT /note="A -> S (in prostate cancer; somatic mutation)" FT /id="VAR_009742" FT VARIANT 597 FT /note="A -> T (in AIS; abolishes dimerization; FT dbSNP:rs137852569)" FT /evidence="ECO:0000269|PubMed:10590024, FT ECO:0000269|PubMed:7649358" FT /id="VAR_009743" FT VARIANT 598 FT /note="S -> G (in PAIS; normal androgen binding; does not FT activate transcription; impairs DNA binding; FT dbSNP:rs142280455)" FT /evidence="ECO:0000269|PubMed:1316540" FT /id="VAR_009744" FT VARIANT 598 FT /note="S -> T (in a patient with severe hypospadias)" FT /evidence="ECO:0000269|PubMed:10092153" FT /id="VAR_009745" FT VARIANT 602 FT /note="C -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:7981689" FT /id="VAR_009746" FT VARIANT 605 FT /note="D -> Y (in PAIS)" FT /evidence="ECO:0000269|PubMed:7981687" FT /id="VAR_009747" FT VARIANT 608 FT /note="R -> Q (in PAIS and breast cancer; FT dbSNP:rs137852573)" FT /evidence="ECO:0000269|PubMed:10221692, FT ECO:0000269|PubMed:1303262, ECO:0000269|PubMed:9039340, FT ECO:0000269|PubMed:9543136" FT /id="VAR_004684" FT VARIANT 609 FT /note="R -> K (in PAIS and breast cancer; defective nuclear FT localization; dbSNP:rs137852576)" FT /evidence="ECO:0000269|PubMed:1424203, FT ECO:0000269|PubMed:8281139, ECO:0000269|PubMed:9196614" FT /id="VAR_004685" FT VARIANT 611 FT /note="N -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:9039340" FT /id="VAR_009748" FT VARIANT 612 FT /note="C -> Y (in AIS)" FT /id="VAR_009749" FT VARIANT 616 FT /note="R -> H (in AIS and PAIS; dbSNP:rs754201976)" FT /evidence="ECO:0000269|PubMed:7970939, FT ECO:0000269|PubMed:8162033, ECO:0000269|PubMed:8413310, FT ECO:0000269|PubMed:9698822" FT /id="VAR_009751" FT VARIANT 616 FT /note="R -> P (in AIS)" FT /evidence="ECO:0000269|PubMed:1999491" FT /id="VAR_009752" FT VARIANT 616 FT /note="Missing (in AIS)" FT /evidence="ECO:0000269|PubMed:8162033" FT /id="VAR_009750" FT VARIANT 617 FT /note="L -> P (in AIS; dbSNP:rs1555990488)" FT /evidence="ECO:0000269|PubMed:8647313" FT /id="VAR_009753" FT VARIANT 617 FT /note="L -> R (in PAIS)" FT /evidence="ECO:0000269|PubMed:8126121" FT /id="VAR_009754" FT VARIANT 618 FT /note="R -> P (in AIS and PAIS; loss of DNA-binding FT activity)" FT /evidence="ECO:0000269|PubMed:1316540, FT ECO:0000269|PubMed:1999491" FT /id="VAR_009755" FT VARIANT 620 FT /note="C -> Y (in prostate cancer; loss of DNA binding; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:10598582, FT ECO:0000269|PubMed:10706109" FT /id="VAR_009756" FT VARIANT 630 FT /note="R -> Q (in prostate cancer; dbSNP:rs868669253)" FT /evidence="ECO:0000269|PubMed:9184448" FT /id="VAR_009757" FT VARIANT 631 FT /note="K -> T (in prostate cancer)" FT /id="VAR_009758" FT VARIANT 646 FT /note="A -> D (in dbSNP:rs1800053)" FT /evidence="ECO:0000269|PubMed:9554755" FT /id="VAR_004686" FT VARIANT 648 FT /note="S -> N (in prostate cancer; dbSNP:rs137852584)" FT /id="VAR_009760" FT VARIANT 665 FT /note="I -> N (in AIS and PAIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_004687" FT VARIANT 671 FT /note="Q -> R (in prostate cancer)" FT /id="VAR_009761" FT VARIANT 672 FT /note="P -> H (in PAIS)" FT /id="VAR_009762" FT VARIANT 673 FT /note="I -> T (in prostate cancer)" FT /id="VAR_009763" FT VARIANT 678 FT /note="L -> P (in AIS; dbSNP:rs137852579)" FT /evidence="ECO:0000269|PubMed:7537149" FT /id="VAR_004688" FT VARIANT 682 FT /note="E -> K (in AIS; dbSNP:rs1555995816)" FT /evidence="ECO:0000269|PubMed:10221692, FT ECO:0000269|PubMed:8325950" FT /id="VAR_009764" FT VARIANT 683 FT /note="P -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013474" FT VARIANT 684 FT /note="G -> A (found in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10629558, FT ECO:0000269|PubMed:9000575" FT /id="VAR_009765" FT VARIANT 685 FT /note="V -> I (in AIS; dbSNP:rs1555995822)" FT /evidence="ECO:0000269|PubMed:10425033" FT /id="VAR_009766" FT VARIANT 687 FT /note="C -> R (in PAIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009767" FT VARIANT 688 FT /note="A -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009768" FT VARIANT 689 FT /note="G -> E (in AIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009769" FT VARIANT 691 FT /note="Missing (in PAIS)" FT /evidence="ECO:0000269|Ref.126" FT /id="VAR_009770" FT VARIANT 693 FT /note="Missing (in AIS)" FT /id="VAR_004689" FT VARIANT 696 FT /note="D -> H (in AIS)" FT /evidence="ECO:0000269|PubMed:1775137" FT /id="VAR_004690" FT VARIANT 696 FT /note="D -> N (in AIS; almost complete loss of androgen FT binding and transcription activation; dbSNP:rs1555995840)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:1775137" FT /id="VAR_004691" FT VARIANT 696 FT /note="D -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:9554754" FT /id="VAR_004692" FT VARIANT 701 FT /note="L -> M (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009771" FT VARIANT 702 FT /note="L -> F (in AIS; dbSNP:rs1555995851)" FT /id="VAR_009772" FT VARIANT 702 FT /note="L -> H (found in prostate cancer; FT dbSNP:rs864622007)" FT /evidence="ECO:0000269|PubMed:10569618, FT ECO:0000269|PubMed:8274409, ECO:0000269|PubMed:9438000" FT /id="VAR_009773" FT VARIANT 703 FT /note="S -> A (in AIS)" FT /id="VAR_009774" FT VARIANT 704 FT /note="S -> C (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009775" FT VARIANT 704 FT /note="S -> G (in PAIS and AIS)" FT /evidence="ECO:0000269|PubMed:9302173" FT /id="VAR_004693" FT VARIANT 706 FT /note="N -> S (in AIS; dbSNP:rs925822435)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:7671849" FT /id="VAR_009776" FT VARIANT 706 FT /note="N -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:11744994" FT /id="VAR_013475" FT VARIANT 708 FT /note="L -> R (in AIS; dbSNP:rs137852585)" FT /evidence="ECO:0000269|PubMed:8626869" FT /id="VAR_004694" FT VARIANT 709 FT /note="G -> A (in PAIS)" FT /evidence="ECO:0000269|PubMed:7981687, FT ECO:0000269|PubMed:9329414" FT /id="VAR_009777" FT VARIANT 709 FT /note="G -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:10425033" FT /id="VAR_009778" FT VARIANT 711 FT /note="R -> T (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009779" FT VARIANT 712 FT /note="Q -> E (in PAIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013476" FT VARIANT 713 FT /note="L -> F (in PAIS; dbSNP:rs137852595)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009780" FT VARIANT 716 FT /note="V -> M (in prostate cancer; gain in function; FT dbSNP:rs1340026226)" FT /evidence="ECO:0000269|PubMed:8145761" FT /id="VAR_009781" FT VARIANT 718 FT /note="K -> E (in prostate cancer)" FT /id="VAR_009782" FT VARIANT 721 FT /note="K -> E (in prostate cancer; found in bone FT metastases)" FT /id="VAR_009783" FT VARIANT 722 FT /note="A -> T (in prostate cancer; somatic mutation; FT dbSNP:rs137852583)" FT /id="VAR_009784" FT VARIANT 723 FT /note="L -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:9627582" FT /id="VAR_009785" FT VARIANT 724 FT /note="P -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009786" FT VARIANT 725 FT /note="G -> D (in AIS and prostate cancer)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009787" FT VARIANT 726 FT /note="F -> L (in a patient with severe hypospadias; FT dbSNP:rs1555996810)" FT /evidence="ECO:0000269|PubMed:10092153, FT ECO:0000269|PubMed:7671849" FT /id="VAR_009788" FT VARIANT 727 FT /note="R -> L (in HPCX3; dbSNP:rs137852593)" FT /evidence="ECO:0000269|PubMed:8530589" FT /id="VAR_009789" FT VARIANT 728 FT /note="N -> K (in AIS; dbSNP:rs768869912)" FT /evidence="ECO:0000269|PubMed:7993455" FT /id="VAR_009790" FT VARIANT 729 FT /note="L -> S (in PAIS)" FT /id="VAR_009791" FT VARIANT 731 FT /note="V -> M (in prostate cancer; increases transcription FT activation; dbSNP:rs137852571)" FT /evidence="ECO:0000269|PubMed:15525515, FT ECO:0000269|PubMed:1631125, ECO:0000269|PubMed:7591265" FT /id="VAR_004695" FT VARIANT 733 FT /note="D -> N (in AIS)" FT /evidence="ECO:0000269|PubMed:9252933" FT /id="VAR_004696" FT VARIANT 733 FT /note="D -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_004697" FT VARIANT 734 FT /note="Q -> H (in PAIS)" FT /evidence="ECO:0000269|PubMed:9627582" FT /id="VAR_009792" FT VARIANT 738 FT /note="I -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:7671849" FT /id="VAR_009793" FT VARIANT 742 FT /note="W -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:1464650" FT /id="VAR_009794" FT VARIANT 743 FT /note="M -> I (in PAIS)" FT /evidence="ECO:0000269|PubMed:8824883" FT /id="VAR_004698" FT VARIANT 743 FT /note="M -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:7970939" FT /id="VAR_009795" FT VARIANT 744 FT /note="G -> E (in AIS; dbSNP:rs137852600)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013477" FT VARIANT 744 FT /note="G -> V (in PAIS and AIS; dbSNP:rs137852600)" FT /evidence="ECO:0000269|PubMed:8096390, FT ECO:0000269|PubMed:8325932, ECO:0000269|PubMed:9768671, FT ECO:0000269|Ref.118" FT /id="VAR_004699" FT VARIANT 745 FT /note="L -> F (in AIS and prostate cancer)" FT /evidence="ECO:0000269|PubMed:7626493" FT /id="VAR_009796" FT VARIANT 746 FT /note="M -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:7970939" FT /id="VAR_009797" FT VARIANT 747 FT /note="V -> M (in PAIS and AIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009798" FT VARIANT 749 FT /note="A -> D (in PAIS)" FT /id="VAR_009799" FT VARIANT 749 FT /note="A -> T (in prostate cancer)" FT /id="VAR_009800" FT VARIANT 749 FT /note="A -> V (in prostate cancer)" FT /id="VAR_009801" FT VARIANT 750 FT /note="M -> I (in prostate cancer)" FT /id="VAR_009802" FT VARIANT 750 FT /note="M -> V (in PAIS and AIS; dbSNP:rs1085307685)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:1487249, ECO:0000269|PubMed:8990010" FT /id="VAR_004700" FT VARIANT 751 FT /note="G -> D (in AIS; loss of androgen binding)" FT /evidence="ECO:0000269|PubMed:9328206" FT /id="VAR_004701" FT VARIANT 751 FT /note="G -> S (in prostate cancer)" FT /id="VAR_009803" FT VARIANT 752 FT /note="W -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:7626493" FT /id="VAR_009804" FT VARIANT 753 FT /note="R -> Q (in AIS; dbSNP:rs1057523747)" FT /evidence="ECO:0000269|PubMed:9544375, FT ECO:0000269|PubMed:9698822" FT /id="VAR_004702" FT VARIANT 755 FT /note="F -> L (in PAIS and prostate cancer)" FT /evidence="ECO:0000269|PubMed:7981687, FT ECO:0000269|PubMed:9039340" FT /id="VAR_009805" FT VARIANT 755 FT /note="F -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:8103398, ECO:0000269|Ref.118" FT /id="VAR_004703" FT VARIANT 756 FT /note="T -> A (in prostate cancer)" FT /id="VAR_009806" FT VARIANT 757 FT /note="N -> S (in PAIS; dbSNP:rs141425171)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009807" FT VARIANT 758 FT /note="V -> A (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009808" FT VARIANT 759 FT /note="N -> T (in PAIS; 50% reduction in transactivation)" FT /evidence="ECO:0000269|PubMed:9607727" FT /id="VAR_009809" FT VARIANT 760 FT /note="S -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:1480178" FT /id="VAR_009810" FT VARIANT 760 FT /note="S -> P (in prostate cancer)" FT /id="VAR_009811" FT VARIANT 763 FT /note="L -> F (in AIS; loss of androgen binding)" FT /evidence="ECO:0000269|PubMed:9328206" FT /id="VAR_004704" FT VARIANT 764 FT /note="Y -> C (in PAIS and prostate cancer; partial loss of FT androgen binding; dbSNP:rs137852567)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:2010552, ECO:0000269|PubMed:7581399" FT /id="VAR_004705" FT VARIANT 764 FT /note="Y -> H (in AIS)" FT /evidence="ECO:0000269|PubMed:7671849" FT /id="VAR_009812" FT VARIANT 765 FT /note="F -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:7970939" FT /id="VAR_009813" FT VARIANT 766 FT /note="A -> T (in AIS; loss of androgen binding; FT dbSNP:rs1555996863)" FT /evidence="ECO:0000269|PubMed:1426313, FT ECO:0000269|PubMed:9252933, ECO:0000269|PubMed:9328206, FT ECO:0000269|PubMed:9856504" FT /id="VAR_004707" FT VARIANT 766 FT /note="A -> V (in AIS)" FT /id="VAR_009814" FT VARIANT 767 FT /note="P -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009815" FT VARIANT 768 FT /note="D -> E (in AIS)" FT /evidence="ECO:0000269|Ref.118" FT /id="VAR_009816" FT VARIANT 769 FT /note="L -> P (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009817" FT VARIANT 772 FT /note="N -> H (in PAIS; dbSNP:rs886041352)" FT /evidence="ECO:0000269|PubMed:7981687" FT /id="VAR_009818" FT VARIANT 773 FT /note="E -> A (in PAIS)" FT /evidence="ECO:0000269|PubMed:10022458" FT /id="VAR_009819" FT VARIANT 773 FT /note="E -> G (in PAIS)" FT /evidence="ECO:0000269|PubMed:9196614" FT /id="VAR_009820" FT VARIANT 775 FT /note="R -> C (in AIS; frequent mutation; loss of androgen FT binding; dbSNP:rs137852562)" FT /evidence="ECO:0000269|PubMed:1609793, FT ECO:0000269|PubMed:1856263, ECO:0000269|PubMed:2082179, FT ECO:0000269|PubMed:8990010, ECO:0000269|PubMed:9544375" FT /id="VAR_004709" FT VARIANT 775 FT /note="R -> H (in AIS and PAIS; almost complete loss of FT androgen binding; dbSNP:rs137852572)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:1609793, ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:7671849" FT /id="VAR_004708" FT VARIANT 780 FT /note="R -> W (in AIS)" FT /evidence="ECO:0000269|PubMed:7581399, FT ECO:0000269|PubMed:7981687, ECO:0000269|PubMed:9007482" FT /id="VAR_004710" FT VARIANT 781 FT /note="M -> I (in PAIS and AIS; dbSNP:rs137852589)" FT /evidence="ECO:0000269|PubMed:8768864, FT ECO:0000269|PubMed:8824883, ECO:0000269|PubMed:8990010" FT /id="VAR_004711" FT VARIANT 783 FT /note="S -> N (in prostate cancer; somatic mutation)" FT /id="VAR_009821" FT VARIANT 785 FT /note="C -> Y (in AIS; loss of androgen binding and of FT transactivation)" FT /evidence="ECO:0000269|PubMed:9856504" FT /id="VAR_004712" FT VARIANT 788 FT /note="M -> V (in AIS; dbSNP:rs137852570)" FT /evidence="ECO:0000269|PubMed:1569163" FT /id="VAR_004713" FT VARIANT 789 FT /note="R -> S (in AIS; dbSNP:rs1254203917)" FT /id="VAR_009822" FT VARIANT 791 FT /note="L -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:7962294" FT /id="VAR_009823" FT VARIANT 792 FT /note="S -> P (in prostate cancer and AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009824" FT VARIANT 794 FT /note="E -> D (in dbSNP:rs1414341563)" FT /evidence="ECO:0000269|PubMed:8213813" FT /id="VAR_009825" FT VARIANT 795 FT /note="F -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:8990010" FT /id="VAR_004714" FT VARIANT 799 FT /note="Q -> E (in PAIS, AIS and prostate cancer; reduced FT transcription activation; dbSNP:rs137852591)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:7511268, ECO:0000269|PubMed:7671849, FT ECO:0000269|PubMed:8628719, ECO:0000269|PubMed:8824883, FT ECO:0000269|PubMed:9851768" FT /id="VAR_004715" FT VARIANT 807 FT /note="C -> Y (in PAIS; dbSNP:rs1064793480)" FT /evidence="ECO:0000269|PubMed:8339746" FT /id="VAR_009826" FT VARIANT 808 FT /note="M -> R (in AIS; loss of transactivation)" FT /evidence="ECO:0000269|PubMed:8281140" FT /id="VAR_004716" FT VARIANT 808 FT /note="M -> T (in PAIS; dbSNP:rs137852592)" FT /evidence="ECO:0000269|PubMed:10543676" FT /id="VAR_009827" FT VARIANT 808 FT /note="M -> V (in AIS; 25% androgen binding)" FT /evidence="ECO:0000269|PubMed:7581399" FT /id="VAR_004717" FT VARIANT 813 FT /note="L -> F (in AIS; dbSNP:rs1555997625)" FT /evidence="ECO:0000269|PubMed:10458483" FT /id="VAR_009828" FT VARIANT 815 FT /note="S -> N (in AIS and PAIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_004718" FT VARIANT 821 FT /note="G -> A (in AIS)" FT /evidence="ECO:0000269|PubMed:9610419" FT /id="VAR_009829" FT VARIANT 822 FT /note="L -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_009830" FT VARIANT 828 FT /note="F -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013478" FT VARIANT 831 FT /note="L -> P (in prostate cancer)" FT /id="VAR_009831" FT VARIANT 832 FT /note="R -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:7633398" FT /id="VAR_004719" FT VARIANT 832 FT /note="R -> Q (in AIS; loss of androgen binding; FT dbSNP:rs1386577803)" FT /evidence="ECO:0000269|PubMed:10458483, FT ECO:0000269|PubMed:2082179, ECO:0000269|PubMed:7633398" FT /id="VAR_004720" FT VARIANT 835 FT /note="Y -> C (in AIS; loss of androgen binding; FT dbSNP:rs1057521122)" FT /evidence="ECO:0000269|PubMed:1464650" FT /id="VAR_009832" FT VARIANT 841 FT /note="R -> C (in AIS; dbSNP:rs137852577)" FT /evidence="ECO:0000269|PubMed:8040309, FT ECO:0000269|PubMed:8824883, ECO:0000269|PubMed:9768671" FT /id="VAR_004721" FT VARIANT 841 FT /note="R -> G (in PAIS)" FT /evidence="ECO:0000269|PubMed:9856504" FT /id="VAR_004722" FT VARIANT 841 FT /note="R -> H (in AIS; dbSNP:rs9332969)" FT /evidence="ECO:0000269|PubMed:7909256, FT ECO:0000269|PubMed:8040309, ECO:0000269|PubMed:8126121, FT ECO:0000269|PubMed:8205256, ECO:0000269|PubMed:8325950, FT ECO:0000269|PubMed:8830623, ECO:0000269|PubMed:9039340" FT /id="VAR_004723" FT VARIANT 841 FT /note="R -> S (in PAIS)" FT /evidence="ECO:0000269|PubMed:10502786" FT /id="VAR_009229" FT VARIANT 842 FT /note="I -> S (in PAIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009833" FT VARIANT 843 FT /note="I -> T (in AIS; dbSNP:rs9332970)" FT /evidence="ECO:0000269|PubMed:8325950, FT ECO:0000269|PubMed:9039340" FT /id="VAR_004724" FT VARIANT 847 FT /note="R -> G (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009834" FT VARIANT 855 FT /note="R -> K (in PAIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009835" FT VARIANT 856 FT /note="R -> C (in AIS; dbSNP:rs886041132)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:7581399, ECO:0000269|PubMed:9001799, FT ECO:0000269|PubMed:9255042, ECO:0000269|Ref.118" FT /id="VAR_004725" FT VARIANT 856 FT /note="R -> H (in AIS; strongly reduced transcription FT activation; dbSNP:rs9332971)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:8097257, ECO:0000269|PubMed:8824883, FT ECO:0000269|PubMed:9039340, ECO:0000269|PubMed:9106550" FT /id="VAR_004726" FT VARIANT 857 FT /note="F -> L (in AIS; dbSNP:rs137852598)" FT /evidence="ECO:0000269|PubMed:10690872, FT ECO:0000269|PubMed:8339746" FT /id="VAR_009836" FT VARIANT 864 FT /note="L -> R (in AIS)" FT /id="VAR_009837" FT VARIANT 865 FT /note="D -> G (in AIS)" FT /evidence="ECO:0000269|PubMed:1480178" FT /id="VAR_009838" FT VARIANT 865 FT /note="D -> N (in AIS; loss of androgen binding; FT dbSNP:rs1555997810)" FT /evidence="ECO:0000269|PubMed:9328206" FT /id="VAR_004727" FT VARIANT 866 FT /note="S -> P (in AIS; dbSNP:rs137852597)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009839" FT VARIANT 867 FT /note="V -> E (in AIS)" FT /id="VAR_004728" FT VARIANT 867 FT /note="V -> L (in PAIS; dbSNP:rs137852564)" FT /evidence="ECO:0000269|PubMed:1424203, FT ECO:0000269|PubMed:8325950, ECO:0000269|PubMed:8446106" FT /id="VAR_004729" FT VARIANT 867 FT /note="V -> M (in AIS and prostate cancer; FT dbSNP:rs137852564)" FT /evidence="ECO:0000269|PubMed:2082179, FT ECO:0000269|PubMed:2594783, ECO:0000269|PubMed:8446106, FT ECO:0000269|PubMed:9039340" FT /id="VAR_004730" FT VARIANT 870 FT /note="I -> M (in PAIS; dbSNP:rs137852574)" FT /evidence="ECO:0000269|PubMed:8097257, FT ECO:0000269|PubMed:8824883" FT /id="VAR_004731" FT VARIANT 871 FT /note="A -> G (in PAIS)" FT /evidence="ECO:0000269|PubMed:9329414" FT /id="VAR_009840" FT VARIANT 871 FT /note="A -> V (in PAIS; dbSNP:rs143040492)" FT /evidence="ECO:0000269|PubMed:8033918" FT /id="VAR_009841" FT VARIANT 872 FT /note="R -> G (in AIS)" FT /evidence="ECO:0000269|PubMed:10022458" FT /id="VAR_009842" FT VARIANT 875 FT /note="H -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013479" FT VARIANT 875 FT /note="H -> Y (in prostate cancer; increases affinity for FT testosterone and androgen sensitivity; increased FT transcription activation; dbSNP:rs137852581)" FT /evidence="ECO:0000269|PubMed:17591767" FT /id="VAR_009843" FT VARIANT 878 FT /note="T -> A (found in prostate cancer; found in bone FT metastases; alters receptor specificity so that FT transcription is activated by antiandrogens such as FT cyproterone acetate; dbSNP:rs137852578)" FT /evidence="ECO:0000269|PubMed:10363963, FT ECO:0000269|PubMed:10569618, ECO:0000269|PubMed:1562539, FT ECO:0000269|PubMed:16129672, ECO:0000269|PubMed:17311914, FT ECO:0000269|PubMed:2260966, ECO:0000269|PubMed:25091737, FT ECO:0000269|PubMed:8187068, ECO:0000269|PubMed:8274409, FT ECO:0000269|PubMed:8827083" FT /id="VAR_004732" FT VARIANT 878 FT /note="T -> S (in prostate cancer; dbSNP:rs137852580)" FT /id="VAR_009844" FT VARIANT 880 FT /note="D -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013480" FT VARIANT 881 FT /note="L -> Q (in prostate cancer)" FT /id="VAR_009845" FT VARIANT 882 FT /note="L -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:7641413" FT /id="VAR_009846" FT VARIANT 887 FT /note="M -> V (in AIS; dbSNP:rs755226547)" FT /evidence="ECO:0000269|PubMed:10359561" FT /id="VAR_009847" FT VARIANT 890 FT /note="V -> M (in AIS and PAIS; dbSNP:rs886041133)" FT /evidence="ECO:0000269|PubMed:8126121, FT ECO:0000269|PubMed:9160185" FT /id="VAR_009848" FT VARIANT 891 FT /note="D -> N (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10363963" FT /id="VAR_009849" FT VARIANT 892 FT /note="F -> L (in prostate cancer and AIS)" FT /evidence="ECO:0000269|PubMed:24737579" FT /id="VAR_009850" FT VARIANT 893 FT /note="P -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:10221770, FT ECO:0000269|PubMed:10404311, ECO:0000269|Ref.185" FT /id="VAR_004733" FT VARIANT 896 FT /note="M -> T (in AIS; low androgen binding and FT transactivation)" FT /evidence="ECO:0000269|PubMed:16129672, FT ECO:0000269|PubMed:9856504" FT /id="VAR_004734" FT VARIANT 897 FT /note="A -> T (in prostate cancer)" FT /id="VAR_009851" FT VARIANT 899 FT /note="I -> T (in AIS; dbSNP:rs1555998105)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009852" FT VARIANT 903 FT /note="Q -> R (in prostate cancer; dbSNP:rs137852582)" FT /id="VAR_009853" FT VARIANT 904 FT /note="V -> M (in PAIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009854" FT VARIANT 905 FT /note="P -> H (in AIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009855" FT VARIANT 905 FT /note="P -> S (in AIS)" FT /id="VAR_009856" FT VARIANT 908 FT /note="L -> F (in AIS; almost complete loss of FT transcription activation)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:9328206" FT /id="VAR_004735" FT VARIANT 910 FT /note="G -> E (in prostate cancer)" FT /id="VAR_009857" FT VARIANT 910 FT /note="G -> R (in PAIS)" FT /evidence="ECO:0000269|PubMed:8550758" FT /id="VAR_009858" FT VARIANT 911 FT /note="K -> R (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:9438000" FT /id="VAR_009859" FT VARIANT 912 FT /note="V -> L (in PAIS)" FT /evidence="ECO:0000269|PubMed:10470409" FT /id="VAR_009860" FT VARIANT 914 FT /note="P -> S (in PAIS)" FT /id="VAR_004736" FT VARIANT 917 FT /note="F -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:9302173" FT /id="VAR_009861" FT VARIANT 918 FT /note="H -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009862" FT VARIANT 920 FT /note="Q -> R (in prostate cancer)" FT /id="VAR_009863" FT MUTAGEN 83 FT /note="S->A: Reduced cell growth." FT /evidence="ECO:0000269|PubMed:20980437" FT MUTAGEN 225 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 269 FT /note="Y->F: Decrease of CSK-induced phosphorylation and FT phosphorylation by TNK2. Complete loss of TNK2-dependent FT phosphorylation; when associated with F-365." FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760" FT MUTAGEN 309 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 348 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 359 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 364 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 365 FT /note="Y->F: Decrease of CSK-induced phosphorylation and FT phosphorylation by TNK2. Complete loss of TNK2-dependent FT phosphorylation; when associated with F-269." FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760" FT MUTAGEN 395 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 535 FT /note="Y->F: Greatest decrease of CSK-induced FT phosphorylation and inhibition of transcriptional activity FT induced by EGF." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 552 FT /note="Y->F: Decrease in CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 702 FT /note="L->A: Alters receptor specificity, so that FT transcription is activated by the antiandrogen cyproterone FT acetate." FT /evidence="ECO:0000269|PubMed:17311914" FT MUTAGEN 721 FT /note="K->A: Loss of transcription activation in the FT presence of androgen and of interaction with NCOA2." FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:17591767" FT MUTAGEN 742 FT /note="W->L: Strongly decreased transcription activation in FT the presence of androgen." FT /evidence="ECO:0000269|PubMed:16129672" FT MUTAGEN 846 FT /note="K->R: Prevents ubiquitination by RNF6. Prevents AR FT transcriptional activation by RNF14 in absence of hormone." FT /evidence="ECO:0000269|PubMed:19345326" FT MUTAGEN 848 FT /note="K->R: Partially prevents ubiquitination by RNF6." FT /evidence="ECO:0000269|PubMed:19345326" FT MUTAGEN 898 FT /note="E->A,Q: Reduced transcription activation in the FT presence of androgen." FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:17591767" FT MUTAGEN 898 FT /note="E->K,R: Loss of transcription activation in the FT presence of androgen." FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:17591767" FT MUTAGEN 916 FT /note="Y->F: Decrease in CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT CONFLICT 168 FT /note="G -> A (in Ref. 5; AAA51780)" FT /evidence="ECO:0000305" FT CONFLICT 214 FT /note="A -> R (in Ref. 3 and 6; AAA51771/AAA51772)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="G -> E (in Ref. 2; AAA51775 and 13; AAA51770)" FT /evidence="ECO:0000305" FT CONFLICT 566 FT /note="E -> K (in Ref. 15; AAA51774)" FT /evidence="ECO:0000305" FT CONFLICT 635 FT /note="L -> P (in Ref. 19; AAB21256/AAB21257)" FT /evidence="ECO:0000305" FT CONFLICT 676 FT /note="N -> I (in Ref. 19; AAB21256/AAB21257)" FT /evidence="ECO:0000305" FT CONFLICT 811 FT /note="L -> M (in Ref. 5; AAA51780)" FT /evidence="ECO:0000305" FT HELIX 22..29 FT /evidence="ECO:0007829|PDB:3V49" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:1XJ7" FT HELIX 673..681 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 692..694 FT /evidence="ECO:0007829|PDB:5VO4" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 726..728 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 731..758 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 761..766 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 769..771 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 773..778 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 782..797 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 802..813 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 815..818 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 825..844 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 850..883 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 885..888 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 894..902 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 904..908 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 911..914 FT /evidence="ECO:0007829|PDB:8E1A" SQ SEQUENCE 920 AA; 99188 MW; A73432C55D39AE06 CRC64; MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REVIQNPGPR HPEAASAAPP GASLLLLQQQ QQQQQQQQQQ QQQQQQQQQQ ETSPRQQQQQ QGEDGSPQAH RRGPTGYLVL DEEQQPSQPQ SALECHPERG CVPEPGAAVA ASKGLPQQLP APPDEDDSAA PSTLSLLGPT FPGLSSCSAD LKDILSEAST MQLLQQQQQE AVSEGSSSGR AREASGAPTS SKDNYLGGTS TISDNAKELC KAVSVSMGLG VEALEHLSPG EQLRGDCMYA PLLGVPPAVR PTPCAPLAEC KGSLLDDSAG KSTEDTAEYS PFKGGYTKGL EGESLGCSGS AAAGSSGTLE LPSTLSLYKS GALDEAAAYQ SRDYYNFPLA LAGPPPPPPP PHPHARIKLE NPLDYGSAWA AAAAQCRYGD LASLHGAGAA GPGSGSPSAA ASSSWHTLFT AEEGQLYGPC GGGGGGGGGG GGGGGGGGGG GGGEAGAVAP YGYTRPPQGL AGQESDFTAP DVWYPGGMVS RVPYPSPTCV KSEMGPWMDS YSGPYGDMRL ETARDHVLPI DYYFPPQKTC LICGDEASGC HYGALTCGSC KVFFKRAAEG KQKYLCASRN DCTIDKFRRK NCPSCRLRKC YEAGMTLGAR KLKKLGNLKL QEEGEASSTT SPTEETTQKL TVSHIEGYEC QPIFLNVLEA IEPGVVCAGH DNNQPDSFAA LLSSLNELGE RQLVHVVKWA KALPGFRNLH VDDQMAVIQY SWMGLMVFAM GWRSFTNVNS RMLYFAPDLV FNEYRMHKSR MYSQCVRMRH LSQEFGWLQI TPQEFLCMKA LLLFSIIPVD GLKNQKFFDE LRMNYIKELD RIIACKRKNP TSCSRRFYQL TKLLDSVQPI ARELHQFTFD LLIKSHMVSV DFPEMMAEII SVQVPKILSG KVKPIYFHTQ // ID APC_HUMAN Reviewed; 2843 AA. AC P25054; B7Z2B6; D3DT03; Q15162; Q15163; Q93042; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 16-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 276. DE RecName: Full=Adenomatous polyposis coli protein; DE Short=Protein APC; DE AltName: Full=Deleted in polyposis 2.5; GN Name=APC {ECO:0000312|HGNC:HGNC:583}; Synonyms=DP2.5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A AND 2), AND VARIANT ASP-1822. RC TISSUE=Fetal brain; RX PubMed=1678319; DOI=10.1016/0092-8674(81)90022-2; RA Joslyn G., Carlson M., Thliveris A., Albertsen H., Gelbert L., Samowitz W., RA Groden J., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., RA Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J.D., RA Wasmuth J.J., le Paslier D., Abderrahim H., Cohen D., Leppert M., White R.; RT "Identification of deletion mutations and three new genes at the familial RT polyposis locus."; RL Cell 66:601-613(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND VARIANT ASP-1822. RX PubMed=1651562; DOI=10.1126/science.1651562; RA Kinzler K.W., Nilbert M.C., Su L.-K., Vogelstein B., Bryan T.M., Levy D.B., RA Smith K.J., Preisinger A.C., Hedge P., McKechnie D., Finniear R., RA Markham A., Groffen J., Boguski M.S., Altschul S.F., Horii A.K., Ando H., RA Miyoshi Y., Miki Y., Nishisho I., Nakamura Y.; RT "Identification of FAP locus genes from chromosome 5q21."; RL Science 253:661-665(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH ARHGEF4, AND IDENTIFICATION IN A COMPLEX WITH ARHGEF4 AND RP CTNNB1. RX PubMed=10947987; DOI=10.1126/science.289.5482.1194; RA Kawasaki Y., Senda T., Ishidate T., Koyama R., Morishita T., Iwayama Y., RA Higuchi O., Akiyama T.; RT "Asef, a link between the tumor suppressor APC and G-protein signaling."; RL Science 289:1194-1197(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-1822. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1135 (ISOFORM 1B). RC TISSUE=Amygdala {ECO:0000312|EMBL:BAH11802.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1506-1524. RX PubMed=1310068; RA Miki Y., Nishisho I., Horii A., Miyoshi Y., Utsunomiya J., Kinzler K.W., RA Vogelstein B., Nakamura Y.; RT "Disruption of the APC gene by a retrotransposal insertion of L1 sequence RT in a colon cancer."; RL Cancer Res. 52:643-645(1992). RN [8] RP INTERACTION WITH ALPHA- AND BETA-CATENINS. RX PubMed=8259519; DOI=10.1126/science.8259519; RA Su L.-K., Vogelstein B., Kinzler K.W.; RT "Association of the APC tumor suppressor protein with catenins."; RL Science 262:1734-1737(1993). RN [9] RP INTERACTION WITH DLG1. RX PubMed=8638125; DOI=10.1126/science.272.5264.1020; RA Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G.-H., RA Kawahara T., Kobayashi S., Okada M., Toyoshima K., Akiyama T.; RT "Binding of APC to the human homolog of the Drosophila discs large tumor RT suppressor protein."; RL Science 272:1020-1023(1996). RN [10] RP INTERACTION WITH DLG3. RC TISSUE=Fetal brain; RX PubMed=9188857; DOI=10.1038/sj.onc.1201087; RA Makino K., Kuwahara H., Masuko N., Nishiyama Y., Morisaki T., Sasaki J., RA Nakao M., Kuwano A., Nakata M., Ushio Y., Saya H.; RT "Cloning and characterization of NE-dlg: a novel human homolog of the RT Drosophila discs large (dlg) tumor suppressor protein interacts with the RT APC protein."; RL Oncogene 14:2425-2433(1997). RN [11] RP INTERACTION WITH APC2. RX PubMed=11691822; RA Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., RA King C.R., Byers S.W.; RT "Human APC2 localization and allelic imbalance."; RL Cancer Res. 61:7978-7984(2001). RN [12] RP INTERACTION WITH MAPRE1; MAPRE2 AND MAPRE3. RX PubMed=14514668; DOI=10.1074/jbc.m306194200; RA Bu W., Su L.-K.; RT "Characterization of functional domains of human EB1 family proteins."; RL J. Biol. Chem. 278:49721-49731(2003). RN [13] RP UBIQUITINATION. RX PubMed=15355978; DOI=10.1074/jbc.m404655200; RA Choi J., Park S.Y., Costantini F., Jho E.-H., Joo C.-K.; RT "Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome RT pathway in a process facilitated by Axin."; RL J. Biol. Chem. 279:49188-49198(2004). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP SUBCELLULAR LOCATION, INTERACTION WITH SCRIB, AND MUTAGENESIS OF THR-2841 RP AND VAL-2843. RX PubMed=16611247; DOI=10.1111/j.1365-2443.2006.00954.x; RA Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T., RA Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y.; RT "Human scribble, a novel tumor suppressor identified as a target of high- RT risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous RT polyposis coli."; RL Genes Cells 11:453-464(2006). RN [16] RP FUNCTION, INTERACTION WITH MAPRE1 AND ACTIN, AND PHOSPHORYLATION. RX PubMed=17293347; DOI=10.1074/jbc.m610615200; RA Moseley J.B., Bartolini F., Okada K., Wen Y., Gundersen G.G., Goode B.L.; RT "Regulated binding of adenomatous polyposis coli protein to actin."; RL J. Biol. Chem. 282:12661-12668(2007). RN [17] RP FUNCTION, AND INTERACTION WITH SPATA13. RX PubMed=17599059; DOI=10.1038/sj.onc.1210574; RA Kawasaki Y., Sagara M., Shibata Y., Shirouzu M., Yokoyama S., Akiyama T.; RT "Identification and characterization of Asef2, a guanine-nucleotide RT exchange factor specific for Rac1 and Cdc42."; RL Oncogene 26:7620-7627(2007). RN [18] RP DEUBIQUITINATION. RX PubMed=18281465; DOI=10.1101/gad.463208; RA Tran H., Hamada F., Schwarz-Romond T., Bienz M.; RT "Trabid, a new positive regulator of Wnt-induced transcription with RT preference for binding and cleaving K63-linked ubiquitin chains."; RL Genes Dev. 22:528-542(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2671, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780; SER-1042; SER-1360; RP SER-1861; SER-1863; SER-1864; THR-2151; SER-2260; SER-2270; SER-2283; RP SER-2473; SER-2535; SER-2671; SER-2674; THR-2679 AND SER-2789, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY. RX PubMed=19527921; DOI=10.1016/j.canlet.2009.05.016; RA Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T.; RT "Adenomatous polyposis coli 1A is likely to be methylated as a passenger in RT human gastric carcinogenesis."; RL Cancer Lett. 285:182-189(2009). RN [23] RP INTERACTION WITH MAPRE1, AND SUBCELLULAR LOCATION. RX PubMed=19632184; DOI=10.1016/j.cell.2009.04.065; RA Honnappa S., Gouveia S.M., Weisbrich A., Damberger F.F., Bhavesh N.S., RA Jawhari H., Grigoriev I., van Rijssel F.J., Buey R.M., Lawera A., RA Jelesarov I., Winkler F.K., Wuthrich K., Akhmanova A., Steinmetz M.O.; RT "An EB1-binding motif acts as a microtubule tip localization signal."; RL Cell 138:366-376(2009). RN [24] RP FUNCTION. RX PubMed=19893577; DOI=10.1038/embor.2009.233; RA Kawasaki Y., Tsuji S., Muroya K., Furukawa S., Shibata Y., Okuno M., RA Ohwada S., Akiyama T.; RT "The adenomatous polyposis coli-associated exchange factors Asef and Asef2 RT are required for adenoma formation in Apc(Min/+)mice."; RL EMBO Rep. 10:1355-1362(2009). RN [25] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19151759; DOI=10.1038/onc.2008.478; RA Sagara M., Kawasaki Y., Iemura S.I., Natsume T., Takai Y., Akiyama T.; RT "Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization RT and are involved in HGF-induced cell migration."; RL Oncogene 28:1357-1365(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744 AND SER-780, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP INTERACTION WITH AMER1. RX PubMed=21498506; DOI=10.1074/jbc.m111.224881; RA Tanneberger K., Pfister A.S., Kriz V., Bryja V., Schambony A., Behrens J.; RT "Structural and functional characterization of the Wnt inhibitor APC RT membrane recruitment 1 (Amer1)."; RL J. Biol. Chem. 286:19204-19214(2011). RN [30] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=21643010; DOI=10.1038/onc.2011.201; RA Rohlin A., Engwall Y., Fritzell K., Goeransson K., Bergsten A., RA Einbeigi Z., Nilbert M., Karlsson P., Bjoerk J., Nordling M.; RT "Inactivation of promoter 1B of APC causes partial gene silencing: evidence RT for a significant role of the promoter in regulation and causative of RT familial adenomatous polyposis."; RL Oncogene 30:4977-4989(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1861; SER-1863 AND SER-1864, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP INTERACTION WITH AMER2. RX PubMed=22128170; DOI=10.1074/jbc.m111.308650; RA Pfister A.S., Tanneberger K., Schambony A., Behrens J.; RT "Amer2 protein is a novel negative regulator of Wnt/beta-Catenin signaling RT involved in neuroectodermal patterning."; RL J. Biol. Chem. 287:1734-1741(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-748; SER-908; RP SER-1042; SER-1371; SER-1385; THR-1438; SER-1774; SER-1861; SER-2260; RP SER-2283; SER-2569; SER-2674; SER-2724 AND SER-2789, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH JPT1. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [37] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=27217144; DOI=10.1038/srep26011; RA Yamaguchi K., Nagayama S., Shimizu E., Komura M., Yamaguchi R., Shibuya T., RA Arai M., Hatakeyama S., Ikenoue T., Ueno M., Miyano S., Imoto S., RA Furukawa Y.; RT "Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B RT is responsible for familial adenomatous polyposis."; RL Sci. Rep. 6:26011-26011(2016). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 2-55. RX PubMed=10926498; DOI=10.1006/jmbi.2000.3895; RA Day C.L., Alber T.; RT "Crystal structure of the amino-terminal coiled-coil domain of the APC RT tumor suppressor."; RL J. Mol. Biol. 301:147-156(2000). RN [39] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1021-1035 IN COMPLEX WITH CTNNB1. RX PubMed=11707392; DOI=10.1093/emboj/20.22.6203; RA Eklof Spink K., Fridman S.G., Weis W.I.; RT "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis RT coli revealed by the structure of an APC-beta-catenin complex."; RL EMBO J. 20:6203-6212(2001). RN [40] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2034-2049 IN COMPLEX WITH AXIN1, RP AND INTERACTION WITH AXIN1. RX PubMed=10811618; DOI=10.1093/emboj/19.10.2270; RA Spink K.E., Polakis P., Weis W.I.; RT "Structural basis of the axin-adenomatous polyposis coli interaction."; RL EMBO J. 19:2270-2279(2000). RN [41] RP STRUCTURE BY NMR OF 1578-1596 IN COMPLEX WITH ASAP1, AND INTERACTION WITH RP ASAP1. RX PubMed=20509626; DOI=10.1021/bi100563z; RA Kaieda S., Matsui C., Mimori-Kiyosue Y., Ikegami T.; RT "Structural basis of the recognition of the SAMP motif of adenomatous RT polyposis coli by the Src-homology 3 domain."; RL Biochemistry 49:5143-5153(2010). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 407-775, AND DOMAIN ARM REPEATS. RX PubMed=21871439; DOI=10.1016/j.bbrc.2011.08.044; RA Zhang Z., Lin K., Gao L., Chen L., Shi X., Wu G.; RT "Crystal structure of the armadillo repeat domain of adenomatous polyposis RT coli which reveals its inherent flexibility."; RL Biochem. Biophys. Res. Commun. 412:732-736(2011). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 396-732 IN COMPLEX WITH KHDRBS1, RP INTERACTION WITH KHDRBS1, AND MUTAGENESIS OF LYS-516 AND ARG-549. RX PubMed=22000517; DOI=10.1016/j.str.2011.07.013; RA Morishita E.C., Murayama K., Kato-Murayama M., Ishizuka-Katsura Y., RA Tomabechi Y., Hayashi T., Terada T., Handa N., Shirouzu M., Akiyama T., RA Yokoyama S.; RT "Crystal structures of the armadillo repeat domain of adenomatous polyposis RT coli and its complex with the tyrosine-rich domain of Sam68."; RL Structure 19:1496-1508(2011). RN [44] RP VARIANTS FAP1. RX PubMed=1651563; DOI=10.1126/science.1651563; RA Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., RA Koyama K., Utsunomiya J., Baba S., Hedge P., Markham A., Krush A.J., RA Petersen G.M., Hamilton S.R., Nilbert M.C., Levy D.B., Bryan T.M., RA Preisinger A.C., Smith K.J., Su L.-K., Kinzler K.W., Vogelstein B.; RT "Mutations of chromosome 5q21 genes in FAP and colorectal cancer RT patients."; RL Science 253:665-669(1991). RN [45] RP VARIANT FAP1 GLY-911. RX PubMed=1338904; DOI=10.1093/hmg/1.4.229; RA Miyoshi Y., Nagase H., Ando H., Ichii S., Nakatsuru S., Aoki T., Miki Y., RA Mori T., Nakamura Y.; RT "Somatic mutations of the APC gene in colorectal tumors: mutation cluster RT region in the APC gene."; RL Hum. Mol. Genet. 1:229-233(1992). RN [46] RP VARIANTS FAP1. RX PubMed=1338691; DOI=10.1093/hmg/1.8.559; RA Nakatsuru S., Yanagisawa A., Ichii S., Tahara E., Kato Y., Nakamura Y., RA Horii A.; RT "Somatic mutation of the APC gene in gastric cancer: frequent mutations in RT very well differentiated adenocarcinoma and signet-ring cell carcinoma."; RL Hum. Mol. Genet. 1:559-563(1992). RN [47] RP VARIANTS FAP1 MET-1292 AND TRP-1348, AND VARIANTS ASP-1118; VAL-1304 AND RP SER-2502. RX PubMed=1338764; DOI=10.1002/humu.1380010603; RA Nagase H., Miyoshi Y., Horii A., Aoki T., Petersen G.M., Vogelstein B., RA Maher E., Ogawa M., Maruyama M., Utsunomiya J., Baba S., Nakamura Y.; RT "Screening for germ-line mutations in familial adenomatous polyposis RT patients: 61 new patients and a summary of 150 unrelated patients."; RL Hum. Mutat. 1:467-473(1992). RN [48] RP VARIANTS FAP1 CYS-2621 AND PHE-2839. RX PubMed=1316610; DOI=10.1073/pnas.89.10.4452; RA Miyoshi Y., Ando H., Nagase H., Nishisho I., Horii A., Miki Y., Mori T., RA Utsunomiya J., Baba S., Petersen G.; RT "Germ-line mutations of the APC gene in 53 familial adenomatous polyposis RT patients."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4452-4456(1992). RN [49] RP VARIANTS FAP1 CYS-414; THR-784 AND LEU-1176. RX PubMed=8111410; DOI=10.1002/humu.1380020602; RA Nagase H., Nakamura Y.; RT "Mutations of the APC (adenomatous polyposis coli) gene."; RL Hum. Mutat. 2:425-434(1993). RN [50] RP VARIANT FAP1 TRP-99. RC TISSUE=Peripheral blood lymphocyte; RX PubMed=7833149; DOI=10.1016/0959-8049(94)00294-f; RA Dobbie Z., Spycher M., Huerliman R., Ammann R., Ammann T., Roth J., RA Mueller A., Mueller H., Scott R.J.; RT "Mutational analysis of the first 14 exons of the adenomatous polyposis RT coli (APC) gene."; RL Eur. J. Cancer 30A:1709-1713(1994). RN [51] RP VARIANT FAP1 GLY-722. RX PubMed=7833931; DOI=10.1093/hmg/3.9.1687; RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RT "Four novel mutations of the APC (adenomatous polyposis coli) gene in FAP RT patients."; RL Hum. Mol. Genet. 3:1687-1688(1994). RN [52] RP ERRATUM OF PUBMED:7833931. RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RL Hum. Mol. Genet. 3:1918-1918(1994). RN [53] RP INVOLVEMENT IN FAP1. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [54] RP INVOLVEMENT IN DESMD. RX PubMed=8940264; RA Eccles D.M., van der Luijt R.B., Breukel C., Bullman H., Bunyan D., RA Fisher A., Barber J., du Boulay C., Primrose J., Burn J., Fodde R.; RT "Hereditary desmoid disease due to a frameshift mutation at codon 1924 of RT the APC gene."; RL Am. J. Hum. Genet. 59:1193-1201(1996). RN [55] RP VARIANT HEPATOBLASTOMA CYS-1395. RX PubMed=8764128; RA Oda H., Imai Y., Nakatsuru Y., Hata J., Ishikawa T.; RT "Somatic mutations of the APC gene in sporadic hepatoblastomas."; RL Cancer Res. 56:3320-3323(1996). RN [56] RP VARIANT FAP1 ILE-171. RX PubMed=8990002; RX DOI=10.1002/(sici)1098-1004(1997)9:1<7::aid-humu2>3.0.co;2-8; RA van der Luijt R.B., Meera Khan P., Vasen H.F.A., Tops C.M.J., RA van Leeuwen-Cornelisse I.S.J., Wijnen J.T., van der Klift H.M., Plug R.J., RA Griffioen G., Fodde R.; RT "Molecular analysis of the APC gene in 105 Dutch kindreds with familial RT adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and RT southern analysis."; RL Hum. Mutat. 9:7-16(1997). RN [57] RP VARIANTS COLORECTAL CARCINOMA THR-880; ILE-890 AND VAL-1508. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [58] RP VARIANT LYS-1307. RX PubMed=9731522; DOI=10.1038/1666; RA Redston M., Nathanson K.L., Yuan Z.Q., Neuhausen S.L., Satagopan J., RA Wong N., Yang D., Nafa D., Abrahamson J., Ozcelik H., Antin-Ozerkis D., RA Andrulis I., Daly M., Pinsky L., Schrag D., Gallinger S., Kaback M., RA King M.-C., Woodage T., Brody L.C., Godwin A., Warner E., Weber B., RA Foulkes W., Offit K.; RT "The APC I1307K allele and breast cancer risk."; RL Nat. Genet. 20:13-14(1998). RN [59] RP VARIANTS LYS-1307 AND GLN-1317. RC TISSUE=Peripheral blood; RX PubMed=9724771; DOI=10.1073/pnas.95.18.10722; RA Frayling I.M., Beck N.E., Ilyas M., Dove-Edwin I., Goodman P., Pack K., RA Bell J.A., Williams C.B., Hodgson S.V., Thomas H.J.W., Talbot I.C., RA Bodmer W.F., Tomlinson I.P.M.; RT "The APC variants I1307K and E1317Q are associated with colorectal tumors, RT but not always with a family history."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10722-10727(1998). RN [60] RP VARIANT LYS-1307. RX PubMed=9731533; DOI=10.1038/1722; RA Woodage T., King S.M., Wacholder S., Hartge P., Struewing J.P., McAdams M., RA Laken S.J., Tucker M.A., Brody L.C.; RT "The APC I1307K allele and cancer risk in a community-based study of RT Ashkenazi Jews."; RL Nat. Genet. 20:62-65(1998). RN [61] RP VARIANT LYS-1307. RX PubMed=9973276; DOI=10.1086/302262; RA Gryfe R., Di Nicola N., Lal G., Gallinger S., Redston M.; RT "Inherited colorectal polyposis and cancer risk of the APC I1307K RT polymorphism."; RL Am. J. Hum. Genet. 64:378-384(1999). RN [62] RP VARIANTS GLY-1057; CYS-1171; ASP-1822 AND THR-2738. RX PubMed=9950360; RA Wallis Y.L., Morton D.G., McKeown C.M., Macdonald F.; RT "Molecular analysis of the APC gene in 205 families: extended genotype- RT phenotype correlations in FAP and evidence for the role of APC amino acid RT changes in colorectal cancer predisposition."; RL J. Med. Genet. 36:14-20(1999). RN [63] RP VARIANT FAP1 PRO-1184. RX PubMed=10470088; DOI=10.1038/12511; RA Lamlum H., Ilyas M., Rowan A., Clark S., Johnson V., Bell J.A., RA Frayling I.M., Efstathiou J., Pack K., Payne S., Roylance R., Gorman P., RA Sheer D., Neale K., Phillips R., Talbot I.C., Bodmer W.F., RA Tomlinson I.P.M.; RT "The type of somatic mutation at APC in familial adenomatous polyposis is RT determined by the site of the germline mutation: a new facet to Knudson's RT 'two-hit' hypothesis."; RL Nat. Med. 5:1071-1075(1999). RN [64] RP VARIANTS MDB VAL-1296; ILE-1472 AND GLY-1495. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [65] RP INVOLVEMENT IN DESMD. RX PubMed=10782927; DOI=10.1034/j.1399-0004.2000.570306.x; RA Couture J., Mitri A., Lagace R., Smits R., Berk T., Bouchard H.-L., RA Fodde R., Alman B., Bapat B.; RT "A germline mutation at the extreme 3' end of the APC gene results in a RT severe desmoid phenotype and is associated with overexpression of beta- RT catenin in the desmoid tumor."; RL Clin. Genet. 57:205-212(2000). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] PHE-1254. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [67] RP INVOLVEMENT IN GAPPS. RX PubMed=27087319; DOI=10.1016/j.ajhg.2016.03.001; RA Li J., Woods S.L., Healey S., Beesley J., Chen X., Lee J.S., RA Sivakumaran H., Wayte N., Nones K., Waterfall J.J., Pearson J., Patch A.M., RA Senz J., Ferreira M.A., Kaurah P., Mackenzie R., Heravi-Moussavi A., RA Hansford S., Lannagan T.R.M., Spurdle A.B., Simpson P.T., da Silva L., RA Lakhani S.R., Clouston A.D., Bettington M., Grimpen F., Busuttil R.A., RA Di Costanzo N., Boussioutas A., Jeanjean M., Chong G., Fabre A., RA Olschwang S., Faulkner G.J., Bellos E., Coin L., Rioux K., Bathe O.F., RA Wen X., Martin H.C., Neklason D.W., Davis S.R., Walker R.L., Calzone K.A., RA Avital I., Heller T., Koh C., Pineda M., Rudloff U., Quezado M., RA Pichurin P.N., Hulick P.J., Weissman S.M., Newlin A., Rubinstein W.S., RA Sampson J.E., Hamman K., Goldgar D., Poplawski N., Phillips K., RA Schofield L., Armstrong J., Kiraly-Borri C., Suthers G.K., Huntsman D.G., RA Foulkes W.D., Carneiro F., Lindor N.M., Edwards S.L., French J.D., RA Waddell N., Meltzer P.S., Worthley D.L., Schrader K.A., Chenevix-Trench G.; RT "Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and RT Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis RT Variant."; RL Am. J. Hum. Genet. 98:830-842(2016). RN [68] RP INVOLVEMENT IN GAPPS. RX PubMed=27343414; DOI=10.1016/j.gie.2016.06.023; RA Repak R., Kohoutova D., Podhola M., Rejchrt S., Minarik M., Benesova L., RA Lesko M., Bures J.; RT "The first European family with gastric adenocarcinoma and proximal RT polyposis of the stomach: case report and review of the literature."; RL Gastrointest. Endosc. 84:718-725(2016). RN [69] RP INVOLVEMENT IN MDB. RX PubMed=29753700; DOI=10.1016/s1470-2045(18)30242-0; RA Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., RA Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., RA Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., RA Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., RA Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., RA Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., RA Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., RA MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., RA Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., RA Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., RA Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., RA Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., RA Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., RA Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., RA Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., RA Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.; RT "Spectrum and prevalence of genetic predisposition in medulloblastoma: a RT retrospective genetic study and prospective validation in a clinical trial RT cohort."; RL Lancet Oncol. 19:785-798(2018). RN [70] RP INVOLVEMENT IN GAPPS. RX PubMed=33242120; DOI=10.1007/s12328-020-01290-6; RA Kanemitsu K., Iwatsuki M., Yamashita K., Komohara Y., Morinaga T., RA Iwagami S., Eto K., Nagai Y., Kurashige J., Baba Y., Yoshida N., Baba H.; RT "Two Asian families with gastric adenocarcinoma and proximal polyposis of RT the stomach successfully treated via laparoscopic total gastrectomy."; RL Clin. J. Gastroenterol. 14:92-97(2021). CC -!- FUNCTION: Tumor suppressor. Promotes rapid degradation of CTNNB1 and CC participates in Wnt signaling as a negative regulator. APC activity is CC correlated with its phosphorylation state. Activates the GEF activity CC of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)- CC induced cell migration. Required for MMP9 up-regulation via the JNK CC signaling pathway in colorectal tumor cells. Associates with both CC microtubules and actin filaments, components of the cytoskeleton CC (PubMed:17293347). Plays a role in mediating the organization of F- CC actin into ordered bundles (PubMed:17293347). Functions downstream of CC Rho GTPases and DIAPH1 to selectively stabilize microtubules (By CC similarity). Acts as a mediator of ERBB2-dependent stabilization of CC microtubules at the cell cortex. It is required for the localization of CC MACF1 to the cell membrane and this localization of MACF1 is critical CC for its function in microtubule stabilization. CC {ECO:0000250|UniProtKB:Q61315, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19151759, ECO:0000269|PubMed:19893577, CC ECO:0000269|PubMed:20937854}. CC -!- SUBUNIT: Forms homooligomers (Probable). Found in a complex consisting CC of ARHGEF4, APC and CTNNB1 (PubMed:10947987). Found in a complex CC composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). The CC complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with APC2 CC (PubMed:11691822). Interacts with DLG1 (via PDZ domains) and DLG3 (via CC PDZ domains) (PubMed:8638125, PubMed:9188857). Interacts with CC alpha- and beta-catenins (PubMed:8259519). Interacts with AXIN1 (via CC RGS domain) (PubMed:10811618). Interacts with ARHGEF4 (via N-terminus) CC (PubMed:10947987). Interacts (via C-terminal residues 2674-2843) with CC MAPRE1 (via C-terminal residues 206-211); the interaction inhibits CC association with and bundling of F-actin (PubMed:14514668, CC PubMed:17293347, PubMed:19632184). Interacts with MAPRE2 and MAPRE3 CC (via C-terminus) (PubMed:14514668). Interacts with DIAPH1; DIAPH1 acts CC as a scaffold protein for MAPRE1 and APC to stabilize microtubules and CC promote cell migration (By similarity). Interacts with DIAPH2 (By CC similarity). Interacts with SCRIB; may mediate APC targeting to CC adherens junctions of epithelial cells (PubMed:16611247). Interacts CC with SPATA13 (via N-terminus and SH3 domain) (PubMed:17599059). CC Interacts with ASAP1 (via SH3 domain) (PubMed:20509626). Interacts (at CC the cell membrane) with AMER1 and AMER2 (via ARM repeats) CC (PubMed:21498506, PubMed:22128170). Interacts with KHDRBS1 CC (PubMed:22000517). Interacts with actin; binds both to F-actin and CC actin filament bundles (PubMed:17293347). CC {ECO:0000250|UniProtKB:P70478, ECO:0000250|UniProtKB:Q61315, CC ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:11707392, CC ECO:0000269|PubMed:14514668, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20509626, CC ECO:0000269|PubMed:21498506, ECO:0000269|PubMed:22000517, CC ECO:0000269|PubMed:22128170, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:8259519, ECO:0000269|PubMed:8638125, CC ECO:0000269|PubMed:9188857, ECO:0000305}. CC -!- INTERACTION: CC P25054; Q5JTC6: AMER1; NbExp=4; IntAct=EBI-727707, EBI-6169747; CC P25054; Q8N944: AMER3; NbExp=8; IntAct=EBI-727707, EBI-8869590; CC P25054; Q9NR80-3: ARHGEF4; NbExp=5; IntAct=EBI-727707, EBI-13639160; CC P25054; O15169: AXIN1; NbExp=17; IntAct=EBI-727707, EBI-710484; CC P25054; O14936: CASK; NbExp=2; IntAct=EBI-727707, EBI-1215506; CC P25054; P60953: CDC42; NbExp=9; IntAct=EBI-727707, EBI-81752; CC P25054; P49674: CSNK1E; NbExp=8; IntAct=EBI-727707, EBI-749343; CC P25054; P35221: CTNNA1; NbExp=3; IntAct=EBI-727707, EBI-701918; CC P25054; P35222: CTNNB1; NbExp=22; IntAct=EBI-727707, EBI-491549; CC P25054; Q12959: DLG1; NbExp=11; IntAct=EBI-727707, EBI-357481; CC P25054; Q15700: DLG2; NbExp=2; IntAct=EBI-727707, EBI-80426; CC P25054; Q92796: DLG3; NbExp=2; IntAct=EBI-727707, EBI-80440; CC P25054; P78352: DLG4; NbExp=3; IntAct=EBI-727707, EBI-80389; CC P25054; O14640: DVL1; NbExp=6; IntAct=EBI-727707, EBI-723489; CC P25054; P54792: DVL1P1; NbExp=2; IntAct=EBI-727707, EBI-7848109; CC P25054; O14641: DVL2; NbExp=2; IntAct=EBI-727707, EBI-740850; CC P25054; Q96RT1: ERBIN; NbExp=2; IntAct=EBI-727707, EBI-993903; CC P25054; P14923: JUP; NbExp=3; IntAct=EBI-727707, EBI-702484; CC P25054; Q07666: KHDRBS1; NbExp=4; IntAct=EBI-727707, EBI-1364; CC P25054; Q14114: LRP8; NbExp=2; IntAct=EBI-727707, EBI-2681187; CC P25054; Q86UL8: MAGI2; NbExp=5; IntAct=EBI-727707, EBI-311035; CC P25054; Q15691: MAPRE1; NbExp=6; IntAct=EBI-727707, EBI-1004115; CC P25054; Q14160: SCRIB; NbExp=8; IntAct=EBI-727707, EBI-357345; CC P25054; Q96N96: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13618641; CC P25054; Q96N96-1: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13638906; CC P25054; Q96N96-2: SPATA13; NbExp=2; IntAct=EBI-727707, EBI-13639118; CC P25054; O14907: TAX1BP3; NbExp=5; IntAct=EBI-727707, EBI-723259; CC P25054; P63104: YWHAZ; NbExp=2; IntAct=EBI-727707, EBI-347088; CC P25054; Q02248: Ctnnb1; Xeno; NbExp=8; IntAct=EBI-727707, EBI-397872; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:16611247}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. Cell CC projection, lamellipodium {ECO:0000269|PubMed:19151759}. Cell CC projection, ruffle membrane {ECO:0000269|PubMed:19151759}. Cytoplasm CC {ECO:0000269|PubMed:10947987}. Cell membrane CC {ECO:0000269|PubMed:10947987, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:20937854}. Note=Associated with the microtubule CC network at the growing distal tip of microtubules (PubMed:19632184). CC MAPRE1 may be required for targeting to the growing microtubule plus CC ends (PubMed:19632184). Accumulates in the lamellipodium and ruffle CC membrane in response to hepatocyte growth factor (HGF) treatment CC (PubMed:19151759). The MEMO1-RHOA-DIAPH1 signaling pathway controls CC localization of the phosphorylated form to the cell membrane CC (PubMed:20937854). {ECO:0000269|PubMed:19151759, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1A {ECO:0000303|PubMed:19527921}; Synonyms=Long CC {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-1; Sequence=Displayed; CC Name=2; Synonyms=Short {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-2; Sequence=VSP_004115; CC Name=1B {ECO:0000303|PubMed:19527921}; CC IsoId=P25054-3; Sequence=VSP_059027, VSP_059028; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tissues: brain, small CC intestine, colon, thymus, skeletal muscle, heart, prostate, lung, CC spleen, ovary, testis kidney, placenta, blood and liver CC (PubMed:21643010, PubMed:27217144). Isoform 1A: Very strongly expressed CC in brain but has relatively low expression levels in other tissues CC (PubMed:19527921, PubMed:21643010, PubMed:27217144). Isoform 1B: CC Predominant form in all tissues except for brain, including gastric CC mucosa and blood (PubMed:19527921, PubMed:21643010, PubMed:27217144). CC {ECO:0000269|PubMed:19527921, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144}. CC -!- DOMAIN: The microtubule tip localization signal (MtLS) motif; mediates CC interaction with MAPRE1 and targeting to the growing microtubule plus CC ends. {ECO:0000250}. CC -!- DOMAIN: The basic region (residues 2167-2674) mediates the association CC with both microtubule and actin proteins and promotes the bundling of CC F-actin. {ECO:0000269|PubMed:17293347}. CC -!- PTM: Phosphorylated; phosphorylation enhances the F-actin bundling CC activity (PubMed:17293347). Phosphorylated by GSK3B. CC {ECO:0000269|PubMed:17293347}. CC -!- PTM: Ubiquitinated, leading to its degradation by the proteasome. CC Ubiquitination is facilitated by Axin. Deubiquitinated by CC ZRANB1/TRABID. {ECO:0000269|PubMed:15355978, CC ECO:0000269|PubMed:18281465}. CC -!- DISEASE: Familial adenomatous polyposis 1 (FAP1) [MIM:175100]: An CC autosomal dominant cancer predisposition syndrome characterized by CC adenomatous polyps of the colon and rectum, but also of upper CC gastrointestinal tract (ampullary, duodenal and gastric adenomas). This CC is a viciously premalignant disease with one or more polyps progressing CC through dysplasia to malignancy in untreated gene carriers with a CC median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, CC ECO:0000269|PubMed:1316610, ECO:0000269|PubMed:1338691, CC ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, CC ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144, ECO:0000269|PubMed:7661930, CC ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, CC ECO:0000269|PubMed:8111410, ECO:0000269|PubMed:8990002}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Desmoid disease, hereditary (DESMD) [MIM:135290]: An autosomal CC dominant disease characterized by multifocal fibromatosis of the CC abdominal wall and mesentery. Desmoid tumors can also affect paraspinal CC muscles, breast, occiput, arms, and lower ribs. CC {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:29753700}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric adenocarcinoma and proximal polyposis of the stomach CC (GAPPS) [MIM:619182]: A familial gastric polyposis syndrome CC characterized by autosomal dominant transmission of fundic gland CC polyposis with occasional hyperplastic and adenomatous polyps, sparing CC of the gastric antrum, and a significant risk of intestinal-type CC gastric adenocarcinoma development. Colorectal polyposis is not CC observed, and family history does not include colorectal cancer. CC {ECO:0000269|PubMed:27087319, ECO:0000269|PubMed:27343414, CC ECO:0000269|PubMed:33242120}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- MISCELLANEOUS: APC mutations have led to some interesting observations. CC (1) the great majority of the mutations found to date would result in CC truncation of the APC product. (2) almost all the mutations have CC occurred within the first half of the coding sequence, and somatic CC mutations in colorectal tumors are further clustered in a particular CC region, called MCR (mutation cluster region). (3) most identified point CC mutations in the APC gene are transitions from cytosine to other CC nucleotides. (4) the location of germline mutations tends to correlate CC with the number of colorectal polyps in FAP1 patients. Inactivation of CC both alleles of the APC gene seems to be required as an early event to CC develop most adenomas and carcinomas in the colon and rectum as well as CC some of those in the stomach. CC -!- MISCELLANEOUS: [Isoform 1B]: Produced by alternative promoter usage. CC {ECO:0000269|PubMed:19527921}. CC -!- SIMILARITY: Belongs to the adenomatous polyposis coli (APC) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases Adenomatous CC Polyposis Coli (APC); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/APC"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/118/APC"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M73548; AAA60353.1; -; mRNA. DR EMBL; M73548; AAA60354.1; -; mRNA. DR EMBL; M74088; AAA03586.1; -; mRNA. DR EMBL; AC008575; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC136500; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471086; EAW49002.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49007.1; -; Genomic_DNA. DR EMBL; AK294544; BAH11802.1; -; mRNA. DR EMBL; S78214; AAB21145.2; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS4107.1; -. [P25054-1] DR PIR; A37261; RBHUAP. DR RefSeq; NP_000029.2; NM_000038.5. [P25054-1] DR RefSeq; NP_001120982.1; NM_001127510.3. [P25054-1] DR RefSeq; NP_001120983.2; NM_001127511.3. [P25054-3] DR RefSeq; NP_001341824.1; NM_001354895.2. [P25054-1] DR RefSeq; NP_001341832.1; NM_001354903.2. [P25054-2] DR RefSeq; NP_001394379.1; NM_001407450.1. [P25054-1] DR RefSeq; NP_001394387.1; NM_001407458.1. [P25054-2] DR RefSeq; NP_001394388.1; NM_001407459.1. [P25054-2] DR RefSeq; NP_001394389.1; NM_001407460.1. [P25054-2] DR PDB; 1DEB; X-ray; 2.40 A; A/B=2-55. DR PDB; 1EMU; X-ray; 1.90 A; B=2034-2049. DR PDB; 1JPP; X-ray; 3.10 A; C/D=1021-1035. DR PDB; 1M5I; X-ray; 2.00 A; A=126-250. DR PDB; 1T08; X-ray; 2.10 A; C=1484-1498. DR PDB; 1TH1; X-ray; 2.50 A; C/D=1362-1540. DR PDB; 1V18; X-ray; 2.10 A; B=1482-1528. DR PDB; 2RQU; NMR; -; B=1578-1596. DR PDB; 3AU3; X-ray; 2.10 A; A=396-732. DR PDB; 3NMW; X-ray; 1.60 A; A/B=407-751. DR PDB; 3NMX; X-ray; 2.30 A; A/B/C=407-751. DR PDB; 3NMZ; X-ray; 3.01 A; A/B=303-739. DR PDB; 3QHE; X-ray; 2.40 A; A/C=396-732. DR PDB; 3RL7; X-ray; 2.30 A; G/H/I/J/K/L=2833-2843. DR PDB; 3RL8; X-ray; 2.20 A; F=2833-2843. DR PDB; 3T7U; X-ray; 2.90 A; A/B=407-775. DR PDB; 4G69; X-ray; 2.00 A; B=2833-2843. DR PDB; 4YJE; X-ray; 1.90 A; A=407-751. DR PDB; 4YJL; X-ray; 2.10 A; A/B/C/D/E/F=407-751. DR PDB; 4YK6; X-ray; 1.70 A; A=407-751. DR PDB; 5B6G; X-ray; 1.99 A; A=407-751. DR PDB; 5IZ6; X-ray; 2.15 A; A=407-751. DR PDB; 5IZ8; X-ray; 3.06 A; A/B=407-751. DR PDB; 5IZ9; X-ray; 2.93 A; A=407-751. DR PDB; 5IZA; X-ray; 1.50 A; A=407-751. DR PDB; 5Z8H; X-ray; 1.79 A; A=407-741. DR PDB; 7F6M; X-ray; 2.40 A; A=407-751. DR PDB; 7F7O; X-ray; 2.80 A; A=407-738. DR PDB; 7XTY; X-ray; 2.10 A; C/D=2833-2843. DR PDB; 8GSJ; X-ray; 2.10 A; A=407-738. DR PDB; 8X2Q; X-ray; 2.00 A; A=126-250. DR PDBsum; 1DEB; -. DR PDBsum; 1EMU; -. DR PDBsum; 1JPP; -. DR PDBsum; 1M5I; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 1V18; -. DR PDBsum; 2RQU; -. DR PDBsum; 3AU3; -. DR PDBsum; 3NMW; -. DR PDBsum; 3NMX; -. DR PDBsum; 3NMZ; -. DR PDBsum; 3QHE; -. DR PDBsum; 3RL7; -. DR PDBsum; 3RL8; -. DR PDBsum; 3T7U; -. DR PDBsum; 4G69; -. DR PDBsum; 4YJE; -. DR PDBsum; 4YJL; -. DR PDBsum; 4YK6; -. DR PDBsum; 5B6G; -. DR PDBsum; 5IZ6; -. DR PDBsum; 5IZ8; -. DR PDBsum; 5IZ9; -. DR PDBsum; 5IZA; -. DR PDBsum; 5Z8H; -. DR PDBsum; 7F6M; -. DR PDBsum; 7F7O; -. DR PDBsum; 7XTY; -. DR PDBsum; 8GSJ; -. DR PDBsum; 8X2Q; -. DR BMRB; P25054; -. DR SMR; P25054; -. DR BioGRID; 106821; 370. DR ComplexPortal; CPX-107; Beta-catenin destruction core complex, APC-AXIN1-GSK3A variant. DR ComplexPortal; CPX-109; Beta-catenin destruction core complex, APC-AXIN1-GSK3B variant. DR ComplexPortal; CPX-439; Beta-catenin destruction core complex, APC-AXIN2-GSK3B variant. DR ComplexPortal; CPX-441; Beta-catenin destruction core complex, APC-AXIN2-GSK3A variant. DR CORUM; P25054; -. DR DIP; DIP-33556N; -. DR FunCoup; P25054; 1537. DR IntAct; P25054; 301. DR MINT; P25054; -. DR STRING; 9606.ENSP00000257430; -. DR BindingDB; P25054; -. DR ChEMBL; CHEMBL3233; -. DR GlyCosmos; P25054; 3 sites, 2 glycans. DR GlyGen; P25054; 8 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (4 sites). DR iPTMnet; P25054; -. DR PhosphoSitePlus; P25054; -. DR BioMuta; APC; -. DR DMDM; 97535708; -. DR jPOST; P25054; -. DR MassIVE; P25054; -. DR PaxDb; 9606-ENSP00000257430; -. DR PeptideAtlas; P25054; -. DR ProteomicsDB; 54247; -. [P25054-1] DR ProteomicsDB; 54248; -. [P25054-2] DR ProteomicsDB; 6428; -. DR Pumba; P25054; -. DR Antibodypedia; 1054; 757 antibodies from 45 providers. DR DNASU; 324; -. DR Ensembl; ENST00000257430.9; ENSP00000257430.4; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000507379.6; ENSP00000423224.2; ENSG00000134982.20. [P25054-3] DR Ensembl; ENST00000508376.6; ENSP00000427089.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000509732.6; ENSP00000426541.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000512211.7; ENSP00000423828.3; ENSG00000134982.20. [P25054-1] DR GeneID; 324; -. DR KEGG; hsa:324; -. DR MANE-Select; ENST00000257430.9; ENSP00000257430.4; NM_000038.6; NP_000029.2. DR UCSC; uc003kpy.5; human. [P25054-1] DR UCSC; uc063gan.1; human. DR AGR; HGNC:583; -. DR CIViC; 324; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA24875; -. DR CTD; 324; -. DR DisGeNET; 324; -. DR GeneCards; APC; -. DR GeneReviews; APC; -. DR HGNC; HGNC:583; APC. DR HPA; ENSG00000134982; Tissue enhanced (brain). DR MalaCards; APC; -. DR MIM; 114550; phenotype. DR MIM; 135290; phenotype. DR MIM; 155255; phenotype. DR MIM; 175100; phenotype. DR MIM; 611731; gene. DR MIM; 613659; phenotype. DR MIM; 619182; phenotype. DR OpenTargets; ENSG00000134982; -. DR Orphanet; 261584; 5q22 microdeletion syndrome. DR Orphanet; 220460; Attenuated familial adenomatous polyposis. DR Orphanet; 3258; Cenani-Lenz syndrome. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 314022; Gastric adenocarcinoma and proximal polyposis of the stomach. DR VEuPathDB; HostDB:ENSG00000134982; -. DR eggNOG; KOG2122; Eukaryota. DR GeneTree; ENSGT00530000063749; -. DR HOGENOM; CLU_001012_0_0_1; -. DR InParanoid; P25054; -. DR OMA; DHEKHSP; -. DR OrthoDB; 5918429at2759; -. DR PAN-GO; P25054; 14 GO annotations based on evolutionary models. DR PhylomeDB; P25054; -. DR BioCyc; MetaCyc:ENSG00000134982-MONOMER; -. DR PathwayCommons; P25054; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5467333; APC truncation mutants are not K63 polyubiquitinated. DR Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding. DR Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex. DR Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR SignaLink; P25054; -. DR SIGNOR; P25054; -. DR Agora; ENSG00000134982; -. DR BioGRID-ORCS; 324; 172 hits in 1170 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D8D47D1F; Synthetic Condensate 000297. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; APC; human. DR EvolutionaryTrace; P25054; -. DR GeneWiki; Adenomatous_polyposis_coli; -. DR GenomeRNAi; 324; -. DR Pharos; P25054; Tchem. DR PRO; PR:P25054; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P25054; protein. DR Bgee; ENSG00000134982; Expressed in substantia nigra pars compacta and 207 other cell types or tissues. DR ExpressionAtlas; P25054; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:CACAO. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0070840; F:dynein complex binding; IPI:CAFA. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0051010; F:microtubule plus-end binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IDA:DisProt. DR GO; GO:0019887; F:protein kinase regulator activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:MGI. DR GO; GO:0070830; P:bicellular tight junction assembly; NAS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; NAS:UniProtKB. DR GO; GO:0001708; P:cell fate specification; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0003170; P:heart valve development; ISS:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:MGI. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:MGI. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:MGI. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IGI:MGI. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:CAFA. DR GO; GO:0031274; P:positive regulation of pseudopodium assembly; IMP:MGI. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; NAS:ComplexPortal. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:MGI. DR GO; GO:0060632; P:regulation of microtubule-based movement; IEP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IMP:UniProtKB. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR DisProt; DP00519; -. DR FunFam; 1.25.10.10:FF:000035; adenomatous polyposis coli protein 2; 1. DR FunFam; 1.10.287.450:FF:000001; adenomatous polyposis coli protein isoform X1; 1. DR Gene3D; 1.20.5.10; -; 1. DR Gene3D; 1.10.287.450; Helix hairpin bin; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00035; -. DR InterPro; IPR009240; APC_15aa_rpt. DR InterPro; IPR009234; APC_basic_dom. DR InterPro; IPR026831; APC_dom. DR InterPro; IPR026818; Apc_fam. DR InterPro; IPR032038; APC_N. DR InterPro; IPR036149; APC_N_sf. DR InterPro; IPR041257; APC_rep. DR InterPro; IPR009223; APC_rpt. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR009232; EB1-bd. DR InterPro; IPR009224; SAMP. DR PANTHER; PTHR12607:SF11; ADENOMATOUS POLYPOSIS COLI PROTEIN; 1. DR PANTHER; PTHR12607; ADENOMATOUS POLYPOSIS COLI PROTEIN FAMILY; 1. DR Pfam; PF05972; APC_15aa; 4. DR Pfam; PF05956; APC_basic; 1. DR Pfam; PF16689; APC_N_CC; 1. DR Pfam; PF05923; APC_r; 7. DR Pfam; PF18797; APC_rep; 1. DR Pfam; PF16634; APC_u13; 1. DR Pfam; PF16635; APC_u14; 1. DR Pfam; PF16636; APC_u15; 1. DR Pfam; PF16630; APC_u5; 1. DR Pfam; PF16633; APC_u9; 1. DR Pfam; PF00514; Arm; 3. DR Pfam; PF16629; Arm_APC_u3; 1. DR Pfam; PF05937; EB1_binding; 1. DR Pfam; PF05924; SAMP; 3. DR Pfam; PF11414; Suppressor_APC; 1. DR SMART; SM00185; ARM; 7. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF58050; N-terminal coiled coil domain from apc; 1. DR SUPFAM; SSF82931; Tumor suppressor gene product Apc; 1. DR PROSITE; PS50176; ARM_REPEAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; KW Alternative splicing; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; Membrane; KW Microtubule; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Tumor suppressor; Ubl conjugation; Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..2843 FT /note="Adenomatous polyposis coli protein" FT /id="PRO_0000064627" FT REPEAT 453..495 FT /note="ARM 1" FT REPEAT 505..547 FT /note="ARM 2" FT REPEAT 548..591 FT /note="ARM 3" FT REPEAT 592..638 FT /note="ARM 4" FT REPEAT 639..683 FT /note="ARM 5" FT REPEAT 684..725 FT /note="ARM 6" FT REPEAT 726..767 FT /note="ARM 7" FT REGION 239..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..878 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 923..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 958..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 960..1337 FT /note="Responsible for down-regulation through a process FT mediated by direct ubiquitination" FT REGION 1020..1169 FT /note="Interaction with catenins" FT /evidence="ECO:0000269|PubMed:8259519" FT REGION 1099..1169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1190..1244 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1311..1376 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1403..1475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1526..1569 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1583..1611 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1664..1717 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1729..1836 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1893 FT /note="Highly charged" FT REGION 1881..1950 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1965..2011 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2035..2059 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000269|PubMed:10811618" FT REGION 2043..2072 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2147..2635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2167..2674 FT /note="Basic region" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2475..2843 FT /note="Interaction with DLG1" FT /evidence="ECO:0000269|PubMed:8638125" FT REGION 2667..2714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2674..2843 FT /note="Interaction with MAPRE1" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2729..2843 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 2..61 FT /evidence="ECO:0000255" FT COILED 127..248 FT /evidence="ECO:0000255" FT MOTIF 2803..2806 FT /note="Microtubule tip localization signal" FT MOTIF 2841..2843 FT /note="PDZ-binding" FT COMPBIAS 241..261 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..282 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 290..299 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 833..843 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 844..857 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 869..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 927..943 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 961..971 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1107..1130 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1146..1159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1190..1224 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1225..1244 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1335..1345 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1355..1366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1448..1466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1540..1564 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1683..1698 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1735..1744 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1785..1794 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1804..1813 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1881..1896 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1897..1913 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1928..1938 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1939..1950 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1979..1991 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2169..2187 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2203..2223 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2257..2271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2286..2331 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2348..2369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2370..2409 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2418..2427 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2459..2477 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2518..2535 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2555..2568 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2569..2579 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2580..2592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2593..2608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2620..2635 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2668..2679 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2741..2757 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2763..2774 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2784..2812 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 107 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 744 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 748 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 908 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1038 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1392 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1438 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1774 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1863 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1971 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1973 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2088 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2093 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2125 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2129 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2132 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2151 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2260 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2283 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2473 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2535 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2569 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2671 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2679 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2710 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..45 FT /note="MAAASYDQLLKQVEALKMENSNLRQELEDNSNHLTKLETEASNMK -> MYA FT SLGSGPVAPLPASVPPSVLGSWSTGGSRSCVRQETKSPGGARTSGHWASVWQ (in FT isoform 1B)" FT /id="VSP_059027" FT VAR_SEQ 217..244 FT /note="Missing (in isoform 1B)" FT /id="VSP_059028" FT VAR_SEQ 312..412 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:1678319" FT /id="VSP_004115" FT VARIANT 99 FT /note="R -> W (in FAP1; benign; dbSNP:rs139196838)" FT /evidence="ECO:0000269|PubMed:7833149" FT /id="VAR_009613" FT VARIANT 171 FT /note="S -> I (in FAP1)" FT /evidence="ECO:0000269|PubMed:8990002" FT /id="VAR_005032" FT VARIANT 414 FT /note="R -> C (in FAP1; benign; dbSNP:rs137854567)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005033" FT VARIANT 722 FT /note="S -> G (in FAP1)" FT /evidence="ECO:0000269|PubMed:7833931" FT /id="VAR_009614" FT VARIANT 784 FT /note="S -> T (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005034" FT VARIANT 817 FT /note="G -> C (in gastric cancer)" FT /id="VAR_005035" FT VARIANT 870 FT /note="P -> S (in dbSNP:rs33974176)" FT /id="VAR_053976" FT VARIANT 880 FT /note="I -> T (in colorectal carcinoma and gastric cancer; FT from a patient with MMRCS; dbSNP:rs1400295986)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_005036" FT VARIANT 890 FT /note="V -> I (in colorectal carcinoma; from a patient with FT MMRCS; dbSNP:rs779998847)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012975" FT VARIANT 906 FT /note="S -> Y (in colorectal tumor)" FT /id="VAR_005037" FT VARIANT 911 FT /note="E -> G (in FAP1 and colorectal tumor)" FT /evidence="ECO:0000269|PubMed:1338904" FT /id="VAR_005038" FT VARIANT 942 FT /note="N -> D (in gastric cancer)" FT /id="VAR_005039" FT VARIANT 1027 FT /note="Y -> C (in colorectal tumor; dbSNP:rs869312784)" FT /id="VAR_005040" FT VARIANT 1057 FT /note="E -> G (found in a family whose members exhibit FT gastrointestinal cancers and multiple pigmented cutaneous FT lesions; uncertain significance)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_009615" FT VARIANT 1118 FT /note="N -> D (in dbSNP:rs140493115)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005041" FT VARIANT 1120 FT /note="G -> E (in gastric cancer; dbSNP:rs28933379)" FT /id="VAR_005042" FT VARIANT 1171 FT /note="R -> C (in dbSNP:rs201830995)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008992" FT VARIANT 1171 FT /note="R -> H (in gastric cancer; dbSNP:rs372481703)" FT /id="VAR_005043" FT VARIANT 1176 FT /note="P -> L (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005044" FT VARIANT 1184 FT /note="A -> P (in FAP1)" FT /evidence="ECO:0000269|PubMed:10470088" FT /id="VAR_009616" FT VARIANT 1197 FT /note="F -> S (in gastric cancer)" FT /id="VAR_005045" FT VARIANT 1254 FT /note="I -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035794" FT VARIANT 1259 FT /note="I -> T (in gastric cancer)" FT /id="VAR_005046" FT VARIANT 1292 FT /note="T -> M (in FAP1; uncertain significance; FT dbSNP:rs371113837)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005047" FT VARIANT 1296 FT /note="A -> V (in MDB; sporadic; dbSNP:rs1291513037)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017653" FT VARIANT 1304 FT /note="I -> V (in dbSNP:rs770157475)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005048" FT VARIANT 1307 FT /note="I -> K (probable risk factor for colon and breast FT cancer; dbSNP:rs1801155)" FT /evidence="ECO:0000269|PubMed:9724771, FT ECO:0000269|PubMed:9731522, ECO:0000269|PubMed:9731533, FT ECO:0000269|PubMed:9973276" FT /id="VAR_005049" FT VARIANT 1312 FT /note="G -> E (in gastric cancer)" FT /id="VAR_005050" FT VARIANT 1313 FT /note="T -> A (in FAP1 and colorectal tumor; FT dbSNP:rs863225349)" FT /id="VAR_005051" FT VARIANT 1317 FT /note="E -> Q (may contribute to colorectal tumor FT development; dbSNP:rs1801166)" FT /evidence="ECO:0000269|PubMed:9724771" FT /id="VAR_009617" FT VARIANT 1326 FT /note="V -> A (in gastric cancer)" FT /id="VAR_005052" FT VARIANT 1348 FT /note="R -> W (in FAP1)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005053" FT VARIANT 1395 FT /note="S -> C (in hepatoblastoma; dbSNP:rs137854578)" FT /evidence="ECO:0000269|PubMed:8764128" FT /id="VAR_065133" FT VARIANT 1422 FT /note="D -> H (in colorectal tumor)" FT /id="VAR_005054" FT VARIANT 1472 FT /note="V -> I (in MDB; sporadic; dbSNP:rs878853445)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017654" FT VARIANT 1495 FT /note="S -> G (in MDB; sporadic)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017655" FT VARIANT 1496 FT /note="T -> S (in dbSNP:rs2229996)" FT /id="VAR_020141" FT VARIANT 1508 FT /note="A -> V (in colorectal carcinoma from a patient with FT MMRCS)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012976" FT VARIANT 1822 FT /note="V -> D (in dbSNP:rs459552)" FT /evidence="ECO:0000269|PubMed:1651562, FT ECO:0000269|PubMed:1678319, ECO:0000269|PubMed:9950360, FT ECO:0000269|Ref.5" FT /id="VAR_008993" FT VARIANT 1882 FT /note="R -> T (in dbSNP:rs34157245)" FT /id="VAR_053977" FT VARIANT 1973 FT /note="S -> T (in dbSNP:rs4987109)" FT /id="VAR_020142" FT VARIANT 2499 FT /note="V -> L (in dbSNP:rs33941929)" FT /id="VAR_053978" FT VARIANT 2502 FT /note="G -> S (in dbSNP:rs2229995)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005055" FT VARIANT 2621 FT /note="S -> C (in FAP1; benign; dbSNP:rs72541816)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005056" FT VARIANT 2738 FT /note="I -> T (in dbSNP:rs863224552)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008994" FT VARIANT 2839 FT /note="L -> F (in FAP1; dbSNP:rs876658156)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005057" FT MUTAGEN 516 FT /note="K->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 549 FT /note="R->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 2841 FT /note="T->L: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT MUTAGEN 2843 FT /note="V->Q: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT CONFLICT 184 FT /note="M -> L (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 970 FT /note="S -> N (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1309 FT /note="E -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1325..1331 FT /note="AVSQHPR -> SSVHSTLE (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1355 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1591 FT /note="A -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2723 FT /note="N -> T (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2755 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT HELIX 6..53 FT /evidence="ECO:0007829|PDB:1DEB" FT HELIX 132..169 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:8X2Q" FT HELIX 180..204 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 208..238 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 328..338 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 343..350 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 353..360 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 377..393 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 407..426 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:3AU3" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 446..456 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 460..468 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 471..486 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 492..509 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 513..521 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 523..531 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 532..534 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 538..552 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 557..565 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 568..578 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 582..596 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 600..607 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 612..619 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 625..627 FT /evidence="ECO:0007829|PDB:3NMW" FT HELIX 629..646 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 650..658 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 661..668 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 674..687 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 688..690 FT /evidence="ECO:0007829|PDB:5IZ8" FT HELIX 692..700 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 703..708 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 709..712 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 716..731 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 739..742 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 1027..1030 FT /evidence="ECO:0007829|PDB:1JPP" FT HELIX 1470..1479 FT /evidence="ECO:0007829|PDB:1TH1" FT HELIX 1520..1524 FT /evidence="ECO:0007829|PDB:1V18" FT HELIX 2036..2045 FT /evidence="ECO:0007829|PDB:1EMU" FT STRAND 2841..2843 FT /evidence="ECO:0007829|PDB:7XTY" SQ SEQUENCE 2843 AA; 311646 MW; 77E194AE4A91DC5A CRC64; MAAASYDQLL KQVEALKMEN SNLRQELEDN SNHLTKLETE ASNMKEVLKQ LQGSIEDEAM ASSGQIDLLE RLKELNLDSS NFPGVKLRSK MSLRSYGSRE GSVSSRSGEC SPVPMGSFPR RGFVNGSRES TGYLEELEKE RSLLLADLDK EEKEKDWYYA QLQNLTKRID SLPLTENFSL QTDMTRRQLE YEARQIRVAM EEQLGTCQDM EKRAQRRIAR IQQIEKDILR IRQLLQSQAT EAERSSQNKH ETGSHDAERQ NEGQGVGEIN MATSGNGQGS TTRMDHETAS VLSSSSTHSA PRRLTSHLGT KVEMVYSLLS MLGTHDKDDM SRTLLAMSSS QDSCISMRQS GCLPLLIQLL HGNDKDSVLL GNSRGSKEAR ARASAALHNI IHSQPDDKRG RREIRVLHLL EQIRAYCETC WEWQEAHEPG MDQDKNPMPA PVEHQICPAV CVLMKLSFDE EHRHAMNELG GLQAIAELLQ VDCEMYGLTN DHYSITLRRY AGMALTNLTF GDVANKATLC SMKGCMRALV AQLKSESEDL QQVIASVLRN LSWRADVNSK KTLREVGSVK ALMECALEVK KESTLKSVLS ALWNLSAHCT ENKADICAVD GALAFLVGTL TYRSQTNTLA IIESGGGILR NVSSLIATNE DHRQILRENN CLQTLLQHLK SHSLTIVSNA CGTLWNLSAR NPKDQEALWD MGAVSMLKNL IHSKHKMIAM GSAAALRNLM ANRPAKYKDA NIMSPGSSLP SLHVRKQKAL EAELDAQHLS ETFDNIDNLS PKASHRSKQR HKQSLYGDYV FDTNRHDDNR SDNFNTGNMT VLSPYLNTTV LPSSSSSRGS LDSSRSEKDR SLERERGIGL GNYHPATENP GTSSKRGLQI STTAAQIAKV MEEVSAIHTS QEDRSSGSTT ELHCVTDERN ALRRSSAAHT HSNTYNFTKS ENSNRTCSMP YAKLEYKRSS NDSLNSVSSS DGYGKRGQMK PSIESYSEDD ESKFCSYGQY PADLAHKIHS ANHMDDNDGE LDTPINYSLK YSDEQLNSGR QSPSQNERWA RPKHIIEDEI KQSEQRQSRN QSTTYPVYTE STDDKHLKFQ PHFGQQECVS PYRSRGANGS ETNRVGSNHG INQNVSQSLC QEDDYEDDKP TNYSERYSEE EQHEEEERPT NYSIKYNEEK RHVDQPIDYS LKYATDIPSS QKQSFSFSKS SSGQSSKTEH MSSSSENTST PSSNAKRQNQ LHPSSAQSRS GQPQKAATCK VSSINQETIQ TYCVEDTPIC FSRCSSLSSL SSAEDEIGCN QTTQEADSAN TLQIAEIKEK IGTRSAEDPV SEVPAVSQHP RTKSSRLQGS SLSSESARHK AVEFSSGAKS PSKSGAQTPK SPPEHYVQET PLMFSRCTSV SSLDSFESRS IASSVQSEPC SGMVSGIISP SDLPDSPGQT MPPSRSKTPP PPPQTAQTKR EVPKNKAPTA EKRESGPKQA AVNAAVQRVQ VLPDADTLLH FATESTPDGF SCSSSLSALS LDEPFIQKDV ELRIMPPVQE NDNGNETESE QPKESNENQE KEAEKTIDSE KDLLDDSDDD DIEILEECII SAMPTKSSRK AKKPAQTASK LPPPVARKPS QLPVYKLLPS QNRLQPQKHV SFTPGDDMPR VYCVEGTPIN FSTATSLSDL TIESPPNELA AGEGVRGGAQ SGEFEKRDTI PTEGRSTDEA QGGKTSSVTI PELDDNKAEE GDILAECINS AMPKGKSHKP FRVKKIMDQV QQASASSSAP NKNQLDGKKK KPTSPVKPIP QNTEYRTRVR KNADSKNNLN AERVFSDNKD SKKQNLKNNS KVFNDKLPNN EDRVRGSFAF DSPHHYTPIE GTPYCFSRND SLSSLDFDDD DVDLSREKAE LRKAKENKES EAKVTSHTEL TSNQQSANKT QAIAKQPINR GQPKPILQKQ STFPQSSKDI PDRGAATDEK LQNFAIENTP VCFSHNSSLS SLSDIDQENN NKENEPIKET EPPDSQGEPS KPQASGYAPK SFHVEDTPVC FSRNSSLSSL SIDSEDDLLQ ECISSAMPKK KKPSRLKGDN EKHSPRNMGG ILGEDLTLDL KDIQRPDSEH GLSPDSENFD WKAIQEGANS IVSSLHQAAA AACLSRQASS DSDSILSLKS GISLGSPFHL TPDQEEKPFT SNKGPRILKP GEKSTLETKK IESESKGIKG GKKVYKSLIT GKVRSNSEIS GQMKQPLQAN MPSISRGRTM IHIPGVRNSS SSTSPVSKKG PPLKTPASKS PSEGQTATTS PRGAKPSVKS ELSPVARQTS QIGGSSKAPS RSGSRDSTPS RPAQQPLSRP IQSPGRNSIS PGRNGISPPN KLSQLPRTSS PSTASTKSSG SGKMSYTSPG RQMSQQNLTK QTGLSKNASS IPRSESASKG LNQMNNGNGA NKKVELSRMS STKSSGSESD RSERPVLVRQ STFIKEAPSP TLRRKLEESA SFESLSPSSR PASPTRSQAQ TPVLSPSLPD MSLSTHSSVQ AGGWRKLPPN LSPTIEYNDG RPAKRHDIAR SHSESPSRLP INRSGTWKRE HSKHSSSLPR VSTWRRTGSS SSILSASSES SEKAKSEDEK HVNSISGTKQ SKENQVSAKG TWRKIKENEF SPTNSTSQTV SSGATNGAES KTLIYQMAPA VSKTEDVWVR IEDCPINNPR SGRSPTGNTP PVIDSVSEKA NPNIKDSKDN QAKQNVGNGS VPMRTVGLEN RLNSFIQVDA PDQKGTEIKP GQNNPVPVSE TNESSIVERT PFSSSSSSKH SSPSGTVAAR VTPFNYNPSP RKSSADSTSA RPSQIPTPVN NNTKKRDSKT DSTESSGTQS PKRHSGSYLV TSV // ID ATM_HUMAN Reviewed; 3056 AA. AC Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 22-JAN-2014, sequence version 4. DT 28-JAN-2026, entry version 269. DE RecName: Full=Serine-protein kinase ATM; DE EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; DE AltName: Full=Ataxia telangiectasia mutated; DE Short=A-T mutated; GN Name=ATM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003. RX PubMed=8589678; DOI=10.1093/hmg/4.11.2025; RA Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., RA Shiloh Y., Rotman G.; RT "The complete sequence of the coding region of the ATM gene reveals RT similarity to cell cycle regulators in different species."; RL Hum. Mol. Genet. 4:2025-2032(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS RP CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287. RX PubMed=8665503; RA Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L., RA Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G., RA Croce C.M., Negrini M.; RT "The ATM gene and susceptibility to breast cancer: analysis of 38 breast RT tumors reveals no evidence for mutation."; RL Cancer Res. 56:2726-2732(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9199932; DOI=10.1101/gr.7.6.592; RA Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A., RA Gilad S., Shiloh Y., Rosenthal A.; RT "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic RT DNA containing the entire ATM gene."; RL Genome Res. 7:592-605(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548 RP DEL. RX PubMed=8789452; DOI=10.1093/hmg/5.1.145; RA Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T., RA McGuire G.M., Thick J.A., Taylor A.M.R.; RT "Mutations revealed by sequencing the 5' half of the gene for ataxia RT telangiectasia."; RL Hum. Mol. Genet. 5:145-149(1996). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24. RX PubMed=9108147; DOI=10.1093/nar/25.9.1678; RA Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A., RA Elroy-Stein O., Shiloh Y., Rotman G.; RT "Ataxia-telangiectasia: structural diversity of untranslated sequences RT suggests complex post-transcriptional regulation of ATM gene expression."; RL Nucleic Acids Res. 25:1678-1684(1997). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428 RP DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003. RC TISSUE=Fibroblast; RX PubMed=7792600; DOI=10.1126/science.7792600; RA Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., RA Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., RA Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., RA Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., RA Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.; RT "A single ataxia telangiectasia gene with a product similar to PI-3 RT kinase."; RL Science 268:1749-1753(1995). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056. RX PubMed=8521392; RA Rasio D., Negrini M., Croce C.M.; RT "Genomic organization of the ATM locus involved in ataxia-telangiectasia."; RL Cancer Res. 55:6053-6057(1995). RN [12] RP PHOSPHORYLATION. RX PubMed=8969240; DOI=10.1074/jbc.271.52.33693; RA Chen G., Lee E.Y.-H.P.; RT "The product of the ATM gene is a 370-kDa nuclear phosphoprotein."; RL J. Biol. Chem. 271:33693-33697(1996). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=9050866; DOI=10.1073/pnas.94.5.1840; RA Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., RA Tagle D.A.; RT "The ataxia-telangiectasia gene product, a constitutively expressed nuclear RT protein that is not up-regulated following genome damage."; RL Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997). RN [14] RP SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824. RX PubMed=9150358; DOI=10.1038/sj.onc.1201037; RA Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., RA Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., RA Ramsay J., Gatti R.A., Lavin M.F.; RT "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and RT discrimination between mutated and normal forms."; RL Oncogene 14:1911-1921(1997). RN [15] RP CATALYTIC ACTIVITY. RX PubMed=8988033; RA Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.; RT "ATM gene product phosphorylates I kappa B-alpha."; RL Cancer Res. 57:24-27(1997). RN [16] RP INTERACTION WITH ABL1. RX PubMed=9168117; DOI=10.1038/387520a0; RA Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., RA Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., RA Kufe D., Lavin M.F.; RT "Interaction between ATM protein and c-Abl in response to DNA damage."; RL Nature 387:520-523(1997). RN [17] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [18] RP FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY. RX PubMed=9843217; DOI=10.1038/3882; RA Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., RA Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.; RT "ATM associates with and phosphorylates p53: mapping the region of RT interaction."; RL Nat. Genet. 20:398-400(1998). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=9707615; DOI=10.1073/pnas.95.17.10146; RA Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S., RA Darnell R.B., Shiloh Y., Kastan M.B.; RT "ATM binds to beta-adaptin in cytoplasmic vesicles."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TP53. RX PubMed=9733514; DOI=10.1126/science.281.5383.1674; RA Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L., RA Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.; RT "Enhanced phosphorylation of p53 by ATM in response to DNA damage."; RL Science 281:1674-1677(1998). RN [21] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND RP ASN-2875. RX PubMed=9733515; DOI=10.1126/science.281.5383.1677; RA Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., RA Appella E., Kastan M.B., Siliciano J.D.; RT "Activation of the ATM kinase by ionizing radiation and phosphorylation of RT p53."; RL Science 281:1677-1679(1998). RN [22] RP DNA-BINDING. RX PubMed=10500142; DOI=10.1073/pnas.96.20.11134; RA Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J., RA Jackson S.P.; RT "Purification and DNA binding properties of the ataxia-telangiectasia gene RT product ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF BRCA1. RX PubMed=10550055; DOI=10.1126/science.286.5442.1162; RA Cortez D., Wang Y., Qin J., Elledge S.J.; RT "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage RT response to double-strand breaks."; RL Science 286:1162-1166(1999). RN [24] RP IDENTIFICATION OF ATM AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [25] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10766245; DOI=10.1038/35007091; RA Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J., RA Kastan M.B.; RT "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway."; RL Nature 404:613-617(2000). RN [26] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10839545; DOI=10.1038/35013089; RA Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., RA O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., RA Livingston D.M., Weaver D.T.; RT "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a RT DNA damage response."; RL Nature 405:477-482(2000). RN [27] RP FUNCTION IN PHOSPHORYLATION OF CTIP. RX PubMed=10910365; DOI=10.1038/35018134; RA Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P., RA Lee W.-H.; RT "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA RT damage response."; RL Nature 406:210-215(2000). RN [28] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10802669; DOI=10.1038/75508; RA Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., RA Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.; RT "ATM-dependent phosphorylation of nibrin in response to radiation RT exposure."; RL Nat. Genet. 25:115-119(2000). RN [29] RP FUNCTION IN PHOSPHORYLATION OF CHEK2. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [30] RP FUNCTION IN PHOSPHORYLATION OF TERF1. RX PubMed=11375976; DOI=10.1074/jbc.m011534200; RA Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.; RT "Telomeric protein Pin2/TRF1 as an important ATM target in response to RT double strand DNA breaks."; RL J. Biol. Chem. 276:29282-29291(2001). RN [31] RP INTERACTION WITH RAD17. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [32] RP FUNCTION IN PHOSPHORYLATION OF FANCD2. RX PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x; RA Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., RA Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.; RT "Convergence of the Fanconi anemia and ataxia telangiectasia signaling RT pathways."; RL Cell 109:459-472(2002). RN [33] RP PHOSPHORYLATION BY NUAK1. RX PubMed=12409306; DOI=10.1074/jbc.m206025200; RA Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.; RT "Identification of a novel protein kinase mediating Akt survival signaling RT to the ATM protein."; RL J. Biol. Chem. 278:48-53(2003). RN [34] RP PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF RP SER-1981. RX PubMed=12556884; DOI=10.1038/nature01368; RA Bakkenist C.J., Kastan M.B.; RT "DNA damage activates ATM through intermolecular autophosphorylation and RT dimer dissociation."; RL Nature 421:499-506(2003). RN [35] RP FUNCTION IN DNA DAMAGE RESPONSE. RX PubMed=14871926; DOI=10.1101/gad.1176004; RA Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T., RA Wang X.F.; RT "Requirement of protein phosphatase 5 in DNA-damage-induced ATM RT activation."; RL Genes Dev. 18:249-254(2004). RN [36] RP FUNCTION IN PHOSPHORYLATION OF DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [37] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [38] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=15064416; DOI=10.1126/science.1091496; RA Lee J.-H., Paull T.T.; RT "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 RT complex."; RL Science 304:93-96(2004). RN [39] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [40] RP FUNCTION. RX PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015; RA Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.; RT "ATM-dependent phosphorylation of ATF2 is required for the DNA damage RT response."; RL Mol. Cell 18:577-587(2005). RN [41] RP INTERACTION WITH KAT8. RX PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005; RA Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T., RA Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.; RT "Involvement of human MOF in ATM function."; RL Mol. Cell. Biol. 25:5292-5305(2005). RN [42] RP FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY. RX PubMed=16086026; DOI=10.1038/nsmb972; RA Kaygun H., Marzluff W.F.; RT "Regulated degradation of replication-dependent histone mRNAs requires both RT ATR and Upf1."; RL Nat. Struct. Mol. Biol. 12:794-800(2005). RN [43] RP PHOSPHORYLATION AT SER-1981, AND ACETYLATION. RX PubMed=16141325; DOI=10.1073/pnas.0504211102; RA Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.; RT "A role for the Tip60 histone acetyltransferase in the acetylation and RT activation of ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005). RN [44] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP PHOSPHORYLATION AT SER-1981. RX PubMed=15790808; DOI=10.1126/science.1108297; RA Lee J.H., Paull T.T.; RT "ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 RT complex."; RL Science 308:551-554(2005). RN [45] RP PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC RP ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=16858402; DOI=10.1038/sj.emboj.7601231; RA Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.; RT "Involvement of novel autophosphorylation sites in ATM activation."; RL EMBO J. 25:3504-3514(2006). RN [46] RP INTERACTION WITH ATMIN. RX PubMed=17525732; DOI=10.1038/sj.emboj.7601733; RA Kanu N., Behrens A.; RT "ATMIN defines an NBS1-independent pathway of ATM signalling."; RL EMBO J. 26:2933-2941(2007). RN [47] RP ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND RP LYS-3018. RX PubMed=17923702; DOI=10.1128/mcb.01382-07; RA Sun Y., Xu Y., Roy K., Price B.D.; RT "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase RT activity."; RL Mol. Cell. Biol. 27:8502-8509(2007). RN [48] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [49] RP INTERACTION WITH CEP164. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [51] RP INTERACTION WITH NABP2. RX PubMed=18449195; DOI=10.1038/nature06883; RA Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K., RA Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K., RA Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K., RA White M.F., Khanna K.K.; RT "Single-stranded DNA-binding protein hSSB1 is critical for genomic RT stability."; RL Nature 453:677-681(2008). RN [52] RP INTERACTION WITH DDX1. RX PubMed=18710941; DOI=10.1128/mcb.01053-08; RA Li L., Monckton E.A., Godbout R.; RT "A role for DEAD box 1 at DNA double-strand breaks."; RL Mol. Cell. Biol. 28:6413-6425(2008). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [54] RP FUNCTION AS DYRK2 KINASE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [55] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [56] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [57] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [59] RP PHOSPHORYLATION AT SER-1981. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [61] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21757780; DOI=10.1074/jbc.m111.258152; RA Gatei M., Jakob B., Chen P., Kijas A.W., Becherel O.J., Gueven N., RA Birrell G., Lee J.H., Paull T.T., Lerenthal Y., Fazry S., RA Taucher-Scholz G., Kalb R., Schindler D., Waltes R., Doerk T., Lavin M.F.; RT "ATM protein-dependent phosphorylation of Rad50 protein regulates DNA RT repair and cell cycle control."; RL J. Biol. Chem. 286:31542-31556(2011). RN [62] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP FUNCTION. RX PubMed=24534091; DOI=10.1002/embj.201386064; RA Wang Q., Goldstein M., Alexander P., Wakeman T.P., Sun T., Feng J., Lou Z., RA Kastan M.B., Wang X.F.; RT "Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular RT response to DNA double-strand breaks."; RL EMBO J. 33:862-877(2014). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [66] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PEX5, RP AND MUTAGENESIS OF ARG-3047. RX PubMed=26344566; DOI=10.1038/ncb3230; RA Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., RA Dere R., Tait-Mulder J., Lee J.H., Paull T.T., Pandita R.K., Charaka V.K., RA Pandita T.K., Kastan M.B., Walker C.L.; RT "ATM functions at the peroxisome to induce pexophagy in response to ROS."; RL Nat. Cell Biol. 17:1259-1269(2015). RN [67] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26240375; DOI=10.1093/nar/gkv754; RA Kijas A.W., Lim Y.C., Bolderson E., Cerosaletti K., Gatei M., Jakob B., RA Tobias F., Taucher-Scholz G., Gueven N., Oakley G., Concannon P., RA Wolvetang E., Khanna K.K., Wiesmueller L., Lavin M.F.; RT "ATM-dependent phosphorylation of MRE11 controls extent of resection during RT homology directed repair by signalling through Exonuclease 1."; RL Nucleic Acids Res. 43:8352-8367(2015). RN [68] RP FUNCTION IN PHOSPHORYLATION OF FBXW7. RX PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010; RA Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.; RT "FBXW7 facilitates nonhomologous end-joining via K63-linked RT polyubiquitylation of XRCC4."; RL Mol. Cell 61:419-433(2016). RN [69] RP FUNCTION. RX PubMed=29203878; DOI=10.1038/s41467-017-02114-x; RA Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D., RA Zhu X.D.; RT "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair RT pathway choice."; RL Nat. Commun. 8:1921-1921(2017). RN [70] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [71] RP FUNCTION. RX PubMed=30612738; DOI=10.1016/j.cell.2018.11.024; RA Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J., RA Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L., RA Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T., RA Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M., RA Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T., RA Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.; RT "UBQLN4 represses homologous recombination and is overexpressed in RT aggressive tumors."; RL Cell 0:0-0(2019). RN [72] RP FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY. RX PubMed=30886146; DOI=10.1038/s41467-019-09175-0; RA Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.; RT "UFL1 promotes histone H4 ufmylation and ATM activation."; RL Nat. Commun. 10:1242-1242(2019). RN [73] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30952868; DOI=10.1038/s41467-019-09641-9; RA Ha G.H., Ji J.H., Chae S., Park J., Kim S., Lee J.K., Kim Y., Min S., RA Park J.M., Kang T.H., Lee H., Cho H., Lee C.W.; RT "Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at RT DNA double-strand breaks."; RL Nat. Commun. 10:1577-1577(2019). RN [74] RP ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF RP LYS-3016. RX PubMed=30944854; DOI=10.1126/sciadv.aav1118; RA Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L., RA Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.; RT "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA RT damage repair."; RL Sci. Adv. 5:EAAV1118-EAAV1118(2019). RN [75] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=38128537; DOI=10.1016/j.cell.2023.11.022; RA Chen Y., Wu J., Zhai L., Zhang T., Yin H., Gao H., Zhao F., Wang Z., RA Yang X., Jin M., Huang B., Ding X., Li R., Yang J., He Y., Wang Q., RA Wang W., Kloeber J.A., Li Y., Hao B., Zhang Y., Wang J., Tan M., Li K., RA Wang P., Lou Z., Yuan J.; RT "Metabolic regulation of homologous recombination repair by MRE11 RT lactylation."; RL Cell 187:294-311(2024). RN [76] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1} RP STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND RP SUBUNIT. RX PubMed=28508083; DOI=10.1126/sciadv.1700933; RA Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B., RA Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.; RT "Structures of closed and open conformations of dimeric human ATM."; RL Sci. Adv. 3:E1700933-E1700933(2017). RN [77] {ECO:0007744|PDB:7SIC, ECO:0007744|PDB:7SID} RP STRUCTURE BY ELECTRON MICROSCOPY (2.51 ANGSTROMS) IN COMPLEX WITH NBN, RP FUNCTION, INTERACTION WITH NBN, AND ACTIVITY REGULATION. RX PubMed=35076389; DOI=10.7554/elife.74218; RA Warren C., Pavletich N.P.; RT "Structure of the human ATM kinase and mechanism of Nbs1 binding."; RL Elife 11:0-0(2022). RN [78] RP VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827. RX PubMed=8755918; RA McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y., RA Lennox G.G., Taylor A.M.R.; RT "Mutations associated with variant phenotypes in ataxia-telangiectasia."; RL Am. J. Hum. Genet. 59:320-330(1996). RN [79] RP VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438. RX PubMed=8808599; RA Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D., RA Concannon P.; RT "A high frequency of distinct ATM gene mutations in ataxia- RT telangiectasia."; RL Am. J. Hum. Genet. 59:839-846(1996). RN [80] RP VARIANTS 705-TYR--SER-707 DELINS PHE-ILE-PRO AND 2546-SER--ILE-2548 DEL, RP AND VARIANTS CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691. RX PubMed=8797579; RA Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., RA Croce C.M., Hammarstroem L.; RT "ATM mutations in cancer families."; RL Cancer Res. 56:4130-4133(1996). RN [81] RP VARIANT AT 705-TYR--SER-707 DELINS PHE-ILE-PRO, AND VARIANTS LEU-858 AND RP ARG-1054. RX PubMed=9043869; DOI=10.1159/000472231; RA Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M., RA James M.R., Negrini M., Webster A.D.B., Hammarstroem L.; RT "Exon-scanning mutation analysis of the ATM gene in patients with ataxia- RT telangiectasia."; RL Eur. J. Hum. Genet. 4:352-355(1996). RN [82] RP VARIANT AT ARG-2867. RX PubMed=8698354; DOI=10.1007/s004390050202; RA Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.; RT "New mutations in the ataxia telangiectasia gene."; RL Hum. Genet. 98:246-249(1996). RN [83] RP VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND RP GLY-2904. RX PubMed=8845835; DOI=10.1093/hmg/5.4.433; RA Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., RA Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., RA Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., RA Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.; RT "Predominance of null mutations in ataxia-telangiectasia."; RL Hum. Mol. Genet. 5:433-439(1996). RN [84] RP POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407; RP SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442; RP 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810 RP DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890. RX PubMed=9288106; DOI=10.1038/ng0997-96; RA Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C., RA Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.; RT "Clustering of missense mutations in the ataxia-telangiectasia gene in a RT sporadic T-cell leukaemia."; RL Nat. Genet. 17:96-99(1997). RN [85] RP POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008. RX PubMed=9334731; DOI=10.1038/nm1097-1155; RA Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., RA Bar-Shira A., James M.R., Lichter P., Doehner H.; RT "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia."; RL Nat. Med. 3:1155-1159(1997). RN [86] RP VARIANT AT CYS-2832. RX PubMed=9443866; DOI=10.1086/301673; RA Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S., RA Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E., RA Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.; RT "Ataxia-telangiectasia: identification and detection of founder-effect RT mutations in the ATM gene in ethnic populations."; RL Am. J. Hum. Genet. 62:86-97(1998). RN [87] RP POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001; RP ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 RP DEL; ASP-2554; GLY-2668 AND CYS-2827. RX PubMed=9463314; DOI=10.1086/301706; RA Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., RA Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., RA Byrd P.J., Taylor A.M.R.; RT "ATM mutations and phenotypes in ataxia-telangiectasia families in the RT British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, RT and breast cancer."; RL Am. J. Hum. Genet. 62:334-345(1998). RN [88] RP VARIANT AT 1812-ALA-PHE-1813 DELINS VAL. RX PubMed=9497252; DOI=10.1086/301755; RA Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M., RA Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.; RT "Genotype-phenotype relationships in ataxia-telangiectasia and variants."; RL Am. J. Hum. Genet. 62:551-561(1998). RN [89] RP VARIANT AT PRO-2656. RX PubMed=9450874; RX DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.3.co;2-8; RA Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E., RA Ohno K., Hori N., Sato K., Takeshita K.; RT "Ataxia-telangiectasia without immunodeficiency: novel point mutations RT within and adjacent to the phosphatidylinositol 3-kinase-like domain."; RL Am. J. Med. Genet. 75:141-144(1998). RN [90] RP VARIANT TPLL GLY-2486. RX PubMed=9573030; RA Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., RA Stern M.-H.; RT "Inactivation of the ATM gene in T-cell prolymphocytic leukemias."; RL Blood 91:3920-3926(1998). RN [91] RP VARIANTS 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND VARIANT RP VAL-1853. RX PubMed=9872980; DOI=10.1101/gr.8.12.1245; RA Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C., RA Fodor S.P.A., Tagle D.A., Collins F.S.; RT "Strategies for mutational analysis of the large multiexon ATM gene using RT high-density oligonucleotide arrays."; RL Genome Res. 8:1245-1258(1998). RN [92] RP VARIANT AT 2625-ASP-ALA-2626 DELINS GLU-PRO. RX PubMed=9521587; DOI=10.1007/s004390050675; RA van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M., RA van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.; RT "A double missense mutation in the ATM gene of a Dutch family with ataxia RT telangiectasia."; RL Hum. Genet. 102:187-191(1998). RN [93] RP VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853. RX PubMed=9711876; RX DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f; RA Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M., RA Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O., RA Hayashi K.; RT "ATM mutations in patients with ataxia telangiectasia screened by a RT hierarchical strategy."; RL Hum. Mutat. 12:186-195(1998). RN [94] RP VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566. RX PubMed=9792409; RX DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h; RA Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J., RA Jaspers N.G.J., van 't Veer L.J.; RT "ATM germline mutations in classical ataxia-telangiectasia patients in the RT Dutch population."; RL Hum. Mutat. 12:330-337(1998). RN [95] RP VARIANTS AT ARG-2491 AND GLY-2909. RX PubMed=9792410; RX DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9; RA Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T., RA Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J., RA Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.; RT "Ataxia-telangiectasia in the Japanese population: identification of RT R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being RT relatively common mutations."; RL Hum. Mutat. 12:338-343(1998). RN [96] RP VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008. RX PubMed=9488043; DOI=10.1038/sj.onc.1201603; RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RT "ATM is usually rearranged in T-cell prolymphocytic leukaemia."; RL Oncogene 16:789-796(1998). RN [97] RP ERRATUM OF PUBMED:9488043. RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RL Oncogene 16:2955-2955(1998). RN [98] RP POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853; RP ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018. RX PubMed=10397742; RA Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.; RT "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic RT lymphocytic leukemia."; RL Blood 94:748-753(1999). RN [99] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424. RX PubMed=9892178; RA Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., RA Albitar M., Reed J.C., Croce C.M.; RT "ATM mutations in B-cell chronic lymphocytic leukemia."; RL Cancer Res. 59:24-27(1999). RN [100] RP VARIANT AT PRO-1465. RX PubMed=10234507; DOI=10.1038/sj.ejhg.5200288; RA Izatt L., Vessey C., Hodgson S.V., Solomon E.; RT "Rapid and efficient ATM mutation detection by fluorescent chemical RT cleavage of mismatch: identification of four novel mutations."; RL Eur. J. Hum. Genet. 7:310-320(1999). RN [101] RP VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853 RP AND SER-2765. RX PubMed=10534763; RX DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.3.co;2-o; RA Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G., RA Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.; RT "Identification of germline missense mutations and rare allelic variants in RT the ATM gene in early-onset breast cancer."; RL Genes Chromosomes Cancer 26:286-294(1999). RN [102] RP VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227; RP ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49; RP LEU-858; ARG-1054; ASN-1853 AND VAL-1853. RX PubMed=9887333; DOI=10.1093/hmg/8.1.69; RA Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B., RA Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A., RA Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.; RT "Characterization of ATM gene mutations in 66 ataxia telangiectasia RT families."; RL Hum. Mol. Genet. 8:69-79(1999). RN [103] RP VARIANTS AT 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL; RP 1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER; RP 2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056 RP DEL AND ARG-2855, AND VARIANT CYS-49. RX PubMed=10425038; RX DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e; RA Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J., RA Wang Z., Yang Z., Cheng R., Gatti R.A.; RT "New mutations, polymorphisms, and rare variants in the ATM gene detected RT by a novel SSCP strategy."; RL Hum. Mutat. 14:156-162(1999). RN [104] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054; RP THR-2274 AND ALA-2695. RX PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4; RA Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., RA Moss P.A.H., Taylor A.M.R.; RT "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic RT lymphocytic leukaemia."; RL Lancet 353:26-29(1999). RN [105] RP VARIANT ARG-1054. RX PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0; RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RT "Missense mutations at ATM gene and cancer risk."; RL Lancet 353:1276-1276(1999). RN [106] RP ERRATUM OF PUBMED:10217116. RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RL Lancet 354:780-780(1999). RN [107] RP VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL; RP GLN-2625; CYS-2832; 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND RP VARIANTS VAL-1853 AND ILE-2438. RX PubMed=10817650; RX DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#; RA Li A., Swift M.; RT "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A- RT T patients."; RL Am. J. Med. Genet. 92:170-177(2000). RN [108] RP VARIANTS AT 35-ARG--VAL-3056 DEL; LEU-292; 393-TRP--VAL-3056 DEL; ARG-950; RP LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063; RP CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-ARG--SER-2549 DEL; GLU-2625; RP PRO-2626 AND ARG-2702, AND VARIANT CYS-49. RX PubMed=10873394; DOI=10.1006/mgme.2000.2998; RA Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O., RA Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.; RT "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein RT expression, mutations, and radiosensitivity."; RL Mol. Genet. Metab. 70:122-133(2000). RN [109] RP VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008. RX PubMed=10706620; DOI=10.1073/pnas.050400997; RA Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.; RT "Mantle cell lymphoma is characterized by inactivation of the ATM gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000). RN [110] RP VARIANTS TRP-45 AND CYS-49. RX PubMed=11897822; DOI=10.1136/jmg.39.3.192; RA Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H., RA Boerresen-Dale A.L., Winqvist R.; RT "ATM mutations in Finnish breast cancer patients."; RL J. Med. Genet. 39:192-196(2002). RN [111] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250; RP PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546; RP LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054; RP PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475; RP SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961; RP ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443; RP ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [112] RP VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396 RP AND HIS-2719. RX PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x; RA Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S., RA Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.; RT "ATM germline mutations in Spanish early-onset breast cancer patients RT negative for BRCA1/BRCA2 mutations."; RL Clin. Genet. 73:465-473(2008). RN [113] RP FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743; RP THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; RP ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND RP CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322; RP ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF RP LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452; RP SER-2685; PRO-2699; ASP-2708 AND GLN-2730. RX PubMed=19431188; DOI=10.1002/humu.21034; RA Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.; RT "Modeling ATM mutant proteins from missense changes confirms retained RT kinase activity."; RL Hum. Mutat. 30:1222-1230(2009). RN [114] RP VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND RP VAL-1853. RX PubMed=28202063; DOI=10.1186/s12920-017-0244-7; RA Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H., RA Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.; RT "Next-generation sequencing in familial breast cancer patients from RT Lebanon."; RL BMC Med. Genomics 10:8-8(2017). RN [115] RP VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627; RP LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046; RP ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND RP PHOSPHORYLATION. RX PubMed=27664052; DOI=10.1007/s12017-016-8440-8; RA Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J., RA Santamaria M., Santos J.L., Molina I.J.; RT "Molecular and functional characterization of a cohort of Spanish patients RT with ataxia-telangiectasia."; RL NeuroMolecular Med. 19:161-174(2017). RN [116] RP VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869; RP ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464; RP PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056. RX PubMed=28726808; DOI=10.1038/gim.2017.85; RA Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A., RA Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.; RT "Prevalence of germ-line mutations in cancer genes among pancreatic cancer RT patients with a positive family history."; RL Genet. Med. 20:119-127(2018). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon double strand breaks (DSBs), apoptosis and genotoxic CC stresses such as ionizing ultraviolet A light (UVA), thereby acting as CC a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, CC PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, CC PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, CC PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). CC Recognizes the substrate consensus sequence [ST]-Q (PubMed:10550055, CC PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, CC PubMed:15448695, PubMed:15456891, PubMed:15916964, PubMed:17923702, CC PubMed:24534091, PubMed:9733514). Phosphorylates 'Ser-139' of histone CC variant H2AX at double strand breaks (DSBs), thereby regulating DNA CC damage response mechanism (By similarity). Also plays a role in pre-B CC cell allelic exclusion, a process leading to expression of a single CC immunoglobulin heavy chain allele to enforce clonality and monospecific CC recognition by the B-cell antigen receptor (BCR) expressed on CC individual B-lymphocytes. After the introduction of DNA breaks by the CC RAG complex on one immunoglobulin allele, acts by mediating a CC repositioning of the second allele to pericentromeric heterochromatin, CC preventing accessibility to the RAG complex and recombination of the CC second allele. Also involved in signal transduction and cell cycle CC control. May function as a tumor suppressor. Necessary for activation CC of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, CC NFKBIA, BRCA1, CREBBP/CBP, RBBP8/CTIP, FBXO46, MRE11, nibrin (NBN), CC RAD50, RAD17, PELI1, TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C CC (PubMed:10550055, PubMed:10766245, PubMed:10802669, PubMed:10839545, CC PubMed:10910365, PubMed:10973490, PubMed:11375976, PubMed:12086603, CC PubMed:15456891, PubMed:19965871, PubMed:21757780, PubMed:24534091, CC PubMed:26240375, PubMed:26774286, PubMed:30171069, PubMed:30612738, CC PubMed:30886146, PubMed:30952868, PubMed:38128537, PubMed:9733515, CC PubMed:9843217). May play a role in vesicle and/or protein transport. CC Could play a role in T-cell development, gonad and neurological CC function. Plays a role in replication-dependent histone mRNA CC degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in CC response to genotoxic stress prevents its MDM2-mediated ubiquitination CC and subsequent proteasome degradation (PubMed:19965871). Phosphorylates CC ATF2 which stimulates its function in DNA damage response CC (PubMed:15916964). Phosphorylates ERCC6 which is essential for its CC chromatin remodeling activity at DNA double-strand breaks CC (PubMed:29203878). Phosphorylates TTC5/STRAP at 'Ser-203' in the CC cytoplasm in response to DNA damage, which promotes TTC5/STRAP nuclear CC localization (PubMed:15448695). Also involved in pexophagy by mediating CC phosphorylation of PEX5: translocated to peroxisomes in response to CC reactive oxygen species (ROS), and catalyzes phosphorylation of PEX5, CC promoting PEX5 ubiquitination and induction of pexophagy CC (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245, CC ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545, CC ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, CC ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:21757780, ECO:0000269|PubMed:24534091, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:26344566, CC ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30612738, CC ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515, CC ECO:0000269|PubMed:9843217}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:26240375, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30886146, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:21757780, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:9843217, ECO:0000305|PubMed:15448695}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:24534091, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:8988033, CC ECO:0000269|PubMed:9843217}; CC -!- ACTIVITY REGULATION: Activated by the MRN (MRE11-RAD50-NBS1) complex in CC response to DNA double strand breaks (DSBs), which recruits ATM to DSBs CC and promotes its activation (PubMed:15064416, PubMed:15790808, CC PubMed:35076389). Inhibited by wortmannin (PubMed:9766667). CC {ECO:0000269|PubMed:15064416, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Homodimer (PubMed:12556884, PubMed:15790808, PubMed:28508083). CC Dimers or tetramers in inactive state (PubMed:12556884, CC PubMed:15790808, PubMed:28508083). On DNA damage, autophosphorylation CC dissociates ATM into monomers rendering them catalytically active CC (PubMed:12556884, PubMed:28508083). Binds p53/TP53, ABL1, BRCA1 and CC TERF1 (PubMed:15790808, PubMed:9168117, PubMed:9843217). Interacts with CC NBN (via FxF/Y motif) (PubMed:35076389). Part of the BRCA1-associated CC genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, CC MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). Interacts with RAD17; DNA damage promotes the CC association (PubMed:11418864). Interacts with EEF1E1; the interaction, CC induced on DNA damage, up-regulates TP53 (PubMed:15680327). Interacts CC with KAT8, NABP2, ATMIN and CEP164 (PubMed:15923642, PubMed:17525732, CC PubMed:18283122, PubMed:18449195). Interacts with AP2B1 and AP3B2; the CC interaction occurs in cytoplasmic vesicles (By similarity). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with DDX1 (PubMed:18710941). Interacts with CC BRAT1 (PubMed:22977523). Interacts with CYREN (via XLF motif) (By CC similarity). Interacts (via microbody targeting signal) with PEX5; CC promoting translocation to peroxisomes in response to reactive oxygen CC species (ROS) (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10783165, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15680327, CC ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:15923642, CC ECO:0000269|PubMed:17525732, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:18449195, ECO:0000269|PubMed:18710941, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9168117, CC ECO:0000269|PubMed:9843217}. CC -!- INTERACTION: CC Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428; CC Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543; CC Q13315; P31749: AKT1; NbExp=5; IntAct=EBI-495465, EBI-296087; CC Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202; CC Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195; CC Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340; CC Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477; CC Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279; CC Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542; CC Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644; CC Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336; CC Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228; CC Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844; CC Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374; CC Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132; CC Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083; CC Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674; CC Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997; CC Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018; CC Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637; CC Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540; CC Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680; CC Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle CC {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:Q62388}. Peroxisome matrix CC {ECO:0000269|PubMed:26344566}. Note=Primarily nuclear (PubMed:9050866, CC PubMed:9150358). Found also in endocytic vesicles in association with CC beta-adaptin (PubMed:9707615). Translocated to peroxisomes in response CC to reactive oxygen species (ROS) by PEX5 (PubMed:26344566). CC {ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9707615}. CC -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver, CC lung, placenta, brain, heart, spleen, thymus, testis, ovary, small CC intestine, colon and leukocytes. CC -!- INDUCTION: By ionizing radiation. CC -!- DOMAIN: The FATC domain is required for interaction with KAT5. CC {ECO:0000269|PubMed:16141325}. CC -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306). CC Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA CC damage-mediated activation of the kinase (PubMed:12556884, CC PubMed:15790808, PubMed:16141325, PubMed:16858402, PubMed:21144835, CC PubMed:27664052). During the late stages of DNA damage response, CC dephosphorylated following deacetylation by SIRT7, leading to ATM CC deactivation (PubMed:30944854). {ECO:0000269|PubMed:12409306, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:30944854}. CC -!- PTM: Acetylation, on DNA damage, is required for activation of the CC kinase activity, dimer-monomer transition, and subsequent CC autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325, CC PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro CC by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late CC stages of DNA damage response, promoting ATM dephosphorylation and CC subsequent deactivation (PubMed:30944854). CC {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}. CC -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive CC disorder characterized by progressive cerebellar ataxia, dilation of CC the blood vessels in the conjunctiva and eyeballs, immunodeficiency, CC growth retardation and sexual immaturity. Patients have a strong CC predisposition to cancer; about 30% of patients develop tumors, CC particularly lymphomas and leukemias. Cells from affected individuals CC are highly sensitive to damage by ionizing radiation and resistant to CC inhibition of DNA synthesis following irradiation. CC {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, CC ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, CC ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, CC ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, CC ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, CC ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, CC ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, CC ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, CC ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, CC ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, CC ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute CC lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). CC TPLL is characterized by a high white blood cell count, with a CC predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, CC skin lesions and serous effusion. The clinical course is highly CC aggressive, with poor response to chemotherapy and short survival time. CC TPLL occurs both in adults as a sporadic disease and in younger AT CC patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, CC ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, CC ECO:0000269|PubMed:9573030}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin CC lymphomas (BNHL), including mantle cell lymphoma (MCL). CC {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, CC ECO:0000269|PubMed:9288106}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic CC lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in CC the elderly. It is characterized by the accumulation of mature CD5+ B- CC lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. CC {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, CC ECO:0000269|PubMed:9892178}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/123/ATM"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry; CC URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33841; AAC50289.1; -; mRNA. DR EMBL; U55757; AAB38309.1; -; Genomic_DNA. DR EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55757; AAB38310.1; -; Genomic_DNA. DR EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U82828; AAB65827.1; -; Genomic_DNA. DR EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA. DR EMBL; X91196; CAA62603.1; -; mRNA. DR EMBL; U67092; AAC51298.1; -; Genomic_DNA. DR EMBL; AY220758; AAO26044.1; -; Genomic_DNA. DR EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA. DR EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA. DR CCDS; CCDS31669.1; -. DR PIR; A43100; A43100. DR RefSeq; NP_000042.3; NM_000051.3. DR RefSeq; NP_001338763.1; NM_001351834.2. DR RefSeq; XP_005271619.2; XM_005271562.6. DR RefSeq; XP_006718906.1; XM_006718843.5. DR RefSeq; XP_006718908.1; XM_006718845.1. DR RefSeq; XP_011541142.1; XM_011542840.4. DR RefSeq; XP_016873279.1; XM_017017790.3. DR RefSeq; XP_047282931.1; XM_047426975.1. DR RefSeq; XP_047282932.1; XM_047426976.1. DR RefSeq; XP_054224846.1; XM_054368871.1. DR RefSeq; XP_054224847.1; XM_054368872.1. DR RefSeq; XP_054224848.1; XM_054368873.1. DR RefSeq; XP_054224849.1; XM_054368874.1. DR RefSeq; XP_054224850.1; XM_054368875.1. DR RefSeq; XP_054224851.1; XM_054368876.1. DR PDB; 5NP0; EM; 5.70 A; A/B=1-3056. DR PDB; 5NP1; EM; 5.70 A; A=1-3056. DR PDB; 6HKA; NMR; -; A=3024-3056. DR PDB; 6K9K; EM; 7.82 A; A=1-3056. DR PDB; 6K9L; EM; 4.27 A; A/B=1-3056. DR PDB; 7NI4; EM; 3.00 A; A/B=1-3056. DR PDB; 7NI5; EM; 2.78 A; A/B=1-3056. DR PDB; 7NI6; EM; 2.80 A; A/B=1-3056. DR PDB; 7SIC; EM; 2.51 A; A/B=1-3056. DR PDB; 7SID; EM; 2.53 A; A/C=1-3056. DR PDB; 8OXM; EM; 3.30 A; A/B=1-3056. DR PDB; 8OXO; EM; 3.00 A; A/B=1-3056. DR PDB; 8OXP; EM; 2.60 A; A/B=1-3056. DR PDB; 8OXQ; EM; 2.50 A; A/B=1-3056. DR PDBsum; 5NP0; -. DR PDBsum; 5NP1; -. DR PDBsum; 6HKA; -. DR PDBsum; 6K9K; -. DR PDBsum; 6K9L; -. DR PDBsum; 7NI4; -. DR PDBsum; 7NI5; -. DR PDBsum; 7NI6; -. DR PDBsum; 7SIC; -. DR PDBsum; 7SID; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8OXP; -. DR PDBsum; 8OXQ; -. DR EMDB; EMD-12350; -. DR EMDB; EMD-12351; -. DR EMDB; EMD-12352; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-17267; -. DR EMDB; EMD-17268; -. DR EMDB; EMD-25140; -. DR EMDB; EMD-25141; -. DR EMDB; EMD-3669; -. DR EMDB; EMD-3672; -. DR EMDB; EMD-9949; -. DR EMDB; EMD-9950; -. DR SMR; Q13315; -. DR BioGRID; 106962; 345. DR CORUM; Q13315; -. DR DIP; DIP-182N; -. DR FunCoup; Q13315; 3527. DR IntAct; Q13315; 175. DR MINT; Q13315; -. DR STRING; 9606.ENSP00000278616; -. DR BindingDB; Q13315; -. DR ChEMBL; CHEMBL3797; -. DR DrugBank; DB02289; 2-Aminopropanedioic Acid. DR DrugBank; DB00201; Caffeine. DR GuidetoPHARMACOLOGY; 1934; -. DR GlyCosmos; Q13315; 4 sites, 2 glycans. DR GlyGen; Q13315; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q13315; -. DR PhosphoSitePlus; Q13315; -. DR BioMuta; ATM; -. DR DMDM; 317373479; -. DR CPTAC; CPTAC-2874; -. DR CPTAC; CPTAC-2875; -. DR CPTAC; CPTAC-2876; -. DR CPTAC; CPTAC-3210; -. DR CPTAC; CPTAC-3211; -. DR CPTAC; CPTAC-3212; -. DR CPTAC; CPTAC-3213; -. DR CPTAC; CPTAC-5976; -. DR CPTAC; CPTAC-5977; -. DR CPTAC; CPTAC-5978; -. DR CPTAC; CPTAC-5979; -. DR CPTAC; CPTAC-912; -. DR CPTAC; CPTAC-913; -. DR jPOST; Q13315; -. DR MassIVE; Q13315; -. DR PaxDb; 9606-ENSP00000278616; -. DR PeptideAtlas; Q13315; -. DR ProteomicsDB; 59303; -. DR Pumba; Q13315; -. DR Antibodypedia; 3596; 1462 antibodies from 49 providers. DR CPTC; Q13315; 4 antibodies. DR DNASU; 472; -. DR Ensembl; ENST00000278616.10; ENSP00000278616.4; ENSG00000149311.23. DR Ensembl; ENST00000452508.7; ENSP00000388058.2; ENSG00000149311.23. DR Ensembl; ENST00000601453.3; ENSP00000469471.2; ENSG00000149311.23. DR Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.23. DR Ensembl; ENST00000713844.1; ENSP00000519149.1; ENSG00000149311.23. DR GeneID; 472; -. DR KEGG; hsa:472; -. DR MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3. DR UCSC; uc001pkb.1; human. DR AGR; HGNC:795; -. DR CIViC; 472; 50 evidence items across 37 molecular profiles. DR ClinPGx; PA61; -. DR CTD; 472; -. DR DisGeNET; 472; -. DR GeneCards; ATM; -. DR GeneReviews; ATM; -. DR HGNC; HGNC:795; ATM. DR HPA; ENSG00000149311; Low tissue specificity. DR MalaCards; ATM; -. DR MIM; 208900; phenotype. DR MIM; 607585; gene. DR OpenTargets; ENSG00000149311; -. DR Orphanet; 100; Ataxia-telangiectasia. DR Orphanet; 370109; Ataxia-telangiectasia variant. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 52416; Mantle cell lymphoma. DR VEuPathDB; HostDB:ENSG00000149311; -. DR eggNOG; KOG0892; Eukaryota. DR GeneTree; ENSGT00670000098061; -. DR HOGENOM; CLU_000178_3_1_1; -. DR InParanoid; Q13315; -. DR OMA; SEVYMKW; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13315; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q13315; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13315; -. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-912446; Meiotic recombination. DR Reactome; R-HSA-9664873; Pexophagy. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q13315; -. DR SIGNOR; Q13315; -. DR Agora; ENSG00000149311; -. DR BioGRID-ORCS; 472; 54 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR ChiTaRS; ATM; human. DR GeneWiki; Ataxia_telangiectasia_mutated; -. DR GenomeRNAi; 472; -. DR Pharos; Q13315; Tchem. DR PRO; PR:Q13315; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q13315; protein. DR Bgee; ENSG00000149311; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q13315; baseline and differential. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:1990391; C:DNA repair complex; IDA:MGI. DR GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL. DR GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:CAFA. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000729; P:DNA double-strand break processing; IDA:UniProt. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IMP:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB. DR GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI. DR GO; GO:0000425; P:pexophagy; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL. DR GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProt. DR GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome. DR GO; GO:2000785; P:regulation of autophagosome assembly; IC:UniProt. DR GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl. DR CDD; cd05171; PIKKc_ATM; 1. DR FunFam; 1.10.1070.11:FF:000011; Serine-protein kinase ATM; 1. DR FunFam; 3.30.1010.10:FF:000015; Serine-protein kinase ATM; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR038980; ATM_plant. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR044107; PIKKc_ATM. DR InterPro; IPR021668; TAN. DR PANTHER; PTHR37079; SERINE/THREONINE-PROTEIN KINASE ATM; 1. DR PANTHER; PTHR37079:SF4; SERINE_THREONINE-PROTEIN KINASE ATM; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF11640; TAN; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01342; TAN; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage; KW DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus; KW Peroxisome; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3056 FT /note="Serine-protein kinase ATM" FT /id="PRO_0000088840" FT DOMAIN 1940..2566 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2686..2998 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3024..3056 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1373..1382 FT /note="Interaction with ABL1" FT /evidence="ECO:0000269|PubMed:9168117" FT REGION 2692..2698 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2867..2875 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2887..2911 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 3046..3048 FT /note="Microbody targeting signal; atypical" FT /evidence="ECO:0000269|PubMed:26344566" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 367 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1893 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1981 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16141325, FT ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:30944854, ECO:0007744|PubMed:17525332" FT MOD_RES 1983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 2996 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 3016 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17923702, FT ECO:0000269|PubMed:30944854" FT VARIANT 23 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587779858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041545" FT VARIANT 35..3056 FT /note="Missing (in AT; dbSNP:rs55861249)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085060" FT VARIANT 45 FT /note="R -> W (found in a patient with breast cancer; FT uncertain significance; dbSNP:rs3218684)" FT /evidence="ECO:0000269|PubMed:11897822" FT /id="VAR_056678" FT VARIANT 49 FT /note="S -> C (in dbSNP:rs1800054)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333" FT /id="VAR_010798" FT VARIANT 68 FT /note="I -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083373" FT VARIANT 126 FT /note="D -> E (in dbSNP:rs2234997)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010799" FT VARIANT 140 FT /note="D -> H (in dbSNP:rs55633650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041546" FT VARIANT 182 FT /note="V -> L (in dbSNP:rs3218707)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010800" FT VARIANT 224 FT /note="K -> E (in AT; uncertain significance; FT dbSNP:rs145053092)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010801" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs56123940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041547" FT VARIANT 292 FT /note="P -> L (in AT; decrease phosphorylation of target FT proteins; increases protein abundance; dbSNP:rs747727055)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314" FT /id="VAR_010802" FT VARIANT 323 FT /note="I -> V (in AT; loss of protein expression; FT dbSNP:rs587781511)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:27664052" FT /id="VAR_010803" FT VARIANT 332 FT /note="Y -> C (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9892178" FT /id="VAR_010804" FT VARIANT 333 FT /note="S -> F (in dbSNP:rs28904919)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041548" FT VARIANT 337 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs138398778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041549" FT VARIANT 337 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs202160435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041550" FT VARIANT 341 FT /note="V -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083374" FT VARIANT 350 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs371713984)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010805" FT VARIANT 352 FT /note="I -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs369203092)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010806" FT VARIANT 374..3056 FT /note="Missing (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085061" FT VARIANT 393..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085062" FT VARIANT 410 FT /note="V -> A (in dbSNP:rs56128736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041551" FT VARIANT 504 FT /note="N -> S (in dbSNP:rs56365018)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041552" FT VARIANT 514 FT /note="G -> D (in dbSNP:rs2235000)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010807" FT VARIANT 540 FT /note="C -> Y (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041553" FT VARIANT 546 FT /note="L -> V (no effect on phosphorylation of target FT proteins; dbSNP:rs2227924)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188" FT /id="VAR_041554" FT VARIANT 570 FT /note="F -> S (in AT; dbSNP:rs777301065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010808" FT VARIANT 582 FT /note="F -> L (in dbSNP:rs2235006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041555" FT VARIANT 597 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083375" FT VARIANT 661 FT /note="D -> A (found in a patient with familial breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28202063" FT /id="VAR_083376" FT VARIANT 699 FT /note="E -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083377" FT VARIANT 705..707 FT /note="YSS -> FIP (in AT)" FT /evidence="ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869" FT /id="VAR_010809" FT VARIANT 707 FT /note="S -> P (in dbSNP:rs4986761)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063" FT /id="VAR_010810" FT VARIANT 759 FT /note="S -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083378" FT VARIANT 761 FT /note="T -> S (in dbSNP:rs2235011)" FT /id="VAR_056679" FT VARIANT 768 FT /note="N -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010812" FT VARIANT 785 FT /note="R -> C (in AT; dbSNP:rs587778065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010813" FT VARIANT 788 FT /note="S -> R (in dbSNP:rs641252)" FT /id="VAR_056680" FT VARIANT 813 FT /note="N -> S (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083379" FT VARIANT 814 FT /note="D -> E (in dbSNP:rs3218695)" FT /id="VAR_056681" FT VARIANT 848 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254046)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041556" FT VARIANT 858 FT /note="F -> L (in dbSNP:rs1800056)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010814" FT VARIANT 869 FT /note="A -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083380" FT VARIANT 872 FT /note="P -> S (in dbSNP:rs3218673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041557" FT VARIANT 897 FT /note="F -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083381" FT VARIANT 924 FT /note="R -> W (found in a patient with familial breast FT cancer; uncertain significance; dbSNP:rs55723361)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063" FT /id="VAR_041558" FT VARIANT 935 FT /note="T -> A (in dbSNP:rs35813135)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041559" FT VARIANT 935 FT /note="T -> M (in dbSNP:rs3218708)" FT /id="VAR_056682" FT VARIANT 942 FT /note="L -> F (in dbSNP:rs3218688)" FT /id="VAR_056683" FT VARIANT 950 FT /note="L -> R (in AT; dbSNP:rs786203054)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010815" FT VARIANT 1001 FT /note="L -> Q (in AT; risk factor for T-cell acute FT lymphoblastic leukemia)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010816" FT VARIANT 1040 FT /note="M -> V (in dbSNP:rs3092857)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010817" FT VARIANT 1046 FT /note="L -> P (in AT; loss of protein expression; FT dbSNP:rs568461905)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077237" FT VARIANT 1054 FT /note="P -> R (in AT; likely benign; no effect on FT phosphorylation of target proteins; dbSNP:rs1800057)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, FT ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333" FT /id="VAR_010818" FT VARIANT 1082 FT /note="H -> L (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010819" FT VARIANT 1091 FT /note="E -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010820" FT VARIANT 1171..3056 FT /note="Missing (in AT; uncertain significance; increases FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085063" FT VARIANT 1179 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041560" FT VARIANT 1255 FT /note="L -> V (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083382" FT VARIANT 1313 FT /note="E -> Q (in dbSNP:rs3092841)" FT /id="VAR_056684" FT VARIANT 1321 FT /note="M -> I (in dbSNP:rs35184530)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041561" FT VARIANT 1322 FT /note="L -> I (no effect on phosphorylation of target FT proteins; dbSNP:rs144535256)" FT /evidence="ECO:0000269|PubMed:19431188" FT /id="VAR_080300" FT VARIANT 1380 FT /note="H -> Y (in dbSNP:rs3092856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041562" FT VARIANT 1382 FT /note="P -> S (in dbSNP:rs55859590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041563" FT VARIANT 1407 FT /note="I -> T (in T-prolymphocytic leukemia; FT dbSNP:rs1234250980)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010821" FT VARIANT 1420 FT /note="L -> F (in dbSNP:rs1800058)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579" FT /id="VAR_010822" FT VARIANT 1420 FT /note="L -> P (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010823" FT VARIANT 1427 FT /note="A -> T (in dbSNP:rs2229021)" FT /id="VAR_056685" FT VARIANT 1463 FT /note="F -> S (found in B-cell non-Hodgkin lymphoma; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010825" FT VARIANT 1465 FT /note="L -> P (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs730881391)" FT /evidence="ECO:0000269|PubMed:10234507, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010826" FT VARIANT 1466..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs730881369)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085064" FT VARIANT 1469 FT /note="I -> M (in a renal papillary cancer sample; somatic FT mutation; dbSNP:rs775047783)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041564" FT VARIANT 1474 FT /note="H -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083383" FT VARIANT 1475 FT /note="Y -> C (in dbSNP:rs34640941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041565" FT VARIANT 1488 FT /note="L -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083384" FT VARIANT 1541 FT /note="L -> F (in dbSNP:rs3092849)" FT /id="VAR_056686" FT VARIANT 1566 FT /note="P -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010827" FT VARIANT 1570 FT /note="V -> A (in dbSNP:rs140856217)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010828" FT VARIANT 1650 FT /note="N -> S (in dbSNP:rs55870064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041566" FT VARIANT 1682 FT /note="D -> H (in T-prolymphocytic leukemia; FT dbSNP:rs121434217)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010829" FT VARIANT 1691 FT /note="S -> R (in AT, B-cell chronic lymphocytic leukemia FT and familial cancer patients; no effect on phosphorylation FT of target proteins; dbSNP:rs1800059)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010830" FT VARIANT 1729 FT /note="V -> L (in dbSNP:rs3092907)" FT /id="VAR_056687" FT VARIANT 1730..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs764389018)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085065" FT VARIANT 1739 FT /note="N -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041567" FT VARIANT 1743 FT /note="T -> I (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs587779844)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010831" FT VARIANT 1812..1813 FT /note="AF -> V (in AT)" FT /evidence="ECO:0000269|PubMed:9497252" FT /id="VAR_010832" FT VARIANT 1839..3056 FT /note="Missing (in AT; uncertain significance; reduces FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085066" FT VARIANT 1853 FT /note="D -> N (in dbSNP:rs1801516)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333" FT /id="VAR_010833" FT VARIANT 1853 FT /note="D -> V (might contribute to B-cell chronic FT lymphocytic leukemia; dbSNP:rs1801673)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010834" FT VARIANT 1910 FT /note="L -> H (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010835" FT VARIANT 1913 FT /note="V -> G (in AT; dbSNP:rs1060501688)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010836" FT VARIANT 1916 FT /note="M -> I (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041568" FT VARIANT 1945 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041569" FT VARIANT 1953 FT /note="T -> R (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010837" FT VARIANT 1961 FT /note="Y -> C (found in a patient with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; decreased FT phosphorylation of target proteins; dbSNP:rs56399311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808" FT /id="VAR_041570" FT VARIANT 1983 FT /note="S -> N (in dbSNP:rs659243)" FT /evidence="ECO:0000269|PubMed:16554811" FT /id="VAR_041571" FT VARIANT 1991 FT /note="E -> D (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs587782274)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041572" FT VARIANT 2016 FT /note="D -> G (in AT; uncertain significance; FT dbSNP:rs587781302)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010838" FT VARIANT 2023 FT /note="G -> R (in AT; loss of protein expression; FT dbSNP:rs11212587)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077238" FT VARIANT 2034 FT /note="R -> Q (in dbSNP:rs3218670)" FT /id="VAR_056688" FT VARIANT 2063 FT /note="G -> E (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs866290641)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010839" FT VARIANT 2067 FT /note="A -> D (in AT; dbSNP:rs397514577)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010840" FT VARIANT 2068 FT /note="L -> S (in AT; decreased protein abundance; loss of FT DNA damage induced protein autophosphorylation; FT dbSNP:rs1555114558)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077239" FT VARIANT 2079 FT /note="V -> I (in dbSNP:rs1800060)" FT /evidence="ECO:0000269|PubMed:8665503" FT /id="VAR_010841" FT VARIANT 2080 FT /note="Y -> D (in AT; loss of DNA damage induced protein FT autophosphorylation; dbSNP:rs1064795467)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077240" FT VARIANT 2105 FT /note="R -> T (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083385" FT VARIANT 2139 FT /note="E -> G (in T-prolymphocytic leukemia; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:9488043" FT /id="VAR_010842" FT VARIANT 2164 FT /note="E -> K (in T-prolymphocytic leukemia; FT dbSNP:rs1317619286)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010843" FT VARIANT 2218 FT /note="S -> C (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010844" FT VARIANT 2224..2227 FT /note="MALR -> IS (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010845" FT VARIANT 2227 FT /note="R -> C (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs564652222)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010846" FT VARIANT 2246..2252 FT /note="CIKDILT -> H (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10873394" FT /id="VAR_010847" FT VARIANT 2274 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT uncertain significance; no effect on phosphorylation of FT target proteins; dbSNP:rs567060474)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010848" FT VARIANT 2287 FT /note="G -> A (found in a patient with familial pancreatic FT cancer; uncertain significance; dbSNP:rs1800061)" FT /evidence="ECO:0000269|PubMed:28726808, FT ECO:0000269|PubMed:8665503" FT /id="VAR_010849" FT VARIANT 2307 FT /note="L -> F (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; FT dbSNP:rs56009889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041573" FT VARIANT 2332 FT /note="L -> P (in dbSNP:rs4988111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041574" FT VARIANT 2335 FT /note="T -> K (in dbSNP:rs3092831)" FT /id="VAR_056689" FT VARIANT 2356 FT /note="I -> F (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs876658517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041575" FT VARIANT 2396 FT /note="T -> S (found in a patient with T-prolymphocytic FT leukemia; uncertain significance; also found in a patient FT with early-onset breast cancer; uncertain significance; FT dbSNP:rs370559102)" FT /evidence="ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010850" FT VARIANT 2408 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs730881315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041576" FT VARIANT 2418 FT /note="K -> KK (in mantle cell lymphoma)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010851" FT VARIANT 2420 FT /note="A -> P (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010852" FT VARIANT 2423 FT /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010853" FT VARIANT 2424 FT /note="V -> G (in AT; also found in B-cell chronic FT lymphocytic leukemia and T-prolymphocytic leukemia; risk FT factor for breast cancer; decreased phosphorylation of FT target proteins; dbSNP:rs28904921)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010854" FT VARIANT 2427..2428 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia; lack of phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010855" FT VARIANT 2438 FT /note="T -> I (in dbSNP:rs147604227)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:8808599" FT /id="VAR_010856" FT VARIANT 2442 FT /note="Q -> P (in T-prolymphocytic leukemia; also in a lung FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010857" FT VARIANT 2443 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587782310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041577" FT VARIANT 2464 FT /note="C -> R (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a small cell FT lung cancer sample; uncertain significance; FT dbSNP:rs55801750)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041578" FT VARIANT 2470 FT /note="Y -> D (in AT; dbSNP:rs876659365)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010858" FT VARIANT 2486 FT /note="R -> G (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9573030" FT /id="VAR_010859" FT VARIANT 2491 FT /note="W -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010860" FT VARIANT 2492 FT /note="L -> R (in dbSNP:rs56399857)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041579" FT VARIANT 2524 FT /note="A -> P (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083386" FT VARIANT 2531 FT /note="M -> T (found in patients with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083387" FT VARIANT 2546..2548 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia and T-cell acute lymphoblastic leukemia; lack of FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, FT ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358, FT ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314" FT /id="VAR_010861" FT VARIANT 2547..2549 FT /note="Missing (in AT; dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085067" FT VARIANT 2554 FT /note="H -> D (in AT; lack of phosphorylation of target FT proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010862" FT VARIANT 2570 FT /note="E -> G (in dbSNP:rs28904920)" FT /id="VAR_056690" FT VARIANT 2625..2626 FT /note="DA -> EP (in AT; dbSNP:rs267606668)" FT /evidence="ECO:0000269|PubMed:9521587" FT /id="VAR_010864" FT VARIANT 2625 FT /note="D -> E (in AT; uncertain significance; FT dbSNP:rs1196903858)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085068" FT VARIANT 2625 FT /note="D -> Q (in AT; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010863" FT VARIANT 2626 FT /note="A -> P (in AT; uncertain significance; FT dbSNP:rs267606669)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085069" FT VARIANT 2627 FT /note="Y -> H (in AT; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077241" FT VARIANT 2640 FT /note="T -> I (in dbSNP:rs4988125)" FT /id="VAR_056691" FT VARIANT 2656 FT /note="L -> P (in AT; dbSNP:rs121434218)" FT /evidence="ECO:0000269|PubMed:9450874" FT /id="VAR_010865" FT VARIANT 2662 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010866" FT VARIANT 2664 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs1471563800)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085070" FT VARIANT 2666 FT /note="T -> A (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs745775382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041580" FT VARIANT 2668 FT /note="E -> G (in AT; uncertain significance; no effect on FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010868" FT VARIANT 2695 FT /note="G -> A (in T-prolymphocytic leukemia and B-cell FT chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010869" FT VARIANT 2702 FT /note="I -> R (in AT; dbSNP:rs876659735)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010870" FT VARIANT 2709 FT /note="G -> S (in dbSNP:rs3218680)" FT /id="VAR_056692" FT VARIANT 2719 FT /note="R -> H (found in a patient with early-onset breast FT cancer; uncertain significance; dbSNP:rs55982963)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426" FT /id="VAR_041581" FT VARIANT 2722 FT /note="L -> R (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010871" FT VARIANT 2725 FT /note="D -> G (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs1555128314)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010872" FT VARIANT 2725 FT /note="D -> V (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010873" FT VARIANT 2726 FT /note="A -> V (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010874" FT VARIANT 2732 FT /note="F -> L (in T-prolymphocytic leukemia; FT dbSNP:rs876659619)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010875" FT VARIANT 2765 FT /note="G -> S (may contribute to breast cancer; lack of FT phosphorylation of target proteins; dbSNP:rs748634900)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010876" FT VARIANT 2810 FT /note="K -> Q (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083388" FT VARIANT 2810 FT /note="Missing (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010877" FT VARIANT 2824 FT /note="C -> Y (in AT; dbSNP:rs876660927)" FT /evidence="ECO:0000269|PubMed:9150358" FT /id="VAR_010878" FT VARIANT 2827 FT /note="F -> C (in AT; mild; decreased phosphorylation of FT target proteins; dbSNP:rs121434216)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314" FT /id="VAR_010879" FT VARIANT 2829 FT /note="P -> L (in AT; dbSNP:rs938431501)" FT /evidence="ECO:0000269|PubMed:9711876" FT /id="VAR_010880" FT VARIANT 2832 FT /note="R -> C (in AT; also found in B-cell non-Hodgkin FT lymphoma; increases protein abundance; dbSNP:rs587779872)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9443866" FT /id="VAR_010881" FT VARIANT 2832 FT /note="R -> H (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083389" FT VARIANT 2834 FT /note="F -> L (in AT; decreased protein abundance)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077242" FT VARIANT 2842 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041582" FT VARIANT 2849..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587778080)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085071" FT VARIANT 2849 FT /note="R -> P (in AT; dbSNP:rs587782202)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010882" FT VARIANT 2855..2856 FT /note="SV -> RI (in AT; lack of phosphorylation of target FT proteins; dbSNP:rs587781353)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9872980" FT /id="VAR_010884" FT VARIANT 2855 FT /note="S -> R (in AT; uncertain significance; FT dbSNP:rs780905851)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010883" FT VARIANT 2860 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8845835" FT /id="VAR_010885" FT VARIANT 2867 FT /note="G -> R (in AT)" FT /evidence="ECO:0000269|PubMed:8698354, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010886" FT VARIANT 2870 FT /note="D -> N (in dbSNP:rs55798854)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041583" FT VARIANT 2871..2872 FT /note="RH -> S (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010887" FT VARIANT 2890 FT /note="L -> V (in T-prolymphocytic leukemia; FT dbSNP:rs587779874)" FT /evidence="ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9488043" FT /id="VAR_010888" FT VARIANT 2904 FT /note="E -> G (in AT; dbSNP:rs786202826)" FT /evidence="ECO:0000269|PubMed:8845835" FT /id="VAR_010889" FT VARIANT 2909 FT /note="R -> G (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010890" FT VARIANT 2974 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083390" FT VARIANT 3003 FT /note="N -> D (in AT; decreased protein abundance; FT dbSNP:rs1137889)" FT /evidence="ECO:0000269|PubMed:27664052, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, FT ECO:0000269|PubMed:8665503" FT /id="VAR_077243" FT VARIANT 3006 FT /note="A -> P (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs876658767)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010892" FT VARIANT 3008 FT /note="R -> C (in AT; also found in T-prolymphocytic FT leukemia and mantle cell lymphoma; lack of phosphorylation FT of target proteins; dbSNP:rs587782292)" FT /evidence="ECO:0000269|PubMed:10706620, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, FT ECO:0000269|PubMed:9872980" FT /id="VAR_010893" FT VARIANT 3008 FT /note="R -> H (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs587781894)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010894" FT VARIANT 3018 FT /note="K -> N (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010895" FT VARIANT 3029 FT /note="G -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083391" FT VARIANT 3056 FT /note="V -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083392" FT MUTAGEN 367 FT /note="S->A: Loss of IR-induced S-367 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-1893 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1807 FT /note="K->E: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1893 FT /note="S->A: Loss of IR-induced S-1893 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1941 FT /note="V->L: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1981 FT /note="S->A: Loss of IR-induced S-1981 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1893 FT autophosphorylation. No dimer disruption." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 1981 FT /note="S->D,E: Disrupts the dimer." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 2019 FT /note="Y->C: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2039 FT /note="E->K: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2338 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2394 FT /note="S->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2452 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2685 FT /note="S->T: No effect on phosphorylation of target FT proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2699 FT /note="P->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2708 FT /note="D->N: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2730 FT /note="Q->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2870 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 2875 FT /note="N->K: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 3016 FT /note="K->Q: Mimics acetylation, preventing FT dephosphorylation and subsequent ATM deactivation during FT the late stage of DNA damage response." FT /evidence="ECO:0000269|PubMed:30944854" FT MUTAGEN 3016 FT /note="K->R: Loss of DNA damage-inducible acetylation. FT Retains constitutive kinase activity, but blocks DNA FT damage-induced kinase activation. Disrupts dimer and FT abolishes S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3018 FT /note="K->R: Retains DNA damage-inducible acetylation and FT S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3047 FT /note="R->Q: Abolished interaction with PEX5 and FT translocation to peroxisomes in response to reactive oxygen FT species (ROS)." FT /evidence="ECO:0000269|PubMed:26344566" FT CONFLICT 46 FT /note="H -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="N -> I (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="Y -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 488 FT /note="W -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="T -> A (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="K -> N (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="Q -> K (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="E -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="Q -> L (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1049 FT /note="L -> W (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1089 FT /note="A -> V (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT HELIX 6..17 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 20..33 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 36..41 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 57..73 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 90..108 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 109..112 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 117..129 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 135..148 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 149..151 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 153..158 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 161..176 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 183..201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 210..222 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 229..242 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 244..246 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 248..268 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 273..290 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 292..294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 298..300 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 306..323 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 343..356 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 410..422 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 424..426 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 429..431 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 432..442 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 445..447 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 452..466 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 474..492 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 493..496 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 498..500 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 501..513 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 521..524 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 525..527 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 528..530 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 536..548 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 572..580 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 605..607 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 608..615 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 617..619 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 620..628 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 684..704 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 713..731 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 732..735 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 737..741 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 744..765 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 771..786 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 792..794 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 795..806 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 809..822 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 892..911 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 920..930 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 941..953 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 957..959 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 973..979 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 980..982 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 984..994 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 995..997 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 998..1002 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1009..1030 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1031..1033 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1036..1052 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1060..1063 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1066..1069 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1070..1076 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1083..1092 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1093..1096 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1113..1132 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1144..1164 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1169..1181 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1187..1201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1206..1212 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1214..1223 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1227..1229 FT /evidence="ECO:0007829|PDB:7NI5" FT TURN 1231..1233 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1236..1238 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1244..1261 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1265..1275 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1279..1285 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1287..1294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1295..1297 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1299..1303 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1306..1322 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1325..1327 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1332..1338 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1340..1348 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1383..1396 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1397..1399 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1404..1408 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1413..1428 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1432..1450 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1453..1455 FT /evidence="ECO:0007829|PDB:7SID" FT TURN 1456..1460 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1461..1477 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1485..1508 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1513..1515 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1517..1527 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1528..1530 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1532..1545 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1546..1551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1553..1560 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1567..1569 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1572..1582 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1583..1585 FT /evidence="ECO:0007829|PDB:7NI6" FT HELIX 1590..1601 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1607..1610 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1611..1623 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1625..1634 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1635..1637 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 1639..1641 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1643..1658 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1661..1663 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1664..1677 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1694..1702 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1706..1721 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1723..1725 FT /evidence="ECO:0007829|PDB:8OXO" FT HELIX 1727..1742 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1744..1753 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1754..1756 FT /evidence="ECO:0007829|PDB:7NI4" FT HELIX 1759..1763 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1764..1767 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1785..1789 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1792..1795 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1802..1815 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1822..1825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1828..1831 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1835..1851 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1857..1874 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1903..1917 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1922..1924 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1927..1930 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1938..1947 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1951..1973 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1986..1997 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2001..2012 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2016..2019 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2023..2028 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 2029..2038 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2042..2051 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2057..2070 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2074..2087 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2093..2105 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2124..2136 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2140..2159 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2166..2168 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2170..2190 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2195..2210 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2211..2214 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2217..2236 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2240..2242 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2245..2264 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2269..2281 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2290..2301 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2305..2322 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2328..2348 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2353..2359 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2361..2370 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2377..2406 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2408..2421 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2437..2475 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2481..2483 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2484..2493 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2494..2496 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2498..2507 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2508..2510 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2513..2516 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2520..2525 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2529..2531 FT /evidence="ECO:0007829|PDB:7SID" FT STRAND 2533..2535 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2537..2551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2553..2564 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2565..2567 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2568..2572 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2593..2612 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2614..2632 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2637..2640 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2652..2655 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2659..2663 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2665..2667 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2673..2675 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2682..2686 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2688..2692 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2695..2697 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2700..2706 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2707..2709 FT /evidence="ECO:0007829|PDB:7NI4" FT STRAND 2711..2717 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2723..2740 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2743..2748 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2757..2759 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2761..2763 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2765..2768 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2773..2775 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2776..2780 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2783..2785 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2787..2791 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2798..2807 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2808..2810 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2813..2825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2833..2838 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2842..2866 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2873..2875 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2876..2879 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2880..2882 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2885..2887 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2894..2899 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2900..2902 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2906..2908 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2912..2916 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2920..2925 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2926..2940 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2942..2953 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2964..2970 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3002..3017 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 3020..3025 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3028..3040 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3042..3047 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3050..3052 FT /evidence="ECO:0007829|PDB:8OXQ" SQ SEQUENCE 3056 AA; 350687 MW; C0B4866E1E3199E2 CRC64; MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV // ID ATR_HUMAN Reviewed; 2644 AA. AC Q13535; Q59HB2; Q7KYL3; Q93051; Q9BXK4; DT 29-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 3. DT 28-JAN-2026, entry version 219. DE RecName: Full=Serine/threonine-protein kinase ATR; DE EC=2.7.11.1 {ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; DE AltName: Full=Ataxia telangiectasia and Rad3-related protein; DE AltName: Full=FRAP-related protein 1; GN Name=ATR {ECO:0000303|PubMed:14729973, ECO:0000312|HGNC:HGNC:882}; GN Synonyms=FRP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8978690; DOI=10.1002/j.1460-2075.1996.tb01054.x; RA Bentley N.J., Holtzman D.A., Flaggs G., Keegan K.S., DeMaggio A., RA Ford J.C., Hoekstra M., Carr A.M.; RT "The Schizosaccharomyces pombe rad3 checkpoint gene."; RL EMBO J. 15:6641-6651(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=T-cell; RX PubMed=8610130; DOI=10.1073/pnas.93.7.2850; RA Cimprich K.A., Shin T.B., Keith C.T., Schreiber S.L.; RT "cDNA cloning and gene mapping of a candidate human cell cycle checkpoint RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 93:2850-2855(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 433-526 (ISOFORMS 1 AND 2), AND RP TISSUE SPECIFICITY. RX PubMed=11470508; DOI=10.1016/s0378-1119(01)00543-1; RA Mannino J.L., Kim W.-J., Wernick M., Nguyen S.V., Braquet R., Adamson A.W., RA Den Z., Batzer M.A., Collins C.C., Brown K.D.; RT "Evidence for alternate splicing within the mRNA transcript encoding the RT DNA damage response kinase ATR."; RL Gene 272:35-43(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2155-2644 (ISOFORM 3). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=8843195; DOI=10.1101/gad.10.19.2423; RA Keegan K.S., Holtzman D.A., Plug A.W., Christenson E.R., Brainerd E.E., RA Flaggs G., Bentley N.J., Taylor E.M., Meyn M.S., Moss S.B., Carr A.M., RA Ashley T., Hoekstra M.F.; RT "The Atr and Atm protein kinases associate with different sites along RT meiotically pairing chromosomes."; RL Genes Dev. 10:2423-2437(1996). RN [6] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [7] RP FUNCTION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=9427750; DOI=10.1093/emboj/17.1.159; RA Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., RA Schreiber S.L., Friend S.H.; RT "Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA- RT damaging agents and defects in cell cycle checkpoints."; RL EMBO J. 17:159-169(1998). RN [8] RP FUNCTION, AND MUTAGENESIS OF ASP-2494. RX PubMed=9636169; DOI=10.1073/pnas.95.13.7445; RA Wright J.A., Keegan K.S., Herendeen D.R., Bentley N.J., Carr A.M., RA Hoekstra M.F., Concannon P.; RT "Protein kinase mutants of human ATR increase sensitivity to UV and RT ionizing radiation and abrogate cell cycle checkpoint control."; RL Proc. Natl. Acad. Sci. U.S.A. 95:7445-7450(1998). RN [9] RP INTERACTION WITH HDAC2, AND IDENTIFICATION IN A COMPLEX CONTAINING HDAC2 RP AND CHD4. RX PubMed=10545197; DOI=10.1021/bi991614n; RA Schmidt D.R., Schreiber S.L.; RT "Molecular association between ATR and two components of the nucleosome RT remodeling and deacetylating complex, HDAC2 and CHD4."; RL Biochemistry 38:14711-14717(1999). RN [10] RP FUNCTION, AND MUTAGENESIS OF LYS-2327 AND ASP-2475. RX PubMed=9925639; DOI=10.1101/gad.13.2.152; RA Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., RA Shieh S.-Y., Taya Y., Prives C., Abraham R.T.; RT "A role for ATR in the DNA damage-induced phosphorylation of p53."; RL Genes Dev. 13:152-157(1999). RN [11] RP COFACTOR, AND FUNCTION. RX PubMed=10608806; DOI=10.1074/jbc.274.53.37538; RA Kim S.-T., Lim D.-S., Canman C.E., Kastan M.B.; RT "Substrate specificities and identification of putative substrates of ATM RT kinase family members."; RL J. Biol. Chem. 274:37538-37543(1999). RN [12] RP FUNCTION, AUTOPHOSPHORYLATION, MUTAGENESIS OF ASP-2494, AND ACTIVITY RP REGULATION. RX PubMed=10597277; DOI=10.1038/sj.onc.1203077; RA Hall-Jackson C.A., Cross D.A.E., Morrice N., Smythe C.; RT "ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate RT specificity distinct from DNA-PK."; RL Oncogene 18:6707-6713(1999). RN [13] RP FUNCTION. RX PubMed=10859164; RA Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K., Luo G., RA Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J.; RT "Chk1 is an essential kinase that is regulated by Atr and required for the RT G(2)/M DNA damage checkpoint."; RL Genes Dev. 14:1448-1459(2000). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-2327. RX PubMed=11114888; DOI=10.1101/gad.851000; RA Tibbetts R.S., Cortez D., Brumbaugh K.M., Scully R., Livingston D., RA Elledge S.J., Abraham R.T.; RT "Functional interactions between BRCA1 and the checkpoint kinase ATR during RT genotoxic stress."; RL Genes Dev. 14:2989-3002(2000). RN [15] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11673449; DOI=10.1074/jbc.c100569200; RA Ward I.M., Chen J.; RT "Histone H2AX is phosphorylated in an ATR-dependent manner in response to RT replicational stress."; RL J. Biol. Chem. 276:47759-47762(2001). RN [16] RP FUNCTION. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ATRIP. RX PubMed=11721054; DOI=10.1126/science.1065521; RA Cortez D., Guntuku S., Qin J., Elledge S.J.; RT "ATR and ATRIP: partners in checkpoint signaling."; RL Science 294:1713-1716(2001). RN [18] RP FUNCTION. RX PubMed=12526805; DOI=10.1016/s0092-8674(02)01113-3; RA Casper A.M., Nghiem P., Arlt M.F., Glover T.W.; RT "ATR regulates fragile site stability."; RL Cell 111:779-789(2002). RN [19] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11865061; DOI=10.1128/mcb.22.6.1834-1843.2002; RA Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J.; RT "Hypoxia links ATR and p53 through replication arrest."; RL Mol. Cell. Biol. 22:1834-1843(2002). RN [20] RP DNA-BINDING, AND MUTAGENESIS OF LYS-2327. RX PubMed=12011431; DOI=10.1073/pnas.102167799; RA Uensal-Kacmaz K., Makhov A.M., Griffith J.D., Sancar A.; RT "Preferential binding of ATR protein to UV-damaged DNA."; RL Proc. Natl. Acad. Sci. U.S.A. 99:6673-6678(2002). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=12814551; DOI=10.1016/s0960-9822(03)00376-2; RA Barr S.M., Leung C.G., Chang E.E., Cimprich K.A.; RT "ATR kinase activity regulates the intranuclear translocation of ATR and RT RPA following ionizing radiation."; RL Curr. Biol. 13:1047-1051(2003). RN [22] RP INTERACTION WITH CLSPN. RX PubMed=12766152; DOI=10.1074/jbc.m301136200; RA Chini C.C.S., Chen J.; RT "Human claspin is required for replication checkpoint control."; RL J. Biol. Chem. 278:30057-30062(2003). RN [23] RP FUNCTION, INTERACTION WITH MSH2, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [24] RP FUNCTION, DNA-BINDING, AND IDENTIFICATION IN A COMPLEX WITH RPA AND ATRIP. RX PubMed=12791985; DOI=10.1126/science.1083430; RA Zou L., Elledge S.J.; RT "Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes."; RL Science 300:1542-1548(2003). RN [25] RP INTERACTION WITH BCR-ABL. RX PubMed=15050919; DOI=10.1016/s1535-6108(04)00056-x; RA Dierov J., Dierova R., Carroll M.; RT "BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S RT phase checkpoint."; RL Cancer Cell 5:275-285(2004). RN [26] RP FUNCTION. RX PubMed=14742437; DOI=10.1074/jbc.c300554200; RA Ward I.M., Minn K., Chen J.; RT "UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation RT requires replication stress."; RL J. Biol. Chem. 279:9677-9680(2004). RN [27] RP DNA-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=14871897; DOI=10.1074/jbc.m314212200; RA Dart D.A., Adams K.E., Akerman I., Lakin N.D.; RT "Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S- RT phase."; RL J. Biol. Chem. 279:16433-16440(2004). RN [28] RP FUNCTION. RX PubMed=15314022; DOI=10.1101/gad.1196104; RA Andreassen P.R., D'Andrea A.D., Taniguchi T.; RT "ATR couples FANCD2 monoubiquitination to the DNA-damage response."; RL Genes Dev. 18:1958-1963(2004). RN [29] RP FUNCTION. RX PubMed=15496423; DOI=10.1093/hmg/ddh335; RA Alderton G.K., Joenje H., Varon R., Borglum A.D., Jeggo P.A., RA O'Driscoll M.; RT "Seckel syndrome exhibits cellular features demonstrating defects in the RT ATR-signalling pathway."; RL Hum. Mol. Genet. 13:3127-3138(2004). RN [30] RP FUNCTION, SUBUNIT, IDENTIFICATION IN A COMPLEX WITH ATRIP AND RPA1, RP DNA-BINDING, AND ACTIVITY REGULATION. RX PubMed=14729973; DOI=10.1128/mcb.24.3.1292-1300.2003; RA Uensal-Kacmaz K., Sancar A.; RT "Quaternary structure of ATR and effects of ATRIP and replication protein A RT on its DNA binding and kinase activities."; RL Mol. Cell. Biol. 24:1292-1300(2004). RN [31] RP FUNCTION. RX PubMed=15210935; DOI=10.1073/pnas.0403410101; RA Cortez D., Glick G., Elledge S.J.; RT "Minichromosome maintenance proteins are direct targets of the ATM and ATR RT checkpoint kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10078-10083(2004). RN [32] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [33] RP INTERACTION WITH ATRIP. RX PubMed=15758953; DOI=10.1038/nature03442; RA Falck J., Coates J., Jackson S.P.; RT "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA RT damage."; RL Nature 434:605-611(2005). RN [34] RP ACTIVITY REGULATION. RX PubMed=16530042; DOI=10.1016/j.cell.2005.12.041; RA Kumagai A., Lee J., Yoo H.Y., Dunphy W.G.; RT "TopBP1 activates the ATR-ATRIP complex."; RL Cell 124:943-955(2006). RN [35] RP INTERACTION WITH CEP164, AND SUBCELLULAR LOCATION. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [36] RP INVOLVEMENT IN SCKL1. RX PubMed=12640452; DOI=10.1038/ng1129; RA O'Driscoll M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., Goodship J.A.; RT "A splicing mutation affecting expression of ataxia-telangiectasia and RT Rad3-related protein (ATR) results in Seckel syndrome."; RL Nat. Genet. 33:497-501(2003). RN [37] RP FUNCTION IN DNA DAMAGE RESPONSE, AUTOPHOSPHORYLATION, AND SUBCELLULAR RP LOCATION. RX PubMed=16260606; DOI=10.1128/mcb.25.22.9910-9919.2005; RA Zhang J., Bao S., Furumai R., Kucera K.S., Ali A., Dean N.M., Wang X.F.; RT "Protein phosphatase 5 is required for ATR-mediated checkpoint RT activation."; RL Mol. Cell. Biol. 25:9910-9919(2005). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428 AND THR-1989, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [41] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [42] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [43] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [44] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [45] RP FUNCTION IN DNA REPAIR, AND PHOSPHORYLATION AT SER-428. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [46] RP PHOSPHORYLATION AT THR-1989, AND MUTAGENESIS OF THR-1989. RX PubMed=21705319; DOI=10.1074/jbc.m111.248914; RA Nam E.A., Zhao R., Glick G.G., Bansbach C.E., Friedman D.B., Cortez D.; RT "Thr-1989 phosphorylation is a marker of active ataxia telangiectasia- RT mutated and Rad3-related (ATR) kinase."; RL J. Biol. Chem. 286:28707-28714(2011). RN [47] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-428; SER-435 AND RP THR-1989, ACTIVITY REGULATION, AND INTERACTION WITH ATRIP AND TOPBP1. RX PubMed=21777809; DOI=10.1016/j.molcel.2011.06.019; RA Liu S., Shiotani B., Lahiri M., Marechal A., Tse A., Leung C.C., RA Glover J.N., Yang X.H., Zou L.; RT "ATR autophosphorylation as a molecular switch for checkpoint activation."; RL Mol. Cell 43:192-202(2011). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435; SER-436 AND THR-1989, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23273981; DOI=10.1016/j.molcel.2012.11.020; RA Peterson S.E., Li Y., Wu-Baer F., Chait B.T., Baer R., Yan H., RA Gottesman M.E., Gautier J.; RT "Activation of DSB processing requires phosphorylation of CtIP by ATR."; RL Mol. Cell 49:657-667(2013). RN [51] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=25083873; DOI=10.1016/j.cell.2014.05.046; RA Kumar A., Mazzanti M., Mistrik M., Kosar M., Beznoussenko G.V., RA Mironov A.A., Garre M., Parazzoli D., Shivashankar G.V., Scita G., RA Bartek J., Foiani M.; RT "ATR mediates a checkpoint at the nuclear envelope in response to RT mechanical stress."; RL Cell 158:633-646(2014). RN [52] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND ACTIVITY RP REGULATION. RX PubMed=27723720; DOI=10.1038/ncb3415; RA Bass T.E., Luzwick J.W., Kavanaugh G., Carroll C., Dungrawala H., RA Glick G.G., Feldkamp M.D., Putney R., Chazin W.J., Cortez D.; RT "ETAA1 acts at stalled replication forks to maintain genome integrity."; RL Nat. Cell Biol. 18:1185-1195(2016). RN [53] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=27723717; DOI=10.1038/ncb3422; RA Haahr P., Hoffmann S., Tollenaere M.A., Ho T., Toledo L.I., Mann M., RA Bekker-Jensen S., Raeschle M., Mailand N.; RT "Activation of the ATR kinase by the RPA-binding protein ETAA1."; RL Nat. Cell Biol. 18:1196-1207(2016). RN [54] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=30139873; DOI=10.1126/science.aap9346; RA Saldivar J.C., Hamperl S., Bocek M.J., Chung M., Bass T.E., RA Cisneros-Soberanis F., Samejima K., Xie L., Paulson J.R., Earnshaw W.C., RA Cortez D., Meyer T., Cimprich K.A.; RT "An intrinsic S/G2 checkpoint enforced by ATR."; RL Science 361:806-810(2018). RN [55] RP FUNCTION, AND INTERACTION WITH UHRF2. RX PubMed=33848395; DOI=10.1111/gtc.12851; RA Hanaki S., Habara M., Shimada M.; RT "UV-induced activation of ATR is mediated by UHRF2."; RL Genes Cells 26:447-454(2021). RN [56] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37788673; DOI=10.1016/j.molcel.2023.09.003; RA Joo Y.K., Black E.M., Trier I., Haakma W., Zou L., Kabeche L.; RT "ATR promotes clearance of damaged DNA and damaged cells by rupturing RT micronuclei."; RL Mol. Cell 83:3642-3658(2023). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37832547; DOI=10.1016/j.molcel.2023.09.023; RA Kovacs M.T., Vallette M., Wiertsema P., Dingli F., Loew D., Nader G.P.F., RA Piel M., Ceccaldi R.; RT "DNA damage induces nuclear envelope rupture through ATR-mediated RT phosphorylation of lamin A/C."; RL Mol. Cell 83:3659-3668(2023). RN [58] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-64; TYR-90; ASN-297; ILE-316; MET-959; RP HIS-1087; GLY-1213; PRO-1488; ASN-1607; SER-1612; GLY-2002; ALA-2120; RP ASP-2132; ILE-2233; GLN-2425; ALA-2434; LYS-2438 AND GLN-2537. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [59] RP VARIANT FCTCS ARG-2144. RX PubMed=22341969; DOI=10.1016/j.ajhg.2012.01.007; RA Tanaka A., Weinel S., Nagy N., O'Driscoll M., Lai-Cheong J.E., RA Kulp-Shorten C.L., Knable A., Carpenter G., Fisher S.A., Hiragun M., RA Yanase Y., Hide M., Callen J., McGrath J.A.; RT "Germline mutation in ATR in autosomal- dominant oropharyngeal cancer RT syndrome."; RL Am. J. Hum. Genet. 90:511-517(2012). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon genotoxic stresses such as ionizing radiation (IR), CC ultraviolet light (UV), or DNA replication stalling, thereby acting as CC a DNA damage sensor (PubMed:10597277, PubMed:10608806, PubMed:10859164, CC PubMed:11721054, PubMed:12791985, PubMed:12814551, PubMed:14657349, CC PubMed:14729973, PubMed:14742437, PubMed:15210935, PubMed:15496423, CC PubMed:16260606, PubMed:21144835, PubMed:21777809, PubMed:23273981, CC PubMed:25083873, PubMed:27723717, PubMed:27723720, PubMed:30139873, CC PubMed:33848395, PubMed:37788673, PubMed:37832547, PubMed:9427750, CC PubMed:9636169). Recognizes the substrate consensus sequence [ST]-Q CC (PubMed:10597277, PubMed:10608806, PubMed:10859164, PubMed:11721054, CC PubMed:12791985, PubMed:12814551, PubMed:14657349, PubMed:14729973, CC PubMed:14742437, PubMed:15210935, PubMed:15496423, PubMed:16260606, CC PubMed:21144835, PubMed:23273981, PubMed:27723717, PubMed:27723720, CC PubMed:33848395, PubMed:9427750, PubMed:9636169). Phosphorylates BRCA1, CC CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1 and p53/TP53, which collectively CC inhibit DNA replication and mitosis and promote DNA repair, CC recombination and apoptosis (PubMed:11114888, PubMed:11418864, CC PubMed:11865061, PubMed:21777809, PubMed:23273981, PubMed:25083873, CC PubMed:9925639). Phosphorylates 'Ser-139' of histone variant H2AX at CC sites of DNA damage, thereby regulating DNA damage response mechanism CC (PubMed:11673449). Required for FANCD2 ubiquitination CC (PubMed:15314022). Critical for maintenance of fragile site stability CC and efficient regulation of centrosome duplication (PubMed:12526805). CC Acts as a regulator of the S-G2 transition by restricting the activity CC of CDK1 during S-phase to prevent premature entry into G2 CC (PubMed:30139873). Acts as a regulator of the nuclear envelope CC integrity in response to DNA damage and stress (PubMed:25083873, CC PubMed:37788673, PubMed:37832547). Acts as a mechanical stress sensor CC at the nuclear envelope: relocalizes to the nuclear envelope in CC response to mechanical stress and mediates a checkpoint via CC phosphorylation of CHEK1 (PubMed:25083873). Also promotes nuclear CC envelope rupture in response to DNA damage by mediating phosphorylation CC of LMNA at 'Ser-282', leading to lamin disassembly (PubMed:37832547). CC Involved in the inflammatory response to genome instability and double- CC stranded DNA breaks: acts by localizing to micronuclei arising from CC genome instability and catalyzing phosphorylation of LMNA at 'Ser-395', CC priming LMNA for subsequent phosphorylation by CDK1 and micronuclei CC envelope rupture (PubMed:37788673). The rupture of micronuclear CC envelope triggers the cGAS-STING pathway thereby activating the type I CC interferon response and innate immunity (PubMed:37788673). Positively CC regulates the restart of stalled replication forks following activation CC by the KHDC3L-OOEP scaffold complex (By similarity). CC {ECO:0000250|UniProtKB:Q9JKK8, ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:10608806, ECO:0000269|PubMed:10859164, CC ECO:0000269|PubMed:11114888, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:11673449, ECO:0000269|PubMed:11721054, CC ECO:0000269|PubMed:11865061, ECO:0000269|PubMed:12526805, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14729973, CC ECO:0000269|PubMed:14742437, ECO:0000269|PubMed:15210935, CC ECO:0000269|PubMed:15314022, ECO:0000269|PubMed:15496423, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:21144835, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:23273981, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:33848395, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547, ECO:0000269|PubMed:9427750, CC ECO:0000269|PubMed:9636169, ECO:0000269|PubMed:9925639}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:10608806}; CC -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is CC directly stimulated by TOPBP1 (PubMed:16530042, PubMed:21777809). ATR CC kinase activity is also directly activated by ETAA1, independently of CC TOPBP1 (PubMed:27723717, PubMed:27723720, PubMed:30139873). Activated CC by DNA and inhibited by BCR-ABL oncogene (PubMed:10597277). Slightly CC activated by ATRIP (PubMed:14729973). Inhibited by caffeine, wortmannin CC and LY294002 (PubMed:9766667). {ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:16530042, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Forms a heterodimer with ATRIP, forming the ATR-ATRIP complex CC (PubMed:11721054, PubMed:12791985, PubMed:14729973, PubMed:15758953, CC PubMed:21777809). Present in a complex containing ATRIP and RPA-coated CC single-stranded DNA (PubMed:12791985, PubMed:14729973). Binds to DNA, CC and to UV-damaged DNA with higher affinity (PubMed:12791985). Interacts CC with MSH2 and HDAC2 (PubMed:14657349). Present in a complex containing CC CHD4 and HDAC2 (PubMed:10545197). Interacts with EEF1E1, the CC interaction is enhanced by UV irradiation (PubMed:15680327). Interacts CC with CLSPN and CEP164 (PubMed:12766152, PubMed:18283122). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with BCR-ABL after genotoxic stress CC (PubMed:15050919). Interacts with UHRF2; this interaction promotes ATR CC activation (PubMed:33848395). Interacts (when phosphorylated) with CC TOPBP1; interaction takes place when ATR is autophosphorylated at Thr- CC 1989, leading to ATR activation by TOPBP1 (PubMed:21705319, CC PubMed:21777809). {ECO:0000269|PubMed:10545197, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:12766152, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:14657349, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:15050919, CC ECO:0000269|PubMed:15680327, ECO:0000269|PubMed:15758953, CC ECO:0000269|PubMed:18283122, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650, CC ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:33848395}. CC -!- INTERACTION: CC Q13535; Q8WXE1: ATRIP; NbExp=5; IntAct=EBI-968983, EBI-747353; CC Q13535; Q99459: CDC5L; NbExp=3; IntAct=EBI-968983, EBI-374880; CC Q13535; P50750: CDK9; NbExp=3; IntAct=EBI-968983, EBI-1383449; CC Q13535; Q9BW66: CINP; NbExp=5; IntAct=EBI-968983, EBI-739784; CC Q13535; Q9Y6K9: IKBKG; NbExp=2; IntAct=EBI-968983, EBI-81279; CC Q13535; O43156: TTI1; NbExp=2; IntAct=EBI-968983, EBI-1055680; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11114888, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:11865061, CC ECO:0000269|PubMed:12814551, ECO:0000269|PubMed:14871897, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:8843195}. Chromosome CC {ECO:0000269|PubMed:11673449}. Nucleus envelope CC {ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}. Note=Depending on the cell type, it can CC also be found in PML nuclear bodies (PubMed:12814551). Recruited to CC chromatin during S-phase (PubMed:14871897). Redistributes to discrete CC nuclear foci upon DNA damage, hypoxia or replication fork stalling CC (PubMed:27723720). Relocalizes to the nuclear envelope in response to CC mechanical stress or DNA damage (PubMed:25083873, PubMed:37832547). CC Also localizes to the micronuclear envelope in response to response to CC genome instability (PubMed:37788673). {ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723720, CC ECO:0000269|PubMed:37788673, ECO:0000269|PubMed:37832547}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q13535-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13535-2; Sequence=VSP_013305, VSP_013304; CC Name=3; CC IsoId=Q13535-3; Sequence=VSP_036907, VSP_036908; CC -!- TISSUE SPECIFICITY: Ubiquitous, with highest expression in testis. CC {ECO:0000269|PubMed:11470508, ECO:0000269|PubMed:8610130, CC ECO:0000269|PubMed:8843195}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Isoform 2 is found in pancreas, CC placenta and liver but not in heart, testis and ovary. CC {ECO:0000269|PubMed:11470508}. CC -!- PTM: Phosphorylated (PubMed:21144835). Autophosphorylation at Thr-1989 CC in response to DNA damage promotes interaction with TOPBP1 and CC activation of ATR (PubMed:21705319, PubMed:21777809). CC {ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:21705319, CC ECO:0000269|PubMed:21777809}. CC -!- DISEASE: Seckel syndrome 1 (SCKL1) [MIM:210600]: A rare autosomal CC recessive disorder characterized by proportionate dwarfism of prenatal CC onset associated with low birth weight, growth retardation, severe CC microcephaly with a bird-headed like appearance, and intellectual CC disability. {ECO:0000269|PubMed:12640452}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) CC [MIM:614564]: A disease characterized by cutaneous telangiectases in CC infancy with patchy alopecia over areas of affected skin, thinning of CC the lateral eyebrows, and mild dental and nail anomalies. Affected CC individuals are at increased risk of developing oropharyngeal cancer, CC and other malignancies have been reported as well. CC {ECO:0000269|PubMed:22341969}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/728/ATR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y09077; CAA70298.1; -; mRNA. DR EMBL; U76308; AAC50929.1; -; mRNA. DR EMBL; U49844; AAC50405.1; -; mRNA. DR EMBL; AF325699; AAK26749.1; -; Genomic_DNA. DR EMBL; AB208847; BAD92084.1; -; mRNA. DR CCDS; CCDS3124.1; -. [Q13535-1] DR CCDS; CCDS93402.1; -. [Q13535-2] DR RefSeq; NP_001175.2; NM_001184.4. [Q13535-1] DR RefSeq; NP_001341508.1; NM_001354579.2. [Q13535-2] DR PDB; 5YZ0; EM; 4.70 A; A/B=1-2644. DR PDB; 9L40; EM; 2.87 A; A/B=1-2644. DR PDB; 9L43; EM; 3.83 A; A/B=1-2644. DR PDB; 9L45; EM; 3.95 A; A/B=1-2644. DR PDB; 9L46; EM; 6.29 A; A/B=1-2644. DR PDB; 9L4B; EM; 3.20 A; A/B=1-2644. DR PDB; 9L4C; EM; 4.06 A; A/B=1-2644. DR PDB; 9L4D; EM; 3.79 A; A/B=8-2644. DR PDB; 9L4F; EM; 6.22 A; A/B=1-2644. DR PDBsum; 5YZ0; -. DR PDBsum; 9L40; -. DR PDBsum; 9L43; -. DR PDBsum; 9L45; -. DR PDBsum; 9L46; -. DR PDBsum; 9L4B; -. DR PDBsum; 9L4C; -. DR PDBsum; 9L4D; -. DR PDBsum; 9L4F; -. DR AlphaFoldDB; Q13535; -. DR EMDB; EMD-62801; -. DR EMDB; EMD-62804; -. DR EMDB; EMD-62806; -. DR EMDB; EMD-62807; -. DR EMDB; EMD-62808; -. DR EMDB; EMD-62809; -. DR EMDB; EMD-62811; -. DR EMDB; EMD-62812; -. DR EMDB; EMD-6862; -. DR SMR; Q13535; -. DR BioGRID; 107027; 243. DR ComplexPortal; CPX-3622; ATR-ATRIP DNA damage-sensing kinase complex. DR CORUM; Q13535; -. DR DIP; DIP-35308N; -. DR FunCoup; Q13535; 3607. DR IntAct; Q13535; 96. DR MINT; Q13535; -. DR STRING; 9606.ENSP00000343741; -. DR BindingDB; Q13535; -. DR ChEMBL; CHEMBL5024; -. DR DrugBank; DB11794; Berzosertib. DR DrugBank; DB14917; Ceralasertib. DR DrugBank; DB19041; Elimusertib. DR GuidetoPHARMACOLOGY; 1935; -. DR CarbonylDB; Q13535; -. DR GlyGen; Q13535; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q13535; -. DR PhosphoSitePlus; Q13535; -. DR BioMuta; ATR; -. DR DMDM; 62286460; -. DR CPTAC; CPTAC-3214; -. DR CPTAC; CPTAC-3215; -. DR jPOST; Q13535; -. DR MassIVE; Q13535; -. DR PaxDb; 9606-ENSP00000343741; -. DR PeptideAtlas; Q13535; -. DR ProteomicsDB; 59521; -. [Q13535-1] DR ProteomicsDB; 59522; -. [Q13535-2] DR ProteomicsDB; 59523; -. [Q13535-3] DR Pumba; Q13535; -. DR Antibodypedia; 18078; 557 antibodies from 41 providers. DR CPTC; Q13535; 1 antibody. DR DNASU; 545; -. DR Ensembl; ENST00000350721.9; ENSP00000343741.4; ENSG00000175054.17. [Q13535-1] DR Ensembl; ENST00000661310.1; ENSP00000499589.1; ENSG00000175054.17. [Q13535-2] DR GeneID; 545; -. DR KEGG; hsa:545; -. DR MANE-Select; ENST00000350721.9; ENSP00000343741.4; NM_001184.4; NP_001175.2. DR UCSC; uc003eux.5; human. [Q13535-1] DR AGR; HGNC:882; -. DR CIViC; 545; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA74; -. DR CTD; 545; -. DR DisGeNET; 545; -. DR GeneCards; ATR; -. DR HGNC; HGNC:882; ATR. DR HPA; ENSG00000175054; Low tissue specificity. DR MalaCards; ATR; -. DR MIM; 210600; phenotype. DR MIM; 601215; gene. DR MIM; 614564; phenotype. DR OpenTargets; ENSG00000175054; -. DR Orphanet; 313846; Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome. DR Orphanet; 808; Seckel syndrome. DR VEuPathDB; HostDB:ENSG00000175054; -. DR eggNOG; KOG0890; Eukaryota. DR GeneTree; ENSGT00940000155714; -. DR HOGENOM; CLU_000178_2_1_1; -. DR InParanoid; Q13535; -. DR OMA; SMYIGWC; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13535; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13535; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13535; -. DR Reactome; R-HSA-1221632; Meiotic synapsis. DR Reactome; R-HSA-176187; Activation of ATR in response to replication stress. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6783310; Fanconi Anemia Pathway. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR SignaLink; Q13535; -. DR SIGNOR; Q13535; -. DR Agora; ENSG00000175054; -. DR BioGRID-ORCS; 545; 746 hits in 1209 CRISPR screens. DR CD-CODE; 804901D1; Nuclear speckle. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; D3B9EAFD; Synthetic Condensate 000362. DR ChiTaRS; ATR; human. DR GeneWiki; Ataxia_telangiectasia_and_Rad3_related; -. DR GenomeRNAi; 545; -. DR Pharos; Q13535; Tchem. DR PRO; PR:Q13535; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q13535; protein. DR Bgee; ENSG00000175054; Expressed in Brodmann (1909) area 23 and 205 other cell types or tissues. DR ExpressionAtlas; Q13535; baseline and differential. DR GO; GO:0070310; C:ATR-ATRIP complex; IPI:ComplexPortal. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:MGI. DR GO; GO:0032407; F:MutSalpha complex binding; IDA:MGI. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IMP:BHF-UCL. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IBA:GO_Central. DR GO; GO:0006260; P:DNA replication; TAS:Reactome. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProt. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IC:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0036297; P:interstrand cross-link repair; TAS:Reactome. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; IDA:UniProt. DR GO; GO:0008156; P:negative regulation of DNA replication; IMP:UniProtKB. DR GO; GO:0051081; P:nuclear membrane disassembly; IDA:UniProtKB. DR GO; GO:0006139; P:nucleobase-containing compound metabolic process; NAS:ComplexPortal. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:0070198; P:protein localization to chromosome, telomeric region; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0031297; P:replication fork processing; ISS:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl. DR GO; GO:0009612; P:response to mechanical stimulus; IDA:UniProtKB. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR CDD; cd00892; PIKKc_ATR; 1. DR FunFam; 1.10.1070.11:FF:000009; Putative serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.10.10:FF:000149; Serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.40.10:FF:000142; Serine/threonine-protein kinase ATR; 1. DR FunFam; 3.30.1010.10:FF:000011; serine/threonine-protein kinase ATR; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 2. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR056802; ATR-like_M-HEAT. DR InterPro; IPR056803; ATR-like_N-HEAT. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR021133; HEAT_type_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR InterPro; IPR012993; UME. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF69; SERINE_THREONINE-PROTEIN KINASE ATR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF25030; M-HEAT_ATR; 1. DR Pfam; PF25032; N-HEAT_ATR; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF08064; UME; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM00802; UME; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF48452; TPR-like; 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50077; HEAT_REPEAT; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; Dwarfism; KW Intellectual disability; Kinase; Manganese; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..2644 FT /note="Serine/threonine-protein kinase ATR" FT /id="PRO_0000088844" FT REPEAT 799..835 FT /note="HEAT 1" FT REPEAT 1329..1365 FT /note="HEAT 2" FT DOMAIN 1640..2185 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2296..2604 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2612..2644 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 418..450 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2302..2308 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2472..2480 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2492..2516 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976" FT MOD_RES 435 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21777809, FT ECO:0007744|PubMed:23186163" FT MOD_RES 436 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1989 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:21705319, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 450 FT /note="E -> D (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013305" FT VAR_SEQ 451..514 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013304" FT VAR_SEQ 2588..2610 FT /note="AKTHVLDIEQRLQGVIKTRNRVT -> VSRRYSLIWAVVLISTNELDMQL FT (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036907" FT VAR_SEQ 2611..2644 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036908" FT VARIANT 64 FT /note="T -> A (in dbSNP:rs35306038)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041584" FT VARIANT 90 FT /note="H -> Y (in dbSNP:rs28897763)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041585" FT VARIANT 211 FT /note="M -> T (in dbSNP:rs2227928)" FT /id="VAR_050532" FT VARIANT 297 FT /note="K -> N (in dbSNP:rs2229033)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041586" FT VARIANT 316 FT /note="V -> I (in dbSNP:rs28897764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041587" FT VARIANT 959 FT /note="V -> M (in dbSNP:rs28910271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041588" FT VARIANT 1087 FT /note="Y -> H (in dbSNP:rs34253059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041589" FT VARIANT 1213 FT /note="S -> G (in dbSNP:rs34766606)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041590" FT VARIANT 1488 FT /note="A -> P (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041591" FT VARIANT 1526 FT /note="I -> V (in dbSNP:rs34124242)" FT /id="VAR_050533" FT VARIANT 1607 FT /note="S -> N (in dbSNP:rs55724025)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041592" FT VARIANT 1612 FT /note="N -> S (in dbSNP:rs55894265)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041593" FT VARIANT 2002 FT /note="A -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041594" FT VARIANT 2120 FT /note="G -> A (in dbSNP:rs35134774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041595" FT VARIANT 2132 FT /note="Y -> D (in dbSNP:rs28910273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041596" FT VARIANT 2144 FT /note="Q -> R (in FCTCS; dbSNP:rs387906797)" FT /evidence="ECO:0000269|PubMed:22341969" FT /id="VAR_067919" FT VARIANT 2233 FT /note="S -> I (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041597" FT VARIANT 2425 FT /note="R -> Q (in dbSNP:rs2229032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041598" FT VARIANT 2434 FT /note="P -> A (in dbSNP:rs33972295)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041599" FT VARIANT 2438 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs2108261462)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041600" FT VARIANT 2537 FT /note="E -> Q (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041601" FT MUTAGEN 1989 FT /note="T->A: Impaired autophosphorylation, leading to FT decreased activation of ATR." FT /evidence="ECO:0000269|PubMed:21705319" FT MUTAGEN 2327 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:11114888, FT ECO:0000269|PubMed:12011431, ECO:0000269|PubMed:9925639" FT MUTAGEN 2475 FT /note="D->A: Abolishes kinase activity; increases FT sensitivity to IR and impairs translocation to nuclear foci FT upon DNA damage." FT /evidence="ECO:0000269|PubMed:12814551, FT ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9925639" FT MUTAGEN 2494 FT /note="D->E: Abolishes kinase activity; reduces cell FT viability, augments sensitivity to IR and UV." FT /evidence="ECO:0000269|PubMed:10597277, FT ECO:0000269|PubMed:9636169" FT CONFLICT 92 FT /note="A -> R (in Ref. 1; CAA70298/AAC50929)" FT /evidence="ECO:0000305" SQ SEQUENCE 2644 AA; 301367 MW; 11BC22297FB9A802 CRC64; MGEHGLELAS MIPALRELGS ATPEEYNTVV QKPRQILCQF IDRILTDVNV VAVELVKKTD SQPTSVMLLD FIQHIMKSSP LMFVNVSGSH EAKGSCIEFS NWIITRLLRI AATPSCHLLH KKICEVICSL LFLFKSKSPA IFGVLTKELL QLFEDLVYLH RRNVMGHAVE WPVVMSRFLS QLDEHMGYLQ SAPLQLMSMQ NLEFIEVTLL MVLTRIIAIV FFRRQELLLW QIGCVLLEYG SPKIKSLAIS FLTELFQLGG LPAQPASTFF SSFLELLKHL VEMDTDQLKL YEEPLSKLIK TLFPFEAEAY RNIEPVYLNM LLEKLCVMFE DGVLMRLKSD LLKAALCHLL QYFLKFVPAG YESALQVRKV YVRNICKALL DVLGIEVDAE YLLGPLYAAL KMESMEIIEE IQCQTQQENL SSNSDGISPK RRRLSSSLNP SKRAPKQTEE IKHVDMNQKS ILWSALKQKA ESLQISLEYS GLKNPVIEML EGIAVVLQLT ALCTVHCSHQ NMNCRTFKDC QHKSKKKPSV VITWMSLDFY TKVLKSCRSL LESVQKLDLE ATIDKVVKIY DALIYMQVNS SFEDHILEDL CGMLSLPWIY SHSDDGCLKL TTFAANLLTL SCRISDSYSP QAQSRCVFLL TLFPRRIFLE WRTAVYNWAL QSSHEVIRAS CVSGFFILLQ QQNSCNRVPK ILIDKVKDDS DIVKKEFASI LGQLVCTLHG MFYLTSSLTE PFSEHGHVDL FCRNLKATSQ HECSSSQLKA SVCKPFLFLL KKKIPSPVKL AFIDNLHHLC KHLDFREDET DVKAVLGTLL NLMEDPDKDV RVAFSGNIKH ILESLDSEDG FIKELFVLRM KEAYTHAQIS RNNELKDTLI LTTGDIGRAA KGDLVPFALL HLLHCLLSKS ASVSGAAYTE IRALVAAKSV KLQSFFSQYK KPICQFLVES LHSSQMTALP NTPCQNADVR KQDVAHQREM ALNTLSEIAN VFDFPDLNRF LTRTLQVLLP DLAAKASPAA SALIRTLGKQ LNVNRREILI NNFKYIFSHL VCSCSKDELE RALHYLKNET EIELGSLLRQ DFQGLHNELL LRIGEHYQQV FNGLSILASF ASSDDPYQGP RDIISPELMA DYLQPKLLGI LAFFNMQLLS SSVGIEDKKM ALNSLMSLMK LMGPKHVSSV RVKMMTTLRT GLRFKDDFPE LCCRAWDCFV RCLDHACLGS LLSHVIVALL PLIHIQPKET AAIFHYLIIE NRDAVQDFLH EIYFLPDHPE LKKIKAVLQE YRKETSESTD LQTTLQLSMK AIQHENVDVR IHALTSLKET LYKNQEKLIK YATDSETVEP IISQLVTVLL KGCQDANSQA RLLCGECLGE LGAIDPGRLD FSTTETQGKD FTFVTGVEDS SFAYGLLMEL TRAYLAYADN SRAQDSAAYA IQELLSIYDC REMETNGPGH QLWRRFPEHV REILEPHLNT RYKSSQKSTD WSGVKKPIYL SKLGSNFAEW SASWAGYLIT KVRHDLASKI FTCCSIMMKH DFKVTIYLLP HILVYVLLGC NQEDQQEVYA EIMAVLKHDD QHTINTQDIA SDLCQLSTQT VFSMLDHLTQ WARHKFQALK AEKCPHSKSN RNKVDSMVST VDYEDYQSVT RFLDLIPQDT LAVASFRSKA YTRAVMHFES FITEKKQNIQ EHLGFLQKLY AAMHEPDGVA GVSAIRKAEP SLKEQILEHE SLGLLRDATA CYDRAIQLEP DQIIHYHGVV KSMLGLGQLS TVITQVNGVH ANRSEWTDEL NTYRVEAAWK LSQWDLVENY LAADGKSTTW SVRLGQLLLS AKKRDITAFY DSLKLVRAEQ IVPLSAASFE RGSYQRGYEY IVRLHMLCEL EHSIKPLFQH SPGDSSQEDS LNWVARLEMT QNSYRAKEPI LALRRALLSL NKRPDYNEMV GECWLQSARV ARKAGHHQTA YNALLNAGES RLAELYVERA KWLWSKGDVH QALIVLQKGV ELCFPENETP PEGKNMLIHG RAMLLVGRFM EETANFESNA IMKKYKDVTA CLPEWEDGHF YLAKYYDKLM PMVTDNKMEK QGDLIRYIVL HFGRSLQYGN QFIYQSMPRM LTLWLDYGTK AYEWEKAGRS DRVQMRNDLG KINKVITEHT NYLAPYQFLT AFSQLISRIC HSHDEVFVVL MEIIAKVFLA YPQQAMWMMT AVSKSSYPMR VNRCKEILNK AIHMKKSLEK FVGDATRLTD KLLELCNKPV DGSSSTLSMS THFKMLKKLV EEATFSEILI PLQSVMIPTL PSILGTHANH ASHEPFPGHW AYIAGFDDMV EILASLQKPK KISLKGSDGK FYIMMCKPKD DLRKDCRLME FNSLINKCLR KDAESRRREL HIRTYAVIPL NDECGIIEWV NNTAGLRPIL TKLYKEKGVY MTGKELRQCM LPKSAALSEK LKVFREFLLP RHPPIFHEWF LRTFPDPTSW YSSRSAYCRS TAVMSMVGYI LGLGDRHGEN ILFDSLTGEC VHVDFNCLFN KGETFEVPEI VPFRLTHNMV NGMGPMGTEG LFRRACEVTM RLMRDQREPL MSVLKTFLHD PLVEWSKPVK GHSKAPLNET GEVVNEKAKT HVLDIEQRLQ GVIKTRNRVT GLPLSIEGHV HYLIQEATDE NLLCQMYLGW TPYM // ID AURKA_HUMAN Reviewed; 403 AA. AC O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5; DT 27-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 3. DT 28-JAN-2026, entry version 254. DE RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393}; DE EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; DE AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084}; DE AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231}; DE Short=ARK-1 {ECO:0000303|PubMed:9153231}; DE Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916}; DE AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771}; DE AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}; DE AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714}; DE AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241}; GN Name=AURKA {ECO:0000312|HGNC:HGNC:11393}; GN Synonyms=AIK {ECO:0000303|PubMed:9153231}, GN AIRK1 {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393}, GN AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1 {ECO:0000250|UniProtKB:P97477}, GN BTAK {ECO:0000303|PubMed:9771714}, IAK1 {ECO:0000250|UniProtKB:P97477}, GN STK15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, GN STK6 {ECO:0000303|PubMed:9771714}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT RP VAL-57. RC TISSUE=Blood; RX PubMed=9153231; DOI=10.1074/jbc.272.21.13766; RA Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K., RA Okano Y.; RT "Cell cycle-dependent expression and spindle pole localization of a novel RT human protein kinase, Aik, related to Aurora of Drosophila and yeast RT Ipl1."; RL J. Biol. Chem. 272:13766-13771(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57. RX PubMed=9514916; DOI=10.1006/bbrc.1998.8250; RA Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J., RA Jenkins N.A., Copeland N.G., Yagita H., Okumura K.; RT "cDNA cloning, expression, subcellular localization, and chromosomal RT assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 RT and 2."; RL Biochem. Biophys. Res. Commun. 244:285-292(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57. RC TISSUE=Mammary gland; RX PubMed=9771714; DOI=10.1038/2496; RA Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R., RA Sen S.; RT "Tumour amplified kinase STK15/BTAK induces centrosome amplification, RT aneuploidy and transformation."; RL Nat. Genet. 20:189-193(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang L., Thibodeau S.N.; RT "Mutational analysis of the STK15 gene in human tumors."; RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57. RC TISSUE=Cervix, Colon, Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, AND SUBCELLULAR LOCATION. RX PubMed=9606188; DOI=10.1093/emboj/17.11.3052; RA Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., RA Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., RA Novotny M., Slamon D.J., Plowman G.D.; RT "A homologue of Drosophila aurora kinase is oncogenic and amplified in RT human colorectal cancers."; RL EMBO J. 17:3052-3065(1998). RN [9] RP UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205. RX PubMed=10851084; DOI=10.1038/sj.onc.1203609; RA Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., RA Furukawa K., Urano T.; RT "Degradation of human Aurora2 protein kinase by the anaphase-promoting RT complex-ubiquitin-proteasome pathway."; RL Oncogene 19:2812-2819(2000). RN [10] RP FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288, RP UBIQUITINATION, AND ACTIVITY REGULATION. RX PubMed=11039908; DOI=10.1038/sj.onc.1203847; RA Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.; RT "The mitotic serine/threonine kinase Aurora2/AIK is regulated by RT phosphorylation and degradation."; RL Oncogene 19:4906-4916(2000). RN [11] RP FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF RP PHE-165 AND PHE-346, AND PHOSPHORYLATION. RX PubMed=11551964; DOI=10.1074/jbc.m107540200; RA Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.; RT "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and RT protein phosphatase 1 through mitotic cell division cycle."; RL J. Biol. Chem. 276:46219-46224(2001). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=12576638; DOI=10.1247/csf.27.457; RA Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M., RA Dotsu M.; RT "Molecular dynamics of Aurora-A kinase in living mitotic cells RT simultaneously visualized with histone H3 and nuclear membrane protein RT importinalpha."; RL Cell Struct. Funct. 27:457-467(2002). RN [13] RP FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x; RA Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., RA Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., RA Saya H.; RT "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian RT cells."; RL Genes Cells 7:1173-1182(2002). RN [14] RP INDUCTION. RX PubMed=11790771; DOI=10.1074/jbc.m108252200; RA Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S., RA Ishigatsubo Y.; RT "Cell-cycle-dependent regulation of human aurora A transcription is RT mediated by periodic repression of E4TF1."; RL J. Biol. Chem. 277:10719-10726(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288. RX PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1; RA Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., RA Hatakeyama K., Saya H.; RT "Aurora-A and an interacting activator, the LIM protein Ajuba, are required RT for mitotic commitment in human cells."; RL Cell 114:585-598(2003). RN [16] RP FUNCTION. RX PubMed=14523000; DOI=10.1074/jbc.m306275200; RA Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.; RT "Aurora-A kinase maintains the fidelity of early and late mitotic events in RT HeLa cells."; RL J. Biol. Chem. 278:51786-51795(2003). RN [17] RP INTERACTION WITH TACC1. RX PubMed=14603251; DOI=10.1038/sj.onc.1206972; RA Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., RA Prigent C., Seraphin B., Jacquemier J., Birnbaum D.; RT "TACC1-chTOG-Aurora A protein complex in breast cancer."; RL Oncogene 22:8102-8116(2003). RN [18] RP FUNCTION. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [19] RP RETRACTED PAPER. RX PubMed=14990569; DOI=10.1074/jbc.m311780200; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RT "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M RT transition."; RL J. Biol. Chem. 279:19643-19648(2004). RN [20] RP RETRACTION NOTICE OF PUBMED:14990569. RX PubMed=26341884; DOI=10.1074/jbc.a115.311780; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RL J. Biol. Chem. 290:22311-22311(2015). RN [21] RP FUNCTION. RX PubMed=15128871; DOI=10.1242/jcs.01108; RA Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., RA Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., RA Prigent C., Ducommun B.; RT "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the RT G2-M transition."; RL J. Cell Sci. 117:2523-2531(2004). RN [22] RP FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [23] RP INTERACTION WITH CPEB1. RX PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x; RA Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E., RA Saya H., Hirota T.; RT "Over-expression of Aurora-A targets cytoplasmic polyadenylation element RT binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1."; RL Genes Cells 10:627-638(2005). RN [24] RP PHOSPHORYLATION AT THR-288 AND SER-342. RX PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035; RA Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.; RT "The GIT-associated kinase PAK targets to the centrosome and regulates RT Aurora-A."; RL Mol. Cell 20:237-249(2005). RN [25] RP INDUCTION, AND FUNCTION. RX PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005; RA Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.; RT "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP RT as a transforming target of Aurora-A."; RL Mol. Cell. Biol. 25:5789-5800(2005). RN [26] RP INTERACTION WITH BORA. RX PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002; RA Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., RA Knoblich J.A.; RT "Mitotic activation of the kinase Aurora-A requires its binding partner RT Bora."; RL Dev. Cell 11:147-157(2006). RN [27] RP FUNCTION. RX PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578; RA Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.; RT "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of RT centrosome-dependent microtubule nucleation."; RL Cancer Res. 67:11186-11194(2007). RN [28] RP FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP ASP-274 AND THR-288. RX PubMed=17604723; DOI=10.1016/j.cell.2007.04.035; RA Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.; RT "HEF1-dependent Aurora A activation induces disassembly of the primary RT cilium."; RL Cell 129:1351-1363(2007). RN [29] RP INTERACTION WITH ARHGEF2. RX PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014; RA Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.; RT "GEF-H1 modulates localized RhoA activation during cytokinesis under the RT control of mitotic kinases."; RL Dev. Cell 12:699-712(2007). RN [30] RP SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT RP SER-51. RX PubMed=17229885; DOI=10.1091/mbc.e06-12-1152; RA Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.; RT "Functional interaction of Aurora-A and PP2A during mitosis."; RL Mol. Biol. Cell 18:1233-1241(2007). RN [31] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=17726514; DOI=10.1371/journal.pone.0000784; RA North B.J., Verdin E.; RT "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during RT mitosis."; RL PLoS ONE 2:E784-E784(2007). RN [32] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=17360485; DOI=10.1073/pnas.0608798104; RA Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., RA Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., RA Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., RA Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.; RT "Antitumor activity of MLN8054, an orally active small-molecule inhibitor RT of Aurora A kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [34] RP FUNCTION. RX PubMed=18615013; DOI=10.1038/nature07185; RA Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., RA Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.; RT "Polo-like kinase-1 is activated by aurora A to promote checkpoint RT recovery."; RL Nature 455:119-123(2008). RN [35] RP FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3. RX PubMed=19812038; DOI=10.1074/jbc.m109.055897; RA Khazaei M.R., Puschel A.W.; RT "Phosphorylation of the par polarity complex protein Par3 at serine 962 is RT mediated by aurora A and regulates its function in neuronal polarity."; RL J. Biol. Chem. 284:33571-33579(2009). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A. RX PubMed=19351716; DOI=10.1242/jcs.044321; RA Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.; RT "Plk1 and Aurora A regulate the depolymerase activity and the cellular RT localization of Kif2a."; RL J. Cell Sci. 122:1334-1341(2009). RN [37] RP FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288, RP AND MUTAGENESIS OF THR-287. RX PubMed=19668197; DOI=10.1038/ncb1919; RA Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S., RA Saya H., Wynshaw-Boris A., Hirotsune S.; RT "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation RT by modulation of microtubule dynamics."; RL Nat. Cell Biol. 11:1057-1068(2009). RN [38] RP INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION. RX PubMed=19357306; DOI=10.1073/pnas.0900833106; RA Fu J., Bian M., Liu J., Jiang Q., Zhang C.; RT "A single amino acid change converts Aurora-A into Aurora-B-like kinase in RT terms of partner specificity and cellular function."; RL Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009). RN [39] RP FUNCTION, INTERACTION WITH CIMAP3, AND ACTIVATION BY CIMAP3. RX PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005; RA Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B., RA Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.; RT "Pitchfork regulates primary cilia disassembly and left-right asymmetry."; RL Dev. Cell 19:66-77(2010). RN [40] RP IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN. RX PubMed=20596670; DOI=10.3892/ijo_00000691; RA Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y., RA Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.; RT "Functional characterization of AIBp, a novel Aurora-A binding protein in RT centrosome structure and spindle formation."; RL Int. J. Oncol. 37:429-436(2010). RN [41] RP INTERACTION WITH GADD45A. RX PubMed=20460379; DOI=10.1074/jbc.m109.069344; RA Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., RA Montoya G., Campos-Olivas R., Blanco F.J.; RT "Solution structure of human growth arrest and DNA damage 45alpha RT (Gadd45alpha) and its interactions with proliferating cell nuclear antigen RT (PCNA) and Aurora A kinase."; RL J. Biol. Chem. 285:22196-22201(2010). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [44] RP REVIEW ON FUNCTION. RX PubMed=14625535; DOI=10.1038/nrm1245; RA Carmena M., Earnshaw W.C.; RT "The cellular geography of aurora kinases."; RL Nat. Rev. Mol. Cell Biol. 4:842-854(2003). RN [45] RP REVIEW ON FUNCTION. RX PubMed=19774610; DOI=10.1002/em.20533; RA Lukasiewicz K.B., Lingle W.L.; RT "Aurora A, centrosome structure, and the centrosome cycle."; RL Environ. Mol. Mutagen. 50:602-619(2009). RN [46] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004; RA Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C., RA Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I., RA Gius D., Deng C.X.; RT "SIRT2 maintains genome integrity and suppresses tumorigenesis through RT regulating APC/C activity."; RL Cancer Cell 20:487-499(2011). RN [47] RP INTERACTION WITH HNRNPU. RX PubMed=21242313; DOI=10.1242/jcs.063347; RA Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S., RA Fukui K.; RT "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule RT attachment and contributes to the targeting of Aurora-A to mitotic RT spindles."; RL J. Cell Sci. 124:394-404(2011). RN [48] RP INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=23213400; DOI=10.1242/bio.2011018; RA Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.; RT "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora- RT A."; RL Biol. Open 1:82-91(2012). RN [49] RP INTERACTION WITH FRY. RX PubMed=22753416; DOI=10.1074/jbc.m112.378968; RA Ikeda M., Chiba S., Ohashi K., Mizuno K.; RT "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation."; RL J. Biol. Chem. 287:27670-27681(2012). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=25657325; DOI=10.1091/mbc.e14-09-1366; RA Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.; RT "CENP-32 is required to maintain centrosomal dominance in bipolar spindle RT assembly."; RL Mol. Biol. Cell 26:1225-1237(2015). RN [51] RP INTERACTION WITH HNRNPU. RX PubMed=25986610; DOI=10.1128/mcb.01312-14; RA Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L., RA Lees-Miller S.P.; RT "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is RT required for mitosis."; RL Mol. Cell. Biol. 35:2699-2713(2015). RN [52] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=27192185; DOI=10.1080/15384101.2016.1187342; RA Meunier S., Timon K., Vernos I.; RT "Aurora-A regulates MCRS1 function during mitosis."; RL Cell Cycle 15:1779-1786(2016). RN [53] RP FUNCTION. RX PubMed=27335426; DOI=10.1242/jcs.184416; RA Kotak S., Afshar K., Busso C., Goenczy P.; RT "Aurora A kinase regulates proper spindle positioning in C. elegans and in RT human cells."; RL J. Cell Sci. 129:3015-3025(2016). RN [54] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [55] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP FOXP1. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=30538148; DOI=10.1261/rna.069773.118; RA Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D., RA Pellman D., Kennedy S., Slack F.J.; RT "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing RT factor."; RL RNA 25:352-363(2019). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE, RP AND CATALYTIC ACTIVITY. RX PubMed=12237287; DOI=10.1074/jbc.c200426200; RA Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., RA Lippke J.A., Austen D.A.; RT "Crystal structure of aurora-2, an oncogenic serine/threonine kinase."; RL J. Biol. Chem. 277:42419-42422(2002). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2, RP MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND RP THR-288, AND REGION ACTIVATION SEGMENT. RX PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7; RA Bayliss R., Sardon T., Vernos I., Conti E.; RT "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle."; RL Mol. Cell 12:851-862(2003). RN [60] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP RP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053; RA Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., RA Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., RA Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.; RT "SAR and inhibitor complex structure determination of a novel class of RT potent and specific Aurora kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 16:1320-1323(2006). RN [61] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH RP SYNTHETIC INHIBITORS, AND FUNCTION. RX PubMed=17125279; DOI=10.1021/jm060897w; RA Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., RA Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., RA Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., RA Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., RA Vianello P.; RT "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent RT aurora kinase inhibitor with a favorable antitumor kinase inhibition RT profile."; RL J. Med. Chem. 49:7247-7251(2006). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND RP TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBUNIT. RX PubMed=18662907; DOI=10.1110/ps.036590.108; RA Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., RA Kirkpatrick R.B., Lai Z.; RT "Modulation of kinase-inhibitor interactions by auxiliary protein binding: RT crystallography studies on Aurora A interactions with VX-680 and with RT TPX2."; RL Protein Sci. 17:1791-1797(2008). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP, RP CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH RP TPX2. RX PubMed=19801554; DOI=10.1074/jbc.m109.032722; RA Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., RA Bayliss R., Linardopoulos S.; RT "A cancer-associated aurora A mutant is mislocalized and misregulated due RT to loss of interaction with TPX2."; RL J. Biol. Chem. 284:33177-33184(2009). RN [64] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19140666; DOI=10.1021/jm801270e; RA Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H., RA Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y., RA Hsieh H.P.; RT "Structure-based drug design of novel Aurora kinase A inhibitors: RT structural basis for potency and specificity."; RL J. Med. Chem. 52:1050-1062(2009). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19402633; DOI=10.1021/jm9000314; RA Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J., RA Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J., RA Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L., RA Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.; RT "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually RT high selectivity against Aurora B."; RL J. Med. Chem. 52:3300-3307(2009). RN [66] RP X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND RP ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF RP CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY. RX PubMed=27837025; DOI=10.1073/pnas.1610626113; RA Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L., RA Bayliss R.; RT "Structural basis of N-Myc binding by Aurora-A and its destabilization by RT kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016). RN [67] RP VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57. RX PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149; RA Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., RA Nagase H.; RT "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) RT coordinately increase esophageal cancer risk."; RL Cancer Res. 65:3548-3554(2005). RN [68] RP VARIANTS ILE-31 AND VAL-57. RX PubMed=16011022; RA Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M., RA Zhang X.; RT "Linkage disequilibrium and haplotype analysis of two single nucleotide RT polymorphisms in STK15 in Chinese."; RL Yi Chuan Xue Bao 32:331-336(2005). RN [69] RP VARIANT ILE-31. RX PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002; RA Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., RA Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., RA Burwinkel B.; RT "Aurora kinases A and B and familial breast cancer risk."; RL Cancer Lett. 247:266-272(2007). RN [70] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174 RP AND VAL-373. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [71] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN. RX PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654; RA Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C., RA Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.; RT "NEDD9 regulates actin dynamics through cortactin deacetylation in an RT AURKA/HDAC6-dependent manner."; RL Mol. Cancer Res. 12:681-693(2014). RN [72] RP FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-288. RX PubMed=26246606; DOI=10.1091/mbc.e15-02-0113; RA Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A., RA Koehler K., Huebner A., Griffis E.R.; RT "The nucleoporin ALADIN regulates Aurora A localization to ensure robust RT mitotic spindle formation."; RL Mol. Biol. Cell 26:3424-3438(2015). CC -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the CC regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, CC PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). CC Associates with the centrosome and the spindle microtubules during CC mitosis and plays a critical role in various mitotic events including CC the establishment of mitotic spindle, centrosome duplication, CC centrosome separation as well as maturation, chromosomal alignment, CC spindle assembly checkpoint, and cytokinesis (PubMed:14523000, CC PubMed:26246606). Required for normal spindle positioning during CC mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex CC during metaphase (PubMed:27335426). Required for initial activation of CC CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates CC numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, CC DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, CC p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, CC PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, CC PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1- CC mediated kinetochore fiber assembly and mitotic progression CC (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity CC (PubMed:19351716). Important for microtubule formation and/or CC stabilization (PubMed:18056443). Required for normal axon formation CC (PubMed:19812038). Plays a role in microtubule remodeling during CC neurite extension (PubMed:19668197). Also acts as a key regulatory CC component of the p53/TP53 pathway, and particularly the checkpoint- CC response pathways critical for oncogenic transformation of cells, by CC phosphorylating and destabilizing p53/TP53 (PubMed:14702041). CC Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) CC isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia CC outgrowth (By similarity). Required for cilia disassembly via CC phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin CC (PubMed:17604723, PubMed:20643351). Regulates protein levels of the CC anti-apoptosis protein BIRC5 by suppressing the expression of the CC SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through CC the phosphorylation of the transcription factor FOXP1 CC (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724, CC ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279, CC ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723, CC ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27192185, CC ECO:0000269|PubMed:27335426, ECO:0000269|PubMed:28218735}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; CC -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream CC event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2 CC act also as activators. Inactivated by the G2 checkpoint. Inhibited by CC GADD45A and p53/TP53, and through dephosphorylation by protein CC phosphatase type 1 (PP1). MLN8054 is also a potent and selective CC inhibitor. Activated during the early phase of cilia disassembly in the CC presence of CIMAP3. Inhibited by the small molecule inhibitor VX-680 CC (PubMed:28218735). {ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within CC the complex NEDD9 acts as a scaffold protein and is required for CC complex formation (PubMed:24574519). Identified in a complex with AUNIP CC and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity). CC Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the CC protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC CC (PubMed:11551964, PubMed:14580337, PubMed:14603251, PubMed:15966895, CC PubMed:17229885, PubMed:18662907, PubMed:19357306, PubMed:19668197, CC PubMed:19801554, PubMed:21225229, PubMed:27837025). Also interacts with CC its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53 CC (PubMed:14702041, PubMed:16890155, PubMed:17488622, PubMed:19351716, CC PubMed:19812038). Interaction with BORA promotes phosphorylation of CC PLK1 (By similarity). Interacts with CIMAP3 (PubMed:20643351). CC Interacts with GADD45A, competing with its oligomerization CC (PubMed:20460379). Interacts (via C-terminus) with AUNIP (via C- CC terminus) (PubMed:20596670). Interacts with FRY; this interaction CC facilitates AURKA-mediated PLK1 phosphorylation (PubMed:22753416). CC Interacts with SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with CC MYCN; interaction is phospho-independent and triggers AURKA activation; CC AURKA competes with FBXW7 for binding to unphosphorylated MYCN but not CC for binding to phosphorylated MYCN (PubMed:27837025). Interacts with CC HNRNPU (PubMed:21242313, PubMed:25986610). Interacts with AAAS CC (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400). CC Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA- CC mediated phosphorylation of HDAC6 promotes deacetylation of alpha- CC tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287, CC ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337, CC ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622, CC ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038, CC ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670, CC ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400, CC ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}. CC -!- INTERACTION: CC O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665; CC O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823; CC O14965; Q6PGQ7: BORA; NbExp=3; IntAct=EBI-448680, EBI-719836; CC O14965; P15056: BRAF; NbExp=5; IntAct=EBI-448680, EBI-365980; CC O14965; P00533: EGFR; NbExp=5; IntAct=EBI-448680, EBI-297353; CC O14965; P06730: EIF4E; NbExp=2; IntAct=EBI-448680, EBI-73440; CC O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185; CC O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456; CC O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266; CC O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907; CC O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972; CC O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369; CC O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579; CC O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768; CC O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990; CC O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317; CC O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606; CC O14965; Q9ULW0: TPX2; NbExp=10; IntAct=EBI-448680, EBI-1037322; CC O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm, CC cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231, CC ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome, centriole CC {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection CC {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium CC {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane CC {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in CC developing neurons (By similarity). Localizes at the centrosome in CC mitotic cells from early prophase until telophase, but also localizes CC to the spindle pole MTs from prophase to anaphase (PubMed:17229885, CC PubMed:21225229, PubMed:9606188). Colocalized with SIRT2 at centrosome CC (PubMed:22014574). Moves to the midbody during both telophase and CC cytokinesis (PubMed:17726514). Associates with both the pericentriolar CC material (PCM) and centrioles (PubMed:22014574). The localization to CC the spindle poles is regulated by AAAS (PubMed:26246606). CC {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606, CC ECO:0000269|PubMed:9606188}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal CC muscle, thymus and spleen. Also highly expressed in colon, ovarian, CC prostate, neuroblastoma, breast and cervical cancer cell lines. CC -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates CC during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997, CC ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}. CC -!- PTM: Activated by phosphorylation at Thr-288; this brings about a CC change in the conformation of the activation segment. Phosphorylation CC at Thr-288 varies during the cell cycle and is highest during M phase. CC Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be CC phosphorylated by several kinases, including PAK and PKA. Protein CC phosphatase type 1 (PP1) binds AURKA and inhibits its activity by CC dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342 CC decreases the kinase activity. PPP2CA controls degradation by CC dephosphorylating Ser-51 at the end of mitosis. CC {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907, CC ECO:0000269|PubMed:19668197}. CC -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex CC SCF(FBXL7) during mitosis, leading to its degradation by the proteasome CC (By similarity). Ubiquitinated by CHFR, leading to its degradation by CC the proteasome (By similarity). Ubiquitinated by the anaphase-promoting CC complex (APC), leading to its degradation by the proteasome CC (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18 CC ligase leading to its activation at the centrosome which is required CC for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated CC by CUL3-KLHL18 ligase does not lead to its degradation by the CC proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:23213400}. CC -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are CC uncoupled, and this amplification is associated with cancer and with an CC increase in the levels of chromosomal instability. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2 CC different proteins (PubMed:9771714). It is clear that they are the same CC protein. {ECO:0000305|PubMed:9771714}. CC -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation CC of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M CC transition was withdrawn due to data manipulation of flow cytometry CC data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/730/AURKA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA. DR EMBL; AF008551; AAC12708.1; -; mRNA. DR EMBL; AF011467; AAC23448.1; -; Genomic_DNA. DR EMBL; AF011468; AAC63902.1; -; mRNA. DR EMBL; AF195947; AAF29508.1; -; Genomic_DNA. DR EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75550.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75551.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75552.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75553.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75554.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75555.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75556.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75557.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75558.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75559.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75561.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75562.1; -; Genomic_DNA. DR EMBL; BC001280; AAH01280.1; -; mRNA. DR EMBL; BC002499; AAH02499.1; -; mRNA. DR EMBL; BC006423; AAH06423.1; -; mRNA. DR EMBL; BC027464; AAH27464.1; -; mRNA. DR CCDS; CCDS13451.1; -. DR PIR; JC5974; JC5974. DR RefSeq; NP_001310232.1; NM_001323303.2. DR RefSeq; NP_001310233.1; NM_001323304.2. DR RefSeq; NP_001310234.1; NM_001323305.2. DR RefSeq; NP_001411346.1; NM_001424417.1. DR RefSeq; NP_003591.2; NM_003600.3. DR RefSeq; NP_940835.1; NM_198433.3. DR RefSeq; NP_940836.1; NM_198434.3. DR RefSeq; NP_940837.1; NM_198435.3. DR RefSeq; NP_940838.1; NM_198436.3. DR RefSeq; NP_940839.1; NM_198437.3. DR PDB; 1MQ4; X-ray; 1.90 A; A=125-391. DR PDB; 1MUO; X-ray; 2.90 A; A=107-403. DR PDB; 1OL5; X-ray; 2.50 A; A=122-403. DR PDB; 1OL6; X-ray; 3.00 A; A=122-403. DR PDB; 1OL7; X-ray; 2.75 A; A=122-403. DR PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403. DR PDB; 2C6D; X-ray; 2.20 A; A=124-398. DR PDB; 2C6E; X-ray; 2.10 A; A/B=123-401. DR PDB; 2DWB; X-ray; 2.50 A; A=122-403. DR PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403. DR PDB; 2J50; X-ray; 3.00 A; A/B=126-403. DR PDB; 2NP8; X-ray; 2.25 A; A=125-391. DR PDB; 2W1C; X-ray; 3.24 A; A=122-389. DR PDB; 2W1D; X-ray; 2.97 A; A=122-389. DR PDB; 2W1E; X-ray; 2.93 A; A=122-389. DR PDB; 2W1F; X-ray; 2.85 A; A=122-389. DR PDB; 2W1G; X-ray; 2.71 A; A=122-389. DR PDB; 2WQE; X-ray; 2.50 A; A=127-388. DR PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403. DR PDB; 2WTW; X-ray; 3.30 A; A=122-403. DR PDB; 2X6D; X-ray; 2.80 A; A=122-403. DR PDB; 2X6E; X-ray; 3.35 A; A=122-403. DR PDB; 2X81; X-ray; 2.91 A; A=126-391. DR PDB; 2XNE; X-ray; 2.80 A; A=122-392. DR PDB; 2XNG; X-ray; 2.60 A; A=122-403. DR PDB; 2XRU; X-ray; 2.90 A; A=126-403. DR PDB; 3COH; X-ray; 2.70 A; A/B=124-391. DR PDB; 3E5A; X-ray; 2.30 A; A=125-391. DR PDB; 3EFW; X-ray; 2.29 A; A/B=125-391. DR PDB; 3FDN; X-ray; 1.90 A; A=123-401. DR PDB; 3H0Y; X-ray; 2.50 A; A=124-391. DR PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391. DR PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391. DR PDB; 3HA6; X-ray; 2.36 A; A=125-391. DR PDB; 3K5U; X-ray; 2.35 A; A=123-401. DR PDB; 3LAU; X-ray; 2.10 A; A=125-399. DR PDB; 3M11; X-ray; 2.75 A; A=123-401. DR PDB; 3MYG; X-ray; 2.40 A; A=125-391. DR PDB; 3NRM; X-ray; 3.05 A; A=126-403. DR PDB; 3O50; X-ray; 2.00 A; A/B=125-391. DR PDB; 3O51; X-ray; 3.20 A; A=125-391. DR PDB; 3P9J; X-ray; 2.80 A; A=125-391. DR PDB; 3QBN; X-ray; 3.50 A; A=124-403. DR PDB; 3R21; X-ray; 2.90 A; A=126-391. DR PDB; 3R22; X-ray; 2.90 A; A=126-391. DR PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UO4; X-ray; 2.45 A; A=123-401. DR PDB; 3UO5; X-ray; 2.70 A; A=123-401. DR PDB; 3UO6; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOD; X-ray; 2.50 A; A=123-401. DR PDB; 3UOH; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401. DR PDB; 3UOK; X-ray; 2.95 A; A/B=123-401. DR PDB; 3UOL; X-ray; 2.40 A; A/B=123-401. DR PDB; 3UP2; X-ray; 2.30 A; A=123-401. DR PDB; 3UP7; X-ray; 3.05 A; A=123-401. DR PDB; 3VAP; X-ray; 2.66 A; A=125-391. DR PDB; 3W10; X-ray; 2.70 A; A=126-403. DR PDB; 3W16; X-ray; 2.80 A; A=126-403. DR PDB; 3W18; X-ray; 2.50 A; A/B=126-403. DR PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388. DR PDB; 4B0G; X-ray; 2.50 A; A=122-403. DR PDB; 4BN1; X-ray; 2.50 A; A=122-403. DR PDB; 4BYI; X-ray; 2.60 A; A=122-403. DR PDB; 4BYJ; X-ray; 2.75 A; A=122-403. DR PDB; 4C3P; X-ray; 2.69 A; A/D=122-403. DR PDB; 4C3R; X-ray; 2.79 A; A=122-403. DR PDB; 4CEG; X-ray; 2.10 A; A=122-403. DR PDB; 4DEA; X-ray; 2.45 A; A=123-401. DR PDB; 4DEB; X-ray; 3.05 A; A=123-401. DR PDB; 4DED; X-ray; 3.05 A; A=123-401. DR PDB; 4DEE; X-ray; 2.30 A; A=123-401. DR PDB; 4DHF; X-ray; 2.80 A; A/B=126-391. DR PDB; 4J8M; X-ray; 1.85 A; A=123-401. DR PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401. DR PDB; 4JAI; X-ray; 3.20 A; A=122-396. DR PDB; 4JAJ; X-ray; 2.70 A; A=122-396. DR PDB; 4JBO; X-ray; 2.49 A; A=123-401. DR PDB; 4JBP; X-ray; 2.45 A; A=123-401. DR PDB; 4JBQ; X-ray; 2.30 A; A=123-401. DR PDB; 4O0S; X-ray; 2.50 A; A=122-403. DR PDB; 4O0U; X-ray; 2.60 A; A=122-403. DR PDB; 4O0W; X-ray; 2.60 A; A=122-403. DR PDB; 4PRJ; X-ray; 2.80 A; A=124-391. DR PDB; 4UYN; X-ray; 1.90 A; A=125-399. DR PDB; 4UZD; X-ray; 3.20 A; A/B=125-399. DR PDB; 4UZH; X-ray; 2.00 A; A=125-399. DR PDB; 4ZS0; X-ray; 3.00 A; A=122-403. DR PDB; 4ZTQ; X-ray; 2.80 A; A=122-403. DR PDB; 4ZTR; X-ray; 2.85 A; A=122-403. DR PDB; 4ZTS; X-ray; 2.90 A; A=122-403. DR PDB; 5AAD; X-ray; 3.10 A; A=122-403. DR PDB; 5AAE; X-ray; 3.11 A; A=122-403. DR PDB; 5AAF; X-ray; 2.78 A; A=122-403. DR PDB; 5AAG; X-ray; 2.85 A; A=122-403. DR PDB; 5DN3; X-ray; 2.05 A; A=125-391. DR PDB; 5DNR; X-ray; 1.95 A; A=125-391. DR PDB; 5DOS; X-ray; 2.98 A; A=126-390. DR PDB; 5DPV; X-ray; 2.29 A; A=126-390. DR PDB; 5DR2; X-ray; 2.46 A; A=128-390. DR PDB; 5DR6; X-ray; 2.53 A; A=126-390. DR PDB; 5DR9; X-ray; 2.47 A; A=126-390. DR PDB; 5DRD; X-ray; 2.13 A; A=126-390. DR PDB; 5DT0; X-ray; 2.15 A; A=126-390. DR PDB; 5DT3; X-ray; 2.33 A; A=126-390. DR PDB; 5DT4; X-ray; 2.86 A; A=126-390. DR PDB; 5EW9; X-ray; 2.18 A; A=123-390. DR PDB; 5G15; X-ray; 2.06 A; A=122-403. DR PDB; 5G1X; X-ray; 1.72 A; A=122-403. DR PDB; 5L8J; X-ray; 1.68 A; A=122-403. DR PDB; 5L8K; X-ray; 1.79 A; A=122-403. DR PDB; 5L8L; X-ray; 1.67 A; A=122-403. DR PDB; 5LXM; X-ray; 2.08 A; A=122-403. DR PDB; 5OBJ; X-ray; 2.90 A; A=125-391. DR PDB; 5OBR; X-ray; 2.62 A; A=125-391. DR PDB; 5ODT; X-ray; 2.02 A; A=122-403. DR PDB; 5ONE; X-ray; 2.60 A; A=122-403. DR PDB; 5ORL; X-ray; 1.69 A; A=127-391. DR PDB; 5ORN; X-ray; 2.19 A; A=127-391. DR PDB; 5ORO; X-ray; 2.12 A; A=127-391. DR PDB; 5ORP; X-ray; 2.19 A; A=127-391. DR PDB; 5ORR; X-ray; 2.09 A; A=127-391. DR PDB; 5ORS; X-ray; 1.98 A; A=127-391. DR PDB; 5ORT; X-ray; 2.56 A; A=127-391. DR PDB; 5ORV; X-ray; 1.88 A; A=127-391. DR PDB; 5ORW; X-ray; 2.00 A; A=127-391. DR PDB; 5ORX; X-ray; 1.88 A; A=127-391. DR PDB; 5ORY; X-ray; 1.99 A; A=127-391. DR PDB; 5ORZ; X-ray; 1.92 A; A=127-391. DR PDB; 5OS0; X-ray; 1.74 A; A=127-391. DR PDB; 5OS1; X-ray; 1.90 A; A=127-391. DR PDB; 5OS2; X-ray; 1.92 A; A=127-391. DR PDB; 5OS3; X-ray; 1.81 A; A=127-391. DR PDB; 5OS4; X-ray; 1.88 A; A=127-391. DR PDB; 5OS5; X-ray; 1.74 A; A=125-392. DR PDB; 5OS6; X-ray; 2.20 A; A=127-391. DR PDB; 5OSD; X-ray; 1.99 A; A=125-391. DR PDB; 5OSE; X-ray; 1.90 A; A=127-391. DR PDB; 5OSF; X-ray; 1.89 A; A=127-391. DR PDB; 5ZAN; X-ray; 2.85 A; A=123-403. DR PDB; 6C2R; X-ray; 1.96 A; A=125-391. DR PDB; 6C2T; X-ray; 1.73 A; A=125-391. DR PDB; 6C83; X-ray; 2.55 A; A/B=122-403. DR PDB; 6CPE; X-ray; 2.45 A; A=122-403. DR PDB; 6CPF; X-ray; 2.30 A; A=122-403. DR PDB; 6CPG; X-ray; 2.80 A; A/D=122-403. DR PDB; 6GRA; X-ray; 2.60 A; A=122-403. DR PDB; 6HJJ; X-ray; 2.13 A; A=122-403. DR PDB; 6HJK; X-ray; 2.40 A; A=122-403. DR PDB; 6I2U; X-ray; 2.50 A; A=122-403. DR PDB; 6R49; X-ray; 2.21 A; A=122-403. DR PDB; 6R4A; X-ray; 1.94 A; A=122-403. DR PDB; 6R4B; X-ray; 2.15 A; A=122-403. DR PDB; 6R4C; X-ray; 2.04 A; A=122-403. DR PDB; 6R4D; X-ray; 2.01 A; A=122-403. DR PDB; 6VPG; X-ray; 2.64 A; A=117-389. DR PDB; 6VPH; X-ray; 2.14 A; A=117-389. DR PDB; 6VPI; X-ray; 2.00 A; A=117-389. DR PDB; 6VPJ; X-ray; 2.10 A; A=117-389. DR PDB; 6VPL; X-ray; 1.86 A; A/B=117-389. DR PDB; 6VPM; X-ray; 1.58 A; A/B=117-389. DR PDB; 6XKA; X-ray; 2.65 A; A=117-389. DR PDB; 6Z4Y; X-ray; 2.25 A; A=122-403. DR PDB; 7AYH; X-ray; 2.80 A; A=122-403. DR PDB; 7AYI; X-ray; 2.86 A; A=122-403. DR PDB; 7FIC; X-ray; 2.32 A; A=127-391. DR PDB; 7O2V; X-ray; 3.10 A; A=116-403. DR PDB; 7ZTL; X-ray; 1.90 A; A=122-403. DR PDB; 8C14; X-ray; 1.93 A; A=125-391. DR PDB; 8C15; X-ray; 2.41 A; A=126-388. DR PDB; 8C1D; X-ray; 2.12 A; A=126-388. DR PDB; 8C1E; X-ray; 2.80 A; A=125-391. DR PDB; 8C1F; X-ray; 1.92 A; A=126-388. DR PDB; 8C1G; X-ray; 1.96 A; A=126-388. DR PDB; 8C1H; X-ray; 2.23 A; A=126-388. DR PDB; 8C1I; X-ray; 2.81 A; A=126-388. DR PDB; 8C1K; X-ray; 2.43 A; A=126-390. DR PDB; 8C1M; X-ray; 2.84 A; A=125-391. DR PDB; 8GUW; X-ray; 2.70 A; A/B/C=123-403. DR PDB; 8JF4; X-ray; 2.89 A; A=127-389. DR PDB; 8JG8; X-ray; 2.90 A; A=127-389. DR PDB; 8JMX; X-ray; 2.95 A; A=127-389. DR PDB; 8OF5; X-ray; 1.97 A; A=122-403. DR PDB; 8PR7; X-ray; 2.76 A; A/D=122-403. DR PDB; 8SSO; X-ray; 1.97 A; A/D=122-403. DR PDB; 8SSP; X-ray; 2.60 A; A=122-403. DR PDB; 9BZG; X-ray; 1.80 A; A=122-403. DR PDB; 9BZL; X-ray; 1.81 A; B=122-403. DR PDBsum; 1MQ4; -. DR PDBsum; 1MUO; -. DR PDBsum; 1OL5; -. DR PDBsum; 1OL6; -. DR PDBsum; 1OL7; -. DR PDBsum; 2BMC; -. DR PDBsum; 2C6D; -. DR PDBsum; 2C6E; -. DR PDBsum; 2DWB; -. DR PDBsum; 2J4Z; -. DR PDBsum; 2J50; -. DR PDBsum; 2NP8; -. DR PDBsum; 2W1C; -. DR PDBsum; 2W1D; -. DR PDBsum; 2W1E; -. DR PDBsum; 2W1F; -. DR PDBsum; 2W1G; -. DR PDBsum; 2WQE; -. DR PDBsum; 2WTV; -. DR PDBsum; 2WTW; -. DR PDBsum; 2X6D; -. DR PDBsum; 2X6E; -. DR PDBsum; 2X81; -. DR PDBsum; 2XNE; -. DR PDBsum; 2XNG; -. DR PDBsum; 2XRU; -. DR PDBsum; 3COH; -. DR PDBsum; 3E5A; -. DR PDBsum; 3EFW; -. DR PDBsum; 3FDN; -. DR PDBsum; 3H0Y; -. DR PDBsum; 3H0Z; -. DR PDBsum; 3H10; -. DR PDBsum; 3HA6; -. DR PDBsum; 3K5U; -. DR PDBsum; 3LAU; -. DR PDBsum; 3M11; -. DR PDBsum; 3MYG; -. DR PDBsum; 3NRM; -. DR PDBsum; 3O50; -. DR PDBsum; 3O51; -. DR PDBsum; 3P9J; -. DR PDBsum; 3QBN; -. DR PDBsum; 3R21; -. DR PDBsum; 3R22; -. DR PDBsum; 3UNZ; -. DR PDBsum; 3UO4; -. DR PDBsum; 3UO5; -. DR PDBsum; 3UO6; -. DR PDBsum; 3UOD; -. DR PDBsum; 3UOH; -. DR PDBsum; 3UOJ; -. DR PDBsum; 3UOK; -. DR PDBsum; 3UOL; -. DR PDBsum; 3UP2; -. DR PDBsum; 3UP7; -. DR PDBsum; 3VAP; -. DR PDBsum; 3W10; -. DR PDBsum; 3W16; -. DR PDBsum; 3W18; -. DR PDBsum; 3W2C; -. DR PDBsum; 4B0G; -. DR PDBsum; 4BN1; -. DR PDBsum; 4BYI; -. DR PDBsum; 4BYJ; -. DR PDBsum; 4C3P; -. DR PDBsum; 4C3R; -. DR PDBsum; 4CEG; -. DR PDBsum; 4DEA; -. DR PDBsum; 4DEB; -. DR PDBsum; 4DED; -. DR PDBsum; 4DEE; -. DR PDBsum; 4DHF; -. DR PDBsum; 4J8M; -. DR PDBsum; 4J8N; -. DR PDBsum; 4JAI; -. DR PDBsum; 4JAJ; -. DR PDBsum; 4JBO; -. DR PDBsum; 4JBP; -. DR PDBsum; 4JBQ; -. DR PDBsum; 4O0S; -. DR PDBsum; 4O0U; -. DR PDBsum; 4O0W; -. DR PDBsum; 4PRJ; -. DR PDBsum; 4UYN; -. DR PDBsum; 4UZD; -. DR PDBsum; 4UZH; -. DR PDBsum; 4ZS0; -. DR PDBsum; 4ZTQ; -. DR PDBsum; 4ZTR; -. DR PDBsum; 4ZTS; -. DR PDBsum; 5AAD; -. DR PDBsum; 5AAE; -. DR PDBsum; 5AAF; -. DR PDBsum; 5AAG; -. DR PDBsum; 5DN3; -. DR PDBsum; 5DNR; -. DR PDBsum; 5DOS; -. DR PDBsum; 5DPV; -. DR PDBsum; 5DR2; -. DR PDBsum; 5DR6; -. DR PDBsum; 5DR9; -. DR PDBsum; 5DRD; -. DR PDBsum; 5DT0; -. DR PDBsum; 5DT3; -. DR PDBsum; 5DT4; -. DR PDBsum; 5EW9; -. DR PDBsum; 5G15; -. DR PDBsum; 5G1X; -. DR PDBsum; 5L8J; -. DR PDBsum; 5L8K; -. DR PDBsum; 5L8L; -. DR PDBsum; 5LXM; -. DR PDBsum; 5OBJ; -. DR PDBsum; 5OBR; -. DR PDBsum; 5ODT; -. DR PDBsum; 5ONE; -. DR PDBsum; 5ORL; -. DR PDBsum; 5ORN; -. DR PDBsum; 5ORO; -. DR PDBsum; 5ORP; -. DR PDBsum; 5ORR; -. DR PDBsum; 5ORS; -. DR PDBsum; 5ORT; -. DR PDBsum; 5ORV; -. DR PDBsum; 5ORW; -. DR PDBsum; 5ORX; -. DR PDBsum; 5ORY; -. DR PDBsum; 5ORZ; -. DR PDBsum; 5OS0; -. DR PDBsum; 5OS1; -. DR PDBsum; 5OS2; -. DR PDBsum; 5OS3; -. DR PDBsum; 5OS4; -. DR PDBsum; 5OS5; -. DR PDBsum; 5OS6; -. DR PDBsum; 5OSD; -. DR PDBsum; 5OSE; -. DR PDBsum; 5OSF; -. DR PDBsum; 5ZAN; -. DR PDBsum; 6C2R; -. DR PDBsum; 6C2T; -. DR PDBsum; 6C83; -. DR PDBsum; 6CPE; -. DR PDBsum; 6CPF; -. DR PDBsum; 6CPG; -. DR PDBsum; 6GRA; -. DR PDBsum; 6HJJ; -. DR PDBsum; 6HJK; -. DR PDBsum; 6I2U; -. DR PDBsum; 6R49; -. DR PDBsum; 6R4A; -. DR PDBsum; 6R4B; -. DR PDBsum; 6R4C; -. DR PDBsum; 6R4D; -. DR PDBsum; 6VPG; -. DR PDBsum; 6VPH; -. DR PDBsum; 6VPI; -. DR PDBsum; 6VPJ; -. DR PDBsum; 6VPL; -. DR PDBsum; 6VPM; -. DR PDBsum; 6XKA; -. DR PDBsum; 6Z4Y; -. DR PDBsum; 7AYH; -. DR PDBsum; 7AYI; -. DR PDBsum; 7FIC; -. DR PDBsum; 7O2V; -. DR PDBsum; 7ZTL; -. DR PDBsum; 8C14; -. DR PDBsum; 8C15; -. DR PDBsum; 8C1D; -. DR PDBsum; 8C1E; -. DR PDBsum; 8C1F; -. DR PDBsum; 8C1G; -. DR PDBsum; 8C1H; -. DR PDBsum; 8C1I; -. DR PDBsum; 8C1K; -. DR PDBsum; 8C1M; -. DR PDBsum; 8GUW; -. DR PDBsum; 8JF4; -. DR PDBsum; 8JG8; -. DR PDBsum; 8JMX; -. DR PDBsum; 8OF5; -. DR PDBsum; 8PR7; -. DR PDBsum; 8SSO; -. DR PDBsum; 8SSP; -. DR PDBsum; 9BZG; -. DR PDBsum; 9BZL; -. DR AlphaFoldDB; O14965; -. DR SMR; O14965; -. DR BioGRID; 112666; 697. DR CORUM; O14965; -. DR DIP; DIP-33068N; -. DR ELM; O14965; -. DR FunCoup; O14965; 1695. DR IntAct; O14965; 219. DR MINT; O14965; -. DR STRING; 9606.ENSP00000216911; -. DR BindingDB; O14965; -. DR ChEMBL; CHEMBL4722; -. DR DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole. DR DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE. DR DrugBank; DB07266; AKI-001. DR DrugBank; DB05220; Alisertib. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB05169; AT9283. DR DrugBank; DB06347; Cenisertib. DR DrugBank; DB05198; CYC116. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB16891; ENMD-981693. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB18019; Erbumine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB12556; MK-5108. DR DrugBank; DB13061; MLN8054. DR DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE. DR DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB13059; PF-03814735. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB06134; SNS-314. DR DrugCentral; O14965; -. DR GuidetoPHARMACOLOGY; 1936; -. DR GlyGen; O14965; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14965; -. DR PhosphoSitePlus; O14965; -. DR BioMuta; AURKA; -. DR CPTAC; CPTAC-1341; -. DR CPTAC; CPTAC-3083; -. DR CPTAC; CPTAC-3084; -. DR jPOST; O14965; -. DR MassIVE; O14965; -. DR PaxDb; 9606-ENSP00000216911; -. DR PeptideAtlas; O14965; -. DR ProteomicsDB; 48339; -. DR Pumba; O14965; -. DR ABCD; O14965; 7 sequenced antibodies. DR Antibodypedia; 1129; 1084 antibodies from 47 providers. DR DNASU; 6790; -. DR Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.19. DR Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.19. DR Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.19. DR Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.19. DR Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.19. DR Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.19. DR Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.19. DR GeneID; 6790; -. DR KEGG; hsa:6790; -. DR MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1. DR UCSC; uc002xxe.1; human. DR AGR; HGNC:11393; -. DR CIViC; 6790; 8 evidence items across 3 molecular profiles. DR ClinPGx; PA36201; -. DR CTD; 6790; -. DR DisGeNET; 6790; -. DR GeneCards; AURKA; -. DR HGNC; HGNC:11393; AURKA. DR HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; AURKA; -. DR MIM; 603072; gene. DR OpenTargets; ENSG00000087586; -. DR VEuPathDB; HostDB:ENSG00000087586; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000154900; -. DR InParanoid; O14965; -. DR OMA; KIMNLMF; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; O14965; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14965; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O14965; -. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA. DR SignaLink; O14965; -. DR SIGNOR; O14965; -. DR Agora; ENSG00000087586; -. DR BioGRID-ORCS; 6790; 713 hits in 1214 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; AURKA; human. DR EvolutionaryTrace; O14965; -. DR GeneWiki; Aurora_A_kinase; -. DR GenomeRNAi; 6790; -. DR Pharos; O14965; Tchem. DR PRO; PR:O14965; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; O14965; protein. DR Bgee; ENSG00000087586; Expressed in oocyte and 159 other cell types or tissues. DR ExpressionAtlas; O14965; baseline and differential. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB. DR GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0042585; C:germinal vesicle; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:HPA. DR GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0045120; C:pronucleus; IEA:Ensembl. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035175; F:histone H3S10 kinase activity; IEA:Ensembl. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051642; P:centrosome localization; IEA:Ensembl. DR GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0097421; P:liver regeneration; IDA:MGI. DR GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc. DR GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0009611; P:response to wounding; IDA:MGI. DR GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl. DR GO; GO:0007051; P:spindle organization; IMP:UniProtKB. DR CDD; cd14116; STKc_Aurora-A; 1. DR DisProt; DP03125; -. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000235; Serine/threonine-protein kinase ark1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR030611; AURKA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane; KW Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm; KW Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..403 FT /note="Aurora kinase A" FT /id="PRO_0000086692" FT DOMAIN 133..383 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..125 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 280..293 FT /note="Activation segment" FT /evidence="ECO:0000269|PubMed:14580337" FT COMPBIAS 27..83 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 91..101 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 114..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 256 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027, FT ECO:0000269|PubMed:14580337" FT BINDING 143 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 162 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 211..213 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 260..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 274 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 51 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17229885" FT MOD_RES 287 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:19668197" FT MOD_RES 288 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11039908, FT ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907, FT ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606" FT MOD_RES 342 FT /note="Phosphoserine; by PKA and PAK" FT /evidence="ECO:0000269|PubMed:16246726" FT CROSSLNK 258 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 11 FT /note="G -> R (in dbSNP:rs6069717)" FT /id="VAR_030840" FT VARIANT 31 FT /note="F -> I (in dbSNP:rs2273535)" FT /evidence="ECO:0000269|PubMed:15867347, FT ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714" FT /id="VAR_030841" FT VARIANT 50 FT /note="P -> L (in dbSNP:rs34572020)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041127" FT VARIANT 57 FT /note="I -> V (increased kinase activity; dbSNP:rs1047972)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, FT ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714" FT /id="VAR_030842" FT VARIANT 104 FT /note="S -> L (in dbSNP:rs2230743)" FT /id="VAR_061745" FT VARIANT 155 FT /note="S -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; reduces interaction with TPX2)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041128" FT VARIANT 174 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; constitutively enhanced kinase activity)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041129" FT VARIANT 373 FT /note="M -> V (in dbSNP:rs33923703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041130" FT MUTAGEN 162 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14702041" FT MUTAGEN 165 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 198 FT /note="G->N: Reduces interaction with TPX2. Reduces kinase FT activity tenfold. Promotes interaction with the AURKB FT binding partners INCENP and BIRC5 that are normally not FT bound by AURKA." FT /evidence="ECO:0000269|PubMed:19357306" FT MUTAGEN 205 FT /note="R->A: Reduces ubiquitination and proteasomal FT degradation." FT /evidence="ECO:0000269|PubMed:10851084" FT MUTAGEN 274 FT /note="D->N: Abolishes cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:17604723" FT MUTAGEN 287 FT /note="T->A: No direct effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 287 FT /note="T->E: Enhances interaction with TPX2." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 288 FT /note="T->A: Reduces cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:17604723" FT MUTAGEN 288 FT /note="T->D: Mimics phosphorylation state and increases FT kinase activity." FT /evidence="ECO:0000269|PubMed:11039908" FT MUTAGEN 290 FT /note="C->A: Enhances stability; when associated with A- FT 393." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 334 FT /note="Y->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 335 FT /note="Q->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 346 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 393 FT /note="C->A: Enhances stability; when associated with A- FT 290." FT /evidence="ECO:0000269|PubMed:27837025" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 133..141 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 143..152 FT /evidence="ECO:0007829|PDB:6VPM" FT TURN 153..156 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 157..165 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 166..172 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 175..185 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:3UO6" FT STRAND 196..201 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:2J50" FT HELIX 218..225 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 230..249 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6XKA" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:3UOL" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:5ORL" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:5L8L" FT HELIX 288..291 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:5L8J" FT HELIX 298..302 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 304..306 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:6C2T" FT HELIX 310..324 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 334..342 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 350..352 FT /evidence="ECO:0007829|PDB:8JF4" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 368..370 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 374..378 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 381..386 FT /evidence="ECO:0007829|PDB:6VPM" SQ SEQUENCE 403 AA; 45823 MW; 7C2E7B438D969187 CRC64; MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS // ID BAP1_HUMAN Reviewed; 729 AA. AC Q92560; A8K993; Q6LEM0; Q7Z5E8; DT 05-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1998, sequence version 2. DT 28-JAN-2026, entry version 194. DE RecName: Full=Ubiquitin carboxyl-terminal hydrolase BAP1 {ECO:0000305}; DE EC=3.4.19.12 {ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:9528852}; DE AltName: Full=BRCA1-associated protein 1 {ECO:0000303|PubMed:9528852}; DE AltName: Full=Cerebral protein 6 {ECO:0000303|Ref.2}; GN Name=BAP1 {ECO:0000303|PubMed:9528852, ECO:0000312|HGNC:HGNC:950}; GN Synonyms=KIAA0272 {ECO:0000303|PubMed:9039502}; GN ORFNames=hucep-6 {ECO:0000303|Ref.2}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, MUTAGENESIS OF CYS-91 AND RP LEU-691, INTERACTION WITH BRCA1, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, RP AND MISCELLANEOUS. RC TISSUE=B-cell; RX PubMed=9528852; DOI=10.1038/sj.onc.1201861; RA Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., RA Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minna J., Borodovsky A., RA Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S., RA Prendergast G.C., Rauscher F.J. III; RT "BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and RT enhances BRCA1-mediated cell growth suppression."; RL Oncogene 16:1097-1112(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RA Yoshimoto M., Yazaki M., Takayama K., Matsumoto K.; RT "Biological functions of a novel human gene, hucep-6, which is specifically RT expressed in the central nervous system."; RL Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=9039502; DOI=10.1093/dnares/3.5.321; RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O., RA Tanaka A., Kotani H., Miyajima N., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. VI. The RT coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of RT cDNA clones from cell line KG-1 and brain."; RL DNA Res. 3:321-329(1996). RN [4] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 164-729. RC TISSUE=Medulloblastoma; RX PubMed=12800201; DOI=10.1002/ijc.11208; RA Behrends U., Schneider I., Roessler S., Frauenknecht H., Golbeck A., RA Lechner B., Eigenstetter G., Zobywalski C., Mueller-Weihrich S., RA Graubner U., Schmid I., Sackerer D., Spaeth M., Goetz C., Prantl F., RA Asmuss H.-P., Bise K., Mautner J.; RT "Novel tumor antigens identified by autologous antibody screening of RT childhood medulloblastoma cDNA libraries."; RL Int. J. Cancer 106:244-251(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-369; SER-521; RP SER-537; SER-585 AND SER-597, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS ASP-95 AND VAL-178. RX PubMed=10546591; DOI=10.1016/s0304-3835(99)90004-6; RA Jensen D.E., Rauscher F.J. III; RT "Defining biochemical functions for the BRCA1 tumor suppressor protein: RT analysis of the BRCA1 binding protein BAP1."; RL Cancer Lett. 143:S13-S17(1999). RN [16] RP FUNCTION. RX PubMed=12485996; DOI=10.1093/emboj/cdf691; RA Mallery D.L., Vandenberg C.J., Hiom K.; RT "Activation of the E3 ligase function of the BRCA1/BARD1 complex by RT polyubiquitin chains."; RL EMBO J. 21:6755-6762(2002). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, MUTAGENESIS OF RP CYS-91; 656-LYS--ARG-661 AND 717-ARG--ARG-722, AND CHARACTERIZATION OF RP VARIANTS ASP-95 AND VAL-178. RX PubMed=18757409; DOI=10.1158/0008-5472.can-08-0365; RA Ventii K.H., Devi N.S., Friedrich K.L., Chernova T.A., Tighiouart M., RA Van Meir E.G., Wilkinson K.D.; RT "BRCA1-associated protein-1 is a tumor suppressor that requires RT deubiquitinating activity and nuclear localization."; RL Cancer Res. 68:6953-6962(2008). RN [18] RP FUNCTION, INTERACTION WITH BARD1 AND BRCA1, AND CHARACTERIZATION OF VARIANT RP KURIS SER-91. RX PubMed=19117993; DOI=10.1158/0008-5472.can-08-3355; RA Nishikawa H., Wu W., Koike A., Kojima R., Gomi H., Fukuda M., Ohta T.; RT "BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer RT activity."; RL Cancer Res. 69:111-119(2009). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, MUTAGENESIS OF RP 363-ASN--TYR-366, AND CHARACTERIZATION OF VARIANT KURIS SER-91. RX PubMed=19815555; DOI=10.1074/jbc.m109.046755; RA Machida Y.J., Machida Y., Vashisht A.A., Wohlschlegel J.A., Dutta A.; RT "The deubiquitinating enzyme BAP1 regulates cell growth via interaction RT with HCF-1."; RL J. Biol. Chem. 284:34179-34188(2009). RN [20] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, AND MUTAGENESIS OF RP CYS-91 AND 363-ASN--TYR-366. RX PubMed=19188440; DOI=10.1128/mcb.01517-08; RA Misaghi S., Ottosen S., Izrael-Tomasevic A., Arnott D., Lamkanfi M., RA Lee J., Liu J., O'Rourke K., Dixit V.M., Wilson A.C.; RT "Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 RT with cell cycle regulator host cell factor 1."; RL Mol. Cell. Biol. 29:2181-2192(2009). RN [21] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, INTERACTION WITH YY1 AND RP HCFC1, IDENTIFICATION BY MASS SPECTROMETRY, AND CHARACTERIZATION OF VARIANT RP KURIS SER-91. RX PubMed=20805357; DOI=10.1128/mcb.00396-10; RA Yu H., Mashtalir N., Daou S., Hammond-Martel I., Ross J., Sui G., RA Hart G.W., Rauscher F.J. III, Drobetsky E., Milot E., Shi Y., Affar el B.; RT "The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and RT HCF-1 and is a critical regulator of gene expression."; RL Mol. Cell. Biol. 30:5071-5085(2010). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE PR-DUB COMPLEX, AND RP INTERACTION WITH ASXL1. RX PubMed=20436459; DOI=10.1038/nature08966; RA Scheuermann J.C., de Ayala Alonso A.G., Oktaba K., Ly-Hartig N., RA McGinty R.K., Fraterman S., Wilm M., Muir T.W., Muller J.; RT "Histone H2A deubiquitinase activity of the Polycomb repressive complex PR- RT DUB."; RL Nature 465:243-247(2010). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF 691-LEU--LYS-711. RX PubMed=24703950; DOI=10.1016/j.molcel.2014.03.002; RA Mashtalir N., Daou S., Barbour H., Sen N.N., Gagnon J., Hammond-Martel I., RA Dar H.H., Therrien M., Affar E.B.; RT "Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic RT sequestration mediated by the atypical ubiquitin ligase UBE2O."; RL Mol. Cell 54:392-406(2014). RN [24] RP SUBCELLULAR LOCATION, AND INTERACTION WITH FOXK2. RX PubMed=24748658; DOI=10.1093/nar/gku274; RA Ji Z., Mohammed H., Webber A., Ridsdale J., Han N., Carroll J.S., RA Sharrocks A.D.; RT "The forkhead transcription factor FOXK2 acts as a chromatin targeting RT factor for the BAP1-containing histone deubiquitinase complex."; RL Nucleic Acids Res. 42:6232-6242(2014). RN [25] RP IDENTIFICATION IN THE PR-DUB COMPLEX, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=24634419; DOI=10.1002/pmic.201400013; RA Baymaz H.I., Fournier A., Laget S., Ji Z., Jansen P.W., Smits A.H., RA Ferry L., Mensinga A., Poser I., Sharrocks A., Defossez P.A., Vermeulen M.; RT "MBD5 and MBD6 interact with the human PR-DUB complex through their methyl- RT CpG-binding domain."; RL Proteomics 14:2179-2189(2014). RN [26] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, DOMAIN, AND RP MUTAGENESIS OF ASN-251; LEU-635 AND 713-ARG--GLN-729. RX PubMed=30258054; DOI=10.1038/s41467-018-06186-1; RA Foglizzo M., Middleton A.J., Burgess A.E., Crowther J.M., Dobson R.C.J., RA Murphy J.M., Day C.L., Mace P.D.; RT "A bidentate Polycomb Repressive-Deubiquitinase complex is required for RT efficient activity on nucleosomes."; RL Nat. Commun. 9:3932-3932(2018). RN [27] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, SUBCELLULAR LOCATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=30664650; DOI=10.1038/s41467-018-08255-x; RA Campagne A., Lee M.K., Zielinski D., Michaud A., Le Corre S., Dingli F., RA Chen H., Shahidian L.Z., Vassilev I., Servant N., Loew D., Pasmant E., RA Postel-Vinay S., Wassef M., Margueron R.; RT "BAP1 complex promotes transcription by opposing PRC1-mediated H2A RT ubiquitylation."; RL Nat. Commun. 10:348-348(2019). RN [28] RP FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=34170818; DOI=10.7554/elife.63254; RA Perez-Garcia V., Lea G., Lopez-Jimenez P., Okkenhaug H., Burton G.J., RA Moffett A., Turco M.Y., Hemberger M.; RT "BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition RT during trophoblast differentiation and invasion."; RL Elife 10:0-0(2021). RN [29] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, INTERACTION WITH ASXL1, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=36180891; DOI=10.1186/s13059-022-02776-x; RA Tsuboyama N., Szczepanski A.P., Zhao Z., Wang L.; RT "MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent RT cancer."; RL Genome Biol. 23:206-206(2022). RN [30] {ECO:0007744|PDB:7VPW} RP X-RAY CRYSTALLOGRAPHY (3.76 ANGSTROMS) OF 706-724, SUBUNIT, INTERACTION RP WITH TNPO1; KPNA1 AND KPNA2, SUBCELLULAR LOCATION, DOMAIN NLS, RP UBIQUITINATION, MUTAGENESIS OF 684-GLN--GLN-729, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=35446349; DOI=10.1083/jcb.202201094; RA Yang T.J., Li T.N., Huang R.S., Pan M.Y., Lin S.Y., Lin S., Wu K.P., RA Wang L.H., Hsu S.D.; RT "Tumor suppressor BAP1 nuclear import is governed by transportin-1."; RL J. Cell Biol. 221:0-0(2022). RN [31] {ECO:0007744|PDB:8H1T} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) IN COMPLEX WITH ASXL1; RP UBB AND THE CHROMATOSOME COMPLEX, INTERACTION WITH ASXL1 AND CHROMATOSOME RP COMPLEX, DOMAIN C-TERMINAL TAIL AND UCH, AND MUTAGENESIS OF 56-ARG--ARG-60; RP 697-SER--GLN-729; 699-ARG--GLN-702; ARG-699; ARG-700; ARG-701; GLN-702; RP GLY-703; ARG-708; 711-LYS--ARG-718; 711-LYS--GLN-729; ARG-713 AND RP 718-ARG--GLN-729. RX PubMed=36991118; DOI=10.1038/s41586-023-05841-y; RA Ge W., Yu C., Li J., Yu Z., Li X., Zhang Y., Liu C.P., Li Y., Tian C., RA Zhang X., Li G., Zhu B., Xu R.M.; RT "Basis of the H2AK119specificity of the Polycomb repressive RT deubiquitinase."; RL Nature 616:176-182(2023). RN [32] {ECO:0007744|PDB:8SVF} RP STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN COMPLEX WITH ASXL1; RP UBC AND THE XENOPUS NUCLEOSOME COMPLEX, INTERACTION WITH ASXL1 AND THE RP NUCLEOSOME COMPLEX, DOMAIN UCH AND ARG-FINGER, AND MUTAGENESIS OF RP 56-ARG--ARG-60; ARG-56; ARG-59; 699-ARG--ARG-701; 699-ARG-ARG-700; ARG-699 RP AND ARG-701. RX PubMed=37556531; DOI=10.1126/sciadv.adg9832; RA Thomas J.F., Valencia-Sanchez M.I., Tamburri S., Gloor S.L., RA Rustichelli S., Godinez-Lopez V., De Ioannes P., Lee R., Abini-Agbomson S., RA Gretarsson K., Burg J.M., Hickman A.R., Sun L., Gopinath S., Taylor H.F., RA Sun Z.W., Ezell R.J., Vaidya A., Meiners M.J., Cheek M.A., Rice W.J., RA Svetlov V., Nudler E., Lu C., Keogh M.C., Pasini D., Armache K.J.; RT "Structural basis of histone H2A lysine 119 deubiquitination by Polycomb RT repressive deubiquitinase BAP1/ASXL1."; RL Sci. Adv. 9:eadg9832-eadg9832(2023). RN [33] RP VARIANT TPDS1 267-GLN--GLN-729 DEL, AND INVOLVEMENT IN TPDS1. RX PubMed=21941004; DOI=10.1136/jmedgenet-2011-100156; RA Abdel-Rahman M.H., Pilarski R., Cebulla C.M., Massengill J.B., RA Christopher B.N., Boru G., Hovland P., Davidorf F.H.; RT "Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, RT meningioma, and other cancers."; RL J. Med. Genet. 48:856-859(2011). RN [34] RP INVOLVEMENT IN MESOM, AND VARIANTS CYS-63; VAL-81; TRP-91; ASP-95; ALA-315 RP AND VAL-685. RX PubMed=21642991; DOI=10.1038/ng.855; RA Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., RA Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S., RA Zhou Q., Shen R., Olshen A., Rusch V., Ladanyi M.; RT "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic RT mutations and 3p21.1 losses in malignant pleural mesothelioma."; RL Nat. Genet. 43:668-672(2011). RN [35] RP INVOLVEMENT IN TPDS1. RX PubMed=21874003; DOI=10.1038/ng.910; RA Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P., RA Windpassinger C., Wackernagel W., Loy S., Wolf I., Viale A., Lash A.E., RA Pirun M., Socci N.D., Rutten A., Palmedo G., Abramson D., Offit K., Ott A., RA Becker J.C., Cerroni L., Kutzner H., Bastian B.C., Speicher M.R.; RT "Germline mutations in BAP1 predispose to melanocytic tumors."; RL Nat. Genet. 43:1018-1021(2011). RN [36] RP INVOLVEMENT IN TPDS1 AND MESOM. RX PubMed=21874000; DOI=10.1038/ng.912; RA Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., RA Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A., RA Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M.; RT "Germline BAP1 mutations predispose to malignant mesothelioma."; RL Nat. Genet. 43:1022-1025(2011). RN [37] RP VARIANT TPDS1 ALA-93. RX PubMed=23684012; DOI=10.1016/j.ajhg.2013.04.012; RA Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., RA Dubois-d'Enghien C., Richaudeau B., Renaudin X., Sellers J., Nicolas A., RA Sastre-Garau X., Desjardins L., Gyapay G., Raynal V., Sinilnikova O.M., RA Andrieu N., Manie E., de Pauw A., Gesta P., Bonadona V., Maugard C.M., RA Penet C., Avril M.F., Barillot E., Cabaret O., Delattre O., Richard S., RA Caron O., Benfodda M., Hu H.H., Soufir N., Bressac-de Paillerets B., RA Stoppa-Lyonnet D., Stern M.H.; RT "Germline BAP1 mutations predispose to renal cell carcinomas."; RL Am. J. Hum. Genet. 92:974-980(2013). RN [38] RP VARIANT PHE-47. RX PubMed=25080371; DOI=10.1111/cge.12472; RA de la Fouchardiere A., Cabaret O., Savin L., Combemale P., Schvartz H., RA Penet C., Bonadona V., Soufir N., Bressac-de Paillerets B.; RT "Germline BAP1 mutations predispose also to multiple basal cell RT carcinomas."; RL Clin. Genet. 88:273-277(2015). RN [39] RP FUNCTION, INTERACTION WITH FOXK1 AND FOXK2, PHOSPHORYLATION AT THR-493, RP MUTAGENESIS OF SER-489; SER-492; THR-493 AND THR-495, AND CHARACTERIZATION RP OF VARIANT KURIS SER-91. RX PubMed=25451922; DOI=10.1074/jbc.m114.609834; RA Okino Y., Machida Y., Frankland-Searby S., Machida Y.J.; RT "BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the RT ubiquitin-mediated activation of FoxK2 target genes."; RL J. Biol. Chem. 290:1580-1591(2015). RN [40] RP INVOLVEMENT IN UVM2. RX PubMed=25687217; DOI=10.3109/13816810.2015.1010734; RA Cebulla C.M., Binkley E.M., Pilarski R., Massengill J.B., Rai K., RA Liebner D.A., Marino M.J., Singh A.D., Abdel-Rahman M.H.; RT "Analysis of BAP1 Germline gene mutation in young uveal melanoma RT patients."; RL Ophthalmic Genet. 36:126-131(2015). RN [41] RP CHARACTERIZATION OF VARIANTS PHE-47; VAL-81; ASP-95 AND VAL-178. RX PubMed=26680512; DOI=10.1038/srep18462; RA Bhattacharya S., Hanpude P., Maiti T.K.; RT "Cancer associated missense mutations in BAP1 catalytic domain induce RT amyloidogenic aggregation: A new insight in enzymatic inactivation."; RL Sci. Rep. 5:18462-18462(2015). RN [42] RP INVOLVEMENT IN UVM2. RX PubMed=32002398; DOI=10.1159/000499570; RA Yu M.D., Masoomian B., Shields J.A., Shields C.L.; RT "BAP1 germline mutation associated with bilateral primary uveal melanoma."; RL Ocul. Oncol. Pathol. 6:10-14(2020). RN [43] RP VARIANTS KURIS ALA-12; THR-12; LYS-31; PRO-49; ARG-91; GLY-91; SER-91; RP ARG-169 AND GLN-718, CHARACTERIZATION OF VARIANTS KURIS THR-12; ARG-91; RP SER-91; ARG-169 AND GLN-718, INVOLVEMENT IN KURIS, FUNCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=35051358; DOI=10.1016/j.ajhg.2021.12.011; RG Undiagnosed Diseases Network; RA Kuery S., Ebstein F., Molle A., Besnard T., Lee M.K., Vignard V., Hery T., RA Nizon M., Mancini G.M.S., Giltay J.C., Cogne B., McWalter K., Deb W., RA Mor-Shaked H., Li H., Schnur R.E., Wentzensen I.M., Denomme-Pichon A.S., RA Fourgeux C., Verheijen F.W., Faurie E., Schot R., Stevens C.A., Smits D.J., RA Barr E., Sheffer R., Bernstein J.A., Stimach C.L., Kovitch E., Shashi V., RA Schoch K., Smith W., van Jaarsveld R.H., Hurst A.C.E., Smith K., RA Baugh E.H., Bohm S.G., Vyhnalkova E., Ryba L., Delnatte C., Neira J., RA Bonneau D., Toutain A., Rosenfeld J.A., Audebert-Bellanger S., RA Gilbert-Dussardier B., Odent S., Laumonnier F., Berger S.I., Smith A.C.M., RA Bourdeaut F., Stern M.H., Redon R., Krueger E., Margueron R., Bezieau S., RA Poschmann J., Isidor B.; RT "Rare germline heterozygous missense variants in BRCA1-associated protein RT 1, BAP1, cause a syndromic neurodevelopmental disorder."; RL Am. J. Hum. Genet. 109:361-372(2022). CC -!- FUNCTION: Deubiquitinating enzyme that plays a key role in chromatin by CC mediating deubiquitination of histone H2A and HCFC1 (PubMed:12485996, CC PubMed:18757409, PubMed:20436459, PubMed:25451922, PubMed:35051358). CC Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) CC complex, a complex that specifically mediates deubiquitination of CC histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1) CC (PubMed:20436459, PubMed:25451922, PubMed:30664650, PubMed:35051358). CC Does not deubiquitinate monoubiquitinated histone H2B (PubMed:20436459, CC PubMed:30664650). The PR-DUB complex is an epigenetic regulator of gene CC expression and acts as a transcriptional coactivator, affecting genes CC involved in development, cell communication, signaling, cell CC proliferation and cell viability (PubMed:20805357, PubMed:30664650, CC PubMed:36180891). Antagonizes PRC1 mediated H2AK119ub1 CC monoubiquitination (PubMed:30664650). As part of the PR-DUB complex, CC associates with chromatin enriched in histone marks H3K4me1, H3K4me3, CC and H3K27Ac, but not in H3K27me3 (PubMed:36180891). Recruited to CC specific gene-regulatory regions by YY1 (PubMed:20805357). Acts as a CC regulator of cell growth by mediating deubiquitination of HCFC1 N- CC terminal and C-terminal chains, with some specificity toward 'Lys-48'- CC linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin CC chains (PubMed:19188440, PubMed:19815555). Deubiquitination of HCFC1 CC does not lead to increase stability of HCFC1 (PubMed:19188440, CC PubMed:19815555). Interferes with the BRCA1 and BARD1 heterodimer CC activity by inhibiting their ability to mediate ubiquitination and CC autoubiquitination (PubMed:19117993). It however does not mediate CC deubiquitination of BRCA1 and BARD1 (PubMed:19117993). Able to mediate CC autodeubiquitination via intramolecular interactions to counteract CC monoubiquitination at the nuclear localization signal (NLS), thereby CC protecting it from cytoplasmic sequestration (PubMed:24703950). CC Negatively regulates epithelial-mesenchymal transition (EMT) of CC trophoblast stem cells during placental development by regulating genes CC involved in epithelial cell integrity, cell adhesion and cytoskeletal CC organization (PubMed:34170818). {ECO:0000269|PubMed:12485996, CC ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:20805357, CC ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:25451922, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:34170818, CC ECO:0000269|PubMed:35051358, ECO:0000269|PubMed:36180891}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide CC and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76- CC residue protein attached to proteins as an intracellular targeting CC signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:20436459, CC ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:9528852}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=4.7 uM for ubiquitin-7-amido-4-methylcoumarin (UB-AMC) CC {ECO:0000269|PubMed:30258054}; CC -!- SUBUNIT: Core component of the polycomb repressive deubiquitinase (PR- CC DUB) complex, at least composed of BAP1, one of ASXL1, ASXL2 or CC (probably) ASXL3, and one of MBD5 or MBD6 (PubMed:20436459, CC PubMed:24634419, PubMed:30664650, PubMed:36180891). The PR-DUB core CC associates with a number of accessory proteins, including FOXK1, FOXK2, CC KDM1B, HCFC1, YY1 and OGT; KDM1B specifically associates with ASXL2 PR- CC DUB complexes (Probable) (PubMed:20805357, PubMed:30664650). The BAP1 CC deubiquitinase activity is not required for PR-DUB assembly CC (PubMed:20805357). Homodimerizes (via coiled-coil hinge-region between CC the UCH and ULD domains) to mediate assembly of 2 copies of the BAP1- CC ASXL heterodimer into a bisymmetric tetramer; dimerization enhances CC association with nucleosomes (PubMed:30258054, PubMed:35446349). The CC PR-DUB complex associates with nucleosomes to mediate deubiquitination CC of 'lys-120' of histone H2AK118ub1 substrates; the association requires CC the positively charged C-terminal tail of BAP1 (PubMed:30258054, CC PubMed:36991118, PubMed:37556531). Interacts (via ULD domain) with CC ASXL1 (via DEUBAD domain); the interaction is direct and forms a CC ubiquitin binding cleft (PubMed:36180891, PubMed:36991118, CC PubMed:37556531). The interaction with ASXL1 stabilizes BAP1 but is not CC required for nucleosome binding (PubMed:36180891). Associates (via C- CC terminus) with nucleosome and chromatosome complexes through direct CC interaction with DNA and the histone3/4 dimer; this association CC displaces the histone-2A C-terminal tail, extending and orienting the CC H2AK118ub1 substrate towards the BAP1 deubiquitinase active site CC (PubMed:36991118, PubMed:37556531). Also interacts (via arginine CC finger) directly with the histone H2A-H2B acidic patch; this CC interaction is not critical for nucleosome-chromatosome association but CC may play a role in orienting the H2AK118ub1 substrate towards the PR- CC DUB complex active site (PubMed:36991118). Interacts with BRCA1 (via CC the RING finger) (PubMed:19117993, PubMed:9528852). Interacts (via HBM- CC like motif) with HCFC1 (PubMed:19188440, PubMed:19815555, CC PubMed:20805357). Interacts (via a C-terminal region overlapping the CC ULD domain) with YY1; the interaction is direct and requires the CC interaction with HCFC1 (PubMed:20805357). Interacts (when CC phosphorylated at Thr-493) with FOXK1 (PubMed:25451922). Interacts CC (when phosphorylated at Thr-493) with FOXK2; leading to recruitment of CC the PR-DUB complex and repression of FOXK2 target genes CC (PubMed:24748658, PubMed:25451922). Interacts (via non-classical PY- CC NLS) with TNPO1/transportin-1 (via HEAT repeats 8-12); the interaction CC is direct, mediates BAP1 nuclear localization and disrupts BAP1 CC homodimerization (PubMed:35446349). Interacts (via C-terminus) with CC KPNA1/importin alpha5 and KPNA2/importin alpha1; these interactions can CC contribute to BAP1 nuclear localization but are less important than the CC interaction with TNPO1/transportin-1 (PubMed:35446349). The interaction CC with TNPO1/transportin-1 disrupts homodimerization and blocks CC ubiquitination by UBE2O (PubMed:35446349). CC {ECO:0000269|PubMed:19117993, ECO:0000269|PubMed:19188440, CC ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20436459, CC ECO:0000269|PubMed:20805357, ECO:0000269|PubMed:24634419, CC ECO:0000269|PubMed:24748658, ECO:0000269|PubMed:25451922, CC ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:30664650, CC ECO:0000269|PubMed:35446349, ECO:0000269|PubMed:36180891, CC ECO:0000269|PubMed:36991118, ECO:0000269|PubMed:37556531, CC ECO:0000269|PubMed:9528852, ECO:0000305|PubMed:24634419}. CC -!- INTERACTION: CC Q92560; Q8IXJ9: ASXL1; NbExp=9; IntAct=EBI-1791447, EBI-1646500; CC Q92560; P15056: BRAF; NbExp=4; IntAct=EBI-1791447, EBI-365980; CC Q92560; P38398: BRCA1; NbExp=3; IntAct=EBI-1791447, EBI-349905; CC Q92560; P38398-5: BRCA1; NbExp=2; IntAct=EBI-1791447, EBI-2015072; CC Q92560; P51610: HCFC1; NbExp=6; IntAct=EBI-1791447, EBI-396176; CC Q92560; Q14573: ITPR3; NbExp=12; IntAct=EBI-1791447, EBI-351055; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18757409, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:24703950}. Nucleus {ECO:0000269|PubMed:18757409, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:24748658, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:35051358, CC ECO:0000269|PubMed:35446349, ECO:0000269|PubMed:9528852}. Chromosome CC {ECO:0000269|PubMed:30664650}. Note=Mainly nuclear (PubMed:24703950, CC PubMed:30664650). Binds to chromatin (PubMed:30664650). Localizes to CC the cytoplasm when monoubiquitinated by the E2/E3 hybrid ubiquitin- CC protein ligase UBE2O (PubMed:24703950). Recruitment to chromatin is CC dependent on ASXL1/2/3 and recruitment to specific genes on FOXK1/2 (By CC similarity). Nuclear localization is redundantly mediated by the CC importin and transportin systems; TNPO1/transportin-1 is the major CC mediator of nuclear localization (PubMed:35446349). CC {ECO:0000250|UniProtKB:Q99PU7, ECO:0000269|PubMed:24703950, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:35446349}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis, placenta and ovary CC (PubMed:9528852). Expressed in breast (PubMed:9528852). levels in the CC placenta increase over the course of pregnancy (PubMed:34170818). CC {ECO:0000269|PubMed:34170818, ECO:0000269|PubMed:9528852}. CC -!- DEVELOPMENTAL STAGE: Expressed in trophoblast stem cells during CC placenta development (at protein levels) (PubMed:34170818). Decreased CC expression levels correlate with epithelial-mesenchymal transition CC (EMT) during trophoblast cell differentiation (at protein level) CC (PubMed:34170818). {ECO:0000269|PubMed:34170818}. CC -!- DOMAIN: Possesses 2 overlapping nuclear localization sequences (NLS), a CC classic bipartite NLS and a non-classical PY-NLS (PubMed:35446349). The CC classical NLS probably mediates import via the importin alpha/beta CC system while the PY-NLS mediates nuclear import via the transportin CC system (PubMed:35446349). {ECO:0000269|PubMed:35446349}. CC -!- DOMAIN: The positively charged C-terminal tail stabilizes the CC interaction with nucleosomes/chromatosomes through interaction with the CC DNA backbone (PubMed:30258054, PubMed:36991118). Binding of ASXL1 just CC upstream of the positively charged C-terminal tail may stabilize its CC orientation to align the PR-DUB with its H2AK118ub1 substrate CC (PubMed:36991118). {ECO:0000269|PubMed:30258054, CC ECO:0000269|PubMed:36991118}. CC -!- DOMAIN: The ubiquitin C-terminal hydrolase (UCH) domain, together with CC the DEUBAD domain of ASXL1, forms the ubiquitin binding cleft of the CC PR-DUB complex. {ECO:0000269|PubMed:36991118, CC ECO:0000269|PubMed:37556531}. CC -!- DOMAIN: The positively charged Arg-finger motif mediates interaction CC with the histone H2A-H2B acidic patch; this interaction is critical for CC nucleosomal H2AK119ub1 deubiquitination activity but not nucleosomal CC binding. {ECO:0000269|PubMed:37556531}. CC -!- PTM: Ubiquitinated: monoubiquitinated at multiple sites within its CC nuclear localization signal (NLS) BY UBE2O, leading to cytoplasmic CC retention (PubMed:24703950). Able to mediate autodeubiquitination via CC intramolecular interactions to counteract cytoplasmic retention CC (PubMed:24703950). Monoubiquitinated on at least 4 sites near or within CC its PY-NLS (PubMed:35446349). {ECO:0000269|PubMed:24703950, CC ECO:0000269|PubMed:35446349}. CC -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive CC neoplasm of the serosal lining of the chest. It appears as broad sheets CC of cells, with some regions containing spindle-shaped, sarcoma-like CC cells and other regions showing adenomatous patterns. Pleural CC mesotheliomas have been linked to exposure to asbestos. CC {ECO:0000269|PubMed:21642991, ECO:0000269|PubMed:21874000}. Note=The CC gene represented in this entry is involved in disease pathogenesis. CC -!- DISEASE: Tumor predisposition syndrome 1 (TPDS1) [MIM:614327]: An CC autosomal dominant condition characterized by predisposition to develop CC a variety of tumors, including benign melanocytic tumors as well as CC several malignant tumors, including uveal melanoma, cutaneous melanoma, CC malignant mesothelioma on exposure to asbestos, lung adenocarcinoma and CC meningioma. {ECO:0000269|PubMed:21874000, ECO:0000269|PubMed:21874003, CC ECO:0000269|PubMed:21941004, ECO:0000269|PubMed:23684012}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Melanoma, uveal, 2 (UVM2) [MIM:606661]: Most common CC intraocular malignancy, arising from melanocytes in the iris, ciliary CC body, or choroid. Metastases develop in more than 30% of case patients, CC almost invariably in the liver, with poor prognosis. CC {ECO:0000269|PubMed:25687217, ECO:0000269|PubMed:32002398}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Kury-Isidor syndrome (KURIS) [MIM:619762]: An autosomal CC dominant neurodevelopmental disorder characterized mainly by mild CC global developmental delay apparent from infancy or early childhood, CC and behavioral problems, including autism in most patients. CC Intellectual development may be mildly delayed, borderline, or even CC normal. Additional variable systemic features may include poor overall CC growth, hypotonia, distal skeletal anomalies, seizures, and non- CC specific dysmorphic facial features. {ECO:0000269|PubMed:19117993, CC ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, CC ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:35051358}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: May act as a tumor suppressor. CC {ECO:0000269|PubMed:9528852}. CC -!- SIMILARITY: Belongs to the peptidase C12 family. BAP1 subfamily. CC {ECO:0000305}. CC -!- CAUTION: According to a report, interaction with FOXK2 is not dependent CC on phosphorylation of BAP1 (PubMed:24748658). However, it was later CC shown that phosphorylation at Thr-493 promotes interaction with FOXK2 CC (PubMed:25451922). {ECO:0000269|PubMed:24748658, CC ECO:0000269|PubMed:25451922}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA13401.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/755/BAP1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045581; AAC15970.1; -; mRNA. DR EMBL; D88812; BAB46921.1; -; mRNA. DR EMBL; D87462; BAA13401.2; ALT_INIT; mRNA. DR EMBL; AK292608; BAF85297.1; -; mRNA. DR EMBL; CH471055; EAW65220.1; -; Genomic_DNA. DR EMBL; BC001596; AAH01596.1; -; mRNA. DR EMBL; AY130008; AAN05092.1; -; mRNA. DR CCDS; CCDS2853.1; -. DR RefSeq; NP_004647.1; NM_004656.4. DR PDB; 7VPW; X-ray; 3.76 A; B=706-724. DR PDB; 8H1T; EM; 3.00 A; L=1-729. DR PDB; 8SVF; EM; 3.20 A; K=1-729. DR PDBsum; 7VPW; -. DR PDBsum; 8H1T; -. DR PDBsum; 8SVF; -. DR AlphaFoldDB; Q92560; -. DR EMDB; EMD-34431; -. DR EMDB; EMD-40789; -. DR SMR; Q92560; -. DR BioGRID; 113911; 1328. DR ComplexPortal; CPX-414; PR-DUB complex. DR CORUM; Q92560; -. DR DIP; DIP-47004N; -. DR FunCoup; Q92560; 3418. DR IntAct; Q92560; 113. DR MINT; Q92560; -. DR STRING; 9606.ENSP00000417132; -. DR BindingDB; Q92560; -. DR ChEMBL; CHEMBL1293314; -. DR MEROPS; C12.004; -. DR GlyGen; Q92560; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q92560; -. DR MetOSite; Q92560; -. DR PhosphoSitePlus; Q92560; -. DR BioMuta; BAP1; -. DR DMDM; 68565074; -. DR jPOST; Q92560; -. DR MassIVE; Q92560; -. DR PaxDb; 9606-ENSP00000417132; -. DR PeptideAtlas; Q92560; -. DR ProteomicsDB; 75316; -. DR Pumba; Q92560; -. DR Antibodypedia; 3812; 492 antibodies from 39 providers. DR DNASU; 8314; -. DR Ensembl; ENST00000460680.6; ENSP00000417132.1; ENSG00000163930.10. DR GeneID; 8314; -. DR KEGG; hsa:8314; -. DR MANE-Select; ENST00000460680.6; ENSP00000417132.1; NM_004656.4; NP_004647.1. DR UCSC; uc003ddx.5; human. DR AGR; HGNC:950; -. DR CIViC; 8314; 18 evidence items across 13 molecular profiles. DR ClinPGx; PA25254; -. DR CTD; 8314; -. DR DisGeNET; 8314; -. DR GeneCards; BAP1; -. DR GeneReviews; BAP1; -. DR HGNC; HGNC:950; BAP1. DR HPA; ENSG00000163930; Low tissue specificity. DR MalaCards; BAP1; -. DR MIM; 156240; phenotype. DR MIM; 603089; gene. DR MIM; 606661; phenotype. DR MIM; 614327; phenotype. DR MIM; 619762; phenotype. DR OpenTargets; ENSG00000163930; -. DR Orphanet; 289539; BAP1-related tumor predisposition syndrome. DR Orphanet; 618; Familial melanoma. DR Orphanet; 2495; Meningioma. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR Orphanet; 50251; Pleural mesothelioma. DR Orphanet; 39044; Uveal melanoma. DR VEuPathDB; HostDB:ENSG00000163930; -. DR eggNOG; KOG2778; Eukaryota. DR GeneTree; ENSGT00940000156388; -. DR HOGENOM; CLU_018316_5_0_1; -. DR InParanoid; Q92560; -. DR OMA; RIAYEQK; -. DR OrthoDB; 1924260at2759; -. DR PAN-GO; Q92560; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q92560; -. DR BRENDA; 3.4.19.12; 2681. DR PathwayCommons; Q92560; -. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR SignaLink; Q92560; -. DR SIGNOR; Q92560; -. DR Agora; ENSG00000163930; -. DR BioGRID-ORCS; 8314; 488 hits in 1221 CRISPR screens. DR ChiTaRS; BAP1; human. DR GeneWiki; BAP1; -. DR GenomeRNAi; 8314; -. DR Pharos; Q92560; Tbio. DR PRO; PR:Q92560; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q92560; protein. DR Bgee; ENSG00000163930; Expressed in left testis and 164 other cell types or tissues. DR ExpressionAtlas; Q92560; baseline and differential. DR GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0035517; C:PR-DUB complex; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl. DR GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB. DR GO; GO:0140950; F:histone H2A deubiquitinase activity; IMP:UniProtKB. DR GO; GO:0008233; F:peptidase activity; NAS:UniProtKB. DR GO; GO:0035726; P:common myeloid progenitor cell proliferation; IEA:Ensembl. DR GO; GO:0043249; P:erythrocyte maturation; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0061484; P:hematopoietic stem cell homeostasis; IEA:Ensembl. DR GO; GO:0031507; P:heterochromatin formation; IBA:GO_Central. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0070661; P:leukocyte proliferation; IEA:Ensembl. DR GO; GO:0061519; P:macrophage homeostasis; IEA:Ensembl. DR GO; GO:0000278; P:mitotic cell cycle; IEA:Ensembl. DR GO; GO:0035520; P:monoubiquitinated protein deubiquitination; IDA:UniProtKB. DR GO; GO:0033028; P:myeloid cell apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0070050; P:neuron cellular homeostasis; IEA:Ensembl. DR GO; GO:0030223; P:neutrophil differentiation; IEA:Ensembl. DR GO; GO:0043363; P:nucleate erythrocyte differentiation; IEA:Ensembl. DR GO; GO:0036344; P:platelet morphogenesis; IEA:Ensembl. DR GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL. DR GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB. DR GO; GO:0071108; P:protein K48-linked deubiquitination; IMP:UniProtKB. DR GO; GO:0036211; P:protein modification process; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IMP:UniProtKB. DR GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl. DR GO; GO:0002574; P:thrombocyte differentiation; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro. DR CDD; cd09617; Peptidase_C12_UCH37_BAP1; 1. DR FunFam; 1.20.58.860:FF:000002; Ubiquitin carboxyl-terminal hydrolase; 1. DR FunFam; 3.40.532.10:FF:000002; Ubiquitin carboxyl-terminal hydrolase; 1. DR Gene3D; 1.20.58.860; -; 1. DR Gene3D; 3.40.532.10; Peptidase C12, ubiquitin carboxyl-terminal hydrolase; 1. DR InterPro; IPR038765; Papain-like_cys_pep_sf. DR InterPro; IPR001578; Peptidase_C12_UCH. DR InterPro; IPR036959; Peptidase_C12_UCH_sf. DR InterPro; IPR041507; UCH_C. DR PANTHER; PTHR10589; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1. DR PANTHER; PTHR10589:SF28; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE BAP1; 1. DR Pfam; PF01088; Peptidase_C12; 1. DR Pfam; PF18031; UCH_C; 1. DR PRINTS; PR00707; UBCTHYDRLASE. DR SUPFAM; SSF54001; Cysteine proteinases; 1. DR PROSITE; PS52048; UCH_DOMAIN; 1. DR PROSITE; PS52049; ULD; 1. PE 1: Evidence at protein level; KW 3D-structure; Chromatin regulator; Chromosome; Coiled coil; Cytoplasm; KW Developmental protein; Differentiation; Disease variant; Hydrolase; KW Intellectual disability; Nucleus; Phosphoprotein; Protease; KW Proteomics identification; Reference proteome; Thiol protease; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..729 FT /note="Ubiquitin carboxyl-terminal hydrolase BAP1" FT /id="PRO_0000211069" FT DOMAIN 4..235 FT /note="UCH catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT DOMAIN 670..698 FT /note="ULD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01394" FT REGION 301..351 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 372..435 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 464..524 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 575..623 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 596..721 FT /note="Interaction with BRCA1" FT REGION 642..686 FT /note="Interaction with YY1" FT /evidence="ECO:0000269|PubMed:20805357" FT REGION 699..701 FT /note="Interaction with nucleosomal DNA forming a DNA clamp FT with ASXL1" FT /evidence="ECO:0000269|PubMed:37556531" FT REGION 703..729 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 713..729 FT /note="Positively charged C-terminal extension (CTE)" FT /evidence="ECO:0000269|PubMed:30258054, FT ECO:0000269|PubMed:36991118" FT COILED 636..656 FT /evidence="ECO:0000255" FT MOTIF 56..60 FT /note="Arg-finger motif" FT /evidence="ECO:0000269|PubMed:37556531" FT MOTIF 363..366 FT /note="HBM-like motif" FT /evidence="ECO:0000269|PubMed:19188440, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, FT ECO:0000269|PubMed:25451922" FT MOTIF 699..722 FT /note="Classical bipartite Nuclear localization signal FT (NLS)" FT /evidence="ECO:0000269|PubMed:18757409, FT ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:35446349" FT MOTIF 717..724 FT /note="Non-classical PY-nuclear localization signal (PY- FT NLS)" FT /evidence="ECO:0000269|PubMed:35446349" FT COMPBIAS 395..409 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 480..524 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 582..598 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 599..614 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 91 FT /note="Nucleophile" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, FT ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, FT ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:9528852" FT ACT_SITE 169 FT /note="Proton donor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT SITE 85 FT /note="Transition state stabilizer" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT SITE 184 FT /note="Important for enzyme activity" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT MOD_RES 292 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 369 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99PU7" FT MOD_RES 493 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:25451922" FT MOD_RES 521 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 585 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 597 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 12 FT /note="P -> A (in KURIS; dbSNP:rs2153228682)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086937" FT VARIANT 12 FT /note="P -> T (in KURIS; loss-of-function variant; FT increased steady-state levels of ubiquitinated H2A are FT found in patient cells; unable to rescue impaired H2AK119ub FT deubiquitination when expressed in BAP1-deficient cells; FT does not affect localization to the nucleus; FT dbSNP:rs2153228682)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086938" FT VARIANT 31 FT /note="E -> K (in KURIS; uncertain significance; FT dbSNP:rs2153228535)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086939" FT VARIANT 47 FT /note="I -> F (found in a primary uveal melanoma; somatic FT mutation; induces cytoplasmic accumulation; loss of FT deubiquitinase activity; up-regulates heat shock response; FT induces formation of amyloid-beta aggregates; FT dbSNP:rs2153228345)" FT /evidence="ECO:0000269|PubMed:25080371, FT ECO:0000269|PubMed:26680512" FT /id="VAR_075251" FT VARIANT 49 FT /note="L -> P (in KURIS; uncertain significance; FT dbSNP:rs2153228340)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086940" FT VARIANT 63 FT /note="S -> C (found in a malignant pleural mesothelioma FT sample; somatic mutation; dbSNP:rs747311942)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065976" FT VARIANT 81 FT /note="F -> V (found in a malignant pleural mesothelioma FT sample; somatic mutation; induces cytoplasmic accumulation; FT loss of deubiquitinase activity; up-regulates heat shock FT response; induces formation of amyloid-beta aggregates)" FT /evidence="ECO:0000269|PubMed:21642991, FT ECO:0000269|PubMed:26680512" FT /id="VAR_065977" FT VARIANT 91 FT /note="C -> G (in KURIS; dbSNP:rs1705222655)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086941" FT VARIANT 91 FT /note="C -> R (in KURIS; loss-of-function variant; unable FT to rescue impaired H2AK119ub deubiquitination when FT expressed in BAP1-deficient cells; does not affect FT localization to the nucleus; dbSNP:rs1705222655)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086942" FT VARIANT 91 FT /note="C -> S (in KURIS; loss-of-function variant; FT increased steady-state level of ubiquitinated H2A are found FT in patient cells; unable to rescue impaired H2AK119ub FT deubiquitination when expressed in BAP1-deficient cells; FT abolishes deubiquitinase activity; does not affect its FT ability to interfere with BRCA1 E3 ligase activity; does FT not affect localization to the nucleus; has a dominant FT negative effect on cell growth; does not affect interaction FT with FOXK1 and FOXK2; has no effect on PR-DUB complex FT assembly; unable to activate transcription; FT dbSNP:rs1559591264)" FT /evidence="ECO:0000269|PubMed:19117993, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, FT ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:35051358" FT /id="VAR_086943" FT VARIANT 91 FT /note="C -> W (found in a malignant pleural mesothelioma FT sample; dbSNP:rs2153228144)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065978" FT VARIANT 93 FT /note="T -> A (in TPDS1; significantly increased risk for FT renal cell carcinoma; dbSNP:rs375129361)" FT /evidence="ECO:0000269|PubMed:23684012" FT /id="VAR_087531" FT VARIANT 95 FT /note="A -> D (in a lung cancer sample; also found in a FT malignant pleural mesothelioma cell line; induces FT cytoplasmic accumulation; loss of deubiquitinase activity; FT up-regulates heat shock response; induces formation of FT amyloid-beta aggregates)" FT /evidence="ECO:0000269|PubMed:10546591, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:21642991, FT ECO:0000269|PubMed:26680512" FT /id="VAR_063498" FT VARIANT 169 FT /note="H -> R (in KURIS; loss-of-function variant; unable FT to rescue impaired H2AK119ub deubiquitination when FT expressed in BAP1-deficient cells; does not affect FT localization to the nucleus; dbSNP:rs2153227828)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086944" FT VARIANT 178 FT /note="G -> V (in a lung cancer sample; induces cytoplasmic FT accumulation; impairs deubiquitinase activity; up-regulates FT heat shock response; induces formation of beta-amyloid FT aggregates; dbSNP:rs2153227803)" FT /evidence="ECO:0000269|PubMed:10546591, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:26680512" FT /id="VAR_063499" FT VARIANT 267..729 FT /note="Missing (in TPDS1)" FT /evidence="ECO:0000269|PubMed:21941004" FT /id="VAR_087532" FT VARIANT 315 FT /note="E -> A (found in a malignant pleural mesothelioma FT sample; dbSNP:rs149974450)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065979" FT VARIANT 616 FT /note="V -> E (in dbSNP:rs35353781)" FT /id="VAR_051517" FT VARIANT 685 FT /note="E -> V (found in a malignant pleural mesothelioma FT cell line)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065980" FT VARIANT 718 FT /note="R -> Q (in KURIS; uncertain significance; able to FT rescue impaired H2AK119ub deubiquitination when expressed FT in BAP1-deficient cells; does not affect localization to FT the nucleus; dbSNP:rs1440748203)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086945" FT MUTAGEN 56..60 FT /note="RRSRR->AASAA: Probably disrupts interaction with the FT histone H2A-H2B acidic patch. Severely attenuates FT deubiquitination of histone H2AK119ub1 substrates in the FT context of the nucleosome but does not disrupt nucleosome FT interaction." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 56 FT /note="R->C: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 59 FT /note="R->W: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 91 FT /note="C->A: Abolishes deubiquitinase activity. Has no FT effect on interaction with HCFC1." FT /evidence="ECO:0000269|PubMed:18757409, FT ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:9528852" FT MUTAGEN 251 FT /note="N->R: Severely attenuates deubiquitination of FT histone H2AK119ub1 substrates, possibly due to disruption FT of homodimerization." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 363..366 FT /note="NHNY->AAAA: Abolishes interaction with HCFC1 without FT affecting interaction with FOXK1 and FOXK2." FT /evidence="ECO:0000269|PubMed:19188440, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922" FT MUTAGEN 489 FT /note="S->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 492 FT /note="S->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 493 FT /note="T->A,L: Abolished interaction with FOXK1 and FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 495 FT /note="T->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 635 FT /note="L->A: Severely attenuated deubiquitination of FT histone H2AK119ub1 substrates, possibly due to disruption FT of homodimerization. No effect on intrinsic catalytic FT activity." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 656..661 FT /note="KRKKFK->AAAAAA: Does not affect nuclear FT localization." FT /evidence="ECO:0000269|PubMed:18757409" FT MUTAGEN 684..729 FT /note="Missing: Predominantly localizes to the cytosol." FT /evidence="ECO:0000269|PubMed:35446349" FT MUTAGEN 691..711 FT /note="Missing: Abolishes ubiquitination by UBE2O." FT /evidence="ECO:0000269|PubMed:24703950" FT MUTAGEN 691 FT /note="L->P: Abolishes interaction with BRCA1." FT /evidence="ECO:0000269|PubMed:9528852" FT MUTAGEN 697..729 FT /note="Missing: Abolishes deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome, FT probably due to disruption of nucleosome interaction. Does FT not affect deubiquitination of H2AK119ub1 on free FT histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 699..702 FT /note="Missing: Severely reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome but only mildly disrupts nucleosome FT interaction." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 699..701 FT /note="RRR->AAA: Reduced nucleosomal binding." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 699..700 FT /note="RR->DD: Reduced nucleosomal binding." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 699 FT /note="R->W: Slight or no reduction of deubiquitination FT efficiency towards H2AK119ub1 substrates in the context of FT the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 700 FT /note="R->Q: Slightly reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 701 FT /note="R->C: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 702 FT /note="Missing: Slightly reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 703 FT /note="G->P,R: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 708 FT /note="R->A: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 711..729 FT /note="Missing: Disrupts nucleosome interaction and FT abolishes deubiquitination activity towards H2AK119ub1 FT substrates in the context of the nucleosome. Does not FT affect deubiquitination of H2AK119ub1 on free histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 711..718 FT /note="Missing: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome, FT probably due to disruption of nucleosome interaction. Does FT not affect deubiquitination of H2AK119ub1 on free FT histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 713..729 FT /note="Missing: Impairs deubiquitination activity of FT histone H2AK118ub1 substrates, probably due to disruption FT of nucleosome association." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 713 FT /note="R->A: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 717..722 FT /note="RRKRSR->AAAAAA: Abolishes nuclear localization." FT /evidence="ECO:0000269|PubMed:18757409" FT MUTAGEN 718..729 FT /note="Missing: Disrupts nucleosome interaction and reduces FT deubiquitination activity towards H2AK119ub1 substrates in FT the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT HELIX 12..22 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 46..52 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 55..59 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 68..70 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 91..101 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:8SVF" FT HELIX 110..119 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:8SVF" FT HELIX 124..132 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 135..143 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 148..151 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 167..175 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 178..186 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 191..195 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 203..217 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 228..234 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 237..242 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 648..667 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 672..685 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 688..694 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 700..703 FT /evidence="ECO:0007829|PDB:8H1T" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:8SVF" SQ SEQUENCE 729 AA; 80362 MW; 031DA03AE1841D85 CRC64; MNKGWLELES DPGLFTLLVE DFGVKGVQVE EIYDLQSKCQ GPVYGFIFLF KWIEERRSRR KVSTLVDDTS VIDDDIVNNM FFAHQLIPNS CATHALLSVL LNCSSVDLGP TLSRMKDFTK GFSPESKGYA IGNAPELAKA HNSHARPEPR HLPEKQNGLS AVRTMEAFHF VSYVPITGRL FELDGLKVYP IDHGPWGEDE EWTDKARRVI MERIGLATAG EPYHDIRFNL MAVVPDRRIK YEARLHVLKV NRQTVLEALQ QLIRVTQPEL IQTHKSQESQ LPEESKSASN KSPLVLEANR APAASEGNHT DGAEEAAGSC AQAPSHSPPN KPKLVVKPPG SSLNGVHPNP TPIVQRLPAF LDNHNYAKSP MQEEEDLAAG VGRSRVPVRP PQQYSDDEDD YEDDEEDDVQ NTNSALRYKG KGTGKPGALS GSADGQLSVL QPNTINVLAE KLKESQKDLS IPLSIKTSSG AGSPAVAVPT HSQPSPTPSN ESTDTASEIG SAFNSPLRSP IRSANPTRPS SPVTSHISKV LFGEDDSLLR VDCIRYNRAV RDLGPVISTG LLHLAEDGVL SPLALTEGGK GSSPSIRPIQ GSQGSSSPVE KEVVEATDSR EKTGMVRPGE PLSGEKYSPK ELLALLKCVE AEIANYEACL KEEVEKRKKF KIDDQRRTHN YDEFICTFIS MLAQEGMLAN LVEQNISVRR RQGVSIGRLH KQRKPDRRKR SRPYKAKRQ // ID BARD1_HUMAN Reviewed; 777 AA. AC Q99728; F6MDH7; F6MDH8; F6MDH9; O43574; Q53SS5; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 239. DE RecName: Full=BRCA1-associated RING domain protein 1; DE Short=BARD-1; DE EC=2.3.2.27 {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:20351172}; DE AltName: Full=RING-type E3 ubiquitin transferase BARD1 {ECO:0000305}; GN Name=BARD1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=B-cell; RX PubMed=8944023; DOI=10.1038/ng1296-430; RA Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., RA Yang M.-C.W., Hwang L.-Y., Bowcock A.M., Baer R.; RT "Identification of a RING protein that can interact in vivo with the BRCA1 RT gene product."; RL Nat. Genet. 14:430-440(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-24; GLU-153; SER-378; RP MET-507; SER-557; HIS-564; CYS-658; LEU-695 AND ASN-761. RX PubMed=9425226; DOI=10.1093/hmg/7.2.195; RA Thai T.H., Du F., Tsan J.T., Jin Y., Phung A., Spillman M.A., Massa H.F., RA Muller C.Y., Ashfaq R., Mathis J.M., Miller D.S., Trask B.J., Baer R., RA Bowcock A.M.; RT "Mutations in the BRCA1-associated RING domain (BARD1) gene in primary RT breast, ovarian and uterine cancers."; RL Hum. Mol. Genet. 7:195-202(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), AND RP ALTERNATIVE SPLICING. RX PubMed=18089818; DOI=10.1158/0008-5472.can-07-2370; RA Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C.E., Bertoni F., RA Zeillinger R., Irminger-Finger I.; RT "Oncogenic BARD1 isoforms expressed in gynecological cancers."; RL Cancer Res. 67:11876-11885(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP DOMAINS. RX PubMed=10026184; DOI=10.1074/jbc.274.9.5659; RA Meza J.E., Brzovic P.S., King M.-C., Klevit R.E.; RT "Mapping the functional domains of BRCA1. Interaction of the ring finger RT domains of BRCA1 and BARD1."; RL J. Biol. Chem. 274:5659-5665(1999). RN [7] RP POSSIBLE FUNCTION. RX PubMed=10477523; DOI=10.1126/science.285.5433.1576; RA Kleiman F.E., Manley J.L.; RT "Functional interaction of BRCA1-associated BARD1 with polyadenylation RT factor CstF-50."; RL Science 285:1576-1579(1999). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=12890688; DOI=10.1074/jbc.c300249200; RA Wu-Baer F., Lagrazon K., Yuan W., Baer R.; RT "The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an RT unconventional linkage involving lysine residue K6 of ubiquitin."; RL J. Biol. Chem. 278:34743-34746(2003). RN [9] RP FUNCTION, AND INTERACTION WITH BRCA1. RX PubMed=14976165; DOI=10.1093/hmg/ddh095; RA Morris J.R., Solomon E.; RT "BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, RT dependent on K6 of ubiquitin, in cells during DNA replication and repair."; RL Hum. Mol. Genet. 13:807-817(2004). RN [10] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=17643122; DOI=10.1038/nsmb1277; RA Kim H., Huang J., Chen J.; RT "CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage RT response."; RL Nat. Struct. Mol. Biol. 14:710-715(2007). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391 AND THR-394, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [13] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=19261749; DOI=10.1101/gad.1770309; RA Wang B., Hurov K., Hofmann K., Elledge S.J.; RT "NBA1, a new player in the Brca1 A complex, is required for DNA damage RT resistance and checkpoint control."; RL Genes Dev. 23:729-739(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=20351172; DOI=10.1128/mcb.01056-09; RA Wu-Baer F., Ludwig T., Baer R.; RT "The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 RT tumor suppressor and inhibits its enzymatic function."; RL Mol. Cell. Biol. 30:2787-2798(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186 AND THR-299, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-170, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-160; LYS-170; LYS-423 AND RP LYS-548, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [19] RP STRUCTURE BY NMR OF 26-140 IN COMPLEX WITH BRCA1 AND ZINC IONS, AND RP SUBUNIT. RX PubMed=11573085; DOI=10.1038/nsb1001-833; RA Brzovic P.S., Rajagopal P., Hoyt D.W., King M.C., Klevit R.E.; RT "Structure of a BRCA1-BARD1 heterodimeric RING-RING complex."; RL Nat. Struct. Biol. 8:833-837(2001). RN [20] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 568-777. RX PubMed=17550235; DOI=10.1021/bi700323t; RA Birrane G., Varma A.K., Soni A., Ladias J.A.; RT "Crystal structure of the BARD1 BRCT domains."; RL Biochemistry 46:7706-7712(2007). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 569-777, INTERACTION WITH CSTF1, RP DOMAIN STRUCTURE, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18842000; DOI=10.1021/bi801115g; RA Edwards R.A., Lee M.S., Tsutakawa S.E., Williams R.S., Nazeer I., RA Kleiman F.E., Tainer J.A., Glover J.N.; RT "The BARD1 C-terminal domain structure and interactions with RT polyadenylation factor CstF-50."; RL Biochemistry 47:11446-11456(2008). RN [22] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 425-555, IDENTIFICATION BY MASS RP SPECTROMETRY, DOMAINS ANK REPEATS, AND DOMAIN STRUCTURE. RX PubMed=18480049; DOI=10.1074/jbc.m802333200; RA Fox D. III, Le Trong I., Rajagopal P., Brzovic P.S., Stenkamp R.E., RA Klevit R.E.; RT "Crystal structure of the BARD1 ankyrin repeat domain and its functional RT consequences."; RL J. Biol. Chem. 283:21179-21186(2008). CC -!- FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer CC specifically mediates the formation of 'Lys-6'-linked polyubiquitin CC chains and coordinates a diverse range of cellular pathways such as DNA CC damage repair, ubiquitination and transcriptional regulation to CC maintain genomic stability. Plays a central role in the control of the CC cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 CC ligase activity that is required for its tumor suppressor function. CC Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing CC and RNAP II stability by inhibiting pre-mRNA 3' cleavage. CC {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:20351172}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:12890688, CC ECO:0000269|PubMed:20351172}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Homo- and heterodimer. Heterodimer (RING-type zinc finger) CC with BRCA1. Heterodimer (via ANK repeats and BRCT domains) with CC CSTF1/CSTF-50. Component of the BRCA1-A complex, at least composed of CC the BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36, BABAM2 and CC BABAM1/NBA1. Interacts with UBXN1. {ECO:0000269|PubMed:11573085, CC ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:17643122, ECO:0000269|PubMed:18842000, CC ECO:0000269|PubMed:19261749, ECO:0000269|PubMed:20351172}. CC -!- INTERACTION: CC Q99728; P31749: AKT1; NbExp=3; IntAct=EBI-473181, EBI-296087; CC Q99728; Q9Y2T1: AXIN2; NbExp=3; IntAct=EBI-473181, EBI-4400025; CC Q99728; P38398: BRCA1; NbExp=20; IntAct=EBI-473181, EBI-349905; CC Q99728; P38398-1: BRCA1; NbExp=3; IntAct=EBI-473181, EBI-21498346; CC Q99728; Q9P2H0: CEP126; NbExp=2; IntAct=EBI-473181, EBI-473176; CC Q99728; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-473181, EBI-739624; CC Q99728; Q12873: CHD3; NbExp=2; IntAct=EBI-473181, EBI-523590; CC Q99728; Q05048: CSTF1; NbExp=4; IntAct=EBI-473181, EBI-1789619; CC Q99728; P33240: CSTF2; NbExp=8; IntAct=EBI-473181, EBI-711360; CC Q99728; O00471: EXOC5; NbExp=3; IntAct=EBI-473181, EBI-949824; CC Q99728; Q8IZU0: FAM9B; NbExp=3; IntAct=EBI-473181, EBI-10175124; CC Q99728; Q9Y2X7: GIT1; NbExp=2; IntAct=EBI-473181, EBI-466061; CC Q99728; Q08379: GOLGA2; NbExp=6; IntAct=EBI-473181, EBI-618309; CC Q99728; O75031: HSF2BP; NbExp=3; IntAct=EBI-473181, EBI-7116203; CC Q99728; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-473181, EBI-11522367; CC Q99728; O95251: KAT7; NbExp=2; IntAct=EBI-473181, EBI-473199; CC Q99728; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-473181, EBI-14069005; CC Q99728; Q6A162: KRT40; NbExp=3; IntAct=EBI-473181, EBI-10171697; CC Q99728; O95751: LDOC1; NbExp=7; IntAct=EBI-473181, EBI-740738; CC Q99728; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-473181, EBI-11522433; CC Q99728; O95453: PARN; NbExp=4; IntAct=EBI-473181, EBI-372832; CC Q99728; Q15276: RABEP1; NbExp=3; IntAct=EBI-473181, EBI-447043; CC Q99728; O14776: TCERG1; NbExp=2; IntAct=EBI-473181, EBI-473271; CC Q99728; Q13077: TRAF1; NbExp=3; IntAct=EBI-473181, EBI-359224; CC Q99728; Q8N720: ZNF655; NbExp=3; IntAct=EBI-473181, EBI-625509; CC Q99728-1; Q13526: PIN1; NbExp=4; IntAct=EBI-21498323, EBI-714158; CC -!- SUBCELLULAR LOCATION: Nucleus. Note=During S phase of the cell cycle, CC colocalizes with BRCA1 into discrete subnuclear foci. Can translocate CC to the cytoplasm. Localizes at sites of DNA damage at double-strand CC breaks (DSBs); recruitment to DNA damage sites is mediated by the CC BRCA1-A complex. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=FL; CC IsoId=Q99728-1; Sequence=Displayed; CC Name=alpha; CC IsoId=Q99728-2; Sequence=VSP_055876; CC Name=beta; CC IsoId=Q99728-3; Sequence=VSP_055874, VSP_055875; CC Name=gamma; CC IsoId=Q99728-4; Sequence=VSP_055877, VSP_055878; CC -!- PTM: Processed during apoptosis. The homodimer is more susceptible to CC proteolytic cleavage than the BARD1/BRCA1 heterodimer. CC -!- CAUTION: It is uncertain whether Met-1 or Met-26 is the initiator. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/756/BARD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U76638; AAB38316.1; -; mRNA. DR EMBL; AF038042; AAB99978.1; -; Genomic_DNA. DR EMBL; AF038034; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038035; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038036; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038037; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038038; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038039; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038040; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038041; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; JF790280; AEF57471.1; -; mRNA. DR EMBL; JF790281; AEF57472.1; -; mRNA. DR EMBL; JF790282; AEF57473.1; -; mRNA. DR EMBL; AC016708; AAX93130.1; -; Genomic_DNA. DR EMBL; BC126426; AAI26427.1; -; mRNA. DR CCDS; CCDS2397.1; -. [Q99728-1] DR CCDS; CCDS74646.1; -. [Q99728-2] DR RefSeq; NP_000456.2; NM_000465.4. [Q99728-1] DR RefSeq; NP_001269472.1; NM_001282543.2. [Q99728-2] DR PDB; 1JM7; NMR; -; B=26-140. DR PDB; 2NTE; X-ray; 1.90 A; A/B=568-777. DR PDB; 2R1Z; X-ray; 2.10 A; A/B=569-777. DR PDB; 3C5R; X-ray; 2.00 A; A/B=425-555. DR PDB; 3FA2; X-ray; 2.20 A; A/B=566-777. DR PDB; 6M14; X-ray; 1.88 A; A/B=568-777. DR PDB; 7E8I; EM; 3.10 A; K=425-777. DR PDB; 7JZV; EM; 3.90 A; B=26-140. DR PDB; 7LYB; EM; 3.28 A; N=26-122. DR PDB; 7LYC; EM; 2.94 A; N=415-777. DR PDB; 8GRQ; EM; 3.87 A; M=26-117. DR PDBsum; 1JM7; -. DR PDBsum; 2NTE; -. DR PDBsum; 2R1Z; -. DR PDBsum; 3C5R; -. DR PDBsum; 3FA2; -. DR PDBsum; 6M14; -. DR PDBsum; 7E8I; -. DR PDBsum; 7JZV; -. DR PDBsum; 7LYB; -. DR PDBsum; 7LYC; -. DR PDBsum; 8GRQ; -. DR AlphaFoldDB; Q99728; -. DR EMDB; EMD-22581; -. DR EMDB; EMD-23591; -. DR EMDB; EMD-23592; -. DR EMDB; EMD-31020; -. DR EMDB; EMD-34212; -. DR EMDB; EMD-6340; -. DR EMDB; EMD-6400; -. DR SMR; Q99728; -. DR BioGRID; 107056; 331. DR ComplexPortal; CPX-715; BRCA1-BARD1 complex. DR ComplexPortal; CPX-955; BRCC E3 ubiquitin ligase complex. DR CORUM; Q99728; -. DR DIP; DIP-5972N; -. DR FunCoup; Q99728; 1110. DR IntAct; Q99728; 68. DR MINT; Q99728; -. DR STRING; 9606.ENSP00000260947; -. DR BindingDB; Q99728; -. DR GlyGen; Q99728; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q99728; -. DR PhosphoSitePlus; Q99728; -. DR BioMuta; BARD1; -. DR DMDM; 116241265; -. DR jPOST; Q99728; -. DR MassIVE; Q99728; -. DR PaxDb; 9606-ENSP00000260947; -. DR PeptideAtlas; Q99728; -. DR ProteomicsDB; 78442; -. [Q99728-1] DR Pumba; Q99728; -. DR Antibodypedia; 20039; 288 antibodies from 35 providers. DR DNASU; 580; -. DR Ensembl; ENST00000260947.9; ENSP00000260947.4; ENSG00000138376.12. [Q99728-1] DR Ensembl; ENST00000617164.5; ENSP00000480470.1; ENSG00000138376.12. [Q99728-2] DR Ensembl; ENST00000620057.4; ENSP00000481988.1; ENSG00000138376.12. [Q99728-4] DR GeneID; 580; -. DR KEGG; hsa:580; -. DR MANE-Select; ENST00000260947.9; ENSP00000260947.4; NM_000465.4; NP_000456.2. DR UCSC; uc002veu.4; human. [Q99728-1] DR AGR; HGNC:952; -. DR CIViC; 580; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25256; -. DR CTD; 580; -. DR DisGeNET; 580; -. DR GeneCards; BARD1; -. DR HGNC; HGNC:952; BARD1. DR HPA; ENSG00000138376; Low tissue specificity. DR MalaCards; BARD1; -. DR MIM; 601593; gene. DR OpenTargets; ENSG00000138376; -. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR VEuPathDB; HostDB:ENSG00000138376; -. DR eggNOG; KOG0504; Eukaryota. DR eggNOG; KOG4362; Eukaryota. DR GeneTree; ENSGT00940000156532; -. DR HOGENOM; CLU_021642_0_0_1; -. DR InParanoid; Q99728; -. DR OMA; LGQCEHV; -. DR OrthoDB; 2384350at2759; -. DR PAN-GO; Q99728; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99728; -. DR BRENDA; 2.3.2.27; 2681. DR PathwayCommons; Q99728; -. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5689901; Metalloprotease DUBs. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9663199; Defective DNA double strand break response due to BRCA1 loss of function. DR Reactome; R-HSA-9699150; Defective DNA double strand break response due to BARD1 loss of function. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q99728; -. DR SIGNOR; Q99728; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000138376; -. DR BioGRID-ORCS; 580; 517 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BARD1; human. DR EvolutionaryTrace; Q99728; -. DR GeneWiki; BARD1; -. DR GenomeRNAi; 580; -. DR Pharos; Q99728; Tbio. DR PRO; PR:Q99728; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q99728; protein. DR Bgee; ENSG00000138376; Expressed in secondary oocyte and 204 other cell types or tissues. DR ExpressionAtlas; Q99728; baseline and differential. DR GO; GO:0070531; C:BRCA1-A complex; IDA:UniProtKB. DR GO; GO:0070532; C:BRCA1-B complex; IPI:ComplexPortal. DR GO; GO:0031436; C:BRCA1-BARD1 complex; IDA:UniProtKB. DR GO; GO:0070533; C:BRCA1-C complex; IPI:ComplexPortal. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0000152; C:nuclear ubiquitin ligase complex; IDA:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000151; C:ubiquitin ligase complex; NAS:UniProtKB. DR GO; GO:0140863; F:histone H2AK127 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0140864; F:histone H2AK129 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0019900; F:kinase binding; NAS:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; IDA:MGI. DR GO; GO:0061649; F:ubiquitin-modified histone reader activity; TAS:ARUK-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; NAS:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:ComplexPortal. DR GO; GO:0006338; P:chromatin remodeling; TAS:ARUK-UCL. DR GO; GO:0006974; P:DNA damage response; NAS:UniProtKB. DR GO; GO:0006281; P:DNA repair; NAS:ComplexPortal. DR GO; GO:0110025; P:DNA strand resection involved in replication fork processing; NAS:ComplexPortal. DR GO; GO:0035825; P:homologous recombination; NAS:ComplexPortal. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; NAS:ComplexPortal. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045786; P:negative regulation of cell cycle; NAS:ComplexPortal. DR GO; GO:0031441; P:negative regulation of mRNA 3'-end processing; NAS:UniProtKB. DR GO; GO:0046826; P:negative regulation of protein export from nucleus; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045732; P:positive regulation of protein catabolic process; NAS:UniProtKB. DR GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; NAS:UniProtKB. DR GO; GO:2000001; P:regulation of DNA damage checkpoint; NAS:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0042325; P:regulation of phosphorylation; IMP:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ARUK-UCL. DR GO; GO:0001894; P:tissue homeostasis; TAS:UniProtKB. DR CDD; cd17734; BRCT_Bard1_rpt1; 1. DR CDD; cd17720; BRCT_Bard1_rpt2; 1. DR CDD; cd16496; RING-HC_BARD1; 1. DR FunFam; 1.25.40.20:FF:000032; BCL-6 corepressor isoform X1; 1. DR FunFam; 3.30.40.10:FF:000349; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000013; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000019; BRCA1 associated RING domain 1; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 2. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR039503; BARD1_Znf-RING. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR24171; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 39-RELATED; 1. DR PANTHER; PTHR24171:SF8; BRCA1-ASSOCIATED RING DOMAIN PROTEIN 1; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF14835; zf-RING_6; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 3. DR SMART; SM00292; BRCT; 2. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 3. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; DNA damage; DNA repair; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Transferase; KW Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..777 FT /note="BRCA1-associated RING domain protein 1" FT /id="PRO_0000055819" FT REPEAT 427..459 FT /note="ANK 1" FT REPEAT 460..492 FT /note="ANK 2" FT REPEAT 493..525 FT /note="ANK 3" FT REPEAT 526..546 FT /note="ANK 4; degenerate" FT DOMAIN 560..653 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 667..777 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT ZN_FING 50..87 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 26..119 FT /note="Interaction with BRCA1" FT REGION 167..211 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 356..404 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 554..558 FT /note="Flexible linker" FT COMPBIAS 197..209 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 389..404 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 186 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 299 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 391 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 394 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT CROSSLNK 160 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 423 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 548 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..24 FT /note="MPDNRQPRNRQPRIRSGNEPRSAP -> MVAVPGPTVAPRSTAWRSCCAARV FT (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055874" FT VAR_SEQ 25..121 FT /note="Missing (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055875" FT VAR_SEQ 54..72 FT /note="Missing (in isoform alpha)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055876" FT VAR_SEQ 122..127 FT /note="DLKEDK -> GRHTFC (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055877" FT VAR_SEQ 128..777 FT /note="Missing (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055878" FT VARIANT 24 FT /note="P -> S (in dbSNP:rs1048108)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010354" FT VARIANT 153 FT /note="K -> E (in dbSNP:rs753377280)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010355" FT VARIANT 186 FT /note="S -> G (in dbSNP:rs16852741)" FT /id="VAR_038371" FT VARIANT 241 FT /note="S -> C (in dbSNP:rs3738885)" FT /id="VAR_020109" FT VARIANT 378 FT /note="R -> S (in dbSNP:rs2229571)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_024611" FT VARIANT 507 FT /note="V -> M (in dbSNP:rs2070094)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010356" FT VARIANT 557 FT /note="C -> S (in dbSNP:rs28997576)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010357" FT VARIANT 564 FT /note="Q -> H (in an ovarian clear cell adenocarcinoma; FT dbSNP:rs1168537193)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010358" FT VARIANT 645 FT /note="C -> R (in dbSNP:rs2228456)" FT /id="VAR_038372" FT VARIANT 658 FT /note="R -> C (in dbSNP:rs3738888)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010359" FT VARIANT 695 FT /note="V -> L (in a breast cancer sample; somatic mutation; FT dbSNP:rs111367604)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010360" FT VARIANT 728 FT /note="S -> F (in dbSNP:rs13389423)" FT /id="VAR_028309" FT VARIANT 761 FT /note="S -> N (in an uterine cancer sample; somatic FT mutation; dbSNP:rs142155101)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010361" FT CONFLICT 85 FT /note="V -> A (in Ref. 3; AEF57473)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="R -> Q (in Ref. 1; AAB38316 and 3; AEF57471/ FT AEF57472)" FT /evidence="ECO:0000305" FT HELIX 35..45 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 51..53 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 58..61 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 64..67 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 72..75 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 78..81 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 99..115 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 431..438 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 441..449 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 459..461 FT /evidence="ECO:0007829|PDB:7LYC" FT HELIX 464..470 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 474..482 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 497..503 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 507..515 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 530..533 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 537..543 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 571..576 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 579..591 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:2NTE" FT STRAND 606..613 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 618..625 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 634..642 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 648..651 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 656..665 FT /evidence="ECO:0007829|PDB:6M14" FT TURN 671..674 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 676..679 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 684..686 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 688..697 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 701..705 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 712..716 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 729..731 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 735..739 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 741..744 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 748..752 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 755..759 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 760..769 FT /evidence="ECO:0007829|PDB:6M14" SQ SEQUENCE 777 AA; 86648 MW; 95E2D904046B5646 CRC64; MPDNRQPRNR QPRIRSGNEP RSAPAMEPDG RGAWAHSRAA LDRLEKLLRC SRCTNILREP VCLGGCEHIF CSNCVSDCIG TGCPVCYTPA WIQDLKINRQ LDSMIQLCSK LRNLLHDNEL SDLKEDKPRK SLFNDAGNKK NSIKMWFSPR SKKVRYVVSK ASVQTQPAIK KDASAQQDSY EFVSPSPPAD VSERAKKASA RSGKKQKKKT LAEINQKWNL EAEKEDGEFD SKEESKQKLV SFCSQPSVIS SPQINGEIDL LASGSLTESE CFGSLTEVSL PLAEQIESPD TKSRNEVVTP EKVCKNYLTS KKSLPLENNG KRGHHNRLSS PISKRCRTSI LSTSGDFVKQ TVPSENIPLP ECSSPPSCKR KVGGTSGRKN SNMSDEFISL SPGTPPSTLS SSSYRRVMSS PSAMKLLPNM AVKRNHRGET LLHIASIKGD IPSVEYLLQN GSDPNVKDHA GWTPLHEACN HGHLKVVELL LQHKALVNTT GYQNDSPLHD AAKNGHVDIV KLLLSYGASR NAVNIFGLRP VDYTDDESMK SLLLLPEKNE SSSASHCSVM NTGQRRDGPL VLIGSGLSSE QQKMLSELAV ILKAKKYTEF DSTVTHVVVP GDAVQSTLKC MLGILNGCWI LKFEWVKACL RRKVCEQEEK YEIPEGPRRS RLNREQLLPK LFDGCYFYLW GTFKHHPKDN LIKLVTAGGG QILSRKPKPD SDVTQTINTV AYHARPDSDQ RFCTQYIIYE DLCNYHPERV RQGKVWKAPS SWFIDCVMSF ELLPLDS // ID BAX_HUMAN Reviewed; 192 AA. AC Q07812; A8K4W1; P55269; Q07814; Q07815; Q8WZ49; Q9NR76; Q9NYG7; Q9UCZ6; AC Q9UCZ7; Q9UQD6; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 246. DE RecName: Full=Apoptosis regulator BAX; DE AltName: Full=Bcl-2-like protein 4; DE Short=Bcl2-L-4; GN Name=BAX; Synonyms=BCL2L4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), FUNCTION, RP SUBUNIT, AND SUBCELLULAR LOCATION. RC TISSUE=B-cell; RX PubMed=8358790; DOI=10.1016/0092-8674(93)90509-o; RA Oltvai Z.N., Milliman C.L., Korsmeyer S.J.; RT "Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that RT accelerates programmed cell death."; RL Cell 74:609-619(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA). RX PubMed=7607685; DOI=10.1016/0888-7543(95)80180-t; RA Apte S.S., Mattei M.-G., Olsen B.R.; RT "Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of RT a novel alternatively spliced transcript, BAX delta."; RL Genomics 26:592-594(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EPSILON). RC TISSUE=Brain; RX PubMed=9920818; DOI=10.1006/bbrc.1998.0130; RA Shi B., Triebe D., Kajiji S., Iwata K.K., Bruskin A., Mahajna J.; RT "Identification and characterization of baxepsilon, a novel bax variant RT missing the BH2 and the transmembrane domains."; RL Biochem. Biophys. Res. Commun. 254:779-785(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND SIGMA), FUNCTION, RP INTERACTION WITH BCL2A1 AND BCL2L1, AND TISSUE SPECIFICITY. RX PubMed=10772918; DOI=10.1006/bbrc.2000.2537; RA Schmitt E., Paquet C., Beauchemin M., Dever-Bertrand J., Bertrand R.; RT "Characterization of Bax-sigma, a cell death-inducing isoform of Bax."; RL Biochem. Biophys. Res. Commun. 270:868-879(2000). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSI), AND TISSUE SPECIFICITY. RX PubMed=11912183; DOI=10.1093/hmg/11.6.675; RA Cartron P.F., Oliver L., Martin S., Moreau C., LeCabellec M.T., RA Jezequel P., Meflah K., Vallette F.M.; RT "The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, RT is correlated with an increased survival of glioblastoma multiforme RT patients."; RL Hum. Mol. Genet. 11:675-687(2002). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA). RC TISSUE=Ovarian carcinoma; RA Perez R.P., Sanville H.; RT "Bax mRNA splice variant lacking exons 2 and 3."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-77 AND 98-118, AND VARIANTS ARG-67 AND RP VAL-108. RX PubMed=7475270; RA Meijerink J.P.P., Smetsers T.F.C.M., Sloetjes A.W., Linders E.H.P., RA Mensink E.J.B.M.; RT "Bax mutations in cell lines derived from hematological malignancies."; RL Leukemia 9:1828-1832(1995). RN [12] RP MUTAGENESIS, AND FUNCTION OF BH3 MOTIF. RX PubMed=8521816; DOI=10.1002/j.1460-2075.1995.tb00246.x; RA Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J., RA Elangovan B., Chinnadurai G., Lutz R.J.; RT "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death RT and protein binding functions."; RL EMBO J. 14:5589-5596(1995). RN [13] RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-184. RX PubMed=10228148; DOI=10.1093/emboj/18.9.2330; RA Nechushtan A., Smith C.L., Hsu Y.-T., Youle R.J.; RT "Conformation of the Bax C-terminus regulates subcellular location and cell RT death."; RL EMBO J. 18:2330-2341(1999). RN [14] RP FUNCTION, AND INTERACTION WITH MOAP1. RX PubMed=11060313; DOI=10.1074/jbc.m008955200; RA Tan K.O., Tan K.M.L., Chan S.-L., Yee K.S.Y., Bevort M., Ang K.C., Yu V.C.; RT "MAP-1, a novel proapoptotic protein containing a BH3-like motif that RT associates with Bax through its Bcl-2 homology domains."; RL J. Biol. Chem. 276:2802-2807(2001). RN [15] RP INTERACTION WITH SH3GLB1. RX PubMed=11259440; DOI=10.1074/jbc.m101527200; RA Cuddeback S.M., Yamaguchi H., Komatsu K., Miyashita T., Yamada M., Wu C., RA Singh S., Wang H.-G.; RT "Molecular cloning and characterization of Bif-1. A novel Src homology 3 RT domain-containing protein that associates with Bax."; RL J. Biol. Chem. 276:20559-20565(2001). RN [16] RP INTERACTION WITH ADENOVIRUS PROTEIN E1B 19K. RX PubMed=11462023; DOI=10.1128/jvi.75.16.7506-7516.2001; RA Sundararajan R., White E.; RT "E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha- RT mediated apoptosis."; RL J. Virol. 75:7506-7516(2001). RN [17] RP INTERACTION WITH HUMANIN. RX PubMed=12732850; DOI=10.1038/nature01627; RA Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., RA Reed J.C.; RT "Humanin peptide suppresses apoptosis by interfering with Bax activation."; RL Nature 423:456-461(2003). RN [18] RP INTERACTION WITH SFN AND YWHAZ, AND SUBCELLULAR LOCATION. RX PubMed=15071501; DOI=10.1038/sj.emboj.7600194; RA Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., RA Yoshioka K., Masuyama N., Gotoh Y.; RT "JNK promotes Bax translocation to mitochondria through phosphorylation of RT 14-3-3 proteins."; RL EMBO J. 23:1889-1899(2004). RN [19] RP INTERACTION WITH NOL3. RX PubMed=15004034; DOI=10.1074/jbc.m400695200; RA Gustafsson A.B., Tsai J.G., Logue S.E., Crow M.T., Gottlieb R.A.; RT "Apoptosis repressor with caspase recruitment domain protects against cell RT death by interfering with Bax activation."; RL J. Biol. Chem. 279:21233-21238(2004). RN [20] RP INTERACTION WITH HHV-5 PROTEIN UL37. RX PubMed=15004026; DOI=10.1074/jbc.m308408200; RA Poncet D., Larochette N., Pauleau A.L., Boya P., Jalil A.A., Cartron P.F., RA Vallette F., Schnebelen C., Bartle L.M., Skaletskaya A., Boutolleau D., RA Martinou J.C., Goldmacher V.S., Kroemer G., Zamzami N.; RT "An anti-apoptotic viral protein that recruits Bax to mitochondria."; RL J. Biol. Chem. 279:22605-22614(2004). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CLU. RX PubMed=16113678; DOI=10.1038/ncb1291; RA Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y.; RT "Clusterin inhibits apoptosis by interacting with activated Bax."; RL Nat. Cell Biol. 7:909-915(2005). RN [22] RP FUNCTION, AND INTERACTION WITH MOAP1. RX PubMed=16199525; DOI=10.1073/pnas.0503524102; RA Tan K.O., Fu N.Y., Sukumaran S.K., Chan S.L., Kang J.H., Poon K.L., RA Chen B.S., Yu V.C.; RT "MAP-1 is a mitochondrial effector of Bax."; RL Proc. Natl. Acad. Sci. U.S.A. 102:14623-14628(2005). RN [23] RP INTERACTION WITH FAIM2/LFG2. RX PubMed=16964429; RA Reimers K., Choi C.Y., Mau-Thek E., Vogt P.M.; RT "Sequence analysis shows that Lifeguard belongs to a new evolutionarily RT conserved cytoprotective family."; RL Int. J. Mol. Med. 18:729-734(2006). RN [24] RP INTERACTION WITH GIMAP3 AND GIMAP5. RX PubMed=16509771; DOI=10.1371/journal.pbio.0040103; RA Nitta T., Nasreen M., Seike T., Goji A., Ohigashi I., Miyazaki T., Ohta T., RA Kanno M., Takahama Y.; RT "IAN family critically regulates survival and development of T RT lymphocytes."; RL PLoS Biol. 4:593-605(2006). RN [25] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [26] RP INTERACTION WITH RNF144B. RX PubMed=20300062; DOI=10.1038/emboj.2010.39; RA Benard G., Neutzner A., Peng G., Wang C., Livak F., Youle R.J., RA Karbowski M.; RT "IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax RT and apoptosis activation."; RL EMBO J. 29:1458-1471(2010). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [28] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2L1. RX PubMed=21458670; DOI=10.1016/j.cell.2011.02.034; RA Edlich F., Banerjee S., Suzuki M., Cleland M.M., Arnoult D., Wang C., RA Neutzner A., Tjandra N., Youle R.J.; RT "Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol."; RL Cell 145:104-116(2011). RN [29] RP INTERACTION WITH BCL2L10. RX PubMed=23235460; DOI=10.1038/cddis.2012.178; RA Rautureau G.J., Yabal M., Yang H., Huang D.C., Kvansakul M., Hinds M.G.; RT "The restricted binding repertoire of Bcl-B leaves Bim as the universal RT BH3-only prosurvival Bcl-2 protein antagonist."; RL Cell Death Dis. 3:e443-e443(2012). RN [30] RP INTERACTION WITH RTL10/BOP. RX PubMed=23055042; DOI=10.1007/s13238-012-2069-7; RA Zhang X., Weng C., Li Y., Wang X., Jiang C., Li X., Xu Y., Chen Q., Pan L., RA Tang H.; RT "Human Bop is a novel BH3-only member of the Bcl-2 protein family."; RL Protein Cell 3:790-801(2012). RN [31] RP FUNCTION, INTERACTION WITH IRF3 AND BCL2, AND SUBCELLULAR LOCATION. RX PubMed=25609812; DOI=10.1128/jvi.02959-14; RA Wei B., Cui Y., Huang Y., Liu H., Li L., Li M., Ruan K.C., Zhou Q., RA Wang C.; RT "Tom70 mediates Sendai virus-induced apoptosis on mitochondria."; RL J. Virol. 89:3804-3818(2015). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [33] RP INTERACTION WITH ENTEROVIRUS 71 PROTEIN 2B, AND SUBCELLULAR LOCATION. RX PubMed=27558414; DOI=10.1128/jvi.01499-16; RA Cong H., Du N., Yang Y., Song L., Zhang W., Tien P.; RT "Enterovirus 71 2B induces cell apoptosis by directly inducing the RT conformational activation of the proapoptotic protein Bax."; RL J. Virol. 90:9862-9877(2016). RN [34] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=29531808; DOI=10.1038/s41420-017-0006-5; RA Kuriyama S., Tsuji T., Sakuma T., Yamamoto T., Tanaka M.; RT "PLEKHN1 promotes apoptosis by enhancing Bax-Bak hetero-oligomerization RT through interaction with Bid in human colon cancer."; RL Cell. Death. Discov. 4:11-11(2018). RN [35] RP FORMATION OF FIBERS WITH HUMANIN, AND MUTAGENESIS OF 172-THR--GLY-192 AND RP SER-184. RX PubMed=31690630; DOI=10.1074/jbc.ra119.011297; RA Morris D.L., Kastner D.W., Johnson S., Strub M.P., He Y., Bleck C.K.E., RA Lee D.Y., Tjandra N.; RT "Humanin induces conformational changes in the apoptosis regulator BAX and RT sequesters it into fibers, preventing mitochondrial outer-membrane RT permeabilization."; RL J. Biol. Chem. 294:19055-19065(2019). RN [36] RP FUNCTION, DEUBIQUITINATION BY USP12, MUTAGENESIS OF LYS-128; LYS-189 AND RP LYS-190, SUBCELLULAR LOCATION, AND UBIQUITINATION AT LYS-128 AND LYS-190. RX PubMed=36361894; DOI=10.3390/ijms232113107; RA Choi H.S., Lim E.S., Baek K.H.; RT "Deubiquitinating Enzyme USP12 Regulates the Pro-Apoptosis Protein Bax."; RL Int. J. Mol. Sci. 23:0-0(2022). RN [37] RP STRUCTURE BY NMR, SUBCELLULAR LOCATION, AND SUBUNIT. RX PubMed=11106734; DOI=10.1016/s0092-8674(00)00167-7; RA Suzuki M., Youle R.J., Tjandra N.; RT "Structure of Bax: coregulation of dimer formation and intracellular RT localization."; RL Cell 103:645-654(2000). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-19 IN COMPLEX WITH ANTIBODY RP FRAGMENT. RX PubMed=16946732; DOI=10.1038/sj.cdd.4402025; RA Peyerl F.W., Dai S., Murphy G.A., Crawford F., White J., Marrack P., RA Kappler J.W.; RT "Elucidation of some Bax conformational changes through crystallization of RT an antibody-peptide complex."; RL Cell Death Differ. 14:447-452(2007). RN [39] RP STRUCTURE BY NMR IN COMPLEX WITH BCL2L11, FUNCTION, SUBUNIT, MUTAGENESIS OF RP LYS-21, AND INTERACTION WITH BCL2L11. RX PubMed=18948948; DOI=10.1038/nature07396; RA Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., RA Tu H.C., Kim H., Cheng E.H., Tjandra N., Walensky L.D.; RT "BAX activation is initiated at a novel interaction site."; RL Nature 455:1076-1081(2008). RN [40] RP X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 48-81 IN COMPLEXES WITH BCL2L1 RP AND MCL1, INTERACTION WITH MCL1; BCL2; BCL2L1 AND BCL2L2, FUNCTION, AND RP MUTAGENESIS OF MET-74. RX PubMed=21199865; DOI=10.1074/jbc.m110.161281; RA Czabotar P.E., Lee E.F., Thompson G.V., Wardak A.Z., Fairlie W.D., RA Colman P.M.; RT "Mutation to Bax beyond the BH3 domain disrupts interactions with pro- RT survival proteins and promotes apoptosis."; RL J. Biol. Chem. 286:7123-7131(2011). RN [41] RP VARIANTS GLU-11; ARG-67 AND VAL-108. RX PubMed=9531611; RA Meijerink J.P.P., Mensink E.J.B.M., Wang K., Sedlak T.W., Sloetjes A.W., RA de Witte T., Waksman G., Korsmeyer S.J.; RT "Hematopoietic malignancies demonstrate loss-of-function mutations of RT BAX."; RL Blood 91:2991-2997(1998). RN [42] RP INTERACTION WITH XRCC6. RX PubMed=15023334; DOI=10.1016/s1097-2765(04)00094-2; RA Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., RA Miller C., Frye R., Ploegh H., Kessler B.M., Sinclair D.A.; RT "Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax- RT mediated apoptosis."; RL Mol. Cell 13:627-638(2004). RN [43] RP UBIQUITINATION. RX PubMed=18362350; DOI=10.1073/pnas.0706700105; RA Amsel A.D., Rathaus M., Kronman N., Cohen H.Y.; RT "Regulation of the proapoptotic factor Bax by Ku70-dependent RT deubiquitylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:5117-5122(2008). CC -!- FUNCTION: Plays a role in the mitochondrial apoptotic process CC (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, CC PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, CC PubMed:36361894, PubMed:8358790, PubMed:8521816). Under normal CC conditions, BAX is largely cytosolic via constant retrotranslocation CC from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which CC avoids accumulation of toxic BAX levels at the mitochondrial outer CC membrane (MOM) (PubMed:21458670). Under stress conditions, undergoes a CC conformation change that causes translocation to the mitochondrion CC membrane, leading to the release of cytochrome c that then triggers CC apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, CC PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, CC PubMed:25609812, PubMed:8358790, PubMed:8521816). Promotes activation CC of CASP3, and thereby apoptosis (PubMed:10772918, PubMed:11060313, CC PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, CC PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816). CC {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11060313, CC ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16199525, CC ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:21199865, CC ECO:0000269|PubMed:21458670, ECO:0000269|PubMed:25609812, CC ECO:0000269|PubMed:36361894, ECO:0000269|PubMed:8358790, CC ECO:0000269|PubMed:8521816}. CC -!- SUBUNIT: Homodimer. Forms higher oligomers under stress conditions. CC Forms heterooligomers with BAK (PubMed:29531808). Interacts with CC BCL2L11. Interaction with BCL2L11 promotes BAX oligomerization and CC association with mitochondrial membranes, with subsequent release of CC cytochrome c. Forms heterodimers with BCL2, BCL2L1 isoform Bcl-X(L), CC BCL2L2, MCL1 and A1 (PubMed:25609812). Interacts with SH3GLB1. CC Interacts with humanin; forms fibers with humanin which results in BAX CC conformational changes and sequestering of BAX into the fibers, CC preventing BAX activation (PubMed:12732850, PubMed:31690630). Interacts CC with SFN and YWHAZ; the interaction occurs in the cytoplasm. Under CC stress conditions, JNK-mediated phosphorylation of SFN and YWHAZ, CC releases BAX to mitochondria. Interacts with RNF144B, which regulates CC the ubiquitin-dependent stability of BAX. Interacts with CLU under CC stress conditions that cause a conformation change leading to BAX CC oligomerization and association with mitochondria. Does not interact CC with CLU in unstressed cells. Interacts with FAIM2/LFG2. Interacts with CC RTL10/BOP. Interacts (via a C-terminal 33 residues) with NOL3 (via CARD CC domain); inhibits BAX activation and translocation and consequently CC cytochrome c release from mitochondria. Interacts with GIMAP3/IAN4 and CC GIMAP5/IAN5; this interaction is increased, when cells initiate CC apoptosis upon IL2 withdrawal (PubMed:16509771). Interacts with IRF3; CC the interaction is direct, increases upon Sendai virus infection and CC mediates the formation of the apoptosis complex CC TOMM70:HSP90AA1:IRF3:BAX (PubMed:25609812). Interacts with MOAP1, CC facilitating BAX-dependent mitochondrial outer membrane CC permeabilization and apoptosis (PubMed:11060313, PubMed:16199525). CC Interacts with BCL2L10/BCL-B (PubMed:23235460). Interacts with non- CC acetylated XRCC6/Ku70; this interaction leads to BAX sequestration in CC the cytosol, away from the mitochondria, preventing BAX-mediated CC apoptosis (PubMed:15023334). {ECO:0000269|PubMed:11060313, CC ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440, CC ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026, CC ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15023334, CC ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:16113678, CC ECO:0000269|PubMed:16199525, ECO:0000269|PubMed:16509771, CC ECO:0000269|PubMed:16946732, ECO:0000269|PubMed:16964429, CC ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:20300062, CC ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:23055042, CC ECO:0000269|PubMed:23235460, ECO:0000269|PubMed:25609812, CC ECO:0000269|PubMed:29531808, ECO:0000269|PubMed:31690630, CC ECO:0000269|PubMed:8358790}. CC -!- SUBUNIT: [Isoform Sigma]: Interacts with BCL2A1 and BCL2L1 isoform Bcl- CC X(L). {ECO:0000269|PubMed:10772918}. CC -!- SUBUNIT: (Microbial infection) Interacts with adenovirus E1B 19K CC protein; this interaction blocks BAX oligomerization (PubMed:11462023). CC {ECO:0000269|PubMed:11462023}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein vMIA/UL37. {ECO:0000269|PubMed:15004026}. CC -!- SUBUNIT: (Microbial infection) Interacts with enterovirus protein 2B; CC this interaction activates BAX-induced apoptosis. CC {ECO:0000269|PubMed:27558414}. CC -!- INTERACTION: CC Q07812; Q16611: BAK1; NbExp=6; IntAct=EBI-516580, EBI-519866; CC Q07812; Q07812: BAX; NbExp=29; IntAct=EBI-516580, EBI-516580; CC Q07812; P10415: BCL2; NbExp=16; IntAct=EBI-516580, EBI-77694; CC Q07812; Q07817-1: BCL2L1; NbExp=24; IntAct=EBI-516580, EBI-287195; CC Q07812; Q9HD36: BCL2L10; NbExp=3; IntAct=EBI-516580, EBI-2126349; CC Q07812; O43521: BCL2L11; NbExp=22; IntAct=EBI-516580, EBI-526406; CC Q07812; Q9HB09: BCL2L12; NbExp=3; IntAct=EBI-516580, EBI-3940897; CC Q07812; Q92843: BCL2L2; NbExp=8; IntAct=EBI-516580, EBI-707714; CC Q07812; P55957: BID; NbExp=17; IntAct=EBI-516580, EBI-519672; CC Q07812; O75460: ERN1; NbExp=2; IntAct=EBI-516580, EBI-371750; CC Q07812; O75031: HSF2BP; NbExp=3; IntAct=EBI-516580, EBI-7116203; CC Q07812; P22001: KCNA3; NbExp=2; IntAct=EBI-516580, EBI-8627664; CC Q07812; Q07820: MCL1; NbExp=11; IntAct=EBI-516580, EBI-1003422; CC Q07812; Q8IVG9: MT-RNR2; NbExp=5; IntAct=EBI-516580, EBI-8643752; CC Q07812; Q9ULZ3: PYCARD; NbExp=7; IntAct=EBI-516580, EBI-751215; CC Q07812; Q7Z419: RNF144B; NbExp=5; IntAct=EBI-516580, EBI-2129982; CC Q07812; Q7L3V2: RTL10; NbExp=2; IntAct=EBI-516580, EBI-10697720; CC Q07812; Q9Y371-1: SH3GLB1; NbExp=2; IntAct=EBI-516580, EBI-5291808; CC Q07812; P37840: SNCA; NbExp=4; IntAct=EBI-516580, EBI-985879; CC Q07812; Q9P2Y5: UVRAG; NbExp=6; IntAct=EBI-516580, EBI-2952704; CC Q07812; P12956: XRCC6; NbExp=2; IntAct=EBI-516580, EBI-353208; CC Q07812; P70444: Bid; Xeno; NbExp=2; IntAct=EBI-516580, EBI-783400; CC Q07812; PRO_0000223236 [P70444]: Bid; Xeno; NbExp=2; IntAct=EBI-516580, EBI-2128640; CC Q07812; Q99MI6: Gimap3; Xeno; NbExp=2; IntAct=EBI-516580, EBI-15572304; CC Q07812; Q8BWF2: Gimap5; Xeno; NbExp=2; IntAct=EBI-516580, EBI-15572348; CC Q07812; P97287: Mcl1; Xeno; NbExp=2; IntAct=EBI-516580, EBI-707292; CC Q07812; P17361: OPG035; Xeno; NbExp=3; IntAct=EBI-516580, EBI-7115640; CC Q07812; P49334: TOM22; Xeno; NbExp=3; IntAct=EBI-516580, EBI-12527; CC Q07812; P23644: TOM40; Xeno; NbExp=2; IntAct=EBI-516580, EBI-12539; CC Q07812; P24391: tom40; Xeno; NbExp=2; IntAct=EBI-516580, EBI-1791540; CC Q07812; P07213: TOM70; Xeno; NbExp=2; IntAct=EBI-516580, EBI-12551; CC Q07812; P16778: UL37; Xeno; NbExp=2; IntAct=EBI-516580, EBI-16026491; CC Q07812; PRO_0000037647 [P26662]; Xeno; NbExp=3; IntAct=EBI-516580, EBI-9099462; CC -!- SUBCELLULAR LOCATION: [Isoform Alpha]: Mitochondrion outer membrane CC {ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:29531808}; Single-pass CC membrane protein {ECO:0000255}. Cytoplasm {ECO:0000269|PubMed:27558414, CC ECO:0000269|PubMed:29531808}. Nucleus {ECO:0000269|PubMed:36361894}. CC Note=Colocalizes with 14-3-3 proteins in the cytoplasm. Under stress CC conditions, undergoes a conformation change that causes release from CC JNK-phosphorylated 14-3-3 proteins and translocation to the CC mitochondrion membrane. Upon Sendai virus infection, recruited to the CC mitochondrion through interaction with IRF3 (PubMed:25609812). CC {ECO:0000269|PubMed:25609812}. CC -!- SUBCELLULAR LOCATION: [Isoform Beta]: Cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform Gamma]: Cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform Delta]: Cytoplasm {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=8; CC Name=Alpha; CC IsoId=Q07812-1; Sequence=Displayed; CC Name=Beta; CC IsoId=Q07812-2, Q07814-1; CC Sequence=VSP_031237; CC Name=Gamma; CC IsoId=Q07812-3, Q07815-1; CC Sequence=VSP_031234, VSP_031236; CC Name=Delta; CC IsoId=Q07812-4, P55269-1; CC Sequence=VSP_031235; CC Name=Epsilon; CC IsoId=Q07812-5; Sequence=VSP_031240; CC Name=Zeta; CC IsoId=Q07812-6; Sequence=VSP_031239; CC Name=Psi; CC IsoId=Q07812-7; Sequence=VSP_031238; CC Name=Sigma; CC IsoId=Q07812-8; Sequence=VSP_037475; CC -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues. Isoform Psi CC is found in glial tumors. Isoform Alpha is expressed in spleen, breast, CC ovary, testis, colon and brain, and at low levels in skin and lung. CC Isoform Sigma is expressed in spleen, breast, ovary, testis, lung, CC colon, brain and at low levels in skin. Isoform Alpha and isoform Sigma CC are expressed in pro-myelocytic leukemia, histiocytic lymphoma, CC Burkitt's lymphoma, T-cell lymphoma, lymphoblastic leukemia, breast CC adenocarcinoma, ovary adenocarcinoma, prostate carcinoma, prostate CC adenocarcinoma, lung carcinoma, epidermoid carcinoma, small cell lung CC carcinoma and colon adenocarcinoma cell lines. CC {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11912183}. CC -!- DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX for CC their pro-apoptotic activity and for their interaction with anti- CC apoptotic members of the Bcl-2 family. {ECO:0000269|PubMed:8521816}. CC -!- PTM: Ubiquitinated in the absence of XRCC6/Ku70 (PubMed:18362350). CC Ubiquitination promotes protein degradation (PubMed:18362350). CC Ubiquitinated on Lys-128 and Lys-190. 'Lys-63'-linked polyubiquitin CC chains on Lys-128 are removed by USP12. {ECO:0000269|PubMed:18362350, CC ECO:0000269|PubMed:36361894}. CC -!- SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/128/BAX"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L22473; AAA03619.1; -; mRNA. DR EMBL; L22474; AAA03620.1; -; mRNA. DR EMBL; L22475; AAA03621.1; -; mRNA. DR EMBL; U19599; AAC50142.1; -; mRNA. DR EMBL; AF007826; AAD22706.1; -; mRNA. DR EMBL; AF247393; AAF71267.1; -; mRNA. DR EMBL; AJ417988; CAD10744.1; -; mRNA. DR EMBL; AF250190; AAF82094.1; -; mRNA. DR EMBL; AK291076; BAF83765.1; -; mRNA. DR EMBL; AY217036; AAO22992.1; -; Genomic_DNA. DR EMBL; CH471177; EAW52418.1; -; Genomic_DNA. DR EMBL; CH471177; EAW52417.1; -; Genomic_DNA. DR EMBL; BC014175; AAH14175.1; -; mRNA. DR CCDS; CCDS12742.1; -. [Q07812-1] DR CCDS; CCDS12743.1; -. [Q07812-4] DR CCDS; CCDS12744.1; -. [Q07812-2] DR CCDS; CCDS12745.2; -. [Q07812-8] DR PIR; A47538; A47538. DR PIR; B47538; B47538. DR PIR; C47538; C47538. DR PIR; I38921; I38921. DR PIR; JC7255; JC7255. DR RefSeq; NP_001278357.1; NM_001291428.1. DR RefSeq; NP_001278360.1; NM_001291431.2. [Q07812-6] DR RefSeq; NP_004315.1; NM_004324.4. [Q07812-2] DR RefSeq; NP_620116.1; NM_138761.4. [Q07812-1] DR RefSeq; NP_620118.1; NM_138763.4. [Q07812-4] DR RefSeq; NP_620119.2; NM_138764.5. [Q07812-8] DR PDB; 1F16; NMR; -; A=1-192. DR PDB; 2G5B; X-ray; 2.30 A; I/J/K/L=13-19. DR PDB; 2K7W; NMR; -; A=1-192. DR PDB; 2LR1; NMR; -; A=1-192. DR PDB; 3PK1; X-ray; 2.49 A; B/D=48-81. DR PDB; 3PL7; X-ray; 2.61 A; C=48-81. DR PDB; 4BD2; X-ray; 2.21 A; A=1-171. DR PDB; 4BD6; X-ray; 2.49 A; A=1-171, C=48-81. DR PDB; 4BD7; X-ray; 2.80 A; A/B/C/D=1-171. DR PDB; 4BD8; X-ray; 2.22 A; A/B/C/D=1-171. DR PDB; 4BDU; X-ray; 3.00 A; A/B/C/D=53-128. DR PDB; 4S0O; X-ray; 1.90 A; A/B=1-192. DR PDB; 4S0P; X-ray; 3.25 A; A/B=1-192. DR PDB; 4UF2; X-ray; 3.00 A; B=50-77. DR PDB; 4ZIE; X-ray; 1.80 A; A=1-166. DR PDB; 4ZIF; X-ray; 2.40 A; A=1-166. DR PDB; 4ZIG; X-ray; 2.20 A; A=1-166. DR PDB; 4ZIH; X-ray; 2.50 A; A=1-164. DR PDB; 4ZII; X-ray; 2.19 A; A=1-170. DR PDB; 5W5X; X-ray; 2.50 A; A=1-192. DR PDB; 5W5Z; X-ray; 2.00 A; A=32-192. DR PDB; 5W60; X-ray; 1.80 A; A=1-192. DR PDB; 5W61; X-ray; 2.30 A; A=1-192. DR PDB; 6EB6; X-ray; 2.02 A; A=1-192. DR PDB; 6L8V; NMR; -; A/B=53-128. DR PDB; 6L95; NMR; -; A/B=166-192. DR PDB; 6TRR; X-ray; 2.12 A; B=50-77. DR PDB; 6XY6; X-ray; 2.91 A; B/D/F/H/J/L/N/P=50-77. DR PDB; 7ADT; X-ray; 2.21 A; C/U=50-77. DR PDB; 8G1T; X-ray; 2.09 A; A/B/C/D/E/F/G/H=53-128. DR PDB; 8SPE; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a/b/c/d=53-128. DR PDB; 8SPF; X-ray; 2.20 A; A/B/C/D/E/F=53-128. DR PDB; 8SPZ; X-ray; 2.40 A; A/B/C/D=53-128. DR PDB; 8SRX; X-ray; 2.09 A; B/D=53-128. DR PDB; 8SRY; X-ray; 2.40 A; B/D=53-128. DR PDB; 8SVK; X-ray; 2.25 A; A/B/C/D=53-128. DR PDB; 9IXU; EM; 3.19 A; A/B/C/D/E/F/G/H=1-192. DR PDBsum; 1F16; -. DR PDBsum; 2G5B; -. DR PDBsum; 2K7W; -. DR PDBsum; 2LR1; -. DR PDBsum; 3PK1; -. DR PDBsum; 3PL7; -. DR PDBsum; 4BD2; -. DR PDBsum; 4BD6; -. DR PDBsum; 4BD7; -. DR PDBsum; 4BD8; -. DR PDBsum; 4BDU; -. DR PDBsum; 4S0O; -. DR PDBsum; 4S0P; -. DR PDBsum; 4UF2; -. DR PDBsum; 4ZIE; -. DR PDBsum; 4ZIF; -. DR PDBsum; 4ZIG; -. DR PDBsum; 4ZIH; -. DR PDBsum; 4ZII; -. DR PDBsum; 5W5X; -. DR PDBsum; 5W5Z; -. DR PDBsum; 5W60; -. DR PDBsum; 5W61; -. DR PDBsum; 6EB6; -. DR PDBsum; 6L8V; -. DR PDBsum; 6L95; -. DR PDBsum; 6TRR; -. DR PDBsum; 6XY6; -. DR PDBsum; 7ADT; -. DR PDBsum; 8G1T; -. DR PDBsum; 8SPE; -. DR PDBsum; 8SPF; -. DR PDBsum; 8SPZ; -. DR PDBsum; 8SRX; -. DR PDBsum; 8SRY; -. DR PDBsum; 8SVK; -. DR PDBsum; 9IXU; -. DR AlphaFoldDB; Q07812; -. DR BMRB; Q07812; -. DR EMDB; EMD-60977; -. DR SASBDB; Q07812; -. DR SMR; Q07812; -. DR BioGRID; 107057; 150. DR ComplexPortal; CPX-1988; BAX oligomer. DR CORUM; Q07812; -. DR DIP; DIP-232N; -. DR FunCoup; Q07812; 1141. DR IntAct; Q07812; 87. DR MINT; Q07812; -. DR STRING; 9606.ENSP00000293288; -. DR BindingDB; Q07812; -. DR ChEMBL; CHEMBL5318; -. DR DrugBank; DB12756; TAK-901. DR DrugBank; DB16447; Thymoquinone. DR TCDB; 1.A.21.1.2; the bcl-2 (bcl-2) family. DR GlyGen; Q07812; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q07812; -. DR MetOSite; Q07812; -. DR PhosphoSitePlus; Q07812; -. DR SwissPalm; Q07812; -. DR BioMuta; BAX; -. DR DMDM; 728945; -. DR jPOST; Q07812; -. DR MassIVE; Q07812; -. DR PaxDb; 9606-ENSP00000293288; -. DR PeptideAtlas; Q07812; -. DR ProteomicsDB; 58529; -. [Q07812-1] DR ProteomicsDB; 58530; -. [Q07812-2] DR ProteomicsDB; 58531; -. [Q07812-3] DR ProteomicsDB; 58532; -. [Q07812-4] DR ProteomicsDB; 58533; -. [Q07812-5] DR ProteomicsDB; 58534; -. [Q07812-6] DR ProteomicsDB; 58535; -. [Q07812-7] DR ProteomicsDB; 58536; -. [Q07812-8] DR Pumba; Q07812; -. DR TopDownProteomics; Q07812-1; -. [Q07812-1] DR TopDownProteomics; Q07812-2; -. [Q07812-2] DR TopDownProteomics; Q07812-5; -. [Q07812-5] DR TopDownProteomics; Q07812-6; -. [Q07812-6] DR TopDownProteomics; Q07812-8; -. [Q07812-8] DR ABCD; Q07812; 22 sequenced antibodies. DR Antibodypedia; 3777; 2176 antibodies from 53 providers. DR CPTC; Q07812; 1 antibody. DR DNASU; 581; -. DR Ensembl; ENST00000293288.12; ENSP00000293288.8; ENSG00000087088.22. [Q07812-2] DR Ensembl; ENST00000345358.12; ENSP00000263262.9; ENSG00000087088.22. [Q07812-1] DR Ensembl; ENST00000354470.7; ENSP00000346461.3; ENSG00000087088.22. [Q07812-4] DR Ensembl; ENST00000356483.8; ENSP00000348871.4; ENSG00000087088.22. [Q07812-5] DR Ensembl; ENST00000415969.6; ENSP00000389971.2; ENSG00000087088.22. [Q07812-8] DR Ensembl; ENST00000515540.5; ENSP00000426328.1; ENSG00000087088.22. [Q07812-3] DR GeneID; 581; -. DR KEGG; hsa:581; -. DR MANE-Select; ENST00000345358.12; ENSP00000263262.9; NM_138761.4; NP_620116.1. DR UCSC; uc002plf.2; human. [Q07812-1] DR AGR; HGNC:959; -. DR CIViC; 581; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25269; -. DR CTD; 581; -. DR DisGeNET; 581; -. DR GeneCards; BAX; -. DR HGNC; HGNC:959; BAX. DR HPA; ENSG00000087088; Low tissue specificity. DR MalaCards; BAX; -. DR MIM; 600040; gene. DR OpenTargets; ENSG00000087088; -. DR VEuPathDB; HostDB:ENSG00000087088; -. DR eggNOG; KOG4728; Eukaryota. DR GeneTree; ENSGT01130000278292; -. DR HOGENOM; CLU_3279262_0_0_1; -. DR InParanoid; Q07812; -. DR OMA; QCCGDSE; -. DR OrthoDB; 6080198at2759; -. DR PAN-GO; Q07812; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q07812; -. DR PathwayCommons; Q07812; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-114294; Activation, translocation and oligomerization of BAX. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2. DR Reactome; R-HSA-9603505; NTRK3 as a dependence receptor. DR SignaLink; Q07812; -. DR SIGNOR; Q07812; -. DR Agora; ENSG00000087088; -. DR BioGRID-ORCS; 581; 32 hits in 1176 CRISPR screens. DR ChiTaRS; BAX; human. DR EvolutionaryTrace; Q07812; -. DR GeneWiki; Bcl-2-associated_X_protein; -. DR GenomeRNAi; 581; -. DR Pharos; Q07812; Tchem. DR PRO; PR:Q07812; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q07812; protein. DR Bgee; ENSG00000087088; Expressed in mucosa of transverse colon and 168 other cell types or tissues. DR ExpressionAtlas; Q07812; baseline and differential. DR GO; GO:0097145; C:BAK complex; IDA:ARUK-UCL. DR GO; GO:0097144; C:BAX complex; IDA:UniProtKB. DR GO; GO:0097136; C:Bcl-2 family protein complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC-UCL. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:HGNC-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB. DR GO; GO:0005757; C:mitochondrial permeability transition pore complex; IDA:HGNC-UCL. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:AgBase. DR GO; GO:0005634; C:nucleus; IDA:AgBase. DR GO; GO:0046930; C:pore complex; IDA:BHF-UCL. DR GO; GO:0051434; F:BH3 domain binding; IDA:UniProtKB. DR GO; GO:0015267; F:channel activity; IDA:BHF-UCL. DR GO; GO:0030544; F:Hsp70 protein binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0008289; F:lipid binding; IDA:HGNC-UCL. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:HGNC-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IDA:HGNC-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:DIBU. DR GO; GO:1902262; P:apoptotic process involved in blood vessel morphogenesis; IEA:Ensembl. DR GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0060057; P:apoptotic process involved in mammary gland involution; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IDA:HGNC-UCL. DR GO; GO:0001783; P:B cell apoptotic process; IDA:HGNC-UCL. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0002358; P:B cell homeostatic proliferation; IEA:Ensembl. DR GO; GO:0002352; P:B cell negative selection; IEA:Ensembl. DR GO; GO:1990117; P:B cell receptor apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0060402; P:calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; TAS:ParkinsonsUK-UCL. DR GO; GO:0034644; P:cellular response to UV; IEA:Ensembl. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl. DR GO; GO:0045136; P:development of secondary sexual characteristics; IEA:Ensembl. DR GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl. DR GO; GO:0032469; P:endoplasmic reticulum calcium ion homeostasis; TAS:UniProtKB. DR GO; GO:1904019; P:epithelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010248; P:establishment or maintenance of transmembrane electrochemical gradient; IDA:HGNC-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IMP:HGNC-UCL. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IBA:GO_Central. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IC:BHF-UCL. DR GO; GO:0009566; P:fertilization; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0021854; P:hypothalamus development; IEA:Ensembl. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:HGNC-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; TAS:ParkinsonsUK-UCL. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IDA:HGNC-UCL. DR GO; GO:0008053; P:mitochondrial fusion; IDA:HGNC-UCL. DR GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0002262; P:myeloid cell homeostasis; IEA:Ensembl. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0032471; P:negative regulation of endoplasmic reticulum calcium ion concentration; IEA:Ensembl. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:0010917; P:negative regulation of mitochondrial membrane potential; IDA:UniProtKB. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:1902512; P:positive regulation of apoptotic DNA fragmentation; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; IEA:Ensembl. DR GO; GO:0002904; P:positive regulation of B cell apoptotic process; IEA:Ensembl. DR GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0048087; P:positive regulation of developmental pigmentation; IEA:Ensembl. DR GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IEA:Ensembl. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1903896; P:positive regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL. DR GO; GO:1902110; P:positive regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:2000673; P:positive regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:HGNC-UCL. DR GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:2000243; P:positive regulation of reproductive process; IEA:Ensembl. DR GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0051204; P:protein insertion into mitochondrial membrane; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl. DR GO; GO:0033599; P:regulation of mammary gland epithelial cell proliferation; IEA:Ensembl. DR GO; GO:1902445; P:regulation of mitochondrial membrane permeability involved in programmed necrotic cell death; IEA:Ensembl. DR GO; GO:0051881; P:regulation of mitochondrial membrane potential; IDA:HGNC-UCL. DR GO; GO:0006808; P:regulation of nitrogen utilization; IEA:Ensembl. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0032976; P:release of matrix enzymes from mitochondria; IDA:HGNC-UCL. DR GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:0048678; P:response to axon injury; IEA:Ensembl. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IDA:HGNC-UCL. DR GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl. DR GO; GO:0046666; P:retinal cell programmed cell death; IEA:Ensembl. DR GO; GO:0060011; P:Sertoli cell proliferation; IEA:Ensembl. DR GO; GO:0048515; P:spermatid differentiation; IEA:Ensembl. DR GO; GO:0097435; P:supramolecular fiber organization; IDA:UniProtKB. DR GO; GO:0001777; P:T cell homeostatic proliferation; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR CDD; cd06845; Bcl-2_like; 1. DR DisProt; DP02540; -. DR FunFam; 1.10.437.10:FF:000004; apoptosis regulator BAX isoform X2; 1. DR Gene3D; 1.10.437.10; Blc2-like; 1. DR InterPro; IPR036834; Bcl-2-like_sf. DR InterPro; IPR046371; Bcl-2_BH1-3. DR InterPro; IPR026298; Bcl-2_fam. DR InterPro; IPR002475; Bcl2-like. DR InterPro; IPR020717; Bcl2_BH1_motif_CS. DR InterPro; IPR020726; Bcl2_BH2_motif_CS. DR InterPro; IPR020728; Bcl2_BH3_motif_CS. DR PANTHER; PTHR11256:SF42; APOPTOSIS REGULATOR BAX; 1. DR PANTHER; PTHR11256; BCL-2 RELATED; 1. DR Pfam; PF00452; Bcl-2; 1. DR PRINTS; PR01862; BCL2FAMILY. DR SMART; SM00337; BCL; 1. DR SUPFAM; SSF56854; Bcl-2 inhibitors of programmed cell death; 1. DR PROSITE; PS50062; BCL2_FAMILY; 1. DR PROSITE; PS01080; BH1; 1. DR PROSITE; PS01258; BH2; 1. DR PROSITE; PS01259; BH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm; KW Host-virus interaction; Isopeptide bond; Membrane; Mitochondrion; KW Mitochondrion outer membrane; Nucleus; Proteomics identification; KW Reference proteome; Transmembrane; Transmembrane helix; Tumor suppressor; KW Ubl conjugation. FT CHAIN 1..192 FT /note="Apoptosis regulator BAX" FT /id="PRO_0000143053" FT TRANSMEM 172..192 FT /note="Helical" FT /evidence="ECO:0000255" FT MOTIF 59..73 FT /note="BH3" FT /evidence="ECO:0000269|PubMed:8521816" FT MOTIF 98..118 FT /note="BH1" FT MOTIF 150..165 FT /note="BH2" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:25944712" FT CROSSLNK 128 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36361894" FT CROSSLNK 190 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36361894" FT VAR_SEQ 1..78 FT /note="Missing (in isoform Zeta)" FT /evidence="ECO:0000303|Ref.6" FT /id="VSP_031239" FT VAR_SEQ 1..19 FT /note="Missing (in isoform Psi)" FT /evidence="ECO:0000303|PubMed:11912183" FT /id="VSP_031238" FT VAR_SEQ 12..41 FT /note="GPTSSEQIMKTGALLLQGFIQDRAGRMGGE -> VSSRIEQGEWGGRHPSWP FT WTRCLRMRPPRS (in isoform Gamma)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031234" FT VAR_SEQ 30..78 FT /note="Missing (in isoform Delta)" FT /evidence="ECO:0000303|PubMed:7607685" FT /id="VSP_031235" FT VAR_SEQ 42..192 FT /note="Missing (in isoform Gamma)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031236" FT VAR_SEQ 125..192 FT /note="LCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIF FT VAGVLTASLTIWKKMG -> GVKWRDLGSLQPLPPGFKRFTCLSIPRSWDYRPCAPRCR FT N (in isoform Epsilon)" FT /evidence="ECO:0000303|PubMed:9920818" FT /id="VSP_031240" FT VAR_SEQ 159..192 FT /note="DGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG -> VRLLKPPHPHHRAL FT TTAPAPPSLPPATPLGPWAFWSRSQWCPLPIFRSSDVVYNAFSLRV (in isoform FT Beta)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031237" FT VAR_SEQ 159..171 FT /note="Missing (in isoform Sigma)" FT /evidence="ECO:0000303|PubMed:10772918" FT /id="VSP_037475" FT VARIANT 11 FT /note="G -> E (in a plasmacytoma cell line; FT dbSNP:rs555248599)" FT /evidence="ECO:0000269|PubMed:9531611" FT /id="VAR_013575" FT VARIANT 39 FT /note="G -> R (in dbSNP:rs36017265)" FT /id="VAR_047053" FT VARIANT 67 FT /note="G -> R (in a T-cell acute lymphoblastic leukemia FT cell line; loss of heterodimerization with Bcl-2 or Bcl- FT X(L); dbSNP:rs398122513)" FT /evidence="ECO:0000269|PubMed:7475270, FT ECO:0000269|PubMed:9531611" FT /id="VAR_007809" FT VARIANT 108 FT /note="G -> V (in a Burkitt lymphoma; loss of FT homodimerization)" FT /evidence="ECO:0000269|PubMed:7475270, FT ECO:0000269|PubMed:9531611" FT /id="VAR_013576" FT MUTAGEN 21 FT /note="K->E: Reduces interaction with BCL2L11, FT homooligomerization and triggering of apoptosis." FT /evidence="ECO:0000269|PubMed:18948948" FT MUTAGEN 74 FT /note="M->D,E: Strongly reduced interaction with MCL1, FT BCL2, BCL2L1 and BCL2L2. No effect on cytochrome c release FT and subsequent apoptosis triggered by etoposide." FT /evidence="ECO:0000269|PubMed:21199865" FT MUTAGEN 128 FT /note="K->R: Partial loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT MUTAGEN 172..192 FT /note="Missing: Enhanced fiber formation with humanin." FT /evidence="ECO:0000269|PubMed:31690630" FT MUTAGEN 184 FT /note="S->D,E,H,K: Constitutive cytoplasmic location." FT /evidence="ECO:0000269|PubMed:10228148" FT MUTAGEN 184 FT /note="S->V: Constitutive mitochondrial location. Enhanced FT fiber formation with humanin." FT /evidence="ECO:0000269|PubMed:10228148, FT ECO:0000269|PubMed:31690630" FT MUTAGEN 189 FT /note="K->R: No loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT MUTAGEN 190 FT /note="K->R: Partial loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT TURN 2..4 FT /evidence="ECO:0007829|PDB:2K7W" FT STRAND 10..14 FT /evidence="ECO:0007829|PDB:1F16" FT HELIX 16..34 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2K7W" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 43..45 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 54..71 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 74..82 FT /evidence="ECO:0007829|PDB:4ZIE" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 88..99 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 107..147 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 149..154 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 159..164 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 167..169 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 170..187 FT /evidence="ECO:0007829|PDB:5W60" SQ SEQUENCE 192 AA; 21184 MW; 6C0CDB0A7DEE4994 CRC64; MDGSGEQPRG GGPTSSEQIM KTGALLLQGF IQDRAGRMGG EAPELALDPV PQDASTKKLS ECLKRIGDEL DSNMELQRMI AAVDTDSPRE VFFRVAADMF SDGNFNWGRV VALFYFASKL VLKALCTKVP ELIRTIMGWT LDFLRERLLG WIQDQGGWDG LLSYFGTPTW QTVTIFVAGV LTASLTIWKK MG // ID BIRC5_HUMAN Reviewed; 142 AA. AC O15392; A2SUH6; B2R4R1; Q2I3N8; Q4VGX0; Q53F61; Q5MGC6; Q6FHL2; Q75SP2; AC Q9P2W8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2012, sequence version 3. DT 28-JAN-2026, entry version 252. DE RecName: Full=Baculoviral IAP repeat-containing protein 5; DE AltName: Full=Apoptosis inhibitor 4; DE AltName: Full=Apoptosis inhibitor survivin; GN Name=BIRC5; Synonyms=API4, IAP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=9256286; DOI=10.1038/nm0897-917; RA Ambrosini G., Adida C., Altieri D.C.; RT "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma."; RL Nat. Med. 3:917-921(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=10626797; RA Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D.; RT "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the RT apoptosis inhibitor survivin with different antiapoptotic properties."; RL Cancer Res. 59:6097-6102(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RX PubMed=11084331; DOI=10.1016/s0960-9822(00)00769-7; RA Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., RA Choo K.H.; RT "Survivin and the inner centromere protein INCENP show similar cell-cycle RT localization and gene knockout phenotype."; RL Curr. Biol. 10:1319-1328(2000). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY. RC TISSUE=Myeloid leukemia cell; RX PubMed=14741722; DOI=10.1016/j.bbrc.2003.12.178; RA Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., RA Inuzuka M.; RT "Identification of a novel splice variant of the human anti-apoptosis gene RT survivin."; RL Biochem. Biophys. Res. Commun. 314:902-907(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY. RC TISSUE=Mammary cancer; RX PubMed=16329164; DOI=10.1080/10425170500226490; RA Zheng W., Ma X., Wei D., Wang T., Ma Y., Yang S.; RT "Molecular cloning and bioinformatics analysis of a novel spliced variant RT of survivin from human breast cancer cells."; RL DNA Seq. 16:321-328(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Neuroblastoma; RA Kageyama H., Islam A., Takayasu H., Nakagawara A.; RT "An isoform of survivin (survivin-beta) which has 23 amino acids insertion RT into the BIR domain."; RL Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7). RA Caldas H., Honsey L.E., Altura R.A.; RT "Survivin 2 alpha: a novel survivin splice variant expressed in human RT malignancies."; RL Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6). RC TISSUE=Myeloid leukemia cell; RA Vietri M.T., Cioffi M., Sessa M., Sica V., Molinari A.M.; RT "Identification of a novel survivin splicing variant 3alpha in acute RT myeloid leukemia."; RL Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-129. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [14] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Mammary gland, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [16] RP FUNCTION. RX PubMed=9859993; DOI=10.1038/25141; RA Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., RA Altieri D.C.; RT "Control of apoptosis and mitotic spindle checkpoint by survivin."; RL Nature 396:580-584(1998). RN [17] RP PHOSPHORYLATION AT THR-34. RX PubMed=11069302; DOI=10.1073/pnas.240390697; RA O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., RA Tognin S., Marchisio P.C., Altieri D.C.; RT "Regulation of apoptosis at cell division by p34cdc2 phosphorylation of RT survivin."; RL Proc. Natl. Acad. Sci. U.S.A. 97:13103-13107(2000). RN [18] RP FUNCTION IN APOPTOSIS SUPPRESSION, INTERACTION WITH LAMTOR5/HBXIP, RP MUTAGENESIS OF THR-34, AND SUBCELLULAR LOCATION. RX PubMed=12773388; DOI=10.1093/emboj/cdg263; RA Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., RA Reed J.C.; RT "HBXIP functions as a cofactor of survivin in apoptosis suppression."; RL EMBO J. 22:2729-2740(2003). RN [19] RP INTERACTION WITH INCENP, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-117, RP AND MUTAGENESIS OF THR-117. RX PubMed=14610074; DOI=10.1074/jbc.m311299200; RA Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C.; RT "Aurora-B phosphorylation in vitro identifies a residue of survivin that is RT essential for its localization and binding to inner centromere protein RT (INCENP) in vivo."; RL J. Biol. Chem. 279:5655-5660(2004). RN [20] RP INTERACTION WITH CDCA8. RX PubMed=15249581; DOI=10.1083/jcb.200404001; RA Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R., RA Nigg E.A., Gerloff D.L., Earnshaw W.C.; RT "Borealin: a novel chromosomal passenger required for stability of the RT bipolar mitotic spindle."; RL J. Cell Biol. 166:179-191(2004). RN [21] RP SUBCELLULAR LOCATION, AND INTERACTION WITH BIRC2/C-IAP1. RX PubMed=15665297; DOI=10.1158/0008-5472.210.65.1; RA Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.; RT "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle."; RL Cancer Res. 65:210-218(2005). RN [22] RP REVIEW ON FUNCTION. RX PubMed=16344111; DOI=10.1016/s0074-7696(05)47002-3; RA Wheatley S.P., McNeish I.A.; RT "Survivin: a protein with dual roles in mitosis and apoptosis."; RL Int. Rev. Cytol. 247:35-88(2005). RN [23] RP FUNCTION, INTERACTION WITH USP9X, SUBCELLULAR LOCATION, UBIQUITINATION, AND RP MUTAGENESIS OF LYS-23; LYS-62; LYS-78 AND LYS-79. RX PubMed=16322459; DOI=10.1126/science.1120160; RA Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y.; RT "Chromosome alignment and segregation regulated by ubiquitination of RT survivin."; RL Science 310:1499-1504(2005). RN [24] RP MUTAGENESIS OF ASP-70; ASP-71 AND 70-ASP--ASP-71. RX PubMed=16762323; DOI=10.1016/j.bbrc.2006.05.131; RA Cao L., Yan X., Wu Y., Hu H., Li Q., Zhou T., Jiang S., Yu L.; RT "Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of Survivin RT with Aurora B and causes multinucleation in HeLa cells."; RL Biochem. Biophys. Res. Commun. 346:400-407(2006). RN [25] RP INTERACTION WITH CDCA8. RX PubMed=16239925; DOI=10.1038/sj.embor.7400562; RA Vader G., Kauw J.J.W., Medema R.H., Lens S.M.A.; RT "Survivin mediates targeting of the chromosomal passenger complex to the RT centromere and midbody."; RL EMBO Rep. 7:85-92(2006). RN [26] RP INTERACTION WITH CDCA8. RX PubMed=16427043; DOI=10.1016/j.yexcr.2005.12.015; RA Chang J.-L., Chen T.-H., Wang C.-F., Chiang Y.-H., Huang Y.-L., Wong F.-H., RA Chou C.-K., Chen C.-M.; RT "Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein RT and its nuclear accumulation is linked to poor prognosis for human gastric RT cancer."; RL Exp. Cell Res. 312:962-973(2006). RN [27] RP INTERACTION WITH EVI5. RX PubMed=16764853; DOI=10.1016/j.yexcr.2006.03.032; RA Faitar S.L., Sossey-Alaoui K., Ranalli T.A., Cowell J.K.; RT "EVI5 protein associates with the INCENP-aurora B kinase-survivin RT chromosomal passenger complex and is involved in the completion of RT cytokinesis."; RL Exp. Cell Res. 312:2325-2335(2006). RN [28] RP FUNCTION, AND INTERACTION WITH CDCA8. RX PubMed=16291752; DOI=10.1074/jbc.m508773200; RA Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., RA Wheatley S.P.; RT "Molecular analysis of survivin isoforms: evidence that alternatively RT spliced variants do not play a role in mitosis."; RL J. Biol. Chem. 281:1286-1295(2006). RN [29] RP INTERACTION WITH CDCA8. RX PubMed=16436504; DOI=10.1091/mbc.e05-08-0727; RA Lens S.M.A., Rodriguez J.A., Vader G., Span S.W., Giaccone G., Medema R.H.; RT "Uncoupling the central spindle-associated function of the chromosomal RT passenger complex from its role at centromeres."; RL Mol. Biol. Cell 17:1897-1909(2006). RN [30] RP INTERACTION WITH BIRC6/BRUCE. RX PubMed=18329369; DOI=10.1016/j.cell.2008.01.012; RA Pohl C., Jentsch S.; RT "Final stages of cytokinesis and midbody ring formation are controlled by RT BRUCE."; RL Cell 132:832-845(2008). RN [31] RP INDUCTION. RX PubMed=17993464; DOI=10.1074/jbc.m704035200; RA Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.; RT "Cartilage oligomeric matrix protein protects cells against death by RT elevating members of the IAP family of survival proteins."; RL J. Biol. Chem. 283:648-659(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-34, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [33] RP FUNCTION, INTERACTION WITH RAN; AURKB AND CDCA8, SUBCELLULAR LOCATION, RP DEVELOPMENTAL STAGE, AND MUTAGENESIS OF GLU-65. RX PubMed=18591255; DOI=10.1128/mcb.02039-07; RA Xia F., Canovas P.M., Guadagno T.M., Altieri D.C.; RT "A survivin-ran complex regulates spindle formation in tumor cells."; RL Mol. Cell. Biol. 28:5299-5311(2008). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21364656; DOI=10.1038/cddis.2010.25; RA Knauer S.K., Heinrich U.R., Bier C., Habtemichael N., Docter D., RA Helling K., Mann W.J., Stauber R.H.; RT "An otoprotective role for the apoptosis inhibitor protein survivin."; RL Cell Death Dis. 1:E51-E51(2010). RN [35] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAT3 AND XPO1/CRM1, RP ACETYLATION AT LYS-23; LYS-90; LYS-110; LYS-112; LYS-115; LYS-121 AND RP LYS-129, MUTAGENESIS OF LYS-129, AND CHARACTERIZATION OF VARIANT GLU-129. RX PubMed=20826784; DOI=10.1074/jbc.m110.152777; RA Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., RA Elenitoba-Johnson K.S., Chin Y.E., Altura R.A.; RT "Acetylation directs survivin nuclear localization to repress STAT3 RT oncogenic activity."; RL J. Biol. Chem. 285:36129-36137(2010). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20627126; DOI=10.1016/j.mcn.2010.07.003; RA Habtemichael N., Heinrich U.R., Knauer S.K., Schmidtmann I., Bier C., RA Docter D., Brochhausen C., Helling K., Brieger J., Stauber R.H., Mann W.J.; RT "Expression analysis suggests a potential cytoprotective role of Birc5 in RT the inner ear."; RL Mol. Cell. Neurosci. 45:297-305(2010). RN [37] RP FUNCTION, HISTONE-BINDING, AND MUTAGENESIS OF ARG-18; TRP-25; CYS-33; RP CYS-57 AND TRP-67. RX PubMed=20929775; DOI=10.1126/science.1194498; RA Yamagishi Y., Honda T., Tanno Y., Watanabe Y.; RT "Two histone marks establish the inner centromere and chromosome bi- RT orientation."; RL Science 330:239-243(2010). RN [38] RP PHOSPHORYLATION AT THR-48, AND MUTAGENESIS OF THR-48. RX PubMed=21252625; DOI=10.4161/cc.10.3.14758; RA Barrett R.M., Colnaghi R., Wheatley S.P.; RT "Threonine 48 in the BIR domain of survivin is critical to its mitotic and RT anti-apoptotic activities and can be phosphorylated by CK2 in vitro."; RL Cell Cycle 10:538-548(2011). RN [39] RP INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [40] RP FUNCTION, SUBUNIT, AND INTERACTION WITH XIAP/BIRC4 AND DIABLO/SMAC. RX PubMed=21536684; DOI=10.1074/jbc.m111.237586; RA Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V., RA Kopantzev E.P., Shakhparonov M.I.; RT "Survivin monomer plays an essential role in apoptosis regulation."; RL J. Biol. Chem. 286:23296-23307(2011). RN [41] RP PHOSPHORYLATION AT THR-34 BY CDK15. RX PubMed=24866247; DOI=10.1016/j.bbrc.2014.05.070; RA Park M.H., Kim S.Y., Kim Y.J., Chung Y.H.; RT "ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing RT phosphorylation of survivin Thr34."; RL Biochem. Biophys. Res. Commun. 450:129-134(2014). RN [42] RP UBIQUITINATION. RX PubMed=24793696; DOI=10.1016/j.molcel.2014.03.046; RA Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., Xiong Y.; RT "CUL9 mediates the functions of the 3M complex and ubiquitylates survivin RT to maintain genome integrity."; RL Mol. Cell 54:805-819(2014). RN [43] RP FUNCTION, INTERACTION WITH FBXL7, AND MUTAGENESIS OF 90-LYS-LYS-91 AND RP GLU-126. RX PubMed=25778398; DOI=10.1074/jbc.m114.629931; RA Liu Y., Lear T., Iannone O., Shiva S., Corey C., Rajbhandari S., Jerome J., RA Chen B.B., Mallampalli R.K.; RT "The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by RT Mediating the Ubiquitylation and Proteasomal Degradation of Survivin."; RL J. Biol. Chem. 290:11843-11852(2015). RN [44] RP SUBUNIT, AND PHOSPHORYLATION AT SER-20. RX PubMed=27332895; DOI=10.1371/journal.pone.0157305; RA Sasai K., Katayama H., Hawke D.H., Sen S.; RT "Aurora-C interactions with survivin and INCENP reveal shared and distinct RT features compared with Aurora-B chromosome passenger protein complex."; RL PLoS ONE 11:E0157305-E0157305(2016). RN [45] RP FUNCTION, AND INTERACTION WITH FBXL7. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [46] RP INTERACTION WITH EPSTEIN-BARR VIRUS EBNA1 (MICROBIAL INFECTION). RX PubMed=28077791; DOI=10.18632/oncotarget.14540; RA Dheekollu J., Malecka K., Wiedmer A., Delecluse H.J., Chiang A.K., RA Altieri D.C., Messick T.E., Lieberman P.M.; RT "Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal RT latency."; RL Oncotarget 8:7248-7264(2017). RN [47] RP DEUBIQUITINATION BY USP35 AND USP38. RX PubMed=34438346; DOI=10.1016/j.bbrc.2021.08.050; RA Wang W., Lin H., Zheng E., Hou Z., Liu Y., Huang W., Chen D., Feng J., RA Li J., Li L.; RT "Regulation of survivin protein stability by USP35 is evolutionarily RT conserved."; RL Biochem. Biophys. Res. Commun. 574:48-55(2021). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF ISOFORM 1. RX PubMed=10949039; DOI=10.1016/s1097-2765(05)00020-1; RA Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O., RA Margolis R.L.; RT "Crystal structure of human survivin reveals a bow tie-shaped dimer with RT two unusual alpha-helical extensions."; RL Mol. Cell 6:183-189(2000). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF ISOFORM 1. RX PubMed=10876248; DOI=10.1038/76838; RA Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P.; RT "Structure of the human anti-apoptotic protein survivin reveals a dimeric RT arrangement."; RL Nat. Struct. Biol. 7:602-608(2000). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT, RP AND INTERACTION WITH CDCA8 AND INCENP. RX PubMed=17956729; DOI=10.1016/j.cell.2007.07.045; RA Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E.; RT "Structure of a Survivin-Borealin-INCENP core complex reveals how RT chromosomal passengers travel together."; RL Cell 131:271-285(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS). RX PubMed=19530738; DOI=10.1021/bi900530v; RA Bourhis E., Lingel A., Phung Q., Fairbrother W.J., Cochran A.G.; RT "Phosphorylation of a borealin dimerization domain is required for proper RT chromosome segregation."; RL Biochemistry 48:6783-6793(2009). CC -!- FUNCTION: Multitasking protein that has dual roles in promoting cell CC proliferation and preventing apoptosis (PubMed:20627126, CC PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). CC Component of a chromosome passage protein complex (CPC) which is CC essential for chromosome alignment and segregation during mitosis and CC cytokinesis (PubMed:16322459). Acts as an important regulator of the CC localization of this complex; directs CPC movement to different CC locations from the inner centromere during prometaphase to midbody CC during cytokinesis and participates in the organization of the center CC spindle by associating with polymerized microtubules (PubMed:20826784). CC Involved in the recruitment of CPC to centromeres during early mitosis CC via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) CC during mitosis (PubMed:20929775). The complex with RAN plays a role in CC mitotic spindle formation by serving as a physical scaffold to help CC deliver the RAN effector molecule TPX2 to microtubules CC (PubMed:18591255). May counteract a default induction of apoptosis in CC G2/M phase (PubMed:9859993). The acetylated form represses STAT3 CC transactivation of target gene promoters (PubMed:20826784). May play a CC role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 CC (PubMed:21536684). Essential for the maintenance of mitochondrial CC integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do CC not appear to play vital roles in mitosis (PubMed:12773388, CC PubMed:16291752). Isoform 3 shows a marked reduction in its anti- CC apoptotic effects when compared with the displayed wild-type isoform CC (PubMed:10626797). {ECO:0000269|PubMed:10626797, CC ECO:0000269|PubMed:12773388, ECO:0000269|PubMed:16291752, CC ECO:0000269|PubMed:16322459, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:20929775, ECO:0000269|PubMed:21364656, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735, ECO:0000269|PubMed:9859993}. CC -!- SUBUNIT: Monomer or homodimer. Exists as a homodimer in the apo state CC and as a monomer in the CPC-bound state. The monomer protects cells CC against apoptosis more efficiently than the dimer. Only the dimeric CC form is capable of enhancing tubulin stability in cells. When CC phosphorylated, interacts with LAMTOR5/HBXIP; the resulting complex CC binds pro-CASP9, as well as active CASP9, but much less efficiently. CC Component of the chromosomal passenger complex (CPC) composed of at CC least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; in the CC complex forms a triple-helix bundle-based subcomplex with INCENP and CC CDCA8 (PubMed:17956729). Interacts with JTB. Interacts (via BIR domain) CC with histone H3 phosphorylated at 'Thr-3' (H3pT3). Interacts with EVI5. CC Interacts with GTP-bound RAN in both the S and M phases of the cell CC cycle. Interacts with USP9X. Interacts with tubulin. Interacts with CC BIRC2/c-IAP1. The acetylated form at Lys-129 interacts with STAT3. The CC monomeric form deacetylated at Lys-129 interacts with XPO1/CRM1. The CC monomeric form interacts with XIAP/BIRC4. Both the dimeric and CC monomeric form can interact with DIABLO/SMAC. Interacts with CC BIRC6/bruce. Interacts with FBXL7; this interaction facilitates the CC polyubiquitination and subsequent proteasomal degradation of BIRC5 by CC the SCF(FBXL7) E3 ubiquitin-protein ligase complex (PubMed:25778398, CC PubMed:28218735). {ECO:0000269|PubMed:12773388, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:15249581, CC ECO:0000269|PubMed:15665297, ECO:0000269|PubMed:16239925, CC ECO:0000269|PubMed:16291752, ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:16427043, ECO:0000269|PubMed:16436504, CC ECO:0000269|PubMed:16764853, ECO:0000269|PubMed:17956729, CC ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus (EBV) CC EBNA1; this interaction is probably important for EBV episome CC maintenance in Burkitt's lymphoma cells. {ECO:0000269|PubMed:28077791}. CC -!- INTERACTION: CC O15392; Q92870-2: APBB2; NbExp=3; IntAct=EBI-518823, EBI-21535880; CC O15392; P05067: APP; NbExp=3; IntAct=EBI-518823, EBI-77613; CC O15392; P05067-2: APP; NbExp=3; IntAct=EBI-518823, EBI-17264467; CC O15392; O14965: AURKA; NbExp=2; IntAct=EBI-518823, EBI-448680; CC O15392; Q96GD4: AURKB; NbExp=13; IntAct=EBI-518823, EBI-624291; CC O15392; Q9UQB9: AURKC; NbExp=10; IntAct=EBI-518823, EBI-3926851; CC O15392; Q14457: BECN1; NbExp=3; IntAct=EBI-518823, EBI-949378; CC O15392; O15392: BIRC5; NbExp=2; IntAct=EBI-518823, EBI-518823; CC O15392; Q15834: CCDC85B; NbExp=3; IntAct=EBI-518823, EBI-739674; CC O15392; Q53HL2: CDCA8; NbExp=21; IntAct=EBI-518823, EBI-979174; CC O15392; P06493: CDK1; NbExp=6; IntAct=EBI-518823, EBI-444308; CC O15392; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-518823, EBI-25840379; CC O15392; Q9NR28: DIABLO; NbExp=2; IntAct=EBI-518823, EBI-517508; CC O15392; Q86XJ1: GAS2L3; NbExp=4; IntAct=EBI-518823, EBI-9248152; CC O15392; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-518823, EBI-11110431; CC O15392; P42858: HTT; NbExp=15; IntAct=EBI-518823, EBI-466029; CC O15392; Q9NQS7: INCENP; NbExp=11; IntAct=EBI-518823, EBI-307907; CC O15392; O43504: LAMTOR5; NbExp=3; IntAct=EBI-518823, EBI-713382; CC O15392; Q96CV9: OPTN; NbExp=3; IntAct=EBI-518823, EBI-748974; CC O15392; Q7Z412: PEX26; NbExp=3; IntAct=EBI-518823, EBI-752057; CC O15392; Q9BXM7: PINK1; NbExp=3; IntAct=EBI-518823, EBI-2846068; CC O15392; P62826: RAN; NbExp=7; IntAct=EBI-518823, EBI-286642; CC O15392; P37840: SNCA; NbExp=3; IntAct=EBI-518823, EBI-985879; CC O15392; Q13148: TARDBP; NbExp=6; IntAct=EBI-518823, EBI-372899; CC O15392; P09936: UCHL1; NbExp=3; IntAct=EBI-518823, EBI-714860; CC O15392; O14980: XPO1; NbExp=2; IntAct=EBI-518823, EBI-355867; CC O15392-1; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518838, EBI-624291; CC O15392-1; O15392-1: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518838; CC O15392-1; O15392-2: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518842; CC O15392-1; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518838, EBI-979174; CC O15392-2; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518842, EBI-624291; CC O15392-2; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518842, EBI-979174; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21364656}. Nucleus CC {ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:21364656}. Chromosome {ECO:0000269|PubMed:14610074}. CC Chromosome, centromere {ECO:0000269|PubMed:11084331, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:16322459}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:11084331}. Chromosome, CC centromere, kinetochore {ECO:0000269|PubMed:11084331}. Midbody CC {ECO:0000269|PubMed:15665297}. Note=Localizes at the centromeres from CC prophase to metaphase, at the spindle midzone during anaphase and a the CC midbody during telophase and cytokinesis. Accumulates in the nucleus CC upon treatment with leptomycin B (LMB), a XPO1/CRM1 nuclear export CC inhibitor (By similarity). Localizes on chromosome arms and inner CC centromeres from prophase through metaphase. Localizes to kinetochores CC in metaphase, distributes to the midzone microtubules in anaphase and CC at telophase, localizes exclusively to the midbody (PubMed:11084331). CC Colocalizes with AURKB at mitotic chromosomes (PubMed:14610074). CC Acetylation at Lys-129 directs its localization to the nucleus by CC enhancing homodimerization and thereby inhibiting XPO1/CRM1-mediated CC nuclear export (PubMed:20826784). {ECO:0000250|UniProtKB:E3SCZ8, CC ECO:0000269|PubMed:11084331, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:20826784}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Alpha; CC IsoId=O15392-1; Sequence=Displayed; CC Name=2; Synonyms=2B, Beta; CC IsoId=O15392-2; Sequence=VSP_002454; CC Name=3; Synonyms=DeltaEx3; CC IsoId=O15392-3; Sequence=VSP_020338; CC Name=4; Synonyms=3B; CC IsoId=O15392-4; Sequence=VSP_020342; CC Name=5; Synonyms=SI; CC IsoId=O15392-5; Sequence=VSP_020341; CC Name=6; Synonyms=3 alpha; CC IsoId=O15392-6; Sequence=VSP_020339; CC Name=7; Synonyms=2 alpha; CC IsoId=O15392-7; Sequence=VSP_020340; CC -!- TISSUE SPECIFICITY: Expressed only in fetal kidney and liver, and to CC lesser extent, lung and brain (PubMed:10626797). Abundantly expressed CC in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in CC high-grade lymphomas (PubMed:14741722, PubMed:16329164). Also expressed CC in various renal cell carcinoma cell lines (PubMed:10626797). Expressed CC in cochlea including the organ of Corti, the lateral wall, the CC interdental cells of the Limbus as well as in Schwann cells and cells CC of the cochlear nerve and the spiral ganglions (at protein level). Not CC expressed in cells of the inner and outer sulcus or the Reissner's CC membrane (at protein level) (PubMed:20627126, PubMed:21364656). CC {ECO:0000269|PubMed:10626797, ECO:0000269|PubMed:14741722, CC ECO:0000269|PubMed:16329164, ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:21364656}. CC -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent and peaks at CC mitosis. {ECO:0000269|PubMed:18591255}. CC -!- INDUCTION: Up-regulated by COMP. {ECO:0000269|PubMed:17993464}. CC -!- DOMAIN: The BIR repeat is necessary and sufficient for LAMTOR5 binding. CC {ECO:0000269|PubMed:12773388}. CC -!- PTM: Ubiquitinated by the Cul9-RING ubiquitin-protein ligase complex, CC leading to its degradation. Ubiquitination is required for centrosomal CC targeting. Deubiquitinated by USP35 or USP38; leading to stabilization CC (PubMed:34438346). {ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:24793696, ECO:0000269|PubMed:34438346}. CC -!- PTM: In vitro phosphorylation at Thr-117 by AURKB prevents interaction CC with INCENP and localization to mitotic chromosomes (PubMed:14610074). CC Phosphorylation at Thr-48 by CK2 is critical for its mitotic and anti- CC apoptotic activities (PubMed:21252625). Phosphorylation at Thr-34 by CC CDK15 is critical for its anti-apoptotic activity (PubMed:24866247). CC Phosphorylation at Ser-20 by AURKC is critical for regulation of proper CC chromosome alignment and segregation, and possibly cytokinesis. CC {ECO:0000269|PubMed:11069302, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:21252625, ECO:0000269|PubMed:24866247, CC ECO:0000269|PubMed:27332895}. CC -!- PTM: Acetylation at Lys-129 by CBP results in its homodimerization, CC while deacetylation promotes the formation of monomers which CC heterodimerize with XPO1/CRM1 which facilitates its nuclear export. The CC acetylated form represses STAT3 transactivation. The dynamic CC equilibrium between its acetylation and deacetylation at Lys-129 CC determines its interaction with XPO1/CRM1, its subsequent subcellular CC localization, and its ability to inhibit STAT3 transactivation. CC {ECO:0000269|PubMed:20826784}. CC -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U75285; AAC51660.1; -; Genomic_DNA. DR EMBL; AF077350; AAD34226.1; -; mRNA. DR EMBL; AB154416; BAD11155.1; -; mRNA. DR EMBL; AY830084; AAW22624.1; -; mRNA. DR EMBL; AB028869; BAA93676.1; -; mRNA. DR EMBL; AY927772; AAY15202.1; -; mRNA. DR EMBL; DQ227257; ABB76601.1; -; mRNA. DR EMBL; DQ310375; ABC42341.1; -; mRNA. DR EMBL; DQ310376; ABC42342.1; -; mRNA. DR EMBL; DQ310377; ABC42343.1; -; mRNA. DR EMBL; DQ310378; ABC42344.1; -; mRNA. DR EMBL; DQ310379; ABC42345.1; -; mRNA. DR EMBL; CR541740; CAG46540.1; -; mRNA. DR EMBL; AK223428; BAD97148.1; -; mRNA. DR EMBL; AK311917; BAG34858.1; -; mRNA. DR EMBL; AY795969; AAV40840.1; -; Genomic_DNA. DR EMBL; AC087645; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89514.1; -; Genomic_DNA. DR EMBL; BC008718; AAH08718.1; -; mRNA. DR EMBL; BC034148; AAH34148.1; -; mRNA. DR EMBL; BC065497; AAH65497.1; -; mRNA. DR CCDS; CCDS11755.1; -. [O15392-1] DR CCDS; CCDS32751.1; -. [O15392-3] DR CCDS; CCDS32752.1; -. [O15392-2] DR RefSeq; NP_001012270.1; NM_001012270.2. [O15392-3] DR RefSeq; NP_001012271.1; NM_001012271.1. DR RefSeq; NP_001159.2; NM_001168.2. DR PDB; 1E31; X-ray; 2.71 A; A/B=1-142. DR PDB; 1F3H; X-ray; 2.58 A; A/B=1-142. DR PDB; 1XOX; NMR; -; A/B=1-117. DR PDB; 2QFA; X-ray; 1.40 A; A=1-142. DR PDB; 2RAW; X-ray; 2.40 A; A=1-142. DR PDB; 2RAX; X-ray; 3.30 A; A/E/X=1-120. DR PDB; 3UEC; X-ray; 2.18 A; A=1-142. DR PDB; 3UED; X-ray; 2.70 A; A/C=1-142. DR PDB; 3UEE; X-ray; 2.61 A; A/C=1-142. DR PDB; 3UEF; X-ray; 2.45 A; A/C=1-142. DR PDB; 3UEG; X-ray; 2.80 A; A/B=1-142. DR PDB; 3UEH; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UEI; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIG; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UIH; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UII; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UIJ; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIK; X-ray; 2.70 A; A/B=1-142. DR PDB; 4A0I; X-ray; 2.60 A; A/B=1-142. DR PDB; 4A0J; X-ray; 2.80 A; A/B=1-142. DR PDB; 4A0N; X-ray; 2.74 A; A=1-142. DR PDB; 6SHO; X-ray; 3.20 A; A/B=1-142. DR PDB; 6YIE; X-ray; 3.49 A; A/D=1-142. DR PDB; 6YIF; X-ray; 1.81 A; A=1-142. DR PDB; 6YIH; X-ray; 2.55 A; A=1-142. DR PDB; 7LBK; X-ray; 2.70 A; A/B=1-142. DR PDB; 7LBO; X-ray; 2.50 A; A/B=1-142. DR PDB; 7LBP; X-ray; 2.60 A; A/C=1-142. DR PDB; 7LBQ; X-ray; 2.69 A; A=1-142. DR PDB; 8RUP; EM; 2.42 A; K=1-142. DR PDBsum; 1E31; -. DR PDBsum; 1F3H; -. DR PDBsum; 1XOX; -. DR PDBsum; 2QFA; -. DR PDBsum; 2RAW; -. DR PDBsum; 2RAX; -. DR PDBsum; 3UEC; -. DR PDBsum; 3UED; -. DR PDBsum; 3UEE; -. DR PDBsum; 3UEF; -. DR PDBsum; 3UEG; -. DR PDBsum; 3UEH; -. DR PDBsum; 3UEI; -. DR PDBsum; 3UIG; -. DR PDBsum; 3UIH; -. DR PDBsum; 3UII; -. DR PDBsum; 3UIJ; -. DR PDBsum; 3UIK; -. DR PDBsum; 4A0I; -. DR PDBsum; 4A0J; -. DR PDBsum; 4A0N; -. DR PDBsum; 6SHO; -. DR PDBsum; 6YIE; -. DR PDBsum; 6YIF; -. DR PDBsum; 6YIH; -. DR PDBsum; 7LBK; -. DR PDBsum; 7LBO; -. DR PDBsum; 7LBP; -. DR PDBsum; 7LBQ; -. DR PDBsum; 8RUP; -. DR AlphaFoldDB; O15392; -. DR BMRB; O15392; -. DR EMDB; EMD-19513; -. DR SASBDB; O15392; -. DR SMR; O15392; -. DR BioGRID; 106829; 111. DR ComplexPortal; CPX-111; Survivin homodimer complex. DR ComplexPortal; CPX-116; Chromosomal passenger complex. DR CORUM; O15392; -. DR DIP; DIP-34662N; -. DR ELM; O15392; -. DR FunCoup; O15392; 1567. DR IntAct; O15392; 57. DR MINT; O15392; -. DR STRING; 9606.ENSP00000301633; -. DR BindingDB; O15392; -. DR ChEMBL; CHEMBL5989; -. DR DrugBank; DB16095; APG-1387. DR DrugBank; DB04115; Berberine. DR DrugBank; DB12085; LCL-161. DR DrugBank; DB05141; LY2181308. DR DrugBank; DB00206; Reserpine. DR DrugBank; DB16305; Xevinapant. DR DrugCentral; O15392; -. DR GuidetoPHARMACOLOGY; 2795; -. DR MEROPS; I32.005; -. DR iPTMnet; O15392; -. DR PhosphoSitePlus; O15392; -. DR BioMuta; BIRC5; -. DR jPOST; O15392; -. DR MassIVE; O15392; -. DR PeptideAtlas; O15392; -. DR ProteomicsDB; 48627; -. [O15392-1] DR ProteomicsDB; 48628; -. [O15392-2] DR ProteomicsDB; 48629; -. [O15392-3] DR ProteomicsDB; 48630; -. [O15392-4] DR ProteomicsDB; 48631; -. [O15392-5] DR ProteomicsDB; 48632; -. [O15392-6] DR ProteomicsDB; 48633; -. [O15392-7] DR Pumba; O15392; -. DR ABCD; O15392; 5 sequenced antibodies. DR Antibodypedia; 1073; 1831 antibodies from 53 providers. DR DNASU; 332; -. DR Ensembl; ENST00000374948.6; ENSP00000364086.1; ENSG00000089685.16. [O15392-3] DR Ensembl; ENST00000590449.1; ENSP00000465868.1; ENSG00000089685.16. [O15392-7] DR Ensembl; ENST00000590925.6; ENSP00000467336.1; ENSG00000089685.16. [O15392-4] DR Ensembl; ENST00000592734.5; ENSP00000466617.1; ENSG00000089685.16. [O15392-6] DR GeneID; 332; -. DR KEGG; hsa:332; -. DR UCSC; uc002jvh.4; human. [O15392-1] DR AGR; HGNC:593; -. DR CIViC; 332; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA25362; -. DR CTD; 332; -. DR DisGeNET; 332; -. DR GeneCards; BIRC5; -. DR HGNC; HGNC:593; BIRC5. DR HPA; ENSG00000089685; Tissue enhanced (bone marrow, lymphoid tissue, testis). DR MIM; 603352; gene. DR OpenTargets; ENSG00000089685; -. DR VEuPathDB; HostDB:ENSG00000089685; -. DR GeneTree; ENSGT00510000047537; -. DR HOGENOM; CLU_1869818_0_0_1; -. DR InParanoid; O15392; -. DR OrthoDB; 2196114at2759; -. DR PAN-GO; O15392; 6 GO annotations based on evolutionary models. DR PathwayCommons; O15392; -. DR Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal. DR Reactome; R-HSA-2467813; Separation of Sister Chromatids. DR Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-5663220; RHO GTPases Activate Formins. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-68877; Mitotic Prometaphase. DR Reactome; R-HSA-8951664; Neddylation. DR Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation. DR SignaLink; O15392; -. DR SIGNOR; O15392; -. DR Agora; ENSG00000089685; -. DR BioGRID-ORCS; 332; 826 hits in 1161 CRISPR screens. DR CD-CODE; 3F4CB227; Synthetic Condensate 000322. DR CD-CODE; 45F3D8EC; Synthetic Condensate 000342. DR CD-CODE; 7230F6EA; Synthetic Condensate 000328. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BIRC5; human. DR EvolutionaryTrace; O15392; -. DR GeneWiki; Survivin; -. DR GenomeRNAi; 332; -. DR Pharos; O15392; Tchem. DR PRO; PR:O15392; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O15392; protein. DR Bgee; ENSG00000089685; Expressed in ventricular zone and 127 other cell types or tissues. DR ExpressionAtlas; O15392; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IPI:UniProtKB. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005881; C:cytoplasmic microtubule; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0031021; C:interphase microtubule organizing center; IDA:UniProtKB. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:ComplexPortal. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0000228; C:nuclear chromosome; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:1990713; C:survivin complex; IPI:ComplexPortal. DR GO; GO:0050897; F:cobalt ion binding; NAS:UniProtKB. DR GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW. DR GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB. DR GO; GO:0015631; F:tubulin binding; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IMP:UniProtKB. DR GO; GO:0050000; P:chromosome localization; IMP:UniProtKB. DR GO; GO:0007059; P:chromosome segregation; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0090307; P:mitotic spindle assembly; NAS:ComplexPortal. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0051256; P:mitotic spindle midzone assembly; NAS:ComplexPortal. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:1902425; P:positive regulation of attachment of mitotic spindle microtubules to kinetochore; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; NAS:ComplexPortal. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; NAS:ComplexPortal. DR GO; GO:1901970; P:positive regulation of mitotic sister chromatid separation; NAS:ComplexPortal. DR GO; GO:0031503; P:protein-containing complex localization; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IEP:UniProtKB. DR CDD; cd00022; BIR; 1. DR DisProt; DP03719; -. DR FunFam; 1.10.1170.10:FF:000009; Baculoviral IAP repeat-containing protein 5; 1. DR Gene3D; 1.10.1170.10; Inhibitor Of Apoptosis Protein (2mihbC-IAP-1), Chain A; 1. DR IDEAL; IID00186; -. DR InterPro; IPR051190; Baculoviral_IAP. DR InterPro; IPR001370; BIR_rpt. DR PANTHER; PTHR46771:SF3; BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5; 1. DR PANTHER; PTHR46771; DETERIN; 1. DR Pfam; PF00653; BIR; 1. DR SMART; SM00238; BIR; 1. DR SUPFAM; SSF57924; Inhibitor of apoptosis (IAP) repeat; 1. DR PROSITE; PS50143; BIR_REPEAT_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cell cycle; KW Cell division; Centromere; Chromosome; Chromosome partition; Cytoplasm; KW Cytoskeleton; Host-virus interaction; Kinetochore; Metal-binding; KW Microtubule; Mitosis; Nucleus; Phosphoprotein; Protease inhibitor; KW Proteomics identification; Reference proteome; Repressor; KW Thiol protease inhibitor; Transcription; Transcription regulation; KW Ubl conjugation; Zinc. FT CHAIN 1..142 FT /note="Baculoviral IAP repeat-containing protein 5" FT /id="PRO_0000122356" FT REPEAT 18..88 FT /note="BIR" FT BINDING 57 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 60 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 77 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 84 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT SITE 126 FT /note="Interaction with FBXL7" FT /evidence="ECO:0000269|PubMed:25778398" FT MOD_RES 20 FT /note="Phosphoserine; by AURKC" FT /evidence="ECO:0000269|PubMed:27332895" FT MOD_RES 23 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 34 FT /note="Phosphothreonine; by CDK1 and CDK15" FT /evidence="ECO:0000269|PubMed:11069302, FT ECO:0000269|PubMed:24866247, ECO:0007744|PubMed:18691976" FT MOD_RES 48 FT /note="Phosphothreonine; by CK2; in vitro" FT /evidence="ECO:0000269|PubMed:21252625" FT MOD_RES 90 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 110 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 112 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 115 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 117 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:14610074" FT MOD_RES 121 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 129 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MQRKPTIRRKNLRKLRRKCAVPSSSWLPWIEASGRSCL FT VPEWLHHFQGLFPGATSLPVGPLAMS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10626797" FT /id="VSP_020338" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MRELC (in isoform 6)" FT /evidence="ECO:0000303|Ref.8" FT /id="VSP_020339" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> M (in isoform 7)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_020340" FT VAR_SEQ 74 FT /note="I -> IGPGTVAYACNTSTLGGRGGRITR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10626797, ECO:0000303|Ref.6" FT /id="VSP_002454" FT VAR_SEQ 105..142 FT /note="DRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD -> VRETLPPPRS FT FIR (in isoform 5)" FT /evidence="ECO:0000303|PubMed:16329164" FT /id="VSP_020341" FT VAR_SEQ 114..142 FT /note="AKETNNKKKEFEETAKKVRRAIEQLAAMD -> ERALLAE (in isoform FT 4)" FT /evidence="ECO:0000303|PubMed:14741722" FT /id="VSP_020342" FT VARIANT 129 FT /note="K -> E (loss of acetylation; localization primarily FT within the cytoplasm; increased likelihood of existing as FT monomer; stronger binding to XPO1/CRM1; dbSNP:rs2071214)" FT /evidence="ECO:0000269|PubMed:16625196, FT ECO:0000269|PubMed:20826784" FT /id="VAR_021071" FT MUTAGEN 18 FT /note="R->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 23 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-62; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 25 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 33 FT /note="C->R: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 34 FT /note="T->A: Loss of LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 34 FT /note="T->E: Higher affinity for LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 48 FT /note="T->A,E: Localizes normally during mitosis but cannot FT support cell proliferation. Increased affinity for FT CDCA8/borealin." FT /evidence="ECO:0000269|PubMed:21252625" FT MUTAGEN 57 FT /note="C->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 62 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 65 FT /note="E->A: Almost abolishes RAN-binding. Does not disrupt FT binding to AURKB or CDCA8. Disrupts mitotic spindle FT assembly. Does not disrupt nuclear export." FT /evidence="ECO:0000269|PubMed:18591255" FT MUTAGEN 67 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 70 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-71." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 71 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-70." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 78 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 79 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-78." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 84 FT /note="C->A: Loss of cytoprotection." FT MUTAGEN 90..91 FT /note="KK->RR: Loss of FBXL7 mediated polyubiquitination." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 117 FT /note="T->A: Prevents phosphorylation by AURKB. Still able FT to localize correctly but prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 117 FT /note="T->E: Mimics phosphorylation. Disrupts subcellular FT localization during mitosis and prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 126 FT /note="E->A: Loss of FBXL7 binding." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 129 FT /note="K->A,Q: Mimics acetylation. Localization primarily FT within the nucleus." FT /evidence="ECO:0000269|PubMed:20826784" FT MUTAGEN 129 FT /note="K->R: Loss of acetylation. Localization primarily FT within the cytoplasm." FT /evidence="ECO:0000269|PubMed:20826784" FT CONFLICT 57..58 FT /note="CF -> WV (in Ref. 5; AAW22624)" FT /evidence="ECO:0000305" FT CONFLICT 58 FT /note="F -> L (in Ref. 11; BAD97148)" FT /evidence="ECO:0000305" FT CONFLICT 128 FT /note="A -> V (in Ref. 9; CAG46540)" FT /evidence="ECO:0000305" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 11..13 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 15..20 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 29..32 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 35..40 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 43..45 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 49..51 FT /evidence="ECO:0007829|PDB:3UIG" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 73..80 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:1F3H" FT HELIX 85..88 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 98..139 FT /evidence="ECO:0007829|PDB:2QFA" SQ SEQUENCE 142 AA; 16389 MW; 9E7CADCDF2822286 CRC64; MGAPTLPPAW QPFLKDHRIS TFKNWPFLEG CACTPERMAE AGFIHCPTEN EPDLAQCFFC FKELEGWEPD DDPIEEHKKH SSGCAFLSVK KQFEELTLGE FLKLDRERAK NKIAKETNNK KKEFEETAKK VRRAIEQLAA MD // ID BRDT_HUMAN Reviewed; 947 AA. AC Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1; AC Q7Z4A6; Q8IWI6; DT 30-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 4. DT 28-JAN-2026, entry version 165. DE RecName: Full=Bromodomain testis-specific protein; DE AltName: Full=Cancer/testis antigen 9; DE Short=CT9; DE AltName: Full=RING3-like protein; GN Name=BRDT; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP VARIANTS LYS-62 AND LEU-696. RX PubMed=9367677; DOI=10.1006/geno.1997.5000; RA Jones M.H., Numata M., Shimane M.; RT "Identification and characterization of BRDT: a testis-specific gene RT related to the bromodomain genes RING3 and Drosophila fsh."; RL Genomics 45:529-534(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ALTERNATIVE SPLICING, RP TISSUE SPECIFICITY, AND VARIANTS LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=15647849; RA Zheng Y., Yuan W., Zhou Z., Xu M., Sha J.-H.; RT "Molecular cloning and expression of a novel alternative splice variant of RT BRDT gene."; RL Int. J. Mol. Med. 15:315-321(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANTS RP LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS LYS-62 AND RP LEU-696. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-462 (ISOFORM 1), AND VARIANTS RP LYS-62; ASN-238 AND LYS-410. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP TISSUE SPECIFICITY, AND IDENTIFICATION AS A CANCER/TESTIS ANTIGEN. RX PubMed=10704737; DOI=10.1016/s0304-3835(99)00385-7; RA Scanlan M.J., Altorki N.K., Gure A.O., Williamson B., Jungbluth A., RA Chen Y.-T., Old L.J.; RT "Expression of cancer-testis antigens in lung cancer: definition of RT bromodomain testis-specific gene (BRDT) as a new CT gene, CT9."; RL Cancer Lett. 150:155-164(2000). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-2; GLN-6; VAL-89; ASN-238; TYR-288; RP LYS-357; LYS-410 AND ALA-542. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=20538714; DOI=10.1530/rep-10-0139; RA Steilmann C., Cavalcanti M.C., Bartkuhn M., Pons-Kuhnemann J., RA Schuppe H.C., Weidner W., Steger K., Paradowska A.; RT "The interaction of modified histones with the bromodomain testis-specific RT (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile RT men."; RL Reproduction 140:435-443(2010). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF NUCLEAR LOCALIZATION SIGNAL. RX PubMed=22971749; DOI=10.1248/bpb.b12-00527; RA Fukazawa H., Masumi A.; RT "The conserved 12-amino acid stretch in the inter-bromodomain region of BET RT family proteins functions as a nuclear localization signal."; RL Biol. Pharm. Bull. 35:2064-2068(2012). RN [11] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [12] {ECO:0007744|PDB:2RFJ} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 21-137, FUNCTION, SUBUNIT, AND RP DOMAIN. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [13] {ECO:0007744|PDB:4FLP} RP X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 21-137 IN COMPLEX WITH JQ1, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=22901802; DOI=10.1016/j.cell.2012.06.045; RA Matzuk M.M., McKeown M.R., Filippakopoulos P., Li Q., Ma L., Agno J.E., RA Lemieux M.E., Picaud S., Yu R.N., Qi J., Knapp S., Bradner J.E.; RT "Small-molecule inhibition of BRDT for male contraception."; RL Cell 150:673-684(2012). RN [14] RP VARIANT SPGF21 ASP-928, AND CHARACTERIZATION OF VARIANT SPGF21 ASP-928. RX PubMed=28199965; DOI=10.18632/oncotarget.15251; RA Li L., Sha Y., Wang X., Li P., Wang J., Kee K., Wang B.; RT "Whole-exome sequencing identified a homozygous BRDT mutation in a patient RT with acephalic spermatozoa."; RL Oncotarget 8:19914-19922(2017). CC -!- FUNCTION: Testis-specific chromatin protein that specifically binds CC histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, CC respectively) and plays a key role in spermatogenesis (PubMed:22464331, CC PubMed:22901802). Required in late pachytene spermatocytes: plays a CC role in meiotic and post-meiotic cells by binding to acetylated CC histones at the promoter of specific meiotic and post-meiotic genes, CC facilitating their activation at the appropriate time CC (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds CC to hyperacetylated histones and participates in their general removal CC from DNA (PubMed:22901802). Also recognizes and binds a subset of CC butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' CC (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' CC (H4K5ac) (By similarity). Also acts as a component of the splicing CC machinery in pachytene spermatocytes and round spermatids and CC participates in 3'-UTR truncation of specific mRNAs in post-meiotic CC spermatids (By similarity). Required for chromocenter organization, a CC structure comprised of peri-centromeric heterochromatin. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:22901802, CC ECO:0000269|PubMed:9367677}. CC -!- SUBUNIT: Interacts with mRNA splicing machinery proteins SRSF2, DDX5, CC HNRNPK and TARDBP. Interacts with the acetylated N-terminus of histone CC H1, H2, H3 and H4. Interacts with P-TEFb components CDK9 and CC CCNT1/cyclin-T1. Interacts with SMARCE1 (By similarity). Interacts with CC the acetylated N-terminus of histone H1.4, H2A, H2B, H3 and H4. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20538714, CC ECO:0000269|PubMed:22901802, ECO:0000269|PubMed:22971749, CC ECO:0000269|PubMed:25593309}. Note=Detected on chromatin. CC {ECO:0000250|UniProtKB:Q91Y44}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=Q58F21-1; Sequence=Displayed; CC Name=2; Synonyms=BRDT-NY; CC IsoId=Q58F21-2; Sequence=VSP_019118; CC Name=3; CC IsoId=Q58F21-3; Sequence=VSP_044511; CC Name=4; CC IsoId=Q58F21-4; Sequence=VSP_044510; CC Name=5; CC IsoId=Q58F21-5; Sequence=VSP_044509; CC -!- TISSUE SPECIFICITY: Testis-specific. A 3-fold higher expression is seen CC in adult testis than in embryo testis. Expression seems to be CC correlated with histone H4 hyperacetylation during the haploid phase of CC spermatogenesis (spermiogenesis). No expression, or very low expression CC is seen in patients' testes with abnormal spermatogenesis. Expressed in CC cancers such as non-small cell lung cancer and squamous cell carcinomas CC of the head and neck as well as of esophagus, but not in melanoma or in CC cancers of the colon, breast, kidney and bladder. CC {ECO:0000269|PubMed:10704737, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:9367677}. CC -!- DEVELOPMENTAL STAGE: Expressed in embryo testis. CC -!- DOMAIN: Bromo domains mediate interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). CC Bromo domain 1 mediates binding with histone H4 acetylated at 'Lys-5' CC and 'Lys-8' (H4K5ac and H4K8ac, respectively) (PubMed:22901802). The CC bromo domains also recognize and bind a subset of butyrylated histones: CC able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is CC not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity). CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- PTM: Ubiquitinated in a SPOP-dependent manner, leading to proteasomal CC degradation. {ECO:0000250|UniProtKB:Q91Y44}. CC -!- DISEASE: Spermatogenic failure 21 (SPGF21) [MIM:617644]: An infertility CC disorder caused by spermatogenesis defects and characterized by CC acephalic spermatozoa in the semen of affected individuals. SPGF21 CC inheritance is autosomal recessive. {ECO:0000269|PubMed:28199965}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: BRDT is a promising target for male contraception. CC Inhibition by thienodiazepine inhibitor (+)-JQ1 that binds Asn-109, CC prevents recognition of acetylated histone H4, causing a complete and CC reversible contraceptive effect in male mice (PubMed:22901802). CC {ECO:0000305|PubMed:22901802}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH05281.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH47900.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH62700.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=Asking life to be patient CC - Issue 144 of November 2012; CC URL="https://www.proteinspotlight.org/back_issues/144"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF019085; AAB87862.1; -; mRNA. DR EMBL; AY338951; AAQ16198.1; -; mRNA. DR EMBL; AK303008; BAH13876.1; -; mRNA. DR EMBL; AK302758; BAH13797.1; -; mRNA. DR EMBL; AK316442; BAH14813.1; -; mRNA. DR EMBL; AC114486; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471097; EAW73106.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73107.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73108.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73110.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73111.1; -; Genomic_DNA. DR EMBL; BC005281; AAH05281.1; ALT_SEQ; mRNA. DR EMBL; BC017582; AAH17582.1; -; mRNA. DR EMBL; BC047900; AAH47900.1; ALT_SEQ; mRNA. DR EMBL; BC062700; AAH62700.1; ALT_SEQ; mRNA. DR CCDS; CCDS55615.1; -. [Q58F21-4] DR CCDS; CCDS55616.1; -. [Q58F21-5] DR CCDS; CCDS735.1; -. [Q58F21-1] DR RefSeq; NP_001229734.2; NM_001242805.2. [Q58F21-1] DR RefSeq; NP_001229735.2; NM_001242806.2. [Q58F21-3] DR RefSeq; NP_001229736.2; NM_001242807.2. [Q58F21-4] DR RefSeq; NP_001229737.2; NM_001242808.2. [Q58F21-4] DR RefSeq; NP_001229739.2; NM_001242810.2. [Q58F21-5] DR RefSeq; NP_001717.3; NM_001726.4. [Q58F21-1] DR RefSeq; NP_997072.2; NM_207189.4. [Q58F21-1] DR RefSeq; XP_006710918.1; XM_006710855.5. [Q58F21-1] DR RefSeq; XP_006710919.1; XM_006710856.5. [Q58F21-1] DR RefSeq; XP_011540334.1; XM_011542032.4. [Q58F21-1] DR RefSeq; XP_011540336.1; XM_011542034.4. [Q58F21-1] DR RefSeq; XP_011540337.1; XM_011542035.4. [Q58F21-1] DR RefSeq; XP_011540338.1; XM_011542036.4. [Q58F21-1] DR RefSeq; XP_047284905.1; XM_047428949.1. [Q58F21-1] DR RefSeq; XP_047284911.1; XM_047428955.1. [Q58F21-1] DR RefSeq; XP_047284923.1; XM_047428967.1. [Q58F21-1] DR PDB; 2RFJ; X-ray; 2.05 A; A/B/C=21-137. DR PDB; 4FLP; X-ray; 2.23 A; A/B=21-137. DR PDB; 4KCX; X-ray; 2.00 A; A/B=21-137. DR PDB; 5VBQ; X-ray; 1.65 A; A/B=29-137. DR PDB; 5VBR; X-ray; 1.90 A; A/B=29-137. DR PDB; 7BJY; X-ray; 2.22 A; A/B=29-137. DR PDB; 7L73; X-ray; 1.46 A; A=29-137. DR PDB; 7L99; X-ray; 1.90 A; A/B/C/D=269-380. DR PDB; 7L9A; X-ray; 2.27 A; A/B=269-380. DR PDB; 7LEJ; X-ray; 1.73 A; A=266-378. DR PDB; 7LEK; X-ray; 2.75 A; A/B/C/D=266-378. DR PDB; 7LEL; X-ray; 2.15 A; A/B/C/D=266-378. DR PDB; 7LEM; X-ray; 1.89 A; A/B=29-137. DR PDB; 7MRC; X-ray; 1.55 A; A/B=29-137. DR PDB; 7MRD; X-ray; 1.39 A; A/B=29-137. DR PDB; 7MRG; X-ray; 1.99 A; A/B=29-137. DR PDB; 7MRH; X-ray; 1.98 A; A/B=29-137. DR PDB; 7UBO; X-ray; 1.82 A; A/B/C/D=29-137. DR PDB; 7UUU; X-ray; 1.52 A; A=29-137. DR PDB; 8CZA; X-ray; 2.96 A; A/B/C/D/E/F=29-137. DR PDB; 8YHS; X-ray; 1.50 A; A=21-137. DR PDBsum; 2RFJ; -. DR PDBsum; 4FLP; -. DR PDBsum; 4KCX; -. DR PDBsum; 5VBQ; -. DR PDBsum; 5VBR; -. DR PDBsum; 7BJY; -. DR PDBsum; 7L73; -. DR PDBsum; 7L99; -. DR PDBsum; 7L9A; -. DR PDBsum; 7LEJ; -. DR PDBsum; 7LEK; -. DR PDBsum; 7LEL; -. DR PDBsum; 7LEM; -. DR PDBsum; 7MRC; -. DR PDBsum; 7MRD; -. DR PDBsum; 7MRG; -. DR PDBsum; 7MRH; -. DR PDBsum; 7UBO; -. DR PDBsum; 7UUU; -. DR PDBsum; 8CZA; -. DR PDBsum; 8YHS; -. DR AlphaFoldDB; Q58F21; -. DR SASBDB; Q58F21; -. DR SMR; Q58F21; -. DR BioGRID; 107143; 78. DR FunCoup; Q58F21; 517. DR IntAct; Q58F21; 2. DR STRING; 9606.ENSP00000387822; -. DR BindingDB; Q58F21; -. DR ChEMBL; CHEMBL1795185; -. DR DrugBank; DB17021; JQ1. DR DrugCentral; Q58F21; -. DR GuidetoPHARMACOLOGY; 2729; -. DR GlyGen; Q58F21; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q58F21; -. DR PhosphoSitePlus; Q58F21; -. DR BioMuta; BRDT; -. DR DMDM; 226694198; -. DR jPOST; Q58F21; -. DR MassIVE; Q58F21; -. DR PaxDb; 9606-ENSP00000387822; -. DR PeptideAtlas; Q58F21; -. DR ProteomicsDB; 1029; -. DR ProteomicsDB; 62618; -. [Q58F21-1] DR ProteomicsDB; 62619; -. [Q58F21-2] DR Antibodypedia; 3212; 136 antibodies from 22 providers. DR DNASU; 676; -. DR Ensembl; ENST00000362005.7; ENSP00000354568.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000370389.6; ENSP00000359416.2; ENSG00000137948.19. [Q58F21-5] DR Ensembl; ENST00000394530.7; ENSP00000378038.3; ENSG00000137948.19. [Q58F21-4] DR Ensembl; ENST00000399546.7; ENSP00000387822.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000402388.1; ENSP00000384051.1; ENSG00000137948.19. [Q58F21-1] DR GeneID; 676; -. DR KEGG; hsa:676; -. DR MANE-Select; ENST00000399546.7; ENSP00000387822.3; NM_207189.4; NP_997072.2. DR UCSC; uc001dol.5; human. [Q58F21-1] DR AGR; HGNC:1105; -. DR ClinPGx; PA25418; -. DR CTD; 676; -. DR DisGeNET; 676; -. DR GeneCards; BRDT; -. DR HGNC; HGNC:1105; BRDT. DR HPA; ENSG00000137948; Tissue enriched (testis). DR MalaCards; BRDT; -. DR MIM; 602144; gene. DR MIM; 617644; phenotype. DR OpenTargets; ENSG00000137948; -. DR VEuPathDB; HostDB:ENSG00000137948; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000154549; -. DR HOGENOM; CLU_001499_0_0_1; -. DR InParanoid; Q58F21; -. DR OMA; DFKTMFL; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; Q58F21; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q58F21; -. DR PathwayCommons; Q58F21; -. DR SignaLink; Q58F21; -. DR SIGNOR; Q58F21; -. DR Agora; ENSG00000137948; -. DR BioGRID-ORCS; 676; 15 hits in 1166 CRISPR screens. DR ChiTaRS; BRDT; human. DR EvolutionaryTrace; Q58F21; -. DR GeneWiki; BRDT; -. DR GenomeRNAi; 676; -. DR Pharos; Q58F21; Tchem. DR PRO; PR:Q58F21; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q58F21; protein. DR Bgee; ENSG00000137948; Expressed in left testis and 97 other cell types or tissues. DR ExpressionAtlas; Q58F21; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0140008; F:histone H4 reader activity; IEA:Ensembl. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0007141; P:male meiosis I; ISS:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0043484; P:regulation of RNA splicing; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW. DR GO; GO:0035092; P:sperm DNA condensation; ISS:UniProtKB. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR DisProt; DP03058; -. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR031354; BRD4_CDT. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF175; BROMODOMAIN TESTIS-SPECIFIC PROTEIN; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF17105; BRD4_CDT; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Bromodomain; KW Chromatin regulator; Coiled coil; Differentiation; Disease variant; KW Meiosis; mRNA processing; mRNA splicing; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Spermatogenesis; KW Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..947 FT /note="Bromodomain testis-specific protein" FT /id="PRO_0000239225" FT DOMAIN 27..133 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 267..376 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 500..582 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 202..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 395..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 444..511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 610..698 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 882..924 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 417..470 FT /evidence="ECO:0000255" FT COILED 591..621 FT /evidence="ECO:0000255" FT MOTIF 209..220 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22971749" FT COMPBIAS 217..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..462 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 470..481 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 482..494 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..662 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 674..692 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 885..924 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 109 FT /ligand="JQ1" FT /ligand_id="ChEBI:CHEBI:137113" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:22901802, FT ECO:0007744|PDB:4FLP" FT SITE 109 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT SITE 114 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT MOD_RES 187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT VAR_SEQ 1..73 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_044509" FT VAR_SEQ 1 FT /note="M -> MTCTCRQDSKQLRM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15647849" FT /id="VSP_019118" FT VAR_SEQ 65..110 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044510" FT VAR_SEQ 148 FT /note="K -> KGKAG (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044511" FT VARIANT 2 FT /note="S -> F (in dbSNP:rs55806733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041924" FT VARIANT 6 FT /note="R -> Q (in dbSNP:rs56273490)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041925" FT VARIANT 62 FT /note="Q -> K (in dbSNP:rs10783071)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15647849, FT ECO:0000269|PubMed:9367677, ECO:0000269|Ref.5" FT /id="VAR_026584" FT VARIANT 89 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs781375003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041926" FT VARIANT 238 FT /note="K -> N (in dbSNP:rs1156281)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026585" FT VARIANT 288 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041927" FT VARIANT 336 FT /note="K -> T (in dbSNP:rs1064567)" FT /id="VAR_047327" FT VARIANT 357 FT /note="E -> K (in dbSNP:rs34674879)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041928" FT VARIANT 410 FT /note="N -> K (in dbSNP:rs3088232)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026586" FT VARIANT 542 FT /note="P -> A (in dbSNP:rs55912588)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041929" FT VARIANT 605 FT /note="R -> Q (in dbSNP:rs35327986)" FT /id="VAR_047328" FT VARIANT 696 FT /note="P -> L (in dbSNP:rs10747493)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15647849, ECO:0000269|PubMed:9367677, FT ECO:0000269|Ref.5" FT /id="VAR_047329" FT VARIANT 928 FT /note="G -> D (in SPGF21; uncertain significance; no effect FT on protein expression; dbSNP:rs754258809)" FT /evidence="ECO:0000269|PubMed:28199965" FT /id="VAR_079306" FT CONFLICT 42 FT /note="D -> N (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="P -> S (in Ref. 6; AAH05281)" FT /evidence="ECO:0000305" FT CONFLICT 80 FT /note="K -> I (in Ref. 6; AAH62700)" FT /evidence="ECO:0000305" FT CONFLICT 265 FT /note="K -> E (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="K -> S (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 462 FT /note="E -> K (in Ref. 6; AAH17582)" FT /evidence="ECO:0000305" FT CONFLICT 477 FT /note="Q -> R (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 552 FT /note="I -> M (in Ref. 2; AAQ16198)" FT /evidence="ECO:0000305" FT CONFLICT 686 FT /note="N -> H (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 893 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 915 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT HELIX 29..37 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 39..45 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:7MRD" FT STRAND 53..55 FT /evidence="ECO:0007829|PDB:2RFJ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 66..69 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 76..84 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 91..108 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 114..131 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 266..284 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 289..292 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:7LEJ" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7L99" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 319..327 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 334..351 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 357..373 FT /evidence="ECO:0007829|PDB:7LEJ" SQ SEQUENCE 947 AA; 107954 MW; 09C0FD8690E217BB CRC64; MSLPSRQTAI IVNPPPPEYI NTKKNGRLTN QLQYLQKVVL KDLWKHSFSW PFQRPVDAVK LQLPDYYTII KNPMDLNTIK KRLENKYYAK ASECIEDFNT MFSNCYLYNK PGDDIVLMAQ ALEKLFMQKL SQMPQEEQVV GVKERIKKGT QQNIAVSSAK EKSSPSATEK VFKQQEIPSV FPKTSISPLN VVQGASVNSS SQTAAQVTKG VKRKADTTTP ATSAVKASSE FSPTFTEKSV ALPPIKENMP KNVLPDSQQQ YNVVKTVKVT EQLRHCSEIL KEMLAKKHFS YAWPFYNPVD VNALGLHNYY DVVKNPMDLG TIKEKMDNQE YKDAYKFAAD VRLMFMNCYK YNPPDHEVVT MARMLQDVFE THFSKIPIEP VESMPLCYIK TDITETTGRE NTNEASSEGN SSDDSEDERV KRLAKLQEQL KAVHQQLQVL SQVPFRKLNK KKEKSKKEKK KEKVNNSNEN PRKMCEQMRL KEKSKRNQPK KRKQQFIGLK SEDEDNAKPM NYDEKRQLSL NINKLPGDKL GRVVHIIQSR EPSLSNSNPD EIEIDFETLK ASTLRELEKY VSACLRKRPL KPPAKKIMMS KEELHSQKKQ ELEKRLLDVN NQLNSRKRQT KSDKTQPSKA VENVSRLSES SSSSSSSSES ESSSSDLSSS DSSDSESEMF PKFTEVKPND SPSKENVKKM KNECIPPEGR TGVTQIGYCV QDTTSANTTL VHQTTPSHVM PPNHHQLAFN YQELEHLQTV KNISPLQILP PSGDSEQLSN GITVMHPSGD SDTTMLESEC QAPVQKDIKI KNADSWKSLG KPVKPSGVMK SSDELFNQFR KAAIEKEVKA RTQELIRKHL EQNTKELKAS QENQRDLGNG LTVESFSNKI QNKCSGEEQK EHQQSSEAQD KSKLWLLKDR DLARQKEQER RRREAMVGTI DMTLQSDIMT MFENNFD // ID C1RL_HUMAN Reviewed; 487 AA. AC Q9NZP8; Q53GX9; DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 26-FEB-2008, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Complement C1r subcomponent-like protein; DE Short=C1r-LP; DE Short=C1r-like protein; DE EC=3.4.21.-; DE AltName: Full=C1r-like serine protease analog protein; DE Short=CLSPa; DE Flags: Precursor; GN Name=C1RL; Synonyms=C1RL1, C1RLP, CLSPA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, INDUCTION, AND VARIANT VAL-285. RC TISSUE=Dendritic cell; RX PubMed=15358180; DOI=10.1016/j.bbrc.2004.06.127; RA Lin N., Liu S., Li N., Wu P., An H., Yu Y., Wan T., Cao X.; RT "A novel human dendritic cell-derived C1r-like serine protease analog RT inhibits complement-mediated cytotoxicity."; RL Biochem. Biophys. Res. Commun. 321:329-336(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=15527420; DOI=10.1042/bj20041196; RA Ligoudistianou C., Xu Y., Garnier G., Circolo A., Volanakis J.E.; RT "A novel human complement-related protein, C1r-like protease (C1r-LP), RT specifically cleaves pro-C1s."; RL Biochem. J. 387:165-173(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RA Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y., RA Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] RP FUNCTION, AND MUTAGENESIS OF SER-436. RX PubMed=15385675; DOI=10.1073/pnas.0405692101; RA Wicher K.B., Fries E.; RT "Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by RT the complement C1r-like protein."; RL Proc. Natl. Acad. Sci. U.S.A. 101:14390-14395(2004). RN [6] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-166; ASN-242 AND ASN-296. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [7] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-147; ASN-242 AND ASN-296. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [8] RP GLYCOSYLATION AT ASN-242. RX PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200; RA Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B., RA Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L., RA Ying W.T., He S.M., Qian X.H.; RT "A strategy for precise and large scale identification of core fucosylated RT glycoproteins."; RL Mol. Cell. Proteomics 8:913-923(2009). CC -!- FUNCTION: Mediates the proteolytic cleavage of HP/haptoglobin in the CC endoplasmic reticulum. {ECO:0000269|PubMed:15358180, CC ECO:0000269|PubMed:15385675, ECO:0000269|PubMed:15527420}. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:15358180}. CC -!- TISSUE SPECIFICITY: Highly expressed in placenta, liver, kidney, CC pancreas, moderately in lung, spleen, prostate, ovary, colon, and PBL, CC and weakly in heart, skeletal muscle, thymus, testis, and small CC intestine. Expressed in PC-3 (prostate adenocarcinoma) and SK-OV-3 CC (ovary adenocarcinoma) cells, but not in LoVo and HT-29 (colon CC adenocarcinoma), SMMC7721 (hepatocellular carcinoma), CaoV-3 (ovary CC adenocarcinoma), HeLa (cervix epithelioid carcinoma), MCF-7 (breast CC adenocarcinoma), U-251MG (glioma) or A-549 (lung carcinoma) cells. CC Widely expressed in myeloid leukemia cell lines, including K-562 CC (chronic myelogenous leukemia), THP-1 (myelomonocytic leukemia), HL-60 CC and NB4 (promyelocytic leukemia), and KG-1 (acute myelogenous leukemia) CC cells. Expressed mainly in the liver and in serum (at protein level). CC {ECO:0000269|PubMed:15358180, ECO:0000269|PubMed:15527420}. CC -!- INDUCTION: Up-regulated in monocytes and dendritic cells (DC) CC undergoing maturation or activation. {ECO:0000269|PubMed:15358180}. CC -!- SIMILARITY: Belongs to the peptidase S1 family. {ECO:0000255|PROSITE- CC ProRule:PRU00274}. CC -!- CAUTION: Does not associate with the C1 complex. According to CC PubMed:15385675, doesn't cleave the proform of complement C1s. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF178985; AAF44349.1; -; mRNA. DR EMBL; AK222802; BAD96522.1; -; mRNA. DR EMBL; AC018653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC094008; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC233309; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS8573.1; -. DR RefSeq; NP_001284569.1; NM_001297640.1. DR RefSeq; NP_057630.2; NM_016546.4. DR AlphaFoldDB; Q9NZP8; -. DR SMR; Q9NZP8; -. DR BioGRID; 119431; 11. DR FunCoup; Q9NZP8; 178. DR IntAct; Q9NZP8; 6. DR STRING; 9606.ENSP00000266542; -. DR MEROPS; S01.189; -. DR GlyConnect; 1143; 11 N-Linked glycans (3 sites). DR GlyCosmos; Q9NZP8; 6 sites, 14 glycans. DR GlyGen; Q9NZP8; 7 sites, 32 N-linked glycans (4 sites), 2 O-linked glycans (2 sites). DR iPTMnet; Q9NZP8; -. DR PhosphoSitePlus; Q9NZP8; -. DR BioMuta; C1RL; -. DR DMDM; 182705204; -. DR CPTAC; non-CPTAC-1102; -. DR jPOST; Q9NZP8; -. DR MassIVE; Q9NZP8; -. DR PaxDb; 9606-ENSP00000266542; -. DR PeptideAtlas; Q9NZP8; -. DR ProteomicsDB; 83474; -. DR Pumba; Q9NZP8; -. DR Antibodypedia; 1734; 115 antibodies from 21 providers. DR DNASU; 51279; -. DR Ensembl; ENST00000266542.9; ENSP00000266542.4; ENSG00000139178.13. DR Ensembl; ENST00000671752.1; ENSP00000500804.1; ENSG00000288124.1. DR GeneID; 51279; -. DR KEGG; hsa:51279; -. DR MANE-Select; ENST00000266542.9; ENSP00000266542.4; NM_016546.4; NP_057630.2. DR UCSC; uc001qsn.4; human. DR AGR; HGNC:21265; -. DR ClinPGx; PA134957759; -. DR CTD; 51279; -. DR DisGeNET; 51279; -. DR GeneCards; C1RL; -. DR HGNC; HGNC:21265; C1RL. DR HPA; ENSG00000139178; Tissue enhanced (liver). DR MalaCards; C1RL; -. DR MIM; 608974; gene. DR OpenTargets; ENSG00000139178; -. DR VEuPathDB; HostDB:ENSG00000139178; -. DR eggNOG; KOG3627; Eukaryota. DR GeneTree; ENSGT00940000162495; -. DR HOGENOM; CLU_006842_0_0_1; -. DR InParanoid; Q9NZP8; -. DR OMA; QHESHNF; -. DR OrthoDB; 6261922at2759; -. DR PAN-GO; Q9NZP8; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9NZP8; -. DR BRENDA; 3.4.21.41; 2681. DR PathwayCommons; Q9NZP8; -. DR SignaLink; Q9NZP8; -. DR SIGNOR; Q9NZP8; -. DR Agora; ENSG00000139178; -. DR BioGRID-ORCS; 51279; 7 hits in 1151 CRISPR screens. DR ChiTaRS; C1RL; human. DR GenomeRNAi; 51279; -. DR Pharos; Q9NZP8; Tbio. DR PRO; PR:Q9NZP8; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9NZP8; protein. DR Bgee; ENSG00000139178; Expressed in right lobe of liver and 99 other cell types or tissues. DR ExpressionAtlas; Q9NZP8; baseline and differential. DR GO; GO:0072562; C:blood microparticle; IBA:GO_Central. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0004252; F:serine-type endopeptidase activity; IBA:GO_Central. DR GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0031638; P:zymogen activation; IBA:GO_Central. DR CDD; cd00041; CUB; 1. DR CDD; cd00190; Tryp_SPc; 1. DR FunFam; 2.40.10.10:FF:000035; Complement C1r subcomponent; 1. DR FunFam; 2.40.10.10:FF:000037; Complement C1r subcomponent; 1. DR FunFam; 2.60.120.290:FF:000044; Complement C1r subcomponent like; 1. DR Gene3D; 2.10.70.10; Complement Module, domain 1; 1. DR Gene3D; 2.60.120.290; Spermadhesin, CUB domain; 1. DR Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2. DR InterPro; IPR000859; CUB_dom. DR InterPro; IPR009003; Peptidase_S1_PA. DR InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin. DR InterPro; IPR001314; Peptidase_S1A. DR InterPro; IPR035914; Sperma_CUB_dom_sf. DR InterPro; IPR035976; Sushi/SCR/CCP_sf. DR InterPro; IPR001254; Trypsin_dom. DR InterPro; IPR033116; TRYPSIN_SER. DR PANTHER; PTHR24255:SF26; COMPLEMENT C1R SUBCOMPONENT-LIKE PROTEIN; 1. DR PANTHER; PTHR24255; COMPLEMENT COMPONENT 1, S SUBCOMPONENT-RELATED; 1. DR Pfam; PF00431; CUB; 1. DR Pfam; PF00089; Trypsin; 1. DR PRINTS; PR00722; CHYMOTRYPSIN. DR SMART; SM00042; CUB; 1. DR SMART; SM00020; Tryp_SPc; 1. DR SUPFAM; SSF57535; Complement control module/SCR domain; 1. DR SUPFAM; SSF49854; Spermadhesin, CUB domain; 1. DR SUPFAM; SSF50494; Trypsin-like serine proteases; 1. DR PROSITE; PS01180; CUB; 1. DR PROSITE; PS50240; TRYPSIN_DOM; 1. DR PROSITE; PS00135; TRYPSIN_SER; 1. PE 1: Evidence at protein level; KW Complement pathway; Disulfide bond; Glycoprotein; Hydrolase; Immunity; KW Innate immunity; Protease; Proteomics identification; Reference proteome; KW Secreted; Serine protease; Signal; Sushi. FT SIGNAL 1..35 FT /evidence="ECO:0000255" FT CHAIN 36..487 FT /note="Complement C1r subcomponent-like protein" FT /id="PRO_0000318678" FT DOMAIN 39..163 FT /note="CUB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00059" FT DOMAIN 165..230 FT /note="Sushi" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00302" FT DOMAIN 245..484 FT /note="Peptidase S1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT ACT_SITE 283 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT ACT_SITE 339 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT ACT_SITE 436 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT CARBOHYD 147 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 166 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218" FT CARBOHYD 296 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 363 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 94..112 FT /evidence="ECO:0000250" FT DISULFID 195..228 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00302" FT DISULFID 402..421 FT /evidence="ECO:0000250" FT DISULFID 432..462 FT /evidence="ECO:0000250" FT VARIANT 285 FT /note="I -> V (in dbSNP:rs3742089)" FT /evidence="ECO:0000269|PubMed:15358180" FT /id="VAR_038852" FT MUTAGEN 436 FT /note="S->A: Unable to cleave HP." FT /evidence="ECO:0000269|PubMed:15385675" FT CONFLICT 94 FT /note="C -> R (in Ref. 3; BAD96522)" FT /evidence="ECO:0000305" FT CONFLICT 99 FT /note="V -> A (in Ref. 3; BAD96522)" FT /evidence="ECO:0000305" FT CONFLICT 349 FT /note="I -> M (in Ref. 3; BAD96522)" FT /evidence="ECO:0000305" SQ SEQUENCE 487 AA; 53498 MW; 6DE7CE9EA08C7990 CRC64; MPGPRVWGKY LWRSPHSKGC PGAMWWLLLW GVLQACPTRG SVLLAQELPQ QLTSPGYPEP YGKGQESSTD IKAPEGFAVR LVFQDFDLEP SQDCAGDSVT ISFVGSDPSQ FCGQQGSPLG RPPGQREFVS SGRSLRLTFR TQPSSENKTA HLHKGFLALY QTVAVNYSQP ISEASRGSEA INAPGDNPAK VQNHCQEPYY QAAAAGALTC ATPGTWKDRQ DGEEVLQCMP VCGRPVTPIA QNQTTLGSSR AKLGNFPWQA FTSIHGRGGG ALLGDRWILT AAHTIYPKDS VSLRKNQSVN VFLGHTAIDE MLKLGNHPVH RVVVHPDYRQ NESHNFSGDI ALLELQHSIP LGPNVLPVCL PDNETLYRSG LLGYVSGFGM EMGWLTTELK YSRLPVAPRE ACNAWLQKRQ RPEVFSDNMF CVGDETQRHS VCQGDSGSVY VVWDNHAHHW VATGIVSWGI GCGEGYDFYT KVLSYVDWIK GVMNGKN // ID CADH1_HUMAN Reviewed; 882 AA. AC P12830; A8K1U7; Q13799; Q14216; Q15855; Q16194; Q4PJ14; Q9UII8; DT 01-OCT-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1993, sequence version 3. DT 28-JAN-2026, entry version 271. DE RecName: Full=Cadherin-1 {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=CAM 120/80; DE AltName: Full=Epithelial cadherin {ECO:0000305}; DE Short=E-cadherin {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=Uvomorulin {ECO:0000303|PubMed:8459805}; DE AltName: CD_antigen=CD324; DE Contains: DE RecName: Full=E-Cad/CTF1; DE Contains: DE RecName: Full=E-Cad/CTF2; DE Contains: DE RecName: Full=E-Cad/CTF3; DE Flags: Precursor; GN Name=CDH1 {ECO:0000312|HGNC:HGNC:1748}; GN Synonyms=CDHE, UVO {ECO:0000312|HGNC:HGNC:1748}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=8459805; DOI=10.1007/bf00996219; RA Bussemakers M.J.G., Mees S.G.M., van Bokhoven A., Debruyne F.M.J., RA Schalken J.A.; RT "Molecular cloning and characterization of the human E-cadherin cDNA."; RL Mol. Biol. Rep. 17:123-128(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 274-GLY--PRO-277 DEL. RX PubMed=8127895; DOI=10.1073/pnas.91.5.1858; RA Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W., RA Sugimura T., Hirohashi S.; RT "E-cadherin gene mutations in human gastric carcinoma cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1858-1862(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Liver; RX PubMed=8185635; DOI=10.1006/bbrc.1994.1656; RA Rimm D.L., Morrow J.S.; RT "Molecular cloning of human E-cadherin suggests a novel subdivision of the RT cadherin superfamily."; RL Biochem. Biophys. Res. Commun. 200:1754-1761(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 586-591, RP PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION. RC TISSUE=Epidermal carcinoma; RX PubMed=10597309; DOI=10.1038/sj.onc.1203191; RA Ito K., Okamoto I., Araki N., Kawano Y., Nakao M., Fujiyama S., Tomita K., RA Mimori T., Saya H.; RT "Calcium influx triggers the sequential proteolysis of extracellular and RT cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from RT cell-cell contacts."; RL Oncogene 18:7080-7090(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Shibamoto S., Fukudome Y., Yanagihara K.; RT "Mutant E-cadherin."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hippocampus, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-478; THR-617; MET-832 RP AND LYS-880. RG NIEHS SNPs program; RL Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=8093045; DOI=10.1006/bbrc.1994.2321; RA Bussemakers M.J.G., Giroldi L.A., van Bokhoven A., Schalken J.A.; RT "Transcriptional regulation of the human E-cadherin gene in human prostate RT cancer cell lines: characterization of the human E-cadherin gene RT promoter."; RL Biochem. Biophys. Res. Commun. 203:1284-1290(1994). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RC TISSUE=Placenta; RX PubMed=7543680; DOI=10.1073/pnas.92.16.7416; RA Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S.; RT "Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in RT human carcinomas."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7416-7419(1995). RN [12] RP INTERACTION WITH CTNNB1 AND PKP2. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [13] RP INTERACTION WITH PIP5K1C. RX PubMed=17261850; DOI=10.1083/jcb.200606023; RA Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G., RA Anderson R.A.; RT "Type I gamma phosphatidylinositol phosphate kinase modulates adherens RT junction and E-cadherin trafficking via a direct interaction with mu 1B RT adaptin."; RL J. Cell Biol. 176:343-353(2007). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-882. RC TISSUE=Placenta; RX PubMed=7601454; DOI=10.1016/0888-7543(95)80212-5; RA Berx G., Staes K., van Hengel J., Molemans F., Bussemakers M.J.G., RA van Bokhoven A., van Roy F.; RT "Cloning and characterization of the human invasion suppressor gene E- RT cadherin (CDH1)."; RL Genomics 26:281-289(1995). RN [15] RP PROTEIN SEQUENCE OF 155-174, AND FUNCTION AS L.MONOCYTOGENES RECEPTOR RP (MICROBIAL INFECTION). RX PubMed=8601315; DOI=10.1016/s0092-8674(00)81070-3; RA Mengaud J., Ohayon H., Gounon P., Mege R.M., Cossart P.; RT "E-cadherin is the receptor for internalin, a surface protein required for RT entry of L. monocytogenes into epithelial cells."; RL Cell 84:923-932(1996). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 172-311 (ISOFORM 1/2), AND TISSUE RP SPECIFICITY. RC TISSUE=Liver; RX PubMed=3263290; DOI=10.1111/j.1432-0436.1988.tb00593.x; RA Mansouri A., Spurr N., Goodfellow P.N., Kemler R.; RT "Characterization and chromosomal localization of the gene encoding the RT human cell adhesion molecule uvomorulin."; RL Differentiation 38:67-71(1988). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 265-392 (ISOFORM 1). RC TISSUE=Liver; RA Frixen U.H.; RL Submitted (MAR-1990) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-476, AND VARIANTS ALA-370 AND RP ASP-473. RX PubMed=8033105; RA Becker K.-F., Atkinson M.J., Reich U., Becker I., Nekarda H., Siewert J.R., RA Hoefler H.; RT "E-cadherin gene mutations provide clues to diffuse type gastric RT carcinomas."; RL Cancer Res. 54:3845-3852(1994). RN [19] RP PROTEIN SEQUENCE OF 701-714 AND 732-742, PROTEOLYTIC PROCESSING BY RP GAMMA-SECRETASE/PS1 AND A MEMBRANE-BOUND METALLOPROTEINASE, AND MUTAGENESIS RP OF 759-GLY--GLY-761. RX PubMed=11953314; DOI=10.1093/emboj/21.8.1948; RA Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., RA Baki L., Wen P., Efthimiopoulos S., Shao Z., Wisniewski T., Robakis N.K.; RT "A presenilin-1/gamma-secretase cleavage releases the E-cadherin RT intracellular domain and regulates disassembly of adherens junctions."; RL EMBO J. 21:1948-1956(2002). RN [20] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION). RX PubMed=23532847; DOI=10.1074/jbc.m113.459875; RA Sumitomo T., Nakata M., Higashino M., Terao Y., Kawabata S.; RT "Group A streptococcal cysteine protease cleaves epithelial junctions and RT contributes to bacterial translocation."; RL J. Biol. Chem. 288:13317-13324(2013). RN [21] RP DOMAIN CATENIN-BINDING. RX PubMed=2349235; DOI=10.1073/pnas.87.11.4246; RA Ozawa M., Ringwald M., Kemler R.; RT "Uvomorulin-catenin complex formation is regulated by a specific domain in RT the cytoplasmic region of the cell adhesion molecule."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4246-4250(1990). RN [22] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [23] RP FUNCTION AS L.MONOCYTOGENES RECEPTOR (MICROBIAL INFECTION), AND MUTAGENESIS RP OF PRO-170. RX PubMed=10406800; DOI=10.1093/emboj/18.14.3956; RA Lecuit M., Dramsi S., Gottardi C., Fedor-Chaiken M., Gumbiner B., RA Cossart P.; RT "A single amino acid in E-cadherin responsible for host specificity towards RT the human pathogen Listeria monocytogenes."; RL EMBO J. 18:3956-3963(1999). RN [24] RP PROTEOLYTIC PROCESSING. RX PubMed=11076937; DOI=10.1074/jbc.m006102200; RA Steinhusen U., Weiske J., Badock V., Tauber R., Bommert K., Huber O.; RT "Cleavage and shedding of E-cadherin after induction of apoptosis."; RL J. Biol. Chem. 276:4972-4980(2001). RN [25] RP INTERACTION WITH PSEN1. RX PubMed=11226248; DOI=10.1073/pnas.041603398; RA Baki L., Marambaud P., Efthimiopoulos S., Georgakopoulos A., Wen P., RA Cui W., Shioi J., Koo E., Ozawa M., Friedrich V.L., Robakis N.K.; RT "Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 RT association, and regulates stability and function of the cadherin/catenin RT adhesion complex."; RL Proc. Natl. Acad. Sci. U.S.A. 98:2381-2386(2001). RN [26] RP INTERCHAIN DISULFIDE BOND. RX PubMed=11856755; DOI=10.1074/jbc.m200916200; RA Makagiansar I.T., Nguyen P.D., Ikesue A., Kuczera K., Dentler W., RA Urbauer J.L., Galeva N., Alterman M., Siahaan T.J.; RT "Disulfide bond formation promotes the cis- and trans-dimerization of the RT E-cadherin-derived first repeat."; RL J. Biol. Chem. 277:16002-16010(2002). RN [27] RP FUNCTION. RX PubMed=11976333; DOI=10.1074/jbc.m201984200; RA Meigs T.E., Fedor-Chaiken M., Kaplan D.D., Brackenbury R., Casey P.J.; RT "Galpha12 and Galpha13 negatively regulate the adhesive functions of RT cadherin."; RL J. Biol. Chem. 277:24594-24600(2002). RN [28] RP INTERACTION WITH DLGAP5, AND SUBCELLULAR LOCATION. RX PubMed=14699157; DOI=10.1074/jbc.m309843200; RA Laprise P., Viel A., Rivard N.; RT "Human homolog of disc-large is required for adherens junction assembly and RT differentiation of human intestinal epithelial cells."; RL J. Biol. Chem. 279:10157-10166(2004). RN [29] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [30] RP INTERACTION WITH CTNND1. RX PubMed=15240885; DOI=10.1073/pnas.0401366101; RA Krakstad B.F., Ardawatia V.V., Aragay A.M.; RT "A role for Galpha12/Galpha13 in p120ctn regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10314-10319(2004). RN [31] RP INTERACTION WITH PSEN1 AND CTNNB1, AND MUTAGENESIS OF 759-GLY--GLY-761. RX PubMed=16126725; DOI=10.1074/jbc.m507503200; RA Serban G., Kouchi Z., Baki L., Georgakopoulos A., Litterst C.M., Shioi J., RA Robakis N.K.; RT "Cadherins mediate both the association between PS1 and beta-catenin and RT the effects of PS1 on beta-catenin stability."; RL J. Biol. Chem. 280:36007-36012(2005). RN [32] RP SUBCELLULAR LOCATION. RX PubMed=15689490; DOI=10.1091/mbc.e04-10-0867; RA Lock J.G., Stow J.L.; RT "Rab11 in recycling endosomes regulates the sorting and basolateral RT transport of E-cadherin."; RL Mol. Biol. Cell 16:1744-1755(2005). RN [33] RP FUNCTION OF E-CAD/CTF2. RX PubMed=16417575; DOI=10.1111/j.1471-4159.2005.03616.x; RA Agiostratidou G., Muros R.M., Shioi J., Marambaud P., Robakis N.K.; RT "The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic RT degradation of A beta precursors."; RL J. Neurochem. 96:1182-1188(2006). RN [34] RP INDUCTION. RX PubMed=17893710; DOI=10.1038/cr.2007.79; RA Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q., Mu Y.-M.; RT "Induction of the LRP16 gene by estrogen promotes the invasive growth of RT Ishikawa human endometrial cancer cells through the downregulation of E- RT cadherin."; RL Cell Res. 17:869-880(2007). RN [35] RP INVOLVEMENT IN LBC. RX PubMed=17660459; DOI=10.1136/jmg.2007.051268; RA Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J., RA Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N., Oliveira C., RA Collins L., Schnitt S., Garber J.E., Huntsman D.; RT "Germline E-cadherin mutations in familial lobular breast cancer."; RL J. Med. Genet. 44:726-731(2007). RN [36] RP SUBCELLULAR LOCATION. RX PubMed=18343367; DOI=10.1016/j.yexcr.2008.01.031; RA Kanno M., Isa Y., Aoyama Y., Yamamoto Y., Nagai M., Ozawa M., Kitajima Y.; RT "P120-catenin is a novel desmoglein 3 interacting partner: identification RT of the p120-catenin association site of desmoglein 3."; RL Exp. Cell Res. 314:1683-1692(2008). RN [37] RP GLYCOSYLATION AT ASN-558; ASN-570; ASN-622 AND ASN-637, AND MUTAGENESIS OF RP ASN-637. RX PubMed=18491227; DOI=10.1007/s10719-008-9133-9; RA Zhou F., Su J., Fu L., Yang Y., Zhang L., Wang L., Zhao H., Zhang D., RA Li Z., Zha X.; RT "Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded RT incorrectly and arrested in endoplasmic reticulum, then sequentially RT degraded by ERAD."; RL Glycoconj. J. 25:727-740(2008). RN [38] RP INTERACTION WITH LIMA1. RX PubMed=18093941; DOI=10.1073/pnas.0710504105; RA Abe K., Takeichi M.; RT "EPLIN mediates linkage of the cadherin catenin complex to F-actin and RT stabilizes the circumferential actin belt."; RL Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008). RN [39] RP REVIEW ON CADHERINS. RX PubMed=20066110; DOI=10.1101/cshperspect.a003053; RA Shapiro L., Weis W.I.; RT "Structure and biochemistry of cadherins and catenins."; RL Cold Spring Harb. Perspect. Biol. 1:A3053-A3053(2009). RN [40] RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=19403558; DOI=10.1093/hmg/ddp194; RA Pinho S.S., Reis C.A., Paredes J., Magalhaes A.M., Ferreira A.C., RA Figueiredo J., Xiaogang W., Carneiro F., Gaertner F., Seruca R.; RT "The role of N-acetylglucosaminyltransferase III and V in the post- RT transcriptional modifications of E-cadherin."; RL Hum. Mol. Genet. 18:2599-2608(2009). RN [41] RP INTERACTION WITH TBC1D2. RX PubMed=20116244; DOI=10.1016/j.cub.2009.12.053; RA Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E., RA Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R., Braga V.M.; RT "Armus is a Rac1 effector that inactivates Rab7 and regulates E-cadherin RT degradation."; RL Curr. Biol. 20:198-208(2010). RN [42] RP SUBCELLULAR LOCATION, AND INTERACTION WITH DDR1. RX PubMed=20432435; DOI=10.1002/jcp.22134; RA Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L., Hwang C.C., RA Wang H.M., Wang C.Z.; RT "DDR1 regulates the stabilization of cell surface E-cadherin and E- RT cadherin-mediated cell aggregation."; RL J. Cell. Physiol. 224:387-397(2010). RN [43] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [44] RP SUBCELLULAR LOCATION. RX PubMed=20859650; DOI=10.1007/s00018-010-0531-3; RA Gosavi P., Kundu S.T., Khapare N., Sehgal L., Karkhanis M.S., Dalal S.N.; RT "E-cadherin and plakoglobin recruit plakophilin3 to the cell border to RT initiate desmosome assembly."; RL Cell. Mol. Life Sci. 68:1439-1454(2011). RN [45] RP UBIQUITINATION BY CBLL1. RX PubMed=21283129; DOI=10.1038/cr.2011.17; RA Zhou W.J., Geng Z.H., Chi S., Zhang W., Niu X.F., Lan S.J., Ma L., Yang X., RA Wang L.J., Ding Y.Q., Geng J.G.; RT "Slit-Robo signaling induces malignant transformation through Hakai- RT mediated E-cadherin degradation during colorectal epithelial cell RT carcinogenesis."; RL Cell Res. 21:609-626(2011). RN [46] RP UBIQUITINATION BY A SKP2-CONTAINING SCF COMPLEX, AND PHOSPHORYLATION BY RP CSNK1A1. RX PubMed=22770219; DOI=10.1016/j.cell.2012.05.038; RA Inuzuka H., Gao D., Finley L.W., Yang W., Wan L., Fukushima H., Chin Y.R., RA Zhai B., Shaik S., Lau A.W., Wang Z., Gygi S.P., Nakayama K., RA Teruya-Feldstein J., Toker A., Haigis M.C., Pandolfi P.P., Wei W.; RT "Acetylation-dependent regulation of Skp2 function."; RL Cell 150:179-193(2012). RN [47] RP PHOSPHORYLATION AT TYR-753; TYR-754 AND TYR-755, AND MUTAGENESIS OF RP TYR-754. RX PubMed=22252131; DOI=10.1038/emboj.2011.496; RA Mukherjee M., Chow S.Y., Yusoff P., Seetharaman J., Ng C., Sinniah S., RA Koh X.W., Asgar N.F., Li D., Yim D., Jackson R.A., Yew J., Qian J., Iyu A., RA Lim Y.P., Zhou X., Sze S.K., Guy G.R., Sivaraman J.; RT "Structure of a novel phosphotyrosine-binding domain in Hakai that targets RT E-cadherin."; RL EMBO J. 31:1308-1319(2012). RN [48] RP INTERACTION WITH DSG3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-770 AND SER-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [50] RP IDENTIFICATION IN A COMPLEX WITH PKP3 AND RAP1A, INTERACTION WITH PKP3 AND RP RAP1A, AND SUBCELLULAR LOCATION. RX PubMed=25208567; DOI=10.1091/mbc.e14-05-0968; RA Todorovic V., Koetsier J.L., Godsel L.M., Green K.J.; RT "Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens RT junction maturation."; RL Mol. Biol. Cell 25:3749-3764(2014). RN [51] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=27760340; DOI=10.1016/j.immuni.2016.09.014; RA Cronan M.R., Beerman R.W., Rosenberg A.F., Saelens J.W., Johnson M.G., RA Oehlers S.H., Sisk D.M., Jurcic Smith K.L., Medvitz N.A., Miller S.E., RA Trinh L.A., Fraser S.E., Madden J.F., Turner J., Stout J.E., Lee S., RA Tobin D.M.; RT "Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma RT Formation and Promotes Infection."; RL Immunity 45:861-876(2016). RN [52] RP SUBCELLULAR LOCATION. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [53] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-175. RX PubMed=29999492; DOI=10.7554/elife.37629; RA Shafraz O., Ruebsam M., Stahley S.N., Caldara A.L., Kowalczyk A.P., RA Niessen C.M., Sivasankar S.; RT "E-cadherin binds to desmoglein to facilitate desmosome assembly."; RL Elife 7:0-0(2018). RN [54] RP INTERACTION WITH SPEF1. RX PubMed=31473225; DOI=10.1053/j.gastro.2019.08.031; RA Tapia R., Perez-Yepez E.A., Carlino M.J., Karandikar U.C., Kralicek S.E., RA Estes M.K., Hecht G.A.; RT "Sperm Flagellar 1 Binds Actin in Intestinal Epithelial Cells and RT Contributes to Formation of Filopodia and Lamellipodia."; RL Gastroenterology 157:1544-1555(2019). RN [55] RP INDUCTION. RX PubMed=31835537; DOI=10.3390/ijms20246221; RA Uttagomol J., Ahmad U.S., Rehman A., Huang Y., Laly A.C., Kang A., RA Soetaert J., Chance R., Teh M.T., Connelly J.T., Wan H.; RT "Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and RT Phospho-YAP in Keratinocyte Responses to Mechanical Forces."; RL Int. J. Mol. Sci. 20:0-0(2019). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=33596089; DOI=10.1091/mbc.e20-12-0775; RA Raya-Sandino A., Luissint A.C., Kusters D.H.M., Narayanan V., Flemming S., RA Garcia-Hernandez V., Godsel L.M., Green K.J., Hagen S.J., Conway D.E., RA Parkos C.A., Nusrat A.; RT "Regulation of intestinal epithelial intercellular adhesion and barrier RT function by desmosomal cadherin desmocollin-2."; RL Mol. Biol. Cell 32:753-768(2021). RN [57] RP SUBCELLULAR LOCATION. RX PubMed=36309486; DOI=10.1038/s41419-022-05326-2; RA Myo Min K.K., Rojas-Canales D., Penko D., DeNichilo M., Cockshell M.P., RA Ffrench C.B., Thompson E.J., Asplund O., Drogemuller C.J., Prasad R.B., RA Groop L., Grey S.T., Thomas H.E., Loudovaris T., Kay T.W., Mahoney M.G., RA Jessup C.F., Coates P.T., Bonder C.S.; RT "Desmoglein-2 is important for islet function and beta-cell survival."; RL Cell Death Dis. 13:911-911(2022). RN [58] {ECO:0007744|PDB:1O6S} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), SUBUNIT (MICROBIAL RP INFECTION), AND MUTAGENESIS OF TRP-156 AND PRO-170. RX PubMed=12526809; DOI=10.1016/s0092-8674(02)01136-4; RA Schubert W.-D., Urbanke C., Ziehm T., Beier V., Machner M.P., Domann E., RA Wehland J., Chakraborty T., Heinz D.W.; RT "Structure of internalin, a major invasion protein of Listeria RT monocytogenes, in complex with its human receptor E-cadherin."; RL Cell 111:825-836(2002). RN [59] RP REVIEW ON VARIANTS. RX PubMed=9744472; RX DOI=10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d; RA Berx G., Becker K.-F., Hoefler H., van Roy F.; RT "Mutations of the human E-cadherin (CDH1) gene."; RL Hum. Mutat. 12:226-237(1998). RN [60] {ECO:0007744|PDB:2OMV, ECO:0007744|PDB:2OMY} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), AND SUBUNIT RP (MICROBIAL INFECTION). RX PubMed=17540170; DOI=10.1016/j.cell.2007.03.049; RA Wollert T., Pasche B., Rochon M., Deppenmeier S., van den Heuvel J., RA Gruber A.D., Heinz D.W., Lengeling A., Schubert W.D.; RT "Extending the host range of Listeria monocytogenes by rational protein RT design."; RL Cell 129:891-902(2007). RN [61] {ECO:0007744|PDB:2OMU, ECO:0007744|PDB:2OMZ} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, AND SUBUNIT (MICROBIAL INFECTION). RX PubMed=17715295; DOI=10.1073/pnas.0702199104; RA Wollert T., Heinz D.W., Schubert W.D.; RT "Thermodynamically reengineering the listerial invasion complex InlA/E- RT cadherin."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13960-13965(2007). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 155-367, AND CALCIUM-BINDING RP SITES. RX PubMed=17850815; DOI=10.1016/j.jmb.2007.08.011; RA Parisini E., Higgins J.M., Liu J.H., Brenner M.B., Wang J.H.; RT "The crystal structure of human E-cadherin domains 1 and 2, and comparison RT with other cadherins in the context of adhesion mechanism."; RL J. Mol. Biol. 373:401-411(2007). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 155-253 IN COMPLEX WITH KLRG1. RX PubMed=19604491; DOI=10.1016/j.immuni.2009.04.019; RA Li Y., Hofmann M., Wang Q., Teng L., Chlewicki L.K., Pircher H., RA Mariuzza R.A.; RT "Structure of natural killer cell receptor KLRG1 bound to E-cadherin RT reveals basis for MHC-independent missing self recognition."; RL Immunity 31:35-46(2009). RN [64] RP VARIANT LOBULAR BREAST CARCINOMA SER-315. RX PubMed=7961105; DOI=10.1111/j.1349-7006.1994.tb02902.x; RA Kanai Y., Oda T., Tsuda H., Ochiai A., Hirohashi S.; RT "Point mutation of the E-cadherin gene in invasive lobular carcinoma of the RT breast."; RL Jpn. J. Cancer Res. 85:1035-1039(1994). RN [65] RP VARIANTS THR-617 AND VAL-711, AND VARIANT OVARIAN CANCER GLY-838. RX PubMed=8075649; DOI=10.1038/ng0594-98; RA Risinger J.I., Berchuck A., Kohler M.F., Boyd J.; RT "Mutations of the E-cadherin gene in human gynecologic cancers."; RL Nat. Genet. 7:98-102(1994). RN [66] RP VARIANT PRO-193. RX PubMed=8797891; DOI=10.1111/j.1349-7006.1996.tb02109.x; RA Muta H., Noguchi M., Kanai Y., Ochiai A., Nawata H., Hirohashi S.; RT "E-cadherin gene mutations in signet ring cell carcinoma of the stomach."; RL Jpn. J. Cancer Res. 87:843-848(1996). RN [67] RP VARIANTS ASP-400 DEL AND 418-ASP--PHE-423 DEL. RX PubMed=9045944; DOI=10.1111/j.1349-7006.1996.tb03125.x; RA Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T., RA Terashima M., Saito K., Satodate R.; RT "Inactivation of the E-cadherin gene in primary gastric carcinomas and RT gastric carcinoma cell lines."; RL Jpn. J. Cancer Res. 87:1153-1159(1996). RN [68] RP VARIANT THYROID CANCER THR-592. RX PubMed=8985087; RX DOI=10.1002/(sici)1097-0215(19970106)70:1<32::aid-ijc5>3.0.co;2-7; RA Soares P., Berx G., van Roy F., Sobrinho-Simoes M.; RT "E-cadherin gene alterations are rare events in thyroid tumors."; RL Int. J. Cancer 70:32-38(1997). RN [69] RP VARIANT DGLBC ASP-336, AND VARIANT ILE-470. RX PubMed=9537325; DOI=10.1038/32918; RA Guilford P.J., Hopkins J.B.W., Harraway J., McLeod M., McLeod N., RA Harawira P., Taite H., Scoular R., Miller A., Reeve A.E.; RT "E-cadherin germline mutations in familial gastric cancer."; RL Nature 392:402-405(1998). RN [70] RP VARIANTS DGLBC GLY-244 AND ALA-487. RX PubMed=10319582; DOI=10.1007/s100380050137; RA Yoon K.-A., Ku J.-L., Yang H.-K., Kim W.H., Park S.Y., Park J.-G.; RT "Germline mutations of E-cadherin gene in Korean familial gastric cancer RT patients."; RL J. Hum. Genet. 44:177-180(1999). RN [71] RP VARIANT ALA-340. RX PubMed=10896919; DOI=10.1136/gut.47.2.262; RA Kim H.C., Wheeler J.M.D., Kim J.C., Ilyas M., Beck N.E., Kim B.S., RA Park K.C., Bodmer W.F.; RT "The E-cadherin gene (CDH1) variants T340A and L599V in gastric and RT colorectal cancer patients in Korea."; RL Gut 47:262-267(2000). RN [72] RP VARIANT ALA-270. RX PubMed=11705864; RA Ikonen T., Matikainen M., Mononen N., Hyytinen E.R., Helin H.J., RA Tommola S., Tammela T.L., Pukkala E., Schleutker J., Kallioniemi O.-P., RA Koivisto P.A.; RT "Association of E-cadherin germ-line alterations with prostate cancer."; RL Clin. Cancer Res. 7:3465-3471(2001). RN [73] RP VARIANT THR-592. RX PubMed=11562785; DOI=10.3892/ijmm.8.4.439; RA Salahshor S., Hou H., Diep C.B., Loukola A., Zhang H., Liu T., Chen J., RA Iselius L., Rubio C., Lothe R.A., Aaltonen L., Sun X.F., Lindmark G., RA Lindblom A.; RT "A germline E-cadherin mutation in a family with gastric and colon RT cancer."; RL Int. J. Mol. Med. 8:439-443(2001). RN [74] RP VARIANT ALA-340. RX PubMed=11968083; DOI=10.1002/humu.10068; RA Oliveira C., Bordin M.C., Grehan N., Huntsman D., Suriano G., Machado J.C., RA Kiviluoto T., Aaltonen L., Jackson C.E., Seruca R., Caldas C.; RT "Screening E-cadherin in gastric cancer families reveals germline mutations RT only in hereditary diffuse gastric cancer kindred."; RL Hum. Mutat. 19:510-517(2002). RN [75] RP VARIANT DGLBC MET-832. RX PubMed=12216071; DOI=10.1002/ijc.10633; RA Yabuta T., Shinmura K., Tani M., Yamaguchi S., Yoshimura K., Katai H., RA Nakajima T., Mochiki E., Tsujinaka T., Takami M., Hirose K., Yamaguchi A., RA Takenoshita S., Yokota J.; RT "E-cadherin gene variants in gastric cancer families whose probands are RT diagnosed with diffuse gastric cancer."; RL Int. J. Cancer 101:434-441(2002). RN [76] RP VARIANTS THR-617 AND VAL-634, AND CHARACTERIZATION OF VARIANTS ALA-340; RP THR-617 AND VAL-634. RX PubMed=12588804; DOI=10.1093/hmg/ddg048; RA Suriano G., Oliveira C., Ferreira P., Machado J.C., Bordin M.C., RA De Wever O., Bruyneel E.A., Moguilevsky N., Grehan N., Porter T.R., RA Richards F.M., Hruban R.H., Roviello F., Huntsman D., Mareel M., RA Carneiro F., Caldas C., Seruca R.; RT "Identification of CDH1 germline missense mutations associated with RT functional inactivation of the E-cadherin protein in young gastric cancer RT probands."; RL Hum. Mol. Genet. 12:575-582(2003). RN [77] RP VARIANTS ILE-282 AND ASN-777. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [78] RP INVOLVEMENT IN BCDS1, VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, RP CHARACTERIZATION OF VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, AND RP SUBCELLULAR LOCATION. RX PubMed=28301459; DOI=10.1038/gim.2017.11; RA Ghoumid J., Stichelbout M., Jourdain A.S., Frenois F., Lejeune-Dumoulin S., RA Alex-Cordier M.P., Lebrun M., Guerreschi P., Duquennoy-Martinot V., RA Vinchon M., Ferri J., Jung M., Vicaire S., Vanlerberghe C., Escande F., RA Petit F., Manouvrier-Hanu S.; RT "Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to RT mutations in CDH1 and CTNND1."; RL Genet. Med. 19:1013-1021(2017). CC -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins CC (PubMed:11976333). They preferentially interact with themselves in a CC homophilic manner in connecting cells; cadherins may thus contribute to CC the sorting of heterogeneous cell types. CDH1 is involved in mechanisms CC regulating cell-cell adhesions, mobility and proliferation of CC epithelial cells (PubMed:11976333). Promotes organization of radial CC actin fiber structure and cellular response to contractile forces, via CC its interaction with AMOTL2 which facilitates anchoring of radial actin CC fibers to CDH1 junction complexes at the cell membrane (By similarity). CC Plays a role in the early stages of desmosome cell-cell junction CC formation via facilitating the recruitment of DSG2 and DSP to desmosome CC plaques (PubMed:29999492). Has a potent invasive suppressor role. It is CC a ligand for integrin alpha-E/beta-7. {ECO:0000250|UniProtKB:F1PAA9, CC ECO:0000269|PubMed:11976333, ECO:0000269|PubMed:16417575, CC ECO:0000269|PubMed:29999492}. CC -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta CC precursors. Has a strong inhibitory effect on APP C99 and C83 CC production. {ECO:0000269|PubMed:16417575}. CC -!- FUNCTION: (Microbial infection) Serves as a receptor for Listeria CC monocytogenes; internalin A (InlA) binds to this protein and promotes CC uptake of the bacteria. {ECO:0000269|PubMed:10406800, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:8601315}. CC -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11856755). Component of an CC E-cadherin/ catenin adhesion complex composed of at least E- CC cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and CC potentially alpha-catenin/CTNNA1; the complex is located to adherens CC junctions (PubMed:16126725, PubMed:7982500). Found in a complex CC composed of CDH1, RAP1A and PKP3; PKP3 acts as a scaffold protein CC within the complex, the complex is required for CDH1 localization to CC mature desmosome cell junctions (PubMed:25208567). Interacts with the CC TRPV4 and CTNNB1 complex (By similarity). Interacts with CTNND1 CC (PubMed:15240885). The stable association of CTNNA1 is controversial as CC CTNNA1 was shown not to bind to F-actin when assembled in the complex CC (By similarity). Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1 (By similarity). CC Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of CC cadherin-based adherens junctions (CAJs) (PubMed:11226248, CC PubMed:16126725). Interacts with AJAP1 and DLGAP5 (PubMed:14595118, CC PubMed:14699157). Interacts with TBC1D2 (PubMed:20116244). Interacts CC with LIMA1 (PubMed:18093941). Interacts with CAV1. Interacts with CC PIP5K1C (PubMed:17261850). Interacts with RAB8B (By similarity). CC Interacts with RAPGEF2 (By similarity). Interacts with DDR1; this CC stabilizes CDH1 at the cell surface and inhibits its internalization CC (PubMed:20432435). Interacts with KLRG1 (PubMed:19604491). Forms a CC ternary complex composed of ADAM10, CADH1 and EPHA4; within the CC complex, CADH1 is cleaved by ADAM10 which disrupts adherens junctions CC (By similarity). Interacts with SPEF1 (PubMed:31473225). Interacts with CC CTNNB1 and PKP2 (PubMed:11790773). Interacts with AMOTL2; the CC interaction may facilitate binding of radial actin fibers to cell CC junction complexes (By similarity). Interacts with DSG3; the CC interaction is required for CDH1 localization to developing adherens CC junctions (PubMed:22294297). {ECO:0000250, CC ECO:0000250|UniProtKB:F1PAA9, ECO:0000250|UniProtKB:P09803, CC ECO:0000250|UniProtKB:Q9R0T4, ECO:0000269|PubMed:11226248, CC ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:11856755, CC ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:14595118, CC ECO:0000269|PubMed:14699157, ECO:0000269|PubMed:15240885, CC ECO:0000269|PubMed:16126725, ECO:0000269|PubMed:17261850, CC ECO:0000269|PubMed:18093941, ECO:0000269|PubMed:19604491, CC ECO:0000269|PubMed:20116244, ECO:0000269|PubMed:20432435, CC ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:31473225, ECO:0000269|PubMed:7982500}. CC -!- SUBUNIT: (Microbial infection) Interacts with L.monocytogenes InlA CC (PubMed:12526809, PubMed:17540170, PubMed:17715295). The formation of CC the complex between InlA and cadherin-1 is calcium-dependent CC (PubMed:12526809). {ECO:0000269|PubMed:12526809, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295}. CC -!- INTERACTION: CC P12830; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-727477, EBI-10176008; CC P12830; P30260: CDC27; NbExp=2; IntAct=EBI-727477, EBI-994813; CC P12830; P12830: CDH1; NbExp=8; IntAct=EBI-727477, EBI-727477; CC P12830; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-727477, EBI-21670927; CC P12830; P35221: CTNNA1; NbExp=8; IntAct=EBI-727477, EBI-701918; CC P12830; P35222: CTNNB1; NbExp=23; IntAct=EBI-727477, EBI-491549; CC P12830; O60716: CTNND1; NbExp=9; IntAct=EBI-727477, EBI-701927; CC P12830; P49184: DNASE1L1; NbExp=3; IntAct=EBI-727477, EBI-20894690; CC P12830; Q9H8V3: ECT2; NbExp=3; IntAct=EBI-727477, EBI-1054039; CC P12830; P00533: EGFR; NbExp=4; IntAct=EBI-727477, EBI-297353; CC P12830; P16422: EPCAM; NbExp=3; IntAct=EBI-727477, EBI-1171184; CC P12830; P11362: FGFR1; NbExp=3; IntAct=EBI-727477, EBI-1028277; CC P12830; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-727477, EBI-10975491; CC P12830; Q9UHB6: LIMA1; NbExp=2; IntAct=EBI-727477, EBI-351479; CC P12830; P43356: MAGEA2B; NbExp=3; IntAct=EBI-727477, EBI-5650739; CC P12830; Q7Z434: MAVS; NbExp=3; IntAct=EBI-727477, EBI-995373; CC P12830; P08581: MET; NbExp=2; IntAct=EBI-727477, EBI-1039152; CC P12830; Q8NCR3: MFI; NbExp=3; IntAct=EBI-727477, EBI-744790; CC P12830; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-727477, EBI-25834188; CC P12830; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-727477, EBI-3446748; CC P12830; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-727477, EBI-11750983; CC P12830; Q8N323: NXPE1; NbExp=3; IntAct=EBI-727477, EBI-25834085; CC P12830; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-727477, EBI-473160; CC P12830; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-727477, EBI-2557132; CC P12830; P62136: PPP1CA; NbExp=2; IntAct=EBI-727477, EBI-357253; CC P12830; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-727477, EBI-2860740; CC P12830; P17612: PRKACA; NbExp=3; IntAct=EBI-727477, EBI-476586; CC P12830; Q15139: PRKD1; NbExp=7; IntAct=EBI-727477, EBI-1181072; CC P12830; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-727477, EBI-709652; CC P12830; P49768: PSEN1; NbExp=2; IntAct=EBI-727477, EBI-297277; CC P12830; P50454: SERPINH1; NbExp=3; IntAct=EBI-727477, EBI-350723; CC P12830; Q02978: SLC25A11; NbExp=3; IntAct=EBI-727477, EBI-359174; CC P12830; P12931: SRC; NbExp=2; IntAct=EBI-727477, EBI-621482; CC P12830; P48775: TDO2; NbExp=3; IntAct=EBI-727477, EBI-743494; CC P12830; P37173: TGFBR2; NbExp=3; IntAct=EBI-727477, EBI-296151; CC P12830; Q9BT49: THAP7; NbExp=3; IntAct=EBI-727477, EBI-741350; CC P12830; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-727477, EBI-1220488; CC P12830; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-727477, EBI-1037322; CC P12830; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-727477, EBI-25830993; CC P12830; Q9BQ29; NbExp=3; IntAct=EBI-727477, EBI-22013570; CC P12830; A0A0S2C3P2: cagA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-55025805; CC P12830; Q9JIY2: Cbll1; Xeno; NbExp=21; IntAct=EBI-727477, EBI-7644904; CC P12830; P0DJM0: inlA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-1035388; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:18343367, ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:27760340, ECO:0000269|PubMed:28169360}. Cell CC membrane {ECO:0000269|PubMed:19403558, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:28301459, ECO:0000269|PubMed:36309486}; Single-pass CC type I membrane protein. Endosome {ECO:0000269|PubMed:15689490}. Golgi CC apparatus, trans-Golgi network {ECO:0000269|PubMed:15689490}. Cytoplasm CC {ECO:0000269|PubMed:22294297}. Cell junction, desmosome CC {ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492, CC ECO:0000269|PubMed:33596089}. Note=Colocalizes with DLGAP5 at sites of CC cell-cell contact in intestinal epithelial cells. Anchored to actin CC microfilaments through association with alpha-, beta- and gamma- CC catenin. Sequential proteolysis induced by apoptosis or calcium influx, CC results in translocation from sites of cell-cell contact to the CC cytoplasm. Colocalizes with RAB11A endosomes during its transport from CC the Golgi apparatus to the plasma membrane. Recruited to desmosomes at CC the initial assembly phase and also accumulates progressively at mature CC desmosome cell-cell junctions (PubMed:25208567, PubMed:29999492). CC Localizes to cell-cell contacts as keratinocyte differentiation CC progresses (By similarity). {ECO:0000250|UniProtKB:P09803, CC ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P12830-1; Sequence=Displayed; CC Name=2; CC IsoId=P12830-2; Sequence=VSP_055586; CC -!- TISSUE SPECIFICITY: Expressed in granuloma macrophages (at protein CC level) (PubMed:27760340). Expressed in the skin (at protein level) CC (PubMed:22294297). Expressed in the liver (PubMed:3263290). CC {ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:27760340, CC ECO:0000269|PubMed:3263290}. CC -!- INDUCTION: Induced in the hours following cyclic mechanical strain in CC keratinocytes (PubMed:31835537). Expression is repressed by MACROD1 CC (PubMed:17893710). {ECO:0000269|PubMed:17893710, CC ECO:0000269|PubMed:31835537}. CC -!- DOMAIN: Three calcium ions are usually bound at the interface of each CC cadherin domain and strengthen the connections, imparting a strong CC curvature to the full-length ectodomain. {ECO:0000269|PubMed:2349235}. CC -!- PTM: During apoptosis or with calcium influx, cleaved by a membrane- CC bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 CC (PubMed:10597309, PubMed:11076937, PubMed:11953314). Processing by the CC metalloproteinase, induced by calcium influx, causes disruption of CC cell-cell adhesion and the subsequent release of beta-catenin into the CC cytoplasm (PubMed:10597309). The residual membrane-tethered cleavage CC product is rapidly degraded via an intracellular proteolytic pathway CC (PubMed:10597309). Cleavage by caspase-3 releases the cytoplasmic tail CC resulting in disintegration of the actin microfilament system CC (PubMed:11076937). The gamma-secretase-mediated cleavage promotes CC disassembly of adherens junctions (PubMed:11953314). During development CC of the cochlear organ of Corti, cleavage by ADAM10 at adherens CC junctions promotes pillar cell separation (By similarity). CC {ECO:0000250|UniProtKB:P09803, ECO:0000269|PubMed:10597309, CC ECO:0000269|PubMed:11076937, ECO:0000269|PubMed:11953314}. CC -!- PTM: N-glycosylation at Asn-637 is essential for expression, folding CC and trafficking. Addition of bisecting N-acetylglucosamine by MGAT3 CC modulates its cell membrane location (PubMed:19403558). CC {ECO:0000269|PubMed:18491227, ECO:0000269|PubMed:19403558}. CC -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which requires CC prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by CBLL1/HAKAI, CC requires prior phosphorylation at Tyr-754. CC {ECO:0000269|PubMed:21283129, ECO:0000269|PubMed:22252131, CC ECO:0000269|PubMed:22770219}. CC -!- PTM: O-glycosylated. O-manosylated by TMTC1, TMTC2, TMTC3 or TMTC4. CC Thr-285 and Thr-509 are O-mannosylated by TMTC2 or TMTC4 but not TMTC1 CC or TMTC3. {ECO:0000250|UniProtKB:P09803}. CC -!- PTM: (Microbial infection) Cleaved by S.pyogenes SpeB protease; leading CC to its degradation (PubMed:23532847). Degradation by SpeB promotes CC bacterial translocation across the host epithelial barrier CC (PubMed:23532847). {ECO:0000269|PubMed:23532847}. CC -!- DISEASE: Diffuse gastric and lobular breast cancer syndrome (DGLBC) CC [MIM:137215]: A cancer predisposition syndrome with increased CC susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a CC malignant disease characterized by poorly differentiated infiltrating CC lesions resulting in thickening of the stomach. Malignant tumors start CC in the stomach, can spread to the esophagus or the small intestine, and CC can extend through the stomach wall to nearby lymph nodes and organs. CC It also can metastasize to other parts of the body. In addition to CC gastric cancer, most female mutation carriers develop lobular carcinoma CC of the breast. {ECO:0000269|PubMed:10319582, CC ECO:0000269|PubMed:12216071, ECO:0000269|PubMed:9537325}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. Heterozygous CDH1 germline mutations are CC responsible for familial cases of diffuse gastric cancer. Somatic CC mutations has also been found in patients with sporadic diffuse gastric CC cancer and lobular breast cancer. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast CC cancer that begins in the milk-producing glands (lobules) of the CC breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in CC this entry may be involved in disease pathogenesis. CC -!- DISEASE: Blepharocheilodontic syndrome 1 (BCDS1) [MIM:119580]: A form CC of blepharocheilodontic syndrome, a rare autosomal dominant disorder. CC It is characterized by lower eyelid ectropion, upper eyelid CC distichiasis, euryblepharon, bilateral cleft lip and palate, and CC features of ectodermal dysplasia, including hair anomalies, conical CC teeth and tooth agenesis. An additional rare manifestation is CC imperforate anus. There is considerable phenotypic variability among CC affected individuals. {ECO:0000269|PubMed:28301459}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: May play a role in blister formation in Pemphigus CC vulgaris patients, expression is lost at sites of cell-cell contact CC between the basal and suprabasal layers in blisters and immediately CC adjacent to blisters. {ECO:0000269|PubMed:22294297}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA61259.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/166/CDH1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=E-cadherin entry; CC URL="https://en.wikipedia.org/wiki/E-cadherin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z13009; CAA78353.1; -; mRNA. DR EMBL; Z18923; CAA79356.1; -; mRNA. DR EMBL; L08599; AAA61259.1; ALT_FRAME; mRNA. DR EMBL; AB025105; BAA88956.1; -; mRNA. DR EMBL; AK290012; BAF82701.1; -; mRNA. DR EMBL; AK312551; BAG35448.1; -; mRNA. DR EMBL; DQ090940; AAY68225.1; -; Genomic_DNA. DR EMBL; AC099314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471092; EAW83243.1; -; Genomic_DNA. DR EMBL; CH471092; EAW83244.1; -; Genomic_DNA. DR EMBL; L34545; AAA21764.1; -; Genomic_DNA. DR EMBL; D49685; BAA08537.1; -; Genomic_DNA. DR EMBL; Z35402; CAA84586.1; -; Genomic_DNA. DR EMBL; Z35403; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35404; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35405; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35406; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35407; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35408; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35409; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35410; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35411; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35412; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35413; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35414; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35415; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; X12790; CAA31279.1; -; mRNA. DR EMBL; X52279; CAA36522.1; -; mRNA. DR EMBL; S72492; AAD14108.1; -; Genomic_DNA. DR EMBL; S72397; AAD14108.1; JOINED; Genomic_DNA. DR EMBL; S72491; AAD14108.1; JOINED; Genomic_DNA. DR CCDS; CCDS10869.1; -. [P12830-1] DR CCDS; CCDS82005.1; -. [P12830-2] DR PIR; S37654; IJHUCE. DR RefSeq; NP_001304113.1; NM_001317184.2. [P12830-2] DR RefSeq; NP_001304114.1; NM_001317185.1. DR RefSeq; NP_001304115.1; NM_001317186.1. DR RefSeq; NP_004351.1; NM_004360.5. [P12830-1] DR PDB; 1O6S; X-ray; 1.80 A; B=156-255. DR PDB; 2O72; X-ray; 2.00 A; A=155-367. DR PDB; 2OMT; X-ray; 2.00 A; B=156-255. DR PDB; 2OMU; X-ray; 1.80 A; B=156-255. DR PDB; 2OMV; X-ray; 1.90 A; B=156-255. DR PDB; 2OMX; X-ray; 1.70 A; B=156-258. DR PDB; 2OMY; X-ray; 1.70 A; B=156-254. DR PDB; 2OMZ; X-ray; 1.60 A; B=156-254. DR PDB; 3FF7; X-ray; 1.80 A; A/B=155-253. DR PDB; 3FF8; X-ray; 2.00 A; A/B=155-254. DR PDB; 3L6X; X-ray; 2.40 A; B=756-773. DR PDB; 3L6Y; X-ray; 3.00 A; B/D/F=756-773. DR PDB; 4ZT1; X-ray; 1.92 A; A/B=157-367. DR PDB; 4ZTE; X-ray; 2.13 A; A/B=157-367. DR PDB; 6CXY; X-ray; 2.20 A; C=155-371. DR PDB; 6OLE; EM; 3.10 A; y=693-730. DR PDB; 6OLF; EM; 3.90 A; y=693-730. DR PDB; 6OLG; EM; 3.40 A; A=693-730. DR PDB; 6VEL; X-ray; 2.65 A; C=155-371. DR PDB; 7STZ; X-ray; 2.95 A; C/D=155-698. DR PDB; 8H62; X-ray; 1.91 A; B=155-367. DR PDBsum; 1O6S; -. DR PDBsum; 2O72; -. DR PDBsum; 2OMT; -. DR PDBsum; 2OMU; -. DR PDBsum; 2OMV; -. DR PDBsum; 2OMX; -. DR PDBsum; 2OMY; -. DR PDBsum; 2OMZ; -. DR PDBsum; 3FF7; -. DR PDBsum; 3FF8; -. DR PDBsum; 3L6X; -. DR PDBsum; 3L6Y; -. DR PDBsum; 4ZT1; -. DR PDBsum; 4ZTE; -. DR PDBsum; 6CXY; -. DR PDBsum; 6OLE; -. DR PDBsum; 6OLF; -. DR PDBsum; 6OLG; -. DR PDBsum; 6VEL; -. DR PDBsum; 7STZ; -. DR PDBsum; 8H62; -. DR AlphaFoldDB; P12830; -. DR EMDB; EMD-25883; -. DR EMDB; EMD-25884; -. DR EMDB; EMD-25886; -. DR EMDB; EMD-25892; -. DR SMR; P12830; -. DR BioGRID; 107434; 777. DR CORUM; P12830; -. DR DIP; DIP-477N; -. DR ELM; P12830; -. DR FunCoup; P12830; 811. DR IntAct; P12830; 146. DR MINT; P12830; -. DR STRING; 9606.ENSP00000261769; -. DR BindingDB; P12830; -. DR ChEMBL; CHEMBL2321609; -. DR TCDB; 8.A.204.1.1; the cadhesin (cdh) family. DR UniLectin; P12830; -. DR GlyCosmos; P12830; 13 sites, No reported glycans. DR GlyGen; P12830; 16 sites, 2 O-linked glycans (3 sites). DR iPTMnet; P12830; -. DR PhosphoSitePlus; P12830; -. DR SwissPalm; P12830; -. DR BioMuta; CDH1; -. DR DMDM; 399166; -. DR CPTAC; CPTAC-1599; -. DR CPTAC; CPTAC-5772; -. DR CPTAC; CPTAC-5773; -. DR CPTAC; non-CPTAC-5366; -. DR CPTAC; non-CPTAC-5367; -. DR CPTAC; non-CPTAC-5370; -. DR CPTAC; non-CPTAC-5541; -. DR CPTAC; non-CPTAC-5542; -. DR jPOST; P12830; -. DR MassIVE; P12830; -. DR PaxDb; 9606-ENSP00000261769; -. DR PeptideAtlas; P12830; -. DR ProteomicsDB; 52879; -. [P12830-1] DR ProteomicsDB; 84533; -. DR Pumba; P12830; -. DR TopDownProteomics; P12830-2; -. [P12830-2] DR ABCD; P12830; 29 sequenced antibodies. DR Antibodypedia; 1347; 3254 antibodies from 63 providers. DR CPTC; P12830; 4 antibodies. DR DNASU; 999; -. DR Ensembl; ENST00000261769.10; ENSP00000261769.4; ENSG00000039068.21. [P12830-1] DR Ensembl; ENST00000422392.6; ENSP00000414946.2; ENSG00000039068.21. [P12830-2] DR GeneID; 999; -. DR KEGG; hsa:999; -. DR MANE-Select; ENST00000261769.10; ENSP00000261769.4; NM_004360.5; NP_004351.1. DR UCSC; uc002ewg.2; human. [P12830-1] DR AGR; HGNC:1748; -. DR CIViC; 999; 4 evidence items across 4 molecular profiles. DR ClinPGx; PA26282; -. DR CTD; 999; -. DR DisGeNET; 999; -. DR GeneCards; CDH1; -. DR GeneReviews; CDH1; -. DR HGNC; HGNC:1748; CDH1. DR HPA; ENSG00000039068; Tissue enhanced (parathyroid). DR MalaCards; CDH1; -. DR MIM; 119580; phenotype. DR MIM; 137215; phenotype. DR MIM; 167000; phenotype. DR MIM; 192090; gene. DR MIM; 608089; phenotype. DR OpenTargets; ENSG00000039068; -. DR Orphanet; 1997; Blepharo-cheilo-odontic syndrome. DR Orphanet; 199306; Cleft lip/palate. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 26106; Hereditary diffuse gastric cancer. DR VEuPathDB; HostDB:ENSG00000039068; -. DR eggNOG; KOG3594; Eukaryota. DR GeneTree; ENSGT00940000157175; -. DR HOGENOM; CLU_005284_2_1_1; -. DR InParanoid; P12830; -. DR OrthoDB; 6079678at2759; -. DR PAN-GO; P12830; 8 GO annotations based on evolutionary models. DR PhylomeDB; P12830; -. DR PathwayCommons; P12830; -. DR Reactome; R-HSA-1474228; Degradation of the extracellular matrix. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9764562; Regulation of CDH1 mRNA translation by microRNAs. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR Reactome; R-HSA-9926550; Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P12830; -. DR SIGNOR; P12830; -. DR Agora; ENSG00000039068; -. DR BioGRID-ORCS; 999; 47 hits in 1173 CRISPR screens. DR ChiTaRS; CDH1; human. DR EvolutionaryTrace; P12830; -. DR GeneWiki; CDH1_(gene); -. DR GenomeRNAi; 999; -. DR Pharos; P12830; Tbio. DR PRO; PR:P12830; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P12830; protein. DR Bgee; ENSG00000039068; Expressed in jejunal mucosa and 158 other cell types or tissues. DR ExpressionAtlas; P12830; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0043296; C:apical junction complex; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0030057; C:desmosome; IDA:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0016600; C:flotillin complex; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005765; C:lysosomal membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005802; C:trans-Golgi network; IMP:BHF-UCL. DR GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0098631; F:cell adhesion mediator activity; IDA:UniProt. DR GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0032794; F:GTPase activating protein binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl. DR GO; GO:0034332; P:adherens junction organization; IMP:UniProtKB. DR GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0000902; P:cell morphogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IDA:BHF-UCL. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IDA:BHF-UCL. DR GO; GO:0007043; P:cell-cell junction assembly; IBA:GO_Central. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0071285; P:cellular response to lithium ion; IDA:UniProtKB. DR GO; GO:0002159; P:desmosome assembly; IMP:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; NAS:UniProtKB. DR GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL. DR GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0031175; P:neuron projection development; IEA:Ensembl. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; IMP:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB. DR GO; GO:0099576; P:regulation of protein catabolic process at postsynapse, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0071503; P:response to heparin; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0007416; P:synapse assembly; IBA:GO_Central. DR CDD; cd00031; CA_like; 1. DR CDD; cd11304; Cadherin_repeat; 3. DR FunFam; 2.60.40.60:FF:000011; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000191; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000019; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000022; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000027; Cadherin 2; 1. DR FunFam; 4.10.900.10:FF:000001; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000031; Cadherin 3; 1. DR Gene3D; 2.60.40.60; Cadherins; 6. DR Gene3D; 4.10.900.10; TCF3-CBD (Catenin binding domain); 1. DR InterPro; IPR039808; Cadherin. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR020894; Cadherin_CS. DR InterPro; IPR014868; Cadherin_pro_dom. DR InterPro; IPR000233; Cadherin_Y-type_LIR. DR InterPro; IPR027397; Catenin-bd_sf. DR PANTHER; PTHR24027:SF319; CADHERIN-1; 1. DR PANTHER; PTHR24027; CADHERIN-23; 1. DR Pfam; PF01049; CADH_Y-type_LIR; 1. DR Pfam; PF00028; Cadherin; 5. DR Pfam; PF08758; Cadherin_pro; 1. DR PRINTS; PR00205; CADHERIN. DR SMART; SM00112; CA; 4. DR SMART; SM01055; Cadherin_pro; 1. DR SUPFAM; SSF49313; Cadherin-like; 6. DR PROSITE; PS00232; CADHERIN_1; 3. DR PROSITE; PS50268; CADHERIN_2; 5. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell junction; KW Cell membrane; Cleavage on pair of basic residues; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Endosome; Glycoprotein; Golgi apparatus; Membrane; KW Metal-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix; KW Ubl conjugation. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT PROPEP 23..154 FT /evidence="ECO:0000255" FT /id="PRO_0000003715" FT CHAIN 155..882 FT /note="Cadherin-1" FT /id="PRO_0000003716" FT CHAIN 701..882 FT /note="E-Cad/CTF1" FT /id="PRO_0000236067" FT CHAIN 732..882 FT /note="E-Cad/CTF2" FT /id="PRO_0000236068" FT CHAIN 751..882 FT /note="E-Cad/CTF3" FT /id="PRO_0000236069" FT TOPO_DOM 155..709 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 710..730 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 731..882 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 155..262 FT /note="Cadherin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 263..375 FT /note="Cadherin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 376..486 FT /note="Cadherin 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 487..593 FT /note="Cadherin 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 594..697 FT /note="Cadherin 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT REGION 747..767 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 758..769 FT /note="Required for binding CTNND1 and PSEN1" FT REGION 811..882 FT /note="Required for binding alpha, beta and gamma catenins" FT COMPBIAS 755..767 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 288 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT SITE 364..365 FT /note="Cleavage; by S.pyogenes SpeB" FT /evidence="ECO:0000269|PubMed:23532847" FT SITE 700..701 FT /note="Cleavage; by a metalloproteinase" FT SITE 731..732 FT /note="Cleavage; by gamma-secretase/PS1" FT SITE 750..751 FT /note="Cleavage; by caspase-3" FT MOD_RES 753 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 754 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 755 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 793 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 838 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 840 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 846 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 280 FT /note="O-linked (Man...) serine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 285 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 358 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 470 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 472 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 509 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 570 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 576 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 578 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 580 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 622 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 637 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT DISULFID 163 FT /note="Interchain" FT VAR_SEQ 380..440 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_055586" FT VARIANT 72 FT /note="D -> N (in dbSNP:rs35606263)" FT /id="VAR_048500" FT VARIANT 123 FT /note="H -> Y (in a gastric cancer sample; FT dbSNP:rs1555514482)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001306" FT VARIANT 193 FT /note="T -> P (in a diffuse gastric cancer sample; FT dbSNP:rs1597891014)" FT /evidence="ECO:0000269|PubMed:8797891" FT /id="VAR_001307" FT VARIANT 244 FT /note="D -> G (in DGLBC; likely benign; FT dbSNP:rs1064794231)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008712" FT VARIANT 254 FT /note="D -> Y (in BCDS1; abolishes protein abundance; loss FT of cell membrane localization; dbSNP:rs1555515445)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079392" FT VARIANT 257 FT /note="D -> V (in BCDS1; slightly decreases protein FT abundance; loss of cell membrane localization; FT dbSNP:rs1555515446)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079393" FT VARIANT 270 FT /note="S -> A (in dbSNP:rs587776399)" FT /evidence="ECO:0000269|PubMed:11705864" FT /id="VAR_013970" FT VARIANT 274..277 FT /note="Missing (found in gastric carcinoma cell lines)" FT /evidence="ECO:0000269|PubMed:8127895" FT /id="VAR_001308" FT VARIANT 282 FT /note="M -> I (in a breast cancer sample; somatic mutation; FT dbSNP:rs200932258)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033026" FT VARIANT 315 FT /note="N -> S (in lobular breast carcinoma)" FT /evidence="ECO:0000269|PubMed:7961105" FT /id="VAR_001309" FT VARIANT 336 FT /note="E -> D (in DGLBC; likely pathogenic; FT dbSNP:rs267606712)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001310" FT VARIANT 340 FT /note="T -> A (found in gastric and colorectal cancer FT samples; cells exhibited decreased aggregation increased FT invasiveness and non-uniform migration in vitro compared to FT cells transfected with wild-type sequence; FT dbSNP:rs116093741)" FT /evidence="ECO:0000269|PubMed:10896919, FT ECO:0000269|PubMed:11968083, ECO:0000269|PubMed:12588804" FT /id="VAR_013971" FT VARIANT 370 FT /note="D -> A (in a diffuse gastric cancer sample; FT dbSNP:rs2152132676)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001311" FT VARIANT 393 FT /note="I -> N (in dbSNP:rs34466743)" FT /id="VAR_048501" FT VARIANT 400 FT /note="Missing (in a gastric carcinoma sample; loss of FT heterozygosity)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001312" FT VARIANT 418..423 FT /note="Missing (in a gastric carcinoma sample)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001313" FT VARIANT 454 FT /note="Missing (in BCDS1; decreases protein abundance; loss FT of cell membrane localization)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079394" FT VARIANT 463 FT /note="E -> Q (in a gastric carcinoma sample; FT dbSNP:rs1960961009)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001314" FT VARIANT 470 FT /note="T -> I (in dbSNP:rs370864592)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001315" FT VARIANT 473 FT /note="V -> D (in a diffuse gastric cancer sample; FT dbSNP:rs2152134881)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001317" FT VARIANT 473 FT /note="V -> I (in dbSNP:rs36087757)" FT /id="VAR_048502" FT VARIANT 478 FT /note="L -> P (in dbSNP:rs35520415)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023357" FT VARIANT 487 FT /note="V -> A (in DGLBC; dbSNP:rs1960965342)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008713" FT VARIANT 592 FT /note="A -> T (in dbSNP:rs35187787)" FT /evidence="ECO:0000269|PubMed:11562785, FT ECO:0000269|PubMed:8985087" FT /id="VAR_001318" FT VARIANT 598 FT /note="R -> Q (in a gastric cancer sample; FT dbSNP:rs780759537)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001319" FT VARIANT 617 FT /note="A -> T (detected in an endometrial cancer sample; FT loss of heterozygosity; cells exhibited an intermediate FT phenotype concerning aggregation invasiveness and migration FT in vitro compared to cells transfected with wild-type FT sequence; dbSNP:rs33935154)" FT /evidence="ECO:0000269|PubMed:12588804, FT ECO:0000269|PubMed:8075649, ECO:0000269|Ref.7" FT /id="VAR_001320" FT VARIANT 630 FT /note="L -> V (in dbSNP:rs2276331)" FT /id="VAR_021868" FT VARIANT 634 FT /note="A -> V (found in a gastric cancer sample; cells FT exhibited decreased aggregation increased invasiveness and FT non-uniform migration in vitro compared to cells FT transfected with wild-type sequence; dbSNP:rs121964878)" FT /evidence="ECO:0000269|PubMed:12588804" FT /id="VAR_055431" FT VARIANT 695 FT /note="C -> R (in dbSNP:rs9282655)" FT /id="VAR_021869" FT VARIANT 711 FT /note="L -> V (detected in an endometrial cancer sample; FT dbSNP:rs121964871)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001321" FT VARIANT 777 FT /note="D -> N (in dbSNP:rs372989292)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033027" FT VARIANT 832 FT /note="V -> M (in DGLBC; benign; dbSNP:rs35572355)" FT /evidence="ECO:0000269|PubMed:12216071, ECO:0000269|Ref.7" FT /id="VAR_023358" FT VARIANT 838 FT /note="S -> G (in an ovarian carcinoma sample; somatic FT mutation; loss of heterozygosity; dbSNP:rs121964872)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001322" FT VARIANT 880 FT /note="E -> K (in dbSNP:rs34507583)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023359" FT MUTAGEN 156 FT /note="W->A,S: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 156 FT /note="W->D: Protein is partially unfolded, no longer binds FT L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->A,E,V: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->E: No longer adheres to L.monocytogenes InlA FT coated beads, nor do cells take up InlA coated beads." FT /evidence="ECO:0000269|PubMed:10406800" FT MUTAGEN 175 FT /note="L->D: Reduces localization to desmosome cell-cell FT junctions. Also reduces the localization of DSG2 and DSP to FT desmosome cell-cell junctions." FT /evidence="ECO:0000269|PubMed:29999492" FT MUTAGEN 637 FT /note="N->Q: CDH1 becomes a substrate for ERAD and is FT retro-translocated from ER to cytoplasm." FT /evidence="ECO:0000269|PubMed:18491227" FT MUTAGEN 754 FT /note="Y->F: Abolishes binding to CBLL1." FT /evidence="ECO:0000269|PubMed:22252131" FT MUTAGEN 759..761 FT /note="GGG->AAA: Binds to CTNNB1 but abolishes interaction FT of CTNNB1 with PSEN1. Abolishes gamma-secretase cleavage." FT /evidence="ECO:0000269|PubMed:11953314, FT ECO:0000269|PubMed:16126725" FT CONFLICT 10 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 29 FT /note="H -> L (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 47 FT /note="E -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 70..71 FT /note="SL -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 483 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 530 FT /note="A -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 543 FT /note="S -> F (in Ref. 2; CAA79356)" FT /evidence="ECO:0000305" FT CONFLICT 615 FT /note="I -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 634..636 FT /note="ASA -> RVP (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="R -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 882 FT /note="D -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT STRAND 163..166 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 169..177 FT /evidence="ECO:0007829|PDB:2OMZ" FT HELIX 181..184 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 189..195 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 213..216 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 265..272 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 292..294 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 301..309 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 316..319 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 321..323 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 325..328 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 335..337 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 340..348 FT /evidence="ECO:0007829|PDB:8H62" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 356..366 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 374..384 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 394..396 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 410..417 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 423..428 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 429..432 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 433..440 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 448..460 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 470..477 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 485..498 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 522..527 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 533..535 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 537..539 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 541..544 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 557..568 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 576..586 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 594..596 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 599..607 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 610..615 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 622..625 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 627..633 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 638..644 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 648..656 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 660..673 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 675..691 FT /evidence="ECO:0007829|PDB:7STZ" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:3L6X" SQ SEQUENCE 882 AA; 97456 MW; E427118043A13C67 CRC64; MGPWSRSLSA LLLLLQVSSW LCQEPEPCHP GFDAESYTFT VPRRHLERGR VLGRVNFEDC TGRQRTAYFS LDTRFKVGTD GVITVKRPLR FHNPQIHFLV YAWDSTYRKF STKVTLNTVG HHHRPPPHQA SVSGIQAELL TFPNSSPGLR RQKRDWVIPP ISCPENEKGP FPKNLVQIKS NKDKEGKVFY SITGQGADTP PVGVFIIERE TGWLKVTEPL DRERIATYTL FSHAVSSNGN AVEDPMEILI TVTDQNDNKP EFTQEVFKGS VMEGALPGTS VMEVTATDAD DDVNTYNAAI AYTILSQDPE LPDKNMFTIN RNTGVISVVT TGLDRESFPT YTLVVQAADL QGEGLSTTAT AVITVTDTND NPPIFNPTTY KGQVPENEAN VVITTLKVTD ADAPNTPAWE AVYTILNDDG GQFVVTTNPV NNDGILKTAK GLDFEAKQQY ILHVAVTNVV PFEVSLTTST ATVTVDVLDV NEAPIFVPPE KRVEVSEDFG VGQEITSYTA QEPDTFMEQK ITYRIWRDTA NWLEINPDTG AISTRAELDR EDFEHVKNST YTALIIATDN GSPVATGTGT LLLILSDVND NAPIPEPRTI FFCERNPKPQ VINIIDADLP PNTSPFTAEL THGASANWTI QYNDPTQESI ILKPKMALEV GDYKINLKLM DNQNKDQVTT LEVSVCDCEG AAGVCRKAQP VEAGLQIPAI LGILGGILAL LILILLLLLF LRRRAVVKEP LLPPEDDTRD NVYYYDEEGG GEEDQDFDLS QLHRGLDARP EVTRNDVAPT LMSVPRYLPR PANPDEIGNF IDENLKAADT DPTAPPYDSL LVFDYEGSGS EAASLSSLNS SESDKDQDYD YLNEWGNRFK KLADMYGGGE DD // ID CEMIP_HUMAN Reviewed; 1361 AA. AC Q8WUJ3; Q6L9J5; Q9H1K5; Q9NPN9; Q9ULM1; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 13-APR-2004, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Cell migration-inducing and hyaluronan-binding protein; DE EC=3.2.1.35 {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; DE AltName: Full=Hyaluronan binding protein involved in hyaluronan depolymerization {ECO:0000303|PubMed:23509262}; DE Flags: Precursor; GN Name=CEMIP {ECO:0000312|HGNC:HGNC:29213}; GN Synonyms=HYBID {ECO:0000303|PubMed:23509262}, KIAA1199; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS CYS-187; HIS-187 AND TYR-783, AND RP VARIANTS ARG-783; ILE-1109 AND ALA-1169. RX PubMed=14577002; DOI=10.1007/s10038-003-0079-2; RA Abe S., Usami S., Nakamura Y.; RT "Mutations in the gene encoding KIAA1199 protein, an inner-ear protein RT expressed in Deiters' cells and the fibrocytes, as the cause of RT nonsyndromic hearing loss."; RL J. Hum. Genet. 48:564-570(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16157444; DOI=10.1016/j.canlet.2005.07.028; RA Michishita E., Garces G., Barrett J.C., Horikawa I.; RT "Upregulation of the KIAA1199 gene is associated with cellular mortality."; RL Cancer Lett. 239:71-77(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 349-1361 (ISOFORM 1), AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 558-1361. RG The European IMAGE consortium; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 862-1361. RX PubMed=11247670; DOI=10.1006/geno.2000.6466; RA Wines M.E., Lee L., Katari M.S., Zhang L., DeRossi C., Shi Y., Perkins S., RA Feldman M., McCombie W.R., Holdener B.C.; RT "Identification of mesoderm development (mesd) candidate genes by RT comparative mapping and genome sequence analysis."; RL Genomics 72:88-98(2001). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12471561; DOI=10.1086/345398; RA Abe S., Katagiri T., Saito-Hisaminato A., Usami S., Inoue Y., Tsunoda T., RA Nakamura Y.; RT "Identification of CRYM as a candidate responsible for nonsyndromic RT deafness, through cDNA microarray analysis of human cochlear and vestibular RT tissues."; RL Am. J. Hum. Genet. 72:73-82(2003). RN [9] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=19434458; DOI=10.1245/s10434-009-0469-6; RA Matsuzaki S., Tanaka F., Mimori K., Tahara K., Inoue H., Mori M.; RT "Clinicopathologic significance of KIAA1199 overexpression in human gastric RT cancer."; RL Ann. Surg. Oncol. 16:2042-2051(2009). RN [10] RP PROBABLE FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21772334; DOI=10.1038/bjc.2011.268; RA Birkenkamp-Demtroder K., Maghnouj A., Mansilla F., Thorsen K., RA Andersen C.L., Oster B., Hahn S., Orntoft T.F.; RT "Repression of KIAA1199 attenuates Wnt-signalling and decreases the RT proliferation of colon cancer cells."; RL Br. J. Cancer 105:552-561(2011). RN [11] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=22970280; DOI=10.1371/journal.pone.0044661; RA Kuscu C., Evensen N., Kim D., Hu Y.J., Zucker S., Cao J.; RT "Transcriptional and epigenetic regulation of KIAA1199 gene expression in RT human breast cancer."; RL PLoS ONE 7:E44661-E44661(2012). RN [12] RP FUNCTION IN CANCER, INTERACTION WITH HSPA5, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [13] RP INTERACTION WITH EPHA2 AND ITPR3, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [14] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, HYALURONIC ACID-BINDING, INTERACTION WITH CLATHRIN, SUBCELLULAR RP LOCATION, INDUCTION, AND CHARACTERIZATION OF VARIANTS CYS-187; HIS-187; RP ARG-783 AND ILE-1109. RX PubMed=23509262; DOI=10.1073/pnas.1215432110; RA Yoshida H., Nagaoka A., Kusaka-Kikushima A., Tobiishi M., Kawabata K., RA Sayo T., Sakai S., Sugiyama Y., Enomoto H., Okada Y., Inoue S.; RT "KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding RT protein involved in hyaluronan depolymerization."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5612-5617(2013). RN [15] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, GLYCOSYLATION, RP SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND SIGNAL SEQUENCE CLEAVAGE RP SITE. RX PubMed=24269685; DOI=10.1016/j.febslet.2013.11.017; RA Yoshida H., Nagaoka A., Nakamura S., Tobiishi M., Sugiyama Y., Inoue S.; RT "N-Terminal signal sequence is required for cellular trafficking and RT hyaluronan-depolymerization of KIAA1199."; RL FEBS Lett. 588:111-116(2014). CC -!- FUNCTION: Mediates depolymerization of hyaluronic acid (HA) via the CC cell membrane-associated clathrin-coated pit endocytic pathway. Binds CC to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to CC produce an intermediate-sized product, a process that may occur through CC rapid vesicle endocytosis and recycling without intracytoplasmic CC accumulation or digestion in lysosomes. Involved in hyaluronan CC catabolism in the dermis of the skin and arthritic synovium. Positively CC regulates epithelial-mesenchymal transition (EMT), and hence tumor cell CC growth, invasion and cancer dissemination. In collaboration with CC HSPA5/BIP, promotes cancer cell migration in a calcium and PKC- CC dependent manner. May be involved in hearing. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:24269685}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D- CC glucosamine and D-glucuronate residues in hyaluronate.; EC=3.2.1.35; CC Evidence={ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; CC -!- ACTIVITY REGULATION: Activity is up-regulated by histamine. CC {ECO:0000269|PubMed:23509262}. CC -!- SUBUNIT: Interacts with EPHA2 and ITPR3. Interacts with HSPA5/BIP; the CC interaction induces calcium leakage from the endoplasmic reticulum and CC cell migration. Interacts with clathrin heavy chain/CLTC. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23936024, CC ECO:0000269|PubMed:23990668}. CC -!- INTERACTION: CC Q8WUJ3; P53621: COPA; NbExp=2; IntAct=EBI-310606, EBI-356273; CC Q8WUJ3; Q93100: PHKB; NbExp=2; IntAct=EBI-310606, EBI-740559; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Endoplasmic reticulum. Cell CC membrane. Membrane, clathrin-coated pit. Secreted. Note=Retained in the CC endoplasmic reticulum (ER) in a HSPA5/BIP-dependent manner. Colocalized CC with clathrin heavy chain/CLTC in clathrin-coated vesicles. Strongly CC detected in the cytoplasm of breast carcinoma cells, whereas poorly CC detected in adjacent normal epithelial cells, stromal cells, or benign CC breast tissues. Localized in the nucleus and cytoplasm of colon CC adenocarcinomas. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WUJ3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WUJ3-2; Sequence=VSP_009814, VSP_009815; CC -!- TISSUE SPECIFICITY: Expressed in dermal and in synovial fibroblasts. CC Strongly expressed in gastric cancers compared with the paired normal CC tissues. Strongly expressed in both ductal carcinoma and invasive CC breast cancer cells compared with benign epithelial cells (at protein CC level). Strongly expressed in brain, placenta, prostate, breast, lung CC and testis. Expressed in fibroblasts, epithelial cells and cancer CC cells. In ear, it is specifically expressed in inner ear. Expressed in CC cochlea and vestibule tissues. Strongly expressed in gastric cancers CC compared with the paired normal tissues. Strongly expressed in colon CC adenocarcinomas compared with normal colonic mucosas. Strongly CC expressed in breast cancer as compared to normal breast tissue. CC {ECO:0000269|PubMed:10574462, ECO:0000269|PubMed:12471561, CC ECO:0000269|PubMed:16157444, ECO:0000269|PubMed:19434458, CC ECO:0000269|PubMed:21772334, ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:23990668}. CC -!- INDUCTION: Up-regulated by histamine. Up-regulated by the adapter CC protein complex 1 (AP-1) and NF-kappaB/RELA. Down-regulated by CC transforming growth factor TGFB1. {ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23509262}. CC -!- DOMAIN: The signal sequence is essential in mediating its proper CC translocation, hyaluronic acid (HA) degradation activity and secretion. CC -!- PTM: N-glycosylated; glycosylation is not necessary for HA-binding. CC {ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:24269685}. CC -!- SIMILARITY: Belongs to the CEMIP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB103330; BAD02451.1; -; mRNA. DR EMBL; CH471136; EAW99111.1; -; Genomic_DNA. DR EMBL; BC020256; AAH20256.1; -; mRNA. DR EMBL; AB033025; BAA86513.1; -; mRNA. DR EMBL; AL359061; CAB94391.1; -; mRNA. DR EMBL; AY007811; AAG41059.1; -; mRNA. DR CCDS; CCDS10315.1; -. [Q8WUJ3-1] DR RefSeq; NP_001280227.1; NM_001293298.2. [Q8WUJ3-1] DR RefSeq; NP_001280233.1; NM_001293304.2. [Q8WUJ3-1] DR RefSeq; NP_061159.1; NM_018689.3. [Q8WUJ3-1] DR RefSeq; XP_047288856.1; XM_047432900.1. [Q8WUJ3-1] DR RefSeq; XP_054234488.1; XM_054378513.1. [Q8WUJ3-1] DR AlphaFoldDB; Q8WUJ3; -. DR SMR; Q8WUJ3; -. DR BioGRID; 121452; 96. DR FunCoup; Q8WUJ3; 405. DR IntAct; Q8WUJ3; 15. DR MINT; Q8WUJ3; -. DR STRING; 9606.ENSP00000378177; -. DR CarbonylDB; Q8WUJ3; -. DR GlyCosmos; Q8WUJ3; 7 sites, No reported glycans. DR GlyGen; Q8WUJ3; 8 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q8WUJ3; -. DR PhosphoSitePlus; Q8WUJ3; -. DR BioMuta; CEMIP; -. DR DMDM; 46396475; -. DR jPOST; Q8WUJ3; -. DR MassIVE; Q8WUJ3; -. DR PaxDb; 9606-ENSP00000378177; -. DR PeptideAtlas; Q8WUJ3; -. DR ProteomicsDB; 74690; -. [Q8WUJ3-1] DR ProteomicsDB; 74691; -. [Q8WUJ3-2] DR Antibodypedia; 27890; 248 antibodies from 26 providers. DR DNASU; 57214; -. DR Ensembl; ENST00000220244.7; ENSP00000220244.3; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000356249.9; ENSP00000348583.5; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000394685.8; ENSP00000378177.3; ENSG00000103888.18. [Q8WUJ3-1] DR GeneID; 57214; -. DR KEGG; hsa:57214; -. DR MANE-Select; ENST00000394685.8; ENSP00000378177.3; NM_001293298.2; NP_001280227.1. DR UCSC; uc002bfw.2; human. [Q8WUJ3-1] DR AGR; HGNC:29213; -. DR ClinPGx; PA134967531; -. DR CTD; 57214; -. DR DisGeNET; 57214; -. DR GeneCards; CEMIP; -. DR HGNC; HGNC:29213; CEMIP. DR HPA; ENSG00000103888; Tissue enhanced (endometrium). DR MIM; 608366; gene. DR OpenTargets; ENSG00000103888; -. DR VEuPathDB; HostDB:ENSG00000103888; -. DR eggNOG; ENOG502QT0K; Eukaryota. DR GeneTree; ENSGT00940000153636; -. DR HOGENOM; CLU_005606_1_0_1; -. DR InParanoid; Q8WUJ3; -. DR OMA; YGRADED; -. DR OrthoDB; 120976at2759; -. DR PAN-GO; Q8WUJ3; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8WUJ3; -. DR PathwayCommons; Q8WUJ3; -. DR Reactome; R-HSA-2160916; Hyaluronan degradation. DR SignaLink; Q8WUJ3; -. DR Agora; ENSG00000103888; -. DR BioGRID-ORCS; 57214; 16 hits in 1143 CRISPR screens. DR ChiTaRS; CEMIP; human. DR GeneWiki; KIAA1199; -. DR GenomeRNAi; 57214; -. DR Pharos; Q8WUJ3; Tbio. DR PRO; PR:Q8WUJ3; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q8WUJ3; protein. DR Bgee; ENSG00000103888; Expressed in choroid plexus epithelium and 132 other cell types or tissues. DR ExpressionAtlas; Q8WUJ3; baseline and differential. DR GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:UniProtKB. DR GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell. DR GO; GO:0030665; C:clathrin-coated vesicle membrane; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0032050; F:clathrin heavy chain binding; IDA:UniProtKB. DR GO; GO:0046923; F:ER retention sequence binding; IDA:UniProtKB. DR GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB. DR GO; GO:0004415; F:hyalurononglucosaminidase activity; IMP:UniProtKB. DR GO; GO:0030214; P:hyaluronan catabolic process; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:1900020; P:positive regulation of protein kinase C activity; IDA:UniProtKB. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd13941; PANDER_like_KIAA1199; 1. DR CDD; cd13938; PANDER_like_TMEM2; 1. DR InterPro; IPR052252; CEMIP/CEMIP2. DR InterPro; IPR055401; CEMIP_beta-hel_dom. DR InterPro; IPR055400; CEMIP_X. DR InterPro; IPR019316; G8_domain. DR InterPro; IPR039477; ILEI/PANDER_dom. DR InterPro; IPR011050; Pectin_lyase_fold/virulence. DR InterPro; IPR039473; TMEM2_PANDER-like. DR InterPro; IPR025155; WxxW_domain. DR PANTHER; PTHR15535:SF15; CELL MIGRATION-INDUCING AND HYALURONAN-BINDING PROTEIN; 1. DR PANTHER; PTHR15535; TRANSMEMBRANE PROTEIN 2-RELATED; 1. DR Pfam; PF24606; CEMIP_beta-hel; 1. DR Pfam; PF24605; CEMIP_X; 1. DR Pfam; PF10162; G8; 1. DR Pfam; PF15711; ILEI; 2. DR Pfam; PF13330; Mucin2_WxxW; 2. DR SMART; SM01225; G8; 1. DR SUPFAM; SSF51126; Pectin lyase-like; 1. DR PROSITE; PS51484; G8; 1. DR PROSITE; PS52031; GG_LECTIN; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Coated pit; Cytoplasm; KW Endoplasmic reticulum; Glycoprotein; Glycosidase; Hyaluronic acid; KW Hydrolase; Lectin; Membrane; Nucleus; Proteomics identification; KW Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..30 FT /evidence="ECO:0000269|PubMed:24269685" FT CHAIN 31..1361 FT /note="Cell migration-inducing and hyaluronan-binding FT protein" FT /id="PRO_0000021538" FT DOMAIN 44..166 FT /note="G8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00817" FT DOMAIN 176..317 FT /note="GG-type lectin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REPEAT 572..594 FT /note="PbH1 1" FT REPEAT 595..617 FT /note="PbH1 2" FT REPEAT 719..741 FT /note="PbH1 3" FT REPEAT 798..819 FT /note="PbH1 4" FT DOMAIN 1227..1361 FT /note="GG-type lectin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REGION 295..591 FT /note="Necessary for its endoplasmic reticulum (ER) FT retention and interaction with HSPA5" FT /evidence="ECO:0000269|PubMed:23990668" FT CARBOHYD 119 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 165 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 312 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 370 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 420 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 889 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 921 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 978..992 FT /note="NWLVRHPDCINVPDW -> KWHSLASKAASGPSG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009814" FT VAR_SEQ 993..1361 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009815" FT VARIANT 187 FT /note="R -> C (in a family with non-syndromic hearing loss; FT reduces hyaluronic acid degradation activity; FT dbSNP:rs368854657)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018165" FT VARIANT 187 FT /note="R -> H (in two unrelated families with non-syndromic FT hearing loss; reduces hyaluronic acid (HA) degradation FT activity; dbSNP:rs144446375)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018166" FT VARIANT 783 FT /note="H -> R (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs12441101)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018167" FT VARIANT 783 FT /note="H -> Y (in a sporadic case of non-syndromic hearing FT loss; dbSNP:rs996035812)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018168" FT VARIANT 1109 FT /note="V -> I (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs751807711)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018169" FT VARIANT 1169 FT /note="P -> A (in dbSNP:rs16972583)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018170" FT CONFLICT 558..564 FT /note="HFHLAGD -> TRPPTRP (in Ref. 6; CAB94391)" FT /evidence="ECO:0000305" FT CONFLICT 862 FT /note="H -> T (in Ref. 7; AAG41059)" FT /evidence="ECO:0000305" SQ SEQUENCE 1361 AA; 152998 MW; 40CDFFB84F99516C CRC64; MGAAGRQDFL FKAMLTISWL TLTCFPGATS TVAAGCPDQS PELQPWNPGH DQDHHVHIGQ GKTLLLTSSA TVYSIHISEG GKLVIKDHDE PIVLRTRHIL IDNGGELHAG SALCPFQGNF TIILYGRADE GIQPDPYYGL KYIGVGKGGA LELHGQKKLS WTFLNKTLHP GGMAEGGYFF ERSWGHRGVI VHVIDPKSGT VIHSDRFDTY RSKKESERLV QYLNAVPDGR ILSVAVNDEG SRNLDDMARK AMTKLGSKHF LHLGFRHPWS FLTVKGNPSS SVEDHIEYHG HRGSAAARVF KLFQTEHGEY FNVSLSSEWV QDVEWTEWFD HDKVSQTKGG EKISDLWKAH PGKICNRPID IQATTMDGVN LSTEVVYKKG QDYRFACYDR GRACRSYRVR FLCGKPVRPK LTVTIDTNVN STILNLEDNV QSWKPGDTLV IASTDYSMYQ AEEFQVLPCR SCAPNQVKVA GKPMYLHIGE EIDGVDMRAE VGLLSRNIIV MGEMEDKCYP YRNHICNFFD FDTFGGHIKF ALGFKAAHLE GTELKHMGQQ LVGQYPIHFH LAGDVDERGG YDPPTYIRDL SIHHTFSRCV TVHGSNGLLI KDVVGYNSLG HCFFTEDGPE ERNTFDHCLG LLVKSGTLLP SDRDSKMCKM ITEDSYPGYI PKPRQDCNAV STFWMANPNN NLINCAAAGS EETGFWFIFH HVPTGPSVGM YSPGYSEHIP LGKFYNNRAH SNYRAGMIID NGVKTTEASA KDKRPFLSII SARYSPHQDA DPLKPREPAI IRHFIAYKNQ DHGAWLRGGD VWLDSCRFAD NGIGLTLASG GTFPYDDGSK QEIKNSLFVG ESGNVGTEMM DNRIWGPGGL DHSGRTLPIG QNFPIRGIQL YDGPINIQNC TFRKFVALEG RHTSALAFRL NNAWQSCPHN NVTGIAFEDV PITSRVFFGE PGPWFNQLDM DGDKTSVFHD VDGSVSEYPG SYLTKNDNWL VRHPDCINVP DWRGAICSGC YAQMYIQAYK TSNLRMKIIK NDFPSHPLYL EGALTRSTHY QQYQPVVTLQ KGYTIHWDQT APAELAIWLI NFNKGDWIRV GLCYPRGTTF SILSDVHNRL LKQTSKTGVF VRTLQMDKVE QSYPGRSHYY WDEDSGLLFL KLKAQNEREK FAFCSMKGCE RIKIKALIPK NAGVSDCTAT AYPKFTERAV VDVPMPKKLF GSQLKTKDHF LEVKMESSKQ HFFHLWNDFA YIEVDGKKYP SSEDGIQVVV IDGNQGRVVS HTSFRNSILQ GIPWQLFNYV ATIPDNSIVL MASKGRYVSR GPWTRVLEKL GADRGLKLKE QMAFVGFKGS FRPIWVTLDT EDHKAKIFQV VPIPVVKKKK L // ID CHK2_HUMAN Reviewed; 543 AA. AC O96017; A8K3Y9; B7ZBF3; B7ZBF4; B7ZBF5; Q6QA03; Q6QA04; Q6QA05; Q6QA06; AC Q6QA07; Q6QA08; Q6QA10; Q6QA11; Q6QA12; Q6QA13; Q9HBS5; Q9HCQ8; Q9UGF0; AC Q9UGF1; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 28-JAN-2026, entry version 256. DE RecName: Full=Serine/threonine-protein kinase Chk2 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:37943659}; DE AltName: Full=CHK2 checkpoint homolog; DE AltName: Full=Cds1 homolog; DE Short=Hucds1; DE Short=hCds1; DE AltName: Full=Checkpoint kinase 2; GN Name=CHEK2 {ECO:0000312|HGNC:HGNC:16627}; Synonyms=CDS1, CHK2, RAD53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN PHOSPHORYLATION OF RP CDC25C, AND MUTAGENESIS OF ASP-347. RX PubMed=9836640; DOI=10.1126/science.282.5395.1893; RA Matsuoka S., Huang M., Elledge S.J.; RT "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase."; RL Science 282:1893-1897(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN MITOSIS. RX PubMed=9889122; DOI=10.1016/s0960-9822(99)80041-4; RA Blasina A., van de Weyer I., Laus M.C., Luyten W.H.M.L., Parker A.E., RA McGowan C.H.; RT "A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 RT phosphatase."; RL Curr. Biol. 9:1-10(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION IN PHOSPHORYLATION OF RP CDC25C. RX PubMed=10097108; DOI=10.1073/pnas.96.7.3745; RA Brown A.L., Lee C.-H., Schwarz J.K., Mitiku N., Piwnica-Worms H., RA Chung J.H.; RT "A human Cds1-related kinase that functions downstream of ATM protein in RT the cellular response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3745-3750(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6; 7; 8; 9; 10; 11 AND RP 12), AND SUBCELLULAR LOCATION. RC TISSUE=Mammary gland; RX PubMed=15361853; DOI=10.1038/sj.onc.1207928; RA Staalesen V., Falck J., Geisler S., Bartkova J., Boerresen-Dale A.-L., RA Lukas J., Lillehaug J.R., Bartek J., Lonning P.E.; RT "Alternative splicing and mutation status of CHEK2 in stage III breast RT cancer."; RL Oncogene 23:8535-8544(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9). RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Colon carcinoma; RA Shao R.-G., Zhang H., Yu Q., Pommier Y.; RT "Chk2/HuCds1 cell cycle checkpoint protein kinase from human colon RT carcinoma HT29 cells: regulation by autophosphorylation and DNA-dependent RT protein kinase and inhibition by cell cycle regulatory drugs."; RL Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12). RC TISSUE=T-cell; RA Ogawa A., Okabe-Nakamura A.; RT "An alternative spliced Chk2."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 13). RX PubMed=15498874; DOI=10.1073/pnas.0404089101; RA Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X., RA Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X., RA Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.; RT "Large-scale cDNA transfection screening for genes related to cancer RT development and progression."; RL Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-85; THR-157; MET-436; RP LYS-446; ILE-447; SER-448; LYS-501 AND VAL-512. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF BRCA1, AND INTERACTION WITH BRCA1. RX PubMed=10724175; DOI=10.1038/35004614; RA Lee J.S., Collins K.M., Brown A.L., Lee C.H., Chung J.H.; RT "hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage RT response."; RL Nature 404:201-204(2000). RN [15] RP PHOSPHORYLATION AT THR-68 BY ATM. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [16] RP PHOSPHORYLATION AT THR-383 AND THR-387, AND MUTAGENESIS OF THR-383 AND RP THR-387. RX PubMed=11390408; DOI=10.1074/jbc.m104414200; RA Lee C.H., Chung J.H.; RT "The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation RT events on hCds1 that is induced by ionizing radiation."; RL J. Biol. Chem. 276:30537-30541(2001). RN [17] RP FUNCTION IN INTRA S-PHASE CHECKPOINT, FUNCTION IN PHOSPHORYLATION OF RP CDC25A, INTERACTION WITH CDC25A, MUTAGENESIS OF ASP-347, CHARACTERIZATION RP OF VARIANT COLON CANCER TRP-145, AND CHARACTERIZATION OF VARIANT THR-157. RX PubMed=11298456; DOI=10.1038/35071124; RA Falck J., Mailand N., Syljuaasen R.G., Bartek J., Lukas J.; RT "The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA RT synthesis."; RL Nature 410:842-847(2001). RN [18] RP INVOLVEMENT IN SUSCEPTIBILITY TO BC. RX PubMed=12094328; DOI=10.1086/341943; RA Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., RA Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., RA Holli K., Blomqvist C., Bartek J., Kallioniemi O.P., Nevanlinna H.; RT "A CHEK2 genetic variant contributing to a substantial fraction of familial RT breast cancer."; RL Am. J. Hum. Genet. 71:432-438(2002). RN [19] RP HOMODIMERIZATION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF THR-68. RX PubMed=11901158; DOI=10.1074/jbc.m200822200; RA Ahn J.Y., Li X., Davis H.L., Canman C.E.; RT "Phosphorylation of threonine 68 promotes oligomerization and RT autophosphorylation of the Chk2 protein kinase via the forkhead-associated RT domain."; RL J. Biol. Chem. 277:19389-19395(2002). RN [20] RP FUNCTION IN APOPTOSIS, FUNCTION IN PHOSPHORYLATION OF PML, AND SUBCELLULAR RP LOCATION. RX PubMed=12402044; DOI=10.1038/ncb869; RA Yang S., Kuo C., Bisi J.E., Kim M.K.; RT "PML-dependent apoptosis after DNA damage is regulated by the checkpoint RT kinase hCds1/Chk2."; RL Nat. Cell Biol. 4:865-870(2002). RN [21] RP INTERACTION WITH TP53BP1. RX PubMed=12364621; DOI=10.1126/science.1076182; RA Wang B., Matsuoka S., Carpenter P.B., Elledge S.J.; RT "53BP1, a mediator of the DNA damage checkpoint."; RL Science 298:1435-1438(2002). RN [22] RP FUNCTION, INTERACTION WITH PML AND TP53, AND SUBCELLULAR LOCATION. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [23] RP FUNCTION IN TRANSCRIPTION REGULATION, FUNCTION IN APOPTOSIS, AND FUNCTION RP IN PHOSPHORYLATION OF E2F1. RX PubMed=12717439; DOI=10.1038/ncb974; RA Stevens C., Smith L., La Thangue N.B.; RT "Chk2 activates E2F-1 in response to DNA damage."; RL Nat. Cell Biol. 5:401-409(2003). RN [24] RP FUNCTION IN DNA DAMAGE RESPONSE, AND INTERACTION WITH MDC1. RX PubMed=12607004; DOI=10.1038/nature01447; RA Lou Z., Minter-Dykhouse K., Wu X., Chen J.; RT "MDC1 is coupled to activated CHK2 in mammalian DNA damage response RT pathways."; RL Nature 421:957-961(2003). RN [25] RP REVIEW ON PHOSPHORYLATION OF TP53 AND OTHER SUBSTRATES. RX PubMed=15279791; DOI=10.1016/j.dnarep.2004.03.033; RA Ahn J., Urist M., Prives C.; RT "The Chk2 protein kinase."; RL DNA Repair 3:1039-1047(2004). RN [26] RP ACTIVITY REGULATION, PHOSPHORYLATION AT THR-68 BY MAP3K20, AND MUTAGENESIS RP OF THR-68 AND ASP-368. RX PubMed=15342622; DOI=10.1074/jbc.m409961200; RA Tosti E., Waldbaum L., Warshaw G., Gross E.A., Ruggieri R.; RT "The stress kinase MRK contributes to regulation of DNA damage checkpoints RT through a p38gamma-independent pathway."; RL J. Biol. Chem. 279:47652-47660(2004). RN [27] RP FUNCTION IN TP53 ACTIVATION, AND FUNCTION IN PHOSPHORYLATION OF MDM4. RX PubMed=16163388; DOI=10.1038/sj.emboj.7600812; RA Chen L., Gilkes D.M., Pan Y., Lane W.S., Chen J.; RT "ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 RT activation after DNA damage."; RL EMBO J. 24:3411-3422(2005). RN [28] RP PHOSPHORYLATION AT THR-68, AND DEPHOSPHORYLATION AT THR-68 BY PPM1D. RX PubMed=16311512; DOI=10.1038/sj.cdd.4401801; RA Fujimoto H., Onishi N., Kato N., Takekawa M., Xu X.Z., Kosugi A., Kondo T., RA Imamura M., Oishi I., Yoda A., Minami Y.; RT "Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 RT phosphatase."; RL Cell Death Differ. 13:1170-1180(2006). RN [29] RP PHOSPHORYLATION AT SER-62; THR-68 AND SER-73, AND MUTAGENESIS OF SER-73. RX PubMed=16481012; DOI=10.1016/j.mrfmmm.2005.12.002; RA Bahassi el M., Myer D.L., McKenney R.J., Hennigan R.F., Stambrook P.J.; RT "Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its RT full activation by ATM and a downstream checkpoint in response to DNA RT damage."; RL Mutat. Res. 596:166-176(2006). RN [30] RP FUNCTION IN PHOSPHORYLATION OF RB1. RX PubMed=17380128; DOI=10.1038/sj.emboj.7601652; RA Inoue Y., Kitagawa M., Taya Y.; RT "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB RT and E2F-1 after DNA damage."; RL EMBO J. 26:2083-2093(2007). RN [31] RP FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-456, UBIQUITINATION, AND RP MUTAGENESIS OF SER-456. RX PubMed=17715138; DOI=10.1074/jbc.m704642200; RA Kass E.M., Ahn J., Tanaka T., Freed-Pastor W.A., Keezer S., Prives C.; RT "Stability of checkpoint kinase 2 is regulated via phosphorylation at RT serine 456."; RL J. Biol. Chem. 282:30311-30321(2007). RN [32] RP FUNCTION IN DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION OF FOXM1. RX PubMed=17101782; DOI=10.1128/mcb.01068-06; RA Tan Y., Raychaudhuri P., Costa R.H.; RT "Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate RT expression of DNA repair genes."; RL Mol. Cell. Biol. 27:1007-1016(2007). RN [33] RP FUNCTION IN PHOSPHORYLATION OF NEK6. RX PubMed=18728393; DOI=10.4161/cc.7.17.6551; RA Lee M.Y., Kim H.J., Kim M.A., Jee H.J., Kim A.J., Bae Y.S., Park J.I., RA Chung J.H., Yun J.; RT "Nek6 is involved in G2/M phase cell cycle arrest through DNA damage- RT induced phosphorylation."; RL Cell Cycle 7:2705-2709(2008). RN [34] RP FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-379, MUTAGENESIS OF SER-379, RP UBIQUITINATION, AND INTERACTION WITH CUL1. RX PubMed=18644861; DOI=10.1128/mcb.00821-08; RA Lovly C.M., Yan L., Ryan C.E., Takada S., Piwnica-Worms H.; RT "Regulation of Chk2 ubiquitination and signaling through RT autophosphorylation of serine 379."; RL Mol. Cell. Biol. 28:5874-5885(2008). RN [35] RP FUNCTION IN RAD51-MEDIATED DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION OF RP BRCA2. RX PubMed=18317453; DOI=10.1038/onc.2008.17; RA Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E., RA Stambrook P.J.; RT "The checkpoint kinases Chk1 and Chk2 regulate the functional associations RT between hBRCA2 and Rad51 in response to DNA damage."; RL Oncogene 27:3977-3985(2008). RN [36] RP PHOSPHORYLATION BY PLK4. RX PubMed=19164942; DOI=10.4161/cc.8.2.7355; RA Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.; RT "Polo-like kinase 4 phosphorylates Chk2."; RL Cell Cycle 8:327-329(2009). RN [37] RP FUNCTION IN PHOSPHORYLATION OF BRCA1, AND FUNCTION IN CHROMOSOMAL RP STABILITY. RX PubMed=20364141; DOI=10.1038/ncb2051; RA Stolz A., Ertych N., Kienitz A., Vogel C., Schneider V., Fritz B., RA Jacob R., Dittmar G., Weichert W., Petersen I., Bastians H.; RT "The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in RT human somatic cells."; RL Nat. Cell Biol. 12:492-499(2010). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [39] RP INVOLVEMENT IN SUSCEPTIBILITY TO BC, VARIANTS CYS-180 AND TYR-371, AND RP CHARACTERIZATION OF VARIANT TYR-371. RX PubMed=21618645; DOI=10.1002/humu.21538; RA Liu Y., Liao J., Xu Y., Chen W., Liu D., Ouyang T., Li J., Wang T., Fan Z., RA Fan T., Lin B., Xu X., Xie Y.; RT "A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk RT in Chinese women."; RL Hum. Mutat. 32:1000-1003(2011). RN [40] RP UBIQUITINATION BY RNF8. RX PubMed=22266820; DOI=10.1038/nsmb.2211; RA Feng L., Chen J.; RT "The E3 ligase RNF8 regulates KU80 removal and NHEJ repair."; RL Nat. Struct. Mol. Biol. 19:201-206(2012). RN [41] RP FUNCTION, AND INTERACTION WITH CCAR2 AND SIRT1. RX PubMed=25361978; DOI=10.1093/nar/gku1065; RA Magni M., Ruscica V., Buscemi G., Kim J.E., Nachimuthu B.T., Fontanella E., RA Delia D., Zannini L.; RT "Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced RT apoptosis."; RL Nucleic Acids Res. 42:13150-13160(2014). RN [42] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=32001251; DOI=10.1016/j.jmb.2020.01.021; RA Hembram D.S.S., Negi H., Biswas P., Tripathi V., Bhushan L., Shet D., RA Kumar V., Das R.; RT "The Viral SUMO-Targeted Ubiquitin Ligase ICP0 is Phosphorylated and RT Activated by Host Kinase Chk2."; RL J. Mol. Biol. 432:1952-1977(2020). RN [43] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37943659; DOI=10.1016/j.celrep.2023.113402; RA Liu J., Lu S., Zheng L., Guo Q., Cao L., Xiao Y., Chen D., Zou Y., Liu X., RA Deng C., Zhang S., Yang R., Wang Y., Zhang Y., Zhang N., Song X., Xing C., RA Wang Z., Cao L.; RT "ATM-CHK2-TRIM32 axis regulates ATG7 ubiquitination to initiate autophagy RT under oxidative stress."; RL Cell Rep. 42:113402-113402(2023). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 64-212. RX PubMed=12049740; DOI=10.1016/s1097-2765(02)00527-0; RA Li J., Williams B.L., Haire L.F., Goldberg M., Wilker E., Durocher D., RA Yaffe M.B., Jackson S.P., Smerdon S.J.; RT "Structural and functional versatility of the FHA domain in DNA-damage RT signaling by the tumor suppressor kinase Chk2."; RL Mol. Cell 9:1045-1054(2002). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 210-531 IN COMPLEX WITH ADP AND RP INHIBITOR, HOMODIMERIZATION, AND AUTOPHOSPHORYLATION. RX PubMed=16794575; DOI=10.1038/sj.emboj.7601209; RA Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., Garrett M.D., RA Mittnacht S., Pearl L.H.; RT "Trans-activation of the DNA-damage signalling protein kinase Chk2 by T- RT loop exchange."; RL EMBO J. 25:3179-3190(2006). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 84-502 OF HOMODIMER. RX PubMed=19782031; DOI=10.1016/j.molcel.2009.09.007; RA Cai Z., Chehab N.H., Pavletich N.P.; RT "Structure and activation mechanism of the CHK2 DNA damage checkpoint RT kinase."; RL Mol. Cell 35:818-829(2009). RN [47] RP INTERACTION WITH CDKN2AIP. RX PubMed=24825908; DOI=10.1074/jbc.m114.547208; RA Cheung C.T., Singh R., Kalra R.S., Kaul S.C., Wadhwa R.; RT "Collaborator of ARF (CARF) regulates proliferative fate of human cells by RT dose-dependent regulation of DNA damage signaling."; RL J. Biol. Chem. 289:18258-18269(2014). RN [48] RP VARIANT THR-157, AND VARIANT COLON CANCER TRP-145. RX PubMed=10617473; DOI=10.1126/science.286.5449.2528; RA Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C.R., RA Shannon K.E., Lubratovich M., Versalis S.J., Isselbacher K.J., RA Fraumeni J.F. Jr., Birch J.M., Li F.P., Garber J.E., Haber D.A.; RT "Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome."; RL Science 286:2528-2531(1999). RN [49] RP VARIANT THR-157. RX PubMed=11461078; DOI=10.1054/bjoc.2001.1858; RA Allinen M., Huusko P., Maentyniemi S., Launonen V., Winqvist R.; RT "Mutation analysis of the CHK2 gene in families with hereditary breast RT cancer."; RL Br. J. Cancer 85:209-212(2001). RN [50] RP VARIANT TPDS4 TRP-145. RX PubMed=11719428; RA Lee S.B., Kim S.H., Bell D.W., Wahrer D.C.R., Schiripo T.A., Jorczak M.M., RA Sgroi D.C., Garber J.E., Li F.P., Nichols K.E., Varley J.M., Godwin A.K., RA Shannon K.M., Harlow E., Haber D.A.; RT "Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni RT Syndrome."; RL Cancer Res. 61:8062-8067(2001). RN [51] RP VARIANT MULTIPLE CANCERS LYS-59. RX PubMed=12052256; DOI=10.1186/bcr435; RA Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Hafsteinsdottir S.H., RA Ragnarsson G., Barkardottir R.B., Arason A., Egilsson V., RA Bergthorsson J.T.; RT "Mutation analysis of the CHK2 gene in breast carcinoma and other RT cancers."; RL Breast Cancer Res. 4:R4-R4(2002). RN [52] RP VARIANT BC GLY-117, AND VARIANTS GLN-137 AND HIS-180. RX PubMed=12454775; DOI=10.1038/sj.bjc.6600637; RA Sodha N., Bullock S., Taylor R., Mitchell G., Guertl-Lackner B., RA Williams R.D., Bevan S., Bishop K., McGuire S., Houlston R.S., Eeles R.A.; RT "CHEK2 variants in susceptibility to breast cancer and evidence of RT retention of the wild type allele in tumours."; RL Br. J. Cancer 87:1445-1448(2002). RN [53] RP VARIANTS SER-17 AND LEU-85, AND INVOLVEMENT IN OSRC. RX PubMed=11746983; DOI=10.1002/gcc.1207; RA Miller C.W., Ikezoe T., Krug U., Hofmann W.K., Tavor S., Vegesna V., RA Tsukasaki K., Takeuchi S., Koeffler H.P.; RT "Mutations of the CHK2 gene are found in some osteosarcomas, but are rare RT in breast, lung, and ovarian tumors."; RL Genes Chromosomes Cancer 33:17-21(2002). RN [54] RP VARIANTS PROSTATE CANCER LYS-64; PRO-145; ARG-167; CYS-180; HIS-180; RP CYS-181; HIS-181; LYS-239; PHE-251; HIS-318; PRO-323; CYS-327 AND LYS-476, RP AND VARIANT THR-157. RX PubMed=12533788; DOI=10.1086/346094; RA Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., RA Qian C., Marks A.F., Slager S.L., Peterson B.J., Smith D.I., Cheville J.C., RA Blute M.L., Jacobsen S.J., Schaid D.J., Tindall D.J., Thibodeau S.N., RA Liu W.; RT "Mutations in CHEK2 associated with prostate cancer risk."; RL Am. J. Hum. Genet. 72:270-280(2003). RN [55] RP VARIANT BC GLY-117, AND VARIANTS TRP-145 AND THR-157. RX PubMed=12610780; DOI=10.1086/373965; RA Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M., RA Evans D.G., Eccles D., Meijers C., Lohman F., Klijn J., RA van den Ouweland A., Brady A., Cole T., Collins A., Cox H., Donaldson A., RA Eeles R., Evans G., Gregory H., Gray J., Houlston R., Lalloo F., RA Lucassen A., Mackay J., Mitchell G., Morrison P., Murday V., Narod S., RA Patterson J., Peretz T., Phelan C.M., Rogers M., Schofield A., Tonin P., RA Weber B., Weber W., Futreal P.A., Nathanson K.L., Weber B.L., Easton D.F., RA Stratton M.R., Rahman N.; RT "Variants in CHEK2 other than 1100delC do not make a major contribution to RT breast cancer susceptibility."; RL Am. J. Hum. Genet. 72:1023-1028(2003). RN [56] RP VARIANT THR-157. RX PubMed=14612911; DOI=10.1038/sj.bjc.6601425; RA Seppaelae E.H., Ikonen T., Mononen N., Autio V., Roekman A., RA Matikainen M.P., Tammela T.L.J., Schleutker J.; RT "CHEK2 variants associate with hereditary prostate cancer."; RL Br. J. Cancer 89:1966-1970(2003). RN [57] RP VARIANT THR-157. RX PubMed=15492928; DOI=10.1086/426403; RA Cybulski C., Gorski B., Huzarski T., Masojc B., Mierzejewski M., RA Debniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J., RA Zlowocka E., Lenner M., Grabowska E., Nej K., Castaneda J., Medrek K., RA Szymanska A., Szymanska J., Kurzawski G., Suchy J., Oszurek O., Witek A., RA Narod S.A., Lubinski J.; RT "CHEK2 is a multiorgan cancer susceptibility gene."; RL Am. J. Hum. Genet. 75:1131-1135(2004). RN [58] RP VARIANTS TRP-145 AND THR-157. RX PubMed=15535844; DOI=10.1186/bcr933; RA Friedrichsen D.M., Malone K.E., Doody D.R., Daling J.R., Ostrander E.A.; RT "Frequency of CHEK2 mutations in a population based, case-control study of RT breast cancer in young women."; RL Breast Cancer Res. 6:R629-R635(2004). RN [59] RP VARIANT THR-157. RX PubMed=15087378; DOI=10.1158/0008-5472.can-04-0341; RA Cybulski C., Huzarski T., Gorski B., Masojc B., Mierzejewski M., RA Debniak T., Gliniewicz B., Matyjasik J., Zlowocka E., Kurzawski G., RA Sikorski A., Posmyk M., Szwiec M., Czajka R., Narod S.A., Lubinski J.; RT "A novel founder CHEK2 mutation is associated with increased prostate RT cancer risk."; RL Cancer Res. 64:2677-2679(2004). RN [60] RP VARIANT THR-157. RX PubMed=15095295; DOI=10.1002/ijc.20073; RA Dufault M.R., Betz B., Wappenschmidt B., Hofmann W., Bandick K., Golla A., RA Pietschmann A., Nestle-Kraemling C., Rhiem K., Huettner C., von Lindern C., RA Dall P., Kiechle M., Untch M., Jonat W., Meindl A., Scherneck S., RA Niederacher D., Schmutzler R.K., Arnold N.; RT "Limited relevance of the CHEK2 gene in hereditary breast cancer."; RL Int. J. Cancer 110:320-325(2004). RN [61] RP VARIANT THR-157. RX PubMed=15239132; DOI=10.1002/ijc.20299; RA Kilpivaara O., Vahteristo P., Falck J., Syrjaekoski K., Eerola H., RA Easton D., Bartkova J., Lukas J., Heikkilae P., Aittomaeki K., Holli K., RA Blomqvist C., Kallioniemi O.-P., Bartek J., Nevanlinna H.; RT "CHEK2 variant I157T may be associated with increased breast cancer risk."; RL Int. J. Cancer 111:543-547(2004). RN [62] RP VARIANTS LEU-85 AND PHE-428. RX PubMed=15649950; DOI=10.1093/hmg/ddi052; RA Shaag A., Walsh T., Renbaum P., Kirchhoff T., Nafa K., Shiovitz S., RA Mandell J.B., Welcsh P., Lee M.K., Ellis N., Offit K., Levy-Lahad E., RA King M.-C.; RT "Functional and genomic approaches reveal an ancient CHEK2 allele RT associated with breast cancer in the Ashkenazi Jewish population."; RL Hum. Mol. Genet. 14:555-563(2005). RN [63] RP VARIANT THR-157. RX PubMed=15810020; DOI=10.1002/ijc.21022; RA Bogdanova N., Enbetaen-Dubrowinskaja N., Feshchenko S., Lazjuk G.I., RA Rogov Y.I., Dammann O., Bremer M., Karstens J.H., Sohn C., Doerk T.; RT "Association of two mutations in the CHEK2 gene with breast cancer."; RL Int. J. Cancer 116:263-266(2005). RN [64] RP VARIANT BC GLY-117, AND VARIANTS GLN-137; TRP-145; THR-157 AND HIS-180. RX PubMed=15818573; DOI=10.1002/path.1764; RA van Puijenbroek M., van Asperen C.J., van Mil A., Devilee P., van Wezel T., RA Morreau H.; RT "Homozygosity for a CHEK2*1100delC mutation identified in familial RT colorectal cancer does not lead to a severe clinical phenotype."; RL J. Pathol. 206:198-204(2005). RN [65] RP VARIANT BC CYS-390, CHARACTERIZATION OF VARIANT BC CYS-390, AND FUNCTION. RX PubMed=25619829; DOI=10.1038/onc.2014.443; RA Wang N., Ding H., Liu C., Li X., Wei L., Yu J., Liu M., Ying M., Gao W., RA Jiang H., Wang Y.; RT "A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese RT breast cancer patients impairs its activity and is associated with RT increased breast cancer risk."; RL Oncogene 34:5198-5205(2015). CC -!- FUNCTION: Serine/threonine-protein kinase which is required for CC checkpoint-mediated cell cycle arrest, activation of DNA repair and CC apoptosis in response to the presence of DNA double-strand breaks. May CC also negatively regulate cell cycle progression during unperturbed cell CC cycles. Following activation, phosphorylates numerous effectors CC preferentially at the consensus sequence [L-X-R-X-X-S/T] CC (PubMed:37943659). Regulates cell cycle checkpoint arrest through CC phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their CC activity. Inhibition of CDC25 phosphatase activity leads to increased CC inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks CC cell cycle progression. May also phosphorylate NEK6 which is involved CC in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation CC of BRCA2, enhancing the association of RAD51 with chromatin which CC promotes DNA repair by homologous recombination. Also stimulates the CC transcription of genes involved in DNA repair (including BRCA2) through CC the phosphorylation and activation of the transcription factor FOXM1. CC Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and CC PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate CC inhibition by MDM2, leading to accumulation of active p53/TP53. CC Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also CC controls the transcription of pro-apoptotic genes through CC phosphorylation of the transcription factor E2F1. Tumor suppressor, it CC may also have a DNA damage-independent function in mitotic spindle CC assembly by phosphorylating BRCA1. Its absence may be a cause of the CC chromosomal instability observed in some cancer cells. Promotes the CC CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 CC inhibition (PubMed:25361978). Under oxidative stress, promotes ATG7 CC ubiquitination by phosphorylating the E3 ubiquitin ligase TRIM32 at CC 'Ser-55' leading to positive regulation of the autophagosme assembly CC (PubMed:37943659). {ECO:0000250|UniProtKB:Q9Z265, CC ECO:0000269|PubMed:10097108, ECO:0000269|PubMed:10724175, CC ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12402044, CC ECO:0000269|PubMed:12607004, ECO:0000269|PubMed:12717439, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:16163388, CC ECO:0000269|PubMed:17101782, ECO:0000269|PubMed:17380128, CC ECO:0000269|PubMed:17715138, ECO:0000269|PubMed:18317453, CC ECO:0000269|PubMed:18644861, ECO:0000269|PubMed:18728393, CC ECO:0000269|PubMed:20364141, ECO:0000269|PubMed:25361978, CC ECO:0000269|PubMed:25619829, ECO:0000269|PubMed:37943659, CC ECO:0000269|PubMed:9836640, ECO:0000269|PubMed:9889122}. CC -!- FUNCTION: (Microbial infection) Phosphorylates herpes simplex virus CC 1/HHV-1 protein ICP0 and thus activates its SUMO-targeted ubiquitin CC ligase activity. {ECO:0000269|PubMed:32001251}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:37943659}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Activated through phosphorylation at Thr-68 by ATM CC in response to DNA double-strand breaks. Activation is modulated by CC several mediators including MDC1 and TP53BP1. Induces homodimerization CC with exchange of the T-loop/activation segment between protomers and CC transphosphorylation of the protomers. The autophosphorylated kinase CC dimer is fully active. Negatively regulated by PPM1D through CC dephosphorylation of Thr-68. {ECO:0000269|PubMed:15342622}. CC -!- SUBUNIT: Homodimer. Homodimerization is part of the activation process CC but the dimer may dissociate following activation. Interacts with PML. CC Interacts with TP53. Interacts with RB1; phosphorylates RB1. Interacts CC with BRCA1. Interacts (phosphorylated at Thr-68) with MDC1; requires CC ATM-mediated phosphorylation of CHEK2. Interacts with TP53BP1; CC modulates CHEK2 phosphorylation at Thr-68 in response to ionizing CC radiation. Interacts with CDC25A; phosphorylates CDC25A and mediates CC its degradation in response to ionizing radiation. Interacts with CUL1; CC mediates CHEK2 ubiquitination and regulation. Interacts with CDKN2AIP. CC Interacts (via protein kinase domain) with CCAR2 (via N-terminus). CC Interacts with SIRT1. {ECO:0000269|PubMed:10724175, CC ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12364621, CC ECO:0000269|PubMed:12607004, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:16794575, ECO:0000269|PubMed:18644861, CC ECO:0000269|PubMed:24825908, ECO:0000269|PubMed:25361978}. CC -!- INTERACTION: CC O96017; Q9NY61: AATF; NbExp=4; IntAct=EBI-1180783, EBI-372428; CC O96017; P30304: CDC25A; NbExp=2; IntAct=EBI-1180783, EBI-747671; CC O96017; Q9UQ88-1: CDK11A; NbExp=2; IntAct=EBI-1180783, EBI-11579223; CC O96017; O96017: CHEK2; NbExp=6; IntAct=EBI-1180783, EBI-1180783; CC O96017; Q9Y248: GINS2; NbExp=2; IntAct=EBI-1180783, EBI-747491; CC O96017; Q13007: IL24; NbExp=3; IntAct=EBI-1180783, EBI-3915542; CC O96017; P52292: KPNA2; NbExp=7; IntAct=EBI-1180783, EBI-349938; CC O96017; Q96KN1: LRATD2; NbExp=3; IntAct=EBI-1180783, EBI-9057780; CC O96017; Q00987: MDM2; NbExp=6; IntAct=EBI-1180783, EBI-389668; CC O96017; P56645: PER3; NbExp=2; IntAct=EBI-1180783, EBI-2827813; CC O96017; P53350: PLK1; NbExp=7; IntAct=EBI-1180783, EBI-476768; CC O96017; O15355: PPM1G; NbExp=2; IntAct=EBI-1180783, EBI-725702; CC O96017; Q15172: PPP2R5A; NbExp=3; IntAct=EBI-1180783, EBI-641666; CC O96017; Q15173: PPP2R5B; NbExp=2; IntAct=EBI-1180783, EBI-1369497; CC O96017; Q13362-1: PPP2R5C; NbExp=3; IntAct=EBI-1180783, EBI-1266170; CC O96017; Q13362-2: PPP2R5C; NbExp=2; IntAct=EBI-1180783, EBI-1266173; CC O96017; Q13362-3: PPP2R5C; NbExp=4; IntAct=EBI-1180783, EBI-1266176; CC O96017; Q16537: PPP2R5E; NbExp=3; IntAct=EBI-1180783, EBI-968374; CC O96017; P06400: RB1; NbExp=3; IntAct=EBI-1180783, EBI-491274; CC O96017; Q5VTR2: RNF20; NbExp=3; IntAct=EBI-1180783, EBI-2372238; CC O96017; P04637: TP53; NbExp=3; IntAct=EBI-1180783, EBI-366083; CC O96017; Q93009: USP7; NbExp=2; IntAct=EBI-1180783, EBI-302474; CC O96017; P55072: VCP; NbExp=2; IntAct=EBI-1180783, EBI-355164; CC O96017; P18887: XRCC1; NbExp=8; IntAct=EBI-1180783, EBI-947466; CC O96017; PRO_0000037319 [P0C6X7]: rep; Xeno; NbExp=2; IntAct=EBI-1180783, EBI-25487926; CC O96017; P06725: UL83; Xeno; NbExp=2; IntAct=EBI-1180783, EBI-9545359; CC O96017; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-1180783, EBI-6904388; CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Note=Isoform 10 is present CC throughout the cell. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 12]: Nucleus. CC -!- SUBCELLULAR LOCATION: Nucleus, PML body. Nucleus, nucleoplasm. CC Note=Recruited into PML bodies together with TP53. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Name=1; CC IsoId=O96017-1; Sequence=Displayed; CC Name=2; Synonyms=ins2; CC IsoId=O96017-2; Sequence=VSP_014564, VSP_014567, VSP_014568; CC Name=3; Synonyms=del2-12; CC IsoId=O96017-3; Sequence=VSP_014559; CC Name=4; Synonyms=del2-3; CC IsoId=O96017-4; Sequence=VSP_014558; CC Name=5; Synonyms=del4; CC IsoId=O96017-5; Sequence=VSP_014565, VSP_014566; CC Name=6; Synonyms=sub3; CC IsoId=O96017-6; Sequence=VSP_014562, VSP_014563; CC Name=7; Synonyms=del9-12; CC IsoId=O96017-7; Sequence=VSP_014572, VSP_014573; CC Name=8; Synonyms=del7; CC IsoId=O96017-8; Sequence=VSP_014569, VSP_014570; CC Name=9; Synonyms=insx; CC IsoId=O96017-9; Sequence=VSP_014557; CC Name=10; Synonyms=iso2; CC IsoId=O96017-10; Sequence=VSP_014560, VSP_014561; CC Name=11; Synonyms=iso1; CC IsoId=O96017-11; Sequence=VSP_014556; CC Name=12; Synonyms=del9; CC IsoId=O96017-12; Sequence=VSP_014571; CC Name=13; CC IsoId=O96017-13; Sequence=VSP_045148; CC -!- TISSUE SPECIFICITY: High expression is found in testis, spleen, colon CC and peripheral blood leukocytes. Low expression is found in other CC tissues. CC -!- PTM: Phosphorylated. Phosphorylated at Ser-73 by PLK3 in response to CC DNA damage, promoting phosphorylation at Thr-68 by ATM and the G2/M CC transition checkpoint. Phosphorylation at Thr-68 induces CC homodimerization. Autophosphorylates at Thr-383 and Thr-387 in the T- CC loop/activation segment upon dimerization to become fully active and CC phosphorylate its substrates like for instance CDC25C. DNA damage- CC induced autophosphorylation at Ser-379 induces CUL1-mediated CC ubiquitination and regulates the pro-apoptotic function. CC Phosphorylation at Ser-456 also regulates ubiquitination. CC Phosphorylated by PLK4. {ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11390408, ECO:0000269|PubMed:15342622, CC ECO:0000269|PubMed:16311512, ECO:0000269|PubMed:16481012, CC ECO:0000269|PubMed:17715138, ECO:0000269|PubMed:18644861, CC ECO:0000269|PubMed:19164942}. CC -!- PTM: Ubiquitinated. CUL1-mediated ubiquitination regulates the pro- CC apoptotic function. Ubiquitination may also regulate protein stability. CC Ubiquitinated by RNF8 via 'Lys-48'-linked ubiquitination. CC -!- DISEASE: Tumor predisposition syndrome 4 (TPDS4) [MIM:609265]: A CC disorder characterized by an increased risk for developing various CC types of benign and/or malignant neoplasms that arise at an accelerated CC rate and in different organs. {ECO:0000269|PubMed:11719428}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:12533788}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating CC in bone-forming cells, affecting the ends of long bones. CC {ECO:0000269|PubMed:11746983}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:12094328, CC ECO:0000269|PubMed:12454775, ECO:0000269|PubMed:12610780, CC ECO:0000269|PubMed:15818573, ECO:0000269|PubMed:21618645, CC ECO:0000269|PubMed:25619829}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Retains low level of catalytic activity. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 10]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 12]: Lacks enzymatic activity. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CHK2 subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/312/CHEK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF086904; AAC83693.1; -; mRNA. DR EMBL; AJ131197; CAA10319.1; -; mRNA. DR EMBL; AF096279; AAD11784.1; -; mRNA. DR EMBL; AY551295; AAS58456.1; -; mRNA. DR EMBL; AY551296; AAS58457.1; -; mRNA. DR EMBL; AY551297; AAS58458.1; -; mRNA. DR EMBL; AY551298; AAS58459.1; -; mRNA. DR EMBL; AY551299; AAS58460.1; -; mRNA. DR EMBL; AY551300; AAS58461.1; -; mRNA. DR EMBL; AY551301; AAS58462.1; -; mRNA. DR EMBL; AY551302; AAS58463.1; -; mRNA. DR EMBL; AY551303; AAS58464.1; -; mRNA. DR EMBL; AY551304; AAS58465.1; -; mRNA. DR EMBL; AY551305; AAS58466.1; -; mRNA. DR EMBL; CR456418; CAG30304.1; -; mRNA. DR EMBL; AF174135; AAD48504.1; -; mRNA. DR EMBL; AB040105; BAB17231.1; -; mRNA. DR EMBL; AK290754; BAF83443.1; -; mRNA. DR EMBL; AF217975; AAG17218.1; -; mRNA. DR EMBL; AY800241; AAV41895.1; -; Genomic_DNA. DR EMBL; AL117330; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL121825; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471095; EAW59755.1; -; Genomic_DNA. DR EMBL; BC004207; AAH04207.1; -; mRNA. DR CCDS; CCDS13843.1; -. [O96017-1] DR CCDS; CCDS13844.1; -. [O96017-12] DR CCDS; CCDS33629.1; -. [O96017-9] DR RefSeq; NP_001005735.1; NM_001005735.3. [O96017-9] DR RefSeq; NP_001244316.1; NM_001257387.3. [O96017-13] DR RefSeq; NP_001424871.1; NM_001437942.1. [O96017-13] DR RefSeq; NP_009125.1; NM_007194.4. [O96017-1] DR RefSeq; NP_665861.1; NM_145862.3. [O96017-12] DR PDB; 1GXC; X-ray; 2.70 A; A/D/G/J=64-212. DR PDB; 2CN5; X-ray; 2.25 A; A=210-531. DR PDB; 2CN8; X-ray; 2.70 A; A=210-531. DR PDB; 2W0J; X-ray; 2.05 A; A=210-531. DR PDB; 2W7X; X-ray; 2.07 A; A=210-531. DR PDB; 2WTC; X-ray; 3.00 A; A=210-531. DR PDB; 2WTD; X-ray; 2.75 A; A=210-531. DR PDB; 2WTI; X-ray; 2.50 A; A=210-531. DR PDB; 2WTJ; X-ray; 2.10 A; A=210-531. DR PDB; 2XBJ; X-ray; 2.30 A; A=210-531. DR PDB; 2XK9; X-ray; 2.35 A; A=210-531. DR PDB; 2XM8; X-ray; 3.40 A; A=210-531. DR PDB; 2XM9; X-ray; 2.50 A; A=210-531. DR PDB; 2YCF; X-ray; 1.77 A; A=210-530. DR PDB; 2YCQ; X-ray; 2.05 A; A=210-531. DR PDB; 2YCR; X-ray; 2.20 A; A=210-531. DR PDB; 2YCS; X-ray; 2.35 A; A=210-531. DR PDB; 2YIQ; X-ray; 1.89 A; A=210-531. DR PDB; 2YIR; X-ray; 2.10 A; A=210-531. DR PDB; 2YIT; X-ray; 2.20 A; A=210-531. DR PDB; 3I6U; X-ray; 3.00 A; A/B=84-502. DR PDB; 3I6W; X-ray; 3.25 A; A/B/C/D/E/F/G/H=70-512. DR PDB; 3VA4; X-ray; 1.54 A; C=63-73. DR PDB; 4A9R; X-ray; 2.85 A; A=210-531. DR PDB; 4A9S; X-ray; 2.66 A; A=210-531. DR PDB; 4A9T; X-ray; 2.70 A; A=210-531. DR PDB; 4A9U; X-ray; 2.48 A; A=210-531. DR PDB; 4BDA; X-ray; 2.60 A; A=210-531. DR PDB; 4BDB; X-ray; 2.50 A; A=210-531. DR PDB; 4BDC; X-ray; 3.00 A; A=210-531. DR PDB; 4BDD; X-ray; 2.67 A; A=210-531. DR PDB; 4BDE; X-ray; 2.55 A; A=210-531. DR PDB; 4BDF; X-ray; 2.70 A; A=210-531. DR PDB; 4BDG; X-ray; 2.84 A; A=210-531. DR PDB; 4BDH; X-ray; 2.70 A; A=210-531. DR PDB; 4BDI; X-ray; 2.32 A; A=210-531. DR PDB; 4BDJ; X-ray; 3.01 A; A=210-531. DR PDB; 4BDK; X-ray; 3.30 A; A=210-531. DR PDBsum; 1GXC; -. DR PDBsum; 2CN5; -. DR PDBsum; 2CN8; -. DR PDBsum; 2W0J; -. DR PDBsum; 2W7X; -. DR PDBsum; 2WTC; -. DR PDBsum; 2WTD; -. DR PDBsum; 2WTI; -. DR PDBsum; 2WTJ; -. DR PDBsum; 2XBJ; -. DR PDBsum; 2XK9; -. DR PDBsum; 2XM8; -. DR PDBsum; 2XM9; -. DR PDBsum; 2YCF; -. DR PDBsum; 2YCQ; -. DR PDBsum; 2YCR; -. DR PDBsum; 2YCS; -. DR PDBsum; 2YIQ; -. DR PDBsum; 2YIR; -. DR PDBsum; 2YIT; -. DR PDBsum; 3I6U; -. DR PDBsum; 3I6W; -. DR PDBsum; 3VA4; -. DR PDBsum; 4A9R; -. DR PDBsum; 4A9S; -. DR PDBsum; 4A9T; -. DR PDBsum; 4A9U; -. DR PDBsum; 4BDA; -. DR PDBsum; 4BDB; -. DR PDBsum; 4BDC; -. DR PDBsum; 4BDD; -. DR PDBsum; 4BDE; -. DR PDBsum; 4BDF; -. DR PDBsum; 4BDG; -. DR PDBsum; 4BDH; -. DR PDBsum; 4BDI; -. DR PDBsum; 4BDJ; -. DR PDBsum; 4BDK; -. DR AlphaFoldDB; O96017; -. DR SMR; O96017; -. DR BioGRID; 116369; 255. DR CORUM; O96017; -. DR DIP; DIP-24270N; -. DR ELM; O96017; -. DR FunCoup; O96017; 2619. DR IntAct; O96017; 159. DR MINT; O96017; -. DR STRING; 9606.ENSP00000372023; -. DR BindingDB; O96017; -. DR ChEMBL; CHEMBL2527; -. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05786; Irofulven. DR DrugBank; DB05149; XL844. DR DrugCentral; O96017; -. DR GuidetoPHARMACOLOGY; 1988; -. DR GlyGen; O96017; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; O96017; -. DR MetOSite; O96017; -. DR PhosphoSitePlus; O96017; -. DR BioMuta; CHEK2; -. DR CPTAC; CPTAC-5892; -. DR CPTAC; CPTAC-5893; -. DR CPTAC; CPTAC-5894; -. DR jPOST; O96017; -. DR MassIVE; O96017; -. DR PaxDb; 9606-ENSP00000372023; -. DR PeptideAtlas; O96017; -. DR ProteomicsDB; 51198; -. [O96017-1] DR ProteomicsDB; 51199; -. [O96017-10] DR ProteomicsDB; 51200; -. [O96017-11] DR ProteomicsDB; 51201; -. [O96017-12] DR ProteomicsDB; 51202; -. [O96017-2] DR ProteomicsDB; 51203; -. [O96017-3] DR ProteomicsDB; 51204; -. [O96017-4] DR ProteomicsDB; 51205; -. [O96017-5] DR ProteomicsDB; 51206; -. [O96017-6] DR ProteomicsDB; 51207; -. [O96017-7] DR ProteomicsDB; 51208; -. [O96017-8] DR ProteomicsDB; 51209; -. [O96017-9] DR ProteomicsDB; 81589; -. DR Pumba; O96017; -. DR ABCD; O96017; 1 sequenced antibody. DR Antibodypedia; 278; 2028 antibodies from 51 providers. DR CPTC; O96017; 2 antibodies. DR DNASU; 11200; -. DR Ensembl; ENST00000348295.7; ENSP00000329012.5; ENSG00000183765.25. [O96017-12] DR Ensembl; ENST00000382580.6; ENSP00000372023.2; ENSG00000183765.25. [O96017-9] DR Ensembl; ENST00000403642.5; ENSP00000384919.1; ENSG00000183765.25. [O96017-4] DR Ensembl; ENST00000404276.6; ENSP00000385747.1; ENSG00000183765.25. [O96017-1] DR Ensembl; ENST00000405598.5; ENSP00000386087.1; ENSG00000183765.25. [O96017-1] DR Ensembl; ENST00000417588.5; ENSP00000412901.1; ENSG00000183765.25. [O96017-5] DR Ensembl; ENST00000425190.7; ENSP00000390244.2; ENSG00000183765.25. [O96017-13] DR Ensembl; ENST00000433728.5; ENSP00000404400.1; ENSG00000183765.25. [O96017-8] DR Ensembl; ENST00000439346.6; ENSP00000396903.2; ENSG00000183765.25. [O96017-5] DR Ensembl; ENST00000448511.5; ENSP00000404567.1; ENSG00000183765.25. [O96017-6] DR Ensembl; ENST00000649563.1; ENSP00000496928.1; ENSG00000183765.25. [O96017-13] DR Ensembl; ENST00000650281.1; ENSP00000497000.1; ENSG00000183765.25. [O96017-1] DR GeneID; 11200; -. DR KEGG; hsa:11200; -. DR MANE-Select; ENST00000404276.6; ENSP00000385747.1; NM_007194.4; NP_009125.1. DR UCSC; uc003adt.2; human. [O96017-1] DR AGR; HGNC:16627; -. DR CIViC; 11200; 9 evidence items across 6 molecular profiles. DR ClinPGx; PA404; -. DR CTD; 11200; -. DR DisGeNET; 11200; -. DR GeneCards; CHEK2; -. DR GeneReviews; CHEK2; -. DR HGNC; HGNC:16627; CHEK2. DR HPA; ENSG00000183765; Low tissue specificity. DR MalaCards; CHEK2; -. DR MIM; 114480; phenotype. DR MIM; 176807; phenotype. DR MIM; 259500; phenotype. DR MIM; 604373; gene. DR MIM; 609265; phenotype. DR OpenTargets; ENSG00000183765; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 668; Osteosarcoma. DR VEuPathDB; HostDB:ENSG00000183765; -. DR eggNOG; KOG0615; Eukaryota. DR GeneTree; ENSGT00800000124190; -. DR HOGENOM; CLU_070593_1_0_1; -. DR InParanoid; O96017; -. DR OMA; MLCAVQY; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; O96017; 4 GO annotations based on evolutionary models. DR PhylomeDB; O96017; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O96017; -. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69601; Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A. DR Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex. DR SignaLink; O96017; -. DR SIGNOR; O96017; -. DR Agora; ENSG00000183765; -. DR BioGRID-ORCS; 11200; 24 hits in 1201 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; CHEK2; human. DR EvolutionaryTrace; O96017; -. DR GeneWiki; CHEK2; -. DR GenomeRNAi; 11200; -. DR Pharos; O96017; Tchem. DR PRO; PR:O96017; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; O96017; protein. DR Bgee; ENSG00000183765; Expressed in primordial germ cell in gonad and 107 other cell types or tissues. DR ExpressionAtlas; O96017; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:1903926; P:cellular response to bisphenol A; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; TAS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:MGI. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0044773; P:mitotic DNA damage checkpoint signaling; IBA:GO_Central. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IMP:UniProtKB. DR GO; GO:0090307; P:mitotic spindle assembly; IMP:UniProtKB. DR GO; GO:2000002; P:negative regulation of DNA damage checkpoint; IEA:Ensembl. DR GO; GO:2000210; P:positive regulation of anoikis; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030163; P:protein catabolic process; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0042176; P:regulation of protein catabolic process; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0090399; P:replicative senescence; NAS:BHF-UCL. DR GO; GO:1903416; P:response to glycoside; IEA:Ensembl. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:MGI. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR CDD; cd22666; FHA_CHK2; 1. DR CDD; cd14084; STKc_Chk2; 1. DR DisProt; DP01797; -. DR FunFam; 1.10.510.10:FF:000354; Serine/threonine-protein kinase Chk2; 1. DR FunFam; 2.60.200.20:FF:000011; Serine/threonine-protein kinase Chk2; 1. DR FunFam; 3.30.200.20:FF:000255; serine/threonine-protein kinase Chk2 isoform X1; 1. DR Gene3D; 2.60.200.20; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000253; FHA_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR PANTHER; PTHR44167; OVARIAN-SPECIFIC SERINE/THREONINE-PROTEIN KINASE LOK-RELATED; 1. DR PANTHER; PTHR44167:SF24; SERINE_THREONINE-PROTEIN KINASE CHK2; 1. DR Pfam; PF00498; FHA; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00240; FHA; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS50006; FHA_DOMAIN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell cycle; KW Cell division; Disease variant; DNA damage; DNA repair; KW Host-virus interaction; Kinase; Li-Fraumeni syndrome; Magnesium; KW Metal-binding; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Tumor suppressor; Ubl conjugation. FT CHAIN 1..543 FT /note="Serine/threonine-protein kinase Chk2" FT /id="PRO_0000085858" FT DOMAIN 113..175 FT /note="FHA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00086" FT DOMAIN 220..486 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..66 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 368..394 FT /note="T-loop/activation segment" FT REGION 506..538 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 8..22 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 23..62 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 506..517 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 523..534 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 347 FT /note="Proton acceptor" FT BINDING 227..234 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 249 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 302..308 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 351..352 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 368 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 62 FT /note="Phosphoserine; by PLK3" FT /evidence="ECO:0000269|PubMed:16481012" FT MOD_RES 68 FT /note="Phosphothreonine; by ATM and MAP3K20" FT /evidence="ECO:0000269|PubMed:10973490, FT ECO:0000269|PubMed:15342622, ECO:0000269|PubMed:16311512, FT ECO:0000269|PubMed:16481012" FT MOD_RES 73 FT /note="Phosphoserine; by PLK3" FT /evidence="ECO:0000269|PubMed:16481012" FT MOD_RES 379 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18644861" FT MOD_RES 383 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11390408" FT MOD_RES 387 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11390408" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17715138" FT VAR_SEQ 1..221 FT /note="Missing (in isoform 13)" FT /evidence="ECO:0000303|PubMed:15498874" FT /id="VSP_045148" FT VAR_SEQ 75..392 FT /note="Missing (in isoform 11)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014556" FT VAR_SEQ 107..487 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014559" FT VAR_SEQ 107..197 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014558" FT VAR_SEQ 107 FT /note="E -> ETESGHVTQSDLELLLSSDPPASASQSAGIRGVRHHPRPVCSLK FT (in isoform 9)" FT /evidence="ECO:0000303|PubMed:15361853, FT ECO:0000303|PubMed:15461802" FT /id="VSP_014557" FT VAR_SEQ 131..147 FT /note="KRTDKYRTYSKKHFRIF -> EFRSYSFYLP (in isoform 10)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014560" FT VAR_SEQ 148..543 FT /note="Missing (in isoform 10)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014561" FT VAR_SEQ 150..165 FT /note="VGPKNSYIAYIEDHSG -> ENLSCPYRIWFNFCLF (in isoform 6)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014562" FT VAR_SEQ 166..543 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014563" FT VAR_SEQ 198..224 FT /note="VFVFFDLTVDDQSVYPKALRDEYIMSK -> EKILKIYSLSRFSKIRRGAVA FT HVFNPS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097108, FT ECO:0000303|PubMed:15361853" FT /id="VSP_014564" FT VAR_SEQ 199..203 FT /note="FVFFD -> VPVER (in isoform 5)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014565" FT VAR_SEQ 204..543 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014566" FT VAR_SEQ 228..234 FT /note="SGACGEV -> GRGWQIT (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097108, FT ECO:0000303|PubMed:15361853" FT /id="VSP_014567" FT VAR_SEQ 235..543 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097108, FT ECO:0000303|PubMed:15361853" FT /id="VSP_014568" FT VAR_SEQ 283..289 FT /note="PCIIKIK -> DGRGRAV (in isoform 8)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014569" FT VAR_SEQ 290..543 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014570" FT VAR_SEQ 337..365 FT /note="Missing (in isoform 12)" FT /evidence="ECO:0000303|PubMed:15361853, ECO:0000303|Ref.7" FT /id="VSP_014571" FT VAR_SEQ 337..339 FT /note="YLH -> MKT (in isoform 7)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014572" FT VAR_SEQ 340..543 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014573" FT VARIANT 17 FT /note="A -> S (found in an osteogenic sarcoma sample; FT somatic mutation; might influence susceptibility to breast FT cancer; dbSNP:rs137853008)" FT /evidence="ECO:0000269|PubMed:11746983" FT /id="VAR_019101" FT VARIANT 59 FT /note="T -> K (in multiple cancers; dbSNP:rs149991239)" FT /evidence="ECO:0000269|PubMed:12052256" FT /id="VAR_026630" FT VARIANT 64 FT /note="E -> K (in prostate cancer; somatic mutation; FT dbSNP:rs141568342)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019107" FT VARIANT 85 FT /note="P -> L (found in an osteogenic sarcoma sample; FT somatic mutation; dbSNP:rs17883862)" FT /evidence="ECO:0000269|PubMed:11746983, FT ECO:0000269|PubMed:15649950, ECO:0000269|Ref.10" FT /id="VAR_019102" FT VARIANT 117 FT /note="R -> G (in BC; dbSNP:rs28909982)" FT /evidence="ECO:0000269|PubMed:12454775, FT ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15818573" FT /id="VAR_022461" FT VARIANT 137 FT /note="R -> Q (might influence susceptibility to breast FT cancer; dbSNP:rs368570187)" FT /evidence="ECO:0000269|PubMed:12454775, FT ECO:0000269|PubMed:15818573" FT /id="VAR_022462" FT VARIANT 145 FT /note="R -> P (in prostate cancer; somatic mutation; FT dbSNP:rs587781667)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019108" FT VARIANT 145 FT /note="R -> W (in TPDS4; loss of the ability to interact FT with and phosphorylate CDC25A and to promote CDC25A FT degradation in response to ionizing radiation; FT dbSNP:rs137853007)" FT /evidence="ECO:0000269|PubMed:10617473, FT ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11719428, FT ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15535844, FT ECO:0000269|PubMed:15818573" FT /id="VAR_008554" FT VARIANT 157 FT /note="I -> T (might influence susceptibility to different FT types of cancer; loss of the ability to interact with and FT phosphorylate CDC25A and to promote CDC25A degradation in FT response to ionizing radiation; dbSNP:rs17879961)" FT /evidence="ECO:0000269|PubMed:10617473, FT ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11461078, FT ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:12610780, FT ECO:0000269|PubMed:14612911, ECO:0000269|PubMed:15087378, FT ECO:0000269|PubMed:15095295, ECO:0000269|PubMed:15239132, FT ECO:0000269|PubMed:15492928, ECO:0000269|PubMed:15535844, FT ECO:0000269|PubMed:15810020, ECO:0000269|PubMed:15818573, FT ECO:0000269|Ref.10" FT /id="VAR_008555" FT VARIANT 167 FT /note="G -> R (in prostate cancer; somatic mutation; FT dbSNP:rs72552322)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019109" FT VARIANT 180 FT /note="R -> C (in prostate cancer; somatic mutation; FT dbSNP:rs77130927)" FT /evidence="ECO:0000269|PubMed:12533788, FT ECO:0000269|PubMed:21618645" FT /id="VAR_019103" FT VARIANT 180 FT /note="R -> H (in prostate cancer; somatic mutation; FT dbSNP:rs137853009)" FT /evidence="ECO:0000269|PubMed:12454775, FT ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:15818573" FT /id="VAR_019110" FT VARIANT 181 FT /note="R -> C (in prostate cancer; somatic mutation; FT dbSNP:rs137853010)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019104" FT VARIANT 181 FT /note="R -> H (in prostate cancer; somatic mutation; FT dbSNP:rs121908701)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019105" FT VARIANT 239 FT /note="E -> K (in prostate cancer; germline mutation; FT dbSNP:rs121908702)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019106" FT VARIANT 251 FT /note="I -> F (in prostate cancer; uncertain significance; FT dbSNP:rs587780189)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019111" FT VARIANT 318 FT /note="R -> H (in prostate cancer; uncertain significance; FT somatic mutation; dbSNP:rs143611747)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019112" FT VARIANT 323 FT /note="T -> P (in prostate cancer; somatic mutation; FT dbSNP:rs750984976)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019113" FT VARIANT 327 FT /note="Y -> C (in prostate cancer; uncertain significance; FT somatic mutation; dbSNP:rs587780194)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019114" FT VARIANT 347 FT /note="D -> N (in dbSNP:rs28909980)" FT /id="VAR_029154" FT VARIANT 371 FT /note="H -> Y (confers a moderate risk of breast cancer; FT partially reduces kinase activity; dbSNP:rs531398630)" FT /evidence="ECO:0000269|PubMed:21618645" FT /id="VAR_066012" FT VARIANT 390 FT /note="Y -> C (in BC; does not phosphorylate p53/TP53; FT dbSNP:rs200928781)" FT /evidence="ECO:0000269|PubMed:25619829" FT /id="VAR_073020" FT VARIANT 406 FT /note="R -> H (in dbSNP:rs200649225)" FT /id="VAR_024572" FT VARIANT 428 FT /note="S -> F (may increase breast cancer risk; FT dbSNP:rs137853011)" FT /evidence="ECO:0000269|PubMed:15649950" FT /id="VAR_022463" FT VARIANT 436 FT /note="L -> M (in dbSNP:rs17882922)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021117" FT VARIANT 446 FT /note="N -> K (in dbSNP:rs17880867)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021118" FT VARIANT 447 FT /note="F -> I (in dbSNP:rs17881473)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021119" FT VARIANT 448 FT /note="I -> S (in dbSNP:rs17886163)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021120" FT VARIANT 476 FT /note="T -> K (in prostate cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019115" FT VARIANT 500 FT /note="S -> C (in dbSNP:rs28909981)" FT /id="VAR_029155" FT VARIANT 501 FT /note="E -> K (in dbSNP:rs17883172)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021121" FT VARIANT 512 FT /note="L -> V (in dbSNP:rs17882942)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021122" FT MUTAGEN 68 FT /note="T->A: Loss of activation and phosphorylation." FT /evidence="ECO:0000269|PubMed:11901158, FT ECO:0000269|PubMed:15342622" FT MUTAGEN 73 FT /note="S->A: Impaired activation, phosphorylation by ATM FT and G2/M transition checkpoint." FT /evidence="ECO:0000269|PubMed:16481012" FT MUTAGEN 347 FT /note="D->A: Loss of kinase activity and of the ability to FT phosphorylate CDC25A." FT /evidence="ECO:0000269|PubMed:11298456, FT ECO:0000269|PubMed:9836640" FT MUTAGEN 368 FT /note="D->N: Loss of autophosphorylation activity." FT /evidence="ECO:0000269|PubMed:15342622" FT MUTAGEN 379 FT /note="S->A: Abrogates autophosphorylation at Ser-379 and FT prevents ubiquitination." FT /evidence="ECO:0000269|PubMed:18644861" FT MUTAGEN 383 FT /note="T->A: Loss of phosphorylation in response to FT ionizing radiation." FT /evidence="ECO:0000269|PubMed:11390408" FT MUTAGEN 387 FT /note="T->A: Loss of phosphorylation in response to FT ionizing radiation." FT /evidence="ECO:0000269|PubMed:11390408" FT MUTAGEN 456 FT /note="S->A: Increased ubiquitination and degradation by FT the proteasome." FT /evidence="ECO:0000269|PubMed:17715138" FT STRAND 94..98 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 100..103 FT /evidence="ECO:0007829|PDB:3I6U" FT STRAND 106..108 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:1GXC" FT HELIX 128..132 FT /evidence="ECO:0007829|PDB:1GXC" FT HELIX 135..138 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 154..162 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 187..193 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 197..203 FT /evidence="ECO:0007829|PDB:1GXC" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:3I6U" FT HELIX 214..219 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 230..239 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 240..243 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 244..251 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 253..256 FT /evidence="ECO:0007829|PDB:3I6U" FT HELIX 270..279 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 288..302 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 307..309 FT /evidence="ECO:0007829|PDB:4BDD" FT HELIX 310..313 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2W7X" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 353..361 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4BDE" FT HELIX 379..385 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:2WTJ" FT HELIX 393..398 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 399..403 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 407..422 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:2CN5" FT HELIX 436..442 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 449..452 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 457..466 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 471..473 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 489..502 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 504..506 FT /evidence="ECO:0007829|PDB:2WTJ" SQ SEQUENCE 543 AA; 60915 MW; 28890ACF3C1F3408 CRC64; MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS QSSHSSSGTL SSLETVSTQE LYSIPEDQEP EDQEPEEPTP APWARLWALQ DGFANLECVN DNYWFGRDKS CEYCFDEPLL KRTDKYRTYS KKHFRIFREV GPKNSYIAYI EDHSGNGTFV NTELVGKGKR RPLNNNSEIA LSLSRNKVFV FFDLTVDDQS VYPKALRDEY IMSKTLGSGA CGEVKLAFER KTCKKVAIKI ISKRKFAIGS AREADPALNV ETEIEILKKL NHPCIIKIKN FFDAEDYYIV LELMEGGELF DKVVGNKRLK EATCKLYFYQ MLLAVQYLHE NGIIHRDLKP ENVLLSSQEE DCLIKITDFG HSKILGETSL MRTLCGTPTY LAPEVLVSVG TAGYNRAVDC WSLGVILFIC LSGYPPFSEH RTQVSLKDQI TSGKYNFIPE VWAEVSEKAL DLVKKLLVVD PKARFTTEEA LRHPWLQDED MKRKFQDLLS EENESTALPQ VLAQPSTSRK RPREGEAEGA ETTKRPAVCA AVL // ID CPNE3_HUMAN Reviewed; 537 AA. AC O75131; A8KA47; Q8IYA1; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1998, sequence version 1. DT 28-JAN-2026, entry version 200. DE RecName: Full=Copine-3 {ECO:0000305}; DE AltName: Full=Copine III {ECO:0000303|PubMed:11041869, ECO:0000312|HGNC:HGNC:2316}; GN Name=CPNE3 {ECO:0000312|HGNC:HGNC:2316}; GN Synonyms=CPN3, KIAA0636 {ECO:0000303|PubMed:9734811}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, TISSUE SPECIFICITY, RP AND PHOSPHORYLATION. RX PubMed=11041869; DOI=10.1021/bi001250v; RA Caudell E.G., Caudell J.J., Tang C.-H., Yu T.-K., Frederick M.J., RA Grimm E.A.; RT "Characterization of human copine III as a phosphoprotein with associated RT kinase activity."; RL Biochemistry 39:13034-13043(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=9734811; DOI=10.1093/dnares/5.3.169; RA Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., RA Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. X. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 5:169-176(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-412. RC TISSUE=Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY. RX PubMed=12949241; DOI=10.1189/jlb.0203083; RA Cowland J.B., Carter D., Bjerregaard M.D., Johnsen A.H., Borregaard N., RA Lollike K.; RT "Tissue expression of copines and isolation of copines I and III from the RT cytosol of human neutrophils."; RL J. Leukoc. Biol. 74:379-388(2003). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=21087455; DOI=10.1111/j.1742-4658.2010.07935.x; RA Perestenko P.V., Pooler A.M., Noorbakhshnia M., Gray A., Bauccio C., RA Jeffrey McIlhinney R.A.; RT "Copines-1, -2, -3, -6 and -7 show different calcium-dependent RT intracellular membrane translocation and targeting."; RL FEBS J. 277:5174-5189(2010). RN [8] RP FUNCTION, INTERACTION WITH ERBB2; RACK1 AND SHC1, SUBCELLULAR LOCATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-243, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-197, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Calcium-dependent phospholipid-binding protein that plays a CC role in ERBB2-mediated tumor cell migration in response to growth CC factor heregulin stimulation (PubMed:20010870). CC {ECO:0000269|PubMed:20010870}. CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC -!- SUBUNIT: Monomer (PubMed:12949241). Interacts with ERBB2 CC (preferentially with the tyrosine phosphorylated form); this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC SHC1; this interaction may mediate the binding of CPNE3 with ERBB2 CC (PubMed:20010870). Interacts with RACK1 (PubMed:20010870). CC {ECO:0000269|PubMed:12949241, ECO:0000269|PubMed:20010870}. CC -!- INTERACTION: CC O75131; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-718988, EBI-717399; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20010870, CC ECO:0000269|PubMed:21087455}. Cytoplasm {ECO:0000269|PubMed:12949241, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21087455}. Cell CC membrane {ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21087455}. CC Cell junction {ECO:0000269|PubMed:20010870}. Cell junction, focal CC adhesion {ECO:0000269|PubMed:20010870}. Note=Associates to the membrane CC in a calcium-dependent manner (PubMed:20010870). Translocates to the CC cell membrane and the nucleus in a calcium- or growth factor heregulin- CC dependent manner (PubMed:20010870, PubMed:21087455). Colocalizes with CC the tyrosine phosphorylated ERBB2 form at cell membrane and focal CC adhesions in a calcium- or growth factor heregulin-dependent manner CC (PubMed:20010870). {ECO:0000269|PubMed:20010870, CC ECO:0000269|PubMed:21087455}. CC -!- TISSUE SPECIFICITY: Expressed in breast and weakly in prostate and CC ovarian tissues (PubMed:20010870). Expressed in neutrophils (at protein CC level) (PubMed:12949241). Widely expressed (PubMed:11041869). Expressed CC in the brain. Expressed in neutrophil precursors from the bone marrow CC and peripheral blood (PubMed:12949241). Expressed in primary breast CC tumors and ovarian endometrioid adenocarcinoma (PubMed:20010870). CC {ECO:0000269|PubMed:11041869, ECO:0000269|PubMed:12949241, CC ECO:0000269|PubMed:20010870}. CC -!- PTM: Phosphorylated on serine and threonine residues (PubMed:11041869). CC {ECO:0000269|PubMed:11041869}. CC -!- SIMILARITY: Belongs to the copine family. {ECO:0000305}. CC -!- CAUTION: Was reported to have a protein kinase activity. CC {ECO:0000305|PubMed:11041869}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA31611.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF077226; AAD46074.2; -; mRNA. DR EMBL; AB014536; BAA31611.2; ALT_INIT; mRNA. DR EMBL; AK292912; BAF85601.1; -; mRNA. DR EMBL; BC036242; AAH36242.1; -; mRNA. DR EMBL; BC066597; AAH66597.1; -; mRNA. DR CCDS; CCDS6243.1; -. DR RefSeq; NP_003900.1; NM_003909.5. DR RefSeq; XP_005251150.1; XM_005251093.5. DR RefSeq; XP_016869434.1; XM_017013945.3. DR RefSeq; XP_024303090.1; XM_024447322.2. DR RefSeq; XP_047278349.1; XM_047422393.1. DR RefSeq; XP_047278350.1; XM_047422394.1. DR RefSeq; XP_047278351.1; XM_047422395.1. DR RefSeq; XP_054217423.1; XM_054361448.1. DR RefSeq; XP_054217424.1; XM_054361449.1. DR RefSeq; XP_054217425.1; XM_054361450.1. DR RefSeq; XP_054217426.1; XM_054361451.1. DR RefSeq; XP_054217427.1; XM_054361452.1. DR RefSeq; XP_054217428.1; XM_054361453.1. DR AlphaFoldDB; O75131; -. DR SMR; O75131; -. DR BioGRID; 114412; 124. DR FunCoup; O75131; 1341. DR IntAct; O75131; 51. DR MINT; O75131; -. DR STRING; 9606.ENSP00000477590; -. DR TCDB; 8.A.210.1.2; the plasma membrane repair (pmr) family. DR GlyCosmos; O75131; 1 site, 1 glycan. DR GlyGen; O75131; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75131; -. DR MetOSite; O75131; -. DR PhosphoSitePlus; O75131; -. DR SwissPalm; O75131; -. DR BioMuta; CPNE3; -. DR jPOST; O75131; -. DR MassIVE; O75131; -. DR PaxDb; 9606-ENSP00000477590; -. DR PeptideAtlas; O75131; -. DR ProteomicsDB; 49793; -. DR Pumba; O75131; -. DR Antibodypedia; 25495; 163 antibodies from 29 providers. DR DNASU; 8895; -. DR Ensembl; ENST00000517490.6; ENSP00000477590.1; ENSG00000085719.14. DR GeneID; 8895; -. DR KEGG; hsa:8895; -. DR MANE-Select; ENST00000517490.6; ENSP00000477590.1; NM_003909.5; NP_003900.1. DR UCSC; uc033bsf.1; human. DR AGR; HGNC:2316; -. DR ClinPGx; PA26833; -. DR CTD; 8895; -. DR DisGeNET; 8895; -. DR GeneCards; CPNE3; -. DR HGNC; HGNC:2316; CPNE3. DR HPA; ENSG00000085719; Low tissue specificity. DR MIM; 604207; gene. DR OpenTargets; ENSG00000085719; -. DR VEuPathDB; HostDB:ENSG00000085719; -. DR eggNOG; KOG1327; Eukaryota. DR GeneTree; ENSGT00940000154968; -. DR HOGENOM; CLU_020452_3_2_1; -. DR InParanoid; O75131; -. DR OMA; EMAAQCV; -. DR OrthoDB; 5855668at2759; -. DR PAN-GO; O75131; 5 GO annotations based on evolutionary models. DR PhylomeDB; O75131; -. DR PathwayCommons; O75131; -. DR Reactome; R-HSA-1483206; Glycerophospholipid biosynthesis. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; O75131; -. DR Agora; ENSG00000085719; -. DR BioGRID-ORCS; 8895; 9 hits in 1158 CRISPR screens. DR ChiTaRS; CPNE3; human. DR GenomeRNAi; 8895; -. DR Pharos; O75131; Tbio. DR PRO; PR:O75131; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O75131; protein. DR Bgee; ENSG00000085719; Expressed in tongue squamous epithelium and 211 other cell types or tissues. DR ExpressionAtlas; O75131; baseline and differential. DR GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005544; F:calcium-dependent phospholipid binding; IDA:UniProtKB. DR GO; GO:0048306; F:calcium-dependent protein binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0005543; F:phospholipid binding; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0038128; P:ERBB2 signaling pathway; IDA:UniProtKB. DR GO; GO:0046474; P:glycerophospholipid biosynthetic process; TAS:Reactome. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR CDD; cd04048; C2A_Copine; 1. DR CDD; cd04047; C2B_Copine; 1. DR CDD; cd01459; vWA_copine_like; 1. DR FunFam; 2.60.40.150:FF:000042; Copine 3; 1. DR FunFam; 2.60.40.150:FF:000099; Copine 3; 1. DR Gene3D; 2.60.40.150; C2 domain; 2. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037768; C2B_Copine. DR InterPro; IPR045052; Copine. DR InterPro; IPR010734; Copine_C. DR InterPro; IPR002035; VWF_A. DR InterPro; IPR036465; vWFA_dom_sf. DR PANTHER; PTHR10857; COPINE; 1. DR PANTHER; PTHR10857:SF22; COPINE-3; 1. DR Pfam; PF00168; C2; 2. DR Pfam; PF07002; Copine; 1. DR SMART; SM00239; C2; 2. DR SMART; SM00327; VWA; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 2. DR SUPFAM; SSF53300; vWA-like; 1. DR PROSITE; PS50004; C2; 2. PE 1: Evidence at protein level; KW Calcium; Cell junction; Cell membrane; Cytoplasm; KW Direct protein sequencing; Membrane; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat. FT CHAIN 1..537 FT /note="Copine-3" FT /id="PRO_0000144838" FT DOMAIN 1..115 FT /note="C2 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 124..247 FT /note="C2 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 291..513 FT /note="VWFA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" FT BINDING 22 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 22 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 28 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 83 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 83 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 93 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 154 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 154 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 160 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 216 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 216 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 218 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 218 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 224 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 197 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 243 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 252 FT /note="E -> D (in dbSNP:rs41333046)" FT /id="VAR_048848" FT VARIANT 412 FT /note="T -> M (in dbSNP:rs2304789)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_024424" FT CONFLICT 394 FT /note="P -> Q (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" FT CONFLICT 419 FT /note="Q -> R (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" FT CONFLICT 475 FT /note="R -> H (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" SQ SEQUENCE 537 AA; 60131 MW; 91F2C5EAD611B842 CRC64; MAAQCVTKVA LNVSCANLLD KDIGSKSDPL CVLFLNTSGQ QWYEVERTER IKNCLNPQFS KTFIIDYYFE VVQKLKFGVY DIDNKTIELS DDDFLGECEC TLGQIVSSKK LTRPLVMKTG RPAGKGSITI SAEEIKDNRV VLFEMEARKL DNKDLFGKSD PYLEFHKQTS DGNWLMVHRT EVVKNNLNPV WRPFKISLNS LCYGDMDKTI KVECYDYDND GSHDLIGTFQ TTMTKLKEAS RSSPVEFECI NEKKRQKKKS YKNSGVISVK QCEITVECTF LDYIMGGCQL NFTVGVDFTG SNGDPRSPDS LHYISPNGVN EYLTALWSVG LVIQDYDADK MFPAFGFGAQ IPPQWQVSHE FPMNFNPSNP YCNGIQGIVE AYRSCLPQIK LYGPTNFSPI INHVARFAAA ATQQQTASQY FVLLIITDGV ITDLDETRQA IVNASRLPMS IIIVGVGGAD FSAMEFLDGD GGSLRSPLGE VAIRDIVQFV PFRQFQNAPK EALAQCVLAE IPQQVVGYFN TYKLLPPKNP ATKQQKQ // ID CTNB1_HUMAN Reviewed; 781 AA. AC P35222; A8K1L7; Q8NEW9; Q8NI94; Q9H391; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1994, sequence version 1. DT 28-JAN-2026, entry version 272. DE RecName: Full=Catenin beta-1 {ECO:0000312|HGNC:HGNC:2514}; DE AltName: Full=Beta-catenin {ECO:0000303|PubMed:7806582}; GN Name=CTNNB1 {ECO:0000312|HGNC:HGNC:2514}; Synonyms=CTNNB; GN ORFNames=OK/SW-cl.35, PRO2286; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=7806582; DOI=10.1083/jcb.127.6.2061; RA Huelsken J., Birchmeier W., Behrens J.; RT "E-cadherin and APC compete for the interaction with beta-catenin and the RT cytoskeleton."; RL J. Cell Biol. 127:2061-2069(1994). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Fetal liver; RA Zhang C., Yu Y., Zhang S., Wei H., Bi J., Zhou G., Dong C., Zai Y., Xu W., RA Gao F., Liu M., He F.; RT "Functional prediction of the coding sequences of 75 new genes deduced by RT analysis of cDNA clones from human fetal liver."; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-688. RG NIEHS SNPs program; RL Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-312. RX PubMed=12019147; RA Kim J.-S., Crooks H., Dracheva T., Nishanian T.G., Singh B., Jen J., RA Waldman T.; RT "Oncogenic beta-catenin is required for bone morphogenetic protein 4 RT expression in human cancer cells."; RL Cancer Res. 62:2744-2748(2002). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 258-781. RC TISSUE=Colon adenocarcinoma; RA Shichijo S., Itoh K.; RT "Identification of immuno-peptidmics that are recognized by tumor-reactive RT CTL generated from TIL of colon cancer patients."; RL Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [11] RP CHROMOSOMAL TRANSLOCATION WITH PLAG1. RX PubMed=9020842; DOI=10.1038/ng0297-170; RA Kas K., Voz M.L., Roeijer E., Astroem A.-K., Meyen E., Stenman G., RA Van de Ven W.J.M.; RT "Promoter swapping between the genes for a novel zinc finger protein and RT beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) RT translocations."; RL Nat. Genet. 15:170-174(1997). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH PLAG1. RX PubMed=10029085; RA Astroem A.-K., Voz M.L., Kas K., Roeijer E., Wedell B., Mandahl N., RA Van de Ven W., Mark J., Stenman G.; RT "Conserved mechanism of PLAG1 activation in salivary gland tumors with and RT without chromosome 8q12 abnormalities: identification of SII as a new RT fusion partner gene."; RL Cancer Res. 59:918-923(1999). RN [13] RP STIMULATION OF TYROSINE PHOSPHORYLATION BY EGF, AND DEPHOSPHORYLATION BY RP PTPRF. RX PubMed=10187801; DOI=10.1074/jbc.274.15.10173; RA Mueller T., Choidas A., Reichmann E., Ullrich A.; RT "Phosphorylation and free pool of beta-catenin are regulated by tyrosine RT kinases and tyrosine phosphatases during epithelial cell migration."; RL J. Biol. Chem. 274:10173-10183(1999). RN [14] RP SUBCELLULAR LOCATION. RX PubMed=10725230; DOI=10.1242/jcs.113.8.1481; RA Mariner D.J., Wang J., Reynolds A.B.; RT "ARVCF localizes to the nucleus and adherens junction and is mutually RT exclusive with p120(ctn) in E-cadherin complexes."; RL J. Cell Sci. 113:1481-1490(2000). RN [15] RP INTERACTION WITH LEF1; APC; AXIN1; AXIN2 AND TCF7L2, PHOSPHORYLATION BY RP GSK3B, AND MUTAGENESIS OF PHE-253; HIS-260; LYS-292; LYS-345; TRP-383; RP ARG-386; ASN-426; LYS-435; ARG-469; HIS-470 AND LYS-508. RX PubMed=10966653; DOI=10.1038/79039; RA von Kries J.P., Winbeck G., Asbrand C., Schwarz-Romond T., Sochnikova N., RA Dell'Oro A., Behrens J., Birchmeier W.; RT "Hot spots in beta-catenin for interactions with LEF-1, conductin and RT APC."; RL Nat. Struct. Biol. 7:800-807(2000). RN [16] RP TISSUE SPECIFICITY, AND VARIANT PTR TYR-32. RX PubMed=11703283; DOI=10.1046/j.1365-2133.2001.04455.x; RA Moreno-Bueno G., Gamallo C., Perez-Gallego L., Contreras F., Palacios J.; RT "Beta-catenin expression in pilomatrixomas. Relationship with beta-catenin RT gene mutations and comparison with beta-catenin expression in normal hair RT follicles."; RL Br. J. Dermatol. 145:576-581(2001). RN [17] RP INTERACTION WITH LEF1, AND INHIBITION BY CTNNBIP1 BINDING. RX PubMed=11751639; DOI=10.1101/gad.946501; RA Tutter A.V., Fryer C.J., Jones K.A.; RT "Chromatin-specific regulation of LEF-1-beta-catenin transcription RT activation and inhibition in vitro."; RL Genes Dev. 15:3342-3354(2001). RN [18] RP RETRACTED PAPER. RX PubMed=11279024; DOI=10.1074/jbc.m100194200; RA Piedra J., Martinez D., Castano J., Miravet S., Dunach M., RA de Herreros A.G.; RT "Regulation of beta-catenin structure and activity by tyrosine RT phosphorylation."; RL J. Biol. Chem. 276:20436-20443(2001). RN [19] RP INTERACTION WITH SPN/CD43 CYTOPLASMIC TAIL. RX PubMed=15003504; DOI=10.1016/j.bbrc.2004.02.011; RA Andersson C.X., Fernandez-Rodriguez J., Laos S., Sikut R., Sikut A., RA Baeckstroem D., Hansson G.C.; RT "CD43 has a functional NLS, interacts with beta-catenin, and affects gene RT expression."; RL Biochem. Biophys. Res. Commun. 316:12-17(2004). RN [20] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=21118991; DOI=10.1091/mbc.e10-05-0440; RA Hay-Koren A., Caspi M., Zilberberg A., Rosin-Arbesfeld R.; RT "The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin."; RL Mol. Biol. Cell 22:399-411(2011). RN [21] RP RETRACTION NOTICE OF PUBMED:11279024. RX PubMed=27226643; DOI=10.1074/jbc.a116.100194; RA Piedra J., Martinez D., Castano J., Miravet S., Dunach M., RA de Herreros A.G.; RL J. Biol. Chem. 291:11463-11463(2016). RN [22] RP INTERACTION WITH CTNNA3. RX PubMed=11590244; DOI=10.1242/jcs.114.17.3177; RA Janssens B., Goossens S., Staes K., Gilbert B., van Hengel J., Colpaert C., RA Bruyneel E., Mareel M., van Roy F.; RT "AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein RT mediating strong cell-cell adhesion."; RL J. Cell Sci. 114:3177-3188(2001). RN [23] RP INTERACTION WITH SIAH1, AND UBIQUITINATION. RX PubMed=11389839; DOI=10.1016/s1097-2765(01)00242-8; RA Matsuzawa S., Reed J.C.; RT "Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin RT degradation linked to p53 responses."; RL Mol. Cell 7:915-926(2001). RN [24] RP INTERACTION WITH SIAH1, AND UBIQUITINATION. RX PubMed=11389840; DOI=10.1016/s1097-2765(01)00241-6; RA Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L., White R.L., RA Matsunami N.; RT "Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to RT the adenomatous polyposis coli protein."; RL Mol. Cell 7:927-936(2001). RN [25] RP INVOLVEMENT IN MESOM. RX PubMed=11464291; DOI=10.1038/sj.onc.1204557; RA Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., RA Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T., Yoshioka H., RA Imaizumi M., Ueda Y., Takahashi M., Shimokata K.; RT "Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer RT and malignant mesothelioma and identification of a new 3p21.3 homozygous RT deletion."; RL Oncogene 20:4249-4257(2001). RN [26] RP INTERACTION WITH PTPRU. RX PubMed=12501215; DOI=10.1021/bi026095u; RA Yan H.-X., He Y.-Q., Dong H., Zhang P., Zeng J.-Z., Cao H.-F., Wu M.-C., RA Wang H.-Y.; RT "Physical and functional interaction between receptor-like protein tyrosine RT phosphatase PCP-2 and beta-catenin."; RL Biochemistry 41:15854-15860(2002). RN [27] RP PHOSPHORYLATION AT SER-45, CHARACTERIZATION OF VARIANT HEPATOCELLULAR RP CARCINOMA ALA-41, CHARACTERIZATION OF VARIANT DESMOID TUMOR ALA-41, AND RP CHARACTERIZATION OF VARIANT HEPATOBLASTOMA ALA-41. RX PubMed=12051714; DOI=10.1016/s0006-291x(02)00485-0; RA Hagen T., Vidal-Puig A.; RT "Characterisation of the phosphorylation of beta-catenin at the GSK-3 RT priming site Ser45."; RL Biochem. Biophys. Res. Commun. 294:324-328(2002). RN [28] RP INTERACTION WITH CXADR. RX PubMed=12297051; DOI=10.1016/s0092-8674(02)00912-1; RA Walters R.W., Freimuth P., Moninger T.O., Ganske I., Zabner J., Welsh M.J.; RT "Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing RT virus escape."; RL Cell 110:789-799(2002). RN [29] RP PHOSPHORYLATION AT SER-23 AND SER-29 BY GSK3B, PHOSPHORYLATION AT THR-41, RP MUTAGENESIS OF SER-29, CHARACTERIZATION OF VARIANTS HEPATOCELLULAR RP CARCINOMA ARG-23; ALA-37 AND ALA-41, CHARACTERIZATION OF VARIANT PTR RP TYR-33, CHARACTERIZATION OF VARIANT MDB ALA-37, CHARACTERIZATION OF VARIANT RP DESMOID TUMOR ALA-41, AND CHARACTERIZATION OF VARIANT HEPATOBLASTOMA RP ALA-41. RX PubMed=12027456; DOI=10.1006/excr.2002.5520; RA van Noort M., van de Wetering M., Clevers H.; RT "Identification of two novel regulated serines in the N-terminus of beta- RT catenin."; RL Exp. Cell Res. 276:264-272(2002). RN [30] RP INTERACTION WITH CDH1 AND PKP2, AND SUBCELLULAR LOCATION. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [31] RP WNT SIGNALING MODULATES PHOSPHORYLATION. RX PubMed=11834740; DOI=10.1074/jbc.m111635200; RA van Noort M., Meeldijk J., van der Zee R., Destree O., Clevers H.; RT "Wnt signaling controls the phosphorylation status of beta-catenin."; RL J. Biol. Chem. 277:17901-17905(2002). RN [32] RP PHOSPHORYLATION, AND INTERACTION OF PHOSPHORYLATED CTNNB1 WITH BTRC. RX PubMed=12077367; DOI=10.1242/jcs.115.13.2771; RA Sadot E., Conacci-Sorrell M., Zhurinsky J., Shnizer D., Lando Z., RA Zharhary D., Kam Z., Ben-Ze'ev A., Geiger B.; RT "Regulation of S33/S37 phosphorylated beta-catenin in normal and RT transformed cells."; RL J. Cell Sci. 115:2771-2780(2002). RN [33] RP INTERACTION WITH PTPRJ. RX PubMed=12370829; DOI=10.1038/sj.onc.1205858; RA Holsinger L.J., Ward K., Duffield B., Zachwieja J., Jallal B.; RT "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts RT with p120(ctn)."; RL Oncogene 21:7067-7076(2002). RN [34] RP INTERACTION WITH PCDH11Y. RX PubMed=12420223; DOI=10.1038/sj.onc.1205991; RA Chen M.-W., Vacherot F., De La Taille A., Gil-Diez-De-Medina S., Shen R., RA Friedman R.A., Burchardt M., Chopin D.K., Buttyan R.; RT "The emergence of protocadherin-PC expression during the acquisition of RT apoptosis-resistance by prostate cancer cells."; RL Oncogene 21:7861-7871(2002). RN [35] RP INTERACTION WITH NHERF1. RX PubMed=12830000; DOI=10.1053/jhep.2003.50270; RA Shibata T., Chuma M., Kokubu A., Sakamoto M., Hirohashi S.; RT "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is RT over-expressed in hepatocellular carcinoma."; RL Hepatology 38:178-186(2003). RN [36] RP REVIEW. RX PubMed=10679188; DOI=10.1006/bbrc.1999.1860; RA Kikuchi A.; RT "Regulation of beta-catenin signaling in the Wnt pathway."; RL Biochem. Biophys. Res. Commun. 268:243-248(2000). RN [37] RP PHOSPHORYLATION AT TYR-142 BY FYN. RX PubMed=12640114; DOI=10.1128/mcb.23.7.2287-2297.2003; RA Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N., RA Garcia de Herreros A., Dunach M.; RT "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin RT Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction."; RL Mol. Cell. Biol. 23:2287-2297(2003). RN [38] RP INTERACTION WITH CBY1. RX PubMed=12712206; DOI=10.1038/nature01570; RA Takemaru K., Yamaguchi S., Lee Y.S., Zhang Y., Carthew R.W., Moon R.T.; RT "Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless RT pathway."; RL Nature 422:905-909(2003). RN [39] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [40] RP INTERACTION WITH CBY1, AND SUBCELLULAR LOCATION. RX PubMed=16424001; DOI=10.1158/0008-5472.can-05-3124; RA Jung Y., Bang S., Choi K., Kim E., Kim Y., Kim J., Park J., Koo H., RA Moon R.T., Song K., Lee I.; RT "TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving RT antagonistic activity of Chibby."; RL Cancer Res. 66:723-728(2006). RN [41] RP SUBCELLULAR LOCATION, AND INTERACTION WITH NANOS1. RX PubMed=17047063; DOI=10.1158/0008-5472.can-05-3096; RA Strumane K., Bonnomet A., Stove C., Vandenbroucke R., Nawrocki-Raby B., RA Bruyneel E., Mareel M., Birembaut P., Berx G., van Roy F.; RT "E-cadherin regulates human Nanos1, which interacts with p120ctn and RT induces tumor cell migration and invasion."; RL Cancer Res. 66:10007-10015(2006). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH EMD. RX PubMed=16858403; DOI=10.1038/sj.emboj.7601230; RA Markiewicz E., Tilgner K., Barker N., van de Wetering M., Clevers H., RA Dorobek M., Hausmanowa-Petrusewicz I., Ramaekers F.C.S., Broers J.L.V., RA Blankesteijn W.M., Salpingidou G., Wilson R.G., Ellis J.A., Hutchison C.J.; RT "The inner nuclear membrane protein emerin regulates beta-catenin activity RT by restricting its accumulation in the nucleus."; RL EMBO J. 25:3275-3285(2006). RN [44] RP INTERACTION WITH MUC1, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009; RA Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.; RT "MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism."; RL Biochim. Biophys. Acta 1773:1028-1038(2007). RN [45] RP INTERACTION WITH GLIS2, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=17289029; DOI=10.1016/j.febslet.2007.01.058; RA Kim Y.-S., Kang H.S., Jetten A.M.; RT "The Kruppel-like zinc finger protein Glis2 functions as a negative RT modulator of the Wnt/beta-catenin signaling pathway."; RL FEBS Lett. 581:858-864(2007). RN [46] RP PHOSPHORYLATION AT SER-191 AND SER-246, INTERACTION WITH CDK5, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17009320; DOI=10.1002/jcb.21041; RA Munoz J.P., Huichalaf C.H., Orellana D., Maccioni R.B.; RT "cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal RT cells."; RL J. Cell. Biochem. 100:738-749(2007). RN [47] RP INTERACTION WITH FHIT, IDENTIFICATION IN A COMPLEX WITH LEF1, AND FUNCTION. RX PubMed=18077326; DOI=10.1073/pnas.0703664105; RA Weiske J., Albring K.F., Huber O.; RT "The tumor suppressor Fhit acts as a repressor of beta-catenin RT transcriptional activity."; RL Proc. Natl. Acad. Sci. U.S.A. 104:20344-20349(2007). RN [48] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH NEK2. RX PubMed=18086858; DOI=10.1101/gad.1596308; RA Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H. Jr., O'Toole E.T., RA Winey M., Salmon E.D., Casey P.J., Nelson W.J., Barth A.I.; RT "beta-Catenin is a Nek2 substrate involved in centrosome separation."; RL Genes Dev. 22:91-105(2008). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-556 AND SER-675, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [50] RP INTERACTION WITH SOX7. RX PubMed=18819930; DOI=10.1158/1541-7786.mcr-07-2175; RA Guo L., Zhong D., Lau S., Liu X., Dong X.Y., Sun X., Yang V.W., RA Vertino P.M., Moreno C.S., Varma V., Dong J.T., Zhou W.; RT "Sox7 Is an independent checkpoint for beta-catenin function in prostate RT and colon epithelial cells."; RL Mol. Cancer Res. 6:1421-1430(2008). RN [51] RP INTERACTION WITH CHD8. RX PubMed=18378692; DOI=10.1128/mcb.00322-08; RA Thompson B.A., Tremblay V., Lin G., Bochar D.A.; RT "CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta- RT catenin target genes."; RL Mol. Cell. Biol. 28:3894-3904(2008). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [53] RP INTERACTION WITH CBY1. RX PubMed=19435523; DOI=10.1186/1471-2199-10-41; RA Mofunanya A., Li F.Q., Hsieh J.C., Takemaru K.; RT "Chibby forms a homodimer through a heptad repeat of leucine residues in RT its C-terminal coiled-coil motif."; RL BMC Mol. Biol. 10:41-41(2009). RN [54] RP INTERACTION WITH TCF7L2 AND TNIK. RX PubMed=19816403; DOI=10.1038/emboj.2009.285; RA Mahmoudi T., Li V.S.W., Ng S.S., Taouatas N., Vries R.G.J., Mohammed S., RA Heck A.J., Clevers H.; RT "The kinase TNIK is an essential activator of Wnt target genes."; RL EMBO J. 28:3329-3340(2009). RN [55] RP FUNCTION. RX PubMed=18957423; DOI=10.1074/jbc.m805612200; RA Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V.; RT "Down-regulation of death-associated protein kinase-2 is required for beta- RT catenin-induced anoikis resistance of malignant epithelial cells."; RL J. Biol. Chem. 284:2012-2022(2009). RN [56] RP INTERACTION WITH RUVBL2; APPL2; APPL1; HDAC1 AND HDAC2. RX PubMed=19433865; DOI=10.1074/jbc.m109.007237; RA Rashid S., Pilecka I., Torun A., Olchowik M., Bielinska B., Miaczynska M.; RT "Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta- RT catenin/TCF-mediated transcription."; RL J. Biol. Chem. 284:18115-18128(2009). RN [57] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [58] RP PHOSPHORYLATION AT SER-33 AND SER-37 BY HIPK2, AND UBIQUITINATION. RX PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099; RA Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.; RT "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for RT phosphorylation and proteasomal degradation."; RL Biochem. Biophys. Res. Commun. 394:966-971(2010). RN [59] RP INTERACTION WITH SESTD1. RX PubMed=20164195; DOI=10.1074/jbc.m109.068304; RA Miehe S., Bieberstein A., Arnould I., Ihdene O., Rutten H., Strubing C.; RT "The phospholipid-binding protein SESTD1 is a novel regulator of the RT transient receptor potential channels TRPC4 and TRPC5."; RL J. Biol. Chem. 285:12426-12434(2010). RN [60] RP INTERACTION WITH TRPC4. RX PubMed=19996314; DOI=10.1074/jbc.m109.060301; RA Graziani A., Poteser M., Heupel W.M., Schleifer H., Krenn M., RA Drenckhahn D., Romanin C., Baumgartner W., Groschner K.; RT "Cell-cell contact formation governs Ca2+ signaling by TRPC4 in the RT vascular endothelium: evidence for a regulatory TRPC4-beta-catenin RT interaction."; RL J. Biol. Chem. 285:4213-4223(2010). RN [61] RP INTERACTION WITH CDK5. RX PubMed=19693690; DOI=10.1007/s11033-009-9752-7; RA Li Q., Liu X., Zhang M., Ye G., Qiao Q., Ling Y., Wu Y., Zhang Y., Yu L.; RT "Characterization of a novel human CDK5 splicing variant that inhibits RT Wnt/beta-catenin signaling."; RL Mol. Biol. Rep. 37:2415-2421(2010). RN [62] RP PHOSPHORYLATION AT TYR-64; TYR-142; TYR-331 AND TYR-333, INTERACTION WITH RP PTK6, AND MUTAGENESIS OF TYR-64. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [63] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [64] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [65] RP FUNCTION IN INSULIN INTERNALIZATION, SUBCELLULAR LOCATION, INTERACTION WITH RP CDK2, AND PHOSPHORYLATION BY CDK2. RX PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019; RA Fiset A., Xu E., Bergeron S., Marette A., Pelletier G., Siminovitch K.A., RA Olivier M., Beauchemin N., Faure R.L.; RT "Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and RT regulates insulin internalization."; RL Cell. Signal. 23:911-919(2011). RN [66] RP INTERACTION WITH PKT7. RX PubMed=21132015; DOI=10.1038/embor.2010.185; RA Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F., RA Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M., Shin W.-S., RA Lee S.-T., Kodjabachian L., Borg J.-P.; RT "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin RT canonical signalling."; RL EMBO Rep. 12:43-49(2011). RN [67] RP INTERACTION WITH NDRG2. RX PubMed=21247902; DOI=10.1074/jbc.m110.170803; RA Hwang J., Kim Y., Kang H.B., Jaroszewski L., Deacon A.M., Lee H., RA Choi W.C., Kim K.J., Kim C.H., Kang B.S., Lee J.O., Oh T.K., Kim J.W., RA Wilson I.A., Kim M.H.; RT "Crystal structure of the human N-Myc downstream-regulated gene 2 protein RT provides insight into its role as a tumor suppressor."; RL J. Biol. Chem. 286:12450-12460(2011). RN [68] RP INTERACTION WITH PKM ISOFORM M2, PHOSPHORYLATION AT TYR-333, AND RP MUTAGENESIS OF TYR-333. RX PubMed=22056988; DOI=10.1038/nature10598; RA Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., RA Lu Z.; RT "Nuclear PKM2 regulates beta-catenin transactivation upon EGFR RT activation."; RL Nature 480:118-122(2011). RN [69] RP INTERACTION WITH AHI1. RX PubMed=21623382; DOI=10.1038/nm.2380; RA Lancaster M.A., Gopal D.J., Kim J., Saleem S.N., Silhavy J.L., Louie C.M., RA Thacker B.E., Williams Y., Zaki M.S., Gleeson J.G.; RT "Defective Wnt-dependent cerebellar midline fusion in a mouse model of RT Joubert syndrome."; RL Nat. Med. 17:726-731(2011). RN [70] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-552, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [71] RP IDENTIFICATION IN A COMPLEX WITH HINT1 AND MITF, AND FUNCTION. RX PubMed=22647378; DOI=10.4161/cc.20765; RA Genovese G., Ghosh P., Li H., Rettino A., Sioletic S., Cittadini A., RA Sgambato A.; RT "The tumor suppressor HINT1 regulates MITF and beta-catenin transcriptional RT activity in melanoma cells."; RL Cell Cycle 11:2206-2215(2012). RN [72] RP FUNCTION, INTERACTION WITH FERMT2, IDENTIFICATION IN A COMPLEX WITH FERMT2 RP AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=22699938; DOI=10.1038/embor.2012.88; RA Yu Y., Wu J., Wang Y., Zhao T., Ma B., Liu Y., Fang W., Zhu W.G., Zhang H.; RT "Kindlin 2 forms a transcriptional complex with beta-catenin and TCF4 to RT enhance Wnt signalling."; RL EMBO Rep. 13:750-758(2012). RN [73] RP FUNCTION, AND INTERACTION WITH PML. RX PubMed=22155184; DOI=10.1053/j.gastro.2011.11.041; RA Satow R., Shitashige M., Jigami T., Fukami K., Honda K., Kitabayashi I., RA Yamada T.; RT "Beta-catenin inhibits promyelocytic leukemia protein tumor suppressor RT function in colorectal cancer cells."; RL Gastroenterology 142:572-581(2012). RN [74] RP SUBCELLULAR LOCATION. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [75] RP INVOLVEMENT IN NEDSDV. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [76] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [77] RP SUBCELLULAR LOCATION, AND INTERACTION WITH FAM53B. RX PubMed=25183871; DOI=10.1242/dev.108415; RA Kizil C., Kuechler B., Yan J.J., Oezhan G., Moro E., Argenton F., Brand M., RA Weidinger G., Antos C.L.; RT "Simplet/Fam53b is required for Wnt signal transduction by regulating beta- RT catenin nuclear localization."; RL Development 141:3529-3539(2014). RN [78] RP GLYCOSYLATION AT SER-23, AND SUBCELLULAR LOCATION. RX PubMed=24342833; DOI=10.1016/j.yexcr.2013.11.021; RA Ha J.R., Hao L., Venkateswaran G., Huang Y.H., Garcia E., Persad S.; RT "beta-catenin is O-GlcNAc glycosylated at Serine 23: implications for beta- RT catenin's subcellular localization and transactivator function."; RL Exp. Cell Res. 321:153-166(2014). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-552, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP INTERACTION WITH RNF220. RX PubMed=25266658; DOI=10.1128/mcb.00731-14; RA Ma P., Yang X., Kong Q., Li C., Yang S., Li Y., Mao B.; RT "The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7- RT mediated deubiquitination of beta-catenin."; RL Mol. Cell. Biol. 34:4355-4366(2014). RN [81] RP ACETYLATION AT LYS-49, AND DEACETYLATION. RX PubMed=24824780; DOI=10.1002/ijc.28967; RA Pangon L., Mladenova D., Watkins L., Van Kralingen C., Currey N., RA Al-Sohaily S., Lecine P., Borg J.P., Kohonen-Corish M.R.; RT "MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in RT the cytoplasm."; RL Int. J. Cancer 136:55-64(2015). RN [82] RP INTERACTION WITH JPT1, AND PHOSPHORYLATION AT SER-33. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [83] RP INTERACTION WITH CTNND2. RX PubMed=25807484; DOI=10.1038/nature14186; RA Turner T.N., Sharma K., Oh E.C., Liu Y.P., Collins R.L., Sosa M.X., RA Auer D.R., Brand H., Sanders S.J., Moreno-De-Luca D., Pihur V., Plona T., RA Pike K., Soppet D.R., Smith M.W., Cheung S.W., Martin C.L., State M.W., RA Talkowski M.E., Cook E., Huganir R., Katsanis N., Chakravarti A.; RT "Loss of delta-catenin function in severe autism."; RL Nature 520:51-56(2015). RN [84] RP INTERACTION WITH GID8; AXIN1 AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=28829046; DOI=10.1038/cr.2017.107; RA Lu Y., Xie S., Zhang W., Zhang C., Gao C., Sun Q., Cai Y., Xu Z., Xiao M., RA Xu Y., Huang X., Wu X., Liu W., Wang F., Kang Y., Zhou T.; RT "Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and RT colorectal tumorigenesis."; RL Cell Res. 27:1422-1440(2017). RN [85] RP IDENTIFICATION IN A CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=28051089; DOI=10.1038/mi.2016.120; RA Caldwell J.M., Collins M.H., Kemme K.A., Sherrill J.D., Wen T., Rochman M., RA Stucke E.M., Amin L., Tai H., Putnam P.E., Jimenez-Dalmaroni M.J., RA Wormald M.R., Porollo A., Abonia J.P., Rothenberg M.E.; RT "Cadherin 26 is an alpha integrin-binding epithelial receptor regulated RT during allergic inflammation."; RL Mucosal Immunol. 10:1190-1201(2017). RN [86] RP INTERACTION WITH TCF7L2/TCF4 AND HERPES VIRUS 8 PROTEIN VPK (MICROBIAL RP INFECTION). RX PubMed=29432739; DOI=10.1016/j.bbrc.2018.02.089; RA Cha S., Kang M.S., Seo T.; RT "KSHV vPK inhibits Wnt signaling via preventing interactions between beta- RT catenin and TCF4."; RL Biochem. Biophys. Res. Commun. 497:381-387(2018). RN [87] RP SUBCELLULAR LOCATION, INTERACTION WITH TMEM170B, AND TISSUE SPECIFICITY. RX PubMed=29367600; DOI=10.1038/s41419-017-0128-y; RA Li M., Han Y., Zhou H., Li X., Lin C., Zhang E., Chi X., Hu J., Xu H.; RT "Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene RT that inhibits the Wnt/beta-catenin pathway."; RL Cell Death Dis. 9:91-91(2018). RN [88] RP INVOLVEMENT IN EVR7, AND VARIANT EVR7 CYS-710. RX PubMed=28575650; DOI=10.1016/j.ajhg.2017.05.001; RA Panagiotou E.S., Sanjurjo Soriano C., Poulter J.A., Lord E.C., Dzulova D., RA Kondo H., Hiyoshi A., Chung B.H., Chu Y.W., Lai C.H.Y., Tafoya M.E., RA Karjosukarso D., Collin R.W.J., Topping J., Downey L.M., Ali M., RA Inglehearn C.F., Toomes C.; RT "Defects in the cell signaling mediator beta-catenin cause the retinal RT vascular condition FEVR."; RL Am. J. Hum. Genet. 100:960-968(2017). RN [89] RP INTERACTION WITH IRF2BPL, AND VARIANT TYR-33. RX PubMed=29374064; DOI=10.1158/0008-5472.can-17-2403; RA Higashimori A., Dong Y., Zhang Y., Kang W., Nakatsu G., Ng S.S.M., RA Arakawa T., Sung J.J.Y., Chan F.K.L., Yu J.; RT "Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL- RT beta-Catenin Signaling Axis."; RL Cancer Res. 78:1643-1656(2018). RN [90] RP INTERACTION WITH SOX30 AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=29739711; DOI=10.1016/j.ebiom.2018.04.026; RA Han F., Liu W.B., Shi X.Y., Yang J.T., Zhang X., Li Z.M., Jiang X., Yin L., RA Li J.J., Huang C.S., Cao J., Liu J.Y.; RT "SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via RT Transcriptional and Posttranslational Regulation of beta-Catenin in Lung RT Cancer."; RL EBioMedicine 31:253-266(2018). RN [91] RP INTERACTION WITH FLYWCH1. RX PubMed=30097457; DOI=10.1158/1541-7786.mcr-18-0262; RA Muhammad B.A., Almozyan S., Babaei-Jadidi R., Onyido E.K., Saadeddin A., RA Kashfi S.H., Spencer-Dene B., Ilyas M., Lourdusamy A., Behrens A., RA Nateri A.S.; RT "FLYWCH1, a Novel Suppressor of Nuclear beta-Catenin, Regulates Migration RT and Morphology in Colorectal Cancer."; RL Mol. Cancer Res. 16:1977-1990(2018). RN [92] RP FUNCTION, INTERACTION WITH DSG2, AND SUBCELLULAR LOCATION. RX PubMed=29910125; DOI=10.1016/j.stemcr.2018.05.009; RA Park J., Son Y., Lee N.G., Lee K., Lee D.G., Song J., Lee J., Kim S., RA Cho M.J., Jang J.H., Lee J., Park J.G., Kim Y.G., Kim J.S., Lee J., RA Cho Y.S., Park Y.J., Han B.S., Bae K.H., Han S., Kang B., Haam S., RA Lee S.H., Lee S.C., Min J.K.; RT "DSG2 Is a Functional Cell Surface Marker for Identification and Isolation RT of Human Pluripotent Stem Cells."; RL Stem Cell Reports 11:115-127(2018). RN [93] RP INTERACTION WITH FBXO16, SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=30714168; DOI=10.1002/path.5252; RA Paul D., Islam S., Manne R.K., Dinesh U.S., Malonia S.K., Maity B., RA Boppana R., Rapole S., Shetty P.K., Santra M.K.; RT "F-box protein FBXO16 functions as a tumor suppressor by attenuating RT nuclear beta-catenin function."; RL J. Pathol. 248:266-279(2019). RN [94] RP INTERACTION WITH LMBR1L. RX PubMed=31073040; DOI=10.1126/science.aau0812; RA Choi J.H., Zhong X., McAlpine W., Liao T.C., Zhang D., Fang B., Russell J., RA Ludwig S., Nair-Gill E., Zhang Z., Wang K.W., Misawa T., Zhan X., Choi M., RA Wang T., Li X., Tang M., Sun Q., Yu L., Murray A.R., Moresco E.M.Y., RA Beutler B.; RT "LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling."; RL Science 364:0-0(2019). RN [95] RP PHOSPHORYLATION AT THR-556 (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=31801859; DOI=10.1128/jvi.01847-19; RA You H., Lin Y., Lin F., Yang M., Li J., Zhang R., Huang Z., Shen Q., RA Tang R., Zheng C.; RT "beta-Catenin Is Required for the cGAS/STING Signaling Pathway but RT Antagonized by the Herpes Simplex Virus 1 US3 Protein."; RL J. Virol. 94:0-0(2020). RN [96] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 133-664. RX PubMed=11136974; DOI=10.1016/s0092-8674(00)00192-6; RA Graham T.A., Weaver C., Mao F., Kimelman D., Xu W.; RT "Crystal structure of a beta-catenin/Tcf complex."; RL Cell 103:885-896(2000). RN [97] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 134-664 IN COMPLEX WITH TCF7L2, RP AND MUTAGENESIS OF LYS-312 AND LYS-435. RX PubMed=11713475; DOI=10.1038/nsb718; RA Graham T.A., Ferkey D.M., Mao F., Kimelman D., Xu W.; RT "Tcf4 can specifically recognize beta-catenin using alternative RT conformations."; RL Nat. Struct. Biol. 8:1048-1052(2001). RN [98] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-668 IN COMPLEX WITH TCF7L2. RX PubMed=11713476; DOI=10.1038/nsb720; RA Poy F., Lepourcelet M., Shivdasani R.A., Eck M.J.; RT "Structure of a human Tcf4-beta-catenin complex."; RL Nat. Struct. Biol. 8:1053-1057(2001). RN [99] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-664 IN COMPLEX WITH CTNNBIP1, RP AND MUTAGENESIS OF PHE-660 AND ARG-661. RX PubMed=12408824; DOI=10.1016/s1097-2765(02)00637-8; RA Graham T.A., Clements W.K., Kimelman D., Xu W.; RT "The crystal structure of the beta-catenin/ICAT complex reveals the RT inhibitory mechanism of ICAT."; RL Mol. Cell 10:563-571(2002). RN [100] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1-136 IN COMPLEX WITH BCL9 AND RP TCF7L2, INTERACTION WITH BCL9; BCL9L CDH3 AND TCF7L2, AND MUTAGENESIS OF RP TYR-142; LEU-156; LEU-159 AND LEU-178. RX PubMed=17052462; DOI=10.1016/j.molcel.2006.09.001; RA Sampietro J., Dahlberg C.L., Cho U.S., Hinds T.R., Kimelman D., Xu W.; RT "Crystal structure of a beta-catenin/BCL9/Tcf4 complex."; RL Mol. Cell 24:293-300(2006). RN [101] {ECO:0007744|PDB:3TX7} RP X-RAY CRYSTALLOGRAPHY (2.76 ANGSTROMS) OF 183-663 COMPLEX WITH NR5A2, RP FUNCTION, AND INTERACTION WITH NR5A2. RX PubMed=22187462; DOI=10.1073/pnas.1117036108; RA Yumoto F., Nguyen P., Sablin E.P., Baxter J.D., Webb P., Fletterick R.J.; RT "Structural basis of coactivation of liver receptor homolog-1 by beta- RT catenin."; RL Proc. Natl. Acad. Sci. U.S.A. 109:143-148(2012). RN [102] RP VARIANTS COLORECTAL CANCER TYR-33 AND SER-45 DEL. RX PubMed=9065402; DOI=10.1126/science.275.5307.1787; RA Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., RA Kinzler K.W.; RT "Activation of beta-catenin-Tcf signaling in colon cancer by mutations in RT beta-catenin or APC."; RL Science 275:1787-1790(1997). RN [103] RP VARIANTS HEPATOBLASTOMA TYR-32; VAL-34; CYS-37 AND ALA-41. RX PubMed=9927029; RA Koch A., Denkhaus D., Albrecht S., Leuschner I., von Schweinitz D., RA Pietsch T.; RT "Childhood hepatoblastomas frequently carry a mutated degradation targeting RT box of the beta-catenin gene."; RL Cancer Res. 59:269-273(1999). RN [104] RP VARIANT HEPATOBLASTOMA ALA-41. RX PubMed=10398436; RX DOI=10.1002/(sici)1098-2264(199908)25:4<399::aid-gcc14>3.3.co;2-o; RA Blaeker H., Hofmann W.J., Rieker R.J., Penzel R., Graf M., Otto H.F.; RT "Beta-catenin accumulation and mutation of the CTNNB1 gene in RT hepatoblastoma."; RL Genes Chromosomes Cancer 25:399-402(1999). RN [105] RP VARIANTS OVARIAN CANCER CYS-37; ILE-41 AND ALA-41. RX PubMed=10391090; DOI=10.1111/j.1349-7006.1999.tb00777.x; RA Sagae S., Kobayashi K., Nishioka Y., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: RT frequent mutations in endometrioid carcinomas."; RL Jpn. J. Cancer Res. 90:510-515(1999). RN [106] RP VARIANT DESMOID TUMOR ALA-41. RX PubMed=10655994; DOI=10.1136/jcp.52.9.695; RA Shitoh K., Konishi F., Iijima T., Ohdaira T., Sakai K., Kanazawa K., RA Miyaki M.; RT "A novel case of a sporadic desmoid tumour with mutation of the beta RT catenin gene."; RL J. Clin. Pathol. 52:695-696(1999). RN [107] RP VARIANTS PTR GLY-32; TYR-32; PHE-33; TYR-33; GLU-34; CYS-37; PHE-37 AND RP ILE-41. RX PubMed=10192393; DOI=10.1038/7747; RA Chan E.F., Gat U., McNiff J.M., Fuchs E.; RT "A common human skin tumour is caused by activating mutations in beta- RT catenin."; RL Nat. Genet. 21:410-413(1999). RN [108] RP VARIANTS HEPATOCELLULAR CARCINOMA ARG-23; 25-TRP--SER-33 DEL; ALA-32; RP GLY-32; TYR-32; LEU-33; PHE-33; ARG-34; SER-35; ALA-37; 37-SER-GLY-38 RP DELINS TRP; TYR-37; ALA-41; ILE-41; PHE-45 AND PRO-45. RX PubMed=10435629; DOI=10.1038/sj.onc.1202800; RA Legoix P., Bluteau O., Bayer J., Perret C., Balabaud C., Belghiti J., RA Franco D., Thomas G., Laurent-Puig P., Zucman-Rossi J.; RT "Beta-catenin mutations in hepatocellular carcinoma correlate with a low RT rate of loss of heterozygosity."; RL Oncogene 18:4044-4046(1999). RN [109] RP VARIANTS MDB PHE-33 AND ALA-37. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [110] RP VARIANT NEDSDV PRO-388. RX PubMed=25326669; DOI=10.1007/s00439-014-1498-1; RA Kuechler A., Willemsen M.H., Albrecht B., Bacino C.A., Bartholomew D.W., RA van Bokhoven H., van den Boogaard M.J., Bramswig N., Buettner C., RA Cremer K., Czeschik J.C., Engels H., van Gassen K., Graf E., van Haelst M., RA He W., Hogue J.S., Kempers M., Koolen D., Monroe G., de Munnik S., RA Pastore M., Reis A., Reuter M.S., Tegay D.H., Veltman J., Visser G., RA van Hasselt P., Smeets E.E., Vissers L., Wieland T., Wissink W., Yntema H., RA Zink A.M., Strom T.M., Luedecke H.J., Kleefstra T., Wieczorek D.; RT "De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause RT of intellectual disability: expanding the mutational and clinical RT spectrum."; RL Hum. Genet. 134:97-109(2015). RN [111] RP VARIANT NEDSDV 558-GLN--LEU-781 DEL. RX PubMed=28514307; DOI=10.1097/md.0000000000006914; RA Li N., Xu Y., Li G., Yu T., Yao R.E., Wang X., Wang J.; RT "Exome sequencing identifies a de novo mutation of CTNNB1 gene in a patient RT mainly presented with retinal detachment, lens and vitreous opacities, RT microcephaly, and developmental delay: Case report and literature review."; RL Medicine (Baltimore) 96:E6914-E6914(2017). RN [112] RP VARIANT ASN-292, AND CHARACTERIZATION OF VARIANT ASN-292. RX PubMed=38173341; DOI=10.1210/clinem/dgad757; RA Huybrechts Y., Appelman-Dijkstra N.M., Steenackers E., Van Beylen W., RA Mortier G., Hendrickx G., Van Hul W.; RT "A mosaic variant in CTNNB1/beta-catenin as a novel cause for osteopathia RT striata with cranial sclerosis."; RL J. Clin. Endocrinol. Metab. 0:0-0(2024). CC -!- FUNCTION: Key downstream component of the canonical Wnt signaling CC pathway (PubMed:17524503, PubMed:18077326, PubMed:18086858, CC PubMed:18957423, PubMed:21262353, PubMed:22155184, PubMed:22647378, CC PubMed:22699938). In the absence of Wnt, forms a complex with AXIN1, CC AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N- CC terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and CC its subsequent degradation by the proteasome (PubMed:17524503, CC PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, CC PubMed:22155184, PubMed:22647378, PubMed:22699938). In the presence of CC Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, CC where it acts as a coactivator for transcription factors of the TCF/LEF CC family, leading to activate Wnt responsive genes (PubMed:17524503, CC PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, CC PubMed:22155184, PubMed:22647378, PubMed:22699938). Also acts as a CC coactivator for other transcription factors, such as NR5A2 CC (PubMed:22187462). Promotes epithelial to mesenchymal CC transition/mesenchymal to epithelial transition (EMT/MET) via driving CC transcription of CTNNB1/TCF-target genes (PubMed:29910125). Involved in CC the regulation of cell adhesion, as component of an E-cadherin:catenin CC adhesion complex (By similarity). Acts as a negative regulator of CC centrosome cohesion (PubMed:18086858). Involved in the CC CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization CC (PubMed:21262353). Blocks anoikis of malignant kidney and intestinal CC epithelial cells and promotes their anchorage-independent growth by CC down-regulating DAPK2 (PubMed:18957423). Disrupts PML function and PML- CC NB formation by inhibiting RANBP2-mediated sumoylation of PML CC (PubMed:22155184). Promotes neurogenesis by maintaining sympathetic CC neuroblasts within the cell cycle (By similarity). Involved in CC chondrocyte differentiation via interaction with SOX9: SOX9-binding CC competes with the binding sites of TCF/LEF within CTNNB1, thereby CC inhibiting the Wnt signaling (By similarity). Acts as a positive CC regulator of odontoblast differentiation during mesenchymal tooth germ CC formation, via promoting the transcription of differentiation factors CC such as LEF1, BMP2 and BMP4 (By similarity). Activity is repressed in a CC MSX1-mediated manner at the bell stage of mesenchymal tooth germ CC formation which prevents premature differentiation of odontoblasts (By CC similarity). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18957423, CC ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:22155184, CC ECO:0000269|PubMed:22187462, ECO:0000269|PubMed:22647378, CC ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:29910125}. CC -!- SUBUNIT: Two separate complex-associated pools are found in the CC cytoplasm. The majority is present as component of an E- CC cadherin:catenin adhesion complex composed of at least E-cadherin/CDH1 CC and beta-catenin/CTNNB1, and possibly alpha-catenin/CTNNA1; the complex CC is located to adherens junctions. The stable association of CTNNA1 is CC controversial as CTNNA1 was shown not to bind to F-actin when assembled CC in the complex. Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1. Another cytoplasmic CC pool is part of a large complex containing AXIN1, AXIN2, APC, CSNK1A1 CC and GSK3B that promotes phosphorylation on N-terminal Ser and Thr CC residues and ubiquitination of CTNNB1 via BTRC and its subsequent CC degradation by the proteasome. Wnt-dependent activation of DVL CC antagonizes the action of GSK3B. When GSK3B activity is inhibited the CC complex dissociates, CTNNB1 is dephosphorylated and is no longer CC targeted for destruction. The stabilized protein translocates to the CC nucleus, where it binds TCF/LEF-1 family members, BCL9, BCL9L and CC possibly also RUVBL1 and CHD8. Binds CTNNBIP and EP300. CTNNB1 forms a CC ternary complex with LEF1 and EP300 that is disrupted by CTNNBIP1 CC binding. Interacts with TAX1BP3 (via the PDZ domain); this interaction CC inhibits the transcriptional activity of CTNNB1. Interacts with AJAP1, CC BAIAP1, CARM1, CTNNA3, CXADR and PCDH11Y. Binds NHERF1. Interacts with CC GLIS2 and MUC1. Interacts with SLC30A9. Interacts with XIRP1. Interacts CC directly with AXIN1; the interaction is regulated by CDK2 CC phosphorylation of AXIN1. Interacts with SCRIB. Interacts with RAPGEF2. CC Interacts with PTPRU (via the cytoplasmic juxtamembrane domain). CC Interacts with EMD. Interacts with TNIK and TCF7L2. Interacts with CC SESTD1 and TRPC4. Interacts with CAV1. Interacts with TRPV4. The TRPV4 CC and CTNNB1 complex can interact with CDH1. Interacts with VCL. CC Interacts with PTPRJ. Interacts with PKT7 and CDK2. Interacts with FAT1 CC (via the cytoplasmic domain). Interacts with NANOS1 and NDRG2. CC Interacts with isoform 1 of NEK2. Interacts with both isoform 1 and CC isoform 2 of CDK5. Interacts with PTK6. Interacts with SOX7; this CC interaction may lead to proteasomal degradation of active CTNNB1 and CC thus inhibition of Wnt/beta-catenin-stimulated transcription. CC Identified in a complex with HINT1 and MITF. Interacts with FHIT. The CC CTNNB1 and TCF7L2/TCF4 complex interacts with PML (isoform PML-4). CC Interacts with FERMT2. Identified in a complex with TCF7L2/TCF4 and CC FERMT2 (PubMed:22699938, PubMed:29739711). Interacts with RORA. May CC interact with P-cadherin/CDH3. Interacts with RNF220 (PubMed:25266658). CC Interacts with CTNND2 (PubMed:25807484). Interacts (via the C-terminal CC region) with CBY1 (PubMed:12712206, PubMed:16424001, PubMed:19435523). CC The complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with DLG5 (By CC similarity). Interacts with FAM53B; promoting translocation to the CC nucleus (PubMed:25183871). Interacts with TMEM170B (PubMed:29367600). CC Interacts with AHI1 (PubMed:21623382). Interacts with GID8 CC (PubMed:28829046). Component of an cadherin:catenin adhesion complex CC composed of at least of CDH26, beta-catenin/CTNNB1, alpha- CC catenin/CTNNA1 and p120 catenin/CTNND1 (PubMed:28051089). Forms a CC complex comprising APPL1, RUVBL2, APPL2, HDAC1 and HDAC2 CC (PubMed:19433865). Interacts with IRF2BPL; mediates the ubiquitination CC and degradation of CTNNB1 (PubMed:29374064). Interacts with AMFR (By CC similarity). Interacts with LMBR1L (PubMed:31073040). Interacts with CC SOX30; prevents interaction of CTNNB1 with TCF7L2/TCF4 and leads to CC inhibition of Wnt signaling (PubMed:29739711). Interacts with SOX9; CC inhibiting CTNNB1 activity by competing with the binding sites of CC TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling (By CC similarity). Interacts with SPN/CD43 cytoplasmic tail CC (PubMed:15003504). Interacts (when phosphorylated at Tyr-333) with CC isoform M2 of PKM (PKM2); promoting transcription activation CC (PubMed:22056988). Interacts with PKP2 (via HEAD domain) CC (PubMed:11790773). Interacts with CDH1 (PubMed:11790773). Interacts CC (when unphosphorylated) with FLYWCH1, perhaps preventing interaction of CC CTNNB1 with TCF4, and thereby regulating transcription activation; CC phosphorylation of CTNNB1 may inhibit the interaction CC (PubMed:30097457). Interacts (via the central armadillo domains) with CC probable transcriptional regulator ADNP (via N-terminal region); CC interaction is direct and stabilizes CTNNB1 by modulating its CC phosphorylation by glycogen synthase kinase-3 beta GSK3B (By CC similarity). Interacts with NR5A2 (PubMed:22187462). Interacts with CC DSG2; the interaction promotes localization of CTNNB1 at cell junctions CC thus reducing its nuclear localization and subsequent transcription of CC CTNNB1/TCF-target genes (PubMed:29910125). Interacts with FBXO16 CC (PubMed:30714168). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:10966653, ECO:0000269|PubMed:11389839, CC ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:11590244, CC ECO:0000269|PubMed:11713475, ECO:0000269|PubMed:11713476, CC ECO:0000269|PubMed:11751639, ECO:0000269|PubMed:11790773, CC ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:12297051, CC ECO:0000269|PubMed:12370829, ECO:0000269|PubMed:12408824, CC ECO:0000269|PubMed:12420223, ECO:0000269|PubMed:12501215, CC ECO:0000269|PubMed:12712206, ECO:0000269|PubMed:12830000, CC ECO:0000269|PubMed:14595118, ECO:0000269|PubMed:15003504, CC ECO:0000269|PubMed:16424001, ECO:0000269|PubMed:16858403, CC ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17047063, CC ECO:0000269|PubMed:17052462, ECO:0000269|PubMed:17289029, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18378692, CC ECO:0000269|PubMed:18819930, ECO:0000269|PubMed:19433865, CC ECO:0000269|PubMed:19435523, ECO:0000269|PubMed:19693690, CC ECO:0000269|PubMed:19816403, ECO:0000269|PubMed:19996314, CC ECO:0000269|PubMed:20026641, ECO:0000269|PubMed:20164195, CC ECO:0000269|PubMed:21132015, ECO:0000269|PubMed:21247902, CC ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21623382, CC ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:22155184, CC ECO:0000269|PubMed:22187462, ECO:0000269|PubMed:22647378, CC ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:25266658, CC ECO:0000269|PubMed:25807484, ECO:0000269|PubMed:28051089, CC ECO:0000269|PubMed:28829046, ECO:0000269|PubMed:29367600, CC ECO:0000269|PubMed:29374064, ECO:0000269|PubMed:29432739, CC ECO:0000269|PubMed:29739711, ECO:0000269|PubMed:29910125, CC ECO:0000269|PubMed:30714168, ECO:0000269|PubMed:31073040, CC ECO:0000269|PubMed:7982500, ECO:0000305|PubMed:31073040}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein CC vPK; this interaction inhibits the Wnt signaling pathway. CC {ECO:0000269|PubMed:29432739}. CC -!- INTERACTION: CC P35222; P01023: A2M; NbExp=3; IntAct=EBI-491549, EBI-640741; CC P35222; P00519: ABL1; NbExp=2; IntAct=EBI-491549, EBI-375543; CC P35222; O43707: ACTN4; NbExp=7; IntAct=EBI-491549, EBI-351526; CC P35222; Q02952: AKAP12; NbExp=2; IntAct=EBI-491549, EBI-2562430; CC P35222; Q5JTC6: AMER1; NbExp=9; IntAct=EBI-491549, EBI-6169747; CC P35222; P25054: APC; NbExp=22; IntAct=EBI-491549, EBI-727707; CC P35222; P10275: AR; NbExp=15; IntAct=EBI-491549, EBI-608057; CC P35222; Q5T5U3: ARHGAP21; NbExp=2; IntAct=EBI-491549, EBI-1642518; CC P35222; O15169: AXIN1; NbExp=44; IntAct=EBI-491549, EBI-710484; CC P35222; Q9Y2T1: AXIN2; NbExp=2; IntAct=EBI-491549, EBI-4400025; CC P35222; O00512: BCL9; NbExp=5; IntAct=EBI-491549, EBI-533127; CC P35222; A1Z199: BCR/ABL fusion; NbExp=2; IntAct=EBI-491549, EBI-7286259; CC P35222; P23560-2: BDNF; NbExp=3; IntAct=EBI-491549, EBI-12275524; CC P35222; Q2LD37: BLTP1; NbExp=2; IntAct=EBI-491549, EBI-2683809; CC P35222; Q9Y297: BTRC; NbExp=8; IntAct=EBI-491549, EBI-307461; CC P35222; P55212: CASP6; NbExp=3; IntAct=EBI-491549, EBI-718729; CC P35222; P35520: CBS; NbExp=3; IntAct=EBI-491549, EBI-740135; CC P35222; Q6P1J9: CDC73; NbExp=10; IntAct=EBI-491549, EBI-930143; CC P35222; P12830: CDH1; NbExp=23; IntAct=EBI-491549, EBI-727477; CC P35222; P19022: CDH2; NbExp=12; IntAct=EBI-491549, EBI-2256711; CC P35222; P33151: CDH5; NbExp=11; IntAct=EBI-491549, EBI-2903122; CC P35222; Q92793: CREBBP; NbExp=2; IntAct=EBI-491549, EBI-81215; CC P35222; P02511: CRYAB; NbExp=6; IntAct=EBI-491549, EBI-739060; CC P35222; P35221: CTNNA1; NbExp=8; IntAct=EBI-491549, EBI-701918; CC P35222; P26232: CTNNA2; NbExp=5; IntAct=EBI-491549, EBI-3953920; CC P35222; Q9UI47-1: CTNNA3; NbExp=4; IntAct=EBI-491549, EBI-21980640; CC P35222; Q9NSA3: CTNNBIP1; NbExp=19; IntAct=EBI-491549, EBI-747082; CC P35222; Q9NYF0: DACT1; NbExp=3; IntAct=EBI-491549, EBI-3951744; CC P35222; G5E9A7: DMWD; NbExp=3; IntAct=EBI-491549, EBI-10976677; CC P35222; P26358: DNMT1; NbExp=8; IntAct=EBI-491549, EBI-719459; CC P35222; Q8TEK3: DOT1L; NbExp=3; IntAct=EBI-491549, EBI-2619253; CC P35222; P18146: EGR1; NbExp=7; IntAct=EBI-491549, EBI-2834611; CC P35222; P50402: EMD; NbExp=3; IntAct=EBI-491549, EBI-489887; CC P35222; P29317: EPHA2; NbExp=2; IntAct=EBI-491549, EBI-702104; CC P35222; Q9UKB1: FBXW11; NbExp=4; IntAct=EBI-491549, EBI-355189; CC P35222; Q96AC1: FERMT2; NbExp=13; IntAct=EBI-491549, EBI-4399465; CC P35222; Q92915-2: FGF14; NbExp=3; IntAct=EBI-491549, EBI-12836320; CC P35222; P11362: FGFR1; NbExp=3; IntAct=EBI-491549, EBI-1028277; CC P35222; P49789: FHIT; NbExp=4; IntAct=EBI-491549, EBI-741760; CC P35222; Q08050: FOXM1; NbExp=16; IntAct=EBI-491549, EBI-866480; CC P35222; P04406: GAPDH; NbExp=3; IntAct=EBI-491549, EBI-354056; CC P35222; P14136: GFAP; NbExp=3; IntAct=EBI-491549, EBI-744302; CC P35222; Q9BZE0: GLIS2; NbExp=6; IntAct=EBI-491549, EBI-7251368; CC P35222; P49841: GSK3B; NbExp=20; IntAct=EBI-491549, EBI-373586; CC P35222; Q9UBN7: HDAC6; NbExp=4; IntAct=EBI-491549, EBI-301697; CC P35222; Q16665: HIF1A; NbExp=4; IntAct=EBI-491549, EBI-447269; CC P35222; O00291: HIP1; NbExp=3; IntAct=EBI-491549, EBI-473886; CC P35222; P07900: HSP90AA1; NbExp=3; IntAct=EBI-491549, EBI-296047; CC P35222; P42858: HTT; NbExp=14; IntAct=EBI-491549, EBI-466029; CC P35222; P08069: IGF1R; NbExp=3; IntAct=EBI-491549, EBI-475981; CC P35222; P46940: IQGAP1; NbExp=3; IntAct=EBI-491549, EBI-297509; CC P35222; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-491549, EBI-1055254; CC P35222; O75564: JRK; NbExp=3; IntAct=EBI-491549, EBI-8607681; CC P35222; Q14678: KANK1; NbExp=2; IntAct=EBI-491549, EBI-2556221; CC P35222; P13473-2: LAMP2; NbExp=3; IntAct=EBI-491549, EBI-21591415; CC P35222; Q9UJU2: LEF1; NbExp=10; IntAct=EBI-491549, EBI-926131; CC P35222; Q8WVC0: LEO1; NbExp=2; IntAct=EBI-491549, EBI-932432; CC P35222; Q14114-3: LRP8; NbExp=3; IntAct=EBI-491549, EBI-25832196; CC P35222; Q9GZQ8: MAP1LC3B; NbExp=5; IntAct=EBI-491549, EBI-373144; CC P35222; Q9Y2H9: MAST1; NbExp=2; IntAct=EBI-491549, EBI-3385920; CC P35222; P51608: MECP2; NbExp=3; IntAct=EBI-491549, EBI-1189067; CC P35222; P55197: MLLT10; NbExp=5; IntAct=EBI-491549, EBI-1104952; CC P35222; Q92597: NDRG1; NbExp=3; IntAct=EBI-491549, EBI-716486; CC P35222; P19404: NDUFV2; NbExp=3; IntAct=EBI-491549, EBI-713665; CC P35222; P19838: NFKB1; NbExp=3; IntAct=EBI-491549, EBI-300010; CC P35222; Q15599: NHERF2; NbExp=3; IntAct=EBI-491549, EBI-1149760; CC P35222; P29474: NOS3; NbExp=4; IntAct=EBI-491549, EBI-1391623; CC P35222; O00482-1: NR5A2; NbExp=5; IntAct=EBI-491549, EBI-15960777; CC P35222; P49757: NUMB; NbExp=2; IntAct=EBI-491549, EBI-915016; CC P35222; P49757-3: NUMB; NbExp=3; IntAct=EBI-491549, EBI-10692196; CC P35222; P14618: PKM; NbExp=4; IntAct=EBI-491549, EBI-353408; CC P35222; P14618-1: PKM; NbExp=3; IntAct=EBI-491549, EBI-4304679; CC P35222; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-491549, EBI-5280197; CC P35222; Q03431: PTH1R; NbExp=4; IntAct=EBI-491549, EBI-2860297; CC P35222; Q13308: PTK7; NbExp=5; IntAct=EBI-491549, EBI-2803245; CC P35222; P08575: PTPRC; NbExp=2; IntAct=EBI-491549, EBI-1341; CC P35222; P23470: PTPRG; NbExp=2; IntAct=EBI-491549, EBI-2258115; CC P35222; Q12913: PTPRJ; NbExp=2; IntAct=EBI-491549, EBI-2264500; CC P35222; P49023: PXN; NbExp=4; IntAct=EBI-491549, EBI-702209; CC P35222; P62826: RAN; NbExp=3; IntAct=EBI-491549, EBI-286642; CC P35222; Q04206: RELA; NbExp=3; IntAct=EBI-491549, EBI-73886; CC P35222; Q13761: RUNX3; NbExp=12; IntAct=EBI-491549, EBI-925990; CC P35222; Q9Y265: RUVBL1; NbExp=3; IntAct=EBI-491549, EBI-353675; CC P35222; Q01826: SATB1; NbExp=9; IntAct=EBI-491549, EBI-743747; CC P35222; Q14160: SCRIB; NbExp=4; IntAct=EBI-491549, EBI-357345; CC P35222; Q9H6I2: SOX17; NbExp=2; IntAct=EBI-491549, EBI-9106753; CC P35222; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-491549, EBI-5235340; CC P35222; P12931: SRC; NbExp=2; IntAct=EBI-491549, EBI-621482; CC P35222; O14907: TAX1BP3; NbExp=6; IntAct=EBI-491549, EBI-723259; CC P35222; P15884: TCF4; NbExp=22; IntAct=EBI-491549, EBI-533224; CC P35222; P36402: TCF7; NbExp=4; IntAct=EBI-491549, EBI-2119465; CC P35222; Q9NQB0: TCF7L2; NbExp=27; IntAct=EBI-491549, EBI-924724; CC P35222; O14746: TERT; NbExp=2; IntAct=EBI-491549, EBI-1772203; CC P35222; Q9UKE5: TNIK; NbExp=3; IntAct=EBI-491549, EBI-1051794; CC P35222; P11388: TOP2A; NbExp=5; IntAct=EBI-491549, EBI-539628; CC P35222; O14656-2: TOR1A; NbExp=3; IntAct=EBI-491549, EBI-25847109; CC P35222; Q13625: TP53BP2; NbExp=5; IntAct=EBI-491549, EBI-77642; CC P35222; O95071: UBR5; NbExp=6; IntAct=EBI-491549, EBI-358329; CC P35222; P11473: VDR; NbExp=2; IntAct=EBI-491549, EBI-286357; CC P35222; Q9GZV5: WWTR1; NbExp=4; IntAct=EBI-491549, EBI-747743; CC P35222; P46937: YAP1; NbExp=16; IntAct=EBI-491549, EBI-1044059; CC P35222; P46937-3: YAP1; NbExp=2; IntAct=EBI-491549, EBI-6558686; CC P35222; O35625: Axin1; Xeno; NbExp=4; IntAct=EBI-491549, EBI-2365912; CC P35222; Q9YGY0: axin1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-1037449; CC P35222; Q67FY2: Bcl9l; Xeno; NbExp=2; IntAct=EBI-491549, EBI-5234367; CC P35222; P33724: CAV1; Xeno; NbExp=5; IntAct=EBI-491549, EBI-79998; CC P35222; P26231: Ctnna1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-647895; CC P35222; P27782: Lef1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-984464; CC P35222; Q01887: Ryk; Xeno; NbExp=2; IntAct=EBI-491549, EBI-16110594; CC P35222; P18012: sctB; Xeno; NbExp=4; IntAct=EBI-491549, EBI-491541; CC P35222; P40645: Sox6; Xeno; NbExp=2; IntAct=EBI-491549, EBI-3505685; CC P35222; Q9DBG9: Tax1bp3; Xeno; NbExp=3; IntAct=EBI-491549, EBI-1161647; CC P35222; Q9EPK5: Wwtr1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-1211920; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:29739711, CC ECO:0000269|PubMed:29910125, ECO:0000269|PubMed:31801859}. Nucleus CC {ECO:0000269|PubMed:21118991, ECO:0000269|PubMed:24342833, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:28829046, CC ECO:0000269|PubMed:29367600, ECO:0000269|PubMed:29739711, CC ECO:0000269|PubMed:29910125, ECO:0000269|PubMed:30714168, CC ECO:0000269|PubMed:31801859}. Cytoplasm, cytoskeleton CC {ECO:0000250|UniProtKB:B6V8E6}. Cell junction, adherens junction CC {ECO:0000269|PubMed:10725230, ECO:0000269|PubMed:22294297}. Cell CC junction {ECO:0000250|UniProtKB:B6V8E6}. Cell membrane CC {ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:24342833}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, CC cytoskeleton, spindle pole. Synapse {ECO:0000250|UniProtKB:Q02248}. CC Cytoplasm, cytoskeleton, cilium basal body CC {ECO:0000250|UniProtKB:Q02248}. Note=Colocalized with RAPGEF2 and TJP1 CC at cell-cell contacts (By similarity). Cytoplasmic when it is un-stable CC (highly phosphorylated) or bound to CDH1. Translocates to the nucleus CC when it is stabilized (low level of phosphorylation). Interaction with CC GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD CC inhibits nuclear localization. The majority of CTNNB1 is localized to CC the cell membrane. In interphase, colocalizes with CROCC between CEP250 CC puncta at the proximal end of centrioles, and this localization is CC dependent on CROCC and CEP250. In mitosis, when NEK2 activity CC increases, it localizes to centrosomes at spindle poles independent of CC CROCC. Colocalizes with CDK5 in the cell-cell contacts and plasma CC membrane of undifferentiated and differentiated neuroblastoma cells. CC Interaction with FAM53B promotes translocation to the nucleus CC (PubMed:25183871). Translocates to the nucleus in the presence of CC SNAIL1 (By similarity). Ca(2+)-mediated localization to the cell CC membrane in dental epithelial cells is inhibited via WNT3A (By CC similarity). Localizes to cell-cell contacts as keratinocyte CC differentiation progresses (By similarity). CC {ECO:0000250|UniProtKB:B6V8E6, ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:25183871}. CC -!- TISSUE SPECIFICITY: Expressed in several hair follicle cell types: CC basal and peripheral matrix cells, and cells of the outer and inner CC root sheaths. Expressed in colon. Present in cortical neurons (at CC protein level). Expressed in breast cancer tissues (at protein level) CC (PubMed:29367600). {ECO:0000269|PubMed:11703283, CC ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17289029, CC ECO:0000269|PubMed:29367600}. CC -!- PTM: Phosphorylation at Ser-552 by AMPK promotes stabilization of the CC protein, enhancing TCF/LEF-mediated transcription (By similarity). CC Phosphorylation by GSK3B requires prior phosphorylation of Ser-45 by CC another kinase (PubMed:10966653, PubMed:12027456, PubMed:12051714). CC Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33 CC (PubMed:12077367, PubMed:25169422). Phosphorylated by NEK2 CC (PubMed:18086858). EGF stimulates tyrosine phosphorylation CC (PubMed:10187801). Phosphorylated on Ser-33 and Ser-37 by HIPK2 and CC GSK3B, this phosphorylation triggers proteasomal degradation CC (PubMed:20307497). Phosphorylation on Ser-191 and Ser-246 by CDK5 CC (PubMed:17009320). Phosphorylation by CDK2 regulates insulin CC internalization (PubMed:21262353). Phosphorylation by PTK6 at Tyr-64, CC Tyr-142, Tyr-331 and/or Tyr-333 with the predominant site at Tyr-64 is CC not essential for inhibition of transcriptional activity CC (PubMed:20026641). Phosphorylation by SRC at Tyr-333 promotes CC interaction with isoform M2 of PKM (PKM2); promoting transcription CC activation (PubMed:22056988). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:10187801, ECO:0000269|PubMed:10966653, CC ECO:0000269|PubMed:12027456, ECO:0000269|PubMed:12051714, CC ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:17009320, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:21262353, CC ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:25169422}. CC -!- PTM: Ubiquitinated by the SCF(BTRC) E3 ligase complex when CC phosphorylated by GSK3B, leading to its degradation (PubMed:12077367). CC Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, CC SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent CC proteasomal degradation (PubMed:11389839, PubMed:11389840, CC PubMed:20307497). Ubiquitinated and degraded following interaction with CC SOX9 (By similarity). Ubiquitinated via 'Lys-11'- and 'Lys-29'-linked CC ubiquitin chains by UBR5, leading to its stabilization CC (PubMed:21118991). Ubiquitinated by the SCF-FBXO16 E3 ubiquitin ligase, CC leading to proteasomal degradation (PubMed:30714168). CC {ECO:0000250|UniProtKB:Q02248, ECO:0000269|PubMed:11389839, CC ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:12077367, CC ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:21118991, CC ECO:0000269|PubMed:30714168}. CC -!- PTM: S-nitrosylation at Cys-619 within adherens junctions promotes CC VEGF-induced, NO-dependent endothelial cell permeability by disrupting CC interaction with E-cadherin, thus mediating disassembly adherens CC junctions. {ECO:0000250|UniProtKB:Q02248}. CC -!- PTM: O-glycosylation at Ser-23 decreases nuclear localization and CC transcriptional activity, and increases localization to the plasma CC membrane and interaction with E-cadherin CDH1. CC {ECO:0000269|PubMed:24342833}. CC -!- PTM: Deacetylated at Lys-49 by SIRT1. {ECO:0000269|PubMed:24824780}. CC -!- PTM: Phosphorylated at Thr-556 by herpes virus 1/HHV-1 leading to CC CTNNB1 inhibition. {ECO:0000269|PubMed:24824780}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:9065402}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Activating mutations in CTNNB1 have oncogenic activity CC resulting in tumor development. Somatic mutations are found in various CC tumor types, including colon cancers, ovarian and prostate carcinomas, CC hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant CC embryonal tumors mainly affecting young children in the first three CC years of life. CC -!- DISEASE: Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. CC {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, CC ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:10391090}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving CTNNB1 is found in CC salivary gland pleiomorphic adenomas, the most common benign epithelial CC tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1. CC {ECO:0000269|PubMed:10029085, ECO:0000269|PubMed:9020842}. CC -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive CC neoplasm of the serosal lining of the chest. It appears as broad sheets CC of cells, with some regions containing spindle-shaped, sarcoma-like CC cells and other regions showing adenomatous patterns. Pleural CC mesotheliomas have been linked to exposure to asbestos. CC {ECO:0000269|PubMed:11464291}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Neurodevelopmental disorder with spastic diplegia and visual CC defects (NEDSDV) [MIM:615075]: An autosomal dominant disorder CC characterized by global developmental delay, severe intellectual CC disability with absent or very limited speech, microcephaly, CC spasticity, and visual abnormalities. {ECO:0000269|PubMed:23033978, CC ECO:0000269|PubMed:25326669, ECO:0000269|PubMed:28514307}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Vitreoretinopathy, exudative 7 (EVR7) [MIM:617572]: An CC autosomal dominant form of exudative vitreoretinopathy, a disorder of CC the retinal vasculature characterized by an abrupt cessation of growth CC of peripheral capillaries, leading to an avascular peripheral retina. CC This may lead to compensatory retinal neovascularization, which is CC thought to be induced by hypoxia from the initial avascular insult. New CC vessels are prone to leakage and rupture causing exudates and bleeding, CC followed by scarring, retinal detachment and blindness. Clinical CC features can be highly variable, even within the same family. Patients CC with mild forms of the disease are asymptomatic, and their only disease CC related abnormality is an arc of avascular retina in the extreme CC temporal periphery. {ECO:0000269|PubMed:28575650}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the beta-catenin family. {ECO:0000305}. CC -!- CAUTION: A paper showing an interaction with TBP and phosphorylation at CC Tyr-86 and Tyr-654 has been retracted due to panel duplication in CC several figures. {ECO:0000269|PubMed:11279024, CC ECO:0000305|PubMed:27226643}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG35511.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=BAB93475.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/71/CTNNB1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-catenin entry; CC URL="https://en.wikipedia.org/wiki/Beta-catenin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X87838; CAA61107.1; -; mRNA. DR EMBL; Z19054; CAA79497.1; -; mRNA. DR EMBL; AF130085; AAG35511.1; ALT_SEQ; mRNA. DR EMBL; AY463360; AAR18817.1; -; Genomic_DNA. DR EMBL; AK289932; BAF82621.1; -; mRNA. DR EMBL; AC104307; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64625.1; -; Genomic_DNA. DR EMBL; BC058926; AAH58926.1; -; mRNA. DR EMBL; AY081165; AAL89457.1; -; Genomic_DNA. DR EMBL; AB062292; BAB93475.1; ALT_INIT; mRNA. DR CCDS; CCDS2694.1; -. DR PIR; A38973; A38973. DR RefSeq; NP_001091679.1; NM_001098209.2. DR RefSeq; NP_001091680.1; NM_001098210.2. DR RefSeq; NP_001425800.1; NM_001438871.1. DR RefSeq; NP_001425801.1; NM_001438872.1. DR RefSeq; NP_001425802.1; NM_001438873.1. DR RefSeq; NP_001895.1; NM_001904.4. DR RefSeq; XP_024309124.1; XM_024453356.2. DR RefSeq; XP_047303434.1; XM_047447478.1. DR RefSeq; XP_047303435.1; XM_047447479.1. DR RefSeq; XP_047303436.1; XM_047447480.1. DR RefSeq; XP_054201285.1; XM_054345310.1. DR RefSeq; XP_054201286.1; XM_054345311.1. DR RefSeq; XP_054201287.1; XM_054345312.1. DR RefSeq; XP_054201288.1; XM_054345313.1. DR PDB; 1G3J; X-ray; 2.10 A; A/C=133-664. DR PDB; 1JDH; X-ray; 1.90 A; A=135-663. DR PDB; 1JPW; X-ray; 2.50 A; A/B/C=131-670. DR PDB; 1LUJ; X-ray; 2.50 A; A=150-663. DR PDB; 1P22; X-ray; 2.95 A; C=19-44. DR PDB; 1QZ7; X-ray; 2.20 A; A=133-665. DR PDB; 1T08; X-ray; 2.10 A; A=146-664. DR PDB; 1TH1; X-ray; 2.50 A; A/B=133-664. DR PDB; 2G57; NMR; -; A=19-44. DR PDB; 2GL7; X-ray; 2.60 A; A/D=138-686. DR PDB; 2Z6H; X-ray; 2.20 A; A=138-781. DR PDB; 3DIW; X-ray; 2.10 A; C/D=772-781. DR PDB; 3FQN; X-ray; 1.65 A; C=30-39. DR PDB; 3FQR; X-ray; 1.70 A; C=30-39. DR PDB; 3SL9; X-ray; 2.20 A; A/B/E/G=141-305. DR PDB; 3SLA; X-ray; 2.50 A; A/B/C/D/E=141-306. DR PDB; 3TX7; X-ray; 2.76 A; A=138-663. DR PDB; 4DJS; X-ray; 3.03 A; A=148-665. DR PDB; 6M90; X-ray; 2.05 A; C=17-48. DR PDB; 6M91; X-ray; 2.40 A; C=17-48. DR PDB; 6M92; X-ray; 2.35 A; C=17-48. DR PDB; 6M93; X-ray; 2.50 A; C=17-48. DR PDB; 6M94; X-ray; 2.70 A; C=17-48. DR PDB; 6O9B; X-ray; 2.20 A; C=41-49. DR PDB; 6O9C; X-ray; 2.45 A; C=41-49. DR PDB; 6WLX; X-ray; 2.20 A; B=671-677. DR PDB; 6WNX; X-ray; 2.50 A; C/F/I=31-39. DR PDB; 7AFW; X-ray; 1.81 A; A=141-305. DR PDB; 7AR4; X-ray; 2.60 A; AAA=134-665. DR PDB; 7UWI; X-ray; 2.32 A; A=143-663. DR PDB; 7UWO; X-ray; 2.75 A; A=134-665. DR PDB; 7ZRB; X-ray; 3.43 A; A/B=133-664. DR PDB; 8EI9; X-ray; 3.90 A; A=134-665. DR PDB; 8EIA; X-ray; 3.60 A; A=134-665. DR PDB; 8EIB; X-ray; 3.76 A; A=134-665. DR PDB; 8EIC; X-ray; 2.62 A; A=134-665. DR PDB; 8RU3; X-ray; 2.00 A; A=134-665. DR PDB; 8RU4; X-ray; 2.13 A; A/B=145-665. DR PDB; 8VME; X-ray; 2.30 A; C=35-61. DR PDB; 8VMF; X-ray; 2.50 A; C=35-61. DR PDB; 8Y0G; X-ray; 2.50 A; A=138-686. DR PDB; 8Y0P; X-ray; 2.62 A; A/B=138-686. DR PDB; 8Y14; X-ray; 2.80 A; A=138-686. DR PDB; 8Z0U; X-ray; 2.21 A; A=138-686. DR PDB; 8Z10; X-ray; 2.35 A; A=138-686. DR PDB; 8Z5J; X-ray; 2.80 A; A=138-686. DR PDB; 8Z61; X-ray; 2.50 A; A=138-686. DR PDBsum; 1G3J; -. DR PDBsum; 1JDH; -. DR PDBsum; 1JPW; -. DR PDBsum; 1LUJ; -. DR PDBsum; 1P22; -. DR PDBsum; 1QZ7; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 2G57; -. DR PDBsum; 2GL7; -. DR PDBsum; 2Z6H; -. DR PDBsum; 3DIW; -. DR PDBsum; 3FQN; -. DR PDBsum; 3FQR; -. DR PDBsum; 3SL9; -. DR PDBsum; 3SLA; -. DR PDBsum; 3TX7; -. DR PDBsum; 4DJS; -. DR PDBsum; 6M90; -. DR PDBsum; 6M91; -. DR PDBsum; 6M92; -. DR PDBsum; 6M93; -. DR PDBsum; 6M94; -. DR PDBsum; 6O9B; -. DR PDBsum; 6O9C; -. DR PDBsum; 6WLX; -. DR PDBsum; 6WNX; -. DR PDBsum; 7AFW; -. DR PDBsum; 7AR4; -. DR PDBsum; 7UWI; -. DR PDBsum; 7UWO; -. DR PDBsum; 7ZRB; -. DR PDBsum; 8EI9; -. DR PDBsum; 8EIA; -. DR PDBsum; 8EIB; -. DR PDBsum; 8EIC; -. DR PDBsum; 8RU3; -. DR PDBsum; 8RU4; -. DR PDBsum; 8VME; -. DR PDBsum; 8VMF; -. DR PDBsum; 8Y0G; -. DR PDBsum; 8Y0P; -. DR PDBsum; 8Y14; -. DR PDBsum; 8Z0U; -. DR PDBsum; 8Z10; -. DR PDBsum; 8Z5J; -. DR PDBsum; 8Z61; -. DR AlphaFoldDB; P35222; -. DR SMR; P35222; -. DR BioGRID; 107880; 1008. DR ComplexPortal; CPX-316; beta1-catenin - LEF1 complex. DR CORUM; P35222; -. DR DIP; DIP-122N; -. DR FunCoup; P35222; 2315. DR IntAct; P35222; 361. DR MINT; P35222; -. DR STRING; 9606.ENSP00000495360; -. DR BindingDB; P35222; -. DR ChEMBL; CHEMBL5866; -. DR DrugBank; DB03904; Urea. DR GlyCosmos; P35222; 4 sites, 1 glycan. DR GlyGen; P35222; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (4 sites). DR iPTMnet; P35222; -. DR MetOSite; P35222; -. DR PhosphoSitePlus; P35222; -. DR SwissPalm; P35222; -. DR BioMuta; CTNNB1; -. DR DMDM; 461854; -. DR CPTAC; CPTAC-1745; -. DR CPTAC; non-CPTAC-3265; -. DR CPTAC; non-CPTAC-3266; -. DR CPTAC; non-CPTAC-5365; -. DR CPTAC; non-CPTAC-5715; -. DR CPTAC; non-CPTAC-5716; -. DR jPOST; P35222; -. DR MassIVE; P35222; -. DR PaxDb; 9606-ENSP00000344456; -. DR PeptideAtlas; P35222; -. DR PRIDE; P35222; -. DR Pumba; P35222; -. DR ABCD; P35222; 7 sequenced antibodies. DR Antibodypedia; 3432; 5164 antibodies from 59 providers. DR DNASU; 1499; -. DR Ensembl; ENST00000349496.11; ENSP00000344456.5; ENSG00000168036.20. DR Ensembl; ENST00000396183.7; ENSP00000379486.3; ENSG00000168036.20. DR Ensembl; ENST00000396185.8; ENSP00000379488.3; ENSG00000168036.20. DR Ensembl; ENST00000405570.6; ENSP00000385604.1; ENSG00000168036.20. DR Ensembl; ENST00000431914.6; ENSP00000412219.2; ENSG00000168036.20. DR Ensembl; ENST00000433400.6; ENSP00000387455.2; ENSG00000168036.20. DR Ensembl; ENST00000441708.2; ENSP00000401599.2; ENSG00000168036.20. DR Ensembl; ENST00000450969.6; ENSP00000409302.2; ENSG00000168036.20. DR Ensembl; ENST00000642248.1; ENSP00000495244.1; ENSG00000168036.20. DR Ensembl; ENST00000642315.1; ENSP00000495076.1; ENSG00000168036.20. DR Ensembl; ENST00000642426.1; ENSP00000495719.1; ENSG00000168036.20. DR Ensembl; ENST00000642992.1; ENSP00000496385.1; ENSG00000168036.20. DR Ensembl; ENST00000643031.1; ENSP00000495450.1; ENSG00000168036.20. DR Ensembl; ENST00000643297.1; ENSP00000494677.1; ENSG00000168036.20. DR Ensembl; ENST00000643541.1; ENSP00000494411.1; ENSG00000168036.20. DR Ensembl; ENST00000643977.1; ENSP00000494053.1; ENSG00000168036.20. DR Ensembl; ENST00000643992.1; ENSP00000493610.1; ENSG00000168036.20. DR Ensembl; ENST00000644867.1; ENSP00000495992.1; ENSG00000168036.20. DR Ensembl; ENST00000645210.1; ENSP00000496180.1; ENSG00000168036.20. DR Ensembl; ENST00000645320.1; ENSP00000495360.1; ENSG00000168036.20. DR Ensembl; ENST00000645982.1; ENSP00000494845.1; ENSG00000168036.20. DR Ensembl; ENST00000646369.1; ENSP00000494914.1; ENSG00000168036.20. DR Ensembl; ENST00000646725.1; ENSP00000496021.1; ENSG00000168036.20. DR Ensembl; ENST00000647390.1; ENSP00000493533.1; ENSG00000168036.20. DR Ensembl; ENST00000647413.2; ENSP00000493583.2; ENSG00000168036.20. DR GeneID; 1499; -. DR KEGG; hsa:1499; -. DR MANE-Select; ENST00000349496.11; ENSP00000344456.5; NM_001904.4; NP_001895.1. DR UCSC; uc003ckp.3; human. DR AGR; HGNC:2514; -. DR CIViC; 1499; 1 clinical assertion and 42 evidence items across 16 molecular profiles. DR ClinPGx; PA27013; -. DR CTD; 1499; -. DR DisGeNET; 1499; -. DR GeneCards; CTNNB1; -. DR GeneReviews; CTNNB1; -. DR HGNC; HGNC:2514; CTNNB1. DR HPA; ENSG00000168036; Low tissue specificity. DR MalaCards; CTNNB1; -. DR MIM; 114500; phenotype. DR MIM; 116806; gene. DR MIM; 132600; phenotype. DR MIM; 155255; phenotype. DR MIM; 156240; phenotype. DR MIM; 167000; phenotype. DR MIM; 181030; phenotype. DR MIM; 615075; phenotype. DR MIM; 617572; phenotype. DR OpenTargets; ENSG00000168036; -. DR Orphanet; 952; Acrofacial dysostosis, Weyers type. DR Orphanet; 689430; Adenoid ameloblastoma. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 891; Familial exudative vitreoretinopathy. DR Orphanet; 404473; Intellectual disability-peripheral spasticity-exudative vitreoretinopathy syndrome. DR Orphanet; 569248; Microcystic stromal tumor. DR Orphanet; 2780; Osteopathia striata-cranial sclerosis syndrome. DR Orphanet; 33402; Pediatric hepatocellular carcinoma. DR Orphanet; 91414; Pilomatrixoma. DR VEuPathDB; HostDB:ENSG00000168036; -. DR eggNOG; KOG4203; Eukaryota. DR GeneTree; ENSGT00940000155471; -. DR InParanoid; P35222; -. DR OMA; YPKLVYT; -. DR OrthoDB; 195736at2759; -. DR PAN-GO; P35222; 12 GO annotations based on evolutionary models. DR PhylomeDB; P35222; -. DR PathwayCommons; P35222; -. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-201681; TCF dependent signaling in response to WNT. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1). DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-525793; Myogenesis. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling. DR Reactome; R-HSA-9733709; Cardiogenesis. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9762292; Regulation of CDH11 function. DR Reactome; R-HSA-9764302; Regulation of CDH19 Expression and Function. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9793380; Formation of paraxial mesoderm. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9824272; Somitogenesis. DR Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. DR Reactome; R-HSA-9825892; Regulation of MITF-M-dependent genes involved in cell cycle and proliferation. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9833576; CDH11 homotypic and heterotypic interactions. DR Reactome; R-HSA-9834899; Specification of the neural plate border. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR SignaLink; P35222; -. DR SIGNOR; P35222; -. DR Agora; ENSG00000168036; -. DR BioGRID-ORCS; 1499; 103 hits in 1178 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 53379B70; LEF1/Beta-catenin condensate. DR CD-CODE; 7FF4107C; Beta-Catenin Destruction Complex. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CTNNB1; human. DR EvolutionaryTrace; P35222; -. DR GeneWiki; Beta-catenin; -. DR GenomeRNAi; 1499; -. DR Pharos; P35222; Tchem. DR PRO; PR:P35222; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P35222; protein. DR Bgee; ENSG00000168036; Expressed in adrenal tissue and 204 other cell types or tissues. DR ExpressionAtlas; P35222; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0045177; C:apical part of cell; IEA:Ensembl. DR GO; GO:0016327; C:apicolateral plasma membrane; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:BHF-UCL. DR GO; GO:1990711; C:beta-catenin-ICAT complex; IEA:Ensembl. DR GO; GO:1990907; C:beta-catenin-TCF complex; IDA:FlyBase. DR GO; GO:0070369; C:beta-catenin-TCF7L2 complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0016342; C:catenin complex; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:BHF-UCL. DR GO; GO:0071944; C:cell periphery; IDA:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IDA:MGI. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0000791; C:euchromatin; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005916; C:fascia adherens; IEA:Ensembl. DR GO; GO:0016600; C:flotillin complex; IEA:Ensembl. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0031528; C:microvillus membrane; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0099092; C:postsynaptic density, intracellular component; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0098831; C:presynaptic active zone cytoplasmic component; IEA:Ensembl. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0034750; C:Scrib-APC-beta-catenin complex; IEA:Ensembl. DR GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell. DR GO; GO:0045202; C:synapse; ISS:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0030018; C:Z disc; IEA:Ensembl. DR GO; GO:0045294; F:alpha-catenin binding; IPI:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; IPI:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; ISS:ParkinsonsUK-UCL. DR GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL. DR GO; GO:1990226; F:histone methyltransferase binding; ISS:ARUK-UCL. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0019900; F:kinase binding; IPI:BHF-UCL. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:BHF-UCL. DR GO; GO:0016922; F:nuclear receptor binding; IPI:BHF-UCL. DR GO; GO:0019902; F:phosphatase binding; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0019903; F:protein phosphatase binding; IBA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL. DR GO; GO:0046332; F:SMAD binding; IPI:BHF-UCL. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001221; F:transcription coregulator binding; ISS:ARUK-UCL. DR GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; EXP:DisProt. DR GO; GO:0090425; P:acinar cell differentiation; IEA:Ensembl. DR GO; GO:0034333; P:adherens junction assembly; IMP:BHF-UCL. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0036520; P:astrocyte-dopaminergic neuron signaling; IEA:Ensembl. DR GO; GO:0045453; P:bone resorption; IEA:Ensembl. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0044338; P:canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation; IEA:Ensembl. DR GO; GO:0007155; P:cell adhesion; IMP:BHF-UCL. DR GO; GO:0001708; P:cell fate specification; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEA:Ensembl. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IMP:BHF-UCL. DR GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0022009; P:central nervous system vasculogenesis; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0061550; P:cranial ganglion development; IEA:Ensembl. DR GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0035995; P:detection of muscle stretch; TAS:BHF-UCL. DR GO; GO:1990791; P:dorsal root ganglion development; IEA:Ensembl. DR GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl. DR GO; GO:0007398; P:ectoderm development; IEA:Ensembl. DR GO; GO:0000578; P:embryonic axis specification; IEA:Ensembl. DR GO; GO:1990403; P:embryonic brain development; IEA:Ensembl. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl. DR GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl. DR GO; GO:0035050; P:embryonic heart tube development; IEA:Ensembl. DR GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl. DR GO; GO:0036023; P:embryonic skeletal limb joint morphogenesis; ISS:BHF-UCL. DR GO; GO:0001711; P:endodermal cell fate commitment; IEA:Ensembl. DR GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:ARUK-UCL. DR GO; GO:0002064; P:epithelial cell development; IEA:Ensembl. DR GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0001837; P:epithelial to mesenchymal transition; TAS:HGNC-UCL. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0060856; P:establishment of blood-brain barrier; IEA:Ensembl. DR GO; GO:1990963; P:establishment of blood-retinal barrier; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0061198; P:fungiform papilla formation; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0035112; P:genitalia morphogenesis; IEA:Ensembl. DR GO; GO:0007403; P:glial cell fate determination; IEA:Ensembl. DR GO; GO:0035315; P:hair cell differentiation; TAS:BHF-UCL. DR GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl. DR GO; GO:0060789; P:hair follicle placode formation; IEA:Ensembl. DR GO; GO:0030902; P:hindbrain development; IEA:Ensembl. DR GO; GO:0021854; P:hypothalamus development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0021819; P:layer formation in cerebral cortex; IEA:Ensembl. DR GO; GO:0002089; P:lens morphogenesis in camera-type eye; IEA:Ensembl. DR GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0060492; P:lung induction; IEA:Ensembl. DR GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl. DR GO; GO:0030539; P:male genitalia development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IEA:Ensembl. DR GO; GO:0072497; P:mesenchymal stem cell differentiation; IMP:ARUK-UCL. DR GO; GO:0060231; P:mesenchymal to epithelial transition; IMP:UniProtKB. DR GO; GO:0003338; P:metanephros morphogenesis; IEA:Ensembl. DR GO; GO:1904948; P:midbrain dopaminergic neuron differentiation; ISS:ParkinsonsUK-UCL. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0016525; P:negative regulation of angiogenesis; ISS:BHF-UCL. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0003340; P:negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis; IEA:Ensembl. DR GO; GO:0045976; P:negative regulation of mitotic cell cycle, embryonic; ISS:UniProtKB. DR GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl. DR GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0033234; P:negative regulation of protein sumoylation; IDA:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0072079; P:nephron tubule formation; IEA:Ensembl. DR GO; GO:0001840; P:neural plate development; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0048664; P:neuron fate determination; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:1990138; P:neuron projection extension; IMP:UniProtKB. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IMP:ARUK-UCL. DR GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0060066; P:oviduct development; IEA:Ensembl. DR GO; GO:0031016; P:pancreas development; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:1905555; P:positive regulation of blood vessel branching; IMP:BHF-UCL. DR GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0045597; P:positive regulation of cell differentiation; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000017; P:positive regulation of determination of dorsal identity; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl. DR GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0010909; P:positive regulation of heparan sulfate proteoglycan biosynthetic process; IMP:BHF-UCL. DR GO; GO:0034112; P:positive regulation of homotypic cell-cell adhesion; IGI:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:2000288; P:positive regulation of myoblast proliferation; IEA:Ensembl. DR GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISS:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:ParkinsonsUK-UCL. DR GO; GO:1901331; P:positive regulation of odontoblast differentiation; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl. DR GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:ARUK-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:0034394; P:protein localization to cell surface; IMP:BHF-UCL. DR GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB. DR GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl. DR GO; GO:0045765; P:regulation of angiogenesis; TAS:BHF-UCL. DR GO; GO:0090279; P:regulation of calcium ion import; IDA:BHF-UCL. DR GO; GO:0030997; P:regulation of centriole-centriole cohesion; IDA:UniProtKB. DR GO; GO:0070602; P:regulation of centromeric sister chromatid cohesion; IMP:BHF-UCL. DR GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; IMP:UniProtKB. DR GO; GO:0048145; P:regulation of fibroblast proliferation; TAS:BHF-UCL. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0050767; P:regulation of neurogenesis; TAS:ParkinsonsUK-UCL. DR GO; GO:2000008; P:regulation of protein localization to cell surface; IDA:BHF-UCL. DR GO; GO:0031396; P:regulation of protein ubiquitination; IMP:DisProt. DR GO; GO:0003266; P:regulation of secondary heart field cardioblast proliferation; IEA:Ensembl. DR GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0051963; P:regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0042129; P:regulation of T cell proliferation; IEA:Ensembl. DR GO; GO:0051884; P:regulation of timing of anagen; IEA:Ensembl. DR GO; GO:0072053; P:renal inner medulla development; IEA:Ensembl. DR GO; GO:0072054; P:renal outer medulla development; IEA:Ensembl. DR GO; GO:0072033; P:renal vesicle formation; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl. DR GO; GO:0019827; P:stem cell population maintenance; TAS:BHF-UCL. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0061549; P:sympathetic ganglion development; ISS:UniProtKB. DR GO; GO:0050808; P:synapse organization; IEA:Ensembl. DR GO; GO:0097091; P:synaptic vesicle clustering; IEA:Ensembl. DR GO; GO:0048489; P:synaptic vesicle transport; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd21724; CTNNAbd_CTNNB1; 1. DR DisProt; DP01119; -. DR FunFam; 1.25.10.10:FF:000015; Catenin beta-1; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00039; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR013284; Beta-catenin. DR PANTHER; PTHR45976; ARMADILLO SEGMENT POLARITY PROTEIN; 1. DR Pfam; PF00514; Arm; 4. DR PRINTS; PR01869; BCATNINFAMLY. DR SMART; SM00185; ARM; 12. DR SUPFAM; SSF48371; ARM repeat; 1. DR PROSITE; PS50176; ARM_REPEAT; 9. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Cell adhesion; Cell junction; KW Cell membrane; Cell projection; Chromosomal rearrangement; Cytoplasm; KW Cytoskeleton; Disease variant; Glycoprotein; Host-virus interaction; KW Intellectual disability; Membrane; Neurogenesis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; S-nitrosylation; KW Synapse; Transcription; Transcription regulation; Ubl conjugation; KW Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..781 FT /note="Catenin beta-1" FT /id="PRO_0000064271" FT REPEAT 151..191 FT /note="ARM 1" FT REPEAT 193..234 FT /note="ARM 2" FT REPEAT 235..276 FT /note="ARM 3" FT REPEAT 277..318 FT /note="ARM 4" FT REPEAT 319..360 FT /note="ARM 5" FT REPEAT 361..389 FT /note="ARM 6" FT REPEAT 400..441 FT /note="ARM 7" FT REPEAT 442..484 FT /note="ARM 8" FT REPEAT 489..530 FT /note="ARM 9" FT REPEAT 531..571 FT /note="ARM 10" FT REPEAT 594..636 FT /note="ARM 11" FT REPEAT 637..666 FT /note="ARM 12" FT REGION 2..23 FT /note="Interaction with VCL" FT /evidence="ECO:0000250" FT REGION 34..57 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 156..178 FT /note="Interaction with BCL9" FT /evidence="ECO:0000269|PubMed:17052462" FT REGION 705..781 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 772..781 FT /note="Interaction with SCRIB" FT /evidence="ECO:0000250" FT COMPBIAS 734..745 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 23 FT /note="Phosphoserine; by GSK3-beta; alternate" FT /evidence="ECO:0000269|PubMed:12027456" FT MOD_RES 29 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:12027456" FT MOD_RES 33 FT /note="Phosphoserine; by GSK3-beta and HIPK2" FT /evidence="ECO:0000269|PubMed:20307497, FT ECO:0000269|PubMed:25169422" FT MOD_RES 37 FT /note="Phosphoserine; by GSK3-beta and HIPK2" FT /evidence="ECO:0000269|PubMed:20307497" FT MOD_RES 41 FT /note="Phosphothreonine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:12027456, FT ECO:0000269|PubMed:30714168" FT MOD_RES 45 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:12051714" FT MOD_RES 49 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24824780" FT MOD_RES 64 FT /note="Phosphotyrosine; by PTK6" FT /evidence="ECO:0000269|PubMed:20026641" FT MOD_RES 142 FT /note="Phosphotyrosine; by FYN and PTK6" FT /evidence="ECO:0000269|PubMed:12640114, FT ECO:0000269|PubMed:20026641" FT MOD_RES 191 FT /note="Phosphoserine; by CDK5" FT /evidence="ECO:0000269|PubMed:17009320, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 246 FT /note="Phosphoserine; by CDK5" FT /evidence="ECO:0000269|PubMed:17009320" FT MOD_RES 331 FT /note="Phosphotyrosine; by PTK6" FT /evidence="ECO:0000269|PubMed:20026641" FT MOD_RES 333 FT /note="Phosphotyrosine; by SRC and PTK6" FT /evidence="ECO:0000269|PubMed:22056988, FT ECO:0000305|PubMed:20026641" FT MOD_RES 552 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 556 FT /note="(Microbial infection) Phosphothreonine" FT /evidence="ECO:0000269|PubMed:31801859" FT MOD_RES 556 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 619 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000250|UniProtKB:Q02248" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:20068231" FT CARBOHYD 23 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:24342833" FT VARIANT 23 FT /note="S -> R (in hepatocellular carcinoma; no effect; FT dbSNP:rs1413975856)" FT /evidence="ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:12027456" FT /id="VAR_017612" FT VARIANT 25..33 FT /note="Missing (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017613" FT VARIANT 32 FT /note="D -> A (in hepatocellular carcinoma; FT dbSNP:rs121913396)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017614" FT VARIANT 32 FT /note="D -> G (in PTR and hepatocellular carcinoma; FT dbSNP:rs121913396)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629" FT /id="VAR_017615" FT VARIANT 32 FT /note="D -> Y (in PTR, hepatoblastoma and hepatocellular FT carcinoma; dbSNP:rs28931588)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629, ECO:0000269|PubMed:11703283, FT ECO:0000269|PubMed:9927029" FT /id="VAR_017616" FT VARIANT 33 FT /note="S -> F (in PTR, MDB and hepatocellular carcinoma; FT dbSNP:rs121913400)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629, ECO:0000269|PubMed:10666372" FT /id="VAR_017617" FT VARIANT 33 FT /note="S -> L (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017618" FT VARIANT 33 FT /note="S -> Y (in colorectal cancer and PTR; constitutively FT active Wnt signaling pathway; enhances transactivation of FT target genes; dbSNP:rs121913400)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:12027456, ECO:0000269|PubMed:29374064, FT ECO:0000269|PubMed:9065402" FT /id="VAR_017619" FT VARIANT 34 FT /note="G -> E (in PTR; dbSNP:rs28931589)" FT /evidence="ECO:0000269|PubMed:10192393" FT /id="VAR_017620" FT VARIANT 34 FT /note="G -> R (in hepatocellular carcinoma; FT dbSNP:rs121913399)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017621" FT VARIANT 34 FT /note="G -> V (in hepatoblastoma; dbSNP:rs28931589)" FT /evidence="ECO:0000269|PubMed:9927029" FT /id="VAR_017622" FT VARIANT 35 FT /note="I -> S (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017623" FT VARIANT 37..38 FT /note="SG -> W (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017628" FT VARIANT 37 FT /note="S -> A (in MDB and hepatocellular carcinoma; FT enhances transactivation of target genes; FT dbSNP:rs121913228)" FT /evidence="ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456" FT /id="VAR_017624" FT VARIANT 37 FT /note="S -> C (in PTR, hepatoblastoma and ovarian cancer; FT dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10391090, ECO:0000269|PubMed:9927029" FT /id="VAR_017625" FT VARIANT 37 FT /note="S -> F (in PTR; dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10192393" FT /id="VAR_017626" FT VARIANT 37 FT /note="S -> Y (in hepatocellular carcinoma; FT dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017627" FT VARIANT 41 FT /note="T -> A (in hepatoblastoma and hepatocellular FT carcinoma; also in a desmoid tumor; strongly reduces FT phosphorylation and degradation; abolishes phosphorylation FT on Ser-33 and Ser-37 and enhances transactivation of target FT genes; dbSNP:rs121913412)" FT /evidence="ECO:0000269|PubMed:10391090, FT ECO:0000269|PubMed:10398436, ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:10655994, ECO:0000269|PubMed:12027456, FT ECO:0000269|PubMed:12051714, ECO:0000269|PubMed:9927029" FT /id="VAR_017629" FT VARIANT 41 FT /note="T -> I (in PTR, hepatocellular carcinoma and ovarian FT cancer; dbSNP:rs121913413)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10391090, ECO:0000269|PubMed:10435629" FT /id="VAR_017630" FT VARIANT 45 FT /note="S -> F (in hepatocellular carcinoma; FT dbSNP:rs121913409)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017631" FT VARIANT 45 FT /note="S -> P (in hepatocellular carcinoma; FT dbSNP:rs121913407)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017632" FT VARIANT 45 FT /note="Missing (in colorectal cancer)" FT /evidence="ECO:0000269|PubMed:9065402" FT /id="VAR_055430" FT VARIANT 292 FT /note="K -> N (found in a patient with features of FT osteopathia striata cranial sclerosis; uncertain FT significance; results in increased Wnt signaling)" FT /evidence="ECO:0000269|PubMed:38173341" FT /id="VAR_089205" FT VARIANT 388 FT /note="L -> P (in NEDSDV)" FT /evidence="ECO:0000269|PubMed:25326669" FT /id="VAR_072282" FT VARIANT 558..781 FT /note="Missing (in NEDSDV; the patient also manifest FT features of exudative vitreoretinopathy)" FT /evidence="ECO:0000269|PubMed:28514307" FT /id="VAR_079199" FT VARIANT 688 FT /note="M -> V (in dbSNP:rs4135384)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_018954" FT VARIANT 710 FT /note="R -> C (in EVR7; uncertain significance; FT dbSNP:rs748653573)" FT /evidence="ECO:0000269|PubMed:28575650" FT /id="VAR_079200" FT MUTAGEN 29 FT /note="S->F: No effect." FT /evidence="ECO:0000269|PubMed:12027456" FT MUTAGEN 64 FT /note="Y->F: Abolishes phosphorylation by PTK6." FT /evidence="ECO:0000269|PubMed:20026641" FT MUTAGEN 142 FT /note="Y->E: No effect on interaction with BCL9 and BCL9L." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 156 FT /note="L->A: Abolishes interaction with BCL9 but no effect FT on interaction with CDH3; when associated with A-159." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 159 FT /note="L->A: No effect on interaction with BCL9 and CDH3. FT Abolishes interaction with BCL9 but no effect on FT interaction with CDH3; when associated with A-156." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 178 FT /note="L->A: No effect on interaction with BCL9 and CDH3." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 253 FT /note="F->A: Abolishes or strongly reduces AXIN2 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 260 FT /note="H->A: Abolishes or strongly reduces AXIN1 and AXIN2 FT binding. Strongly reduces phosphorylation and degradation; FT when associated with A-386 and A-383." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 292 FT /note="K->A: Abolishes or strongly reduces AXIN1 and AXIN2 FT binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 312 FT /note="K->E: Abolishes TCF7L2 binding." FT /evidence="ECO:0000269|PubMed:11713475" FT MUTAGEN 333 FT /note="Y->F: Abolished phosphorylation by SRC and FT interaction with isoform M2 of PKM (PKM2)." FT /evidence="ECO:0000269|PubMed:22056988" FT MUTAGEN 345 FT /note="K->A: Abolishes APC binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 383 FT /note="W->A: Abolishes APC binding. Strongly reduces FT phosphorylation and degradation; when associated with A-260 FT and A-386." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 386 FT /note="R->A: Strongly reduces APC binding. Strongly reduces FT phosphorylation and degradation; when associated with A-260 FT and A-383." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 426 FT /note="N->A: Abolishes TCF7L2 and LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 435 FT /note="K->A: Strongly reduces or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653, FT ECO:0000269|PubMed:11713475" FT MUTAGEN 435 FT /note="K->E: Abolishes TCF7L2 binding." FT /evidence="ECO:0000269|PubMed:10966653, FT ECO:0000269|PubMed:11713475" FT MUTAGEN 469 FT /note="R->A: Abolishes TCF7L2 binding, and strongly reduces FT or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 470 FT /note="H->A: Abolishes TCF7L2 binding, and strongly reduces FT or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 508 FT /note="K->A: Abolishes TCF7L2 and LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 660 FT /note="F->A: Abolishes CTNNBIP1 binding; when associated FT with A-661." FT /evidence="ECO:0000269|PubMed:12408824" FT MUTAGEN 661 FT /note="R->A: Abolishes CTNNBIP1 binding; when associated FT with A-660." FT /evidence="ECO:0000269|PubMed:12408824" FT TURN 20..22 FT /evidence="ECO:0007829|PDB:2G57" FT STRAND 23..26 FT /evidence="ECO:0007829|PDB:2G57" FT TURN 27..29 FT /evidence="ECO:0007829|PDB:2G57" FT TURN 39..41 FT /evidence="ECO:0007829|PDB:2G57" FT HELIX 145..160 FT /evidence="ECO:0007829|PDB:7AFW" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:7UWO" FT HELIX 165..179 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 182..189 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 208..221 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 236..243 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 249..265 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 269..275 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 278..284 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 291..303 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 309..317 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 320..330 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 334..347 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 353..359 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 362..367 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 368..371 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 375..389 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 392..394 FT /evidence="ECO:0007829|PDB:7ZRB" FT HELIX 399..408 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 414..427 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 428..430 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 432..440 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 443..454 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 458..471 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 478..487 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 491..496 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:4DJS" FT HELIX 504..517 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 521..523 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 532..547 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 550..552 FT /evidence="ECO:0007829|PDB:1QZ7" FT STRAND 554..557 FT /evidence="ECO:0007829|PDB:1QZ7" FT STRAND 561..563 FT /evidence="ECO:0007829|PDB:1T08" FT HELIX 566..580 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 584..592 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 596..601 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 602..604 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 608..621 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 625..633 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:8Y0G" FT HELIX 637..642 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 649..662 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 663..665 FT /evidence="ECO:0007829|PDB:2Z6H" FT HELIX 668..682 FT /evidence="ECO:0007829|PDB:2Z6H" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:2Z6H" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3DIW" SQ SEQUENCE 781 AA; 85497 MW; CB78F165A3EEF86E CRC64; MATQADLMEL DMAMEPDRKA AVSHWQQQSY LDSGIHSGAT TTAPSLSGKG NPEEEDVDTS QVLYEWEQGF SQSFTQEQVA DIDGQYAMTR AQRVRAAMFP ETLDEGMQIP STQFDAAHPT NVQRLAEPSQ MLKHAVVNLI NYQDDAELAT RAIPELTKLL NDEDQVVVNK AAVMVHQLSK KEASRHAIMR SPQMVSAIVR TMQNTNDVET ARCTAGTLHN LSHHREGLLA IFKSGGIPAL VKMLGSPVDS VLFYAITTLH NLLLHQEGAK MAVRLAGGLQ KMVALLNKTN VKFLAITTDC LQILAYGNQE SKLIILASGG PQALVNIMRT YTYEKLLWTT SRVLKVLSVC SSNKPAIVEA GGMQALGLHL TDPSQRLVQN CLWTLRNLSD AATKQEGMEG LLGTLVQLLG SDDINVVTCA AGILSNLTCN NYKNKMMVCQ VGGIEALVRT VLRAGDREDI TEPAICALRH LTSRHQEAEM AQNAVRLHYG LPVVVKLLHP PSHWPLIKAT VGLIRNLALC PANHAPLREQ GAIPRLVQLL VRAHQDTQRR TSMGGTQQQF VEGVRMEEIV EGCTGALHIL ARDVHNRIVI RGLNTIPLFV QLLYSPIENI QRVAAGVLCE LAQDKEAAEA IEAEGATAPL TELLHSRNEG VATYAAAVLF RMSEDKPQDY KKRLSVELTS SLFRTEPMAW NETADLGLDI GAQGEPLGYR QDDPSYRSFH SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD L // ID DCLK3_HUMAN Reviewed; 648 AA. AC Q9C098; DT 03-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 03-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 164. DE RecName: Full=Serine/threonine-protein kinase DCLK3; DE EC=2.7.11.1; DE AltName: Full=Doublecortin domain-containing protein 3C; DE AltName: Full=Doublecortin-like and CAM kinase-like 3; DE AltName: Full=Doublecortin-like kinase 3; GN Name=DCLK3; Synonyms=DCAMKL3, DCDC3C, KIAA1765; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-105. RC TISSUE=Brain; RX PubMed=11214970; DOI=10.1093/dnares/7.6.347; RA Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:347-355(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 41-648. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-24; LEU-108; LYS-422; ASN-472; CYS-554; RP ARG-570; ALA-596 AND ASP-633. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DA523113; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AB051552; BAB21856.1; -; mRNA. DR CCDS; CCDS43064.1; -. DR RefSeq; NP_208382.1; NM_033403.1. DR AlphaFoldDB; Q9C098; -. DR SMR; Q9C098; -. DR BioGRID; 124530; 6. DR FunCoup; Q9C098; 1100. DR IntAct; Q9C098; 8. DR STRING; 9606.ENSP00000394484; -. DR BindingDB; Q9C098; -. DR ChEMBL; CHEMBL6123; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9C098; -. DR iPTMnet; Q9C098; -. DR PhosphoSitePlus; Q9C098; -. DR BioMuta; DCLK3; -. DR DMDM; 115502142; -. DR CPTAC; CPTAC-2832; -. DR CPTAC; CPTAC-2833; -. DR jPOST; Q9C098; -. DR MassIVE; Q9C098; -. DR PaxDb; 9606-ENSP00000394484; -. DR PeptideAtlas; Q9C098; -. DR ProteomicsDB; 79972; -. DR Antibodypedia; 28151; 105 antibodies from 30 providers. DR DNASU; 85443; -. DR Ensembl; ENST00000416516.2; ENSP00000394484.2; ENSG00000163673.9. DR GeneID; 85443; -. DR KEGG; hsa:85443; -. DR UCSC; uc003cgi.2; human. DR AGR; HGNC:19005; -. DR ClinPGx; PA162383403; -. DR CTD; 85443; -. DR DisGeNET; 85443; -. DR GeneCards; DCLK3; -. DR HGNC; HGNC:19005; DCLK3. DR HPA; ENSG00000163673; Tissue enhanced (brain, testis). DR MIM; 613167; gene. DR OpenTargets; ENSG00000163673; -. DR VEuPathDB; HostDB:ENSG00000163673; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000159476; -. DR HOGENOM; CLU_000288_94_2_1; -. DR InParanoid; Q9C098; -. DR OMA; VRAQKKW; -. DR OrthoDB; 1738954at2759; -. DR PAN-GO; Q9C098; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9C098; -. DR PathwayCommons; Q9C098; -. DR SignaLink; Q9C098; -. DR Agora; ENSG00000163673; -. DR BioGRID-ORCS; 85443; 15 hits in 1178 CRISPR screens. DR GenomeRNAi; 85443; -. DR Pharos; Q9C098; Tchem. DR PRO; PR:Q9C098; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9C098; protein. DR Bgee; ENSG00000163673; Expressed in sural nerve and 98 other cell types or tissues. DR ExpressionAtlas; Q9C098; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0034504; P:protein localization to nucleus; IBA:GO_Central. DR CDD; cd14185; STKc_DCKL3; 1. DR FunFam; 1.10.510.10:FF:000066; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000057; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW ATP-binding; Cytoplasm; Kinase; Nucleotide-binding; Nucleus; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..648 FT /note="Serine/threonine-protein kinase DCLK3" FT /id="PRO_0000252254" FT DOMAIN 356..613 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 86..127 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 150..345 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..648 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 98..127 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 213..234 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 255..266 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 277..303 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 312..338 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 477 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 362..370 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 385 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 24 FT /note="R -> Q (in dbSNP:rs56070233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040444" FT VARIANT 108 FT /note="P -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040445" FT VARIANT 422 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373605259)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040446" FT VARIANT 472 FT /note="S -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040447" FT VARIANT 554 FT /note="R -> C (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs374711533)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040448" FT VARIANT 570 FT /note="G -> R (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040449" FT VARIANT 596 FT /note="V -> A (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040450" FT VARIANT 633 FT /note="E -> D (in dbSNP:rs35704209)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040451" SQ SEQUENCE 648 AA; 73814 MW; 09E37E51920F2A21 CRC64; MGKEPLTLKS IQVAVEELYP NKARALTLAQ HSRAPSPRLR SRLFSKALKG DHRCGETETP KSCSEVAGCK AAMRHQGKIP EELSLDDRAR TQKKWGRGKW EPEPSSKPPR EATLEERHAR GEKHLGVEIE KTSGEIIRCE KCKRERELQQ SLERERLSLG TSELDMGKGP MYDVEKLVRT RSCRRSPEAN PASGEEGWKG DSHRSSPRNP TQELRRPSKS MDKKEDRGPE DQESHAQGAA KAKKDLVEVL PVTEEGLREV KKDTRPMSRS KHGGWLLREH QAGFEKLRRT RGEEKEAEKE KKPCMSGGRR MTLRDDQPAK LEKEPKTRPE ENKPERPSGR KPRPMGIIAA NVEKHYETGR VIGDGNFAVV KECRHRETRQ AYAMKIIDKS RLKGKEDMVD SEILIIQSLS HPNIVKLHEV YETDMEIYLI LEYVQGGDLF DAIIESVKFP EPDAALMIMD LCKALVHMHD KSIVHRDLKP ENLLVQRNED KSTTLKLADF GLAKHVVRPI FTVCGTPTYV APEILSEKGY GLEVDMWAAG VILYILLCGF PPFRSPERDQ DELFNIIQLG HFEFLPPYWD NISDAAKDLV SRLLVVDPKK RYTAHQVLQH PWIETAGKTN TVKRQKQVSP SSEGHFRSQH KRVVEQVS // ID DLEC1_HUMAN Reviewed; 1755 AA. AC Q9Y238; Q9NSW0; Q9NTG5; DT 25-OCT-2005, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 165. DE RecName: Full=Deleted in lung and esophageal cancer protein 1; DE AltName: Full=Deleted in lung cancer protein 1; DE Short=DLC-1; GN Name=DLEC1 {ECO:0000312|EMBL:BAA77624.1}; GN Synonyms=DLC1 {ECO:0000303|PubMed:10213508}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:BAA77624.1} RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, RP PUTATIVE FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND RP INVOLVEMENT IN LUNG CANCER; ESOPHAGEAL CANCER AND RENAL CANCER. RX PubMed=10213508; RA Daigo Y., Nishiwaki T., Kawasoe T., Tamari M., Tsuchiya E., Nakamura Y.; RT "Molecular cloning of a candidate tumor suppressor gene, DLC1, from RT chromosome 3p21.3."; RL Cancer Res. 59:1966-1972(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 595-1755 (ISOFORM 2), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1417-1755 (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP VARIANT [LARGE SCALE ANALYSIS] ARG-351. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [5] RP SUBCELLULAR LOCATION, AND INTERACTION WITH ALPHA-TUBULIN; BETA-TUBULIN; RP BBS2; BBS4; BBS5; MKKS; TCP1; CCT2; CCT3; CCT4; CCT5 AND CCT7. RX PubMed=33144677; DOI=10.1038/s41598-020-75957-y; RA Okitsu Y., Nagano M., Yamagata T., Ito C., Toshimori K., Dohra H., RA Fujii W., Yogo K.; RT "Dlec1 is required for spermatogenesis and male fertility in mice."; RL Sci. Rep. 10:18883-18883(2020). CC -!- FUNCTION: Essential for spermatogenesis and male fertility (By CC similarity). May play an important role in sperm head and tail CC formation (By similarity). May act as a tumor suppressor by inhibiting CC cell proliferation. {ECO:0000250|UniProtKB:Q8BLA1, CC ECO:0000269|PubMed:10213508}. CC -!- SUBUNIT: Interacts with alpha- and beta-tubulin (PubMed:33144677). CC Interacts with BBS2, BBS4, BBS5, MKKS, TCP1, CCT2, CCT3, CCT4, CCT5 and CC CCT7 (PubMed:33144677). {ECO:0000269|PubMed:33144677}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10213508, CC ECO:0000269|PubMed:33144677}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Comment=At least six differentially spliced products may exist. CC {ECO:0000303|PubMed:10213508}; CC Name=1 {ECO:0000303|PubMed:10213508}; CC IsoId=Q9Y238-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y238-2; Sequence=VSP_051847, VSP_051848, VSP_051849; CC Name=3; Synonyms=1S3 {ECO:0000303|PubMed:10213508}; CC IsoId=Q9Y238-3; Sequence=VSP_051850; CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined. Expression is CC highest in prostate and testis. {ECO:0000269|PubMed:10213508}. CC -!- DISEASE: Note=DLEC1 silencing due to promoter methylation and aberrant CC transcription are implicated in the development of different cancers, CC including esophageal (ESCR), renal and lung cancers (LNCR). CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The gene represented in this entry may be involved in CC disease pathogenesis. DLEC1 silencing due to promoter methylation and CC aberrant transcription are implicated in the development of lung CC cancer. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10213508}. Note=The CC gene represented in this entry may be involved in disease pathogenesis. CC DLEC1 silencing due to promoter methylation and aberrant transcription CC may be implicated in the development of esophageal cancer. CC -!- MISCELLANEOUS: [Isoform 2]: Levels of this splice isoform may be CC increased in cancer cell lines and primary cancers. CC {ECO:0000303|PubMed:10213508, ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Levels of this splice isoform are increased CC in cancer cell lines and primary cancers. CC {ECO:0000269|PubMed:10213508}. CC -!- SEQUENCE CAUTION: CC Sequence=CAB70676.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305}; CC Sequence=CAB70884.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB026898; BAA77624.1; -; Genomic_DNA. DR EMBL; AB020522; BAA77247.1; -; mRNA. DR EMBL; AC144536; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP006309; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL137706; CAB70884.2; ALT_INIT; Transcribed_RNA. DR EMBL; AL137282; CAB70676.1; ALT_SEQ; mRNA. DR CCDS; CCDS2672.2; -. [Q9Y238-1] DR PIR; T46351; T46351. DR PIR; T46406; T46406. DR RefSeq; NP_001308082.1; NM_001321153.1. DR RefSeq; NP_031361.2; NM_007335.4. [Q9Y238-1] DR RefSeq; NP_031363.2; NM_007337.4. [Q9Y238-3] DR AlphaFoldDB; Q9Y238; -. DR SMR; Q9Y238; -. DR BioGRID; 115266; 14. DR FunCoup; Q9Y238; 173. DR STRING; 9606.ENSP00000308597; -. DR GlyGen; Q9Y238; 1 site. DR iPTMnet; Q9Y238; -. DR PhosphoSitePlus; Q9Y238; -. DR BioMuta; DLEC1; -. DR DMDM; 296434480; -. DR jPOST; Q9Y238; -. DR MassIVE; Q9Y238; -. DR PaxDb; 9606-ENSP00000308597; -. DR PeptideAtlas; Q9Y238; -. DR ProteomicsDB; 85633; -. [Q9Y238-1] DR ProteomicsDB; 85634; -. [Q9Y238-2] DR ProteomicsDB; 85635; -. [Q9Y238-3] DR Antibodypedia; 6364; 173 antibodies from 25 providers. DR DNASU; 9940; -. DR Ensembl; ENST00000308059.11; ENSP00000308597.6; ENSG00000008226.21. [Q9Y238-1] DR Ensembl; ENST00000346219.7; ENSP00000315914.5; ENSG00000008226.21. [Q9Y238-3] DR GeneID; 9940; -. DR KEGG; hsa:9940; -. DR MANE-Select; ENST00000308059.11; ENSP00000308597.6; NM_007335.4; NP_031361.2. DR UCSC; uc003cho.2; human. [Q9Y238-1] DR AGR; HGNC:2899; -. DR ClinPGx; PA27353; -. DR CTD; 9940; -. DR DisGeNET; 9940; -. DR GeneCards; DLEC1; -. DR HGNC; HGNC:2899; DLEC1. DR HPA; ENSG00000008226; Tissue enhanced (choroid plexus, fallopian tube, testis). DR MalaCards; DLEC1; -. DR MIM; 133239; phenotype. DR MIM; 211980; phenotype. DR MIM; 604050; gene. DR OpenTargets; ENSG00000008226; -. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000008226; -. DR eggNOG; ENOG502QQQ5; Eukaryota. DR GeneTree; ENSGT00390000006098; -. DR HOGENOM; CLU_003422_0_0_1; -. DR InParanoid; Q9Y238; -. DR OMA; LIKYTWE; -. DR OrthoDB; 2115465at2759; -. DR PAN-GO; Q9Y238; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y238; -. DR PathwayCommons; Q9Y238; -. DR SignaLink; Q9Y238; -. DR Agora; ENSG00000008226; -. DR BioGRID-ORCS; 9940; 11 hits in 1140 CRISPR screens. DR ChiTaRS; DLEC1; human. DR GenomeRNAi; 9940; -. DR Pharos; Q9Y238; Tbio. DR PRO; PR:Q9Y238; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9Y238; protein. DR Bgee; ENSG00000008226; Expressed in right uterine tube and 144 other cell types or tissues. DR ExpressionAtlas; Q9Y238; baseline and differential. DR GO; GO:0005929; C:cilium; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043014; F:alpha-tubulin binding; IDA:UniProtKB. DR GO; GO:0048487; F:beta-tubulin binding; IDA:UniProtKB. DR GO; GO:0015631; F:tubulin binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0002357; P:defense response to tumor cell; IMP:ARUK-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB. DR FunFam; 2.60.40.10:FF:002933; Deleted in lung and esophageal cancer protein 1; 1. DR FunFam; 2.60.40.10:FF:002936; DLEC1, cilia and flagella associated protein; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR InterPro; IPR033304; DLEC1. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR059041; Ig_DLEC1_1. DR PANTHER; PTHR46348; DELETED IN LUNG AND ESOPHAGEAL CANCER PROTEIN 1; 1. DR PANTHER; PTHR46348:SF1; DELETED IN LUNG AND ESOPHAGEAL CANCER PROTEIN 1; 1. DR Pfam; PF23277; Ig_Dlec1_1; 1. DR Pfam; PF23316; Ig_DLEC1_6th; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cytoplasm; Differentiation; KW Proteomics identification; Reference proteome; Spermatogenesis; KW Tumor suppressor. FT CHAIN 1..1755 FT /note="Deleted in lung and esophageal cancer protein 1" FT /id="PRO_0000079929" FT REGION 1..39 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1339..1360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1529..1553 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 30..39 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 704 FT /note="E -> MARLRGGRIPAMPQPSPGQPAGTQWCFQGTVFALQ (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051847" FT VAR_SEQ 856..885 FT /note="GPALIINVSALQFGLLRLGQKATNSIQIRN -> PFSLVCSAWGRKPQTPSR FT SGTSASSQPHGA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051848" FT VAR_SEQ 886..1755 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051849" FT VAR_SEQ 1675..1755 FT /note="QQEPAKAAVAFRVSPNSGLLEARSANAPPTSIALQVFFTARSSELYESTMVV FT EGVLGEKSCTLRLRGQGSYDERYMLPHQP -> VVSCTSPRWWWKVCSVRSPAPCGSGA FT KAPMMRDTCCLTSPEAPPQPSAPGPSWRKNIAQGLGAALQHKDTDLGTWGPLGSSWNGR FT TPFHNGLSLGPHDMSSELT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051850" FT VARIANT 79 FT /note="L -> R (in dbSNP:rs7625806)" FT /id="VAR_056860" FT VARIANT 192 FT /note="S -> F (in dbSNP:rs34012183)" FT /id="VAR_056861" FT VARIANT 351 FT /note="P -> R (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035908" FT VARIANT 1022 FT /note="K -> N (in dbSNP:rs36012922)" FT /id="VAR_056862" FT VARIANT 1150 FT /note="N -> D (in dbSNP:rs9840172)" FT /id="VAR_056863" FT VARIANT 1227 FT /note="L -> P (in dbSNP:rs9810085)" FT /id="VAR_056864" FT CONFLICT 704 FT /note="E -> M (in Ref. 2; CAB70884)" FT /evidence="ECO:0000305" FT CONFLICT 1442 FT /note="G -> R (in Ref. 1; BAA77624/BAA77247)" FT /evidence="ECO:0000305" SQ SEQUENCE 1755 AA; 195684 MW; CD4BDB5EEF24DF98 CRC64; METRSSKTRR SLASRTNECQ GTMWAPTSPP AGSSSPSQPT WKSSLYSSLA YSEAFHYSFA ARPRRLTQLA LAQRPEPQLL RLRPSSLRTQ DISHLLTGVF RNLYSAEVIG DEVSASLIKA RGSENERHEE FVDQLQQIRE LYKQRLDEFE MLERHITQAQ ARAIAENERV MSQAGVQDLE SLVRLPPVKS VSRWCIDSEL LRKHHLISPE DYYTDTVPFH SAPKGISLPG CSKLTFSCEK RSVQKKELNK KLEDSCRKKL AEFEDELDHT VDSLTWNLTP KAKERTREPL KKASQPRNKN WMNHLRVPQR ELDRLLLARM ESRNHFLKNP RFFPPNTRYG GKSLVFPPKK PAPIGEFQST EPEQSCADTP VFLAKPPIGF FTDYEIGPVY EMVIALQNTT TTSRYLRVLP PSTPYFALGL GMFPGKGGMV APGMTCQYIV QFFPDCLGDF DDFILVETQS AHTLLIPLQA RRPPPVLTLS PVLDCGYCLI GGVKMTRFIC KNVGFSVGRF CIMPKTSWPP LSFKAIATVG FVEQPPFGIL PSVFELAPGH AILVEVLFSP KSLGKAEQTF IIMCDNCQIK ELVTIGIGQL IALDLIYISG EKSQPDPGEL TDLTAQHFIR FEPENLRSTA RKQLIIRNAT HVELAFYWQI MKPNLQPLMP GETFSMDSIK CYPDKETAFS IMPRKGVLSP HTDHEFILSF SPHELRDFHS VLQMVLEEVP EPVSSEAESL GHSSYSVDDV IVLEIEVKGS VEPFQVLLEP YALIIPGENY IGINVKKAFK MWNNSKSPIR YLWGKISDCH IIEVEPGTGV IEPSEVGDFE LNFTGGVPGP TSQDLLCEIE DSPSPVVLHI EAVFKGPALI INVSALQFGL LRLGQKATNS IQIRNVSQLP ATWRMKESPV SLQERPEDVS PFDIEPSSGQ LHSLGECRVD ITLEALHCQH LETVLELEVE NGAWSYLPVY AEVQKPHVYL QSSQVEVRNL YLGVPTKTTI TLINGTLLPT QFHWGKLLGH QAEFCMVTVS PKHGLLGPSE ECQLKLELTA HTQEELTHLA LPCHVSGMKK PLVLGISGKP QGLQVAITIS KESSDCSTEQ WPGHPKELRL DFGSAVPLRT RVTRQLILTN RSPIRTRFSL KFEYFGSPQN SLSKKTSLPN MPPALLKTVR MQEHLAKREQ LDFMESMLSH GKGAAFFPHF SQGMLGPYQQ LCIDITGCAN MWGEYWDNLI CTVGDLLPEV IPVHMAAVGC PISSLRTTSY TIDQAQKEPA MRFGTQVSGG DTVTRTLRLN NSSPCDIRLD WETYVPEDKE DRLVELLVFY GPPFPLRDQA GNELVCPDTP EGGCLLWSPG PSSSSEFSHE TDSSVEGSSS ASNRVAQKLI SVILQAHEGV PSGHLYCISP KQVVVPAGGS STIYISFTPM VLSPEILHKV ECTGYALGFM SLDSKVEREI PGKRHRLQDF AVGPLKLDLH SYVRPAQLSV ELDYGGSMEF QCQASDLIPE QPCSGVLSEL VTTHHLKLTN TTEIPHYFRL MVSRPFSVSQ DGASQDHRAP GPGQKQECEE ETASADKQLV LQAQENMLVN VSFSLSLELL SYQKLPADQT LPGVDIQQSA SGEREMVFTQ NLLLEYTNQT TQVVPLRAVV AVPELQLSTS WVDFGTCFVS QQRVREVYLM NLSGCRSYWT MLMGQQEPAK AAVAFRVSPN SGLLEARSAN APPTSIALQV FFTARSSELY ESTMVVEGVL GEKSCTLRLR GQGSYDERYM LPHQP // ID DSE_HUMAN Reviewed; 958 AA. AC Q9UL01; Q5R3K6; DT 07-FEB-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 175. DE RecName: Full=Dermatan-sulfate epimerase; DE Short=DS epimerase; DE EC=5.1.3.19 {ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}; DE AltName: Full=Chondroitin-glucuronate 5-epimerase; DE AltName: Full=Squamous cell carcinoma antigen recognized by T-cells 2; DE Short=SART-2; DE Flags: Precursor; GN Name=DSE; Synonyms=SART2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10679095; DOI=10.4049/jimmunol.164.5.2565; RA Nakao M., Shichijo S., Imaizumi T., Inoue Y., Matsunaga K., Yamada A., RA Kikuchi M., Tsuda N., Ohta K., Takamori S., Yamana H., Fujita H., Itoh K.; RT "Identification of a gene coding for a new squamous cell carcinoma antigen RT recognized by the CTL."; RL J. Immunol. 164:2565-2574(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, RP PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=7092807; DOI=10.1042/bj2010489; RA Malmstroem A., Aberg L.; RT "Biosynthesis of dermatan sulphate. Assay and properties of the uronosyl C- RT 5 epimerase."; RL Biochem. J. 201:489-493(1982). RN [5] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=16505484; DOI=10.1074/jbc.m513373200; RA Maccarana M., Olander B., Malmstroem J., Tiedemann K., Aebersold R., RA Lindahl U., Li J.-P., Malmstroem A.; RT "Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is RT identical to SART2."; RL J. Biol. Chem. 281:11560-11568(2006). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, GLYCOSYLATION AT RP ASN-183; ASN-336; ASN-642 AND ASN-648, AND MUTAGENESIS OF HIS-203; HIS-205; RP TYR-256; TYR-261; LYS-331 AND HIS-450. RX PubMed=19004833; DOI=10.1074/jbc.m805479200; RA Pacheco B., Maccarana M., Goodlett D.R., Malmstroem A., Malmstroem L.; RT "Identification of the active site of DS-epimerase 1 and requirement of N- RT glycosylation for enzyme function."; RL J. Biol. Chem. 284:1741-1747(2009). RN [7] {ECO:0007744|PDB:6HZN} RP X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 23-775 IN COMPLEX WITH MANGANESE RP IONS, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, GLYCOSYLATION AT RP ASN-183; ASN-336; ASN-411; ASN-642 AND ASN-648, AND MUTAGENESIS OF TRP-98; RP ASP-147; PRO-383; HIS-452; GLU-470 AND TYR-473. RX DOI=10.1039/D0SC05971D; RA Hasan M., Khakzad H., Happonen L., Sundin A., Unge J., Mueller U., RA Malmstrom J., Westergren-Thorsson G., Malmstrom L., Ellervik U., RA Malmstrom A., Tykesson E.; RT "The structure of human dermatan sulfate epimerase 1 emphasizes the RT importance of C5-epimerization of glucuronic acid in higher organisms."; RL Chem. Sci. 11:0-0(2020). RN [8] RP VARIANT EDSMC2 LEU-268, AND CHARACTERIZATION OF VARIANT EDSMC2 LEU-268. RX PubMed=23704329; DOI=10.1093/hmg/ddt227; RA Mueller T., Mizumoto S., Suresh I., Komatsu Y., Vodopiutz J., Dundar M., RA Straub V., Lingenhel A., Melmer A., Lechner S., Zschocke J., Sugahara K., RA Janecke A.R.; RT "Loss of dermatan sulfate epimerase (DSE) function results in RT musculocontractural Ehlers-Danlos syndrome."; RL Hum. Mol. Genet. 22:3761-3772(2013). CC -!- FUNCTION: Converts D-glucuronic acid to L-iduronic acid (IdoUA) CC residues. Plays an important role in the biosynthesis of the CC glycosaminoglycan/mucopolysaccharide dermatan sulfate. CC {ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, CC ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}. CC -!- CATALYTIC ACTIVITY: CC Reaction=chondroitin 4'-sulfate = dermatan 4'-sulfate; CC Xref=Rhea:RHEA:21084, Rhea:RHEA-COMP:9829, Rhea:RHEA-COMP:9965, CC ChEBI:CHEBI:58422, ChEBI:CHEBI:58465; EC=5.1.3.19; CC Evidence={ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, CC ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:7092807}; CC Note=Also has weak activity in the presence of Mg(2+) or Ca(2+) ions. CC {ECO:0000269|PubMed:7092807}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=0.12 mM for chondroitin {ECO:0000269|PubMed:7092807}; CC pH dependence: CC Optimum pH is 5.5. {ECO:0000269|PubMed:7092807}; CC -!- PATHWAY: Glycan metabolism; chondroitin sulfate biosynthesis. CC {ECO:0000305|PubMed:16505484, ECO:0000305|PubMed:19004833, CC ECO:0000305|PubMed:7092807, ECO:0000305|Ref.7}. CC -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis. CC {ECO:0000305|PubMed:16505484, ECO:0000305|PubMed:19004833, CC ECO:0000305|PubMed:7092807, ECO:0000305|Ref.7}. CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:10679095, ECO:0000305|PubMed:7092807}; Multi-pass CC membrane protein {ECO:0000305}. Golgi apparatus membrane CC {ECO:0000269|PubMed:10679095}; Multi-pass membrane protein CC {ECO:0000305}. Cytoplasmic vesicle membrane CC {ECO:0000269|PubMed:10679095}; Multi-pass membrane protein CC {ECO:0000305}. Microsome membrane {ECO:0000269|PubMed:7092807}; Multi- CC pass membrane protein {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Ubiquitously expressed with higher expression in CC kidney and ovary and lower expression in brain, colon and thymus. Also CC expressed in renal cell carcinomas, brain tumors, and in a part of CC melanomas and adenocarcinomas from organs other than the breast. CC Expressed in squamous cell carcinomas (SCC), glioma, and some CC adenocarcinoma cell lines, but not in breast cancer cell lines or any CC normal tissues (at protein level). {ECO:0000269|PubMed:10679095}. CC -!- PTM: N-glycosylated (PubMed:19004833, Ref.7). Glycosylation is CC important for enzymatic activity (PubMed:19004833). CC {ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7}. CC -!- DISEASE: Ehlers-Danlos syndrome, musculocontractural type 2 (EDSMC2) CC [MIM:615539]: A form of Ehlers-Danlos syndrome characterized by CC progressive multisystem manifestations, including joint dislocations CC and deformities, skin hyperextensibility, skin bruisability and CC fragility with recurrent large subcutaneous hematomas, cardiac CC valvular, respiratory, gastrointestinal, and ophthalmologic CC complications. Motor developmental delay is associated with muscle CC hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in CC histology in adulthood. {ECO:0000269|PubMed:23704329}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the dermatan-sulfate isomerase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF098066; AAF00087.1; -; mRNA. DR EMBL; Z84488; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039245; AAH39245.1; -; mRNA. DR CCDS; CCDS5107.1; -. DR RefSeq; NP_001074445.1; NM_001080976.3. DR RefSeq; NP_001309866.1; NM_001322937.2. DR RefSeq; NP_001309867.1; NM_001322938.2. DR RefSeq; NP_001309868.1; NM_001322939.1. DR RefSeq; NP_001309869.1; NM_001322940.1. DR RefSeq; NP_001309870.1; NM_001322941.1. DR RefSeq; NP_001309872.1; NM_001322943.1. DR RefSeq; NP_001309873.1; NM_001322944.1. DR RefSeq; NP_037484.1; NM_013352.4. DR PDB; 6HZN; X-ray; 2.41 A; A=23-775. DR PDBsum; 6HZN; -. DR AlphaFoldDB; Q9UL01; -. DR SMR; Q9UL01; -. DR BioGRID; 118977; 39. DR FunCoup; Q9UL01; 1086. DR IntAct; Q9UL01; 32. DR MINT; Q9UL01; -. DR STRING; 9606.ENSP00000494147; -. DR GlyCosmos; Q9UL01; 5 sites, No reported glycans. DR GlyGen; Q9UL01; 6 sites, 2 N-linked glycans (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q9UL01; -. DR PhosphoSitePlus; Q9UL01; -. DR BioMuta; DSE; -. DR DMDM; 74762778; -. DR jPOST; Q9UL01; -. DR MassIVE; Q9UL01; -. DR PaxDb; 9606-ENSP00000332151; -. DR PeptideAtlas; Q9UL01; -. DR ProteomicsDB; 84921; -. DR Antibodypedia; 3106; 80 antibodies from 20 providers. DR DNASU; 29940; -. DR Ensembl; ENST00000331677.7; ENSP00000332151.2; ENSG00000111817.20. DR Ensembl; ENST00000452085.7; ENSP00000404049.2; ENSG00000111817.20. DR Ensembl; ENST00000644252.3; ENSP00000494147.2; ENSG00000111817.20. DR GeneID; 29940; -. DR KEGG; hsa:29940; -. DR MANE-Select; ENST00000644252.3; ENSP00000494147.2; NM_013352.4; NP_037484.1. DR UCSC; uc003pws.5; human. DR AGR; HGNC:21144; -. DR ClinPGx; PA162384080; -. DR CTD; 29940; -. DR DisGeNET; 29940; -. DR GeneCards; DSE; -. DR GeneReviews; DSE; -. DR HGNC; HGNC:21144; DSE. DR HPA; ENSG00000111817; Low tissue specificity. DR MalaCards; DSE; -. DR MIM; 605942; gene. DR MIM; 615539; phenotype. DR OpenTargets; ENSG00000111817; -. DR Orphanet; 2953; Musculocontractural Ehlers-Danlos syndrome. DR VEuPathDB; HostDB:ENSG00000111817; -. DR eggNOG; ENOG502QPWZ; Eukaryota. DR GeneTree; ENSGT00390000006522; -. DR HOGENOM; CLU_308813_0_0_1; -. DR InParanoid; Q9UL01; -. DR OMA; FFIHAVC; -. DR OrthoDB; 5946629at2759; -. DR PAN-GO; Q9UL01; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UL01; -. DR BioCyc; MetaCyc:HS03472-MONOMER; -. DR BRENDA; 5.1.3.19; 2681. DR PathwayCommons; Q9UL01; -. DR Reactome; R-HSA-2022923; DS-GAG biosynthesis. DR SignaLink; Q9UL01; -. DR UniPathway; UPA00755; -. DR UniPathway; UPA00756; -. DR Agora; ENSG00000111817; -. DR BioGRID-ORCS; 29940; 10 hits in 1149 CRISPR screens. DR ChiTaRS; DSE; human. DR GeneWiki; DSE_(gene); -. DR GenomeRNAi; 29940; -. DR Pharos; Q9UL01; Tbio. DR PRO; PR:Q9UL01; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q9UL01; protein. DR Bgee; ENSG00000111817; Expressed in parietal pleura and 198 other cell types or tissues. DR ExpressionAtlas; Q9UL01; baseline and differential. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC-UCL. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:HGNC-UCL. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0047757; F:chondroitin-glucuronate 5-epimerase activity; IDA:HGNC-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0050654; P:chondroitin sulfate proteoglycan metabolic process; IBA:GO_Central. DR GO; GO:0050651; P:dermatan sulfate proteoglycan biosynthetic process; IDA:UniProtKB. DR GO; GO:0050655; P:dermatan sulfate proteoglycan metabolic process; IBA:GO_Central. DR GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IEA:UniProtKB-UniPathway. DR FunFam; 1.50.10.100:FF:000001; dermatan-sulfate epimerase isoform X1; 1. DR FunFam; 2.70.98.70:FF:000001; dermatan-sulfate epimerase isoform X1; 1. DR Gene3D; 2.70.98.70; -; 1. DR Gene3D; 1.50.10.100; Chondroitin AC/alginate lyase; 1. DR InterPro; IPR008929; Chondroitin_lyas. DR InterPro; IPR052447; Dermatan-Sulfate_Isomerase. DR PANTHER; PTHR15532; -; 1. DR PANTHER; PTHR15532:SF3; DERMATAN-SULFATE EPIMERASE; 1. DR SUPFAM; SSF48230; Chondroitin AC/alginate lyase; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasmic vesicle; Disease variant; Ehlers-Danlos syndrome; KW Endoplasmic reticulum; Glycoprotein; Golgi apparatus; Isomerase; Manganese; KW Membrane; Metal-binding; Microsome; Proteomics identification; KW Reference proteome; Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..958 FT /note="Dermatan-sulfate epimerase" FT /id="PRO_0000223311" FT TOPO_DOM 23..902 FT /note="Lumenal" FT /evidence="ECO:0000305" FT TRANSMEM 903..923 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 924..933 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 934..954 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 955..958 FT /note="Lumenal" FT /evidence="ECO:0000305" FT ACT_SITE 205 FT /note="Proton donor" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT ACT_SITE 261 FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT ACT_SITE 473 FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT BINDING 452 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT BINDING 470 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT BINDING 481 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT SITE 450 FT /note="Critical for catalysis" FT /evidence="ECO:0000269|PubMed:19004833" FT CARBOHYD 183 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 411 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT CARBOHYD 642 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 648 FT /note="N-linked (GlcNAc...) (paucimannose) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT VARIANT 25 FT /note="T -> I (in dbSNP:rs10485183)" FT /id="VAR_034481" FT VARIANT 34 FT /note="P -> L (in dbSNP:rs35548455)" FT /id="VAR_053833" FT VARIANT 268 FT /note="S -> L (in EDSMC2; shows a loss of epimerase FT activity towards partially desulfated dermatan sulfate; FT patient-derived fibroblasts show also a significant FT reduction in activity; dbSNP:rs398122361)" FT /evidence="ECO:0000269|PubMed:23704329" FT /id="VAR_070911" FT VARIANT 282 FT /note="I -> V (in dbSNP:rs34994230)" FT /id="VAR_053834" FT MUTAGEN 98 FT /note="W->A: Severely impairs catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 147 FT /note="D->A: Impairs catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 203 FT /note="H->A,N: Severely impairs catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 205 FT /note="H->A,N: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 256 FT /note="Y->A: Moderately reduced catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 261 FT /note="Y->A,F: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 331 FT /note="K->A: No significant effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 383 FT /note="P->A: Very low levels of protein expression and no FT detectable catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 450 FT /note="H->A,N: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 452 FT /note="H->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 470 FT /note="E->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 473 FT /note="Y->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 53..61 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 65..80 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 82..85 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 91..94 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 101..115 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 120..134 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 149..165 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 171..191 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 192..194 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 196..198 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 205..222 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 226..247 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 258..280 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 288..298 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 323..332 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 338..349 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 352..354 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 360..366 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 367..373 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 384..387 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 391..394 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 395..398 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 399..403 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 414..418 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 424..432 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 437..439 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 442..445 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 457..461 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 484..488 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 515..518 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 524..531 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 534..540 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 542..544 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 547..549 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 551..562 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 565..574 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 582..592 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 602..609 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 612..620 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 629..633 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 639..641 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 644..652 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 655..665 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 671..678 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 680..691 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 693..701 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 704..707 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 709..713 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 723..725 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 738..746 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 750..765 FT /evidence="ECO:0007829|PDB:6HZN" SQ SEQUENCE 958 AA; 109773 MW; A3D05C6194B4D2F9 CRC64; MRTHTRGAPS VFFIYLLCFV SAYITDENPE VMIPFTNANY DSHPMLYFSR AEVAELQLRA ASSHEHIAAR LTEAVHTMLS SPLEYLPPWD PKDYSARWNE IFGNNLGALA MFCVLYPENI EARDMAKDYM ERMAAQPSWL VKDAPWDEVP LAHSLVGFAT AYDFLYNYLS KTQQEKFLEV IANASGYMYE TSYRRGWGFQ YLHNHQPTNC MALLTGSLVL MNQGYLQEAY LWTKQVLTIM EKSLVLLREV TDGSLYEGVA YGSYTTRSLF QYMFLVQRHF NINHFGHPWL KQHFAFMYRT ILPGFQRTVA IADSNYNWFY GPESQLVFLD KFVMRNGSGN WLADQIRRNR VVEGPGTPSK GQRWCTLHTE FLWYDGSLKS VPPPDFGTPT LHYFEDWGVV TYGSALPAEI NRSFLSFKSG KLGGRAIYDI VHRNKYKDWI KGWRNFNAGH EHPDQNSFTF APNGVPFITE ALYGPKYTFF NNVLMFSPAV SKSCFSPWVG QVTEDCSSKW SKYKHDLAAS CQGRVVAAEE KNGVVFIRGE GVGAYNPQLN LKNVQRNLIL LHPQLLLLVD QIHLGEESPL ETAASFFHNV DVPFEETVVD GVHGAFIRQR DGLYKMYWMD DTGYSEKATF ASVTYPRGYP YNGTNYVNVT MHLRSPITRA AYLFIGPSID VQSFTVHGDS QQLDVFIATS KHAYATYLWT GEATGQSAFA QVIADRHKIL FDRNSAIKSS IVPEVKDYAA IVEQNLQHFK PVFQLLEKQI LSRVRNTASF RKTAERLLRF SDKRQTEEAI DRIFAISQQQ QQQSKSKKNR RAGKRYKFVD AVPDIFAQIE VNEKKIRQKA QILAQKELPI DEDEEMKDLL DFADVTYEKH KNGGLIKGRF GQARMVTTTH SRAPSLSASY TRLFLILNIA IFFVMLAMQL TYFQRAQSLH GQRCLYAVLL IDSCILLWLY SSCSQSQC // ID E2AK2_HUMAN Reviewed; 551 AA. AC P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4; DT 01-FEB-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 2. DT 28-JAN-2026, entry version 260. DE RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase; DE EC=2.7.11.1; DE AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2; DE Short=eIF-2A protein kinase 2; DE AltName: Full=Interferon-inducible RNA-dependent protein kinase; DE AltName: Full=P1/eIF-2A protein kinase; DE AltName: Full=Protein kinase RNA-activated; DE Short=PKR; DE Short=Protein kinase R {ECO:0000303|PubMed:11438532}; DE AltName: Full=Tyrosine-protein kinase EIF2AK2; DE EC=2.7.10.2; DE AltName: Full=p68 kinase; GN Name=EIF2AK2; Synonyms=PKR, PRKR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118 AND RP 309-325, AND INDUCTION. RX PubMed=1695551; DOI=10.1016/0092-8674(90)90374-n; RA Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M., Williams B.R.G., RA Hovanessian A.G.; RT "Molecular cloning and characterization of the human double-stranded RNA- RT activated protein kinase induced by interferon."; RL Cell 62:379-390(1990). RN [2] RP SEQUENCE REVISION. RA Meurs E.; RL Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5; RA Thomis D.C., Doohan J.P., Samuel C.E.; RT "Mechanism of interferon action: cDNA structure, expression, and regulation RT of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from RT human cells."; RL Virology 188:33-46(1992). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RX PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9; RA Kuhen K.L., Shen X., Samuel C.E.; RT "Mechanism of interferon action sequence of the human interferon-inducible RT RNA-dependent protein kinase (PKR) deduced from genomic clones."; RL Gene 178:191-193(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8812437; DOI=10.1006/geno.1996.0446; RA Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G., RA Tanaka H., Samuel C.E.; RT "Structural organization of the human gene (PKR) encoding an interferon- RT inducible RNA-dependent protein kinase (PKR) and differences from its mouse RT homolog."; RL Genomics 36:197-201(1996). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9726442; DOI=10.1089/jir.1998.18.609; RA Xu Z., Williams B.R.; RT "Genomic features of human PKR: alternative splicing and a polymorphic CGG RT repeat in the 5'-untranslated region."; RL J. Interferon Cytokine Res. 18:609-616(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Prostatic carcinoma; RA Bienvenut W.V., Gao M., Leug H.; RL Submitted (JUN-2009) to UniProtKB. RN [14] RP INTERACTION WITH DNAJC3. RX PubMed=8576172; DOI=10.1074/jbc.271.3.1702; RA Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.; RT "The P58 cellular inhibitor complexes with the interferon-induced, double- RT stranded RNA-dependent protein kinase, PKR, to regulate its RT autophosphorylation and activity."; RL J. Biol. Chem. 271:1702-1707(1996). RN [15] RP INTERACTION WITH HIV-1 TAT. RX PubMed=9079663; DOI=10.1074/jbc.272.13.8388; RA Brand S.R., Kobayashi R., Mathews M.B.; RT "The Tat protein of human immunodeficiency virus type 1 is a substrate and RT inhibitor of the interferon-induced, virally activated protein kinase, RT PKR."; RL J. Biol. Chem. 272:8388-8395(1997). RN [16] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9143277; DOI=10.1006/viro.1997.8493; RA Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E., RA Polyak S.J., Gretch D.R., Katze M.G.; RT "Evidence that hepatitis C virus resistance to interferon is mediated RT through repression of the PKR protein kinase by the nonstructural 5A RT protein."; RL Virology 230:217-227(1997). RN [17] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9710605; DOI=10.1128/mcb.18.9.5208; RA Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M., RA Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.; RT "Control of PKR protein kinase by hepatitis C virus nonstructural 5A RT protein: molecular mechanisms of kinase regulation."; RL Mol. Cell. Biol. 18:5208-5218(1998). RN [18] RP INTERACTION WITH INFLUENZA A NS1 PROTEIN. RX PubMed=9781815; DOI=10.1089/jir.1998.18.757; RA Tan S.L., Katze M.G.; RT "Biochemical and genetic evidence for complex formation between the RT influenza A virus NS1 protein and the interferon-induced PKR protein RT kinase."; RL J. Interferon Cytokine Res. 18:757-766(1998). RN [19] RP INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION). RX PubMed=10390359; DOI=10.1126/science.285.5424.107; RA Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.; RT "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 RT protein."; RL Science 285:107-110(1999). RN [20] RP FUNCTION, AND INTERACTION WITH IKBKB. RX PubMed=10848580; DOI=10.1128/mcb.20.13.4532-4542.2000; RA Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.; RT "PKR stimulates NF-kappaB irrespective of its kinase function by RT interacting with the IkappaB kinase complex."; RL Mol. Cell. Biol. 20:4532-4542(2000). RN [21] RP INTERACTION WITH TARBP2. RX PubMed=11438532; DOI=10.1074/jbc.m103584200; RA Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S., RA Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F., RA Gatignol A.; RT "Two dimerization domains in the trans-activation response RNA-binding RT protein (TRBP) individually reverse the protein kinase R inhibition of HIV- RT 1 long terminal repeat expression."; RL J. Biol. Chem. 276:33899-33905(2001). RN [22] RP PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255 AND RP THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242; THR-255; RP THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE PROTEIN. RX PubMed=11152499; DOI=10.1128/jvi.75.3.1265-1273.2001; RA Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C., RA Mathews M.B.; RT "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple RT competition with autophosphorylation sites in the RNA-binding domain."; RL J. Virol. 75:1265-1273(2001). RN [23] RP MUTAGENESIS OF LYS-60; ALA-67; THR-446 AND THR-451, AND PHOSPHORYLATION AT RP THR-446 AND THR-451. RX PubMed=11337501; DOI=10.1074/jbc.m102108200; RA Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E., RA Mathews M.B., Ozato K., Hinnebusch A.G.; RT "Binding of double-stranded RNA to protein kinase PKR is required for RT dimerization and promotes critical autophosphorylation events in the RT activation loop."; RL J. Biol. Chem. 276:24946-24958(2001). RN [24] RP INTERACTION WITH HHV-8 PROTEIN VIRF2 (MICROBIAL INFECTION). RX PubMed=11160738; DOI=10.1128/jvi.75.5.2345-2352.2001; RA Burysek L., Pitha P.M.; RT "Latently expressed human herpesvirus 8-encoded interferon regulatory RT factor 2 inhibits double-stranded RNA-activated protein kinase."; RL J. Virol. 75:2345-2352(2001). RN [25] RP FUNCTION, AND INTERACTION WITH HHV-1 US11 (MICROBIAL INFECTION). RX PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002; RA Cassady K.A., Gross M.; RT "The herpes simplex virus type 1 U(S)11 protein interacts with protein RT kinase R in infected cells and requires a 30-amino-acid sequence adjacent RT to a kinase substrate domain."; RL J. Virol. 76:2029-2035(2002). RN [26] RP INTERACTION WITH NPM1, AND ACTIVITY REGULATION. RX PubMed=12882984; DOI=10.1074/jbc.m301392200; RA Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W., RA Faulkner G.R., Speckhart A., Bagby G.C.; RT "Nucleophosmin interacts with and inhibits the catalytic function of RT eukaryotic initiation factor 2 kinase PKR."; RL J. Biol. Chem. 278:41709-41717(2003). RN [27] RP FUNCTION, AND INTERACTION WITH MAP2K6. RX PubMed=15229216; DOI=10.1074/jbc.m406554200; RA Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.; RT "Protein kinase R (PKR) interacts with and activates mitogen-activated RT protein kinase kinase 6 (MKK6) in response to double-stranded RNA RT stimulation."; RL J. Biol. Chem. 279:37670-37676(2004). RN [28] RP IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70. RX PubMed=15299030; DOI=10.1074/jbc.m403884200; RA Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.; RT "The Fanconi anemia proteins functionally interact with the protein kinase RT regulated by RNA (PKR)."; RL J. Biol. Chem. 279:43910-43919(2004). RN [29] RP FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR RP LOCATION. RX PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004; RA Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H., RA Alcami J., Esteban M.; RT "TRAF family proteins link PKR with NF-kappa B activation."; RL Mol. Cell. Biol. 24:4502-4512(2004). RN [30] RP INHIBITION BY VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=15207627; DOI=10.1016/j.virol.2004.03.012; RA Langland J.O., Jacobs B.L.; RT "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains RT of E3L."; RL Virology 324:419-429(2004). RN [31] RP REVIEW. RX PubMed=17158706; DOI=10.1128/mmbr.00027-06; RA Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., RA Esteban M.; RT "Impact of protein kinase PKR in cell biology: from antiviral to RT antiproliferative action."; RL Microbiol. Mol. Biol. Rev. 70:1032-1060(2006). RN [32] RP INTERACTION WITH HCMV TRS1 (MICROBIAL INFECTION). RX PubMed=16987971; DOI=10.1128/jvi.00957-06; RA Hakki M., Marshall E.E., De Niro K.L., Geballe A.P.; RT "Binding and nuclear relocalization of protein kinase R by human RT cytomegalovirus TRS1."; RL J. Virol. 80:11817-11826(2006). RN [33] RP PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293. RX PubMed=16373505; DOI=10.1073/pnas.0508207103; RA Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.; RT "Tyrosine phosphorylation acts as a molecular switch to full-scale RT activation of the eIF2alpha RNA-dependent protein kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006). RN [34] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=16951545; DOI=10.1016/s1016-8478(23)17385-7; RA Liang Y., Kang C.B., Yoon H.S.; RT "Molecular and structural characterization of the domain 2 of hepatitis C RT virus non-structural protein 5A."; RL Mol. Cells 22:13-20(2006). RN [35] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=17451199; DOI=10.3748/wjg.v13.i8.1195; RA Veillon P., Payan C., Le Guillou-Guillemette H., Gaudy C., Lunel F.; RT "Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b RT during interferon or combined interferon-ribavirin therapy."; RL World J. Gastroenterol. 13:1195-1203(2007). RN [36] RP INTERACTION WITH HCV MATURE CORE PROTEIN (MICROBIAL INFECTION). RX PubMed=17267064; DOI=10.1016/j.virusres.2006.12.010; RA Yan X.B., Battaglia S., Boucreux D., Chen Z., Brechot C., Pavio N.; RT "Mapping of the interacting domains of hepatitis C virus core protein and RT the double-stranded RNA-activated protein kinase PKR."; RL Virus Res. 125:79-87(2007). RN [37] RP INTERACTION WITH ADAR. RX PubMed=17079286; DOI=10.1128/jvi.01527-06; RA Nie Y., Hammond G.L., Yang J.H.; RT "Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus RT infection."; RL J. Virol. 81:917-923(2007). RN [38] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003; RA Cole J.L.; RT "Activation of PKR: an open and shut case?"; RL Trends Biochem. Sci. 32:57-62(2007). RN [39] RP FUNCTION, INTERACTION WITH NCK1, AND ACTIVITY REGULATION. RX PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112; RA Cardin E., Larose L.; RT "Nck-1 interacts with PKR and modulates its activation by dsRNA."; RL Biochem. Biophys. Res. Commun. 377:231-235(2008). RN [40] RP INTERACTION WITH DUS2L, AND ACTIVITY REGULATION. RX PubMed=18096616; DOI=10.1093/nar/gkm1129; RA Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V., RA Patel R.C.; RT "Interaction of human tRNA-dihydrouridine synthase-2 with interferon- RT induced protein kinase PKR."; RL Nucleic Acids Res. 36:998-1008(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP MUTAGENESIS OF ASP-486, AND INTERACTION WITH VACCINIA VIRUS PROTEIN K3 RP (MICROBIAL INFECTION). RX PubMed=18971339; DOI=10.1073/pnas.0805524105; RA Seo E.J., Liu F., Kawagishi-Kobayashi M., Ung T.L., Cao C., Dar A.C., RA Sicheri F., Dever T.E.; RT "Protein kinase PKR mutants resistant to the poxvirus pseudosubstrate K3L RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 105:16894-16899(2008). RN [43] RP FUNCTION. RX PubMed=19507191; DOI=10.1002/jcp.21848; RA Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J., RA Martinelli G., Cocco L., Martelli A.M.; RT "PKR activity is required for acute leukemic cell maintenance and growth: a RT role for PKR-mediated phosphatase activity to regulate GSK-3 RT phosphorylation."; RL J. Cell. Physiol. 221:232-241(2009). RN [44] RP FUNCTION, AND INTERACTION WITH DHX9. RX PubMed=19229320; DOI=10.1371/journal.ppat.1000311; RA Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.; RT "An antiviral response directed by PKR phosphorylation of the RNA helicase RT A."; RL PLoS Pathog. 5:E1000311-E1000311(2009). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [46] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007; RA Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P., Ahn B.Y.; RT "PKR protein kinase is activated by hepatitis C virus and inhibits viral RT replication through translational control."; RL Virus Res. 142:51-56(2009). RN [47] RP FUNCTION. RX PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008; RA Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.; RT "A role for protein kinase PKR in the mediation of Epstein-Barr virus RT latent membrane protein-1-induced IL-6 and IL-10 expression."; RL Cytokine 50:210-219(2010). RN [48] RP FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS TYROSINE-PROTEIN RP KINASE. RX PubMed=20395957; DOI=10.1038/embor.2010.45; RA Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.; RT "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers RT Cdc2 polyubiquitination and G2 arrest under genotoxic stresses."; RL EMBO Rep. 11:393-399(2010). RN [49] RP FUNCTION. RX PubMed=21123651; DOI=10.1101/gad.1965010; RA Harashima A., Guettouche T., Barber G.N.; RT "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase RT PKR constitutes a novel mechanism of translational regulation and cellular RT defense."; RL Genes Dev. 24:2640-2653(2010). RN [50] RP INTERACTION WITH HRSV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=20519500; DOI=10.1074/jbc.m109.077321; RA Groskreutz D.J., Babor E.C., Monick M.M., Varga S.M., Hunninghake G.W.; RT "Respiratory syncytial virus limits alpha subunit of eukaryotic translation RT initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and RT viral replication."; RL J. Biol. Chem. 285:24023-24031(2010). RN [51] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x; RA Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N., RA Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.; RT "Double-stranded RNA-activated protein kinase inhibits hepatitis C virus RT replication but may be not essential in interferon treatment."; RL Liver Int. 30:311-318(2010). RN [52] RP FUNCTION, AND PHOSPHORYLATION AT THR-451. RX PubMed=20685959; DOI=10.1091/mbc.e10-06-0481; RA Yang X., Nath A., Opperman M.J., Chan C.; RT "The double-stranded RNA-dependent protein kinase differentially regulates RT insulin receptor substrates 1 and 2 in HepG2 cells."; RL Mol. Biol. Cell 21:3449-3458(2010). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x; RA Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F., Hugon J.; RT "Modulation of tau phosphorylation by the kinase PKR: implications in RT Alzheimer's disease."; RL Brain Pathol. 21:189-200(2011). RN [56] RP REVIEW. RX PubMed=21924887; DOI=10.1016/j.coi.2011.08.009; RA Pfaller C.K., Li Z., George C.X., Samuel C.E.; RT "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old RT players as modulators of the interferon response."; RL Curr. Opin. Immunol. 23:573-582(2011). RN [57] RP REVIEW. RX PubMed=21166592; DOI=10.1089/jir.2010.0099; RA Pindel A., Sadler A.; RT "The role of protein kinase R in the interferon response."; RL J. Interferon Cytokine Res. 31:59-70(2011). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION. RX PubMed=21072047; DOI=10.1038/leu.2010.264; RA Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I., RA Martelli A.M., Follo M.Y., Cocco L.; RT "Multiple forms of PKR present in the nuclei of acute leukemia cells RT represent an active kinase that is responsive to stress."; RL Leukemia 25:236-245(2011). RN [59] RP FUNCTION IN HBV RESTRICTION. RX PubMed=21710204; DOI=10.1007/s10059-011-1059-6; RA Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.; RT "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B virus RT replication."; RL Mol. Cells 32:167-172(2011). RN [60] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [61] RP REVIEW. RX PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010; RA Lacy-Hulbert A., Stuart L.M.; RT "Penetration resistance: PKR's other talent."; RL Immunity 36:695-696(2012). RN [62] RP FUNCTION. RX PubMed=22948139; DOI=10.1074/jbc.m112.390039; RA McAllister C.S., Taghavi N., Samuel C.E.; RT "Protein kinase PKR amplification of interferon beta induction occurs RT through initiation factor eIF-2alpha-mediated translational control."; RL J. Biol. Chem. 287:36384-36392(2012). RN [63] RP FUNCTION, AND INTERACTION WITH STAT3. RX PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013; RA Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., RA Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O., RA Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.; RT "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity."; RL Mol. Cell 48:667-680(2012). RN [64] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [65] RP FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND RP AUTOPHOSPHORYLATION. RX PubMed=22801494; DOI=10.1038/nature11290; RA Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., RA Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., RA Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., RA Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.; RT "Novel role of PKR in inflammasome activation and HMGB1 release."; RL Nature 488:670-674(2012). RN [66] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [67] RP REVIEW. RX PubMed=23092889; DOI=10.1126/scisignal.2003511; RA Kang R., Tang D.; RT "PKR-dependent inflammatory signals."; RL Sci. Signal. 5:PE47-PE47(2012). RN [68] RP FUNCTION. RX PubMed=22381929; DOI=10.1016/j.virol.2012.01.029; RA Taghavi N., Samuel C.E.; RT "Protein kinase PKR catalytic activity is required for the PKR-dependent RT activation of mitogen-activated protein kinases and amplification of RT interferon beta induction following virus infection."; RL Virology 427:208-216(2012). RN [69] RP REVIEW. RX PubMed=23202496; DOI=10.3390/v4112598; RA Dabo S., Meurs E.F.; RT "dsRNA-dependent protein kinase PKR and its role in stress, signaling and RT HCV infection."; RL Viruses 4:2598-2635(2012). RN [70] RP TISSUE SPECIFICITY. RX PubMed=23403623; DOI=10.1182/blood-2012-09-456400; RA Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.; RT "PKR regulates proliferation, differentiation and survival of murine RT hematopoietic stem/progenitor cells."; RL Blood 121:3364-3374(2013). RN [71] RP REVIEW. RX PubMed=23354059; DOI=10.1007/s00018-012-1252-6; RA Donnelly N., Gorman A.M., Gupta S., Samali A.; RT "The eIF2alpha kinases: their structures and functions."; RL Cell. Mol. Life Sci. 70:3493-3511(2013). RN [72] RP FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ACTIVITY REGULATION. RX PubMed=23229543; DOI=10.1074/jbc.m112.401851; RA Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.; RT "Activation of double-stranded RNA-activated protein kinase (PKR) by RT interferon-stimulated gene 15 (ISG15) modification down-regulates protein RT translation."; RL J. Biol. Chem. 288:2839-2847(2013). RN [73] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [74] RP INTERACTION WITH TOSCANA VIRUS PROTEIN NSS (MICROBIAL INFECTION), AND RP ACTIVITY REGULATION. RX PubMed=23325696; DOI=10.1128/jvi.02506-12; RA Kalveram B., Ikegami T.; RT "Toscana virus NSs protein promotes degradation of double-stranded RNA- RT dependent protein kinase."; RL J. Virol. 87:3710-3718(2013). RN [75] RP FUNCTION IN MV RESTRICTION. RX PubMed=23115276; DOI=10.1128/jvi.02270-12; RA Okonski K.M., Samuel C.E.; RT "Stress granule formation induced by measles virus is protein kinase PKR RT dependent and impaired by RNA adenosine deaminase ADAR1."; RL J. Virol. 87:756-766(2013). RN [76] RP FUNCTION. RX PubMed=23372823; DOI=10.1371/journal.pone.0055108; RA Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.; RT "Protein kinase regulated by dsRNA downregulates the interferon production RT in dengue virus- and dsrna-stimulated human lung epithelial cells."; RL PLoS ONE 8:E55108-E55108(2013). RN [77] RP FUNCTION IN HCV RESTRICTION. RX PubMed=23399035; DOI=10.1016/j.virol.2013.01.015; RA Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M., Shih J.W., RA Wang R.Y.; RT "The modulation of hepatitis C virus 1a replication by PKR is dependent on RT NF-kB mediated interferon beta response in Huh7.5.1 cells."; RL Virology 438:28-36(2013). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [79] RP INTERACTION WITH VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=25740987; DOI=10.1128/jvi.03288-14; RA Dueck K.J., Hu Y.S., Chen P., Deschambault Y., Lee J., Varga J., Cao J.; RT "Mutational analysis of vaccinia virus E3 protein: the biological functions RT do not correlate with its biochemical capacity to bind double-stranded RT RNA."; RL J. Virol. 89:5382-5394(2015). RN [80] RP INTERACTION WITH MBIP AND MOCS2B, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=26705305; DOI=10.1093/jmcb/mjv070; RA Suganuma T., Swanson S.K., Florens L., Washburn M.P., Workman J.L.; RT "Moco biosynthesis and the ATAC acetyltransferase engage translation RT initiation by inhibiting latent PKR activity."; RL J. Mol. Cell Biol. 8:44-50(2016). RN [81] RP MUTAGENESIS OF PHE-489; THR-496; ILE-502; LYS-510 AND GLN-516, RP CHARACTERIZATION OF VARIANT VAL-506, AND INTERACTION WITH HCMV TRS1 RP (MICROBIAL INFECTION). RX PubMed=27780231; DOI=10.1371/journal.ppat.1005966; RA Carpentier K.S., Esparo N.M., Child S.J., Geballe A.P.; RT "A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated RT Viral Antagonists."; RL PLoS Pathog. 12:e1005966-e1005966(2016). RN [82] RP INTERACTION WITH HUMAN HERPES VIRUS 8 PROTEIN KTA/ORF57 (MICROBIAL RP INFECTION). RX PubMed=29084250; DOI=10.1371/journal.ppat.1006677; RA Sharma N.R., Majerciak V., Kruhlak M.J., Zheng Z.M.; RT "KSHV inhibits stress granule formation by viral ORF57 blocking PKR RT activation."; RL PLoS Pathog. 13:e1006677-e1006677(2017). RN [83] {ECO:0007744|PDB:1QU6} RP STRUCTURE BY NMR OF 1-170, AND DOMAIN. RX PubMed=9736623; DOI=10.1093/emboj/17.18.5458; RA Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.; RT "Structure of the double-stranded RNA-binding domain of the protein kinase RT PKR reveals the molecular basis of its dsRNA-mediated activation."; RL EMBO J. 17:5458-5465(1998). RN [84] {ECO:0007744|PDB:2A19, ECO:0007744|PDB:2A1A} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 258-550 IN COMPLEX WITH RP EIF2S1/EIF-2ALPHA, PHOSPHORYLATION AT THR-446, DOMAIN, SUBUNIT, COFACTOR, RP AND INTERACTION WITH EIF2S1/EIF-2ALPHA. RX PubMed=16179258; DOI=10.1016/j.cell.2005.06.044; RA Dar A.C., Dever T.E., Sicheri F.; RT "Higher-order substrate recognition of eIF2alpha by the RNA-dependent RT protein kinase PKR."; RL Cell 122:887-900(2005). RN [85] {ECO:0007744|PDB:6D3K, ECO:0007744|PDB:6D3L} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 229-551, AND SUBUNIT. RX PubMed=31246429; DOI=10.1021/acs.biochem.9b00161; RA Mayo C.B., Erlandsen H., Mouser D.J., Feinstein A.G., Robinson V.L., RA May E.R., Cole J.L.; RT "Structural Basis of Protein Kinase R Autophosphorylation."; RL Biochemistry 58:2967-2977(2019). RN [86] RP INVOLVEMENT IN LEUDEN, FUNCTION, VARIANTS LEUDEN LEU-11; SER-32; PHE-97; RP SER-109; VAL-109; PHE-133; SER-325 AND CYS-461, CHARACTERIZATION OF RP VARIANTS LEUDEN LEU-11; PHE-133 AND CYS-461, AND VARIANT GLN-114. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [87] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [88] RP VARIANTS DYT33 THR-32; ARG-130 AND ALA-138, CHARACTERIZATION OF VARIANTS RP DYT33 THR-32 AND ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33236446; DOI=10.1002/ana.25973; RA Kuipers D.J.S., Mandemakers W., Lu C.S., Olgiati S., Breedveld G.J., RA Fevga C., Tadic V., Carecchio M., Osterman B., Sagi-Dain L., Wu-Chou Y.H., RA Chen C.C., Chang H.C., Wu S.L., Yeh T.H., Weng Y.H., Elia A.E., RA Panteghini C., Marotta N., Pauly M.G., Kuehn A.A., Volkmann J., Lace B., RA Meijer I.A., Kandaswamy K., Quadri M., Garavaglia B., Lohmann K., Bauer P., RA Mencacci N.E., Lubbe S.J., Klein C., Bertoli-Avella A.M., Bonifati V.; RT "EIF2AK2 Missense Variants Associated with Early Onset Generalized RT Dystonia."; RL Ann. Neurol. 89:485-497(2021). RN [89] RP VARIANT DYT33 ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33866603; DOI=10.1002/ana.26081; RA Musacchio T., Zech M., Reich M.M., Winkelmann J., Volkmann J.; RT "A Recurrent EIF2AK2 Missense Variant Causes Autosomal-Dominant Isolated RT Dystonia."; RL Ann. Neurol. 89:1257-1258(2021). RN [90] RP VARIANT DYT33 ARG-130. RX PubMed=35146068; DOI=10.1002/mdc3.13371; RA Magrinelli F., Moualek D., Tazir M., Pacha L.A., Verghese A., Bhatia K.P., RA Maroofian R., Houlden H.; RT "Heterozygous EIF2AK2 Variant Causes Adolescence-Onset Generalized Dystonia RT Partially Responsive to DBS."; RL Mov. Disord. Clin. Pract. 9:268-271(2022). CC -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase CC that phosphorylates the alpha subunit of eukaryotic translation CC initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the CC innate immune response to viral infection (PubMed:18835251, CC PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, CC PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral CC replication via the integrated stress response (ISR): EIF2S1/eIF-2- CC alpha phosphorylation in response to viral infection converts CC EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting CC to a shutdown of cellular and viral protein synthesis, while CC concomitantly initiating the preferential translation of ISR-specific CC mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, CC PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its CC antiviral activity on a wide range of DNA and RNA viruses including CC hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) CC and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, CC PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, CC PubMed:23399035). Also involved in the regulation of signal CC transduction, apoptosis, cell proliferation and differentiation: CC phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, CC ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, CC PubMed:19229320, PubMed:22214662). In addition to serine/threonine- CC protein kinase activity, also has tyrosine-protein kinase activity and CC phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its CC ubiquitination and proteasomal degradation (PubMed:20395957). Either as CC an adapter protein and/or via its kinase activity, can regulate various CC signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling CC pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) CC involved in the expression of genes encoding pro-inflammatory cytokines CC and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates CC the NF-kappa-B pathway via interaction with IKBKB and TRAF family of CC proteins and activates the p38 MAP kinase pathway via interaction with CC MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as CC both a positive and negative regulator of the insulin signaling pathway CC (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the CC inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at CC 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A CC which activates FOXO1, which in turn up-regulates the expression of CC insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate CC NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 CC and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the CC regulation of the cytoskeleton by binding to gelsolin (GSN), CC sequestering the protein in an inactive conformation away from actin CC (By similarity). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, CC ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, CC ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, CC ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, CC ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, CC ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, CC ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, CC ECO:0000269|PubMed:32197074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:16179258, ECO:0000303|PubMed:31246429}; CC -!- ACTIVITY REGULATION: Initially produced in an inactive form and is CC activated by binding to viral dsRNA, which causes dimerization and CC autophosphorylation in the activation loop and stimulation of function. CC ISGylation can activate it in the absence of viral infection. Can also CC be activated by heparin, pro-inflammatory stimuli, growth factors, CC cytokines, oxidative stress and the cellular protein PRKRA. Activity is CC markedly stimulated by manganese ions. Activation is blocked by the CC viral components HIV-1 Tat protein and large amounts of HIV-1 trans- CC activation response (TAR) RNA element as well as by the cellular CC proteins TARBP2, DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana CC virus (TOS) and Rift valley fever virus (RVFV) NSS which promote its CC proteasomal degradation. Inhibited by vaccinia virus protein E3, CC probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251, CC ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: Homodimer (PubMed:16179258, PubMed:31246429). Interacts with CC STRBP (By similarity). Interacts with DNAJC3. Forms a complex with CC FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1. Interacts CC with IRS1 (By similarity). The inactive form interacts with NCK1 and CC GSN. Interacts (via the kinase catalytic domain) with STAT3 (via SH2 CC domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). CC Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 CC and AIM2. Interacts (via DRBM 1 domain) with DUS2L (via DRBM domain). CC Interacts with DHX9 (via N-terminus) and this interaction is dependent CC upon activation of the kinase. Interacts with EIF2S1/EIF-2ALPHA; this CC interaction induces a conformational change in EIF2S1 and its CC phosphorylation by EIF2AK2 (PubMed:16179258). Interacts with MBIP; the CC interaction is direct and leads to inhibition of EIF2AK2 self- CC activating autophosphorylation (PubMed:26705305). Interacts with the CC molybdopterin synthase complex subunit MOCS2B; the interaction is CC direct and enhances the interaction between EIF2AK2 and MBIP CC (PubMed:26705305). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10390359, ECO:0000269|PubMed:10848580, CC ECO:0000269|PubMed:11438532, ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:15299030, ECO:0000269|PubMed:16179258, CC ECO:0000269|PubMed:17079286, ECO:0000269|PubMed:18096616, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19229320, CC ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:25740987, ECO:0000269|PubMed:26705305, CC ECO:0000269|PubMed:31246429, ECO:0000269|PubMed:8576172, CC ECO:0000269|PubMed:9079663, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9781815}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) TRS1; this interaction retains EIF2AK2 to the nucleus and CC prevents its activation. {ECO:0000269|PubMed:16987971, CC ECO:0000269|PubMed:27780231}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia virus protein K3 CC (K3L); this interaction inhibits EIF2AK2. CC {ECO:0000269|PubMed:18971339}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes simplex CC virus 1 (HHV-1) protein US11 in an RNA-dependent manner. CC {ECO:0000269|PubMed:11836380}. CC -!- SUBUNIT: (Microbial infection) The inactive form interacts with Toscana CC virus (TOS) NSS. {ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein v- CC IRF2; this interaction inhibits EIF2AK2 activation. CC {ECO:0000269|PubMed:11160738}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia protein E3. CC {ECO:0000269|PubMed:25740987}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with CC Hepatitis C virus (HCV) mature core protein (via N-terminus); this CC interaction induces the autophosphorylation of EIF2AK2. CC {ECO:0000269|PubMed:17267064}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC non-structural protein 5A (NS5A); this interaction leads to disruption CC of EIF2AK2 dimerization by NS5A. {ECO:0000269|PubMed:16951545, CC ECO:0000269|PubMed:17451199, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9710605}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks CC its inhibitory effect on protein synthesis and cell growth. CC {ECO:0000269|PubMed:9143277}. CC -!- SUBUNIT: (Microbial infection) Interacts with human respiratory CC syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2 CC phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation CC shutoff. {ECO:0000269|PubMed:20519500}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 8 CC protein MTA/ORF57; this interaction inhibits stress granule formation. CC {ECO:0000269|PubMed:29084250}. CC -!- INTERACTION: CC P19525; P78563-4: ADARB1; NbExp=3; IntAct=EBI-640775, EBI-12002366; CC P19525; P06493: CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308; CC P19525; Q7L2E3: DHX30; NbExp=4; IntAct=EBI-640775, EBI-1211456; CC P19525; Q96C10: DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193; CC P19525; Q08211: DHX9; NbExp=4; IntAct=EBI-640775, EBI-352022; CC P19525; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506; CC P19525; Q6P2E9: EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038; CC P19525; P19525: EIF2AK2; NbExp=2; IntAct=EBI-640775, EBI-640775; CC P19525; P05198: EIF2S1; NbExp=5; IntAct=EBI-640775, EBI-1056162; CC P19525; P56537: EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243; CC P19525; Q8IY81: FTSJ3; NbExp=3; IntAct=EBI-640775, EBI-744088; CC P19525; Q9HCE1: MOV10; NbExp=3; IntAct=EBI-640775, EBI-1055820; CC P19525; Q96P20: NLRP3; NbExp=6; IntAct=EBI-640775, EBI-6253230; CC P19525; P06748: NPM1; NbExp=4; IntAct=EBI-640775, EBI-78579; CC P19525; O75569: PRKRA; NbExp=6; IntAct=EBI-640775, EBI-713955; CC P19525; O75569-1: PRKRA; NbExp=3; IntAct=EBI-640775, EBI-15588172; CC P19525; Q9NUL3: STAU2; NbExp=3; IntAct=EBI-640775, EBI-722938; CC P19525; Q15633: TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581; CC P19525; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615; CC P19525; Q9UL40: ZNF346; NbExp=4; IntAct=EBI-640775, EBI-2462313; CC P19525; Q27968: DNAJC3; Xeno; NbExp=5; IntAct=EBI-640775, EBI-640793; CC P19525; P0DTC9: N; Xeno; NbExp=8; IntAct=EBI-640775, EBI-25475856; CC P19525; P20639: OPG041; Xeno; NbExp=3; IntAct=EBI-640775, EBI-8674942; CC P19525; P04487: US11; Xeno; NbExp=3; IntAct=EBI-640775, EBI-6150681; CC P19525; Q2HR71: vIRF-2; Xeno; NbExp=2; IntAct=EBI-640775, EBI-8876177; CC P19525; PRO_0000278746 [O92972]; Xeno; NbExp=2; IntAct=EBI-640775, EBI-6918883; CC P19525; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-640775, EBI-6904269; CC P19525; PRO_0000037576 [P27958]; Xeno; NbExp=5; IntAct=EBI-640775, EBI-8753518; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15121867, CC ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:26705305}. Nucleus {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:15121867}. Note=Nuclear CC localization is elevated in acute leukemia, myelodysplastic syndrome CC (MDS), melanoma, breast, colon, prostate and lung cancer patient CC samples or cell lines as well as neurocytes from advanced Creutzfeldt- CC Jakob disease patients. {ECO:0000269|PubMed:21072047}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P19525-1; Sequence=Displayed; CC Name=2; CC IsoId=P19525-2; Sequence=VSP_046177; CC -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone marrow CC compared to non-hematopoietic tissues such as small intestine, liver, CC or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer CC disease (AD) brain. Elevated levels seen in breast and colon CC carcinomas, and which correlates with tumor progression and CC invasiveness or risk of progression. {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:23403623}. CC -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}. CC -!- DOMAIN: Contains 2 dsRNA-binding domain (DRBM) (PubMed:9736623). The N- CC terminus contains the catalytic domain dimerization. The C-terminus CC binds EIF2S1/EIF2-alpha (PubMed:16179258). CC {ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:9736623}. CC -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues. CC Autophosphorylation of Thr-451 is dependent on Thr-446 and is CC stimulated by dsRNA binding and dimerization. Autophosphorylation CC apparently leads to the activation of the kinase. Tyrosine CC autophosphorylation is essential for efficient dsRNA-binding, CC dimerization, and kinase activation. Autophosphorylation is inhibited CC by the concerted action of ATAC complex subunit MBIP and molybdopterin CC synthase complex subunit MOCS2B (PubMed:26705305). CC {ECO:0000269|PubMed:11152499, ECO:0000269|PubMed:11337501, CC ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:16373505, CC ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. CC -!- DISEASE: Leukoencephalopathy, developmental delay, and episodic CC neurologic regression syndrome (LEUDEN) [MIM:618877]: An autosomal CC dominant disorder characterized by global developmental delay apparent CC in early childhood, cognitive impairment, ataxia, poor or absent speech CC with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, CC and abnormal involuntary movements. Affected individuals also exhibit CC neurological regression in the setting of febrile illness or infection. CC Many patients have seizures. Brain imaging shows diffuse white matter CC abnormalities with poor myelination. {ECO:0000269|PubMed:32197074}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Dystonia 33 (DYT33) [MIM:619687]: A form of dystonia, a CC disorder defined by the presence of sustained involuntary muscle CC contraction, often leading to abnormal postures. DYT33 is a slowly CC progressive form characterized by onset of focal or generalized CC dystonia in the first decades of life. Disease manifestations are CC variable. Some patients show ambulation difficulties, dysarthria, or CC dysphagia. Some affected individuals may manifest motor delay, lower CC limb spasticity, and mild developmental delay with intellectual CC disability. DYT33 penetrance is incomplete. Inheritance can be CC autosomal dominant or recessive. {ECO:0000269|PubMed:33236446, CC ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41866/EIF2AK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M35663; AAA36409.1; -; mRNA. DR EMBL; M85294; AAA18253.1; -; mRNA. DR EMBL; U50648; AAC50768.1; -; Genomic_DNA. DR EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; AF167472; AAF13156.1; -; Genomic_DNA. DR EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AY302136; AAP57628.1; -; mRNA. DR EMBL; AK290655; BAF83344.1; -; mRNA. DR EMBL; AK313818; BAG36554.1; -; mRNA. DR EMBL; AY228338; AAO38055.1; -; Genomic_DNA. DR EMBL; AC007899; AAY24317.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00407.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00408.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00409.1; -; Genomic_DNA. DR EMBL; BC093676; AAH93676.1; -; mRNA. DR EMBL; BC101475; AAI01476.1; -; mRNA. DR CCDS; CCDS1786.1; -. [P19525-1] DR CCDS; CCDS46259.1; -. [P19525-2] DR PIR; JC5225; JC5225. DR RefSeq; NP_001129123.1; NM_001135651.3. [P19525-1] DR RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2] DR RefSeq; NP_002750.1; NM_002759.4. [P19525-1] DR RefSeq; XP_011531289.1; XM_011532987.3. [P19525-1] DR RefSeq; XP_054198993.1; XM_054343018.1. [P19525-1] DR PDB; 1QU6; NMR; -; A=1-170. DR PDB; 2A19; X-ray; 2.50 A; B/C=258-550. DR PDB; 2A1A; X-ray; 2.80 A; B=258-550. DR PDB; 3UIU; X-ray; 2.90 A; A/B=254-551. DR PDB; 6D3K; X-ray; 2.60 A; A/B/C=229-551. DR PDB; 6D3L; X-ray; 3.10 A; A=229-551. DR PDB; 7OBK; X-ray; 1.80 A; B=541-551. DR PDB; 7OBL; X-ray; 1.80 A; B=541-551. DR PDB; 8BI7; X-ray; 1.40 A; B=541-551. DR PDB; 8I9J; EM; 6.39 A; A=1-170. DR PDB; 8IZN; EM; 6.67 A; A=1-170. DR PDBsum; 1QU6; -. DR PDBsum; 2A19; -. DR PDBsum; 2A1A; -. DR PDBsum; 3UIU; -. DR PDBsum; 6D3K; -. DR PDBsum; 6D3L; -. DR PDBsum; 7OBK; -. DR PDBsum; 7OBL; -. DR PDBsum; 8BI7; -. DR PDBsum; 8I9J; -. DR PDBsum; 8IZN; -. DR AlphaFoldDB; P19525; -. DR BMRB; P19525; -. DR EMDB; EMD-35274; -. DR EMDB; EMD-35866; -. DR SMR; P19525; -. DR BioGRID; 111596; 395. DR DIP; DIP-2657N; -. DR FunCoup; P19525; 998. DR IntAct; P19525; 176. DR MINT; P19525; -. DR STRING; 9606.ENSP00000233057; -. DR BindingDB; P19525; -. DR ChEMBL; CHEMBL5785; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07995; H-89. DR DrugBank; DB00328; Indomethacin. DR DrugCentral; P19525; -. DR GuidetoPHARMACOLOGY; 2016; -. DR GlyGen; P19525; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P19525; -. DR PhosphoSitePlus; P19525; -. DR SwissPalm; P19525; -. DR BioMuta; EIF2AK2; -. DR DMDM; 125527; -. DR jPOST; P19525; -. DR MassIVE; P19525; -. DR PaxDb; 9606-ENSP00000233057; -. DR PeptideAtlas; P19525; -. DR ProteomicsDB; 19391; -. DR ProteomicsDB; 53670; -. [P19525-1] DR Pumba; P19525; -. DR TopDownProteomics; P19525-1; -. [P19525-1] DR Antibodypedia; 3548; 1196 antibodies from 44 providers. DR DNASU; 5610; -. DR Ensembl; ENST00000233057.9; ENSP00000233057.4; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000395127.6; ENSP00000378559.2; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000405334.5; ENSP00000385014.1; ENSG00000055332.20. [P19525-2] DR Ensembl; ENST00000647926.1; ENSP00000497534.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000679507.1; ENSP00000506024.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681463.1; ENSP00000505138.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681507.1; ENSP00000505772.1; ENSG00000055332.20. [P19525-1] DR GeneID; 5610; -. DR KEGG; hsa:5610; -. DR MANE-Select; ENST00000233057.9; ENSP00000233057.4; NM_001135651.3; NP_001129123.1. DR UCSC; uc010fab.3; human. [P19525-1] DR AGR; HGNC:9437; -. DR ClinPGx; PA33779; -. DR CTD; 5610; -. DR DisGeNET; 5610; -. DR GeneCards; EIF2AK2; -. DR HGNC; HGNC:9437; EIF2AK2. DR HPA; ENSG00000055332; Low tissue specificity. DR MalaCards; EIF2AK2; -. DR MIM; 176871; gene. DR MIM; 618877; phenotype. DR MIM; 619687; phenotype. DR OpenTargets; ENSG00000055332; -. DR Orphanet; 256; Early-onset generalized limb-onset dystonia. DR VEuPathDB; HostDB:ENSG00000055332; -. DR eggNOG; KOG1033; Eukaryota. DR GeneTree; ENSGT00940000160736; -. DR HOGENOM; CLU_023682_1_0_1; -. DR InParanoid; P19525; -. DR OMA; KIACEMM; -. DR OrthoDB; 341578at2759; -. DR PAN-GO; P19525; 2 GO annotations based on evolutionary models. DR PhylomeDB; P19525; -. DR PathwayCommons; P19525; -. DR Reactome; R-HSA-1169408; ISG15 antiviral mechanism. DR Reactome; R-HSA-169131; Inhibition of PKR. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-9833109; Evasion by RSV of host interferon responses. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SignaLink; P19525; -. DR SIGNOR; P19525; -. DR Agora; ENSG00000055332; -. DR BioGRID-ORCS; 5610; 13 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; EIF2AK2; human. DR EvolutionaryTrace; P19525; -. DR GeneWiki; Protein_kinase_R; -. DR GenomeRNAi; 5610; -. DR Pharos; P19525; Tchem. DR PRO; PR:P19525; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P19525; protein. DR Bgee; ENSG00000055332; Expressed in endometrium epithelium and 211 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005840; C:ribosome; TAS:AgBase. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:UniProt. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019888; F:protein phosphatase regulator activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProt. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IEP:ARUK-UCL. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB. DR GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB. DR GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IMP:UniProtKB. DR GO; GO:0006412; P:translation; IEA:Ensembl. DR CDD; cd19903; DSRM_EIF2AK2_rpt1; 1. DR CDD; cd19904; DSRM_EIF2AK2_rpt2; 1. DR CDD; cd14047; STKc_EIF2AK2_PKR; 1. DR DisProt; DP03944; -. DR FunFam; 3.30.160.20:FF:000045; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.160.20:FF:000062; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.200.20:FF:000536; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 1.10.510.10:FF:000251; eukaryotic translation initiation factor 2-alpha kinase 3; 1. DR Gene3D; 3.30.160.20; -; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00443; -. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR014720; dsRBD_dom. DR InterPro; IPR044452; EIF2AK2_DSRM_1. DR InterPro; IPR044453; EIF2AK2_DSRM_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF163; INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00035; dsrm; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00358; DSRM; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54768; dsRNA-binding domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50137; DS_RBD; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Antiviral defense; KW ATP-binding; Cytoplasm; Direct protein sequencing; Disease variant; KW Dystonia; Host-virus interaction; Immunity; Innate immunity; KW Isopeptide bond; Kinase; Magnesium; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Tyrosine-protein kinase; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..551 FT /note="Interferon-induced, double-stranded RNA-activated FT protein kinase" FT /id="PRO_0000085945" FT DOMAIN 9..77 FT /note="DRBM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 100..167 FT /note="DRBM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 267..538 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 331..343 FT /note="1" FT REPEAT 345..357 FT /note="2" FT REGION 2..180 FT /note="(Microbial infection) Interaction with HCV NS5A" FT /evidence="ECO:0000269|PubMed:17267064" FT REGION 202..222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 266..551 FT /note="Interaction with TRAF5" FT /evidence="ECO:0000269|PubMed:15121867" FT REGION 266..362 FT /note="Dimerization" FT /evidence="ECO:0000269|PubMed:16179258" FT REGION 331..357 FT /note="2 X 13 AA approximate repeats" FT REGION 379..496 FT /note="Interaction with EIF2S1/EIF-2ALPHA" FT /evidence="ECO:0000269|PubMed:16179258" FT COMPBIAS 202..215 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 414 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 273..281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 296 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 432 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000305|PubMed:16179258, FT ECO:0000305|PubMed:31246429" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT MOD_RES 83 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11152499, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 88 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 89 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 90 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 101 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 242 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 255 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 258 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 293 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 446 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:16179258" FT MOD_RES 451 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:20685959" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 542 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 69 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT VAR_SEQ 263..303 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_046177" FT VARIANT 11 FT /note="M -> L (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084260" FT VARIANT 32 FT /note="N -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084261" FT VARIANT 32 FT /note="N -> T (in DYT33; uncertain significance; gain-of- FT function variant resulting in increased levels of FT phosphorylated EIF2AK2 and EIF2A in patient cells compared FT to controls)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086715" FT VARIANT 97 FT /note="S -> F (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084262" FT VARIANT 109 FT /note="A -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084263" FT VARIANT 109 FT /note="A -> V (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084264" FT VARIANT 114 FT /note="L -> Q (found in a patient with dysmorphic facies, FT syndactyly, congenital microcephaly and global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084265" FT VARIANT 130 FT /note="G -> R (in DYT33; gain-of-function variant resulting FT in increased levels of phosphorylated EIF2AK2 and EIF2A in FT patient cells compared to controls)" FT /evidence="ECO:0000269|PubMed:33236446, FT ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068" FT /id="VAR_086716" FT VARIANT 133 FT /note="Y -> F (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084266" FT VARIANT 138 FT /note="G -> A (in DYT33; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086717" FT VARIANT 325 FT /note="G -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084267" FT VARIANT 428 FT /note="V -> E (in dbSNP:rs56219559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040474" FT VARIANT 439 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040475" FT VARIANT 461 FT /note="S -> C (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084268" FT VARIANT 506 FT /note="I -> V (no effect on PKR inhibition by HCMV protein FT TRS1; dbSNP:rs34821155)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:27780231" FT /id="VAR_040476" FT MUTAGEN 59..60 FT /note="SK->AA: In FL-PKR-2AI; moderate loss of activity but FT no effect on dsRNA binding." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 60 FT /note="K->A: Impairs dsRNA binding but not dimerization or FT activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 67 FT /note="A->E: Significant loss of activity; loss of dsRNA FT binding and dimerization." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 83 FT /note="S->A: No effect on enzymatic activity; when FT associated with A-88; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 88 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 89 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 90 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-89." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 149..150 FT /note="TK->AA: In FL-PKR-2AII; no effect on activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 242 FT /note="S->A: Moderate loss of activity; when associated FT with A-255 and A-258." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 244..296 FT /note="Missing: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 255 FT /note="T->A: Moderate loss of activity; when associated FT with A-242 and A-255." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 258 FT /note="T->A: Moderate loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 296 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 446 FT /note="T->A: Significant loss of activity and impairs FT autophosphorylation of T-451." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 451 FT /note="T->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 486 FT /note="D->V: 15-fold decrease in K3L binding affinity and FT thus resistance of mutated PKR to K3L inhibition." FT /evidence="ECO:0000269|PubMed:18971339" FT MUTAGEN 489 FT /note="F->S: Loss of PKR inhibition by HCMV protein TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 496 FT /note="T->K: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 502 FT /note="I->T: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 510 FT /note="K->R: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 516 FT /note="Q->E: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT CONFLICT 102 FT /note="I -> M (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 224 FT /note="S -> R (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 512 FT /note="K -> E (in Ref. 6; AAF13156)" FT /evidence="ECO:0000305" FT STRAND 5..7 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 26..32 FT /evidence="ECO:0007829|PDB:1QU6" FT TURN 35..37 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 41..50 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 61..76 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 102..111 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 115..123 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 125..138 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 144..149 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 150..167 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 261..266 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 267..274 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:2A19" FT TURN 287..289 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 303..305 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 306..314 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 323..332 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 358..366 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 388..407 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:2A1A" FT HELIX 417..419 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 420..424 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 433..435 FT /evidence="ECO:0007829|PDB:6D3L" FT STRAND 437..440 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 468..482 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 488..499 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:3UIU" FT HELIX 509..518 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 523..525 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 529..539 FT /evidence="ECO:0007829|PDB:2A19" SQ SEQUENCE 551 AA; 62094 MW; 815AD83ACAB45DA3 CRC64; MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK KSPEKNERHT C // ID ECT2_HUMAN Reviewed; 914 AA. AC Q9H8V3; Q0MT80; Q2M269; Q6U836; Q9NSV8; Q9NVW9; DT 26-SEP-2001, integrated into UniProtKB/Swiss-Prot. DT 16-NOV-2011, sequence version 4. DT 28-JAN-2026, entry version 195. DE RecName: Full=Protein ECT2; DE AltName: Full=Epithelial cell-transforming sequence 2 oncogene; GN Name=ECT2 {ECO:0000312|HGNC:HGNC:3155}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=10579713; DOI=10.1083/jcb.147.5.921; RA Tatsumoto T., Xie X., Blumenthal R., Okamoto I., Miki T.; RT "Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M RT phases, and involved in cytokinesis."; RL J. Cell Biol. 147:921-928(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=14587037; DOI=10.1002/jcb.10688; RA Saito S., Tatsumoto T., Lorenzi M.V., Chedid M., Kapoor V., Sakata H., RA Rubin J.S., Miki T.; RT "Rho exchange factor ECT2 is induced by growth factors and regulates RT cytokinesis through the N-terminal cell cycle regulator-related domains."; RL J. Cell. Biochem. 90:819-836(2003). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH PKP4, AND RP SUBCELLULAR LOCATION. RX PubMed=17115030; DOI=10.1038/ncb1504; RA Wolf A., Keil R., Gotzl O., Mun A., Schwarze K., Lederer M., RA Huttelmaier S., Hatzfeld M.; RT "The armadillo protein p0071 regulates Rho signalling during cytokinesis."; RL Nat. Cell Biol. 8:1432-1440(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 662-914 (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP FUNCTION, HOMODIMERIZATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 379-ARG--ARG-381; 402-ARG--ARG-404 AND 596-PRO--ARG-599. RX PubMed=14645260; DOI=10.1074/jbc.m306725200; RA Saito S., Liu X.F., Kamijo K., Raziuddin R., Tatsumoto T., Okamoto I., RA Chen X., Lee C.C., Lorenzi M.V., Ohara N., Miki T.; RT "Deregulation and mislocalization of the cytokinesis regulator ECT2 RT activate the Rho signaling pathways leading to malignant transformation."; RL J. Biol. Chem. 279:7169-7179(2004). RN [9] RP FUNCTION, INTERACTION WITH PARD3; PARD6A; PARD6B AND PRKCQ, INDUCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=15254234; DOI=10.1128/mcb.24.15.6665-6675.2004; RA Liu X.F., Ishida H., Raziuddin R., Miki T.; RT "Nucleotide exchange factor ECT2 interacts with the polarity protein RT complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta RT activity."; RL Mol. Cell. Biol. 24:6665-6675(2004). RN [10] RP FUNCTION, HOMODIMERIZATION, HOMOOLIGOMERIZATION, AND MUTAGENESIS OF RP TRP-336. RX PubMed=15545273; DOI=10.1074/jbc.m409298200; RA Kim J.E., Billadeau D.D., Chen J.; RT "The tandem BRCT domains of Ect2 are required for both negative and RT positive regulation of Ect2 in cytokinesis."; RL J. Biol. Chem. 280:5733-5739(2005). RN [11] RP FUNCTION. RX PubMed=15642749; DOI=10.1083/jcb.200408085; RA Oceguera-Yanez F., Kimura K., Yasuda S., Higashida C., Kitamura T., RA Hiraoka Y., Haraguchi T., Narumiya S.; RT "Ect2 and MgcRacGAP regulate the activation and function of Cdc42 in RT mitosis."; RL J. Cell Biol. 168:221-232(2005). RN [12] RP FUNCTION, INTERACTION WITH RACGAP1, MUTAGENESIS OF THR-373, AND SUBCELLULAR RP LOCATION. RX PubMed=16103226; DOI=10.1083/jcb.200501097; RA Yuce O., Piekny A., Glotzer M.; RT "An ECT2-centralspindlin complex regulates the localization and function of RT RhoA."; RL J. Cell Biol. 170:571-582(2005). RN [13] RP INTERACTION WITH RACGAP1. RX PubMed=16129829; DOI=10.1073/pnas.0504145102; RA Zhao W.-M., Fang G.; RT "MgcRacGAP controls the assembly of the contractile ring and the initiation RT of cytokinesis."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13158-13163(2005). RN [14] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16495035; DOI=10.1016/j.cellsig.2006.01.007; RA Liu X.F., Ohno S., Miki T.; RT "Nucleotide exchange factor ECT2 regulates epithelial cell polarity."; RL Cell. Signal. 18:1604-1615(2006). RN [15] RP INTERACTION WITH NEDD9, AND SUBCELLULAR LOCATION. RX PubMed=16394104; DOI=10.1091/mbc.e05-03-0237; RA Dadke D., Jarnik M., Pugacheva E.N., Singh M.K., Golemis E.A.; RT "Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA RT activation cycle."; RL Mol. Biol. Cell 17:1204-1217(2006). RN [16] RP FUNCTION, IDENTIFICATION IN THE CENTRALSPINDLIN COMPLEX, INTERACTION WITH RP KIF23 AND RACGAP1, AND SUBCELLULAR LOCATION. RX PubMed=16236794; DOI=10.1091/mbc.e05-06-0569; RA Kamijo K., Ohara N., Abe M., Uchimura T., Hosoya H., Lee J.S., Miki T.; RT "Dissecting the role of Rho-mediated signaling in contractile ring RT formation."; RL Mol. Biol. Cell 17:43-55(2006). RN [17] RP FUNCTION, HOMODIMERIZATION, PHOSPHORYLATION AT THR-373, AND MUTAGENESIS OF RP THR-373. RX PubMed=16170345; DOI=10.1038/sj.onc.1209078; RA Hara T., Abe M., Inoue H., Yu L.R., Veenstra T.D., Kang Y.H., Lee K.S., RA Miki T.; RT "Cytokinesis regulator ECT2 changes its conformation through RT phosphorylation at Thr-341 in G2/M phase."; RL Oncogene 25:566-578(2006). RN [18] RP PHOSPHORYLATION AT THR-444, INTERACTION WITH PLK1, AND MUTAGENESIS OF RP THR-444 AND THR-846. RX PubMed=16247472; DOI=10.1038/sj.onc.1209124; RA Niiya F., Tatsumoto T., Lee K.S., Miki T.; RT "Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates RT association of the mitotic kinase Plk1 and accumulation of GTP-bound RT RhoA."; RL Oncogene 25:827-837(2006). RN [19] RP INTERACTION WITH RAB11FIP3. RX PubMed=18511905; DOI=10.1038/emboj.2008.112; RA Simon G.C., Schonteich E., Wu C.C., Piekny A., Ekiert D., Yu X., RA Gould G.W., Glotzer M., Prekeris R.; RT "Sequential Cyk-4 binding to ECT2 and FIP3 regulates cleavage furrow RT ingression and abscission during cytokinesis."; RL EMBO J. 27:1791-1803(2008). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-370; THR-373; RP SER-376; SER-842 AND THR-846, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [22] RP FUNCTION. RX PubMed=19129481; DOI=10.1091/mbc.e08-01-0001; RA Asiedu M., Wu D., Matsumura F., Wei Q.; RT "Centrosome/spindle pole-associated protein regulates cytokinesis via RT promoting the recruitment of MyoGEF to the central spindle."; RL Mol. Biol. Cell 20:1428-1440(2009). RN [23] RP FUNCTION, INTERACTION WITH PARD6A AND PRKCI, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=19617897; DOI=10.1038/onc.2009.217; RA Justilien V., Fields A.P.; RT "Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular RT transformation."; RL Oncogene 28:3597-3607(2009). RN [24] RP FUNCTION, INTERACTION WITH KIF23 AND RACGAP1, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF THR-184 AND LYS-226. RX PubMed=19468300; DOI=10.1371/journal.pbio.1000110; RA Wolfe B.A., Takaki T., Petronczki M., Glotzer M.; RT "Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF RT complex to initiate cleavage furrow formation."; RL PLoS Biol. 7:E1000110-E1000110(2009). RN [25] RP INTERACTION WITH RACGAP1. RX PubMed=19468302; DOI=10.1371/journal.pbio.1000111; RA Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., RA Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., RA Jallepalli P.V.; RT "Plk1 self-organization and priming phosphorylation of HsCYK-4 at the RT spindle midzone regulate the onset of division in human cells."; RL PLoS Biol. 7:E1000111-E1000111(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP FUNCTION, PHOSPHORYLATION AT THR-359, MUTAGENESIS OF THR-359, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=21189248; DOI=10.1074/jbc.m110.196113; RA Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P.; RT "Oncogenic activity of Ect2 is regulated through protein kinase C iota- RT mediated phosphorylation."; RL J. Biol. Chem. 286:8149-8157(2011). RN [29] RP FUNCTION, AND INDUCTION. RX PubMed=21373644; DOI=10.1371/journal.pone.0017108; RA Srougi M.C., Burridge K.; RT "The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RT RhoB-mediated cell death after DNA damage."; RL PLoS ONE 6:E17108-E17108(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-367; SER-716; RP SER-861 AND SER-866, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-611, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [34] RP X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) OF 268-361. RG Structural genomics consortium (SGC); RT "Crystal structure of the second BRCT domain of epithelial cell RT transforming 2 (ECT2)."; RL Submitted (JAN-2010) to the PDB data bank. RN [35] {ECO:0007744|PDB:4N40} RP X-RAY CRYSTALLOGRAPHY (3.11 ANGSTROMS) OF 45-356, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RACGAP1, AND MUTAGENESIS OF THR-184 AND RP LYS-226. RX PubMed=25068414; DOI=10.1016/j.febslet.2014.07.019; RA Zou Y., Shao Z., Peng J., Li F., Gong D., Wang C., Zuo X., Zhang Z., Wu J., RA Shi Y., Gong Q.; RT "Crystal structure of triple-BRCT-domain of ECT2 and insights into the RT binding characteristics to CYK-4."; RL FEBS Lett. 588:2911-2920(2014). RN [36] {ECO:0007744|PDB:6L30} RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 173-865, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RHOA, DOMAIN, IDENTIFICATION BY MASS RP SPECTROMETRY, AND MUTAGENESIS OF TRP-338; ARG-488; ARG-570; ALA-573; RP ARG-586; PRO-601; PHE-652; TYR-656; ARG-670; PRO-734 AND CYS-796. RX PubMed=31888991; DOI=10.1073/pnas.1913054117; RA Chen M., Pan H., Sun L., Shi P., Zhang Y., Li L., Huang Y., Chen J., RA Jiang P., Fang X., Wu C., Chen Z.; RT "Structure and regulation of human epithelial cell transforming 2 RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 117:1027-1035(2020). RN [37] RP VARIANT [LARGE SCALE ANALYSIS] PRO-833. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: Guanine nucleotide exchange factor (GEF) that catalyzes the CC exchange of GDP for GTP. Promotes guanine nucleotide exchange on the CC Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. CC Required for signal transduction pathways involved in the regulation of CC cytokinesis. Component of the centralspindlin complex that serves as a CC microtubule-dependent and Rho-mediated signaling required for the CC myosin contractile ring formation during the cell cycle cytokinesis. CC Regulates the translocation of RHOA from the central spindle to the CC equatorial region. Plays a role in the control of mitotic spindle CC assembly; regulates the activation of CDC42 in metaphase for the CC process of spindle fibers attachment to kinetochores before chromosome CC congression. Involved in the regulation of epithelial cell polarity; CC participates in the formation of epithelial tight junctions in a CC polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. CC Plays a role in the regulation of neurite outgrowth. Inhibits CC phenobarbital (PB)-induced NR1I3 nuclear translocation. Stimulates the CC activity of RAC1 through its association with the oncogenic PARD6A- CC PRKCI complex in cancer cells, thereby acting to coordinately drive CC tumor cell proliferation and invasion. Also stimulates genotoxic CC stress-induced RHOB activity in breast cancer cells leading to their CC cell death. {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:14645260, CC ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:15642749, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16170345, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:16495035, ECO:0000269|PubMed:19129481, CC ECO:0000269|PubMed:19468300, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21373644, CC ECO:0000269|PubMed:25068414, ECO:0000269|PubMed:31888991}. CC -!- ACTIVITY REGULATION: Autoinhibited by the C-terminal PH domain which CC folds back and binds to the surface of the DH domain, blocking binding CC of RHOA to the catalytic center of the DH domain (PubMed:31888991). The CC 2nd BRCT domain is also involved in inhibition, probably by helping to CC impede RHOA binding (PubMed:31888991). Allosterically activated by CC binding of activated GTP-bound RHOA to the PH domain which stimulates CC the release of PH inhibition and promotes the binding of substrate RHOA CC to the catalytic center (PubMed:31888991). Binding of phosphorylated CC RACGAP1 to the N-terminal BRCT domain-containing region also releases CC autoinhibition (PubMed:25068414). {ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- SUBUNIT: Homodimer (PubMed:14645260, PubMed:15545273, PubMed:16170345). CC Homooligomer (PubMed:15545273). Found in the centralspindlin complex CC (PubMed:16236794). Interacts with NR1I3 (By similarity). Interacts CC (Thr-359 phosphorylated form) with PARD6A; the interaction is observed CC in cancer cells (PubMed:15254234, PubMed:19617897). Interacts (Thr-359 CC phosphorylated form) with PRKCI; the interaction is observed in cancer CC cells (PubMed:19617897). Interacts with PKP4; the interaction is CC observed at the midbody (PubMed:22814378). Interacts with RACGAP1/CYK4; CC the interaction is direct, occurs in a microtubule-dependent manner, CC occurs at anaphase and during cytokinesis, is inhibited in metaphase by CC phosphorylation of ECT2 on Thr-373 and is stimulated in early anaphase CC by dephosphorylation of ECT2 probably on Thr-373 through CDK1 activity CC (PubMed:16103226, PubMed:16129829, PubMed:16236794, PubMed:19468300, CC PubMed:19468302, PubMed:25068414). Interacts with PLK1; the interaction CC is stimulated upon its phosphorylation on Thr-444 (PubMed:16247472). CC Interacts with RHOA; the interaction results in allosteric activation CC of ECT2 (PubMed:31888991). Interacts with KIF23, PARD3, PARD6B and CC PRKCQ (PubMed:15254234, PubMed:16236794). Interacts with NEDD9/HEF1 CC (PubMed:16394104). {ECO:0000250|UniProtKB:Q07139, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:15545273, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16129829, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16247472, CC ECO:0000269|PubMed:16394104, ECO:0000269|PubMed:19468300, CC ECO:0000269|PubMed:19468302, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:22814378, ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- INTERACTION: CC Q9H8V3; P12830: CDH1; NbExp=3; IntAct=EBI-1054039, EBI-727477; CC Q9H8V3; P35221: CTNNA1; NbExp=3; IntAct=EBI-1054039, EBI-701918; CC Q9H8V3; Q02241: KIF23; NbExp=2; IntAct=EBI-1054039, EBI-306852; CC Q9H8V3; P16333: NCK1; NbExp=3; IntAct=EBI-1054039, EBI-389883; CC Q9H8V3; O00444: PLK4; NbExp=3; IntAct=EBI-1054039, EBI-746202; CC Q9H8V3; Q9H0H5: RACGAP1; NbExp=15; IntAct=EBI-1054039, EBI-717233; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16495035, CC ECO:0000269|PubMed:19617897}. Cytoplasm {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16394104}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:17115030, ECO:0000269|PubMed:19468300}. Cleavage CC furrow {ECO:0000269|PubMed:10579713}. Midbody CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16394104, CC ECO:0000269|PubMed:17115030}. Cell junction CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16495035}. Cell CC junction, tight junction {ECO:0000269|PubMed:15254234}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:17115030}. Note=Sequestered within the nucleus CC during interphase (PubMed:10579713). Dispersed throughout the cytoplasm CC upon breakdown of the nuclear envelope during mitosis CC (PubMed:10579713). Colocalizes with the centralspindlin complex to the CC mitotic spindles during anaphase/metaphase, the cleavage furrow during CC telophase and at the midbody at the end of cytokinesis CC (PubMed:10579713). Colocalized with RhoA at the midbody CC (PubMed:10579713). Its subcellular localization to tight junction is CC increased by calcium (PubMed:15254234). {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:15254234}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9H8V3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H8V3-2; Sequence=VSP_041976, VSP_041977; CC Name=3; CC IsoId=Q9H8V3-3; Sequence=VSP_041978; CC Name=4; CC IsoId=Q9H8V3-4; Sequence=VSP_041977; CC -!- TISSUE SPECIFICITY: Expressed in lung epithelial cells (at protein CC level). Expressed in squamous cell carcinoma, primary non-small cell CC lung cancer tumors and lung adenocarcinoma. CC {ECO:0000269|PubMed:19617897}. CC -!- INDUCTION: Up-regulated by calcium in cells forming cell-cell contact CC sites. Up-regulated by DNA damaging agents like H(2)O(2) or ionizing CC radiation (IR). {ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:21373644}. CC -!- DOMAIN: The BRCT domains 1 and 2 are required for intramolecular CC interaction, but not for intermolecular oligomerization CC (PubMed:15545273). The BRCT domains negatively inhibit its GEF activity CC in interphase cells (PubMed:15545273, PubMed:31888991). The same BRCT CC domains may act as a positive regulatory motif for the completion of CC cytokinesis after the breakdown of nuclear membrane during mitosis CC (PubMed:15545273). {ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:31888991}. CC -!- PTM: Phosphorylated by PLK1 in vitro. Hyperphosphorylated during the G2 CC phase of the cell cycle. Phosphorylation at Thr-373 occurs during the CC G2/M phase, relieves its auto-inhibition status and stimulates its GEF CC activity. Phosphorylation at Thr-444 in G2/M phase is required for CC subsequent binding with PLK1 and Rho exchange activation. CC Dephosphorylated at the time of cytokinesis. Phosphorylation at Thr-359 CC is required for its transformation activity in cancer cells. CC {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:21189248}. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91624.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40400/ECT2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY376439; AAQ83675.1; -; mRNA. DR EMBL; DQ847274; ABH10140.1; -; mRNA. DR EMBL; AK001323; BAA91624.1; ALT_INIT; mRNA. DR EMBL; AK023267; BAB14498.1; -; mRNA. DR EMBL; AK314581; BAG37157.1; -; mRNA. DR EMBL; AC108667; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC112086; AAI12087.1; -; mRNA. DR EMBL; AL137710; CAB70886.1; -; mRNA. DR CCDS; CCDS3220.1; -. [Q9H8V3-4] DR CCDS; CCDS58860.1; -. [Q9H8V3-1] DR CCDS; CCDS87168.1; -. [Q9H8V3-2] DR RefSeq; NP_001245244.1; NM_001258315.2. [Q9H8V3-1] DR RefSeq; NP_001245245.1; NM_001258316.2. [Q9H8V3-4] DR RefSeq; NP_001336023.1; NM_001349094.2. [Q9H8V3-3] DR RefSeq; NP_001336024.1; NM_001349095.2. [Q9H8V3-3] DR RefSeq; NP_001336025.1; NM_001349096.2. [Q9H8V3-3] DR RefSeq; NP_001336027.1; NM_001349098.2. [Q9H8V3-1] DR RefSeq; NP_001336028.1; NM_001349099.2. [Q9H8V3-1] DR RefSeq; NP_001336029.1; NM_001349100.2. [Q9H8V3-1] DR RefSeq; NP_001336031.1; NM_001349102.2. [Q9H8V3-2] DR RefSeq; NP_060568.3; NM_018098.5. [Q9H8V3-4] DR RefSeq; XP_047303563.1; XM_047447607.1. [Q9H8V3-3] DR RefSeq; XP_047303564.1; XM_047447608.1. [Q9H8V3-3] DR RefSeq; XP_047303565.1; XM_047447609.1. [Q9H8V3-3] DR RefSeq; XP_047303573.1; XM_047447617.1. [Q9H8V3-1] DR RefSeq; XP_047303574.1; XM_047447618.1. [Q9H8V3-1] DR RefSeq; XP_047303583.1; XM_047447627.1. [Q9H8V3-4] DR RefSeq; XP_047303584.1; XM_047447628.1. [Q9H8V3-4] DR RefSeq; XP_047303585.1; XM_047447629.1. [Q9H8V3-4] DR RefSeq; XP_047303586.1; XM_047447630.1. [Q9H8V3-4] DR RefSeq; XP_054201507.1; XM_054345532.1. [Q9H8V3-3] DR RefSeq; XP_054201508.1; XM_054345533.1. [Q9H8V3-3] DR RefSeq; XP_054201509.1; XM_054345534.1. [Q9H8V3-3] DR RefSeq; XP_054201517.1; XM_054345542.1. [Q9H8V3-1] DR RefSeq; XP_054201518.1; XM_054345543.1. [Q9H8V3-1] DR RefSeq; XP_054201528.1; XM_054345553.1. [Q9H8V3-4] DR RefSeq; XP_054201529.1; XM_054345554.1. [Q9H8V3-4] DR RefSeq; XP_054201530.1; XM_054345555.1. [Q9H8V3-4] DR RefSeq; XP_054201531.1; XM_054345556.1. [Q9H8V3-4] DR PDB; 3L46; X-ray; 1.48 A; A/B=268-361. DR PDB; 4N40; X-ray; 3.11 A; A=45-356. DR PDB; 6L30; X-ray; 2.80 A; A=173-865. DR PDBsum; 3L46; -. DR PDBsum; 4N40; -. DR PDBsum; 6L30; -. DR AlphaFoldDB; Q9H8V3; -. DR SMR; Q9H8V3; -. DR BioGRID; 108223; 896. DR CORUM; Q9H8V3; -. DR DIP; DIP-47496N; -. DR FunCoup; Q9H8V3; 1534. DR IntAct; Q9H8V3; 46. DR MINT; Q9H8V3; -. DR STRING; 9606.ENSP00000376457; -. DR GlyGen; Q9H8V3; 6 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; Q9H8V3; -. DR MetOSite; Q9H8V3; -. DR PhosphoSitePlus; Q9H8V3; -. DR SwissPalm; Q9H8V3; -. DR BioMuta; ECT2; -. DR DMDM; 357529579; -. DR jPOST; Q9H8V3; -. DR MassIVE; Q9H8V3; -. DR PaxDb; 9606-ENSP00000376457; -. DR PeptideAtlas; Q9H8V3; -. DR ProteomicsDB; 81243; -. [Q9H8V3-1] DR ProteomicsDB; 81244; -. [Q9H8V3-2] DR ProteomicsDB; 81245; -. [Q9H8V3-3] DR Pumba; Q9H8V3; -. DR Antibodypedia; 33733; 365 antibodies from 31 providers. DR DNASU; 1894; -. DR Ensembl; ENST00000232458.9; ENSP00000232458.5; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000392692.8; ENSP00000376457.3; ENSG00000114346.15. [Q9H8V3-1] DR Ensembl; ENST00000417960.5; ENSP00000415876.1; ENSG00000114346.15. [Q9H8V3-2] DR Ensembl; ENST00000441497.6; ENSP00000412259.2; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000540509.5; ENSP00000443160.2; ENSG00000114346.15. [Q9H8V3-4] DR GeneID; 1894; -. DR KEGG; hsa:1894; -. DR MANE-Select; ENST00000392692.8; ENSP00000376457.3; NM_001258315.2; NP_001245244.1. DR UCSC; uc003fih.4; human. [Q9H8V3-1] DR AGR; HGNC:3155; -. DR ClinPGx; PA27600; -. DR CTD; 1894; -. DR DisGeNET; 1894; -. DR GeneCards; ECT2; -. DR HGNC; HGNC:3155; ECT2. DR HPA; ENSG00000114346; Low tissue specificity. DR MIM; 600586; gene. DR OpenTargets; ENSG00000114346; -. DR VEuPathDB; HostDB:ENSG00000114346; -. DR eggNOG; KOG3524; Eukaryota. DR GeneTree; ENSGT00940000156299; -. DR HOGENOM; CLU_008187_0_0_1; -. DR InParanoid; Q9H8V3; -. DR OMA; PIYDVHK; -. DR OrthoDB; 9997817at2759; -. DR PAN-GO; Q9H8V3; 5 GO annotations based on evolutionary models. DR PathwayCommons; Q9H8V3; -. DR Reactome; R-HSA-193648; NRAGE signals death through JNK. DR Reactome; R-HSA-416482; G alpha (12/13) signalling events. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SignaLink; Q9H8V3; -. DR SIGNOR; Q9H8V3; -. DR Agora; ENSG00000114346; -. DR BioGRID-ORCS; 1894; 654 hits in 1167 CRISPR screens. DR ChiTaRS; ECT2; human. DR EvolutionaryTrace; Q9H8V3; -. DR GeneWiki; ECT2; -. DR GenomeRNAi; 1894; -. DR Pharos; Q9H8V3; Tbio. DR PRO; PR:Q9H8V3; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9H8V3; protein. DR Bgee; ENSG00000114346; Expressed in secondary oocyte and 166 other cell types or tissues. DR ExpressionAtlas; Q9H8V3; baseline and differential. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0097149; C:centralspindlin complex; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0090630; P:activation of GTPase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0070830; P:bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0032467; P:positive regulation of cytokinesis; IDA:UniProtKB. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:1903438; P:positive regulation of mitotic cytokinetic process; IMP:UniProt. DR GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:UniProtKB. DR GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB. DR GO; GO:2000431; P:regulation of cytokinesis, actomyosin contractile ring assembly; IEA:InterPro. DR GO; GO:0045859; P:regulation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome. DR CDD; cd17733; BRCT_Ect2_rpt1; 1. DR CDD; cd17732; BRCT_Ect2_rpt2; 1. DR CDD; cd01229; PH_Ect2; 1. DR CDD; cd00160; RhoGEF; 1. DR FunFam; 3.40.50.10190:FF:000058; Epithelial cell transforming 2; 1. DR FunFam; 1.20.900.10:FF:000022; protein ECT2 isoform X1; 1. DR FunFam; 3.40.50.10190:FF:000015; protein ECT2 isoform X1; 1. DR FunFam; 2.30.29.30:FF:000162; protein ECT2 isoform X2; 1. DR FunFam; 3.40.50.10190:FF:000016; protein ECT2 isoform X3; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 3. DR Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR035899; DBL_dom_sf. DR InterPro; IPR000219; DH_dom. DR InterPro; IPR026817; Ect2. DR InterPro; IPR049396; ECT2_BRCT0. DR InterPro; IPR049395; ECT2_PH. DR InterPro; IPR001331; GDS_CDC24_CS. DR InterPro; IPR011993; PH-like_dom_sf. DR PANTHER; PTHR16777; PROTEIN ECT2; 1. DR PANTHER; PTHR16777:SF2; PROTEIN ECT2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF21243; ECT2_BRCT0; 1. DR Pfam; PF21242; ECT2_PH; 1. DR Pfam; PF12738; PTCB-BRCT; 1. DR Pfam; PF00621; RhoGEF; 1. DR SMART; SM00292; BRCT; 2. DR SMART; SM00325; RhoGEF; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF48065; DBL homology domain (DH-domain); 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00741; DH_1; 1. DR PROSITE; PS50010; DH_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division; KW Cell junction; Cytoplasm; Cytoskeleton; Differentiation; KW Guanine-nucleotide releasing factor; Isopeptide bond; Neurogenesis; KW Nucleus; Oncogene; Phosphoprotein; Protein transport; KW Proteomics identification; Reference proteome; Repeat; Tight junction; KW Transport; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..914 FT /note="Protein ECT2" FT /id="PRO_0000080938" FT DOMAIN 171..260 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 266..354 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 452..641 FT /note="DH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00062" FT DOMAIN 675..794 FT /note="PH" FT REGION 388..449 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 857..884 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 378..382 FT /note="Nuclear localization signal" FT MOTIF 401..405 FT /note="Nuclear localization signal" FT COMPBIAS 418..429 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 432..449 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 359 FT /note="Phosphothreonine; by PKC/PRKCI" FT /evidence="ECO:0000269|PubMed:21189248, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 373 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16170345, FT ECO:0007744|PubMed:18669648" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 444 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16247472" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 842 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 846 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 611 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 44 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041976" FT VAR_SEQ 71..101 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041977" FT VAR_SEQ 886..914 FT /note="GIPSPSLVSLPSFFERRSHTLSRSTTHLI -> ITHSVSTSNVIGFTKHVYV FT QRLNSTGGRSQYSWFQSVRHSAFRASFSEILEGNTDFSNFKKVLSKSSLTFVKN (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_041978" FT VARIANT 15 FT /note="S -> T (in dbSNP:rs34703432)" FT /id="VAR_047064" FT VARIANT 833 FT /note="T -> P (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035975" FT MUTAGEN 184 FT /note="T->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 226 FT /note="K->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 336 FT /note="W->R: Inhibits homodimerization. Increases binding FT with RhoA and GEF activity." FT /evidence="ECO:0000269|PubMed:15545273" FT MUTAGEN 338 FT /note="W->A: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 359 FT /note="T->A: Inhibits its phosphorylation and anchorage- FT independent growth and invasion in cancer cells. Does not FT inhibit its GEF activity." FT /evidence="ECO:0000269|PubMed:21189248" FT MUTAGEN 373 FT /note="T->A: Does not inhibit its Rho exchange activity. FT Increases interaction with RACGAP1. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 373 FT /note="T->D: Does not inhibit subcellular localization or FT homodimerization. Enhances its Rho exchange activity." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 379..381 FT /note="KRR->AAA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 402..404 FT /note="RKR->AKA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 444 FT /note="T->A: Diminishes its phosphorylation status. Reduces FT its interaction with PLK1 and Rho exchange activity. Does FT not change its subcellular localization. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 444 FT /note="T->D: Does not reduce its interaction with PLK1, FT change its subcellular localization and Rho exchange FT activity." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 488 FT /note="R->C: Partially releases inhibition." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 570 FT /note="R->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 573 FT /note="A->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 586 FT /note="R->Q: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 596..599 FT /note="PVQR->AAAA: Inhibits activation of the transforming FT activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 601 FT /note="P->S: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 652 FT /note="F->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Localizes correctly but FT fails to rescue the cytokinesis defect caused by knockdown FT of endogenous ECT2 in contrast to the wild-type protein FT which rescues this defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 656 FT /note="Y->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Fails to rescue the FT cytokinesis defect caused by knockdown of endogenous ECT2 FT in contrast to the wild-type protein which rescues this FT defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 670 FT /note="R->Q: Marked increase in GEF activity and rescues FT the cytokinesis defect caused by depletion of endogenous FT ECT2. When expressed in a cancer cell line, causes faster FT cell proliferation than the wild-type protein." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 734 FT /note="P->D: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RhoA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 796 FT /note="C->K: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RHOA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 846 FT /note="T->A: Diminishes its phosphorylation status." FT /evidence="ECO:0000269|PubMed:16247472" FT CONFLICT 66 FT /note="I -> T (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 276 FT /note="L -> F (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="E -> D (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 63..70 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 107..112 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 115..119 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 124..129 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 136..143 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 147..149 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 151..159 FT /evidence="ECO:0007829|PDB:4N40" FT TURN 173..178 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 180..184 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 189..201 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 215..224 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 241..249 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 260..263 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 264..266 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 278..280 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 309..313 FT /evidence="ECO:0007829|PDB:3L46" FT TURN 315..317 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 334..343 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 349..351 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 453..477 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 479..483 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 495..502 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 505..522 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 532..552 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 554..567 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 569..579 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 582..584 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 589..611 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 622..634 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 642..657 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 664..667 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 672..687 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 691..697 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 700..706 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 726..734 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 738..744 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 748..758 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 761..763 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 767..773 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 780..795 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 803..807 FT /evidence="ECO:0007829|PDB:6L30" SQ SEQUENCE 914 AA; 103505 MW; F40FC4F982FB8C78 CRC64; MAENSVLTST TGRTSLADSS IFDSKVTEIS KENLLIGSTS YVEEEMPQIE TRVILVQEAG KQEELIKALK TIKIMEVPVI KIKESCPGKS DEKLIKSVIN MDIKVGFVKM ESVEEFEGLD SPEFENVFVV TDFQDSVFND LYKADCRVIG PPVVLNCSQK GEPLPFSCRP LYCTSMMNLV LCFTGFRKKE ELVRLVTLVH HMGGVIRKDF NSKVTHLVAN CTQGEKFRVA VSLGTPIMKP EWIYKAWERR NEQDFYAAVD DFRNEFKVPP FQDCILSFLG FSDEEKTNME EMTEMQGGKY LPLGDERCTH LVVEENIVKD LPFEPSKKLY VVKQEWFWGS IQMDARAGET MYLYEKANTP ELKKSVSMLS LNTPNSNRKR RRLKETLAQL SRETDVSPFP PRKRPSAEHS LSIGSLLDIS NTPESSINYG DTPKSCTKSS KSSTPVPSKQ SARWQVAKEL YQTESNYVNI LATIIQLFQV PLEEEGQRGG PILAPEEIKT IFGSIPDIFD VHTKIKDDLE DLIVNWDESK SIGDIFLKYS KDLVKTYPPF VNFFEMSKET IIKCEKQKPR FHAFLKINQA KPECGRQSLV ELLIRPVQRL PSVALLLNDL KKHTADENPD KSTLEKAIGS LKEVMTHINE DKRKTEAQKQ IFDVVYEVDG CPANLLSSHR SLVQRVETIS LGEHPCDRGE QVTLFLFNDC LEIARKRHKV IGTFRSPHGQ TRPPASLKHI HLMPLSQIKK VLDIRETEDC HNAFALLVRP PTEQANVLLS FQMTSDELPK ENWLKMLCRH VANTICKADA ENLIYTADPE SFEVNTKDMD STLSRASRAI KKTSKKVTRA FSFSKTPKRA LRRALMTSHG SVEGRSPSSN DKHVMSRLSS TSSLAGIPSP SLVSLPSFFE RRSHTLSRST THLI // ID EHBP1_HUMAN Reviewed; 1231 AA. AC Q8NDI1; O94977; Q53TG7; Q53TV6; Q580X2; Q6NX72; Q6PIT3; Q6QNV2; Q9NWI9; DT 01-MAY-2007, integrated into UniProtKB/Swiss-Prot. DT 10-FEB-2009, sequence version 3. DT 28-JAN-2026, entry version 172. DE RecName: Full=EH domain-binding protein 1; GN Name=EHBP1; Synonyms=KIAA0903, NACSIN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, IDENTIFICATION BY MASS RP SPECTROMETRY, SUBCELLULAR LOCATION, AND INTERACTION WITH EHD2. RX PubMed=14676205; DOI=10.1074/jbc.m307702200; RA Guilherme A., Soriano N.A., Bose S., Holik J., Bose A., Pomerleau D.P., RA Furcinitti P., Leszyk J., Corvera S., Czech M.P.; RT "EHD2 and the novel EH domain binding protein EHBP1 couple endocytosis to RT the actin cytoskeleton."; RL J. Biol. Chem. 279:10593-10605(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Castellano-Munoz M., Fernandez-Chacon R.; RT "Functional analysis of NACSIN (KIAA0903) in membrane trafficking."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Placenta, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-341 (ISOFORM 2). RC TISSUE=Adipose tissue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 270-1231. RC TISSUE=Brain; RX PubMed=10048485; DOI=10.1093/dnares/5.6.355; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:355-364(1998). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-436, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171; SER-174; SER-177; RP SER-432; SER-436; SER-710; SER-964 AND SER-1058, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171; SER-174; SER-432 AND RP SER-436, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171; SER-174 AND SER-436, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-436 AND SER-1058, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171; SER-302; SER-307; RP SER-408; SER-428; SER-436; THR-694; SER-781 AND SER-1058, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-335; SER-432; SER-436; RP SER-854 AND SER-1058, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP INTERACTION WITH RAB8A; RAB10; RAB13 AND RAB15, DOMAIN, FUNCTION, RP ISOPRENYLATION, AND SUBCELLULAR LOCATION. RX PubMed=27552051; DOI=10.7554/elife.18675; RA Rai A., Oprisko A., Campos J., Fu Y., Friese T., Itzen A., Goody R.S., RA Gazdag E.M., Muller M.P.; RT "bMERB domains are bivalent Rab8 family effectors evolved by gene RT duplication."; RL Elife 5:E18675-E18675(2016). RN [18] RP STRUCTURE BY NMR OF 443-548. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the CH domain from human EH domain binding protein RT 1."; RL Submitted (JUN-2006) to the PDB data bank. RN [19] RP VARIANT [LARGE SCALE ANALYSIS] THR-395. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [20] RP INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER. RX PubMed=18264098; DOI=10.1038/ng.89; RA Gudmundsson J., Sulem P., Rafnar T., Bergthorsson J.T., Manolescu A., RA Gudbjartsson D., Agnarsson B.A., Sigurdsson A., Benediktsdottir K.R., RA Blondal T., Jakobsdottir M., Stacey S.N., Kostic J., Kristinsson K.T., RA Birgisdottir B., Ghosh S., Magnusdottir D.N., Thorlacius S., RA Thorleifsson G., Zheng S.L., Sun J., Chang B.-L., Elmore J.B., Breyer J.P., RA McReynolds K.M., Bradley K.M., Yaspan B.L., Wiklund F., Stattin P., RA Lindstroem S., Adami H.-O., McDonnell S.K., Schaid D.J., Cunningham J.M., RA Wang L., Cerhan J.R., St Sauver J.L., Isaacs S.D., Wiley K.E., Partin A.W., RA Walsh P.C., Polo S., Ruiz-Echarri M., Navarrete S., Fuertes F., Saez B., RA Godino J., Weijerman P.C., Swinkels D.W., Aben K.K., Witjes J.A., RA Suarez B.K., Helfand B.T., Frigge M.L., Kristjansson K., Ober C., RA Jonsson E., Einarsson G.V., Xu J., Gronberg H., Smith J.R., Thibodeau S.N., RA Isaacs W.B., Catalona W.J., Mayordomo J.I., Kiemeney L.A., RA Barkardottir R.B., Gulcher J.R., Thorsteinsdottir U., Kong A., RA Stefansson K.; RT "Common sequence variants on 2p15 and Xp11.22 confer susceptibility to RT prostate cancer."; RL Nat. Genet. 40:281-283(2008). CC -!- FUNCTION: May play a role in actin reorganization. Links clathrin- CC mediated endocytosis to the actin cytoskeleton. May act as Rab effector CC protein and play a role in vesicle trafficking (PubMed:14676205, CC PubMed:27552051). Required for perinuclear sorting and insulin- CC regulated recycling of SLC2A4/GLUT4 in adipocytes (By similarity). CC {ECO:0000250|UniProtKB:Q69ZW3, ECO:0000269|PubMed:14676205, CC ECO:0000305|PubMed:27552051}. CC -!- SUBUNIT: Interacts with EHD1 (By similarity). Interacts with EHD2. CC Interacts with RAB8A, RAB10, RAB13 and RAB15 (in their GTP-bound CC forms); at least in case of RAB8A may bind 2 molecules of RAB8A CC simultaneously through a high and a low affinity binding site, CC respectively. {ECO:0000250|UniProtKB:Q69ZW3, CC ECO:0000269|PubMed:14676205, ECO:0000269|PubMed:27552051}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14676205}. Membrane CC {ECO:0000269|PubMed:14676205}. Endosome {ECO:0000305|PubMed:27552051}. CC Note=Mostly found in cytosol and plasma membrane. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q8NDI1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8NDI1-2; Sequence=VSP_024834; CC Name=3; CC IsoId=Q8NDI1-3; Sequence=VSP_024834, VSP_024835; CC -!- DOMAIN: The CAAX motif is a signal for prenylation and required for CC endosomal colocalization with Rab8 and Rab10. CC {ECO:0000269|PubMed:27552051}. CC -!- DOMAIN: The bivalent Mical/EHBP Rab binding (bMERB) domain, mediates CC binding to Rab8, Rab10, Rab10, Rab13 and Rab15 (in their GTP-bound CC forms). {ECO:0000269|PubMed:27552051}. CC -!- PTM: Prenylated (Probable). Farnelysation (predominant) and CC geranylgeranylation has been observed in vitro. CC {ECO:0000269|PubMed:27552051}. CC -!- DISEASE: Prostate cancer, hereditary, 12 (HPC12) [MIM:611868]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:18264098}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91391.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY531390; AAS48537.1; -; mRNA. DR EMBL; AY331186; AAQ97141.1; -; mRNA. DR EMBL; AL833968; CAD38814.1; -; mRNA. DR EMBL; AC007098; AAY14789.1; -; Genomic_DNA. DR EMBL; AC009501; AAY24356.1; -; Genomic_DNA. DR EMBL; AC092567; AAX82024.1; -; Genomic_DNA. DR EMBL; BC029477; AAH29477.1; -; mRNA. DR EMBL; BC067215; AAH67215.1; -; mRNA. DR EMBL; AK000828; BAA91391.1; ALT_SEQ; mRNA. DR EMBL; AB020710; BAA74926.1; -; mRNA. DR CCDS; CCDS1872.1; -. [Q8NDI1-1] DR CCDS; CCDS46299.1; -. [Q8NDI1-2] DR CCDS; CCDS46300.1; -. [Q8NDI1-3] DR RefSeq; NP_001136086.1; NM_001142614.2. [Q8NDI1-2] DR RefSeq; NP_001136087.1; NM_001142615.3. [Q8NDI1-3] DR RefSeq; NP_001136088.1; NM_001142616.3. [Q8NDI1-3] DR RefSeq; NP_001341141.1; NM_001354212.1. [Q8NDI1-1] DR RefSeq; NP_001341142.1; NM_001354213.1. [Q8NDI1-1] DR RefSeq; NP_001341143.1; NM_001354214.1. [Q8NDI1-1] DR RefSeq; NP_001341147.1; NM_001354218.1. [Q8NDI1-3] DR RefSeq; NP_056067.2; NM_015252.5. [Q8NDI1-1] DR RefSeq; XP_005264283.1; XM_005264226.4. [Q8NDI1-1] DR RefSeq; XP_005264284.1; XM_005264227.2. [Q8NDI1-2] DR RefSeq; XP_011531017.1; XM_011532715.4. [Q8NDI1-1] DR RefSeq; XP_047299700.1; XM_047443744.1. [Q8NDI1-1] DR RefSeq; XP_047299701.1; XM_047443745.1. [Q8NDI1-1] DR RefSeq; XP_047299702.1; XM_047443746.1. [Q8NDI1-2] DR RefSeq; XP_047299703.1; XM_047443747.1. [Q8NDI1-2] DR RefSeq; XP_047299704.1; XM_047443748.1. [Q8NDI1-2] DR RefSeq; XP_047299705.1; XM_047443749.1. [Q8NDI1-2] DR RefSeq; XP_047299711.1; XM_047443755.1. [Q8NDI1-3] DR RefSeq; XP_047299712.1; XM_047443756.1. [Q8NDI1-3] DR RefSeq; XP_047299713.1; XM_047443757.1. [Q8NDI1-3] DR RefSeq; XP_054197058.1; XM_054341083.1. [Q8NDI1-1] DR RefSeq; XP_054197059.1; XM_054341084.1. [Q8NDI1-1] DR RefSeq; XP_054197060.1; XM_054341085.1. [Q8NDI1-1] DR RefSeq; XP_054197061.1; XM_054341086.1. [Q8NDI1-1] DR RefSeq; XP_054197062.1; XM_054341087.1. [Q8NDI1-2] DR RefSeq; XP_054197063.1; XM_054341088.1. [Q8NDI1-2] DR RefSeq; XP_054197064.1; XM_054341089.1. [Q8NDI1-2] DR RefSeq; XP_054197065.1; XM_054341090.1. [Q8NDI1-2] DR RefSeq; XP_054197066.1; XM_054341091.1. [Q8NDI1-2] DR RefSeq; XP_054197075.1; XM_054341100.1. [Q8NDI1-3] DR RefSeq; XP_054197076.1; XM_054341101.1. [Q8NDI1-3] DR RefSeq; XP_054197077.1; XM_054341102.1. [Q8NDI1-3] DR PDB; 2D89; NMR; -; A=443-548. DR PDB; 6ZSH; X-ray; 2.20 A; A/C=1060-1162, B/D=440-550. DR PDB; 6ZSI; X-ray; 1.91 A; C/D=1060-1212. DR PDB; 6ZSJ; X-ray; 2.00 A; C/D=1060-1212. DR PDBsum; 2D89; -. DR PDBsum; 6ZSH; -. DR PDBsum; 6ZSI; -. DR PDBsum; 6ZSJ; -. DR AlphaFoldDB; Q8NDI1; -. DR BMRB; Q8NDI1; -. DR SMR; Q8NDI1; -. DR BioGRID; 116893; 138. DR CORUM; Q8NDI1; -. DR ELM; Q8NDI1; -. DR FunCoup; Q8NDI1; 3002. DR IntAct; Q8NDI1; 62. DR MINT; Q8NDI1; -. DR STRING; 9606.ENSP00000263991; -. DR GlyGen; Q8NDI1; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q8NDI1; -. DR MetOSite; Q8NDI1; -. DR PhosphoSitePlus; Q8NDI1; -. DR BioMuta; EHBP1; -. DR DMDM; 223590228; -. DR jPOST; Q8NDI1; -. DR MassIVE; Q8NDI1; -. DR PaxDb; 9606-ENSP00000263991; -. DR PeptideAtlas; Q8NDI1; -. DR ProteomicsDB; 73032; -. [Q8NDI1-1] DR ProteomicsDB; 73033; -. [Q8NDI1-2] DR ProteomicsDB; 73034; -. [Q8NDI1-3] DR Pumba; Q8NDI1; -. DR Antibodypedia; 30724; 79 antibodies from 23 providers. DR DNASU; 23301; -. DR Ensembl; ENST00000263991.9; ENSP00000263991.5; ENSG00000115504.16. [Q8NDI1-1] DR Ensembl; ENST00000405015.7; ENSP00000384143.3; ENSG00000115504.16. [Q8NDI1-3] DR Ensembl; ENST00000405289.5; ENSP00000385524.1; ENSG00000115504.16. [Q8NDI1-2] DR Ensembl; ENST00000431489.6; ENSP00000403783.1; ENSG00000115504.16. [Q8NDI1-3] DR GeneID; 23301; -. DR KEGG; hsa:23301; -. DR MANE-Select; ENST00000431489.6; ENSP00000403783.1; NM_001142616.3; NP_001136088.1. [Q8NDI1-3] DR UCSC; uc002sby.4; human. [Q8NDI1-1] DR AGR; HGNC:29144; -. DR ClinPGx; PA128394620; -. DR CTD; 23301; -. DR DisGeNET; 23301; -. DR GeneCards; EHBP1; -. DR HGNC; HGNC:29144; EHBP1. DR HPA; ENSG00000115504; Low tissue specificity. DR MalaCards; EHBP1; -. DR MIM; 609922; gene. DR MIM; 611868; phenotype. DR OpenTargets; ENSG00000115504; -. DR VEuPathDB; HostDB:ENSG00000115504; -. DR eggNOG; KOG0035; Eukaryota. DR GeneTree; ENSGT00940000157597; -. DR HOGENOM; CLU_004178_1_1_1; -. DR InParanoid; Q8NDI1; -. DR OMA; QQSSCDN; -. DR OrthoDB; 5972258at2759; -. DR PAN-GO; Q8NDI1; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8NDI1; -. DR PathwayCommons; Q8NDI1; -. DR SignaLink; Q8NDI1; -. DR Agora; ENSG00000115504; -. DR BioGRID-ORCS; 23301; 10 hits in 1156 CRISPR screens. DR ChiTaRS; EHBP1; human. DR EvolutionaryTrace; Q8NDI1; -. DR GenomeRNAi; 23301; -. DR Pharos; Q8NDI1; Tbio. DR PRO; PR:Q8NDI1; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q8NDI1; protein. DR Bgee; ENSG00000115504; Expressed in sural nerve and 209 other cell types or tissues. DR ExpressionAtlas; Q8NDI1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR CDD; cd21254; CH_EHBP1; 1. DR FunFam; 1.10.418.10:FF:000023; EH domain-binding protein 1 isoform X1; 1. DR Gene3D; 1.10.418.10; Calponin-like domain; 1. DR InterPro; IPR022735; bMERB_dom. DR InterPro; IPR001715; CH_dom. DR InterPro; IPR036872; CH_dom_sf. DR InterPro; IPR050540; F-actin_Monoox_Mical. DR InterPro; IPR019448; NT-C2. DR PANTHER; PTHR23167; CALPONIN HOMOLOGY DOMAIN-CONTAINING PROTEIN DDB_G0272472-RELATED; 1. DR PANTHER; PTHR23167:SF43; EH DOMAIN-BINDING PROTEIN 1; 1. DR Pfam; PF12130; bMERB_dom; 1. DR Pfam; PF00307; CH; 1. DR Pfam; PF10358; NT-C2; 1. DR SMART; SM00033; CH; 1. DR SMART; SM01203; DUF3585; 1. DR SUPFAM; SSF47576; Calponin-homology domain, CH-domain; 1. DR PROSITE; PS51848; BMERB; 1. DR PROSITE; PS51840; C2_NT; 1. DR PROSITE; PS50021; CH; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Coiled coil; Cytoplasm; Endocytosis; KW Endosome; Lipoprotein; Membrane; Phosphoprotein; Prenylation; KW Protein transport; Proteomics identification; Reference proteome; KW Transport. FT CHAIN 1..1231 FT /note="EH domain-binding protein 1" FT /id="PRO_0000285202" FT DOMAIN 8..158 FT /note="C2 NT-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01186" FT DOMAIN 443..548 FT /note="Calponin-homology (CH)" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00044" FT DOMAIN 1056..1212 FT /note="bMERB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01195" FT REGION 264..318 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 358..440 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 616..675 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 737..764 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 777..800 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 837..865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 895..941 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 960..996 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1025..1065 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1198..1231 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 185..210 FT /evidence="ECO:0000255" FT COILED 808..879 FT /evidence="ECO:0000255" FT COILED 1076..1100 FT /evidence="ECO:0000255" FT COILED 1136..1230 FT /evidence="ECO:0000255" FT MOTIF 1228..1231 FT /note="CAAX motif" FT /evidence="ECO:0000305|PubMed:27552051" FT COMPBIAS 302..318 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 625..635 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..675 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 737..753 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 754..764 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 790..800 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 839..849 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 895..904 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 905..919 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 960..976 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 979..996 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1026..1065 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1209..1231 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 171 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 174 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231" FT MOD_RES 177 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 222 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q69ZW3" FT MOD_RES 302 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 335 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 408 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 426 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q69ZW3" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 432 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:24275569" FT MOD_RES 436 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 636 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q69ZW3" FT MOD_RES 694 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 710 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 781 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 854 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 964 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1058 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 212..246 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14676205, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334" FT /id="VSP_024834" FT VAR_SEQ 905..940 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_024835" FT VARIANT 395 FT /note="R -> T (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035913" FT VARIANT 755 FT /note="K -> Q (in dbSNP:rs17432615)" FT /id="VAR_031992" FT CONFLICT 105 FT /note="E -> V (in Ref. 5; AAH29477)" FT /evidence="ECO:0000305" FT CONFLICT 112 FT /note="K -> R (in Ref. 2; AAQ97141 and 3; CAD38814)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="E -> G (in Ref. 2; AAQ97141 and 3; CAD38814)" FT /evidence="ECO:0000305" FT CONFLICT 256 FT /note="D -> V (in Ref. 2; AAQ97141 and 3; CAD38814)" FT /evidence="ECO:0000305" FT CONFLICT 342 FT /note="R -> G (in Ref. 2; AAQ97141 and 3; CAD38814)" FT /evidence="ECO:0000305" FT HELIX 445..456 FT /evidence="ECO:0007829|PDB:6ZSH" FT TURN 457..459 FT /evidence="ECO:0007829|PDB:6ZSH" FT STRAND 466..469 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 470..472 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 476..485 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 487..489 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:2D89" FT HELIX 500..513 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 522..528 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 533..547 FT /evidence="ECO:0007829|PDB:6ZSH" FT HELIX 1076..1101 FT /evidence="ECO:0007829|PDB:6ZSI" FT HELIX 1110..1160 FT /evidence="ECO:0007829|PDB:6ZSI" FT HELIX 1164..1166 FT /evidence="ECO:0007829|PDB:6ZSI" FT HELIX 1169..1198 FT /evidence="ECO:0007829|PDB:6ZSI" FT TURN 1199..1201 FT /evidence="ECO:0007829|PDB:6ZSI" SQ SEQUENCE 1231 AA; 140017 MW; FFF39B65BCC0FC0A CRC64; MASVWKRLQR VGKHASKFQF VASYQELMVE CTKKWQPDKL VVVWTRRSRR KSSKAHSWQP GIKNPYRGVV VWPVPENIEI TVTLFKDPHA EEFEDKEWTF VIENESPSGR RKALATSSIN MKQYASPMPT QTDVKLKFKP LSKKVVSAAL QFSLSCIFLR EGKATDEDMQ SLASLMSMKQ ADIGNLDDFE EDNEDDDENR VNQEEKAAKI TEIVNQLNAL SSLDEDQDDC IKQANMRSAK SASSSEELIN KLNFLDEAEK DLATVNSNPF DDPDAAELNP FGDPDSEEPI TETASPRKTE DSFYNNSYNP FKEVQTPQYL NPFDEPEAFV TIKDSPPQST KRKNIRPVDM SKYLYADSSK TEEEELDESN PFYEPKSTPP PNNLVNPVQE LETERRVKRK APAPPVLSPK TGVLNENTVS AGKDLSTSPK PSPIPSPVLG RKPNASQSLL VWCKEVTKNY RGVKITNFTT SWRNGLSFCA ILHHFRPDLI DYKSLNPQDI KENNKKAYDG FASIGISRLL EPSDMVLLAI PDKLTVMTYL YQIRAHFSGQ ELNVVQIEEN SSKSTYKVGN YETDTNSSVD QEKFYAELSD LKREPELQQP ISGAVDFLSQ DDSVFVNDSG VGESESEHQT PDDHLSPSTA SPYCRRTKSD TEPQKSQQSS GRTSGSDDPG ICSNTDSTQA QVLLGKKRLL KAETLELSDL YVSDKKKDMS PPFICEETDE QKLQTLDIGS NLEKEKLENS RSLECRSDPE SPIKKTSLSP TSKLGYSYSR DLDLAKKKHA SLRQTESDPD ADRTTLNHAD HSSKIVQHRL LSRQEELKER ARVLLEQARR DAALKAGNKH NTNTATPFCN RQLSDQQDEE RRRQLRERAR QLIAEARSGV KMSELPSYGE MAAEKLKERS KASGDENDNI EIDTNEEIPE GFVVGGGDEL TNLENDLDTP EQNSKLVDLK LKKLLEVQPQ VANSPSSAAQ KAVTESSEQD MKSGTEDLRT ERLQKTTERF RNPVVFSKDS TVRKTQLQSF SQYIENRPEM KRQRSIQEDT KKGNEEKAAI TETQRKPSED EVLNKGFKDT SQYVVGELAA LENEQKQIDT RAALVEKRLR YLMDTGRNTE EEEAMMQEWF MLVNKKNALI RRMNQLSLLE KEHDLERRYE LLNRELRAML AIEDWQKTEA QKRREQLLLD ELVALVNKRD ALVRDLDAQE KQAEEEDEHL ERTLEQNKGK MAKKEEKCVL Q // ID EPCAM_HUMAN Reviewed; 314 AA. AC P16422; P18180; Q6FG26; Q6FG49; Q96C47; Q9UCD0; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 13-NOV-2007, sequence version 2. DT 28-JAN-2026, entry version 223. DE RecName: Full=Epithelial cell adhesion molecule; DE Short=Ep-CAM; DE AltName: Full=Adenocarcinoma-associated antigen; DE AltName: Full=Cell surface glycoprotein Trop-1; DE AltName: Full=Epithelial cell surface antigen; DE AltName: Full=Epithelial glycoprotein; DE Short=EGP; DE AltName: Full=Epithelial glycoprotein 314; DE Short=EGP314; DE Short=hEGP314; DE AltName: Full=KS 1/4 antigen; DE AltName: Full=KSA; DE AltName: Full=Major gastrointestinal tumor-associated protein GA733-2; DE AltName: Full=Tumor-associated calcium signal transducer 1; DE AltName: CD_antigen=CD326; DE Flags: Precursor; GN Name=EPCAM; Synonyms=GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RC TISSUE=Lung adenocarcinoma; RX PubMed=2463074; RA Strnad J., Hamilton A.E., Beavers L.S., Gamboa G.C., Apelgren L.D., RA Taber L.D., Sportsman J.R., Bumol T.F., Sharp J.D., Gadski R.A.; RT "Molecular cloning and characterization of a human RT adenocarcinoma/epithelial cell surface antigen complementary DNA."; RL Cancer Res. 49:314-317(1989). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RX PubMed=2469722; RA Perez M.S., Walker L.E.; RT "Isolation and characterization of a cDNA encoding the KS1/4 epithelial RT carcinoma marker."; RL J. Immunol. 142:3662-3667(1989). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RX PubMed=2108441; DOI=10.1073/pnas.87.7.2755; RA Simon B., Podolsky D.K., Moldenhauer G., Isselbacher K.J., RA Gattoni-Celli S., Brand S.J.; RT "Epithelial glycoprotein is a member of a family of epithelial cell surface RT antigens homologous to nidogen, a matrix adhesion protein."; RL Proc. Natl. Acad. Sci. U.S.A. 87:2755-2759(1990). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Colon carcinoma; RX PubMed=2333300; DOI=10.1073/pnas.87.9.3542; RA Szala S., Froehlich M., Scollon M., Kasai Y., Steplewski Z., Koprowski H., RA Linnenbach A.J.; RT "Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:3542-3546(1990). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Lymphoma; RX PubMed=8382772; DOI=10.1128/mcb.13.3.1507-1515.1993; RA Linnenbach A.J., Seng B.A., Wu S., Robbins S., Scollon M., Pyrc J.J., RA Druck T., Huebner K.; RT "Retroposition in a family of carcinoma-associated antigen genes."; RL Mol. Cell. Biol. 13:1507-1515(1993). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-115. RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PRELIMINARY PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 81-126. RC TISSUE=Placenta; RX PubMed=2911574; DOI=10.1073/pnas.86.1.27; RA Linnenbach A.J., Wojcierowski J., Wu S., Pyrc J.J., Ross A.H., RA Dietzschold B., Speicher D., Koprowski H.; RT "Sequence investigation of the major gastrointestinal tumor-associated RT antigen gene family, GA733."; RL Proc. Natl. Acad. Sci. U.S.A. 86:27-31(1989). RN [11] RP PROTEIN SEQUENCE OF 82-100, AND SUBUNIT. RX PubMed=7693697; DOI=10.1016/s0021-9258(20)80515-8; RA Bjoerk P., Joensson U., Svedberg H., Larsson K., Lind P., Dillner J., RA Hedlund G., Dohlsten M., Kalland T.; RT "Isolation, partial characterization, and molecular cloning of a human RT colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse RT monoclonal antibody."; RL J. Biol. Chem. 268:24232-24241(1993). RN [12] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-74 AND ASN-111. RX PubMed=11080501; DOI=10.1074/jbc.m008839200; RA Chong J.M., Speicher D.W.; RT "Determination of disulfide bond assignments and N-glycosylation sites of RT the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, RT KSA, and Ep-CAM)."; RL J. Biol. Chem. 276:5804-5813(2001). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15195135; DOI=10.1038/sj.onc.1207610; RA Muenz M., Kieu C., Mack B., Schmitt B., Zeidler R., Gires O.; RT "The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell RT proliferation."; RL Oncogene 23:5748-5758(2004). RN [14] RP FUNCTION. RX PubMed=15922867; DOI=10.1016/j.canlet.2004.11.048; RA Muenz M., Zeidler R., Gires O.; RT "The tumour-associated antigen EpCAM upregulates the fatty acid binding RT protein E-FABP."; RL Cancer Lett. 225:151-157(2005). RN [15] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CLDN7. RX PubMed=16054130; DOI=10.1016/j.yexcr.2005.06.013; RA Ladwein M., Pape U.F., Schmidt D.S., Schnoelzer M., Fiedler S., RA Langbein L., Franke W.W., Moldenhauer G., Zoeller M.; RT "The cell-cell adhesion molecule EpCAM interacts directly with the tight RT junction protein claudin-7."; RL Exp. Cell Res. 309:345-357(2005). RN [16] RP GLYCOSYLATION AT ASN-74; ASN-111 AND ASN-198, AND MUTAGENESIS OF ASN-74; RP ASN-111 AND ASN-198. RX PubMed=18508581; DOI=10.2741/3075; RA Munz M., Fellinger K., Hofmann T., Schmitt B., Gires O.; RT "Glycosylation is crucial for stability of tumour and cancer stem cell RT antigen EpCAM."; RL Front. Biosci. 13:5195-5201(2008). RN [17] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-198. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [18] RP INVOLVEMENT IN LYNCH8. RX PubMed=19098912; DOI=10.1038/ng.283; RA Ligtenberg M.J., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., RA Voorendt M., Lee T.Y., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J., RA Tsui W.Y., Kong C.K., Brunner H.G., van Kessel A.G., Yuen S.T., RA van Krieken J.H., Leung S.Y., Hoogerbrugge N.; RT "Heritable somatic methylation and inactivation of MSH2 in families with RT Lynch syndrome due to deletion of the 3' exons of TACSTD1."; RL Nat. Genet. 41:112-117(2009). RN [19] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20064925; DOI=10.1074/jbc.m109.077081; RA Lu T.Y., Lu R.M., Liao M.Y., Yu J., Chung C.H., Kao C.F., Wu H.C.; RT "Epithelial cell adhesion molecule regulation is associated with the RT maintenance of the undifferentiated phenotype of human embryonic stem RT cells."; RL J. Biol. Chem. 285:8719-8732(2010). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19785009; DOI=10.1002/stem.221; RA Ng V.Y., Ang S.N., Chan J.X., Choo A.B.; RT "Characterization of epithelial cell adhesion molecule as a surface marker RT on undifferentiated human embryonic stem cells."; RL Stem Cells 28:29-35(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP VARIANT DIAR5 TYR-66, AND INVOLVEMENT IN DIAR5. RX PubMed=18572020; DOI=10.1053/j.gastro.2008.05.036; RA Sivagnanam M., Mueller J.L., Lee H., Chen Z., Nelson S.F., Turner D., RA Zlotkin S.H., Pencharz P.B., Ngan B.Y., Libiger O., Schork N.J., RA Lavine J.E., Taylor S., Newbury R.O., Kolodner R.D., Hoffman H.M.; RT "Identification of EpCAM as the gene for congenital tufting enteropathy."; RL Gastroenterology 135:429-437(2008). RN [23] RP VARIANTS DIAR5 76-SER--ALA-314 DEL; ARG-103; CYS-105; ILE-120 AND RP 132-GLU--ALA-314 DEL, AND INVOLVEMENT IN DIAR5. RX PubMed=24142340; DOI=10.1007/s00439-013-1380-6; RA Salomon J., Goulet O., Canioni D., Brousse N., Lemale J., Tounian P., RA Coulomb A., Marinier E., Hugot J.P., Ruemmele F., Dufier J.L., Roche O., RA Bodemer C., Colomb V., Talbotec C., Lacaille F., Campeotto F., RA Cerf-Bensussan N., Janecke A.R., Mueller T., Koletzko S., Bonnefont J.P., RA Lyonnet S., Munnich A., Poirier F., Smahi A.; RT "Genetic characterization of congenital tufting enteropathy: epcam RT associated phenotype and involvement of SPINT2 in the syndromic form."; RL Hum. Genet. 133:299-310(2014). CC -!- FUNCTION: May act as a physical homophilic interaction molecule between CC intestinal epithelial cells (IECs) and intraepithelial lymphocytes CC (IELs) at the mucosal epithelium for providing immunological barrier as CC a first line of defense against mucosal infection. Plays a role in CC embryonic stem cells proliferation and differentiation. Up-regulates CC the expression of FABP5, MYC and cyclins A and E. CC {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:15922867, CC ECO:0000269|PubMed:19785009, ECO:0000269|PubMed:20064925}. CC -!- SUBUNIT: Monomer. Interacts with phosphorylated CLDN7. CC {ECO:0000269|PubMed:16054130, ECO:0000269|PubMed:7693697}. CC -!- INTERACTION: CC P16422; P27797: CALR; NbExp=3; IntAct=EBI-1171184, EBI-1049597; CC P16422; P12830: CDH1; NbExp=3; IntAct=EBI-1171184, EBI-727477; CC P16422; Q15078: CDK5R1; NbExp=3; IntAct=EBI-1171184, EBI-746189; CC P16422; P36957: DLST; NbExp=3; IntAct=EBI-1171184, EBI-351007; CC P16422; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-1171184, EBI-1055945; CC -!- SUBCELLULAR LOCATION: Lateral cell membrane CC {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:16054130, CC ECO:0000269|PubMed:19785009}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:16054130}. Cell junction, tight junction CC {ECO:0000269|PubMed:16054130}. Note=Colocalizes with CLDN7 at the CC lateral cell membrane and tight junction. CC {ECO:0000269|PubMed:16054130}. CC -!- TISSUE SPECIFICITY: Highly and selectively expressed by CC undifferentiated rather than differentiated embryonic stem cells (ESC). CC Levels rapidly diminish as soon as ESC's differentiate (at protein CC levels). Expressed in almost all epithelial cell membranes but not on CC mesodermal or neural cell membranes. Found on the surface of CC adenocarcinoma. {ECO:0000269|PubMed:20064925}. CC -!- PTM: Hyperglycosylated in carcinoma tissue as compared with autologous CC normal epithelia. Glycosylation at Asn-198 is crucial for protein CC stability. {ECO:0000269|PubMed:11080501, ECO:0000269|PubMed:18508581, CC ECO:0000269|PubMed:19159218}. CC -!- DISEASE: Diarrhea 5, with tufting enteropathy, congenital (DIAR5) CC [MIM:613217]: An intractable diarrhea of infancy characterized by CC villous atrophy and absence of inflammation, with intestinal epithelial CC cell dysplasia manifesting as focal epithelial tufts in the duodenum CC and jejunum. {ECO:0000269|PubMed:18572020, CC ECO:0000269|PubMed:24142340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lynch syndrome 8 (LYNCH8) [MIM:613244]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:19098912}. Note=The disease is caused by variants CC affecting the gene represented in this entry. LYNCH8 results from CC heterozygous deletion of 3-prime exons of EPCAM and intergenic regions CC directly upstream of MSH2, resulting in transcriptional read-through CC and epigenetic silencing of MSH2 in tissues expressing EPCAM. CC -!- SIMILARITY: Belongs to the EPCAM family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42459/TACSTD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M32325; AAA36151.1; -; mRNA. DR EMBL; X14758; CAA32870.1; -; mRNA. DR EMBL; M26481; AAA59543.1; -; mRNA. DR EMBL; M32306; AAA35723.1; -; mRNA. DR EMBL; M33011; AAA35861.1; -; mRNA. DR EMBL; M93036; AAB00775.1; -; Genomic_DNA. DR EMBL; M93029; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93030; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93031; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93032; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93033; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93034; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93035; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; CR542259; CAG47055.1; -; mRNA. DR EMBL; CR542283; CAG47078.1; -; mRNA. DR EMBL; AC079775; AAY15095.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00218.1; -; Genomic_DNA. DR EMBL; BC014785; AAH14785.1; -; mRNA. DR CCDS; CCDS1833.1; -. DR PIR; B48149; B48149. DR RefSeq; NP_002345.2; NM_002354.3. DR PDB; 4MZV; X-ray; 1.86 A; A=24-265. DR PDB; 6I07; X-ray; 2.35 A; C/D=24-265. DR PDBsum; 4MZV; -. DR PDBsum; 6I07; -. DR AlphaFoldDB; P16422; -. DR SMR; P16422; -. DR BioGRID; 110250; 42. DR CORUM; P16422; -. DR FunCoup; P16422; 328. DR IntAct; P16422; 26. DR MINT; P16422; -. DR STRING; 9606.ENSP00000263735; -. DR ChEMBL; CHEMBL3580493; -. DR DrugBank; DB06607; Catumaxomab. DR DrugBank; DB06072; Citatuzumab Bogatox. DR DrugBank; DB11075; Hypromellose. DR DrugBank; DB05831; ING-1. DR DrugBank; DB05319; Oportuzumab monatox. DR DrugBank; DB09336; Technetium Tc-99m nofetumomab merpentan. DR GlyConnect; 1217; 34 N-Linked glycans (3 sites). DR GlyCosmos; P16422; 3 sites, 34 glycans. DR GlyGen; P16422; 6 sites, 63 N-linked glycans (3 sites), 2 O-linked glycans (3 sites). DR iPTMnet; P16422; -. DR MetOSite; P16422; -. DR PhosphoSitePlus; P16422; -. DR SwissPalm; P16422; -. DR BioMuta; EPCAM; -. DR DMDM; 160266056; -. DR CPTAC; CPTAC-502; -. DR CPTAC; CPTAC-503; -. DR jPOST; P16422; -. DR MassIVE; P16422; -. DR PaxDb; 9606-ENSP00000263735; -. DR PeptideAtlas; P16422; -. DR ProteomicsDB; 53359; -. DR Pumba; P16422; -. DR ABCD; P16422; 30 sequenced antibodies. DR Antibodypedia; 3539; 5006 antibodies from 64 providers. DR DNASU; 4072; -. DR Ensembl; ENST00000263735.9; ENSP00000263735.4; ENSG00000119888.12. DR GeneID; 4072; -. DR KEGG; hsa:4072; -. DR MANE-Select; ENST00000263735.9; ENSP00000263735.4; NM_002354.3; NP_002345.2. DR UCSC; uc002rvx.4; human. DR AGR; HGNC:11529; -. DR CIViC; 4072; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA35493; -. DR CTD; 4072; -. DR DisGeNET; 4072; -. DR GeneCards; EPCAM; -. DR GeneReviews; EPCAM; -. DR HGNC; HGNC:11529; EPCAM. DR HPA; ENSG00000119888; Tissue enhanced (intestine). DR MalaCards; EPCAM; -. DR MIM; 185535; gene. DR MIM; 613217; phenotype. DR MIM; 613244; phenotype. DR OpenTargets; ENSG00000119888; -. DR Orphanet; 92050; Congenital tufting enteropathy. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000119888; -. DR eggNOG; ENOG502QVSU; Eukaryota. DR GeneTree; ENSGT00390000018245; -. DR HOGENOM; CLU_075326_0_0_1; -. DR InParanoid; P16422; -. DR OMA; CQCKSIG; -. DR OrthoDB; 8953056at2759; -. DR PAN-GO; P16422; 2 GO annotations based on evolutionary models. DR PhylomeDB; P16422; -. DR BRENDA; 2.4.1.37; 2681. DR BRENDA; 2.4.1.40; 2681. DR PathwayCommons; P16422; -. DR Reactome; R-HSA-202733; Cell surface interactions at the vascular wall. DR Reactome; R-HSA-9638630; Attachment of bacteria to epithelial cells. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P16422; -. DR SIGNOR; P16422; -. DR Agora; ENSG00000119888; -. DR BioGRID-ORCS; 4072; 34 hits in 1164 CRISPR screens. DR ChiTaRS; EPCAM; human. DR EvolutionaryTrace; P16422; -. DR GeneWiki; Epithelial_cell_adhesion_molecule; -. DR GenomeRNAi; 4072; -. DR Pharos; P16422; Tbio. DR PRO; PR:P16422; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P16422; protein. DR Bgee; ENSG00000119888; Expressed in jejunal mucosa and 176 other cell types or tissues. DR ExpressionAtlas; P16422; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:MGI. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; IBA:GO_Central. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IMP:UniProtKB. DR GO; GO:0048863; P:stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd00191; TY; 1. DR FunFam; 4.10.800.10:FF:000015; Epithelial cell adhesion molecule; 1. DR Gene3D; 4.10.800.10; Thyroglobulin type-1; 1. DR InterPro; IPR049420; EPCAM-Trop-2_C. DR InterPro; IPR043406; EPCAM/Trop-2. DR InterPro; IPR041630; EpCAM_N. DR InterPro; IPR000716; Thyroglobulin_1. DR InterPro; IPR036857; Thyroglobulin_1_sf. DR PANTHER; PTHR14168:SF2; EPITHELIAL CELL ADHESION MOLECULE; 1. DR PANTHER; PTHR14168; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER; 1. DR Pfam; PF21283; EPCAM-Trop-2_C; 1. DR Pfam; PF18635; EpCAM_N; 1. DR Pfam; PF00086; Thyroglobulin_1; 1. DR SMART; SM00211; TY; 1. DR SUPFAM; SSF57610; Thyroglobulin type-1 domain; 1. DR PROSITE; PS00484; THYROGLOBULIN_1_1; 1. DR PROSITE; PS51162; THYROGLOBULIN_1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Cell junction; Cell membrane; Direct protein sequencing; KW Disease variant; Disulfide bond; Glycoprotein; KW Hereditary nonpolyposis colorectal cancer; Membrane; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Tight junction; Transmembrane; Transmembrane helix; Tumor antigen. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..314 FT /note="Epithelial cell adhesion molecule" FT /id="PRO_0000022467" FT TOPO_DOM 24..265 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 266..288 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 289..314 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 63..135 FT /note="Thyroglobulin type-1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500" FT CARBOHYD 74 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:11080501, FT ECO:0000269|PubMed:18508581" FT CARBOHYD 111 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:11080501, FT ECO:0000269|PubMed:18508581" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18508581, FT ECO:0000269|PubMed:19159218" FT DISULFID 27..46 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 29..59 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 38..48 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 66..99 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 110..116 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 118..135 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT VARIANT 66 FT /note="C -> Y (in DIAR5; dbSNP:rs267606785)" FT /evidence="ECO:0000269|PubMed:18572020" FT /id="VAR_063829" FT VARIANT 76..314 FT /note="Missing (in DIAR5; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089317" FT VARIANT 103 FT /note="G -> R (in DIAR5; uncertain significance; FT dbSNP:rs1346393896)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089318" FT VARIANT 105 FT /note="F -> C (in DIAR5; uncertain significance)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089319" FT VARIANT 115 FT /note="M -> T (in dbSNP:rs1126497)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2108441, ECO:0000269|PubMed:2463074, FT ECO:0000269|PubMed:2469722" FT /id="VAR_018329" FT VARIANT 120 FT /note="N -> I (in DIAR5; uncertain significance; FT dbSNP:rs2103747763)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089320" FT VARIANT 132..314 FT /note="Missing (in DIAR5; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089321" FT MUTAGEN 74 FT /note="N->A: Changed glycosylation pattern. Complete loss FT of glycosylation and substantial decrease in protein FT expression; when associated with A-111 and A-198." FT /evidence="ECO:0000269|PubMed:18508581" FT MUTAGEN 111 FT /note="N->A: Changed glycosylation pattern. Complete loss FT of glycosylation and substantial decrease in protein FT expression; when associated with A-74 and A-198." FT /evidence="ECO:0000269|PubMed:18508581" FT MUTAGEN 198 FT /note="N->A: Decreased glycosylation, reduced protein FT stability and significant decrease in protein expression. FT Complete loss of glycosylation and substantial decrease in FT protein expression; when associated with A-74 and A-111." FT /evidence="ECO:0000269|PubMed:18508581" FT CONFLICT 277 FT /note="I -> M (in Ref. 1; AAA36151/CAA32870 and 2; FT AAA59543)" FT /evidence="ECO:0000305" FT CONFLICT 303 FT /note="K -> R (in Ref. 6; CAG47055)" FT /evidence="ECO:0000305" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 46..50 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 65..72 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 107..111 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 141..150 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 159..173 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 178..180 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 181..187 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 199..201 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 209..220 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 234..237 FT /evidence="ECO:0007829|PDB:6I07" FT HELIX 244..246 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 248..255 FT /evidence="ECO:0007829|PDB:4MZV" SQ SEQUENCE 314 AA; 34932 MW; 023FCE418B2F1079 CRC64; MAPPQVLAFG LLLAAATATF AAAQEECVCE NYKLAVNCFV NNNRQCQCTS VGAQNTVICS KLAAKCLVMK AEMNGSKLGR RAKPEGALQN NDGLYDPDCD ESGLFKAKQC NGTSMCWCVN TAGVRRTDKD TEITCSERVR TYWIIIELKH KAREKPYDSK SLRTALQKEI TTRYQLDPKF ITSILYENNV ITIDLVQNSS QKTQNDVDIA DVAYYFEKDV KGESLFHSKK MDLTVNGEQL DLDPGQTLIY YVDEKAPEFS MQGLKAGVIA VIVVVVIAVV AGIVVLVISR KKRMAKYEKA EIKEMGEMHR ELNA // ID EPHA8_HUMAN Reviewed; 1005 AA. AC P29322; Q6IN80; Q8IUX6; Q9NUA9; Q9P269; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 235. DE RecName: Full=Ephrin type-A receptor 8; DE EC=2.7.10.1; DE AltName: Full=EPH- and ELK-related kinase; DE AltName: Full=EPH-like kinase 3; DE Short=EK3; DE Short=hEK3; DE AltName: Full=Tyrosine-protein kinase receptor EEK; DE Flags: Precursor; GN Name=EPHA8; Synonyms=EEK, HEK3, KIAA1459; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-1005 (ISOFORM 1), AND VARIANT RP GLN-612. RC TISSUE=Brain; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 706-726. RX PubMed=1648701; RA Chan J., Watt V.M.; RT "eek and erk, new members of the eph subclass of receptor protein-tyrosine RT kinases."; RL Oncogene 6:1057-1061(1991). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP INTERACTION WITH FYN. RX PubMed=10498895; DOI=10.1038/sj.onc.1202917; RA Choi S., Park S.; RT "Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn RT binding to the Tyr-615 site by enhancing tyrosine kinase activity."; RL Oncogene 18:5413-5422(1999). RN [7] RP INTERACTION WITH PIK3CG. RX PubMed=11416136; DOI=10.1128/mcb.21.14.4579-4597.2001; RA Gu C., Park S.; RT "The EphA8 receptor regulates integrin activity through p110gamma RT phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent RT manner."; RL Mol. Cell. Biol. 21:4579-4597(2001). RN [8] RP INTERACTION WITH ANKS1B. RX PubMed=17875921; DOI=10.1128/mcb.00794-07; RA Shin J., Gu C., Park E., Park S.; RT "Identification of phosphotyrosine binding domain-containing proteins as RT novel downstream targets of the EphA8 signaling function."; RL Mol. Cell. Biol. 27:8113-8126(2007). RN [9] RP INTERACTION WITH TIAM1. RX PubMed=20496116; DOI=10.1007/s10059-010-0075-2; RA Yoo S., Shin J., Park S.; RT "EphA8-ephrinA5 signaling and clathrin-mediated endocytosis is regulated by RT Tiam-1, a Rac-specific guanine nucleotide exchange factor."; RL Mol. Cells 29:603-609(2010). RN [10] RP STRUCTURE BY NMR OF 437-534 AND 932-1000. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain and of sterile alpha motif RT (SAM) domain of EPH receptor A8 protein."; RL Submitted (NOV-2005) to the PDB data bank. RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] SER-45; LEU-60; LYS-123; CYS-179; LEU-198 RP AND LEU-860. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, CC EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. CC With EFNA5 may regulate integrin-mediated cell adhesion and migration CC on fibronectin substrate but also neurite outgrowth. During development CC of the nervous system also plays a role in axon guidance. Downstream CC effectors of the EPHA8 signaling pathway include FYN which promotes CC cell adhesion upon activation by EPHA8 and the MAP kinases in the CC stimulation of neurite outgrowth (By similarity). {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses. May also form CC heterodimers with other ephrin receptors (By similarity). Interacts CC with FYN; possible downstream effector of EPHA8 in regulation of cell CC adhesion. Interacts with PIK3CG; regulates integrin-mediated cell CC adhesion to substrate. Interacts with TIAM1; regulates clathrin- CC mediated endocytosis of EPHA8. Interacts with ANKS1A and ANKS1B; EPHA8 CC kinase activity-independent but stimulated by EPHA8 ubiquitination. CC {ECO:0000250, ECO:0000269|PubMed:10498895, ECO:0000269|PubMed:11416136, CC ECO:0000269|PubMed:17875921, ECO:0000269|PubMed:20496116}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:O09127}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection CC {ECO:0000250|UniProtKB:O09127}. Early endosome membrane CC {ECO:0000250|UniProtKB:O09127}. Note=Undergoes clathrin-mediated CC endocytosis upon EFNA5-binding and is targeted to early endosomes. CC {ECO:0000250|UniProtKB:O09127}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29322-1; Sequence=Displayed; CC Name=2; CC IsoId=P29322-2; Sequence=VSP_041946, VSP_041947; CC -!- PTM: Phosphorylated. Phosphorylation is stimulated upon binding of its CC ligands including EFNA2, EFNA3 and EFNA5. Autophosphorylation on Tyr- CC 616 is critical for association with FYN. Autophosphorylation on Tyr- CC 839 modulates tyrosine kinase activity (By similarity). {ECO:0000250}. CC -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor CC stability and activity through proteasomal degradation. ANKS1A prevents CC ubiquitination and degradation (By similarity). {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA41980.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL035703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC038796; AAH38796.1; -; mRNA. DR EMBL; BC072417; AAH72417.2; -; mRNA. DR EMBL; AB040892; BAA95983.1; -; mRNA. DR EMBL; X59291; CAA41980.1; ALT_INIT; Genomic_DNA. DR CCDS; CCDS225.1; -. [P29322-1] DR CCDS; CCDS30626.1; -. [P29322-2] DR PIR; S23361; S23361. DR RefSeq; NP_001006944.1; NM_001006943.3. [P29322-2] DR RefSeq; NP_065387.1; NM_020526.5. [P29322-1] DR PDB; 1UCV; NMR; -; A=933-1000. DR PDB; 1X5L; NMR; -; A=437-534. DR PDB; 3KUL; X-ray; 2.15 A; A/B=602-909. DR PDBsum; 1UCV; -. DR PDBsum; 1X5L; -. DR PDBsum; 3KUL; -. DR AlphaFoldDB; P29322; -. DR BMRB; P29322; -. DR SMR; P29322; -. DR BioGRID; 108360; 162. DR CORUM; P29322; -. DR FunCoup; P29322; 354. DR IntAct; P29322; 151. DR MINT; P29322; -. DR STRING; 9606.ENSP00000166244; -. DR BindingDB; P29322; -. DR ChEMBL; CHEMBL4134; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P29322; -. DR GuidetoPHARMACOLOGY; 1828; -. DR GlyCosmos; P29322; 3 sites, No reported glycans. DR GlyGen; P29322; 4 sites, 1 O-linked glycan (1 site). DR iPTMnet; P29322; -. DR PhosphoSitePlus; P29322; -. DR BioMuta; EPHA8; -. DR DMDM; 19857975; -. DR CPTAC; CPTAC-2820; -. DR CPTAC; CPTAC-3204; -. DR jPOST; P29322; -. DR MassIVE; P29322; -. DR PaxDb; 9606-ENSP00000166244; -. DR PeptideAtlas; P29322; -. DR ProteomicsDB; 54538; -. [P29322-1] DR ProteomicsDB; 54539; -. [P29322-2] DR Antibodypedia; 4046; 174 antibodies from 33 providers. DR DNASU; 2046; -. DR Ensembl; ENST00000166244.8; ENSP00000166244.3; ENSG00000070886.12. [P29322-1] DR Ensembl; ENST00000374644.8; ENSP00000363775.4; ENSG00000070886.12. [P29322-2] DR GeneID; 2046; -. DR KEGG; hsa:2046; -. DR MANE-Select; ENST00000166244.8; ENSP00000166244.3; NM_020526.5; NP_065387.1. DR UCSC; uc001bfw.4; human. [P29322-1] DR AGR; HGNC:3391; -. DR ClinPGx; PA27823; -. DR CTD; 2046; -. DR DisGeNET; 2046; -. DR GeneCards; EPHA8; -. DR HGNC; HGNC:3391; EPHA8. DR HPA; ENSG00000070886; Tissue enriched (choroid). DR MIM; 176945; gene. DR OpenTargets; ENSG00000070886; -. DR VEuPathDB; HostDB:ENSG00000070886; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160469; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P29322; -. DR OMA; MRMNIDD; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29322; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29322; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29322; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29322; -. DR SIGNOR; P29322; -. DR Agora; ENSG00000070886; -. DR BioGRID-ORCS; 2046; 11 hits in 1180 CRISPR screens. DR ChiTaRS; EPHA8; human. DR EvolutionaryTrace; P29322; -. DR GeneWiki; EPHA8; -. DR GenomeRNAi; 2046; -. DR Pharos; P29322; Tchem. DR PRO; PR:P29322; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29322; protein. DR Bgee; ENSG00000070886; Expressed in endothelial cell and 47 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0043005; C:neuron projection; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0031175; P:neuron projection development; ISS:UniProtKB. DR GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0030155; P:regulation of cell adhesion; ISS:UniProtKB. DR GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; ISS:UniProtKB. DR GO; GO:0006929; P:substrate-dependent cell migration; ISS:UniProtKB. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09550; SAM_EPH-A8; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR FunFam; 1.10.150.50:FF:000058; ephrin type-A receptor 8; 1. DR FunFam; 3.30.200.20:FF:000143; Ephrin type-B receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF7; EPHRIN TYPE-A RECEPTOR 8; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Developmental protein; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..1005 FT /note="Ephrin type-A receptor 8" FT /id="PRO_0000016822" FT TOPO_DOM 28..542 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 543..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..1005 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..209 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..438 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 439..534 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 635..896 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 930..994 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 564..570 FT /note="Mediates interaction with ANKS1A and ANKS1B" FT /evidence="ECO:0000250" FT REGION 589..644 FT /note="Mediates interaction with PIK3CG and required for FT endocytosis" FT /evidence="ECO:0000250" FT MOTIF 1003..1005 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 760 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 641..649 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 667 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 616 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT MOD_RES 839 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT CARBOHYD 340 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 432 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 439..495 FT /note="APSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEKDKEMQSYSTL FT KAVTT -> GRRRNSVPQRPGPPASPASDPSRDQSSAGDVLWAFRQVPLWPCAPHQDPE FT LEALHCL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041946" FT VAR_SEQ 496..1005 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041947" FT VARIANT 45 FT /note="G -> S (in dbSNP:rs45498698)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042153" FT VARIANT 60 FT /note="V -> L (in dbSNP:rs56402644)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042154" FT VARIANT 123 FT /note="N -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042155" FT VARIANT 179 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1557556639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042156" FT VARIANT 198 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042157" FT VARIANT 321 FT /note="P -> L (in dbSNP:rs56656925)" FT /id="VAR_061292" FT VARIANT 444 FT /note="V -> M (in dbSNP:rs2295021)" FT /id="VAR_022107" FT VARIANT 612 FT /note="E -> Q (in dbSNP:rs999765)" FT /evidence="ECO:0000269|PubMed:10819331" FT /id="VAR_024514" FT VARIANT 860 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042158" FT CONFLICT 237 FT /note="S -> L (in Ref. 3; BAA95983)" FT /evidence="ECO:0000305" FT STRAND 456..460 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 472..482 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 488..499 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 507..510 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:1X5L" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 635..643 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 644..646 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 647..654 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 662..669 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 675..688 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 699..703 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 705..707 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 710..714 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 721..726 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 727..730 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 734..753 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 766..768 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 774..776 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 802..804 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 807..812 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 817..832 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 833..835 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 838..841 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 844..852 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 865..874 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 879..881 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 885..897 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 935..941 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 945..947 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 948..953 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 959..962 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 967..973 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 978..995 FT /evidence="ECO:0007829|PDB:1UCV" SQ SEQUENCE 1005 AA; 111003 MW; 6FBF85535E4212B3 CRC64; MAPARGRLPP ALWVVTAAAA AATCVSAARG EVNLLDTSTI HGDWGWLTYP AHGWDSINEV DESFQPIHTY QVCNVMSPNQ NNWLRTSWVP RDGARRVYAE IKFTLRDCNS MPGVLGTCKE TFNLYYLESD RDLGASTQES QFLKIDTIAA DESFTGADLG VRRLKLNTEV RSVGPLSKRG FYLAFQDIGA CLAILSLRIY YKKCPAMVRN LAAFSEAVTG ADSSSLVEVR GQCVRHSEER DTPKMYCSAE GEWLVPIGKC VCSAGYEERR DACVACELGF YKSAPGDQLC ARCPPHSHSA APAAQACHCD LSYYRAALDP PSSACTRPPS APVNLISSVN GTSVTLEWAP PLDPGGRSDI TYNAVCRRCP WALSRCEACG SGTRFVPQQT SLVQASLLVA NLLAHMNYSF WIEAVNGVSD LSPEPRRAAV VNITTNQAAP SQVVVIRQER AGQTSVSLLW QEPEQPNGII LEYEIKYYEK DKEMQSYSTL KAVTTRATVS GLKPGTRYVF QVRARTSAGC GRFSQAMEVE TGKPRPRYDT RTIVWICLTL ITGLVVLLLL LICKKRHCGY SKAFQDSDEE KMHYQNGQAP PPVFLPLHHP PGKLPEPQFY AEPHTYEEPG RAGRSFTREI EASRIHIEKI IGSGDSGEVC YGRLRVPGQR DVPVAIKALK AGYTERQRRD FLSEASIMGQ FDHPNIIRLE GVVTRGRLAM IVTEYMENGS LDTFLRTHDG QFTIMQLVGM LRGVGAGMRY LSDLGYVHRD LAARNVLVDS NLVCKVSDFG LSRVLEDDPD AAYTTTGGKI PIRWTAPEAI AFRTFSSASD VWSFGVVMWE VLAYGERPYW NMTNRDVISS VEEGYRLPAP MGCPHALHQL MLDCWHKDRA QRPRFSQIVS VLDALIRSPE SLRATATVSR CPPPAFVRSC FDLRGGSGGG GGLTVGDWLD SIRMGRYRDH FAAGGYSSLG MVLRMNAQDV RALGITLMGH QKKILGSIQT MRAQLTSTQG PRRHL // ID EPHAA_HUMAN Reviewed; 1008 AA. AC Q5JZY3; A4FU89; J3KPB5; Q6NW42; DT 27-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 03-APR-2013, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Ephrin type-A receptor 10; DE EC=2.7.10.1; DE Flags: Precursor; GN Name=EPHA10; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), RP ALTERNATIVE SPLICING, FUNCTION, AND TISSUE SPECIFICITY. RC TISSUE=Testis; RX PubMed=15777695; DOI=10.1016/j.bbagen.2005.01.011; RA Aasheim H.-C., Patzke S., Hjorthaug H.S., Finne E.F.; RT "Characterization of a novel Eph receptor tyrosine kinase, EphA10, RT expressed in testis."; RL Biochim. Biophys. Acta 1723:1-7(2005). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 501-1008 (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INVOLVEMENT IN DFNA88. RX PubMed=36048850; DOI=10.1093/hmg/ddac223; RA Huang S., Ma L., Liu X., He C., Li J., Hu Z., Jiang L., Liu Y., Liu X., RA Feng Y., Cai X.; RT "A non-coding variant in 5' untranslated region drove up-regulation of RT pseudo-kinase EPHA10 and caused non-syndromic hearing loss in humans."; RL Hum. Mol. Genet. 32:720-731(2023). RN [5] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-150; LYS-220; ILE-281; PRO-630; ARG-775 RP AND THR-956. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor for members of the ephrin-A family. Binds to EFNA3, CC EFNA4 and EFNA5. {ECO:0000269|PubMed:15777695}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC -!- INTERACTION: CC Q5JZY3-3; Q8N9N5: BANP; NbExp=3; IntAct=EBI-10244652, EBI-744695; CC Q5JZY3-3; Q13557: CAMK2D; NbExp=3; IntAct=EBI-10244652, EBI-351018; CC Q5JZY3-3; Q13643: FHL3; NbExp=3; IntAct=EBI-10244652, EBI-741101; CC Q5JZY3-3; Q12800: TFCP2; NbExp=3; IntAct=EBI-10244652, EBI-717422; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane {ECO:0000305}; Single- CC pass type I membrane protein {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane {ECO:0000305}; Single- CC pass type I membrane protein {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q5JZY3-1; Sequence=Displayed; CC Name=2; Synonyms=Epha10s; CC IsoId=Q5JZY3-2; Sequence=VSP_015772, VSP_015773; CC Name=3; Synonyms=Epha10*; CC IsoId=Q5JZY3-3; Sequence=VSP_015774, VSP_015775; CC -!- TISSUE SPECIFICITY: Mainly expressed in testis. CC {ECO:0000269|PubMed:15777695}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- DISEASE: Deafness, autosomal dominant, 88 (DFNA88) [MIM:620283]: A form CC of non-syndromic, sensorineural hearing loss. Sensorineural hearing CC loss results from damage to the neural receptors of the inner ear, the CC nerve pathways to the brain, or the area of the brain that receives CC sound information. DFNA88 is characterized by postlingual, progressive CC and severe hearing loss with tinnitus. {ECO:0000269|PubMed:36048850}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAI12934.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ872185; CAI43321.1; -; Genomic_DNA. DR EMBL; AJ781169; CAG77605.1; -; mRNA. DR EMBL; AC104336; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC067734; AAH67734.1; -; mRNA. DR EMBL; BC112933; AAI12934.1; ALT_INIT; mRNA. DR CCDS; CCDS41305.1; -. [Q5JZY3-1] DR CCDS; CCDS425.1; -. [Q5JZY3-2] DR RefSeq; NP_001092909.1; NM_001099439.2. [Q5JZY3-1] DR RefSeq; NP_775912.2; NM_173641.3. [Q5JZY3-2] DR AlphaFoldDB; Q5JZY3; -. DR SMR; Q5JZY3; -. DR BioGRID; 129927; 85. DR FunCoup; Q5JZY3; 264. DR IntAct; Q5JZY3; 84. DR STRING; 9606.ENSP00000362139; -. DR ChEMBL; CHEMBL2363043; -. DR GlyCosmos; Q5JZY3; 2 sites, No reported glycans. DR GlyGen; Q5JZY3; 2 sites. DR iPTMnet; Q5JZY3; -. DR PhosphoSitePlus; Q5JZY3; -. DR BioMuta; EPHA10; -. DR DMDM; 476007830; -. DR jPOST; Q5JZY3; -. DR MassIVE; Q5JZY3; -. DR PaxDb; 9606-ENSP00000362139; -. DR PeptideAtlas; Q5JZY3; -. DR ProteomicsDB; 63538; -. [Q5JZY3-1] DR ProteomicsDB; 63539; -. [Q5JZY3-2] DR ProteomicsDB; 63540; -. [Q5JZY3-3] DR Antibodypedia; 51311; 274 antibodies from 31 providers. DR DNASU; 284656; -. DR Ensembl; ENST00000319637.6; ENSP00000316395.6; ENSG00000183317.18. [Q5JZY3-2] DR Ensembl; ENST00000373048.9; ENSP00000362139.4; ENSG00000183317.18. [Q5JZY3-1] DR GeneID; 284656; -. DR KEGG; hsa:284656; -. DR MANE-Select; ENST00000373048.9; ENSP00000362139.4; NM_001099439.2; NP_001092909.1. DR UCSC; uc001cbw.5; human. [Q5JZY3-1] DR AGR; HGNC:19987; -. DR ClinPGx; PA134938798; -. DR CTD; 284656; -. DR DisGeNET; 284656; -. DR GeneCards; EPHA10; -. DR HGNC; HGNC:19987; EPHA10. DR HPA; ENSG00000183317; Tissue enhanced (brain, intestine, testis). DR MalaCards; EPHA10; -. DR MIM; 611123; gene. DR MIM; 620283; phenotype. DR OpenTargets; ENSG00000183317; -. DR VEuPathDB; HostDB:ENSG00000183317; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160752; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; Q5JZY3; -. DR OMA; ATQLVCM; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q5JZY3; 8 GO annotations based on evolutionary models. DR PathwayCommons; Q5JZY3; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; Q5JZY3; -. DR SIGNOR; Q5JZY3; -. DR Agora; ENSG00000183317; -. DR BioGRID-ORCS; 284656; 11 hits in 1186 CRISPR screens. DR ChiTaRS; EPHA10; human. DR GeneWiki; EPHA10; -. DR GenomeRNAi; 284656; -. DR Pharos; Q5JZY3; Tbio. DR PRO; PR:Q5JZY3; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q5JZY3; protein. DR Bgee; ENSG00000183317; Expressed in sperm and 129 other cell types or tissues. DR ExpressionAtlas; Q5JZY3; baseline and differential. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IBA:GO_Central. DR CDD; cd10487; EphR_LBD_A10; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05064; PTKc_EphR_A10; 1. DR FunFam; 1.10.510.10:FF:000360; Ephrin type-A receptor 10; 1. DR FunFam; 2.60.40.10:FF:001125; Ephrin type-A receptor 10; 1. DR FunFam; 1.10.150.50:FF:000066; ephrin type-A receptor 10; 1. DR FunFam; 3.30.200.20:FF:000505; ephrin type-A receptor 10; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF16; EPHRIN TYPE-A RECEPTOR 10; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF07647; SAM_2; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell membrane; Deafness; Glycoprotein; KW Kinase; Membrane; Non-syndromic deafness; Nucleotide-binding; KW Proteomics identification; Receptor; Reference proteome; Repeat; Secreted; KW Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase. FT SIGNAL 1..33 FT /evidence="ECO:0000255" FT CHAIN 34..1008 FT /note="Ephrin type-A receptor 10" FT /id="PRO_0000042157" FT TOPO_DOM 34..565 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 566..586 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 587..1008 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 35..216 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 340..452 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 456..554 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 645..900 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 933..997 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 322..342 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 311 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 486 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 284..295 FT /note="ACPPGFYKVSPR -> GIQLAGGRGVGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:15777695" FT /id="VSP_015772" FT VAR_SEQ 296..1008 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:15777695" FT /id="VSP_015773" FT VAR_SEQ 889..892 FT /note="ERPR -> LPPH (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_015774" FT VAR_SEQ 893..1008 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_015775" FT VARIANT 103 FT /note="V -> L (in dbSNP:rs34557762)" FT /id="VAR_055992" FT VARIANT 150 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs771803475)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042159" FT VARIANT 220 FT /note="T -> K (in dbSNP:rs56276182)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042160" FT VARIANT 281 FT /note="F -> I (in dbSNP:rs4653328)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042161" FT VARIANT 629 FT /note="L -> P (in dbSNP:rs17511304)" FT /id="VAR_055993" FT VARIANT 630 FT /note="L -> P (in dbSNP:rs1645827659)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042162" FT VARIANT 645 FT /note="V -> I (in dbSNP:rs12405650)" FT /id="VAR_055994" FT VARIANT 749 FT /note="G -> E (in dbSNP:rs6671088)" FT /id="VAR_055995" FT VARIANT 775 FT /note="H -> R (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042163" FT VARIANT 807 FT /note="R -> Q (in dbSNP:rs6670599)" FT /id="VAR_055996" FT VARIANT 956 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042164" FT CONFLICT 458 FT /note="D -> G (in Ref. 1; CAI43321)" FT /evidence="ECO:0000305" FT CONFLICT 503 FT /note="T -> A (in Ref. 1; CAI43321)" FT /evidence="ECO:0000305" SQ SEQUENCE 1008 AA; 109716 MW; 82D60740B7B6B9BD CRC64; METCAGPHPL RLFLCRMQLC LALLLGPWRP GTAEEVILLD SKASQAELGW TALPSNGWEE ISGVDEHDRP IRTYQVCNVL EPNQDNWLQT GWISRGRGQR IFVELQFTLR DCSSIPGAAG TCKETFNVYY LETEADLGRG RPRLGGSRPR KIDTIAADES FTQGDLGERK MKLNTEVREI GPLSRRGFHL AFQDVGACVA LVSVRVYYKQ CRATVRGLAT FPATAAESAF STLVEVAGTC VAHSEGEPGS PPRMHCGADG EWLVPVGRCS CSAGFQERGD FCEACPPGFY KVSPRRPLCS PCPEHSRALE NASTFCVCQD SYARSPTDPP SASCTRPPSA PRDLQYSLSR SPLVLRLRWL PPADSGGRSD VTYSLLCLRC GREGPAGACE PCGPRVAFLP RQAGLRERAA TLLHLRPGAR YTVRVAALNG VSGPAAAAGT TYAQVTVSTG PGAPWEEDEI RRDRVEPQSV SLSWREPIPA GAPGANDTEY EIRYYEKGQS EQTYSMVKTG APTVTVTNLK PATRYVFQIR AASPGPSWEA QSFNPSIEVQ TLGEAASGSR DQSPAIVVTV VTISALLVLG SVMSVLAIWR RPCSYGKGGG DAHDEEELYF HFKVPTRRTF LDPQSCGDLL QAVHLFAKEL DAKSVTLERS LGGGRFGELC CGCLQLPGRQ ELLVAVHMLR DSASDSQRLG FLAEALTLGQ FDHSHIVRLE GVVTRGSTLM IVTEYMSHGA LDGFLRRHEG QLVAGQLMGL LPGLASAMKY LSEMGYVHRG LAARHVLVSS DLVCKISGFG RGPRDRSEAV YTTMSGRSPA LWAAPETLQF GHFSSASDVW SFGIIMWEVM AFGERPYWDM SGQDVIKAVE DGFRLPPPRN CPNLLHRLML DCWQKDPGER PRFSQIHSIL SKMVQDPEPP KCALTTCPRP PTPLADRAFS TFPSFGSVGA WLEALDLCRY KDSFAAAGYG SLEAVAEMTA QDLVSLGISL AEHREALLSG ISALQARVLQ LQGQGVQV // ID EPHB4_HUMAN Reviewed; 987 AA. AC P54760; B5A970; B5A971; B5A972; Q7Z635; Q9BTA5; Q9BXP0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=Ephrin type-B receptor 4; DE EC=2.7.10.1; DE AltName: Full=Hepatoma transmembrane kinase; DE AltName: Full=Tyrosine-protein kinase TYRO11; DE Flags: Precursor; GN Name=EPHB4; Synonyms=HTK, MYK1, TYRO11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=8188704; DOI=10.1016/s0021-9258(17)36776-5; RA Bennett B.D., Wang Z., Kuang W.J., Wang A., Groopman J.E., Goeddel D.V., RA Scadden D.T.; RT "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase RT of the EPH subfamily."; RL J. Biol. Chem. 269:14211-14218(1994). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11239002; DOI=10.1093/nar/29.6.1352; RA Wilson M.D., Riemer C., Martindale D.W., Schnupf P., Boright A.P., RA Cheung T.L., Hardy D.M., Schwartz S., Scherer S.W., Tsui L.-C., Miller W., RA Koop B.F.; RT "Comparative analysis of the gene-dense ACHE/TFR2 region on human RT chromosome 7q22 with the orthologous region on mouse chromosome 5."; RL Nucleic Acids Res. 29:1352-1365(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-162. RC TISSUE=Ovary, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=12734395; DOI=10.1242/jcs.00426; RA Fueller T., Korff T., Kilian A., Dandekar G., Augustin H.G.; RT "Forward EphB4 signaling in endothelial cells controls cellular repulsion RT and segregation from ephrinB2 positive cells."; RL J. Cell Sci. 116:2461-2470(2003). RN [7] RP FUNCTION IN ANGIOGENESIS. RX PubMed=16424904; DOI=10.1038/sj.emboj.7600949; RA Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J., RA Hammes H.P., Grobholz R., Ullrich A., Vajkoczy P.; RT "EphB4 controls blood vascular morphogenesis during postnatal RT angiogenesis."; RL EMBO J. 25:628-641(2006). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-976, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911; THR-976 AND TYR-987, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769; SER-770 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-943, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 17-196 IN COMPLEX WITH EFNB2, RP MUTAGENESIS OF LEU-95, AND DISULFIDE BOND. RX PubMed=16867992; DOI=10.1074/jbc.m605766200; RA Chrencik J.E., Brooun A., Kraus M.L., Recht M.I., Kolatkar A.R., Han G.W., RA Seifert J.M., Widmer H., Auer M., Kuhn P.; RT "Structural and biophysical characterization of the EphB4*ephrinB2 protein- RT protein interaction and receptor specificity."; RL J. Biol. Chem. 281:28185-28192(2006). RN [16] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 17-196 IN COMPLEX WITH RP ANTAGONISTIC PEPTIDE, AND DISULFIDE BOND. RX PubMed=16472751; DOI=10.1016/j.str.2005.11.011; RA Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R., RA Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P.; RT "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 RT antagonist peptide complex reveals the determinants for receptor RT specificity."; RL Structure 14:321-330(2006). RN [17] RP STRUCTURE BY NMR OF 434-529. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain from human ephrin type-B RT receptor 4."; RL Submitted (JUL-2007) to the PDB data bank. RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-67; ILE-113; LEU-346; VAL-371; GLU-576; RP HIS-678; THR-882; TRP-889 AND ASP-890. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [19] RP INVOLVEMENT IN LMPHM7, VARIANTS LMPHM7 GLN-739 AND SER-782, RP CHARACTERIZATION OF VARIANTS LMPHM7 GLU-739 AND SER-782, AND FUNCTION. RX PubMed=27400125; DOI=10.1172/jci85794; RA Martin-Almedina S., Martinez-Corral I., Holdhus R., Vicente A., Fotiou E., RA Lin S., Petersen K., Simpson M.A., Hoischen A., Gilissen C., Jeffery H., RA Atton G., Karapouliou C., Brice G., Gordon K., Wiseman J.W., Wedin M., RA Rockson S.G., Jeffery S., Mortimer P.S., Snyder M.P., Berland S., RA Mansour S., Makinen T., Ostergaard P.; RT "EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic- RT related hydrops fetalis."; RL J. Clin. Invest. 126:3080-3088(2016). RN [20] RP VARIANTS CMAVM2 LYS-59; PRO-74; TYR-115 DEL; 130-TRP--TYR-987 DEL; RP 161-VAL-LYS-162 DELINS LEU; PRO-187; 244-GLN--TYR-987 DEL; ARG-268; RP 352-ARG--TYR-987 DEL; 375-GLY--TYR-987 DEL; 431-ARG--TYR-987 DEL; GLY-469; RP ARG-516; 520-GLN--TYR-987 DEL; 596-TYR--TYR-987 DEL; TRP-656; LYS-664; RP THR-725; 739-ARG--TYR-987 DEL; ASP-745; ARG-789; SER-789; 806-TYR--TYR-987 RP DEL; ARG-807; LEU-820; THR-820; TRP-838; ARG-845; TYR-856; TRP-864 AND RP PRO-874, CHARACTERIZATION OF VARIANTS CMAVM2 LYS-664; TRP-838; ARG-845 AND RP TRP-864, INVOLVEMENT IN CMAVM2, AND SUBCELLULAR LOCATION. RX PubMed=28687708; DOI=10.1161/circulationaha.116.026886; RA Amyere M., Revencu N., Helaers R., Pairet E., Baselga E., Cordisco M., RA Chung W., Dubois J., Lacour J.P., Martorell L., Mazereeuw-Hautier J., RA Pyeritz R.E., Amor D.J., Bisdorff A., Blei F., Bombei H., Dompmartin A., RA Brooks D., Dupont J., Gonzalez-Ensenat M.A., Frieden I., Gerard M., RA Kvarnung M., Hanson-Kahn A.K., Hudgins L., Leaute-Labreze C., McCuaig C., RA Metry D., Parent P., Paul C., Petit F., Phan A., Quere I., Salhi A., RA Turner A., Vabres P., Vicente A., Wargon O., Watanabe S., Weibel L., RA Wilson A., Willing M., Mulliken J.B., Boon L.M., Vikkula M.; RT "Germline loss-of-function mutations in EPHB4 cause a second form of RT capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RT RAS-MAPK signaling."; RL Circulation 136:1037-1048(2017). RN [21] RP VARIANT CMAVM2 GLY-802, AND INVOLVEMENT IN CMAVM2. RX PubMed=28730721; DOI=10.1111/pde.13208; RA Yu J., Streicher J.L., Medne L., Krantz I.D., Yan A.C.; RT "EPHB4 mutation implicated in capillary malformation-arteriovenous RT malformation syndrome: A case report."; RL Pediatr. Dermatol. 34:E227-E230(2017). RN [22] RP VARIANTS CMAVM2 ARG-107 AND GLU-870, AND INVOLVEMENT IN CMAVM2. RX PubMed=29444212; DOI=10.1093/brain/awy020; RA Vivanti A., Ozanne A., Grondin C., Saliou G., Quevarec L., Maurey H., RA Aubourg P., Benachi A., Gut M., Gut I., Martinovic J., Senat M.V., Tawk M., RA Melki J.; RT "Loss of function mutations in EPHB4 are responsible for vein of Galen RT aneurysmal malformation."; RL Brain 141:979-988(2018). RN [23] RP VARIANT GLY-509, CHARACTERIZATION OF VARIANT GLY-509, VARIANTS CMAVM2 RP ASN-650 AND LEU-867, CHARACTERIZATION OF VARIANTS CMAVM2 ASN-650 AND RP LEU-867, INVOLVEMENT IN CMAVM2, FUNCTION, AND INTERACTION WITH RASA1. RX PubMed=30578106; DOI=10.1016/j.neuron.2018.11.041; RA Duran D., Zeng X., Jin S.C., Choi J., Nelson-Williams C., Yatsula B., RA Gaillard J., Furey C.G., Lu Q., Timberlake A.T., Dong W., Sorscher M.A., RA Loring E., Klein J., Allocco A., Hunt A., Conine S., Karimy J.K., RA Youngblood M.W., Zhang J., DiLuna M.L., Matouk C.C., Mane S., RA Tikhonova I.R., Castaldi C., Lopez-Giraldez F., Knight J., Haider S., RA Soban M., Alper S.L., Komiyama M., Ducruet A.F., Zabramski J.M., Dardik A., RA Walcott B.P., Stapleton C.J., Aagaard-Kienitz B., Rodesch G., Jackson E., RA Smith E.R., Orbach D.B., Berenstein A., Bilguvar K., Vikkula M., Gunel M., RA Lifton R.P., Kahle K.T.; RT "Mutations in chromatin modifier and ephrin signaling genes in vein of RT Galen malformation."; RL Neuron 101:429-443(2019). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Together with its CC cognate ligand/functional ligand EFNB2 it is involved in the regulation CC of cell adhesion and migration, and plays a central role in heart CC morphogenesis, angiogenesis and blood vessel remodeling and CC permeability. EPHB4-mediated forward signaling controls cellular CC repulsion and segregation from EFNB2-expressing cells. CC {ECO:0000269|PubMed:12734395, ECO:0000269|PubMed:16424904, CC ECO:0000269|PubMed:27400125, ECO:0000269|PubMed:30578106}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with RASA1; the interaction depends on EPHB4 tyrosine- CC phosphorylation (PubMed:30578106). {ECO:0000250, CC ECO:0000269|PubMed:30578106}. CC -!- INTERACTION: CC P54760; P52799: EFNB2; NbExp=7; IntAct=EBI-702121, EBI-7532268; CC P54760; P54756: EPHA5; NbExp=2; IntAct=EBI-702121, EBI-1383718; CC P54760; Q9UF33: EPHA6; NbExp=2; IntAct=EBI-702121, EBI-3950019; CC P54760; Q15375: EPHA7; NbExp=3; IntAct=EBI-702121, EBI-1383428; CC P54760; P01588: EPO; NbExp=6; IntAct=EBI-702121, EBI-1027362; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28687708, CC ECO:0000269|PubMed:8188704}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:8188704}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P54760-1; Sequence=Displayed; CC Name=2; CC IsoId=P54760-2; Sequence=VSP_056024, VSP_056025; CC Name=3; CC IsoId=P54760-3; Sequence=VSP_056020, VSP_056021; CC Name=4; CC IsoId=P54760-4; Sequence=VSP_056022, VSP_056023; CC -!- TISSUE SPECIFICITY: Abundantly expressed in placenta but also detected CC in kidney, liver, lung, pancreas, skeletal muscle and heart. Expressed CC in primitive and myeloid, but not lymphoid, hematopoietic cells. Also CC observed in cell lines derived from liver, breast, colon, lung, CC melanocyte and cervix. {ECO:0000269|PubMed:8188704}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal heart, lung, liver and to a CC lower extent in brain. Not expressed in adult brain. CC {ECO:0000269|PubMed:8188704}. CC -!- PTM: Phosphorylated; autophosphorylation is stimulated by EFNB2. CC -!- DISEASE: Lymphatic malformation 7 (LMPHM7) [MIM:617300]: A form of CC primary lymphedema, a disease characterized by swelling of body parts CC due to developmental anomalies and functional defects of the lymphatic CC system. Patients with lymphedema may suffer from recurrent local CC infections. LMPHM7 is an autosomal dominant form with variable CC expressivity. Some individuals present with severe non-immune hydrops CC fetalis, which may cause perinatal demise or fully resolve after the CC neonatal period. Others present with no edema and have milder clinical CC features, such as atrial septal defect or varicose veins as adults. CC {ECO:0000269|PubMed:27400125}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Capillary malformation-arteriovenous malformation 2 (CMAVM2) CC [MIM:618196]: An autosomal dominant disorder characterized by multiple, CC round to oval or more irregularly shaped macules that are pinkish red CC in color and are randomly distributed across the body. These capillary CC malformations are associated with either arteriovenous malformation, CC arteriovenous fistula, or Parkes Weber syndrome. CC {ECO:0000269|PubMed:28687708, ECO:0000269|PubMed:28730721, CC ECO:0000269|PubMed:29444212, ECO:0000269|PubMed:30578106}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07695; AAA20598.1; -; mRNA. DR EMBL; AF312032; AAK21010.1; -; Genomic_DNA. DR EMBL; EU826608; ACF47644.1; -; mRNA. DR EMBL; EU826609; ACF47645.1; -; mRNA. DR EMBL; EU826610; ACF47646.1; -; mRNA. DR EMBL; BC004264; AAH04264.1; -; mRNA. DR EMBL; BC052804; AAH52804.1; -; mRNA. DR CCDS; CCDS5706.1; -. [P54760-1] DR PIR; A54092; A54092. DR RefSeq; NP_004435.3; NM_004444.4. [P54760-1] DR PDB; 2BBA; X-ray; 1.65 A; A=17-196. DR PDB; 2E7H; NMR; -; A=434-529. DR PDB; 2HLE; X-ray; 2.05 A; A=17-196. DR PDB; 2QKQ; X-ray; 2.10 A; A/B=896-977. DR PDB; 2VWU; X-ray; 2.00 A; A=598-899. DR PDB; 2VWV; X-ray; 1.90 A; A=598-899. DR PDB; 2VWW; X-ray; 1.90 A; A=598-899. DR PDB; 2VWX; X-ray; 1.65 A; A=598-899. DR PDB; 2VWY; X-ray; 1.65 A; A=598-899. DR PDB; 2VWZ; X-ray; 1.65 A; A=598-899. DR PDB; 2VX0; X-ray; 2.10 A; A=598-899. DR PDB; 2VX1; X-ray; 1.65 A; A=598-899. DR PDB; 2X9F; X-ray; 1.75 A; A=598-899. DR PDB; 2XVD; X-ray; 1.70 A; A=598-899. DR PDB; 2YN8; X-ray; 2.11 A; A/B=598-892. DR PDB; 3ZEW; X-ray; 2.50 A; A/B=598-892. DR PDB; 4AW5; X-ray; 2.33 A; A=605-890. DR PDB; 4BB4; X-ray; 1.65 A; A=598-899. DR PDB; 6FNI; X-ray; 1.47 A; A=598-892. DR PDB; 6FNJ; X-ray; 1.24 A; A/B=598-892. DR PDB; 6FNK; X-ray; 1.05 A; A=598-892. DR PDB; 6FNL; X-ray; 1.27 A; A=598-892. DR PDB; 6FNM; X-ray; 1.16 A; A=598-892. DR PDBsum; 2BBA; -. DR PDBsum; 2E7H; -. DR PDBsum; 2HLE; -. DR PDBsum; 2QKQ; -. DR PDBsum; 2VWU; -. DR PDBsum; 2VWV; -. DR PDBsum; 2VWW; -. DR PDBsum; 2VWX; -. DR PDBsum; 2VWY; -. DR PDBsum; 2VWZ; -. DR PDBsum; 2VX0; -. DR PDBsum; 2VX1; -. DR PDBsum; 2X9F; -. DR PDBsum; 2XVD; -. DR PDBsum; 2YN8; -. DR PDBsum; 3ZEW; -. DR PDBsum; 4AW5; -. DR PDBsum; 4BB4; -. DR PDBsum; 6FNI; -. DR PDBsum; 6FNJ; -. DR PDBsum; 6FNK; -. DR PDBsum; 6FNL; -. DR PDBsum; 6FNM; -. DR AlphaFoldDB; P54760; -. DR BMRB; P54760; -. DR SASBDB; P54760; -. DR SMR; P54760; -. DR BioGRID; 108364; 154. DR FunCoup; P54760; 1222. DR IntAct; P54760; 108. DR MINT; P54760; -. DR STRING; 9606.ENSP00000350896; -. DR BindingDB; P54760; -. DR ChEMBL; CHEMBL5147; -. DR DrugBank; DB07256; 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE. DR DrugBank; DB07252; 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07251; N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE. DR DrugBank; DB07250; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07253; N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine. DR DrugBank; DB07255; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07249; N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine. DR DrugBank; DB07254; N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE. DR DrugBank; DB11973; Tesevatinib. DR DrugCentral; P54760; -. DR GuidetoPHARMACOLOGY; 1833; -. DR TCDB; 8.A.23.1.15; the basigin (basigin) family. DR GlyConnect; 1214; 3 N-Linked glycans (1 site). DR GlyCosmos; P54760; 3 sites, 3 glycans. DR GlyGen; P54760; 4 sites, 10 N-linked glycans (3 sites). DR iPTMnet; P54760; -. DR PhosphoSitePlus; P54760; -. DR SwissPalm; P54760; -. DR BioMuta; EPHB4; -. DR DMDM; 19860819; -. DR CPTAC; CPTAC-2788; -. DR CPTAC; CPTAC-2841; -. DR CPTAC; CPTAC-2919; -. DR jPOST; P54760; -. DR MassIVE; P54760; -. DR PaxDb; 9606-ENSP00000350896; -. DR PeptideAtlas; P54760; -. DR ProteomicsDB; 56715; -. [P54760-1] DR Pumba; P54760; -. DR Antibodypedia; 4623; 752 antibodies from 43 providers. DR CPTC; P54760; 2 antibodies. DR DNASU; 2050; -. DR Ensembl; ENST00000358173.8; ENSP00000350896.3; ENSG00000196411.11. [P54760-1] DR Ensembl; ENST00000616502.4; ENSP00000482702.1; ENSG00000196411.11. [P54760-3] DR GeneID; 2050; -. DR KEGG; hsa:2050; -. DR MANE-Select; ENST00000358173.8; ENSP00000350896.3; NM_004444.5; NP_004435.3. DR UCSC; uc011kkg.2; human. [P54760-1] DR AGR; HGNC:3395; -. DR CIViC; 2050; 1 evidence item across 1 molecular profile. DR ClinPGx; PA27827; -. DR CTD; 2050; -. DR DisGeNET; 2050; -. DR GeneCards; EPHB4; -. DR GeneReviews; EPHB4; -. DR HGNC; HGNC:3395; EPHB4. DR HPA; ENSG00000196411; Low tissue specificity. DR MalaCards; EPHB4; -. DR MIM; 600011; gene. DR MIM; 617300; phenotype. DR MIM; 618196; phenotype. DR OpenTargets; ENSG00000196411; -. DR Orphanet; 693912; EPHB4-related capillary malformation-arteriovenous malformation. DR Orphanet; 568065; EPHB4-related lymphatic-related hydrops fetalis. DR Orphanet; 90186; Meige disease. DR Orphanet; 1053; Vein of Galen aneurysmal malformation. DR VEuPathDB; HostDB:ENSG00000196411; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160057; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P54760; -. DR OMA; STKCRAC; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54760; 9 GO annotations based on evolutionary models. DR PhylomeDB; P54760; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54760; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54760; -. DR SIGNOR; P54760; -. DR Agora; ENSG00000196411; -. DR BioGRID-ORCS; 2050; 13 hits in 1190 CRISPR screens. DR ChiTaRS; EPHB4; human. DR EvolutionaryTrace; P54760; -. DR GeneWiki; EPH_receptor_B4; -. DR GenomeRNAi; 2050; -. DR Pharos; P54760; Tchem. DR PRO; PR:P54760; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P54760; protein. DR Bgee; ENSG00000196411; Expressed in olfactory bulb and 209 other cell types or tissues. DR ExpressionAtlas; P54760; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IDA:UniProt. DR GO; GO:0007155; P:cell adhesion; IDA:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IDA:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB. DR CDD; cd10474; EphR_LBD_B4; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09554; SAM_EPH-B4; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000071; Ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.10:FF:000787; ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.1770:FF:000003; ephrin type-B receptor 4; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR037636; EPH-B4_SAM. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034290; EphB4_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF19; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; ATP-binding; KW Cell membrane; Developmental protein; Disease variant; Disulfide bond; KW Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Repeat; Signal; KW Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..15 FT /evidence="ECO:0000255" FT CHAIN 16..987 FT /note="Ephrin type-B receptor 4" FT /id="PRO_0000016834" FT TOPO_DOM 16..539 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 540..560 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 561..987 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 17..202 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 323..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 436..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 615..899 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 907..971 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 965..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 985..987 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT COMPBIAS 976..987 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 769 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 911 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 943 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 976 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 335 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..184 FT DISULFID 97..107 FT VAR_SEQ 270..306 FT /note="ACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRV -> GRRGSQQRAVP FT EDVRKPGRAAGAEAGSQLPGAGTGAL (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056020" FT VAR_SEQ 307..987 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056021" FT VAR_SEQ 406..414 FT /note="VTALNGVSS -> YLLQCLTSG (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056022" FT VAR_SEQ 415..987 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056023" FT VAR_SEQ 507..516 FT /note="VRARSEAGYG -> RARAGGSSWP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056024" FT VAR_SEQ 517..987 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056025" FT VARIANT 59 FT /note="E -> K (in CMAVM2; uncertain significance; FT dbSNP:rs1584667224)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081689" FT VARIANT 67 FT /note="P -> L (in dbSNP:rs34653459)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042181" FT VARIANT 74 FT /note="R -> P (in CMAVM2; uncertain significance; FT dbSNP:rs61735971)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081690" FT VARIANT 107 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1562974383)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081691" FT VARIANT 113 FT /note="V -> I (in dbSNP:rs55866373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042182" FT VARIANT 115 FT /note="Missing (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081692" FT VARIANT 130..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081693" FT VARIANT 161..162 FT /note="VK -> L (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081694" FT VARIANT 162 FT /note="K -> R (in dbSNP:rs17854760)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_071163" FT VARIANT 187 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584666053)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081695" FT VARIANT 244..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081696" FT VARIANT 268 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs201816920)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081697" FT VARIANT 346 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267601191)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042183" FT VARIANT 352..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081698" FT VARIANT 371 FT /note="A -> V (in dbSNP:rs55720981)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042184" FT VARIANT 375..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081699" FT VARIANT 431..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081700" FT VARIANT 469 FT /note="V -> G (in CMAVM2; uncertain significance; FT dbSNP:rs1584662591)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081701" FT VARIANT 509 FT /note="A -> G (does not affect tyrosine phosphorylation; FT does not affect interaction with RASA1; dbSNP:rs146937374)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081702" FT VARIANT 516 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs776305185)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081703" FT VARIANT 520..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081704" FT VARIANT 576 FT /note="D -> E (in dbSNP:rs36050247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042185" FT VARIANT 596..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081705" FT VARIANT 650 FT /note="K -> N (in CMAVM2; highly decreased tyrosine FT phosphorylation; highly decreased interaction with RASA1; FT dbSNP:rs1584658113)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081706" FT VARIANT 656 FT /note="R -> W (in CMAVM2; uncertain significance; FT dbSNP:rs745584371)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081707" FT VARIANT 664 FT /note="E -> K (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1562969219)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081708" FT VARIANT 678 FT /note="R -> H (in dbSNP:rs55692440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042186" FT VARIANT 725 FT /note="A -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1159930961)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081709" FT VARIANT 739..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081710" FT VARIANT 739 FT /note="R -> Q (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519263)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078063" FT VARIANT 745 FT /note="N -> D (in CMAVM2; dbSNP:rs1584654433)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081711" FT VARIANT 782 FT /note="I -> S (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519264)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078064" FT VARIANT 789 FT /note="P -> R (in CMAVM2; uncertain significance; FT dbSNP:rs753075600)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081712" FT VARIANT 789 FT /note="P -> S (in CMAVM2; uncertain significance; FT dbSNP:rs1417508111)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081713" FT VARIANT 802 FT /note="D -> G (in CMAVM2; dbSNP:rs776410552)" FT /evidence="ECO:0000269|PubMed:28730721" FT /id="VAR_081714" FT VARIANT 806..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081715" FT VARIANT 807 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1330628156)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081716" FT VARIANT 820 FT /note="P -> L (in CMAVM2; uncertain significance; FT dbSNP:rs1584653650)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081717" FT VARIANT 820 FT /note="P -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1584653653)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081718" FT VARIANT 838 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs764827256)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081719" FT VARIANT 845 FT /note="C -> R (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1584653054)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081720" FT VARIANT 856 FT /note="C -> Y (in CMAVM2; dbSNP:rs1584653005)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081721" FT VARIANT 864 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs769965440)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081722" FT VARIANT 867 FT /note="F -> L (in CMAVM2; loss of tyrosine phosphorylation; FT loss of interaction with RASA1; dbSNP:rs1584652949)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081723" FT VARIANT 870 FT /note="V -> E (in CMAVM2; uncertain significance; FT dbSNP:rs1584652920)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081724" FT VARIANT 874 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584652900)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081725" FT VARIANT 882 FT /note="A -> T (in dbSNP:rs34918225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042187" FT VARIANT 889 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs762016655)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042188" FT VARIANT 890 FT /note="E -> D (in dbSNP:rs35638378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042189" FT MUTAGEN 95 FT /note="L->R: Reduces binding affinity for EFNB2." FT /evidence="ECO:0000269|PubMed:16867992" FT CONFLICT 62 FT /note="D -> E (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="Y -> D (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 464 FT /note="V -> W (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 926..927 FT /note="ES -> AR (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT STRAND 17..22 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 23..25 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 33..36 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 43..48 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 70..74 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 84..95 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 109..121 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 135..142 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2HLE" FT TURN 151..153 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 154..156 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 160..166 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 171..182 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 184..196 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 449..453 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 460..462 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 466..473 FT /evidence="ECO:0007829|PDB:2E7H" FT TURN 479..481 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 482..496 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 503..510 FT /evidence="ECO:0007829|PDB:2E7H" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 615..623 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 625..634 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:6FNJ" FT STRAND 642..649 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 655..668 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 679..683 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 685..694 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 701..707 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 708..710 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 761..763 FT /evidence="ECO:0007829|PDB:6FNI" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:2VWX" FT HELIX 784..786 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 789..794 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 799..814 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 815..817 FT /evidence="ECO:0007829|PDB:6FNI" FT TURN 820..823 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 826..834 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 847..856 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 861..863 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 867..879 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 881..884 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 912..918 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 922..924 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 925..930 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 936..939 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 944..950 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 955..965 FT /evidence="ECO:0007829|PDB:2QKQ" SQ SEQUENCE 987 AA; 108270 MW; 11A004622F194706 CRC64; MELRVLLCWA SLAAALEETL LNTKLETADL KWVTFPQVDG QWEELSGLDE EQHSVRTYEV CDVQRAPGQA HWLRTGWVPR RGAVHVYATL RFTMLECLSL PRAGRSCKET FTVFYYESDA DTATALTPAW MENPYIKVDT VAAEHLTRKR PGAEATGKVN VKTLRLGPLS KAGFYLAFQD QGACMALLSL HLFYKKCAQL TVNLTRFPET VPRELVVPVA GSCVVDAVPA PGPSPSLYCR EDGQWAEQPV TGCSCAPGFE AAEGNTKCRA CAQGTFKPLS GEGSCQPCPA NSHSNTIGSA VCQCRVGYFR ARTDPRGAPC TTPPSAPRSV VSRLNGSSLH LEWSAPLESG GREDLTYALR CRECRPGGSC APCGGDLTFD PGPRDLVEPW VVVRGLRPDF TYTFEVTALN GVSSLATGPV PFEPVNVTTD REVPPAVSDI RVTRSSPSSL SLAWAVPRAP SGAVLDYEVK YHEKGAEGPS SVRFLKTSEN RAELRGLKRG ASYLVQVRAR SEAGYGPFGQ EHHSQTQLDE SEGWREQLAL IAGTAVVGVV LVLVVIVVAV LCLRKQSNGR EAEYSDKHGQ YLIGHGTKVY IDPFTYEDPN EAVREFAKEI DVSYVKIEEV IGAGEFGEVC RGRLKAPGKK ESCVAIKTLK GGYTERQRRE FLSEASIMGQ FEHPNIIRLE GVVTNSMPVM ILTEFMENGA LDSFLRLNDG QFTVIQLVGM LRGIASGMRY LAEMSYVHRD LAARNILVNS NLVCKVSDFG LSRFLEENSS DPTYTSSLGG KIPIRWTAPE AIAFRKFTSA SDAWSYGIVM WEVMSFGERP YWDMSNQDVI NAIEQDYRLP PPPDCPTSLH QLMLDCWQKD RNARPRFPQV VSALDKMIRN PASLKIVARE NGGASHPLLD QRQPHYSAFG SVGEWLRAIK MGRYEESFAA AGFGSFELVS QISAEDLLRI GVTLAGHQKK ILASVQHMKS QAKPGTPGGT GGPAPQY // ID ERBB2_HUMAN Reviewed; 1255 AA. AC P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-1987, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Receptor tyrosine-protein kinase erbB-2; DE EC=2.7.10.1; DE AltName: Full=Metastatic lymph node gene 19 protein; DE Short=MLN 19; DE AltName: Full=Proto-oncogene Neu; DE AltName: Full=Proto-oncogene c-ErbB-2; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER2; DE AltName: Full=p185erbB2; DE AltName: CD_antigen=CD340; DE Flags: Precursor; GN Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003577; DOI=10.1038/319230a0; RA Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., RA Saito T., Toyoshima K.; RT "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal RT growth factor receptor."; RL Nature 319:230-234(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ALA-1170. RX PubMed=2999974; DOI=10.1126/science.2999974; RA Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., RA Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., RA Ullrich A.; RT "Tyrosine kinase receptor with extensive homology to EGF receptor shares RT chromosomal location with neu oncogene."; RL Science 230:1132-1139(1985). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND RP ALA-1170. RG NIEHS SNPs program; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A., RA Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y., RA Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T., RA Sugano S., Nomura N., Isogai T.; RT "NEDO human cDNA sequencing project focused on splicing variants."; RL Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1). RX PubMed=3039351; DOI=10.1128/mcb.7.7.2597-2601.1987; RA Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.; RT "Human HER2 (neu) promoter: evidence for multiple mechanisms for RT transcriptional initiation."; RL Mol. Cell. Biol. 7:2597-2601(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6). RC TISSUE=Fetal brain; RX PubMed=24722188; DOI=10.1038/ncomms4650; RA Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M., RA Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I., RA Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A., RA Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D., RA Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.; RT "Protein interaction network of alternatively spliced isoforms from brain RT links genetic risk factors for autism."; RL Nat. Commun. 5:3650-3650(2014). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031. RX PubMed=2995967; DOI=10.1073/pnas.82.19.6497; RA Semba K., Kamata N., Toyoshima K., Yamamoto T.; RT "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- RT 1/epidermal growth factor-receptor gene and is amplified in a human RT salivary gland adenocarcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909. RC TISSUE=Mammary carcinoma; RX PubMed=2992089; DOI=10.1126/science.2992089; RA King C.R., Kraus M.H., Aaronson S.A.; RT "Amplification of a novel v-erbB-related gene in a human mammary RT carcinoma."; RL Science 229:974-976(1985). RN [11] RP NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170. RX PubMed=8104414; DOI=10.1089/dna.1993.12.611; RA Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.; RT "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene."; RL DNA Cell Biol. 12:611-615(1993). RN [12] RP INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [13] RP IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A RP COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [14] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012; RA Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M., RA Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., Hung M.C.; RT "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine RT kinase receptor ErbB-2."; RL Cancer Cell 6:251-261(2004). RN [16] RP INTERACTION WITH PLXNB1. RX PubMed=15210733; DOI=10.1083/jcb.200312094; RA Swiercz J.M., Kuner R., Offermanns S.; RT "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine RT kinase ErbB-2."; RL J. Cell Biol. 165:869-880(2004). RN [17] RP INTERACTION WITH MEMO1. RX PubMed=15156151; DOI=10.1038/ncb1134; RA Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.; RT "Memo mediates ErbB2-driven cell motility."; RL Nat. Cell Biol. 6:515-522(2004). RN [18] RP SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH RP KPNB1; RANBP2; CRM1; EEA1 AND CLTC. RX PubMed=16314522; DOI=10.1128/mcb.25.24.11005-11018.2005; RA Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G., RA Wang S.C., Hung M.C.; RT "Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell RT surface receptor."; RL Mol. Cell. Biol. 25:11005-11018(2005). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [20] RP FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION, RP AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712. RX PubMed=16794579; DOI=10.1038/sj.emboj.7601191; RA Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., RA Baselga J., Arribas J.; RT "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative RT initiation of translation."; RL EMBO J. 25:3234-3244(2006). RN [21] RP INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [22] RP PHOSPHORYLATION AT TYR-1248. RX PubMed=17554007; DOI=10.1523/jneurosci.5381-06.2007; RA Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A., RA Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L., RA Offermanns S., Kuner R.; RT "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and RT patterning of the developing nervous system in vivo."; RL J. Neurosci. 27:6333-6347(2007). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP INTERACTION WITH PTK6, AND ACTIVITY REGULATION. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [26] RP FUNCTION IN NUCLEUS. RX PubMed=19372587; DOI=10.1158/1541-7786.mcr-08-0316; RA Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.; RT "ErbB2-mediated Src and signal transducer and activator of transcription 3 RT activation leads to transcriptional up-regulation of p21Cip1 and RT chemoresistance in breast cancer cells."; RL Mol. Cancer Res. 7:592-600(2009). RN [27] RP INTERACTION WITH CPNE3. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [28] RP FUNCTION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP CHROMOSOMAL REARRANGEMENT WITH CDK12. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [31] RP FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR RP LOCATION. RX PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504; RA Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y., RA Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H., RA Hung M.C.; RT "Nuclear ErbB2 enhances translation and cell growth by activating RT transcription of ribosomal RNA genes."; RL Cancer Res. 71:4269-4279(2011). RN [32] RP INTERACTION WITH EGFR. RX PubMed=21190959; DOI=10.1210/en.2010-0940; RA Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N., Qiu X., RA Kumar U.; RT "Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in RT the presence of somatostatin receptor 5 modulate signaling pathways."; RL Endocrinology 152:931-945(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083 AND RP THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [37] RP PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND RP DEPHOSPHORYLATION BY PTPN12. RX PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016; RA Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H., Wang W., RA Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z., Yi F., Sun J.P., RA Yu X.; RT "Crystal structure and substrate specificity of PTPN12."; RL Cell Rep. 15:1345-1358(2016). RN [38] RP INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION. RX PubMed=31138794; DOI=10.1038/s41467-019-10275-0; RA Pietilae M., Sahgal P., Peuhu E., Jaentti N.Z., Paatero I., Naervae E., RA Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., Padzik A., Sihto H., RA Joensuu H., Blomqvist M., Saarinen I., Bostroem P.J., Taimen P., Ivaska J.; RT "SORLA regulates endosomal trafficking and oncogenic fitness of HER2."; RL Nat. Commun. 10:2340-2340(2019). RN [39] RP INTERACTION WITH SH3BGRL, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP TYR-877 AND TYR-1196. RX PubMed=32381043; DOI=10.1186/s13046-020-01577-z; RA Li H., Zhang M., Wei Y., Haider F., Lin Y., Guan W., Liu Y., Zhang S., RA Yuan R., Yang X., Yang S., Wang H.; RT "SH3BGRL confers innate drug resistance in breast cancer by stabilizing RT HER2 activation on cell membrane."; RL J. Exp. Clin. Cancer Res. 39:81-81(2020). RN [40] RP SUBCELLULAR LOCATION. RX PubMed=34380438; DOI=10.1186/s12860-021-00379-1; RA Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C., RA Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S., RA Scartezzini P., Ghiotto F.; RT "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates RT migration in the MDA-MB-231 cell line."; RL BMC Mol. Cell Biol. 22:41-41(2021). RN [41] RP INTERACTION WITH ROR1. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND RP BETA-2 MICROGLOBULIN. RX PubMed=10593938; DOI=10.1074/jbc.274.51.36422; RA Kuhns J.J., Batalia M.A., Yan S., Collins E.J.; RT "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of RT interactions with the center of the peptide."; RL J. Biol. Chem. 274:36422-36427(1999). RN [43] RP X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH ERBIN, RP AND INTERACTION WITH ERBIN. RX PubMed=12444095; DOI=10.1074/jbc.c200571200; RA Birrane G., Chung J., Ladias J.A.; RT "Novel mode of ligand recognition by the Erbin PDZ domain."; RL J. Biol. Chem. 278:1399-1402(2003). RN [44] RP STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION WITH RP GRB7. RX PubMed=12975581; DOI=10.1023/a:1025498409113; RA Ivancic M., Daly R.J., Lyons B.A.; RT "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and RT structural basis for Grb7 binding to ErbB2."; RL J. Biomol. NMR 27:205-219(2003). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN. RX PubMed=12610629; DOI=10.1038/nature01392; RA Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., RA Denney D.W. Jr., Leahy D.J.; RT "Structure of the extracellular region of HER2 alone and in complex with RT the Herceptin Fab."; RL Nature 421:756-760(2003). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF RP 317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187; ASN-259 AND RP ASN-530. RX PubMed=15093539; DOI=10.1016/s1535-6108(04)00083-2; RA Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., RA Sliwkowski M.X.; RT "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab RT complex."; RL Cancer Cell 5:317-328(2004). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND RP ASN-530. RX PubMed=19299620; DOI=10.1126/science.1165480; RA Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., RA Peale F., Ross S., Wiesmann C., Fuh G.; RT "Variants of the antibody herceptin that interact with HER2 and VEGF at the RT antigen binding site."; RL Science 323:1610-1614(2009). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH ENGINEERED RP ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-68; ASN-259 AND RP ASN-571. RX PubMed=20696930; DOI=10.1073/pnas.1005025107; RA Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.; RT "Structural basis for high-affinity HER2 receptor binding by an engineered RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH RP INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION. RX PubMed=21454582; DOI=10.1074/jbc.m110.206193; RA Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G., Jennings A., RA Iwamoto K., Habuka N., Hirokawa A., Ishikawa T., Tanaka T., Miki H., RA Ohta Y., Sogabe S.; RT "Structural analysis of the mechanism of inhibition and allosteric RT activation of the kinase domain of HER2 protein."; RL J. Biol. Chem. 286:18756-18765(2011). RN [50] RP VARIANTS VAL-654 AND VAL-655. RX PubMed=8095488; DOI=10.1006/geno.1993.1081; RA Ehsani A., Low J., Wallace R.B., Wu A.M.; RT "Characterization of a new allele of the human ERBB2 gene by allele- RT specific competition hybridization."; RL Genomics 15:426-429(1993). RN [51] RP INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857, VARIANT RP GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774 INS AND RP VAL-GLY-SER-779 INS. RX PubMed=15457249; DOI=10.1038/431525b; RG Cancer genome project and collaborative group; RA Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., RA Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M., RA Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A., RA Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K., RA Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K., RA Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J., RA West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., RA Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B., RA Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T., RA Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R., RA Stratton M.R.; RT "Lung cancer: intragenic ERBB2 kinase mutations in tumours."; RL Nature 431:525-526(2004). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND RP ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP INVOLVEMENT IN VSCN2, VARIANT VSCN2 VAL-710, CHARACTERIZATION OF VARIANT RP VSCN2 VAL-710, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=33497358; DOI=10.1172/jci145837; RA Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M., RA Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A., RA Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M., RA Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P., RA Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C., RA Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T., RA Lyonnet S., Amiel J., Bondurand N.; RT "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder RT with gastrointestinal dysmotility in humans."; RL J. Clin. Invest. 131:0-0(2021). CC -!- FUNCTION: Protein tyrosine kinase that is part of several cell surface CC receptor complexes, but that apparently needs a coreceptor for ligand CC binding. Essential component of a neuregulin-receptor complex, although CC neuregulins do not interact with it alone. GP30 is a potential ligand CC for this receptor. Regulates outgrowth and stabilization of peripheral CC microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 CC signaling pathway elicits the phosphorylation and thus the inhibition CC of GSK3B at cell membrane. This prevents the phosphorylation of APC and CC CLASP2, allowing its association with the cell membrane. In turn, CC membrane-bound APC allows the localization of MACF1 to the cell CC membrane, which is required for microtubule capture and stabilization. CC {ECO:0000305}. CC -!- FUNCTION: In the nucleus is involved in transcriptional regulation. CC Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter CC and activates its transcription. Implicated in transcriptional CC activation of CDKN1A; the function involves STAT3 and SRC. Involved in CC the transcription of rRNA genes by RNA Pol I and enhances protein CC synthesis and cell growth. {ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:21454582}; CC -!- ACTIVITY REGULATION: Activated by dimerization. Not activated by EGF, CC TGF-alpha and amphiregulin. Interaction with PTK6 increases its CC intrinsic kinase activity. {ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:21454582}. CC -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and CC ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:16978839, CC PubMed:21190959). Part of a complex with EGFR and either PIK3C2A or CC PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 CC (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts CC (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). CC Interacts with MUC1; the interaction is enhanced by heregulin (HRG) CC (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with CC GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated CC on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, CC RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 CC (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). CC Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts CC (preferentially with the tyrosine phosphorylated form) with CPNE3; this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction CC suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with CC SORL1; this interaction regulates ERBB2 subcellular distribution by CC promoting its recycling after internalization from endosomes back to CC the plasma membrane, hence stimulates ERBB2-mediated signaling CC (PubMed:31138794). Interacts with SH3BGRL (PubMed:32381043). Interacts CC with ROR1 (PubMed:36949068). {ECO:0000250|UniProtKB:P70424, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:12975581, CC ECO:0000269|PubMed:15093539, ECO:0000269|PubMed:15156151, CC ECO:0000269|PubMed:15210733, ECO:0000269|PubMed:16314522, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21190959, CC ECO:0000269|PubMed:21454582, ECO:0000269|PubMed:21555369, CC ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:31138794, CC ECO:0000269|PubMed:32381043, ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC P04626; P00519: ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543; CC P04626; P42684: ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694; CC P04626; P15309: ACP3; NbExp=2; IntAct=EBI-641062, EBI-1222012; CC P04626; P60709: ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944; CC P04626; Q92625: ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612; CC P04626; O00213: APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694; CC P04626; O75815: BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336; CC P04626; Q9HB71: CACYBP; NbExp=2; IntAct=EBI-641062, EBI-1047302; CC P04626; Q16543: CDC37; NbExp=5; IntAct=EBI-641062, EBI-295634; CC P04626; Q9NSE2: CISH; NbExp=4; IntAct=EBI-641062, EBI-617866; CC P04626; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194; CC P04626; P46109: CRKL; NbExp=2; IntAct=EBI-641062, EBI-910; CC P04626; Q93034: CUL5; NbExp=2; IntAct=EBI-641062, EBI-1057139; CC P04626; Q99704: DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360; CC P04626; Q8TEW6: DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542; CC P04626; Q15075: EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113; CC P04626; P98172: EFNB1; NbExp=12; IntAct=EBI-641062, EBI-538287; CC P04626; P00533: EGFR; NbExp=25; IntAct=EBI-641062, EBI-297353; CC P04626; P04626: ERBB2; NbExp=12; IntAct=EBI-641062, EBI-641062; CC P04626; P21860: ERBB3; NbExp=30; IntAct=EBI-641062, EBI-720706; CC P04626; Q15303: ERBB4; NbExp=5; IntAct=EBI-641062, EBI-80371; CC P04626; Q9UJM3: ERRFI1; NbExp=4; IntAct=EBI-641062, EBI-2941912; CC P04626; P09769: FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732; CC P04626; P06241: FYN; NbExp=2; IntAct=EBI-641062, EBI-515315; CC P04626; O75791: GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418; CC P04626; P62993: GRB2; NbExp=8; IntAct=EBI-641062, EBI-401755; CC P04626; Q14451: GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191; CC P04626; P07900: HSP90AA1; NbExp=6; IntAct=EBI-641062, EBI-296047; CC P04626; P08238: HSP90AB1; NbExp=5; IntAct=EBI-641062, EBI-352572; CC P04626; P14625: HSP90B1; NbExp=2; IntAct=EBI-641062, EBI-359129; CC P04626; P11021: HSPA5; NbExp=3; IntAct=EBI-641062, EBI-354921; CC P04626; P46940: IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509; CC P04626; P35568: IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592; CC P04626; Q08881: ITK; NbExp=2; IntAct=EBI-641062, EBI-968552; CC P04626; P23458: JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438; CC P04626; Q14974: KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758; CC P04626; Q96JA1: LRIG1; NbExp=7; IntAct=EBI-641062, EBI-2865191; CC P04626; O75367: MACROH2A1; NbExp=6; IntAct=EBI-641062, EBI-2868511; CC P04626; O75367-3: MACROH2A1; NbExp=3; IntAct=EBI-641062, EBI-6250866; CC P04626; Q9UQF2: MAPK8IP1; NbExp=4; IntAct=EBI-641062, EBI-78404; CC P04626; Q13387: MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813; CC P04626; P42679: MATK; NbExp=2; IntAct=EBI-641062, EBI-751664; CC P04626; Q9Y316: MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564; CC P04626; O43639: NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635; CC P04626; Q02297-7: NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927; CC P04626; O00750: PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107; CC P04626; P27986: PIK3R1; NbExp=12; IntAct=EBI-641062, EBI-79464; CC P04626; O00459: PIK3R2; NbExp=8; IntAct=EBI-641062, EBI-346930; CC P04626; Q92569: PIK3R3; NbExp=10; IntAct=EBI-641062, EBI-79893; CC P04626; P19174: PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387; CC P04626; P16885: PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403; CC P04626; O95602: POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472; CC P04626; Q13882: PTK6; NbExp=4; IntAct=EBI-641062, EBI-1383632; CC P04626; Q06124: PTPN11; NbExp=4; IntAct=EBI-641062, EBI-297779; CC P04626; Q05209: PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035; CC P04626; Q99952: PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210; CC P04626; Q99952-1: PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708; CC P04626; P23467: PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766; CC P04626; P08575: PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341; CC P04626; Q12913: PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500; CC P04626; Q15262: PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052; CC P04626; Q16827: PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739; CC P04626; Q15256: PTPRR; NbExp=2; IntAct=EBI-641062, EBI-2265659; CC P04626; P49792: RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138; CC P04626; P20936: RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476; CC P04626; O95980: RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742; CC P04626; Q9NP31: SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630; CC P04626; P29353: SHC1; NbExp=16; IntAct=EBI-641062, EBI-78835; CC P04626; P98077: SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023; CC P04626; Q92529: SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084; CC P04626; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854; CC P04626; O15524: SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198; CC P04626; O43791: SPOP; NbExp=6; IntAct=EBI-641062, EBI-743549; CC P04626; P12931: SRC; NbExp=11; IntAct=EBI-641062, EBI-621482; CC P04626; P42224: STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697; CC P04626; P40763: STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675; CC P04626; P31948: STIP1; NbExp=2; IntAct=EBI-641062, EBI-1054052; CC P04626; Q7KZ85: SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547; CC P04626; P43405: SYK; NbExp=7; IntAct=EBI-641062, EBI-78302; CC P04626; Q9Y490: TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036; CC P04626; Q63HR2: TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753; CC P04626; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488; CC P04626; Q96D37: VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353; CC P04626; P52735: VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549; CC P04626; O14980: XPO1; NbExp=3; IntAct=EBI-641062, EBI-355867; CC P04626; P62258: YWHAE; NbExp=2; IntAct=EBI-641062, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32381043}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection, CC ruffle membrane {ECO:0000269|PubMed:34380438}; Single-pass type I CC membrane protein {ECO:0000255}. Note=Internalized from the cell CC membrane in response to EGF stimulation. {ECO:0000269|PubMed:32381043}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:33497358}; Single-pass CC type I membrane protein {ECO:0000255}. Early endosome CC {ECO:0000269|PubMed:31138794}. Cytoplasm, perinuclear region. Nucleus. CC Note=Translocation to the nucleus requires endocytosis, probably CC endosomal sorting and is mediated by importin beta-1/KPNB1. Also CC detected in VPS35-positive endosome-to-TGN retrograde vesicles CC (PubMed:31138794). {ECO:0000269|PubMed:31138794}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=6; CC Name=1; Synonyms=ERBB2, HER2; CC IsoId=P04626-1; Sequence=Displayed; CC Name=2; Synonyms=CTF-611; CC IsoId=P04626-2; Sequence=VSP_039249; CC Name=3; Synonyms=CTF-687; CC IsoId=P04626-3; Sequence=VSP_039250; CC Name=4; CC IsoId=P04626-4; Sequence=VSP_039248; CC Name=5; CC IsoId=P04626-5; Sequence=VSP_054787; CC Name=6; Synonyms=B; CC IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues including CC primary breast tumors and tumors from small bowel, esophagus, kidney CC and mouth. {ECO:0000269|PubMed:15380516}. CC -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one CC subunit of the dimeric receptor phosphorylates tyrosine residues on the CC other subunit (Probable). Ligand-binding increases phosphorylation on CC tyrosine residues (PubMed:27134172, PubMed:33497358). Signaling via CC SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). CC Dephosphorylated by PTPN12 (PubMed:27134172). CC {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172, CC ECO:0000269|PubMed:33497358, ECO:0000305}. CC -!- POLYMORPHISM: There are four alleles due to the variations in positions CC 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; CC allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val- CC 654/Val-655) has a frequency of 0.012. CC -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The protein represented in this CC entry is involved in disease pathogenesis. CC -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to CC truncated CDK12 protein not in-frame with ERBB2. CC {ECO:0000269|PubMed:21097718}. CC -!- DISEASE: Visceral neuropathy, familial, 2, autosomal recessive (VSCN2) CC [MIM:619465]: An autosomal recessive disorder characterized by CC intestinal dysmotility due to aganglionosis (Hirschsprung disease), CC hypoganglionosis, and/or chronic intestinal pseudoobstruction. Patients CC also show peripheral axonal neuropathy, hypotonia, mild developmental CC delay, unilateral ptosis, and sensorineural hearing loss. CC {ECO:0000269|PubMed:33497358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met- CC 611 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met- CC 687 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform CC 1. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/162/ERBB2"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry; CC URL="https://en.wikipedia.org/wiki/ERBB2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AH001455; AAA35808.1; -; Genomic_DNA. DR EMBL; X03363; CAA27060.1; -; mRNA. DR EMBL; M11730; AAA75493.1; -; mRNA. DR EMBL; M12036; AAA35978.1; -; Genomic_DNA. DR EMBL; AY208911; AAO18082.1; -; Genomic_DNA. DR EMBL; AK295195; BAG58195.1; -; mRNA. DR EMBL; CH471152; EAW60597.1; -; Genomic_DNA. DR EMBL; BC167147; AAI67147.1; -; mRNA. DR EMBL; M16792; AAA58637.1; -; Genomic_DNA. DR EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; KJ534964; AHW56604.1; -; mRNA. DR EMBL; L29395; AAA35809.1; -; Genomic_DNA. DR EMBL; M95667; AAC37531.1; -; Genomic_DNA. DR CCDS; CCDS32642.1; -. [P04626-1] DR CCDS; CCDS45667.1; -. [P04626-5] DR CCDS; CCDS74052.1; -. [P04626-4] DR PIR; A24571; A24571. DR RefSeq; NP_001005862.1; NM_001005862.3. [P04626-5] DR RefSeq; NP_001276865.1; NM_001289936.2. [P04626-4] DR RefSeq; NP_001276867.1; NM_001289938.1. DR RefSeq; NP_001369711.1; NM_001382782.1. [P04626-5] DR RefSeq; NP_001369712.1; NM_001382783.1. [P04626-5] DR RefSeq; NP_004439.2; NM_004448.4. [P04626-1] DR RefSeq; XP_047291546.1; XM_047435590.1. [P04626-4] DR PDB; 1MFG; X-ray; 1.25 A; B=1247-1255. DR PDB; 1MFL; X-ray; 1.88 A; B=1247-1255. DR PDB; 1MW4; NMR; -; B=1135-1144. DR PDB; 1N8Z; X-ray; 2.52 A; C=23-629. DR PDB; 1QR1; X-ray; 2.40 A; C/F=654-662. DR PDB; 1S78; X-ray; 3.25 A; A/B=23-646. DR PDB; 2A91; X-ray; 2.50 A; A=22-530. DR PDB; 2JWA; NMR; -; A/B=641-684. DR PDB; 2KS1; NMR; -; A=641-684. DR PDB; 2L4K; NMR; -; B=1135-1144. DR PDB; 2N2A; NMR; -; A/B=644-700. DR PDB; 3BE1; X-ray; 2.90 A; A=23-646. DR PDB; 3H3B; X-ray; 2.45 A; A/B=23-214. DR PDB; 3MZW; X-ray; 2.90 A; A=23-646. DR PDB; 3N85; X-ray; 3.20 A; A=23-646. DR PDB; 3PP0; X-ray; 2.25 A; A/B=703-1029. DR PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028. DR PDB; 3WLW; X-ray; 3.09 A; A/B=23-586. DR PDB; 3WSQ; X-ray; 3.50 A; A=23-586. DR PDB; 4GFU; X-ray; 2.00 A; F=1246-1252. DR PDB; 4HRL; X-ray; 2.55 A; C=24-219. DR PDB; 4HRM; X-ray; 3.20 A; A/C=24-219. DR PDB; 4HRN; X-ray; 2.65 A; C/D=529-625. DR PDB; 4NND; X-ray; 2.50 A; C/E/F/H=1109-1114. DR PDB; 5K33; X-ray; 3.30 A; C=23-629. DR PDB; 5KWG; X-ray; 4.30 A; C=23-653. DR PDB; 5MY6; X-ray; 2.25 A; A=24-645. DR PDB; 5O4G; X-ray; 3.00 A; C=23-628. DR PDB; 5OB4; NMR; -; A/B=641-684. DR PDB; 5TQS; X-ray; 1.88 A; E/F/G/H=1218-1228. DR PDB; 6ATT; X-ray; 3.77 A; A=23-652. DR PDB; 6BGT; X-ray; 2.70 A; C=1-652. DR PDB; 6J71; X-ray; 2.92 A; A=22-639. DR PDB; 6LBX; X-ray; 2.03 A; B=531-626. DR PDB; 6OGE; EM; 4.36 A; A=23-644. DR PDB; 7JXH; X-ray; 3.27 A; A/B/C/D/E/F/G/H=703-1024. DR PDB; 7MN5; EM; 2.93 A; B=1-1029. DR PDB; 7MN6; EM; 3.09 A; B=1-1029. DR PDB; 7MN8; EM; 3.45 A; B=1-1029. DR PDB; 7PCD; X-ray; 1.77 A; A=703-1029. DR PDB; 7QVK; X-ray; 3.10 A; AAA=23-646. DR PDB; 8FFJ; EM; 7.50 A; X=23-644. DR PDB; 8HGO; EM; 3.31 A; B=1-693. DR PDB; 8HGP; EM; 4.53 A; B=1-693. DR PDB; 8JYQ; X-ray; 1.75 A; C/F=611-618. DR PDB; 8JYR; X-ray; 1.69 A; A=23-216. DR PDB; 8PWH; EM; 3.17 A; E=23-646. DR PDB; 8Q6J; EM; 3.30 A; E=23-646. DR PDB; 8U4K; EM; 4.27 A; B=24-629. DR PDB; 8U4L; EM; 3.31 A; B=24-629. DR PDB; 8U8X; X-ray; 1.69 A; A=694-1029. DR PDB; 8VB5; X-ray; 1.48 A; A=703-1029. DR PDB; 8VQD; EM; 2.61 A; A=23-652. DR PDB; 8VQE; EM; 2.67 A; A/B=23-652. DR PDB; 9IUT; X-ray; 2.09 A; C/F=611-618. DR PDB; 9L1S; EM; 3.00 A; A=23-652. DR PDBsum; 1MFG; -. DR PDBsum; 1MFL; -. DR PDBsum; 1MW4; -. DR PDBsum; 1N8Z; -. DR PDBsum; 1QR1; -. DR PDBsum; 1S78; -. DR PDBsum; 2A91; -. DR PDBsum; 2JWA; -. DR PDBsum; 2KS1; -. DR PDBsum; 2L4K; -. DR PDBsum; 2N2A; -. DR PDBsum; 3BE1; -. DR PDBsum; 3H3B; -. DR PDBsum; 3MZW; -. DR PDBsum; 3N85; -. DR PDBsum; 3PP0; -. DR PDBsum; 3RCD; -. DR PDBsum; 3WLW; -. DR PDBsum; 3WSQ; -. DR PDBsum; 4GFU; -. DR PDBsum; 4HRL; -. DR PDBsum; 4HRM; -. DR PDBsum; 4HRN; -. DR PDBsum; 4NND; -. DR PDBsum; 5K33; -. DR PDBsum; 5KWG; -. DR PDBsum; 5MY6; -. DR PDBsum; 5O4G; -. DR PDBsum; 5OB4; -. DR PDBsum; 5TQS; -. DR PDBsum; 6ATT; -. DR PDBsum; 6BGT; -. DR PDBsum; 6J71; -. DR PDBsum; 6LBX; -. DR PDBsum; 6OGE; -. DR PDBsum; 7JXH; -. DR PDBsum; 7MN5; -. DR PDBsum; 7MN6; -. DR PDBsum; 7MN8; -. DR PDBsum; 7PCD; -. DR PDBsum; 7QVK; -. DR PDBsum; 8FFJ; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8JYQ; -. DR PDBsum; 8JYR; -. DR PDBsum; 8PWH; -. DR PDBsum; 8Q6J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR PDBsum; 8U8X; -. DR PDBsum; 8VB5; -. DR PDBsum; 8VQD; -. DR PDBsum; 8VQE; -. DR PDBsum; 9IUT; -. DR PDBsum; 9L1S; -. DR AlphaFoldDB; P04626; -. DR BMRB; P04626; -. DR EMDB; EMD-17993; -. DR EMDB; EMD-18188; -. DR EMDB; EMD-18189; -. DR EMDB; EMD-18190; -. DR EMDB; EMD-20055; -. DR EMDB; EMD-29044; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR EMDB; EMD-43439; -. DR EMDB; EMD-43440; -. DR EMDB; EMD-62753; -. DR SMR; P04626; -. DR BioGRID; 108376; 731. DR CORUM; P04626; -. DR DIP; DIP-8N; -. DR ELM; P04626; -. DR FunCoup; P04626; 2287. DR IntAct; P04626; 558. DR MINT; P04626; -. DR STRING; 9606.ENSP00000269571; -. DR BindingDB; P04626; -. DR ChEMBL; CHEMBL1824; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12302; CP-724714. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB14967; Margetuximab. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB06226; Nelipepimut-S. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB06366; Pertuzumab. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB12183; Sapitinib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB11973; Tesevatinib. DR DrugBank; DB00072; Trastuzumab. DR DrugBank; DB05773; Trastuzumab emtansine. DR DrugBank; DB11652; Tucatinib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB15471; Zanidatamab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P04626; -. DR GuidetoPHARMACOLOGY; 2019; -. DR MoonDB; P04626; Predicted. DR TCDB; 8.A.23.1.39; the basigin (basigin) family. DR CarbonylDB; P04626; -. DR GlyConnect; 1710; 13 N-Linked glycans (5 sites), 1 O-Linked glycan (1 site). DR GlyCosmos; P04626; 9 sites, 13 glycans. DR GlyGen; P04626; 10 sites, 27 N-linked glycans (7 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P04626; -. DR PhosphoSitePlus; P04626; -. DR SwissPalm; P04626; -. DR BioMuta; ERBB2; -. DR DMDM; 119533; -. DR CPTAC; CPTAC-192; -. DR CPTAC; CPTAC-193; -. DR CPTAC; CPTAC-194; -. DR CPTAC; CPTAC-195; -. DR CPTAC; CPTAC-3045; -. DR CPTAC; CPTAC-3046; -. DR CPTAC; CPTAC-5777; -. DR CPTAC; CPTAC-5827; -. DR CPTAC; CPTAC-5839; -. DR CPTAC; CPTAC-5864; -. DR CPTAC; CPTAC-693; -. DR CPTAC; non-CPTAC-5384; -. DR CPTAC; non-CPTAC-5385; -. DR CPTAC; non-CPTAC-5386; -. DR CPTAC; non-CPTAC-5547; -. DR CPTAC; non-CPTAC-5732; -. DR CPTAC; non-CPTAC-5733; -. DR jPOST; P04626; -. DR MassIVE; P04626; -. DR PaxDb; 9606-ENSP00000269571; -. DR PeptideAtlas; P04626; -. DR ProteomicsDB; 51718; -. [P04626-1] DR ProteomicsDB; 51719; -. [P04626-2] DR ProteomicsDB; 51720; -. [P04626-3] DR ProteomicsDB; 51721; -. [P04626-4] DR Pumba; P04626; -. DR ABCD; P04626; 341 sequenced antibodies. DR Antibodypedia; 740; 6685 antibodies from 63 providers. DR CPTC; P04626; 4 antibodies. DR DNASU; 2064; -. DR Ensembl; ENST00000269571.10; ENSP00000269571.4; ENSG00000141736.15. [P04626-1] DR Ensembl; ENST00000584601.5; ENSP00000462438.1; ENSG00000141736.15. [P04626-5] DR GeneID; 2064; -. DR KEGG; hsa:2064; -. DR MANE-Select; ENST00000269571.10; ENSP00000269571.4; NM_004448.4; NP_004439.2. DR UCSC; uc060esv.1; human. [P04626-1] DR AGR; HGNC:3430; -. DR CIViC; 2064; 2 clinical assertions and 302 evidence items across 174 molecular profiles. DR ClinPGx; PA27844; -. DR CTD; 2064; -. DR DisGeNET; 2064; -. DR GeneCards; ERBB2; -. DR HGNC; HGNC:3430; ERBB2. DR HPA; ENSG00000141736; Low tissue specificity. DR MalaCards; ERBB2; -. DR MIM; 137800; phenotype. DR MIM; 164870; gene. DR MIM; 167000; phenotype. DR MIM; 211980; phenotype. DR MIM; 613659; phenotype. DR MIM; 619465; phenotype. DR OpenTargets; ENSG00000141736; -. DR Orphanet; 99976; Adenocarcinoma of the oesophagus and oesophagogastric junction. DR Orphanet; 2800; Extramammary Paget disease. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 213726; Serous carcinoma of the corpus uteri. DR VEuPathDB; HostDB:ENSG00000141736; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000158232; -. DR InParanoid; P04626; -. DR OMA; DRHCLPC; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P04626; 10 GO annotations based on evolutionary models. DR PhylomeDB; P04626; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P04626; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab. DR Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib. DR Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib. DR Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib. DR Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib. DR Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib. DR Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788. DR Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P04626; -. DR SIGNOR; P04626; -. DR Agora; ENSG00000141736; -. DR BioGRID-ORCS; 2064; 92 hits in 1209 CRISPR screens. DR ChiTaRS; ERBB2; human. DR EvolutionaryTrace; P04626; -. DR GeneWiki; HER2/neu; -. DR GenomeRNAi; 2064; -. DR Pharos; P04626; Tclin. DR PRO; PR:P04626; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04626; protein. DR Bgee; ENSG00000141736; Expressed in lower esophagus mucosa and 186 other cell types or tissues. DR ExpressionAtlas; P04626; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0043209; C:myelin sheath; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0002116; C:semaphorin receptor complex; ISS:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; ISS:BHF-UCL. DR GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:BHF-UCL. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0042060; P:wound healing; IDA:BHF-UCL. DR CDD; cd00064; FU; 3. DR CDD; cd05109; PTKc_HER2; 1. DR CDD; cd12094; TM_ErbB2; 1. DR DisProt; DP01484; -. DR FunFam; 1.20.5.100:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000009; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000010; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000184; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 4.10.1140.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 1.20.5.100; Cytochrome c1, transmembrane anchor, C-terminal; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 4.10.1140.10; membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor like domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00293; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF137; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative initiation; Alternative splicing; KW ATP-binding; Cell membrane; Cell projection; Chromosomal rearrangement; KW Cytoplasm; Disease variant; Disulfide bond; Endosome; Glycoprotein; Kinase; KW Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Signal; KW Transcription; Transcription regulation; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..1255 FT /note="Receptor tyrosine-protein kinase erbB-2" FT /id="PRO_0000016669" FT TOPO_DOM 23..652 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 653..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 720..987 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 676..689 FT /note="Required for interaction with KPNB1 and EEA1" FT /evidence="ECO:0000269|PubMed:16314522" FT REGION 1035..1179 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1195..1197 FT /note="Interaction with PIK3C2B" FT /evidence="ECO:0000305" FT REGION 1196..1255 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..689 FT /note="Nuclear localization signal" FT COMPBIAS 1146..1155 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 845 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 726..734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 753 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 182 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 877 FT /note="Phosphotyrosine" FT /evidence="ECO:0000305|PubMed:32381043" FT MOD_RES 1054 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 1078 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P06494" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1107 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1112 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1139 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1166 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1196 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172, FT ECO:0000305|PubMed:32381043" FT MOD_RES 1248 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17554007, FT ECO:0000269|PubMed:27134172, ECO:0007744|PubMed:17081983" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW" FT CARBOHYD 124 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 187 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255, ECO:0007744|PDB:1N8Z, FT ECO:0007744|PDB:1S78, ECO:0007744|PDB:2A91, FT ECO:0007744|PDB:3N85" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85" FT CARBOHYD 530 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0007744|PDB:1S78" FT CARBOHYD 571 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:3MZW" FT CARBOHYD 629 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 26..53 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 162..192 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 195..204 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 199..212 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 220..227 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 224..235 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 236..244 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 240..252 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 255..264 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 268..295 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 299..311 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 315..331 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 334..338 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 342..367 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 475..504 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 511..520 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 515..528 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 531..540 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 544..560 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 563..576 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 567..584 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 587..596 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:4HRN" FT DISULFID 600..623 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3N85" FT DISULFID 626..634 FT /evidence="ECO:0007744|PDB:3N85" FT DISULFID 630..642 FT /evidence="ECO:0007744|PDB:3N85" FT VAR_SEQ 1..686 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_039250" FT VAR_SEQ 1..610 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_039249" FT VAR_SEQ 1..30 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_054787" FT VAR_SEQ 1..23 FT /note="MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_039248" FT VAR_SEQ 633..648 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055902" FT VAR_SEQ 771..883 FT /note="AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDL FT LNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADG FT GK -> TISNLFSNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLWGCRGEP FT RVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTRAGGSTQHLQRDTYGREPRVPGSGR FT ASVNQKAKSAEALMCPQGAGKA (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055903" FT VAR_SEQ 884..1255 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055904" FT VARIANT 452 FT /note="W -> C (in dbSNP:rs4252633)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_016317" FT VARIANT 654 FT /note="I -> V (in allele B3; dbSNP:rs1801201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488" FT /id="VAR_004077" FT VARIANT 655 FT /note="I -> V (in allele B2 and allele B3; FT dbSNP:rs1136201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3" FT /id="VAR_004078" FT VARIANT 710 FT /note="A -> V (in VSCN2; almost complete loss of ERBB2 and FT ERBB3 phosphorylation in the presence or in the absence of FT NRG1 stimulation, suggesting alteration of downstream FT signaling; does not affect the subcellular localization at FT the cell membrane; dbSNP:rs2145813505)" FT /evidence="ECO:0000269|PubMed:33497358" FT /id="VAR_086107" FT VARIANT 755 FT /note="L -> P (in LNCR; uncertain significance; somatic FT mutation; dbSNP:rs121913469)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055432" FT VARIANT 768 FT /note="L -> S (in dbSNP:rs56366519)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042097" FT VARIANT 774 FT /note="M -> MAYVM (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055433" FT VARIANT 776 FT /note="G -> S (in GASC; uncertain significance; somatic FT mutation; dbSNP:rs28933369)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042098" FT VARIANT 779 FT /note="S -> SVGS (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055434" FT VARIANT 857 FT /note="N -> S (in OC; uncertain significance; somatic FT mutation; dbSNP:rs28933370)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042099" FT VARIANT 914 FT /note="E -> K (in GLM; uncertain significance; somatic FT mutation; dbSNP:rs28933368)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055435" FT VARIANT 1170 FT /note="P -> A (in dbSNP:rs1058808)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2999974, ECO:0000269|PubMed:8104414, FT ECO:0000269|Ref.3" FT /id="VAR_016318" FT VARIANT 1216 FT /note="A -> D (in dbSNP:rs55943169)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042100" FT MUTAGEN 317..318 FT /note="LH->AA: Reduces dimerization with ERBB3." FT /evidence="ECO:0000269|PubMed:15093539" FT MUTAGEN 611 FT /note="M->A: Prevents synthesis of isoform 2." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 687 FT /note="M->A: Prevents synthesis of isoform 3." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 706 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 712 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT STRAND 25..27 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 39..50 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 55..64 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 84..88 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 92..95 FT /evidence="ECO:0007829|PDB:3H3B" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 112..117 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 123..125 FT /evidence="ECO:0007829|PDB:8PWH" FT TURN 130..132 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 152..156 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 217..219 FT /evidence="ECO:0007829|PDB:1N8Z" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 227..231 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 240..248 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 271..274 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 284..286 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 294..298 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 319..323 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 329..333 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:2A91" FT HELIX 348..350 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 358..360 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 361..364 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 368..376 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 378..382 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 385..387 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 394..400 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 405..408 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 410..413 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:8PWH" FT HELIX 423..425 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 430..435 FT /evidence="ECO:0007829|PDB:3WLW" FT TURN 438..440 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 441..447 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 463..469 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 476..479 FT /evidence="ECO:0007829|PDB:8VQE" FT HELIX 482..485 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 493..499 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3N85" FT HELIX 516..518 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 520..524 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 532..536 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 539..542 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 553..556 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 559..562 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 565..567 FT /evidence="ECO:0007829|PDB:3WSQ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 575..580 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 583..592 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 602..604 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 605..608 FT /evidence="ECO:0007829|PDB:8PWH" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:8JYQ" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 630..632 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:6J71" FT HELIX 651..678 FT /evidence="ECO:0007829|PDB:2JWA" FT HELIX 684..690 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 691..697 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 720..729 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 732..739 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 748..755 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 762..765 FT /evidence="ECO:0007829|PDB:3RCD" FT HELIX 770..775 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 787..799 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 806..813 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 814..816 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 819..838 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 848..850 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 851..855 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 866..870 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 886..888 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 891..896 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 901..916 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 922..925 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 949..958 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 963..965 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 969..980 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 983..985 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 989..992 FT /evidence="ECO:0007829|PDB:3PP0" FT HELIX 1003..1007 FT /evidence="ECO:0007829|PDB:3PP0" FT TURN 1008..1011 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 1140..1142 FT /evidence="ECO:0007829|PDB:1MW4" SQ SEQUENCE 1255 AA; 137910 MW; 39E9DFDA04DCF962 CRC64; MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV // ID ERBB4_HUMAN Reviewed; 1308 AA. AC Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 251. DE RecName: Full=Receptor tyrosine-protein kinase erbB-4; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene-like protein c-ErbB-4; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER4; DE AltName: Full=p180erbB4; DE Contains: DE RecName: Full=ERBB4 intracellular domain; DE Short=4ICD; DE Short=E4ICD; DE AltName: Full=s80HER4; DE Flags: Precursor; GN Name=ERBB4; Synonyms=HER4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE RP RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=8383326; DOI=10.1073/pnas.90.5.1746; RA Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W., RA Foy L., Neubauer M.G., Shoyab M.; RT "Ligand-specific activation of HER4/p180erbB4, a fourth member of the RT epidermal growth factor receptor family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE RP SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING. RC TISSUE=Fetal brain; RX PubMed=9334263; DOI=10.1074/jbc.272.42.26761; RA Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., RA Klagsbrun M.; RT "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific RT tissue distribution and differential processing in response to phorbol RT ester."; RL J. Biol. Chem. 272:26761-26768(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; RP JM-A CYT-2 AND JM-B CYT-2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1; RA Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.; RT "Characterization of a breast cancer cell differentiation factor that RT specifically activates the HER4/p180erbB4 receptor."; RL J. Biol. Chem. 268:18407-18410(1993). RN [6] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7902537; DOI=10.1038/366473a0; RA Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M., RA Buckley S.; RT "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4."; RL Nature 366:473-475(1993). RN [7] RP FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND RP PIK3R1. RX PubMed=8617750; DOI=10.1074/jbc.271.9.4813; RA Cohen B.D., Green J.M., Foy L., Fell H.P.; RT "HER4-mediated biological and biochemical properties in NIH 3T3 cells. RT Evidence for HER1-HER4 heterodimers."; RL J. Biol. Chem. 271:4813-4818(1996). RN [8] RP INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION. RX PubMed=8570211; RA Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., RA Stern D.F.; RT "Betacellulin activates the epidermal growth factor receptor and erbB-4, RT and induces cellular response patterns distinct from those stimulated by RT epidermal growth factor or neuregulin-beta."; RL Oncogene 12:345-353(1996). RN [9] RP FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN RP ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND RP AUTOPHOSPHORYLATION. RX PubMed=9135143; DOI=10.1093/emboj/16.6.1268; RA Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.; RT "Activation of HER4 by heparin-binding EGF-like growth factor stimulates RT chemotaxis but not proliferation."; RL EMBO J. 16:1268-1278(1997). RN [10] RP INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION. RX PubMed=9168115; DOI=10.1038/387512a0; RA Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., RA Lai C.; RT "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases."; RL Nature 387:512-516(1997). RN [11] RP INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [12] RP INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION. RX PubMed=9275162; DOI=10.1073/pnas.94.18.9562; RA Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., RA Crowley C., Brush J., Godowski P.J.; RT "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and RT activates ErbB4."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997). RN [13] RP INTERACTION WITH GRB7. RX PubMed=9516479; DOI=10.1074/jbc.273.13.7717; RA Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., RA Wallasch C., Daly R.J.; RT "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals RT a novel target selectivity for erbB3."; RL J. Biol. Chem. 273:7717-7724(1998). RN [14] RP INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [15] RP ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1, RP INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE RP SPECIFICITY. RX PubMed=10353604; DOI=10.1038/sj.onc.1202612; RA Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.; RT "Characterization of a naturally occurring ErbB4 isoform that does not bind RT or activate phosphatidyl inositol 3-kinase."; RL Oncogene 18:2607-2615(1999). RN [16] RP FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN RP CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION. RX PubMed=10348342; DOI=10.1038/sj.onc.1202631; RA Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., RA Yarden Y.; RT "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor RT tyrosine kinase."; RL Oncogene 18:2681-2689(1999). RN [17] RP FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN RP PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND RP ALTERNATIVE SPLICING. RX PubMed=10722704; DOI=10.1074/jbc.275.12.8641; RA Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., RA Elenius K.; RT "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase RT mediates proliferation but not survival or chemotaxis."; RL J. Biol. Chem. 275:8641-8649(2000). RN [18] RP PROTEOLYTIC PROCESSING. RX PubMed=10744726; DOI=10.1074/jbc.275.14.10379; RA Rio C., Buxbaum J.D., Peschon J.J., Corfas G.; RT "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of RT erbB4/HER4."; RL J. Biol. Chem. 275:10379-10387(2000). RN [19] RP FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH RP PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC RP AUTOPHOSPHORYLATION. RX PubMed=10867024; DOI=10.1074/jbc.c901015199; RA Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., RA Carraway K.L. III; RT "Ligand discrimination in signaling through an ErbB4 receptor homodimer."; RL J. Biol. Chem. 275:19803-19807(2000). RN [20] RP INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2. RX PubMed=10725395; DOI=10.1073/pnas.97.7.3596; RA Garcia R.A., Vasudevan K., Buonanno A.; RT "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at RT neuronal synapses."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000). RN [21] RP FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES, RP AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=11178955; DOI=10.1006/bbrc.2001.4302; RA Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.; RT "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at RT different concentrations in intact cells."; RL Biochem. Biophys. Res. Commun. 281:25-31(2001). RN [22] RP MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND RP INHIBITING CELL PROLIFERATION. RX PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001; RA Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., RA Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III; RT "Her4 mediates ligand-dependent antiproliferative and differentiation RT responses in human breast cancer cells."; RL Mol. Cell. Biol. 21:4265-4275(2001). RN [23] RP FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH RP YAP1, AND MUTAGENESIS OF TYR-1301. RX PubMed=12807903; DOI=10.1074/jbc.m305597200; RA Komuro A., Nagai M., Navin N.E., Sudol M.; RT "WW domain-containing protein YAP associates with ErbB-4 and acts as a co- RT transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that RT translocates to the nucleus."; RL J. Biol. Chem. 278:33334-33341(2003). RN [24] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [25] RP INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR RP LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684. RX PubMed=15534001; DOI=10.1083/jcb.200403155; RA Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S., RA Marrero L., Jones F.E.; RT "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by RT functioning as a STAT5A nuclear chaperone."; RL J. Cell Biol. 167:469-478(2004). RN [26] RP INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [27] RP FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675. RX PubMed=15746097; DOI=10.1074/jbc.m412457200; RA Vidal G.A., Naresh A., Marrero L., Jones F.E.; RT "Presenilin-dependent gamma-secretase processing regulates multiple RT ERBB4/HER4 activities."; RL J. Biol. Chem. 280:19777-19783(2005). RN [28] RP FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH RP BCL2. RX PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368; RA Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., RA Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.; RT "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting RT apoptosis of breast cancer cells."; RL Cancer Res. 66:6412-6420(2006). RN [29] RP INTERACTION WITH CBFA2T3. RX PubMed=16815842; DOI=10.1074/jbc.m603998200; RA Linggi B., Carpenter G.; RT "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional RT repression."; RL J. Biol. Chem. 281:25373-25380(2006). RN [30] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16251361; DOI=10.1091/mbc.e05-05-0402; RA Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., RA Egeblad M., Elenius K.; RT "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 RT isoform promote ligand-independent survival and cancer cell growth."; RL Mol. Biol. Cell 17:67-79(2006). RN [31] RP FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING, RP AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A. RX PubMed=16837552; DOI=10.1091/mbc.e06-02-0101; RA Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L., RA Feng S.M., Elenius K., Earp H.S. III; RT "The intracellular domain of ErbB4 induces differentiation of mammary RT epithelial cells."; RL Mol. Biol. Cell 17:4118-4129(2006). RN [32] RP MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056. RX PubMed=17120616; DOI=10.3727/000000006783981134; RA Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II; RT "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling RT to inhibition of colony formation by human mammary cell lines."; RL Oncol. Res. 16:179-193(2006). RN [33] RP FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR RP LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF RP VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000. RX PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145; RA Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., RA Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.; RT "HER4 D-box sequences regulate mitotic progression and degradation of the RT nuclear HER4 cleavage product s80HER4."; RL Cancer Res. 67:6582-6590(2007). RN [34] RP INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN RP TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [35] RP FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND RP MUTAGENESIS OF LYS-751. RX PubMed=17486069; DOI=10.1038/sj.onc.1210501; RA Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M., RA Silvennoinen O., Yarden Y., Elenius K.; RT "Differential nuclear localization and kinase activity of alternative ErbB4 RT intracellular domains."; RL Oncogene 26:6905-6914(2007). RN [36] RP PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; RP TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH RP PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006; RA Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.; RT "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation RT that are unusually selective in their recruitment properties."; RL Chem. Biol. 15:808-817(2008). RN [37] RP INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1. RX PubMed=19193720; DOI=10.1096/fj.08-121947; RA Zeng F., Xu J., Harris R.C.; RT "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK RT II cells."; RL FASEB J. 23:1935-1945(2009). RN [38] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY RP REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; RP ASP-861; GLU-872 AND THR-926. RX PubMed=19098003; DOI=10.1074/jbc.m805438200; RA Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S., RA Elenius K.; RT "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting RT signal transduction pathways in cancer."; RL J. Biol. Chem. 284:5582-5591(2009). RN [39] RP INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301. RX PubMed=19561640; DOI=10.1038/onc.2009.162; RA Li Y., Zhou Z., Alimandi M., Chen C.; RT "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length RT ErbB4 for ubiquitin-mediated degradation in breast cancer."; RL Oncogene 28:2948-2958(2009). RN [40] RP INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; RP ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND SRRT, FUNCTION, RP SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042; RA Gilmore-Hebert M., Ramabhadran R., Stern D.F.; RT "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage RT response pathways."; RL Mol. Cancer Res. 8:1388-1398(2010). RN [41] RP ACTIVITY REGULATION. RX PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015; RA Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., RA Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.; RT "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting RT with erbB3 and erbB4 in glioblastoma cell lines."; RL Exp. Cell Res. 317:1476-1489(2011). RN [42] RP REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT. RX PubMed=14504474; RA Jones F.E., Golding J.P., Gassmann M.; RT "ErbB4 signaling during breast and neural development: novel genetic models RT reveal unique ErbB4 activities."; RL Cell Cycle 2:555-559(2003). RN [43] RP REVIEW. RX PubMed=15944951; DOI=10.14670/hh-20.1005; RA Zaczek A., Brandt B., Bielawski K.P.; RT "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase RT receptors and the consequences for therapeutic approaches."; RL Histol. Histopathol. 20:1005-1015(2005). RN [44] RP REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT. RX PubMed=18437540; DOI=10.1007/s10911-008-9080-x; RA Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III; RT "ErbB4/HER4: role in mammary gland development, differentiation and growth RT inhibition."; RL J. Mammary Gland Biol. Neoplasia 13:235-246(2008). RN [45] RP REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN. RX PubMed=18473151; DOI=10.1007/s10911-008-9076-6; RA Jones F.E.; RT "HER4 intracellular domain (4ICD) activity in the developing mammary gland RT and breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:247-258(2008). RN [46] RP REVIEW ON LIGAND SPECIFICITY AND SIGNALING. RX PubMed=18454307; DOI=10.1007/s10911-008-9079-3; RA Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.; RT "Role of ErbB4 in breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:259-268(2008). RN [47] RP REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH. RX PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1; RA Xu Y., Li X., Liu X., Zhou M.; RT "Neuregulin-1/ErbB signaling and chronic heart failure."; RL Adv. Pharmacol. 59:31-51(2010). RN [48] RP REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE RP SPECIFICITY; SIGNALING AND ROLE IN DISEASE. RX PubMed=21811097; DOI=10.4161/cc.10.16.17194; RA Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., RA Elenius K.; RT "Function of ERBB4 is determined by alternative splicing."; RL Cell Cycle 10:2647-2657(2011). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; RP ASN-495 AND ASN-576. RX PubMed=16203964; DOI=10.1073/pnas.0507591102; RA Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.; RT "The extracellular region of ErbB4 adopts a tethered conformation in the RT absence of ligand."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710; RP MET-766; LEU-864 AND ILE-947. RX PubMed=18287036; DOI=10.1073/pnas.0708281105; RA Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., RA Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., RA Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., RA Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., RA Waterson A.G., Williams J.D., White W.L., Uehling D.E.; RT "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as RT tunable covalent modifiers of ErbB kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN RP COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP AUTOPHOSPHORYLATION, AND SUBUNIT. RX PubMed=18334220; DOI=10.1016/j.str.2007.12.016; RA Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., RA Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.; RT "Mechanism of activation and inhibition of the HER4/ErbB4 kinase."; RL Structure 16:460-467(2008). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19 RP GLN-927 AND TRP-1275. RX PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008; RA Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., RA Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H., RA Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T., RA Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N., RA Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A., RA Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., RA Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., RA Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., RA Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., RA Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H., RA Nishizawa M.; RT "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause RT amyotrophic lateral sclerosis type 19."; RL Am. J. Hum. Genet. 93:900-905(2013). CC -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell CC surface receptor for neuregulins and EGF family members and regulates CC development of the heart, the central nervous system and the mammary CC gland, gene transcription, cell proliferation, differentiation, CC migration and apoptosis. Required for normal cardiac muscle CC differentiation during embryonic development, and for postnatal CC cardiomyocyte proliferation. Required for normal development of the CC embryonic central nervous system, especially for normal neural crest CC cell migration and normal axon guidance. Required for mammary gland CC differentiation, induction of milk proteins and lactation. Acts as CC cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and CC the EGF family members BTC, EREG and HBEGF. Ligand binding triggers CC receptor dimerization and autophosphorylation at specific tyrosine CC residues that then serve as binding sites for scaffold proteins and CC effectors. Ligand specificity and signaling is modulated by alternative CC splicing, proteolytic processing, and by the formation of heterodimers CC with other ERBB family members, thereby creating multiple combinations CC of intracellular phosphotyrosines that trigger ligand- and context- CC specific cellular responses. Mediates phosphorylation of SHC1 and CC activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CC CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the CC activation of phosphatidylinositol 3-kinase and AKT1 and protect cells CC against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate CC reorganization of the actin cytoskeleton and promote cell migration in CC response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the CC phosphotyrosine that mediates interaction with PIK3R1, and hence do not CC phosphorylate PIK3R1, do not protect cells against apoptosis, and do CC not promote reorganization of the actin cytoskeleton and cell CC migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM- CC A CYT-2 gives rise to the corresponding soluble intracellular domains CC (4ICD) that translocate to the nucleus, promote nuclear import of CC STAT5A, activation of STAT5A, mammary epithelium differentiation, cell CC proliferation and activation of gene expression. The ERBB4 soluble CC intracellular domains (4ICD) colocalize with STAT5A at the CSN2 CC promoter to regulate transcription of milk proteins during lactation. CC The ERBB4 soluble intracellular domains can also translocate to CC mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, CC ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9334263}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750}; CC -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization CC and activation by autophosphorylation on tyrosine residues. In vitro CC kinase activity is increased by Mg(2+). Inhibited by PD153035, CC lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS. CC {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954, CC ECO:0000269|PubMed:8617750}. CC -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or CC heterodimer with another ERBB family member upon ligand binding, thus CC forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CC CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 CC (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ CC domain). Interacts with MUC1. Interacts (via its PPxy motifs) with CC WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 CC (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and CC isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) CC with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CC CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 CC but represses ERBB4-mediated transcriptional activity. Interacts with CC PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU, CC AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 and SRRT. Interacts CC (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. CC Interacts with SHC1. Interacts with GRB2. Interacts (soluble CC intracellular domain) with STAT5A. Interacts (soluble intracellular CC domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250, CC ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395, CC ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036, CC ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537, CC ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975, CC ECO:0000269|PubMed:9516479}. CC -!- INTERACTION: CC Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694; CC Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049; CC Q15303; Q12959: DLG1; NbExp=4; IntAct=EBI-80371, EBI-357481; CC Q15303; Q15700: DLG2; NbExp=3; IntAct=EBI-80371, EBI-80426; CC Q15303; Q92796: DLG3; NbExp=4; IntAct=EBI-80371, EBI-80440; CC Q15303; P78352: DLG4; NbExp=9; IntAct=EBI-80371, EBI-80389; CC Q15303; P00533: EGFR; NbExp=4; IntAct=EBI-80371, EBI-297353; CC Q15303; P04626: ERBB2; NbExp=5; IntAct=EBI-80371, EBI-641062; CC Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706; CC Q15303; P62993: GRB2; NbExp=7; IntAct=EBI-80371, EBI-401755; CC Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558; CC Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572; CC Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198; CC Q15303; Q96JA1: LRIG1; NbExp=3; IntAct=EBI-80371, EBI-2865191; CC Q15303; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-80371, EBI-311035; CC Q15303; Q02297-6: NRG1; NbExp=3; IntAct=EBI-80371, EBI-15651799; CC Q15303; Q06124: PTPN11; NbExp=2; IntAct=EBI-80371, EBI-297779; CC Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058; CC Q15303; P29353: SHC1; NbExp=6; IntAct=EBI-80371, EBI-78835; CC Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743; CC Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059; CC Q15303; P62258: YWHAE; NbExp=2; IntAct=EBI-80371, EBI-356498; CC Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In CC response to NRG1 treatment, the activated receptor is internalized. CC -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus CC {ECO:0000269|PubMed:17486069}. Mitochondrion CC {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing CC E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is CC translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is CC found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=JM-A CYT-1; CC IsoId=Q15303-1; Sequence=Displayed; CC Name=JM-B CYT-1; CC IsoId=Q15303-2; Sequence=VSP_002895; CC Name=JM-A CYT-2; CC IsoId=Q15303-3; Sequence=VSP_022148; CC Name=JM-B CYT-2; CC IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart, CC kidney, in addition to skeletal muscle, parathyroid, cerebellum, CC pituitary, spleen, testis and breast. Lower levels in thymus, lung, CC salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 CC are expressed in cerebellum, but only the isoform JM-B is expressed in CC the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}. CC -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. CC Proteolytic processing in response to ligand or 12-O- CC tetradecanoylphorbol-13-acetate stimulation results in the production CC of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 CC kDa fragments (m80HER4), which are further processed by a presenilin- CC dependent gamma-secretase to release a cytoplasmic intracellular domain CC (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). CC Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 CC are more readily degraded by the proteasome than fragments of isoform CC JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CC CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not CC processed by ADAM17, precluding further processing by gamma-secretase. CC {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to ligand CC binding. Autophosphorylation occurs in trans, i.e. one subunit of the CC dimeric receptor phosphorylates tyrosine residues on the other subunit. CC Ligands trigger phosphorylation at specific tyrosine residues, thereby CC creating binding sites for scaffold proteins and effectors. CC Constitutively phosphorylated at a basal level when overexpressed in CC heterologous systems; ligand binding leads to increased CC phosphorylation. Phosphorylation at Tyr-1035 is important for CC interaction with STAT1. Phosphorylation at Tyr-1056 is important for CC interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for CC interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute CC to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively CC phosphorylated on tyrosine residues in a ligand-independent manner. CC E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9168115}. CC -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is CC ubiquitinated by the APC/C complex and targeted to proteasomal CC degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are CC ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is CC ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720}. CC -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A CC neurodegenerative disorder affecting upper motor neurons in the brain CC and lower motor neurons in the brain stem and spinal cord, resulting in CC fatal paralysis. Sensory abnormalities are absent. The pathologic CC hallmarks of the disease include pallor of the corticospinal tract due CC to loss of motor neurons, presence of ubiquitin-positive inclusions CC within surviving motor neurons, and deposition of pathologic CC aggregates. The etiology of amyotrophic lateral sclerosis is likely to CC be multifactorial, involving both genetic and environmental factors. CC The disease is inherited in 5-10% of the cases. CC {ECO:0000269|PubMed:24119685}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates CC E4ICD1 (s80Cyt1). CC -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates CC E4ICD2 (s80Cyt2). {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating CC apoptosis, differentiation, or tumor cell proliferation may be CC explained by the opposite functions of the different isoforms and their CC intracellular fragments, and by the formation of heterodimers with CC other EGF receptor family members (PubMed:18454307, PubMed:21811097). CC Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is CC sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 CC (PubMed:19098003). {ECO:0000305|PubMed:19098003}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07868; AAB59446.1; -; mRNA. DR EMBL; BC112199; AAI12200.1; -; mRNA. DR EMBL; BC143741; AAI43742.1; -; mRNA. DR EMBL; BC143747; AAI43748.1; -; mRNA. DR EMBL; BC143749; AAI43750.1; -; mRNA. DR EMBL; AB209697; BAD92934.1; -; mRNA. DR CCDS; CCDS2394.1; -. [Q15303-1] DR CCDS; CCDS42811.1; -. [Q15303-3] DR PIR; A47253; A47253. DR RefSeq; NP_001036064.1; NM_001042599.2. [Q15303-3] DR RefSeq; NP_001425934.1; NM_001439005.1. [Q15303-2] DR RefSeq; NP_001425935.1; NM_001439006.1. [Q15303-4] DR RefSeq; NP_005226.1; NM_005235.3. [Q15303-1] DR PDB; 2AHX; X-ray; 2.40 A; A/B=26-641. DR PDB; 2L2T; NMR; -; A/B=642-685. DR PDB; 2LCX; NMR; -; A/B=642-685. DR PDB; 2R4B; X-ray; 2.40 A; A/B=690-999. DR PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029. DR PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029. DR PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029. DR PDB; 3U2P; X-ray; 2.57 A; A=26-522. DR PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640. DR PDB; 3U9U; X-ray; 3.42 A; E/F=26-650. DR PDB; 8U4I; EM; 3.38 A; A/B=26-635. DR PDB; 8U4J; EM; 3.70 A; A/B=26-635. DR PDB; 8U4K; EM; 4.27 A; A=26-634. DR PDB; 8U4L; EM; 3.31 A; A=26-634. DR PDBsum; 2AHX; -. DR PDBsum; 2L2T; -. DR PDBsum; 2LCX; -. DR PDBsum; 2R4B; -. DR PDBsum; 3BBT; -. DR PDBsum; 3BBW; -. DR PDBsum; 3BCE; -. DR PDBsum; 3U2P; -. DR PDBsum; 3U7U; -. DR PDBsum; 3U9U; -. DR PDBsum; 8U4I; -. DR PDBsum; 8U4J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR AlphaFoldDB; Q15303; -. DR EMDB; EMD-41883; -. DR EMDB; EMD-41884; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR SMR; Q15303; -. DR BioGRID; 108378; 183. DR CORUM; Q15303; -. DR DIP; DIP-29650N; -. DR ELM; Q15303; -. DR FunCoup; Q15303; 1593. DR IntAct; Q15303; 146. DR MINT; Q15303; -. DR STRING; 9606.ENSP00000342235; -. DR BindingDB; Q15303; -. DR ChEMBL; CHEMBL3009; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12744; CGI-1842. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12325; Idasanutlin. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q15303; -. DR GuidetoPHARMACOLOGY; 1799; -. DR TCDB; 8.A.23.1.17; the basigin (basigin) family. DR GlyCosmos; Q15303; 11 sites, No reported glycans. DR GlyGen; Q15303; 11 sites, 6 N-linked glycans (4 sites). DR iPTMnet; Q15303; -. DR PhosphoSitePlus; Q15303; -. DR BioMuta; ERBB4; -. DR DMDM; 3913590; -. DR jPOST; Q15303; -. DR MassIVE; Q15303; -. DR PaxDb; 9606-ENSP00000342235; -. DR PeptideAtlas; Q15303; -. DR ProteomicsDB; 60520; -. [Q15303-1] DR ProteomicsDB; 60521; -. [Q15303-2] DR ProteomicsDB; 60522; -. [Q15303-3] DR ProteomicsDB; 60523; -. [Q15303-4] DR Pumba; Q15303; -. DR ABCD; Q15303; 1 sequenced antibody. DR Antibodypedia; 1602; 1464 antibodies from 47 providers. DR DNASU; 2066; -. DR Ensembl; ENST00000260943.11; ENSP00000260943.7; ENSG00000178568.16. [Q15303-4] DR Ensembl; ENST00000342788.9; ENSP00000342235.4; ENSG00000178568.16. [Q15303-1] DR Ensembl; ENST00000436443.5; ENSP00000403204.1; ENSG00000178568.16. [Q15303-3] DR GeneID; 2066; -. DR KEGG; hsa:2066; -. DR MANE-Select; ENST00000342788.9; ENSP00000342235.4; NM_005235.3; NP_005226.1. DR UCSC; uc002veg.2; human. [Q15303-1] DR AGR; HGNC:3432; -. DR CIViC; 2066; 9 evidence items across 8 molecular profiles. DR ClinPGx; PA27847; -. DR CTD; 2066; -. DR DisGeNET; 2066; -. DR GeneCards; ERBB4; -. DR HGNC; HGNC:3432; ERBB4. DR HPA; ENSG00000178568; Tissue enhanced (brain, fallopian tube). DR MalaCards; ERBB4; -. DR MIM; 600543; gene. DR MIM; 615515; phenotype. DR OpenTargets; ENSG00000178568; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000178568; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000154695; -. DR InParanoid; Q15303; -. DR OMA; VCHSECL; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; Q15303; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q15303; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15303; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR SignaLink; Q15303; -. DR SIGNOR; Q15303; -. DR Agora; ENSG00000178568; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2066; 33 hits in 1186 CRISPR screens. DR ChiTaRS; ERBB4; human. DR EvolutionaryTrace; Q15303; -. DR GeneWiki; ERBB4; -. DR GenomeRNAi; 2066; -. DR Pharos; Q15303; Tclin. DR PRO; PR:Q15303; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15303; protein. DR Bgee; ENSG00000178568; Expressed in endothelial cell and 154 other cell types or tissues. DR ExpressionAtlas; Q15303; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IEA:Ensembl. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB. DR GO; GO:0050811; F:GABA receptor binding; IEA:Ensembl. DR GO; GO:0038131; F:neuregulin receptor activity; IDA:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IMP:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl. DR GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0038130; P:ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0072046; P:establishment of planar polarity involved in nephron morphogenesis; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007595; P:lactation; IMP:UniProtKB. DR GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl. DR GO; GO:0007399; P:nervous system development; ISS:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IBA:GO_Central. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0007416; P:synapse assembly; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05110; PTKc_HER4; 1. DR CDD; cd12092; TM_ErbB4; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000003; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 6.10.250.880; -; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF90; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; KW Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Disease variant; Disulfide bond; Glycoprotein; KW Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..1308 FT /note="Receptor tyrosine-protein kinase erbB-4" FT /id="PRO_0000016674" FT CHAIN 676..1308 FT /note="ERBB4 intracellular domain" FT /evidence="ECO:0000250" FT /id="PRO_0000396797" FT TOPO_DOM 26..651 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 652..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1308 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 718..985 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1117..1150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..684 FT /note="Nuclear localization signal" FT MOTIF 1032..1035 FT /note="PPxY motif 1" FT MOTIF 1053..1056 FT /note="PPxY motif 2" FT MOTIF 1298..1301 FT /note="PPxY motif 3" FT MOTIF 1306..1308 FT /note="PDZ-binding" FT ACT_SITE 843 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 724..732 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 797..799 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 843..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 875 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1035 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1056 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17120616, FT ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750" FT MOD_RES 1150 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1188 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1202 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1258 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1284 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 253 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 473 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 495 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 548 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 576 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 29..56 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 156..186 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 189..197 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 193..205 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 213..221 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 217..229 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 230..238 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 234..246 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 249..258 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 262..289 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 293..304 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 308..323 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 326..330 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 503..512 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 507..520 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 523..532 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 536..552 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 555..569 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 559..577 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 580..589 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 593..614 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 617..625 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 621..633 FT /evidence="ECO:0000269|PubMed:16203964" FT VAR_SEQ 626..648 FT /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform FT JM-B CYT-1 and isoform JM-B CYT-2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9334263" FT /id="VSP_002895" FT VAR_SEQ 1046..1061 FT /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT- FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4" FT /id="VSP_022148" FT VARIANT 140 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042113" FT VARIANT 303 FT /note="S -> Y (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs1484791833)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042114" FT VARIANT 927 FT /note="R -> Q (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514262)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070810" FT VARIANT 1275 FT /note="R -> W (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514263)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070811" FT MUTAGEN 646 FT /note="Q->C: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:17120616" FT MUTAGEN 675 FT /note="V->A: Abolishes proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:15746097, FT ECO:0000269|PubMed:17638867" FT MUTAGEN 681..684 FT /note="KKKR->EIMG: Abolishes nuclear localization of the FT ERBB4 intracellular domain." FT /evidence="ECO:0000269|PubMed:15534001" FT MUTAGEN 710 FT /note="L->N: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 721 FT /note="V->I: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 751 FT /note="K->R: Abolishes kinase activity. Abolishes FT phosphorylation, proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:11390655, FT ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867" FT MUTAGEN 766 FT /note="M->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 773 FT /note="A->S: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 782 FT /note="R->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 810 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 843 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16978839" FT MUTAGEN 854 FT /note="P->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 861 FT /note="D->Y: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 864 FT /note="L->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 872 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 926 FT /note="T->M: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 947 FT /note="I->R: Constitutively autophosphorylated." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 992 FT /note="R->A: Abolishes APC/C-mediated degradation; when FT associated with A-995 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 995 FT /note="L->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1000 FT /note="D->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-995." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1035 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1301." FT /evidence="ECO:0000269|PubMed:16061658" FT MUTAGEN 1056 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination. Promotes nuclear translocation of ERBB4 FT intracellular domain E4ICD1." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1056 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1301." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1035. Loss of FT interaction with YAP1 and stimulation of transcription." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1056." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:3U7U" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 87..91 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 167..169 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 176..178 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 191..193 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 226..228 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 245..254 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 265..269 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 288..292 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 312..317 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 320..325 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 350..352 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 360..364 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 370..374 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 386..394 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 397..400 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 402..405 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 415..417 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 425..427 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 432..438 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 455..461 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 474..476 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 479..482 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 489..491 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 498..500 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 519..528 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 531..534 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 537..543 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 545..548 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 568..573 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 576..585 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 588..592 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 595..608 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 625..629 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 651..676 FT /evidence="ECO:0007829|PDB:2L2T" FT HELIX 715..717 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 718..729 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 731..737 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 740..743 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 746..752 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 762..773 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 783..787 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 789..791 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 793..797 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 804..810 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 817..836 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 849..853 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 856..859 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 864..869 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 889..893 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 899..914 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 920..923 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 926..928 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 929..934 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 947..955 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 961..963 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 967..977 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 981..983 FT /evidence="ECO:0007829|PDB:2R4B" SQ SEQUENCE 1308 AA; 146808 MW; 5E4AE80985D88761 CRC64; MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV // ID FGFR2_HUMAN Reviewed; 821 AA. AC P21802; B4DFC2; E7EVR6; E9PCR0; P18443; Q01742; Q12922; Q14300; Q14301; AC Q14302; Q14303; Q14304; Q14305; Q14672; Q14718; Q14719; Q1KHY5; Q86YI4; AC Q8IXC7; Q96KL9; Q96KM0; Q96KM1; Q96KM2; Q9NZU2; Q9NZU3; Q9UD01; Q9UD02; AC Q9UIH3; Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7; Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7; AC Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Fibroblast growth factor receptor 2; DE Short=FGFR-2; DE EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; DE AltName: Full=K-sam; DE Short=KGFR; DE AltName: Full=Keratinocyte growth factor receptor; DE AltName: CD_antigen=CD332; DE Flags: Precursor; GN Name=FGFR2; Synonyms=BEK, KGFR, KSAM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Neonatal brain stem; RX PubMed=1697263; DOI=10.1002/j.1460-2075.1990.tb07454.x; RA Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G., Ruta M., RA Burgess W.H., Jaye M., Schlessinger J.; RT "Cloning and expression of two distinct high-affinity receptors cross- RT reacting with acidic and basic fibroblast growth factors."; RL EMBO J. 9:2685-2692(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10). RX PubMed=2172978; DOI=10.1073/pnas.87.20.8180; RA Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C., RA Torriglia A., Courtois Y., Breathnach R.; RT "Related fibroblast growth factor receptor genes exist in the human RT genome."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 11). RX PubMed=1647213; DOI=10.1016/0167-4781(91)90015-e; RA Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.; RT "Two cDNAs encoding novel human FGF receptor."; RL Biochim. Biophys. Acta 1089:244-246(1991). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RC TISSUE=Stomach cancer; RX PubMed=2377625; DOI=10.1073/pnas.87.15.5983; RA Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K., Sakamoto H., RA Katoh O., Yoshida T., Sugimura T., Terada M.; RT "K-sam, an amplified gene in stomach cancer, is a member of the heparin- RT binding growth factor receptor genes."; RL Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 8; 9 AND 16). RX PubMed=1313574; DOI=10.1073/pnas.89.7.2960; RA Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y., RA Sugimura T., Terada M.; RT "K-sam gene encodes secreted as well as transmembrane receptor tyrosine RT kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 16), DOMAIN, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=1400433; DOI=10.1016/s0021-9258(19)36821-8; RA Dell K.R., Williams L.T.; RT "A novel form of fibroblast growth factor receptor 2. Alternative splicing RT of the third immunoglobulin-like domain confers ligand binding RT specificity."; RL J. Biol. Chem. 267:21225-21229(1992). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 13 AND 16), SUBUNIT, DOMAIN, AND RP VARIANT ARG-613. RC TISSUE=Mammary gland; RX PubMed=1309608; DOI=10.1073/pnas.89.1.246; RA Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H., RA Chan A.M.-L., Aaronson S.A.; RT "Determination of ligand-binding specificity by alternative splicing: two RT distinct growth factor receptors encoded by a single gene."; RL Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 13). RC TISSUE=Cornea, and Mammary gland; RX PubMed=7866434; RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RT "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and RT their receptors in human breast cells and tissues: alternative receptors."; RL Cell. Mol. Biol. Res. 40:337-350(1994). RN [9] RP ERRATUM OF PUBMED:7866434. RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RL Cell. Mol. Biol. Res. 40:707-707(1994). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342. RC TISSUE=Blood; RA Steinberger D., Mueller U.; RL Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-613. RX PubMed=10626794; RA Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H., RA Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.; RT "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology- RT mediated recombination, generating preferential expression of specific RT messenger RNAs."; RL Cancer Res. 59:6080-6086(1999). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 7; 8 AND 12). RX PubMed=11856867; DOI=10.1159/000048802; RA Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G., Jabs E.W.; RT "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and RT variations."; RL Cytogenet. Cell Genet. 94:121-126(2001). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3). RA Lind D.L., Cox D.R.; RT "Sequence and polymorphisms in fibroblast growth factor receptor 2 (FGFR2) RT gene in humans."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17). RA Jang J.; RT "Identification of a novel variant of FGFR2."; RL Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186. RG NIEHS SNPs program; RL Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases. RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 15). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427. RX PubMed=10712195; DOI=10.1086/302831; RA Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A., RA Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A., RA Wilkie A.O.M., Jabs E.W.; RT "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome RT and Pfeiffer syndrome."; RL Am. J. Hum. Genet. 66:768-777(2000). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821 (ISOFORMS RP 5; 8 AND 12). RX PubMed=10196476; DOI=10.1016/s0378-1119(99)00047-5; RA Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.; RT "Genomic organization of the human fibroblast growth factor receptor 2 RT (FGFR2) gene and comparative analysis of the human FGFR gene family."; RL Gene 230:69-79(1999). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS TRP-252 AND RP ARG-253. RX PubMed=7668257; RA Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S., Dufresne C., RA Cohen M.M. Jr., Jabs E.W.; RT "Analysis of phenotypic features and FGFR2 mutations in Apert syndrome."; RL Am. J. Hum. Genet. 57:321-328(1995). RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259. RX PubMed=8676562; RA Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F., RA Yamazaki Y., Ohtani H.; RT "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth RT factor receptor 2 and rapid mutational analysis in Apert syndrome."; RL Rinsho Byori 44:435-438(1996). RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318. RX PubMed=8673103; DOI=10.1038/ng0596-48; RA Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P., Stenman G., RA Wilkie A.O.M.; RT "Exclusive paternal origin of new mutations in Apert syndrome."; RL Nat. Genet. 13:48-53(1996). RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289; RP ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354. RX PubMed=7581378; DOI=10.1093/hmg/4.8.1387; RA Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K., Losken H.W., RA Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.; RT "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common RT point mutation shared with Jackson-Weiss syndrome."; RL Hum. Mol. Genet. 4:1387-1390(1995). RN [25] RP FUNCTION (ISOFORM 3), SUBUNIT, AND DOMAIN. RX PubMed=8961926; DOI=10.1021/bi961942c; RA Gray T.E., Eisenstein M., Yayon A., Givol D.; RT "Asparagine-344 is a key residue for ligand binding in keratinocyte growth RT factor receptor."; RL Biochemistry 35:15640-15645(1996). RN [26] RP INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND FUNCTION RP IN CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [27] RP INVOLVEMENT IN SCS, AND VARIANT SCS 269-VAL-VAL-270 DEL. RX PubMed=9585583; DOI=10.1086/301855; RA Paznekas W.A., Cunningham M.L., Howard T.D., Korf B.R., Lipson M.H., RA Grix A.W., Feingold M., Goldberg R., Borochowitz Z., Aleck K., Mulliken J., RA Yin M., Jabs E.W.; RT "Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR RT mutations."; RL Am. J. Hum. Genet. 62:1370-1380(1998). RN [28] RP FUNCTION IN PHOSPHORYLATION OF PAK4; REGULATION OF CELL PROLIFERATION AND RP APOPTOSIS, AND INTERACTION WITH GRB2 AND PAK4. RX PubMed=12529371; DOI=10.1074/jbc.m205875200; RA Lu Y., Pan Z.-Z., Devaux Y., Ray P.; RT "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte RT growth factor receptor and participates in keratinocyte growth factor- RT mediated inhibition of oxidant-induced cell death."; RL J. Biol. Chem. 278:10374-10380(2003). RN [29] RP FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL, RP INTERACTION WITH CBL, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT APRS RP TRP-252. RX PubMed=15190072; DOI=10.1074/jbc.m402469200; RA Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.; RT "Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast RT growth factor receptor-2 activation supports osteoblast differentiation."; RL J. Biol. Chem. 279:36259-36267(2004). RN [30] RP FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS, RP MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION WITH RP PLCG1. RX PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031; RA Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.; RT "Tyrosine 769 of the keratinocyte growth factor receptor is required for RT receptor signaling but not endocytosis."; RL Biochem. Biophys. Res. Commun. 327:523-532(2005). RN [31] RP INTERACTION WITH FGF1; FGF7; FGF8; FGF9; FGF10; FGF19; FGF21; FGF22 AND RP FGF23, AND FUNCTION IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [32] RP FUNCTION IN PHOSPHORYLATION OF PLCG1 (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, GLYCOSYLATION, INTERACTION WITH PLCG1, SUBCELLULAR RP LOCATION, MUTAGENESIS OF ASN-265 AND 656-TYR-TYR-657, UBIQUITINATION, AND RP CHARACTERIZATION OF VARIANT PS PHE-278. RX PubMed=16844695; DOI=10.1074/jbc.m600448200; RA Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.; RT "Intracellular retention, degradation, and signaling of glycosylation- RT deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F."; RL J. Biol. Chem. 281:27292-27305(2006). RN [33] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN PHOSPHORYLATION OF RP FRS2 AND ACTIVATION OF MAP KINASES. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [34] RP FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18374639; DOI=10.1016/j.bone.2008.02.009; RA Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.; RT "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt RT signaling and osteoblast survival."; RL Bone 42:1032-1039(2008). RN [36] RP FUNCTION AS FGF7 RECEPTOR AND IN PHOSPHORYLATION OF PLCG1 AND FRS2, RP CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656 RP AND TYR-657, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19410646; DOI=10.1016/j.cellsig.2009.04.004; RA Luo Y., Yang C., Jin C., Xie R., Wang F., McKeehan W.L.; RT "Novel phosphotyrosine targets of FGFR2IIIb signaling."; RL Cell. Signal. 21:1370-1378(2009). RN [37] RP FUNCTION IN FIBROBLAST PROLIFERATION; ACTIVATION OF MAP KINASES AND RP PHOSPHORYLATION OF PLCG1 AND FRS2, INTERACTION WITH PLCG1 AND FRS2, RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-769. RX PubMed=19103595; DOI=10.1074/jbc.m803998200; RA Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J.; RT "Aberrant receptor internalization and enhanced FRS2-dependent signaling RT contribute to the transforming activity of the fibroblast growth factor RT receptor 2 IIIb C3 isoform."; RL J. Biol. Chem. 284:6227-6240(2009). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [39] RP FUNCTION, AND UBIQUITINATION. RX PubMed=21596750; DOI=10.1074/jbc.m110.197525; RA Severe N., Miraoui H., Marie P.J.; RT "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic RT differentiation in human mesenchymal stromal cells in part by decreased RT Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast RT growth factor receptor 2 ubiquitination."; RL J. Biol. Chem. 286:24443-24450(2011). RN [40] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [41] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, SIGNALING, AND ROLE IN RP DISEASE. RX PubMed=19387476; DOI=10.1038/jid.2009.97; RA Katoh M.; RT "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer RT pathologies."; RL J. Invest. Dermatol. 129:1861-1867(2009). RN [42] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [43] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2. RX PubMed=10830168; DOI=10.1016/s0092-8674(00)80851-x; RA Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.; RT "Crystal structures of two FGF-FGFR complexes reveal the determinants of RT ligand-receptor specificity."; RL Cell 101:413-424(2000). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1 AND RP HEPARIN, AND INTERACTION WITH FGF1 AND HEPARIN. RX PubMed=11069186; DOI=10.1038/35039551; RA Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.; RT "Crystal structure of fibroblast growth factor receptor ectodomain bound to RT ligand and heparin."; RL Nature 407:1029-1034(2000). RN [46] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1. RX PubMed=10618369; DOI=10.1073/pnas.97.1.49; RA Stauber D.J., DiGabriele A.D., Hendrickson W.A.; RT "Structural interactions of fibroblast growth factor receptor with its RT ligands."; RL Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS TRP-252 RP AND ARG-253 IN COMPLEX WITH FGF2. RX PubMed=11390973; DOI=10.1073/pnas.121183798; RA Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., RA Mohammadi M.; RT "Structural basis for fibroblast growth factor receptor 2 activation in RT Apert syndrome."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH FGF10. RX PubMed=12591959; DOI=10.1073/pnas.0436500100; RA Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I., Ron D., RA Aaronson S.A., Mohammadi M.; RT "Structural basis by which alternative splicing confers specificity in RT fibroblast growth factor receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH FGF8, RP FUNCTION AS FGF8 RECEPTOR, INTERACTION WITH FGF8, AND DISULFIDE BONDS. RX PubMed=16384934; DOI=10.1101/gad.1365406; RA Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A., RA Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.; RT "Structural basis by which alternative splicing modulates the organizer RT activity of FGF8 in the brain."; RL Genes Dev. 20:185-198(2006). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP RP ANALOG; PEPTIDE SUBSTRATE AND MAGNESIUM, ACTIVITY REGULATION, RP PHOSPHORYLATION AT TYR-586; TYR-656 AND TYR-657, MUTAGENESIS OF ASN-549 AND RP GLU-565, CHARACTERIZATION OF VARIANT FSPC GLU-526, CHARACTERIZATION OF RP VARIANT CS HIS-549, CHARACTERIZATION OF VARIANTS PS GLY-565 AND ARG-641, RP AND CHARACTERIZATION OF VARIANT CRANIOSYNOSTOSIS ASN-659. RX PubMed=17803937; DOI=10.1016/j.molcel.2007.06.028; RA Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., RA Mohammadi M.; RT "A molecular brake in the kinase hinge region regulates the activity of RT receptor tyrosine kinases."; RL Mol. Cell 27:717-730(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-766 OF VARIANT LADD1 THR-628 RP IN COMPLEX WITH ATP ANALOG, CATALYTIC ACTIVITY, SUBUNIT, AND RP AUTOPHOSPHORYLATION. RX PubMed=18056630; DOI=10.1073/pnas.0709905104; RA Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J.; RT "Structural basis for reduced FGFR2 activity in LADD syndrome: Implications RT for FGFR autoinhibition and activation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:19802-19807(2007). RN [52] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP, RP ACTIVE SITE, IDENTIFICATION BY MASS SPECTROMETRY, AUTOPHOSPHORYLATION, AND RP PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656; TYR-657 AND TYR-769. RX PubMed=19060208; DOI=10.1073/pnas.0807752105; RA Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M., RA Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M.; RT "A crystallographic snapshot of tyrosine trans-phosphorylation in action."; RL Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 458-768 IN COMPLEX WITH RP INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND ACTIVITY RP REGULATION. RX PubMed=21454610; DOI=10.1074/jbc.m110.213736; RA Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J., RA Chen C.R., Chan T.C., France D.S., Ashwell M.A.; RT "A novel mode of protein kinase inhibition exploiting hydrophobic motifs of RT autoinhibited kinases: discovery of ATP-independent inhibitors of RT fibroblast growth factor receptor."; RL J. Biol. Chem. 286:20677-20687(2011). RN [54] RP VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354. RX PubMed=7987400; DOI=10.1038/ng0994-98; RA Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M., Malcolm S.; RT "Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon RT syndrome."; RL Nat. Genet. 8:98-103(1994). RN [55] RP VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344. RX PubMed=7874170; DOI=10.1038/ng1194-275; RA Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J., RA Charnas L.R., Jackson C.E., Jaye M.; RT "Jackson-Weiss and Crouzon syndromes are allelic with mutations in RT fibroblast growth factor receptor 2."; RL Nat. Genet. 8:275-279(1994). RN [56] RP VARIANTS CS PRO-267; PHE-278 AND ARG-290. RX PubMed=7655462; DOI=10.1093/hmg/4.6.1077; RA Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J., RA Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M., RA Reardon W., Malcolm S.; RT "Mutations in the third immunoglobulin domain of the fibroblast growth RT factor receptor-2 gene in Crouzon syndrome."; RL Hum. Mol. Genet. 4:1077-1082(1995). RN [57] RP VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342. RX PubMed=8528214; DOI=10.1093/hmg/4.7.1229; RA Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J., Jones M.C., RA Jabs E.W.; RT "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic RT heterogeneity and phenotypic variability."; RL Hum. Mol. Genet. 4:1229-1233(1995). RN [58] RP VARIANT PS ALA-321. RX PubMed=7719333; DOI=10.1038/ng0295-108; RA Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M., Renier D.; RT "FGFR2 mutations in Pfeiffer syndrome."; RL Nat. Genet. 9:108-108(1995). RN [59] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=7719344; DOI=10.1038/ng0295-165; RA Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J., RA Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P., RA Malcolm S., Winter R.M., Reardon W.; RT "Apert syndrome results from localized mutations of FGFR2 and is allelic RT with Crouzon syndrome."; RL Nat. Genet. 9:165-172(1995). RN [60] RP VARIANTS PS PRO-341; ARG-342 AND TYR-342. RX PubMed=7719345; DOI=10.1038/ng0295-173; RA Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R., Jones B.M., RA Malcolm S., Winter R.M., Oldridge M., Slaney S.F., Poole M.D., RA Wilkie A.O.M.; RT "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon RT syndrome phenotypes."; RL Nat. Genet. 9:173-176(1995). RN [61] RP VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278; ARG-342; RP SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289. RX PubMed=8644708; RA Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A., Abrams L.J., RA Graham J.M. Jr., Feingold M., Moeschler J.B., Rawnsley E., Scott A.F., RA Jabs E.W.; RT "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer RT syndromes: evidence for missense changes, insertions, and a deletion due to RT alternative RNA splicing."; RL Am. J. Hum. Genet. 58:491-498(1996). RN [62] RP VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384. RX PubMed=8946174; DOI=10.1159/000472215; RA Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M., Hayward R., RA Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S., Winter R.M.; RT "Spectrum of craniosynostosis phenotypes associated with novel mutations at RT the fibroblast growth factor receptor 2 locus."; RL Eur. J. Hum. Genet. 4:283-291(1996). RN [63] RP VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL. RX PubMed=8956050; RX DOI=10.1002/(sici)1098-1004(1996)8:4<386::aid-humu18>3.0.co;2-z; RA Steinberger D., Mulliken J.B., Mueller U.; RT "Crouzon syndrome: previously unrecognized deletion, duplication, and point RT mutation within FGFR2 gene."; RL Hum. Mutat. 8:386-390(1996). RN [64] RP VARIANTS BSTVS CYS-372 AND CYS-375. RX PubMed=8696350; DOI=10.1038/ng0896-492; RA Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W., Bamshad M.J., RA Carey J.C., Hall B.D., Stevenson R., Orlow S.J., Cohen M.M. Jr., Jabs E.W.; RT "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis RT gyrata syndrome."; RL Nat. Genet. 13:492-494(1996). RN [65] RP VARIANT PS CYS-290. RX PubMed=9150725; DOI=10.1007/s004390050413; RA Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.; RT "Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 RT (FGFR2) gene is associated with Pfeiffer syndrome."; RL Hum. Genet. 99:602-606(1997). RN [66] RP VARIANT JWS SER-342. RX PubMed=9385368; DOI=10.1007/s004390050584; RA Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F., RA Battaglia P.A.; RT "Jackson-Weiss syndrome: identification of two novel FGFR2 missense RT mutations shared with Crouzon and Pfeiffer craniosynostotic disorders."; RL Hum. Genet. 101:47-50(1997). RN [67] RP VARIANT LEU-252, VARIANT APRS PHE-252, AND VARIANT PS 252-SER-PRO-253 RP DELINS PHE-SER. RX PubMed=9002682; DOI=10.1093/hmg/6.1.137; RA Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M., RA Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G., RA Gagnon D.M., Jabs E.W., Wilkie A.O.M.; RT "Genotype-phenotype correlation for nucleotide substitutions in the IgII- RT IgIII linker of FGFR2."; RL Hum. Mol. Genet. 6:137-143(1997). RN [68] RP VARIANT CS GLU-292. RX PubMed=9152842; DOI=10.1136/jmg.34.5.420; RA Steinberger D., Collmann H., Schmalenberger B., Mueller U.; RT "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with RT Crouzon phenotype and plagiocephaly."; RL J. Med. Genet. 34:420-422(1997). RN [69] RP VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342, RP VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278. RX PubMed=9677057; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<237::aid-ajmg5>3.3.co;2-5; RA Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G., Zatz M., RA Alonso N., Brunoni D., Ribeiro S.F.M.; RT "Description of a new mutation and characterization of FGFR1, FGFR2, and RT FGFR3 mutations among Brazilian patients with syndromic craniosynostoses."; RL Am. J. Med. Genet. 78:237-241(1998). RN [70] RP VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314. RX PubMed=9521581; DOI=10.1007/s004390050668; RA Steinberger D., Vriend G., Mulliken J.B., Mueller U.; RT "The mutations in FGFR2-associated craniosynostoses are clustered in five RT structural elements of immunoglobulin-like domain III of the receptor."; RL Hum. Genet. 102:145-150(1998). RN [71] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=9452027; DOI=10.1002/humu.1380110106; RA Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.; RT "Two common mutations 934C to G and 937C to G of fibroblast growth factor RT receptor 2 (FGFR2) gene in Chinese patients with Apert syndrome."; RL Hum. Mutat. Suppl. 1:S18-S19(1998). RN [72] RP VARIANT PS CYS-351. RX PubMed=9693549; DOI=10.1097/00001665-199805000-00004; RA Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J., Hesseling-Janssen A.L.W., RA van den Ouweland A.M.W.; RT "Pfeiffer's syndrome resulting from an S351C mutation in the fibroblast RT growth factor receptor-2 gene."; RL J. Craniofac. Surg. 9:207-209(1998). RN [73] RP VARIANT PS TRP-252. RX PubMed=9719378; DOI=10.1136/jmg.35.8.677; RA Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.; RT "Presence of the Apert canonical S252W FGFR2 mutation in a patient without RT severe syndactyly."; RL J. Med. Genet. 35:677-679(1998). RN [74] RP VARIANT CS SER-362. RX PubMed=10574673; DOI=10.1597/1545-1569_1999_036_0533_anfgmi_2.3.co_2; RA Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.; RT "A novel FGFR2 gene mutation in Crouzon syndrome associated with apparent RT nonpenetrance."; RL Cleft Palate Craniofac. J. 36:533-541(1999). RN [75] RP VARIANTS PS CYS-340 AND GLY-342. RX PubMed=10394936; DOI=10.1007/s004390050979; RA Cornejo-Roldan L.R., Roessler E., Muenke M.; RT "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer RT syndrome."; RL Hum. Genet. 104:425-431(1999). RN [76] RP VARIANT PS ASP-273 DEL. RX PubMed=10945669; DOI=10.1034/j.1399-0004.2000.580116.x; RA Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A., RA Capra V., Silengo M.; RT "Pfeiffer syndrome type 2 associated with a single amino acid deletion in RT the FGFR2 gene."; RL Clin. Genet. 58:81-83(2000). RN [77] RP VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276; PHE-278; RP TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354 AND PHE-359, RP AND VARIANT PS SER-342. RX PubMed=11173845; DOI=10.1159/000056833; RA Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.; RT "Clustering of FGFR2 gene mutations in patients with Pfeiffer and Crouzon RT syndromes (FGFR2-associated craniosynostoses)."; RL Cytogenet. Cell Genet. 91:134-137(2000). RN [78] RP VARIANT SER-315. RX PubMed=10951518; DOI=10.1038/sj.ejhg.5200499; RA Johnson D., Wall S.A., Mann S., Wilkie A.O.M.; RT "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction RT leading to craniosynostosis?"; RL Eur. J. Hum. Genet. 8:571-577(2000). RN [79] RP VARIANTS ABS2 ARG-342; SER-342 AND CYS-351. RX PubMed=10633130; DOI=10.1136/jmg.37.1.26; RA Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G., RA Nelson I., Malcolm S., Ades L., Sillence D., Kumar D., RA DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M., RA Winter R.M.; RT "Evidence for digenic inheritance in some cases of Antley-Bixler RT syndrome?"; RL J. Med. Genet. 37:26-32(2000). RN [80] RP VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342. RX PubMed=11380921; DOI=10.1046/j.1442-200x.2001.01392.x; RA Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.; RT "Mutation analysis of Crouzon syndrome and identification of one novel RT mutation in Taiwanese patients."; RL Pediatr. Int. 43:263-266(2001). RN [81] RP VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338; HIS-340; RP PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678, VARIANTS PS RP PHE-172; 252-SER-PRO-253 DELINS PHE-SER; CYS-290; CYS-340; PRO-341; RP ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS RP TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT RP CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315. RX PubMed=11781872; DOI=10.1086/338758; RA Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J., Reich E.W., RA Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S., RA McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M., Wilkie A.O.M.; RT "Genomic screening of fibroblast growth-factor receptor 2 reveals a wide RT spectrum of mutations in patients with syndromic craniosynostosis."; RL Am. J. Hum. Genet. 70:472-486(2002). RN [82] RP VARIANT BSTVS CYS-375. RX PubMed=12000365; DOI=10.1034/j.1399-0004.2002.610309.x; RA Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.; RT "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson RT cutis gyrata syndrome."; RL Clin. Genet. 61:218-221(2002). RN [83] RP VARIANT FSPC GLU-526. RX PubMed=16061565; DOI=10.1136/jmg.2004.027888; RA McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R., RA Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.; RT "Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 RT tyrosine kinase domain."; RL J. Med. Genet. 42:656-662(2005). RN [84] RP VARIANTS LADD1 THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER. RX PubMed=16501574; DOI=10.1038/ng1757; RA Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., RA Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., RA Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., RA Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.; RT "Mutations in different components of FGF signaling in LADD syndrome."; RL Nat. Genet. 38:414-417(2006). RN [85] RP VARIANT [LARGE SCALE ANALYSIS] CYS-203. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [86] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272; ASN-283; RP CYS-290 AND THR-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [87] RP VARIANTS BBDS1 ASP-381 AND ARG-391, AND CHARACTERIZATION OF VARIANT BBDS1 RP ARG-391. RX PubMed=22387015; DOI=10.1016/j.ajhg.2012.02.005; RA Merrill A.E., Sarukhanov A., Krejci P., Idoni B., Camacho N., Estrada K.D., RA Lyons K.M., Deixler H., Robinson H., Chitayat D., Curry C.J., Lachman R.S., RA Wilcox W.R., Krakow D.; RT "Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has RT deficient canonical FGF signaling."; RL Am. J. Hum. Genet. 90:550-557(2012). RN [88] RP VARIANT LEU-57. RX PubMed=26429889; DOI=10.1136/jmedgenet-2015-103336; RA Perles Z., Moon S., Ta-Shma A., Yaacov B., Francescatto L., Edvardson S., RA Rein A.J., Elpeleg O., Katsanis N.; RT "A human laterality disorder caused by a homozygous deleterious mutation in RT MMP21."; RL J. Med. Genet. 52:840-847(2015). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays an essential role in the CC regulation of cell proliferation, differentiation, migration and CC apoptosis, and in the regulation of embryonic development. Required for CC normal embryonic patterning, trophoblast function, limb bud CC development, lung morphogenesis, osteogenesis and skin development. CC Plays an essential role in the regulation of osteoblast CC differentiation, proliferation and apoptosis, and is required for CC normal skeleton development. Promotes cell proliferation in CC keratinocytes and immature osteoblasts, but promotes apoptosis in CC differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand CC binding leads to the activation of several signaling cascades. CC Activation of PLCG1 leads to the production of the cellular signaling CC molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC FGFR2 signaling is down-regulated by ubiquitination, internalization CC and degradation. Mutations that lead to constitutive kinase activation CC or impair normal FGFR2 maturation, internalization and degradation lead CC to aberrant signaling. Over-expressed FGFR2 promotes activation of CC STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. Inhibited by ARQ 523 and ARQ CC 069; these compounds maintain the kinase in an inactive conformation CC and inhibit autophosphorylation. {ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:21454610}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts CC predominantly with FGF1 and FGF2, but can also interact with FGF3, CC FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). CC Ligand specificity is determined by tissue-specific expression of CC isoforms, and differences in the third Ig-like domain are crucial for CC ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but CC low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, CC and has much higher affinity for FGF7 than isoform 1 (in vitro). CC Affinity for fibroblast growth factors (FGFs) is increased by heparan CC sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB CC increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 CC and PAK4. Interacts with FLRT2 (By similarity). CC {ECO:0000250|UniProtKB:P21803, ECO:0000269|PubMed:10618369, CC ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11069186, CC ECO:0000269|PubMed:11390973, ECO:0000269|PubMed:12529371, CC ECO:0000269|PubMed:12591959, ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19060208, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:21454610, CC ECO:0000269|PubMed:8663044, ECO:0000269|PubMed:8961926}. CC -!- INTERACTION: CC P21802; P06734: FCER2; NbExp=2; IntAct=EBI-1028658, EBI-10199985; CC P21802; P05230: FGF1; NbExp=3; IntAct=EBI-1028658, EBI-698068; CC P21802; PRO_0000008908 [P05230]: FGF1; NbExp=5; IntAct=EBI-1028658, EBI-6880860; CC P21802; O15520: FGF10; NbExp=2; IntAct=EBI-1028658, EBI-1035684; CC P21802; P09038: FGF2; NbExp=5; IntAct=EBI-1028658, EBI-977447; CC P21802; P09038-2: FGF2; NbExp=2; IntAct=EBI-1028658, EBI-11122080; CC P21802; P11362: FGFR1; NbExp=3; IntAct=EBI-1028658, EBI-1028277; CC P21802; P62993: GRB2; NbExp=6; IntAct=EBI-1028658, EBI-401755; CC P21802; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-1028658, EBI-6358090; CC P21802-1; P05230-1: FGF1; NbExp=2; IntAct=EBI-15489960, EBI-15489950; CC P21802-1; P09038: FGF2; NbExp=2; IntAct=EBI-15489960, EBI-977447; CC P21802-1; P21802-1: FGFR2; NbExp=3; IntAct=EBI-15489960, EBI-15489960; CC P21802-1; P19174: PLCG1; NbExp=9; IntAct=EBI-15489960, EBI-79387; CC P21802-3; P21781: FGF7; NbExp=2; IntAct=EBI-6354683, EBI-3937699; CC P21802-3; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-6354683, EBI-6358090; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on CC osteoblast plasma membrane lipid rafts. After ligand binding, the CC activated receptor is rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 13]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=17; CC Name=1; Synonyms=BEK, FGFR2IIIc; CC IsoId=P21802-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=P21802-2; Sequence=VSP_002978; CC Name=3; Synonyms=BFR-1, FGFR2IIIb, KGFR; CC IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972; CC Name=4; Synonyms=K-sam; CC IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002975, CC VSP_002976; CC Name=5; Synonyms=K-sam-I, BEK, IgIIIc; CC IsoId=P21802-5; Sequence=VSP_002975; CC Name=6; Synonyms=K-sam-IIC2; CC IsoId=P21802-6; Sequence=VSP_002975, VSP_002984; CC Name=7; Synonyms=K-sam-IIC3; CC IsoId=P21802-8; Sequence=VSP_002975, VSP_002978; CC Name=8; Synonyms=K-sam-IV, Soluble KGFR; CC IsoId=P21802-14; Sequence=VSP_002965, VSP_002966; CC Name=9; Synonyms=K-sam-III; CC IsoId=P21802-15; Sequence=VSP_002968; CC Name=10; Synonyms=TK14; CC IsoId=P21802-16; Sequence=VSP_002967, VSP_002975; CC Name=11; CC IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002978; CC Name=12; Synonyms=K-sam-IIC1, KGFR, IgIIIb; CC IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002975; CC Name=13; Synonyms=Soluble KGFR; CC IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002973, VSP_002974; CC Name=14; CC IsoId=P21802-20; Sequence=VSP_019608, VSP_019609; CC Name=15; CC IsoId=P21802-21; Sequence=VSP_002964, VSP_041915; CC Name=16; CC IsoId=P21802-22; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002978; CC Name=17; CC IsoId=P21802-23; Sequence=VSP_041914; CC -!- DOMAIN: The second and third Ig-like domains directly interact with CC fibroblast growth factors (FGF) and heparan sulfate proteoglycans. CC Alternative splicing events affecting the third Ig-like domain are CC crucial for ligand selectivity. {ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:8961926}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on several tyrosine residues. CC Autophosphorylation occurs in trans between the two FGFR molecules CC present in the dimer. Phosphorylation at Tyr-769 is essential for CC interaction with PLCG1. {ECO:0000269|PubMed:15629145, CC ECO:0000269|PubMed:19060208}. CC -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains CC undergo further maturation to an Endo H-resistant form in the Golgi CC apparatus. {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17311277}. CC -!- PTM: Ubiquitinated. FGFR2 is rapidly ubiquitinated after CC autophosphorylation, leading to internalization and degradation. CC Subject to degradation both in lysosomes and by the proteasome. CC {ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:21596750}. CC -!- DISEASE: Crouzon syndrome (CS) [MIM:123500]: An autosomal dominant CC syndrome characterized by craniosynostosis, hypertelorism, exophthalmos CC and external strabismus, parrot-beaked nose, short upper lip, CC hypoplastic maxilla, and a relative mandibular prognathism. CC {ECO:0000269|PubMed:10574673, ECO:0000269|PubMed:11173845, CC ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:17803937, ECO:0000269|PubMed:7581378, CC ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:7874170, CC ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:8946174, CC ECO:0000269|PubMed:8956050, ECO:0000269|PubMed:9152842, CC ECO:0000269|PubMed:9521581, ECO:0000269|PubMed:9677057, CC ECO:0000269|Ref.10}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal CC dominant craniosynostosis syndrome characterized by craniofacial CC abnormalities and abnormality of the feet: broad great toes with medial CC deviation and tarsal-metatarsal coalescence. CC {ECO:0000269|PubMed:7874170, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Apert syndrome (APRS) [MIM:101200]: A syndrome characterized CC by facio-cranio-synostosis, osseous and membranous syndactyly of the CC four extremities, and midface hypoplasia. The craniosynostosis is CC bicoronal and results in acrocephaly of brachysphenocephalic type. CC Syndactyly of the fingers and toes may be total (mitten hands and sock CC feet) or partial affecting the second, third, and fourth digits. CC Intellectual deficit is frequent and often severe, usually being CC associated with cerebral malformations. {ECO:0000269|PubMed:11390973, CC ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, CC ECO:0000269|PubMed:9002682, ECO:0000269|PubMed:9452027, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized CC by the association of craniosynostosis, broad and deviated thumbs and CC big toes, and partial syndactyly of the fingers and toes. Three CC subtypes are known: mild autosomal dominant form (type 1); cloverleaf CC skull, elbow ankylosis, early death, sporadic (type 2); CC craniosynostosis, early demise, sporadic (type 3). CC {ECO:0000269|PubMed:10394936, ECO:0000269|PubMed:10945669, CC ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:7719333, ECO:0000269|PubMed:7719345, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9002682, CC ECO:0000269|PubMed:9150725, ECO:0000269|PubMed:9693549, CC ECO:0000269|PubMed:9719378}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Beare-Stevenson cutis gyrata syndrome (BSTVS) [MIM:123790]: An CC autosomal dominant disease characterized by craniofacial anomalies, CC particularly craniosynostosis, and ear defects, cutis gyrata, CC acanthosis nigricans, anogenital anomalies, skin tags, and prominent CC umbilical stump. The skin furrows have a corrugated appearance and are CC widespread. Cutis gyrata variably affects the scalp, forehead, face, CC preauricular area, neck, trunk, hands, and feet. CC {ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Familial scaphocephaly syndrome (FSPC) [MIM:609579]: An CC autosomal dominant craniosynostosis syndrome characterized by CC scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and CC mild intellectual disability. Scaphocephaly is the most common of the CC craniosynostosis conditions and is characterized by a long, narrow CC head. It is due to premature fusion of the sagittal suture or from CC external deformation. {ECO:0000269|PubMed:16061565, CC ECO:0000269|PubMed:17803937}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome 1 (LADD1) CC [MIM:149730]: A form of lacrimo-auriculo-dento-digital syndrome, an CC autosomal dominant disease characterized by aplastic/hypoplastic CC lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, CC hypodontia and enamel hypoplasia, and distal limb segments anomalies. CC In addition to these cardinal features, facial dysmorphism, CC malformations of the kidney and respiratory system and abnormal CC genitalia have been reported. Craniosynostosis and severe syndactyly CC are not observed. {ECO:0000269|PubMed:16501574, CC ECO:0000269|PubMed:18056630}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Antley-Bixler syndrome, without genital anomalies or CC disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome CC characterized by craniosynostosis, radiohumeral synostosis present from CC the perinatal period, midface hypoplasia, choanal stenosis or atresia, CC femoral bowing and multiple joint contractures. Arachnodactyly and/or CC camptodactyly have also been reported. {ECO:0000269|PubMed:10633130}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Bent bone dysplasia syndrome 1 (BBDS1) [MIM:614592]: A CC perinatal lethal skeletal dysplasia characterized by poor CC mineralization of the calvarium, craniosynostosis, dysmorphic facial CC features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, CC and bent long bones. Dysmorphic facial features included low-set ears, CC hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and CC micrognathia. {ECO:0000269|PubMed:22387015}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Saethre-Chotzen syndrome (SCS) [MIM:101400]: A CC craniosynostosis syndrome characterized by coronal synostosis, CC brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, CC broad halluces, and clinodactyly. {ECO:0000269|PubMed:9585583}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA89296.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89297.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89298.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89299.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89300.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89301.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAG57383.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40570/FGFR2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52832; CAA37014.1; -; mRNA. DR EMBL; M55614; AAA61188.1; -; mRNA. DR EMBL; X56191; CAA39654.1; -; mRNA. DR EMBL; M35718; AAA36152.1; -; mRNA. DR EMBL; M87770; AAA59470.1; -; mRNA. DR EMBL; M87771; AAA59471.1; -; mRNA. DR EMBL; M87772; AAA59472.1; -; mRNA. DR EMBL; M97193; AAA52449.1; -; mRNA. DR EMBL; U11814; AAA68514.1; -; mRNA. DR EMBL; M80634; AAA36147.1; -; mRNA. DR EMBL; Z71929; CAA96492.1; -; mRNA. DR EMBL; AB030073; BAA89296.1; ALT_SEQ; mRNA. DR EMBL; AB030074; BAA89297.1; ALT_SEQ; mRNA. DR EMBL; AB030075; BAA89298.1; ALT_SEQ; mRNA. DR EMBL; AB030076; BAA89299.1; ALT_SEQ; mRNA. DR EMBL; AB030077; BAA89300.1; ALT_SEQ; mRNA. DR EMBL; AB030078; BAA89301.1; ALT_SEQ; mRNA. DR EMBL; AF360695; AAK94205.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94205.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94206.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94206.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94207.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94207.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94208.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94208.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94209.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94209.1; JOINED; Genomic_DNA. DR EMBL; AF487553; AAM74056.1; -; Genomic_DNA. DR EMBL; AB084153; BAC45037.1; -; mRNA. DR EMBL; DQ493927; ABE96832.1; -; Genomic_DNA. DR EMBL; AK294026; BAG57383.1; ALT_INIT; mRNA. DR EMBL; AC009988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039243; AAH39243.2; -; mRNA. DR EMBL; AF169399; AAF43273.1; -; Genomic_DNA. DR EMBL; AF169399; AAF43274.1; -; Genomic_DNA. DR EMBL; AF097353; AAD31560.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097343; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097353; AAD31561.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097344; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097340; AAD31562.1; -; Genomic_DNA. DR EMBL; AF097337; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097338; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097339; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097354; AAD31565.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31567.1; -; Genomic_DNA. DR EMBL; S82438; AAD14392.1; -; Genomic_DNA. DR EMBL; Y17131; CAA76643.1; -; Genomic_DNA. DR EMBL; L49237; AAC41933.1; -; Genomic_DNA. DR EMBL; L49242; AAC41934.1; -; Genomic_DNA. DR EMBL; L49238; AAC41935.1; -; Genomic_DNA. DR EMBL; L49239; AAC41936.1; -; Genomic_DNA. DR EMBL; L49240; AAC41937.1; -; Genomic_DNA. DR EMBL; L49241; AAC41938.1; -; Genomic_DNA. DR CCDS; CCDS31298.1; -. [P21802-1] DR CCDS; CCDS44485.1; -. [P21802-20] DR CCDS; CCDS44486.1; -. [P21802-23] DR CCDS; CCDS44487.1; -. [P21802-15] DR CCDS; CCDS44488.1; -. [P21802-22] DR CCDS; CCDS44489.1; -. [P21802-17] DR CCDS; CCDS53584.1; -. [P21802-21] DR CCDS; CCDS7620.2; -. [P21802-3] DR CCDS; CCDS81515.1; -. [P21802-5] DR PIR; A35969; A35969. DR PIR; A42691; TVHUF2. DR PIR; A45081; A45081. DR PIR; C42691; C42691. DR PIR; S16236; S16236. DR RefSeq; NP_000132.3; NM_000141.5. [P21802-1] DR RefSeq; NP_001138385.1; NM_001144913.1. [P21802-17] DR RefSeq; NP_001138386.1; NM_001144914.1. [P21802-23] DR RefSeq; NP_001138387.1; NM_001144915.2. [P21802-21] DR RefSeq; NP_001138388.1; NM_001144916.1. DR RefSeq; NP_001138389.1; NM_001144917.2. [P21802-15] DR RefSeq; NP_001138390.1; NM_001144918.2. [P21802-20] DR RefSeq; NP_001138391.1; NM_001144919.2. [P21802-22] DR RefSeq; NP_001307583.1; NM_001320654.1. DR RefSeq; NP_001307587.1; NM_001320658.2. [P21802-5] DR RefSeq; NP_001428016.1; NM_001441087.1. [P21802-18] DR RefSeq; NP_075259.4; NM_022970.4. [P21802-3] DR RefSeq; NP_075418.1; NM_023029.2. DR PDB; 1DJS; X-ray; 2.40 A; A=153-362. DR PDB; 1E0O; X-ray; 2.80 A; B/D=148-366. DR PDB; 1EV2; X-ray; 2.20 A; E/F/G/H=147-366. DR PDB; 1GJO; X-ray; 2.40 A; A=456-768. DR PDB; 1II4; X-ray; 2.70 A; E/F/G/H=147-366. DR PDB; 1IIL; X-ray; 2.30 A; E/F/G/H=147-366. DR PDB; 1NUN; X-ray; 2.90 A; B=140-368. DR PDB; 1OEC; X-ray; 2.40 A; A=456-768. DR PDB; 1WVZ; NMR; -; A=147-249. DR PDB; 2FDB; X-ray; 2.28 A; P/R=149-368. DR PDB; 2PSQ; X-ray; 2.40 A; A/B=413-768. DR PDB; 2PVF; X-ray; 1.80 A; A=458-778, B=764-778. DR PDB; 2PVY; X-ray; 2.20 A; A/B/C/D=458-768. DR PDB; 2PWL; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PY3; X-ray; 2.30 A; A/B=458-768. DR PDB; 2PZ5; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZP; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZR; X-ray; 3.00 A; A/B=458-768. DR PDB; 2Q0B; X-ray; 2.90 A; A/B=458-768. DR PDB; 3B2T; X-ray; 1.80 A; A/B=458-766. DR PDB; 3CAF; X-ray; 1.96 A; A=150-249. DR PDB; 3CLY; X-ray; 2.00 A; A=458-778. DR PDB; 3CU1; X-ray; 2.60 A; A/C=150-249. DR PDB; 3DAR; X-ray; 2.20 A; A/B=146-249. DR PDB; 3EUU; X-ray; 2.34 A; A/B=150-249. DR PDB; 3OJ2; X-ray; 2.20 A; C/D=140-313. DR PDB; 3OJM; X-ray; 2.10 A; B=140-313. DR PDB; 3RI1; X-ray; 2.10 A; A/B=458-768. DR PDB; 4J23; X-ray; 3.88 A; A=147-366. DR PDB; 4J95; X-ray; 2.38 A; A/B/C/D=458-768. DR PDB; 4J96; X-ray; 2.30 A; A/B=458-768. DR PDB; 4J97; X-ray; 2.55 A; A/B/C/D=458-768. DR PDB; 4J98; X-ray; 2.31 A; A/B=458-768. DR PDB; 4J99; X-ray; 1.85 A; A/B/C/D=458-768. DR PDB; 4WV1; X-ray; 2.36 A; C/F=153-251. DR PDB; 5EG3; X-ray; 2.61 A; A=458-778. DR PDB; 5UGL; X-ray; 1.86 A; A/B=458-768. DR PDB; 5UGX; X-ray; 2.35 A; A/B=458-768. DR PDB; 5UHN; X-ray; 2.91 A; A/B=458-768. DR PDB; 5UI0; X-ray; 2.05 A; A/B=458-768. DR PDB; 6AGX; X-ray; 2.95 A; A/B/C/D=467-764. DR PDB; 6LVK; X-ray; 2.29 A; A/B=459-768. DR PDB; 6LVL; X-ray; 2.98 A; A/B=459-768. DR PDB; 6V6Q; X-ray; 2.46 A; A/B/C/D=413-821. DR PDB; 7KIA; X-ray; 2.22 A; A/B=461-768. DR PDB; 7KIE; X-ray; 2.47 A; A/B=461-768. DR PDB; 7OZY; X-ray; 2.28 A; AAA/BBB=465-763. DR PDB; 8E1X; X-ray; 2.68 A; A/B=459-768. DR PDB; 8H75; X-ray; 3.75 A; A/B/C/D=459-768. DR PDB; 8STG; X-ray; 3.79 A; A/B=458-769. DR PDB; 8SWE; X-ray; 2.24 A; A/B=458-768. DR PDB; 8U1F; X-ray; 3.33 A; A/B=458-768. DR PDB; 8W2X; X-ray; 2.98 A; A/B=458-768. DR PDB; 8W38; X-ray; 2.60 A; A/B/C/D=458-768. DR PDB; 8W3B; X-ray; 2.23 A; A/B/C/D=458-768. DR PDB; 8W3D; X-ray; 2.04 A; A/B/C/D=458-768. DR PDB; 9U3N; X-ray; 3.25 A; A/B=458-768. DR PDBsum; 1DJS; -. DR PDBsum; 1E0O; -. DR PDBsum; 1EV2; -. DR PDBsum; 1GJO; -. DR PDBsum; 1II4; -. DR PDBsum; 1IIL; -. DR PDBsum; 1NUN; -. DR PDBsum; 1OEC; -. DR PDBsum; 1WVZ; -. DR PDBsum; 2FDB; -. DR PDBsum; 2PSQ; -. DR PDBsum; 2PVF; -. DR PDBsum; 2PVY; -. DR PDBsum; 2PWL; -. DR PDBsum; 2PY3; -. DR PDBsum; 2PZ5; -. DR PDBsum; 2PZP; -. DR PDBsum; 2PZR; -. DR PDBsum; 2Q0B; -. DR PDBsum; 3B2T; -. DR PDBsum; 3CAF; -. DR PDBsum; 3CLY; -. DR PDBsum; 3CU1; -. DR PDBsum; 3DAR; -. DR PDBsum; 3EUU; -. DR PDBsum; 3OJ2; -. DR PDBsum; 3OJM; -. DR PDBsum; 3RI1; -. DR PDBsum; 4J23; -. DR PDBsum; 4J95; -. DR PDBsum; 4J96; -. DR PDBsum; 4J97; -. DR PDBsum; 4J98; -. DR PDBsum; 4J99; -. DR PDBsum; 4WV1; -. DR PDBsum; 5EG3; -. DR PDBsum; 5UGL; -. DR PDBsum; 5UGX; -. DR PDBsum; 5UHN; -. DR PDBsum; 5UI0; -. DR PDBsum; 6AGX; -. DR PDBsum; 6LVK; -. DR PDBsum; 6LVL; -. DR PDBsum; 6V6Q; -. DR PDBsum; 7KIA; -. DR PDBsum; 7KIE; -. DR PDBsum; 7OZY; -. DR PDBsum; 8E1X; -. DR PDBsum; 8H75; -. DR PDBsum; 8STG; -. DR PDBsum; 8SWE; -. DR PDBsum; 8U1F; -. DR PDBsum; 8W2X; -. DR PDBsum; 8W38; -. DR PDBsum; 8W3B; -. DR PDBsum; 8W3D; -. DR PDBsum; 9U3N; -. DR AlphaFoldDB; P21802; -. DR BMRB; P21802; -. DR SMR; P21802; -. DR BioGRID; 108554; 241. DR CORUM; P21802; -. DR DIP; DIP-3788N; -. DR FunCoup; P21802; 1763. DR IntAct; P21802; 206. DR MINT; P21802; -. DR STRING; 9606.ENSP00000410294; -. DR BindingDB; P21802; -. DR ChEMBL; CHEMBL4142; -. DR DrugBank; DB02058; 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. DR DrugBank; DB02491; 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine. DR DrugBank; DB12558; AEE-788. DR DrugBank; DB12903; DEBIO-1347. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB17587; KIN-3248. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB13022; LY-2874455. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB00039; Palifermin. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB01901; Sucrosofate. DR DrugCentral; P21802; -. DR GuidetoPHARMACOLOGY; 1809; -. DR GlyConnect; 1997; 1 N-Linked glycan (1 site). DR GlyCosmos; P21802; 9 sites, 2 glycans. DR GlyGen; P21802; 9 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P21802; -. DR PhosphoSitePlus; P21802; -. DR BioMuta; FGFR2; -. DR DMDM; 120049; -. DR CPTAC; CPTAC-3175; -. DR jPOST; P21802; -. DR MassIVE; P21802; -. DR PaxDb; 9606-ENSP00000410294; -. DR PeptideAtlas; P21802; -. DR ProteomicsDB; 53905; -. [P21802-1] DR ProteomicsDB; 53910; -. [P21802-14] DR ProteomicsDB; 53911; -. [P21802-15] DR ProteomicsDB; 53912; -. [P21802-16] DR ProteomicsDB; 53913; -. [P21802-17] DR ProteomicsDB; 53914; -. [P21802-18] DR ProteomicsDB; 53915; -. [P21802-19] DR ProteomicsDB; 53916; -. [P21802-2] DR ProteomicsDB; 53917; -. [P21802-20] DR ProteomicsDB; 53918; -. [P21802-21] DR ProteomicsDB; 53919; -. [P21802-22] DR ProteomicsDB; 53920; -. [P21802-23] DR ProteomicsDB; 53921; -. [P21802-3] DR ProteomicsDB; 53922; -. [P21802-4] DR ProteomicsDB; 53923; -. [P21802-5] DR ProteomicsDB; 53924; -. [P21802-6] DR ProteomicsDB; 53926; -. [P21802-8] DR TopDownProteomics; P21802-8; -. [P21802-8] DR ABCD; P21802; 5 sequenced antibodies. DR Antibodypedia; 4393; 1424 antibodies from 47 providers. DR DNASU; 2263; -. DR Ensembl; ENST00000346997.6; ENSP00000263451.5; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000351936.11; ENSP00000309878.10; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000356226.8; ENSP00000348559.4; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000357555.9; ENSP00000350166.5; ENSG00000066468.25. [P21802-21] DR Ensembl; ENST00000358487.10; ENSP00000351276.6; ENSG00000066468.25. [P21802-1] DR Ensembl; ENST00000359354.6; ENSP00000352309.2; ENSG00000066468.25. [P21802-14] DR Ensembl; ENST00000360144.7; ENSP00000353262.3; ENSG00000066468.25. [P21802-22] DR Ensembl; ENST00000369056.5; ENSP00000358052.1; ENSG00000066468.25. [P21802-17] DR Ensembl; ENST00000369060.8; ENSP00000358056.4; ENSG00000066468.25. [P21802-15] DR Ensembl; ENST00000369061.8; ENSP00000358057.4; ENSG00000066468.25. [P21802-23] DR Ensembl; ENST00000457416.7; ENSP00000410294.2; ENSG00000066468.25. [P21802-3] DR Ensembl; ENST00000682550.1; ENSP00000507633.1; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000683211.1; ENSP00000508257.1; ENSG00000066468.25. [P21802-5] DR GeneID; 2263; -. DR KEGG; hsa:2263; -. DR MANE-Select; ENST00000358487.10; ENSP00000351276.6; NM_000141.5; NP_000132.3. DR UCSC; uc010qtl.3; human. [P21802-1] DR AGR; HGNC:3689; -. DR CIViC; 2263; 42 evidence items across 27 molecular profiles. DR ClinPGx; PA28128; -. DR CTD; 2263; -. DR DisGeNET; 2263; -. DR GeneCards; FGFR2; -. DR GeneReviews; FGFR2; -. DR HGNC; HGNC:3689; FGFR2. DR HPA; ENSG00000066468; Tissue enriched (brain). DR MalaCards; FGFR2; -. DR MIM; 101200; phenotype. DR MIM; 101400; phenotype. DR MIM; 101600; phenotype. DR MIM; 123150; phenotype. DR MIM; 123500; phenotype. DR MIM; 123790; phenotype. DR MIM; 149730; phenotype. DR MIM; 176943; gene. DR MIM; 207410; phenotype. DR MIM; 609579; phenotype. DR MIM; 614592; phenotype. DR OpenTargets; ENSG00000066468; -. DR Orphanet; 596008; Antley-Bixler syndrome without genital anomaly or disorder of steroidogenesis. DR Orphanet; 87; Apert syndrome. DR Orphanet; 207; Crouzon syndrome. DR Orphanet; 1555; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome. DR Orphanet; 168624; Familial scaphocephaly syndrome, McGillivray type. DR Orphanet; 313855; FGFR2-related bent bone dysplasia. DR Orphanet; 1540; Jackson-Weiss syndrome. DR Orphanet; 2363; Lacrimoauriculodentodigital syndrome. DR Orphanet; 93258; Pfeiffer syndrome type 1. DR Orphanet; 93259; Pfeiffer syndrome type 2. DR Orphanet; 93260; Pfeiffer syndrome type 3. DR Orphanet; 794; Saethre-Chotzen syndrome. DR VEuPathDB; HostDB:ENSG00000066468; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000155447; -. DR HOGENOM; CLU_000288_74_2_1; -. DR InParanoid; P21802; -. DR OMA; PANCTSE; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P21802; 7 GO annotations based on evolutionary models. DR PhylomeDB; P21802; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P21802; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-190375; FGFR2c ligand binding and activation. DR Reactome; R-HSA-190377; FGFR2b ligand binding and activation. DR Reactome; R-HSA-2023837; Signaling by FGFR2 amplification mutants. DR Reactome; R-HSA-2033519; Activated point mutants of FGFR2. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851708; Signaling by FGFR2 IIIa TM. DR Reactome; R-HSA-8853333; Signaling by FGFR2 fusions. DR SignaLink; P21802; -. DR SIGNOR; P21802; -. DR Agora; ENSG00000066468; -. DR BioGRID-ORCS; 2263; 24 hits in 1187 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR2; human. DR EvolutionaryTrace; P21802; -. DR GeneWiki; Fibroblast_growth_factor_receptor_2; -. DR GenomeRNAi; 2263; -. DR Pharos; P21802; Tclin. DR PRO; PR:P21802; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P21802; protein. DR Bgee; ENSG00000066468; Expressed in C1 segment of cervical spinal cord and 202 other cell types or tissues. DR ExpressionAtlas; P21802; baseline and differential. DR GO; GO:0005938; C:cell cortex; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0060076; C:excitatory synapse; ISS:UniProtKB. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; NAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; ISS:UniProtKB. DR GO; GO:0009887; P:animal organ morphogenesis; ISS:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0060348; P:bone development; ISS:UniProtKB. DR GO; GO:0030282; P:bone mineralization; ISS:UniProtKB. DR GO; GO:0060349; P:bone morphogenesis; ISS:UniProtKB. DR GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; ISS:UniProtKB. DR GO; GO:0060442; P:branching involved in prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060445; P:branching involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0060449; P:bud elongation involved in lung branching; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; ISS:UniProtKB. DR GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl. DR GO; GO:0048565; P:digestive tract development; ISS:UniProtKB. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:BHF-UCL. DR GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB. DR GO; GO:0048568; P:embryonic organ development; ISS:UniProtKB. DR GO; GO:0048562; P:embryonic organ morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; IEA:Ensembl. DR GO; GO:0048730; P:epidermis morphogenesis; ISS:UniProtKB. DR GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035603; P:fibroblast growth factor receptor signaling pathway involved in hemopoiesis; ISS:UniProtKB. DR GO; GO:0035602; P:fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell; ISS:UniProtKB. DR GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035604; P:fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow; ISS:UniProtKB. DR GO; GO:0022612; P:gland morphogenesis; ISS:UniProtKB. DR GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB. DR GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB. DR GO; GO:0032808; P:lacrimal gland development; ISS:UniProtKB. DR GO; GO:0060601; P:lateral sprouting from an epithelium; ISS:UniProtKB. DR GO; GO:0060174; P:limb bud formation; ISS:UniProtKB. DR GO; GO:0048286; P:lung alveolus development; ISS:UniProtKB. DR GO; GO:0030324; P:lung development; ISS:UniProtKB. DR GO; GO:0060463; P:lung lobe morphogenesis; ISS:UniProtKB. DR GO; GO:0060484; P:lung-associated mesenchyme development; ISS:UniProtKB. DR GO; GO:0060615; P:mammary gland bud formation; ISS:UniProtKB. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:UniProtKB. DR GO; GO:0048762; P:mesenchymal cell differentiation; ISS:UniProtKB. DR GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; ISS:UniProtKB. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; ISS:UniProtKB. DR GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl. DR GO; GO:0030901; P:midbrain development; ISS:UniProtKB. DR GO; GO:0016331; P:morphogenesis of embryonic epithelium; ISS:UniProtKB. DR GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0042476; P:odontogenesis; ISS:UniProtKB. DR GO; GO:0021769; P:orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035265; P:organ growth; ISS:UniProtKB. DR GO; GO:0030916; P:otic vesicle formation; ISS:UniProtKB. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0060501; P:positive regulation of epithelial cell proliferation involved in lung morphogenesis; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB. DR GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; ISS:UniProtKB. DR GO; GO:0060523; P:prostate epithelial cord elongation; ISS:UniProtKB. DR GO; GO:0060512; P:prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0060688; P:regulation of morphogenesis of a branching structure; ISS:UniProtKB. DR GO; GO:0045667; P:regulation of osteoblast differentiation; TAS:UniProtKB. DR GO; GO:0033688; P:regulation of osteoblast proliferation; TAS:UniProtKB. DR GO; GO:0051150; P:regulation of smooth muscle cell differentiation; ISS:UniProtKB. DR GO; GO:0008589; P:regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0048608; P:reproductive structure development; ISS:UniProtKB. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB. DR GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; ISS:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB. DR GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:UniProtKB. DR GO; GO:0021847; P:ventricular zone neuroblast division; ISS:UniProtKB. DR CDD; cd04973; IgI_1_FGFR; 1. DR CDD; cd05857; IgI_2_FGFR; 1. DR CDD; cd05858; IgI_3_FGFR2; 1. DR CDD; cd05101; PTKc_FGFR2; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000252; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000011; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00546; -. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF130; FIBROBLAST GROWTH FACTOR RECEPTOR 2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Craniosynostosis; Cytoplasmic vesicle; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Glycoprotein; Golgi apparatus; Heparin-binding; KW Immunoglobulin domain; Intellectual disability; Kinase; KW Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..821 FT /note="Fibroblast growth factor receptor 2" FT /id="PRO_0000016783" FT TOPO_DOM 22..377 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 378..398 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 399..821 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 25..125 FT /note="Ig-like C2-type 1" FT DOMAIN 154..247 FT /note="Ig-like C2-type 2" FT DOMAIN 256..358 FT /note="Ig-like C2-type 3" FT DOMAIN 481..770 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 131..151 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 161..178 FT /note="Heparin-binding" FT COMPBIAS 131..144 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 626 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028, FT ECO:0000269|PubMed:19060208" FT BINDING 487..495 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 517 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 565..567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 571 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT MOD_RES 466 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 586 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 656 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 657 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 769 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19060208" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT CARBOHYD 83 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 123 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 228 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 265 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 297 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 331 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 62..107 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 179..231 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT DISULFID 278..342 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT VAR_SEQ 37..152 FT /note="EPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLI FT GEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSEN FT SNNKR -> G (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019608" FT VAR_SEQ 37..125 FT /note="Missing (in isoform 4, isoform 15 and isoform 16)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:2377625" FT /id="VSP_002964" FT VAR_SEQ 250..361 FT /note="Missing (in isoform 17)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_041914" FT VAR_SEQ 250..254 FT /note="ERSPH -> GSQGL (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002965" FT VAR_SEQ 255..821 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002966" FT VAR_SEQ 313 FT /note="K -> KVTK (in isoform 10)" FT /evidence="ECO:0000303|PubMed:2172978" FT /id="VSP_002967" FT VAR_SEQ 314..429 FT /note="Missing (in isoform 9)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002968" FT VAR_SEQ 314..330 FT /note="AAGVNTTDKEIEVLYIR -> HSGINSSNAEVLALF (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002969" FT VAR_SEQ 334..335 FT /note="FE -> EA (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002970" FT VAR_SEQ 341..353 FT /note="TCLAGNSIGISFH -> ICKVSNYIGQANQ (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002971" FT VAR_SEQ 361 FT /note="P -> PKQQ (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002972" FT VAR_SEQ 362..365 FT /note="APGR -> GRRC (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002973" FT VAR_SEQ 366..821 FT /note="Missing (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002974" FT VAR_SEQ 428..429 FT /note="Missing (in isoform 4, isoform 5, isoform 6, isoform FT 7, isoform 10 and isoform 12)" FT /evidence="ECO:0000303|PubMed:1313574, FT ECO:0000303|PubMed:2172978, ECO:0000303|PubMed:2377625" FT /id="VSP_002975" FT VAR_SEQ 429..430 FT /note="Missing (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019609" FT VAR_SEQ 761..821 FT /note="LTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQY FT PHINGSVKT -> PPNPSLMSIFRK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2377625" FT /id="VSP_002976" FT VAR_SEQ 768..821 FT /note="EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSV FT KT -> I (in isoform 2, isoform 7, isoform 11 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:1647213" FT /id="VSP_002978" FT VAR_SEQ 769..821 FT /note="YLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVK FT T -> EKKVSGAVDCHKPPCNPSHLPCVLAVDQ (in isoform 15)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041915" FT VAR_SEQ 778..821 FT /note="QYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT -> PYSP FT CYPDPR (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_002984" FT VARIANT 6 FT /note="R -> P (in dbSNP:rs3750819)" FT /evidence="ECO:0000269|Ref.15" FT /id="VAR_017258" FT VARIANT 57 FT /note="S -> L (in dbSNP:rs56226109)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26429889" FT /id="VAR_042204" FT VARIANT 105 FT /note="Y -> C (in CS; dbSNP:rs1434545235)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8946174" FT /id="VAR_004112" FT VARIANT 172 FT /note="A -> F (in PS; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017259" FT VARIANT 186 FT /note="M -> T (in dbSNP:rs755793)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.15" FT /id="VAR_017260" FT VARIANT 203 FT /note="R -> C (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation; dbSNP:rs2134829270)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_036380" FT VARIANT 252..253 FT /note="SP -> FS (in PS; dbSNP:rs281865420)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:9002682" FT /id="VAR_004116" FT VARIANT 252 FT /note="S -> F (in APRS; requires 2 nucleotide FT substitutions; dbSNP:rs121918498)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004114" FT VARIANT 252 FT /note="S -> L (in dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004113" FT VARIANT 252 FT /note="S -> W (in APRS and PS; common mutation; FT dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:7668257, FT ECO:0000269|PubMed:7719344, ECO:0000269|PubMed:9452027, FT ECO:0000269|PubMed:9677057, ECO:0000269|PubMed:9719378" FT /id="VAR_004115" FT VARIANT 253 FT /note="P -> R (in APRS; common mutation; dbSNP:rs77543610)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, FT ECO:0000269|PubMed:9452027, ECO:0000269|PubMed:9677057" FT /id="VAR_004117" FT VARIANT 263 FT /note="P -> L (in CS; dbSNP:rs779326224)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017261" FT VARIANT 267 FT /note="S -> P (in CS; dbSNP:rs121918505)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7655462" FT /id="VAR_004118" FT VARIANT 268 FT /note="T -> TG (in CS)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004119" FT VARIANT 269..270 FT /note="Missing (in SCS)" FT /evidence="ECO:0000269|PubMed:9585583" FT /id="VAR_075856" FT VARIANT 272 FT /note="G -> V (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042205" FT VARIANT 273 FT /note="Missing (in PS; type 2; dbSNP:rs121918503)" FT /evidence="ECO:0000269|PubMed:10945669" FT /id="VAR_017262" FT VARIANT 276 FT /note="F -> V (in CS; dbSNP:rs1057519036)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:9521581" FT /id="VAR_004120" FT VARIANT 278 FT /note="C -> F (in CS, JWS and PS; forms disulfide-linked FT dimers with constitutive kinase activity, is retained in an FT intracellular compartment and not detected at the cell FT surface; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:16844695, FT ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004121" FT VARIANT 278 FT /note="C -> Y (in CS; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017263" FT VARIANT 281 FT /note="Y -> C (in CS; dbSNP:rs1057519038)" FT /evidence="ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017264" FT VARIANT 283 FT /note="D -> N (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2134313441)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042206" FT VARIANT 287..289 FT /note="Missing (in CS)" FT /id="VAR_004122" FT VARIANT 288 FT /note="I -> S (in CS)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017265" FT VARIANT 289 FT /note="Q -> P (in CS and JWS; dbSNP:rs121918497)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:8644708" FT /id="VAR_004123" FT VARIANT 290 FT /note="W -> C (in PS; severe; also in a lung squamous cell FT carcinoma sample; somatic mutation; dbSNP:rs121918499)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9150725" FT /id="VAR_004124" FT VARIANT 290 FT /note="W -> G (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:8528214" FT /id="VAR_017266" FT VARIANT 290 FT /note="W -> R (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:7655462" FT /id="VAR_004125" FT VARIANT 292 FT /note="K -> E (in CS; dbSNP:rs121918500)" FT /evidence="ECO:0000269|PubMed:9152842" FT /id="VAR_004126" FT VARIANT 301 FT /note="Y -> C (in CS; dbSNP:rs1554930684)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004127" FT VARIANT 314 FT /note="A -> S (in craniosynostosis; dbSNP:rs1358919643)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004128" FT VARIANT 315 FT /note="A -> S (in a non-syndromic craniosynostosis patient FT with abnormal intrauterine history; confers predisposition FT to craniosynostosis; dbSNP:rs121918504)" FT /evidence="ECO:0000269|PubMed:10951518, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017267" FT VARIANT 321 FT /note="D -> A (in PS; dbSNP:rs121918510)" FT /evidence="ECO:0000269|PubMed:7719333" FT /id="VAR_004129" FT VARIANT 328 FT /note="Y -> C (in CS; dbSNP:rs121918493)" FT /evidence="ECO:0000269|PubMed:7874170" FT /id="VAR_004130" FT VARIANT 331 FT /note="N -> I (in CS; dbSNP:rs2134258264)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004131" FT VARIANT 337 FT /note="A -> ANA (in CS)" FT /id="VAR_004132" FT VARIANT 337 FT /note="A -> P (in CS; dbSNP:rs387906676)" FT /evidence="ECO:0000269|PubMed:9677057" FT /id="VAR_017268" FT VARIANT 338 FT /note="G -> E (in CS; dbSNP:rs1057519044)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004133" FT VARIANT 338 FT /note="G -> R (in CS; dbSNP:rs1057519043)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:9677057" FT /id="VAR_015011" FT VARIANT 340 FT /note="Y -> C (in PS; dbSNP:rs1554928884)" FT /evidence="ECO:0000269|PubMed:10394936, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017269" FT VARIANT 340 FT /note="Y -> H (in CS; dbSNP:rs121918489)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7987400" FT /id="VAR_004134" FT VARIANT 341 FT /note="T -> P (in PS and CS; dbSNP:rs121918495)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345" FT /id="VAR_004135" FT VARIANT 342 FT /note="C -> F (in CS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004136" FT VARIANT 342 FT /note="C -> G (in PS; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10394936" FT /id="VAR_017270" FT VARIANT 342 FT /note="C -> R (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004137" FT VARIANT 342 FT /note="C -> S (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7987400, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, FT ECO:0000269|Ref.10" FT /id="VAR_004138" FT VARIANT 342 FT /note="C -> W (in CS; dbSNP:rs121918496)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8528214" FT /id="VAR_017271" FT VARIANT 342 FT /note="C -> Y (in CS and PS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004139" FT VARIANT 344 FT /note="A -> G (in CS and JWS; dbSNP:rs121918492)" FT /evidence="ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004140" FT VARIANT 344 FT /note="A -> P (in CS and PS; dbSNP:rs2134256250)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004141" FT VARIANT 347 FT /note="S -> C (in CS; dbSNP:rs121918494)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004142" FT VARIANT 351 FT /note="S -> C (in CS, PS and ABS2; dbSNP:rs121918502)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:8946174, ECO:0000269|PubMed:9693549" FT /id="VAR_004143" FT VARIANT 354 FT /note="S -> C (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214" FT /id="VAR_004144" FT VARIANT 354 FT /note="S -> Y (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017272" FT VARIANT 356..358 FT /note="Missing (in CS)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004145" FT VARIANT 359 FT /note="V -> F (in CS and PS; dbSNP:rs1274989878)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:8644708" FT /id="VAR_004146" FT VARIANT 362 FT /note="A -> S (in CS)" FT /evidence="ECO:0000269|PubMed:10574673" FT /id="VAR_017273" FT VARIANT 372 FT /note="S -> C (in BSTVS; dbSNP:rs121913477)" FT /evidence="ECO:0000269|PubMed:8696350" FT /id="VAR_017274" FT VARIANT 375 FT /note="Y -> C (in PS and BSTVS; dbSNP:rs121913478)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350" FT /id="VAR_017275" FT VARIANT 381 FT /note="Y -> D (in BBDS1; dbSNP:rs387906678)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067977" FT VARIANT 384 FT /note="G -> R (in CS; dbSNP:rs1554927408)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004147" FT VARIANT 391 FT /note="M -> R (in BBDS1; the mutation selectively reduces FT plasma-membrane levels of the protein and markedly FT diminishes the receptor's responsiveness to extracellular FT FGF; dbSNP:rs387906677)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067978" FT VARIANT 526 FT /note="K -> E (in FSPC; constitutive kinase activity; FT dbSNP:rs121918507)" FT /evidence="ECO:0000269|PubMed:16061565, FT ECO:0000269|PubMed:17803937" FT /id="VAR_023788" FT VARIANT 549 FT /note="N -> H (in CS; constitutive kinase activity; FT dbSNP:rs1057519045)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017276" FT VARIANT 565 FT /note="E -> G (in PS; constitutive kinase activity; FT dbSNP:rs121918506)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017277" FT VARIANT 612 FT /note="R -> T (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1846839725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046071" FT VARIANT 613 FT /note="G -> R (in dbSNP:rs2133933864)" FT /evidence="ECO:0000269|PubMed:10626794, FT ECO:0000269|PubMed:1309608" FT /id="VAR_015012" FT VARIANT 628 FT /note="A -> T (in LADD1; strongly reduced kinase activity; FT dbSNP:rs121918509)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029884" FT VARIANT 641 FT /note="K -> R (in PS; constitutive kinase activity; FT dbSNP:rs1057519047)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017278" FT VARIANT 648 FT /note="A -> T (in LADD1; dbSNP:rs121918508)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029885" FT VARIANT 649..650 FT /note="RD -> S (in LADD1)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029886" FT VARIANT 659 FT /note="K -> N (in craniosynostosis; constitutive kinase FT activity; dbSNP:rs1589722765)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017279" FT VARIANT 663 FT /note="G -> E (in PS; dbSNP:rs2133825396)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017280" FT VARIANT 678 FT /note="R -> G (in CS; dbSNP:rs1845559552)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017281" FT MUTAGEN 265 FT /note="N->Q: Reduced N-glycosylation. Reduced expression at FT the cell surface." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 549 FT /note="N->T: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 565 FT /note="E->A: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 656..657 FT /note="Missing: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 769 FT /note="Y->F: Increases fibroblast proliferation. Decreases FT phosphorylation of PLCG1 and FRS2. Decreases activation of FT MAP kinases." FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19103595" FT CONFLICT 246 FT /note="L -> P (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT CONFLICT 310 FT /note="K -> N (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT STRAND 152..157 FT /evidence="ECO:0007829|PDB:3CAF" FT TURN 159..162 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 166..170 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 175..178 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 181..185 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 188..193 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4WV1" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 211..213 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 215..218 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 238..249 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 287..293 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:3OJ2" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 315..319 FT /evidence="ECO:0007829|PDB:2FDB" FT HELIX 321..323 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:3OJM" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 338..346 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 349..360 FT /evidence="ECO:0007829|PDB:3OJM" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:5UI0" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 481..489 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 490..492 FT /evidence="ECO:0007829|PDB:8W3D" FT STRAND 494..500 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 504..506 FT /evidence="ECO:0007829|PDB:3CLY" FT STRAND 513..518 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 525..541 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 550..554 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 556..558 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 561..565 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 568..571 FT /evidence="ECO:0007829|PDB:1OEC" FT HELIX 572..577 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 585..588 FT /evidence="ECO:0007829|PDB:4J99" FT HELIX 590..592 FT /evidence="ECO:0007829|PDB:8W3D" FT HELIX 594..596 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 600..619 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 629..631 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 632..634 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 636..638 FT /evidence="ECO:0007829|PDB:2PVY" FT STRAND 640..642 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5UGL" FT TURN 652..654 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 655..658 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 659..662 FT /evidence="ECO:0007829|PDB:2PZR" FT STRAND 664..666 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 667..669 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 672..677 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 682..697 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 709..718 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 726..728 FT /evidence="ECO:0007829|PDB:2PZ5" FT HELIX 730..739 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 744..746 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 750..764 FT /evidence="ECO:0007829|PDB:2PVF" FT CONFLICT P21802-16:315 FT /note="T -> L (in Ref. 2; AAA61188)" FT /evidence="ECO:0000305" SQ SEQUENCE 821 AA; 92025 MW; 6CD5001C960ED82F CRC64; MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T // ID FGFR4_HUMAN Reviewed; 802 AA. AC P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8; Q8TDA0; AC Q96KE5; DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot. DT 27-APR-2001, sequence version 2. DT 28-JAN-2026, entry version 248. DE RecName: Full=Fibroblast growth factor receptor 4; DE Short=FGFR-4; DE EC=2.7.10.1; DE AltName: CD_antigen=CD334; DE Flags: Precursor; GN Name=FGFR4; Synonyms=JTK2, TKF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1709094; DOI=10.1002/j.1460-2075.1991.tb07654.x; RA Partanen J.M., Maekelae T.P., Eerola E., Korhonen J., Hirvonen H., RA Claesson-Welsh L., Alitalo K.; RT "FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct RT expression pattern."; RL EMBO J. 10:1347-1354(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS RECEPTOR FOR FGF1 RP AND FGF2. RC TISSUE=Mammary gland; RX PubMed=7680645; DOI=10.1016/s0021-9258(18)53334-2; RA Ron D., Reich R., Chedid M., Lengel C., Cohen O.E., Chan A.M., Neufeld G., RA Miki T., Tronick S.R.; RT "Fibroblast growth factor receptor 4 is a high affinity receptor for both RT acidic and basic fibroblast growth factor but not for keratinocyte growth RT factor."; RL J. Biol. Chem. 268:5388-5394(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-136, TISSUE RP SPECIFICITY, AND SUBCELLULAR LOCATION. RC TISSUE=Intestine; RX PubMed=10631118; DOI=10.1006/bbrc.1999.2010; RA Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T.; RT "Identification of a novel alternative splicing of human FGF receptor 4: RT soluble-form splice variant expressed in human gastrointestinal epithelial RT cells."; RL Biochem. Biophys. Res. Commun. 267:658-662(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9457674; DOI=10.1007/s003359900703; RA Kostrzewa M., Muller U.; RT "Genomic structure and complete sequence of the human FGFR4 gene."; RL Mamm. Genome 9:131-135(1998). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS ILE-10 AND LEU-136, RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=21882254; DOI=10.1002/mc.20848; RA Marshall A.D., van der Ent M.A., Grosveld G.C.; RT "PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma."; RL Mol. Carcinog. 51:807-815(2012). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-136. RA Lind D.L., Cox D.R.; RT "Sequence variation in fibroblast growth factor receptors 3 and 4."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-10; LEU-136 AND RP ARG-388. RG NIEHS SNPs program; RL Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-136. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 609-676. RC TISSUE=Blood; RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [12] RP RETRACTED PAPER. RX PubMed=11781352; DOI=10.1172/jci14036; RA Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.; RT "Targeted expression of a human pituitary tumor-derived isoform of FGF RT receptor-4 recapitulates pituitary tumorigenesis."; RL J. Clin. Invest. 109:69-78(2002). RN [13] RP RETRACTION NOTICE OF PUBMED:11781352. RX PubMed=26237043; DOI=10.1172/jci83399; RA Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.; RL J. Clin. Invest. 125:3303-3303(2015). RN [14] RP PROTEIN SEQUENCE OF 22-38. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [15] RP FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND RP PIK3R1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-754, AND MUTAGENESIS RP OF TYR-754. RX PubMed=7518429; DOI=10.1016/s0021-9258(17)32309-8; RA Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G., Alitalo K.; RT "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). RT Comparison with FGFR-1."; RL J. Biol. Chem. 269:18320-18326(1994). RN [16] RP INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9, AND FUNCTION IN RP CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [17] RP FUNCTION IN CELL DIFFERENTIATION, MUTAGENESIS OF LYS-503, CATALYTIC RP ACTIVITY, AND IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1; FRS2; RP SRC; SHC; GAP43 AND CTTN. RX PubMed=11433297; DOI=10.1038/35083041; RA Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.; RT "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor RT signalling."; RL Nat. Cell Biol. 3:650-657(2001). RN [18] RP INVOLVEMENT IN CANCER. RX PubMed=11830541; RA Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., RA Knyazeva T., Mueller S., Gaertner S., Sures I., Wang H., Imyanitov E., RA Haering H.U., Knayzev P., Iacobelli S., Hoefler H., Ullrich A.; RT "Cancer progression and tumor cell motility are associated with the FGFR4 RT Arg(388) allele."; RL Cancer Res. 62:840-847(2002). RN [19] RP INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23, AND FUNCTION RP IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [20] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN SIGNALING AND IN RP REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [21] RP FUNCTION IN STAT1 PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF RP LYS-503, GLYCOSYLATION, AND PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [22] RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=18756523; DOI=10.1002/ijc.23578; RA Ma Z., Tsuchiya N., Yuasa T., Inoue T., Kumazawa T., Narita S., RA Horikawa Y., Tsuruta H., Obara T., Saito M., Satoh S., Ogawa O., RA Habuchi T.; RT "Polymorphisms of fibroblast growth factor receptor 4 have association with RT the development of prostate cancer and benign prostatic hyperplasia and the RT progression of prostate cancer in a Japanese population."; RL Int. J. Cancer 123:2574-2579(2008). RN [23] RP CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF PLCG1; RP FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ACTIVITY REGULATION, UBIQUITINATION, AND RP SUBCELLULAR LOCATION. RX PubMed=18480409; DOI=10.1091/mbc.e07-12-1219; RA Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.; RT "Ubiquitination of fibroblast growth factor receptor 1 is required for its RT intracellular sorting but not for its endocytosis."; RL Mol. Biol. Cell 19:3390-3403(2008). RN [24] RP CATALYTIC ACTIVITY, FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF CELL RP PROLIFERATION, SUBCELLULAR LOCATION, INTERACTION WITH FGF2 AND HIP1, RP PHOSPHORYLATION AT TYR-642 AND TYR-643, INVOLVEMENT IN CANCER, AND RP CHARACTERIZATION OF VARIANT ARG-388. RX PubMed=18670643; DOI=10.1593/neo.08450; RA Wang J., Yu W., Cai Y., Ren C., Ittmann M.M.; RT "Altered fibroblast growth factor receptor 4 stability promotes prostate RT cancer progression."; RL Neoplasia 10:847-856(2008). RN [25] RP INVOLVEMENT IN CANCER. RX PubMed=20638838; DOI=10.1016/j.ejca.2010.06.017; RA Xu W., Li Y., Wang X., Chen B., Wang Y., Liu S., Xu J., Zhao W., Wu J.; RT "FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis RT including 8555 subjects."; RL Eur. J. Cancer 46:3332-3338(2010). RN [26] RP FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS VIA RP CYP7A1, INTERACTION WITH FGF19; KL AND KLB, AUTOPHOSPHORYLATION, RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=20683963; DOI=10.1002/hep.23708; RA Triantis V., Saeland E., Bijl N., Oude-Elferink R.P., Jansen P.L.; RT "Glycosylation of fibroblast growth factor receptor 4 is a key regulator of RT fibroblast growth factor 19-mediated down-regulation of cytochrome P450 RT 7A1."; RL Hepatology 52:656-666(2010). RN [27] RP FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING. RX PubMed=20018895; DOI=10.1074/jbc.m109.068783; RA Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R., Gupte J., RA Hager T., Wang Z., Lindberg R., Li Y.; RT "FGF19-induced hepatocyte proliferation is mediated through FGFR4 RT activation."; RL J. Biol. Chem. 285:5165-5170(2010). RN [28] RP FUNCTION IN DOWN-REGULATION OF MMP14, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH MMP14. RX PubMed=20798051; DOI=10.1073/pnas.0914459107; RA Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z., RA Alitalo K., Taipale J., Keski-Oja J., Lehti K.; RT "FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a RT membrane type 1 matrix metalloproteinase-FGFR4 complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15786-15791(2010). RN [29] RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=21349172; DOI=10.1186/1471-2407-11-84; RA Xu B., Tong N., Chen S.Q., Hua L.X., Wang Z.J., Zhang Z.D., Chen M.; RT "FGFR4 Gly388Arg polymorphism contributes to prostate cancer development RT and progression: a meta-analysis of 2618 cases and 2305 controls."; RL BMC Cancer 11:84-84(2011). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP INVOLVEMENT IN CANCER. RX PubMed=21412156; DOI=10.1097/cej.0b013e3283457274; RA Frullanti E., Berking C., Harbeck N., Jezequel P., Haugen A., Mawrin C., RA Parise O. Jr., Sasaki H., Tsuchiya N., Dragani T.A.; RT "Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer RT prognostic factor."; RL Eur. J. Cancer Prev. 20:340-347(2011). RN [32] RP FUNCTION IN FGF19 SIGNALING, FUNCTION IN STIMULATION OF CELL PROLIFERATION RP AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND INTERACTION WITH FGF19; RP KLB AND SULFATED GLYCOSAMINOGLYCANS. RX PubMed=21653700; DOI=10.1074/jbc.m111.251140; RA Nakamura M., Uehara Y., Asada M., Honda E., Nagai N., Kimata K., Suzuki M., RA Imamura T.; RT "Sulfated glycosaminoglycans are required for specific and sensitive RT fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and RT betaKlotho."; RL J. Biol. Chem. 286:26418-26423(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [35] RP INTERACTION WITH STAT3, INVOLVEMENT IN CANCER, CHARACTERIZATION OF VARIANT RP ARG-388, AND PHOSPHORYLATION AT TYR-390. RX PubMed=26675719; DOI=10.1038/nature16449; RA Ulaganathan V.K., Sperl B., Rapp U.R., Ullrich A.; RT "Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding RT site."; RL Nature 528:570-574(2015). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426; ASN-516; RP MET-550; THR-712 AND ASN-772. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [37] RP REVIEW ON LIGAND SELECTIVITY AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [38] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [39] RP CHARACTERIZATION OF VARIANT ARG-388, AND FUNCTION IN TUMOR CELL INVASION. RX PubMed=20876804; DOI=10.1158/0008-5472.can-10-1223; RA Sugiyama N., Varjosalo M., Meller P., Lohi J., Hyytiainen M., Kilpinen S., RA Kallioniemi O., Ingvarsen S., Engelholm L.H., Taipale J., Alitalo K., RA Keski-Oja J., Lehti K.; RT "Fibroblast growth factor receptor 4 regulates tumor invasion by coupling RT fibroblast growth factor signaling to extracellular matrix degradation."; RL Cancer Res. 70:7851-7861(2010). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays a role in the regulation of CC cell proliferation, differentiation and migration, and in regulation of CC lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D CC metabolism and phosphate homeostasis. Required for normal down- CC regulation of the expression of CYP7A1, the rate-limiting enzyme in CC bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and CC FRS2. Ligand binding leads to the activation of several signaling CC cascades. Activation of PLCG1 leads to the production of the cellular CC signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and CC its lysosomal degradation. FGFR4 signaling is down-regulated by CC receptor internalization and degradation; MMP14 promotes CC internalization and degradation of FGFR4. Mutations that lead to CC constitutive kinase activation or impair normal FGFR4 inactivation lead CC to aberrant signaling. {ECO:0000269|PubMed:11433297, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409, CC ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20018895, CC ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051, CC ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21653700, CC ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:7680645, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. CC {ECO:0000269|PubMed:18480409}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1, CC FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19, FGF21 and CC FGF23 (in vitro). Binding affinity for FGF family members is enhanced CC by interactions between FGFs and heparan sulfate proteoglycans. CC Interacts with KLB; this strongly increases the affinity for FGF19 and CC FGF23. Affinity for FGF19 is strongly increased by KLB and sulfated CC glycosaminoglycans. KLB and KL both interact with the core-glycosylated CC FGFR4 in the endoplasmic reticulum and promote its degradation, so that CC only FGFR4 with fully mature N-glycans is expressed at the cell CC surface. Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC, CC SHC1, GAP43 and CTTN. Interacts with MMP14 and HIP1 (PubMed:11433297, CC PubMed:16597617, PubMed:17623664, PubMed:18670643, PubMed:20683963, CC PubMed:20798051, PubMed:21653700, PubMed:7518429, PubMed:8663044). CC Interacts with STAT3 (PubMed:26675719). {ECO:0000269|PubMed:11433297, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17623664, CC ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20683963, CC ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:21653700, CC ECO:0000269|PubMed:26675719, ECO:0000269|PubMed:7518429, CC ECO:0000269|PubMed:8663044}. CC -!- INTERACTION: CC P22455; P11362: FGFR1; NbExp=3; IntAct=EBI-6256193, EBI-1028277; CC P22455; P50281: MMP14; NbExp=6; IntAct=EBI-6256193, EBI-992788; CC P22455; P07949: RET; NbExp=2; IntAct=EBI-6256193, EBI-2480756; CC P22455; P34741: SDC2; NbExp=2; IntAct=EBI-6256193, EBI-1172957; CC P22455; Q03167: TGFBR3; NbExp=2; IntAct=EBI-6256193, EBI-2852679; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Endosome. Endoplasmic reticulum. Note=Internalized from the CC cell membrane to recycling endosomes, and from there back to the cell CC membrane. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P22455-1; Sequence=Displayed; CC Name=2; Synonyms=Soluble-form; CC IsoId=P22455-2; Sequence=VSP_035108; CC -!- TISSUE SPECIFICITY: Expressed in gastrointestinal epithelial cells, CC pancreas, and gastric and pancreatic cancer cell lines. CC {ECO:0000269|PubMed:10631118}. CC -!- PTM: N-glycosylated. Full maturation of the glycan chains in the Golgi CC is essential for high affinity interaction with FGF19. CC -!- PTM: Ubiquitinated. Subject to proteasomal degradation when not fully CC glycosylated. {ECO:0000269|PubMed:18480409}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on tyrosine residues. Autophosphorylation CC occurs in trans between the two FGFR molecules present in the dimer. CC {ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:18670643, CC ECO:0000269|PubMed:7518429}. CC -!- DISEASE: Note=FGFR4 variants may be involved in the pathogenesis of CC various cancers. Variant Arg-388 predisposes cancer patients to CC accelerated disease progression and may be associated with poor CC prognosis. It has been found in prostate cancer as well as cancers of CC the breast, colon, head and neck, larynx, lung, skin. CC {ECO:0000269|PubMed:11830541, ECO:0000269|PubMed:18670643, CC ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20638838, CC ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21349172, CC ECO:0000269|PubMed:21412156, ECO:0000269|PubMed:21882254, CC ECO:0000269|PubMed:26675719}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: An additional N-terminally truncated cytoplasmic isoform was CC previously reported to exist. However, the paper was subsequently CC retracted due to concerns regarding duplication of panels in some CC figures. {ECO:0000305|PubMed:11781352, ECO:0000305|PubMed:26237043}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/512/FGFR4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X57205; CAA40490.1; -; mRNA. DR EMBL; L03840; AAB59389.1; -; mRNA. DR EMBL; AF202063; AAF27432.1; -; mRNA. DR EMBL; Y13901; CAA74200.1; -; Genomic_DNA. DR EMBL; AF359246; AAK51435.1; -; mRNA. DR EMBL; JN007471; AEO19712.1; -; mRNA. DR EMBL; JN007472; AEO19713.1; -; mRNA. DR EMBL; JN007473; AEO19714.1; -; mRNA. DR EMBL; JN007474; AEO19715.1; -; mRNA. DR EMBL; JN007475; AEO19716.1; -; mRNA. DR EMBL; JN007476; AEO19717.1; -; mRNA. DR EMBL; JN007477; AEO19718.1; -; mRNA. DR EMBL; JN007478; AEO19719.1; -; mRNA. DR EMBL; JN007479; AEO19720.1; -; mRNA. DR EMBL; JN007480; AEO19721.1; -; mRNA. DR EMBL; JN007481; AEO19722.1; -; mRNA. DR EMBL; JN007482; AEO19723.1; -; mRNA. DR EMBL; AF487555; AAM13666.1; -; Genomic_DNA. DR EMBL; EF571596; ABQ01235.1; -; Genomic_DNA. DR EMBL; AC027314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471195; EAW85036.1; -; Genomic_DNA. DR EMBL; BC011847; AAH11847.1; -; mRNA. DR EMBL; M59373; AAA63208.1; -; mRNA. DR CCDS; CCDS4410.1; -. [P22455-1] DR CCDS; CCDS4411.1; -. [P22455-2] DR PIR; S15345; TVHUF4. DR RefSeq; NP_001278909.1; NM_001291980.1. DR RefSeq; NP_001341913.1; NM_001354984.2. [P22455-1] DR RefSeq; NP_002002.3; NM_002011.4. [P22455-1] DR RefSeq; NP_075252.2; NM_022963.3. [P22455-2] DR RefSeq; NP_998812.1; NM_213647.3. [P22455-1] DR PDB; 4QQ5; X-ray; 2.20 A; A=445-753. DR PDB; 4QQC; X-ray; 2.40 A; A=445-753. DR PDB; 4QQJ; X-ray; 1.68 A; A=445-753. DR PDB; 4QQT; X-ray; 1.50 A; A=445-753. DR PDB; 4QRC; X-ray; 1.90 A; A=445-753. DR PDB; 4R6V; X-ray; 2.35 A; A=445-753. DR PDB; 4TYE; X-ray; 2.80 A; A=447-753. DR PDB; 4TYG; X-ray; 2.40 A; A=447-753. DR PDB; 4TYI; X-ray; 3.40 A; A=447-753. DR PDB; 4TYJ; X-ray; 2.45 A; A=447-753. DR PDB; 4UXQ; X-ray; 1.85 A; A=447-753. DR PDB; 4XCU; X-ray; 1.71 A; A=449-751. DR PDB; 5JKG; X-ray; 2.35 A; A=445-753. DR PDB; 5NUD; X-ray; 2.50 A; A/B=449-753. DR PDB; 5NWZ; X-ray; 2.37 A; A/B=449-753. DR PDB; 5XFF; X-ray; 2.70 A; A=445-753. DR PDB; 5XFJ; X-ray; 3.25 A; A=445-753. DR PDB; 6IUO; X-ray; 2.30 A; A=445-753. DR PDB; 6IUP; X-ray; 2.00 A; A=445-753. DR PDB; 6J6Y; X-ray; 2.15 A; A/D=141-244. DR PDB; 6JPE; X-ray; 1.60 A; A=445-753. DR PDB; 6JPJ; X-ray; 2.64 A; A=445-753. DR PDB; 6NVG; X-ray; 1.99 A; A=450-751. DR PDB; 6NVH; X-ray; 1.90 A; A=450-751. DR PDB; 6NVI; X-ray; 2.12 A; A=450-751. DR PDB; 6NVJ; X-ray; 2.30 A; A=450-751. DR PDB; 6NVK; X-ray; 2.30 A; A=450-751. DR PDB; 6V9C; X-ray; 1.90 A; A=449-751. DR PDB; 6YI8; X-ray; 2.13 A; A/B=447-753. DR PDB; 7DTZ; X-ray; 2.01 A; A=445-753. DR PDB; 7F3M; X-ray; 2.29 A; A=445-753. DR PDB; 7N1J; X-ray; 2.99 A; A/C=245-355. DR PDB; 7TYD; X-ray; 2.86 A; A/C=245-355. DR PDB; 7V29; X-ray; 1.98 A; A/B=445-753. DR PDB; 7VJL; X-ray; 2.90 A; A/B=453-753. DR PDB; 7WCT; X-ray; 2.11 A; A=445-753. DR PDB; 7WCW; X-ray; 2.32 A; A=445-753. DR PDB; 7WCX; X-ray; 2.17 A; A=445-753. DR PDB; 7YBO; X-ray; 2.31 A; A=445-753. DR PDB; 7YBP; X-ray; 2.24 A; A=445-753. DR PDB; 7YBX; X-ray; 2.23 A; A=445-753. DR PDB; 7YC1; X-ray; 2.54 A; A=445-753. DR PDB; 7YC3; X-ray; 1.99 A; A=445-753. DR PDB; 7YSW; EM; 3.03 A; C/E=142-354. DR PDB; 8KH6; X-ray; 1.62 A; A=445-753. DR PDB; 8KH7; X-ray; 1.52 A; A=445-753. DR PDB; 8KH8; X-ray; 1.49 A; A=445-753. DR PDB; 8KH9; X-ray; 1.42 A; A=454-753. DR PDB; 8W5C; X-ray; 2.30 A; A/B=453-752. DR PDB; 8XLQ; X-ray; 1.95 A; A=445-753. DR PDBsum; 4QQ5; -. DR PDBsum; 4QQC; -. DR PDBsum; 4QQJ; -. DR PDBsum; 4QQT; -. DR PDBsum; 4QRC; -. DR PDBsum; 4R6V; -. DR PDBsum; 4TYE; -. DR PDBsum; 4TYG; -. DR PDBsum; 4TYI; -. DR PDBsum; 4TYJ; -. DR PDBsum; 4UXQ; -. DR PDBsum; 4XCU; -. DR PDBsum; 5JKG; -. DR PDBsum; 5NUD; -. DR PDBsum; 5NWZ; -. DR PDBsum; 5XFF; -. DR PDBsum; 5XFJ; -. DR PDBsum; 6IUO; -. DR PDBsum; 6IUP; -. DR PDBsum; 6J6Y; -. DR PDBsum; 6JPE; -. DR PDBsum; 6JPJ; -. DR PDBsum; 6NVG; -. DR PDBsum; 6NVH; -. DR PDBsum; 6NVI; -. DR PDBsum; 6NVJ; -. DR PDBsum; 6NVK; -. DR PDBsum; 6V9C; -. DR PDBsum; 6YI8; -. DR PDBsum; 7DTZ; -. DR PDBsum; 7F3M; -. DR PDBsum; 7N1J; -. DR PDBsum; 7TYD; -. DR PDBsum; 7V29; -. DR PDBsum; 7VJL; -. DR PDBsum; 7WCT; -. DR PDBsum; 7WCW; -. DR PDBsum; 7WCX; -. DR PDBsum; 7YBO; -. DR PDBsum; 7YBP; -. DR PDBsum; 7YBX; -. DR PDBsum; 7YC1; -. DR PDBsum; 7YC3; -. DR PDBsum; 7YSW; -. DR PDBsum; 8KH6; -. DR PDBsum; 8KH7; -. DR PDBsum; 8KH8; -. DR PDBsum; 8KH9; -. DR PDBsum; 8W5C; -. DR PDBsum; 8XLQ; -. DR AlphaFoldDB; P22455; -. DR EMDB; EMD-34084; -. DR SMR; P22455; -. DR BioGRID; 108555; 519. DR CORUM; P22455; -. DR DIP; DIP-5149N; -. DR FunCoup; P22455; 1427. DR IntAct; P22455; 421. DR MINT; P22455; -. DR STRING; 9606.ENSP00000292408; -. DR BindingDB; P22455; -. DR ChEMBL; CHEMBL3973; -. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB16167; Fisogatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB15169; H3B-6527. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB16845; Roblitinib. DR DrugCentral; P22455; -. DR GuidetoPHARMACOLOGY; 1811; -. DR TCDB; 8.A.23.1.9; the basigin (basigin) family. DR GlyConnect; 1938; 7 N-Linked glycans (4 sites). DR GlyCosmos; P22455; 8 sites, 8 glycans. DR GlyGen; P22455; 8 sites, 9 N-linked glycans (5 sites), 1 O-linked glycan (1 site). DR iPTMnet; P22455; -. DR PhosphoSitePlus; P22455; -. DR SwissPalm; P22455; -. DR BioMuta; FGFR4; -. DR DMDM; 13432140; -. DR CPTAC; CPTAC-1768; -. DR CPTAC; CPTAC-3178; -. DR CPTAC; CPTAC-3179; -. DR jPOST; P22455; -. DR MassIVE; P22455; -. DR PaxDb; 9606-ENSP00000292408; -. DR PeptideAtlas; P22455; -. DR ProteomicsDB; 53990; -. [P22455-1] DR ProteomicsDB; 53991; -. [P22455-2] DR ABCD; P22455; 1 sequenced antibody. DR Antibodypedia; 3922; 892 antibodies from 48 providers. DR DNASU; 2264; -. DR Ensembl; ENST00000292408.9; ENSP00000292408.4; ENSG00000160867.16. [P22455-1] DR Ensembl; ENST00000393637.5; ENSP00000377254.1; ENSG00000160867.16. [P22455-2] DR Ensembl; ENST00000502906.5; ENSP00000424960.1; ENSG00000160867.16. [P22455-1] DR GeneID; 2264; -. DR KEGG; hsa:2264; -. DR MANE-Select; ENST00000292408.9; ENSP00000292408.4; NM_213647.3; NP_998812.1. DR UCSC; uc003mfl.4; human. [P22455-1] DR AGR; HGNC:3691; -. DR CIViC; 2264; 11 evidence items across 6 molecular profiles. DR ClinPGx; PA28130; -. DR CTD; 2264; -. DR DisGeNET; 2264; -. DR GeneCards; FGFR4; -. DR HGNC; HGNC:3691; FGFR4. DR HPA; ENSG00000160867; Tissue enhanced (liver, lung). DR MalaCards; FGFR4; -. DR MIM; 134935; gene. DR OpenTargets; ENSG00000160867; -. DR VEuPathDB; HostDB:ENSG00000160867; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000161469; -. DR HOGENOM; CLU_000288_74_3_1; -. DR InParanoid; P22455; -. DR OMA; WYKEGNR; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P22455; 9 GO annotations based on evolutionary models. DR PhylomeDB; P22455; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P22455; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1307965; betaKlotho-mediated ligand binding. DR Reactome; R-HSA-1839128; FGFR4 mutant receptor activation. DR Reactome; R-HSA-190322; FGFR4 ligand binding and activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P22455; -. DR SIGNOR; P22455; -. DR Agora; ENSG00000160867; -. DR BioGRID-ORCS; 2264; 21 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR4; human. DR EvolutionaryTrace; P22455; -. DR GeneWiki; Fibroblast_growth_factor_receptor_4; -. DR GenomeRNAi; 2264; -. DR Pharos; P22455; Tclin. DR PRO; PR:P22455; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P22455; protein. DR Bgee; ENSG00000160867; Expressed in right lobe of liver and 112 other cell types or tissues. DR ExpressionAtlas; P22455; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0030133; C:transport vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IDA:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0055062; P:phosphate ion homeostasis; ISS:UniProtKB. DR GO; GO:0043085; P:positive regulation of catalytic activity; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0070857; P:regulation of bile acid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB. DR GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB. DR CDD; cd05857; IgI_2_FGFR; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000730; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000334; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF343; FIBROBLAST GROWTH FACTOR RECEPTOR 4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Direct protein sequencing; Disulfide bond; Endoplasmic reticulum; Endosome; KW Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 22..802 FT /note="Fibroblast growth factor receptor 4" FT /id="PRO_0000016787" FT TOPO_DOM 22..369 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 370..390 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 391..802 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 22..118 FT /note="Ig-like C2-type 1" FT DOMAIN 152..240 FT /note="Ig-like C2-type 2" FT DOMAIN 249..349 FT /note="Ig-like C2-type 3" FT DOMAIN 467..755 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 119..148 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 612 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 473..481 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 503 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 390 FT /note="Phosphotyrosine; in variant R-388" FT /evidence="ECO:0000269|PubMed:26675719" FT MOD_RES 573 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 642 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18670643" FT MOD_RES 643 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18670643" FT MOD_RES 754 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:7518429" FT CARBOHYD 112 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 258 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 290 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 311 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 57..101 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 172..224 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 271..333 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 353..416 FT /note="EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPA FT TVQKLSRFPLAR -> GTGRIPHLTCDSLTPAGRTKSPTL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10631118" FT /id="VSP_035108" FT VARIANT 10 FT /note="V -> I (in dbSNP:rs1966265)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21882254, ECO:0000269|Ref.7" FT /id="VAR_029185" FT VARIANT 136 FT /note="P -> L (in dbSNP:rs376618)" FT /evidence="ECO:0000269|PubMed:10631118, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21882254, FT ECO:0000269|Ref.6, ECO:0000269|Ref.7, ECO:0000269|Ref.9" FT /id="VAR_042211" FT VARIANT 179 FT /note="T -> A (in dbSNP:rs55675160)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042212" FT VARIANT 388 FT /note="G -> R (in cancer cells, may be associated with FT accelerated disease progression and increased tumor cell FT motility, possibly due to increased stability of the FT protease MMP14; leads to phosphorylation at residue Y-390, FT resulting in prolonged FGFR4 activity; increases FT interaction with STAT3, resulting in STAT3 phosphorylation FT and signaling activation.; dbSNP:rs351855)" FT /evidence="ECO:0000269|PubMed:18670643, FT ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804, FT ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21882254, FT ECO:0000269|PubMed:26675719, ECO:0000269|Ref.7" FT /id="VAR_014797" FT VARIANT 426 FT /note="G -> S (in dbSNP:rs55879131)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046102" FT VARIANT 516 FT /note="D -> N (in dbSNP:rs34158682)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042213" FT VARIANT 529 FT /note="R -> Q (in dbSNP:rs34284947)" FT /id="VAR_049720" FT VARIANT 550 FT /note="V -> M (in breast pleomorphic lobular sample; FT somatic mutation; dbSNP:rs774571806)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046103" FT VARIANT 712 FT /note="P -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046104" FT VARIANT 772 FT /note="S -> N (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046105" FT MUTAGEN 503 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11433297, FT ECO:0000269|PubMed:17311277" FT MUTAGEN 754 FT /note="Y->F: Loss of interaction with PLCG1." FT /evidence="ECO:0000269|PubMed:7518429" FT CONFLICT 121 FT /note="L -> S (in Ref. 3; AAF27432)" FT /evidence="ECO:0000305" FT CONFLICT 194 FT /note="E -> G (in Ref. 3; AAF27432)" FT /evidence="ECO:0000305" FT CONFLICT 297 FT /note="D -> V (in Ref. 1; CAA40490)" FT /evidence="ECO:0000305" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:6J6Y" FT HELIX 152..155 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 159..163 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 168..171 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 181..186 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 201..203 FT /evidence="ECO:0007829|PDB:6J6Y" FT TURN 204..207 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 208..213 FT /evidence="ECO:0007829|PDB:6J6Y" FT HELIX 216..218 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 232..242 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 280..286 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 292..294 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 302..306 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 316..320 FT /evidence="ECO:0007829|PDB:7TYD" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 329..336 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 341..351 FT /evidence="ECO:0007829|PDB:7TYD" FT HELIX 445..448 FT /evidence="ECO:0007829|PDB:4QQ5" FT TURN 458..460 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 480..487 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 489..493 FT /evidence="ECO:0007829|PDB:6NVH" FT STRAND 497..504 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 511..527 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:5XFJ" FT STRAND 536..540 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 542..544 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 547..551 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 558..563 FT /evidence="ECO:0007829|PDB:8KH9" FT TURN 570..572 FT /evidence="ECO:0007829|PDB:6YI8" FT TURN 577..580 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 586..605 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 615..617 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 618..620 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 626..628 FT /evidence="ECO:0007829|PDB:8KH9" FT TURN 631..635 FT /evidence="ECO:0007829|PDB:4XCU" FT HELIX 637..639 FT /evidence="ECO:0007829|PDB:4QQT" FT STRAND 642..644 FT /evidence="ECO:0007829|PDB:4UXQ" FT HELIX 652..655 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 658..663 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 668..683 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 689..692 FT /evidence="ECO:0007829|PDB:6NVH" FT HELIX 695..703 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 716..725 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 730..732 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 736..750 FT /evidence="ECO:0007829|PDB:8KH9" SQ SEQUENCE 802 AA; 87954 MW; B22B259831BB889F CRC64; MRLLLALLGV LLSVPGPPVL SLEASEEVEL EPCLAPSLEQ QEQELTVALG QPVRLCCGRA ERGGHWYKEG SRLAPAGRVR GWRGRLEIAS FLPEDAGRYL CLARGSMIVL QNLTLITGDS LTSSNDDEDP KSHRDPSNRH SYPQQAPYWT HPQRMEKKLH AVPAGNTVKF RCPAAGNPTP TIRWLKDGQA FHGENRIGGI RLRHQHWSLV MESVVPSDRG TYTCLVENAV GSIRYNYLLD VLERSPHRPI LQAGLPANTT AVVGSDVELL CKVYSDAQPH IQWLKHIVIN GSSFGADGFP YVQVLKTADI NSSEVEVLYL RNVSAEDAGE YTCLAGNSIG LSYQSAWLTV LPEEDPTWTA AAPEARYTDI ILYASGSLAL AVLLLLAGLY RGQALHGRHP RPPATVQKLS RFPLARQFSL ESGSSGKSSS SLVRGVRLSS SGPALLAGLV SLDLPLDPLW EFPRDRLVLG KPLGEGCFGQ VVRAEAFGMD PARPDQASTV AVKMLKDNAS DKDLADLVSE MEVMKLIGRH KNIINLLGVC TQEGPLYVIV ECAAKGNLRE FLRARRPPGP DLSPDGPRSS EGPLSFPVLV SCAYQVARGM QYLESRKCIH RDLAARNVLV TEDNVMKIAD FGLARGVHHI DYYKKTSNGR LPVKWMAPEA LFDRVYTHQS DVWSFGILLW EIFTLGGSPY PGIPVEELFS LLREGHRMDR PPHCPPELYG LMRECWHAAP SQRPTFKQLV EALDKVLLAV SEEYLDLRLT FGPYSPSGGD ASSTCSSSDS VFSHDPLPLG SSSFPFGSGV QT // ID FOXA1_HUMAN Reviewed; 472 AA. AC P55317; B2R9H6; B7ZAP5; Q9H2A0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 219. DE RecName: Full=Hepatocyte nuclear factor 3-alpha; DE Short=HNF-3-alpha; DE Short=HNF-3A; DE AltName: Full=Forkhead box protein A1; DE AltName: Full=Transcription factor 3A; DE Short=TCF-3A; GN Name=FOXA1; Synonyms=HNF3A, TCF3A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-72; MET-124 INS RP AND ARG-185. RC TISSUE=Lung; RX PubMed=8652662; DOI=10.1016/0167-4781(96)00058-9; RA Bingle C.D., Gowan S.; RT "Molecular cloning of the forkhead transcription factor HNF-3 alpha from a RT human pulmonary adenocarcinoma cell line."; RL Biochim. Biophys. Acta 1307:17-20(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-72; THR-83; MET-124 RP INS; ARG-185 AND ASN-448. RX PubMed=10899756; DOI=10.1159/000022943; RA Navas M.A., Vaisse C., Boger S., Heimesaat M., Kollee L.A., Stoffel M.; RT "The human HNF-3 genes: cloning, partial sequence and mutation screening in RT patients with impaired glucose homeostasis."; RL Hum. Hered. 50:370-381(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Yu L., Takeda J.; RT "Genetic variation in the HNF-3alpha gene."; RL Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Mammary gland, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12234996; RA Lin L., Miller C.T., Contreras J.I., Prescott M.S., Dagenais S.L., Wu R., RA Yee J., Orringer M.B., Misek D.E., Hanash S.M., Glover T.W., Beer D.G.; RT "The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on RT chromosome band 14q13 is amplified and overexpressed in esophageal and lung RT adenocarcinomas."; RL Cancer Res. 62:5273-5279(2002). RN [9] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15987773; DOI=10.1242/dev.01917; RA Gao N., Ishii K., Mirosevich J., Kuwajima S., Oppenheimer S.R., RA Roberts R.L., Jiang M., Yu X., Shappell S.B., Caprioli R.M., Stoffel M., RA Hayward S.W., Matusik R.J.; RT "Forkhead box A1 regulates prostate ductal morphogenesis and promotes RT epithelial cell maturation."; RL Development 132:3431-3443(2005). RN [10] RP FUNCTION. RX PubMed=16087863; DOI=10.1073/pnas.0505575102; RA Laganiere J., Deblois G., Lefebvre C., Bataille A.R., Robert F., RA Giguere V.; RT "Location analysis of estrogen receptor alpha target promoters reveals that RT FOXA1 defines a domain of the estrogen response."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11651-11656(2005). RN [11] RP FUNCTION IN CELL CYCLE REGULATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=16331276; DOI=10.1038/sj.onc.1209170; RA Williamson E.A., Wolf I., O'Kelly J., Bose S., Tanosaki S., Koeffler H.P.; RT "BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle- RT dependent kinase inhibitor p27(Kip1)."; RL Oncogene 25:1391-1399(2006). RN [12] RP INTERACTION WITH NKX2-1. RX PubMed=17220277; DOI=10.1128/mcb.01133-06; RA Minoo P., Hu L., Xing Y., Zhu N.L., Chen H., Li M., Borok Z., Li C.; RT "Physical and functional interactions between homeodomain NKX2.1 and winged RT helix/forkhead FOXA1 in lung epithelial cells."; RL Mol. Cell. Biol. 27:2155-2165(2007). RN [13] RP FUNCTION IN CELL TYPE-SPECIFIC TRANSCRIPTION, AND DIFFERENTIAL RECRUITMENT RP TO CHROMATIN. RX PubMed=18358809; DOI=10.1016/j.cell.2008.01.018; RA Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., RA Carroll J.S., Liu X.S., Brown M.; RT "FoxA1 translates epigenetic signatures into enhancer-driven lineage- RT specific transcription."; RL Cell 132:958-970(2008). RN [14] RP FUNCTION IN REGULATION OF APOPTOSIS. RX PubMed=19127412; DOI=10.1007/s12192-008-0095-4; RA Song L., Wei X., Zhang B., Luo X., Liu J., Feng Y., Xiao X.; RT "Role of Foxa1 in regulation of bcl2 expression during oxidative-stress- RT induced apoptosis in A549 type II pneumocytes."; RL Cell Stress Chaperones 14:417-425(2009). RN [15] RP INTERACTION WITH FOXA2. RX PubMed=19919681; DOI=10.1186/gb-2009-10-11-r129; RA Motallebipour M., Ameur A., Reddy Bysani M.S., Patra K., Wallerman O., RA Mangion J., Barker M.A., McKernan K.J., Komorowski J., Wadelius C.; RT "Differential binding and co-binding pattern of FOXA1 and FOXA3 and their RT relation to H3K4me3 in HepG2 cells revealed by ChIP-seq."; RL Genome Biol. 10:R129.0-R129.0(2009). RN [16] RP FUNCTION IN ESR1-MEDIATED TRANSCRIPTION REPRESSION, DIFFERENTIAL RP RECRUITMENT TO CHROMATIN, AND INTERACTION WITH HDAC7. RX PubMed=19917725; DOI=10.1128/mcb.00907-09; RA Malik S., Jiang S., Garee J.P., Verdin E., Lee A.V., O'Malley B.W., RA Zhang M., Belaguli N.S., Oesterreich S.; RT "Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM."; RL Mol. Cell. Biol. 30:399-412(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307 AND SER-331, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Transcription factor that is involved in embryonic CC development, establishment of tissue-specific gene expression and CC regulation of gene expression in differentiated tissues. Is thought to CC act as a 'pioneer' factor opening the compacted chromatin for other CC proteins through interactions with nucleosomal core histones and CC thereby replacing linker histones at target enhancer and/or promoter CC sites. Binds DNA with the consensus sequence 5'- CC [AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). Proposed to play CC a role in translating the epigenetic signatures into cell type-specific CC enhancer-driven transcriptional programs. Its differential recruitment CC to chromatin is dependent on distribution of histone H3 methylated at CC 'Lys-5' (H3K4me2) in estrogen-regulated genes. Involved in the CC development of multiple endoderm-derived organ systems such as liver, CC pancreas, lung and prostate; FOXA1 and FOXA2 seem to have at least in CC part redundant roles (By similarity). Modulates the transcriptional CC activity of nuclear hormone receptors. Is involved in ESR1-mediated CC transcription; required for ESR1 binding to the NKX2-1 promoter in CC breast cancer cells; binds to the RPRM promoter and is required for the CC estrogen-induced repression of RPRM. Involved in regulation of CC apoptosis by inhibiting the expression of BCL2. Involved in cell cycle CC regulation by activating expression of CDKN1B, alone or in conjunction CC with BRCA1. Originally described as a transcription activator for a CC number of liver genes such as AFP, albumin, tyrosine aminotransferase, CC PEPCK, etc. Interacts with the cis-acting regulatory regions of these CC genes. Involved in glucose homeostasis. {ECO:0000250, CC ECO:0000269|PubMed:16087863, ECO:0000269|PubMed:16331276, CC ECO:0000269|PubMed:18358809, ECO:0000269|PubMed:19127412, CC ECO:0000269|PubMed:19917725}. CC -!- SUBUNIT: Binds DNA as a monomer (By similarity). Interacts with FOXA2. CC Interacts with NKX2-1. Interacts with HDAC7. Interacts with the histone CC H3-H4 heterodimer. Associates with nucleosomes containing histone H2A. CC Interacts with AR. Interacts with NR0B2 (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC P55317; P10275: AR; NbExp=4; IntAct=EBI-3918034, EBI-608057; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00089, CC ECO:0000269|PubMed:15987773, ECO:0000269|PubMed:16331276}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P55317-1; Sequence=Displayed; CC Name=2; CC IsoId=P55317-2; Sequence=VSP_055094; CC -!- TISSUE SPECIFICITY: Highly expressed in prostate and ESR1-positive CC breast tumors. Overexpressed in esophageal and lung adenocarcinomas. CC {ECO:0000269|PubMed:12234996, ECO:0000269|PubMed:15987773, CC ECO:0000269|PubMed:16331276}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Hepatocyte nuclear factors entry; CC URL="https://en.wikipedia.org/wiki/Hepatocyte_nuclear_factors"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44403/FOXA1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39840; AAB06493.1; -; mRNA. DR EMBL; AF176112; AAD51979.1; -; Genomic_DNA. DR EMBL; AF176111; AAD51979.1; JOINED; Genomic_DNA. DR EMBL; AF303743; AAG40847.1; -; Genomic_DNA. DR EMBL; AF303742; AAG40847.1; JOINED; Genomic_DNA. DR EMBL; AK313785; BAG36523.1; -; mRNA. DR EMBL; AK316360; BAH14731.1; -; mRNA. DR EMBL; AL121790; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471078; EAW65844.1; -; Genomic_DNA. DR EMBL; BC033890; AAH33890.1; -; mRNA. DR CCDS; CCDS9665.1; -. [P55317-1] DR PIR; S70357; S70357. DR RefSeq; NP_004487.2; NM_004496.3. [P55317-1] DR PDB; 7VOX; X-ray; 2.10 A; A/B/C/H=168-264. DR PDB; 8VFY; EM; 2.89 A; O=1-472. DR PDB; 8VFZ; EM; 4.10 A; O/P=1-472. DR PDB; 8VG1; EM; 2.48 A; O=1-472. DR PDB; 8VG2; EM; 3.04 A; O=1-472. DR PDBsum; 7VOX; -. DR PDBsum; 8VFY; -. DR PDBsum; 8VFZ; -. DR PDBsum; 8VG1; -. DR PDBsum; 8VG2; -. DR AlphaFoldDB; P55317; -. DR EMDB; EMD-43194; -. DR EMDB; EMD-43195; -. DR EMDB; EMD-43197; -. DR EMDB; EMD-43198; -. DR SMR; P55317; -. DR BioGRID; 109411; 523. DR CORUM; P55317; -. DR DIP; DIP-57138N; -. DR ELM; P55317; -. DR FunCoup; P55317; 4980. DR IntAct; P55317; 54. DR MINT; P55317; -. DR STRING; 9606.ENSP00000250448; -. DR GlyGen; P55317; 11 sites, 1 O-linked glycan (11 sites). DR iPTMnet; P55317; -. DR PhosphoSitePlus; P55317; -. DR SwissPalm; P55317; -. DR BioMuta; FOXA1; -. DR DMDM; 296434509; -. DR jPOST; P55317; -. DR MassIVE; P55317; -. DR PaxDb; 9606-ENSP00000250448; -. DR PeptideAtlas; P55317; -. DR ProteomicsDB; 56845; -. [P55317-1] DR ProteomicsDB; 7076; -. DR Pumba; P55317; -. DR Antibodypedia; 23304; 1517 antibodies from 44 providers. DR DNASU; 3169; -. DR Ensembl; ENST00000250448.5; ENSP00000250448.3; ENSG00000129514.8. [P55317-1] DR GeneID; 3169; -. DR KEGG; hsa:3169; -. DR MANE-Select; ENST00000250448.5; ENSP00000250448.3; NM_004496.5; NP_004487.2. DR UCSC; uc001wuf.5; human. [P55317-1] DR AGR; HGNC:5021; -. DR ClinPGx; PA201090; -. DR CTD; 3169; -. DR DisGeNET; 3169; -. DR GeneCards; FOXA1; -. DR HGNC; HGNC:5021; FOXA1. DR HPA; ENSG00000129514; Tissue enhanced (prostate, stomach). DR MalaCards; FOXA1; -. DR MIM; 602294; gene. DR OpenTargets; ENSG00000129514; -. DR VEuPathDB; HostDB:ENSG00000129514; -. DR eggNOG; KOG3563; Eukaryota. DR GeneTree; ENSGT00940000162043; -. DR HOGENOM; CLU_027910_4_1_1; -. DR InParanoid; P55317; -. DR OMA; WSSYYTD; -. DR OrthoDB; 5954824at2759; -. DR PAN-GO; P55317; 5 GO annotations based on evolutionary models. DR PhylomeDB; P55317; -. DR PathwayCommons; P55317; -. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR SignaLink; P55317; -. DR SIGNOR; P55317; -. DR Agora; ENSG00000129514; -. DR BioGRID-ORCS; 3169; 64 hits in 1194 CRISPR screens. DR ChiTaRS; FOXA1; human. DR GeneWiki; FOXA1; -. DR GenomeRNAi; 3169; -. DR Pharos; P55317; Tbio. DR PRO; PR:P55317; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P55317; protein. DR Bgee; ENSG00000129514; Expressed in endometrium epithelium and 106 other cell types or tissues. DR ExpressionAtlas; P55317; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005902; C:microvillus; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISS:BHF-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0019904; F:protein domain specific binding; IEA:InterPro. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0061144; P:alveolar secondary septum development; IEA:Ensembl. DR GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0071542; P:dopaminergic neuron differentiation; TAS:ParkinsonsUK-UCL. DR GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl. DR GO; GO:0060743; P:epithelial cell maturation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl. DR GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0060739; P:mesenchymal-epithelial cell signaling involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IEA:Ensembl. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IC:BHF-UCL. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB. DR GO; GO:1904340; P:positive regulation of dopaminergic neuron differentiation; IEA:Ensembl. DR GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IC:BHF-UCL. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl. DR GO; GO:0060741; P:prostate gland stromal morphogenesis; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:1902691; P:respiratory basal cell differentiation; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IDA:UniProtKB. DR GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR CDD; cd20038; FH_FOXA1; 1. DR FunFam; 1.10.10.10:FF:000042; hepatocyte nuclear factor 3-beta; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR InterPro; IPR013638; Fork-head_N. DR InterPro; IPR001766; Fork_head_dom. DR InterPro; IPR018533; Forkhead_box_C. DR InterPro; IPR050211; FOX_domain-containing. DR InterPro; IPR018122; TF_fork_head_CS_1. DR InterPro; IPR030456; TF_fork_head_CS_2. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR PANTHER; PTHR11829; FORKHEAD BOX PROTEIN; 1. DR PANTHER; PTHR11829:SF195; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; 1. DR Pfam; PF00250; Forkhead; 1. DR Pfam; PF08430; Forkhead_N; 1. DR Pfam; PF09354; HNF_C; 1. DR PRINTS; PR00053; FORKHEAD. DR SMART; SM00339; FH; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS00657; FORK_HEAD_1; 1. DR PROSITE; PS00658; FORK_HEAD_2; 1. DR PROSITE; PS50039; FORK_HEAD_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Chromatin regulator; KW Developmental protein; DNA-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation. FT CHAIN 1..472 FT /note="Hepatocyte nuclear factor 3-alpha" FT /id="PRO_0000091792" FT DNA_BIND 169..260 FT /note="Fork-head" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00089" FT REGION 269..392 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 273..289 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 322..332 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 351..366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 331 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..33 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055094" FT VARIANT 72 FT /note="G -> A" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015183" FT VARIANT 83 FT /note="A -> T (in dbSNP:rs7144658)" FT /evidence="ECO:0000269|PubMed:10899756" FT /id="VAR_013457" FT VARIANT 87 FT /note="G -> E (in dbSNP:rs35220193)" FT /id="VAR_055835" FT VARIANT 124 FT /note="M -> MM" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015184" FT VARIANT 185 FT /note="Q -> R" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015185" FT VARIANT 448 FT /note="S -> N (in dbSNP:rs33984772)" FT /evidence="ECO:0000269|PubMed:10899756" FT /id="VAR_013458" FT HELIX 175..184 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 193..203 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 205..208 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 211..224 FT /evidence="ECO:0007829|PDB:7VOX" FT STRAND 228..231 FT /evidence="ECO:0007829|PDB:7VOX" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 248..250 FT /evidence="ECO:0007829|PDB:7VOX" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8VG1" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8VFY" SQ SEQUENCE 472 AA; 49148 MW; B2489523459EEB4C CRC64; MLGTVKMEGH ETSDWNSYYA DTQEAYSSVP VSNMNSGLGS MNSMNTYMTM NTMTTSGNMT PASFNMSYAN PGLGAGLSPG AVAGMPGGSA GAMNSMTAAG VTAMGTALSP SGMGAMGAQQ AASMNGLGPY AAAMNPCMSP MAYAPSNLGR SRAGGGGDAK TFKRSYPHAK PPYSYISLIT MAIQQAPSKM LTLSEIYQWI MDLFPYYRQN QQRWQNSIRH SLSFNDCFVK VARSPDKPGK GSYWTLHPDS GNMFENGCYL RRQKRFKCEK QPGAGGGGGS GSGGSGAKGG PESRKDPSGA SNPSADSPLH RGVHGKTGQL EGAPAPGPAA SPQTLDHSGA TATGGASELK TPASSTAPPI SSGPGALASV PASHPAHGLA PHESQLHLKG DPHYSFNHPF SINNLMSSSE QQHKLDFKAY EQALQYSPYG STLPASLPLG SASVTTRSPI EPSALEPAYY QGVYSRPVLN TS // ID GPER1_HUMAN Reviewed; 375 AA. AC Q99527; A8K6C5; B5BUJ1; O00143; O43494; Q13631; Q6FHL1; Q96F42; Q99981; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 28-JAN-2026, entry version 209. DE RecName: Full=G-protein coupled estrogen receptor 1 {ECO:0000305}; DE AltName: Full=Chemoattractant receptor-like 2; DE AltName: Full=Flow-induced endothelial G-protein coupled receptor 1; DE Short=FEG-1; DE AltName: Full=G protein-coupled estrogen receptor 1; DE AltName: Full=G-protein coupled receptor 30 {ECO:0000303|PubMed:17379646, ECO:0000303|PubMed:18566127}; DE AltName: Full=GPCR-Br; DE AltName: Full=IL8-related receptor DRY12; DE AltName: Full=Lymphocyte-derived G-protein coupled receptor; DE Short=LYGPR; DE AltName: Full=Membrane estrogen receptor; DE Short=mER; GN Name=GPER1 {ECO:0000312|HGNC:HGNC:4485}; GN Synonyms=CEPR, CMKRL2, DRY12, GPER, GPR30 {ECO:0000303|PubMed:17379646, GN ECO:0000303|PubMed:18566127}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8920907; DOI=10.1006/bbrc.1996.1654; RA Owman C.S.O., Blay P., Nilsson C., Lolait S.J.; RT "Cloning of human cDNA encoding a novel heptahelix receptor expressed in RT Burkitt's lymphoma and widely distributed in brain and peripheral RT tissues."; RL Biochem. Biophys. Res. Commun. 228:285-292(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9070864; DOI=10.1006/bbrc.1997.6161; RA Feng Y., Gregor P.; RT "Cloning of a novel member of the G protein-coupled receptor family related RT to peptide receptors."; RL Biochem. Biophys. Res. Commun. 231:651-654(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9398636; DOI=10.1006/bbrc.1997.7734; RA Takada Y., Kato C., Kondo S., Korenaga R., Ando J.; RT "Cloning of cDNAs encoding G protein-coupled receptor expressed in human RT endothelial cells exposed to fluid shear stress."; RL Biochem. Biophys. Res. Commun. 240:737-741(1997). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9141481; DOI=10.1016/s0014-5793(97)00278-0; RA Kvingedal A.M., Smeland E.B.; RT "A novel putative G-protein-coupled receptor expressed in lung, heart and RT lymphoid tissue."; RL FEBS Lett. 407:59-62(1997). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9367686; DOI=10.1006/geno.1997.4972; RA Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J.; RT "Identification of a gene (GPR30) with homology to the G-protein-coupled RT receptor superfamily associated with estrogen receptor expression in breast RT cancer."; RL Genomics 45:607-617(1997). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9479505; DOI=10.1006/geno.1998.5095; RA O'Dowd B.F., Nguyen T., Marchese A., Cheng R., Lynch K.R., Heng H.H.Q., RA Kolakowski L.F. Jr., George S.R.; RT "Discovery of three novel G-protein-coupled receptor genes."; RL Genomics 47:310-313(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Liver; RA McCoy R.L., Perlmutter D.H.; RT "Cloning of novel IL8-related receptors from human hepatic tissue."; RL Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP FUNCTION. RX PubMed=11043579; DOI=10.1210/mend.14.10.0532; RA Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Jr.; RT "Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein- RT coupled receptor homolog, GPR30, and occurs via trans-activation of the RT epidermal growth factor receptor through release of HB-EGF."; RL Mol. Endocrinol. 14:1649-1660(2000). RN [15] RP INDUCTION. RX PubMed=12027886; DOI=10.1046/j.1432-1033.2002.02912.x; RA Ahola T.M., Purmonen S., Pennanen P., Zhuang Y.H., Tuohimaa P., Ylikomi T.; RT "Progestin upregulates G-protein-coupled receptor 30 in breast cancer RT cells."; RL Eur. J. Biochem. 269:2485-2490(2002). RN [16] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15539556; DOI=10.1210/en.2004-1064; RA Thomas P., Pang Y., Filardo E.J., Dong J.; RT "Identity of an estrogen membrane receptor coupled to a G protein in human RT breast cancer cells."; RL Endocrinology 146:624-632(2005). RN [17] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15705806; DOI=10.1126/science.1106943; RA Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R.; RT "A transmembrane intracellular estrogen receptor mediates rapid cell RT signaling."; RL Science 307:1625-1630(2005). RN [18] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=16645038; DOI=10.1210/me.2005-0525; RA Pedram A., Razandi M., Levin E.R.; RT "Nature of functional estrogen receptors at the plasma membrane."; RL Mol. Endocrinol. 20:1996-2009(2006). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=17379646; DOI=10.1210/en.2006-1605; RA Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P.; RT "Activation of the novel estrogen receptor G protein-coupled receptor 30 RT (GPR30) at the plasma membrane."; RL Endocrinology 148:3236-3245(2007). RN [20] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=18566127; DOI=10.1210/en.2008-0269; RA Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., RA Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H.; RT "G protein-coupled receptor 30 localizes to the endoplasmic reticulum and RT is not activated by estradiol."; RL Endocrinology 149:4846-4856(2008). RN [21] RP FUNCTION. RX PubMed=19179659; DOI=10.1161/circresaha.108.190892; RA Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., RA Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., RA Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., RA Resta T.C., Prossnitz E.R., Barton M.; RT "Regulatory role of G protein-coupled estrogen receptor for vascular RT function and obesity."; RL Circ. Res. 104:288-291(2009). RN [22] RP FUNCTION. RX PubMed=19342448; DOI=10.1210/me.2008-0262; RA Quinn J.A., Graeber C.T., Frackelton A.R. Jr., Kim M., Schwarzbauer J.E., RA Filardo E.J.; RT "Coordinate regulation of estrogen-mediated fibronectin matrix assembly and RT epidermal growth factor receptor transactivation by the G protein-coupled RT receptor, GPR30."; RL Mol. Endocrinol. 23:1052-1064(2009). RN [23] RP INTERACTION WITH EGFR AND ESR1, AND INDUCTION. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [24] RP FUNCTION, INTERACTION WITH EGFR, ASSOCIATION WITH CHROMATIN, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [25] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20203690; DOI=10.1038/cdd.2010.20; RA Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., RA Lau K.M.; RT "Activation of GPR30 inhibits the growth of prostate cancer cells through RT sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, RT and induction of G(2) cell-cycle arrest."; RL Cell Death Differ. 17:1511-1523(2010). RN [26] RP ESTROGEN-BINDING, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=19931550; DOI=10.1016/j.steroids.2009.11.005; RA Thomas P., Alyea R., Pang Y., Peyton C., Dong J., Berg A.H.; RT "Conserved estrogen binding and signaling functions of the G protein- RT coupled estrogen receptor 1 (GPER) in mammals and fish."; RL Steroids 75:595-602(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION, AND TISSUE SPECIFICITY. RX PubMed=21427217; DOI=10.1210/en.2010-0979; RA Maiti K., Paul J.W., Read M., Chan E.C., Riley S.C., Nahar P., Smith R.; RT "G-1-activated membrane estrogen receptors mediate increased contractility RT of the human myometrium."; RL Endocrinology 152:2448-2455(2011). RN [28] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=21242460; DOI=10.1161/hypertensionaha.110.161653; RA Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., RA Chorazyczewski J., Feldman R.D.; RT "GPR30 expression is required for the mineralocorticoid receptor- RT independent rapid vascular effects of aldosterone."; RL Hypertension 57:442-451(2011). RN [29] RP SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=21540189; DOI=10.1074/jbc.m111.224071; RA Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J.; RT "Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the RT cell surface occurs via a trans-Golgi-proteasome pathway."; RL J. Biol. Chem. 286:22441-22455(2011). RN [30] RP FUNCTION, INTERACTION WITH KRT7 AND KRT8, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=21149639; DOI=10.1124/mol.110.069500; RA Sanden C., Broselid S., Cornmark L., Andersson K., Daszkiewicz-Nilsson J., RA Martensson U.E., Olde B., Leeb-Lundberg L.M.; RT "G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 RT localizes in the plasma membrane and traffics intracellularly on RT cytokeratin intermediate filaments."; RL Mol. Pharmacol. 79:400-410(2011). RN [31] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21354433; DOI=10.1016/j.steroids.2011.02.018; RA Cheng S.B., Graeber C.T., Quinn J.A., Filardo E.J.; RT "Retrograde transport of the transmembrane estrogen receptor, G-protein- RT coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the RT nucleus."; RL Steroids 76:892-896(2011). RN [32] RP FUNCTION. RX PubMed=23135268; DOI=10.1074/jbc.m112.417303; RA Santolla M.F., Lappano R., De Marco P., Pupo M., Vivacqua A., Sisci D., RA Abonante S., Iacopetta D., Cappello A.R., Dolce V., Maggiolini M.; RT "G protein-coupled estrogen receptor mediates the up-regulation of fatty RT acid synthase induced by 17beta-estradiol in cancer cells and cancer- RT associated fibroblasts."; RL J. Biol. Chem. 287:43234-43245(2012). RN [33] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=23285008; DOI=10.1371/journal.pone.0052357; RA Chakrabarti S., Davidge S.T.; RT "G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial RT inflammation."; RL PLoS ONE 7:E52357-E52357(2012). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=23283935; DOI=10.1152/ajpcell.00203.2012; RA Gros R., Ding Q., Liu B., Chorazyczewski J., Feldman R.D.; RT "Aldosterone mediates its rapid effects in vascular endothelial cells RT through GPER activation."; RL Am. J. Physiol. 304:C532-C540(2013). RN [36] RP FUNCTION, INTERACTION WITH RAMP3, AND SUBCELLULAR LOCATION. RX PubMed=23674134; DOI=10.1530/jme-13-0021; RA Lenhart P.M., Broselid S., Barrick C.J., Leeb-Lundberg L.M., Caron K.M.; RT "G-protein-coupled receptor 30 interacts with receptor activity-modifying RT protein 3 and confers sex-dependent cardioprotection."; RL J. Mol. Endocrinol. 51:191-202(2013). RN [37] RP REVIEW. RX PubMed=22521564; DOI=10.1016/j.steroids.2012.04.001; RA Barton M.; RT "Position paper: The membrane estrogen receptor GPER--Clues and RT questions."; RL Steroids 77:935-942(2012). RN [38] RP REVIEW. RX PubMed=22495674; DOI=10.1210/en.2012-1061; RA Filardo E.J., Thomas P.; RT "Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism RT of action and role in female reproductive cancer, renal and vascular RT physiology."; RL Endocrinology 153:2953-2962(2012). CC -!- FUNCTION: G-protein coupled estrogen receptor that binds to 17-beta- CC estradiol (E2) with high affinity, leading to rapid and transient CC activation of numerous intracellular signaling pathways. Stimulates CC cAMP production, calcium mobilization and tyrosine kinase Src inducing CC the release of heparin-bound epidermal growth factor (HB-EGF) and CC subsequent transactivation of the epidermal growth factor receptor CC (EGFR), activating downstream signaling pathways such as PI3K/Akt and CC ERK/MAPK. Mediates pleiotropic functions among others in the CC cardiovascular, endocrine, reproductive, immune and central nervous CC systems. Has a role in cardioprotection by reducing cardiac hypertrophy CC and perivascular fibrosis in a RAMP3-dependent manner. Regulates CC arterial blood pressure by stimulating vasodilation and reducing CC vascular smooth muscle and microvascular endothelial cell CC proliferation. Plays a role in blood glucose homeostasis contributing CC to the insulin secretion response by pancreatic beta cells. Triggers CC mitochondrial apoptosis during pachytene spermatocyte differentiation. CC Stimulates uterine epithelial cell proliferation. Enhances uterine CC contractility in response to oxytocin. Contributes to thymic atrophy by CC inducing apoptosis. Attenuates TNF-mediated endothelial expression of CC leukocyte adhesion molecules. Promotes neuritogenesis in developing CC hippocampal neurons. Plays a role in acute neuroprotection against CC NMDA-induced excitotoxic neuronal death. Increases firing activity and CC intracellular calcium oscillations in luteinizing hormone-releasing CC hormone (LHRH) neurons. Inhibits early osteoblast proliferation at CC growth plate during skeletal development. Inhibits mature adipocyte CC differentiation and lipid accumulation. Involved in the recruitment of CC beta-arrestin 2 ARRB2 at the plasma membrane in epithelial cells. Also CC functions as a receptor for aldosterone mediating rapid regulation of CC vascular contractibility through the PI3K/ERK signaling pathway. CC Involved in cancer progression regulation. Stimulates cancer-associated CC fibroblast (CAF) proliferation by a rapid genomic response through the CC EGFR/ERK transduction pathway. Associated with EGFR, may act as a CC transcription factor activating growth regulatory genes (c-fos, cyclin CC D1). Promotes integrin alpha-5/beta-1 and fibronectin (FN) matrix CC assembly in breast cancer cells. {ECO:0000269|PubMed:11043579, CC ECO:0000269|PubMed:15539556, ECO:0000269|PubMed:15705806, CC ECO:0000269|PubMed:19179659, ECO:0000269|PubMed:19342448, CC ECO:0000269|PubMed:20203690, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:21242460, CC ECO:0000269|PubMed:21427217, ECO:0000269|PubMed:23135268, CC ECO:0000269|PubMed:23283935, ECO:0000269|PubMed:23285008, CC ECO:0000269|PubMed:23674134}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC Note=Binds 17-beta-estradiol (E2) in plasma membranes with high CC affinity (Kd is 3.3 nM) and displays rapid kinetics of association CC and dissociation. {ECO:0000269|PubMed:15539556, CC ECO:0000269|PubMed:15705806, ECO:0000269|PubMed:19931550}; CC -!- SUBUNIT: Homodimer (Probable). Heterodimer; heterodimerizes with other CC G-protein-coupled receptor (GPCRs) like CRHR1, HTR1A and PAQR8. CC Interacts (via C-terminus tail motif) with DLG4 (via N-terminus tandem CC pair of PDZ domains); the interaction is direct and induces the CC increase of GPER1 protein levels residing at the plasma membrane CC surface in a estradiol-independent manner (By similarity). Interacts CC with RAMP3; the interaction confers proper subcellular localization and CC function in cardioprotection. Interacts with KRT7 and KRT8. Interacts CC with EGFR; the interaction increases after agonist-induced stimulation CC in cancer-associated fibroblasts (CAF). Interacts with EGFR and ESR1. CC {ECO:0000250, ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:23674134, ECO:0000305}. CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}. Cytoplasm, CC perinuclear region. Cytoplasm, cytoskeleton. Cell membrane; Multi-pass CC membrane protein. Basolateral cell membrane; Multi-pass membrane CC protein. Cytoplasmic vesicle membrane; Multi-pass membrane protein. CC Early endosome. Recycling endosome. Golgi apparatus membrane CC {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Golgi CC apparatus, trans-Golgi network. Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:18566127}; Multi-pass membrane protein. Cell CC projection, dendrite {ECO:0000250}. Cell projection, dendritic spine CC membrane {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Cell CC projection, axon {ECO:0000250}. Postsynaptic density {ECO:0000250}. CC Mitochondrion membrane {ECO:0000250}; Multi-pass membrane protein CC {ECO:0000250}. Note=Colocalized with BSN to the active zone of CC presynaptic density. Colocalized with DLG4/PSD95 and neurabin-2 PPP1R9B CC in neuronal synaptosomes (By similarity). Endocytosed in a agonist- and CC arrestin-independent manner. Colocalized with RAMP3 and clathrin-coated CC pits at the plasma membrane. Colocalized with transferrin receptor at CC the plasma membrane and perinuclear region. Accumulated and colocalized CC with RAB11 proteins in recycling endosomes and trans-Golgi network CC (TGN), but does neither recycle back to the cell surface nor traffics CC to late endosome or lysosome. Colocalized with calnexin in the CC endoplasmic reticulum. Traffics to intracellular sites via cytokeratin CC intermediate filaments like KRT7 and KRT8 after constitutive CC endocytosis in epithelial cells. Colocalized with EGFR in the nucleus CC of agonist-induced cancer-associated fibroblasts (CAF). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in placenta, endothelial and epithelial CC cells, non laboring and laboring term myometrium, fibroblasts and CC cancer-associated fibroblasts (CAF), prostate cancer cells and invasive CC adenocarcinoma (at protein level). Ubiquitously expressed, but is most CC abundant in placenta. In brain regions, expressed as a 2.8 kb CC transcript in basal forebrain, frontal cortex, thalamus, hippocampus, CC caudate and putamen. {ECO:0000269|PubMed:20203690, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:21149639, CC ECO:0000269|PubMed:21354433, ECO:0000269|PubMed:21427217, CC ECO:0000269|PubMed:23285008}. CC -!- INDUCTION: Up-regulated by EGF and TGF-alpha in endometrial, ovarian CC and breast tumor cells. Up-regulated by progestin and by phorbol 12- CC myristate 13-acetate (PMA) in breast cancer cell lines. CC {ECO:0000269|PubMed:12027886, ECO:0000269|PubMed:19749156}. CC -!- PTM: Ubiquitinated; ubiquitination occurs at the plasma membrane and CC leads to proteasome-mediated degradation. CC {ECO:0000269|PubMed:21540189}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:21427217}. CC -!- MISCELLANEOUS: Does not bind estradiol according to PubMed:18566127 and CC PubMed:16645038. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. CC {ECO:0000255|PROSITE-ProRule:PRU00521}. CC -!- CAUTION: Data is conflicting regarding whether it fulfills the criteria CC of a membrane-bound estrogen receptor (PubMed:15705806, CC PubMed:17379646). Other reports suggest that it is not CC (PubMed:16645038, PubMed:18566127). {ECO:0000305|PubMed:15705806, CC ECO:0000305|PubMed:16645038, ECO:0000305|PubMed:17379646, CC ECO:0000305|PubMed:18566127}. CC -!- CAUTION: Data is conflicting regarding whether it is localized either CC at the cell membrane (PM) (PubMed:15539556, PubMed:21149639, CC PubMed:21354433, PubMed:21427217, PubMed:21540189, PubMed:23674134). CC Other reports suggest that it localizes at the endoplasmic reticulum CC (ER) (PubMed:15705806, PubMed:18566127). {ECO:0000305|PubMed:15539556, CC ECO:0000305|PubMed:15705806, ECO:0000305|PubMed:18566127, CC ECO:0000305|PubMed:21149639, ECO:0000305|PubMed:21354433, CC ECO:0000305|PubMed:21427217, ECO:0000305|PubMed:21540189, CC ECO:0000305|PubMed:23674134}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44344/GPER"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y08162; CAA69354.1; -; mRNA. DR EMBL; U77827; AAC51173.1; -; Genomic_DNA. DR EMBL; AF015257; AAC51904.1; -; mRNA. DR EMBL; X98510; CAA67133.1; -; mRNA. DR EMBL; U63917; AAB88017.1; -; mRNA. DR EMBL; AF027956; AAC52027.1; -; Genomic_DNA. DR EMBL; U58828; AAB02736.1; -; mRNA. DR EMBL; CR541741; CAG46541.1; -; mRNA. DR EMBL; AK291590; BAF84279.1; -; mRNA. DR EMBL; AB451427; BAG70241.1; -; mRNA. DR EMBL; CH236953; EAL23938.1; -; Genomic_DNA. DR EMBL; CH471144; EAW87194.1; -; Genomic_DNA. DR EMBL; BC011634; AAH11634.1; -; mRNA. DR CCDS; CCDS5322.1; -. DR PIR; G02670; G02670. DR PIR; JC5069; JC5069. DR RefSeq; NP_001035055.1; NM_001039966.2. DR RefSeq; NP_001091671.1; NM_001098201.3. DR RefSeq; NP_001496.1; NM_001505.3. DR PDB; 8XOF; EM; 2.60 A; R=1-375. DR PDB; 8XOG; EM; 2.90 A; R=1-375. DR PDB; 8XOH; EM; 3.20 A; R=1-375. DR PDB; 8XOI; EM; 3.20 A; R=1-375. DR PDB; 8XOJ; EM; 3.10 A; R=1-375. DR PDBsum; 8XOF; -. DR PDBsum; 8XOG; -. DR PDBsum; 8XOH; -. DR PDBsum; 8XOI; -. DR PDBsum; 8XOJ; -. DR AlphaFoldDB; Q99527; -. DR EMDB; EMD-38527; -. DR EMDB; EMD-38528; -. DR EMDB; EMD-38529; -. DR EMDB; EMD-38530; -. DR EMDB; EMD-38531; -. DR SMR; Q99527; -. DR BioGRID; 109110; 4. DR CORUM; Q99527; -. DR FunCoup; Q99527; 533. DR IntAct; Q99527; 1. DR STRING; 9606.ENSP00000380281; -. DR BindingDB; Q99527; -. DR ChEMBL; CHEMBL5872; -. DR DrugBank; DB00783; Estradiol. DR DrugBank; DB13952; Estradiol acetate. DR DrugBank; DB13953; Estradiol benzoate. DR DrugBank; DB13954; Estradiol cypionate. DR DrugBank; DB13955; Estradiol dienanthate. DR DrugBank; DB13956; Estradiol valerate. DR DrugBank; DB01645; Genistein. DR DrugBank; DB18091; LNS-8801. DR DrugBank; DB05939; MK-0354. DR DrugCentral; Q99527; -. DR GuidetoPHARMACOLOGY; 221; -. DR TCDB; 9.A.14.13.19; the g-protein-coupled receptor (gpcr) family. DR GlyCosmos; Q99527; 3 sites, No reported glycans. DR GlyGen; Q99527; 3 sites. DR iPTMnet; Q99527; -. DR PhosphoSitePlus; Q99527; -. DR BioMuta; GPER1; -. DR DMDM; 3023539; -. DR MassIVE; Q99527; -. DR PaxDb; 9606-ENSP00000380281; -. DR PeptideAtlas; Q99527; -. DR Antibodypedia; 10887; 427 antibodies from 34 providers. DR DNASU; 2852; -. DR Ensembl; ENST00000297469.3; ENSP00000297469.3; ENSG00000164850.17. DR Ensembl; ENST00000397088.4; ENSP00000380277.3; ENSG00000164850.17. DR Ensembl; ENST00000397092.5; ENSP00000380281.1; ENSG00000164850.17. DR Ensembl; ENST00000401670.1; ENSP00000385151.1; ENSG00000164850.17. DR GeneID; 2852; -. DR KEGG; hsa:2852; -. DR MANE-Select; ENST00000397088.4; ENSP00000380277.3; NM_001098201.3; NP_001091671.1. DR UCSC; uc003sjz.1; human. DR AGR; HGNC:4485; -. DR ClinPGx; PA28873; -. DR CTD; 2852; -. DR DisGeNET; 2852; -. DR GeneCards; GPER1; -. DR HGNC; HGNC:4485; GPER1. DR HPA; ENSG00000164850; Tissue enhanced (stomach). DR MIM; 601805; gene. DR OpenTargets; ENSG00000164850; -. DR VEuPathDB; HostDB:ENSG00000164850; -. DR eggNOG; ENOG502QU56; Eukaryota. DR GeneTree; ENSGT00940000154307; -. DR HOGENOM; CLU_009579_8_3_1; -. DR InParanoid; Q99527; -. DR OMA; FRTKQHA; -. DR OrthoDB; 5957382at2759; -. DR PAN-GO; Q99527; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99527; -. DR PathwayCommons; Q99527; -. DR Reactome; R-HSA-375276; Peptide ligand-binding receptors. DR Reactome; R-HSA-418594; G alpha (i) signalling events. DR Reactome; R-HSA-9634597; GPER1 signaling. DR SignaLink; Q99527; -. DR SIGNOR; Q99527; -. DR Agora; ENSG00000164850; -. DR BioGRID-ORCS; 2852; 13 hits in 1132 CRISPR screens. DR GeneWiki; GPR30; -. DR GenomeRNAi; 2852; -. DR Pharos; Q99527; Tchem. DR PRO; PR:Q99527; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q99527; protein. DR Bgee; ENSG00000164850; Expressed in body of stomach and 131 other cell types or tissues. DR ExpressionAtlas; Q99527; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043198; C:dendritic shaft; ISS:UniProtKB. DR GO; GO:0044327; C:dendritic spine head; ISS:UniProtKB. DR GO; GO:0032591; C:dendritic spine membrane; ISS:UniProtKB. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0045095; C:keratin filament; IDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; ISS:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB. DR GO; GO:0048786; C:presynaptic active zone; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; ISS:UniProtKB. DR GO; GO:0055037; C:recycling endosome; IDA:UniProtKB. DR GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0038054; F:G protein-coupled estrogen receptor activity; ISS:UniProtKB. DR GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc. DR GO; GO:0030284; F:nuclear estrogen receptor activity; IDA:UniProtKB. DR GO; GO:0005496; F:steroid binding; IDA:UniProtKB. DR GO; GO:1990239; F:steroid hormone binding; IDA:UniProtKB. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030263; P:apoptotic chromosome condensation; ISS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB. DR GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; ISS:UniProtKB. DR GO; GO:0071375; P:cellular response to peptide hormone stimulus; IDA:UniProtKB. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:AgBase. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0010948; P:negative regulation of cell cycle process; IMP:AgBase. DR GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:AgBase. DR GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:AgBase. DR GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB. DR GO; GO:0002695; P:negative regulation of leukocyte activation; IDA:UniProtKB. DR GO; GO:0051055; P:negative regulation of lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:AgBase. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:AgBase. DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW. DR GO; GO:0019228; P:neuronal action potential; ISS:UniProtKB. DR GO; GO:0030264; P:nuclear fragmentation involved in apoptotic nuclear change; ISS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:2000724; P:positive regulation of cardiac vascular smooth muscle cell differentiation; IMP:AgBase. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; ISS:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:UniProtKB. DR GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:AgBase. DR GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IDA:UniProtKB. DR GO; GO:0032024; P:positive regulation of insulin secretion; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0050769; P:positive regulation of neurogenesis; ISS:UniProtKB. DR GO; GO:0001956; P:positive regulation of neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0070474; P:positive regulation of uterine smooth muscle contraction; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:0043401; P:steroid hormone receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042311; P:vasodilation; ISS:UniProtKB. DR CDD; cd14989; 7tmA_GPER1; 1. DR FunFam; 1.20.1070.10:FF:000093; G-protein coupled estrogen receptor 1; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR InterPro; IPR000276; GPCR_Rhodpsn. DR InterPro; IPR017452; GPCR_Rhodpsn_7TM. DR InterPro; IPR047143; GPER1-like. DR PANTHER; PTHR24226:SF2; G-PROTEIN COUPLED ESTROGEN RECEPTOR 1; 1. DR PANTHER; PTHR24226; G-PROTEIN COUPLED RECEPTOR 182 AND ESTROGEN RECEPTOR 1; 1. DR Pfam; PF00001; 7tm_1; 1. DR PRINTS; PR00237; GPCRRHODOPSN. DR SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1. DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1. DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Apoptosis; Cell cycle; Cell membrane; KW Cell projection; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; KW Differentiation; Disulfide bond; Endoplasmic reticulum; Endosome; KW G-protein coupled receptor; Glycoprotein; Golgi apparatus; Immunity; KW Inflammatory response; Innate immunity; Membrane; Mitochondrion; KW Neurogenesis; Nucleus; Postsynaptic cell membrane; KW Proteomics identification; Receptor; Reference proteome; Synapse; KW Transducer; Transmembrane; Transmembrane helix; Ubl conjugation. FT CHAIN 1..375 FT /note="G-protein coupled estrogen receptor 1" FT /id="PRO_0000069310" FT TOPO_DOM 1..62 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 63..84 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 85..96 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 97..120 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 121..132 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 133..153 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 154..175 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 176..194 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 195..220 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 221..236 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 237..259 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 260..280 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 281..306 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 307..327 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 328..375 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT CARBOHYD 25 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 32 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 44 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 130..207 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521" FT VARIANT 16 FT /note="P -> L (in dbSNP:rs11544331)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851" FT /id="VAR_033319" FT CONFLICT 20..21 FT /note="QP -> HA (in Ref. 6; AAC52027)" FT /evidence="ECO:0000305" FT CONFLICT 32..49 FT /note="Missing (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 104 FT /note="A -> G (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 140..146 FT /note="NMYSSVF -> QHVQAASS (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="G -> A (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 184 FT /note="A -> S (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 312 FT /note="A -> T (in Ref. 2; AAC51173)" FT /evidence="ECO:0000305" FT CONFLICT 320 FT /note="N -> T (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 355 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 358 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT HELIX 53..86 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 88..90 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 116..118 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 121..124 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 127..160 FT /evidence="ECO:0007829|PDB:8XOG" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 171..199 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 212..222 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 224..245 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 255..284 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 303..324 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 329..341 FT /evidence="ECO:0007829|PDB:8XOG" SQ SEQUENCE 375 AA; 42248 MW; 0A54EED8A698F075 CRC64; MDVTSQARGV GLEMYPGTAQ PAAPNTTSPE LNLSHPLLGT ALANGTGELS EHQQYVIGLF LSCLYTIFLF PIGFVGNILI LVVNISFREK MTIPDLYFIN LAVADLILVA DSLIEVFNLH ERYYDIAVLC TFMSLFLQVN MYSSVFFLTW MSFDRYIALA RAMRCSLFRT KHHARLSCGL IWMASVSATL VPFTAVHLQH TDEACFCFAD VREVQWLEVT LGFIVPFAII GLCYSLIVRV LVRAHRHRGL RPRRQKALRM ILAVVLVFFV CWLPENVFIS VHLLQRTQPG AAPCKQSFRH AHPLTGHIVN LAAFSNSCLN PLIYSFLGET FRDKLRLYIE QKTNLPALNR FCHAALKAVI PDSTEQSDVR FSSAV // ID GRK6_HUMAN Reviewed; 576 AA. AC P43250; O60541; Q13652; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2002, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=G protein-coupled receptor kinase 6; DE EC=2.7.11.16; DE AltName: Full=G protein-coupled receptor kinase GRK6; GN Name=GRK6; Synonyms=GPRK6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GRK6A). RX PubMed=8366096; DOI=10.1016/s0021-9258(19)36546-9; RA Benovic J.L., Gomez J.; RT "Molecular cloning and expression of GRK6. A new member of the G protein- RT coupled receptor kinase family."; RL J. Biol. Chem. 268:19521-19527(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GRK6B AND GRK6C). RX PubMed=10506199; DOI=10.1074/jbc.274.41.29381; RA Premont R.T., Macrae A.D., Aparicio S.A., Kendall H.E., Welch J.E., RA Lefkowitz R.J.; RT "The GRK4 subfamily of G protein-coupled receptor kinases. Alternative RT splicing, gene organization, and sequence conservation."; RL J. Biol. Chem. 274:29381-29389(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GRK6A). RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 33-576, AND TISSUE SPECIFICITY. RX PubMed=8415712; DOI=10.1073/pnas.90.20.9398; RA Haribabu B., Snyderman R.; RT "Identification of additional members of human G-protein-coupled receptor RT kinase multigene family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:9398-9402(1993). RN [6] RP PALMITOYLATION AT CYS-561; CYS-562 AND CYS-565, AND MUTAGENESIS OF CYS-561; RP CYS-562 AND CYS-565. RX PubMed=7961702; DOI=10.1016/s0021-9258(18)46852-4; RA Stoffel R.H., Randall R.R., Premont R.T., Lefkowitz R.J., Inglese J.; RT "Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid RT modification diversity in the GRK family."; RL J. Biol. Chem. 269:27791-27794(1994). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484 AND THR-485, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP FUNCTION IN PHOSPHORYLATION OF LRP6. RX PubMed=19801552; DOI=10.1074/jbc.m109.047456; RA Chen M., Philipp M., Wang J., Premont R.T., Garrison T.R., Caron M.G., RA Lefkowitz R.J., Chen W.; RT "G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt RT pathway."; RL J. Biol. Chem. 284:35040-35048(2009). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484 AND THR-485, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [10] RP FUNCTION IN PHOSPHORYLATION OF CXCR4. RX PubMed=20048153; DOI=10.1074/jbc.m109.091173; RA Busillo J.M., Armando S., Sengupta R., Meucci O., Bouvier M., Benovic J.L.; RT "Site-specific phosphorylation of CXCR4 is dynamically regulated by RT multiple kinases and results in differential modulation of CXCR4 RT signaling."; RL J. Biol. Chem. 285:7805-7817(2010). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS). RX PubMed=16613860; DOI=10.1074/jbc.m601327200; RA Lodowski D.T., Tesmer V.M., Benovic J.L., Tesmer J.J.; RT "The structure of G protein-coupled receptor kinase (GRK)-6 defines a RT second lineage of GRKs."; RL J. Biol. Chem. 281:16785-16793(2006). RN [12] RP X-RAY CRYSTALLOGRAPHY (2.72 ANGSTROMS) IN COMPLEX WITH AMP AND RP SANGIVAMYCIN, AND MUTAGENESIS OF ILE-6; VAL-7; ASN-9 AND LEU-12. RX PubMed=20729810; DOI=10.1038/emboj.2010.206; RA Boguth C.A., Singh P., Huang C.C., Tesmer J.J.; RT "Molecular basis for activation of G protein-coupled receptor kinases."; RL EMBO J. 29:3249-3259(2010). RN [13] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-31; MET-73 AND MET-275. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Specifically phosphorylates the activated forms of G protein- CC coupled receptors. Such receptor phosphorylation initiates beta- CC arrestin-mediated receptor desensitization, internalization, and CC signaling events leading to their desensitization. Seems to be involved CC in the desensitization of D2-like dopamine receptors in striatum and CC chemokine receptor CXCR4 which is critical for CXCL12-induced cell CC chemotaxis (By similarity). Phosphorylates rhodopsin (RHO) (in vitro) CC and a non G-protein-coupled receptor: LRP6 during Wnt signaling (in CC vitro). {ECO:0000250, ECO:0000269|PubMed:19801552, CC ECO:0000269|PubMed:20048153}. CC -!- CATALYTIC ACTIVITY: CC Reaction=[G-protein-coupled receptor] + ATP = [G-protein-coupled CC receptor]-phosphate + ADP + H(+); Xref=Rhea:RHEA:12008, Rhea:RHEA- CC COMP:11260, Rhea:RHEA-COMP:11261, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.16; CC -!- SUBUNIT: Interacts with GIT1. {ECO:0000250|UniProtKB:P97711}. CC -!- INTERACTION: CC P43250; P05067: APP; NbExp=3; IntAct=EBI-722747, EBI-77613; CC P43250; P32298: GRK4; NbExp=2; IntAct=EBI-722747, EBI-5774453; CC P43250; P08238: HSP90AB1; NbExp=2; IntAct=EBI-722747, EBI-352572; CC P43250; P52205: ROM1; Xeno; NbExp=9; IntAct=EBI-722747, EBI-8176947; CC P43250-2; P05067: APP; NbExp=3; IntAct=EBI-6428342, EBI-77613; CC -!- SUBCELLULAR LOCATION: Membrane; Lipid-anchor. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=GRK6A; CC IsoId=P43250-1; Sequence=Displayed; CC Name=GRK6B; CC IsoId=P43250-2; Sequence=VSP_004938; CC Name=GRK6C; CC IsoId=P43250-3; Sequence=VSP_041813, VSP_041814; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:8415712}. CC -!- PTM: It is uncertain whether palmitoylation is on Cys-561 and/or Cys- CC 562 and/or Cys-565. {ECO:0000269|PubMed:7961702}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. GPRK subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L16862; AAA60175.1; -; mRNA. DR EMBL; AF040751; AAC09273.1; -; mRNA. DR EMBL; AF040752; AAC09274.1; -; mRNA. DR EMBL; AC145098; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC009277; AAH09277.1; -; mRNA. DR EMBL; U00686; AAA03565.1; -; mRNA. DR CCDS; CCDS34303.1; -. [P43250-1] DR CCDS; CCDS43406.1; -. [P43250-3] DR PIR; A48765; A48765. DR RefSeq; NP_001004105.1; NM_001004105.3. [P43250-3] DR RefSeq; NP_001004106.1; NM_001004106.3. [P43250-1] DR RefSeq; NP_002073.2; NM_002082.4. [P43250-2] DR PDB; 2ACX; X-ray; 2.60 A; A/B=1-576. DR PDB; 3NYN; X-ray; 2.72 A; A/B=2-576. DR PDB; 3NYO; X-ray; 2.92 A; A/B=2-576. DR PDBsum; 2ACX; -. DR PDBsum; 3NYN; -. DR PDBsum; 3NYO; -. DR AlphaFoldDB; P43250; -. DR SMR; P43250; -. DR BioGRID; 109128; 143. DR FunCoup; P43250; 2317. DR IntAct; P43250; 141. DR MINT; P43250; -. DR STRING; 9606.ENSP00000347655; -. DR BindingDB; P43250; -. DR ChEMBL; CHEMBL6144; -. DR DrugCentral; P43250; -. DR GuidetoPHARMACOLOGY; 1470; -. DR CarbonylDB; P43250; -. DR iPTMnet; P43250; -. DR PhosphoSitePlus; P43250; -. DR SwissPalm; P43250; -. DR BioMuta; GRK6; -. DR DMDM; 20141386; -. DR jPOST; P43250; -. DR MassIVE; P43250; -. DR PaxDb; 9606-ENSP00000433511; -. DR PeptideAtlas; P43250; -. DR ProteomicsDB; 55602; -. [P43250-1] DR ProteomicsDB; 55603; -. [P43250-2] DR ProteomicsDB; 55604; -. [P43250-3] DR Pumba; P43250; -. DR ABCD; P43250; 1 sequenced antibody. DR Antibodypedia; 17408; 406 antibodies from 38 providers. DR DNASU; 2870; -. DR Ensembl; ENST00000355472.10; ENSP00000347655.5; ENSG00000198055.12. [P43250-1] DR Ensembl; ENST00000355958.9; ENSP00000348230.5; ENSG00000198055.12. [P43250-3] DR Ensembl; ENST00000528793.5; ENSP00000433511.1; ENSG00000198055.12. [P43250-2] DR GeneID; 2870; -. DR KEGG; hsa:2870; -. DR MANE-Select; ENST00000355472.10; ENSP00000347655.5; NM_001004106.3; NP_001004106.1. DR UCSC; uc003mgq.3; human. [P43250-1] DR AGR; HGNC:4545; -. DR ClinPGx; PA28942; -. DR CTD; 2870; -. DR DisGeNET; 2870; -. DR GeneCards; GRK6; -. DR HGNC; HGNC:4545; GRK6. DR HPA; ENSG00000198055; Tissue enhanced (bone). DR MIM; 600869; gene. DR OpenTargets; ENSG00000198055; -. DR VEuPathDB; HostDB:ENSG00000198055; -. DR eggNOG; KOG0986; Eukaryota. DR GeneTree; ENSGT00940000158544; -. DR InParanoid; P43250; -. DR OMA; NYLNPKC; -. DR OrthoDB; 354826at2759; -. DR PAN-GO; P43250; 5 GO annotations based on evolutionary models. DR PhylomeDB; P43250; -. DR BRENDA; 2.7.11.16; 2681. DR PathwayCommons; P43250; -. DR Reactome; R-HSA-418555; G alpha (s) signalling events. DR SignaLink; P43250; -. DR SIGNOR; P43250; -. DR Agora; ENSG00000198055; -. DR BioGRID-ORCS; 2870; 16 hits in 1189 CRISPR screens. DR ChiTaRS; GRK6; human. DR EvolutionaryTrace; P43250; -. DR GeneWiki; GRK6; -. DR GenomeRNAi; 2870; -. DR Pharos; P43250; Tchem. DR PRO; PR:P43250; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P43250; protein. DR Bgee; ENSG00000198055; Expressed in granulocyte and 203 other cell types or tissues. DR ExpressionAtlas; P43250; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0047696; F:beta-adrenergic receptor kinase activity; IDA:CACAO. DR GO; GO:0004703; F:G protein-coupled receptor kinase activity; IBA:GO_Central. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome. DR GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0009966; P:regulation of signal transduction; IBA:GO_Central. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd05630; STKc_GRK6; 1. DR DisProt; DP03187; -. DR FunFam; 1.10.167.10:FF:000009; G protein-coupled receptor kinase; 2. DR FunFam; 1.10.510.10:FF:000074; G protein-coupled receptor kinase; 1. DR Gene3D; 6.10.250.2260; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.167.10; Regulator of G-protein Signalling 4, domain 2; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000239; GPCR_kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016137; RGS. DR InterPro; IPR036305; RGS_sf. DR InterPro; IPR044926; RGS_subdomain_2. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24355:SF15; G PROTEIN-COUPLED RECEPTOR KINASE 6; 1. DR PANTHER; PTHR24355; G PROTEIN-COUPLED RECEPTOR KINASE/RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00615; RGS; 1. DR PRINTS; PR00717; GPCRKINASE. DR SMART; SM00315; RGS; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF48097; Regulator of G-protein signaling, RGS; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50132; RGS; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Kinase; Lipoprotein; KW Membrane; Nucleotide-binding; Palmitate; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Wnt signaling pathway. FT CHAIN 1..576 FT /note="G protein-coupled receptor kinase 6" FT /id="PRO_0000085974" FT DOMAIN 53..171 FT /note="RGS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00171" FT DOMAIN 186..448 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 449..514 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..185 FT /note="N-terminal" FT ACT_SITE 311 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 192..200 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 215 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 264..270 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 315..318 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 484 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 485 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 566 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70293" FT MOD_RES 568 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70293" FT LIPID 561 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:7961702" FT LIPID 562 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:7961702" FT LIPID 565 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:7961702" FT VAR_SEQ 560..576 FT /note="DCCGNCSDSEEELPTRL -> RIAVETAATARKSSPPASSPQPEAPTSSWR FT (in isoform GRK6B)" FT /evidence="ECO:0000303|PubMed:10506199" FT /id="VSP_004938" FT VAR_SEQ 560 FT /note="D -> R (in isoform GRK6C)" FT /evidence="ECO:0000303|PubMed:10506199" FT /id="VSP_041813" FT VAR_SEQ 561..576 FT /note="Missing (in isoform GRK6C)" FT /evidence="ECO:0000303|PubMed:10506199" FT /id="VSP_041814" FT VARIANT 31 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs141014084)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040524" FT VARIANT 73 FT /note="T -> M (in dbSNP:rs56382815)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040525" FT VARIANT 275 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040526" FT MUTAGEN 6 FT /note="I->A: 12-13 fold defects in kinase activity; 180- FT fold defects in kinase activity; when associated with A-7." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 7 FT /note="V->A: 12-13 fold defects in kinase activity; 180- FT fold defects in kinase activity; when associated with A-6." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 9 FT /note="N->A: 140-fold defects in kinase activity." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 12 FT /note="L->A: 1100-fold defects in kinase activity." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 561 FT /note="C->S: Abolishes palmitoylation; when associated with FT S-562 and S-565." FT /evidence="ECO:0000269|PubMed:7961702" FT MUTAGEN 562 FT /note="C->S: Abolishes palmitoylation; when associated with FT S-561 and S-565." FT /evidence="ECO:0000269|PubMed:7961702" FT MUTAGEN 565 FT /note="C->S: Abolishes palmitoylation; when associated with FT S-561 and S-562." FT /evidence="ECO:0000269|PubMed:7961702" FT CONFLICT 60..61 FT /note="QP -> HA (in Ref. 1; AAA60175)" FT /evidence="ECO:0000305" FT CONFLICT 104..105 FT /note="QL -> HV (in Ref. 1; AAA60175)" FT /evidence="ECO:0000305" FT HELIX 3..18 FT /evidence="ECO:0007829|PDB:3NYN" FT STRAND 23..25 FT /evidence="ECO:0007829|PDB:3NYN" FT HELIX 30..33 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 43..48 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 53..57 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 61..71 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 75..91 FT /evidence="ECO:0007829|PDB:2ACX" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 98..109 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 112..114 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 117..120 FT /evidence="ECO:0007829|PDB:3NYN" FT HELIX 123..135 FT /evidence="ECO:0007829|PDB:2ACX" FT TURN 139..142 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 143..153 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 156..162 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 165..177 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 186..195 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 198..205 FT /evidence="ECO:0007829|PDB:2ACX" FT TURN 206..208 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 211..218 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 219..224 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 228..240 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 249..254 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 256..263 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 271..276 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 277..280 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 285..304 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 317..319 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 349..351 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 354..357 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 361..364 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 365..380 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 384..386 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 388..390 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 394..403 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:3NYN" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 435..437 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 438..443 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 446..448 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 453..457 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 477..479 FT /evidence="ECO:0007829|PDB:3NYO" FT HELIX 493..502 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 508..517 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 520..525 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 549..555 FT /evidence="ECO:0007829|PDB:3NYN" SQ SEQUENCE 576 AA; 65991 MW; 3BF8C3B1CDE2BD74 CRC64; MELENIVANT VLLKAREGGG GNRKGKSKKW RQMLQFPHIS QCEELRLSLE RDYHSLCERQ PIGRLLFREF CATRPELSRC VAFLDGVAEY EVTPDDKRKA CGRQLTQNFL SHTGPDLIPE VPRQLVTNCT QRLEQGPCKD LFQELTRLTH EYLSVAPFAD YLDSIYFNRF LQWKWLERQP VTKNTFRQYR VLGKGGFGEV CACQVRATGK MYACKKLEKK RIKKRKGEAM ALNEKQILEK VNSRFVVSLA YAYETKDALC LVLTLMNGGD LKFHIYHMGQ AGFPEARAVF YAAEICCGLE DLHRERIVYR DLKPENILLD DHGHIRISDL GLAVHVPEGQ TIKGRVGTVG YMAPEVVKNE RYTFSPDWWA LGCLLYEMIA GQSPFQQRKK KIKREEVERL VKEVPEEYSE RFSPQARSLC SQLLCKDPAE RLGCRGGSAR EVKEHPLFKK LNFKRLGAGM LEPPFKPDPQ AIYCKDVLDI EQFSTVKGVE LEPTDQDFYQ KFATGSVPIP WQNEMVETEC FQELNVFGLD GSVPPDLDWK GQPPAPPKKG LLQRLFSRQD CCGNCSDSEE ELPTRL // ID GSDME_HUMAN Reviewed; 496 AA. AC O60443; A4D156; B2RAX9; B3KT05; O14590; Q08AQ8; Q9UBV3; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 2. DT 28-JAN-2026, entry version 177. DE RecName: Full=Gasdermin-E {ECO:0000303|PubMed:28459430}; DE AltName: Full=Inversely correlated with estrogen receptor expression 1 {ECO:0000303|PubMed:9523727}; DE Short=ICERE-1 {ECO:0000303|PubMed:9523727}; DE AltName: Full=Non-syndromic hearing impairment protein 5 {ECO:0000303|PubMed:9771715}; DE Contains: DE RecName: Full=Gasdermin-E, N-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-NT {ECO:0000303|PubMed:28459430}; DE Contains: DE RecName: Full=Gasdermin-E, C-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-CT {ECO:0000303|PubMed:28459430}; GN Name=GSDME {ECO:0000303|PubMed:28459430, ECO:0000312|HGNC:HGNC:2810}; GN Synonyms=DFNA5 {ECO:0000303|PubMed:9771715}, GN ICERE1 {ECO:0000303|PubMed:9523727}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INVOLVEMENT RP IN DFNA5. RC TISSUE=Cochlea; RX PubMed=9771715; DOI=10.1038/2503; RA Van Laer L., Huizing E.H., Verstreken M., van Zuijlen D., Wauters J.G., RA Bossuyt P.J., Van de Heyning P., McGuirt W.T., Smith R.J.H., Willems P.J., RA Legan P.K., Richardson G.P., Van Camp G.; RT "Nonsyndromic hearing impairment is associated with a mutation in DFNA5."; RL Nat. Genet. 20:194-197(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Van Laer L., Van Camp G.; RL Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Mei G., Yu W., Gibbs R.A.; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-142. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 5-496 (ISOFORM 1). RC TISSUE=Mammary gland; RX PubMed=9523727; DOI=10.1046/j.1432-1327.1998.2520169.x; RA Thompson D.A., Weigel R.J.; RT "Characterization of a gene that is inversely correlated with estrogen RT receptor expression (ICERE-1) in breast carcinomas."; RL Eur. J. Biochem. 252:169-177(1998). RN [10] RP SEQUENCE REVISION TO C-TERMINUS. RA Thompson D.A.; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [11] RP FUNCTION IN TP53-MEDIATED CELLULAR RESPONSE. RX PubMed=16897187; DOI=10.1007/s10038-006-0004-6; RA Masuda Y., Futamura M., Kamino H., Nakamura Y., Kitamura N., Ohnishi S., RA Miyamoto Y., Ichikawa H., Ohta T., Ohki M., Kiyono T., Egami H., Baba H., RA Arakawa H.; RT "The potential role of DFNA5, a hearing impairment gene, in p53-mediated RT cellular response to DNA damage."; RL J. Hum. Genet. 51:652-664(2006). RN [12] RP INVOLVEMENT IN CRC. RX PubMed=18223688; DOI=10.1038/sj.onc.1211021; RA Kim M.S., Chang X., Yamashita K., Nagpal J.K., Baek J.H., Wu G., Trink B., RA Ratovitski E.A., Mori M., Sidransky D.; RT "Aberrant promoter methylation and tumor suppressive activity of the DFNA5 RT gene in colorectal carcinoma."; RL Oncogene 27:3624-3634(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP FUNCTION. RX PubMed=21522185; DOI=10.1038/ejhg.2011.63; RA Op de Beeck K., Van Camp G., Thys S., Cools N., Callebaut I., Vrijens K., RA Van Nassauw L., Van Tendeloo V.F., Timmermans J.P., Van Laer L.; RT "The DFNA5 gene, responsible for hearing loss and involved in cancer, RT encodes a novel apoptosis-inducing protein."; RL Eur. J. Hum. Genet. 19:965-973(2011). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP INVOLVEMENT IN DFNA5. RX PubMed=19911014; DOI=10.1038/jhg.2009.114; RA Park H.J., Cho H.J., Baek J.I., Ben-Yosef T., Kwon T.J., Griffith A.J., RA Kim U.K.; RT "Evidence for a founder mutation causing DFNA5 hearing loss in East RT Asians."; RL J. Hum. Genet. 55:59-62(2010). RN [18] RP INVOLVEMENT IN DFNA5. RX PubMed=24506266; DOI=10.1111/ahg.12053; RA Nishio A., Noguchi Y., Sato T., Naruse T.K., Kimura A., Takagi A., RA Kitamura K.; RT "A DFNA5 mutation identified in Japanese families with autosomal dominant RT hereditary hearing loss."; RL Ann. Hum. Genet. 78:83-91(2014). RN [19] RP INVOLVEMENT IN DFNA5. RX PubMed=26236191; DOI=10.3389/fncel.2015.00231; RA Van Rossom S., Op de Beeck K., Hristovska V., Winderickx J., Van Camp G.; RT "The deafness gene DFNA5 induces programmed cell death through mitochondria RT and MAPK-related pathways."; RL Front. Cell. Neurosci. 9:231-231(2015). RN [20] RP FUNCTION, AND MUTAGENESIS OF ILE-313; PHE-388 AND ALA-392. RX PubMed=27281216; DOI=10.1038/nature18590; RA Ding J., Wang K., Liu W., She Y., Sun Q., Shi J., Sun H., Wang D.C., RA Shao F.; RT "Pore-forming activity and structural autoinhibition of the gasdermin RT family."; RL Nature 535:111-116(2016). RN [21] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF ASP-267 AND ASP-270. RX PubMed=28459430; DOI=10.1038/nature22393; RA Wang Y., Gao W., Shi X., Ding J., Liu W., He H., Wang K., Shao F.; RT "Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a RT gasdermin."; RL Nature 547:99-103(2017). RN [22] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF PHE-2; LYS-39; LYS-40; RP LYS-41 AND ASP-270. RX PubMed=28045099; DOI=10.1038/ncomms14128; RA Rogers C., Fernandes-Alnemri T., Mayes L., Alnemri D., Cingolani G., RA Alnemri E.S.; RT "Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to RT secondary necrotic/pyroptotic cell death."; RL Nat. Commun. 8:14128-14128(2017). RN [23] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY GZMB, RP DOMAIN, MUTAGENESIS OF PHE-2 AND ASP-270, VARIANTS TYR-14; VAL-18; ASP-24; RP CYS-44; ILE-48; THR-137; GLU-199; LEU-212 AND ASN-217, AND CHARACTERIZATION RP OF VARIANTS TYR-14; VAL-18; ASP-24; CYS-44; ILE-48; THR-137; GLU-199; RP LEU-212 AND ASN-217. RX PubMed=32188940; DOI=10.1038/s41586-020-2071-9; RA Zhang Z., Zhang Y., Xia S., Kong Q., Li S., Liu X., Junqueira C., RA Meza-Sosa K.F., Mok T.M.Y., Ansara J., Sengupta S., Yao Y., Wu H., RA Lieberman J.; RT "Gasdermin E suppresses tumour growth by activating anti-tumour immunity."; RL Nature 579:415-420(2020). RN [24] RP SUCCINATION AT CYS-45; CYS-156; CYS-168; CYS-180; CYS-235; CYS-371; RP CYS-417; CYS-408 AND CYS-489. RX PubMed=32820063; DOI=10.1126/science.abb9818; RA Humphries F., Shmuel-Galia L., Ketelut-Carneiro N., Li S., Wang B., RA Nemmara V.V., Wilson R., Jiang Z., Khalighinejad F., Muneeruddin K., RA Shaffer S.A., Dutta R., Ionete C., Pesiridis S., Yang S., Thompson P.R., RA Fitzgerald K.A.; RT "Succination inactivates gasdermin D and blocks pyroptosis."; RL Science 369:1633-1637(2020). RN [25] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, AND CLEAVAGE BY RP GZMB. RX PubMed=31953257; DOI=10.1126/sciimmunol.aax7969; RA Liu Y., Fang Y., Chen X., Wang Z., Liang X., Zhang T., Liu M., Zhou N., RA Lv J., Tang K., Xie J., Gao Y., Cheng F., Zhou Y., Zhang Z., Hu Y., RA Zhang X., Gao Q., Zhang Y., Huang B.; RT "Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers RT cytokine release syndrome."; RL Sci. Immunol. 5:0-0(2020). RN [26] RP FUNCTION, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-270. RX PubMed=33852854; DOI=10.1016/j.celrep.2021.108998; RA Zhou B., Abbott D.W.; RT "Gasdermin E permits interleukin-1 beta release in distinct sublytic and RT pyroptotic phases."; RL Cell Rep. 35:108998-108998(2021). RN [27] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=35972780; DOI=10.7554/elife.73792; RA Zhao Z., Li Q., Ashraf U., Yang M., Zhu W., Gu J., Chen Z., Gu C., Si Y., RA Cao S., Ye J.; RT "Zika virus causes placental pyroptosis and associated adverse fetal RT outcomes by activating GSDME."; RL Elife 11:0-0(2022). RN [28] RP FUNCTION, ACTIVITY REGULATION, AND ACTIVITY REGULATION (MICROBIAL RP INFECTION). RX PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033; RG COVID Human Genetic Effort; RA Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K., RA Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R., RA Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y., RA Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O., RA Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S., RA Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.; RT "Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung RT epithelial cells."; RL Mol. Cell 82:2385-2400(2022). RN [29] RP FUNCTION, AND UBIQUITINATION AT LYS-120 AND LYS-189. RX PubMed=36607699; DOI=10.1158/0008-5472.can-22-1812; RA Ren Y., Feng M., Hao X., Liu X., Li J., Li P., Gao J., Qi Q., Du L., RA Wang C., Wang Q., Wang Y.; RT "USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer."; RL Cancer Res. 83:1074-1093(2023). RN [30] RP PALMITOYLATION. RX PubMed=38599239; DOI=10.1038/s41586-024-07373-5; RA Du G., Healy L.B., David L., Walker C., El-Baba T.J., Lutomski C.A., RA Goh B., Gu B., Pi X., Devant P., Fontana P., Dong Y., Ma X., Miao R., RA Balasubramanian A., Puthenveetil R., Banerjee A., Luo H.R., Kagan J.C., RA Oh S.F., Robinson C.V., Lieberman J., Wu H.; RT "ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D."; RL Nature 0:0-0(2024). CC -!- FUNCTION: [Gasdermin-E]: Precursor of a pore-forming protein that CC converts non-inflammatory apoptosis to pyroptosis (PubMed:27281216, CC PubMed:28459430, PubMed:33852854, PubMed:35594856, PubMed:36607699). CC This form constitutes the precursor of the pore-forming protein: upon CC cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) CC binds to membranes and forms pores, triggering pyroptosis CC (PubMed:28459430). {ECO:0000269|PubMed:27281216, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856, ECO:0000269|PubMed:36607699}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: Pore-forming protein produced by CC cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory CC apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, CC respectively (PubMed:27281216, PubMed:28459430, PubMed:32188940, CC PubMed:33852854, PubMed:35594856). After cleavage, moves to the plasma CC membrane, homooligomerizes within the membrane and forms pores of 10-15 CC nanometers (nm) of inner diameter, allowing the release of mature CC interleukins (IL1B and IL16) and triggering pyroptosis CC (PubMed:28459430, PubMed:32188940, PubMed:33852854, PubMed:35594856). CC Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, CC such as phosphatidylinositol (4,5)-bisphosphate (PubMed:28459430). CC Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or CC danger signals, such as chemotherapy drugs, to pyroptosis CC (PubMed:27281216, PubMed:28459430, PubMed:32188940). Mediates secondary CC necrosis downstream of the mitochondrial apoptotic pathway and CASP3 CC activation as well as in response to viral agents (PubMed:28045099). CC Exhibits bactericidal activity (PubMed:27281216). Cleavage by GZMB CC promotes tumor suppressor activity by triggering robust anti-tumor CC immunity (PubMed:21522185, PubMed:32188940). Suppresses tumors by CC mediating granzyme-mediated pyroptosis in target cells of natural CC killer (NK) cells: cleavage by granzyme B (GZMB), delivered to target CC cells from NK-cells, triggers pyroptosis of tumor cells and tumor CC suppression (PubMed:31953257, PubMed:32188940). May play a role in the CC p53/TP53-regulated cellular response to DNA damage (PubMed:16897187). CC {ECO:0000269|PubMed:16897187, ECO:0000269|PubMed:21522185, CC ECO:0000269|PubMed:27281216, ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: (Microbial infection) Pore-forming CC protein, which promotes maternal placental pyroptosis in response to CC Zika virus infection, contributing to adverse fetal outcomes. CC {ECO:0000269|PubMed:35972780}. CC -!- ACTIVITY REGULATION: [Gasdermin-E]: The full-length protein before CC cleavage is inactive: intramolecular interactions between N- and C- CC terminal domains mediate autoinhibition in the absence of activation CC signal (PubMed:28045099, PubMed:28459430). The intrinsic pyroptosis- CC inducing activity is carried by the released N-terminal moiety CC (Gasdermin-E, N-terminal) following cleavage by CASP3 or granzyme B CC (GZMB) (PubMed:28459430, PubMed:31953257, PubMed:32188940, CC PubMed:35594856). Activated by NLRP1 in the absence of GSDMD CC expression: NLRP1 cleaves and activates CASP8, promoting downstream CC activation of CASP3 and subsequent activation of GSDME CC (PubMed:33852854, PubMed:35594856). {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- ACTIVITY REGULATION: (Microbial infection) Activated upon human CC coronavirus SARS-CoV-2 infection, leading to lung epithelial cell death CC (PubMed:35594856). Activation takes place in response to (1) activation CC of NLRP1 and (2) inactivation of GSDMD following NLRP1 and GSDMD CC cleavage by the SARS-CoV-2 3C-like proteinase nsp5 (PubMed:35594856). CC {ECO:0000269|PubMed:35594856}. CC -!- SUBUNIT: [Gasdermin-E, N-terminal]: Homooligomer; homooligomeric ring- CC shaped pore complex containing 27-28 subunits when inserted in the CC membrane. {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- INTERACTION: CC O60443; Q96CG3: TIFA; NbExp=3; IntAct=EBI-719315, EBI-740711; CC -!- SUBCELLULAR LOCATION: [Gasdermin-E, N-terminal]: Cell membrane CC {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430}; Multi-pass CC membrane protein {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- SUBCELLULAR LOCATION: [Gasdermin-E]: Cytoplasm, cytosol CC {ECO:0000269|PubMed:28045099}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O60443-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O60443-2; Sequence=VSP_004190; CC Name=3; CC IsoId=O60443-3; Sequence=VSP_044276; CC -!- TISSUE SPECIFICITY: Expressed in cochlea (PubMed:9771715). Low level of CC expression in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas, with highest expression in placenta CC (PubMed:9771715). {ECO:0000269|PubMed:9771715}. CC -!- DOMAIN: Intramolecular interactions between N- and C-terminal domains CC may be important for autoinhibition in the absence of activation CC signal. The intrinsic pyroptosis-inducing activity is carried by the N- CC terminal domain, that is released upon cleavage by CASP3 or granzyme B CC (GZMB). {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: Cleavage at Asp-270 by CASP3 (mature and uncleaved precursor CC forms) or granzyme B (GZMB) relieves autoinhibition and is sufficient CC to initiate pyroptosis. {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: [Gasdermin-E]: Succination by the Krebs cycle intermediate CC fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits CC processing by caspases, and ability to initiate pyroptosis CC (PubMed:32820063). Succination modification is catalyzed by a non- CC enzymatic reaction caused by an accumulation of fumarate CC (PubMed:32820063). {ECO:0000269|PubMed:32820063}. CC -!- PTM: [Gasdermin-E]: Ubiquitinated at Lys-120 and Lys-189 via 'Lys-48'- CC linked polyubiquitin chains, leading to proteasomal degradation. CC Deubiquitinated by USP48, leading to increased stability. CC {ECO:0000269|PubMed:36607699}. CC -!- PTM: Palmitoylated. {ECO:0000269|PubMed:38599239}. CC -!- DISEASE: Deafness, autosomal dominant, 5 (DFNA5) [MIM:600994]: A form CC of non-syndromic sensorineural hearing loss. Sensorineural deafness CC results from damage to the neural receptors of the inner ear, the nerve CC pathways to the brain, or the area of the brain that receives sound CC information. {ECO:0000269|PubMed:19911014, ECO:0000269|PubMed:24506266, CC ECO:0000269|PubMed:26236191, ECO:0000269|PubMed:9771715}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Is a tumor suppressor gene with an important role in CC colorectal cancer (CRC). {ECO:0000303|PubMed:18223688}. CC -!- SIMILARITY: Belongs to the gasdermin family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB83938.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=AAC39635.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF073308; AAC69324.1; -; mRNA. DR EMBL; AF075171; AAC69326.1; -; mRNA. DR EMBL; AF131765; AAD20039.1; -; mRNA. DR EMBL; AK094714; BAG52917.1; -; mRNA. DR EMBL; AK314402; BAG37026.1; -; mRNA. DR EMBL; AC003093; AAB83938.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH236948; EAL24246.1; -; Genomic_DNA. DR EMBL; CH471073; EAW93813.1; -; Genomic_DNA. DR EMBL; BC125065; AAI25066.1; -; mRNA. DR EMBL; AF007790; AAC39635.2; ALT_INIT; mRNA. DR CCDS; CCDS47563.1; -. [O60443-3] DR CCDS; CCDS5389.1; -. [O60443-1] DR RefSeq; NP_001120925.1; NM_001127453.2. [O60443-1] DR RefSeq; NP_001120926.1; NM_001127454.2. [O60443-3] DR RefSeq; NP_001424988.1; NM_001438059.1. [O60443-3] DR RefSeq; NP_004394.1; NM_004403.3. [O60443-1] DR RefSeq; XP_024302438.1; XM_024446670.2. [O60443-1] DR RefSeq; XP_054213373.1; XM_054357398.1. [O60443-1] DR AlphaFoldDB; O60443; -. DR BioGRID; 108049; 65. DR FunCoup; O60443; 518. DR IntAct; O60443; 158. DR MINT; O60443; -. DR STRING; 9606.ENSP00000339587; -. DR TCDB; 1.C.123.1.5; the pore-forming gasdermin (gasdermin) family. DR GlyGen; O60443; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O60443; -. DR PhosphoSitePlus; O60443; -. DR SwissPalm; O60443; -. DR BioMuta; GSDME; -. DR jPOST; O60443; -. DR MassIVE; O60443; -. DR PaxDb; 9606-ENSP00000339587; -. DR PeptideAtlas; O60443; -. DR ProteomicsDB; 3659; -. DR ProteomicsDB; 49403; -. [O60443-1] DR ProteomicsDB; 49404; -. [O60443-2] DR Antibodypedia; 1157; 225 antibodies from 32 providers. DR DNASU; 1687; -. DR Ensembl; ENST00000342947.9; ENSP00000339587.3; ENSG00000105928.17. [O60443-1] DR Ensembl; ENST00000409970.6; ENSP00000387119.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000419307.6; ENSP00000401332.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000645220.1; ENSP00000494186.1; ENSG00000105928.17. [O60443-1] DR GeneID; 1687; -. DR KEGG; hsa:1687; -. DR MANE-Select; ENST00000645220.1; ENSP00000494186.1; NM_001127453.2; NP_001120925.1. DR UCSC; uc003sxa.2; human. [O60443-1] DR AGR; HGNC:2810; -. DR ClinPGx; PA27281; -. DR CTD; 1687; -. DR DisGeNET; 1687; -. DR GeneCards; GSDME; -. DR GeneReviews; GSDME; -. DR HGNC; HGNC:2810; GSDME. DR HPA; ENSG00000105928; Low tissue specificity. DR MalaCards; GSDME; -. DR MIM; 600994; phenotype. DR MIM; 608798; gene. DR OpenTargets; ENSG00000105928; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000105928; -. DR eggNOG; ENOG502QRAB; Eukaryota. DR GeneTree; ENSGT00940000155880; -. DR HOGENOM; CLU_042999_0_0_1; -. DR InParanoid; O60443; -. DR OMA; EMTNDCL; -. DR OrthoDB; 8815334at2759; -. DR PAN-GO; O60443; 2 GO annotations based on evolutionary models. DR PhylomeDB; O60443; -. DR PathwayCommons; O60443; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand. DR Reactome; R-HSA-9710421; Defective pyroptosis. DR SignaLink; O60443; -. DR Agora; ENSG00000105928; -. DR BioGRID-ORCS; 1687; 9 hits in 1147 CRISPR screens. DR ChiTaRS; DFNA5; human. DR GeneWiki; DFNA5; -. DR GenomeRNAi; 1687; -. DR Pharos; O60443; Tbio. DR PRO; PR:O60443; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; O60443; protein. DR Bgee; ENSG00000105928; Expressed in germinal epithelium of ovary and 190 other cell types or tissues. DR ExpressionAtlas; O60443; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:1901612; F:cardiolipin binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0022829; F:wide pore channel activity; IDA:UniProt. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0042491; P:inner ear auditory receptor cell differentiation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0002839; P:positive regulation of immune response to tumor cell; IDA:UniProt. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0012501; P:programmed cell death; IMP:UniProtKB. DR GO; GO:0141201; P:pyroptotic cell death; IDA:UniProt. DR GO; GO:0070269; P:pyroptotic inflammatory response; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; TAS:ProtInc. DR InterPro; IPR040460; Gasdermin_pore. DR InterPro; IPR041263; Gasdermin_PUB. DR InterPro; IPR042377; GSDME. DR PANTHER; PTHR15207:SF1; GASDERMIN-E; 1. DR PANTHER; PTHR15207; NONSYNDROMIC HEARING IMPAIRMENT PROTEIN; 1. DR Pfam; PF04598; Gasdermin; 1. DR Pfam; PF17708; Gasdermin_C; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cytoplasm; Deafness; Isopeptide bond; KW Lipoprotein; Membrane; Necrosis; Non-syndromic deafness; Palmitate; KW Proteomics identification; Reference proteome; Transmembrane; KW Transmembrane beta strand; Tumor suppressor; Ubl conjugation. FT CHAIN 1..496 FT /note="Gasdermin-E" FT /id="PRO_0000148178" FT CHAIN 1..270 FT /note="Gasdermin-E, N-terminal" FT /evidence="ECO:0000269|PubMed:27281216, FT ECO:0000305|PubMed:28459430, ECO:0000305|PubMed:32188940" FT /id="PRO_0000442786" FT CHAIN 271..496 FT /note="Gasdermin-E, C-terminal" FT /evidence="ECO:0000305|PubMed:28459430" FT /id="PRO_0000442787" FT REGION 1..56 FT /note="Membrane targeting domain" FT /evidence="ECO:0000269|PubMed:28045099" FT SITE 270..271 FT /note="Cleavage; by CASP3 or granzyme B" FT /evidence="ECO:0000269|PubMed:28459430, FT ECO:0000269|PubMed:32188940" FT MOD_RES 45 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 156 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 168 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 180 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 235 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 371 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 408 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 417 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 489 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT CROSSLNK 120 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT CROSSLNK 189 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT VAR_SEQ 1..395 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2, ECO:0000303|Ref.3" FT /id="VSP_004190" FT VAR_SEQ 1..164 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044276" FT VARIANT 14 FT /note="D -> Y (in a breast carcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083903" FT VARIANT 18 FT /note="D -> V (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083904" FT VARIANT 24 FT /note="N -> D (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083905" FT VARIANT 44 FT /note="W -> C (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083906" FT VARIANT 48 FT /note="R -> I (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083907" FT VARIANT 137 FT /note="I -> T (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083908" FT VARIANT 142 FT /note="P -> T (in dbSNP:rs754554)" FT /evidence="ECO:0000269|PubMed:12690205" FT /id="VAR_030824" FT VARIANT 174 FT /note="M -> T (in dbSNP:rs876306)" FT /id="VAR_053102" FT VARIANT 199 FT /note="G -> E (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083909" FT VARIANT 207 FT /note="V -> M (in dbSNP:rs12540919)" FT /id="VAR_030825" FT VARIANT 212 FT /note="P -> L (in a melanoma sample; somatic mutation; FT reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083910" FT VARIANT 217 FT /note="I -> N (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083911" FT MUTAGEN 2 FT /note="F->A: No effect on plasma membrane targeting. FT Decreases induction of necrotic activity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-40." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:32188940" FT MUTAGEN 39 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-40 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 40 FT /note="K->A: No effect on plasma membrane targeting. No FT effect on induction of cytotoxivity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-2 or A-39 and A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 41 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-39 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 267 FT /note="D->A: Abolishes cleavage by CASP3. Abolishes FT pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28459430" FT MUTAGEN 270 FT /note="D->A,E: Abolishes cleavage by CASP3 or granzyme B. FT Abolishes pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:32188940, FT ECO:0000269|PubMed:33852854" FT MUTAGEN 313 FT /note="I->D: No spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 388 FT /note="F->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 392 FT /note="A->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" SQ SEQUENCE 496 AA; 54555 MW; A407C9AC31AA716B CRC64; MFAKATRNFL REVDADGDLI AVSNLNDSDK LQLLSLVTKK KRFWCWQRPK YQFLSLTLGD VLIEDQFPSP VVVESDFVKY EGKFANHVSG TLETALGKVK LNLGGSSRVE SQSSFGTLRK QEVDLQQLIR DSAERTINLR NPVLQQVLEG RNEVLCVLTQ KITTMQKCVI SEHMQVEEKC GGIVGIQTKT VQVSATEDGN VTKDSNVVLE IPAATTIAYG VIELYVKLDG QFEFCLLRGK QGGFENKKRI DSVYLDPLVF REFAFIDMPD AAHGISSQDG PLSVLKQATL LLERNFHPFA ELPEPQQTAL SDIFQAVLFD DELLMVLEPV CDDLVSGLSP TVAVLGELKP RQQQDLVAFL QLVGCSLQGG CPGPEDAGSK QLFMTAYFLV SALAEMPDSA AALLGTCCKL QIIPTLCHLL RALSDDGVSD LEDPTLTPLK DTERFGIVQR LFASADISLE RLKSSVKAVI LKDSKVFPLL LCITLNGLCA LGREHS // ID GUC2F_HUMAN Reviewed; 1108 AA. AC P51841; Q9UJF1; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 02-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Retinal guanylyl cyclase 2; DE Short=RETGC-2 {ECO:0000303|PubMed:7777544}; DE EC=4.6.1.2 {ECO:0000269|PubMed:7777544}; DE AltName: Full=Guanylate cyclase 2F, retinal {ECO:0000312|HGNC:HGNC:4691}; DE AltName: Full=Guanylate cyclase F; DE Short=GC-F; DE AltName: Full=Rod outer segment membrane guanylate cyclase 2; DE Short=ROS-GC2; DE Flags: Precursor; GN Name=GUCY2F; Synonyms=GUC2F, RETGC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT GLN-296, TISSUE SPECIFICITY, ACTIVITY RP REGULATION, AND CATALYTIC ACTIVITY. RC TISSUE=Retina; RX PubMed=7777544; DOI=10.1073/pnas.92.12.5535; RA Lowe D.G., Dizhoor A.M., Liu K., Gu Q., Spencer M., Laura R., Lu L., RA Hurley J.B.; RT "Cloning and expression of a second photoreceptor-specific membrane retina RT guanylyl cyclase (RetGC), RetGC-2."; RL Proc. Natl. Acad. Sci. U.S.A. 92:5535-5539(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP VARIANT [LARGE SCALE ANALYSIS] PRO-10. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-40; ASN-160; TRP-230; PRO-284; GLN-305; RP CYS-308; HIS-380; ARG-434; ASP-568; GLN-628; LEU-677; LYS-794; VAL-1010; RP ARG-1052 AND ASP-1055. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP VARIANT ASP-872. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [6] RP ACTIVITY REGULATION. RX PubMed=29515371; DOI=10.3389/fnmol.2018.00052; RA Wimberg H., Janssen-Bienhold U., Koch K.W.; RT "Control of the Nucleotide Cycle in Photoreceptor Cell Extracts by Retinal RT Degeneration Protein 3."; RL Front. Mol. Neurosci. 11:52-52(2018). CC -!- FUNCTION: Responsible for the synthesis of cyclic GMP (cGMP) in rods CC and cones of photoreceptors (PubMed:7777544). Plays an essential role CC in phototransduction, by mediating cGMP replenishment (By similarity). CC May also participate in the trafficking of membrane-associated proteins CC to the photoreceptor outer segment membrane (By similarity). CC {ECO:0000250|UniProtKB:Q5SDA5, ECO:0000269|PubMed:7777544}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP = 3',5'-cyclic GMP + diphosphate; Xref=Rhea:RHEA:13665, CC ChEBI:CHEBI:33019, ChEBI:CHEBI:37565, ChEBI:CHEBI:57746; EC=4.6.1.2; CC Evidence={ECO:0000269|PubMed:7777544}; CC -!- ACTIVITY REGULATION: Activated by GUCA1B when free calcium ions CC concentration is low, and inhibited by GUCA1B when free calcium ions CC concentration is high (PubMed:15772651). Inhibited by RD3 CC (PubMed:29515371). {ECO:0000269|PubMed:15772651, CC ECO:0000269|PubMed:29515371}. CC -!- SUBUNIT: Homodimer (By similarity). Interacts with RD3; promotes the CC exit of GUCY2F from the endoplasmic reticulum and its trafficking to CC the photoreceptor outer segments (By similarity). CC {ECO:0000250|UniProtKB:P51842, ECO:0000250|UniProtKB:Q5SDA5}. CC -!- SUBCELLULAR LOCATION: Photoreceptor outer segment membrane CC {ECO:0000250|UniProtKB:O02740}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- TISSUE SPECIFICITY: Retina. Localized exclusively in the outer nuclear CC layer and inner segments of the rod and cone photoreceptor cells. CC {ECO:0000269|PubMed:7777544}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: There are 9 conserved cysteine residues in sensory guanylate CC cyclases, 6 in the extracellular domain, which may be involved in CC intra- or interchain disulfide bonds. CC -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase CC family. {ECO:0000255|PROSITE-ProRule:PRU00099}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L37378; AAA74451.1; -; mRNA. DR EMBL; AL031387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS14545.1; -. DR PIR; I59385; I59385. DR RefSeq; NP_001513.2; NM_001522.3. DR AlphaFoldDB; P51841; -. DR SMR; P51841; -. DR BioGRID; 109241; 6. DR FunCoup; P51841; 179. DR IntAct; P51841; 6. DR MINT; P51841; -. DR STRING; 9606.ENSP00000218006; -. DR iPTMnet; P51841; -. DR PhosphoSitePlus; P51841; -. DR BioMuta; GUCY2F; -. DR DMDM; 311033391; -. DR jPOST; P51841; -. DR MassIVE; P51841; -. DR PaxDb; 9606-ENSP00000218006; -. DR PeptideAtlas; P51841; -. DR ProteomicsDB; 56431; -. DR Antibodypedia; 29460; 108 antibodies from 18 providers. DR DNASU; 2986; -. DR Ensembl; ENST00000218006.3; ENSP00000218006.2; ENSG00000101890.5. DR GeneID; 2986; -. DR KEGG; hsa:2986; -. DR MANE-Select; ENST00000218006.3; ENSP00000218006.2; NM_001522.3; NP_001513.2. DR UCSC; uc065aqx.1; human. DR AGR; HGNC:4691; -. DR ClinPGx; PA29071; -. DR CTD; 2986; -. DR DisGeNET; 2986; -. DR GeneCards; GUCY2F; -. DR HGNC; HGNC:4691; GUCY2F. DR HPA; ENSG00000101890; Tissue enriched (retina). DR MIM; 300041; gene. DR OpenTargets; ENSG00000101890; -. DR VEuPathDB; HostDB:ENSG00000101890; -. DR eggNOG; KOG1023; Eukaryota. DR GeneTree; ENSGT00940000162146; -. DR HOGENOM; CLU_001072_1_0_1; -. DR InParanoid; P51841; -. DR OMA; QDSQSMR; -. DR OrthoDB; 1890790at2759; -. DR PAN-GO; P51841; 5 GO annotations based on evolutionary models. DR PhylomeDB; P51841; -. DR BRENDA; 4.6.1.2; 2681. DR PathwayCommons; P51841; -. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR SignaLink; P51841; -. DR BioGRID-ORCS; 2986; 10 hits in 794 CRISPR screens. DR ChiTaRS; GUCY2F; human. DR GenomeRNAi; 2986; -. DR Pharos; P51841; Tbio. DR PRO; PR:P51841; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51841; protein. DR Bgee; ENSG00000101890; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 14 other cell types or tissues. DR GO; GO:0005640; C:nuclear outer membrane; TAS:ProtInc. DR GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0120200; C:rod photoreceptor outer segment; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW. DR GO; GO:0004383; F:guanylate cyclase activity; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0001653; F:peptide receptor activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central. DR GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl. DR GO; GO:0050908; P:detection of light stimulus involved in visual perception; IEA:Ensembl. DR GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IBA:GO_Central. DR GO; GO:0022400; P:regulation of opsin-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007601; P:visual perception; TAS:ProtInc. DR CDD; cd07302; CHD; 1. DR CDD; cd06371; PBP1_sensory_GC_DEF-like; 1. DR FunFam; 1.10.510.10:FF:000404; Guanylate cyclase; 1. DR FunFam; 3.30.70.1230:FF:000013; Guanylate cyclase; 1. DR FunFam; 3.40.50.2300:FF:000114; Guanylate cyclase; 1. DR Gene3D; 3.40.50.2300; -; 2. DR Gene3D; 3.30.70.1230; Nucleotide cyclase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001054; A/G_cyclase. DR InterPro; IPR018297; A/G_cyclase_CS. DR InterPro; IPR001828; ANF_lig-bd_rcpt. DR InterPro; IPR050401; Cyclic_nucleotide_synthase. DR InterPro; IPR011645; HNOB_dom_associated. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR029787; Nucleotide_cyclase. DR InterPro; IPR028082; Peripla_BP_I. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR PANTHER; PTHR11920; GUANYLYL CYCLASE; 1. DR PANTHER; PTHR11920:SF349; RETINAL GUANYLYL CYCLASE 2; 1. DR Pfam; PF01094; ANF_receptor; 1. DR Pfam; PF00211; Guanylate_cyc; 1. DR Pfam; PF07701; HNOBA; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00044; CYCc; 1. DR SUPFAM; SSF55073; Nucleotide cyclase; 1. DR SUPFAM; SSF53822; Periplasmic binding protein-like I; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1. DR PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Cell projection; cGMP biosynthesis; Disulfide bond; GTP-binding; Lyase; KW Membrane; Nucleotide-binding; Proteomics identification; KW Reference proteome; Sensory transduction; Signal; Transmembrane; KW Transmembrane helix; Vision. FT SIGNAL 1..50 FT /evidence="ECO:0000255" FT CHAIN 51..1108 FT /note="Retinal guanylyl cyclase 2" FT /id="PRO_0000012386" FT TOPO_DOM 51..467 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 468..490 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 491..1108 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 532..812 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 884..1014 FT /note="Guanylate cyclase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00099" FT DISULFID 104..132 FT /evidence="ECO:0000250" FT DISULFID 452 FT /note="Interchain" FT /evidence="ECO:0000250" FT DISULFID 460 FT /note="Interchain" FT /evidence="ECO:0000250" FT VARIANT 10 FT /note="R -> P (in a breast cancer sample; somatic mutation; FT dbSNP:rs755991142)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036419" FT VARIANT 40 FT /note="S -> C (in dbSNP:rs34228145)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042233" FT VARIANT 160 FT /note="I -> N (in dbSNP:rs33971675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042234" FT VARIANT 230 FT /note="R -> W (in dbSNP:rs33973457)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042235" FT VARIANT 284 FT /note="L -> P (in dbSNP:rs12008095)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_009136" FT VARIANT 296 FT /note="R -> Q (in dbSNP:rs502209)" FT /evidence="ECO:0000269|PubMed:7777544" FT /id="VAR_009137" FT VARIANT 305 FT /note="R -> Q (in dbSNP:rs55966326)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042236" FT VARIANT 308 FT /note="Y -> C (in dbSNP:rs16985750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030633" FT VARIANT 380 FT /note="Q -> H (in dbSNP:rs2272925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030634" FT VARIANT 434 FT /note="G -> R (in dbSNP:rs56293008)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042237" FT VARIANT 568 FT /note="G -> D (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs779221554)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042238" FT VARIANT 628 FT /note="R -> Q (in dbSNP:rs7883913)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030635" FT VARIANT 677 FT /note="V -> L (in dbSNP:rs35474112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042239" FT VARIANT 794 FT /note="E -> K (in dbSNP:rs35726803)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042240" FT VARIANT 872 FT /note="G -> D (in dbSNP:rs148663380)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069424" FT VARIANT 1010 FT /note="A -> V (in dbSNP:rs55735218)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042241" FT VARIANT 1052 FT /note="K -> R (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042242" FT VARIANT 1055 FT /note="E -> D (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042243" SQ SEQUENCE 1108 AA; 124850 MW; B047BBF1A3C009F9 CRC64; MFLGLGRFSR LVLWFAAFRK LLGHHGLASA KFLWCLCLLS VMSLPQQVWT LPYKIGVVGP WACDSLFSKA LPEVAARLAI ERINRDPSFD LSYSFEYVIL NEDCQTSRAL SSFISHHQMA SGFIGPTNPG YCEAASLLGN SWDKGIFSWA CVNYELDNKI SYPTFSRTLP SPIRVLVTVM KYFQWAHAGV ISSDEDIWVH TANRVASALR SHGLPVGVVL TTGQDSQSMR KALQRIHQAD RIRIIIMCMH SALIGGETQM HLLECAHDLK MTDGTYVFVP YDALLYSLPY KHTPYRVLRN NPKLREAYDA VLTITVESQE KTFYQAFTEA AARGEIPEKL EFDQVSPLFG TIYNSIYFIA QAMNNAMKEN GQAGAASLVQ HSRNMQFHGF NQLMRTDSNG NGISEYVILD TNLKEWELHS TYTVDMEMEL LRFGGTPIHF PGGRPPRADA KCWFAEGKIC HGGIDPAFAM MVCLTLLIAL LSINGFAYFI RRRINKIQLI KGPNRILLTL EDVTFINPHF GSKRGSRASV SFQITSEVQS GRSPRLSFSS GSLTPATYEN SNIAIYEGDW VWLKKFSLGD FGDLKSIKSR ASDVFEMMKD LRHENINPLL GFFYDSGMFA IVTEFCSRGS LEDILTNQDV KLDWMFKSSL LLDLIKGMKY LHHREFVHGR LKSRNCVVDG RFVLKVTDYG FNDILEMLRL SEEESSMEEL LWTAPELLRA PRGSRLGSFA GDVYSFAIIM QEVMVRGTPF CMMDLPAQEI INRLKKPPPV YRPVVPPEHA PPECLQLMKQ CWAEAAEQRP TFDEIFNQFK TFNKGKKTNI IDSMLRMLEQ YSSNLEDLIR ERTEELEIEK QKTEKLLTQM LPPSVAESLK KGCTVEPEGF DLVTLYFSDI VGFTTISAMS EPIEVVDLLN DLYTLFDAII GSHDVYKVET IGDAYMVASG LPKRNGSRHA AEIANMSLDI LSSVGTFKMR HMPEVPVRIR IGLHSGPVVA GVVGLTMPRY CLFGDTVNTA SRMESTGLPY RIHVSLSTVT ILQNLSEGYE VELRGRTELK GKGTEETFWL IGKKGFMKPL PVPPPVDKDG QVGHGLQPVE IAAFQRRKAE RQLVRNKP // ID INSR_HUMAN Reviewed; 1382 AA. AC P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 4. DT 28-JAN-2026, entry version 294. DE RecName: Full=Insulin receptor; DE Short=IR; DE EC=2.7.10.1; DE AltName: CD_antigen=CD220; DE Contains: DE RecName: Full=Insulin receptor subunit alpha; DE Contains: DE RecName: Full=Insulin receptor subunit beta; DE Flags: Precursor; GN Name=INSR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2; HIS-171; RP THR-448 AND LYS-492. RX PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4; RA Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.-H., RA Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.; RT "The human insulin receptor cDNA: the structural basis for hormone- RT activated transmembrane signalling."; RL Cell 40:747-758(1985). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49 AND RP 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2. RX PubMed=2983222; DOI=10.1038/313756a0; RA Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., RA Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A., Seeburg P.H., RA Grunfeld C., Rosen O.M., Ramachandran J.; RT "Human insulin receptor and its relationship to the tyrosine kinase family RT of oncogenes."; RL Nature 313:756-761(1985). RN [3] RP SEQUENCE REVISION TO 899-900. RA Chen E.Y.; RL Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2. RC TISSUE=Fetal liver; RX PubMed=2210055; DOI=10.2337/diacare.39.1.123; RA Seino S., Seino M., Bell G.I.; RT "Human insulin-receptor gene. Partial sequence and amplification of exons RT by polymerase chain reaction."; RL Diabetes 39:123-128(1990). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT GLY-2. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=3680248; DOI=10.1016/s0021-9258(18)47714-9; RA Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene. Evidence for promoter activity."; RL J. Biol. Chem. 262:16186-16191(1987). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5; RA Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene."; RL Diabetes Res. Clin. Pract. 7:S31-S33(1989). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2777789; DOI=10.1016/s0021-9258(18)71612-8; RA Tewari D.S., Cook D.M., Taub R.; RT "Characterization of the promoter region and 3' end of the human insulin RT receptor gene."; RL J. Biol. Chem. 264:16238-16245(1989). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RC TISSUE=Skin fibroblast; RX PubMed=2280779; DOI=10.1210/mend-4-4-647; RA McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D., RA Taylor S.I.; RT "Structural and functional analysis of the insulin receptor promoter."; RL Mol. Endocrinol. 4:647-656(1990). RN [11] RP PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780, ACTIVITY RP REGULATION, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=2211730; DOI=10.1016/s0021-9258(17)44805-8; RA Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.; RT "Substructural analysis of the insulin receptor by microsequence analyses RT of limited tryptic fragments isolated by sodium dodecyl sulfate- RT polyacrylamide gel electrophoresis in the absence or presence of RT dithiothreitol."; RL J. Biol. Chem. 265:18673-18681(1990). RN [12] RP PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A HYBRID RP RECEPTOR WITH IGF1R. RC TISSUE=Placenta; RX PubMed=8257688; DOI=10.1021/bi00212a019; RA Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A., RA Fujita-Yamaguchi Y.; RT "Characterization of human placental insulin-like growth factor-I/insulin RT hybrid receptors by protein microsequencing and purification."; RL Biochemistry 32:13531-13536(1993). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE RP SPLICING. RX PubMed=2538124; DOI=10.1016/0006-291x(89)92439-x; RA Seino S., Bell G.I.; RT "Alternative splicing of human insulin receptor messenger RNA."; RL Biochem. Biophys. Res. Commun. 159:312-316(1989). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE SPECIFICITY, RP LIGAND-BINDING, AND AUTOPHOSPHORYLATION. RX PubMed=2369896; DOI=10.1002/j.1460-2075.1990.tb07416.x; RA Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A.; RT "Functionally distinct insulin receptors generated by tissue-specific RT alternative splicing."; RL EMBO J. 9:2409-2413(1990). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085. RX PubMed=2566545; DOI=10.2337/diab.38.6.737; RA Elbein S.C.; RT "Molecular and clinical characterization of an insertional polymorphism of RT the insulin-receptor gene."; RL Diabetes 38:737-743(1989). RN [17] RP PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND RP PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361. RC TISSUE=Placenta; RX PubMed=3166375; DOI=10.1042/bj2520607; RA Tavare J.M., Denton R.M.; RT "Studies on the autophosphorylation of the insulin receptor from human RT placenta. Analysis of the sites phosphorylated by two-dimensional peptide RT mapping."; RL Biochem. J. 252:607-615(1988). RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123. RX PubMed=2544997; DOI=10.1126/science.2544997; RA Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A., RA Nakamura F., Ebina Y., Tatibana M., Makino H.; RT "Human diabetes associated with a deletion of the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:63-66(1989). RN [19] RP PARTIAL PROTEIN SEQUENCE. RX PubMed=3447155; RA Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.; RT "Partial amino acid sequence analyses of human placental insulin RT receptor."; RL Protein Seq. Data Anal. 1:3-6(1987). RN [20] RP MUTAGENESIS OF LYS-1057. RX PubMed=3101064; DOI=10.1073/pnas.84.3.704; RA Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K., RA Pierce S.B., Roth R.A., Rutter W.J.; RT "Replacement of lysine residue 1030 in the putative ATP-binding region of RT the insulin receptor abolishes insulin- and antibody-stimulated glucose RT uptake and receptor kinase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987). RN [21] RP MUTAGENESIS OF TYR-999. RX PubMed=2842060; DOI=10.1016/s0092-8674(88)80008-4; RA White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J., Ullrich A., RA Kahn C.R.; RT "Mutation of the insulin receptor at tyrosine 960 inhibits signal RT transmission but does not affect its tyrosine kinase activity."; RL Cell 54:641-649(1988). RN [22] RP AUTOPHOSPHORYLATION. RX PubMed=1321605; DOI=10.1016/s0006-291x(05)80799-5; RA Dickens M., Tavare J.M.; RT "Analysis of the order of autophosphorylation of human insulin receptor RT tyrosines 1158, 1162 and 1163."; RL Biochem. Biophys. Res. Commun. 186:244-250(1992). RN [23] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541. RX PubMed=1472036; DOI=10.1016/0006-291x(92)92250-2; RA Schaeffer L., Ljungqvist L.; RT "Identification of a disulfide bridge connecting the alpha-subunits of the RT extracellular domain of the insulin receptor."; RL Biochem. Biophys. Res. Commun. 189:650-653(1992). RN [24] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=8452530; DOI=10.1042/bj2900419; RA Soos M.A., Field C.E., Siddle K.; RT "Purified hybrid insulin/insulin-like growth factor-I receptors bind RT insulin-like growth factor-I, but not insulin, with high affinity."; RL Biochem. J. 290:419-426(1993). RN [25] RP FUNCTION, AND INTERACTION WITH PIK3R1. RX PubMed=8276809; DOI=10.1016/s0021-9258(17)42304-0; RA Van Horn D.J., Myers M.G. Jr., Backer J.M.; RT "Direct activation of the phosphatidylinositol 3'-kinase by the insulin RT receptor."; RL J. Biol. Chem. 269:29-32(1994). RN [26] RP INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992; RP ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002. RX PubMed=7559478; DOI=10.1074/jbc.270.40.23258; RA He W., O'Neill T.J., Gustafson T.A.; RT "Distinct modes of interaction of SHC and insulin receptor substrate-1 with RT the insulin receptor NPEY region via non-SH2 domains."; RL J. Biol. Chem. 270:23258-23262(1995). RN [27] RP INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996; RP PRO-997; GLU-998; TYR-999 AND LYS-1057. RX PubMed=7537849; DOI=10.1128/mcb.15.5.2500; RA Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.; RT "Phosphotyrosine-dependent interaction of SHC and insulin receptor RT substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 RT domain."; RL Mol. Cell. Biol. 15:2500-2508(1995). RN [28] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9355755; DOI=10.1042/bj3270209; RA Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.; RT "Insulin receptor/IGF-I receptor hybrids are widely distributed in RT mammalian tissues: quantification of individual receptor species by RT selective immunoprecipitation and immunoblotting."; RL Biochem. J. 327:209-215(1997). RN [29] RP FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND RP INTERACTION WITH STAT5B; IRS1 AND IRS2. RX PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x; RA Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I., RA Van Obberghen E.; RT "Identification of Stat 5B as a substrate of the insulin receptor."; RL Eur. J. Biochem. 250:411-417(1997). RN [30] RP INTERACTION WITH PTPRF. RX PubMed=8995282; DOI=10.1074/jbc.272.11.7519; RA Ahmad F., Goldstein B.J.; RT "Functional association between the insulin receptor and the transmembrane RT protein-tyrosine phosphatase LAR in intact cells."; RL J. Biol. Chem. 272:448-457(1997). RN [31] RP INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE. RX PubMed=8999839; DOI=10.1074/jbc.272.3.1639; RA Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., RA Gustafson T.A., Kusari J.; RT "Protein-tyrosine phosphatase 1B complexes with the insulin receptor in RT vivo and is tyrosine-phosphorylated in the presence of insulin."; RL J. Biol. Chem. 272:1639-1645(1997). RN [32] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1; RA Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D., RA Sesti G.; RT "Distribution of insulin/insulin-like growth factor-I hybrid receptors in RT human tissues."; RL Mol. Cell. Endocrinol. 129:121-126(1997). RN [33] RP TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT). RX PubMed=10207053; DOI=10.1128/mcb.19.5.3278; RA Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., RA Goldfine I.D., Belfiore A., Vigneri R.; RT "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like RT growth factor II receptor in fetal and cancer cells."; RL Mol. Cell. Biol. 19:3278-3288(1999). RN [34] RP INTERACTION WITH ENPP1, AND ACTIVITY REGULATION. RX PubMed=10615944; DOI=10.2337/diabetes.49.1.13; RA Maddux B.A., Goldfine I.D.; RT "Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs RT via direct interaction with the receptor alpha-subunit."; RL Diabetes 49:13-19(2000). RN [35] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=10734133; DOI=10.1074/jbc.275.13.9792; RA Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S., RA Hooft van Huijsduijnen R.; RT "Identification of tyrosine phosphatases that dephosphorylate the insulin RT receptor. A brute force approach based on 'substrate-trapping' mutants."; RL J. Biol. Chem. 275:9792-9796(2000). RN [36] RP INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190. RX PubMed=10803466; DOI=10.1038/sj.onc.1203469; RA Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.; RT "Evidence for an interaction between the insulin receptor and Grb7. A role RT for two of its binding domains, PIR and SH2."; RL Oncogene 19:2052-2059(2000). RN [37] RP INTERACTION WITH SORBS1. RX PubMed=11374898; DOI=10.1006/geno.2001.6541; RA Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y., RA Chuang L.-M.; RT "Cloning, mapping, and characterization of the human sorbin and SH3 domain RT containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin RT signaling in the hepatoma cell line Hep3B."; RL Genomics 74:12-20(2001). RN [38] RP CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ACTIVITY RP REGULATION. RX PubMed=11598120; DOI=10.1074/jbc.m107236200; RA Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.; RT "Multiple activation loop conformations and their regulatory properties in RT the insulin receptor's kinase domain."; RL J. Biol. Chem. 276:46933-46940(2001). RN [39] RP INTERACTION WITH GRB14, AND ACTIVITY REGULATION. RX PubMed=11726652; DOI=10.1074/jbc.m106574200; RA Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J., RA Burnol A.F.; RT "Inhibition of insulin receptor catalytic activity by the molecular adapter RT Grb14."; RL J. Biol. Chem. 277:4845-4852(2002). RN [40] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=12138094; DOI=10.1074/jbc.m202766200; RA Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.; RT "Insulin/insulin-like growth factor I hybrid receptors have different RT biological characteristics depending on the insulin receptor isoform RT involved."; RL J. Biol. Chem. 277:39684-39695(2002). RN [41] RP INTERACTION WITH GRB10, AND ACTIVITY REGULATION. RX PubMed=12493740; DOI=10.1074/jbc.m208518200; RA Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q., Shoelson S.E., RA Liu F.; RT "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)- RT phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the RT association of IRS-1/IRS-2 with the insulin receptor."; RL J. Biol. Chem. 278:8460-8467(2003). RN [42] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2. RX PubMed=12612081; DOI=10.1128/mcb.23.6.2096-2108.2003; RA Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A., RA Meng T.C., Tonks N.K., Tiganis T.; RT "Regulation of insulin receptor signaling by the protein tyrosine RT phosphatase TCPTP."; RL Mol. Cell. Biol. 23:2096-2108(2003). RN [43] RP INTERACTION WITH SOCS7. RX PubMed=16127460; DOI=10.1172/jci23853; RA Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., RA Rothman P.B.; RT "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of RT Langerhans."; RL J. Clin. Invest. 115:2462-2471(2005). RN [44] RP FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005; RA Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V., RA Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P., RA Beguinot F.; RT "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the RT insulin receptor is necessary for insulin metabolic signaling."; RL Mol. Cell. Biol. 25:10803-10814(2005). RN [45] RP DEPHOSPHORYLATION BY PTPRE. RX PubMed=15738637; DOI=10.2108/zsj.22.169; RA Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N., RA Miyazaki H.; RT "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a RT negative regulator of insulin signaling in primary hepatocytes and liver."; RL Zool. Sci. 22:169-175(2005). RN [46] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=16831875; DOI=10.1074/jbc.m605189200; RA Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., RA Mathiasen I.S., Brandt J.; RT "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth RT factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity RT irrespective of the IR splice variant."; RL J. Biol. Chem. 281:25869-25874(2006). RN [47] RP REVIEW ON SIGNALING PATHWAYS. RX PubMed=16493415; DOI=10.1038/nrm1837; RA Taniguchi C.M., Emanuelli B., Kahn C.R.; RT "Critical nodes in signalling pathways: insights into insulin action."; RL Nat. Rev. Mol. Cell Biol. 7:85-96(2006). RN [48] RP REVIEW ON REGULATION OF INSR FUNCTION. RX PubMed=17347799; DOI=10.1007/s00018-007-6359-9; RA Youngren J.F.; RT "Regulation of insulin receptor function."; RL Cell. Mol. Life Sci. 64:873-891(2007). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [50] RP DOMAIN, AND INSULIN-BINDING SITE. RX PubMed=19459609; DOI=10.1021/bi900261q; RA Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.; RT "A thermodynamic study of ligand binding to the first three domains of the RT human insulin receptor: relationship between the receptor alpha-chain C- RT terminal peptide and the site 1 insulin mimetic peptides."; RL Biochemistry 48:5492-5500(2009). RN [51] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [53] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [54] RP INTERACTION WITH NCK1, AND PHOSPHORYLATION AT TYR-1189 AND TYR-1190. RX PubMed=21707536; DOI=10.1042/bj20110799; RA Wu C.L., Buszard B., Teng C.H., Chen W.L., Warr C.G., Tiganis T., RA Meng T.C.; RT "Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling."; RL Biochem. J. 439:151-159(2011). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [56] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [57] RP PHOSPHORYLATION AT TYR-1185 AND TYR-1190. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [58] RP MUTAGENESIS OF LYS-1079, AND UBIQUITINATION AT LYS-1079. RX PubMed=27577745; DOI=10.1038/ncomms12639; RA Nagarajan A., Petersen M.C., Nasiri A.R., Butrico G., Fung A., Ruan H.B., RA Kursawe R., Caprio S., Thibodeau J., Bourgeois-Daigneault M.C., Sun L., RA Gao G., Bhanot S., Jurczak M.J., Green M.R., Shulman G.I., Wajapeyee N.; RT "MARCH1 regulates insulin sensitivity by controlling cell surface insulin RT receptor levels."; RL Nat. Commun. 7:12639-12639(2016). RN [59] RP INTERACTION WITH SORL1. RX PubMed=27322061; DOI=10.1172/jci84708; RA Schmidt V., Schulz N., Yan X., Schuermann A., Kempa S., Kern M., RA Blueher M., Poy M.N., Olivecrona G., Willnow T.E.; RT "SORLA facilitates insulin receptor signaling in adipocytes and exacerbates RT obesity."; RL J. Clin. Invest. 126:2706-2720(2016). RN [60] RP SUBUNIT. RX PubMed=27617429; DOI=10.1038/nsmb.3292; RA Menting J.G., Gajewiak J., MacRaild C.A., Chou D.H., Disotuar M.M., RA Smith N.A., Miller C., Erchegyi J., Rivier J.E., Olivera B.M., Forbes B.E., RA Smith B.J., Norton R.S., Safavi-Hemami H., Lawrence M.C.; RT "A minimized human insulin-receptor-binding motif revealed in a Conus RT geographus venom insulin."; RL Nat. Struct. Mol. Biol. 23:916-920(2016). RN [61] RP S-NITROSYLATION AT CYS-1083, AND MUTAGENESIS OF CYS-462; CYS-825; CYS-834 RP AND CYS-1083. RX PubMed=38056462; DOI=10.1016/j.cell.2023.11.009; RA Zhou H.L., Grimmett Z.W., Venetos N.M., Stomberski C.T., Qian Z., RA McLaughlin P.J., Bansal P.K., Zhang R., Reynolds J.D., Premont R.T., RA Stamler J.S.; RT "An enzyme that selectively S-nitrosylates proteins to regulate insulin RT signaling."; RL Cell 0:0-0(2023). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310. RX PubMed=7997262; DOI=10.1038/372746a0; RA Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.; RT "Crystal structure of the tyrosine kinase domain of the human insulin RT receptor."; RL Nature 372:746-754(1994). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE, RP AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190. RX PubMed=9312016; DOI=10.1093/emboj/16.18.5572; RA Hubbard S.R.; RT "Crystal structure of the activated insulin receptor tyrosine kinase in RT complex with peptide substrate and ATP analog."; RL EMBO J. 16:5572-5581(1997). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG, AND CATALYTIC ACTIVITY. RX PubMed=11124964; DOI=10.1074/jbc.m010161200; RA Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A., RA Hubbard S.R.; RT "Crystallographic and solution studies of an activation loop mutant of the RT insulin receptor tyrosine kinase: insights into kinase mechanism."; RL J. Biol. Chem. 276:10049-10055(2001). RN [65] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-1011. RX PubMed=12707268; DOI=10.1074/jbc.m302425200; RA Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.; RT "Structural and biochemical evidence for an autoinhibitory role for RT tyrosine 984 in the juxtamembrane region of the insulin receptor."; RL J. Biol. Chem. 278:26007-26014(2003). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=14690593; DOI=10.1016/s1097-2765(03)00487-8; RA Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.; RT "Structural basis for recruitment of the adaptor protein APS to the RT activated insulin receptor."; RL Mol. Cell 12:1379-1389(2003). RN [67] RP X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14, RP INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT RP TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001; RA Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R.; RT "Structural basis for inhibition of the insulin receptor by the adaptor RT protein Grb14."; RL Mol. Cell 20:325-333(2005). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1, RP AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16271887; DOI=10.1016/j.str.2005.07.019; RA Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.; RT "Crystal structure of a complex between protein tyrosine phosphatase 1B and RT the insulin receptor tyrosine kinase."; RL Structure 13:1643-1651(2005). RN [69] RP X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN RP ANALOG, DOMAIN, AND DISULFIDE BONDS. RX PubMed=16957736; DOI=10.1038/nature05106; RA McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., RA Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., RA Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., RA Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., RA Fernley R.T., Epa V.C., Ward C.W.; RT "Structure of the insulin receptor ectodomain reveals a folded-over RT conformation."; RL Nature 443:218-221(2006). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT ASN-43; RP ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445, AND RP DISULFIDE BONDS. RX PubMed=16894147; DOI=10.1073/pnas.0605395103; RA Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D., RA Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.; RT "The first three domains of the insulin receptor differ structurally from RT the insulin-like growth factor 1 receptor in the regions governing ligand RT specificity."; RL Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND RP IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190, AND INTERACTION WITH IRS2. RX PubMed=18278056; DOI=10.1038/nsmb.1388; RA Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.; RT "Structural and biochemical characterization of the KRLB region in insulin RT receptor substrate-2."; RL Nat. Struct. Mol. Biol. 15:251-258(2008). RN [72] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH RP INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=18767165; DOI=10.1002/prot.22207; RA Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S., RA Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.; RT "Identification of a key element for hydrogen-bonding patterns between RT protein kinases and their inhibitors."; RL Proteins 73:795-801(2008). RN [73] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077; RA Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., RA Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M., RA Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L., RA Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.; RT "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R RT tyrosine kinase inhibitors towards JNK selectivity."; RL Bioorg. Med. Chem. Lett. 19:360-364(2009). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046; RA Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M., Yang B., RA Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A., Atkins C., Gerding R., RA Hassell A.M., Lei H., Mook R.A. Jr., Moorthy G., Rowand J.L., Stevens K.L., RA Kumar R., Shotwell J.B.; RT "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent RT inhibitors of the IGF-1R receptor tyrosine kinase."; RL Bioorg. Med. Chem. Lett. 19:469-473(2009). RN [75] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110; RA Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B., Tang J., RA Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M., Shewchuck L.M., RA Kumar R., Lei H., Chamberlain S.D.; RT "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent RT inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine RT kinase."; RL Bioorg. Med. Chem. Lett. 19:3136-3140(2009). RN [76] RP X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING REGION, RP AND DISULFIDE BONDS. RX PubMed=20348418; DOI=10.1073/pnas.1001813107; RA Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G., RA Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W., RA Weiss M.A., Lawrence M.C.; RT "Structural resolution of a tandem hormone-binding element in the insulin RT receptor and its implications for design of peptide agonists."; RL Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010). RN [77] RP X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN, RP DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282, AND RP DISULFIDE BONDS. RX PubMed=23302862; DOI=10.1038/nature11781; RA Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K., RA Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J., Chan S.J., RA Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A., Ward C.W., RA Lawrence M.C.; RT "How insulin engages its primary binding site on the insulin receptor."; RL Nature 493:241-245(2013). RN [78] RP VARIANT IRAN TYPE A SER-762. RX PubMed=3283938; DOI=10.1126/science.3283938; RA Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H., RA Imura H., Bell G.I., Steiner D.F.; RT "Insulin-resistant diabetes due to a point mutation that prevents insulin RT proreceptor processing."; RL Science 240:784-787(1988). RN [79] RP VARIANT LEPRCH GLU-487. RX PubMed=2834824; DOI=10.1126/science.2834824; RA Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H., RA Beitz L., McKeon C., Taylor S.I.; RT "Two mutant alleles of the insulin receptor gene in a patient with extreme RT insulin resistance."; RL Science 240:787-790(1988). RN [80] RP VARIANT LEPRCH PRO-260. RX PubMed=2479553; DOI=10.1002/j.1460-2075.1989.tb08387.x; RA Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D., RA Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.; RT "A leucine-to-proline mutation in the insulin receptor in a family with RT insulin resistance."; RL EMBO J. 8:2503-2507(1989). RN [81] RP VARIANT IRAN TYPE A VAL-1035. RX PubMed=2544998; DOI=10.1126/science.2544998; RA Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D., RA Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F., Taylor S.I., RA Kasuga M.; RT "Human diabetes associated with a mutation in the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:66-68(1989). RN [82] RP VARIANT IRAN TYPE A THR-1161. RX PubMed=2168397; DOI=10.1016/s0021-9258(18)77212-8; RA Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.; RT "A naturally occurring mutation of insulin receptor alanine 1134 impairs RT tyrosine kinase function and is associated with dominantly inherited RT insulin resistance."; RL J. Biol. Chem. 265:14979-14985(1990). RN [83] RP CHARACTERIZATION OF VARIANT RMS LYS-42. RX PubMed=2121734; DOI=10.1016/s0021-9258(17)30636-1; RA Kadowaki T., Kadowaki H., Accili D., Taylor S.I.; RT "Substitution of lysine for asparagine at position 15 in the alpha-subunit RT of the human insulin receptor. A mutation that impairs transport of RT receptors to the cell surface and decreases the affinity of insulin RT binding."; RL J. Biol. Chem. 265:19143-19150(1990). RN [84] RP VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A RP SER-489. RX PubMed=2365819; DOI=10.1172/jci114693; RA Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J., RA Gorden P., Taylor S.I.; RT "Five mutant alleles of the insulin receptor gene in patients with genetic RT forms of insulin resistance."; RL J. Clin. Invest. 86:254-264(1990). RN [85] RP VARIANT IRAN TYPE A SER-1227. RX PubMed=1963473; DOI=10.1210/mend-4-8-1183; RA Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.; RT "Functional properties of a naturally occurring Trp1200-->Ser1200 mutation RT of the insulin receptor."; RL Mol. Endocrinol. 4:1183-1191(1990). RN [86] RP VARIANT GLU-1095. RX PubMed=2040394; DOI=10.2337/diab.40.6.777; RA O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S., Moller D.E.; RT "Detection of mutations in insulin-receptor gene in NIDDM patients by RT analysis of single-stranded conformation polymorphisms."; RL Diabetes 40:777-782(1991). RN [87] RP VARIANT IRAN TYPE A GLN-1020. RX PubMed=2002058; DOI=10.1016/s0021-9258(19)67781-1; RA Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O., RA Olefsky J.M.; RT "Insulin resistance and diabetes due to different mutations in the tyrosine RT kinase domain of both insulin receptor gene alleles."; RL J. Biol. Chem. 266:5260-5267(1991). RN [88] RP VARIANT INS RESISTANCE ILE-1180. RX PubMed=1890161; DOI=10.1210/jcem-73-4-894; RA Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P., RA Imperato-Mcginley J., Taylor S.I.; RT "A mutation in the tyrosine kinase domain of the insulin receptor RT associated with insulin resistance in an obese woman."; RL J. Clin. Endocrinol. Metab. 73:894-901(1991). RN [89] RP VARIANTS LEPRCH ALA-55 AND ARG-393. RX PubMed=1607067; DOI=10.2337/diab.41.4.408; RA Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E., RA Pizzo P., Moghetti P., Muggeo M., Roth J.; RT "Detection of mutations in insulin receptor gene by denaturing gradient gel RT electrophoresis."; RL Diabetes 41:408-415(1992). RN [90] RP VARIANT T2D GLN-1191. RX PubMed=1607076; DOI=10.2337/diab.41.4.521; RA Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G., RA Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.; RT "NIDDM associated with mutation in tyrosine kinase domain of insulin RT receptor gene."; RL Diabetes 41:521-526(1992). RN [91] RP VARIANT IRAN TYPE A LEU-1205. RX PubMed=1563582; DOI=10.1007/bf00400927; RA Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y., RA Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I., RA Kadowaki T.; RT "Detection of mutations in the insulin receptor gene in patients with RT insulin resistance by analysis of single-stranded conformational RT polymorphisms."; RL Diabetologia 35:261-266(1992). RN [92] RP VARIANT LEPRCH ARG-58. RX PubMed=1730625; DOI=10.1016/s0021-9258(18)48459-1; RA van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J., RA Lindhout D., Maassen J.A.; RT "An Arg for Gly substitution at position 31 in the insulin receptor, linked RT to insulin resistance, inhibits receptor processing and transport."; RL J. Biol. Chem. 267:66-71(1992). RN [93] RP VARIANT T2D GLN-1158. RX PubMed=1470163; RA Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T., Hagino H., RA Shii K.; RT "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of RT insulin receptor observed in insulin resistant diabetes."; RL Nihon Geka Gakkai Zasshi 93:968-971(1992). RN [94] RP VARIANT MET-1012. RX PubMed=8432414; DOI=10.2337/diab.42.3.429; RA Elbein S.C., Sorensen L.K., Schumacher M.C.; RT "Methionine for valine substitution in exon 17 of the insulin receptor gene RT in a pedigree with familial NIDDM."; RL Diabetes 42:429-434(1993). RN [95] RP VARIANT IRAN TYPE A ASP-1075. RX PubMed=8243830; DOI=10.2337/diab.42.12.1837; RA Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K., RA Itazu T., Kobayashi M.; RT "Ala1048-->Asp mutation in the kinase domain of insulin receptor causes RT defective kinase activity and insulin resistance."; RL Diabetes 42:1837-1844(1993). RN [96] RP VARIANT MET-1012. RX PubMed=8458533; DOI=10.1007/bf00400701; RA van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J., RA van Maldergem L., Herwig J., Maassen J.A.; RT "Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli RT type, express normal insulin receptors."; RL Diabetologia 36:172-174(1993). RN [97] RP VARIANT INS RESISTANCE LEU-1220. RX PubMed=8390949; DOI=10.1007/bf00402277; RA Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K., RA Imamura T., Naitou K., Itazu T., Kobayashi M.; RT "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the RT insulin receptor associated with type A syndrome of insulin resistance."; RL Diabetologia 36:414-422(1993). RN [98] RP VARIANT INS RESISTANCE LEU-220. RX PubMed=8242067; DOI=10.1093/hmg/2.9.1437; RA Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R., RA Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I., Micossi P., RA Barbetti F.; RT "Substitution of Leu for Pro-193 in the insulin receptor in a patient with RT a genetic form of severe insulin resistance."; RL Hum. Mol. Genet. 2:1437-1441(1993). RN [99] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162. RX PubMed=8096518; DOI=10.1016/s0021-9258(18)53063-5; RA Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P., Taylor S.I.; RT "Substitution of glutamic acid for alanine 1135 in the putative 'catalytic RT loop' of the tyrosine kinase domain of the human insulin receptor. A RT mutation that impairs proteolytic processing into subunits and inhibits RT receptor tyrosine kinase activity."; RL J. Biol. Chem. 268:8060-8069(1993). RN [100] RP VARIANT IRAN TYPE A VAL-409. RX PubMed=8388389; DOI=10.1016/s0021-9258(18)82120-2; RA Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J., RA Taylor S.I., Accili D., van Obberghen E.; RT "Antibodies to the extracellular receptor domain restore the hormone- RT insensitive kinase and conformation of the mutant insulin receptor valine RT 382."; RL J. Biol. Chem. 268:11272-11277(1993). RN [101] RP VARIANT LEPRCH MET-146. RX PubMed=8326490; DOI=10.1136/jmg.30.6.470; RA Al-Gazali L.I., Khalil M., Devadas K.; RT "A syndrome of insulin resistance resembling leprechaunism in five sibs of RT consanguineous parents."; RL J. Med. Genet. 30:470-475(1993). RN [102] RP VARIANT LEPRCH PRO-113. RX PubMed=8419945; DOI=10.1073/pnas.90.1.60; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Activation of glucose transport by a natural mutation in the human insulin RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993). RN [103] RP VARIANT IRAN TYPE A GLN-1201. RX PubMed=8288049; DOI=10.2337/diab.43.2.247; RA Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A., RA Morrow L.A., Moses A.C., Flier J.S.; RT "Prevalence of mutations in the insulin receptor gene in subjects with RT features of the type A syndrome of insulin resistance."; RL Diabetes 43:247-255(1994). RN [104] RP VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378, RP AND VARIANT MET-1012. RX PubMed=8314008; DOI=10.2337/diab.43.3.357; RA Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.; RT "Molecular scanning of the insulin receptor gene in syndromes of insulin RT resistance."; RL Diabetes 43:357-368(1994). RN [105] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201. RX PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0; RA Moritz W., Froesch E.R., Boeni-Schnetzler M.; RT "Functional properties of a heterozygous mutation (Arg1174-->Gln) in the RT tyrosine kinase domain of the insulin receptor from a type A insulin RT resistant patient."; RL FEBS Lett. 351:276-280(1994). RN [106] RP VARIANT LEPRCH SER-439. RX PubMed=8188715; DOI=10.1016/s0021-9258(17)36788-1; RA van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J., Moller W., RA Maassen J.A.; RT "A mutation in the insulin receptor that impairs proreceptor processing but RT not insulin binding."; RL J. Biol. Chem. 269:14297-14302(1994). RN [107] RP CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220. RX PubMed=7983039; DOI=10.1016/s0021-9258(18)47384-x; RA Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T., RA Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.; RT "Two naturally occurring mutations in the kinase domain of insulin receptor RT accelerate degradation of the insulin receptor and impair the kinase RT activity."; RL J. Biol. Chem. 269:31019-31027(1994). RN [108] RP VARIANT LEPRCH MET-146. RX PubMed=7815442; DOI=10.1136/jmg.31.9.715; RA Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T., Taylor S.I.; RT "Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor RT gene in five sibs with familial insulin resistance."; RL J. Med. Genet. 31:715-716(1994). RN [109] RP VARIANT T2D ALA-858, AND VARIANT CYS-1361. RX PubMed=7657032; DOI=10.2337/diab.44.9.1081; RA Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T., Ito K., RA Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T., Kagawa S., RA Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.; RT "Frequency of mutations of insulin receptor gene in Japanese patients with RT NIDDM."; RL Diabetes 44:1081-1086(1995). RN [110] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=7538143; DOI=10.1210/jcem.80.5.7538143; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Two mutations in the insulin receptor gene of a patient with RT leprechaunism: application to prenatal diagnosis."; RL J. Clin. Endocrinol. Metab. 80:1496-1501(1995). RN [111] RP VARIANT PHE-1023. RX PubMed=8890729; DOI=10.1530/eje.0.1350357; RA Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.; RT "In-frame exon 2 deletion in insulin receptor RNA in a family with extreme RT insulin resistance in association with defective insulin binding: a case RT report."; RL Eur. J. Endocrinol. 135:357-363(1996). RN [112] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=8636294; DOI=10.1210/jcem.81.2.8636294; RA Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J., RA Flori E., Besmond C., Capeau J., Caron M.; RT "Deletion of Asn281 in the alpha-subunit of the human insulin receptor RT causes constitutive activation of the receptor and insulin RT desensitization."; RL J. Clin. Endocrinol. Metab. 81:719-727(1996). RN [113] RP VARIANT MET-1012. RX PubMed=9199575; DOI=10.1086/515464; RA Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A., RA Rasmussen S.K., Pedersen O.; RT "The Val985Met insulin-receptor variant in the Danish Caucasian population: RT lack of associations with non-insulin-dependent diabetes mellitus or RT insulin resistance."; RL Am. J. Hum. Genet. 60:1532-1535(1997). RN [114] RP VARIANTS IRAN TYPE A GLY-86 AND PRO-89. RX PubMed=9175790; DOI=10.1006/bbrc.1997.6695; RA Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P., RA Renard E., Bringer J., Jaffiol C., Grigorescu F.; RT "Identification of two novel insulin receptor mutations, Asp59Gly and RT Leu62Pro, in type A syndrome of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 234:764-768(1997). RN [115] RP CHARACTERIZATION OF VARIANT LEPRCH MET-937. RX PubMed=9299395; DOI=10.1006/bbrc.1997.7181; RA Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y., Quin J.D., RA MacCuish A.C., Koda N., Fukushima Y., Taylor S.I., Akanuma Y., Yazaki Y., RA Kadowaki T.; RT "Four mutant alleles of the insulin receptor gene associated with genetic RT syndromes of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 237:516-520(1997). RN [116] RP VARIANTS LEPRCH TRP-1119 AND LYS-1206. RX PubMed=9249867; RX DOI=10.1002/(sici)1097-0223(199707)17:7<657::aid-pd132>3.3.co;2-#; RA Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A., RA Conteville P., Magre J., Besmond C., Goossens M., Capeau J., Amselem S.; RT "Molecular analysis of the insulin receptor gene for prenatal diagnosis of RT leprechaunism in two families."; RL Prenat. Diagn. 17:657-663(1997). RN [117] RP VARIANTS LEPRCH TYR-301 AND TRP-1201. RX PubMed=9703342; DOI=10.2337/diab.47.8.1362; RA Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M., O'Rahilly S.; RT "Multiple molecular mechanisms of insulin receptor dysfunction in a patient RT with Donohue syndrome."; RL Diabetes 47:1362-1364(1998). RN [118] RP VARIANTS RMS THR-1143 AND TRP-1158. RX PubMed=10443650; DOI=10.1210/jcem.84.8.5902; RA Longo N., Wang Y., Pasquali M.; RT "Progressive decline in insulin levels in Rabson-Mendenhall syndrome."; RL J. Clin. Endocrinol. Metab. 84:2623-2629(1999). RN [119] RP VARIANTS IRAN TYPE A LEU-167 AND VAL-1055. RX PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x; RA Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J., Carrascosa A., RA Potau N.; RT "Identification of three novel mutations in the insulin receptor gene in RT type A insulin resistant patients."; RL Clin. Genet. 57:67-69(2000). RN [120] RP VARIANT IRAN TYPE A TYR-280. RX PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x; RA Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F., Kaino Y., RA Kida K., Makino H.; RT "Identification of novel C253Y missense and Y864X nonsense mutations in the RT insulin receptor gene in type A insulin-resistant patients."; RL Clin. Genet. 59:194-197(2001). RN [121] RP VARIANT IRAN TYPE A CYS-279. RX PubMed=12107746; DOI=10.1007/s00125-002-0798-5; RA Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J., De Meyts P., RA Maeder C., Kahn C.R., Carpentier J.-L.; RT "An arginine to cysteine(252) mutation in insulin receptors from a patient RT with severe insulin resistance inhibits receptor internalisation but RT preserves signalling events."; RL Diabetologia 45:657-667(2002). RN [122] RP CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925 RP AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201. RX PubMed=12023989; DOI=10.1093/hmg/11.12.1465; RA Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A., RA Giannella-Neto D.; RT "Genotype-phenotype correlation in inherited severe insulin resistance."; RL Hum. Mol. Genet. 11:1465-1475(2002). RN [123] RP VARIANT LEPRCH VAL-362 DEL. RX PubMed=12538626; DOI=10.1210/en.2002-220815; RA George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S., Saudek V., RA Siddle K., Hansen L., O'Rahilly S.; RT "Deletion of V335 from the L2 domain of the insulin receptor results in a RT conformationally abnormal receptor that is unable to bind insulin and RT causes Donohue's syndrome in a human subject."; RL Endocrinology 144:631-637(2003). RN [124] RP VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND RP TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND RP CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458. RX PubMed=12970295; DOI=10.1210/jc.2003-030034; RA Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M., RA D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.; RT "Identification and functional assessment of novel and known insulin RT receptor mutations in five patients with syndromes of severe insulin RT resistance."; RL J. Clin. Endocrinol. Metab. 88:4251-4257(2003). RN [125] RP VARIANT HHF5 GLN-1201. RX PubMed=15161766; DOI=10.2337/diabetes.53.6.1592; RA Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K., Lindholm J., RA Pedersen O., Bech-Nielsen H.; RT "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia RT linked to a mutation in the human insulin receptor gene."; RL Diabetes 53:1592-1598(2004). RN [126] RP VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS RP ARG-236 AND SER-386. RX PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x; RA Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J., RA Didi M., O'Rahilly S.; RT "Functional characterization of a novel insulin receptor mutation RT contributing to Rabson-Mendenhall syndrome."; RL Clin. Endocrinol. (Oxf.) 66:21-26(2007). RN [127] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012; RP VAL-1065 AND ALA-1282. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [128] RP VARIANTS LEPRCH CYS-818 AND 890-ARG--SER-1382 DEL. RX PubMed=22768670; DOI=10.1515/jpem-2011-0448; RA Nobile S., Semple R.K., Carnielli V.P.; RT "A novel mutation of the insulin receptor gene in a preterm infant with RT Donohue syndrome and heart failure."; RL J. Pediatr. Endocrinol. Metab. 25:363-366(2012). RN [129] RP VARIANTS LEPRCH THR-56 AND TYR-286, AND CHARACTERIZATION OF VARIANTS LEPRCH RP THR-56 AND TYR-286. RX PubMed=24498630; DOI=10.1002/mgg3.43; RA Falik Zaccai T.C., Kalfon L., Klar A., Elisha M.B., Hurvitz H., RA Weingarten G., Chechik E., Fleisher Sheffer V., Haj Yahya R., Meidan G., RA Gross-Kieselstein E., Bauman D., Hershkovitz S., Yaron Y., Orr-Urtreger A., RA Wertheimer E.; RT "Two novel mutations identified in familial cases with Donohue syndrome."; RL Mol. Genet. Genomic Med. 2:64-72(2014). RN [130] RP VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND RP 999-TYR--SER-1382 DEL, VARIANTS IRAN TYPE A ASP-489 AND MET-1054, VARIANTS RP LEPRCH PHE-657; ARG-659 AND CYS-818, CHARACTERIZATION OF VARIANTS LEPRCH RP PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937, AND RP CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND RP SER-878. RX PubMed=28765322; DOI=10.2337/db17-0301; RA Hosoe J., Kadowaki H., Miya F., Aizu K., Kawamura T., Miyata I., RA Satomura K., Ito T., Hara K., Tanaka M., Ishiura H., Tsuji S., Suzuki K., RA Takakura M., Boroevich K.A., Tsunoda T., Yamauchi T., Shojima N., RA Kadowaki T.; RT "Structural Basis and Genotype-Phenotype Correlations of INSR Mutations RT Causing Severe Insulin Resistance."; RL Diabetes 66:2713-2723(2017). CC -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic CC actions of insulin. Binding of insulin leads to phosphorylation of CC several intracellular substrates, including, insulin receptor CC substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling CC intermediates. Each of these phosphorylated proteins serve as docking CC proteins for other signaling proteins that contain Src-homology-2 CC domains (SH2 domain) that specifically recognize different CC phosphotyrosine residues, including the p85 regulatory subunit of PI3K CC and SHP2. Phosphorylation of IRSs proteins lead to the activation of CC two main signaling pathways: the PI3K-AKT/PKB pathway, which is CC responsible for most of the metabolic actions of insulin, and the Ras- CC MAPK pathway, which regulates expression of some genes and cooperates CC with the PI3K pathway to control cell growth and differentiation. CC Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to CC the activation of PI3K and the generation of phosphatidylinositol-(3, CC 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates CC several PIP3-dependent serine/threonine kinases, such as PDPK1 and CC subsequently AKT/PKB. The net effect of this pathway is to produce a CC translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic CC vesicles to the cell membrane to facilitate glucose transport. CC Moreover, upon insulin stimulation, activated AKT/PKB is responsible CC for: anti-apoptotic effect of insulin by inducing phosphorylation of CC BAD; regulates the expression of gluconeogenic and lipogenic enzymes by CC controlling the activity of the winged helix or forkhead (FOX) class of CC transcription factors. Another pathway regulated by PI3K-AKT/PKB CC activation is mTORC1 signaling pathway which regulates cell growth and CC metabolism and integrates signals from insulin. AKT mediates insulin- CC stimulated protein synthesis by phosphorylating TSC2 thereby activating CC mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in CC mediating cell growth, survival and cellular differentiation of CC insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers CC the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to CC binding insulin, the insulin receptor can bind insulin-like growth CC factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII CC binding. When present in a hybrid receptor with IGF1R, binds IGF1. CC PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR CC isoform Long are activated with a high affinity by IGF1, with low CC affinity by IGF2 and not significantly activated by insulin, and that CC hybrid receptors composed of IGF1R and INSR isoform Short are activated CC by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that CC hybrid receptors composed of IGF1R and INSR isoform Long and hybrid CC receptors composed of IGF1R and INSR isoform Short have similar binding CC characteristics, both bind IGF1 and have a low affinity for insulin. In CC adipocytes, inhibits lipolysis (By similarity). CC {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, CC ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11598120, CC ECO:0000269|PubMed:12707268, ECO:0000269|PubMed:18278056, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:9312016}; CC -!- ACTIVITY REGULATION: Activated in response to insulin. CC Autophosphorylation activates the kinase activity. PTPN1, PTPRE and CC PTPRF dephosphorylate important tyrosine residues, thereby reducing CC INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the CC catalytic activity of the INSR, they block access of substrates to the CC activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR CC activity, they bind to the activated INRS and interfere with the CC phosphorylation of INSR substrates. {ECO:0000269|PubMed:10615944, CC ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:11726652, CC ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:2211730}. CC -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide CC bonds. The alpha chains carry the insulin-binding regions, while the CC beta chains carry the kinase domain. Forms a hybrid receptor with CC IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta CC chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts CC with SORBS1 but dissociates from it following insulin stimulation. CC Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the CC PTB/PID domains of IRS1 and SHC1. The sequences surrounding the CC phosphorylated NPXY motif contribute differentially to either IRS1 or CC SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2 CC (via PTB domain and 591-786 AA); the 591-786 would be the primary CC anchor of IRS2 to INSR while the PTB domain would have a stabilizing CC action on the interaction with INSR. Interacts with the SH2 domains of CC the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when CC autophosphorylated on tyrosine residues. Interacts with SOCS7. CC Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via CC the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts CC with CAV2 (tyrosine-phosphorylated form); the interaction is increased CC with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with CC ARRB2 (By similarity). Interacts with GRB10; this interaction blocks CC the association between IRS1/IRS2 and INSR, significantly reduces CC insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus CC decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1. CC Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction CC protects the tyrosines in the activation loop from dephosphorylation, CC but promotes dephosphorylation of Tyr-999, this results in decreased CC interaction with, and phosphorylation of, IRS1. Interacts (via subunit CC alpha) with ENPP1 (via 485-599 AA); this interaction blocks CC autophosphorylation. Interacts with PTPRE; this interaction is CC dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts CC with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with CC ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to CC be part of a signaling netwok regulating INSR autophosphorylation and CC endocytosis (By similarity). Interacts with the cone snail venom CC insulin Con-Ins G1 (PubMed:27617429). Interacts with the insulin CC receptor SORL1; this interaction strongly increases its surface CC exposure, hence strengthens insulin signal reception (PubMed:27322061). CC Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like CC region); binding requires autophosphorylation of the INSR C-terminal CC region (PubMed:25187647). Interacts with GNAI3; the interaction is CC probably mediated by CCDC88A/GIV (PubMed:25187647). Interacts with CC LMBRD1 (By similarity). Interacts (in response to insulin stimulation) CC with NCK1; this interaction may recruit PTPN1 to mediate INSR CC dephosphorylation (PubMed:21707536). Interacts with CD248; this CC interaction diminishes INSR autophosphorylation (By similarity). CC {ECO:0000250|UniProtKB:P15127, ECO:0000250|UniProtKB:P15208, CC ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898, CC ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740, CC ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:21707536, CC ECO:0000269|PubMed:2211730, ECO:0000269|PubMed:23302862, CC ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:27322061, CC ECO:0000269|PubMed:27617429, ECO:0000269|PubMed:7537849, CC ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839, CC ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}. CC -!- INTERACTION: CC P06213; Q99490: AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824; CC P06213; Q8NEJ0: DUSP18; NbExp=2; IntAct=EBI-475899, EBI-10698945; CC P06213; Q13322: GRB10; NbExp=4; IntAct=EBI-475899, EBI-80275; CC P06213; P05019: IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275; CC P06213; P08069: IGF1R; NbExp=5; IntAct=EBI-475899, EBI-475981; CC P06213; P14616: INSRR; NbExp=6; IntAct=EBI-475899, EBI-6424336; CC P06213; P35568: IRS1; NbExp=5; IntAct=EBI-475899, EBI-517592; CC P06213; Q9Y4H2: IRS2; NbExp=4; IntAct=EBI-475899, EBI-1049582; CC P06213; Q15323: KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001; CC P06213; Q13257: MAD2L1; NbExp=4; IntAct=EBI-475899, EBI-78203; CC P06213; P27986: PIK3R1; NbExp=9; IntAct=EBI-475899, EBI-79464; CC P06213; P19174: PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387; CC P06213; P18031: PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788; CC P06213; Q06124: PTPN11; NbExp=3; IntAct=EBI-475899, EBI-297779; CC P06213; Q15262: PTPRK; NbExp=2; IntAct=EBI-475899, EBI-474052; CC P06213; Q15256: PTPRR; NbExp=2; IntAct=EBI-475899, EBI-2265659; CC P06213; Q9NRF2: SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491; CC P06213; P29353: SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835; CC P06213; P01317: INS; Xeno; NbExp=5; IntAct=EBI-475899, EBI-3989070; CC P06213; P35570: Irs1; Xeno; NbExp=5; IntAct=EBI-475899, EBI-520230; CC P06213-1; P32121: ARRB2; NbExp=2; IntAct=EBI-15558981, EBI-714559; CC P06213-1; P06213-1: INSR; NbExp=4; IntAct=EBI-15558981, EBI-15558981; CC P06213-1; P18031: PTPN1; NbExp=2; IntAct=EBI-15558981, EBI-968788; CC P06213-1; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-15558981, EBI-21501656; CC P06213-1; P81122: Irs2; Xeno; NbExp=8; IntAct=EBI-15558981, EBI-1369862; CC P06213-1; Q1XH17: Trim72; Xeno; NbExp=2; IntAct=EBI-15558981, EBI-16034016; CC P06213-2; P01308: INS; NbExp=6; IntAct=EBI-9984921, EBI-7090529; CC P06213-2; Q13257: MAD2L1; NbExp=3; IntAct=EBI-9984921, EBI-78203; CC P06213-2; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-9984921, EBI-21501656; CC P06213-2; P01317: INS; Xeno; NbExp=2; IntAct=EBI-9984921, EBI-3989070; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P15208}; CC Single-pass type I membrane protein {ECO:0000305}. Late endosome CC {ECO:0000250|UniProtKB:P15208}. Lysosome CC {ECO:0000250|UniProtKB:P15208}. Note=Binding of insulin to INSR induces CC internalization and lysosomal degradation of the receptor, a means for CC down-regulating this signaling pathway after stimulation. In the CC presence of SORL1, internalized INSR molecules are redirected back to CC the cell surface, thereby preventing their lysosomal catabolism and CC strengthening insulin signal reception. {ECO:0000250|UniProtKB:P15208}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; Synonyms=HIR-B; CC IsoId=P06213-1; Sequence=Displayed; CC Name=Short; Synonyms=HIR-A; CC IsoId=P06213-2; Sequence=VSP_002898; CC -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are predominantly CC expressed in tissue targets of insulin metabolic effects: liver, CC adipose tissue and skeletal muscle but are also expressed in the CC peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta CC vascular endothelium, fibroblasts, monocytes, granulocytes, CC erythrocytes and skin. Isoform Short is preferentially expressed in CC fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found CC as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose CC tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at CC protein level). Overexpressed in several tumors, including breast, CC colon, lung, ovary, and thyroid carcinomas. CC {ECO:0000269|PubMed:10207053, ECO:0000269|PubMed:2369896, CC ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}. CC -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-identical CC regions from two alpha chains, primarily via the C-terminal region of CC the first INSR alpha chain. Residues from the leucine-rich N-terminus CC of the other INSR alpha chain also contribute to this insulin binding CC site. A secondary insulin-binding site is formed by residues at the CC junction of fibronectin type-III domain 1 and 2. CC {ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:19459609, CC ECO:0000269|PubMed:23302862}. CC -!- PTM: After being transported from the endoplasmic reticulum to the CC Golgi apparatus, the single glycosylated precursor is further CC glycosylated and then cleaved, followed by its transport to the plasma CC membrane. {ECO:0000269|PubMed:1472036, ECO:0000269|PubMed:16894147, CC ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973, CC ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to insulin CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Phosphorylation of CC Tyr-999 is required for binding to IRS1, SHC1 and STAT5B CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Dephosphorylated by CC PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190 (PubMed:14690593, CC PubMed:16246733, PubMed:16271887, PubMed:18278056, PubMed:18767165, CC PubMed:3166375, PubMed:9312016). May also be phosphorylated at Tyr-1185 CC and Tyr-1190 by mTORC2 (PubMed:26584640). Dephosphorylated by PTPRF and CC PTPN1 (PubMed:8995282). Dephosphorylated by PTPN2; down-regulates CC insulin-induced signaling (PubMed:10734133, PubMed:12612081). CC Dephosphorylation at Tyr-1189 and Tyr-1190 requires the SH2/SH3 adapter CC protein NCK1, probably to recruit its interaction partner PTPN1 CC (PubMed:21707536). {ECO:0000269|PubMed:10734133, CC ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:21707536, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:8995282, CC ECO:0000269|PubMed:9312016}. CC -!- PTM: S-nitrosylation at Cys-1083 by BLVRB inhibits the receptor CC tyrosine kinase, thereby inhibiting insulin signaling. CC {ECO:0000269|PubMed:38056462}. CC -!- PTM: Ubiquitinated by MARCHF1; leading to degradation thereby reducing CC surface INSR expression. {ECO:0000269|PubMed:27577745}. CC -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin CC resistance syndrome characterized by insulin-resistant diabetes CC mellitus with pineal hyperplasia and somatic abnormalities. Typical CC features include coarse, senile-appearing facies, dental and skin CC abnormalities, abdominal distension, and phallic enlargement. CC Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, CC ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, CC ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most CC severe form of insulin resistance syndrome, characterized by CC intrauterine and postnatal growth retardation and death in early CC infancy. Inheritance is autosomal recessive. CC {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626, CC ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, CC ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630, CC ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143, CC ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, CC ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, CC ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, CC ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Type 2 diabetes mellitus (T2D) [MIM:125853]: A multifactorial CC disorder of glucose homeostasis caused by a lack of sensitivity to CC insulin. Affected individuals usually have an obese body habitus and CC manifestations of a metabolic syndrome characterized by diabetes, CC insulin resistance, hypertension and hypertriglyceridemia. The disease CC results in long-term complications that affect the eyes, kidneys, CC nerves, and blood vessels. {ECO:0000269|PubMed:1470163, CC ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Hyperinsulinemic hypoglycemia, familial, 5 (HHF5) CC [MIM:609968]: A form of hyperinsulinemic hypoglycemia, a clinically and CC genetically heterogeneous disorder characterized by inappropriate CC insulin secretion from the pancreatic beta-cells in the presence of low CC blood glucose levels. HHF5 clinical features include loss of CC consciousness due to hypoglycemia and hypoglycemic seizures. HHF5 CC inheritance is autosomal dominant. {ECO:0000269|PubMed:15161766}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans CC type A (IRAN type A) [MIM:610549]: Characterized by the association of CC severe insulin resistance (manifested by marked hyperinsulinemia and a CC failure to respond to exogenous insulin) with the skin lesion CC acanthosis nigricans and ovarian hyperandrogenism in adolescent female CC subjects. Women frequently present with hirsutism, acne, amenorrhea or CC oligomenorrhea, and virilization. This syndrome is different from the CC type B that has been demonstrated to be secondary to the presence of CC circulating autoantibodies against the insulin receptor. CC {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, CC ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, CC ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, CC ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, CC ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, CC ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, CC ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry; CC URL="https://en.wikipedia.org/wiki/Insulin_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M10051; AAA59174.1; -; mRNA. DR EMBL; X02160; CAA26096.1; -; mRNA. DR EMBL; M32972; AAA59452.1; -; Genomic_DNA. DR EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117172; AAI17173.1; -; mRNA. DR EMBL; J03466; AAA59175.1; -; Genomic_DNA. DR EMBL; J05043; AAA59190.1; -; Genomic_DNA. DR EMBL; M76592; AAC37604.1; -; Genomic_DNA. DR EMBL; AB208861; BAD92098.1; -; mRNA. DR EMBL; M24555; AAA59178.1; -; mRNA. DR EMBL; M29929; AAA59176.1; -; Genomic_DNA. DR EMBL; M29930; AAA59177.1; -; Genomic_DNA. DR EMBL; M27197; AAA86791.1; -; Genomic_DNA. DR EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA. DR CCDS; CCDS12176.1; -. [P06213-1] DR CCDS; CCDS42487.1; -. [P06213-2] DR PIR; A37348; INHUR. DR RefSeq; NP_000199.2; NM_000208.4. [P06213-1] DR RefSeq; NP_001073285.1; NM_001079817.3. [P06213-2] DR PDB; 1GAG; X-ray; 2.70 A; A=1005-1310. DR PDB; 1I44; X-ray; 2.40 A; A=1005-1310. DR PDB; 1IR3; X-ray; 1.90 A; A=1005-1310. DR PDB; 1IRK; X-ray; 2.10 A; A=1005-1310. DR PDB; 1P14; X-ray; 1.90 A; A=1005-1310. DR PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310. DR PDB; 2AUH; X-ray; 3.20 A; A=1005-1310. DR PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310. DR PDB; 2HR7; X-ray; 2.32 A; A/B=28-512. DR PDB; 2MFR; NMR; -; A=940-988. DR PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310. DR PDB; 3BU3; X-ray; 1.65 A; A=1005-1310. DR PDB; 3BU5; X-ray; 2.10 A; A=1005-1310. DR PDB; 3BU6; X-ray; 1.95 A; A=1005-1310. DR PDB; 3EKK; X-ray; 2.10 A; A=1005-1310. DR PDB; 3EKN; X-ray; 2.20 A; A=1005-1310. DR PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322. DR PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744. DR PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744. DR PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744. DR PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310. DR PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744. DR PDB; 4XLV; X-ray; 2.30 A; A=983-1310. DR PDB; 4XSS; X-ray; 3.00 A; E=28-337. DR PDB; 4XST; X-ray; 3.00 A; E=28-337. DR PDB; 4ZXB; X-ray; 3.30 A; E=28-956. DR PDB; 5E1S; X-ray; 2.26 A; A=1005-1310. DR PDB; 5HHW; X-ray; 1.79 A; A=1005-1310. DR PDB; 5J3H; X-ray; 3.27 A; E=28-337. DR PDB; 5KQV; X-ray; 4.40 A; E/F=28-746. DR PDB; 5U1M; X-ray; 1.80 A; B=991-999. DR PDB; 6HN4; EM; 4.20 A; E/F=28-955. DR PDB; 6HN5; EM; 3.20 A; E/F=28-955. DR PDB; 6PXV; EM; 3.20 A; A/C=28-1382. DR PDB; 6PXW; EM; 3.10 A; A/B=28-1382. DR PDB; 6SOF; EM; 4.30 A; A/C=28-746, B/D=795-956. DR PDB; 6VEP; X-ray; 2.90 A; E/K/Q/W=28-337, F/L/R/X=731-746. DR PDB; 6VEQ; X-ray; 3.25 A; E/K=28-337, F/L=731-746. DR PDB; 7BW7; EM; 4.10 A; A/C=28-1382. DR PDB; 7BW8; EM; 3.80 A; A/C=28-1382. DR PDB; 7BWA; EM; 4.90 A; A/C=28-1382. DR PDB; 7KD6; X-ray; 2.60 A; E/K/Q/W=28-337. DR PDB; 7MQO; EM; 3.40 A; E/F=28-956. DR PDB; 7MQR; EM; 4.10 A; E/F=28-955. DR PDB; 7MQS; EM; 4.40 A; E/F=28-955. DR PDB; 7PG0; EM; 7.60 A; A/B=1-1382. DR PDB; 7PG2; EM; 6.70 A; A/B=1-1382. DR PDB; 7PG3; EM; 7.30 A; A/B=1-1382. DR PDB; 7PG4; EM; 9.10 A; A/B=1-1382. DR PDB; 7PHT; NMR; -; A=953-982. DR PDB; 7QID; EM; 5.00 A; A/C=28-746, B/D=763-956. DR PDB; 7S0Q; EM; 3.70 A; B=28-955. DR PDB; 7S8V; EM; 3.73 A; B=28-955. DR PDB; 7U6D; EM; 5.03 A; B/C=28-955. DR PDB; 7U6E; EM; 3.00 A; E/F=28-955. DR PDB; 7YQ3; EM; 3.60 A; E/F=28-946. DR PDB; 7YQ4; EM; 3.95 A; E/F=28-946. DR PDB; 7YQ5; EM; 4.27 A; E/F=28-946. DR PDB; 7YQ6; EM; 4.18 A; E/F=28-946. DR PDB; 8DWN; X-ray; 2.15 A; A=1005-1310. DR PDB; 8GUY; EM; 4.18 A; E/F=28-946. DR PDB; 8U4B; EM; 3.90 A; A/B=1-1382. DR PDB; 8U4C; EM; 3.60 A; A/B=1-1382. DR PDB; 8U4E; EM; 4.20 A; A/B=1-1382. DR PDB; 8VJB; EM; 3.60 A; A/B=1-1382. DR PDB; 8VJC; EM; 3.80 A; A/B=1-1382. DR PDB; 8X06; EM; 3.24 A; A/B=1-1382. DR PDB; 8X2M; EM; 3.31 A; A/B=1-1382. DR PDB; 8XJS; EM; 3.24 A; A/B=1-1382. DR PDB; 8XK1; EM; 3.31 A; A/B=1-1382. DR PDB; 8XKM; EM; 5.00 A; A/B=1-1382. DR PDB; 8XKR; EM; 3.53 A; A/B=1-1382. DR PDB; 8YSZ; EM; 3.38 A; A/B=1-1382. DR PDB; 8YYL; EM; 4.01 A; A/B=1-1382. DR PDB; 8YYS; EM; 4.14 A; A/B=1-1382. DR PDB; 8YYT; EM; 3.60 A; A/B=1-1382. DR PDBsum; 1GAG; -. DR PDBsum; 1I44; -. DR PDBsum; 1IR3; -. DR PDBsum; 1IRK; -. DR PDBsum; 1P14; -. DR PDBsum; 1RQQ; -. DR PDBsum; 2AUH; -. DR PDBsum; 2B4S; -. DR PDBsum; 2HR7; -. DR PDBsum; 2MFR; -. DR PDBsum; 2Z8C; -. DR PDBsum; 3BU3; -. DR PDBsum; 3BU5; -. DR PDBsum; 3BU6; -. DR PDBsum; 3EKK; -. DR PDBsum; 3EKN; -. DR PDBsum; 3ETA; -. DR PDBsum; 3W11; -. DR PDBsum; 3W12; -. DR PDBsum; 3W13; -. DR PDBsum; 4IBM; -. DR PDBsum; 4OGA; -. DR PDBsum; 4XLV; -. DR PDBsum; 4XSS; -. DR PDBsum; 4XST; -. DR PDBsum; 4ZXB; -. DR PDBsum; 5E1S; -. DR PDBsum; 5HHW; -. DR PDBsum; 5J3H; -. DR PDBsum; 5KQV; -. DR PDBsum; 5U1M; -. DR PDBsum; 6HN4; -. DR PDBsum; 6HN5; -. DR PDBsum; 6PXV; -. DR PDBsum; 6PXW; -. DR PDBsum; 6SOF; -. DR PDBsum; 6VEP; -. DR PDBsum; 6VEQ; -. DR PDBsum; 7BW7; -. DR PDBsum; 7BW8; -. DR PDBsum; 7BWA; -. DR PDBsum; 7KD6; -. DR PDBsum; 7MQO; -. DR PDBsum; 7MQR; -. DR PDBsum; 7MQS; -. DR PDBsum; 7PG0; -. DR PDBsum; 7PG2; -. DR PDBsum; 7PG3; -. DR PDBsum; 7PG4; -. DR PDBsum; 7PHT; -. DR PDBsum; 7QID; -. DR PDBsum; 7S0Q; -. DR PDBsum; 7S8V; -. DR PDBsum; 7U6D; -. DR PDBsum; 7U6E; -. DR PDBsum; 7YQ3; -. DR PDBsum; 7YQ4; -. DR PDBsum; 7YQ5; -. DR PDBsum; 7YQ6; -. DR PDBsum; 8DWN; -. DR PDBsum; 8GUY; -. DR PDBsum; 8U4B; -. DR PDBsum; 8U4C; -. DR PDBsum; 8U4E; -. DR PDBsum; 8VJB; -. DR PDBsum; 8VJC; -. DR PDBsum; 8X06; -. DR PDBsum; 8X2M; -. DR PDBsum; 8XJS; -. DR PDBsum; 8XK1; -. DR PDBsum; 8XKM; -. DR PDBsum; 8XKR; -. DR PDBsum; 8YSZ; -. DR PDBsum; 8YYL; -. DR PDBsum; 8YYS; -. DR PDBsum; 8YYT; -. DR AlphaFoldDB; P06213; -. DR BMRB; P06213; -. DR EMDB; EMD-10273; -. DR EMDB; EMD-10311; -. DR EMDB; EMD-13385; -. DR EMDB; EMD-13386; -. DR EMDB; EMD-13387; -. DR EMDB; EMD-13388; -. DR EMDB; EMD-20522; -. DR EMDB; EMD-20523; -. DR EMDB; EMD-23766; -. DR EMDB; EMD-23767; -. DR EMDB; EMD-23949; -. DR EMDB; EMD-23950; -. DR EMDB; EMD-24791; -. DR EMDB; EMD-24927; -. DR EMDB; EMD-26363; -. DR EMDB; EMD-30225; -. DR EMDB; EMD-30227; -. DR EMDB; EMD-30229; -. DR EMDB; EMD-30230; -. DR EMDB; EMD-30231; -. DR EMDB; EMD-34018; -. DR EMDB; EMD-34019; -. DR EMDB; EMD-34021; -. DR EMDB; EMD-34281; -. DR EMDB; EMD-37970; -. DR EMDB; EMD-38017; -. DR EMDB; EMD-38404; -. DR EMDB; EMD-38413; -. DR EMDB; EMD-38420; -. DR EMDB; EMD-38423; -. DR EMDB; EMD-39566; -. DR EMDB; EMD-39675; -. DR EMDB; EMD-39677; -. DR EMDB; EMD-39678; -. DR EMDB; EMD-41877; -. DR EMDB; EMD-41878; -. DR EMDB; EMD-41880; -. DR EMDB; EMD-43279; -. DR EMDB; EMD-43280; -. DR EMDB; EMD-61431; -. DR EMDB; EMD-61432; -. DR EMDB; EMD-61490; -. DR EMDB; EMD-7461; -. DR EMDB; EMD-7462; -. DR EMDB; EMD-7463; -. DR SASBDB; P06213; -. DR SMR; P06213; -. DR BioGRID; 109854; 380. DR DIP; DIP-480N; -. DR ELM; P06213; -. DR FunCoup; P06213; 1946. DR IntAct; P06213; 709. DR MINT; P06213; -. DR STRING; 9606.ENSP00000303830; -. DR BindingDB; P06213; -. DR ChEMBL; CHEMBL1981; -. DR DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID. DR DrugBank; DB03909; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate. DR DrugBank; DB05120; AT1391. DR DrugBank; DB16028; Azemiglitazone. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB09129; Chromic chloride. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11564; Insulin argine. DR DrugBank; DB01306; Insulin aspart. DR DrugBank; DB09456; Insulin beef. DR DrugBank; DB09564; Insulin degludec. DR DrugBank; DB01307; Insulin detemir. DR DrugBank; DB00047; Insulin glargine. DR DrugBank; DB01309; Insulin glulisine. DR DrugBank; DB00030; Insulin human. DR DrugBank; DB16693; Insulin icodec. DR DrugBank; DB00046; Insulin lispro. DR DrugBank; DB11567; Insulin peglispro. DR DrugBank; DB00071; Insulin pork. DR DrugBank; DB11568; Insulin tregopil. DR DrugBank; DB16637; KW-2450 free base. DR DrugBank; DB06075; Linsitinib. DR DrugBank; DB01277; Mecasermin. DR DrugBank; DB14751; Mecasermin rinfabate. DR DrugBank; DB11721; Mitoglitazone. DR DrugBank; DB05115; NN344. DR DrugBank; DB12518; Raclopride. DR DrugBank; DB06156; Tesofensine. DR DrugCentral; P06213; -. DR GuidetoPHARMACOLOGY; 1800; -. DR GlyConnect; 1402; 8 N-Linked glycans (6 sites). DR GlyCosmos; P06213; 21 sites, 11 glycans. DR GlyGen; P06213; 25 sites, 79 N-linked glycans (13 sites), 4 O-linked glycans (6 sites). DR iPTMnet; P06213; -. DR PhosphoSitePlus; P06213; -. DR SwissPalm; P06213; -. DR BioMuta; INSR; -. DR DMDM; 308153655; -. DR CPTAC; CPTAC-1771; -. DR CPTAC; CPTAC-1772; -. DR CPTAC; CPTAC-2814; -. DR CPTAC; CPTAC-3053; -. DR jPOST; P06213; -. DR MassIVE; P06213; -. DR PaxDb; 9606-ENSP00000303830; -. DR PeptideAtlas; P06213; -. DR ProteomicsDB; 51872; -. [P06213-1] DR ProteomicsDB; 51873; -. [P06213-2] DR Pumba; P06213; -. DR ABCD; P06213; 3 sequenced antibodies. DR Antibodypedia; 3403; 2189 antibodies from 53 providers. DR DNASU; 3643; -. DR Ensembl; ENST00000302850.10; ENSP00000303830.4; ENSG00000171105.15. [P06213-1] DR Ensembl; ENST00000341500.9; ENSP00000342838.4; ENSG00000171105.15. [P06213-2] DR GeneID; 3643; -. DR KEGG; hsa:3643; -. DR MANE-Select; ENST00000302850.10; ENSP00000303830.4; NM_000208.4; NP_000199.2. DR UCSC; uc002mgd.2; human. [P06213-1] DR AGR; HGNC:6091; -. DR ClinPGx; PA202; -. DR CTD; 3643; -. DR DisGeNET; 3643; -. DR GeneCards; INSR; -. DR GeneReviews; INSR; -. DR HGNC; HGNC:6091; INSR. DR HPA; ENSG00000171105; Low tissue specificity. DR MalaCards; INSR; -. DR MIM; 125853; phenotype. DR MIM; 147670; gene. DR MIM; 246200; phenotype. DR MIM; 262190; phenotype. DR MIM; 609968; phenotype. DR MIM; 610549; phenotype. DR OpenTargets; ENSG00000171105; -. DR Orphanet; 508; Donohue syndrome. DR Orphanet; 263458; Hyperinsulinism due to INSR deficiency. DR Orphanet; 2297; Insulin-resistance syndrome type A. DR Orphanet; 769; Rabson-Mendenhall syndrome. DR VEuPathDB; HostDB:ENSG00000171105; -. DR eggNOG; KOG4258; Eukaryota. DR GeneTree; ENSGT00940000155404; -. DR HOGENOM; CLU_000288_166_0_1; -. DR InParanoid; P06213; -. DR OMA; AVESNTW; -. DR OrthoDB; 5809444at2759; -. DR PAN-GO; P06213; 12 GO annotations based on evolutionary models. DR PhylomeDB; P06213; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P06213; -. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-74713; IRS activation. DR Reactome; R-HSA-74749; Signal attenuation. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-74752; Signaling by Insulin receptor. DR Reactome; R-HSA-77387; Insulin receptor recycling. DR SABIO-RK; P06213; -. DR SignaLink; P06213; -. DR SIGNOR; P06213; -. DR Agora; ENSG00000171105; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 3643; 15 hits in 1203 CRISPR screens. DR ChiTaRS; INSR; human. DR EvolutionaryTrace; P06213; -. DR GeneWiki; Insulin_receptor; -. DR GenomeRNAi; 3643; -. DR Pharos; P06213; Tclin. DR PRO; PR:P06213; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P06213; protein. DR Bgee; ENSG00000171105; Expressed in buccal mucosa cell and 209 other cell types or tissues. DR ExpressionAtlas; P06213; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0032590; C:dendrite membrane; ISS:ARUK-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; ISS:ARUK-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005899; C:insulin receptor complex; IDA:UniProtKB. DR GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0032809; C:neuronal cell body membrane; ISS:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:BHF-UCL. DR GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL. DR GO; GO:0005525; F:GTP binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043559; F:insulin binding; IDA:UniProtKB. DR GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB. DR GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB. DR GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL. DR GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL. DR GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL. DR GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL. DR GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL. DR GO; GO:0008544; P:epidermis development; IEA:Ensembl. DR GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL. DR GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007612; P:learning; TAS:ARUK-UCL. DR GO; GO:0008584; P:male gonad development; IEA:Ensembl. DR GO; GO:0030238; P:male sex determination; IEA:Ensembl. DR GO; GO:0007613; P:memory; TAS:ARUK-UCL. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IGI:BHF-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0046326; P:positive regulation of D-glucose import; IDA:BHF-UCL. DR GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL. DR GO; GO:0002092; P:positive regulation of receptor internalization; IDA:CACAO. DR GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0031623; P:receptor internalization; IEA:Ensembl. DR GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:BHF-UCL. DR GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL. DR GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:BHF-UCL. DR GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL. DR CDD; cd00063; FN3; 2. DR CDD; cd00064; FU; 1. DR CDD; cd05061; PTKc_InsR; 1. DR FunFam; 1.10.510.10:FF:000050; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.10.220.10:FF:000005; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000087; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000108; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001010; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000026; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000001; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000002; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR040969; Insulin_TMD. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF535; INSULIN RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF17870; Insulin_TMD; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR PIRSF; PIRSF000620; Insulin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 3. DR SMART; SM00261; FU; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 3. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism; KW Cell membrane; Cleavage on pair of basic residues; Diabetes mellitus; KW Direct protein sequencing; Disease variant; Disulfide bond; Endosome; KW Glycoprotein; Isopeptide bond; Kinase; Lysosome; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; S-nitrosylation; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000269|PubMed:2211730, FT ECO:0000269|PubMed:2983222, ECO:0000269|PubMed:8257688" FT CHAIN 28..758 FT /note="Insulin receptor subunit alpha" FT /id="PRO_0000016687" FT CHAIN 763..1382 FT /note="Insulin receptor subunit beta" FT /id="PRO_0000016689" FT TOPO_DOM 28..758 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TOPO_DOM 763..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..979 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 980..1382 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 624..726 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 757..842 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 853..947 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1023..1298 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 686..708 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..741 FT /note="Insulin-binding" FT REGION 746..766 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 999 FT /note="Important for interaction with IRS1, SHC1 and FT STAT5B" FT /evidence="ECO:0000269|PubMed:9428692" FT REGION 1360..1382 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1361..1364 FT /note="PIK3R1-binding" FT ACT_SITE 1159 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000269|PubMed:9312016" FT BINDING 1033 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1057 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1104..1110 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1163..1164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1177 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT SITE 66 FT /note="Insulin-binding" FT /evidence="ECO:0000305" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 401 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 407 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 992 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 999 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1011 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 1083 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:38056462" FT MOD_RES 1185 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1189 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016" FT MOD_RES 1190 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1355 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1361 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 105 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23302862" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 364 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 424 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 445 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19349973" FT CARBOHYD 541 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:1472036, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 633 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 651 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 698 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 769 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2983222" FT CARBOHYD 782 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 920 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 933 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 35..53 FT DISULFID 153..182 FT DISULFID 186..209 FT DISULFID 196..215 FT DISULFID 219..228 FT DISULFID 223..234 FT DISULFID 235..243 FT DISULFID 239..252 FT DISULFID 255..264 FT DISULFID 268..280 FT DISULFID 286..311 FT DISULFID 293..301 FT DISULFID 315..328 FT DISULFID 331..335 FT DISULFID 339..360 FT DISULFID 462..495 FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 551 FT /note="Interchain" FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 674..899 FT DISULFID 825..834 FT CROSSLNK 1079 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:27577745" FT VAR_SEQ 745..756 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:2983222, ECO:0000303|Ref.13" FT /id="VSP_002898" FT VARIANT 2 FT /note="A -> G (in dbSNP:rs7508518)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2210055, ECO:0000269|PubMed:2280779, FT ECO:0000269|PubMed:2777789, ECO:0000269|PubMed:2806055, FT ECO:0000269|PubMed:2859121, ECO:0000269|PubMed:2983222, FT ECO:0000269|PubMed:3680248" FT /id="VAR_058395" FT VARIANT 42 FT /note="N -> K (in RMS; impairs transport to the plasma FT membrane and reduces the affinity to bind insulin; FT dbSNP:rs121913143)" FT /evidence="ECO:0000269|PubMed:2121734, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004079" FT VARIANT 55 FT /note="V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004080" FT VARIANT 56 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; dbSNP:rs1555689937)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079535" FT VARIANT 58 FT /note="G -> R (in LEPRCH; Helmond; inhibits processing and FT transport; dbSNP:rs52836744)" FT /evidence="ECO:0000269|PubMed:1730625" FT /id="VAR_004081" FT VARIANT 86 FT /note="D -> G (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015907" FT VARIANT 89 FT /note="L -> P (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015908" FT VARIANT 113 FT /note="R -> P (in LEPRCH; Atlanta-1; abolishes insulin FT binding; dbSNP:rs121913153)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:8419945" FT /id="VAR_004082" FT VARIANT 119 FT /note="A -> V (in LEPRCH; markedly impairs insulin binding; FT dbSNP:rs1347473020)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015909" FT VARIANT 120 FT /note="L -> Q (in LEPRCH; inhibits receptor processing)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031518" FT VARIANT 146 FT /note="I -> M (in LEPRCH; mild; dbSNP:rs121913159)" FT /evidence="ECO:0000269|PubMed:7815442, FT ECO:0000269|PubMed:8326490" FT /id="VAR_015539" FT VARIANT 167 FT /note="V -> L (in IRAN type A; dbSNP:rs938519025)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015910" FT VARIANT 171 FT /note="Y -> H (in dbSNP:rs1051692)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_058396" FT VARIANT 220 FT /note="P -> L (in Ins resistance; severe; FT dbSNP:rs749094324)" FT /evidence="ECO:0000269|PubMed:8242067" FT /id="VAR_004083" FT VARIANT 228 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041429" FT VARIANT 236 FT /note="H -> R (in RMS and LEPRCH; Winnipeg; may impair FT receptor processing; dbSNP:rs121913145)" FT /evidence="ECO:0000269|PubMed:17201797, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004084" FT VARIANT 256 FT /note="R -> C (in RMS; dbSNP:rs781007453)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079536" FT VARIANT 260 FT /note="L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)" FT /evidence="ECO:0000269|PubMed:2479553" FT /id="VAR_004085" FT VARIANT 279 FT /note="R -> C (in IRAN type A; inhibits receptor FT internalization; dbSNP:rs1568470274)" FT /evidence="ECO:0000269|PubMed:12107746" FT /id="VAR_015540" FT VARIANT 279 FT /note="R -> H (in IRAN type A; interferes with receptor FT processing; dbSNP:rs1329693158)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031519" FT VARIANT 280 FT /note="C -> Y (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:11260230" FT /id="VAR_015911" FT VARIANT 286 FT /note="C -> Y (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079537" FT VARIANT 301 FT /note="C -> Y (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9703342" FT /id="VAR_015912" FT VARIANT 308 FT /note="Missing (in LEPRCH; abolishes insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:8636294" FT /id="VAR_015913" FT VARIANT 350 FT /note="S -> L (in RMS and LEPRCH; dbSNP:rs1974095413)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:8314008" FT /id="VAR_015914" FT VARIANT 362 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:12538626" FT /id="VAR_015541" FT VARIANT 386 FT /note="G -> S (in RMS; may impair receptor processing; FT dbSNP:rs764221583)" FT /evidence="ECO:0000269|PubMed:17201797" FT /id="VAR_031520" FT VARIANT 393 FT /note="G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004086" FT VARIANT 409 FT /note="F -> V (in IRAN type A; dbSNP:rs121913142)" FT /evidence="ECO:0000269|PubMed:8388389" FT /id="VAR_004087" FT VARIANT 439 FT /note="W -> S (in LEPRCH; impairs transport of the receptor FT to the cell surface; dbSNP:rs121913158)" FT /evidence="ECO:0000269|PubMed:8188715" FT /id="VAR_015542" FT VARIANT 448 FT /note="I -> T (in dbSNP:rs1051691)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015915" FT VARIANT 458 FT /note="N -> D (in LEPRCH; partially inhibits receptor FT processing and autophosphorylation; strongly impairs ERK FT phosphorylation; induces wild-type levels of IRS-1 FT phosphorylation; dbSNP:rs121913160)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031521" FT VARIANT 487 FT /note="K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)" FT /evidence="ECO:0000269|PubMed:2834824" FT /id="VAR_004088" FT VARIANT 489 FT /note="N -> D (in IRAN type A; uncertain significance; FT dbSNP:rs1135401742)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079538" FT VARIANT 489 FT /note="N -> S (in IRAN type A; dbSNP:rs121913147)" FT /evidence="ECO:0000269|PubMed:2365819" FT /id="VAR_004089" FT VARIANT 492 FT /note="Q -> K" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015916" FT VARIANT 635 FT /note="S -> L (in RMS; decreases post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079539" FT VARIANT 657 FT /note="V -> F (in LEPRCH; impairs post-translational FT processing; dbSNP:rs1135401737)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079540" FT VARIANT 659 FT /note="W -> R (in LEPRCH; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079541" FT VARIANT 695 FT /note="Q -> R (in dbSNP:rs55906835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041430" FT VARIANT 762 FT /note="R -> S (in IRAN type A; dbSNP:rs121913138)" FT /evidence="ECO:0000269|PubMed:3283938" FT /id="VAR_004090" FT VARIANT 811 FT /note="G -> S (in dbSNP:rs35045353)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041431" FT VARIANT 818 FT /note="Y -> C (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:22768670, FT ECO:0000269|PubMed:28765322" FT /id="VAR_079542" FT VARIANT 830 FT /note="P -> L (in dbSNP:rs2162771)" FT /id="VAR_055986" FT VARIANT 835 FT /note="S -> I (in RMS; impairs post-translational FT processing; dbSNP:rs1135401739)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079543" FT VARIANT 842 FT /note="A -> V (in RMS; decreases post-translational FT processing; dbSNP:rs1135401738)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079544" FT VARIANT 858 FT /note="T -> A (in T2D; dbSNP:rs182552223)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015917" FT VARIANT 874 FT /note="P -> L (in RMS; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079545" FT VARIANT 878 FT /note="N -> S (in RMS; impairs post-translational FT processing; dbSNP:rs887190835)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079546" FT VARIANT 890..1382 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:22768670" FT /id="VAR_079547" FT VARIANT 925 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; abolishes insulin binding; dbSNP:rs1599881881)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015918" FT VARIANT 926 FT /note="R -> W (in LEPRCH; markedly impairs insulin FT binding;impairs post-translational processing; FT dbSNP:rs911929963)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015919" FT VARIANT 937 FT /note="T -> M (in LEPRCH; impaired receptor processing; FT impairs post-translational processing; dbSNP:rs1972802448)" FT /evidence="ECO:0000269|PubMed:28765322, FT ECO:0000269|PubMed:9299395" FT /id="VAR_015920" FT VARIANT 997 FT /note="P -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015921" FT VARIANT 999..1382 FT /note="Missing (in RMS)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079548" FT VARIANT 1012 FT /note="V -> M (in dbSNP:rs1799816)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8432414, FT ECO:0000269|PubMed:8458533, ECO:0000269|PubMed:9199575" FT /id="VAR_004091" FT VARIANT 1020 FT /note="R -> Q (in IRAN type A; dbSNP:rs121913148)" FT /evidence="ECO:0000269|PubMed:2002058" FT /id="VAR_004092" FT VARIANT 1023 FT /note="I -> F" FT /evidence="ECO:0000269|PubMed:8890729" FT /id="VAR_015922" FT VARIANT 1035 FT /note="G -> V (in IRAN type A; dbSNP:rs121913135)" FT /evidence="ECO:0000269|PubMed:2544998" FT /id="VAR_004093" FT VARIANT 1054 FT /note="V -> M (in IRAN type A; uncertain significance; FT dbSNP:rs1135401741)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079549" FT VARIANT 1055 FT /note="A -> V (in IRAN type A; dbSNP:rs1599874183)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015923" FT VARIANT 1065 FT /note="L -> V (in dbSNP:rs56395521)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041432" FT VARIANT 1075 FT /note="A -> D (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:8243830" FT /id="VAR_004094" FT VARIANT 1095 FT /note="K -> E (in a subject with non-insulin dependent FT diabetes mellitus; dbSNP:rs909008899)" FT /evidence="ECO:0000269|PubMed:2040394" FT /id="VAR_015924" FT VARIANT 1119 FT /note="R -> W (in LEPRCH; dbSNP:rs1229730671)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:9249867" FT /id="VAR_015925" FT VARIANT 1143 FT /note="I -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015926" FT VARIANT 1158 FT /note="R -> Q (in T2D)" FT /evidence="ECO:0000269|PubMed:1470163" FT /id="VAR_015927" FT VARIANT 1158 FT /note="R -> W (in RMS; abolishes insulin binding; FT dbSNP:rs111993466)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015928" FT VARIANT 1161 FT /note="A -> T (in IRAN type A; dbSNP:rs121913139)" FT /evidence="ECO:0000269|PubMed:2168397" FT /id="VAR_004095" FT VARIANT 1162 FT /note="A -> E (in IRAN type A; impairs proteolytic FT processing; dbSNP:rs121913154)" FT /evidence="ECO:0000269|PubMed:8096518" FT /id="VAR_004096" FT VARIANT 1180 FT /note="M -> I (in a patient with insulin resistance; FT dbSNP:rs121913157)" FT /evidence="ECO:0000269|PubMed:1890161" FT /id="VAR_004097" FT VARIANT 1191 FT /note="R -> Q (in T2D; dbSNP:rs121913150)" FT /evidence="ECO:0000269|PubMed:1607076" FT /id="VAR_004098" FT VARIANT 1201 FT /note="R -> Q (in HHF5 and IRAN type A; interferes with FT kinase activation by insulin; dbSNP:rs121913156)" FT /evidence="ECO:0000269|PubMed:15161766, FT ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049" FT /id="VAR_015929" FT VARIANT 1201 FT /note="R -> W (in LEPRCH and RMS; reduces insulin binding FT possibly due to reduced receptor levels on the cell FT surface; dbSNP:rs1568426700)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:9703342" FT /id="VAR_015930" FT VARIANT 1205 FT /note="P -> L (in IRAN type A; moderate; FT dbSNP:rs1295645322)" FT /evidence="ECO:0000269|PubMed:1563582, FT ECO:0000269|PubMed:8314008" FT /id="VAR_004099" FT VARIANT 1206 FT /note="E -> D (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity)" FT /evidence="ECO:0000269|PubMed:7983039" FT /id="VAR_015931" FT VARIANT 1206 FT /note="E -> K (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9249867" FT /id="VAR_015932" FT VARIANT 1220 FT /note="W -> L (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity; dbSNP:rs52800171)" FT /evidence="ECO:0000269|PubMed:7983039, FT ECO:0000269|PubMed:8390949" FT /id="VAR_004100" FT VARIANT 1227 FT /note="W -> S (in IRAN type A; dbSNP:rs121913140)" FT /evidence="ECO:0000269|PubMed:1963473" FT /id="VAR_004101" FT VARIANT 1282 FT /note="T -> A (in dbSNP:rs55875349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041433" FT VARIANT 1361 FT /note="Y -> C (in dbSNP:rs13306449)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015933" FT VARIANT 1378 FT /note="R -> Q (in IRAN type A; dbSNP:rs52826008)" FT /evidence="ECO:0000269|PubMed:8314008" FT /id="VAR_015934" FT MUTAGEN 462 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 825 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 834 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 991 FT /note="L->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 992 FT /note="Y->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996..997 FT /note="NP->AA: Abolishes interaction with IRS1. Severely FT disrupts, but does not abolish interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996 FT /note="N->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 997 FT /note="P->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 998 FT /note="E->A: Does not affect interaction with IRS1, SHC1 or FT PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849" FT MUTAGEN 999 FT /note="Y->E: Abolishes interaction with IRS1 and SHC1." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 999 FT /note="Y->F: Has no effect on insulin-stimulated FT autophosphorylation, but inhibits the biological activity FT of the receptor. Abolishes interaction with IRS1 and almost FT completely prevents interaction with SHC1. Has no effect on FT interaction with PIK3R1. Abolishes interaction with FT STAT5B." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 1000 FT /note="L->A,R: Severely reduces interaction with SHC1. Has FT no effect on interaction with IRS1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1002 FT /note="A->D: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1011 FT /note="Y->A: Increases kinase activity." FT /evidence="ECO:0000269|PubMed:12707268" FT MUTAGEN 1057 FT /note="K->A: Abolishes the kinase activity and abolishes FT interaction with IRS1, SHC1, GRB7 and PIK3R1." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1057 FT /note="K->M,R: Abolishes the kinase activity." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1079 FT /note="K->R: Increased cell surface stability." FT /evidence="ECO:0000269|PubMed:27577745" FT MUTAGEN 1083 FT /note="C->A: Reduced S-nitrosylation by BLVRB, leading to FT increased receptor tyrosine kinase activity." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 1159 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1163 FT /note="R->Q: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1189 FT /note="Y->F: Reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT MUTAGEN 1190 FT /note="Y->F: Strongly reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT CONFLICT 601 FT /note="D -> N (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 830 FT /note="P -> E (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1278 FT /note="K -> N (in Ref. 2; CAA26096)" FT /evidence="ECO:0000305" FT STRAND 33..42 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 53..65 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:8X2M" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 118..124 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 141..149 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 171..175 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 187..192 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 224..226 FT /evidence="ECO:0007829|PDB:8X06" FT STRAND 230..232 FT /evidence="ECO:0007829|PDB:7MQO" FT STRAND 243..247 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 305..307 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 310..314 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 323..325 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 327..330 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 338..348 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 351..355 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 356..359 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 377..385 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 390..393 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 395..399 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8X06" FT TURN 422..424 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 425..430 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 437..439 FT /evidence="ECO:0007829|PDB:7U6E" FT TURN 441..443 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 447..450 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 452..458 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 463..472 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 476..478 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 481..483 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 486..490 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 498..500 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 524..526 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 527..536 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 538..540 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 570..573 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 588..597 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 601..603 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 608..610 FT /evidence="ECO:0007829|PDB:4ZXB" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 626..631 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 633..636 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 654..658 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 732..740 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 798..803 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 805..809 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 817..827 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 838..843 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 867..870 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 881..890 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 896..901 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 902..908 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 910..913 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 918..931 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 940..944 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 953..979 FT /evidence="ECO:0007829|PDB:2MFR" FT STRAND 992..995 FT /evidence="ECO:0007829|PDB:5U1M" FT TURN 1003..1005 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1009..1011 FT /evidence="ECO:0007829|PDB:1IR3" FT HELIX 1014..1016 FT /evidence="ECO:0007829|PDB:1IRK" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1023..1031 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1033..1043 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1046..1048 FT /evidence="ECO:0007829|PDB:2Z8C" FT STRAND 1050..1057 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1065..1078 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1089..1093 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1095..1098 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1100..1104 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1111..1117 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1119..1121 FT /evidence="ECO:0007829|PDB:3ETA" FT HELIX 1133..1152 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1154..1156 FT /evidence="ECO:0007829|PDB:2AUH" FT HELIX 1162..1164 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1165..1167 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1173..1175 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1181..1183 FT /evidence="ECO:0007829|PDB:1IRK" FT TURN 1185..1187 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1190..1192 FT /evidence="ECO:0007829|PDB:5HHW" FT STRAND 1194..1198 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1200..1202 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1205..1210 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1215..1230 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1236..1239 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1242..1250 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1263..1272 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1277..1279 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1283..1290 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1291..1293 FT /evidence="ECO:0007829|PDB:5HHW" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1303..1305 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1307..1309 FT /evidence="ECO:0007829|PDB:8DWN" SQ SEQUENCE 1382 AA; 156333 MW; 709A955660739066 CRC64; MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN PS // ID IRAK1_HUMAN Reviewed; 712 AA. AC P51617; D3DWW3; D3DWW4; Q7Z5V4; Q96C06; Q96RL2; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2000, sequence version 2. DT 28-JAN-2026, entry version 237. DE RecName: Full=Interleukin-1 receptor-associated kinase 1 {ECO:0000303|PubMed:16024789}; DE Short=IRAK-1 {ECO:0000303|PubMed:16024789}; DE EC=2.7.11.1; GN Name=IRAK1 {ECO:0000312|HGNC:HGNC:6112}; Synonyms=IRAK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND RP VARIANTS SER-196 AND LEU-532. RX PubMed=8599092; DOI=10.1126/science.271.5252.1128; RA Cao Z., Henzel W.J., Gao X.; RT "IRAK: a kinase associated with the interleukin-1 receptor."; RL Science 271:1128-1131(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=10723722; DOI=10.1007/s003350010035; RA Reichwald K., Thiesen J., Wiehe T., Weitzel J., Poustka W.A., Rosenthal A., RA Platzer M., Stratling W.H., Kioschis P.; RT "Comparative sequence analysis of the MECP2-locus in human and mouse RT reveals new transcribed regions."; RL Mamm. Genome 11:182-190(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY, AND RP PHOSPHORYLATION. RX PubMed=11397809; DOI=10.1074/jbc.m103815200; RA Jensen L.E., Whitehead A.S.; RT "IRAK1b, a novel alternative splice variant of interleukin-1 receptor- RT associated kinase (IRAK), mediates interleukin-1 signaling and has RT prolonged stability."; RL J. Biol. Chem. 276:29037-29044(2001). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RX PubMed=16024789; DOI=10.1128/mcb.25.15.6521-6532.2005; RA Rao N., Nguyen S., Ngo K., Fung-Leung W.P.; RT "A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase RT 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory RT signaling."; RL Mol. Cell. Biol. 25:6521-6532(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INTERACTION WITH MYD88. RX PubMed=9430229; DOI=10.1016/s1074-7613(00)80402-1; RA Wesche H., Henzel W.J., Shillinglaw W., Li S., Cao Z.; RT "MyD88: an adapter that recruits IRAK to the IL-1 receptor complex."; RL Immunity 7:837-847(1997). RN [9] RP INTERACTION WITH TOLLIP. RX PubMed=10854325; DOI=10.1038/35014038; RA Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C., Maschera B., RA Lewis A., Ray K., Tschopp J., Volpe F.; RT "Tollip, a new component of the IL-1R1 pathway, links IRAK to the IL-1 RT receptor."; RL Nat. Cell Biol. 2:346-351(2000). RN [10] RP INTERACTION WITH IRAK4. RX PubMed=11960013; DOI=10.1073/pnas.082100399; RA Li S., Strelow A., Fontana E.J., Wesche H.; RT "IRAK4: a novel member of the IRAK family with the properties of an IRAK- RT kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 99:5567-5572(2002). RN [11] RP INTERACTION WITH PELI1 AND TRAF6. RX PubMed=12496252; DOI=10.1074/jbc.m212112200; RA Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.; RT "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through RT its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK- RT tumor necrosis factor receptor-associated factor 6 (TRAF6) complex."; RL J. Biol. Chem. 278:10952-10956(2003). RN [12] RP FUNCTION IN PHOSPHORYLATION OF PELI2. RX PubMed=12860405; DOI=10.1016/s0014-5793(03)00697-5; RA Strelow A., Kollewe C., Wesche H.; RT "Characterization of Pellino2, a substrate of IRAK1 and IRAK4."; RL FEBS Lett. 547:157-161(2003). RN [13] RP PHOSPHORYLATION BY IRAK4. RX PubMed=12538665; DOI=10.1084/jem.20021790; RA Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J.; RT "Inhibition of interleukin 1 receptor/Toll-like receptor signaling through RT the alternatively spliced, short form of MyD88 is due to its failure to RT recruit IRAK-4."; RL J. Exp. Med. 197:263-268(2003). RN [14] RP INTERACTION WITH PELI3. RX PubMed=12874243; DOI=10.4049/jimmunol.171.3.1500; RA Jensen L.E., Whitehead A.S.; RT "Pellino3, a novel member of the Pellino protein family, promotes RT activation of c-Jun and Elk-1 and may act as a scaffolding protein."; RL J. Immunol. 171:1500-1506(2003). RN [15] RP FUNCTION, AND PHOSPHORYLATION AT THR-66. RX PubMed=14684752; DOI=10.1074/jbc.c300431200; RA Mamidipudi V., Lin C., Seibenhener M.L., Wooten M.W.; RT "Regulation of interleukin receptor-associated kinase (IRAK) RT phosphorylation and signaling by iota protein kinase C."; RL J. Biol. Chem. 279:4161-4165(2004). RN [16] RP PHOSPHORYLATION AT THR-209 AND THR-387, DOMAIN, AND MUTAGENESIS OF THR-209 RP AND THR-387. RX PubMed=14625308; DOI=10.1074/jbc.m309251200; RA Kollewe C., Mackensen A.C., Neumann D., Knop J., Cao P., Li S., Wesche H., RA Martin M.U.; RT "Sequential autophosphorylation steps in the interleukin-1 receptor- RT associated kinase-1 regulate its availability as an adapter in interleukin- RT 1 signaling."; RL J. Biol. Chem. 279:5227-5236(2004). RN [17] RP FUNCTION, AND MUTAGENESIS OF LYS-239. RX PubMed=15084582; DOI=10.1074/jbc.m400785200; RA Qin J., Jiang Z., Qian Y., Casanova J.-L., Li X.; RT "IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor- RT associated kinase phosphorylation and IL-1 responsiveness."; RL J. Biol. Chem. 279:26748-26753(2004). RN [18] RP FUNCTION IN PHOSPHORYLATION OF STAT3. RX PubMed=15465816; DOI=10.1074/jbc.m410369200; RA Huang Y., Li T., Sane D.C., Li L.; RT "IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced RT interleukin-10 gene expression."; RL J. Biol. Chem. 279:51697-51703(2004). RN [19] RP INTERACTION WITH IL1RL1. RX PubMed=16286016; DOI=10.1016/j.immuni.2005.09.015; RA Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., RA Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., RA Kastelein R.A.; RT "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor- RT related protein ST 2 and induces T helper type 2-associated cytokines."; RL Immunity 23:479-490(2005). RN [20] RP FUNCTION IN PHOSPHORYLATION OF IRF7. RX PubMed=15767370; DOI=10.1084/jem.20042372; RA Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F., RA Matsuda M., Coban C., Ishii K.J., Kawai T., Takeuchi O., Akira S.; RT "Interleukin-1 receptor-associated kinase-1 plays an essential role for RT Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} RT induction."; RL J. Exp. Med. 201:915-923(2005). RN [21] RP IDENTIFICATION IN COMPLEX WITH IRAK4; MYD88; PELI1 AND TRAF6. RX PubMed=16951688; DOI=10.1038/ni1383; RA Choi K.C., Lee Y.S., Lim S., Choi H.K., Lee C.H., Lee E.K., Hong S., RA Kim I.H., Kim S.J., Park S.H.; RT "Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor RT signaling through direct interaction with the adapter Pellino-1."; RL Nat. Immunol. 7:1057-1065(2006). RN [22] RP SUMOYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16690127; DOI=10.1016/j.molimm.2006.03.021; RA Su J., Richter K., Zhang C., Gu Q., Li L.; RT "Differential regulation of interleukin-1 receptor associated kinase 1 RT (IRAK1) splice variants."; RL Mol. Immunol. 44:900-905(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF PELI1. RX PubMed=17997719; DOI=10.1042/bj20071365; RA Ordureau A., Smith H., Windheim M., Peggie M., Carrick E., Morrice N., RA Cohen P.; RT "The IRAK-catalysed activation of the E3 ligase function of Pellino RT isoforms induces the Lys63-linked polyubiquitination of IRAK1."; RL Biochem. J. 409:43-52(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [25] RP UBIQUITINATION AT LYS-134 AND LYS-180 BY TRAF6, AND INTERACTION WITH RP IKBKG/NEMO. RX PubMed=18347055; DOI=10.1128/mcb.02098-07; RA Conze D.B., Wu C.J., Thomas J.A., Landstrom A., Ashwell J.D.; RT "Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 RT receptor- and toll-like receptor-mediated NF-kappaB activation."; RL Mol. Cell. Biol. 28:3538-3547(2008). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP UBIQUITINATION. RX PubMed=19675569; DOI=10.1038/nature08247; RA Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W., RA Chen Z.J.; RT "Direct activation of protein kinases by unanchored polyubiquitin chains."; RL Nature 461:114-119(2009). RN [28] RP FUNCTION IN PHOSPHORYLATION OF TIRAP. RX PubMed=20400509; DOI=10.1074/jbc.m109.098137; RA Dunne A., Carpenter S., Brikos C., Gray P., Strelow A., Wesche H., RA Morrice N., O'Neill L.A.; RT "IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation RT of MyD88 adaptor-like (Mal)."; RL J. Biol. Chem. 285:18276-18282(2010). RN [29] RP REVIEW ON FUNCTION. RX PubMed=17890055; DOI=10.1016/j.cellsig.2007.08.009; RA Gottipati S., Rao N.L., Fung-Leung W.P.; RT "IRAK1: a critical signaling mediator of innate immunity."; RL Cell. Signal. 20:269-276(2008). RN [30] RP INTERACTION WITH NFATC4, AND MUTAGENESIS OF ASP-340. RX PubMed=18691762; DOI=10.1016/j.molimm.2008.06.023; RA Wang D., Fasciano S., Li L.; RT "The interleukin-1 receptor associated kinase 1 contributes to the RT regulation of NFAT."; RL Mol. Immunol. 45:3902-3908(2008). RN [31] RP REVIEW ON FUNCTION. RX PubMed=19022706; DOI=10.1016/j.it.2008.10.001; RA Moynagh P.N.; RT "The Pellino family: IRAK E3 ligases with emerging roles in innate immune RT signalling."; RL Trends Immunol. 30:33-42(2009). RN [32] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-371; SER-375 AND SER-556, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP INTERACTION WITH INAVA. RX PubMed=28436939; DOI=10.1172/jci86282; RA Yan J., Hedl M., Abraham C.; RT "An inflammatory bowel disease-risk variant in INAVA decreases pattern RT recognition receptor-induced outcomes."; RL J. Clin. Invest. 127:2192-2205(2017). RN [35] RP INTERACTION WITH MUMPS VIRUS PROTEIN SH. RX PubMed=28659487; DOI=10.1128/jvi.01037-17; RA Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M., RA Finsterbusch T., Geyer H., Mankertz A., Friedrich N.; RT "Mumps virus SH protein inhibits NF-kappaB activation by interacting with RT tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like RT receptor 3 complexes."; RL J. Virol. 91:0-0(2017). RN [36] RP INTERACTION WITH PELI1. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [37] RP INTERACTION WITH ALPHAVIRUS CAPSID PROTEINS (MICROBIAL INFECTION). RX PubMed=33673546; DOI=10.3390/v13030377; RA Landers V.D., Wilkey D.W., Merchant M.L., Mitchell T.C., Sokoloski K.J.; RT "The Alphaviral Capsid Protein Inhibits IRAK1-Dependent TLR Signaling."; RL Viruses 13:0-0(2021). RN [38] RP VARIANTS [LARGE SCALE ANALYSIS] MET-398; MET-412; HIS-421; LEU-532; RP SER-619; MET-625; TRP-638 AND GLY-690. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that plays a critical role in CC initiating innate immune response against foreign pathogens. Involved CC in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly CC recruited by MYD88 to the receptor-signaling complex upon TLR CC activation. Association with MYD88 leads to IRAK1 phosphorylation by CC IRAK4 and subsequent autophosphorylation and kinase activation. CC Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and CC PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, CC the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated CC IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the CC NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA CC and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and CC activation. Alternatively, phosphorylates TIRAP to promote its CC ubiquitination and subsequent degradation. Phosphorylates the CC interferon regulatory factor 7 (IRF7) to induce its activation and CC translocation to the nucleus, resulting in transcriptional activation CC of type I IFN genes, which drive the cell in an antiviral state. When CC sumoylated, translocates to the nucleus and phosphorylates STAT3. CC {ECO:0000269|PubMed:11397809, ECO:0000269|PubMed:12860405, CC ECO:0000269|PubMed:14684752, ECO:0000269|PubMed:15084582, CC ECO:0000269|PubMed:15465816, ECO:0000269|PubMed:15767370, CC ECO:0000269|PubMed:17997719, ECO:0000269|PubMed:20400509}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Homodimer (By similarity). Forms a complex with TRAF6, PELI1, CC IRAK4 and MYD88 (PubMed:16951688). Direct binding of SMAD6 to PELI1 CC prevents complex formation and hence negatively regulates IL1R-TLR CC signaling and eventually NF-kappa-B-mediated gene expression CC (PubMed:16951688). The TRAF6-PELI1-IRAK4-MYD88 complex recruits CC MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B activation CC (PubMed:16951688). Interaction with MYD88 recruits IRAK1 to the CC stimulated receptor complex (PubMed:9430229). Interacts with TOLLIP; CC this interaction occurs in the cytosol prior to receptor activation CC (PubMed:10854325). Interacts with IL1RL1 (PubMed:16286016). Interacts CC with PELI1 and TRAF6 (PubMed:12496252). Interacts (when CC polyubiquitinated) with IKBKG/NEMO (PubMed:18347055). Interacts with CC RSAD2/viperin (By similarity). Interacts with IRAK1BP1 (By similarity). CC Interacts with PELI2 (By similarity). Interacts with ZC3H12A; this CC interaction increases the interaction between ZC3H12A and IKBKB/IKKB CC (By similarity). Interacts with IRAK4 (PubMed:11960013). Interacts with CC PELI3 (PubMed:12874243). Interacts with INAVA; the interaction takes CC place upon PRR stimulation (PubMed:28436939). Interacts (via C- CC terminus) with NFATC4 (via N-terminus) (PubMed:18691762). CC {ECO:0000250|UniProtKB:Q62406, ECO:0000269|PubMed:10854325, CC ECO:0000269|PubMed:11960013, ECO:0000269|PubMed:12496252, CC ECO:0000269|PubMed:12874243, ECO:0000269|PubMed:16286016, CC ECO:0000269|PubMed:16951688, ECO:0000269|PubMed:18347055, CC ECO:0000269|PubMed:18691762, ECO:0000269|PubMed:28436939, CC ECO:0000269|PubMed:29883609, ECO:0000269|PubMed:9430229}. CC -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH; CC this interaction inhibits downstream NF-kappa-B pathway activation. CC {ECO:0000269|PubMed:28659487}. CC -!- SUBUNIT: (Microbial infection) Interacts with alphaviruses SINV, CHIKV, CC RRV, VEEV and EEEV capsid proteins; the interactions lead to inhibition CC of IRAK1-dependent signaling. {ECO:0000269|PubMed:33673546}. CC -!- INTERACTION: CC P51617; O43187: IRAK2; NbExp=3; IntAct=EBI-358664, EBI-447733; CC P51617; Q9Y616: IRAK3; NbExp=3; IntAct=EBI-358664, EBI-447690; CC P51617; Q15306: IRF4; NbExp=2; IntAct=EBI-358664, EBI-751345; CC P51617; Q92985: IRF7; NbExp=2; IntAct=EBI-358664, EBI-968267; CC P51617; Q99836: MYD88; NbExp=4; IntAct=EBI-358664, EBI-447677; CC P51617; Q96FA3: PELI1; NbExp=4; IntAct=EBI-358664, EBI-448369; CC P51617; Q9HAT8: PELI2; NbExp=4; IntAct=EBI-358664, EBI-448407; CC P51617; Q8N2H9-2: PELI3; NbExp=2; IntAct=EBI-358664, EBI-448472; CC P51617; Q13526: PIN1; NbExp=10; IntAct=EBI-358664, EBI-714158; CC P51617; Q86WV6: STING1; NbExp=2; IntAct=EBI-358664, EBI-2800345; CC P51617; P58753: TIRAP; NbExp=3; IntAct=EBI-358664, EBI-528644; CC P51617; Q9Y4K3: TRAF6; NbExp=4; IntAct=EBI-358664, EBI-359276; CC P51617; Q8VCW4: Unc93b1; Xeno; NbExp=2; IntAct=EBI-358664, EBI-6116986; CC P51617; Q5D1E7: Zc3h12a; Xeno; NbExp=3; IntAct=EBI-358664, EBI-5326026; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16690127}. Nucleus CC {ECO:0000269|PubMed:16690127}. Lipid droplet {ECO:0000250}. CC Note=Translocates to the nucleus when sumoylated. RSAD2/viperin CC recruits it to the lipid droplet (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=a; CC IsoId=P51617-1; Sequence=Displayed; CC Name=2; Synonyms=b; CC IsoId=P51617-2; Sequence=VSP_011851; CC Name=3; CC IsoId=P51617-3; Sequence=VSP_011849, VSP_011850, VSP_011851; CC Name=4; CC IsoId=P51617-4; Sequence=VSP_041950; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are ubiquitously expressed CC in all tissues examined, with isoform 1 being more strongly expressed CC than isoform 2. {ECO:0000269|PubMed:11397809}. CC -!- DOMAIN: The ProST region is composed of many proline and serine CC residues (more than 20 of each) and some threonines. This region is the CC site of IRAK-1 hyperphosphorylation. {ECO:0000269|PubMed:14625308}. CC -!- PTM: Following recruitment on the activated receptor complex, CC phosphorylated on Thr-209, probably by IRAK4, resulting in a CC conformational change of the kinase domain, allowing further CC phosphorylations to take place. Thr-387 phosphorylation in the CC activation loop is required to achieve full enzymatic activity. CC {ECO:0000269|PubMed:11397809, ECO:0000269|PubMed:12538665, CC ECO:0000269|PubMed:14625308, ECO:0000269|PubMed:14684752}. CC -!- PTM: Polyubiquitinated by TRAF6 after cell stimulation with IL-1-beta CC by PELI1, PELI2 and PELI3. Polyubiquitination occurs with polyubiquitin CC chains linked through 'Lys-63'. Ubiquitination promotes interaction CC with NEMO/IKBKG. Also sumoylated; leading to nuclear translocation. CC {ECO:0000269|PubMed:16690127, ECO:0000269|PubMed:18347055, CC ECO:0000269|PubMed:19675569}. CC -!- MISCELLANEOUS: [Isoform 2]: Inactive. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. Pelle subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76191; AAC41949.1; -; mRNA. DR EMBL; AF030876; AAC08756.1; -; Genomic_DNA. DR EMBL; AF346607; AAK62888.1; -; mRNA. DR EMBL; DQ054788; AAY88246.1; -; mRNA. DR EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471172; EAW72762.1; -; Genomic_DNA. DR EMBL; CH471172; EAW72763.1; -; Genomic_DNA. DR EMBL; CH471172; EAW72764.1; -; Genomic_DNA. DR EMBL; CH471172; EAW72765.1; -; Genomic_DNA. DR EMBL; BC054000; AAH54000.1; -; mRNA. DR EMBL; BC014963; AAH14963.1; -; mRNA. DR CCDS; CCDS14740.1; -. [P51617-1] DR CCDS; CCDS35443.1; -. [P51617-4] DR CCDS; CCDS35444.1; -. [P51617-2] DR PIR; G02512; G02512. DR RefSeq; NP_001020413.1; NM_001025242.2. [P51617-2] DR RefSeq; NP_001020414.1; NM_001025243.2. [P51617-4] DR RefSeq; NP_001560.2; NM_001569.4. [P51617-1] DR PDB; 6BFN; X-ray; 2.26 A; A/B=194-530. DR PDBsum; 6BFN; -. DR AlphaFoldDB; P51617; -. DR SMR; P51617; -. DR BioGRID; 109863; 365. DR ComplexPortal; CPX-10281; Myddosome core complex. DR CORUM; P51617; -. DR DIP; DIP-397N; -. DR ELM; P51617; -. DR FunCoup; P51617; 1800. DR IntAct; P51617; 221. DR MINT; P51617; -. DR STRING; 9606.ENSP00000358997; -. DR BindingDB; P51617; -. DR ChEMBL; CHEMBL3357; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P51617; -. DR GuidetoPHARMACOLOGY; 2042; -. DR GlyGen; P51617; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P51617; -. DR PhosphoSitePlus; P51617; -. DR BioMuta; IRAK1; -. DR DMDM; 8928535; -. DR CPTAC; CPTAC-2897; -. DR CPTAC; CPTAC-2898; -. DR jPOST; P51617; -. DR MassIVE; P51617; -. DR PaxDb; 9606-ENSP00000358997; -. DR PeptideAtlas; P51617; -. DR ProteomicsDB; 56349; -. [P51617-1] DR ProteomicsDB; 56350; -. [P51617-2] DR ProteomicsDB; 56351; -. [P51617-3] DR ProteomicsDB; 56352; -. [P51617-4] DR Pumba; P51617; -. DR Antibodypedia; 3845; 1016 antibodies from 48 providers. DR DNASU; 3654; -. DR Ensembl; ENST00000369974.6; ENSP00000358991.2; ENSG00000184216.16. [P51617-4] DR Ensembl; ENST00000369980.8; ENSP00000358997.3; ENSG00000184216.16. [P51617-1] DR Ensembl; ENST00000393687.6; ENSP00000377291.2; ENSG00000184216.16. [P51617-2] DR GeneID; 3654; -. DR KEGG; hsa:3654; -. DR MANE-Select; ENST00000369980.8; ENSP00000358997.3; NM_001569.4; NP_001560.2. DR UCSC; uc004fjr.2; human. [P51617-1] DR AGR; HGNC:6112; -. DR ClinPGx; PA29912; -. DR CTD; 3654; -. DR DisGeNET; 3654; -. DR GeneCards; IRAK1; -. DR HGNC; HGNC:6112; IRAK1. DR HPA; ENSG00000184216; Low tissue specificity. DR MalaCards; IRAK1; -. DR MIM; 300283; gene. DR OpenTargets; ENSG00000184216; -. DR Orphanet; 93552; Pediatric systemic lupus erythematosus. DR Orphanet; 536; Systemic lupus erythematosus. DR VEuPathDB; HostDB:ENSG00000184216; -. DR eggNOG; KOG1187; Eukaryota. DR GeneTree; ENSGT00940000160502; -. DR HOGENOM; CLU_000288_173_1_1; -. DR InParanoid; P51617; -. DR OMA; MTQVYES; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P51617; 13 GO annotations based on evolutionary models. DR PhylomeDB; P51617; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P51617; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-209543; p75NTR recruits signalling complexes. DR Reactome; R-HSA-209560; NF-kB is activated and signals survival. DR Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR Reactome; R-HSA-9020702; Interleukin-1 signaling. DR Reactome; R-HSA-937039; IRAK1 recruits IKK complex. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling. DR Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation. DR Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. DR Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome. DR Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane. DR SignaLink; P51617; -. DR SIGNOR; P51617; -. DR Agora; ENSG00000184216; -. DR BioGRID-ORCS; 3654; 20 hits in 816 CRISPR screens. DR ChiTaRS; IRAK1; human. DR GeneWiki; IRAK1; -. DR GenomeRNAi; 3654; -. DR Pharos; P51617; Tchem. DR PRO; PR:P51617; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51617; protein. DR Bgee; ENSG00000184216; Expressed in parotid gland and 203 other cell types or tissues. DR ExpressionAtlas; P51617; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0005811; C:lipid droplet; ISS:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0031072; F:heat shock protein binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IMP:ARUK-UCL. DR GO; GO:0034605; P:cellular response to heat; IEA:Ensembl. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IBA:GO_Central. DR GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IDA:UniProt. DR GO; GO:0038172; P:interleukin-33-mediated signaling pathway; IMP:UniProt. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007254; P:JNK cascade; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IMP:BHF-UCL. DR GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL. DR GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IMP:BHF-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:MGI. DR GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; IMP:ARUK-UCL. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032481; P:positive regulation of type I interferon production; IMP:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IMP:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IEA:UniProtKB-ARBA. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0032496; P:response to lipopolysaccharide; IMP:BHF-UCL. DR GO; GO:0008063; P:Toll signaling pathway; IBA:GO_Central. DR GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IMP:BHF-UCL. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IBA:GO_Central. DR GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome. DR GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome. DR GO; GO:0060337; P:type I interferon-mediated signaling pathway; IMP:BHF-UCL. DR CDD; cd08794; Death_IRAK1; 1. DR DisProt; DP02467; -. DR FunFam; 1.10.533.10:FF:000027; Interleukin-1 receptor-associated kinase 1 (Predicted); 1. DR FunFam; 3.30.200.20:FF:000300; Interleukin-1 receptor-associated kinase 1 (Predicted); 1. DR FunFam; 1.10.510.10:FF:000424; Putative interleukin-1 receptor-associated kinase 1; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_dom. DR InterPro; IPR035533; Death_IRAK1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR27001:SF939; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; 1. DR PANTHER; PTHR27001; OS01G0253100 PROTEIN; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; KW Direct protein sequencing; Host-virus interaction; Immunity; KW Innate immunity; Isopeptide bond; Kinase; Lipid droplet; Magnesium; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..712 FT /note="Interleukin-1 receptor-associated kinase 1" FT /id="PRO_0000086030" FT DOMAIN 27..106 FT /note="Death" FT DOMAIN 212..521 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 105..187 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 110..211 FT /note="ProST region" FT REGION 532..591 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 613..660 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 690..712 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 115..133 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 137..154 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 543..553 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 562..575 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 643..658 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 340 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 218..226 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 342..345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 358 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 66 FT /note="Phosphothreonine; by PKC/PRKCI" FT /evidence="ECO:0000269|PubMed:14684752" FT MOD_RES 131 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 209 FT /note="Phosphothreonine; by IRAK4" FT /evidence="ECO:0000305|PubMed:14625308" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 375 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 387 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14625308" FT MOD_RES 556 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 134 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18347055" FT CROSSLNK 180 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18347055" FT VAR_SEQ 45 FT /note="F -> FGGWRRAAGGREARGLLAPTPDAPRPA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011849" FT VAR_SEQ 435..513 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:16024789" FT /id="VSP_041950" FT VAR_SEQ 478..492 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011850" FT VAR_SEQ 513..542 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:11397809, FT ECO:0000303|PubMed:15489334" FT /id="VSP_011851" FT VARIANT 194 FT /note="R -> H (in dbSNP:rs11465830)" FT /id="VAR_051629" FT VARIANT 196 FT /note="F -> S (in dbSNP:rs1059702)" FT /evidence="ECO:0000269|PubMed:8599092" FT /id="VAR_051630" FT VARIANT 203 FT /note="C -> S (in dbSNP:rs10127175)" FT /id="VAR_051631" FT VARIANT 398 FT /note="T -> M (in dbSNP:rs56340948)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040573" FT VARIANT 412 FT /note="V -> M (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040574" FT VARIANT 421 FT /note="Q -> H (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040575" FT VARIANT 532 FT /note="S -> L (in dbSNP:rs1059703)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8599092" FT /id="VAR_040576" FT VARIANT 619 FT /note="G -> S (in dbSNP:rs34112487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040577" FT VARIANT 625 FT /note="T -> M (in dbSNP:rs35638718)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040578" FT VARIANT 638 FT /note="R -> W (in dbSNP:rs56082801)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040579" FT VARIANT 690 FT /note="S -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040580" FT MUTAGEN 209 FT /note="T->A: Completely abolishes auto-phosphorylation in FT the kinase domain." FT /evidence="ECO:0000269|PubMed:14625308" FT MUTAGEN 239 FT /note="K->S: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15084582" FT MUTAGEN 340 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:18691762" FT MUTAGEN 387 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14625308" FT STRAND 195..197 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 202..209 FT /evidence="ECO:0007829|PDB:6BFN" FT TURN 210..212 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 217..220 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 222..231 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 234..241 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 249..265 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 274..280 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 283..289 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 296..301 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 304..307 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 312..331 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 354..356 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 359..361 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 393..397 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 403..419 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 423..427 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 434..436 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 437..445 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 467..476 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 487..500 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 511..521 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 522..524 FT /evidence="ECO:0007829|PDB:6BFN" SQ SEQUENCE 712 AA; 76537 MW; A7ADED75D3A3981D CRC64; MAGGPGPGEP AAPGAQHFLY EVPPWVMCRF YKVMDALEPA DWCQFAALIV RDQTELRLCE RSGQRTASVL WPWINRNARV ADLVHILTHL QLLRARDIIT AWHPPAPLPS PGTTAPRPSS IPAPAEAEAW SPRKLPSSAS TFLSPAFPGS QTHSGPELGL VPSPASLWPP PPSPAPSSTK PGPESSVSLL QGARPFPFCW PLCEISRGTH NFSEELKIGE GGFGCVYRAV MRNTVYAVKR LKENADLEWT AVKQSFLTEV EQLSRFRHPN IVDFAGYCAQ NGFYCLVYGF LPNGSLEDRL HCQTQACPPL SWPQRLDILL GTARAIQFLH QDSPSLIHGD IKSSNVLLDE RLTPKLGDFG LARFSRFAGS SPSQSSMVAR TQTVRGTLAY LPEEYIKTGR LAVDTDTFSF GVVVLETLAG QRAVKTHGAR TKYLKDLVEE EAEEAGVALR STQSTLQAGL AADAWAAPIA MQIYKKHLDP RPGPCPPELG LGLGQLACCC LHRRAKRRPP MTQVYERLEK LQAVVAGVPG HSEAASCIPP SPQENSYVSS TGRAHSGAAP WQPLAAPSGA SAQAAEQLQR GPNQPVESDE SLGGLSAALR SWHLTPSCPL DPAPLREAGC PQGDTAGESS WGSGPGSRPT AVEGLALGSS ASSSSEPPQI IINPARQKMV QKLALYEDGA LDSLQLLSSS SLPGLGLEQD RQGPEESDEF QS // ID JAK3_HUMAN Reviewed; 1124 AA. AC P52333; Q13259; Q13260; Q13611; Q8N1E8; Q99699; Q9Y6S2; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 2. DT 28-JAN-2026, entry version 245. DE RecName: Full=Tyrosine-protein kinase JAK3 {ECO:0000305}; DE EC=2.7.10.2; DE AltName: Full=Janus kinase 3; DE Short=JAK-3; DE AltName: Full=Leukocyte janus kinase; DE Short=L-JAK; GN Name=JAK3 {ECO:0000312|HGNC:HGNC:6193}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=8022790; DOI=10.1073/pnas.91.14.6374; RA Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.-Q., Lal B.K., RA Lloyd A.R., Kelvin D.J., Staples J.E., Ortaldo J.R., O'Shea J.J.; RT "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase RT expressed in natural killer cells and activated leukocytes."; RL Proc. Natl. Acad. Sci. U.S.A. 91:6374-6378(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING (ISOFORM RP 2). RX PubMed=7559633; DOI=10.1074/jbc.270.42.25028; RA Lai K.S., Jin Y., Graham D.K., Witthuhn B.A., Ihle J.N., Liu E.T.; RT "A kinase-deficient splice variant of the human JAK3 is expressed in RT hematopoietic and epithelial cancer cells."; RL J. Biol. Chem. 270:25028-25036(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=8921370; DOI=10.1006/geno.1996.0520; RA Riedy M.C., Dutra A.S., Blake T.B., Modi W., Lal B.K., Davis J., Bosse A., RA O'Shea J.J., Johnston J.A.; RT "Genomic sequence, organization, and chromosomal localization of human RT JAK3."; RL Genomics 37:57-61(1996). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-132 AND ILE-722. RG SeattleSNPs variation discovery resource; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 36-191. RX PubMed=8662778; DOI=10.1074/jbc.271.24.13976; RA Verbsky J.W., Bach E.A., Fang Y.F., Yang L., Randolph D.A., Fields L.E.; RT "Expression of Janus kinase 3 in human endothelial and other non-lymphoid RT and non-myeloid cells."; RL J. Biol. Chem. 271:13976-13980(1996). RN [9] RP FUNCTION IN IL2 SIGNALING PATHWAY. RX PubMed=8022485; DOI=10.1038/370151a0; RA Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., RA Ortaldo J.R., McVicar D.W., O'Shea J.J.; RT "Phosphorylation and activation of the Jak-3 Janus kinase in response to RT interleukin-2."; RL Nature 370:151-153(1994). RN [10] RP FUNCTION IN IL7 SIGNALING PATHWAY. RX PubMed=7662955; RA Sharfe N., Dadi H.K., Roifman C.M.; RT "JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of RT phosphatidylinositol-3' kinase."; RL Blood 86:2077-2085(1995). RN [11] RP TISSUE SPECIFICITY. RX PubMed=7535338; DOI=10.1084/jem.181.4.1425; RA Musso T., Johnston J.A., Linnekin D., Varesio L., Rowe T.K., O'Shea J.J., RA McVicar D.W.; RT "Regulation of JAK3 expression in human monocytes: phosphorylation in RT response to interleukins 2, 4, and 7."; RL J. Exp. Med. 181:1425-1431(1995). RN [12] RP INTERACTION WITH STAM2. RC TISSUE=Fetal brain; RX PubMed=10899310; DOI=10.1016/s0014-5793(00)01760-9; RA Endo K., Takeshita T., Kasai H., Sasaki Y., Tanaka N., Asao H., Kikuchi K., RA Yamada M., Chenb M., O'Shea J.J., Sugamura K.; RT "STAM2, a new member of the STAM family, binding to the Janus kinases."; RL FEBS Lett. 477:55-61(2000). RN [13] RP INTERACTION WITH SHB. RX PubMed=12200137; DOI=10.1016/s0006-291x(02)02016-8; RA Lindholm C.K.; RT "IL-2 receptor signaling through the Shb adapter protein in T and NK RT cells."; RL Biochem. Biophys. Res. Commun. 296:929-936(2002). RN [14] RP FUNCTION IN CYTOKINE SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION AT RP TYR-980 AND TYR-981 BY PTPN2. RX PubMed=11909529; DOI=10.1016/s0960-9822(02)00697-8; RA Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J.; RT "The T cell protein tyrosine phosphatase is a negative regulator of janus RT family kinases 1 and 3."; RL Curr. Biol. 12:446-453(2002). RN [15] RP DOMAIN. RX PubMed=12351625; DOI=10.1074/jbc.m205156200; RA Saharinen P., Silvennoinen O.; RT "The pseudokinase domain is required for suppression of basal activity of RT Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of RT signal transduction."; RL J. Biol. Chem. 277:47954-47963(2002). RN [16] RP PHOSPHORYLATION AT TYR-785, AND MUTAGENESIS OF TYR-785. RX PubMed=15121872; DOI=10.1128/mcb.24.10.4557-4570.2004; RA Kurzer J.H., Argetsinger L.S., Zhou Y.J., Kouadio J.L., O'Shea J.J., RA Carter-Su C.; RT "Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation RT of JAK2 by SH2-B beta."; RL Mol. Cell. Biol. 24:4557-4570(2004). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [18] RP PHOSPHORYLATION AT TYR-904 AND TYR-939, AND MUTAGENESIS OF LYS-855; TYR-904 RP AND TYR-939. RX PubMed=18250158; DOI=10.1128/mcb.01789-07; RA Cheng H., Ross J.A., Frost J.A., Kirken R.A.; RT "Phosphorylation of human Jak3 at tyrosines 904 and 939 positively RT regulates its activity."; RL Mol. Cell. Biol. 28:2271-2282(2008). RN [19] RP REVIEW ON FUNCTION. RX PubMed=19290934; DOI=10.1111/j.1600-065x.2008.00754.x; RA Ghoreschi K., Laurence A., O'Shea J.J.; RT "Janus kinases in immune cell signaling."; RL Immunol. Rev. 228:273-287(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [22] RP FUNCTION IN IL15 SIGNALING PATHWAY. RX PubMed=20440074; DOI=10.1172/jci41344; RA Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S., RA Dusanter-Fourt I., Verkarre V., Mention J.J., Rahmi G., Kiyono H., RA Butz E.A., Brousse N., Cellier C., Cerf-Bensussan N., Meresse B.; RT "IL-15 triggers an antiapoptotic pathway in human intraepithelial RT lymphocytes that is a potential new target in celiac disease-associated RT inflammation and lymphomagenesis."; RL J. Clin. Invest. 120:2131-2143(2010). RN [23] RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 814-1103 IN COMPLEX WITH RP STAUROSPORINE ANALOG AFN941, AND PHOSPHORYLATION AT TYR-980 AND TYR-981. RX PubMed=15831699; DOI=10.1182/blood-2005-02-0707; RA Boggon T.J., Li Y., Manley P.W., Eck M.J.; RT "Crystal structure of the Jak3 kinase domain in complex with a RT staurosporine analog."; RL Blood 106:996-1002(2005). RN [24] RP VARIANT T(-)B(+)NK(-) SCID CYS-100. RX PubMed=7659163; DOI=10.1038/377065a0; RA Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F., RA Ugazio A.G., Johnston J.A., Candotti F., O'Shea J.J., Vezzoni P., RA Notarangelo L.D.; RT "Mutations of Jak-3 gene in patients with autosomal severe combined immune RT deficiency (SCID)."; RL Nature 377:65-68(1995). RN [25] RP VARIANTS T(-)B(+)NK(-) SCID GLY-481; 586-LEU--MET-592 DEL AND ARG-759. RX PubMed=9354668; RA Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F., RA Mella P., Fiorini M., Ugazio A.G., Badolato R., Notarangelo L.D., Bozzi F., RA Macchi P., Strina D., Vezzoni P., Blaese R.M., O'Shea J.J., Villa A.; RT "Structural and functional basis for JAK3-deficient severe combined RT immunodeficiency."; RL Blood 90:3996-4003(1997). RN [26] RP VARIANT T(-)B(+)NK(-) SCID TRP-582. RX PubMed=9753072; DOI=10.1111/j.1365-2141.1998.tb08990.x; RA Bozzi F., Lefranc G., Villa A., Badolato R., Schumacher R.F., Khalil G., RA Loiselet J., Bresciani S., O'Shea J.J., Vezzoni P., Notarangelo L.D., RA Candotti F.; RT "Molecular and biochemical characterization of JAK3 deficiency in a patient RT with severe combined immunodeficiency over 20 years after bone marrow RT transplantation: implications for treatment."; RL Br. J. Haematol. 102:1363-1366(1998). RN [27] RP VARIANTS T(-)B(+)NK(-) SCID ARG-151 AND SER-910, AND VARIANT ILE-722. RX PubMed=10982185; DOI=10.1007/s004390051012; RA Schumacher R.F., Mella P., Badolato R., Fiorini M., Savoldi G., Giliani S., RA Villa A., Candotti F., Tampalini A., O'Shea J.J., Notarangelo L.D.; RT "Complete genomic organization of the human JAK3 gene and mutation analysis RT in severe combined immunodeficiency by single-strand conformation RT polymorphism."; RL Hum. Genet. 106:73-79(2000). RN [28] RP VARIANTS T(-)B(+)NK(-) SCID ALA-58 DEL; GLU-169 AND SER-589, AND VARIANT RP ILE-722. RX PubMed=14615376; DOI=10.1182/blood-2003-06-2104; RA Roberts J.L., Lengi A., Brown S.M., Chen M., Zhou Y.-J., O'Shea J.J., RA Buckley R.H.; RT "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular RT analyses of 10 patients and outcomes of stem cell transplantation."; RL Blood 103:2009-2018(2004). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-12; HIS-40; THR-132; ARG-151; VAL-521; RP PRO-527; PHE-688 AND ILE-722. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine kinase involved in various processes CC such as cell growth, development, or differentiation. Mediates CC essential signaling events in both innate and adaptive immunity and CC plays a crucial role in hematopoiesis during T-cells development. In CC the cytoplasm, plays a pivotal role in signal transduction via its CC association with type I receptors sharing the common subunit gamma such CC as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to CC cell surface receptors, phosphorylates specific tyrosine residues on CC the cytoplasmic tails of the receptor, creating docking sites for STATs CC proteins. Subsequently, phosphorylates the STATs proteins once they are CC recruited to the receptor. Phosphorylated STATs then form homodimer or CC heterodimers and translocate to the nucleus to activate gene CC transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 CC molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits CC inducing the tyrosine phosphorylation of both receptor subunits on CC their cytoplasmic domain. Then, STAT5A and STAT5B are recruited, CC phosphorylated and activated by JAK1 and JAK3. Once activated, CC dimerized STAT5 translocates to the nucleus and promotes the CC transcription of specific target genes in a cytokine-specific fashion. CC {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:20440074, CC ECO:0000269|PubMed:7662955, ECO:0000269|PubMed:8022485}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Interacts with STAM2 and MYO18A (PubMed:10899310). Interacts CC with SHB (PubMed:12200137). Interacts with CD69 (By similarity). CC {ECO:0000250|UniProtKB:Q62137, ECO:0000269|PubMed:10899310, CC ECO:0000269|PubMed:12200137, ECO:0000269|PubMed:15831699}. CC -!- INTERACTION: CC P52333; Q969H0: FBXW7; NbExp=5; IntAct=EBI-518246, EBI-359574; CC P52333; Q07666: KHDRBS1; NbExp=2; IntAct=EBI-518246, EBI-1364; CC P52333; Q9UNF1: MAGED2; NbExp=5; IntAct=EBI-518246, EBI-725832; CC P52333; P55209: NAP1L1; NbExp=4; IntAct=EBI-518246, EBI-356392; CC P52333; Q13485: SMAD4; NbExp=3; IntAct=EBI-518246, EBI-347263; CC P52333; P51532: SMARCA4; NbExp=5; IntAct=EBI-518246, EBI-302489; CC -!- SUBCELLULAR LOCATION: Endomembrane system {ECO:0000250}; Peripheral CC membrane protein {ECO:0000250}. Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=2; Synonyms=JAK3S, Spleen-JAK3; CC IsoId=P52333-1; Sequence=Displayed; CC Name=1; Synonyms=JAK3B, Breast-JAK3; CC IsoId=P52333-2; Sequence=VSP_004989; CC Name=3; CC IsoId=P52333-4; Sequence=VSP_054165, VSP_054166; CC -!- TISSUE SPECIFICITY: In NK cells and an NK-like cell line but not in CC resting T-cells or in other tissues. The S-form is more commonly seen CC in hematopoietic lines, whereas the B-form is detected in cells both of CC hematopoietic and epithelial origins. {ECO:0000269|PubMed:7535338}. CC -!- DOMAIN: Possesses two phosphotransferase domains. The second one CC probably contains the catalytic domain (By similarity), while the CC presence of slight differences suggest a different role for domain 1. CC {ECO:0000250, ECO:0000269|PubMed:12351625}. CC -!- PTM: Tyrosine phosphorylated in response to IL-2 and IL-4. CC Dephosphorylation of Tyr-980 and Tyr-981 by PTPN2 negatively regulates CC cytokine-mediated signaling (Probable). {ECO:0000305|PubMed:11909529, CC ECO:0000305|PubMed:15121872, ECO:0000305|PubMed:15831699, CC ECO:0000305|PubMed:18250158}. CC -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-cell- CC negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) CC [MIM:600802]: A form of severe combined immunodeficiency (SCID), a CC genetically and clinically heterogeneous group of rare congenital CC disorders characterized by impairment of both humoral and cell-mediated CC immunity, leukopenia, and low or absent antibody levels. Patients CC present in infancy recurrent, persistent infections by opportunistic CC organisms. The common characteristic of all types of SCID is absence of CC T-cell-mediated cellular immunity due to a defect in T-cell CC development. {ECO:0000269|PubMed:10982185, ECO:0000269|PubMed:14615376, CC ECO:0000269|PubMed:7659163, ECO:0000269|PubMed:9354668, CC ECO:0000269|PubMed:9753072}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 1]: May be inactive as it lacks some part of CC the kinase domain. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. JAK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC50227.1; Type=Miscellaneous discrepancy; Note=Wrong choice of CDS. Was erroneously described as an isoform JAK3M while it is a fragmentary mRNA of INSL3.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41032/JAK3"; CC -!- WEB RESOURCE: Name=JAK3base; Note=JAK3 mutation db; CC URL="https://databases.lovd.nl/shared/genes/JAK3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U09607; AAA19626.1; -; mRNA. DR EMBL; U31601; AAC50226.1; -; mRNA. DR EMBL; U31602; AAC50227.1; ALT_SEQ; mRNA. DR EMBL; U70065; AAC50950.1; -; Genomic_DNA. DR EMBL; AF513860; AAM44860.1; -; Genomic_DNA. DR EMBL; AC007201; AAD22741.1; -; Genomic_DNA. DR EMBL; CH471106; EAW84639.1; -; Genomic_DNA. DR EMBL; BC028068; AAH28068.1; -; mRNA. DR EMBL; U57096; AAC50542.1; -; mRNA. DR CCDS; CCDS12366.1; -. [P52333-1] DR PIR; A55747; A55747. DR RefSeq; NP_000206.2; NM_000215.3. [P52333-1] DR RefSeq; NP_001427368.1; NM_001440439.1. [P52333-1] DR PDB; 1YVJ; X-ray; 2.55 A; A=814-1103. DR PDB; 3LXK; X-ray; 2.00 A; A=806-1124. DR PDB; 3LXL; X-ray; 1.74 A; A=806-1124. DR PDB; 3PJC; X-ray; 2.20 A; A=812-1124. DR PDB; 3ZC6; X-ray; 2.42 A; A/B/C/D=813-1100. DR PDB; 3ZEP; X-ray; 2.35 A; A/B/C/D=813-1047, A/B/C/D=813-1100. DR PDB; 4HVD; X-ray; 1.85 A; A=811-1124. DR PDB; 4HVG; X-ray; 2.75 A; A=811-1124. DR PDB; 4HVH; X-ray; 2.30 A; A=811-1124. DR PDB; 4HVI; X-ray; 2.40 A; A=811-1124. DR PDB; 4I6Q; X-ray; 1.85 A; A=811-1124. DR PDB; 4QPS; X-ray; 1.80 A; A/C=811-1103. DR PDB; 4QT1; X-ray; 2.40 A; A=811-1124. DR PDB; 4RIO; X-ray; 2.69 A; A=810-1100. DR PDB; 4V0G; X-ray; 3.00 A; A/B=816-1098. DR PDB; 4Z16; X-ray; 2.90 A; A/B/C/D=811-1124. DR PDB; 5LWM; X-ray; 1.55 A; A=812-1103. DR PDB; 5LWN; X-ray; 1.60 A; A=812-1103. DR PDB; 5TOZ; X-ray; 1.98 A; A=812-1124. DR PDB; 5TTS; X-ray; 2.34 A; A=812-1124. DR PDB; 5TTU; X-ray; 1.72 A; A=812-1124. DR PDB; 5TTV; X-ray; 1.93 A; A=812-1124. DR PDB; 5VO6; X-ray; 2.65 A; A=812-1100. DR PDB; 5W86; X-ray; 2.61 A; A/B/C/D=814-1100. DR PDB; 5WFJ; X-ray; 2.48 A; A=810-1100. DR PDB; 6AAK; X-ray; 2.67 A; A/B/C/D=814-1100. DR PDB; 6DA4; X-ray; 2.90 A; A=812-1124. DR PDB; 6DB3; X-ray; 1.97 A; A=812-1124. DR PDB; 6DB4; X-ray; 1.66 A; A=812-1124. DR PDB; 6DUD; X-ray; 1.66 A; A=812-1124. DR PDB; 6GL9; X-ray; 1.70 A; A/B=812-1103. DR PDB; 6GLA; X-ray; 1.92 A; A/B=812-1103. DR PDB; 6GLB; X-ray; 2.00 A; A/B=812-1103. DR PDB; 6HZV; X-ray; 2.46 A; A/B/C/D=815-1099. DR PDB; 6NY4; X-ray; 2.33 A; A=810-1100. DR PDB; 7APF; X-ray; 1.95 A; A/B=812-1103. DR PDB; 7APG; X-ray; 2.40 A; A/B/C/D=812-1103. DR PDB; 7C3N; X-ray; 1.98 A; A=812-1124. DR PDB; 7Q6H; X-ray; 1.75 A; AAA=806-1124. DR PDB; 7UYV; X-ray; 2.15 A; A/B/C/D=810-1100. DR PDB; 8EXM; X-ray; 2.35 A; D=973-988. DR PDB; 9R5Z; X-ray; 1.80 A; A/B=812-1103. DR PDBsum; 1YVJ; -. DR PDBsum; 3LXK; -. DR PDBsum; 3LXL; -. DR PDBsum; 3PJC; -. DR PDBsum; 3ZC6; -. DR PDBsum; 3ZEP; -. DR PDBsum; 4HVD; -. DR PDBsum; 4HVG; -. DR PDBsum; 4HVH; -. DR PDBsum; 4HVI; -. DR PDBsum; 4I6Q; -. DR PDBsum; 4QPS; -. DR PDBsum; 4QT1; -. DR PDBsum; 4RIO; -. DR PDBsum; 4V0G; -. DR PDBsum; 4Z16; -. DR PDBsum; 5LWM; -. DR PDBsum; 5LWN; -. DR PDBsum; 5TOZ; -. DR PDBsum; 5TTS; -. DR PDBsum; 5TTU; -. DR PDBsum; 5TTV; -. DR PDBsum; 5VO6; -. DR PDBsum; 5W86; -. DR PDBsum; 5WFJ; -. DR PDBsum; 6AAK; -. DR PDBsum; 6DA4; -. DR PDBsum; 6DB3; -. DR PDBsum; 6DB4; -. DR PDBsum; 6DUD; -. DR PDBsum; 6GL9; -. DR PDBsum; 6GLA; -. DR PDBsum; 6GLB; -. DR PDBsum; 6HZV; -. DR PDBsum; 6NY4; -. DR PDBsum; 7APF; -. DR PDBsum; 7APG; -. DR PDBsum; 7C3N; -. DR PDBsum; 7Q6H; -. DR PDBsum; 7UYV; -. DR PDBsum; 8EXM; -. DR PDBsum; 9R5Z; -. DR AlphaFoldDB; P52333; -. DR SMR; P52333; -. DR BioGRID; 109921; 125. DR CORUM; P52333; -. DR DIP; DIP-274N; -. DR FunCoup; P52333; 855. DR IntAct; P52333; 97. DR MINT; P52333; -. DR STRING; 9606.ENSP00000432511; -. DR BindingDB; P52333; -. DR ChEMBL; CHEMBL2148; -. DR DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one. DR DrugBank; DB14973; Abrocitinib. DR DrugBank; DB11817; Baricitinib. DR DrugBank; DB15499; Cerdulatinib. DR DrugBank; DB12566; Decernotinib. DR DrugBank; DB16133; Delgocitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16191; Ifidancitinib. DR DrugBank; DB11763; Momelotinib. DR DrugBank; DB11697; Pacritinib. DR DrugBank; DB11708; Peficitinib. DR DrugBank; DB06321; R-348. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB08877; Ruxolitinib. DR DrugBank; DB08895; Tofacitinib. DR DrugBank; DB15035; Zanubrutinib. DR DrugBank; DB17064; ZM-39923. DR DrugCentral; P52333; -. DR GuidetoPHARMACOLOGY; 2049; -. DR GlyGen; P52333; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P52333; -. DR PhosphoSitePlus; P52333; -. DR BioMuta; JAK3; -. DR DMDM; 50403745; -. DR CPTAC; CPTAC-2905; -. DR CPTAC; CPTAC-2906; -. DR jPOST; P52333; -. DR MassIVE; P52333; -. DR PaxDb; 9606-ENSP00000391676; -. DR PeptideAtlas; P52333; -. DR ProteomicsDB; 56482; -. [P52333-1] DR ProteomicsDB; 56483; -. [P52333-2] DR ProteomicsDB; 71591; -. DR Antibodypedia; 35352; 492 antibodies from 38 providers. DR DNASU; 3718; -. DR Ensembl; ENST00000458235.7; ENSP00000391676.1; ENSG00000105639.21. [P52333-1] DR Ensembl; ENST00000527670.5; ENSP00000432511.1; ENSG00000105639.21. [P52333-1] DR Ensembl; ENST00000534444.1; ENSP00000436421.1; ENSG00000105639.21. [P52333-2] DR GeneID; 3718; -. DR KEGG; hsa:3718; -. DR MANE-Select; ENST00000458235.7; ENSP00000391676.1; NM_000215.4; NP_000206.2. DR UCSC; uc002nhn.5; human. [P52333-1] DR AGR; HGNC:6193; -. DR CIViC; 3718; 3 evidence items across 8 molecular profiles. DR ClinPGx; PA29990; -. DR CTD; 3718; -. DR DisGeNET; 3718; -. DR GeneCards; JAK3; -. DR HGNC; HGNC:6193; JAK3. DR HPA; ENSG00000105639; Tissue enhanced (lymphoid). DR MalaCards; JAK3; -. DR MIM; 600173; gene. DR MIM; 600802; phenotype. DR OpenTargets; ENSG00000105639; -. DR Orphanet; 35078; T-B+ severe combined immunodeficiency due to JAK3 deficiency. DR VEuPathDB; HostDB:ENSG00000105639; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161827; -. DR HOGENOM; CLU_008155_1_0_1; -. DR InParanoid; P52333; -. DR OMA; MENQCHG; -. DR OrthoDB; 1915767at2759; -. DR PAN-GO; P52333; 10 GO annotations based on evolutionary models. DR PhylomeDB; P52333; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P52333; -. DR Reactome; R-HSA-1266695; Interleukin-7 signaling. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-8854691; Interleukin-20 family signaling. DR Reactome; R-HSA-8983432; Interleukin-15 signaling. DR Reactome; R-HSA-8985947; Interleukin-9 signaling. DR Reactome; R-HSA-9020558; Interleukin-2 signaling. DR Reactome; R-HSA-9020958; Interleukin-21 signaling. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR SignaLink; P52333; -. DR SIGNOR; P52333; -. DR Agora; ENSG00000105639; -. DR BioGRID-ORCS; 3718; 15 hits in 1191 CRISPR screens. DR EvolutionaryTrace; P52333; -. DR GeneWiki; Janus_kinase_3; -. DR GenomeRNAi; 3718; -. DR Pharos; P52333; Tclin. DR PRO; PR:P52333; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P52333; protein. DR Bgee; ENSG00000105639; Expressed in granulocyte and 150 other cell types or tissues. DR ExpressionAtlas; P52333; baseline and differential. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IC:UniProt. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0005768; C:endosome; TAS:Reactome. DR GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProt. DR GO; GO:0019897; C:extrinsic component of plasma membrane; IC:UniProt. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005131; F:growth hormone receptor binding; IBA:GO_Central. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProt. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IBA:GO_Central. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; ISS:BHF-UCL. DR GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0035723; P:interleukin-15-mediated signaling pathway; IDA:UniProt. DR GO; GO:0038110; P:interleukin-2-mediated signaling pathway; IDA:UniProt. DR GO; GO:0035771; P:interleukin-4-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0038111; P:interleukin-7-mediated signaling pathway; IDA:UniProt. DR GO; GO:0038113; P:interleukin-9-mediated signaling pathway; IDA:UniProt. DR GO; GO:0035556; P:intracellular signal transduction; ISS:BHF-UCL. DR GO; GO:0002731; P:negative regulation of dendritic cell cytokine production; ISS:BHF-UCL. DR GO; GO:0010561; P:negative regulation of glycoprotein biosynthetic process; ISS:BHF-UCL. DR GO; GO:0032693; P:negative regulation of interleukin-10 production; ISS:BHF-UCL. DR GO; GO:0032695; P:negative regulation of interleukin-12 production; ISS:BHF-UCL. DR GO; GO:0050868; P:negative regulation of T cell activation; ISS:BHF-UCL. DR GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; ISS:BHF-UCL. DR GO; GO:2000329; P:negative regulation of T-helper 17 cell lineage commitment; IDA:UniProt. DR GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0046425; P:regulation of receptor signaling pathway via JAK-STAT; TAS:UniProtKB. DR GO; GO:0070232; P:regulation of T cell apoptotic process; ISS:BHF-UCL. DR GO; GO:0070672; P:response to interleukin-15; TAS:BHF-UCL. DR GO; GO:0070669; P:response to interleukin-2; TAS:BHF-UCL. DR GO; GO:0070670; P:response to interleukin-4; IDA:BHF-UCL. DR GO; GO:0071104; P:response to interleukin-9; TAS:BHF-UCL. DR GO; GO:0043029; P:T cell homeostasis; ISS:BHF-UCL. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; TAS:UniProtKB. DR CDD; cd14208; PTK_Jak3_rpt1; 1. DR CDD; cd05081; PTKc_Jak3_rpt2; 1. DR CDD; cd10380; SH2_Jak3; 1. DR FunFam; 1.10.510.10:FF:000110; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000084; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000135; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000073; Tyrosine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000114; Tyrosine-protein kinase JAK2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR019749; Band_41_domain. DR InterPro; IPR000299; FERM_domain. DR InterPro; IPR041155; FERM_F1. DR InterPro; IPR041046; FERM_F2. DR InterPro; IPR051286; JAK. DR InterPro; IPR041381; JAK1-3/TYK2_PHL_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2. DR InterPro; IPR020775; Tyr_kinase_non-rcpt_Jak3. DR PANTHER; PTHR45807; TYROSINE-PROTEIN KINASE HOPSCOTCH; 1. DR PANTHER; PTHR45807:SF3; TYROSINE-PROTEIN KINASE JAK3; 1. DR Pfam; PF18379; FERM_F1; 1. DR Pfam; PF18377; FERM_F2; 1. DR Pfam; PF17887; Jak1_Phl; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 2. DR Pfam; PF21990; SH2_1; 1. DR PIRSF; PIRSF000636; TyrPK_Jak; 1. DR PRINTS; PR01823; JANUSKINASE. DR PRINTS; PR01826; JANUSKINASE3. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00295; B41; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00219; TyrKc; 2. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR SUPFAM; SSF55550; SH2 domain; 1. DR PROSITE; PS50057; FERM_3; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; ATP-binding; KW Cytoplasm; Disease variant; Immunity; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; SCID; SH2 domain; Transferase; KW Tyrosine-protein kinase. FT CHAIN 1..1124 FT /note="Tyrosine-protein kinase JAK3" FT /id="PRO_0000088115" FT DOMAIN 24..356 FT /note="FERM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00084" FT DOMAIN 375..475 FT /note="SH2; atypical" FT DOMAIN 521..781 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 822..1111 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..223 FT /note="Interaction with cytokine/interferon/growth hormone FT receptors" FT /evidence="ECO:0000250" FT ACT_SITE 949 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 828..836 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 855 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 17 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62137" FT MOD_RES 785 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15121872" FT MOD_RES 904 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:18250158" FT MOD_RES 939 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:18250158" FT MOD_RES 980 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15831699" FT MOD_RES 981 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15831699" FT VAR_SEQ 597..619 FT /note="TMVQEFVHLGAIDMYLRKRGHLV -> ESPPPTHPTPASPKSRLFFPPLF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_054165" FT VAR_SEQ 620..1124 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_054166" FT VAR_SEQ 1071..1124 FT /note="HELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLS FT FS -> SAAGLASVSQSVDWAGVSGKPAGA (in isoform 1)" FT /evidence="ECO:0000303|PubMed:7559633" FT /id="VSP_004989" FT VARIANT 12 FT /note="P -> L (in dbSNP:rs56061056)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041722" FT VARIANT 40 FT /note="R -> H (in dbSNP:rs56384680)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041723" FT VARIANT 58 FT /note="Missing (in T(-)B(+)NK(-) SCID)" FT /evidence="ECO:0000269|PubMed:14615376" FT /id="VAR_019337" FT VARIANT 100 FT /note="Y -> C (in T(-)B(+)NK(-) SCID; dbSNP:rs137852624)" FT /evidence="ECO:0000269|PubMed:7659163" FT /id="VAR_006284" FT VARIANT 132 FT /note="P -> T (in dbSNP:rs3212723)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_019336" FT VARIANT 151 FT /note="P -> R (in T(-)B(+)NK(-) SCID; likely benign; FT dbSNP:rs55778349)" FT /evidence="ECO:0000269|PubMed:10982185, FT ECO:0000269|PubMed:17344846" FT /id="VAR_010492" FT VARIANT 169 FT /note="D -> E (in T(-)B(+)NK(-) SCID; dbSNP:rs147181709)" FT /evidence="ECO:0000269|PubMed:14615376" FT /id="VAR_019338" FT VARIANT 481 FT /note="E -> G (in T(-)B(+)NK(-) SCID)" FT /evidence="ECO:0000269|PubMed:9354668" FT /id="VAR_010493" FT VARIANT 521 FT /note="L -> V (in dbSNP:rs55666418)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041724" FT VARIANT 527 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041725" FT VARIANT 582 FT /note="R -> W (in T(-)B(+)NK(-) SCID; dbSNP:rs193922361)" FT /evidence="ECO:0000269|PubMed:9753072" FT /id="VAR_010494" FT VARIANT 586..592 FT /note="Missing (in T(-)B(+)NK(-) SCID; lack of FT phosphorylation in response to cytokine stimulation)" FT /evidence="ECO:0000269|PubMed:9354668" FT /id="VAR_010495" FT VARIANT 589 FT /note="G -> S (in T(-)B(+)NK(-) SCID; dbSNP:rs886039394)" FT /evidence="ECO:0000269|PubMed:14615376" FT /id="VAR_019339" FT VARIANT 688 FT /note="I -> F (in dbSNP:rs35785705)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041726" FT VARIANT 722 FT /note="V -> I (in dbSNP:rs3213409)" FT /evidence="ECO:0000269|PubMed:10982185, FT ECO:0000269|PubMed:14615376, ECO:0000269|PubMed:17344846, FT ECO:0000269|Ref.4" FT /id="VAR_010496" FT VARIANT 759 FT /note="C -> R (in T(-)B(+)NK(-) SCID; constitutive FT phosphorylation)" FT /evidence="ECO:0000269|PubMed:9354668" FT /id="VAR_010497" FT VARIANT 910 FT /note="L -> S (in T(-)B(+)NK(-) SCID)" FT /evidence="ECO:0000269|PubMed:10982185" FT /id="VAR_010498" FT MUTAGEN 785 FT /note="Y->F: Strong decrease of JAK3 phosphorylation." FT /evidence="ECO:0000269|PubMed:15121872" FT MUTAGEN 855 FT /note="K->A: More than 90% loss of STAT5a activation." FT /evidence="ECO:0000269|PubMed:18250158" FT MUTAGEN 904 FT /note="Y->F: About 40% loss of STAT5a activation." FT /evidence="ECO:0000269|PubMed:18250158" FT MUTAGEN 939 FT /note="Y->F: About 80% loss of STAT5a activation." FT /evidence="ECO:0000269|PubMed:18250158" FT CONFLICT 34 FT /note="G -> A (in Ref. 1; AAA19626)" FT /evidence="ECO:0000305" FT CONFLICT 45 FT /note="F -> S (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 103 FT /note="R -> RS (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 147 FT /note="Missing (in Ref. 8; AAC50542)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="T -> A (in Ref. 8; AAC50542)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="R -> A (in Ref. 1; AAA19626 and 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 222 FT /note="R -> P (in Ref. 1; AAA19626 and 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 271 FT /note="L -> F (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 287 FT /note="Missing (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 610 FT /note="M -> I (in Ref. 2; AAC50226)" FT /evidence="ECO:0000305" FT CONFLICT 845..846 FT /note="GD -> AH (in Ref. 1; AAA19626)" FT /evidence="ECO:0000305" FT CONFLICT 895..897 FT /note="RQS -> EPE (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 896..897 FT /note="QS -> PE (in Ref. 1; AAA19626)" FT /evidence="ECO:0000305" FT STRAND 816..818 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 819..821 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 822..830 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 832..841 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 845..847 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 849..859 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 862..877 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 886..891 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 893..896 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 898..903 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 910..917 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 918..920 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 923..942 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 952..954 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 955..959 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 962..965 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 968..970 FT /evidence="ECO:0007829|PDB:3LXL" FT STRAND 979..982 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 991..993 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 996..1001 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 1003..1005 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1006..1021 FT /evidence="ECO:0007829|PDB:5LWM" FT TURN 1022..1024 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1026..1028 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1030..1037 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 1042..1044 FT /evidence="ECO:0007829|PDB:4QPS" FT HELIX 1046..1055 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1068..1077 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1082..1084 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1088..1102 FT /evidence="ECO:0007829|PDB:5LWM" SQ SEQUENCE 1124 AA; 125099 MW; 895D8563439B2B7C CRC64; MAPPSEETPL IPQRSCSLLS TEAGALHVLL PARGPGPPQR LSFSFGDHLA EDLCVQAAKA SGILPVYHSL FALATEDLSC WFPPSHIFSV EDASTQVLLY RIRFYFPNWF GLEKCHRFGL RKDLASAILD LPVLEHLFAQ HRSDLVSGRL PVGLSLKEQG ECLSLAVLDL ARMAREQAQR PGELLKTVSY KACLPPSLRD LIQGLSFVTR RRIRRTVRRA LRRVAACQAD RHSLMAKYIM DLERLDPAGA AETFHVGLPG ALGGHDGLGL LRVAGDGGIA WTQGEQEVLQ PFCDFPEIVD ISIKQAPRVG PAGEHRLVTV TRTDNQILEA EFPGLPEALS FVALVDGYFR LTTDSQHFFC KEVAPPRLLE EVAEQCHGPI TLDFAINKLK TGGSRPGSYV LRRSPQDFDS FLLTVCVQNP LGPDYKGCLI RRSPTGTFLL VGLSRPHSSL RELLATCWDG GLHVDGVAVT LTSCCIPRPK EKSNLIVVQR GHSPPTSSLV QPQSQYQLSQ MTFHKIPADS LEWHENLGHG SFTKIYRGCR HEVVDGEARK TEVLLKVMDA KHKNCMESFL EAASLMSQVS YRHLVLLHGV CMAGDSTMVQ EFVHLGAIDM YLRKRGHLVP ASWKLQVVKQ LAYALNYLED KGLPHGNVSA RKVLLAREGA DGSPPFIKLS DPGVSPAVLS LEMLTDRIPW VAPECLREAQ TLSLEADKWG FGATVWEVFS GVTMPISALD PAKKLQFYED RQQLPAPKWT ELALLIQQCM AYEPVQRPSF RAVIRDLNSL ISSDYELLSD PTPGALAPRD GLWNGAQLYA CQDPTIFEER HLKYISQLGK GNFGSVELCR YDPLGDNTGA LVAVKQLQHS GPDQQRDFQR EIQILKALHS DFIVKYRGVS YGPGRQSLRL VMEYLPSGCL RDFLQRHRAR LDASRLLLYS SQICKGMEYL GSRRCVHRDL AARNILVESE AHVKIADFGL AKLLPLDKDY YVVREPGQSP IFWYAPESLS DNIFSRQSDV WSFGVVLYEL FTYCDKSCSP SAEFLRMMGC ERDVPALCRL LELLEEGQRL PAPPACPAEV HELMKLCWAP SPQDRPSFSA LGPQLDMLWS GSRGCETHAF TAHPEGKHHS LSFS // ID JUPI2_HUMAN Reviewed; 190 AA. AC Q9H910; B1AJY2; B4DLH4; Q6EIC7; DT 19-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 172. DE RecName: Full=Jupiter microtubule associated homolog 2 {ECO:0000312|HGNC:HGNC:14137}; DE AltName: Full=Hematological and neurological expressed 1-like protein {ECO:0000303|PubMed:15094197}; DE Short=HN1-like protein; GN Name=JPT2 {ECO:0000312|HGNC:HGNC:14137}; GN Synonyms=C16orf34, HN1L {ECO:0000303|PubMed:15094197}; ORFNames=L11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Brain, and Liver; RX PubMed=15094197; DOI=10.1016/j.gene.2004.02.025; RA Zhou G., Wang J., Zhang Y., Zhong C., Ni J., Wang L., Guo J., Zhang K., RA Yu L., Zhao S.; RT "Cloning, expression and subcellular localization of HN1 and HN1L genes, as RT well as characterization of their orthologs, defining an evolutionarily RT conserved gene family."; RL Gene 331:115-123(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND SUBCELLULAR RP LOCATION. RX PubMed=15334068; DOI=10.1038/sj.onc.1207921; RA Petroziello J., Yamane A., Westendorf L., Thompson M., McDonagh C., RA Cerveny C., Law C.-L., Wahl A., Carter P.; RT "Suppression subtractive hybridization and expression profiling identifies RT a unique set of genes overexpressed in non-small-cell lung cancer."; RL Oncogene 23:7734-7745(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Teratocarcinoma, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11157797; DOI=10.1093/hmg/10.4.339; RA Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K., Tufarelli C., RA Kearney L., Buckle V.J., Doggett N.A., Flint J., Higgs D.R.; RT "Sequence, structure and pathology of the fully annotated terminal 2 Mb of RT the short arm of human chromosome 16."; RL Hum. Mol. Genet. 10:339-352(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Skin, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17924679; DOI=10.1021/pr070152u; RA Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; RT "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells RT and high confident phosphopeptide identification by cross-validation of RT MS/MS and MS/MS/MS spectra."; RL J. Proteome Res. 6:4150-4162(2007). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30; THR-35; SER-97 AND RP SER-144, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-69; SER-97; SER-132 RP AND SER-144, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [18] RP FUNCTION, FUNCTION (MICROBIAL INFECTION), SUBUNIT, AND INTERACTION WITH RP TPCN1. RX PubMed=33758061; DOI=10.1126/scisignal.abd5605; RA Gunaratne G.S., Brailoiu E., He S., Unterwald E.M., Patel S., Slama J.T., RA Walseth T.F., Marchant J.S.; RT "Essential requirement for JPT2 in NAADP-evoked Ca2+ signaling."; RL Sci. Signal. 14:0-0(2021). RN [19] RP FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=33758062; DOI=10.1126/scisignal.abd5647; RA Roggenkamp H.G., Khansahib I., Hernandez C.L.C., Zhang Y., Lodygin D., RA Krueger A., Gu F., Moeckl F., Loehndorf A., Wolters V., Woike D., RA Rosche A., Bauche A., Schetelig D., Werner R., Schlueter H., Failla A.V., RA Meier C., Fliegert R., Walseth T.F., Fluegel A., Diercks B.P., Guse A.H.; RT "HN1L/JPT2: A signaling protein that connects NAADP generation to Ca2+ RT microdomain formation."; RL Sci. Signal. 14:0-0(2021). CC -!- FUNCTION: Nicotinic acid adenine dinucleotide phosphate (NAADP) binding CC protein required for NAADP-evoked intracellular calcium release CC (PubMed:33758061, PubMed:33758062). Confers NAADP-sensitivity to the CC two pore channels (TPCs) complex (PubMed:33758061). Enables NAADP to CC activate Ca(2+) release from the endoplasmic reticulum through CC ryanodine receptors (PubMed:33758062). {ECO:0000269|PubMed:33758061, CC ECO:0000269|PubMed:33758062}. CC -!- FUNCTION: (Microbial infection) Involved in the endolysosomal CC trafficking of human coronavirus SARS-CoV-2. CC {ECO:0000269|PubMed:33758061}. CC -!- SUBUNIT: Monomer (PubMed:33758062). Dimer (PubMed:33758062). Interacts CC with TPCN1 (PubMed:33758061). {ECO:0000269|PubMed:33758061, CC ECO:0000269|PubMed:33758062}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15094197, CC ECO:0000269|PubMed:33758062}. Nucleus {ECO:0000269|PubMed:15094197}. CC Note=Colocalizes with type 1 ryanodine receptor (RYR1). CC {ECO:0000269|PubMed:33758062}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=HN1LA; CC IsoId=Q9H910-1; Sequence=Displayed; CC Name=2; Synonyms=HN1LB, HN1LC; CC IsoId=Q9H910-2; Sequence=VSP_014706; CC Name=3; CC IsoId=Q9H910-3; Sequence=VSP_057423; CC -!- TISSUE SPECIFICITY: Expressed in liver, kidney, prostate, testis and CC uterus. {ECO:0000269|PubMed:15094197}. CC -!- INDUCTION: Up-regulated in squamous cell carcinoma (SCC) adenocarcinoma CC (AC), adenosquamous cell carcinoma (ASCC), bronchioalveolar carcinoma CC (BAC), breast and uterus tumors. {ECO:0000269|PubMed:15334068}. CC -!- SIMILARITY: Belongs to the JUPITER family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY323831; AAP72616.1; -; Genomic_DNA. DR EMBL; AY323978; AAP83791.1; -; mRNA. DR EMBL; AY323979; AAP83792.1; -; mRNA. DR EMBL; AY598330; AAT06741.1; -; mRNA. DR EMBL; AK023154; BAB14434.1; -; mRNA. DR EMBL; AE006639; AAK61289.1; -; Genomic_DNA. DR EMBL; AK296998; BAG59536.1; -; mRNA. DR EMBL; AL031009; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL031710; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471112; EAW85635.1; -; Genomic_DNA. DR EMBL; CH471112; EAW85638.1; -; Genomic_DNA. DR EMBL; BC014438; AAH14438.1; -; mRNA. DR EMBL; BC060853; AAH60853.1; -; mRNA. DR CCDS; CCDS10441.1; -. [Q9H910-1] DR RefSeq; NP_001421594.1; NM_001434665.1. [Q9H910-3] DR RefSeq; NP_653171.1; NM_144570.3. [Q9H910-1] DR AlphaFoldDB; Q9H910; -. DR BioGRID; 124774; 60. DR FunCoup; Q9H910; 2606. DR IntAct; Q9H910; 16. DR MINT; Q9H910; -. DR STRING; 9606.ENSP00000248098; -. DR ChEMBL; CHEMBL4295946; -. DR TCDB; 8.A.242.1.1; the naadp-binding protein (jpt2) family. DR GlyGen; Q9H910; 11 sites, 2 O-linked glycans (10 sites). DR iPTMnet; Q9H910; -. DR MetOSite; Q9H910; -. DR PhosphoSitePlus; Q9H910; -. DR BioMuta; JPT2; -. DR jPOST; Q9H910; -. DR MassIVE; Q9H910; -. DR PaxDb; 9606-ENSP00000248098; -. DR PeptideAtlas; Q9H910; -. DR ProteomicsDB; 4534; -. DR ProteomicsDB; 81270; -. [Q9H910-1] DR ProteomicsDB; 81271; -. [Q9H910-2] DR Pumba; Q9H910; -. DR TopDownProteomics; Q9H910-1; -. [Q9H910-1] DR Antibodypedia; 23196; 79 antibodies from 14 providers. DR DNASU; 90861; -. DR Ensembl; ENST00000248098.8; ENSP00000248098.3; ENSG00000206053.14. [Q9H910-1] DR Ensembl; ENST00000382711.9; ENSP00000372158.5; ENSG00000206053.14. [Q9H910-2] DR Ensembl; ENST00000562684.5; ENSP00000457694.1; ENSG00000206053.14. [Q9H910-3] DR GeneID; 90861; -. DR KEGG; hsa:90861; -. DR MANE-Select; ENST00000248098.8; ENSP00000248098.3; NM_144570.3; NP_653171.1. DR UCSC; uc002cmg.4; human. [Q9H910-1] DR UCSC; uc010uvi.3; human. DR AGR; HGNC:14137; -. DR ClinPGx; PA162391043; -. DR CTD; 90861; -. DR DisGeNET; 90861; -. DR GeneCards; JPT2; -. DR HGNC; HGNC:14137; JPT2. DR HPA; ENSG00000206053; Tissue enhanced (brain). DR MIM; 619241; gene. DR OpenTargets; ENSG00000206053; -. DR VEuPathDB; HostDB:ENSG00000206053; -. DR eggNOG; ENOG502S1G7; Eukaryota. DR GeneTree; ENSGT00390000007652; -. DR HOGENOM; CLU_111612_0_0_1; -. DR InParanoid; Q9H910; -. DR OMA; RQFINPP; -. DR OrthoDB; 6367565at2759; -. DR PAN-GO; Q9H910; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9H910; -. DR PathwayCommons; Q9H910; -. DR SignaLink; Q9H910; -. DR Agora; ENSG00000206053; -. DR BioGRID-ORCS; 90861; 10 hits in 1144 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; HN1L; human. DR GeneWiki; HN1L; -. DR GenomeRNAi; 90861; -. DR Pharos; Q9H910; Tbio. DR PRO; PR:Q9H910; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q9H910; protein. DR Bgee; ENSG00000206053; Expressed in epithelium of bronchus and 199 other cell types or tissues. DR ExpressionAtlas; Q9H910; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0075509; P:endocytosis involved in viral entry into host cell; IDA:UniProtKB. DR GO; GO:0050848; P:regulation of calcium-mediated signaling; IMP:UniProtKB. DR InterPro; IPR033335; JUPITER. DR PANTHER; PTHR34930; GEO05313P1; 1. DR PANTHER; PTHR34930:SF5; JUPITER MICROTUBULE ASSOCIATED HOMOLOG 2; 1. DR Pfam; PF17054; JUPITER; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; Cytoplasm; Host-virus interaction; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..190 FT /note="Jupiter microtubule associated homolog 2" FT /id="PRO_0000054921" FT REGION 1..190 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 35..44 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 110..129 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 139..167 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 35 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 45 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 97 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17924679, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 132 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 144 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..17 FT /note="MFQVPDSEGGRAGSRAM -> M (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15094197" FT /id="VSP_014706" FT VAR_SEQ 14 FT /note="S -> SRKWQLLTGSLASTSPSLLSGQGPWAPLQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057423" SQ SEQUENCE 190 AA; 20063 MW; 9132F17687193192 CRC64; MFQVPDSEGG RAGSRAMKPP GGESSNLFGS PEEATPSSRP NRMASNIFGP TEEPQNIPKR TNPPGGKGSG IFDESTPVQT RQHLNPPGGK TSDIFGSPVT ATSRLAHPNK PKDHVFLCEG EEPKSDLKAA RSIPAGAEPG EKGSARKAGP AKEQEPMPTV DSHEPRLGPR PRSHNKVLNP PGGKSSISFY // ID KEAP1_HUMAN Reviewed; 624 AA. AC Q14145; B3KPD5; Q6LEP0; Q8WTX1; Q9BPY9; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2007, sequence version 2. DT 28-JAN-2026, entry version 235. DE RecName: Full=Kelch-like ECH-associated protein 1 {ECO:0000303|PubMed:14585973}; DE AltName: Full=Cytosolic inhibitor of Nrf2 {ECO:0000303|Ref.1}; DE Short=INrf2 {ECO:0000303|Ref.1}; DE AltName: Full=Kelch-like protein 19 {ECO:0000312|HGNC:HGNC:23177}; GN Name=KEAP1 {ECO:0000303|PubMed:14585973, ECO:0000312|HGNC:HGNC:23177}; GN Synonyms=INRF2 {ECO:0000303|Ref.1}, KIAA0132 {ECO:0000303|PubMed:8590280}, GN KLHL19 {ECO:0000312|HGNC:HGNC:23177}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]. RA Dhakshinamoorthy S., Jaiswal A.K.; RT "Human INrf2 gene structure and nucleotide sequence."; RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-349. RC TISSUE=Bone marrow; RX PubMed=8590280; DOI=10.1093/dnares/2.4.167; RA Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. IV. The RT coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of RT cDNA clones from human cell line KG-1."; RL DNA Res. 2:167-174(1995). RN [3] RP SEQUENCE REVISION. RA Ohara O., Nagase T., Kikuno R., Nomura N.; RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, Skin, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, MUTAGENESIS OF CYS-151; CYS-273 AND CYS-288, AND SUBCELLULAR RP LOCATION. RX PubMed=14585973; DOI=10.1128/mcb.23.22.8137-8151.2003; RA Zhang D.D., Hannink M.; RT "Distinct cysteine residues in Keap1 are required for Keap1-dependent RT ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive RT agents and oxidative stress."; RL Mol. Cell. Biol. 23:8137-8151(2003). RN [8] RP INTERACTION WITH NFE2L2 AND BPTF, FUNCTION, TISSUE SPECIFICITY, AND RP SUBCELLULAR LOCATION. RX PubMed=15379550; DOI=10.1021/bi0494166; RA Strachan G.D., Morgan K.L., Otis L.L., Caltagarone J., Gittis A., RA Bowser R., Jordan-Sciutto K.L.; RT "Fetal Alz-50 clone 1 interacts with the human orthologue of the Kelch-like RT Ech-associated protein."; RL Biochemistry 43:12113-12122(2004). RN [9] RP FUNCTION, INTERACTION WITH CUL3 AND RBX1, MUTAGENESIS OF 125-ILE--GLY-127 RP AND 162-TYR--ILE-164, AND UBIQUITINATION. RX PubMed=15572695; DOI=10.1128/mcb.24.24.10941-10953.2004; RA Zhang D.D., Lo S.-C., Cross J.V., Templeton D.J., Hannink M.; RT "Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent RT ubiquitin ligase complex."; RL Mol. Cell. Biol. 24:10941-10953(2004). RN [10] RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH CUL3 AND RBX1, UBIQUITINATION, RP ACTIVITY REGULATION, AND MUTAGENESIS OF CYS-151. RX PubMed=15983046; DOI=10.1074/jbc.m501279200; RA Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M.; RT "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, RT targets Keap1 for degradation by a proteasome-independent pathway."; RL J. Biol. Chem. 280:30091-30099(2005). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE BCR(KEAP1) COMPLEX, RP INTERACTION WITH NFE2L2, AND MUTAGENESIS OF 123-VAL--GLY-127 AND RP 161-MET-TYR-162. RX PubMed=15601839; DOI=10.1128/mcb.25.1.162-171.2005; RA Furukawa M., Xiong Y.; RT "BTB protein Keap1 targets antioxidant transcription factor Nrf2 for RT ubiquitination by the Cullin 3-Roc1 ligase."; RL Mol. Cell. Biol. 25:162-171(2005). RN [12] RP INTERACTION WITH PTMA, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-308 AND RP LEU-310. RX PubMed=15657435; DOI=10.1128/mcb.25.3.1089-1099.2005; RA Karapetian R.N., Evstafieva A.G., Abaeva I.S., Chichkova N.V., RA Filonov G.S., Rubtsov Y.P., Sukhacheva E.A., Melnikov S.V., Schneider U., RA Wanker E.E., Vartapetian A.B.; RT "Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications RT for expression of oxidative stress-protecting genes."; RL Mol. Cell. Biol. 25:1089-1099(2005). RN [13] RP FUNCTION, ACTIVITY REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151. RX PubMed=19489739; DOI=10.1042/bj20090471; RA Eggler A.L., Small E., Hannink M., Mesecar A.D.; RT "Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) RT activation are dependent on the partial molar volume at position 151 of RT Keap1."; RL Biochem. J. 422:171-180(2009). RN [14] RP FUNCTION, AND INTERACTION WITH NFE2L2. RX PubMed=16006525; DOI=10.1073/pnas.0502402102; RA Eggler A.L., Liu G., Pezzuto J.M., van Breemen R.B., Mesecar A.D.; RT "Modifying specific cysteines of the electrophile-sensing human Keap1 RT protein is insufficient to disrupt binding to the Nrf2 domain Neh2."; RL Proc. Natl. Acad. Sci. U.S.A. 102:10070-10075(2005). RN [15] RP INTERACTION WITH NFE2L1. RX PubMed=16687406; DOI=10.1074/jbc.m602802200; RA Wang W., Chan J.Y.; RT "Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal RT transmembrane domain. Inhibition of nuclear translocation and transacting RT function."; RL J. Biol. Chem. 281:19676-19687(2006). RN [16] RP INTERACTION WITH PGAM5, FUNCTION, ACTIVITY REGULATION, DOMAIN, AND RP MUTAGENESIS OF CYS-151; TYR-334; ARG-415; ARG-483 AND TYR-572. RX PubMed=17046835; DOI=10.1074/jbc.m606539200; RA Lo S.-C., Hannink M.; RT "PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox- RT regulated Keap1-dependent ubiquitin ligase complex."; RL J. Biol. Chem. 281:37893-37903(2006). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH CUL3. RX PubMed=17127771; DOI=10.1074/jbc.m607622200; RA Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., Sasi S., RA Dalton T.P., Anderson M.E., Chan J.Y., Morrow J.D., Freeman M.L.; RT "Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the RT association between Keap1 and Cullin3."; RL J. Biol. Chem. 282:2529-2537(2007). RN [18] RP FUNCTION, ACTIVITY REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151. RX PubMed=18251510; DOI=10.1021/tx700302s; RA Rachakonda G., Xiong Y., Sekhar K.R., Stamer S.L., Liebler D.C., RA Freeman M.L.; RT "Covalent modification at Cys151 dissociates the electrophile sensor Keap1 RT from the ubiquitin ligase CUL3."; RL Chem. Res. Toxicol. 21:705-710(2008). RN [19] RP INTERACTION WITH NFE2L2 AND PGAM5. RX PubMed=18387606; DOI=10.1016/j.yexcr.2008.02.014; RA Lo S.-C., Hannink M.; RT "PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to RT mitochondria."; RL Exp. Cell Res. 314:1789-1803(2008). RN [20] RP INTERACTION WITH ENC1, AND SUBCELLULAR LOCATION. RX PubMed=19424503; DOI=10.1371/journal.pone.0005492; RA Wang X.J., Zhang D.D.; RT "Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational RT level."; RL PLoS ONE 4:E5492-E5492(2009). RN [21] RP INTERACTION WITH SQSTM1, AND ACTIVITY REGULATION. RX PubMed=20495340; DOI=10.4161/auto.6.5.12189; RA Fan W., Tang Z., Chen D., Moughon D., Ding X., Chen S., Zhu M., Zhong Q.; RT "Keap1 facilitates p62-mediated ubiquitin aggregate clearance via RT autophagy."; RL Autophagy 6:614-621(2010). RN [22] RP FUNCTION, INTERACTION WITH SQSTM1, ACTIVITY REGULATION, SUBCELLULAR RP LOCATION, AND MUTAGENESIS OF ARG-380; ASN-382; ARG-415; HIS-436; ARG-483; RP TYR-525 AND TYR-572. RX PubMed=20452972; DOI=10.1074/jbc.m110.118976; RA Jain A., Lamark T., Sjoettem E., Larsen K.B., Awuh J.A., Oevervatn A., RA McMahon M., Hayes J.D., Johansen T.; RT "p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a RT positive feedback loop by inducing antioxidant response element-driven gene RT transcription."; RL J. Biol. Chem. 285:22576-22591(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [24] RP INTERACTION WITH SESN1 AND SESN2. RX PubMed=23274085; DOI=10.1016/j.cmet.2012.12.002; RA Bae S.H., Sung S.H., Oh S.Y., Lim J.M., Lee S.K., Park Y.N., Lee H.E., RA Kang D., Rhee S.G.; RT "Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation RT of Keap1 and prevent oxidative liver damage."; RL Cell Metab. 17:73-84(2013). RN [25] RP INTERACTION WITH MAP1LC3B. RX PubMed=24089205; DOI=10.1038/nature12606; RA Tang Z., Lin M.G., Stowe T.R., Chen S., Zhu M., Stearns T., Franco B., RA Zhong Q.; RT "Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar RT satellites."; RL Nature 502:254-257(2013). RN [26] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [27] RP INTERACTION WITH EBOLAVIRUS PROTEIN VP24 (MICROBIAL INFECTION). RX PubMed=24630991; DOI=10.1016/j.celrep.2014.01.043; RA Edwards M.R., Johnson B., Mire C.E., Xu W., Shabman R.S., Speller L.N., RA Leung D.W., Geisbert T.W., Amarasinghe G.K., Basler C.F.; RT "The Marburg virus VP24 protein interacts with Keap1 to activate the RT cytoprotective antioxidant response pathway."; RL Cell Rep. 6:1017-1025(2014). RN [28] RP FUNCTION. RX PubMed=28380357; DOI=10.1016/j.celrep.2017.03.030; RA Lee Y., Chou T.F., Pittman S.K., Keith A.L., Razani B., Weihl C.C.; RT "Keap1/cullin3 modulates p62/SQSTM1 activity via UBA domain RT ubiquitination."; RL Cell Rep. 19:188-202(2017). RN [29] RP FUNCTION, ALKYLATION AT CYS-151; CYS-257; CYS-273 AND CYS-288, ACTIVITY RP REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151. RX PubMed=29590092; DOI=10.1038/nature25986; RA Mills E.L., Ryan D.G., Prag H.A., Dikovskaya D., Menon D., Zaslona Z., RA Jedrychowski M.P., Costa A.S.H., Higgins M., Hams E., Szpyt J., RA Runtsch M.C., King M.S., McGouran J.F., Fischer R., Kessler B.M., RA McGettrick A.F., Hughes M.M., Carroll R.G., Booty L.M., Knatko E.V., RA Meakin P.J., Ashford M.L.J., Modis L.K., Brunori G., Sevin D.C., RA Fallon P.G., Caldwell S.T., Kunji E.R.S., Chouchani E.T., Frezza C., RA Dinkova-Kostova A.T., Hartley R.C., Murphy M.P., O'Neill L.A.; RT "Itaconate is an anti-inflammatory metabolite that activates Nrf2 via RT alkylation of KEAP1."; RL Nature 556:113-117(2018). RN [30] RP CROSS-LINK AT ARG-135 AND CYS-151, ACTIVITY REGULATION, DOMAIN, AND RP MUTAGENESIS OF ARG-15; ARG-135 AND CYS-151. RX PubMed=30323285; DOI=10.1038/s41586-018-0622-0; RA Bollong M.J., Lee G., Coukos J.S., Yun H., Zambaldo C., Chang J.W., RA Chin E.N., Ahmad I., Chatterjee A.K., Lairson L.L., Schultz P.G., RA Moellering R.E.; RT "A metabolite-derived protein modification integrates glycolysis with RT KEAP1-NRF2 signalling."; RL Nature 562:600-604(2018). RN [31] RP REVIEW. RX PubMed=28842501; DOI=10.1074/jbc.r117.800169; RA Suzuki T., Yamamoto M.; RT "Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 RT system during cellular stress."; RL J. Biol. Chem. 292:16817-16824(2017). RN [32] RP UBIQUITINATION. RX PubMed=31953436; DOI=10.1038/s41467-019-14190-2; RA Liu Y., Tao S., Liao L., Li Y., Li H., Li Z., Lin L., Wan X., Yang X., RA Chen L.; RT "TRIM25 promotes the cell survival and growth of hepatocellular carcinoma RT through targeting Keap1-Nrf2 pathway."; RL Nat. Commun. 11:348-348(2020). RN [33] RP FUNCTION, AND DEUBIQUITINATION BY USP25. RX PubMed=37339955; DOI=10.1038/s41467-023-39412-6; RA Cai C., Ma H., Peng J., Shen X., Zhen X., Yu C., Zhang P., Ji F., Wang J.; RT "USP25 regulates KEAP1-NRF2 anti-oxidation axis and its inactivation RT protects acetaminophen-induced liver injury in male mice."; RL Nat. Commun. 14:3648-3648(2023). RN [34] RP INTERACTION WITH PGCKA1, AND MUTAGENESIS OF LYS-615. RX PubMed=36882524; DOI=10.1038/s41388-023-02656-z; RA Huang S., Li J., Wu S., Zheng Z., Wang C., Li H., Zhao L., Zhang X., RA Huang H., Huang C., Xie Q.; RT "C4orf19 inhibits colorectal cancer cell proliferation by competitively RT binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis."; RL Oncogene 42:1333-1346(2023). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 321-609. RX PubMed=15583386; DOI=10.1107/s0907444904024825; RA Li X., Zhang D., Hannink M., Beamer L.J.; RT "Crystallization and initial crystallographic analysis of the Kelch domain RT from human Keap1."; RL Acta Crystallogr. D 60:2346-2348(2004). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 321-609. RX PubMed=16204884; DOI=10.1107/s0907444905022626; RA Beamer L.J., Li X., Bottoms C.A., Hannink M.; RT "Conserved solvent and side-chain interactions in the 1.35 Angstrom RT structure of the Kelch domain of Keap1."; RL Acta Crystallogr. D 61:1335-1342(2005). RN [37] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 321-609 IN COMPLEX WITH NFE2L2, RP SUBUNIT, AND MUTAGENESIS OF TYR-334; ARG-380; ASN-382; ARG-415; HIS-436; RP PHE-478; ARG-483; TYR-525 AND TYR-572. RX PubMed=16888629; DOI=10.1038/sj.emboj.7601243; RA Lo S.-C., Li X., Henzl M.T., Beamer L.J., Hannink M.; RT "Structure of the Keap1:Nrf2 interface provides mechanistic insight into RT Nrf2 signaling."; RL EMBO J. 25:3605-3617(2006). RN [38] {ECO:0007744|PDB:4CXI, ECO:0007744|PDB:4CXJ, ECO:0007744|PDB:4CXT} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 48-180, INTERACTION WITH CUL3, RP AND MUTAGENESIS OF CYS-151. RX PubMed=24896564; DOI=10.1371/journal.pone.0098896; RA Cleasby A., Yon J., Day P.J., Richardson C., Tickle I.J., Williams P.A., RA Callahan J.F., Carr R., Concha N., Kerns J.K., Qi H., Sweitzer T., Ward P., RA Davies T.G.; RT "Structure of the BTB domain of Keap1 and its interaction with the RT triterpenoid antagonist CDDO."; RL PLoS ONE 9:e98896-e98896(2014). RN [39] RP VARIANTS CYS-364 AND CYS-430, AND CHARACTERIZATION OF VARIANTS CYS-364 AND RP CYS-430. RX PubMed=16507366; DOI=10.1016/j.molcel.2006.01.013; RA Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., RA Kang M., Kobayashi A., Yokoyama S., Yamamoto M.; RT "Structural basis for defects of Keap1 activity provoked by its point RT mutations in lung cancer."; RL Mol. Cell 21:689-700(2006). RN [40] RP VARIANTS PHE-167; HIS-236; LEU-284; CYS-333 AND SER-350, AND RP CHARACTERIZATION OF VARIANTS HIS-236 AND CYS-333. RX PubMed=17020408; DOI=10.1371/journal.pmed.0030420; RA Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., RA Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., RA Biswal S.; RT "Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer."; RL PLoS Med. 3:1865-1876(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-23 AND VAL-522. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 CC ubiquitin ligase complex that regulates the response to oxidative CC stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed:14585973, CC PubMed:15379550, PubMed:15572695, PubMed:15601839, PubMed:15983046, CC PubMed:37339955). KEAP1 acts as a key sensor of oxidative and CC electrophilic stress: in normal conditions, the BCR(KEAP1) complex CC mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription CC factor regulating expression of many cytoprotective genes CC (PubMed:15601839, PubMed:16006525). In response to oxidative stress, CC different electrophile metabolites trigger non-enzymatic covalent CC modifications of highly reactive cysteine residues in KEAP1, leading to CC inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, CC promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II CC detoxifying enzymes (PubMed:16006525, PubMed:17127771, PubMed:18251510, CC PubMed:19489739, PubMed:29590092). In response to selective autophagy, CC KEAP1 is sequestered in inclusion bodies following its interaction with CC SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and CC activation of NFE2L2/NRF2 (PubMed:20452972). The BCR(KEAP1) complex CC also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 CC sequestering activity and degradation (PubMed:28380357). The BCR(KEAP1) CC complex also targets BPTF and PGAM5 for ubiquitination and degradation CC by the proteasome (PubMed:15379550, PubMed:17046835). CC {ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15379550, CC ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:16006525, CC ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, CC ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:28380357, CC ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:37339955}. CC -!- ACTIVITY REGULATION: Ubiquitin ligase activity of the BCR(KEAP1) CC complex is inhibited by oxidative stress and electrophile metabolites CC such as sulforaphane (PubMed:15983046, PubMed:17046835, CC PubMed:29590092, PubMed:30323285). Electrophile metabolites react with CC reactive cysteine residues in KEAP1 and trigger non-enzymatic covalent CC modifications of these cysteine residues, leading to inactivate the CC ubiquitin ligase activity of the BCR(KEAP1) complex (PubMed:17127771, CC PubMed:18251510, PubMed:19489739, PubMed:29590092, PubMed:30323285). CC Selective autophagy also inactivates the BCR(KEAP1) complex via CC interaction between KEAP1 and SQSTM1/p62, which sequesters the complex CC in inclusion bodies and promotes its degradation (PubMed:20452972, CC PubMed:20495340). {ECO:0000269|PubMed:15983046, CC ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, CC ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:20495340, CC ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285}. CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15379550, CC ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15983046}. CC -!- SUBUNIT: Component of the BCR(KEAP1) E3 ubiquitin ligase complex, at CC least composed of 2 molecules of CUL3, 2 molecules of KEAP1, and RBX1 CC (PubMed:15572695, PubMed:15601839, PubMed:15983046, PubMed:17127771, CC PubMed:18251510, PubMed:24896564). Interacts with NFE2L2/NRF2; the CC interaction is direct (PubMed:15379550, PubMed:15601839, CC PubMed:16006525, PubMed:16888629, PubMed:18387606). Forms a ternary CC complex with NFE2L2/NRF2 and PGAM5 (PubMed:17046835). Interacts with CC (phosphorylated) SQSTM1/p62; the interaction is direct and inactivates CC the BCR(KEAP1) complex by sequestering it in inclusion bodies, CC promoting its degradation (PubMed:20452972, PubMed:20495340). Interacts CC with NFE2L1 (PubMed:16687406). Interacts with BPTF and PTMA CC (PubMed:15657435). Interacts with MAP1LC3B (PubMed:24089205). Interacts CC indirectly with ENC1 (PubMed:19424503). Interacts with SESN1 and SESN2 CC (PubMed:23274085). Interacts with HSP90AA1 and HSP90AB1 CC (PubMed:26517842). Interacts with PGCKA1; this interaction prevents the CC ubiquitination of KEAP1 by TRIM25, thus protecting KEAP1 from CC degradation (PubMed:36882524). {ECO:0000269|PubMed:15379550, CC ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15657435, ECO:0000269|PubMed:15983046, CC ECO:0000269|PubMed:16006525, ECO:0000269|PubMed:16687406, CC ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835, CC ECO:0000269|PubMed:17127771, ECO:0000269|PubMed:18251510, CC ECO:0000269|PubMed:18387606, ECO:0000269|PubMed:19424503, CC ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:20495340, CC ECO:0000269|PubMed:23274085, ECO:0000269|PubMed:24089205, CC ECO:0000269|PubMed:24896564, ECO:0000269|PubMed:26517842, CC ECO:0000269|PubMed:36882524}. CC -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus protein VP24; CC this interaction activates transcription factor NFE2L2/NRF2 by blocking CC its interaction with KEAP1. {ECO:0000269|PubMed:24630991}. CC -!- INTERACTION: CC Q14145; Q5JTC6: AMER1; NbExp=2; IntAct=EBI-751001, EBI-6169747; CC Q14145; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-751001, EBI-11954519; CC Q14145; P45381: ASPA; NbExp=4; IntAct=EBI-751001, EBI-750475; CC Q14145; O14525-2: ASTN1; NbExp=4; IntAct=EBI-751001, EBI-21977454; CC Q14145; A9UGY9: ATG5; NbExp=3; IntAct=EBI-751001, EBI-10175276; CC Q14145; Q9H1Y0: ATG5; NbExp=3; IntAct=EBI-751001, EBI-1047414; CC Q14145; P15056: BRAF; NbExp=16; IntAct=EBI-751001, EBI-365980; CC Q14145; Q2NKX9: C2orf68; NbExp=3; IntAct=EBI-751001, EBI-11603468; CC Q14145; Q9BWT7: CARD10; NbExp=3; IntAct=EBI-751001, EBI-3866279; CC Q14145; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-751001, EBI-745269; CC Q14145; P02452: COL1A1; NbExp=3; IntAct=EBI-751001, EBI-982999; CC Q14145; P02458-1: COL2A1; NbExp=3; IntAct=EBI-751001, EBI-12375799; CC Q14145; P68400: CSNK2A1; NbExp=3; IntAct=EBI-751001, EBI-347804; CC Q14145; Q13618: CUL3; NbExp=5; IntAct=EBI-751001, EBI-456129; CC Q14145; Q9NX09: DDIT4; NbExp=3; IntAct=EBI-751001, EBI-715104; CC Q14145; Q9NY33: DPP3; NbExp=13; IntAct=EBI-751001, EBI-718333; CC Q14145; Q96JC9: EAF1; NbExp=3; IntAct=EBI-751001, EBI-769261; CC Q14145; Q6P6B1: ERICH5; NbExp=3; IntAct=EBI-751001, EBI-11343491; CC Q14145; P62495: ETF1; NbExp=8; IntAct=EBI-751001, EBI-750990; CC Q14145; Q6P1L5: FAM117B; NbExp=6; IntAct=EBI-751001, EBI-3893327; CC Q14145; Q14440: GPErik; NbExp=3; IntAct=EBI-751001, EBI-10232920; CC Q14145; Q8TDV0: GPR151; NbExp=3; IntAct=EBI-751001, EBI-11955647; CC Q14145; P28799: GRN; NbExp=3; IntAct=EBI-751001, EBI-747754; CC Q14145; B8Q183: GYPA; NbExp=4; IntAct=EBI-751001, EBI-10176190; CC Q14145; P02724: GYPA; NbExp=7; IntAct=EBI-751001, EBI-702665; CC Q14145; P05362: ICAM1; NbExp=3; IntAct=EBI-751001, EBI-1035358; CC Q14145; Q9BYX4: IFIH1; NbExp=3; IntAct=EBI-751001, EBI-6115771; CC Q14145; O14920: IKBKB; NbExp=6; IntAct=EBI-751001, EBI-81266; CC Q14145; Q4KMZ1: IQCC; NbExp=3; IntAct=EBI-751001, EBI-12206419; CC Q14145; P05107: ITGB2; NbExp=3; IntAct=EBI-751001, EBI-300173; CC Q14145; O95198: KLHL2; NbExp=7; IntAct=EBI-751001, EBI-746999; CC Q14145; Q8N4I8: KLHL3; NbExp=3; IntAct=EBI-751001, EBI-10230467; CC Q14145; Q9UH77: KLHL3; NbExp=5; IntAct=EBI-751001, EBI-8524663; CC Q14145; P62310: LSM3; NbExp=6; IntAct=EBI-751001, EBI-348239; CC Q14145; Q13257: MAD2L1; NbExp=8; IntAct=EBI-751001, EBI-78203; CC Q14145; O60336: MAPKBP1; NbExp=3; IntAct=EBI-751001, EBI-947402; CC Q14145; Q9BTE3-2: MCMBP; NbExp=3; IntAct=EBI-751001, EBI-9384556; CC Q14145; Q14494: NFE2L1; NbExp=28; IntAct=EBI-751001, EBI-2804436; CC Q14145; Q16236: NFE2L2; NbExp=41; IntAct=EBI-751001, EBI-2007911; CC Q14145; Q96TA1: NIBAN2; NbExp=9; IntAct=EBI-751001, EBI-2514593; CC Q14145; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-751001, EBI-741158; CC Q14145; Q9NZJ9: NUDT4; NbExp=3; IntAct=EBI-751001, EBI-4280066; CC Q14145; Q9UKX7: NUP50; NbExp=3; IntAct=EBI-751001, EBI-2371082; CC Q14145; Q8N573-5: OXR1; NbExp=3; IntAct=EBI-751001, EBI-10265887; CC Q14145; Q86YC2: PALB2; NbExp=6; IntAct=EBI-751001, EBI-1222653; CC Q14145; Q15149: PLEC; NbExp=3; IntAct=EBI-751001, EBI-297903; CC Q14145; P54619: PRKAG1; NbExp=6; IntAct=EBI-751001, EBI-1181439; CC Q14145; P06454-2: PTMA; NbExp=6; IntAct=EBI-751001, EBI-10194874; CC Q14145; Q6P9E2: RECK; NbExp=6; IntAct=EBI-751001, EBI-10253121; CC Q14145; Q04206: RELA; NbExp=4; IntAct=EBI-751001, EBI-73886; CC Q14145; P58004: SESN2; NbExp=3; IntAct=EBI-751001, EBI-3939642; CC Q14145; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-751001, EBI-358489; CC Q14145; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-751001, EBI-5235340; CC Q14145; Q13501: SQSTM1; NbExp=21; IntAct=EBI-751001, EBI-307104; CC Q14145; Q9UGK3: STAP2; NbExp=3; IntAct=EBI-751001, EBI-1553984; CC Q14145; Q9P0N9: TBC1D7; NbExp=3; IntAct=EBI-751001, EBI-3258000; CC Q14145; P54274: TERF1; NbExp=2; IntAct=EBI-751001, EBI-710997; CC Q14145; Q9Y3Q8: TSC22D4; NbExp=5; IntAct=EBI-751001, EBI-739485; CC Q14145; Q9BRX9: WDR83; NbExp=7; IntAct=EBI-751001, EBI-7705033; CC Q14145; O76024: WFS1; NbExp=3; IntAct=EBI-751001, EBI-720609; CC Q14145; Q9P202: WHRN; NbExp=3; IntAct=EBI-751001, EBI-310886; CC Q14145; P58317: ZNF121; NbExp=3; IntAct=EBI-751001, EBI-1228269; CC Q14145; Q9NX65: ZSCAN32; NbExp=3; IntAct=EBI-751001, EBI-739949; CC Q14145; P38109: ATG42; Xeno; NbExp=3; IntAct=EBI-751001, EBI-21638; CC Q14145; P17709: GLK1; Xeno; NbExp=3; IntAct=EBI-751001, EBI-8744; CC Q14145; O88351: Ikbkb; Xeno; NbExp=2; IntAct=EBI-751001, EBI-447960; CC Q14145; P15314: Irf1; Xeno; NbExp=2; IntAct=EBI-751001, EBI-6115486; CC Q14145; Q64337: Sqstm1; Xeno; NbExp=2; IntAct=EBI-751001, EBI-645025; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14585973, CC ECO:0000269|PubMed:15379550, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15657435, ECO:0000269|PubMed:19424503}. Nucleus CC {ECO:0000269|PubMed:15657435}. Note=Mainly cytoplasmic CC (PubMed:15601839). In response to selective autophagy, relocalizes to CC inclusion bodies following interaction with SQSTM1/p62 CC (PubMed:20452972). {ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:20452972}. CC -!- TISSUE SPECIFICITY: Broadly expressed, with highest levels in skeletal CC muscle. {ECO:0000269|PubMed:15379550}. CC -!- DOMAIN: KEAP1 contains reactive cysteine residues that act as sensors CC for endogenously produced and exogenously encountered small molecules, CC which react with sulfhydryl groups and modify the cysteine sensors, CC leading to impair ability of the BCR(KEAP1) complex to ubiquitinate CC target proteins. {ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, CC ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285}. CC -!- DOMAIN: The Kelch repeats mediate interaction with NFE2L2/NRF2, BPTF CC and PGAM5. {ECO:0000269|PubMed:17046835}. CC -!- PTM: Non-enzymatic covalent modifications of reactive cysteines by CC electrophile metabolites inactivate the BCR(KEAP1) complex CC (PubMed:17127771, PubMed:18251510, PubMed:29590092, PubMed:30323285). CC Accumulation of fumarate promotes the formation of cysteine S- CC succination (S-(2-succinyl)cysteine), leading to inactivate the CC BCR(KEAP1) complex and promote NFE2L2/NRF2 nuclear accumulation and CC activation (By similarity). Nitric oxide-dependent 8-Nitro-cGMP CC formation promotes cysteine guanylation (S-cGMP-cysteine), leading to CC NFE2L2/NRF2 nuclear accumulation and activation (By similarity). CC Itaconate, an anti-inflammatory metabolite generated in response to CC lipopolysaccharide, alkylates cysteines, activating NFE2L2/NRF2 CC (PubMed:29590092). Methylglyoxal, a reactive metabolite that CC accumulates when the glycolytic enzyme PGK1 is inhibited, promotes CC formation of a methylimidazole cross-link between proximal Cys-151 and CC Arg-135 on another KEAP1 molecule, resulting in an inactive dimer that CC inactivates the BCR(KEAP1) complex (PubMed:30323285). CC {ECO:0000250|UniProtKB:Q9Z2X8, ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:29590092, CC ECO:0000269|PubMed:30323285}. CC -!- PTM: Degraded via a proteasomal-independent process during selective CC autophagy: interaction with phosphorylated SQSTM1/p62 sequesters KEAP1 CC in inclusion bodies, leading to its degradation. CC {ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:20452972}. CC -!- PTM: Auto-ubiquitinated by the BCR(KEAP1) complex (PubMed:15572695, CC PubMed:15983046). Quinone-induced oxidative stress, but not CC sulforaphane, increases its ubiquitination (PubMed:15572695, CC PubMed:15983046). Ubiquitination and subsequent degradation is most CC pronounced following prolonged exposure of cells to oxidative stress, CC particularly in glutathione-deficient cells that are highly susceptible CC to oxidative stress (PubMed:15572695, PubMed:15983046). Deubiquitinated CC by USP25; leading to stabilization (PubMed:37339955). Ubiquitinated by CC TRIM25; leading to degradation upon ER stress (PubMed:31953436, CC PubMed:36882524). {ECO:0000269|PubMed:15572695, CC ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:31953436, CC ECO:0000269|PubMed:36882524, ECO:0000269|PubMed:37339955}. CC -!- SIMILARITY: Belongs to the KEAP1 family. {ECO:0000305}. CC -!- CAUTION: The mechanism of inactivation of the BCR(KEAP1) complex by CC covalent modifications of reactive cysteines is unclear. Covalent CC modifications were initially thought to disrupt interaction between CC KEAP1 and NFE2L2/NRF2 (By similarity). Recent publications suggest that CC cysteine modifications disrupt the interaction between KEAP1 and CUL3 CC without affecting the interaction between KEAP1 and NFE2L2/NRF2 CC (PubMed:16006525, PubMed:17127771, PubMed:18251510, PubMed:24896564). CC {ECO:0000250|UniProtKB:Q9Z2X8, ECO:0000269|PubMed:16006525, CC ECO:0000269|PubMed:17127771, ECO:0000269|PubMed:18251510, CC ECO:0000269|PubMed:24896564}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA09481.3; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF361892; AAK43722.1; -; Genomic_DNA. DR EMBL; AF361888; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361889; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361890; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361891; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361886; AAK51082.1; -; mRNA. DR EMBL; D50922; BAA09481.3; ALT_INIT; mRNA. DR EMBL; AK056204; BAG51647.1; -; mRNA. DR EMBL; AC011461; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC002417; AAH02417.1; -; mRNA. DR EMBL; BC002930; AAH02930.1; -; mRNA. DR EMBL; BC015945; AAH15945.1; -; mRNA. DR EMBL; BC021957; AAH21957.2; -; mRNA. DR CCDS; CCDS12239.1; -. DR RefSeq; NP_036421.2; NM_012289.3. DR RefSeq; NP_987096.1; NM_203500.2. DR PDB; 1U6D; X-ray; 1.85 A; X=321-609. DR PDB; 1ZGK; X-ray; 1.35 A; A=321-609. DR PDB; 2FLU; X-ray; 1.50 A; X=321-609. DR PDB; 3VNG; X-ray; 2.10 A; A=321-609. DR PDB; 3VNH; X-ray; 2.10 A; A=321-609. DR PDB; 3ZGC; X-ray; 2.20 A; A/B=321-609. DR PDB; 3ZGD; X-ray; 1.98 A; A/B=321-609. DR PDB; 4CXI; X-ray; 2.35 A; A=48-180. DR PDB; 4CXJ; X-ray; 2.80 A; A=48-180. DR PDB; 4CXT; X-ray; 2.66 A; A=48-180. DR PDB; 4IFJ; X-ray; 1.80 A; A=321-609. DR PDB; 4IFL; X-ray; 1.80 A; X=321-609. DR PDB; 4IFN; X-ray; 2.40 A; X=321-609. DR PDB; 4IN4; X-ray; 2.59 A; A/B/C=321-609. DR PDB; 4IQK; X-ray; 1.97 A; A=321-609. DR PDB; 4L7B; X-ray; 2.41 A; A/B=321-609. DR PDB; 4L7C; X-ray; 2.40 A; A/B/C=321-609. DR PDB; 4L7D; X-ray; 2.25 A; A/B/C=321-609. DR PDB; 4N1B; X-ray; 2.55 A; A/B/C=321-609. DR PDB; 4XMB; X-ray; 2.43 A; A=321-609. DR PDB; 5DAD; X-ray; 2.61 A; A=49-182. DR PDB; 5DAF; X-ray; 2.37 A; A=49-182. DR PDB; 5F72; X-ray; 1.85 A; C/K=321-611. DR PDB; 5GIT; X-ray; 2.19 A; A=48-180. DR PDB; 5NLB; X-ray; 3.45 A; A=51-204. DR PDB; 5WFL; X-ray; 1.93 A; A/B=312-624. DR PDB; 5WFV; X-ray; 1.91 A; A/B=320-612. DR PDB; 5WG1; X-ray; 2.02 A; A/B=320-612. DR PDB; 5WHL; X-ray; 2.50 A; A/B=312-624. DR PDB; 5WHO; X-ray; 2.23 A; A/B=312-624. DR PDB; 5WIY; X-ray; 2.23 A; A/B=312-624. DR PDB; 5X54; X-ray; 2.30 A; A/B=321-609. DR PDB; 6FFM; X-ray; 2.20 A; A=48-180. DR PDB; 6FMP; X-ray; 2.92 A; A/B=321-609. DR PDB; 6FMQ; X-ray; 2.10 A; A/B=321-609. DR PDB; 6HWS; X-ray; 1.75 A; A=321-609. DR PDB; 6LRZ; X-ray; 1.54 A; A=311-616. DR PDB; 6ROG; X-ray; 2.16 A; A/X=321-609. DR PDB; 6SP1; X-ray; 2.57 A; A/B=321-609. DR PDB; 6SP4; X-ray; 2.59 A; A/B/C/D/E/F=321-609. DR PDB; 6T7V; X-ray; 2.60 A; A=321-609. DR PDB; 6T7Z; X-ray; 2.00 A; A=321-609. DR PDB; 6TG8; X-ray; 2.75 A; AAA=322-609. DR PDB; 6TYM; X-ray; 1.42 A; A=321-609. DR PDB; 6TYP; X-ray; 2.50 A; A=321-609. DR PDB; 6UF0; X-ray; 1.96 A; A/B=321-609. DR PDB; 6V6Z; X-ray; 1.60 A; A/B/C/D=321-609. DR PDB; 6W66; X-ray; 3.21 A; C=48-180. DR PDB; 6W67; X-ray; 2.20 A; A=48-180. DR PDB; 6W68; X-ray; 2.55 A; A=48-180. DR PDB; 6W69; X-ray; 2.50 A; A=48-180. DR PDB; 6WCQ; EM; 8.50 A; C=1-624. DR PDB; 6Z6A; X-ray; 2.37 A; A/B=321-609. DR PDB; 7EXI; X-ray; 1.82 A; A=45-180. DR PDB; 7K28; X-ray; 2.15 A; A/B=325-614. DR PDB; 7K29; X-ray; 2.20 A; A/B=324-624. DR PDB; 7K2A; X-ray; 1.90 A; A/B=324-624. DR PDB; 7K2B; X-ray; 2.31 A; A/B=324-624. DR PDB; 7K2C; X-ray; 2.11 A; A/B=325-614. DR PDB; 7K2D; X-ray; 2.21 A; A/B=324-623. DR PDB; 7K2E; X-ray; 2.03 A; A/B=324-624. DR PDB; 7K2F; X-ray; 2.37 A; A/X=312-623. DR PDB; 7K2G; X-ray; 2.15 A; A/B=324-624. DR PDB; 7K2H; X-ray; 2.09 A; A/B=324-624. DR PDB; 7K2I; X-ray; 2.42 A; A/B=324-623. DR PDB; 7K2J; X-ray; 2.52 A; A/B=325-614. DR PDB; 7K2K; X-ray; 1.98 A; A/B=324-624. DR PDB; 7K2L; X-ray; 1.98 A; A=326-609, B=326-614. DR PDB; 7K2M; X-ray; 2.02 A; A/B=326-614. DR PDB; 7K2N; X-ray; 2.22 A; A/B=324-624. DR PDB; 7K2O; X-ray; 2.11 A; A/B=324-624. DR PDB; 7K2P; X-ray; 2.11 A; A/B=324-624. DR PDB; 7K2Q; X-ray; 2.37 A; A/B=325-614. DR PDB; 7K2R; X-ray; 2.10 A; A/B=325-614. DR PDB; 7K2S; X-ray; 2.13 A; A/B=324-624. DR PDB; 7Q5H; X-ray; 2.31 A; A/B=321-609. DR PDB; 7Q6Q; X-ray; 2.55 A; A/B=321-609. DR PDB; 7Q6S; X-ray; 2.14 A; A/B=321-609. DR PDB; 7Q8R; X-ray; 2.28 A; A/B=321-609. DR PDB; 7Q96; X-ray; 2.42 A; A/B=321-609. DR PDB; 7X4W; X-ray; 3.21 A; A/B/C/D/E/F=48-180. DR PDB; 7X4X; X-ray; 2.96 A; A/B/C/D/E/F=48-180. DR PDB; 7XM2; X-ray; 2.30 A; X=321-609. DR PDB; 7XM3; X-ray; 2.80 A; A=321-609. DR PDB; 7XM4; X-ray; 2.70 A; A=321-609. DR PDB; 7XM5; X-ray; 2.40 A; A=321-609. DR PDB; 7XOT; X-ray; 2.70 A; A=321-609. DR PDB; 8EHV; X-ray; 2.29 A; A/B=312-624. DR PDB; 8EJR; X-ray; 2.08 A; A/B=312-624. DR PDB; 8EJS; X-ray; 2.82 A; A/B=312-624. DR PDB; 8IVG; X-ray; 1.80 A; A=310-624. DR PDB; 8IVR; X-ray; 1.50 A; A=310-624. DR PDB; 8IXS; X-ray; 1.48 A; A=310-624. DR PDB; 8PKS; X-ray; 2.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N=471-609. DR PDB; 8PKU; X-ray; 1.73 A; A/B=312-623. DR PDB; 8PKV; X-ray; 1.55 A; A/B=312-623. DR PDB; 8PKW; X-ray; 1.54 A; A/B=312-623. DR PDB; 8PKX; X-ray; 1.79 A; A/B=312-623. DR PDB; 8WFG; X-ray; 2.25 A; A=48-180. DR PDB; 8X34; X-ray; 2.80 A; A/B=324-609. DR PDB; 8XGK; X-ray; 1.32 A; A=310-624. DR PDB; 8XGV; X-ray; 1.42 A; A=310-624. DR PDB; 9DU7; X-ray; 1.87 A; A/B=48-180. DR PDB; 9ETX; X-ray; 2.34 A; A/B=48-213. DR PDB; 9ETY; X-ray; 1.87 A; A/B=48-213. DR PDB; 9J70; X-ray; 2.50 A; A/X=322-609. DR PDB; 9J71; X-ray; 2.99 A; A/B/C/X=322-609. DR PDB; 9J7F; X-ray; 2.99 A; A/B/C/D=322-609. DR PDB; 9J7G; X-ray; 2.99 A; A/B/C/X=322-609. DR PDBsum; 1U6D; -. DR PDBsum; 1ZGK; -. DR PDBsum; 2FLU; -. DR PDBsum; 3VNG; -. DR PDBsum; 3VNH; -. DR PDBsum; 3ZGC; -. DR PDBsum; 3ZGD; -. DR PDBsum; 4CXI; -. DR PDBsum; 4CXJ; -. DR PDBsum; 4CXT; -. DR PDBsum; 4IFJ; -. DR PDBsum; 4IFL; -. DR PDBsum; 4IFN; -. DR PDBsum; 4IN4; -. DR PDBsum; 4IQK; -. DR PDBsum; 4L7B; -. DR PDBsum; 4L7C; -. DR PDBsum; 4L7D; -. DR PDBsum; 4N1B; -. DR PDBsum; 4XMB; -. DR PDBsum; 5DAD; -. DR PDBsum; 5DAF; -. DR PDBsum; 5F72; -. DR PDBsum; 5GIT; -. DR PDBsum; 5NLB; -. DR PDBsum; 5WFL; -. DR PDBsum; 5WFV; -. DR PDBsum; 5WG1; -. DR PDBsum; 5WHL; -. DR PDBsum; 5WHO; -. DR PDBsum; 5WIY; -. DR PDBsum; 5X54; -. DR PDBsum; 6FFM; -. DR PDBsum; 6FMP; -. DR PDBsum; 6FMQ; -. DR PDBsum; 6HWS; -. DR PDBsum; 6LRZ; -. DR PDBsum; 6ROG; -. DR PDBsum; 6SP1; -. DR PDBsum; 6SP4; -. DR PDBsum; 6T7V; -. DR PDBsum; 6T7Z; -. DR PDBsum; 6TG8; -. DR PDBsum; 6TYM; -. DR PDBsum; 6TYP; -. DR PDBsum; 6UF0; -. DR PDBsum; 6V6Z; -. DR PDBsum; 6W66; -. DR PDBsum; 6W67; -. DR PDBsum; 6W68; -. DR PDBsum; 6W69; -. DR PDBsum; 6WCQ; -. DR PDBsum; 6Z6A; -. DR PDBsum; 7EXI; -. DR PDBsum; 7K28; -. DR PDBsum; 7K29; -. DR PDBsum; 7K2A; -. DR PDBsum; 7K2B; -. DR PDBsum; 7K2C; -. DR PDBsum; 7K2D; -. DR PDBsum; 7K2E; -. DR PDBsum; 7K2F; -. DR PDBsum; 7K2G; -. DR PDBsum; 7K2H; -. DR PDBsum; 7K2I; -. DR PDBsum; 7K2J; -. DR PDBsum; 7K2K; -. DR PDBsum; 7K2L; -. DR PDBsum; 7K2M; -. DR PDBsum; 7K2N; -. DR PDBsum; 7K2O; -. DR PDBsum; 7K2P; -. DR PDBsum; 7K2Q; -. DR PDBsum; 7K2R; -. DR PDBsum; 7K2S; -. DR PDBsum; 7Q5H; -. DR PDBsum; 7Q6Q; -. DR PDBsum; 7Q6S; -. DR PDBsum; 7Q8R; -. DR PDBsum; 7Q96; -. DR PDBsum; 7X4W; -. DR PDBsum; 7X4X; -. DR PDBsum; 7XM2; -. DR PDBsum; 7XM3; -. DR PDBsum; 7XM4; -. DR PDBsum; 7XM5; -. DR PDBsum; 7XOT; -. DR PDBsum; 8EHV; -. DR PDBsum; 8EJR; -. DR PDBsum; 8EJS; -. DR PDBsum; 8IVG; -. DR PDBsum; 8IVR; -. DR PDBsum; 8IXS; -. DR PDBsum; 8PKS; -. DR PDBsum; 8PKU; -. DR PDBsum; 8PKV; -. DR PDBsum; 8PKW; -. DR PDBsum; 8PKX; -. DR PDBsum; 8WFG; -. DR PDBsum; 8X34; -. DR PDBsum; 8XGK; -. DR PDBsum; 8XGV; -. DR PDBsum; 9DU7; -. DR PDBsum; 9ETX; -. DR PDBsum; 9ETY; -. DR PDBsum; 9J70; -. DR PDBsum; 9J71; -. DR PDBsum; 9J7F; -. DR PDBsum; 9J7G; -. DR AlphaFoldDB; Q14145; -. DR BMRB; Q14145; -. DR EMDB; EMD-21617; -. DR SMR; Q14145; -. DR BioGRID; 115156; 368. DR ComplexPortal; CPX-8107; CRL3 E3 ubiquitin ligase complex, KEAP1 variant. DR CORUM; Q14145; -. DR DIP; DIP-42134N; -. DR ELM; Q14145; -. DR FunCoup; Q14145; 673. DR IntAct; Q14145; 211. DR MINT; Q14145; -. DR STRING; 9606.ENSP00000377245; -. DR BindingDB; Q14145; -. DR ChEMBL; CHEMBL2069156; -. DR DrugBank; DB04339; Carbocisteine. DR DrugBank; DB08908; Dimethyl fumarate. DR DrugBank; DB12513; Omaveloxolone. DR DrugCentral; Q14145; -. DR GuidetoPHARMACOLOGY; 2757; -. DR GlyCosmos; Q14145; 11 sites, 1 glycan. DR GlyGen; Q14145; 11 sites, 1 O-linked glycan (11 sites). DR iPTMnet; Q14145; -. DR PhosphoSitePlus; Q14145; -. DR SwissPalm; Q14145; -. DR BioMuta; KEAP1; -. DR DMDM; 146345444; -. DR jPOST; Q14145; -. DR MassIVE; Q14145; -. DR PaxDb; 9606-ENSP00000171111; -. DR PeptideAtlas; Q14145; -. DR ProteomicsDB; 59849; -. DR Pumba; Q14145; -. DR ABCD; Q14145; 8 sequenced antibodies. DR Antibodypedia; 1418; 709 antibodies from 40 providers. DR DNASU; 9817; -. DR Ensembl; ENST00000171111.10; ENSP00000171111.4; ENSG00000079999.15. DR Ensembl; ENST00000393623.6; ENSP00000377245.1; ENSG00000079999.15. DR GeneID; 9817; -. DR KEGG; hsa:9817; -. DR MANE-Select; ENST00000171111.10; ENSP00000171111.4; NM_203500.2; NP_987096.1. DR UCSC; uc002moq.2; human. DR AGR; HGNC:23177; -. DR CIViC; 9817; 5 evidence items across 4 molecular profiles. DR ClinPGx; PA134887774; -. DR CTD; 9817; -. DR DisGeNET; 9817; -. DR GeneCards; KEAP1; -. DR HGNC; HGNC:23177; KEAP1. DR HPA; ENSG00000079999; Tissue enhanced (skeletal). DR MalaCards; KEAP1; -. DR MIM; 606016; gene. DR OpenTargets; ENSG00000079999; -. DR Orphanet; 276399; Familial multinodular goiter. DR VEuPathDB; HostDB:ENSG00000079999; -. DR eggNOG; KOG4441; Eukaryota. DR GeneTree; ENSGT00940000159543; -. DR HOGENOM; CLU_004253_14_2_1; -. DR InParanoid; Q14145; -. DR OMA; TECLTEY; -. DR OrthoDB; 45365at2759; -. DR PAN-GO; Q14145; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q14145; -. DR PathwayCommons; Q14145; -. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8951664; Neddylation. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q14145; -. DR SIGNOR; Q14145; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000079999; -. DR BioGRID-ORCS; 9817; 194 hits in 1230 CRISPR screens. DR CD-CODE; 5D6181E1; Synthetic Condensate 000293. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FBAE0D06; Synthetic Condensate 000291. DR ChiTaRS; KEAP1; human. DR EvolutionaryTrace; Q14145; -. DR GeneWiki; KEAP1; -. DR GenomeRNAi; 9817; -. DR Pharos; Q14145; Tclin. DR PRO; PR:Q14145; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q14145; protein. DR Bgee; ENSG00000079999; Expressed in hindlimb stylopod muscle and 201 other cell types or tissues. DR ExpressionAtlas; Q14145; baseline and differential. DR GO; GO:0005884; C:actin filament; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl. DR GO; GO:0016234; C:inclusion body; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL. DR GO; GO:1990756; F:ubiquitin-like ligase-substrate adaptor activity; IDA:UniProt. DR GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl. DR GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:1902883; P:negative regulation of response to oxidative stress; IDA:UniProt. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; IDA:UniProtKB. DR GO; GO:0045604; P:regulation of epidermal cell differentiation; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR CDD; cd18458; BACK_KLHL19_KEAP1; 1. DR CDD; cd18248; BTB_POZ_KLHL19_KEAP1; 1. DR FunFam; 2.120.10.80:FF:000024; Kelch-like ECH-associated protein 1; 1. DR FunFam; 1.25.40.420:FF:000001; Kelch-like family member 12; 1. DR FunFam; 3.30.710.10:FF:000001; Kelch-like family member 20; 1. DR Gene3D; 1.25.40.420; -; 1. DR Gene3D; 2.120.10.80; Kelch-type beta propeller; 1. DR Gene3D; 3.30.710.10; Potassium Channel Kv1.1, Chain A; 1. DR IDEAL; IID00384; -. DR InterPro; IPR011705; BACK. DR InterPro; IPR017096; BTB-kelch_protein. DR InterPro; IPR000210; BTB/POZ_dom. DR InterPro; IPR047098; KEAP1_BACK. DR InterPro; IPR030563; KEAP1_BTB_POZ_dom. DR InterPro; IPR015915; Kelch-typ_b-propeller. DR InterPro; IPR006652; Kelch_1. DR InterPro; IPR011333; SKP1/BTB/POZ_sf. DR PANTHER; PTHR24412; KELCH PROTEIN; 1. DR PANTHER; PTHR24412:SF162; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; 1. DR Pfam; PF07707; BACK; 1. DR Pfam; PF00651; BTB; 1. DR Pfam; PF01344; Kelch_1; 3. DR Pfam; PF24681; Kelch_KLHDC2_KLHL20_DRC7; 1. DR PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1. DR SMART; SM00875; BACK; 1. DR SMART; SM00225; BTB; 1. DR SMART; SM00612; Kelch; 6. DR SUPFAM; SSF117281; Kelch motif; 1. DR SUPFAM; SSF54695; POZ domain; 1. DR PROSITE; PS50097; BTB; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasm; Host-virus interaction; Kelch repeat; Nucleus; KW Proteomics identification; Reference proteome; Repeat; S-nitrosylation; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..624 FT /note="Kelch-like ECH-associated protein 1" FT /id="PRO_0000119093" FT DOMAIN 77..149 FT /note="BTB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00037" FT DOMAIN 184..286 FT /note="BACK" FT REPEAT 327..372 FT /note="Kelch 1" FT REPEAT 373..423 FT /note="Kelch 2" FT REPEAT 424..470 FT /note="Kelch 3" FT REPEAT 471..517 FT /note="Kelch 4" FT REPEAT 518..564 FT /note="Kelch 5" FT REPEAT 565..611 FT /note="Kelch 6" FT SITE 151 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:18251510, FT ECO:0000269|PubMed:29590092" FT SITE 257 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:29590092" FT SITE 273 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:29590092" FT SITE 288 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:29590092" FT SITE 434 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 38 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 151 FT /note="S-(2,3-dicarboxypropyl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 151 FT /note="S-(2-succinyl)cysteine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 151 FT /note="S-nitrosocysteine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 241 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 257 FT /note="S-(2,3-dicarboxypropyl)cysteine" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 273 FT /note="S-(2,3-dicarboxypropyl)cysteine" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 288 FT /note="S-(2,3-dicarboxypropyl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 288 FT /note="S-(2-succinyl)cysteine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 319 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 434 FT /note="S-cGMP-cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 613 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT CROSSLNK 135 FT /note="N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L- FT ornithine (Arg-Cys) (interchain with C-151 in KEAP1)" FT /evidence="ECO:0000269|PubMed:30323285" FT CROSSLNK 151 FT /note="N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L- FT ornithine (Cys-Arg) (interchain with R-135 in KEAP1)" FT /evidence="ECO:0000269|PubMed:30323285" FT VARIANT 23 FT /note="C -> Y (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036084" FT VARIANT 167 FT /note="V -> F (in a lung adenocarcinoma patient)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032102" FT VARIANT 236 FT /note="D -> H (in a NSCLC cell line)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032103" FT VARIANT 284 FT /note="Q -> L (in a lung adenocarcinoma patient)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032104" FT VARIANT 333 FT /note="G -> C (in a NSCLC cell line; strongly reduces FT interaction with NFE2L2/NRF2 and reduces repression of FT NFE2L2/NRF2-dependent gene expression)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032105" FT VARIANT 349 FT /note="D -> N (in dbSNP:rs1048289)" FT /evidence="ECO:0000269|PubMed:8590280" FT /id="VAR_032106" FT VARIANT 350 FT /note="G -> S (in a NSCLC cell line; dbSNP:rs777308626)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032107" FT VARIANT 364 FT /note="G -> C (in a lung adenocarcinoma cell line; also in FT NSCLC cell lines; strongly reduces interaction with NFE2L2/ FT NRF2 and reduces repression of NFE2L2/NRF2-dependent gene FT expression; dbSNP:rs1397945617)" FT /evidence="ECO:0000269|PubMed:16507366" FT /id="VAR_032108" FT VARIANT 430 FT /note="G -> C (in a lung adenocarcinoma patient; somatic FT mutation; strongly reduces interaction with NFE2L2/NRF2 and FT reduces repression of NFE2L2/NRF2-dependent gene FT expression)" FT /evidence="ECO:0000269|PubMed:16507366" FT /id="VAR_032109" FT VARIANT 522 FT /note="A -> V (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036085" FT MUTAGEN 15 FT /note="R->A: Reduced formation of a high-molecular mass FT KEAP1 molecule when methylglyoxal accumulates." FT /evidence="ECO:0000269|PubMed:30323285" FT MUTAGEN 123..127 FT /note="VSIEG->ASAEA: Abolished interaction with FT NFE2L2/NRF2; when associated with 161-A-A-162." FT /evidence="ECO:0000269|PubMed:15601839" FT MUTAGEN 125..127 FT /note="IEG->AAA: Increases ubiquitination and proteolytic FT degradation." FT /evidence="ECO:0000269|PubMed:15572695" FT MUTAGEN 135 FT /note="R->A: Reduced formation of a high-molecular mass FT KEAP1 molecule when methylglyoxal accumulates." FT /evidence="ECO:0000269|PubMed:30323285" FT MUTAGEN 151 FT /note="C->S,N,D,L: Substitution with a small side chain FT that prevents covalent modification by an electrophile; FT promotes constitutive ubiquitination of NFE2L2/NRF2 and FT subsequent repression of phase 2 detoxifying enzymes. FT Resistance of ubiquitination of PGAM5 to inhibition by FT oxidative stress and sulforaphane. Impaired interaction FT with CUL3. Reduced formation of a high-molecular mass KEAP1 FT molecule when methylglyoxal accumulates." FT /evidence="ECO:0000269|PubMed:14585973, FT ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:17046835, FT ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, FT ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285" FT MUTAGEN 151 FT /note="C->W,Y: Substitution with a bulky side chain that FT mimicks covalent modification by an electrophile; prevents FT ubiquitination and degradation of NFE2L2/NRF2, leading to FT constitutive activation of NFE2L2/NRF2 and subsequent FT expression of phase 2 detoxifying enzymes." FT /evidence="ECO:0000269|PubMed:19489739, FT ECO:0000269|PubMed:24896564" FT MUTAGEN 161..162 FT /note="MY->AA: Abolished interaction with NFE2L2/NRF2; when FT associated with 123-A--A-127." FT /evidence="ECO:0000269|PubMed:15601839" FT MUTAGEN 162..164 FT /note="YQI->AAA: Increases ubiquitination and proteolytic FT degradation." FT /evidence="ECO:0000269|PubMed:15572695" FT MUTAGEN 273 FT /note="C->S: Abolishes repression of NFE2L2/NRF2-dependent FT gene expression. Slows down degradation of NFE2L2/NRF2." FT /evidence="ECO:0000269|PubMed:14585973" FT MUTAGEN 288 FT /note="C->S: Abolishes repression of NFE2L2/NRF2-dependent FT gene expression. Slows down degradation of NFE2L2/NRF2." FT /evidence="ECO:0000269|PubMed:14585973" FT MUTAGEN 308 FT /note="L->A: Loss of export from nucleus; when associated FT with A-310." FT /evidence="ECO:0000269|PubMed:15657435" FT MUTAGEN 310 FT /note="L->A: Loss of export from nucleus; when associated FT with A-308." FT /evidence="ECO:0000269|PubMed:15657435" FT MUTAGEN 334 FT /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835" FT MUTAGEN 380 FT /note="R->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Impaired interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 382 FT /note="N->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Impaired interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 415 FT /note="R->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5. Does not affect FT interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972" FT MUTAGEN 436 FT /note="H->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Does not affect interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 478 FT /note="F->A: Abolishes repression of NFE2L2/NRF2-dependent FT gene expression." FT /evidence="ECO:0000269|PubMed:16888629" FT MUTAGEN 483 FT /note="R->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5. Does not affect FT interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972" FT MUTAGEN 525 FT /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Abolishes interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 572 FT /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5. Abolishes FT interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972" FT MUTAGEN 615 FT /note="K->R: Decreases binding to PGCKA1. Increases protein FT half-life." FT /evidence="ECO:0000269|PubMed:36882524" FT CONFLICT 504 FT /note="N -> S (in Ref. 4; BAG51647)" FT /evidence="ECO:0000305" FT STRAND 51..55 FT /evidence="ECO:0007829|PDB:7X4X" FT HELIX 59..72 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 79..83 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 86..88 FT /evidence="ECO:0007829|PDB:5DAD" FT STRAND 91..95 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 97..103 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 105..111 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 113..115 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 116..119 FT /evidence="ECO:0007829|PDB:7X4W" FT STRAND 121..125 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 130..142 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 143..148 FT /evidence="ECO:0007829|PDB:7X4X" FT HELIX 149..151 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 152..161 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 165..177 FT /evidence="ECO:0007829|PDB:7EXI" FT TURN 181..183 FT /evidence="ECO:0007829|PDB:5NLB" FT HELIX 184..194 FT /evidence="ECO:0007829|PDB:5NLB" FT HELIX 199..202 FT /evidence="ECO:0007829|PDB:5NLB" FT STRAND 327..331 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 334..338 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 342..345 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 347..349 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 352..354 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 362..364 FT /evidence="ECO:0007829|PDB:2FLU" FT STRAND 366..370 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 373..377 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 380..383 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 386..389 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 393..396 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 398..400 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 424..428 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 440..444 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 445..448 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 449..452 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 464..468 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 471..475 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 480..483 FT /evidence="ECO:0007829|PDB:6HWS" FT STRAND 487..491 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 492..495 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 496..499 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 511..515 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 518..522 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 534..538 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 539..542 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 543..547 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 558..562 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 565..569 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 574..577 FT /evidence="ECO:0007829|PDB:5F72" FT STRAND 580..585 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 586..589 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 590..596 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 605..609 FT /evidence="ECO:0007829|PDB:1ZGK" SQ SEQUENCE 624 AA; 69666 MW; CE180F3897BB8C97 CRC64; MQPDPRPSGA GACCRFLPLQ SQCPEGAGDA VMYASTECKA EVTPSQHGNR TFSYTLEDHT KQAFGIMNEL RLSQQLCDVT LQVKYQDAPA AQFMAHKVVL ASSSPVFKAM FTNGLREQGM EVVSIEGIHP KVMERLIEFA YTASISMGEK CVLHVMNGAV MYQIDSVVRA CSDFLVQQLD PSNAIGIANF AEQIGCVELH QRAREYIYMH FGEVAKQEEF FNLSHCQLVT LISRDDLNVR CESEVFHACI NWVKYDCEQR RFYVQALLRA VRCHSLTPNF LQMQLQKCEI LQSDSRCKDY LVKIFEELTL HKPTQVMPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSDG TWLRLADLQV PRSGLAGCVV GGLLYAVGGR NNSPDGNTDS SALDCYNPMT NQWSPCAPMS VPRNRIGVGV IDGHIYAVGG SHGCIHHNSV ERYEPERDEW HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI TAMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM KHRRSALGIT VHQGRIYVLG GYDGHTFLDS VECYDPDTDT WSEVTRMTSG RSGVGVAVTM EPCRKQIDQQ NCTC // ID KPCA_HUMAN Reviewed; 672 AA. AC P17252; B5BU22; Q15137; Q32M72; Q96RE4; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 4. DT 28-JAN-2026, entry version 258. DE RecName: Full=Protein kinase C alpha type; DE Short=PKC-A; DE Short=PKC-alpha; DE EC=2.7.11.13 {ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; GN Name=PRKCA; Synonyms=PKCA, PRKACA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-568. RC TISSUE=Blood; RX PubMed=2336401; DOI=10.1093/nar/18.8.2183; RA Finkenzeller G., Marme D., Hug H.; RT "Sequence of human protein kinase C alpha."; RL Nucleic Acids Res. 18:2183-2183(1990). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-568. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-445. RX PubMed=1714454; DOI=10.1016/s0021-9258(18)98596-0; RA McSwine-Kennick R.L., McKeegan E.M., Johnson M.D., Morin M.J.; RT "Phorbol diester-induced alterations in the expression of protein kinase C RT isozymes and their mRNAs. Analysis in wild-type and phorbol diester- RT resistant HL-60 cell clones."; RL J. Biol. Chem. 266:15135-15143(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57. RA Haridasse V., Hackenbruck J., Glazer R.I.; RT "Homo sapiens protein kinase C alpha 5-flanking sequence."; RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-19. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [9] RP FUNCTION IN APOPTOSIS, AND SUBCELLULAR LOCATION. RX PubMed=9738012; DOI=10.1074/jbc.273.39.25436; RA Ruvolo P.P., Deng X., Carr B.K., May W.S.; RT "A functional role for mitochondrial protein kinase Calpha in Bcl2 RT phosphorylation and suppression of apoptosis."; RL J. Biol. Chem. 273:25436-25442(1998). RN [10] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9830023; DOI=10.1074/jbc.273.49.32787; RA St-Denis A., Chano F., Tremblay P., St-Pierre Y., Descoteaux A.; RT "Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a RT murine macrophage cell line."; RL J. Biol. Chem. 273:32787-32792(1998). RN [11] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9873035; DOI=10.1074/jbc.274.2.939; RA Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R.; RT "Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory RT feedback loop in hepatocytes. A role for protein kinase calpha in post- RT transcriptional regulation of ikappabalpha resynthesis."; RL J. Biol. Chem. 274:939-947(1999). RN [12] RP FUNCTION IN APOPTOSIS. RX PubMed=9927633; DOI=10.1124/mol.55.2.396; RA Shen L., Dean N.M., Glazer R.I.; RT "Induction of p53-dependent, insulin-like growth factor-binding protein-3- RT mediated apoptosis in glioblastoma multiforme cells by a protein kinase RT Calpha antisense oligonucleotide."; RL Mol. Pharmacol. 55:396-402(1999). RN [13] RP FUNCTION IN CELL CYCLE PROGRESSION. RX PubMed=10848585; DOI=10.1128/mcb.20.13.4580-4590.2000; RA Besson A., Yong V.W.; RT "Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle RT progression."; RL Mol. Cell. Biol. 20:4580-4590(2000). RN [14] RP FUNCTION IN ANGIOGENESIS. RX PubMed=11909826; DOI=10.1161/01.res.0000012503.30315.e8; RA Wang A., Nomura M., Patan S., Ware J.A.; RT "Inhibition of protein kinase Calpha prevents endothelial cell migration RT and vascular tube formation in vitro and myocardial neovascularization in RT vivo."; RL Circ. Res. 90:609-616(2002). RN [15] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [16] RP FUNCTION IN PLATELET AGGREGATION. RX PubMed=12724315; DOI=10.1074/jbc.m212407200; RA Tabuchi A., Yoshioka A., Higashi T., Shirakawa R., Nishioka H., Kita T., RA Horiuchi H.; RT "Direct demonstration of involvement of protein kinase Calpha in the Ca2+- RT induced platelet aggregation."; RL J. Biol. Chem. 278:26374-26379(2003). RN [17] RP FUNCTION IN PHOSPHORYLATION OF TNNT2/CTNT. RX PubMed=12832403; DOI=10.1074/jbc.m306325200; RA Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J.; RT "Identification of a functionally critical protein kinase C phosphorylation RT residue of cardiac troponin T."; RL J. Biol. Chem. 278:35135-35144(2003). RN [18] RP FUNCTION IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [19] RP FUNCTION IN PHOSPHORYLATION OF TRPC1. RX PubMed=15016832; DOI=10.1074/jbc.m313975200; RA Ahmmed G.U., Mehta D., Vogel S., Holinstat M., Paria B.C., Tiruppathi C., RA Malik A.B.; RT "Protein kinase Calpha phosphorylates the TRPC1 channel and regulates RT store-operated Ca2+ entry in endothelial cells."; RL J. Biol. Chem. 279:20941-20949(2004). RN [20] RP INTERACTION WITH PICK1. RX PubMed=15247289; DOI=10.1074/jbc.m404499200; RA Dev K.K., Nakanishi S., Henley J.M.; RT "The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and RT GluR2 as interacting ligands."; RL J. Biol. Chem. 279:41393-41397(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF CSPG4, AND INTERACTION WITH CSPG4. RX PubMed=15504744; DOI=10.1074/jbc.m411045200; RA Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T., RA Stallcup W.B.; RT "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates RT polarized membrane distribution and cell motility."; RL J. Biol. Chem. 279:55262-55270(2004). RN [22] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [24] RP INTERACTION WITH TRIM41. RX PubMed=17893151; DOI=10.1074/jbc.m703320200; RA Chen D., Gould C., Garza R., Gao T., Hampton R.Y., Newton A.C.; RT "Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin RT ligase."; RL J. Biol. Chem. 282:33776-33787(2007). RN [25] RP FUNCTION IN ANGIOGENESIS. RX PubMed=18056764; DOI=10.1093/cvr/cvm085; RA Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Foerstermann U., Li H.; RT "Protein kinase C alpha promotes angiogenic activity of human endothelial RT cells via induction of vascular endothelial growth factor."; RL Cardiovasc. Res. 78:349-355(2008). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-638 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [29] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [30] RP FUNCTION. RX PubMed=19176525; DOI=10.1074/jbc.m808719200; RA Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.; RT "Phosphorylation of activation transcription factor-2 at serine 121 by RT protein kinase c controls c-Jun-mediated activation of transcription."; RL J. Biol. Chem. 284:8567-8581(2009). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-628, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [34] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-657, AND MUTAGENESIS RP OF LYS-368. RX PubMed=21806543; DOI=10.1042/bj20110678; RA Cameron A.J., Linch M.D., Saurin A.T., Escribano C., Parker P.J.; RT "mTORC2 targets AGC kinases through Sin1-dependent recruitment."; RL Biochem. J. 439:287-297(2011). RN [35] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [36] RP FUNCTION IN PHOSPHORYLATION OF EIF4G1. RX PubMed=21576361; DOI=10.1128/mcb.05589-11; RA Dobrikov M., Dobrikova E., Shveygert M., Gromeier M.; RT "Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) RT by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1."; RL Mol. Cell. Biol. 31:2947-2959(2011). RN [37] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=12417014; DOI=10.1093/oxfordjournals.jbchem.a003272; RA Nakashima S.; RT "Protein kinase C alpha (PKC alpha): regulation and biological function."; RL J. Biochem. 132:669-675(2002). RN [38] RP REVIEW ON FUNCTION. RX PubMed=19969380; DOI=10.1016/j.tips.2009.10.006; RA Konopatskaya O., Poole A.W.; RT "Protein kinase Calpha: disease regulator and therapeutic target."; RL Trends Pharmacol. Sci. 31:8-14(2010). RN [39] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [40] RP FUNCTION IN CELL MIGRATION, AND SUBCELLULAR LOCATION. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10 AND SER-226, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; THR-638 AND SER-657, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25313067; DOI=10.1073/pnas.1418342111; RA Shibata S., Arroyo J.P., Castaneda-Bueno M., Puthumana J., Zhang J., RA Uchida S., Stone K.L., Lam T.T., Lifton R.P.; RT "Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, RT preventing WNK4 degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15556-15561(2014). RN [44] RP INTERACTION WITH PARD3. RX PubMed=27925688; DOI=10.1002/humu.23153; RA Chen X., An Y., Gao Y., Guo L., Rui L., Xie H., Sun M., Lam Hung S., RA Sheng X., Zou J., Bao Y., Guan H., Niu B., Li Z., Finnell R.H., RA Gusella J.F., Wu B.L., Zhang T.; RT "Rare deleterious PARD3 variants in the aPKC-binding region are implicated RT in the pathogenesis of human cranial neural tube defects via disrupting RT apical tight junction formation."; RL Hum. Mutat. 38:378-389(2017). RN [45] RP FUNCTION. RX PubMed=28028151; DOI=10.1084/jem.20160068; RA Xu X., Han L., Zhao G., Xue S., Gao Y., Xiao J., Zhang S., Chen P., RA Wu Z.Y., Ding J., Hu R., Wei B., Wang H.; RT "LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates RT experimental autoimmune encephalomyelitis."; RL J. Exp. Med. 214:209-226(2017). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 320-672 IN COMPLEX WITH RP INHIBITOR. RX PubMed=19827831; DOI=10.1021/jm901108b; RA Wagner J., von Matt P., Sedrani R., Albert R., Cooke N., Ehrhardt C., RA Geiser M., Rummel G., Stark W., Strauss A., Cowan-Jacob S.W., Beerli C., RA Weckbecker G., Evenou J.P., Zenke G., Cottens S.; RT "Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- RT yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein RT kinase C isotypes."; RL J. Med. Chem. 52:6193-6196(2009). RN [48] RP STRUCTURE BY NMR OF 88-169. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second phorbol esters/diacylglycerol binding RT domain of human protein kinase C alpha type."; RL Submitted (APR-2008) to the PDB data bank. RN [49] RP VARIANTS [LARGE SCALE ANALYSIS] SER-98; ASN-467 AND VAL-489. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in positive CC and negative regulation of cell proliferation, apoptosis, CC differentiation, migration and adhesion, tumorigenesis, cardiac CC hypertrophy, angiogenesis, platelet function and inflammation, by CC directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, CC or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. CC Involved in cell proliferation and cell growth arrest by positive and CC negative regulation of the cell cycle. Can promote cell growth by CC phosphorylating and activating RAF1, which mediates the activation of CC the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which CC facilitates active cyclin-dependent kinase (CDK) complex formation in CC glioma cells. In intestinal cells stimulated by the phorbol ester PMA, CC can trigger a cell cycle arrest program which is associated with the CC accumulation of the hyper-phosphorylated growth-suppressive form of RB1 CC and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti- CC apoptotic function in glioma cells and protects them from apoptosis by CC suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia CC cells mediates anti-apoptotic action by phosphorylating BCL2. During CC macrophage differentiation induced by macrophage colony-stimulating CC factor (CSF1), is translocated to the nucleus and is associated with CC macrophage development. After wounding, translocates from focal CC contacts to lamellipodia and participates in the modulation of CC desmosomal adhesion. Plays a role in cell motility by phosphorylating CC CSPG4, which induces association of CSPG4 with extensive lamellipodia CC at the cell periphery and polarization of the cell accompanied by CC increases in cell motility. During chemokine-induced CD4(+) T cell CC migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting CC in its dissociation from LRCH1 and the activation of GTPase CDC42 CC (PubMed:28028151). Is highly expressed in a number of cancer cells CC where it can act as a tumor promoter and is implicated in malignant CC phenotypes of several tumors such as gliomas and breast cancers. CC Negatively regulates myocardial contractility and positively regulates CC angiogenesis, platelet aggregation and thrombus formation in arteries. CC Mediates hypertrophic growth of neonatal cardiomyocytes, in part CC through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA CC treatment, is required to induce cardiomyocyte hypertrophy up to heart CC failure and death, by increasing protein synthesis, protein-DNA ratio CC and cell surface area. Regulates cardiomyocyte function by CC phosphorylating cardiac troponin T (TNNT2/CTNT), which induces CC significant reduction in actomyosin ATPase activity, myofilament CC calcium sensitivity and myocardial contractility. In angiogenesis, is CC required for full endothelial cell migration, adhesion to vitronectin CC (VTN), and vascular endothelial growth factor A (VEGFA)-dependent CC regulation of kinase activation and vascular tube formation. Involved CC in the stabilization of VEGFA mRNA at post-transcriptional level and CC mediates VEGFA-induced cell proliferation. In the regulation of CC calcium-induced platelet aggregation, mediates signals from the CC CD36/GP4 receptor for granule release, and activates the integrin CC heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. CC During response to lipopolysaccharides (LPS), may regulate selective CC LPS-induced macrophage functions involved in host defense and CC inflammation. But in some inflammatory responses, may negatively CC regulate NF-kappa-B-induced genes, through IL1A-dependent induction of CC NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O- CC tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which CC modulates EIF4G1 binding to MKNK1 and may be involved in the regulation CC of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of CC KIT activity. Phosphorylates ATF2 which promotes cooperation between CC ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser- CC 52' facilitating its ubiquitination and proteasomal degradation (By CC similarity). Phosphorylates KLHL3 in response to angiotensin II CC signaling, decreasing the interaction between KLHL3 and WNK4 CC (PubMed:25313067). Phosphorylates and activates LRRK1, which CC phosphorylates RAB proteins involved in intracellular trafficking CC (PubMed:36040231). {ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826, CC ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403, CC ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744, CC ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764, CC ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361, CC ECO:0000269|PubMed:21806543, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:28028151, CC ECO:0000269|PubMed:36040231, ECO:0000269|PubMed:9738012, CC ECO:0000269|PubMed:9830023, ECO:0000269|PubMed:9873035, CC ECO:0000269|PubMed:9927633}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 CC domain. {ECO:0000250|UniProtKB:P05696}; CC -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and CC PRKCG) are activated by calcium and diacylglycerol (DAG) in the CC presence of phosphatidylserine. Three specific sites; Thr-497 CC (activation loop of the kinase domain), Thr-638 (turn motif) and Ser- CC 657 (hydrophobic region), need to be phosphorylated for its full CC activation. {ECO:0000269|PubMed:21806543}. CC -!- SUBUNIT: Recruited in a circadian manner into a nuclear complex which CC also includes BMAL1 and RACK1 (By similarity). Interacts with CC ADAP1/CENTA1 (PubMed:12893243). Interacts with CSPG4 (PubMed:15504744). CC Binds to CAVIN2 in the presence of phosphatidylserine (By similarity). CC Interacts with PRKCABP/PICK1 (via PDZ domain) (PubMed:15247289). CC Interacts with TRIM41 (PubMed:17893151). Interacts with PARD3 CC (PubMed:27925688). Interacts with SOCS2 (By similarity). CC {ECO:0000250|UniProtKB:P05696, ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:15247289, CC ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:17893151, CC ECO:0000269|PubMed:27925688}. CC -!- INTERACTION: CC P17252; Q15027: ACAP1; NbExp=3; IntAct=EBI-1383528, EBI-751746; CC P17252; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1383528, EBI-25646567; CC P17252; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-1383528, EBI-5280499; CC P17252; Q13072: BAGE; NbExp=3; IntAct=EBI-1383528, EBI-25884811; CC P17252; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-1383528, EBI-11524452; CC P17252; Q96A33: CCDC47; NbExp=3; IntAct=EBI-1383528, EBI-720151; CC P17252; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-1383528, EBI-17967022; CC P17252; P15169: CPN1; NbExp=3; IntAct=EBI-1383528, EBI-2116369; CC P17252; P43234: CTSO; NbExp=3; IntAct=EBI-1383528, EBI-2874283; CC P17252; O95424: DEXI; NbExp=3; IntAct=EBI-1383528, EBI-724515; CC P17252; P78352: DLG4; NbExp=2; IntAct=EBI-1383528, EBI-80389; CC P17252; O43598: DNPH1; NbExp=3; IntAct=EBI-1383528, EBI-748674; CC P17252; P21728: DRD1; NbExp=3; IntAct=EBI-1383528, EBI-6624459; CC P17252; P00533: EGFR; NbExp=3; IntAct=EBI-1383528, EBI-297353; CC P17252; P60228: EIF3E; NbExp=3; IntAct=EBI-1383528, EBI-347740; CC P17252; Q96J88-3: EPSTI1; NbExp=3; IntAct=EBI-1383528, EBI-25885343; CC P17252; Q8IVH2-2: FOXP4; NbExp=3; IntAct=EBI-1383528, EBI-25885364; CC P17252; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1383528, EBI-13213391; CC P17252; O14926: FSCN2; NbExp=3; IntAct=EBI-1383528, EBI-21017948; CC P17252; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-1383528, EBI-9088619; CC P17252; P19440-3: GGT1; NbExp=3; IntAct=EBI-1383528, EBI-21558069; CC P17252; Q9UJ42: GPR160; NbExp=3; IntAct=EBI-1383528, EBI-25885139; CC P17252; P62805: H4C9; NbExp=3; IntAct=EBI-1383528, EBI-302023; CC P17252; Q9UBN7: HDAC6; NbExp=2; IntAct=EBI-1383528, EBI-301697; CC P17252; P52597: HNRNPF; NbExp=3; IntAct=EBI-1383528, EBI-352986; CC P17252; Q92826: HOXB13; NbExp=3; IntAct=EBI-1383528, EBI-11317274; CC P17252; Q02363: ID2; NbExp=3; IntAct=EBI-1383528, EBI-713450; CC P17252; Q96FT9-2: IFT43; NbExp=3; IntAct=EBI-1383528, EBI-11944538; CC P17252; P17936: IGFBP3; NbExp=3; IntAct=EBI-1383528, EBI-715709; CC P17252; P26951: IL3RA; NbExp=3; IntAct=EBI-1383528, EBI-1757512; CC P17252; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-1383528, EBI-9996449; CC P17252; Q9Y234: LIPT1; NbExp=4; IntAct=EBI-1383528, EBI-727376; CC P17252; P51884: LUM; NbExp=3; IntAct=EBI-1383528, EBI-725780; CC P17252; Q9H213: MAGEH1; NbExp=3; IntAct=EBI-1383528, EBI-473834; CC P17252; P80192: MAP3K9; NbExp=3; IntAct=EBI-1383528, EBI-3951604; CC P17252; Q15759: MAPK11; NbExp=3; IntAct=EBI-1383528, EBI-298304; CC P17252; A0JLT2-2: MED19; NbExp=3; IntAct=EBI-1383528, EBI-13288755; CC P17252; Q8N983-3: MRPL43; NbExp=3; IntAct=EBI-1383528, EBI-11109389; CC P17252; P49821: NDUFV1; NbExp=3; IntAct=EBI-1383528, EBI-748312; CC P17252; Q2M1J6: OXA1L; NbExp=3; IntAct=EBI-1383528, EBI-9978021; CC P17252; Q9BRX2: PELO; NbExp=3; IntAct=EBI-1383528, EBI-1043580; CC P17252; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-1383528, EBI-2803703; CC P17252; P11309-2: PIM1; NbExp=2; IntAct=EBI-1383528, EBI-1018633; CC P17252; Q6P1J6-2: PLB1; NbExp=3; IntAct=EBI-1383528, EBI-10694821; CC P17252; Q9UNA4: POLI; NbExp=3; IntAct=EBI-1383528, EBI-741774; CC P17252; Q02156: PRKCE; NbExp=2; IntAct=EBI-1383528, EBI-706254; CC P17252; P05129: PRKCG; NbExp=6; IntAct=EBI-1383528, EBI-949799; CC P17252; P07225: PROS1; NbExp=3; IntAct=EBI-1383528, EBI-2803380; CC P17252; Q3YEC7-3: RABL6; NbExp=3; IntAct=EBI-1383528, EBI-25885259; CC P17252; O94844: RHOBTB1; NbExp=3; IntAct=EBI-1383528, EBI-6426999; CC P17252; Q9NWS8-3: RMND1; NbExp=3; IntAct=EBI-1383528, EBI-25884400; CC P17252; Q9ULK6-3: RNF150; NbExp=3; IntAct=EBI-1383528, EBI-36513929; CC P17252; P18077: RPL35A; NbExp=3; IntAct=EBI-1383528, EBI-353383; CC P17252; Q14160: SCRIB; NbExp=3; IntAct=EBI-1383528, EBI-357345; CC P17252; P31431: SDC4; NbExp=2; IntAct=EBI-1383528, EBI-3913237; CC P17252; Q99643: SDHC; NbExp=3; IntAct=EBI-1383528, EBI-1224539; CC P17252; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-1383528, EBI-745901; CC P17252; Q01105-2: SET; NbExp=3; IntAct=EBI-1383528, EBI-7481343; CC P17252; P37840: SNCA; NbExp=3; IntAct=EBI-1383528, EBI-985879; CC P17252; Q9Y5X0: SNX10; NbExp=3; IntAct=EBI-1383528, EBI-10329478; CC P17252; P56693: SOX10; NbExp=3; IntAct=EBI-1383528, EBI-1167533; CC P17252; Q9BRW5: SP2; NbExp=3; IntAct=EBI-1383528, EBI-25868254; CC P17252; O43761: SYNGR3; NbExp=3; IntAct=EBI-1383528, EBI-11321949; CC P17252; P15884: TCF4; NbExp=3; IntAct=EBI-1383528, EBI-533224; CC P17252; Q3YBM2: TMEM176B; NbExp=3; IntAct=EBI-1383528, EBI-2821479; CC P17252; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-1383528, EBI-1390168; CC P17252; P0CG48: UBC; NbExp=2; IntAct=EBI-1383528, EBI-3390054; CC P17252; P13051-2: UNG; NbExp=3; IntAct=EBI-1383528, EBI-25834258; CC P17252; Q8NB14: USP38; NbExp=3; IntAct=EBI-1383528, EBI-2512509; CC P17252; O95498: VNN2; NbExp=3; IntAct=EBI-1383528, EBI-21494555; CC P17252; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-1383528, EBI-12040603; CC P17252; Q9BQ24: ZFYVE21; NbExp=3; IntAct=EBI-1383528, EBI-2849569; CC P17252; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-1383528, EBI-25835471; CC P17252; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-1383528, EBI-12010736; CC P17252; O15535: ZSCAN9; NbExp=3; IntAct=EBI-1383528, EBI-751531; CC P17252; Q24008: inaD; Xeno; NbExp=2; IntAct=EBI-1383528, EBI-195326; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23990668}. Cell CC membrane {ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:36040231}; CC Peripheral membrane protein {ECO:0000305|PubMed:23990668, CC ECO:0000305|PubMed:36040231}. Mitochondrion membrane CC {ECO:0000269|PubMed:9738012}; Peripheral membrane protein CC {ECO:0000305|PubMed:9738012}. Nucleus {ECO:0000250|UniProtKB:P20444}. CC -!- PTM: In response to growth factors, phosphorylated at Thr-631 and Ser- CC 657 by the mTORC2 complex, promoting autophosphorylation and activation CC of PRKCA. {ECO:0000269|PubMed:21806543}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52479; CAA36718.1; -; mRNA. DR EMBL; AB451258; BAG70072.1; -; mRNA. DR EMBL; AB451383; BAG70197.1; -; mRNA. DR EMBL; AC005918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006263; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006947; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC009452; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC060796; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89014.1; -; Genomic_DNA. DR EMBL; BC109273; AAI09274.1; -; mRNA. DR EMBL; BC109274; AAI09275.1; -; mRNA. DR EMBL; M22199; AAA60098.1; -; mRNA. DR EMBL; AF395829; AAK84184.1; -; Genomic_DNA. DR CCDS; CCDS11664.1; -. DR PIR; S09496; KIHUCA. DR RefSeq; NP_002728.2; NM_002737.3. DR PDB; 2ELI; NMR; -; A=93-169. DR PDB; 3IW4; X-ray; 2.80 A; A/B/C=320-672. DR PDB; 4DNL; X-ray; 1.90 A; A=155-293. DR PDB; 4RA4; X-ray; 2.63 A; A=318-672. DR PDB; 8U37; X-ray; 2.48 A; A=320-672. DR PDB; 8UAK; X-ray; 2.82 A; A=320-672. DR PDBsum; 2ELI; -. DR PDBsum; 3IW4; -. DR PDBsum; 4DNL; -. DR PDBsum; 4RA4; -. DR PDBsum; 8U37; -. DR PDBsum; 8UAK; -. DR AlphaFoldDB; P17252; -. DR BMRB; P17252; -. DR SMR; P17252; -. DR BioGRID; 111564; 342. DR CORUM; P17252; -. DR DIP; DIP-531N; -. DR FunCoup; P17252; 2547. DR IntAct; P17252; 209. DR MINT; P17252; -. DR STRING; 9606.ENSP00000408695; -. DR BindingDB; P17252; -. DR ChEMBL; CHEMBL299; -. DR DrugBank; DB12996; Acteoside. DR DrugBank; DB14001; alpha-Tocopherol succinate. DR DrugBank; DB06451; Aprinocarsen. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB11752; Bryostatin 1. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB14002; D-alpha-Tocopherol acetate. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB08846; Ellagic acid. DR DrugBank; DB05013; Ingenol mebutate. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB06819; Phenylbutyric acid. DR DrugBank; DB00144; Phosphatidyl serine. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB00163; Vitamin E. DR DrugCentral; P17252; -. DR GuidetoPHARMACOLOGY; 1482; -. DR GlyGen; P17252; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P17252; -. DR MetOSite; P17252; -. DR PhosphoSitePlus; P17252; -. DR SwissPalm; P17252; -. DR BioMuta; PRKCA; -. DR DMDM; 317373571; -. DR CPTAC; CPTAC-1615; -. DR CPTAC; CPTAC-3172; -. DR CPTAC; CPTAC-3173; -. DR jPOST; P17252; -. DR MassIVE; P17252; -. DR PaxDb; 9606-ENSP00000408695; -. DR PeptideAtlas; P17252; -. DR ProteomicsDB; 53464; -. DR Pumba; P17252; -. DR Antibodypedia; 1464; 1251 antibodies from 49 providers. DR DNASU; 5578; -. DR Ensembl; ENST00000413366.8; ENSP00000408695.3; ENSG00000154229.13. DR GeneID; 5578; -. DR KEGG; hsa:5578; -. DR MANE-Select; ENST00000413366.8; ENSP00000408695.3; NM_002737.3; NP_002728.2. DR UCSC; uc002jfp.2; human. DR AGR; HGNC:9393; -. DR ClinPGx; PA33759; -. DR CTD; 5578; -. DR DisGeNET; 5578; -. DR GeneCards; PRKCA; -. DR HGNC; HGNC:9393; PRKCA. DR HPA; ENSG00000154229; Tissue enhanced (brain). DR MalaCards; PRKCA; -. DR MIM; 176960; gene. DR OpenTargets; ENSG00000154229; -. DR VEuPathDB; HostDB:ENSG00000154229; -. DR eggNOG; KOG0696; Eukaryota. DR GeneTree; ENSGT00940000156104; -. DR HOGENOM; CLU_000288_54_2_1; -. DR InParanoid; P17252; -. DR OMA; VHEIKSH; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P17252; 3 GO annotations based on evolutionary models. DR PhylomeDB; P17252; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P17252; -. DR Reactome; R-HSA-111933; Calmodulin induced events. DR Reactome; R-HSA-114516; Disinhibition of SNARE formation. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1433559; Regulation of KIT signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR Reactome; R-HSA-3000170; Syndecan interactions. DR Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion. DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-4419969; Depolymerization of the Nuclear Lamina. DR Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA. DR Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9010642; ROBO receptors bind AKAP5. DR SABIO-RK; P17252; -. DR SignaLink; P17252; -. DR SIGNOR; P17252; -. DR Agora; ENSG00000154229; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5578; 13 hits in 1191 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PRKCA; human. DR EvolutionaryTrace; P17252; -. DR GeneWiki; PKC_alpha; -. DR GenomeRNAi; 5578; -. DR Pharos; P17252; Tchem. DR PRO; PR:P17252; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P17252; protein. DR Bgee; ENSG00000154229; Expressed in CA1 field of hippocampus and 192 other cell types or tissues. DR ExpressionAtlas; P17252; baseline and differential. DR GO; GO:0035866; C:alphav-beta3 integrin-PKCalpha complex; ISS:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0019992; F:diacylglycerol binding; TAS:Reactome. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0035403; F:histone H3T6 kinase activity; IDA:UniProtKB. DR GO; GO:0005178; F:integrin binding; ISS:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; IEA:Ensembl. DR GO; GO:0002159; P:desmosome assembly; IMP:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007611; P:learning or memory; IEA:Ensembl. DR GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome. DR GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IEA:Ensembl. DR GO; GO:0106071; P:positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0110063; P:positive regulation of angiotensin-activated signaling pathway; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0045780; P:positive regulation of bone resorption; ISS:BHF-UCL. DR GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045921; P:positive regulation of exocytosis; IEA:Ensembl. DR GO; GO:0032024; P:positive regulation of insulin secretion; TAS:Reactome. DR GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0090330; P:regulation of platelet aggregation; IDA:UniProtKB. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl. DR GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl. DR GO; GO:1904627; P:response to phorbol 13-acetate 12-myristate; IEA:Ensembl. DR GO; GO:0000302; P:response to reactive oxygen species; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR CDD; cd20833; C1_cPKC_rpt1; 1. DR CDD; cd20836; C1_cPKC_rpt2; 1. DR CDD; cd04026; C2_PKC_alpha_gamma; 1. DR CDD; cd05615; STKc_cPKC_alpha; 1. DR FunFam; 2.60.40.150:FF:000012; Kinase C alpha type; 1. DR FunFam; 1.10.510.10:FF:000023; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000103; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000006; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000031; Protein kinase C alpha; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR034663; cPKC_alpha. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014375; Protein_kinase_C_a/b/g. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000550; PKC_alpha; 1. DR PRINTS; PR00360; C2DOMAIN. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding; Calcium; KW Cell adhesion; Cell membrane; Cytoplasm; Direct protein sequencing; Kinase; KW Membrane; Metal-binding; Mitochondrion; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Proto-oncogene; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase; KW Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22814378" FT CHAIN 2..672 FT /note="Protein kinase C alpha type" FT /id="PRO_0000055679" FT DOMAIN 158..275 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 339..597 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 598..668 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 36..86 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 101..151 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ACT_SITE 463 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 186 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 193 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 195 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 245 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 247 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 252 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 345..353 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 368 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:21806543" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 10 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 226 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P05696" FT MOD_RES 494 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 495 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 497 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000250|UniProtKB:P04409, ECO:0000305" FT MOD_RES 501 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P05771" FT MOD_RES 628 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 631 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P20444" FT MOD_RES 638 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 657 FT /note="Phosphoserine; by MTOR" FT /evidence="ECO:0000269|PubMed:21806543, FT ECO:0007744|PubMed:24275569" FT MOD_RES 658 FT /note="Phosphotyrosine; by SYK" FT /evidence="ECO:0000250|UniProtKB:P20444" FT VARIANT 98 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042301" FT VARIANT 467 FT /note="D -> N (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042302" FT VARIANT 489 FT /note="M -> V (in dbSNP:rs34406842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042303" FT VARIANT 568 FT /note="V -> I (in dbSNP:rs6504459)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851, ECO:0000269|PubMed:2336401, FT ECO:0000269|Ref.4" FT /id="VAR_050558" FT MUTAGEN 368 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:21806543" FT CONFLICT 50 FT /note="C -> S (in Ref. 6; AAA60098)" FT /evidence="ECO:0000305" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 116..118 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 129..131 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 138..140 FT /evidence="ECO:0007829|PDB:2ELI" FT TURN 141..146 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 161..169 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 172..182 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 194..202 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 222..230 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 233..237 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 239..246 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 254..262 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 263..268 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 271..276 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 282..284 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 336..338 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 339..348 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 351..358 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 364..371 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 372..378 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 381..392 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 410..418 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 422..424 FT /evidence="ECO:0007829|PDB:3IW4" FT HELIX 425..430 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 437..456 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 466..468 FT /evidence="ECO:0007829|PDB:4RA4" FT STRAND 469..471 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 477..479 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 502..504 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 507..510 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 518..533 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 543..552 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 563..572 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 577..579 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 587..592 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 595..597 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 602..606 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 642..645 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 650..653 FT /evidence="ECO:0007829|PDB:8U37" SQ SEQUENCE 672 AA; 76750 MW; 9EB157789A062349 CRC64; MADVFPGNDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVAD EKLHVTVRDA KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNME LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG EDEDELFQSI MEHNVSYPKS LSKEAVSVCK GLMTKHPAKR LGCGPEGERD VREHAFFRRI DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN PQFVHPILQS AV // ID KS6A3_HUMAN Reviewed; 740 AA. AC P51812; B2R9V4; Q4VAP3; Q59H26; Q5JPK8; Q7Z3Z7; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1996, sequence version 1. DT 28-JAN-2026, entry version 235. DE RecName: Full=Ribosomal protein S6 kinase alpha-3; DE Short=S6K-alpha-3; DE EC=2.7.11.1 {ECO:0000269|PubMed:17213202}; DE AltName: Full=90 kDa ribosomal protein S6 kinase 3; DE Short=p90-RSK 3; DE Short=p90RSK3; DE AltName: Full=Insulin-stimulated protein kinase 1; DE Short=ISPK-1; DE AltName: Full=MAP kinase-activated protein kinase 1b; DE Short=MAPK-activated protein kinase 1b; DE Short=MAPKAP kinase 1b; DE Short=MAPKAPK-1b; DE AltName: Full=Ribosomal S6 kinase 2; DE Short=RSK-2; DE AltName: Full=pp90RSK2; GN Name=RPS6KA3; Synonyms=ISPK1, MAPKAPK1B, RSK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta, and T-cell; RX PubMed=7813820; DOI=10.2337/diab.44.1.90; RA Bjoerbaek C., Vik T.A., Echwald S.M., Webb G.C., Wang J.P., Yang P.-Y., RA Vestergaard H., Richmond K., Hansen T., Erikson R.L., Miklos G.L.G., RA Cohen P.T.W., Pedersen O.; RT "Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and RT analysis of coding regions and mRNA levels of the ISPK-1 and the protein RT phosphatase-1 genes in muscle from NIDDM patients."; RL Diabetes 44:90-97(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2-582. RC TISSUE=Skeletal muscle; RX PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351; RA Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.; RT "Human rsk isoforms: cloning and characterization of tissue-specific RT expression."; RL Am. J. Physiol. 266:C351-C359(1994). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-735. RX PubMed=12777533; DOI=10.1093/molbev/msg134; RA Kitano T., Schwarz C., Nickel B., Paeaebo S.; RT "Gene diversity patterns at 10 X-chromosomal loci in humans and RT chimpanzees."; RL Mol. Biol. Evol. 20:1281-1289(2003). RN [8] RP FUNCTION IN PHOSPHORYLATION OF GSK3B. RX PubMed=8250835; DOI=10.1042/bj2960015; RA Sutherland C., Leighton I.A., Cohen P.; RT "Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new RT kinase connections in insulin and growth-factor signalling."; RL Biochem. J. 296:15-19(1993). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9770464; DOI=10.1073/pnas.95.21.12202; RA De Cesare D., Jacquot S., Hanauer A., Sassone-Corsi P.; RT "Rsk-2 activity is necessary for epidermal growth factor-induced RT phosphorylation of CREB protein and transcription of c-fos gene."; RL Proc. Natl. Acad. Sci. U.S.A. 95:12202-12207(1998). RN [10] RP FUNCTION IN PHOSPHORYLATION OF HISTONE H3. RX PubMed=10436156; DOI=10.1126/science.285.5429.886; RA Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L., Jacquot S., RA Hanauer A., Allis C.D.; RT "Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation RT of histone H3."; RL Science 285:886-891(1999). RN [11] RP FUNCTION IN PHOSPHORYLATION OF DAPK1. RX PubMed=16213824; DOI=10.1016/j.cub.2005.08.050; RA Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.; RT "The tumor suppressor DAP kinase is a target of RSK-mediated survival RT signaling."; RL Curr. Biol. 15:1762-1767(2005). RN [12] RP FUNCTION IN PHOSPHORYLATION OF NR4A1/NUR77. RX PubMed=16223362; DOI=10.1042/bj20050967; RA Wingate A.D., Campbell D.G., Peggie M., Arthur J.S.; RT "Nur77 is phosphorylated in cells by RSK in response to mitogenic RT stimulation."; RL Biochem. J. 393:715-724(2006). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH NFATC4, RP AND SUBCELLULAR LOCATION. RX PubMed=17213202; DOI=10.1074/jbc.m611322200; RA Cho Y.-Y., Yao K., Bode A.M., Bergen H.R. III, Madden B.J., Oh S.-M., RA Ermakova S., Kang B.S., Choi H.S., Shim J.-H., Dong Z.; RT "RSK2 mediates muscle cell differentiation through regulation of NFAT3."; RL J. Biol. Chem. 282:8380-8392(2007). RN [15] RP FUNCTION IN PHOSPHORYLATION OF RPS6. RX PubMed=17360704; DOI=10.1074/jbc.m700906200; RA Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J., RA Sonenberg N., Blenis J.; RT "RAS/ERK signaling promotes site-specific ribosomal protein S6 RT phosphorylation via RSK and stimulates cap-dependent translation."; RL J. Biol. Chem. 282:14056-14064(2007). RN [16] RP FUNCTION IN MTOR SIGNALING. RX PubMed=18722121; DOI=10.1016/j.cub.2008.07.078; RA Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., RA Roux P.P.; RT "Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK- RT mediated raptor phosphorylation."; RL Curr. Biol. 18:1269-1277(2008). RN [17] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=18508509; DOI=10.2741/3003; RA Carriere A., Ray H., Blenis J., Roux P.P.; RT "The RSK factors of activating the Ras/MAPK signaling cascade."; RL Front. Biosci. 13:4258-4275(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375; RP SER-386; SER-415; SER-556 AND SER-715, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369 AND SER-375, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375; RP SER-386; SER-415 AND SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-415, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365 AND SER-369, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-415 AND RP SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-369; SER-386; SER-415 AND RP SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [28] RP FUNCTION IN PHOSPHORYLATION OF EPHA2. RX PubMed=26158630; DOI=10.1038/ncomms8679; RA Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., RA Fukuoka J., Koizumi K., Saiki I., Sakurai H.; RT "Crucial roles of RSK in cell motility by catalysing serine phosphorylation RT of EphA2."; RL Nat. Commun. 6:7679-7679(2015). RN [29] RP VARIANTS CLS VAL-75 AND ALA-227. RX PubMed=8955270; DOI=10.1038/384567a0; RA Trivier E., de Cesare D., Jacquot S., Pannetier S., Zackai E., Young I., RA Mandel J.-L., Sassone-Corsi P., Hanauer A.; RT "Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome."; RL Nature 384:567-570(1996). RN [30] RP VARIANTS CLS PHE-82; GLN-127; TYR-154; VAL-225 AND ASP-431, AND VARIANT RP SER-38. RX PubMed=9837815; DOI=10.1086/302153; RA Jacquot S., Merienne K., de Cesare D., Pannetier S., Mandel J.-L., RA Sassone-Corsi P., Hanauer A.; RT "Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive RT allelic heterogeneity and a high rate of De novo mutations."; RL Am. J. Hum. Genet. 63:1631-1640(1998). RN [31] RP VARIANTS CLS TRP-114 AND GLN-729. RX PubMed=10094187; DOI=10.1038/sj.ejhg.5200231; RA Abidi F., Jacquot S., Lassiter C., Trivier E., Hanauer A., Schwartz C.E.; RT "Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS)."; RL Eur. J. Hum. Genet. 7:20-26(1999). RN [32] RP VARIANT CLS LYS-189. RX PubMed=10528858; DOI=10.1136/jmg.36.10.775; RA Manouvrier-Hanu S., Amiel J., Jacquot S., Merienne K., Moerman A., RA Coeslier A., Labarriere F., Vallee L., Croquette M.F., Hanauer A.; RT "Unreported RSK2 missense mutation in two male sibs with an unusually mild RT form of Coffin-Lowry syndrome."; RL J. Med. Genet. 36:775-778(1999). RN [33] RP VARIANT XLID19 TRP-383, AND CHARACTERIZATION OF VARIANT XLID19 TRP-383. RX PubMed=10319851; DOI=10.1038/8719; RA Merienne K., Jacquot S., Pannetier S., Zeniou M., Bankier A., Gecz J., RA Mandel J.L., Mulley J., Sassone-Corsi P., Hanauer A.; RT "A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental RT retardation."; RL Nat. Genet. 22:13-14(1999). RN [34] RP VARIANT CLS SER-268. RX PubMed=14986828; DOI=10.1046/j.1399-0004.2003.00166.x; RA Martinez-Garay I., Ballesta M.J., Oltra S., Orellana C., Palomeque A., RA Molto M.D., Prieto F., Martinez F.; RT "Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2) causing RT Coffin-Lowry syndrome."; RL Clin. Genet. 64:491-496(2003). RN [35] RP VARIANT CLS ILE-477 DEL. RX PubMed=15214012; DOI=10.1002/ajmg.a.30056; RA Facher J.J., Regier E.J., Jacobs G.H., Siwik E., Delaunoy J.P., Robin N.H.; RT "Cardiomyopathy in Coffin-Lowry syndrome."; RL Am. J. Med. Genet. A 128:176-178(2004). RN [36] RP VARIANTS XLID19 SER-115; GLY-152 DEL AND ASP-202 DEL. RX PubMed=17100996; DOI=10.1111/j.1399-0004.2006.00723.x; RA Field M., Tarpey P., Boyle J., Edkins S., Goodship J., Luo Y., Moon J., RA Teague J., Stratton M.R., Futreal P.A., Wooster R., Raymond F.L., RA Turner G.; RT "Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and RT nonsyndromic X-linked mental retardation."; RL Clin. Genet. 70:509-515(2006). RN [37] RP VARIANT [LARGE SCALE ANALYSIS] VAL-416. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [38] RP VARIANTS [LARGE SCALE ANALYSIS] SER-38; CYS-483; PHE-608 AND CYS-723. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK CC (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and CC stress-induced activation of the transcription factors CREB1, ETV1/ER81 CC and NR4A1/NUR77, regulates translation through RPS6 and EIF4B CC phosphorylation, and mediates cellular proliferation, survival, and CC differentiation by modulating mTOR signaling and repressing pro- CC apoptotic function of BAD and DAPK1 (PubMed:16213824, PubMed:16223362, CC PubMed:17360704, PubMed:9770464). In fibroblast, is required for EGF- CC stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which CC results in the subsequent transcriptional activation of several CC immediate-early genes (PubMed:10436156, PubMed:9770464). In response to CC mitogenic stimulation (EGF and PMA), phosphorylates and activates CC NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP CC (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the CC transcription regulation of several genes by phosphorylating GSK3B at CC 'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates CC RPS6 in response to serum or EGF via an mTOR-independent mechanism and CC promotes translation initiation by facilitating assembly of the CC preinitiation complex (PubMed:17360704). In response to insulin, CC phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and CC stimulating cap-dependent translation (PubMed:18508509, CC PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by CC directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits CC TSC2 ability to suppress mTOR signaling, and mediates phosphorylation CC of RPTOR, which regulates mTORC1 activity and may promote rapamycin- CC sensitive signaling independently of the PI3K/AKT pathway CC (PubMed:18722121). Mediates cell survival by phosphorylating the pro- CC apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic CC function (PubMed:16213824). Promotes the survival of hepatic stellate CC cells by phosphorylating CEBPB in response to the hepatotoxin carbon CC tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in CC cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, CC which promotes CDKN1B association with 14-3-3 proteins and prevents its CC translocation to the nucleus and inhibition of G1 progression (By CC similarity). In LPS-stimulated dendritic cells, is involved in TLR4- CC induced macropinocytosis, and in myeloma cells, acts as effector of CC FGFR3-mediated transformation signaling, after direct phosphorylation CC at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced CC MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity). CC Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and CC YWHAE binding sites and which contribute to the negative regulation of CC MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser- CC 897', the RPS6KA-EPHA2 signaling pathway controls cell migration CC (PubMed:26158630). Acts as a regulator of osteoblast differentiation by CC mediating phosphorylation of ATF4, thereby promoting ATF4 CC transactivation activity (By similarity). CC {ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156, CC ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362, CC ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121, CC ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835, CC ECO:0000269|PubMed:9770464, ECO:0000303|PubMed:18508509, CC ECO:0000303|PubMed:18813292}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17213202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation, CC phosphorylated at Thr-577 in the C-terminal kinase domain (CTKD) by CC MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates CC Ser-386, allowing binding of PDPK1, which in turn phosphorylates Ser- CC 227 in the N-terminal kinase domain (NTDK) leading to the full CC activation of the protein and subsequent phosphorylation of the CC substrates by the NTKD. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=3.56 uM for NFATC4 {ECO:0000269|PubMed:17213202}; CC Vmax=11.5 umol/min/ug enzyme toward ATP CC {ECO:0000269|PubMed:17213202}; CC -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in CC quiescent cells. Transiently dissociates following mitogenic CC stimulation (By similarity). Interacts with NFATC4, ETV1/ER81 and CC FGFR1. {ECO:0000250, ECO:0000269|PubMed:17213202}. CC -!- INTERACTION: CC P51812; Q02410: APBA1; NbExp=2; IntAct=EBI-1046616, EBI-368690; CC P51812; P46379-2: BAG6; NbExp=3; IntAct=EBI-1046616, EBI-10988864; CC P51812; P67870: CSNK2B; NbExp=8; IntAct=EBI-1046616, EBI-348169; CC P51812; Q12959: DLG1; NbExp=3; IntAct=EBI-1046616, EBI-357481; CC P51812; P09471: GNAO1; NbExp=3; IntAct=EBI-1046616, EBI-715087; CC P51812; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1046616, EBI-352572; CC P51812; O14901: KLF11; NbExp=3; IntAct=EBI-1046616, EBI-948266; CC P51812; Q86UL8: MAGI2; NbExp=3; IntAct=EBI-1046616, EBI-311035; CC P51812; P28482: MAPK1; NbExp=12; IntAct=EBI-1046616, EBI-959949; CC P51812; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-1046616, EBI-11750983; CC P51812; Q15599: NHERF2; NbExp=2; IntAct=EBI-1046616, EBI-1149760; CC P51812; Q6P4D5-2: PABIR3; NbExp=3; IntAct=EBI-1046616, EBI-9091052; CC P51812; Q5T2W1: PDZK1; NbExp=2; IntAct=EBI-1046616, EBI-349819; CC P51812; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-1046616, EBI-9090282; CC P51812; Q14160: SCRIB; NbExp=2; IntAct=EBI-1046616, EBI-357345; CC P51812; Q7Z698: SPRED2; NbExp=4; IntAct=EBI-1046616, EBI-7082156; CC P51812; Q9P202: WHRN; NbExp=2; IntAct=EBI-1046616, EBI-310886; CC P51812; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-1046616, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17213202}. Cytoplasm CC {ECO:0000269|PubMed:17213202}. CC -!- TISSUE SPECIFICITY: Expressed in many tissues, highest levels in CC skeletal muscle. CC -!- PTM: Activated by phosphorylation at Ser-227 by PDPK1. CC Autophosphorylated on Ser-386, as part of the activation process. May CC be phosphorylated at Thr-365 and Ser-369 by MAPK1/ERK2 and MAPK3/ERK1. CC Can also be activated via phosphorylation at Ser-386 by MAPKAPK2. CC -!- PTM: N-terminal myristoylation results in an activated kinase in the CC absence of added growth factors. CC -!- DISEASE: Coffin-Lowry syndrome (CLS) [MIM:303600]: An X-linked disorder CC characterized by intellectual disability associated with facial and CC digital dysmorphisms, progressive skeletal malformations, growth CC retardation, hearing deficit and paroxysmal movement disorders. CC {ECO:0000269|PubMed:10094187, ECO:0000269|PubMed:10528858, CC ECO:0000269|PubMed:14986828, ECO:0000269|PubMed:15214012, CC ECO:0000269|PubMed:8955270, ECO:0000269|PubMed:9837815}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intellectual developmental disorder, X-linked 19 (XLID19) CC [MIM:300844]: A disorder characterized by significantly below average CC general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. CC {ECO:0000269|PubMed:10319851, ECO:0000269|PubMed:17100996}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92170.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U08316; AAA81952.1; -; mRNA. DR EMBL; AK313932; BAG36651.1; -; mRNA. DR EMBL; AB208933; BAD92170.1; ALT_INIT; mRNA. DR EMBL; AL732366; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL807772; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC096301; AAH96301.1; -; mRNA. DR EMBL; BC096302; AAH96302.1; -; mRNA. DR EMBL; BC096303; AAH96303.1; -; mRNA. DR EMBL; L07599; AAC82495.1; -; mRNA. DR EMBL; AB102662; BAC81131.1; -; mRNA. DR CCDS; CCDS14197.1; -. DR PIR; I38556; I38556. DR RefSeq; NP_004577.1; NM_004586.3. DR PDB; 4D9T; X-ray; 2.40 A; A=399-740. DR PDB; 4D9U; X-ray; 2.40 A; A=399-740. DR PDB; 4JG6; X-ray; 2.60 A; A=399-740. DR PDB; 4JG7; X-ray; 3.00 A; A=399-740. DR PDB; 4JG8; X-ray; 3.10 A; A=399-740. DR PDB; 4NUS; X-ray; 2.39 A; A=39-359. DR PDB; 4NW5; X-ray; 1.94 A; A=39-359. DR PDB; 4NW6; X-ray; 1.74 A; A=39-359. DR PDB; 5D9K; X-ray; 2.55 A; A/B=39-366. DR PDB; 5D9L; X-ray; 2.15 A; A=39-359. DR PDB; 7OPO; X-ray; 2.75 A; A/C/E/G/I/K=39-351. DR PDB; 8EQ5; X-ray; 1.80 A; A=46-346. DR PDB; 8R58; X-ray; 2.31 A; A=39-351. DR PDB; 8XEY; X-ray; 2.65 A; A=400-740. DR PDB; 8XFY; X-ray; 3.20 A; A/B/C/D/E/F/G/H/I/J=40-359. DR PDBsum; 4D9T; -. DR PDBsum; 4D9U; -. DR PDBsum; 4JG6; -. DR PDBsum; 4JG7; -. DR PDBsum; 4JG8; -. DR PDBsum; 4NUS; -. DR PDBsum; 4NW5; -. DR PDBsum; 4NW6; -. DR PDBsum; 5D9K; -. DR PDBsum; 5D9L; -. DR PDBsum; 7OPO; -. DR PDBsum; 8EQ5; -. DR PDBsum; 8R58; -. DR PDBsum; 8XEY; -. DR PDBsum; 8XFY; -. DR AlphaFoldDB; P51812; -. DR SMR; P51812; -. DR BioGRID; 112111; 215. DR DIP; DIP-38247N; -. DR FunCoup; P51812; 2985. DR IntAct; P51812; 146. DR MINT; P51812; -. DR STRING; 9606.ENSP00000368884; -. DR BindingDB; P51812; -. DR ChEMBL; CHEMBL2345; -. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P51812; -. DR GuidetoPHARMACOLOGY; 1528; -. DR GlyCosmos; P51812; 1 site, 1 glycan. DR GlyGen; P51812; 6 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P51812; -. DR MetOSite; P51812; -. DR PhosphoSitePlus; P51812; -. DR BioMuta; RPS6KA3; -. DR DMDM; 1730070; -. DR CPTAC; CPTAC-2899; -. DR CPTAC; CPTAC-2900; -. DR jPOST; P51812; -. DR MassIVE; P51812; -. DR PaxDb; 9606-ENSP00000368884; -. DR PeptideAtlas; P51812; -. DR ProteomicsDB; 56408; -. DR Pumba; P51812; -. DR Antibodypedia; 1004; 599 antibodies from 40 providers. DR DNASU; 6197; -. DR Ensembl; ENST00000379565.9; ENSP00000368884.3; ENSG00000177189.15. DR GeneID; 6197; -. DR KEGG; hsa:6197; -. DR MANE-Select; ENST00000379565.9; ENSP00000368884.3; NM_004586.3; NP_004577.1. DR UCSC; uc004czu.4; human. DR AGR; HGNC:10432; -. DR ClinPGx; PA34847; -. DR CTD; 6197; -. DR DisGeNET; 6197; -. DR GeneCards; RPS6KA3; -. DR GeneReviews; RPS6KA3; -. DR HGNC; HGNC:10432; RPS6KA3. DR HPA; ENSG00000177189; Low tissue specificity. DR MalaCards; RPS6KA3; -. DR MIM; 300075; gene. DR MIM; 300844; phenotype. DR MIM; 303600; phenotype. DR OpenTargets; ENSG00000177189; -. DR Orphanet; 192; Coffin-Lowry syndrome. DR Orphanet; 276630; Symptomatic form of Coffin-Lowry syndrome in female carriers. DR Orphanet; 777; X-linked non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000177189; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159370; -. DR HOGENOM; CLU_000288_58_3_1; -. DR InParanoid; P51812; -. DR OMA; QTDEVFY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P51812; 4 GO annotations based on evolutionary models. DR PhylomeDB; P51812; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P51812; -. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-199920; CREB phosphorylation. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR SABIO-RK; P51812; -. DR SignaLink; P51812; -. DR SIGNOR; P51812; -. DR Agora; ENSG00000177189; -. DR BioGRID-ORCS; 6197; 25 hits in 814 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; RPS6KA3; human. DR EvolutionaryTrace; P51812; -. DR GeneWiki; RPS6KA3; -. DR GenomeRNAi; 6197; -. DR Pharos; P51812; Tchem. DR PRO; PR:P51812; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51812; protein. DR Bgee; ENSG00000177189; Expressed in cartilage tissue and 204 other cell types or tissues. DR ExpressionAtlas; P51812; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0007417; P:central nervous system development; TAS:ProtInc. DR GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0045597; P:positive regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0030307; P:positive regulation of cell growth; TAS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0043555; P:regulation of translation in response to stress; TAS:UniProtKB. DR GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0001501; P:skeletal system development; TAS:ProtInc. DR GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14176; STKc_RSK2_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR041905; RPS6KA3_C. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cytoplasm; Disease variant; KW Intellectual disability; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; KW Stress response; Transferase. FT CHAIN 1..740 FT /note="Ribosomal protein S6 kinase alpha-3" FT /id="PRO_0000086203" FT DOMAIN 68..327 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 328..397 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 422..679 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 18..27 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 193 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 539 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 74..82 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 100 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 428..436 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 451 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 227 FT /note="Phosphoserine; by PDPK1" FT /evidence="ECO:0000250|UniProtKB:P18654, ECO:0000305" FT MOD_RES 365 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 369 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 375 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195" FT MOD_RES 386 FT /note="Phosphoserine; by autocatalysis and MAPKAPK2" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:24275569" FT MOD_RES 415 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 529 FT /note="Phosphotyrosine; by FGFR3" FT /evidence="ECO:0000250|UniProtKB:P18654" FT MOD_RES 556 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 715 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VARIANT 38 FT /note="I -> S (in dbSNP:rs56218010)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9837815" FT /id="VAR_006188" FT VARIANT 75 FT /note="G -> V (in CLS; dbSNP:rs122454124)" FT /evidence="ECO:0000269|PubMed:8955270" FT /id="VAR_006189" FT VARIANT 82 FT /note="V -> F (in CLS; dbSNP:rs122454126)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006190" FT VARIANT 114 FT /note="R -> W (in CLS; dbSNP:rs122454127)" FT /evidence="ECO:0000269|PubMed:10094187" FT /id="VAR_006191" FT VARIANT 115 FT /note="T -> S (in XLID19; dbSNP:rs387906703)" FT /evidence="ECO:0000269|PubMed:17100996" FT /id="VAR_065892" FT VARIANT 127 FT /note="H -> Q (in CLS)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006192" FT VARIANT 152 FT /note="Missing (in XLID19; dbSNP:rs398122813)" FT /evidence="ECO:0000269|PubMed:17100996" FT /id="VAR_065893" FT VARIANT 154 FT /note="D -> Y (in CLS)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006193" FT VARIANT 189 FT /note="I -> K (in CLS; dbSNP:rs122454130)" FT /evidence="ECO:0000269|PubMed:10528858" FT /id="VAR_065894" FT VARIANT 202 FT /note="Missing (in XLID19)" FT /evidence="ECO:0000269|PubMed:17100996" FT /id="VAR_065895" FT VARIANT 225 FT /note="A -> V (in CLS; dbSNP:rs879027948)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006194" FT VARIANT 227 FT /note="S -> A (in CLS; dbSNP:rs122454125)" FT /evidence="ECO:0000269|PubMed:8955270" FT /id="VAR_006195" FT VARIANT 268 FT /note="F -> S (in CLS; dbSNP:rs122454131)" FT /evidence="ECO:0000269|PubMed:14986828" FT /id="VAR_065896" FT VARIANT 383 FT /note="R -> W (in XLID19; kinase activity is decreased but FT not abolished; dbSNP:rs122454129)" FT /evidence="ECO:0000269|PubMed:10319851" FT /id="VAR_065897" FT VARIANT 416 FT /note="I -> V (in a breast cancer sample; somatic mutation; FT dbSNP:rs148050184)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035627" FT VARIANT 431 FT /note="G -> D (in CLS)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006196" FT VARIANT 477 FT /note="Missing (in CLS)" FT /evidence="ECO:0000269|PubMed:15214012" FT /id="VAR_065898" FT VARIANT 483 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1271090915)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040629" FT VARIANT 608 FT /note="L -> F (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040630" FT VARIANT 723 FT /note="R -> C (in dbSNP:rs35026425)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040631" FT VARIANT 729 FT /note="R -> Q (in CLS; dbSNP:rs28935171)" FT /evidence="ECO:0000269|PubMed:10094187" FT /id="VAR_006197" FT CONFLICT 89 FT /note="S -> L (in Ref. 5; AAH96303)" FT /evidence="ECO:0000305" FT CONFLICT 410 FT /note="Missing (in Ref. 3; BAD92170)" FT /evidence="ECO:0000305" FT CONFLICT 424 FT /note="V -> L (in Ref. 6; AAC82495)" FT /evidence="ECO:0000305" FT CONFLICT 480 FT /note="K -> N (in Ref. 6; AAC82495)" FT /evidence="ECO:0000305" FT CONFLICT 494 FT /note="Missing (in Ref. 6; AAC82495)" FT /evidence="ECO:0000305" FT STRAND 50..56 FT /evidence="ECO:0007829|PDB:8EQ5" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 68..76 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 78..87 FT /evidence="ECO:0007829|PDB:4NW6" FT TURN 91..94 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:4NW6" FT TURN 105..107 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 109..124 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 133..139 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 142..148 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:5D9K" FT HELIX 155..162 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 167..186 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 189..192 FT /evidence="ECO:0007829|PDB:5D9L" FT HELIX 196..198 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4NUS" FT STRAND 207..209 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:5D9L" FT HELIX 217..223 FT /evidence="ECO:0007829|PDB:4NUS" FT TURN 224..226 FT /evidence="ECO:0007829|PDB:4NUS" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 237..240 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 249..263 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 273..282 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 293..302 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 304..306 FT /evidence="ECO:0007829|PDB:8EQ5" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:4NW6" FT TURN 315..318 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 319..322 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 332..336 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:5D9L" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:4JG7" FT HELIX 412..414 FT /evidence="ECO:0007829|PDB:4D9U" FT TURN 419..421 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 422..430 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 432..441 FT /evidence="ECO:0007829|PDB:4D9T" FT TURN 442..445 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 446..454 FT /evidence="ECO:0007829|PDB:4D9T" FT TURN 455..457 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 461..470 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 479..484 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 486..494 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 513..532 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 542..544 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 554..556 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 557..559 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 571..573 FT /evidence="ECO:0007829|PDB:8XEY" FT HELIX 587..613 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 626..635 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:4D9U" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:4JG6" FT HELIX 650..659 FT /evidence="ECO:0007829|PDB:4D9T" FT TURN 664..666 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 670..673 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 677..680 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 682..684 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 696..710 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 711..713 FT /evidence="ECO:0007829|PDB:4JG8" SQ SEQUENCE 740 AA; 83736 MW; 486AE8357CEAB6C8 CRC64; MPLAQLADPW QKMAVESPSD SAENGQQIMD EPMGEEEINP QTEEVSIKEI AITHHVKEGH EKADPSQFEL LKVLGQGSFG KVFLVKKISG SDARQLYAMK VLKKATLKVR DRVRTKMERD ILVEVNHPFI VKLHYAFQTE GKLYLILDFL RGGDLFTRLS KEVMFTEEDV KFYLAELALA LDHLHSLGII YRDLKPENIL LDEEGHIKLT DFGLSKESID HEKKAYSFCG TVEYMAPEVV NRRGHTQSAD WWSFGVLMFE MLTGTLPFQG KDRKETMTMI LKAKLGMPQF LSPEAQSLLR MLFKRNPANR LGAGPDGVEE IKRHSFFSTI DWNKLYRREI HPPFKPATGR PEDTFYFDPE FTAKTPKDSP GIPPSANAHQ LFRGFSFVAI TSDDESQAMQ TVGVHSIVQQ LHRNSIQFTD GYEVKEDIGV GSYSVCKRCI HKATNMEFAV KIIDKSKRDP TEEIEILLRY GQHPNIITLK DVYDDGKYVY VVTELMKGGE LLDKILRQKF FSEREASAVL FTITKTVEYL HAQGVVHRDL KPSNILYVDE SGNPESIRIC DFGFAKQLRA ENGLLMTPCY TANFVAPEVL KRQGYDAACD IWSLGVLLYT MLTGYTPFAN GPDDTPEEIL ARIGSGKFSL SGGYWNSVSD TAKDLVSKML HVDPHQRLTA ALVLRHPWIV HWDQLPQYQL NRQDAPHLVK GAMAATYSAL NRNQSPVLEP VGRSTLAQRR GIKKITSTAL // ID KS6C1_HUMAN Reviewed; 1066 AA. AC Q96S38; B1APS8; B3KVM4; D3DTA4; Q8TDD3; Q9NSF4; Q9UL66; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 02-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 189. DE RecName: Full=Ribosomal protein S6 kinase delta-1; DE Short=S6K-delta-1; DE EC=2.7.11.1; DE AltName: Full=52 kDa ribosomal protein S6 kinase; DE AltName: Full=Ribosomal S6 kinase-like protein with two PSK domains 118 kDa protein; DE AltName: Full=SPHK1-binding protein; GN Name=RPS6KC1; Synonyms=RPK118; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, INTERACTION RP WITH SPHK1 AND PHOSPHATIDYLINOSITOL 3-PHOSPHATE, SUBCELLULAR LOCATION, AND RP FUNCTION. RX PubMed=12077123; DOI=10.1074/jbc.m201442200; RA Hayashi S., Okada T., Igarashi N., Fujita T., Jahangeer S., Nakamura S.; RT "Identification and characterization of RPK118, a novel sphingosine kinase- RT 1-binding protein."; RL J. Biol. Chem. 277:33319-33324(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Guo J.H., Yu L.; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC TISSUE=Brain; RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 598-1066 (ISOFORM 1). RX PubMed=10552933; DOI=10.1006/geno.1999.5963; RA Zhang H., Yu L., Mao N., Fu Q., Tu Q., Gao J., Zhao S.; RT "Cloning, characterization, and chromosome mapping of RPS6KC1, a novel RT putative member of the ribosome protein S6 kinase family, to chromosome RT 12q12-q13.1."; RL Genomics 61:314-318(1999). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 683-1066 (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PRDX3. RX PubMed=15750338; DOI=10.1016/s1016-8478(23)13134-7; RA Liu L., Yang C., Yuan J., Chen X., Xu J., Wei Y., Yang J., Lin G., Yu L.; RT "RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 RT through pseudo-kinase domains."; RL Mol. Cells 19:39-45(2005). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423 AND SER-427, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-282; SER-423; SER-427; RP SER-455; SER-528; SER-583; SER-605; SER-661; SER-664; SER-667 AND SER-872, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] THR-42; LYS-96; LEU-319; LEU-424; PRO-546; RP ILE-554; SER-575; ALA-663; PHE-853; TYR-1003 AND LYS-1022. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be involved in transmitting sphingosine-1 phosphate CC (SPP)-mediated signaling into the cell (PubMed:12077123). Plays a role CC in the recruitment of PRDX3 to early endosomes (PubMed:15750338). CC {ECO:0000269|PubMed:12077123, ECO:0000269|PubMed:15750338}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with SPHK1 and phosphatidylinositol 3-phosphate CC (PubMed:12077123). Interacts (via PX domain) with PRDX3 CC (PubMed:15750338). {ECO:0000269|PubMed:12077123, CC ECO:0000269|PubMed:15750338}. CC -!- INTERACTION: CC Q96S38; Q8IWF6: DENND6A; NbExp=2; IntAct=EBI-347731, EBI-2834112; CC Q96S38; P11473-2: VDR; NbExp=3; IntAct=EBI-347731, EBI-12874016; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12077123, CC ECO:0000269|PubMed:15750338}. Membrane {ECO:0000269|PubMed:12077123}. CC Early endosome {ECO:0000269|PubMed:15750338}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96S38-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96S38-2; Sequence=VSP_046333; CC -!- TISSUE SPECIFICITY: Highly expressed in testis, skeletal muscle, brain, CC heart, placenta, kidney and liver and weakly expressed in thymus, small CC intestine, lung and colon. {ECO:0000269|PubMed:12077123}. CC -!- DOMAIN: The PX domain is essential for its localization to the early CC endosomes. {ECO:0000269|PubMed:15750338}. CC -!- DOMAIN: The first protein kinase domain appears to be a pseudokinase CC domain as it does not contain the classical characteristics, such as CC the ATP-binding motif, ATP-binding site and active site. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. S6 kinase subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Instead of Lys-820, Arg-820 is found at the binding site. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAB92850.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB070706; BAB63956.1; -; mRNA. DR EMBL; AF477978; AAL84818.1; -; mRNA. DR EMBL; AK122921; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK122989; BAG53836.1; -; mRNA. DR EMBL; AL645860; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL512449; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL583826; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471100; EAW93362.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93363.1; -; Genomic_DNA. DR EMBL; BC104769; AAI04770.1; -; mRNA. DR EMBL; AF037447; AAF13027.1; -; mRNA. DR EMBL; AL356893; CAB92850.1; ALT_INIT; mRNA. DR CCDS; CCDS1513.1; -. [Q96S38-1] DR CCDS; CCDS44317.1; -. [Q96S38-2] DR RefSeq; NP_001129610.1; NM_001136138.4. [Q96S38-2] DR RefSeq; NP_036556.2; NM_012424.4. [Q96S38-1] DR AlphaFoldDB; Q96S38; -. DR SMR; Q96S38; -. DR BioGRID; 117810; 30. DR FunCoup; Q96S38; 1956. DR IntAct; Q96S38; 15. DR STRING; 9606.ENSP00000355927; -. DR ChEMBL; CHEMBL1795193; -. DR iPTMnet; Q96S38; -. DR PhosphoSitePlus; Q96S38; -. DR BioMuta; RPS6KC1; -. DR DMDM; 94717650; -. DR CPTAC; non-CPTAC-5679; -. DR jPOST; Q96S38; -. DR MassIVE; Q96S38; -. DR PaxDb; 9606-ENSP00000355927; -. DR PeptideAtlas; Q96S38; -. DR ProteomicsDB; 3310; -. DR ProteomicsDB; 78062; -. [Q96S38-1] DR Pumba; Q96S38; -. DR TopDownProteomics; Q96S38-1; -. [Q96S38-1] DR Antibodypedia; 34615; 162 antibodies from 27 providers. DR DNASU; 26750; -. DR Ensembl; ENST00000366959.4; ENSP00000355926.3; ENSG00000136643.13. [Q96S38-2] DR Ensembl; ENST00000366960.8; ENSP00000355927.3; ENSG00000136643.13. [Q96S38-1] DR GeneID; 26750; -. DR KEGG; hsa:26750; -. DR MANE-Select; ENST00000366960.8; ENSP00000355927.3; NM_012424.6; NP_036556.2. DR UCSC; uc001hkd.5; human. [Q96S38-1] DR AGR; HGNC:10439; -. DR ClinPGx; PA34854; -. DR CTD; 26750; -. DR DisGeNET; 26750; -. DR GeneCards; RPS6KC1; -. DR HGNC; HGNC:10439; RPS6KC1. DR HPA; ENSG00000136643; Low tissue specificity. DR MalaCards; RPS6KC1; -. DR MIM; 617517; gene. DR OpenTargets; ENSG00000136643; -. DR VEuPathDB; HostDB:ENSG00000136643; -. DR eggNOG; KOG0603; Eukaryota. DR eggNOG; KOG2101; Eukaryota. DR GeneTree; ENSGT00940000155656; -. DR HOGENOM; CLU_014272_0_0_1; -. DR InParanoid; Q96S38; -. DR OMA; GHSSELW; -. DR OrthoDB; 1278353at2759; -. DR PAN-GO; Q96S38; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q96S38; -. DR PathwayCommons; Q96S38; -. DR SignaLink; Q96S38; -. DR SIGNOR; Q96S38; -. DR Agora; ENSG00000136643; -. DR BioGRID-ORCS; 26750; 8 hits in 1164 CRISPR screens. DR ChiTaRS; RPS6KC1; human. DR GeneWiki; RPS6KC1; -. DR GenomeRNAi; 26750; -. DR Pharos; Q96S38; Tdark. DR PRO; PR:Q96S38; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q96S38; protein. DR Bgee; ENSG00000136643; Expressed in sperm and 193 other cell types or tissues. DR ExpressionAtlas; Q96S38; baseline and differential. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IDA:HPA. DR GO; GO:0005764; C:lysosome; IDA:HPA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035091; F:phosphatidylinositol binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd02677; MIT_SNX15; 1. DR CDD; cd07287; PX_RPK118_like; 1. DR CDD; cd05576; STKc_RPK118_like; 1. DR FunFam; 1.10.510.10:FF:000221; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR FunFam; 1.20.58.80:FF:000005; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR FunFam; 3.30.1520.10:FF:000017; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR Gene3D; 1.20.58.80; Phosphotransferase system, lactose/cellobiose-type IIA subunit; 1. DR Gene3D; 3.30.1520.10; Phox-like domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR051866; Intracell_Sig-Traffick_Protein. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR007330; MIT_dom. DR InterPro; IPR036181; MIT_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001683; PX_dom. DR InterPro; IPR036871; PX_dom_sf. DR InterPro; IPR042132; PX_S6K-delta-1. DR InterPro; IPR035053; STK_RPK118-like. DR PANTHER; PTHR15508; RIBOSOMAL PROTEIN S6 KINASE; 1. DR PANTHER; PTHR15508:SF2; RIBOSOMAL PROTEIN S6 KINASE DELTA-1; 1. DR Pfam; PF04212; MIT; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00787; PX; 1. DR SMART; SM00745; MIT; 1. DR SMART; SM00312; PX; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF116846; MIT domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF64268; PX domain; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS50195; PX; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Endosome; Kinase; KW Lipid-binding; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1066 FT /note="Ribosomal protein S6 kinase delta-1" FT /id="PRO_0000233127" FT DOMAIN 8..132 FT /note="PX" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00147" FT DOMAIN 277..305 FT /note="MIT" FT DOMAIN 344..445 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 794..1056 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 207..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 441..509 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..596 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 212..223 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 448..458 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 474..483 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 492..503 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 582..593 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 929 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 801..809 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 820 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 282 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 427 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 449 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 455 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 528 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 583 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 605 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 640 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 661 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 794 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 872 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 36..47 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046333" FT VARIANT 42 FT /note="P -> T (in dbSNP:rs56087470)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040647" FT VARIANT 96 FT /note="E -> K (in dbSNP:rs56032860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040648" FT VARIANT 319 FT /note="P -> L (in dbSNP:rs56369827)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040649" FT VARIANT 424 FT /note="P -> L (in dbSNP:rs56183862)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040650" FT VARIANT 546 FT /note="A -> P (in dbSNP:rs35281247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040651" FT VARIANT 554 FT /note="L -> I (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040652" FT VARIANT 561 FT /note="P -> R (in dbSNP:rs17020314)" FT /id="VAR_051635" FT VARIANT 575 FT /note="N -> S (in dbSNP:rs56060894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040653" FT VARIANT 663 FT /note="G -> A (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040654" FT VARIANT 853 FT /note="L -> F (in dbSNP:rs34080597)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040655" FT VARIANT 1003 FT /note="C -> Y (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040656" FT VARIANT 1022 FT /note="E -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040657" FT CONFLICT 35 FT /note="R -> G (in Ref. 1; BAB63956)" FT /evidence="ECO:0000305" FT CONFLICT 250 FT /note="A -> V (in Ref. 1; BAB63956)" FT /evidence="ECO:0000305" FT CONFLICT 1065 FT /note="Missing (in Ref. 7)" FT /evidence="ECO:0000305" SQ SEQUENCE 1066 AA; 118682 MW; 670EE5965F3B8274 CRC64; MTSYRERSAD LARFYTVTEP QRHPRGYTVY KVTARVVSRR NPEDVQEIIV WKRYSDFKKL HKELWQIHKN LFRHSELFPP FAKGIVFGRF DETVIEERRQ CAEDLLQFSA NIPALYNSKQ LEDFFKGGII NDSSELIGPA EAHSDSLIDT FPECSTEGFS SDSDLVSLTV DVDSLAELDD GMASNQNSPI RTFGLNLSSD SSALGAVASD SEQSKTEEER ESRSLFPGSL KPKLGKRDYL EKAGELIKLA LKKEEEDDYE AASDFYRKGV DLLLEGVQGE SSPTRREAVK RRTAEYLMRA ESISSLYGKP QLDDVSQPPG SLSSRPLWNL RSPAEELKAF RVLGVIDKVL LVMDTRTEQT FILKGLRKSS EYSRNRKTII PRCVPNMVCL HKYIISEESV FLVLQHAEGG KLWSYISKFL NRSPEESFDI KEVKKPTLAK VHLQQPTSSP QDSSSFESRG SDGGSMLKAL PLKSSLTPSS QDDSNQEDDG QDSSPKWPDS GSSSEEECTT SYLTLCNEYG QEKIEPGSLN EEPFMKTEGN GVDTKAIKSF PAHLAADSDS PSTQLRAHEL KFFPNDDPEA VSSPRTSDSL SRSKNSPMEF FRIDSKDSAS ELLGLDFGEK LYSLKSEPLK PFFTLPDGDS ASRSFNTSES KVEFKAQDTI SRGSDDSVPV ISFKDAAFDD VSGTDEGRPD LLVNLPGELE STREAAAMGP TKFTQTNIGI IENKLLEAPD VLCLRLSTEQ CQAHEEKGIE ELSDPSGPKS YSITEKHYAQ EDPRMLFVAA VDHSSSGDMS LLPSSDPKFQ GLGVVESAVT ANNTEESLFR ICSPLSGANE YIASTDTLKT EEVLLFTDQT DDLAKEEPTS LFQRDSETKG ESGLVLEGDK EIHQIFEDLD KKLALASRFY IPEGCIQRWA AEMVVALDAL HREGIVCRDL NPNNILLNDR GHIQLTYFSR WSEVEDSCDS DAIERMYCAP EVGAITEETE ACDWWSLGAV LFELLTGKTL VECHPAGINT HTTLNMPECV SEEARSLIQQ LLQFNPLERL GAGVAGVEDI KSHPFFTPVD WAELMR // ID LN28B_HUMAN Reviewed; 250 AA. AC Q6ZN17; A1L165; B2RPN6; Q5TCM4; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 181. DE RecName: Full=Protein lin-28 homolog B; DE Short=Lin-28B; GN Name=LIN28B; Synonyms=CSDD2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Moss E.G., Kemper K.; RT "Expression of Lin28A and Lin28B in post-implantation mouse embryos."; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, AND INDUCTION. RX PubMed=16971064; DOI=10.1016/j.gene.2006.07.011; RA Guo Y., Chen Y., Ito H., Watanabe A., Ge X., Kodama T., Aburatani H.; RT "Identification and characterization of lin-28 homolog B (LIN28B) in human RT hepatocellular carcinoma."; RL Gene 384:51-61(2006). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=18951094; DOI=10.1016/j.molcel.2008.09.014; RA Heo I., Joo C., Cho J., Ha M., Han J., Kim V.N.; RT "Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA."; RL Mol. Cell 32:276-284(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP FUNCTION, AND RNA-BINDING. RX PubMed=19703396; DOI=10.1016/j.cell.2009.08.002; RA Heo I., Joo C., Kim Y.-K., Ha M., Yoon M.-J., Cho J., Yeom K.-H., Han J., RA Kim V.N.; RT "TUT4 in concert with Lin28 suppresses MicroRNA biogenesis through pre- RT microRNA uridylation."; RL Cell 138:696-708(2009). RN [10] RP POSSIBLE INVOLVEMENT IN CANCERS. RX PubMed=19483683; DOI=10.1038/ng.392; RA Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., RA Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., Shah S.P., RA Tanwar P.S., Mermel C.H., Beroukhim R., Azam M., Teixeira J., Meyerson M., RA Hughes T.P., Llovet J.M., Radich J., Mullighan C.G., Golub T.R., RA Sorensen P.H., Daley G.Q.; RT "Lin28 promotes transformation and is associated with advanced human RT malignancies."; RL Nat. Genet. 41:843-848(2009). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP FUNCTION IN PRE-LET-7 REPRESSION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=22118463; DOI=10.1016/j.cell.2011.10.039; RA Piskounova E., Polytarchou C., Thornton J.E., LaPierre R.J., RA Pothoulakis C., Hagan J.P., Iliopoulos D., Gregory R.I.; RT "Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct RT mechanisms."; RL Cell 147:1066-1079(2011). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-96; SER-105; SER-110 RP AND SER-203, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 24-111, AND ZINC KNUCKLE DOMAIN. RX PubMed=22570413; DOI=10.1093/nar/gks355; RA Mayr F., Schutz A., Doge N., Heinemann U.; RT "The Lin28 cold-shock domain remodels pre-let-7 microRNA."; RL Nucleic Acids Res. 40:7492-7506(2012). CC -!- FUNCTION: Suppressor of microRNA (miRNA) biogenesis, including that of CC let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 CC transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and CC sequester them in the nucleolus, away from the microprocessor complex, CC hence preventing their processing into mature miRNA (PubMed:22118463). CC Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 CC expression is required for normal development and contributes to CC maintain the pluripotent state of embryonic stem cells by preventing CC let-7-mediated differentiation. When overexpressed, recruits CC ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to CC their terminal uridylation and degradation (PubMed:19703396). This CC activity might not be relevant in vivo, as LIN28B-mediated inhibition CC of let-7 miRNA maturation appears to be ZCCHC11-independent CC (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'- CC GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let- CC 7 repression (By similarity). When overexpressed, isoform 1 stimulates CC growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no CC effect on cell growth. {ECO:0000250|UniProtKB:Q45KJ6, CC ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:18951094, CC ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:22118463}. CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, nucleolus CC {ECO:0000269|PubMed:22118463}. Cytoplasm {ECO:0000269|PubMed:16971064}. CC Note=Predominantly nucleolar (PubMed:22118463). In Huh7 cells, CC predominantly cytoplasmic, with only a subset of cells exhibiting CC strong nuclear staining; however, the specificity of the polyclonal CC antibody used in these experiments has not been not documented CC (PubMed:16971064). {ECO:0000269|PubMed:16971064, CC ECO:0000269|PubMed:22118463}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q6ZN17-1; Sequence=Displayed; CC Name=2; Synonyms=LIN28BS; CC IsoId=Q6ZN17-2; Sequence=VSP_027207; CC -!- TISSUE SPECIFICITY: Expressed at high levels in the placenta and, at CC mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is CC only detected in placenta and in moderately and poorly differentiated CC hepatocellular carcinoma cells (at protein level). Isoform 2 is CC detected in fetal liver, non-tumor liver tissues, as well as well- CC differentiated tumor tissues (at protein level). Tends to be up- CC regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as CC in liver, ovarian, and thyroid carcinomas (PubMed:22118463). CC {ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:22118463}. CC -!- INDUCTION: Might be negatively regulated by the microRNA let-7b. CC {ECO:0000269|PubMed:16971064}. CC -!- DOMAIN: The tandem zinc fingers, also referred as zinc knuckle domain CC (ZKD), mediate specific binding to the GGAG/GGUG motif while the CSD CC shows only limited pyrimidine-rich sequence specificity. Both domains CC bind single-stranded nucleic acids. CC -!- SIMILARITY: Belongs to the lin-28 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/45723/LIN28B"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DQ127228; AAZ38897.1; -; mRNA. DR EMBL; AK131411; BAD18558.1; -; mRNA. DR EMBL; AL135911; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z95329; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48434.1; -; Genomic_DNA. DR EMBL; BC127712; AAI27713.1; -; mRNA. DR EMBL; BC127713; AAI27714.1; -; mRNA. DR EMBL; BC137526; AAI37527.1; -; mRNA. DR EMBL; BC137527; AAI37528.1; -; mRNA. DR EMBL; BC141960; AAI41961.1; -; mRNA. DR CCDS; CCDS34504.1; -. [Q6ZN17-1] DR RefSeq; NP_001004317.1; NM_001004317.4. [Q6ZN17-1] DR PDB; 4A4I; X-ray; 1.95 A; A/B=24-111. DR PDBsum; 4A4I; -. DR AlphaFoldDB; Q6ZN17; -. DR SMR; Q6ZN17; -. DR BioGRID; 133142; 363. DR FunCoup; Q6ZN17; 1779. DR IntAct; Q6ZN17; 813. DR MINT; Q6ZN17; -. DR STRING; 9606.ENSP00000344401; -. DR ChEMBL; CHEMBL4295873; -. DR GlyGen; Q6ZN17; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN17; -. DR PhosphoSitePlus; Q6ZN17; -. DR BioMuta; LIN28B; -. DR DMDM; 74758701; -. DR jPOST; Q6ZN17; -. DR MassIVE; Q6ZN17; -. DR PaxDb; 9606-ENSP00000344401; -. DR PeptideAtlas; Q6ZN17; -. DR ProteomicsDB; 67959; -. [Q6ZN17-1] DR ProteomicsDB; 67960; -. [Q6ZN17-2] DR Pumba; Q6ZN17; -. DR Antibodypedia; 32105; 310 antibodies from 36 providers. DR DNASU; 389421; -. DR Ensembl; ENST00000345080.5; ENSP00000344401.4; ENSG00000187772.8. [Q6ZN17-1] DR GeneID; 389421; -. DR KEGG; hsa:389421; -. DR MANE-Select; ENST00000345080.5; ENSP00000344401.4; NM_001004317.4; NP_001004317.1. DR UCSC; uc003pqv.2; human. [Q6ZN17-1] DR AGR; HGNC:32207; -. DR ClinPGx; PA142671543; -. DR CTD; 389421; -. DR DisGeNET; 389421; -. DR GeneCards; LIN28B; -. DR HGNC; HGNC:32207; LIN28B. DR HPA; ENSG00000187772; Tissue enriched (placenta). DR MalaCards; LIN28B; -. DR MIM; 611044; gene. DR OpenTargets; ENSG00000187772; -. DR Orphanet; 635; Neuroblastoma. DR VEuPathDB; HostDB:ENSG00000187772; -. DR eggNOG; KOG3070; Eukaryota. DR GeneTree; ENSGT00940000153295; -. DR HOGENOM; CLU_089169_1_1_1; -. DR InParanoid; Q6ZN17; -. DR OMA; WGNMAEG; -. DR OrthoDB; 422005at2759; -. DR PAN-GO; Q6ZN17; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN17; -. DR PathwayCommons; Q6ZN17; -. DR SignaLink; Q6ZN17; -. DR SIGNOR; Q6ZN17; -. DR Agora; ENSG00000187772; -. DR BioGRID-ORCS; 389421; 55 hits in 1180 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; LIN28B; human. DR EvolutionaryTrace; Q6ZN17; -. DR GenomeRNAi; 389421; -. DR Pharos; Q6ZN17; Tbio. DR PRO; PR:Q6ZN17; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q6ZN17; protein. DR Bgee; ENSG00000187772; Expressed in placenta and 37 other cell types or tissues. DR ExpressionAtlas; Q6ZN17; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0003729; F:mRNA binding; IBA:GO_Central. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0010587; P:miRNA catabolic process; IMP:UniProtKB. DR GO; GO:2000632; P:negative regulation of pre-miRNA processing; IDA:CACAO. DR GO; GO:2000635; P:negative regulation of primary miRNA processing; IDA:CACAO. DR GO; GO:2000627; P:positive regulation of miRNA catabolic process; IMP:CACAO. DR GO; GO:0031054; P:pre-miRNA processing; IMP:UniProtKB. DR GO; GO:0031123; P:RNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0050779; P:RNA destabilization; IDA:CACAO. DR CDD; cd04458; CSP_CDS; 1. DR FunFam; 4.10.60.10:FF:000007; Protein lin-28 homolog A; 1. DR FunFam; 2.40.50.140:FF:000087; Protein lin-28 homolog B; 1. DR Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1. DR Gene3D; 4.10.60.10; Zinc finger, CCHC-type; 1. DR InterPro; IPR011129; CSD. DR InterPro; IPR002059; CSP_DNA-bd. DR InterPro; IPR051373; Lin-28_RNA-binding. DR InterPro; IPR054081; Lin-28A-like_Znf-CCHC_2. DR InterPro; IPR012340; NA-bd_OB-fold. DR InterPro; IPR001878; Znf_CCHC. DR InterPro; IPR036875; Znf_CCHC_sf. DR PANTHER; PTHR46109; PROTEIN LIN-28; 1. DR PANTHER; PTHR46109:SF3; PROTEIN LIN-28 HOMOLOG B; 1. DR Pfam; PF00313; CSD; 1. DR Pfam; PF21890; Lin-28A-like_zf-CCHC_2; 1. DR Pfam; PF00098; zf-CCHC; 1. DR PRINTS; PR00050; COLDSHOCK. DR SMART; SM00357; CSP; 1. DR SMART; SM00343; ZnF_C2HC; 2. DR SUPFAM; SSF50249; Nucleic acid-binding proteins; 1. DR SUPFAM; SSF57756; Retrovirus zinc finger-like domains; 1. DR PROSITE; PS51857; CSD_2; 1. DR PROSITE; PS50158; ZF_CCHC; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; RNA-mediated gene silencing; Zinc; Zinc-finger. FT CHAIN 1..250 FT /note="Protein lin-28 homolog B" FT /id="PRO_0000253793" FT DOMAIN 29..102 FT /note="CSD" FT ZN_FING 127..144 FT /note="CCHC-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT ZN_FING 149..166 FT /note="CCHC-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT REGION 1..26 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 98..126 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 169..250 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 112..125 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT MOTIF 239..250 FT /note="Nucleolar localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT COMPBIAS 114..125 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 173..191 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 210..219 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 220..231 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 129 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 137 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 142 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 151 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 154 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 159 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 164 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT MOD_RES 54 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 105 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 110 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 203 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..70 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_027207" FT STRAND 28..38 FT /evidence="ECO:0007829|PDB:4A4I" FT TURN 39..42 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 43..51 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 54..65 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 71..74 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 95..101 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:4A4I" SQ SEQUENCE 250 AA; 27084 MW; DEF2920C5F1D0BBD CRC64; MAEGGASKGG GEEPGKLPEP AEEESQVLRG TGHCKWFNVR MGFGFISMIN REGSPLDIPV DVFVHQSKLF MEGFRSLKEG EPVEFTFKKS SKGLESIRVT GPGGSPCLGS ERRPKGKTLQ KRKPKGDRCY NCGGLDHHAK ECSLPPQPKK CHYCQSIMHM VANCPHKNVA QPPASSQGRQ EAESQPCTST LPREVGGGHG CTSPPFPQEA RAEISERSGR SPQEASSTKS SIAPEEQSKK GPSVQKRKKT // ID LZTS1_HUMAN Reviewed; 596 AA. AC Q9Y250; D3DSQ6; Q9Y5V7; Q9Y5V8; Q9Y5V9; Q9Y5W0; Q9Y5W1; Q9Y5W2; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 28-JAN-2026, entry version 182. DE RecName: Full=Leucine zipper putative tumor suppressor 1; DE AltName: Full=F37/esophageal cancer-related gene-coding leucine-zipper motif; DE AltName: Full=Fez1; GN Name=LZTS1; Synonyms=FEZ1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6 AND 7), RP INVOLVEMENT IN ESCR, VARIANTS PRO-29 AND GLU-119, FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=10097140; DOI=10.1073/pnas.96.7.3928; RA Ishii H., Baffa R., Numata S., Murakumo Y., Rattan S., Inoue H., Mori M., RA Fidanza V., Alder H., Croce C.M.; RT "The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its RT expression is altered in multiple human tumors."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3928-3933(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, AND ALTERNATIVE SPLICING. RX PubMed=11464283; DOI=10.1038/sj.onc.1204539; RA Cabeza-Arvelaiz Y., Sepulveda J.L., Lebovitz R.M., Thompson T.C., RA Chinault A.C.; RT "Functional identification of LZTS1 as a candidate prostate tumor RT suppressor gene on human chromosome 8p22."; RL Oncogene 20:4169-4179(2001). RN [5] RP FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH EEF1G RP AND CDK1. RX PubMed=11504921; DOI=10.1073/pnas.181222898; RA Ishii H., Vecchione A., Murakumo Y., Baldassarre G., Numata S., RA Trapasso F., Alder H., Baffa R., Croce C.M.; RT "FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates RT mitosis."; RL Proc. Natl. Acad. Sci. U.S.A. 98:10374-10379(2001). RN [6] RP INTERACTION WITH TLK2. RX PubMed=16484223; DOI=10.1074/jbc.m513280200; RA Assmann E.M., Alborghetti M.R., Camargo M.E.R., Kobarg J.; RT "FEZ1 dimerization and interaction with transcription regulatory proteins RT involves its coiled-coil region."; RL J. Biol. Chem. 281:9869-9881(2006). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] {ECO:0007744|PDB:8Y1U} RP X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 346-368 IN COMPLEX WITH ASB7; RP ALOB AND ELOC, AND UBIQUITINATION. RX PubMed=39039081; DOI=10.1038/s41467-024-50556-x; RA Zhou M., Wang X., Li J., Ma J., Bao Z., Yan X., Zhang B., Liu T., Yu Y., RA Mi W., Dong C.; RT "Molecular insights into degron recognition by CRL5ASB7 ubiquitin ligase."; RL Nat. Commun. 15:6177-6177(2024). CC -!- FUNCTION: Involved in the regulation of cell growth. May stabilize the CC active CDC2-cyclin B1 complex and thereby contribute to the regulation CC of the cell cycle and the prevention of uncontrolled cell CC proliferation. May act as a tumor suppressor. CC {ECO:0000269|PubMed:10097140, ECO:0000269|PubMed:11464283, CC ECO:0000269|PubMed:11504921}. CC -!- SUBUNIT: Binds EEF1G, TLK2 and CDK1. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane CC {ECO:0000250}. Cell projection, dendritic spine {ECO:0000250}. CC Postsynaptic density {ECO:0000250}. Synapse {ECO:0000250}. CC Note=Associated with the plasma membrane and with microtubules. CC Detected in dendritic spines, especially in the postsynaptic density CC (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; CC IsoId=Q9Y250-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y250-2; Sequence=VSP_009946; CC Name=3; CC IsoId=Q9Y250-3; Sequence=VSP_009945; CC Name=4; CC IsoId=Q9Y250-4; Sequence=VSP_009944; CC Name=5; CC IsoId=Q9Y250-5; Sequence=VSP_009943; CC Name=6; CC IsoId=Q9Y250-6; Sequence=VSP_009942; CC Name=7; CC IsoId=Q9Y250-7; Sequence=VSP_009940, VSP_009941; CC -!- TISSUE SPECIFICITY: Highly expressed in testis, prostate, spleen, CC thymus, ovary and brain. Detected at lower levels in heart, placenta, CC small intestine, colon, liver, kidney, skeletal muscle and pancreas. CC Not detectable in primary tumors from breast and prostate and in many CC cancer cell lines. {ECO:0000269|PubMed:10097140}. CC -!- PTM: Phosphorylated on serine residues. Hyperphosphorylated by the CC cAMP-dependent kinase PKA during cell-cycle progression. CC -!- PTM: Ubiquitinated by the ECS(ASB7) complex, leading to its CC degradation. {ECO:0000269|PubMed:39039081}. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10097140}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. CC -!- MISCELLANEOUS: Defects in LZTS1 are found in many types of tumors. CC -!- SIMILARITY: Belongs to the LZTS family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/367/LZTS1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF123652; AAD23833.1; -; mRNA. DR EMBL; AF123653; AAD23834.1; -; Genomic_DNA. DR EMBL; AF123654; AAD23835.1; -; mRNA. DR EMBL; AF123655; AAD23836.1; -; mRNA. DR EMBL; AF123656; AAD23837.1; -; mRNA. DR EMBL; AF123657; AAD23838.1; -; mRNA. DR EMBL; AF123658; AAD23839.1; -; mRNA. DR EMBL; AF123659; AAD23840.1; -; mRNA. DR EMBL; CH471080; EAW63753.1; -; Genomic_DNA. DR EMBL; CH471080; EAW63755.1; -; Genomic_DNA. DR EMBL; BC075006; AAH75006.1; -; mRNA. DR EMBL; BC075007; AAH75007.1; -; mRNA. DR CCDS; CCDS6015.1; -. [Q9Y250-1] DR RefSeq; NP_001349813.1; NM_001362884.2. [Q9Y250-1] DR RefSeq; NP_066300.1; NM_021020.5. [Q9Y250-1] DR RefSeq; XP_011542686.1; XM_011544384.3. [Q9Y250-1] DR RefSeq; XP_011542687.1; XM_011544385.3. [Q9Y250-1] DR RefSeq; XP_011542688.1; XM_011544386.3. [Q9Y250-1] DR RefSeq; XP_047277265.1; XM_047421309.1. [Q9Y250-1] DR RefSeq; XP_054215654.1; XM_054359679.1. [Q9Y250-1] DR RefSeq; XP_054215655.1; XM_054359680.1. [Q9Y250-1] DR RefSeq; XP_054215656.1; XM_054359681.1. [Q9Y250-1] DR PDB; 8Y1U; X-ray; 2.41 A; B=346-368. DR PDBsum; 8Y1U; -. DR AlphaFoldDB; Q9Y250; -. DR SMR; Q9Y250; -. DR BioGRID; 116348; 135. DR FunCoup; Q9Y250; 143. DR MINT; Q9Y250; -. DR STRING; 9606.ENSP00000370981; -. DR TCDB; 3.A.34.1.1; the sorting nexins of the escrt complexes (sn-escrt). DR GlyGen; Q9Y250; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9Y250; -. DR PhosphoSitePlus; Q9Y250; -. DR BioMuta; LZTS1; -. DR DMDM; 46396556; -. DR jPOST; Q9Y250; -. DR MassIVE; Q9Y250; -. DR PaxDb; 9606-ENSP00000370981; -. DR PeptideAtlas; Q9Y250; -. DR ProteomicsDB; 85646; -. [Q9Y250-1] DR ProteomicsDB; 85647; -. [Q9Y250-2] DR ProteomicsDB; 85648; -. [Q9Y250-3] DR ProteomicsDB; 85649; -. [Q9Y250-4] DR ProteomicsDB; 85650; -. [Q9Y250-5] DR ProteomicsDB; 85651; -. [Q9Y250-6] DR ProteomicsDB; 85652; -. [Q9Y250-7] DR Antibodypedia; 1747; 241 antibodies from 27 providers. DR DNASU; 11178; -. DR Ensembl; ENST00000265801.6; ENSP00000265801.6; ENSG00000061337.16. [Q9Y250-1] DR Ensembl; ENST00000381569.5; ENSP00000370981.1; ENSG00000061337.16. [Q9Y250-1] DR Ensembl; ENST00000522290.5; ENSP00000429263.1; ENSG00000061337.16. [Q9Y250-4] DR GeneID; 11178; -. DR KEGG; hsa:11178; -. DR MANE-Select; ENST00000381569.5; ENSP00000370981.1; NM_021020.5; NP_066300.1. DR UCSC; uc003wzr.3; human. [Q9Y250-1] DR AGR; HGNC:13861; -. DR ClinPGx; PA30507; -. DR CTD; 11178; -. DR DisGeNET; 11178; -. DR GeneCards; LZTS1; -. DR HGNC; HGNC:13861; LZTS1. DR HPA; ENSG00000061337; Group enriched (brain, parathyroid gland). DR MalaCards; LZTS1; -. DR MIM; 133239; phenotype. DR MIM; 606551; gene. DR OpenTargets; ENSG00000061337; -. DR VEuPathDB; HostDB:ENSG00000061337; -. DR eggNOG; ENOG502QRU7; Eukaryota. DR GeneTree; ENSGT00940000154078; -. DR HOGENOM; CLU_026379_2_1_1; -. DR InParanoid; Q9Y250; -. DR OMA; QKTRGSH; -. DR OrthoDB; 10030037at2759; -. DR PAN-GO; Q9Y250; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y250; -. DR PathwayCommons; Q9Y250; -. DR SignaLink; Q9Y250; -. DR Agora; ENSG00000061337; -. DR BioGRID-ORCS; 11178; 11 hits in 1151 CRISPR screens. DR GeneWiki; LZTS1; -. DR GenomeRNAi; 11178; -. DR Pharos; Q9Y250; Tbio. DR PRO; PR:Q9Y250; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q9Y250; protein. DR Bgee; ENSG00000061337; Expressed in cortical plate and 134 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0016242; P:negative regulation of macroautophagy; IMP:BHF-UCL. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IBA:GO_Central. DR GO; GO:0150052; P:regulation of postsynapse assembly; IEA:Ensembl. DR GO; GO:0048167; P:regulation of synaptic plasticity; IBA:GO_Central. DR InterPro; IPR045329; LZTS. DR PANTHER; PTHR19354:SF5; ZIPPER PUTATIVE TUMOR SUPPRESSOR 1-RELATED; 1. DR PANTHER; PTHR19354; ZIPPER PUTATIVE TUMOR SUPPRESSOR 2 HOMOLOG-LIKE PROTEIN-RELATED; 1. DR Pfam; PF06818; Fez1; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell cycle; Cell membrane; KW Cell projection; Coiled coil; Cytoplasm; Lipoprotein; Membrane; Myristate; KW Phosphoprotein; Proteomics identification; Reference proteome; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT CHAIN 2..596 FT /note="Leucine zipper putative tumor suppressor 1" FT /id="PRO_0000182971" FT REGION 136..193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 295..324 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 256..374 FT /evidence="ECO:0000255" FT COMPBIAS 153..162 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 178..190 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 295..310 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT LIPID 2 FT /note="N-myristoyl glycine" FT /evidence="ECO:0000250" FT VAR_SEQ 55..76 FT /note="SSSKMGKSEDFFYIKVSQKARG -> AMTRCPRASSMSGSCGRRRRRR (in FT isoform 7)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009940" FT VAR_SEQ 77..596 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009941" FT VAR_SEQ 186..571 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009942" FT VAR_SEQ 454..545 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009943" FT VAR_SEQ 468..526 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009944" FT VAR_SEQ 471..503 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009945" FT VAR_SEQ 505..527 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009946" FT VARIANT 29 FT /note="S -> P (found in an esophageal cancer sample; FT esophageal squamous cell carcinoma; somatic mutation; FT dbSNP:rs28937897)" FT /evidence="ECO:0000269|PubMed:10097140" FT /id="VAR_018274" FT VARIANT 50 FT /note="S -> F (in dbSNP:rs34620053)" FT /id="VAR_053490" FT VARIANT 119 FT /note="K -> E (found in an esophageal cancer sample; FT esophageal squamous cell carcinoma; somatic mutation; FT dbSNP:rs119473032)" FT /evidence="ECO:0000269|PubMed:10097140" FT /id="VAR_018275" FT VARIANT 475 FT /note="L -> V (in dbSNP:rs723874)" FT /id="VAR_018276" FT HELIX 347..363 FT /evidence="ECO:0007829|PDB:8Y1U" FT HELIX 364..367 FT /evidence="ECO:0007829|PDB:8Y1U" SQ SEQUENCE 596 AA; 66613 MW; 8ED96C707BA27659 CRC64; MGSVSSLISG HSFHSKHCRA SQYKLRKSSH LKKLNRYSDG LLRFGFSQDS GHGKSSSKMG KSEDFFYIKV SQKARGSHHP DYTALSSGDL GGQAGVDFDP STPPKLMPFS NQLEMGSEKG AVRPTAFKPV LPRSGAILHS SPESASHQLH PAPPDKPKEQ ELKPGLCSGA LSDSGRNSMS SLPTHSTSSS YQLDPLVTPV GPTSRFGGSA HNITQGIVLQ DSNMMSLKAL SFSDGGSKLG HSNKADKGPS CVRSPISTDE CSIQELEQKL LEREGALQKL QRSFEEKELA SSLAYEERPR RCRDELEGPE PKGGNKLKQA SQKSQRAQQV LHLQVLQLQQ EKRQLRQELE SLMKEQDLLE TKLRSYEREK TSFGPALEET QWEVCQKSGE ISLLKQQLKE SQTEVNAKAS EILGLKAQLK DTRGKLEGLE LRTQDLEGAL RTKGLELEVC ENELQRKKNE AELLREKVNL LEQELQELRA QAALARDMGP PTFPEDVPAL QRELERLRAE LREERQGHDQ MSSGFQHERL VWKEEKEKVI QYQKQLQQSY VAMYQRNQRL EKALQQLARG DSAGEPLEVD LEGADIPYED IIATEI // ID M3K9_HUMAN Reviewed; 1104 AA. AC P80192; A3KN85; Q0D2G7; Q6EH31; Q9H2N5; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 214. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 9; DE EC=2.7.11.25; DE AltName: Full=Mixed lineage kinase 1; GN Name=MAP3K9; Synonyms=MLK1, PRKE1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-304; THR-305; SER-308 AND THR-312, AND MUTAGENESIS RP OF LYS-171; THR-304; THR-305; SER-308 AND THR-312. RX PubMed=15610029; DOI=10.1021/bi049866y; RA Durkin J.T., Holskin B.P., Kopec K.K., Reed M.S., Spais C.M., Steffy B.M., RA Gessner G., Angeles T.S., Pohl J., Ator M.A., Meyer S.L.; RT "Phosphoregulation of mixed-lineage kinase 1 activity by multiple RT phosphorylation in the activation loop."; RL Biochemistry 43:16348-16355(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 53-1104 (ISOFORM 2). RA McNee J.J., Dower S.K., Guesdon F.; RT "cDNA sequence and gene organisation of mixed lineage kinase 1."; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 142-535, AND TISSUE SPECIFICITY. RC TISSUE=Colon epithelium; RX PubMed=8477742; DOI=10.1111/j.1432-1033.1993.tb17810.x; RA Dorow D.S., Devereux L., Dietzsch E., de Kretser T.; RT "Identification of a new family of human epithelial protein kinases RT containing two leucine/isoleucine-zipper domains."; RL Eur. J. Biochem. 213:701-710(1993). RN [5] RP ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND PHOSPHORYLATION OF RP MAP2K4/MKK4. RX PubMed=11325962; DOI=10.1074/jbc.m011601200; RA Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., RA Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W., Vaught J.L.; RT "Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase RT family."; RL J. Biol. Chem. 276:25302-25308(2001). RN [6] RP FUNCTION IN THE APOPTOSIS PATHWAY. RX PubMed=11416147; DOI=10.1128/mcb.21.14.4713-4724.2001; RA Xu Z., Maroney A.C., Dobrzanski P., Kukekov N.V., Greene L.A.; RT "The MLK family mediates c-Jun N-terminal kinase activation in neuronal RT apoptosis."; RL Mol. Cell. Biol. 21:4713-4724(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11755341; DOI=10.1016/s0960-894x(01)00690-4; RA Murakata C., Kaneko M., Gessner G., Angeles T.S., Ator M.A., O'Kane T.M., RA McKenna B.A., Thomas B.A., Mathiasen J.R., Saporito M.S., RA Bozyczko-Coyne D., Hudkins R.L.; RT "Mixed lineage kinase activity of indolocarbazole analogues."; RL Bioorg. Med. Chem. Lett. 12:147-150(2002). RN [8] RP POSSIBLE ROLE IN ESOPHAGEAL CANCER. RX PubMed=18241037; DOI=10.1002/ijc.23397; RA Chen J., Guo L., Peiffer D.A., Zhou L., Chan O.T., Bibikova M., RA Wickham-Garcia E., Lu S.H., Zhan Q., Wang-Rodriguez J., Jiang W., Fan J.B.; RT "Genomic profiling of 766 cancer-related genes in archived esophageal RT normal and carcinoma tissues."; RL Int. J. Cancer 122:2249-2254(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 136-406. RX PubMed=18714982; DOI=10.1021/jm8005838; RA Hudkins R.L., Diebold J.L., Tao M., Josef K.A., Park C.H., Angeles T.S., RA Aimone L.D., Husten J., Ator M.A., Meyer S.L., Holskin B.P., Durkin J.T., RA Fedorov A.A., Fedorov E.V., Almo S.C., Mathiasen J.R., Bozyczko-Coyne D., RA Saporito M.S., Scott R.W., Mallamo J.P.; RT "Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective RT dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed- RT lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4- RT phenyltetrahydropyridine models."; RL J. Med. Chem. 51:5680-5689(2008). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-246; CYS-467; GLN-497 AND CYS-646. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. Plays an important role CC in the cascades of cellular responses evoked by changes in the CC environment. Once activated, acts as an upstream activator of the CC MKK/JNK signal transduction cascade through the phosphorylation of CC MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The CC MKK/JNK signaling pathway regulates stress response via activator CC protein-1 (JUN) and GATA4 transcription factors. Also plays a role in CC mitochondrial death signaling pathway, including the release cytochrome CC c, leading to apoptosis. {ECO:0000269|PubMed:11416147, CC ECO:0000269|PubMed:15610029}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Homodimerization via the leucine zipper domains is CC required for autophosphorylation of multiple sites in the activation CC loop and subsequent activation. Autophosphorylation at Thr-312 is the CC key step in activation of MAP3K9/MLK1 and is required for full CC phosphorylation. Autophosphorylation at Thr-304 and Ser-308 have been CC shown to be of secondary importance in the activation of MAP3K9/MLK1. CC CEP-1347 and many indolocarbazole analogs have been shown to act as CC inhibitors of MAP3K9/MLK1 activity. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:11755341, ECO:0000269|PubMed:15610029}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=62 uM for ATP {ECO:0000269|PubMed:11325962}; CC KM=7 uM for myelin basic protein (MBP) as substrate CC {ECO:0000269|PubMed:11325962}; CC -!- SUBUNIT: Homodimer. {ECO:0000250}. CC -!- INTERACTION: CC P80192; P08238: HSP90AB1; NbExp=2; IntAct=EBI-3951604, EBI-352572; CC P80192; Q92993: KAT5; NbExp=3; IntAct=EBI-3951604, EBI-399080; CC P80192; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-3951604, EBI-11742507; CC P80192; P17252: PRKCA; NbExp=3; IntAct=EBI-3951604, EBI-1383528; CC P80192; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-3951604, EBI-9090795; CC P80192; P62258: YWHAE; NbExp=3; IntAct=EBI-3951604, EBI-356498; CC P80192; P61981: YWHAG; NbExp=4; IntAct=EBI-3951604, EBI-359832; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P80192-1; Sequence=Displayed; CC Name=2; CC IsoId=P80192-4; Sequence=VSP_013765; CC -!- TISSUE SPECIFICITY: Expressed in epithelial tumor cell lines of CC colonic, breast and esophageal origin. {ECO:0000269|PubMed:8477742}. CC -!- PTM: Autophosphorylation on serine and threonine residues within the CC activation loop plays a role in enzyme activation. Thr-312 is likely to CC be the main autophosphorylation site. Autophosphorylation also occurs CC on Thr-304 and Ser-308. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:15610029}. CC -!- DISEASE: Note=May play a role in esophageal cancer susceptibility CC and/or development. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAI11408.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY327900; AAQ23054.1; -; mRNA. DR EMBL; BC111407; AAI11408.1; ALT_INIT; mRNA. DR EMBL; BC133706; AAI33707.1; -; mRNA. DR EMBL; AF251442; AAG44591.1; -; mRNA. DR CCDS; CCDS32112.1; -. [P80192-4] DR CCDS; CCDS61488.1; -. [P80192-1] DR PIR; S32467; JU0229. DR RefSeq; NP_001271159.1; NM_001284230.2. [P80192-1] DR RefSeq; NP_149132.2; NM_033141.3. [P80192-4] DR PDB; 3DTC; X-ray; 2.60 A; A=136-406. DR PDB; 4UY9; X-ray; 2.81 A; A/B=135-456. DR PDBsum; 3DTC; -. DR PDBsum; 4UY9; -. DR AlphaFoldDB; P80192; -. DR SMR; P80192; -. DR BioGRID; 110439; 29. DR FunCoup; P80192; 485. DR IntAct; P80192; 32. DR STRING; 9606.ENSP00000451263; -. DR BindingDB; P80192; -. DR ChEMBL; CHEMBL2872; -. DR DrugBank; DB08703; 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P80192; -. DR GuidetoPHARMACOLOGY; 2084; -. DR GlyGen; P80192; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P80192; -. DR PhosphoSitePlus; P80192; -. DR BioMuta; MAP3K9; -. DR DMDM; 116242625; -. DR CPTAC; CPTAC-860; -. DR CPTAC; CPTAC-861; -. DR jPOST; P80192; -. DR MassIVE; P80192; -. DR PaxDb; 9606-ENSP00000451263; -. DR PeptideAtlas; P80192; -. DR ProteomicsDB; 57671; -. [P80192-1] DR ProteomicsDB; 57672; -. [P80192-4] DR Antibodypedia; 75; 343 antibodies from 33 providers. DR DNASU; 4293; -. DR Ensembl; ENST00000554752.7; ENSP00000451612.2; ENSG00000006432.17. [P80192-1] DR Ensembl; ENST00000555993.6; ENSP00000451263.2; ENSG00000006432.17. [P80192-4] DR GeneID; 4293; -. DR KEGG; hsa:4293; -. DR MANE-Select; ENST00000554752.7; ENSP00000451612.2; NM_001284230.2; NP_001271159.1. DR UCSC; uc001xml.5; human. [P80192-1] DR AGR; HGNC:6861; -. DR ClinPGx; PA30607; -. DR CTD; 4293; -. DR DisGeNET; 4293; -. DR GeneCards; MAP3K9; -. DR HGNC; HGNC:6861; MAP3K9. DR HPA; ENSG00000006432; Tissue enhanced (retina). DR MIM; 600136; gene. DR OpenTargets; ENSG00000006432; -. DR VEuPathDB; HostDB:ENSG00000006432; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000158243; -. DR InParanoid; P80192; -. DR OMA; GCGPYRE; -. DR OrthoDB; 339325at2759; -. DR PAN-GO; P80192; 1 GO annotation based on evolutionary models. DR PhylomeDB; P80192; -. DR PathwayCommons; P80192; -. DR SABIO-RK; P80192; -. DR SignaLink; P80192; -. DR SIGNOR; P80192; -. DR Agora; ENSG00000006432; -. DR BioGRID-ORCS; 4293; 8 hits in 1178 CRISPR screens. DR ChiTaRS; MAP3K9; human. DR EvolutionaryTrace; P80192; -. DR GeneWiki; MAP3K9; -. DR GenomeRNAi; 4293; -. DR Pharos; P80192; Tchem. DR PRO; PR:P80192; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P80192; protein. DR Bgee; ENSG00000006432; Expressed in buccal mucosa cell and 161 other cell types or tissues. DR ExpressionAtlas; P80192; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; NAS:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd12059; SH3_MLK1-3; 1. DR CDD; cd14145; STKc_MLK1; 1. DR DisProt; DP02571; -. DR FunFam; 1.10.510.10:FF:000076; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 2.30.30.40:FF:000079; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 3.30.200.20:FF:000085; Mitogen-activated protein kinase kinase kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR035779; MLK1-3_SH3. DR InterPro; IPR016231; MLK1-4. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR PANTHER; PTHR44329:SF35; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF14604; SH3_9; 1. DR PIRSF; PIRSF000556; MAPKKK9_11; 1. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00326; SH3; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Kinase; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; SH3 domain; KW Stress response; Transcription; Transcription regulation; Transferase. FT CHAIN 1..1104 FT /note="Mitogen-activated protein kinase kinase kinase 9" FT /id="PRO_0000086258" FT DOMAIN 52..116 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 144..412 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 12..47 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 430..451 FT /note="Leucine-zipper 1" FT REGION 465..486 FT /note="Leucine-zipper 2" FT REGION 532..636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 675..742 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 781..819 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 890..1038 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 12..22 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 29..39 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..575 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 723..739 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 785..797 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 893..910 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 929..944 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1014..1038 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 268 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 150..158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 171 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 304 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 305 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 308 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 312 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 675 FT /note="M -> MALLAASWVVPIDIE (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_013765" FT VARIANT 246 FT /note="A -> V (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040698" FT VARIANT 467 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs773256562)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040699" FT VARIANT 497 FT /note="R -> Q (in dbSNP:rs56196343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040700" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34322726)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040701" FT MUTAGEN 171 FT /note="K->A: Loss of kinase activity and threonine FT phosphorylation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 304 FT /note="T->A: Reduces threonine phosphorylation. Impairs JNK FT activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 305 FT /note="T->A: Little effect on threonine phosphorylation. FT Mildly impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 308 FT /note="S->A: Impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 312 FT /note="T->A: Loss of threonine phosphorylation. Strongly FT impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT CONFLICT 356 FT /note="A -> R (in Ref. 4)" FT /evidence="ECO:0000305" FT CONFLICT 433 FT /note="M -> T (in Ref. 1; AAQ23054)" FT /evidence="ECO:0000305" FT CONFLICT 511..535 FT /note="KLKDGNRISLPSDFQHKFTVQASPT -> AQPVLPFPHGHSRCPGGTGSSWG FT GQ (in Ref. 4)" FT /evidence="ECO:0000305" FT STRAND 143..153 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 156..163 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 166..172 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 185..197 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 206..210 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 228..232 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 239..258 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 271..273 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 274..278 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 290..292 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 299..301 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 318..323 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 328..344 FT /evidence="ECO:0007829|PDB:3DTC" FT TURN 348..351 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 354..362 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 376..385 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 390..392 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 396..404 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 410..412 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 418..439 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:4UY9" SQ SEQUENCE 1104 AA; 121895 MW; 0F059C867FCE7276 CRC64; MEPSRALLGC LASAAAAAPP GEDGAGAGAE EEEEEEEEAA AAVGPGELGC DAPLPYWTAV FEYEAAGEDE LTLRLGDVVE VLSKDSQVSG DEGWWTGQLN QRVGIFPSNY VTPRSAFSSR CQPGGEDPSC YPPIQLLEID FAELTLEEII GIGGFGKVYR AFWIGDEVAV KAARHDPDED ISQTIENVRQ EAKLFAMLKH PNIIALRGVC LKEPNLCLVM EFARGGPLNR VLSGKRIPPD ILVNWAVQIA RGMNYLHDEA IVPIIHRDLK SSNILILQKV ENGDLSNKIL KITDFGLARE WHRTTKMSAA GTYAWMAPEV IRASMFSKGS DVWSYGVLLW ELLTGEVPFR GIDGLAVAYG VAMNKLALPI PSTCPEPFAK LMEDCWNPDP HSRPSFTNIL DQLTTIEESG FFEMPKDSFH CLQDNWKHEI QEMFDQLRAK EKELRTWEEE LTRAALQQKN QEELLRRREQ ELAEREIDIL ERELNIIIHQ LCQEKPRVKK RKGKFRKSRL KLKDGNRISL PSDFQHKFTV QASPTMDKRK SLINSRSSPP ASPTIIPRLR AIQLTPGESS KTWGRSSVVP KEEGEEEEKR APKKKGRTWG PGTLGQKELA SGDEGSPQRR EKANGLSTPS ESPHFHLGLK SLVDGYKQWS SSAPNLVKGP RSSPALPGFT SLMEMEDEDS EGPGSGESRL QHSPSQSYLC IPFPRGEDGD GPSSDGIHEE PTPVNSATST PQLTPTNSLK RGGAHHRRCE VALLGCGAVL AATGLGFDLL EAGKCQLLPL EEPEPPAREE KKRREGLFQR SSRPRRSTSP PSRKLFKKEE PMLLLGDPSA SLTLLSLSSI SECNSTRSLL RSDSDEIVVY EMPVSPVEAP PLSPCTHNPL VNVRVERFKR DPNQSLTPTH VTLTTPSQPS SHRRTPSDGA LKPETLLASR SPSSNGLSPS PGAGMLKTPS PSRDPGEFPR LPDPNVVFPP TPRRWNTQQD STLERPKTLE FLPRPRPSAN RQRLDPWWFV SPSHARSTSP ANSSSTETPS NLDSCFASSS STVEERPGLP ALLPFQAGPL PPTERTLLDL DAEGQSQDST VPLCRAELNT HRPAPYEIQQ EFWS // ID M3KCL_HUMAN Reviewed; 142 AA. AC P57077; D3DSE0; Q8TCL9; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 07-OCT-2020, sequence version 2. DT 28-JAN-2026, entry version 170. DE RecName: Full=MAP3K7 C-terminal-like protein; DE AltName: Full=TAK1-like protein; GN Name=MAP3K7CL; Synonyms=C21orf7, TAK1L; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE (ISOFORMS 1 AND 2). RA Solans A., Domenech A., Estivill X., de la Luna S.; RT "Cloning and characterization of a new gene, C21orf7, similar to the TAB2- RT binding region of TAK1."; RL Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE (ISOFORM 1). RX PubMed=11707072; DOI=10.1006/geno.2001.6640; RA Reymond A., Friedli M., Neergaard Henrichsen C., Chapot F., Deutsch S., RA Ucla C., Rossier C., Lyle R., Guipponi M., Antonarakis S.E.; RT "From PREDs and open reading frames to cDNA isolation: revisiting the human RT chromosome 21 transcription map."; RL Genomics 78:46-54(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=15168726; DOI=10.1023/b:bigi.0000020468.96238.54; RA Li J., Ji C., Yang Q., Chen J., Gu S., Ying K., Xie Y., Mao Y.; RT "Cloning and characterization of a novel human TGF-beta activated kinase- RT like gene."; RL Biochem. Genet. 42:129-137(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10830953; DOI=10.1038/35012518; RA Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S., RA Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M., RA Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U., RA Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A., RA Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J., RA Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K., RA Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G., RA Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J., RA Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S., RA Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K., RA Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.; RT "The DNA sequence of human chromosome 21."; RL Nature 405:311-319(2000). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). CC -!- INTERACTION: CC P57077; Q13227: GPS2; NbExp=2; IntAct=EBI-748831, EBI-713355; CC P57077-4; Q96MA6: AK8; NbExp=6; IntAct=EBI-10215880, EBI-8466265; CC P57077-4; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-10215880, EBI-742054; CC P57077-4; Q15323: KRT31; NbExp=3; IntAct=EBI-10215880, EBI-948001; CC P57077-4; O76011: KRT34; NbExp=3; IntAct=EBI-10215880, EBI-1047093; CC P57077-4; Q04864: REL; NbExp=3; IntAct=EBI-10215880, EBI-307352; CC P57077-4; Q8N5C8: TAB3; NbExp=6; IntAct=EBI-10215880, EBI-359964; CC P57077-4; P22415: USF1; NbExp=3; IntAct=EBI-10215880, EBI-1054489; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=D {ECO:0000303|Ref.1}; CC IsoId=P57077-4; Sequence=Displayed; CC Name=2; Synonyms=A {ECO:0000303|Ref.1}; CC IsoId=P57077-1; Sequence=VSP_060759; CC -!- TISSUE SPECIFICITY: Detected in lung and peripheral blood leukocytes. CC Expressed predominantly in peripheral blood leukocytes and ubiquitously CC in adult and fetal tissues. Also expressed strongly in breast carcinoma CC GI-101, colon adenocarcinoma GI-112, and prostatic adenocarcinoma PC3. CC {ECO:0000269|PubMed:15168726}. CC -!- DOMAIN: Contains a C-terminal domain similar to that of the C-terminal CC section of MAP3K7. CC -!- SEQUENCE CAUTION: CC Sequence=AAF81752.1; Type=Erroneous translation; Note=Wrong choice of frame.; Evidence={ECO:0000305}; CC Sequence=AAF81753.1; Type=Erroneous translation; Note=Wrong choice of frame.; Evidence={ECO:0000305}; CC Sequence=CAB90434.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF269161; AAF81751.1; -; mRNA. DR EMBL; AF269162; AAF81752.1; ALT_SEQ; mRNA. DR EMBL; AF269163; AAF81753.1; ALT_SEQ; mRNA. DR EMBL; AF269164; AAF81754.1; -; mRNA. DR EMBL; AY033900; AAK68718.1; -; mRNA. DR EMBL; AY171599; AAO16519.1; -; mRNA. DR EMBL; AL713701; CAD28500.1; -; mRNA. DR EMBL; AL163249; CAB90434.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH471079; EAX09921.1; -; Genomic_DNA. DR EMBL; CH471079; EAX09923.1; -; Genomic_DNA. DR EMBL; BC008567; AAH08567.1; -; mRNA. DR CCDS; CCDS13584.1; -. [P57077-1] DR CCDS; CCDS68182.1; -. [P57077-4] DR RefSeq; NP_001273546.1; NM_001286617.2. [P57077-4] DR RefSeq; NP_001273547.1; NM_001286618.2. [P57077-4] DR RefSeq; NP_001273548.1; NM_001286619.2. [P57077-4] DR RefSeq; NP_001273549.1; NM_001286620.2. [P57077-4] DR RefSeq; NP_001273551.1; NM_001286622.1. DR RefSeq; NP_001273553.1; NM_001286624.1. DR RefSeq; NP_001273563.1; NM_001286634.2. [P57077-1] DR RefSeq; NP_001358298.1; NM_001371369.1. [P57077-1] DR RefSeq; NP_001358301.1; NM_001371372.1. [P57077-4] DR RefSeq; NP_001358302.1; NM_001371373.1. [P57077-4] DR RefSeq; NP_001358303.1; NM_001371374.1. [P57077-4] DR RefSeq; NP_064537.1; NM_020152.4. [P57077-1] DR AlphaFoldDB; P57077; -. DR SMR; P57077; -. DR BioGRID; 121239; 11. DR FunCoup; P57077; 1750. DR IntAct; P57077; 9. DR STRING; 9606.ENSP00000382828; -. DR iPTMnet; P57077; -. DR BioMuta; MAP3K7CL; -. DR DMDM; 10719918; -. DR MassIVE; P57077; -. DR PaxDb; 9606-ENSP00000382828; -. DR PeptideAtlas; P57077; -. DR Antibodypedia; 6479; 145 antibodies from 18 providers. DR DNASU; 56911; -. DR Ensembl; ENST00000339024.8; ENSP00000345777.4; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000341618.8; ENSP00000343212.4; ENSG00000156265.18. [P57077-1] DR Ensembl; ENST00000399925.5; ENSP00000382809.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399926.5; ENSP00000382810.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399928.6; ENSP00000382812.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399934.5; ENSP00000382816.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399935.6; ENSP00000382817.2; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399947.6; ENSP00000382828.2; ENSG00000156265.18. [P57077-1] DR Ensembl; ENST00000707854.1; ENSP00000517001.1; ENSG00000291525.1. [P57077-1] DR Ensembl; ENST00000707857.1; ENSP00000517004.1; ENSG00000291525.1. [P57077-1] DR Ensembl; ENST00000707858.1; ENSP00000517005.1; ENSG00000291525.1. [P57077-4] DR Ensembl; ENST00000707860.1; ENSP00000517006.1; ENSG00000291525.1. [P57077-4] DR Ensembl; ENST00000707861.1; ENSP00000517007.1; ENSG00000291525.1. [P57077-4] DR Ensembl; ENST00000707862.1; ENSP00000517008.1; ENSG00000291525.1. [P57077-4] DR GeneID; 56911; -. DR KEGG; hsa:56911; -. DR MANE-Select; ENST00000399928.6; ENSP00000382812.1; NM_001286620.2; NP_001273549.1. DR UCSC; uc002ynd.5; human. [P57077-4] DR AGR; HGNC:16457; -. DR ClinPGx; PA25864; -. DR CTD; 56911; -. DR DisGeNET; 56911; -. DR GeneCards; MAP3K7CL; -. DR HGNC; HGNC:16457; MAP3K7CL. DR HPA; ENSG00000156265; Tissue enhanced (skeletal muscle, tongue). DR MIM; 611110; gene. DR OpenTargets; ENSG00000156265; -. DR VEuPathDB; HostDB:ENSG00000156265; -. DR eggNOG; ENOG502S2UX; Eukaryota. DR GeneTree; ENSGT00770000120675; -. DR HOGENOM; CLU_100451_0_0_1; -. DR InParanoid; P57077; -. DR OMA; MAREFHH; -. DR OrthoDB; 8866809at2759; -. DR PAN-GO; P57077; 0 GO annotations based on evolutionary models. DR PhylomeDB; P57077; -. DR PathwayCommons; P57077; -. DR SignaLink; P57077; -. DR Agora; ENSG00000156265; -. DR BioGRID-ORCS; 56911; 20 hits in 1136 CRISPR screens. DR ChiTaRS; MAP3K7CL; human. DR GeneWiki; C21orf7; -. DR GenomeRNAi; 56911; -. DR Pharos; P57077; Tbio. DR PRO; PR:P57077; -. DR Proteomes; UP000005640; Chromosome 21. DR RNAct; P57077; protein. DR Bgee; ENSG00000156265; Expressed in monocyte and 127 other cell types or tissues. DR ExpressionAtlas; P57077; baseline and differential. DR GO; GO:0005829; C:cytosol; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; HDA:UniProtKB. DR InterPro; IPR042800; Map3k7cl. DR PANTHER; PTHR47140; MAP3K7 C-TERMINAL-LIKE PROTEIN; 1. DR PANTHER; PTHR47140:SF1; MAP3K7 C-TERMINAL-LIKE PROTEIN; 1. PE 1: Evidence at protein level; KW Alternative splicing; Proteomics identification; Reference proteome. FT CHAIN 1..142 FT /note="MAP3K7 C-terminal-like protein" FT /id="PRO_0000072423" FT VAR_SEQ 1..23 FT /note="MISTARVPADKPVRIAFSLNDAS -> MVQLIAPLEVMWNEAADLKPLALSR FT RLECSGGIMAHYSPDLLGPEMESRYFAQVGLEHLASSSPPAFGFLKCLDYSISVLCSAT FT SLAMLEDNPKVSKLATGDWMLTLKPKSITVPVEIPSSPL (in isoform 2)" FT /id="VSP_060759" FT CONFLICT 60 FT /note="K -> R (in Ref. 4; CAD28500)" FT /evidence="ECO:0000305" FT CONFLICT 70 FT /note="H -> L (in Ref. 4; CAD28500)" FT /evidence="ECO:0000305" FT CONFLICT 95 FT /note="K -> E (in Ref. 4; CAD28500)" FT /evidence="ECO:0000305" FT VARIANT P57077-1:112 FT /note="I -> V (in dbSNP:rs3746843)" FT /id="VAR_083830" SQ SEQUENCE 142 AA; 16372 MW; 7F9BCBAF69F25444 CRC64; MISTARVPAD KPVRIAFSLN DASDDTPPED SIPLVFPELD QQLQPLPPCH DSEESMEVFK QHCQIAEEYH EVKKEITLLE QRKKELIAKL DQAEKEKVDA AELVREFEAL TEENRTLRLA QSQCVEQLEK LRIQYQKRQG SS // ID MIEN1_HUMAN Reviewed; 115 AA. AC Q9BRT3; DT 12-DEC-2006, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2001, sequence version 1. DT 28-JAN-2026, entry version 164. DE RecName: Full=Migration and invasion enhancer 1; DE AltName: Full=HBV X-transactivated gene 4 protein; DE AltName: Full=HBV XAg-transactivated protein 4; DE AltName: Full=Protein C35; DE Flags: Precursor; GN Name=MIEN1; Synonyms=C17orf37, RDX12, XTP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND RP ISOPRENYLATION. RX PubMed=17121940; DOI=10.1158/1535-7163.mct-06-0389; RA Evans E.E., Henn A.D., Jonason A., Paris M.J., Schiffhauer L.M., RA Borrello M.A., Smith E.S., Sahasrabudhe D.M., Zauderer M.; RT "C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast RT cancer."; RL Mol. Cancer Ther. 5:2919-2930(2006). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Liu Y., Cheng J., Lu Y., Wang G., Zhang L., Chen J., Li L.; RT "Cloning and identification of human gene 4 transactivated by hepatitis B RT virus X antigen."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [6] RP FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND ISOPRENYLATION AT RP CYS-112. RX PubMed=19503095; DOI=10.1038/onc.2009.145; RA Dasgupta S., Wasson L.M., Rauniyar N., Prokai L., Borejdo J., RA Vishwanatha J.K.; RT "Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of RT prostate cancer cells."; RL Oncogene 28:2860-2872(2009). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [8] RP FUNCTION, SUBCELLULAR LOCATION, ISOPRENYLATION AT CYS-112, AND MUTAGENESIS RP OF CYS-112 AND 112-CYS--LEU-115. RX PubMed=21628459; DOI=10.1074/jbc.m111.254599; RA Dasgupta S., Cushman I., Kpetemey M., Casey P.J., Vishwanatha J.K.; RT "Prenylated c17orf37 induces filopodia formation to promote cell migration RT and metastasis."; RL J. Biol. Chem. 286:25935-25946(2011). RN [9] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [10] RP STRUCTURE BY NMR, AND DISULFIDE BOND. RX PubMed=23284973; DOI=10.1371/journal.pone.0052292; RA Hsu C.H., Shen T.L., Chang C.F., Chang Y.Y., Huang L.Y.; RT "Solution structure of the oncogenic MIEN1 protein reveals a thioredoxin- RT like fold with a redox-active motif."; RL PLoS ONE 7:E52292-E52292(2012). CC -!- FUNCTION: Increases cell migration by inducing filopodia formation at CC the leading edge of migrating cells. Plays a role in regulation of CC apoptosis, possibly through control of CASP3. May be involved in a CC redox-related process. {ECO:0000269|PubMed:19503095, CC ECO:0000269|PubMed:21628459}. CC -!- SUBUNIT: Interacts with GPX1. {ECO:0000250}. CC -!- INTERACTION: CC Q9BRT3; Q03989: ARID5A; NbExp=3; IntAct=EBI-6137472, EBI-948603; CC Q9BRT3; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-6137472, EBI-742054; CC Q9BRT3; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-6137472, EBI-739467; CC Q9BRT3; Q8WUI4-6: HDAC7; NbExp=5; IntAct=EBI-6137472, EBI-12094670; CC Q9BRT3; Q14774: HLX; NbExp=3; IntAct=EBI-6137472, EBI-6678255; CC Q9BRT3; P26583: HMGB2; NbExp=6; IntAct=EBI-6137472, EBI-1057009; CC Q9BRT3; P78424: POU6F2; NbExp=3; IntAct=EBI-6137472, EBI-12029004; CC Q9BRT3; Q04864: REL; NbExp=3; IntAct=EBI-6137472, EBI-307352; CC Q9BRT3; Q04864-2: REL; NbExp=3; IntAct=EBI-6137472, EBI-10829018; CC Q9BRT3; Q15654: TRIP6; NbExp=3; IntAct=EBI-6137472, EBI-742327; CC Q9BRT3; O95231: VENTX; NbExp=3; IntAct=EBI-6137472, EBI-10191303; CC Q9BRT3; A0A0C4DGF1: ZBTB32; NbExp=5; IntAct=EBI-6137472, EBI-10188476; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane; Lipid-anchor; CC Cytoplasmic side. Note=Concentrates at the leading edge of migrating CC cells. Localizes outside membrane raft regions. CC -!- TISSUE SPECIFICITY: Among normal tissues, present only in Leydig cells. CC Strongly up-regulated in breast cancers and in brain cancer distant CC metastasis (at protein level). Up-regulated in prostate cancer cells CC and in the higher grades of prostate adenocarcinoma (at protein level). CC {ECO:0000269|PubMed:17121940, ECO:0000269|PubMed:19503095}. CC -!- PTM: Isoprenylation facilitates association with the plasma membrane CC and enhances the migratory phenotype of cells by inducing increased CC filopodia formation. {ECO:0000269|PubMed:17121940, CC ECO:0000269|PubMed:19503095, ECO:0000269|PubMed:21628459}. CC -!- SIMILARITY: Belongs to the SelWTH family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/52476/MIEN1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY508814; AAR92035.1; -; mRNA. DR EMBL; AF490253; AAO85461.1; -; mRNA. DR EMBL; AC079199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC006006; AAH06006.1; -; mRNA. DR CCDS; CCDS11344.1; -. DR RefSeq; NP_001317135.1; NM_001330206.1. DR RefSeq; NP_115715.3; NM_032339.4. DR PDB; 2LJK; NMR; -; A=1-115. DR PDBsum; 2LJK; -. DR AlphaFoldDB; Q9BRT3; -. DR BMRB; Q9BRT3; -. DR SMR; Q9BRT3; -. DR BioGRID; 124025; 19. DR FunCoup; Q9BRT3; 184. DR IntAct; Q9BRT3; 15. DR STRING; 9606.ENSP00000462998; -. DR iPTMnet; Q9BRT3; -. DR PhosphoSitePlus; Q9BRT3; -. DR SwissPalm; Q9BRT3; -. DR BioMuta; MIEN1; -. DR DMDM; 74732925; -. DR jPOST; Q9BRT3; -. DR MassIVE; Q9BRT3; -. DR PaxDb; 9606-ENSP00000377778; -. DR PeptideAtlas; Q9BRT3; -. DR ProteomicsDB; 78828; -. DR Pumba; Q9BRT3; -. DR Antibodypedia; 28368; 568 antibodies from 26 providers. DR DNASU; 84299; -. DR Ensembl; ENST00000394231.8; ENSP00000377778.3; ENSG00000141741.13. DR GeneID; 84299; -. DR KEGG; hsa:84299; -. DR MANE-Select; ENST00000394231.8; ENSP00000377778.3; NM_032339.5; NP_115715.3. DR UCSC; uc002hsq.4; human. DR AGR; HGNC:28230; -. DR ClinPGx; PA134947080; -. DR CTD; 84299; -. DR DisGeNET; 84299; -. DR GeneCards; MIEN1; -. DR HGNC; HGNC:28230; MIEN1. DR HPA; ENSG00000141741; Low tissue specificity. DR MIM; 611802; gene. DR OpenTargets; ENSG00000141741; -. DR VEuPathDB; HostDB:ENSG00000141741; -. DR eggNOG; ENOG502S3GR; Eukaryota. DR GeneTree; ENSGT00390000010440; -. DR HOGENOM; CLU_068510_4_0_1; -. DR InParanoid; Q9BRT3; -. DR OMA; AAPIKDC; -. DR OrthoDB; 5962009at2759; -. DR PAN-GO; Q9BRT3; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9BRT3; -. DR PathwayCommons; Q9BRT3; -. DR SignaLink; Q9BRT3; -. DR Agora; ENSG00000141741; -. DR BioGRID-ORCS; 84299; 45 hits in 1151 CRISPR screens. DR ChiTaRS; MIEN1; human. DR EvolutionaryTrace; Q9BRT3; -. DR GenomeRNAi; 84299; -. DR Pharos; Q9BRT3; Tbio. DR PRO; PR:Q9BRT3; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9BRT3; protein. DR Bgee; ENSG00000141741; Expressed in mucosa of transverse colon and 184 other cell types or tissues. DR ExpressionAtlas; Q9BRT3; baseline and differential. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0051491; P:positive regulation of filopodium assembly; IDA:UniProtKB. DR FunFam; 3.40.30.10:FF:000131; migration and invasion enhancer 1; 1. DR Gene3D; 3.40.30.10; Glutaredoxin; 1. DR InterPro; IPR011893; Selenoprotein_Rdx-typ. DR InterPro; IPR051441; SelW_related. DR InterPro; IPR036249; Thioredoxin-like_sf. DR NCBIfam; TIGR02174; CXXU_selWTH; 1. DR PANTHER; PTHR15124:SF27; MIGRATION AND INVASION ENHANCER 1; 1. DR PANTHER; PTHR15124; SELENOPROTEIN W; 1. DR Pfam; PF10262; Rdx; 1. DR SUPFAM; SSF52833; Thioredoxin-like; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Apoptosis; Cell membrane; Cytoplasm; KW Disulfide bond; Lipoprotein; Membrane; Prenylation; KW Proteomics identification; Redox-active center; Reference proteome. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..112 FT /note="Migration and invasion enhancer 1" FT /id="PRO_0000265099" FT PROPEP 113..115 FT /note="Removed in mature form" FT /evidence="ECO:0000305" FT /id="PRO_0000396008" FT REGION 1..21 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..10 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT LIPID 112 FT /note="S-geranylgeranyl cysteine" FT /evidence="ECO:0000269|PubMed:19503095, FT ECO:0000269|PubMed:21628459" FT DISULFID 30..33 FT /note="Redox-active" FT /evidence="ECO:0000269|PubMed:23284973" FT MUTAGEN 112..115 FT /note="Missing: No effect on subcellular location. Low FT protein abundance, suggesting that stability is affected." FT /evidence="ECO:0000269|PubMed:21628459" FT MUTAGEN 112 FT /note="C->S: Abolishes prenylation. Predominantly cytosolic FT with little plasma membrane-associated expression. Reduces FT cell migration by affecting filopodia formation." FT /evidence="ECO:0000269|PubMed:21628459" FT STRAND 26..29 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 31..34 FT /evidence="ECO:0007829|PDB:2LJK" FT HELIX 36..46 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 51..53 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 56..59 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 65..68 FT /evidence="ECO:0007829|PDB:2LJK" FT HELIX 77..80 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 86..90 FT /evidence="ECO:0007829|PDB:2LJK" FT HELIX 91..96 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 97..99 FT /evidence="ECO:0007829|PDB:2LJK" SQ SEQUENCE 115 AA; 12403 MW; 5D8B911C0F23DDC1 CRC64; MSGEPGQTSV APPPEEVEPG SGVRIVVEYC EPCGFEATYL ELASAVKEQY PGIEIESRLG GTGAFEIEIN GQLVFSKLEN GGFPYEKDLI EAIRRASNGE TLEKITNSRP PCVIL // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MLH3_HUMAN Reviewed; 1453 AA. AC Q9UHC1; P49751; Q56DK9; Q9P292; Q9UHC0; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 3. DT 28-JAN-2026, entry version 202. DE RecName: Full=DNA mismatch repair protein Mlh3; DE AltName: Full=MutL protein homolog 3; GN Name=MLH3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND RP VARIANTS ASP-826 AND LEU-844. RX PubMed=10615123; DOI=10.1038/71643; RA Lipkin S.M., Wang V., Jacoby R., Banerjee-Basu S., Baxevanis A.D., RA Lynch H.T., Elliott R.M., Collins F.S.; RT "MLH3: a DNA mismatch repair gene associated with mammalian microsatellite RT instability."; RL Nat. Genet. 24:27-35(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH MLH1, AND VARIANT ASP-826. RX PubMed=11292842; DOI=10.1093/nar/29.8.1695; RA Kondo E., Horii A., Fukushige S.; RT "The interacting domains of three MutL heterodimers in man: hMLH1 interacts RT with 36 homologous amino acid residues within hMLH3, hPMS1 and hPMS2."; RL Nucleic Acids Res. 29:1695-1702(2001). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-93; SER-120; GLN-231; RP ILE-420; VAL-492; GLN-600; PRO-606; GLN-624; CYS-647; CYS-720; ILE-723; RP PHE-741; HIS-797; ASP-826; LEU-844; GLY-845; ILE-942; PRO-966; ASN-1073; RP GLU-1105; ASP-1163 AND ARG-1319. RG NIEHS SNPs program; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1189-1453. RC TISSUE=Brain; RX PubMed=7596406; DOI=10.1038/375754a0; RA Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., RA Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.-F., RA Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., RA Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., RA da Silva H.A.R., Haines J.L., Pericak-Vance M.A., Tanzi R.E., Roses A.D., RA Fraser P.E., Rommens J.M., St George-Hyslop P.H.; RT "Cloning of a gene bearing missense mutations in early-onset familial RT Alzheimer's disease."; RL Nature 375:754-760(1995). RN [6] RP INVOLVEMENT IN SOMATIC COLORECTAL CANCER. RX PubMed=11317354; DOI=10.1002/humu.1114; RA Lipkin S.M., Wang V., Stoler D.L., Anderson G.R., Kirsch I., Hadley D., RA Lynch H.T., Collins F.S.; RT "Germline and somatic mutation analyses in the DNA mismatch repair gene RT MLH3: evidence for somatic mutation in colorectal cancers."; RL Hum. Mutat. 17:389-396(2001). RN [7] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [8] RP VARIANTS HNPCC7 GLU-24; SER-499; GLN-624; CYS-647; GLY-817; SER-981; RP SER-1007; THR-1394 AND LYS-1451. RX PubMed=11586295; DOI=10.1038/ng1001-137; RA Wu Y., Berends M.J.W., Sijmons R.H., Mensink R.G.J., Verlind E., Kooi K.A., RA van der Sluis T., Kempinga C., van der Zee A.G.J., Hollema H., RA Buys C.H.C.M., Kleibeuker J.H., Hofstra R.M.W.; RT "A role for MLH3 in hereditary nonpolyposis colorectal cancer."; RL Nat. Genet. 29:137-138(2001). CC -!- FUNCTION: Probably involved in the repair of mismatches in DNA. CC -!- SUBUNIT: Heterodimer of MLH1 and MLH3. Interacts with MTMR15/FAN1. CC {ECO:0000269|PubMed:11292842, ECO:0000269|PubMed:20603073}. CC -!- INTERACTION: CC Q9UHC1; P40692: MLH1; NbExp=7; IntAct=EBI-3893094, EBI-744248; CC Q9UHC1-2; G5E9A7: DMWD; NbExp=3; IntAct=EBI-9089845, EBI-10976677; CC Q9UHC1-2; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-9089845, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9UHC1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UHC1-2; Sequence=VSP_003290; CC -!- TISSUE SPECIFICITY: Ubiquitous. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 7 (HNPCC7) CC [MIM:614385]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:11586295}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:11317354}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC42005.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAC42005.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF195657; AAF23904.1; -; mRNA. DR EMBL; AF195658; AAF23905.1; -; Genomic_DNA. DR EMBL; AB039667; BAA92353.1; -; mRNA. DR EMBL; AY963685; AAX59030.1; -; Genomic_DNA. DR EMBL; AL049780; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L40399; AAC42005.1; ALT_SEQ; mRNA. DR CCDS; CCDS32123.1; -. [Q9UHC1-1] DR CCDS; CCDS9837.1; -. [Q9UHC1-2] DR RefSeq; NP_001035197.1; NM_001040108.2. [Q9UHC1-1] DR RefSeq; NP_055196.2; NM_014381.3. [Q9UHC1-2] DR RefSeq; XP_006720179.1; XM_006720116.5. [Q9UHC1-1] DR RefSeq; XP_016876708.1; XM_017021219.3. [Q9UHC1-2] DR AlphaFoldDB; Q9UHC1; -. DR SMR; Q9UHC1; -. DR BioGRID; 117961; 62. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR FunCoup; Q9UHC1; 1826. DR IntAct; Q9UHC1; 48. DR MINT; Q9UHC1; -. DR STRING; 9606.ENSP00000348020; -. DR CarbonylDB; Q9UHC1; -. DR GlyGen; Q9UHC1; 2 sites, 1 N-linked glycan (1 site). DR iPTMnet; Q9UHC1; -. DR PhosphoSitePlus; Q9UHC1; -. DR BioMuta; MLH3; -. DR DMDM; 317373417; -. DR jPOST; Q9UHC1; -. DR MassIVE; Q9UHC1; -. DR PaxDb; 9606-ENSP00000348020; -. DR PeptideAtlas; Q9UHC1; -. DR ProteomicsDB; 84305; -. [Q9UHC1-1] DR ProteomicsDB; 84306; -. [Q9UHC1-2] DR Antibodypedia; 25763; 155 antibodies from 27 providers. DR DNASU; 27030; -. DR Ensembl; ENST00000355774.7; ENSP00000348020.2; ENSG00000119684.17. [Q9UHC1-1] DR Ensembl; ENST00000380968.6; ENSP00000370355.3; ENSG00000119684.17. [Q9UHC1-2] DR GeneID; 27030; -. DR KEGG; hsa:27030; -. DR MANE-Select; ENST00000355774.7; ENSP00000348020.2; NM_001040108.2; NP_001035197.1. DR UCSC; uc001xrd.1; human. [Q9UHC1-1] DR AGR; HGNC:7128; -. DR ClinPGx; PA30845; -. DR CTD; 27030; -. DR DisGeNET; 27030; -. DR GeneCards; MLH3; -. DR HGNC; HGNC:7128; MLH3. DR HPA; ENSG00000119684; Low tissue specificity. DR MalaCards; MLH3; -. DR MIM; 114500; phenotype. DR MIM; 604395; gene. DR MIM; 614385; phenotype. DR OpenTargets; ENSG00000119684; -. DR VEuPathDB; HostDB:ENSG00000119684; -. DR eggNOG; KOG1977; Eukaryota. DR GeneTree; ENSGT00800000124176; -. DR HOGENOM; CLU_002376_0_0_1; -. DR InParanoid; Q9UHC1; -. DR OMA; HIGREGH; -. DR OrthoDB; 429932at2759; -. DR PAN-GO; Q9UHC1; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHC1; -. DR PathwayCommons; Q9UHC1; -. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; Q9UHC1; -. DR Agora; ENSG00000119684; -. DR BioGRID-ORCS; 27030; 15 hits in 1154 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH3; human. DR GeneWiki; MLH3; -. DR GenomeRNAi; 27030; -. DR Pharos; Q9UHC1; Tbio. DR PRO; PR:Q9UHC1; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9UHC1; protein. DR Bgee; ENSG00000119684; Expressed in monocyte and 191 other cell types or tissues. DR ExpressionAtlas; Q9UHC1; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0032300; C:mismatch repair complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0030983; F:mismatched DNA binding; IEA:InterPro. DR GO; GO:0003696; F:satellite DNA binding; TAS:ProtInc. DR GO; GO:0007144; P:female meiosis I; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IBA:GO_Central. DR GO; GO:0007131; P:reciprocal meiotic recombination; NAS:UniProtKB. DR GO; GO:0007130; P:synaptonemal complex assembly; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03486; MutL_Trans_MLH3; 1. DR FunFam; 3.30.1370.100:FF:000003; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.230.10:FF:000028; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.565.10:FF:000031; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.1540.20:FF:000005; MutL homolog 3; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR Gene3D; 3.30.1540.20; MutL, C-terminal domain, dimerisation subdomain; 1. DR Gene3D; 3.30.1370.100; MutL, C-terminal domain, regulatory subdomain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR014790; MutL_C. DR InterPro; IPR042120; MutL_C_dimsub. DR InterPro; IPR042121; MutL_C_regsub. DR InterPro; IPR037198; MutL_C_sf. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF47; DNA MISMATCH REPAIR PROTEIN MLH3; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF08676; MutL_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SMART; SM00853; MutL_C; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF118116; DNA mismatch repair protein MutL; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleus; KW Proteomics identification; Reference proteome. FT CHAIN 1..1453 FT /note="DNA mismatch repair protein Mlh3" FT /id="PRO_0000178003" FT REGION 624..650 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 933..960 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 935..944 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 945..960 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1215..1238 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_003290" FT VARIANT 24 FT /note="Q -> E (in HNPCC7; dbSNP:rs28937870)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012946" FT VARIANT 93 FT /note="R -> G (in dbSNP:rs28756978)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023338" FT VARIANT 120 FT /note="F -> S (in dbSNP:rs28756979)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023339" FT VARIANT 231 FT /note="K -> Q (in dbSNP:rs28756981)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023340" FT VARIANT 420 FT /note="V -> I (in dbSNP:rs28756982)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023341" FT VARIANT 492 FT /note="L -> V (in dbSNP:rs28756983)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023342" FT VARIANT 494 FT /note="H -> R (in dbSNP:rs760778201)" FT /id="VAR_010790" FT VARIANT 499 FT /note="N -> S (in HNPCC7; dbSNP:rs28937871)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012947" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs28756984)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023343" FT VARIANT 606 FT /note="T -> P (in dbSNP:rs28756985)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023344" FT VARIANT 624 FT /note="E -> Q (in HNPCC7; dbSNP:rs28756986)" FT /evidence="ECO:0000269|PubMed:11586295, ECO:0000269|Ref.3" FT /id="VAR_012948" FT VARIANT 647 FT /note="R -> C (in HNPCC7; dbSNP:rs28756987)" FT /evidence="ECO:0000269|PubMed:11586295, ECO:0000269|Ref.3" FT /id="VAR_012949" FT VARIANT 720 FT /note="Y -> C (in dbSNP:rs28756988)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023345" FT VARIANT 723 FT /note="V -> I (in dbSNP:rs28756989)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023346" FT VARIANT 741 FT /note="V -> F (in dbSNP:rs28756990)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023347" FT VARIANT 797 FT /note="R -> H (in dbSNP:rs28756991)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023348" FT VARIANT 817 FT /note="S -> G (in HNPCC7; dbSNP:rs143278116)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012950" FT VARIANT 826 FT /note="N -> D (in dbSNP:rs175081)" FT /evidence="ECO:0000269|PubMed:10615123, FT ECO:0000269|PubMed:11292842, ECO:0000269|Ref.3" FT /id="VAR_036781" FT VARIANT 844 FT /note="P -> L (in dbSNP:rs175080)" FT /evidence="ECO:0000269|PubMed:10615123, ECO:0000269|Ref.3" FT /id="VAR_023349" FT VARIANT 845 FT /note="S -> G (in dbSNP:rs28756992)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023350" FT VARIANT 942 FT /note="T -> I (in dbSNP:rs17102999)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023351" FT VARIANT 966 FT /note="S -> P (in dbSNP:rs17782839)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023352" FT VARIANT 981 FT /note="G -> S (in HNPCC7; dbSNP:rs377337763)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012951" FT VARIANT 1007 FT /note="N -> S (in HNPCC7; dbSNP:rs776639203)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012952" FT VARIANT 1073 FT /note="D -> N (in dbSNP:rs28756993)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023353" FT VARIANT 1105 FT /note="D -> E (in dbSNP:rs28757008)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023354" FT VARIANT 1163 FT /note="G -> D (in dbSNP:rs28757011)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023355" FT VARIANT 1319 FT /note="G -> R (in dbSNP:rs2139384512)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023356" FT VARIANT 1394 FT /note="A -> T (in HNPCC7; dbSNP:rs138006166)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012953" FT VARIANT 1451 FT /note="E -> K (in HNPCC7; dbSNP:rs28939071)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012954" SQ SEQUENCE 1453 AA; 163711 MW; 3D063427457DB033 CRC64; MIKCLSVEVQ AKLRSGLAIS SLGQCVEELA LNSIDAEAKC VAVRVNMETF QVQVIDNGFG MGSDDVEKVG NRYFTSKCHS VQDLENPRFY GFRGEALANI ADMASAVEIS SKKNRTMKTF VKLFQSGKAL KACEADVTRA SAGTTVTVYN LFYQLPVRRK CMDPRLEFEK VRQRIEALSL MHPSISFSLR NDVSGSMVLQ LPKTKDVCSR FCQIYGLGKS QKLREISFKY KEFELSGYIS SEAHYNKNMQ FLFVNKRLVL RTKLHKLIDF LLRKESIICK PKNGPTSRQM NSSLRHRSTP ELYGIYVINV QCQFCEYDVC MEPAKTLIEF QNWDTLLFCI QEGVKMFLKQ EKLFVELSGE DIKEFSEDNG FSLFDATLQK RVTSDERSNF QEACNNILDS YEMFNLQSKA VKRKTTAENV NTQSSRDSEA TRKNTNDAFL YIYESGGPGH SKMTEPSLQN KDSSCSESKM LEQETIVASE AGENEKHKKS FLEHSSLENP CGTSLEMFLS PFQTPCHFEE SGQDLEIWKE STTVNGMAAN ILKNNRIQNQ PKRFKDATEV GCQPLPFATT LWGVHSAQTE KEKKKESSNC GRRNVFSYGR VKLCSTGFIT HVVQNEKTKS TETEHSFKNY VRPGPTRAQE TFGNRTRHSV ETPDIKDLAS TLSKESGQLP NKKNCRTNIS YGLENEPTAT YTMFSAFQEG SKKSQTDCIL SDTSPSFPWY RHVSNDSRKT DKLIGFSKPI VRKKLSLSSQ LGSLEKFKRQ YGKVENPLDT EVEESNGVTT NLSLQVEPDI LLKDKNRLEN SDVCKITTME HSDSDSSCQP ASHILNSEKF PFSKDEDCLE QQMPSLRESP MTLKELSLFN RKPLDLEKSS ESLASKLSRL KGSERETQTM GMMSRFNELP NSDSSRKDSK LCSVLTQDFC MLFNNKHEKT ENGVIPTSDS ATQDNSFNKN SKTHSNSNTT ENCVISETPL VLPYNNSKVT GKDSDVLIRA SEQQIGSLDS PSGMLMNPVE DATGDQNGIC FQSEESKARA CSETEESNTC CSDWQRHFDV ALGRMVYVNK MTGLSTFIAP TEDIQAACTK DLTTVAVDVV LENGSQYRCQ PFRSDLVLPF LPRARAERTV MRQDNRDTVD DTVSSESLQS LFSEWDNPVF ARYPEVAVDV SSGQAESLAV KIHNILYPYR FTKGMIHSMQ VLQQVDNKFI ACLMSTKTEE NGEAGGNLLV LVDQHAAHER IRLEQLIIDS YEKQQAQGSG RKKLLSSTLI PPLEITVTEE QRRLLWCYHK NLEDLGLEFV FPDTSDSLVL VGKVPLCFVE REANELRRGR STVTKSIVEE FIREQLELLQ TTGGIQGTLP LTVQKVLASQ ACHGAIKFND GLSLQESCRL IEALSSCQLP FQCAHGRPSM LPLADIDHLE QEKQIKPNLT KLRKMAQAWR LFGKAECDTR QSLQQSMPPC EPP // ID MRCKB_HUMAN Reviewed; 1711 AA. AC Q9Y5S2; A9JR72; Q2L7A5; Q86TJ1; Q9ULU5; DT 08-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 04-APR-2006, sequence version 2. DT 28-JAN-2026, entry version 213. DE RecName: Full=Serine/threonine-protein kinase MRCK beta; DE EC=2.7.11.1; DE AltName: Full=CDC42-binding protein kinase beta; DE Short=CDC42BP-beta; DE AltName: Full=DMPK-like beta; DE AltName: Full=Myotonic dystrophy kinase-related CDC42-binding kinase beta; DE Short=MRCK beta; DE Short=Myotonic dystrophy protein kinase-like beta; GN Name=CDC42BPB {ECO:0000312|EMBL:AAD37506.1}; GN Synonyms=KIAA1124 {ECO:0000312|EMBL:BAA86438.2}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD37506.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RC TISSUE=Brain {ECO:0000312|EMBL:AAD37506.1}; RX PubMed=10198171; DOI=10.1006/geno.1999.5769; RA Moncrieff C.L., Bailey M.E., Morrison N., Johnson K.J.; RT "Cloning and chromosomal localization of human Cdc42-binding protein kinase RT beta."; RL Genomics 57:297-300(1999). RN [2] {ECO:0000312|EMBL:BAA86438.2} RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-1203. RC TISSUE=Brain {ECO:0000312|EMBL:BAA86438.2}; RX PubMed=10574461; DOI=10.1093/dnares/6.5.329; RA Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.; RT "Characterization of cDNA clones selected by the GeneMark analysis from RT size-fractionated cDNA libraries from human brain."; RL DNA Res. 6:329-336(1999). RN [3] {ECO:0000305} RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-1077. RG NIEHS SNPs program; RL Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:AAH47871.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-1203. RC TISSUE=PNS {ECO:0000312|EMBL:AAH47871.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH LURAP1 RP AND MYO18A. RX PubMed=18854160; DOI=10.1016/j.cell.2008.09.018; RA Tan I., Yong J., Dong J.M., Lim L., Leung T.; RT "A tripartite complex containing MRCK modulates lamellar actomyosin RT retrograde flow."; RL Cell 135:123-136(2008). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=21240187; DOI=10.1038/emboj.2010.353; RA Huo L., Wen W., Wang R., Kam C., Xia J., Feng W., Zhang M.; RT "Cdc42-dependent formation of the ZO-1/MRCKbeta complex at the leading edge RT controls cell migration."; RL EMBO J. 30:665-678(2011). RN [14] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A AND MYL9/MLC2, AND ACTIVITY RP REGULATION. RX PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054; RA Tan I., Lai J., Yong J., Li S.F., Leung T.; RT "Chelerythrine perturbs lamellar actomyosin filaments by selective RT inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase."; RL FEBS Lett. 585:1260-1268(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690 AND SER-1693, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-423; SER-1680; SER-1682 AND RP SER-1686, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-671, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [19] RP INTERACTION WITH STRP1; STRN3 AND SIKE1. RX PubMed=25743393; DOI=10.1038/ncomms7449; RA Lant B., Yu B., Goudreault M., Holmyard D., Knight J.D., Xu P., Zhao L., RA Chin K., Wallace E., Zhen M., Gingras A.C., Derry W.B.; RT "CCM-3/STRIPAK promotes seamless tube extension through endocytic RT recycling."; RL Nat. Commun. 6:6449-6449(2015). RN [20] RP PROTEOLYTIC CLEAVAGE. RX PubMed=29162624; DOI=10.1083/jcb.201703044; RA Gagliardi P.A., Somale D., Puliafito A., Chiaverina G., di Blasio L., RA Oneto M., Bianchini P., Bussolino F., Primo L.; RT "MRCKalpha is activated by caspase cleavage to assemble an apical actin RT ring for epithelial cell extrusion."; RL J. Cell Biol. 217:231-249(2018). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 2-417 IN COMPLEXES WITH FASUDIL RP AND TPCA-1, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY. RX PubMed=21949762; DOI=10.1371/journal.pone.0024825; RA Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A., Kaye S.J., RA Mezna M., Pang L., Rushbrooke M., Turnbull A., Olson M.F.; RT "Co-crystal structures of inhibitors with MRCKbeta, a key regulator of RT tumor cell invasion."; RL PLoS ONE 6:E24825-E24825(2011). RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-500; GLN-555; GLN-671; TRP-876; RP LYS-1315 AND TYR-1633. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP INVOLVEMENT IN CHOCNS, AND VARIANTS CHOCNS THR-142; TYR-175; MET-293; RP 764-ARG--THR-1711 DEL; CYS-867; PRO-871; PRO-876; TRP-876; GLN-1299 AND RP PRO-1350. RX PubMed=32031333; DOI=10.1002/ajmg.a.61505; RA Chilton I., Okur V., Vitiello G., Selicorni A., Mariani M., Goldenberg A., RA Husson T., Campion D., Lichtenbelt K.D., van Gassen K., Steinraths M., RA Rice J., Roeder E.R., Littlejohn R.O., Srour M., Sebire G., Accogli A., RA Heron D., Heide S., Nava C., Depienne C., Larson A., Niyazov D., Azage M., RA Hoganson G., Burton J., Rush E.T., Jenkins J.L., Saunders C.J., RA Thiffault I., Alaimo J.T., Fleischer J., Groepper D., Gripp K.W., RA Chung W.K.; RT "De novo heterozygous missense and loss-of-function variants in CDC42BPB RT are associated with a neurodevelopmental phenotype."; RL Am. J. Med. Genet. A 182:962-973(2020). CC -!- FUNCTION: Serine/threonine-protein kinase which is an important CC downstream effector of CDC42 and plays a role in the regulation of CC cytoskeleton reorganization and cell migration. Regulates actin CC cytoskeletal reorganization via phosphorylation of PPP1R12C and CC MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A CC and LURAP1, is involved in modulating lamellar actomyosin retrograde CC flow that is crucial to cell protrusion and migration CC (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In CC concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the CC lamellipodium resulting in its activation and subsequent CC phosphorylation of CFL1 which is important for lamellipodial F-actin CC regulation (By similarity). {ECO:0000250|UniProtKB:Q7TT50, CC ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715, CC ECO:0000269|PubMed:21949762}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q5VT25}; CC -!- ACTIVITY REGULATION: Maintained in an inactive, closed conformation by CC an interaction between the kinase domain and the negative CC autoregulatory C-terminal coiled-coil region. Agonist binding to the CC phorbol ester binding site disrupts this, releasing the kinase domain CC to allow N-terminus-mediated dimerization and kinase activation by CC transautophosphorylation (By similarity). Inhibited by chelerythrine CC chloride. {ECO:0000250, ECO:0000269|PubMed:21457715}. CC -!- SUBUNIT: Homodimer and homotetramer via the coiled coil regions CC (PubMed:21949762). Interacts tightly with GTP-bound but not GDP-bound CC CDC42. Interacts with TJP1, when in the presence of catalytically CC active CDC42 (By similarity). Forms a tripartite complex with MYO18A CC and LURAP1 with the latter acting as an adapter connecting CDC42BPB and CC MYO18A. LURAP1 binding results in activation of CDC42BPB by abolition CC of its negative autoregulation (PubMed:18854160). Interacts with CC STRIP1, STRN3 and SIKE1 (PubMed:25743393). Interacts with CPNE4 (via CC VWFA domain). Interacts with LURAP1. Interacts (via AGC-kinase C- CC terminal domain) with FAM89B/LRAP25 (via LRR repeat). Forms a CC tripartite complex with FAM89B/LRAP25 and LIMK1 (By similarity). CC {ECO:0000250|UniProtKB:Q7TT49, ECO:0000250|UniProtKB:Q7TT50, CC ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21949762, CC ECO:0000269|PubMed:25743393}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane CC {ECO:0000269|PubMed:21240187}; Peripheral membrane protein CC {ECO:0000269|PubMed:21240187}; Cytoplasmic side CC {ECO:0000269|PubMed:21240187}. Cell junction CC {ECO:0000269|PubMed:21240187}. Cell projection, lamellipodium CC {ECO:0000250|UniProtKB:Q3UU96}. Note=Displays a dispersed punctate CC distribution and concentrates along the cell periphery, especially at CC the leading edge and cell-cell junction. This concentration is PH- CC domain dependent (By similarity). Detected at the leading edge of CC migrating cells. Localization at the leading edge of migrating cells CC requires interaction with catalytically active CDC42 (PubMed:21240187). CC Localizes in the lamellipodium in a FAM89B/LRAP25-dependent manner (By CC similarity). {ECO:0000250|UniProtKB:O54874, CC ECO:0000250|UniProtKB:Q3UU96, ECO:0000269|PubMed:21240187}. CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined, with high levels CC in heart, brain, placenta and lung. {ECO:0000269|PubMed:10198171}. CC -!- PTM: Proteolytically cleaved by caspases upon apoptosis induction. CC {ECO:0000269|PubMed:29162624}. CC -!- DISEASE: Chilton-Okur-Chung neurodevelopmental syndrome (CHOCNS) CC [MIM:619841]: A disorder characterized by developmental delay, CC intellectual disability, hypotonia, and structural brain abnormalities CC including cerebellar vermis hypoplasia and agenesis or hypoplasia of CC the corpus callosum. Most patients have behavioral abnormalities, CC including autism spectrum disorder, attention deficit and hyperactivity CC disorder, and aggression. About half of patients have dysmorphic facial CC features. Rare involvement of other organ systems may be present. CC {ECO:0000269|PubMed:32031333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. DMPK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH47871.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAA86438.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF128625; AAD37506.1; -; mRNA. DR EMBL; AB032950; BAA86438.2; ALT_INIT; mRNA. DR EMBL; DQ355971; ABC67469.1; -; Genomic_DNA. DR EMBL; BC047871; AAH47871.1; ALT_SEQ; mRNA. DR EMBL; BC155541; AAI55542.1; -; mRNA. DR CCDS; CCDS9978.1; -. DR RefSeq; NP_006026.3; NM_006035.3. DR PDB; 3QFV; X-ray; 2.65 A; A/B=1-415. DR PDB; 3TKU; X-ray; 2.15 A; A/B=2-417. DR PDB; 4UAK; X-ray; 1.73 A; A=2-417. DR PDB; 4UAL; X-ray; 1.71 A; A=2-417. DR PDB; 5OTE; X-ray; 1.68 A; A=2-417. DR PDB; 5OTF; X-ray; 2.00 A; A=2-417. DR PDBsum; 3QFV; -. DR PDBsum; 3TKU; -. DR PDBsum; 4UAK; -. DR PDBsum; 4UAL; -. DR PDBsum; 5OTE; -. DR PDBsum; 5OTF; -. DR AlphaFoldDB; Q9Y5S2; -. DR SMR; Q9Y5S2; -. DR BioGRID; 114947; 127. DR FunCoup; Q9Y5S2; 1147. DR MINT; Q9Y5S2; -. DR STRING; 9606.ENSP00000355237; -. DR BindingDB; Q9Y5S2; -. DR ChEMBL; CHEMBL5052; -. DR DrugCentral; Q9Y5S2; -. DR GlyGen; Q9Y5S2; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q9Y5S2; -. DR MetOSite; Q9Y5S2; -. DR PhosphoSitePlus; Q9Y5S2; -. DR SwissPalm; Q9Y5S2; -. DR BioMuta; CDC42BPB; -. DR DMDM; 92090617; -. DR CPTAC; CPTAC-2986; -. DR CPTAC; non-CPTAC-2985; -. DR CPTAC; non-CPTAC-5628; -. DR CPTAC; non-CPTAC-5629; -. DR jPOST; Q9Y5S2; -. DR MassIVE; Q9Y5S2; -. DR PaxDb; 9606-ENSP00000355237; -. DR PeptideAtlas; Q9Y5S2; -. DR ProteomicsDB; 86490; -. DR Pumba; Q9Y5S2; -. DR Antibodypedia; 14692; 175 antibodies from 28 providers. DR DNASU; 9578; -. DR Ensembl; ENST00000361246.7; ENSP00000355237.2; ENSG00000198752.12. DR GeneID; 9578; -. DR KEGG; hsa:9578; -. DR MANE-Select; ENST00000361246.7; ENSP00000355237.2; NM_006035.4; NP_006026.3. DR UCSC; uc001ymi.2; human. DR AGR; HGNC:1738; -. DR ClinPGx; PA26268; -. DR CTD; 9578; -. DR DisGeNET; 9578; -. DR GeneCards; CDC42BPB; -. DR HGNC; HGNC:1738; CDC42BPB. DR HPA; ENSG00000198752; Low tissue specificity. DR MalaCards; CDC42BPB; -. DR MIM; 614062; gene. DR MIM; 619841; phenotype. DR OpenTargets; ENSG00000198752; -. DR VEuPathDB; HostDB:ENSG00000198752; -. DR eggNOG; KOG0612; Eukaryota. DR GeneTree; ENSGT01030000234517; -. DR HOGENOM; CLU_000288_140_3_1; -. DR InParanoid; Q9Y5S2; -. DR OMA; ELEALKX; -. DR OrthoDB; 10047816at2759; -. DR PAN-GO; Q9Y5S2; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y5S2; -. DR PathwayCommons; Q9Y5S2; -. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013406; RHOQ GTPase cycle. DR Reactome; R-HSA-9013409; RHOJ GTPase cycle. DR SignaLink; Q9Y5S2; -. DR SIGNOR; Q9Y5S2; -. DR Agora; ENSG00000198752; -. DR BioGRID-ORCS; 9578; 15 hits in 1188 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CDC42BPB; human. DR EvolutionaryTrace; Q9Y5S2; -. DR GenomeRNAi; 9578; -. DR Pharos; Q9Y5S2; Tchem. DR PRO; PR:Q9Y5S2; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9Y5S2; protein. DR Bgee; ENSG00000198752; Expressed in stromal cell of endometrium and 186 other cell types or tissues. DR ExpressionAtlas; Q9Y5S2; baseline and differential. DR GO; GO:0042641; C:actomyosin; IDA:UniProtKB. DR GO; GO:0031252; C:cell leading edge; ISS:UniProtKB. DR GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005856; C:cytoskeleton; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; TAS:ProtInc. DR GO; GO:0007163; P:establishment or maintenance of cell polarity; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20865; C1_MRCKbeta; 1. DR CDD; cd00132; CRIB; 1. DR CDD; cd01243; PH_MRCK; 1. DR CDD; cd05624; STKc_MRCK_beta; 1. DR FunFam; 2.30.29.30:FF:000140; CDC42 binding protein kinase beta; 1. DR FunFam; 1.10.510.10:FF:000014; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.20.5.340:FF:000010; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.60.20:FF:000005; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:001044; Serine/threonine-protein kinase MRCK beta; 1. DR FunFam; 3.30.200.20:FF:001209; Serine/threonine-protein kinase MRCK beta; 1. DR Gene3D; 1.20.5.340; -; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR001180; CNH_dom. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR031597; KELK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR057529; MRCK/ROCK_PH. DR InterPro; IPR042718; MRCKB_STKc. DR InterPro; IPR014930; Myotonic_dystrophy_kinase_coil. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050839; Rho-assoc_Ser/Thr_Kinase. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22988; MYOTONIC DYSTROPHY S/T KINASE-RELATED; 1. DR PANTHER; PTHR22988:SF34; SERINE_THREONINE-PROTEIN KINASE MRCK BETA; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00780; CNH; 1. DR Pfam; PF08826; DMPK_coil; 1. DR Pfam; PF15796; KELK; 1. DR Pfam; PF25346; PH_MRCK; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00036; CNH; 1. DR SMART; SM00285; PBD; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50219; CNH; 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Disease variant; Intellectual disability; Kinase; KW Magnesium; Membrane; Metal-binding; Methylation; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..1711 FT /note="Serine/threonine-protein kinase MRCK beta" FT /id="PRO_0000086394" FT DOMAIN 76..342 FT /note="Protein kinase" FT /evidence="ECO:0000250|UniProtKB:Q5VT25, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 343..413 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 1095..1214 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 1240..1513 FT /note="CNH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00795" FT DOMAIN 1583..1596 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT ZN_FING 1025..1075 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 461..484 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 969..1009 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1611..1711 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 431..815 FT /evidence="ECO:0000255" FT COILED 878..939 FT /evidence="ECO:0000255" FT COMPBIAS 463..481 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1641..1650 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1664..1675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 200 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P54265, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 82..90 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P54265, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 105 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:Q5VT25, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 221 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 233 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 239 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 423 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 671 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 954 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q7TT50" FT MOD_RES 1680 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1682 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1686 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1690 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1693 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT VARIANT 142 FT /note="A -> T (in CHOCNS; uncertain significance; FT dbSNP:rs1198710710)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087124" FT VARIANT 175 FT /note="D -> Y (in CHOCNS; uncertain significance; FT dbSNP:rs1595127294)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087125" FT VARIANT 293 FT /note="I -> M (in CHOCNS; uncertain significance; FT dbSNP:rs1016320330)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087126" FT VARIANT 500 FT /note="K -> E (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1158962067)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040834" FT VARIANT 555 FT /note="R -> Q (in dbSNP:rs36001612)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040835" FT VARIANT 671 FT /note="R -> Q (in dbSNP:rs55948035)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040836" FT VARIANT 764..1711 FT /note="Missing (in CHOCNS)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087127" FT VARIANT 867 FT /note="R -> C (in CHOCNS; dbSNP:rs1595472764)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087128" FT VARIANT 871 FT /note="L -> P (in CHOCNS; uncertain significance; FT dbSNP:rs1595472756)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087129" FT VARIANT 876 FT /note="R -> P (in CHOCNS; dbSNP:rs1595472739)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087130" FT VARIANT 876 FT /note="R -> W (in a colorectal adenocarcinoma sample and FT CHOCNS; somatic mutation; dbSNP:rs1595472741)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:32031333" FT /id="VAR_040837" FT VARIANT 1077 FT /note="I -> V (in dbSNP:rs34822377)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_025847" FT VARIANT 1203 FT /note="R -> K (in dbSNP:rs146298297)" FT /evidence="ECO:0000269|PubMed:10574461, FT ECO:0000269|PubMed:15489334" FT /id="VAR_070886" FT VARIANT 1299 FT /note="R -> Q (in CHOCNS; uncertain significance; FT dbSNP:rs1595450393)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087131" FT VARIANT 1315 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040838" FT VARIANT 1350 FT /note="R -> P (in CHOCNS; uncertain significance; FT dbSNP:rs1595450125)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087132" FT VARIANT 1633 FT /note="S -> Y (in dbSNP:rs56412851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040839" FT CONFLICT 1017 FT /note="A -> V (in Ref. 1; AAD37506)" FT /evidence="ECO:0000305" FT CONFLICT 1123 FT /note="D -> E (in Ref. 1; AAD37506)" FT /evidence="ECO:0000305" FT HELIX 3..20 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:3QFV" FT HELIX 27..41 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 44..47 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 50..69 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 73..75 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 86..95 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 101..108 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 109..114 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 115..118 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 121..130 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 133..135 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 139..144 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 146..153 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 161..167 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 168..170 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 174..193 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 203..205 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:5OTF" FT STRAND 227..229 FT /evidence="ECO:0007829|PDB:3QFV" FT STRAND 231..235 FT /evidence="ECO:0007829|PDB:3TKU" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 245..250 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 255..258 FT /evidence="ECO:0007829|PDB:3TKU" FT HELIX 261..276 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 286..294 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 296..299 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 311..318 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 324..326 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 334..337 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 347..349 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 362..365 FT /evidence="ECO:0007829|PDB:4UAK" FT HELIX 396..398 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 403..406 FT /evidence="ECO:0007829|PDB:3QFV" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:3QFV" SQ SEQUENCE 1711 AA; 194315 MW; 041A009E0273ABE0 CRC64; MSAKVRLKKL EQLLLDGPWR NESALSVETL LDVLVCLYTE CSHSALRRDK YVAEFLEWAK PFTQLVKEMQ LHREDFEIIK VIGRGAFGEV AVVKMKNTER IYAMKILNKW EMLKRAETAC FREERDVLVN GDCQWITALH YAFQDENHLY LVMDYYVGGD LLTLLSKFED KLPEDMARFY IGEMVLAIDS IHQLHYVHRD IKPDNVLLDV NGHIRLADFG SCLKMNDDGT VQSSVAVGTP DYISPEILQA MEDGMGKYGP ECDWWSLGVC MYEMLYGETP FYAESLVETY GKIMNHEERF QFPSHVTDVS EEAKDLIQRL ICSRERRLGQ NGIEDFKKHA FFEGLNWENI RNLEAPYIPD VSSPSDTSNF DVDDDVLRNT EILPPGSHTG FSGLHLPFIG FTFTTESCFS DRGSLKSIMQ SNTLTKDEDV QRDLEHSLQM EAYERRIRRL EQEKLELSRK LQESTQTVQS LHGSSRALSN SNRDKEIKKL NEEIERLKNK IADSNRLERQ LEDTVALRQE REDSTQRLRG LEKQHRVVRQ EKEELHKQLV EASERLKSQA KELKDAHQQR KLALQEFSEL NERMAELRAQ KQKVSRQLRD KEEEMEVATQ KVDAMRQEMR RAEKLRKELE AQLDDAVAEA SKERKLREHS ENFCKQMESE LEALKVKQGG RGAGATLEHQ QEISKIKSEL EKKVLFYEEE LVRREASHVL EVKNVKKEVH DSESHQLALQ KEILMLKDKL EKSKRERHNE MEEAVGTIKD KYERERAMLF DENKKLTAEN EKLCSFVDKL TAQNRQLEDE LQDLAAKKES VAHWEAQIAE IIQWVSDEKD ARGYLQALAS KMTEELEALR SSSLGSRTLD PLWKVRRSQK LDMSARLELQ SALEAEIRAK QLVQEELRKV KDANLTLESK LKDSEAKNRE LLEEMEILKK KMEEKFRADT GLKLPDFQDS IFEYFNTAPL AHDLTFRTSS ASEQETQAPK PEASPSMSVA ASEQQEDMAR PPQRPSAVPL PTTQALALAG PKPKAHQFSI KSFSSPTQCS HCTSLMVGLI RQGYACEVCS FACHVSCKDG APQVCPIPPE QSKRPLGVDV QRGIGTAYKG HVKVPKPTGV KKGWQRAYAV VCDCKLFLYD LPEGKSTQPG VIASQVLDLR DDEFSVSSVL ASDVIHATRR DIPCIFRVTA SLLGAPSKTS SLLILTENEN EKRKWVGILE GLQSILHKNR LRNQVVHVPL EAYDSSLPLI KAILTAAIVD ADRIAVGLEE GLYVIEVTRD VIVRAADCKK VHQIELAPRE KIVILLCGRN HHVHLYPWSS LDGAEGSFDI KLPETKGCQL MATATLKRNS GTCLFVAVKR LILCYEIQRT KPFHRKFNEI VAPGSVQCLA VLRDRLCVGY PSGFCLLSIQ GDGQPLNLVN PNDPSLAFLS QQSFDALCAV ELESEEYLLC FSHMGLYVDP QGRRARAQEL MWPAAPVACS CSPTHVTVYS EYGVDVFDVR TMEWVQTIGL RRIRPLNSEG TLNLLNCEPP RLIYFKSKFS GAVLNVPDTS DNSKKQMLRT RSKRRFVFKV PEEERLQQRR EMLRDPELRS KMISNPTNFN HVAHMGPGDG MQVLMDLPLS AVPPSQEERP GPAPTNLARQ PPSRNKPYIS WPSSGGSEPS VTVPLRSMSD PDQDFDKEPD SDSTKHSTPS NSSNPSGPPS PNSPHRSQLP LEGLEQPACD T // ID MSH2_HUMAN Reviewed; 934 AA. AC P43246; B4E2Z2; O75488; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=DNA mismatch repair protein Msh2; DE Short=hMSH2; DE AltName: Full=MutS protein homolog 2; GN Name=MSH2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8252616; DOI=10.1016/0092-8674(93)90546-3; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RT "The human mutator gene homolog MSH2 and its association with hereditary RT nonpolyposis colon cancer."; RL Cell 75:1027-1038(1993). RN [2] RP ERRATUM OF PUBMED:8252616. RX PubMed=8156592; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RL Cell 77:167-167(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LYNCH1 LEU-622 AND RP TYR-639. RX PubMed=8261515; DOI=10.1016/0092-8674(93)90330-s; RA Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., RA Peltomaeki P., Sistonen P., Aaltonen L.A., Nystroem-Lahti M., Guan X.-Y., RA Zhang J., Meltzer P.S., Yu J.-W., Kao F.-T., Chen D.J., Cerosaletti K.M., RA Fournier R.E.K., Todd S., Lewis T., Leach R.J., Naylor S.L., RA Weissenbach J., Mecklin J.-P., Jaervinen H., Petersen G.M., Hamilton S.R., RA Green J., Jass J., Watson P., Lynch H.T., Trent J.M., de la Chapelle A., RA Kinzler K.W., Vogelstein B.; RT "Mutations of a mutS homolog in hereditary nonpolyposis colorectal RT cancer."; RL Cell 75:1215-1225(1993). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN MRTES. RX PubMed=7713503; DOI=10.1006/geno.1994.1661; RA Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Rao M.R.S., Morrison P., RA Wirth L., Finan P.J., Burn J., Chapman P., Earabino C., Merchant E., RA Bishop D.T.; RT "Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds RT for msh2 mutations."; RL Genomics 24:516-526(1994). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-96. RX PubMed=7726159; RA Wijnen J., Vasen H., Khan P.M., Menko F.H., van der Klift H., RA van Leeuwen C., van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer A., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Fodde R.; RT "Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing RT gradient-gel electrophoresis."; RL Am. J. Hum. Genet. 56:1060-1066(1995). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-8; CYS-43; SER-127; RP ASP-322 AND PHE-390. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 375-425. RC TISSUE=Blood; RA Corvello C.M., Bevilacqua R.A.U., Rossi B.M., Simpson A.J.G.; RT "A novel germline mutation at exon 7 of the hMSH2 gene (417 del G) in a RT large HNPCC Brazilian kindred."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP DNA-BINDING. RX PubMed=7923193; RA Fishel R., Ewel A., Lescoe M.K.; RT "Purified human MSH2 protein binds to DNA containing mismatched RT nucleotides."; RL Cancer Res. 54:5539-5542(1994). RN [13] RP DNA-BINDING. RX PubMed=8769132; DOI=10.1006/bbrc.1996.1168; RA Whitehouse A., Taylor G.R., Deeble J., Phillips S.E., Meredith D.M., RA Markham A.F.; RT "A carboxy terminal domain of the hMSH-2 gene product is sufficient for RT binding specific mismatched oligonucleotides."; RL Biochem. Biophys. Res. Commun. 225:289-295(1996). RN [14] RP INTERACTION WITH MSH3 AND MSH6. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [15] RP INTERACTION WITH EXO1. RX PubMed=9788596; RA Schmutte C., Marinescu R.C., Sadoff M.M., Guerrette S., Overhauser J., RA Fishel R.; RT "Human exonuclease I interacts with the mismatch repair protein hMSH2."; RL Cancer Res. 58:4537-4542(1998). RN [16] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [17] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [18] RP FUNCTION, AND MUTAGENESIS OF LYS-675. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [19] RP MISMATCH-BINDING, AND CHARACTERIZATION OF VARIANT LYNCH1 PRO-524. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [20] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [21] RP IDENTIFICATION OF MSH2 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [22] RP INTERACTION WITH EXO1, AND TISSUE SPECIFICITY. RX PubMed=10856833; DOI=10.1016/s0921-8777(00)00012-4; RA Rasmussen L.J., Rasmussen M., Lee B.-I., Rasmussen A.K., Wilson D.M. III, RA Nielsen F.C., Bisgaard H.C.; RT "Identification of factors interacting with hMSH2 in the fetal liver RT utilizing the yeast two-hybrid system. In vivo interaction through the C- RT terminal domains of hEXO1 and hMSH2 and comparative expression analysis."; RL Mutat. Res. 460:41-52(2000). RN [23] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [24] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=11306449; RA Schweizer P., Moisio A.L., Kuismanen S.A., Truninger K., Vierumaeki R., RA Salovaara R., Arola J., Butzow R., Jiricny J., Peltomaeki P., RA Nystroem-Lahti M.; RT "Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas RT in hereditary nonpolyposis colorectal cancer."; RL Cancer Res. 61:2813-2815(2001). RN [25] RP INTERACTION WITH EXO1. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [26] RP INTERACTION WITH EXO1. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [27] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [28] RP INVOLVEMENT IN MMRCS2. RX PubMed=12549480; DOI=10.1086/345297; RA Bougeard G., Charbonnier F., Moerman A., Martin C., Ruchoux M.M., RA Drouot N., Frebourg T.; RT "Early onset brain tumor and lymphoma in MSH2-deficient children."; RL Am. J. Hum. Genet. 72:213-216(2003). RN [29] RP INTERACTION WITH ATR, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [30] RP INTERACTION WITH EXO1. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [31] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [32] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [33] RP INVOLVEMENT IN MMRCS2. RX PubMed=16372347; DOI=10.1002/ajmg.a.31070; RA Mueller A., Schackert H.K., Lange B., Rueschoff J., Fuezesi L., Willert J., RA Burfeind P., Shah P., Becker H., Epplen J.T., Stemmler S.; RT "A novel MSH2 germline mutation in homozygous state in two brothers with RT colorectal cancers diagnosed at the age of 11 and 12 years."; RL Am. J. Med. Genet. A 140:195-199(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [35] RP FUNCTION. RX PubMed=17611581; DOI=10.1038/sj.jid.5700941; RA Seifert M., Scherer S.J., Edelmann W., Bohm M., Meineke V., Lobrich M., RA Tilgen W., Reichrath J.; RT "The DNA-mismatch repair enzyme hMSH2 modulates UV-B-induced cell cycle RT arrest and apoptosis in melanoma cells."; RL J. Invest. Dermatol. 128:203-213(2008). RN [36] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-555, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-921, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [40] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-845; LYS-847; LYS-871 AND LYS-892, RP DEACETYLATION BY HDAC6, UBIQUITINATION AT LYS-845; LYS-847; LYS-871 AND RP LYS-892, AND MUTAGENESIS OF LYS-845; LYS-847; LYS-871 AND LYS-892. RX PubMed=24882211; DOI=10.1016/j.molcel.2014.04.028; RA Zhang M., Xiang S., Joo H.Y., Wang L., Williams K.A., Liu W., Hu C., RA Tong D., Haakenson J., Wang C., Zhang S., Pavlovicz R.E., Jones A., RA Schmidt K.H., Tang J., Dong H., Shan B., Fang B., Radhakrishnan R., RA Glazer P.M., Matthias P., Koomen J., Seto E., Bepler G., Nicosia S.V., RA Chen J., Li C., Gu L., Li G.M., Bai W., Wang H., Zhang X.; RT "HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of RT MutSalpha."; RL Mol. Cell 55:31-46(2014). RN [41] RP FUNCTION, IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND RP MCM8, AND SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [42] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-430, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [43] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; MET-44; VAL-45; SER-127; RP MET-145; ASP-161; ARG-162; ARG-164; PRO-173; ARG-187; PRO-187; VAL-272; RP TYR-333; LEU-519; ASN-603; PRO-636; ALA-674; VAL-688; PHE-697; RP 745-ILE-ILE-746 DEL; LYS-749; THR-834; GLY-886 AND GLU-923, RP CHARACTERIZATION OF VARIANTS ASP-322 AND ILE-722, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [44] RP REVIEW. RX PubMed=8036718; DOI=10.1016/0168-9525(94)90093-0; RA Jiricny J.; RT "Colon cancer and DNA repair: have mismatches met their match?"; RL Trends Genet. 10:164-168(1994). RN [45] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [46] RP REVIEW. RX PubMed=17080293; DOI=10.1007/s10735-006-9062-5; RA Seifert M., Reichrath J.; RT "The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell RT cycle control and apoptosis: implications for pathogenesis, progression and RT therapy of cancer."; RL J. Mol. Histol. 37:301-307(2006). RN [47] RP INTERACTION WITH SMARCAD1. RX PubMed=18675275; DOI=10.1016/j.jmb.2008.07.031; RA Okazaki N., Ikeda S., Ohara R., Shimada K., Yanagawa T., Nagase T., RA Ohara O., Koga H.; RT "The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of RT TSS."; RL J. Mol. Biol. 382:257-265(2008). RN [48] RP INTERACTION WITH SLX4. RX PubMed=19596235; DOI=10.1016/j.cell.2009.06.030; RA Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P., RA Elledge S.J., Harper J.W.; RT "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is RT required for DNA repair."; RL Cell 138:63-77(2009). RN [49] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=21642682; DOI=10.1001/jama.2011.743; RG French Cancer Genetics Network; RA Bonadona V., Bonaiti B., Olschwang S., Grandjouan S., Huiart L., Longy M., RA Guimbaud R., Buecher B., Bignon Y.J., Caron O., Colas C., Nogues C., RA Lejeune-Dumoulin S., Olivier-Faivre L., Polycarpe-Osaer F., Nguyen T.D., RA Desseigne F., Saurin J.C., Berthet P., Leroux D., Duffour J., RA Manouvrier S., Frebourg T., Sobol H., Lasset C., Bonaiti-Pellie C.; RT "Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 RT genes in Lynch syndrome."; RL JAMA 305:2304-2310(2011). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [51] RP VARIANT LYNCH1 ASN-596 DEL. RX PubMed=7874129; RA Mary J.-L., Bishop T., Kolodner R.D., Lipford J.R., Kane M.F., Weber W., RA Torhorst J., Mueller H., Spycher M., Scott R.J.; RT "Mutational analysis of the hMSH2 gene reveals a three base pair deletion RT in a family predisposed to colorectal cancer development."; RL Hum. Mol. Genet. 3:2067-2069(1994). RN [52] RP VARIANTS PHE-390 AND LYS-419. RX PubMed=8690195; DOI=10.1053/gast.1996.v111.pm8690195; RA Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., RA Okumura Y., Kishi N., Iwama T., Mori T., Koike M., Ushio K., Chiba M., RA Nomizu S., Konishi F., Utsunomiya J., Miyaki M.; RT "Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, RT familial polyposis, and sporadic colon cancer."; RL Gastroenterology 111:307-317(1996). RN [53] RP VARIANT ASP-322. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [54] RP VARIANT LYNCH1 ASN-596 DEL, AND VARIANT HIS-167. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [55] RP VARIANT LYNCH1 TYR-506. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [56] RP VARIANT LYNCH1 GLN-46. RX PubMed=8700523; RA Bubb V.J., Curtis L.J., Cunningham C., Dunlop M.G., Carothers A.D., RA Morris R.G., White S., Bird C.C., Wyllie A.H.; RT "Microsatellite instability and the role of hMSH2 in sporadic colorectal RT cancer."; RL Oncogene 12:2641-2649(1996). RN [57] RP VARIANTS LYNCH1 THR-305; ASN-596 DEL AND THR-834. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [58] RP VARIANT LYNCH1 CYS-323. RX PubMed=9240418; DOI=10.1006/bbrc.1997.6942; RA Akiyama Y., Tsubouchi N., Yuasa Y.; RT "Frequent somatic mutations of hMSH3 with reference to microsatellite RT instability in hereditary nonpolyposis colorectal cancers."; RL Biochem. Biophys. Res. Commun. 236:248-252(1997). RN [59] RP VARIANTS LYNCH1 THR-110; ARG-639; LYS-647; HIS-656; THR-679; VAL-729 AND RP ILE-732. RX PubMed=9419403; RA Nakahara M., Yokozaki H., Yasui W., Dohi K., Tahara E.; RT "Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in RT Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Cancer Epidemiol. Biomarkers Prev. 6:1057-1064(1997). RN [60] RP VARIANT SER-596. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [61] RP VARIANT ASP-322. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [62] RP VARIANT LYNCH1 VAL-562. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [63] RP VARIANT LYNCH1 PHE-697, AND VARIANT ASP-322. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [64] RP VARIANT LYNCH1 265-VAL--GLN-314 DEL, AND VARIANTS GLY-641 AND VAL-770. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [65] RP VARIANT ARG-199. RX PubMed=9777949; DOI=10.1016/s0002-9440(10)65662-3; RA Leung S.Y., Chan T.L., Chung L.P., Chan A.S.Y., Fan Y.W., Hung K.N., RA Kwong W.K., Ho J.W.C., Yuen S.T.; RT "Microsatellite instability and mutation of DNA mismatch repair genes in RT gliomas."; RL Am. J. Pathol. 153:1181-1188(1998). RN [66] RP VARIANT CRC TYR-506, AND VARIANT LYNCH1 ILE-688. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [67] RP VARIANT ASP-322. RX PubMed=10023327; DOI=10.1016/s0959-8049(98)00217-2; RA Liu T., Stathopoulos P., Lindblom P., Rubio C., Wasteson Arver B., RA Iselius L., Holmberg E., Groenberg H., Lindblom A.; RT "MSH2 codon 322 Gly to Asp does not seem to confer an increased risk for RT colorectal cancer susceptibility."; RL Eur. J. Cancer 34:1981-1981(1998). RN [68] RP VARIANT LYNCH1 PHE-390. RX PubMed=9621522; DOI=10.1007/s100380050057; RA Okamura S., Koyama K., Miyoshi Y., Monden M., Takami M.; RT "Novel germline mutations of hMSH2 in a patient with hereditary RT nonpolyposis colorectal cancer 'HNPCC' and in a patient with six primary RT cancers."; RL J. Hum. Genet. 43:143-145(1998). RN [69] RP VARIANTS LYNCH1 SER-336 AND ASN-596 DEL. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [70] RP CHARACTERIZATION OF VARIANTS ASP-322; PHE-390; LYS-419; TYR-506; PRO-524; RP LEU-622 AND PHE-697. RX PubMed=10469597; DOI=10.1016/s0960-9822(99)80396-0; RA Drotschmann K., Clark A.B., Kunkel T.A.; RT "Mutator phenotypes of common polymorphisms and missense mutations in RT MSH2."; RL Curr. Biol. 9:907-910(1999). RN [71] RP VARIANTS LYNCH1 GLN-246; SER-596 AND THR-834, AND VARIANT ASP-322. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [72] RP VARIANT LYNCH1 PHE-390. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH1 PRO-636. RX PubMed=10528862; DOI=10.1136/jmg.36.10.792; RA Yuan Z.Q., Wong N., Foulkes W.D., Alpert L., Manganaro F., RA Andreutti-Zaugg C., Iggo R., Anthony K., Hsieh E., Redston M., Pinsky L., RA Trifiro M., Gordon P.H., Lasko D.; RT "A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC RT kindred: implications for clinical screening."; RL J. Med. Genet. 36:790-793(1999). RN [74] RP VARIANTS LYNCH1 ILE-688 AND GLU-845, AND VARIANT MET-8. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANT ASP-322. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANTS LYNCH1 ARG-692 AND ARG-697. RX PubMed=10612836; RX DOI=10.1002/(sici)1098-1004(200001)15:1<116::aid-humu24>3.0.co;2-q; RA Isidro G., Veiga I., Matos P., Almeida S., Bizarro S., Marshall B., RA Baptista M., Leite J., Regateiro F., Soares J., Castedo S., Boavida M.G.; RT "Four novel MSH2 / MLH1 gene mutations in Portuguese HNPCC families."; RL Hum. Mutat. 15:116-116(2000). RN [77] RP VARIANT LYNCH1 ASN-603, AND VARIANT ASP-322. RX PubMed=10829038; DOI=10.1200/jco.2000.18.11.2193; RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RT "Population-based molecular detection of hereditary nonpolyposis colorectal RT cancer."; RL J. Clin. Oncol. 18:2193-2200(2000). RN [78] RP ERRATUM OF PUBMED:10829038. RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RL J. Clin. Oncol. 18:3456-3456(2000). RN [79] RP VARIANTS GASTRIC CANCER PHE-17; GLU-824; ALA-868; GLY-870 AND GLY-873, AND RP VARIANTS LYNCH1 CYS-98; TYR-323; ILE-335; ARG-629 AND VAL-714. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [80] RP VARIANTS LYNCH1 ASP-161; VAL-216 AND ARG-554. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [81] RP CHARACTERIZATION OF VARIANTS ASP-322; LEU-622 AND TYR-639. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [82] RP VARIANT LYNCH1 VAL-813. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [83] RP VARIANTS LYNCH1 VAL-600 AND PHE-723. RX PubMed=11920458; DOI=10.1002/cncr.10332.abs; RA Furukawa T., Konishi F., Shitoh K., Kojima M., Nagai H., Tsukamoto T.; RT "Evaluation of screening strategy for detecting hereditary nonpolyposis RT colorectal carcinoma."; RL Cancer 94:911-920(2002). RN [84] RP VARIANTS LYNCH1 HIS-167; MET-393; PRO-524; ASN-596 DEL; LEU-622; SER-674 RP AND ARG-905, AND CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; MET-393; RP PRO-524; ASN-596 DEL; LEU-622; SER-674 AND ARG-905. RX PubMed=12124176; DOI=10.1016/s1535-6108(02)00073-9; RA Heinen C.D., Wilson T., Mazurek A., Berardini M., Butz C., Fishel R.; RT "HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch RT functions."; RL Cancer Cell 1:469-478(2002). RN [85] RP INVOLVEMENT IN MULTIPLE CAFE-AU-LAIT SPOTS WITH LEUKEMIA. RX PubMed=11809679; RA Whiteside D., McLeod R., Graham G., Steckley J.L., Booth K., RA Somerville M.J., Andrew S.E.; RT "A homozygous germ-line mutation in the human MSH2 gene predisposes to RT hematological malignancy and multiple cafe-au-lait spots."; RL Cancer Res. 62:359-362(2002). RN [86] RP VARIANT ASP-322. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [87] RP VARIANTS LYNCH1 MET-44; VAL-45; ASN-596 DEL; GLY-886 AND GLU-923. RX PubMed=12112654; DOI=10.1002/humu.10083; RA Bisgaard M.L., Jaeger A.C., Myrhoej T., Bernstein I., Nielsen F.C.; RT "Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype RT correlation between patients with and without identified mutation."; RL Hum. Mutat. 20:20-27(2002). RN [88] RP VARIANTS LYNCH1 ILE-102; ASP-163 AND ALA-564, AND VARIANT ASP-322. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [89] RP VARIANTS LYNCH1 HIS-167 AND SER-359. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [90] RP VARIANTS LYNCH1 LEU-92 DEL AND ALA-853, AND VARIANT ASP-322. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [91] RP VARIANTS LYNCH1 PRO-552; SER-583 AND PRO-636. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [92] RP VARIANTS CRC ILE-13 AND ILE-342, AND VARIANT ASP-322. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [93] RP VARIANT LYNCH1 SER-127. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [94] RP VARIANT LYNCH1 PRO-175. RX PubMed=12655568; DOI=10.1002/humu.9127; RA Bartosova Z., Fridrichova I., Bujalkova M., Wolf B., Ilencikova D., RA Krizan P., Hlavcak P., Palaj J., Lukac L., Lukacova M., Boeoer A., RA Haider R., Jiricny J., Nystroem-Lahti M., Marra G.; RT "Novel MLH1 and MSH2 germline mutations in the first HNPCC families RT identified in Slovakia."; RL Hum. Mutat. 21:449-449(2003). RN [95] RP VARIANTS LYNCH1 GLY-163 AND GLY-660. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [96] RP VARIANTS CRC SER-40; VAL-169; ARG-203; PHE-390; LYS-419; CYS-619 AND RP ARG-629, AND VARIANT MET-8. RX PubMed=12792735; RA Yamada K., Zhong X., Kanazawa S., Koike J., Tsujita K., Hemmi H.; RT "Oncogenic pathway of sporadic colorectal cancer with novel germline RT missense mutations in the hMSH2 gene."; RL Oncol. Rep. 10:859-866(2003). RN [97] RP VARIANT LYNCH1 THR-931. RX PubMed=15046096; RA Sun M.H., Cai Q., Fu G., Ren S., Mo S., Xu Y., Ding C., Zhang T., Zhu X., RA Xu X., Min D., Cai S., Luo D., Shi Y., Shi D.; RT "Gene symbol: hMSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 114:409-409(2004). RN [98] RP VARIANT LYNCH1 TYR-671. RX PubMed=15300854; DOI=10.1002/humu.9267; RA Sharp A., Pichert G., Lucassen A., Eccles D.; RT "RNA analysis reveals splicing mutations and loss of expression defects in RT MLH1 and BRCA1."; RL Hum. Mutat. 24:272-272(2004). RN [99] RP VARIANTS LYNCH1 LEU-440 DEL; TYR-506; ARG-629 AND ILE-688. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [100] RP VARIANT LYNCH1 ARG-839, AND VARIANT ARG-629. RX PubMed=15613555; DOI=10.1093/jjco/hyh121; RA Yuan Y., Huang Y.-Q., Cai S.-R., Song Y.-M., Zheng S., Zhang S.-Z.; RT "Genetic characterization of Chinese hereditary non-polyposis colorectal RT cancer by DHPLC and multiplex PCR."; RL Jpn. J. Clin. Oncol. 34:660-666(2004). RN [101] RP VARIANTS LYNCH1 LEU-349 AND ASN-596 DEL. RX PubMed=15342696; DOI=10.1136/jmg.2004.020651; RA Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A.J., RA Westra J., Frebourg T., Espin E., Armengol M., Hamelin R., Yamamoto H., RA Hofstra R.M.W., Seruca R., Lindblom A., Peltomaeki P., Thibodeau S.N., RA Aaltonen L.A., Schwartz S. Jr.; RT "BRAF screening as a low-cost effective strategy for simplifying HNPCC RT genetic testing."; RL J. Med. Genet. 41:664-668(2004). RN [102] RP VARIANT LYNCH1 PHE-93. RX PubMed=15896463; DOI=10.1016/j.canlet.2004.09.051; RA Baudi F., Fersini G., Lavecchia A., Terracciano R., Leone F., Quaresima B., RA Faniello M.C., De Paola L., Doldo P., Cuda G., Costanzo F., Venuta S.; RT "A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC RT family from Southern Italy."; RL Cancer Lett. 223:285-291(2005). RN [103] RP VARIANTS LYNCH1 VAL-169; PHE-390; ALA-564 AND ARG-629, AND VARIANT CRC RP LYS-419. RX PubMed=15996210; DOI=10.1111/j.1399-0004.2005.00469.x; RA Lee S.-C., Guo J.-Y., Lim R., Soo R., Koay E., Salto-Tellez M., Leong A., RA Goh B.-C.; RT "Clinical and molecular characteristics of hereditary non-polyposis RT colorectal cancer families in Southeast Asia."; RL Clin. Genet. 68:137-145(2005). RN [104] RP VARIANT LYNCH1 TYR-283. RX PubMed=15870828; DOI=10.1038/sj.ejhg.5201421; RA Wehner M., Mangold E., Sengteller M., Friedrichs N., Aretz S., Friedl W., RA Propping P., Pagenstecher C.; RT "Hereditary nonpolyposis colorectal cancer: pitfalls in deletion screening RT in MSH2 and MLH1 genes."; RL Eur. J. Hum. Genet. 13:983-986(2005). RN [105] RP VARIANT LYNCH1 ARG-162. RX PubMed=15991316; RA Kohonen-Corish M.R.J., Otway R., Tetlow N., Hornby J., Doe W.F.; RT "Gene symbol: MSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 116:539-539(2005). RN [106] RP VARIANTS LYNCH1 THR-2; LEU-92 DEL; MET-145; PHE-390 AND ALA-853, AND RP VARIANT ASP-322. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [107] RP VARIANTS LYNCH1 PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; RP TYR-333; ASN-603; PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, RP VARIANTS VAL-272; THR-834 AND GLU-923, CHARACTERIZATION OF VARIANTS LYNCH1 RP PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; TYR-333; ASN-603; RP PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, AND CHARACTERIZATION OF RP VARIANTS VAL-272; THR-834 AND GLU-923. RX PubMed=17101317; DOI=10.1053/j.gastro.2006.08.044; RA Ollila S., Sarantaus L., Kariola R., Chan P., Hampel H., Holinski-Feder E., RA Macrae F., Kohonen-Corish M., Gerdes A.-M., Peltomaeki P., Mangold E., RA de la Chapelle A., Greenblatt M., Nystroem M.; RT "Pathogenicity of MSH2 missense mutations is typically associated with RT impaired repair capability of the mutated protein."; RL Gastroenterology 131:1408-1417(2006). RN [108] RP VARIANT LYNCH1 ALA-162. RX PubMed=17128465; RA Leonardis D.; RT "Gene symbol: msh2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 119:675-675(2006). RN [109] RP VARIANT LYNCH1 ARG-674. RX PubMed=18625694; DOI=10.1136/gut.2008.156695; RA Ramsoekh D., Wagner A., van Leerdam M.E., Dinjens W.N., Steyerberg E.W., RA Halley D.J., Kuipers E.J., Dooijes D.; RT "A high incidence of MSH6 mutations in Amsterdam criteria II-negative RT families tested in a diagnostic setting."; RL Gut 57:1539-1544(2008). RN [110] RP VARIANTS GLN-46; LYS-106; ASP-322; SER-596; LEU-670; ILE-779; SER-807; RP HIS-835 AND ARG-911. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [111] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; SER-127; ASP-161; ARG-162; RP ARG-164; PRO-173; PRO-187; VAL-272; TYR-333; ASN-603; PRO-636; ALA-674; RP PHE-697; 745-ILE-ILE-746 DEL; LYS-749; THR-834 AND GLU-923, AND RP CHARACTERIZATION OF VARIANT ASP-322. RX PubMed=18951462; DOI=10.1002/humu.20893; RA Ollila S., Dermadi Bebek D., Jiricny J., Nystroem M.; RT "Mechanisms of pathogenicity in human MSH2 missense mutants."; RL Hum. Mutat. 29:1355-1363(2008). RN [112] RP VARIANTS LYNCH1 LEU-92 DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; RP GLU-645; LEU-696; TYR-748 AND GLN-839, VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723, CHARACTERIZATION OF VARIANTS LYNCH1 LEU-92 RP DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; GLU-645; LEU-696; TYR-748 RP AND GLN-839, AND CHARACTERIZATION OF VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [113] RP CHARACTERIZATION OF VARIANTS LYNCH1 ARG-162; HIS-167 AND SER-359. RX PubMed=18781619; DOI=10.1002/humu.20875; RA Belvederesi L., Bianchi F., Galizia E., Loretelli C., Bracci R., RA Catalani R., Amati M., Cellerino R.; RT "MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a RT human expression system."; RL Hum. Mutat. 29:E296-E309(2008). RN [114] RP CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; THR-305: LEU-622; ARG-639; RP ARG-674; PHE-697 AND THR-834. RX PubMed=18822302; DOI=10.1016/j.mrfmmm.2008.08.015; RA Lutzen A., de Wind N., Georgijevic D., Nielsen F.C., Rasmussen L.J.; RT "Functional analysis of HNPCC-related missense mutations in MSH2."; RL Mutat. Res. 645:44-55(2008). RN [115] RP CHARACTERIZATION OF VARIANTS LYNCH1 MET-44; VAL-45; HIS-167; THR-305; RP PHE-390; ASN-596 DEL; ARG-639; ARG-674; PHE-697; PHE-723 AND GLY-886, AND RP CHARACTERIZATION OF VARIANTS ASP-165; HIS-177; VAL-272; LEU-385; LEU-519; RP ALA-675; GLU-759; VAL-805; GLY-843 AND LEU-860. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [116] RP CHARACTERIZATION OF VARIANTS SER-127; MET-145; GLN-205; ASP-322; PRO-328; RP ILE-367; GLU-487 AND ILE-909. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). RN [117] RP VARIANT LYNCH1 ARG-669. RX PubMed=22371642; DOI=10.3748/wjg.v18.i8.814; RA Zahary M.N., Kaur G., Abu Hassan M.R., Singh H., Naik V.R., Ankathil R.; RT "Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome RT patients."; RL World J. Gastroenterol. 18:814-820(2012). RN [118] RP VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839, AND CHARACTERIZATION RP OF VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 CC heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA CC mismatches thereby initiating DNA repair. When bound, heterodimers bend CC the DNA helix and shields approximately 20 base pairs. MutS alpha CC recognizes single base mismatches and dinucleotide insertion-deletion CC loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion CC loops up to 13 nucleotides long. After mismatch binding, MutS alpha or CC beta forms a ternary complex with the MutL alpha heterodimer, which is CC thought to be responsible for directing the downstream MMR events, CC including strand discrimination, excision, and resynthesis. Recruits CC DNA helicase MCM9 to chromatin which unwinds the mismatch containing CC DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. In melanocytes may CC modulate both UV-B-induced cell cycle regulation and apoptosis. CC {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:17611581, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:26300262, CC ECO:0000269|PubMed:9564049, ECO:0000269|PubMed:9822679, CC ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) or MSH2-MSH3 (MutS beta) CC (PubMed:8942985). Both heterodimers form a ternary complex with MutL CC alpha (MLH1-PMS1) (PubMed:10856833, PubMed:11427529, PubMed:11429708, CC PubMed:12414623, PubMed:14676842, PubMed:9788596). Interacts with MCM9; CC the interaction recruits MCM9 to chromatin (PubMed:26300262). Interacts CC with MCM8 (PubMed:26300262). Interacts with EXO1 (PubMed:10856833, CC PubMed:11427529, PubMed:11429708, PubMed:12414623, PubMed:14676842, CC PubMed:9788596). Part of the BRCA1-associated genome surveillance CC complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 CC and the RAD50-MRE11-NBS1 protein complex (PubMed:10783165). This CC association could be a dynamic process changing throughout the cell CC cycle and within subnuclear domains (PubMed:10783165). Interacts with CC ATR (PubMed:14657349). Interacts with SLX4/BTBD12; this interaction is CC direct and links MutS beta to SLX4, a subunit of different structure- CC specific endonucleases (PubMed:19596235). Interacts with SMARCAD1 CC (PubMed:18675275). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:10856833, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:18675275, ECO:0000269|PubMed:19596235, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:8942985, CC ECO:0000269|PubMed:9788596}. CC -!- INTERACTION: CC P43246; Q92624: APPBP2; NbExp=3; IntAct=EBI-355888, EBI-743771; CC P43246; Q9UQ84-1: EXO1; NbExp=3; IntAct=EBI-355888, EBI-944694; CC P43246; P09429: HMGB1; NbExp=2; IntAct=EBI-355888, EBI-389432; CC P43246; P20585: MSH3; NbExp=14; IntAct=EBI-355888, EBI-1164205; CC P43246; P52701: MSH6; NbExp=11; IntAct=EBI-355888, EBI-395529; CC P43246; Q8IY92: SLX4; NbExp=5; IntAct=EBI-355888, EBI-2370740; CC P43246; P39875: EXO1; Xeno; NbExp=2; IntAct=EBI-355888, EBI-6738; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24882211, CC ECO:0000269|PubMed:26300262}. Chromosome {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P43246-1; Sequence=Displayed; CC Name=2; CC IsoId=P43246-2; Sequence=VSP_045536; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. CC {ECO:0000269|PubMed:10856833}. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- PTM: Sequentially deacetylated and polyubiquitinated by HDAC6, leading CC to MSH2 degradation. {ECO:0000269|PubMed:24882211}. CC -!- DISEASE: Lynch syndrome 1 (LYNCH1) [MIM:120435]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10375096, ECO:0000269|PubMed:10386556, CC ECO:0000269|PubMed:10528862, ECO:0000269|PubMed:10573010, CC ECO:0000269|PubMed:10612836, ECO:0000269|PubMed:10777691, CC ECO:0000269|PubMed:10829038, ECO:0000269|PubMed:11726306, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:11920458, CC ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:12655568, CC ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14635101, CC ECO:0000269|PubMed:15046096, ECO:0000269|PubMed:15300854, CC ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15870828, CC ECO:0000269|PubMed:15896463, ECO:0000269|PubMed:15991316, CC ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:17128465, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18625694, CC ECO:0000269|PubMed:18781619, ECO:0000269|PubMed:18822302, CC ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22371642, CC ECO:0000269|PubMed:7874129, ECO:0000269|PubMed:8261515, CC ECO:0000269|PubMed:8700523, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9048925, CC ECO:0000269|PubMed:9240418, ECO:0000269|PubMed:9298827, CC ECO:0000269|PubMed:9311737, ECO:0000269|PubMed:9419403, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9621522, CC ECO:0000269|PubMed:9718327, ECO:0000269|PubMed:9889267}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:7713503}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000305|PubMed:11306449, CC ECO:0000305|PubMed:21642682}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 2 (MMRCS2) [MIM:619096]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:12549480, CC ECO:0000269|PubMed:16372347}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12792735, CC ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:15996210, CC ECO:0000269|PubMed:9559627}. Note=Disease susceptibility may be CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC27930.1; Type=Frameshift; Note=The frameshift is caused by a single nucleotide deletion which is found in a HNPCC kindred.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/340/MSH2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U03911; AAA18643.1; -; mRNA. DR EMBL; U04045; AAA61870.1; -; mRNA. DR EMBL; U41221; AAA82080.1; ALT_SEQ; Genomic_DNA. DR EMBL; U41206; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41207; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41208; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41210; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41211; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41212; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41213; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41214; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41215; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41216; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41217; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41218; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41219; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41220; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; L47583; AAB59564.1; -; mRNA. DR EMBL; L47582; AAB59565.1; -; mRNA. DR EMBL; L47581; AAA76858.1; -; mRNA. DR EMBL; AY601851; AAS99351.1; -; Genomic_DNA. DR EMBL; AK304496; BAG65304.1; -; mRNA. DR EMBL; BX649122; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC079775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138655; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC021566; AAH21566.1; -; mRNA. DR EMBL; AF066081; AAC27930.1; ALT_FRAME; Genomic_DNA. DR CCDS; CCDS1834.1; -. [P43246-1] DR CCDS; CCDS58709.1; -. [P43246-2] DR PIR; I64819; I64819. DR RefSeq; NP_000242.1; NM_000251.3. [P43246-1] DR RefSeq; NP_001245210.1; NM_001258281.1. [P43246-2] DR RefSeq; NP_001393570.1; NM_001406641.1. [P43246-1] DR PDB; 2O8B; X-ray; 2.75 A; A=1-934. DR PDB; 2O8C; X-ray; 3.37 A; A=1-934. DR PDB; 2O8D; X-ray; 3.00 A; A=1-934. DR PDB; 2O8E; X-ray; 3.30 A; A=1-934. DR PDB; 2O8F; X-ray; 3.25 A; A=1-934. DR PDB; 3THW; X-ray; 3.09 A; A=1-934. DR PDB; 3THX; X-ray; 2.70 A; A=1-934. DR PDB; 3THY; X-ray; 2.89 A; A=1-934. DR PDB; 3THZ; X-ray; 4.30 A; A=1-934. DR PDB; 8AG6; EM; 2.80 A; A=1-934. DR PDB; 8OLX; EM; 3.10 A; A=1-934. DR PDB; 8OM5; EM; 3.52 A; A=1-934. DR PDB; 8OM9; EM; 3.32 A; A=1-934. DR PDB; 8OMA; EM; 3.29 A; A=1-934. DR PDB; 8OMO; EM; 3.43 A; A=1-934. DR PDB; 8OMQ; EM; 3.11 A; A=1-934. DR PDB; 8R7C; X-ray; 2.82 A; A/E=1-930. DR PDB; 8R7E; X-ray; 2.78 A; A/E=1-930. DR PDB; 8R7V; EM; 3.12 A; A=1-934. DR PDB; 8RAU; X-ray; 2.33 A; A=1-934. DR PDB; 8RAV; X-ray; 2.63 A; A=1-934. DR PDB; 8RAW; X-ray; 2.69 A; A=1-934. DR PDB; 8RAX; X-ray; 3.16 A; A=1-934. DR PDB; 8RAZ; X-ray; 2.84 A; A=1-934. DR PDB; 8RB0; X-ray; 2.67 A; A=1-934. DR PDB; 8RB1; X-ray; 2.08 A; A=1-934. DR PDB; 8RB2; X-ray; 2.53 A; A/E=1-934. DR PDB; 8RZ7; EM; 3.37 A; A=1-934. DR PDB; 8RZ8; EM; 3.06 A; A=1-934. DR PDB; 8RZ9; EM; 3.02 A; A=1-934. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 3THW; -. DR PDBsum; 3THX; -. DR PDBsum; 3THY; -. DR PDBsum; 3THZ; -. DR PDBsum; 8AG6; -. DR PDBsum; 8OLX; -. DR PDBsum; 8OM5; -. DR PDBsum; 8OM9; -. DR PDBsum; 8OMA; -. DR PDBsum; 8OMO; -. DR PDBsum; 8OMQ; -. DR PDBsum; 8R7C; -. DR PDBsum; 8R7E; -. DR PDBsum; 8R7V; -. DR PDBsum; 8RAU; -. DR PDBsum; 8RAV; -. DR PDBsum; 8RAW; -. DR PDBsum; 8RAX; -. DR PDBsum; 8RAZ; -. DR PDBsum; 8RB0; -. DR PDBsum; 8RB1; -. DR PDBsum; 8RB2; -. DR PDBsum; 8RZ7; -. DR PDBsum; 8RZ8; -. DR PDBsum; 8RZ9; -. DR AlphaFoldDB; P43246; -. DR EMDB; EMD-15417; -. DR EMDB; EMD-15518; -. DR EMDB; EMD-15519; -. DR EMDB; EMD-16964; -. DR EMDB; EMD-16969; -. DR EMDB; EMD-16971; -. DR EMDB; EMD-16972; -. DR EMDB; EMD-16973; -. DR EMDB; EMD-16974; -. DR EMDB; EMD-18992; -. DR EMDB; EMD-19605; -. DR EMDB; EMD-19606; -. DR EMDB; EMD-19607; -. DR SMR; P43246; -. DR BioGRID; 110573; 329. DR ComplexPortal; CPX-77; DNA mismatch repair MutSbeta complex. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P43246; -. DR DIP; DIP-35054N; -. DR FunCoup; P43246; 3266. DR IntAct; P43246; 111. DR MINT; P43246; -. DR STRING; 9606.ENSP00000233146; -. DR ChEMBL; CHEMBL4296019; -. DR GlyGen; P43246; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P43246; -. DR PhosphoSitePlus; P43246; -. DR SwissPalm; P43246; -. DR BioMuta; MSH2; -. DR DMDM; 1171032; -. DR jPOST; P43246; -. DR MassIVE; P43246; -. DR PaxDb; 9606-ENSP00000233146; -. DR PeptideAtlas; P43246; -. DR ProteomicsDB; 55601; -. [P43246-1] DR ProteomicsDB; 5866; -. DR Pumba; P43246; -. DR Antibodypedia; 4037; 803 antibodies from 50 providers. DR CPTC; P43246; 1 antibody. DR DNASU; 4436; -. DR Ensembl; ENST00000233146.7; ENSP00000233146.2; ENSG00000095002.17. [P43246-1] DR Ensembl; ENST00000543555.6; ENSP00000442697.1; ENSG00000095002.17. [P43246-2] DR GeneID; 4436; -. DR KEGG; hsa:4436; -. DR MANE-Select; ENST00000233146.7; ENSP00000233146.2; NM_000251.3; NP_000242.1. DR UCSC; uc002rvy.3; human. [P43246-1] DR AGR; HGNC:7325; -. DR CIViC; 4436; 8 evidence items across 9 molecular profiles. DR ClinPGx; PA31133; -. DR CTD; 4436; -. DR DisGeNET; 4436; -. DR GeneCards; MSH2; -. DR GeneReviews; MSH2; -. DR HGNC; HGNC:7325; MSH2. DR HPA; ENSG00000095002; Low tissue specificity. DR MalaCards; MSH2; -. DR MIM; 114500; phenotype. DR MIM; 120435; phenotype. DR MIM; 158320; phenotype. DR MIM; 608089; phenotype. DR MIM; 609309; gene. DR MIM; 619096; phenotype. DR OpenTargets; ENSG00000095002; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000095002; -. DR eggNOG; KOG0219; Eukaryota. DR GeneTree; ENSGT00550000074867; -. DR HOGENOM; CLU_002472_10_0_1; -. DR InParanoid; P43246; -. DR OMA; LVRFPQK; -. DR OrthoDB; 295033at2759; -. DR PAN-GO; P43246; 5 GO annotations based on evolutionary models. DR PhylomeDB; P43246; -. DR PathwayCommons; P43246; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5632927; Defective Mismatch Repair Associated With MSH3. DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR SignaLink; P43246; -. DR SIGNOR; P43246; -. DR Agora; ENSG00000095002; -. DR BioGRID-ORCS; 4436; 27 hits in 1168 CRISPR screens. DR ChiTaRS; MSH2; human. DR EvolutionaryTrace; P43246; -. DR GeneWiki; MSH2; -. DR GenomeRNAi; 4436; -. DR Pharos; P43246; Tbio. DR PRO; PR:P43246; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P43246; protein. DR Bgee; ENSG00000095002; Expressed in secondary oocyte and 194 other cell types or tissues. DR ExpressionAtlas; P43246; baseline and differential. DR GO; GO:0000781; C:chromosome, telomeric region; HDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0032302; C:MutSbeta complex; IDA:HGNC-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:Ensembl. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0032137; F:guanine/thymine mispair binding; IMP:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL. DR GO; GO:0019724; P:B cell mediated immunity; ISS:BHF-UCL. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006301; P:DNA damage tolerance; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0043570; P:maintenance of DNA repeat elements; IMP:HGNC-UCL. DR GO; GO:0008584; P:male gonad development; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0006312; P:mitotic recombination; IBA:GO_Central. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL. DR GO; GO:0006119; P:oxidative phosphorylation; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0010224; P:response to UV-B; ISS:BHF-UCL. DR GO; GO:0010165; P:response to X-ray; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IEA:Ensembl. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0002204; P:somatic recombination of immunoglobulin genes involved in immune response; IBA:GO_Central. DR CDD; cd03285; ABC_MSH2_euk; 1. DR FunFam; 1.10.1420.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000009; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000523; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00048; -. DR InterPro; IPR011184; DNA_mismatch_repair_Msh2. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR032642; Msh2_ATP-bd. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF35; DNA MISMATCH REPAIR PROTEIN MSH2; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR PIRSF; PIRSF005813; MSH2; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; KW Hereditary nonpolyposis colorectal cancer; Isopeptide bond; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..934 FT /note="DNA mismatch repair protein Msh2" FT /id="PRO_0000115183" FT REGION 601..671 FT /note="Interaction with EXO1" FT BINDING 669..676 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 555 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 567 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P43247" FT MOD_RES 845 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 847 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 871 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 892 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 921 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 430 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 845 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 847 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 871 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 892 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:17974005" FT /id="VSP_045536" FT VARIANT 2 FT /note="A -> T (in LYNCH1; likely benign; dbSNP:rs63750466)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_054511" FT VARIANT 5 FT /note="P -> Q (decreases protein levels; dbSNP:rs56170584)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079822" FT VARIANT 8 FT /note="T -> M (in dbSNP:rs17217716)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:12792735, ECO:0000269|Ref.9" FT /id="VAR_013171" FT VARIANT 13 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63749907)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043736" FT VARIANT 17 FT /note="V -> F (in gastric cancer; uncertain significance; FT cryptic acceptor splice site suppressed on ex vivo splicing FT assay; dbSNP:rs63750966)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043737" FT VARIANT 33 FT /note="T -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751107)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043738" FT VARIANT 40 FT /note="G -> S (in CRC; uncertain significance; FT dbSNP:rs63751260)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043739" FT VARIANT 43 FT /note="Y -> C (in dbSNP:rs17217723)" FT /evidence="ECO:0000269|Ref.9" FT /id="VAR_019233" FT VARIANT 44 FT /note="T -> M (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs587779085)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043740" FT VARIANT 45 FT /note="A -> V (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs63750285)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043741" FT VARIANT 46 FT /note="H -> Q (in LYNCH1; likely benign; dbSNP:rs33946261)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:8700523" FT /id="VAR_004470" FT VARIANT 55 FT /note="R -> G (decreases protein levels; FT dbSNP:rs587782354)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079823" FT VARIANT 92 FT /note="Missing (in LYNCH1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18561205" FT /id="VAR_043742" FT VARIANT 93 FT /note="L -> F (in LYNCH1; dbSNP:rs63751429)" FT /evidence="ECO:0000269|PubMed:15896463" FT /id="VAR_043743" FT VARIANT 96 FT /note="R -> H (in dbSNP:rs63750002)" FT /evidence="ECO:0000269|PubMed:7726159" FT /id="VAR_004471" FT VARIANT 98 FT /note="Y -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750887)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043744" FT VARIANT 102 FT /note="V -> I (in LYNCH1; likely benign; FT dbSNP:rs193922373)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043745" FT VARIANT 106 FT /note="R -> K (in dbSNP:rs41295286)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038026" FT VARIANT 110 FT /note="K -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043746" FT VARIANT 127 FT /note="N -> S (in LYNCH1; benign; presumed to enhance FT cancer risk considerably when associated with P-328; shows FT significantly decreased repair efficiency when associated FT with variant P-328; dbSNP:rs17217772)" FT /evidence="ECO:0000269|PubMed:12655564, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22581703, ECO:0000269|Ref.9" FT /id="VAR_019234" FT VARIANT 139 FT /note="N -> S (in LYNCH1; dbSNP:rs1553350676)" FT /id="VAR_004472" FT VARIANT 145 FT /note="I -> M (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750124)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_004473" FT VARIANT 161 FT /note="V -> D (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750126)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012936" FT VARIANT 162 FT /note="G -> A (in LYNCH1; dbSNP:rs63750773)" FT /evidence="ECO:0000269|PubMed:17128465" FT /id="VAR_054512" FT VARIANT 162 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; associated with an abnormal subcellular FT localization pattern; affects protein stability; loss of FT protein expression; dbSNP:rs63750624)" FT /evidence="ECO:0000269|PubMed:15991316, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043747" FT VARIANT 163 FT /note="V -> D (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043748" FT VARIANT 163 FT /note="V -> G (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022670" FT VARIANT 164 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750582)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043749" FT VARIANT 165 FT /note="Y -> D (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779163)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067284" FT VARIANT 167 FT /note="D -> H (in LYNCH1; benign; shows reduced mismatch FT binding; does not show a decreased expression level of the FT MutS alpha complex; not associated with an abnormal FT subcellular localization pattern; normal mismatch repair FT activity; dbSNP:rs63750255)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:8872463" FT /id="VAR_004474" FT VARIANT 169 FT /note="I -> V (in LYNCH1 and CRC; likely benign; FT dbSNP:rs63750716)" FT /evidence="ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043750" FT VARIANT 173 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750070)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043751" FT VARIANT 175 FT /note="L -> P (in LYNCH1; dbSNP:rs63751291)" FT /evidence="ECO:0000269|PubMed:12655568" FT /id="VAR_043752" FT VARIANT 177 FT /note="E -> H (in LYNCH1; uncertain significance; normal FT mismatch repair activity; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067285" FT VARIANT 187 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043753" FT VARIANT 187 FT /note="L -> R (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076352" FT VARIANT 198 FT /note="E -> G (in dbSNP:rs63750327)" FT /id="VAR_054513" FT VARIANT 199 FT /note="C -> R (in LYNCH1; also found in a patient with FT glioma; no effect on MSH2 splicing; dbSNP:rs63751110)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9777949" FT /id="VAR_012937" FT VARIANT 203 FT /note="G -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs587779973)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043754" FT VARIANT 205 FT /note="E -> Q (shows no defects; normal mismatch repair FT activity; dbSNP:rs63749984)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068705" FT VARIANT 216 FT /note="I -> V (in LYNCH1; uncertain significance; shows FT slightly reduced mismatch binding or release efficiency; FT dbSNP:rs63749936)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012938" FT VARIANT 246 FT /note="K -> Q (in LYNCH1; uncertain significance; FT dbSNP:rs63750881)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043755" FT VARIANT 265..314 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004475" FT VARIANT 272 FT /note="A -> V (in LYNCH1; benign; shows slightly reduced FT mismatch binding or release efficiency; results in partial FT MSH2 exon 5 skipping; normal mismatch repair activity; FT dbSNP:rs34136999)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043756" FT VARIANT 283 FT /note="D -> Y (in LYNCH1; dbSNP:rs63750381)" FT /evidence="ECO:0000269|PubMed:15870828" FT /id="VAR_043757" FT VARIANT 305 FT /note="A -> T (in LYNCH1; normal mismatch repair activity; FT dbSNP:rs63751454)" FT /evidence="ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004476" FT VARIANT 322 FT /note="G -> D (in dbSNP:rs4987188)" FT /evidence="ECO:0000269|PubMed:10023327, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703, FT ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:9087566, FT ECO:0000269|PubMed:9298827, ECO:0000269|Ref.9" FT /id="VAR_004477" FT VARIANT 323 FT /note="S -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:9240418" FT /id="VAR_012939" FT VARIANT 323 FT /note="S -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043758" FT VARIANT 328 FT /note="A -> P (shows significantly decreased repair FT efficiency when associated with variant S-127; presumed to FT enhance cancer risk considerably when associated with FT variant S-127; dbSNP:rs753237286)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068706" FT VARIANT 331 FT /note="N -> D (in LYNCH1; uncertain significance; no effect FT on MSH2 splicing; dbSNP:rs267607938)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054514" FT VARIANT 333 FT /note="C -> Y (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750828)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043759" FT VARIANT 335 FT /note="T -> I (in LYNCH1; uncertain significance; FT dbSNP:rs63750602)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043760" FT VARIANT 336 FT /note="P -> S (in LYNCH1; dbSNP:rs63751062)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043761" FT VARIANT 342 FT /note="V -> I (in CRC; uncertain significance; FT dbSNP:rs63749879)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043762" FT VARIANT 349 FT /note="P -> L (in LYNCH1; dbSNP:rs587779067)" FT /evidence="ECO:0000269|PubMed:15342696" FT /id="VAR_043763" FT VARIANT 359 FT /note="R -> S (in LYNCH1; shows a decreased expression FT level of the MutS alpha complex; associated with an FT abnormal subcellular localization pattern; FT dbSNP:rs63751617)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:18781619" FT /id="VAR_043764" FT VARIANT 367 FT /note="V -> I (shows no defects; normal mismatch repair FT activity; dbSNP:rs80285180)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068707" FT VARIANT 385 FT /note="P -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs564736113)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067286" FT VARIANT 390 FT /note="L -> F (in LYNCH1 and CRC; benign; may decrease FT mismatch repair activity; dbSNP:rs17224367)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:8690195, FT ECO:0000269|PubMed:9621522, ECO:0000269|Ref.9" FT /id="VAR_004478" FT VARIANT 393 FT /note="K -> M (in LYNCH1; dbSNP:rs1558478490)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_043765" FT VARIANT 419 FT /note="Q -> K (in CRC; likely benign; decreased mismatch FT repair activity; dbSNP:rs63750006)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15996210, FT ECO:0000269|PubMed:8690195" FT /id="VAR_012940" FT VARIANT 440 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043766" FT VARIANT 470 FT /note="V -> E (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607959)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054515" FT VARIANT 487 FT /note="D -> E (decreased mismatch repair activity; FT dbSNP:rs35107951)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068708" FT VARIANT 492 FT /note="M -> V (in LYNCH1)" FT /id="VAR_043767" FT VARIANT 506 FT /note="D -> Y (in LYNCH1 and CRC; sporadic early-onset CRC; FT decreased mismatch repair activity; dbSNP:rs63750492)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_012941" FT VARIANT 519 FT /note="F -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1371291280)" FT /evidence="ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614" FT /id="VAR_067287" FT VARIANT 524 FT /note="R -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751207)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:9889267" FT /id="VAR_004479" FT VARIANT 534 FT /note="R -> P (no effect on protein levels; FT dbSNP:rs587778523)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079824" FT VARIANT 552 FT /note="T -> P (in LYNCH1; dbSNP:rs63750838)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043768" FT VARIANT 554 FT /note="S -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751656)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012942" FT VARIANT 562 FT /note="E -> V (in LYNCH1; dbSNP:rs63750997)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004480" FT VARIANT 564 FT /note="T -> A (in LYNCH1; benign; dbSNP:rs55778204)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043769" FT VARIANT 583 FT /note="N -> S (in LYNCH1; dbSNP:rs201118107)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043770" FT VARIANT 596 FT /note="N -> S (in LYNCH1; uncertain significance; FT dbSNP:rs41295288)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8993976" FT /id="VAR_012943" FT VARIANT 596 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63749831)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:7874129, FT ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9311737" FT /id="VAR_004481" FT VARIANT 600 FT /note="A -> V (in LYNCH1; dbSNP:rs63751236)" FT /evidence="ECO:0000269|PubMed:11920458" FT /id="VAR_043771" FT VARIANT 603 FT /note="D -> N (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; affects protein stability; loss FT of protein expression; dbSNP:rs63750657)" FT /evidence="ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043772" FT VARIANT 610 FT /note="H -> N (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607980)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054516" FT VARIANT 619 FT /note="Y -> C (in CRC; uncertain significance; FT dbSNP:rs63749982)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043773" FT VARIANT 622 FT /note="P -> L (in LYNCH1; decreased mismatch repair FT activity; confers multiple biochemical defects; FT dbSNP:rs28929483)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:8261515" FT /id="VAR_004482" FT VARIANT 629 FT /note="Q -> R (in LYNCH1; benign; dbSNP:rs61756468)" FT /evidence="ECO:0000269|PubMed:12132870, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15996210" FT /id="VAR_043774" FT VARIANT 636 FT /note="A -> P (in LYNCH1; decreased mismatch binding FT activity; dbSNP:rs63750875)" FT /evidence="ECO:0000269|PubMed:10528862, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_012944" FT VARIANT 638 FT /note="R -> G (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607981)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054517" FT VARIANT 639 FT /note="H -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779116)" FT /evidence="ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9419403" FT /id="VAR_043775" FT VARIANT 639 FT /note="H -> Y (in LYNCH1; the equivalent substitution in FT yeast does not affect mismatch repair efficiency in vitro; FT dbSNP:rs28929484)" FT /evidence="ECO:0000269|PubMed:11555625, FT ECO:0000269|PubMed:8261515" FT /id="VAR_004483" FT VARIANT 641 FT /note="C -> G (in dbSNP:rs63749946)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004484" FT VARIANT 645 FT /note="Q -> E (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607982)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054518" FT VARIANT 647 FT /note="E -> K (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043776" FT VARIANT 656 FT /note="Y -> H (in LYNCH1; somatic mutation; FT dbSNP:rs1573567393)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043777" FT VARIANT 660 FT /note="D -> G (in LYNCH1; dbSNP:rs1085308057)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022671" FT VARIANT 669 FT /note="G -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751668)" FT /evidence="ECO:0000269|PubMed:22371642" FT /id="VAR_067761" FT VARIANT 670 FT /note="P -> L (in dbSNP:rs41294982)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038027" FT VARIANT 671 FT /note="N -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63751232)" FT /evidence="ECO:0000269|PubMed:15300854, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043778" FT VARIANT 674 FT /note="G -> A (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs267607996)" FT /evidence="ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_076353" FT VARIANT 674 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:18625694, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614" FT /id="VAR_067288" FT VARIANT 674 FT /note="G -> S (in LYNCH1; somatic mutation; FT dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004485" FT VARIANT 675 FT /note="K -> A (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; requires 2 nucleotide FT substitutions; dbSNP:rs587779128)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067289" FT VARIANT 679 FT /note="I -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043779" FT VARIANT 688 FT /note="M -> I (in LYNCH1; dbSNP:rs63750790)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:9559627" FT /id="VAR_012945" FT VARIANT 688 FT /note="M -> V (in LYNCH1; loss of protein expression; FT dbSNP:rs1573569964)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076354" FT VARIANT 692 FT /note="G -> R (in LYNCH1; dbSNP:rs63750232)" FT /evidence="ECO:0000269|PubMed:10612836" FT /id="VAR_009250" FT VARIANT 696 FT /note="P -> L (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607994)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054519" FT VARIANT 697 FT /note="C -> F (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; confers multiple FT biochemical defects; dbSNP:rs63750398)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9298827" FT /id="VAR_004486" FT VARIANT 697 FT /note="C -> R (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs63750961)" FT /evidence="ECO:0000269|PubMed:10612836, FT ECO:0000269|PubMed:18561205" FT /id="VAR_009251" FT VARIANT 714 FT /note="A -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63751224)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043780" FT VARIANT 722 FT /note="V -> I (in LYNCH1; dbSNP:rs587781996)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076355" FT VARIANT 723 FT /note="S -> F (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63750794)" FT /evidence="ECO:0000269|PubMed:11920458, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:22102614" FT /id="VAR_043781" FT VARIANT 729 FT /note="M -> V (in LYNCH1; somatic mutation; FT dbSNP:rs1558520059)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043782" FT VARIANT 732 FT /note="T -> I (in LYNCH1; somatic mutation; FT dbSNP:rs730881765)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043783" FT VARIANT 745..746 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043784" FT VARIANT 748 FT /note="D -> Y (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608007)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054520" FT VARIANT 749 FT /note="E -> K (in LYNCH1; decreased mismatch repair FT activity; no loss of protein expression; dbSNP:rs63751477)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043785" FT VARIANT 759 FT /note="G -> E (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; dbSNP:rs386833406)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067290" FT VARIANT 770 FT /note="I -> V (in dbSNP:rs63750684)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004487" FT VARIANT 779 FT /note="M -> I (in dbSNP:rs41295292)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038028" FT VARIANT 805 FT /note="L -> V (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs779182536)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067291" FT VARIANT 807 FT /note="T -> S (in dbSNP:rs41295294)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038029" FT VARIANT 813 FT /note="M -> I (no effect on protein levels; FT dbSNP:rs587781678)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079825" FT VARIANT 813 FT /note="M -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63749841)" FT /evidence="ECO:0000269|PubMed:12373605" FT /id="VAR_043786" FT VARIANT 824 FT /note="Q -> E (in gastric cancer; uncertain significance; FT dbSNP:rs63750623)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043787" FT VARIANT 834 FT /note="A -> T (in LYNCH1; likely benign; decreased mismatch FT repair activity; shows no functional defects in gel shift FT assay; dbSNP:rs63750757)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004488" FT VARIANT 835 FT /note="N -> H (in dbSNP:rs41295296)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038030" FT VARIANT 839 FT /note="H -> Q (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608016)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054521" FT VARIANT 839 FT /note="H -> R (in LYNCH1; decreases protein levels; FT dbSNP:rs63750027)" FT /evidence="ECO:0000269|PubMed:15613555, FT ECO:0000269|PubMed:28494185" FT /id="VAR_043788" FT VARIANT 843 FT /note="C -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1667495338)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067292" FT VARIANT 845 FT /note="K -> E (in LYNCH1; dbSNP:rs63750571)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_013172" FT VARIANT 853 FT /note="E -> A (in LYNCH1; uncertain significance; FT dbSNP:rs63750797)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043789" FT VARIANT 860 FT /note="S -> L (in LYNCH1; likely benign; normal mismatch FT repair activity; dbSNP:rs63750849)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067293" FT VARIANT 868 FT /note="P -> A (in gastric cancer; uncertain significance; FT dbSNP:rs63751400)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043790" FT VARIANT 870 FT /note="A -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750709)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043791" FT VARIANT 873 FT /note="C -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750795)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043792" FT VARIANT 886 FT /note="E -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750350)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043793" FT VARIANT 905 FT /note="T -> R (in LYNCH1; likely benign; FT dbSNP:rs267608022)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004489" FT VARIANT 909 FT /note="K -> I (found in a colorectal cancer sample; normal FT mismatch repair activity; dbSNP:rs34319539)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068709" FT VARIANT 911 FT /note="L -> R (in dbSNP:rs41295182)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038031" FT VARIANT 923 FT /note="V -> E (in LYNCH1; uncertain significance; FT dbSNP:rs146421227)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043794" FT VARIANT 931 FT /note="K -> T (in LYNCH1; dbSNP:rs267608023)" FT /evidence="ECO:0000269|PubMed:15046096" FT /id="VAR_043795" FT MUTAGEN 675 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH6 mutant R- FT 1140." FT /evidence="ECO:0000269|PubMed:9564049" FT MUTAGEN 845 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-847, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 847 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 871 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 892 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-871." FT /evidence="ECO:0000269|PubMed:24882211" FT CONFLICT 784 FT /note="F -> I (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT CONFLICT 836 FT /note="F -> S (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT HELIX 14..24 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 33..38 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 48..56 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 65..71 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 82..94 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 117..124 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 129..131 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 137..139 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 147..152 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 160..167 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 168..171 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 172..179 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 197..204 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 208..220 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 229..232 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 234..236 FT /evidence="ECO:0007829|PDB:8OLX" FT HELIX 237..244 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:8OLX" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:2O8E" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 259..262 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 264..277 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 283..285 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 286..288 FT /evidence="ECO:0007829|PDB:8R7E" FT STRAND 289..293 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 304..309 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 321..323 FT /evidence="ECO:0007829|PDB:8OMA" FT HELIX 326..330 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 336..347 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 353..367 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 370..377 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 378..380 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 387..395 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 401..411 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 432..435 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 437..455 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 476..502 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 517..519 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 521..525 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 527..530 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 531..535 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 536..538 FT /evidence="ECO:0007829|PDB:8OMO" FT STRAND 540..544 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8OMQ" FT STRAND 549..552 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 556..563 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 564..567 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 568..585 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 589..613 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 615..617 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 623..625 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 631..637 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 640..644 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:8R7C" FT STRAND 653..658 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 659..661 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 664..668 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 671..674 FT /evidence="ECO:0007829|PDB:8OMO" FT HELIX 675..691 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 695..703 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 706..711 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 718..721 FT /evidence="ECO:0007829|PDB:8OMQ" FT HELIX 724..738 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 744..749 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 750..753 FT /evidence="ECO:0007829|PDB:8R7E" FT HELIX 756..772 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 777..783 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 785..792 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 797..807 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 810..820 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 827..833 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 838..850 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 851..855 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 875..892 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 896..898 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 901..917 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 921..928 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 934 AA; 104743 MW; 664A058C78242E05 CRC64; MAVQPKETLQ LESAAEVGFV RFFQGMPEKP TTTVRLFDRG DFYTAHGEDA LLAAREVFKT QGVIKYMGPA GAKNLQSVVL SKMNFESFVK DLLLVRQYRV EVYKNRAGNK ASKENDWYLA YKASPGNLSQ FEDILFGNND MSASIGVVGV KMSAVDGQRQ VGVGYVDSIQ RKLGLCEFPD NDQFSNLEAL LIQIGPKECV LPGGETAGDM GKLRQIIQRG GILITERKKA DFSTKDIYQD LNRLLKGKKG EQMNSAVLPE MENQVAVSSL SAVIKFLELL SDDSNFGQFE LTTFDFSQYM KLDIAAVRAL NLFQGSVEDT TGSQSLAALL NKCKTPQGQR LVNQWIKQPL MDKNRIEERL NLVEAFVEDA ELRQTLQEDL LRRFPDLNRL AKKFQRQAAN LQDCYRLYQG INQLPNVIQA LEKHEGKHQK LLLAVFVTPL TDLRSDFSKF QEMIETTLDM DQVENHEFLV KPSFDPNLSE LREIMNDLEK KMQSTLISAA RDLGLDPGKQ IKLDSSAQFG YYFRVTCKEE KVLRNNKNFS TVDIQKNGVK FTNSKLTSLN EEYTKNKTEY EEAQDAIVKE IVNISSGYVE PMQTLNDVLA QLDAVVSFAH VSNGAPVPYV RPAILEKGQG RIILKASRHA CVEVQDEIAF IPNDVYFEKD KQMFHIITGP NMGGKSTYIR QTGVIVLMAQ IGCFVPCESA EVSIVDCILA RVGAGDSQLK GVSTFMAEML ETASILRSAT KDSLIIIDEL GRGTSTYDGF GLAWAISEYI ATKIGAFCMF ATHFHELTAL ANQIPTVNNL HVTALTTEET LTMLYQVKKG VCDQSFGIHV AELANFPKHV IECAKQKALE LEEFQYIGES QGYDIMEPAA KKCYLEREQG EKIIQEFLSK VKQMPFTEMS EENITIKLKQ LKAEVIAKNN SFVNEIISRI KVTT // ID MSH6_HUMAN Reviewed; 1360 AA. AC P52701; B4DF41; B4E3I4; F5H2F9; O43706; O43917; Q8TCX4; Q9BTB5; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=DNA mismatch repair protein Msh6 {ECO:0000250|UniProtKB:P54276}; DE Short=hMSH6 {ECO:0000303|PubMed:8942985}; DE AltName: Full=G/T mismatch-binding protein {ECO:0000303|PubMed:7604265}; DE Short=GTBP {ECO:0000303|PubMed:9455487}; DE Short=GTMBP {ECO:0000250|UniProtKB:P54276}; DE AltName: Full=MutS protein homolog 6 {ECO:0000312|HGNC:HGNC:7329}; DE AltName: Full=MutS-alpha 160 kDa subunit; DE Short=p160 {ECO:0000303|PubMed:7604264}; GN Name=MSH6 {ECO:0000312|HGNC:HGNC:7329}; Synonyms=GTBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT GLU-39, AND SUBUNIT. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING. RX PubMed=9455487; DOI=10.1093/dnares/4.5.359; RA Shiwaku H.O., Wakatsuki S., Mori Y., Fukushige S., Horii A.; RT "Alternative splicing of GTBP in normal human tissues."; RL DNA Res. 4:359-362(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-39; VAL-396; ALA-623 RP AND VAL-886. RG NIEHS SNPs program; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 69-1360, AND PARTIAL PROTEIN SEQUENCE. RX PubMed=7604265; DOI=10.1126/science.7604265; RA Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., RA D'Arrigo A., Truong O., Hsuan J.J., Jiricny J.; RT "GTBP, a 160-kilodalton protein essential for mismatch-binding activity in RT human cells."; RL Science 268:1912-1914(1995). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-116. RX PubMed=8838326; DOI=10.1006/geno.1996.0067; RA Nicolaides N.C., Palombo F., Kinzler K.W., Vogelstein B., Jiricny J.; RT "Molecular cloning of the N-terminus of GTBP."; RL Genomics 31:395-397(1996). RN [9] RP CHARACTERIZATION, PARTIAL PROTEIN SEQUENCE, AND SUBUNIT. RX PubMed=7604264; DOI=10.1126/science.7604264; RA Drummond J.T., Li G.-M., Longley M.J., Modrich P.; RT "Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair RT to tumor cells."; RL Science 268:1909-1912(1995). RN [10] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [11] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [12] RP FUNCTION, AND MUTAGENESIS OF LYS-1140. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [13] RP MISMATCH-BINDING. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [14] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [15] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [16] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [17] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [18] RP IDENTIFICATION OF MSH6 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [19] RP INVOLVEMENT IN LYNCH5. RX PubMed=9354786; DOI=10.1038/ng1197-271; RA Miyaki M., Konishi M., Tanaka K., Kikuchi-Yanoshita R., Muraoka M., RA Yasuno M., Igari T., Koike M., Chiba M., Mori T.; RT "Germline mutation of MSH6 as the cause of hereditary nonpolyposis RT colorectal cancer."; RL Nat. Genet. 17:271-272(1997). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219; SER-227 AND SER-261, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-41 AND SER-43, RP VARIANT [LARGE SCALE ANALYSIS] GLU-39, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP INVOLVEMENT IN MMRCS. RX PubMed=17557300; DOI=10.1002/humu.20569; RA Auclair J., Leroux D., Desseigne F., Lasset C., Saurin J.C., Joly M.O., RA Pinson S., Xu X.L., Montmain G., Ruano E., Navarro C., Puisieux A., RA Wang Q.; RT "Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a RT likely cause of PMS2 gene inactivation."; RL Hum. Mutat. 28:1084-1090(2007). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-309, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-79; SER-91; SER-137; RP SER-200; SER-227; SER-252; SER-254; SER-256 AND SER-261, AND IDENTIFICATION RP BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-70 AND LYS-504, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-227 AND RP SER-830, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-219; RP SER-227; SER-252; SER-261; THR-269; SER-274; SER-275; SER-279; SER-280 AND RP SER-309, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-227; RP SER-252; SER-309; THR-488; SER-830; SER-935 AND THR-1010, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP CHARACTERIZATION OF VARIANTS LYNCH5 LEU-128; ILE-144; ARG-566; LEU-623; RP THR-728; GLY-881 DELINS LYS-SER; THR-1087; HIS-1095; LYS-1193 AND GLN-1354, RP CHARACTERIZATION OF VARIANT ARG-1087, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [33] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL12 (MICROBIAL INFECTION). RX PubMed=21957315; DOI=10.1128/jvi.05487-11; RA Mohni K.N., Mastrocola A.S., Bai P., Weller S.K., Heinen C.D.; RT "DNA mismatch repair proteins are required for efficient herpes simplex RT virus 1 replication."; RL J. Virol. 85:12241-12253(2011). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-103 AND RP 105-TRP-TRP-106. RX PubMed=23622243; DOI=10.1016/j.cell.2013.03.025; RA Li F., Mao G., Tong D., Huang J., Gu L., Yang W., Li G.M.; RT "The histone mark H3K36me3 regulates human DNA mismatch repair through its RT interaction with MutSalpha."; RL Cell 153:590-600(2013). RN [35] RP IDENTIFICATION IN THE MMR COMPLEX, AND INTERACTION WITH MCM9. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [37] RP VARIANTS VAL-1213 AND ILE-1260. RX PubMed=7604266; DOI=10.1126/science.7604266; RA Papadopoulos N., Nicolaides N.C., Liu B., Parsons R., Lengauer C., RA Palombo F., D'Arrigo A., Markowitz S., Willson J.K.V., Kinzler K.W., RA Jiricny J., Vogelstein B.; RT "Mutations of GTBP in genetically unstable cells."; RL Science 268:1915-1917(1995). RN [38] RP VARIANTS LYNCH5 ILE-144 AND CYS-850. RX PubMed=10521294; DOI=10.1086/302612; RA Wu Y., Berends M.J.W., Mensink R.G.J., Kempinga C., Sijmons R.H., RA van Der Zee A.G.J., Hollema H., Kleibeuker J.H., Buys C.H.C.M., RA Hofstra R.M.W.; RT "Association of hereditary nonpolyposis colorectal cancer-related tumors RT displaying low microsatellite instability with MSH6 germline mutations."; RL Am. J. Hum. Genet. 65:1291-1298(1999). RN [39] RP VARIANTS CRC ILE-285; ARG-566; GLY-803 AND THR-1087, AND VARIANTS GLU-39; RP ASP-220; VAL-396 AND LEU-800. RX PubMed=10537275; RA Kolodner R.D., Tytell J.D., Schmeits J.L., Kane M.F., Das Gupta R., RA Weger J., Wahlberg S., Fox E.A., Peel D., Ziogas A., Garber J.E., RA Syngal S., Anton-Culver H., Li F.P.; RT "Germ-line msh6 mutations in colorectal cancer families."; RL Cancer Res. 59:5068-5074(1999). RN [40] RP VARIANT LYNCH5 GLU-698. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [41] RP VARIANT CRC MET-1284. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [42] RP VARIANTS CRC VAL-20; ALA-878 AND HIS-901, AND VARIANTS ENDMC VAL-20; RP ALA-878 AND HIS-901. RX PubMed=11153917; DOI=10.1007/s004390000417; RA Charames G.S., Millar A.L., Pal T., Narod S., Bapat B.; RT "Do MSH6 mutations contribute to double primary cancers of the colorectum RT and endometrium?"; RL Hum. Genet. 107:623-629(2000). RN [43] RP VARIANTS GLU-39 AND SER-340. RX PubMed=10699937; RX DOI=10.1002/(sici)1097-0215(20000301)85:5<606::aid-ijc2>3.0.co;2-b; RA Plaschke J., Kruppa C., Tischler R., Bocker T., Pistorius S., Dralle H., RA Rueschoff J., Saeger H.D., Fishel R., Schackert H.K.; RT "Sequence analysis of the mismatch repair gene hMSH6 in the germline of RT patients with familial and sporadic colorectal cancer."; RL Int. J. Cancer 85:606-613(2000). RN [44] RP VARIANTS CRC ALA-685; GLN-772; ALA-800; MET-854; ALA-878; VAL-1031 AND RP ARG-1158. RX PubMed=11470537; DOI=10.1016/s0378-1119(01)00517-0; RA Ohmiya N., Matsumoto S., Yamamoto H., Baranovskaya S., Malkhosyan S.R., RA Perucho M.; RT "Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal RT cancers of the microsatellite mutator phenotype."; RL Gene 272:301-313(2001). RN [45] RP VARIANT LYNCH5 ALA-878. RX PubMed=11586295; DOI=10.1038/ng1001-137; RA Wu Y., Berends M.J.W., Sijmons R.H., Mensink R.G.J., Verlind E., Kooi K.A., RA van der Sluis T., Kempinga C., van der Zee A.G.J., Hollema H., RA Buys C.H.C.M., Kleibeuker J.H., Hofstra R.M.W.; RT "A role for MLH3 in hereditary nonpolyposis colorectal cancer."; RL Nat. Genet. 29:137-138(2001). RN [46] RP VARIANTS CRC ILE-144; ARG-522; MET-725; CYS-850; ALA-878; ASP-1021; RP MET-1100; ILE-1219 AND ASP-1248. RX PubMed=11709755; DOI=10.1086/337944; RA Berends M.J.W., Wu Y., Sijmons R.H., Mensink R.G.J., van der Sluis T., RA Hordijk-Hos J.M., de Vries E.G.E., Hollema H., Karrenbeld A., RA Buys C.H.C.M., van der Zee A.G.J., Hofstra R.M.W., Kleibeuker J.H.; RT "Molecular and clinical characteristics of MSH6 variants: an analysis of 25 RT index carriers of a germline variant."; RL Am. J. Hum. Genet. 70:26-37(2002). RN [47] RP VARIANT CRC HIS-976. RX PubMed=11807791; DOI=10.1002/ijc.10097; RA Plaschke J., Krueger S., Pistorius S., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Involvement of hMSH6 in the development of hereditary and sporadic RT colorectal cancer revealed by immunostaining is based on germline RT mutations, but rarely on somatic inactivation."; RL Int. J. Cancer 97:643-648(2002). RN [48] RP VARIANT LYNCH5 VAL-492. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [49] RP VARIANTS CRC HIS-1095 AND GLN-1354. RX PubMed=12522549; DOI=10.1007/s00439-002-0866-4; RA Kariola R., Otway R., Loennqvist K.E., Raevaara T.E., Macrae F., Vos Y.J., RA Kohonen-Corish M., Hofstra R.M.W., Nystroem-Lahti M.; RT "Two mismatch repair gene mutations found in a colon cancer patient - which RT one is pathogenic?"; RL Hum. Genet. 112:105-109(2003). RN [50] RP VARIANTS GLU-39; ALA-54; ALA-509; MET-854 AND ALA-878. RX PubMed=14520694; DOI=10.1002/ijc.11415; RA Peterlongo P., Nafa K., Lerman G.S., Glogowski E., Shia J., Ye T.Z., RA Markowitz A.J., Guillem J.G., Kolachana P., Boyd J.A., Offit K., RA Ellis N.A.; RT "MSH6 germline mutations are rare in colorectal cancer families."; RL Int. J. Cancer 107:571-579(2003). RN [51] RP VARIANTS LEU-128; LEU-623; THR-728 AND LYS-1193, AND CHARACTERIZATION OF RP VARIANTS LEU-128; LEU-623; THR-728 AND LYS-1193. RX PubMed=15354210; DOI=10.1038/sj.bjc.6602129; RA Kariola R., Hampel H., Frankel W.L., Raevaara T.E., de la Chapelle A., RA Nystroem-Lahti M.; RT "MSH6 missense mutations are often associated with no or low cancer RT susceptibility."; RL Br. J. Cancer 91:1287-1292(2004). RN [52] RP VARIANT LYNCH5 TRP-772. RX PubMed=14974087; DOI=10.1002/humu.9217; RG The German HNPCC consortium; RA Plaschke J., Krueger S., Dietmaier W., Gebert J., Sutter C., Mangold E., RA Pagenstecher C., Holinski-Feder E., Schulmann K., Moeslein G., RA Rueschoff J., Engel C., Evans G., Schackert H.K.; RT "Eight novel MSH6 germline mutations in patients with familial and RT nonfamilial colorectal cancer selected by loss of protein expression in RT tumor tissue."; RL Hum. Mutat. 23:285-285(2004). RN [53] RP VARIANT LYNCH5 VAL-1163. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [54] RP VARIANT CRC PRO-449, AND VARIANT ENDMC PRO-449. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [55] RP VARIANTS CRC ASN-99; ASP-619; VAL-787; ALA-878 AND CYS-1076. RX PubMed=15483016; DOI=10.1200/jco.2004.02.033; RA Plaschke J., Engel C., Krueger S., Holinski-Feder E., Pagenstecher C., RA Mangold E., Moeslein G., Schulmann K., Gebert J., von Knebel Doeberitz M., RA Rueschoff J., Loeffler M., Schackert H.K.; RT "Lower incidence of colorectal cancer and later age of disease onset in 27 RT families with pathogenic MSH6 germline mutations compared with families RT with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal RT cancer consortium."; RL J. Clin. Oncol. 22:4486-4494(2004). RN [56] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-221 AND VAL-492. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [57] RP VARIANTS THR-13; LEU-65; ILE-144; HIS-468; CYS-503; LEU-580; ALA-878; RP LEU-1232 AND GLY-1321. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [58] RP CHARACTERIZATION OF VARIANT LYNCH5 VAL-20, CHARACTERIZATION OF VARIANTS CRC RP HIS-976 AND ASP-1021, AND CHARACTERIZATION OF VARIANTS SER-25; VAL-326; RP VAL-396; VAL-492; CYS-503; ARG-522; ASN-610; CYS-850; ALA-878; TYR-1026; RP SER-1087 AND MET-1225. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [59] RP CHARACTERIZATION OF VARIANTS PRO-435; PRO-585; THR-677; ALA-878; HIS-1095 RP AND GLN-1354. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA CC mismatches thereby initiating DNA repair. When bound, MutS alpha bends CC the DNA helix and shields approximately 20 base pairs, and recognizes CC single base mismatches and dinucleotide insertion-deletion loops (IDL) CC in the DNA. After mismatch binding, forms a ternary complex with the CC MutL alpha heterodimer, which is thought to be responsible for CC directing the downstream MMR events, including strand discrimination, CC excision, and resynthesis. ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. Recruited on CC chromatin in G1 and early S phase via its PWWP domain that specifically CC binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early CC recruitment to chromatin to be replicated allowing a quick CC identification of mismatch repair to initiate the DNA mismatch repair CC reaction. {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:23622243, ECO:0000269|PubMed:9564049, CC ECO:0000269|PubMed:9822679, ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) (PubMed:7604264, PubMed:8942985). CC Forms a ternary complex with MutL alpha (MLH1-PMS1). Interacts with CC MCM9 (PubMed:26300262). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:7604264, CC ECO:0000269|PubMed:8942985}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC protein UL12. {ECO:0000269|PubMed:21957315}. CC -!- INTERACTION: CC P52701; Q9NXL9: MCM9; NbExp=3; IntAct=EBI-395529, EBI-2804985; CC P52701; P43246: MSH2; NbExp=11; IntAct=EBI-395529, EBI-355888; CC P52701; P01106: MYC; NbExp=2; IntAct=EBI-395529, EBI-447544; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23622243}. Chromosome CC {ECO:0000269|PubMed:23622243}. Note=Associates with H3K36me3 via its CC PWWP domain. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=GTBP-N; CC IsoId=P52701-1; Sequence=Displayed; CC Name=GTBP-alt; CC IsoId=P52701-2; Sequence=VSP_003291, VSP_003292; CC Name=3; CC IsoId=P52701-3; Sequence=VSP_054419; CC Name=4; CC IsoId=P52701-4; Sequence=VSP_055020; CC -!- DOMAIN: The PWWP domain specifically recognizes and binds trimethylated CC 'Lys-36' of histone H3 (H3K36me3). {ECO:0000269|PubMed:23622243}. CC -!- PTM: The N-terminus is blocked. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- DISEASE: Lynch syndrome 5 (LYNCH5) [MIM:614350]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10521294, CC ECO:0000269|PubMed:11586295, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14974087, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614, CC ECO:0000269|PubMed:9354786}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:11153917, CC ECO:0000269|PubMed:14961575}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 3 (MMRCS3) [MIM:619097]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:17557300}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10537275, ECO:0000269|PubMed:10699937, CC ECO:0000269|PubMed:11153917, ECO:0000269|PubMed:11470537, CC ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:11807791, CC ECO:0000269|PubMed:12522549, ECO:0000269|PubMed:14520694, CC ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:15483016, CC ECO:0000269|PubMed:22102614}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/344/MSH6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U73737; AAB47425.1; -; Genomic_DNA. DR EMBL; U73732; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73733; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73734; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73736; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; D89645; BAA23674.1; -; Genomic_DNA. DR EMBL; D89646; BAA23675.1; -; mRNA. DR EMBL; AK293921; BAG57302.1; -; mRNA. DR EMBL; AK304735; BAG65496.1; -; mRNA. DR EMBL; AY082894; AAL87401.1; -; Genomic_DNA. DR EMBL; AC006509; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004246; AAH04246.1; -; mRNA. DR EMBL; U54777; AAB39212.2; -; mRNA. DR EMBL; U28946; AAC50461.1; -; mRNA. DR CCDS; CCDS1836.1; -. [P52701-1] DR CCDS; CCDS62906.1; -. [P52701-3] DR PIR; JC5839; JC5839. DR RefSeq; NP_000170.1; NM_000179.3. [P52701-1] DR RefSeq; NP_001268421.1; NM_001281492.2. [P52701-3] DR RefSeq; NP_001268422.1; NM_001281493.2. [P52701-4] DR RefSeq; NP_001268423.1; NM_001281494.2. [P52701-4] DR RefSeq; NP_001393725.1; NM_001406796.1. [P52701-1] DR RefSeq; NP_001393738.1; NM_001406809.1. [P52701-1] DR RefSeq; NP_001393740.1; NM_001406811.1. [P52701-4] DR RefSeq; NP_001393741.1; NM_001406812.1. [P52701-4] DR RefSeq; NP_001393743.1; NM_001406814.1. [P52701-4] DR RefSeq; NP_001393744.1; NM_001406815.1. [P52701-4] DR RefSeq; NP_001393745.1; NM_001406816.1. [P52701-4] DR RefSeq; NP_001393752.1; NM_001406823.1. [P52701-4] DR RefSeq; NP_001393758.1; NM_001406829.1. [P52701-4] DR PDB; 2GFU; NMR; -; A=68-201. DR PDB; 2O8B; X-ray; 2.75 A; B=341-1360. DR PDB; 2O8C; X-ray; 3.37 A; B=341-1360. DR PDB; 2O8D; X-ray; 3.00 A; B=341-1360. DR PDB; 2O8E; X-ray; 3.30 A; B=341-1360. DR PDB; 2O8F; X-ray; 3.25 A; B=341-1360. DR PDB; 6OQM; X-ray; 2.20 A; A=87-198. DR PDB; 8AG6; EM; 2.80 A; B=2-1360. DR PDBsum; 2GFU; -. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 6OQM; -. DR PDBsum; 8AG6; -. DR AlphaFoldDB; P52701; -. DR EMDB; EMD-15417; -. DR SMR; P52701; -. DR BioGRID; 109211; 288. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P52701; -. DR DIP; DIP-32972N; -. DR ELM; P52701; -. DR FunCoup; P52701; 3882. DR IntAct; P52701; 103. DR MINT; P52701; -. DR STRING; 9606.ENSP00000234420; -. DR ChEMBL; CHEMBL4739849; -. DR CarbonylDB; P52701; -. DR GlyCosmos; P52701; 1 site, 1 glycan. DR GlyGen; P52701; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P52701; -. DR MetOSite; P52701; -. DR PhosphoSitePlus; P52701; -. DR SwissPalm; P52701; -. DR BioMuta; MSH6; -. DR DMDM; 68067672; -. DR CPTAC; CPTAC-544; -. DR jPOST; P52701; -. DR MassIVE; P52701; -. DR PaxDb; 9606-ENSP00000234420; -. DR PeptideAtlas; P52701; -. DR ProteomicsDB; 25957; -. DR ProteomicsDB; 4004; -. DR ProteomicsDB; 56502; -. [P52701-1] DR ProteomicsDB; 56503; -. [P52701-2] DR Pumba; P52701; -. DR ABCD; P52701; 6 sequenced antibodies. DR Antibodypedia; 3963; 880 antibodies from 46 providers. DR CPTC; P52701; 2 antibodies. DR DNASU; 2956; -. DR Ensembl; ENST00000234420.11; ENSP00000234420.5; ENSG00000116062.20. [P52701-1] DR Ensembl; ENST00000540021.6; ENSP00000446475.1; ENSG00000116062.20. [P52701-3] DR GeneID; 2956; -. DR KEGG; hsa:2956; -. DR MANE-Select; ENST00000234420.11; ENSP00000234420.5; NM_000179.3; NP_000170.1. DR UCSC; uc002rwd.5; human. [P52701-1] DR AGR; HGNC:7329; -. DR CIViC; 2956; 7 evidence items across 7 molecular profiles. DR ClinPGx; PA184; -. DR CTD; 2956; -. DR DisGeNET; 2956; -. DR GeneCards; MSH6; -. DR GeneReviews; MSH6; -. DR HGNC; HGNC:7329; MSH6. DR HPA; ENSG00000116062; Low tissue specificity. DR MalaCards; MSH6; -. DR MIM; 114500; phenotype. DR MIM; 600678; gene. DR MIM; 608089; phenotype. DR MIM; 614350; phenotype. DR MIM; 619097; phenotype. DR OpenTargets; ENSG00000116062; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000116062; -. DR eggNOG; KOG0217; Eukaryota. DR GeneTree; ENSGT00550000075024; -. DR HOGENOM; CLU_002472_1_3_1; -. DR InParanoid; P52701; -. DR OMA; TPMMAQY; -. DR OrthoDB; 10252754at2759; -. DR PAN-GO; P52701; 4 GO annotations based on evolutionary models. DR PhylomeDB; P52701; -. DR PathwayCommons; P52701; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR SignaLink; P52701; -. DR SIGNOR; P52701; -. DR Agora; ENSG00000116062; -. DR BioGRID-ORCS; 2956; 15 hits in 1169 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MSH6; human. DR EvolutionaryTrace; P52701; -. DR GeneWiki; MSH6; -. DR GenomeRNAi; 2956; -. DR Pharos; P52701; Tbio. DR PRO; PR:P52701; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P52701; protein. DR Bgee; ENSG00000116062; Expressed in ventricular zone and 219 other cell types or tissues. DR ExpressionAtlas; P52701; baseline and differential. DR GO; GO:0000785; C:chromatin; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0140003; F:histone H3K36me3 reader activity; IDA:UniProtKB. DR GO; GO:0030983; F:mismatched DNA binding; IDA:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; ISS:BHF-UCL. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; ISS:BHF-UCL. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0000710; P:meiotic mismatch repair; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0009411; P:response to UV; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; ISS:BHF-UCL. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd05837; PWWP_MSH6; 1. DR FunFam; 1.10.1420.10:FF:000005; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000006; DNA mismatch repair protein; 1. DR FunFam; 2.30.30.140:FF:000069; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000004; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000645; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 2.30.30.140; -; 1. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00054; -. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR017261; DNA_mismatch_repair_MutS/MSH. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR000313; PWWP_dom. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF148; DNA MISMATCH REPAIR PROTEIN MSH6; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR Pfam; PF00855; PWWP; 1. DR PIRSF; PIRSF037677; DNA_mis_repair_Msh6; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SMART; SM00293; PWWP; 1. DR SUPFAM; SSF55271; DNA repair protein MutS, domain I; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF63748; Tudor/PWWP/MBT; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. DR PROSITE; PS50812; PWWP; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Hereditary nonpolyposis colorectal cancer; KW Host-virus interaction; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome. FT CHAIN 1..1360 FT /note="DNA mismatch repair protein Msh6" FT /id="PRO_0000115207" FT DOMAIN 92..154 FT /note="PWWP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00162" FT REGION 1..84 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 195..362 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33..51 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 198..209 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 219..230 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 240..249 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 263..273 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 320..351 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1134..1141 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243" FT MOD_RES 43 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243" FT MOD_RES 70 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 79 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 137 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 219 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:21406692" FT MOD_RES 227 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 254 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 256 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 261 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692" FT MOD_RES 269 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 274 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 275 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 279 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 280 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 309 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 488 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 504 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 830 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 935 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1010 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..302 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055020" FT VAR_SEQ 80..209 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054419" FT VAR_SEQ 1058..1068 FT /note="DVLLCLANYSR -> GKTLNKLVLRL (in isoform GTBP-alt)" FT /evidence="ECO:0000305" FT /id="VSP_003291" FT VAR_SEQ 1069..1360 FT /note="Missing (in isoform GTBP-alt)" FT /evidence="ECO:0000305" FT /id="VSP_003292" FT VARIANT 13 FT /note="K -> T (in dbSNP:rs41294988)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038032" FT VARIANT 20 FT /note="A -> V (in LYNCH5, CRC and ENDMC; likely benign; FT normal mismatch repair activity; dbSNP:rs63750664)" FT /evidence="ECO:0000269|PubMed:11153917, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043943" FT VARIANT 25 FT /note="A -> S (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs267608026)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067294" FT VARIANT 25 FT /note="A -> V (in dbSNP:rs35462442)" FT /id="VAR_038033" FT VARIANT 39 FT /note="G -> E (in dbSNP:rs1042821)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:10699937, ECO:0000269|PubMed:14520694, FT ECO:0000269|PubMed:8942985, ECO:0000269|Ref.4, FT ECO:0007744|PubMed:16964243" FT /id="VAR_004490" FT VARIANT 54 FT /note="G -> A (in dbSNP:rs63751098)" FT /evidence="ECO:0000269|PubMed:14520694" FT /id="VAR_043944" FT VARIANT 65 FT /note="S -> L (in dbSNP:rs41294984)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038034" FT VARIANT 99 FT /note="K -> N (in CRC; uncertain significance; FT dbSNP:rs63751258)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043945" FT VARIANT 128 FT /note="R -> L (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs63750143)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043946" FT VARIANT 144 FT /note="S -> I (in LYNCH5 and CRC; benign; normal mismatch FT repair activity; dbSNP:rs3211299)" FT /evidence="ECO:0000269|PubMed:10521294, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012955" FT VARIANT 220 FT /note="E -> D (in dbSNP:rs1800938)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012956" FT VARIANT 221 FT /note="E -> D (in dbSNP:rs41557217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042274" FT VARIANT 285 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63750878)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012957" FT VARIANT 295 FT /note="K -> R (in multiple colorectal adenoma; FT dbSNP:rs267608051)" FT /id="VAR_043947" FT VARIANT 326 FT /note="A -> V (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs587779323)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067295" FT VARIANT 340 FT /note="F -> S (in dbSNP:rs61753793)" FT /evidence="ECO:0000269|PubMed:10699937" FT /id="VAR_043948" FT VARIANT 396 FT /note="L -> V (in LYNCH5; benign; normal mismatch repair FT activity; dbSNP:rs2020908)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:22102614, ECO:0000269|Ref.4" FT /id="VAR_012958" FT VARIANT 435 FT /note="L -> P (decreased mismatch repair activity; FT dbSNP:rs63751405)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068710" FT VARIANT 449 FT /note="L -> P (in CRC and ENDMC; dbSNP:rs63750741)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043949" FT VARIANT 468 FT /note="R -> H (in dbSNP:rs41295268)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038035" FT VARIANT 492 FT /note="M -> V (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs61754783)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22102614" FT /id="VAR_042275" FT VARIANT 503 FT /note="S -> C (in LYNCH5; likely benign; normal mismatch FT repair activity; dbSNP:rs63750897)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:22102614" FT /id="VAR_038036" FT VARIANT 509 FT /note="V -> A (in dbSNP:rs63751005)" FT /evidence="ECO:0000269|PubMed:14520694" FT /id="VAR_043950" FT VARIANT 522 FT /note="Q -> R (in CRC; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63751009)" FT /evidence="ECO:0000269|PubMed:11709755, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043951" FT VARIANT 538 FT /note="Y -> S (in dbSNP:rs728619)" FT /id="VAR_038037" FT VARIANT 566 FT /note="G -> R (in CRC and LYNCH5; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63749973)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012959" FT VARIANT 580 FT /note="S -> L (in dbSNP:rs41295270)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038038" FT VARIANT 585 FT /note="L -> P (decreased mismatch repair activity; FT dbSNP:rs587779220)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068711" FT VARIANT 610 FT /note="K -> N (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs201735525)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067296" FT VARIANT 619 FT /note="E -> D (in CRC; uncertain significance; FT dbSNP:rs63751121)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043952" FT VARIANT 623 FT /note="P -> A (in dbSNP:rs3136334)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_029244" FT VARIANT 623 FT /note="P -> L (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs63750462)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043953" FT VARIANT 677 FT /note="S -> T (normal mismatch repair activity; FT dbSNP:rs587779224)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068712" FT VARIANT 685 FT /note="G -> A (in CRC; uncertain significance; FT dbSNP:rs63750358)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043954" FT VARIANT 698 FT /note="Q -> E (in HNPCC; uncertain significance; FT dbSNP:rs63750832)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012960" FT VARIANT 725 FT /note="I -> M (in CRC; uncertain significance; FT dbSNP:rs63750304)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043955" FT VARIANT 728 FT /note="K -> T (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs35552856)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043956" FT VARIANT 772 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs63750725)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043957" FT VARIANT 772 FT /note="R -> W (in LYNCH5; dbSNP:rs63750138)" FT /evidence="ECO:0000269|PubMed:14974087" FT /id="VAR_043958" FT VARIANT 787 FT /note="A -> V (in CRC; uncertain significance; FT dbSNP:rs63750637)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043959" FT VARIANT 800 FT /note="V -> A (in CRC; somatic mutation; dbSNP:rs63750895)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043960" FT VARIANT 800 FT /note="V -> L (in dbSNP:rs61748083)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012961" FT VARIANT 803 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63751450)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012962" FT VARIANT 850 FT /note="Y -> C (in LYNCH5 and CRC; uncertain significance; FT normal mismatch repair activity; dbSNP:rs63750389)" FT /evidence="ECO:0000269|PubMed:10521294, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:22102614" FT /id="VAR_012963" FT VARIANT 854 FT /note="K -> M (in CRC; uncertain significance; FT dbSNP:rs34374438)" FT /evidence="ECO:0000269|PubMed:11470537, FT ECO:0000269|PubMed:14520694" FT /id="VAR_043961" FT VARIANT 878 FT /note="V -> A (in LYNCH5, CRC and ENDMC; benign; normal FT mismatch repair activity; dbSNP:rs2020912)" FT /evidence="ECO:0000269|PubMed:11153917, FT ECO:0000269|PubMed:11470537, ECO:0000269|PubMed:11586295, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:14520694, FT ECO:0000269|PubMed:15483016, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22581703" FT /id="VAR_012964" FT VARIANT 881 FT /note="G -> KS (in LYNCH5; uncertain significance; normal FT mismatch repair activity)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076356" FT VARIANT 886 FT /note="I -> V (in dbSNP:rs2020914)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014902" FT VARIANT 901 FT /note="R -> H (in CRC and ENDMC; uncertain significance; FT dbSNP:rs63749889)" FT /evidence="ECO:0000269|PubMed:11153917" FT /id="VAR_043962" FT VARIANT 976 FT /note="R -> H (in CRC; uncertain significance; sporadic; FT normal mismatch repair activity; dbSNP:rs63751113)" FT /evidence="ECO:0000269|PubMed:11807791, FT ECO:0000269|PubMed:22102614" FT /id="VAR_012965" FT VARIANT 1021 FT /note="A -> D (in CRC; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750287)" FT /evidence="ECO:0000269|PubMed:11709755, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043963" FT VARIANT 1026 FT /note="D -> Y (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs267608054)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067297" FT VARIANT 1031 FT /note="D -> V (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs63750804)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043964" FT VARIANT 1076 FT /note="R -> C (in CRC; dbSNP:rs63750617)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043965" FT VARIANT 1087 FT /note="P -> R (in dbSNP:rs63750753)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076357" FT VARIANT 1087 FT /note="P -> S (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750998)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067298" FT VARIANT 1087 FT /note="P -> T (in CRC and LYNCH5; uncertain significance; FT dbSNP:rs63750998)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012966" FT VARIANT 1095 FT /note="R -> H (in CRC and LYNCH5; uncertain significance; FT normal mismatch repair activity; dbSNP:rs63750253)" FT /evidence="ECO:0000269|PubMed:12522549, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_043966" FT VARIANT 1100 FT /note="T -> M (in CRC; uncertain significance; FT dbSNP:rs63750442)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043967" FT VARIANT 1158 FT /note="C -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs63750157)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043968" FT VARIANT 1163 FT /note="E -> V (in LYNCH5; dbSNP:rs63750252)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043969" FT VARIANT 1193 FT /note="E -> K (in LYNCH5; decreased mismatch repair FT activity; displays marked impairment of heterodimerization FT with MSH2; dbSNP:rs63751328)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043970" FT VARIANT 1213 FT /note="D -> V (in dbSNP:rs2104526240)" FT /evidence="ECO:0000269|PubMed:7604266" FT /id="VAR_004491" FT VARIANT 1219 FT /note="T -> I (in CRC; uncertain significance; FT dbSNP:rs63750949)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043971" FT VARIANT 1225 FT /note="T -> M (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750370)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067299" FT VARIANT 1232 FT /note="V -> L (in dbSNP:rs41295276)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038039" FT VARIANT 1234 FT /note="E -> Q (in dbSNP:rs35717727)" FT /id="VAR_038040" FT VARIANT 1248 FT /note="H -> D (in CRC; uncertain significance; FT dbSNP:rs63750882)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043972" FT VARIANT 1260 FT /note="V -> I (in dbSNP:rs63750673)" FT /evidence="ECO:0000269|PubMed:7604266" FT /id="VAR_004492" FT VARIANT 1284 FT /note="T -> M (in CRC; uncertain significance; FT dbSNP:rs63750836)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043973" FT VARIANT 1321 FT /note="R -> G (in dbSNP:rs41295278)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038041" FT VARIANT 1354 FT /note="L -> Q (in CRC and LYNCH5; uncertain significance; FT normal mismatch repair activity; dbSNP:rs267608140)" FT /evidence="ECO:0000269|PubMed:12522549, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_043974" FT MUTAGEN 103 FT /note="Y->A: Abolishes binding to H3K36me3 and DNA mismatch FT repair activity." FT /evidence="ECO:0000269|PubMed:23622243" FT MUTAGEN 105..106 FT /note="WW->AA: Abolishes binding to H3K36me3 and DNA FT mismatch repair activity." FT /evidence="ECO:0000269|PubMed:23622243" FT MUTAGEN 1140 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH2 mutant R- FT 675." FT /evidence="ECO:0000269|PubMed:9564049" FT CONFLICT 36..57 FT /note="AAPGASPSPGGDAAWSEAGPGP -> GCPRGLSFPRRGCGLERGWAWA (in FT Ref. 2; BAA23674/BAA23675)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="M -> V (in Ref. 3; BAG65496)" FT /evidence="ECO:0000305" FT CONFLICT 1358..1360 FT /note="KEL -> D (in Ref. 4; AAL87401)" FT /evidence="ECO:0000305" FT STRAND 74..79 FT /evidence="ECO:0007829|PDB:2GFU" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 106..110 FT /evidence="ECO:0007829|PDB:6OQM" FT TURN 114..116 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 117..120 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 128..133 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 139..144 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 170..183 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 187..191 FT /evidence="ECO:0007829|PDB:2GFU" FT TURN 192..195 FT /evidence="ECO:0007829|PDB:2GFU" FT STRAND 197..199 FT /evidence="ECO:0007829|PDB:2GFU" FT HELIX 366..369 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 371..373 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 400..403 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 408..419 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 420..422 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 423..429 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 432..436 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 437..447 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 453..456 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 458..462 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 463..465 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 466..475 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 480..485 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 489..497 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 511..517 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 519..521 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 526..528 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 538..546 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 554..561 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 563..565 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 568..575 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 591..597 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 603..609 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 610..615 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 624..626 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 630..639 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 640..643 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 644..647 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 657..661 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 671..673 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 678..693 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 697..701 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 712..715 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 737..742 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 758..762 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 768..779 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 785..799 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 802..812 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 818..829 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 831..836 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 838..841 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 847..879 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 885..890 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 894..896 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 897..900 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 906..913 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 918..923 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 936..955 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 959..961 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 968..970 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 973..975 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 978..981 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 983..986 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 995..999 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1002..1005 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1008..1010 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1011..1041 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1044..1066 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1070..1072 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1082..1084 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1089..1094 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1111..1116 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1120..1122 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 1129..1133 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:2O8F" FT HELIX 1140..1154 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1155..1157 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1160..1167 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1171..1176 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1189..1203 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1209..1213 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1215..1218 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1221..1237 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1242..1246 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1250..1255 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1256..1258 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 1260..1269 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1285..1292 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1298..1305 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1310..1322 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1323..1326 FT /evidence="ECO:0007829|PDB:2O8F" FT TURN 1330..1332 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1347..1359 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 1360 AA; 152786 MW; 4A4AA9F8ECB8FFE9 CRC64; MSRQSTLYSF FPKSPALSDA NKASARASRE GGRAAAAPGA SPSPGGDAAW SEAGPGPRPL ARSASPPKAK NLNGGLRRSV APAAPTSCDF SPGDLVWAKM EGYPWWPCLV YNHPFDGTFI REKGKSVRVH VQFFDDSPTR GWVSKRLLKP YTGSKSKEAQ KGGHFYSAKP EILRAMQRAD EALNKDKIKR LELAVCDEPS EPEEEEEMEV GTTYVTDKSE EDNEIESEEE VQPKTQGSRR SSRQIKKRRV ISDSESDIGG SDVEFKPDTK EEGSSDEISS GVGDSESEGL NSPVKVARKR KRMVTGNGSL KRKSSRKETP SATKQATSIS SETKNTLRAF SAPQNSESQA HVSGGGDDSS RPTVWYHETL EWLKEEKRRD EHRRRPDHPD FDASTLYVPE DFLNSCTPGM RKWWQIKSQN FDLVICYKVG KFYELYHMDA LIGVSELGLV FMKGNWAHSG FPEIAFGRYS DSLVQKGYKV ARVEQTETPE MMEARCRKMA HISKYDRVVR REICRIITKG TQTYSVLEGD PSENYSKYLL SLKEKEEDSS GHTRAYGVCF VDTSLGKFFI GQFSDDRHCS RFRTLVAHYP PVQVLFEKGN LSKETKTILK SSLSCSLQEG LIPGSQFWDA SKTLRTLLEE EYFREKLSDG IGVMLPQVLK GMTSESDSIG LTPGEKSELA LSALGGCVFY LKKCLIDQEL LSMANFEEYI PLDSDTVSTT RSGAIFTKAY QRMVLDAVTL NNLEIFLNGT NGSTEGTLLE RVDTCHTPFG KRLLKQWLCA PLCNHYAIND RLDAIEDLMV VPDKISEVVE LLKKLPDLER LLSKIHNVGS PLKSQNHPDS RAIMYEETTY SKKKIIDFLS ALEGFKVMCK IIGIMEEVAD GFKSKILKQV ISLQTKNPEG RFPDLTVELN RWDTAFDHEK ARKTGLITPK AGFDSDYDQA LADIRENEQS LLEYLEKQRN RIGCRTIVYW GIGRNRYQLE IPENFTTRNL PEEYELKSTK KGCKRYWTKT IEKKLANLIN AEERRDVSLK DCMRRLFYNF DKNYKDWQSA VECIAVLDVL LCLANYSRGG DGPMCRPVIL LPEDTPPFLE LKGSRHPCIT KTFFGDDFIP NDILIGCEEE EQENGKAYCV LVTGPNMGGK STLMRQAGLL AVMAQMGCYV PAEVCRLTPI DRVFTRLGAS DRIMSGESTF FVELSETASI LMHATAHSLV LVDELGRGTA TFDGTAIANA VVKELAETIK CRTLFSTHYH SLVEDYSQNV AVRLGHMACM VENECEDPSQ ETITFLYKFI KGACPKSYGF NAARLANLPE EVIQKGHRKA REFEKMNQSL RLFREVCLAS ERSTVDAEAV HKLLTLIKEL // ID MSMB_HUMAN Reviewed; 114 AA. AC P08118; B1API6; P11999; Q13125; Q6IAY9; Q9UC59; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1988, sequence version 1. DT 28-JAN-2026, entry version 207. DE RecName: Full=Beta-microseminoprotein; DE AltName: Full=Immunoglobulin-binding factor; DE Short=IGBF; DE AltName: Full=PN44; DE AltName: Full=Prostate secreted seminal plasma protein; DE AltName: Full=Prostate secretory protein of 94 amino acids; DE Short=PSP-94; DE Short=PSP94; DE AltName: Full=Seminal plasma beta-inhibin; DE Flags: Precursor; GN Name=MSMB; Synonyms=PRSP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RX PubMed=3829888; DOI=10.1089/dna.1987.6.23; RA Mbikay M., Nolet S., Fournier S., Benjannet S., Chapdelaine P., Paradis G., RA Dube J.Y., Tremblay R., Lazure C., Seidah N.G., Chretien M.; RT "Molecular cloning and sequence of the cDNA for a 94-amino-acid seminal RT plasma protein secreted by the human prostate."; RL DNA 6:23-29(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RX PubMed=2590204; DOI=10.1016/0006-291x(89)91812-3; RA Ulvsbaeck M., Lindstroem C., Weiber H., Abrahamsson P.-A., Lilja H., RA Lundwall A.; RT "Molecular cloning of a small prostate protein, known as beta- RT microseminoprotein, PSP94 or beta-inhibin, and demonstration of transcripts RT in non-genital tissues."; RL Biochem. Biophys. Res. Commun. 164:1310-1315(1989). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2322265; DOI=10.1016/0006-291x(90)90648-7; RA Green C.B., Liu W.Y., Kwok S.C.M.; RT "Cloning and nucleotide sequence analysis of the human beta- RT microseminoprotein gene."; RL Biochem. Biophys. Res. Commun. 167:1184-1190(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2054385; DOI=10.1016/0167-4781(91)90016-f; RA Nolet S., Mbikay M., Chretien M.; RT "Prostatic secretory protein PSP94: gene organization and promoter sequence RT in rhesus monkey and human."; RL Biochim. Biophys. Acta 1089:247-249(1991). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RC TISSUE=Prostate; RX PubMed=7506990; DOI=10.1016/0304-3835(93)90049-f; RA Liu A.Y., Bradner R.C., Vessella R.L.; RT "Decreased expression of prostatic secretory protein PSP94 in prostate RT cancer."; RL Cancer Lett. 74:91-99(1993). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP57), AND TISSUE SPECIFICITY. RC TISSUE=Prostate; RX PubMed=7566962; RA Xuan J.W., Chin J.L., Guo Y., Chambers A.F., Finkelman M.A., Clarke M.W.; RT "Alternative splicing of PSP94 (prostatic secretory protein of 94 amino RT acids) mRNA in prostate tissue."; RL Oncogene 11:1041-1047(1995). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RA Baijal-Gupta M., Clarke M.W.; RT "Prostate specific protein (PSP94) expression in a human endometrial cell RT line (KLE)."; RL Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSP94). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSP94). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSP94). RC TISSUE=Prostate; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2-72. RX PubMed=10491085; DOI=10.1046/j.1432-1327.1999.00614.x; RA Maekinen M., Valtonen-Andre C., Lundwall A.; RT "New world, but not old world, monkeys carry several genes encoding beta- RT microseminoprotein."; RL Eur. J. Biochem. 264:407-414(1999). RN [13] RP PROTEIN SEQUENCE OF 21-113. RX PubMed=3995056; DOI=10.1016/0167-4838(85)90200-6; RA Akiyama K., Yoshioka Y., Schmid K., Offner G.D., Troxler R.F., Tsuda R., RA Hara M.; RT "The amino acid sequence of human beta-microseminoprotein."; RL Biochim. Biophys. Acta 829:288-294(1985). RN [14] RP PROTEIN SEQUENCE OF 21-114. RX PubMed=6434350; DOI=10.1016/0014-5793(84)80766-8; RA Seidah N.G., Arbatti N.J., Rochemont J., Sheth A.R., Chretien M.; RT "Complete amino acid sequence of human seminal plasma beta-inhibin. RT Prediction of post Gln-Arg cleavage as a maturation site."; RL FEBS Lett. 175:349-355(1984). RN [15] RP PROTEIN SEQUENCE OF 21-50 AND 113-114. RX PubMed=1930232; DOI=10.1016/s0006-291x(05)81300-2; RA Liang Z.G., Kamada M., Koide S.S.; RT "Structural identity of immunoglobulin binding factor and prostatic RT secretory protein of human seminal plasma."; RL Biochem. Biophys. Res. Commun. 180:356-359(1991). RN [16] RP PROTEIN SEQUENCE OF 21-41, AND TISSUE SPECIFICITY. RC TISSUE=Semen; RX PubMed=7671139; DOI=10.1016/1357-2725(95)00021-g; RA Ohkubo I., Tada T., Ochiai Y., Ueyama H., Eimoto T., Sasaki M.; RT "Human seminal plasma beta-microseminoprotein: its purification, RT characterization, and immunohistochemical localization."; RL Int. J. Biochem. Cell Biol. 27:603-611(1995). RN [17] RP PROTEIN SEQUENCE OF 21-32. RX PubMed=11788998; RX DOI=10.1002/1615-9861(200201)2:1<112::aid-prot112>3.3.co;2-e; RA Ghafouri B., Stahlbom B., Tagesson C., Lindahl M.; RT "Newly identified proteins in human nasal lavage fluid from non-smokers and RT smokers using two-dimensional gel electrophoresis and peptide mass RT fingerprinting."; RL Proteomics 2:112-120(2002). RN [18] RP INTERACTION WITH PI16. RX PubMed=15344909; DOI=10.1042/bj20040290; RA Reeves J.R., Xuan J.W., Arfanis K., Morin C., Garde S.V., Ruiz M.T., RA Wisniewski J., Panchal C., Tanner J.E.; RT "Identification, purification and characterization of a novel human blood RT protein with binding affinity for prostate secretory protein of 94 amino RT acids."; RL Biochem. J. 385:105-114(2005). RN [19] RP INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER. RX PubMed=18264096; DOI=10.1038/ng.91; RA Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., RA Chatterjee N., Welch R., Hutchinson A., Crenshaw A., Cancel-Tassin G., RA Staats B.J., Wang Z., Gonzalez-Bosquet J., Fang J., Deng X., Berndt S.I., RA Calle E.E., Feigelson H.S., Thun M.J., Rodriguez C., Albanes D., RA Virtamo J., Weinstein S., Schumacher F.R., Giovannucci E., Willett W.C., RA Cussenot O., Valeri A., Andriole G.L., Crawford E.D., Tucker M., RA Gerhard D.S., Fraumeni J.F. Jr., Hoover R., Hayes R.B., Hunter D.J., RA Chanock S.J.; RT "Multiple loci identified in a genome-wide association study of prostate RT cancer."; RL Nat. Genet. 40:310-315(2008). RN [20] RP INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER. RX PubMed=22887727; DOI=10.1002/humu.22176; RA Fitzgerald L.M., Zhang X., Kolb S., Kwon E.M., Liew Y.C., Hurtado-Coll A., RA Knudsen B.S., Ostrander E.A., Stanford J.L.; RT "Investigation of the relationship between prostate cancer and MSMB and RT NCOA4 genetic variants and protein expression."; RL Hum. Mutat. 34:149-156(2013). RN [21] RP STRUCTURE BY NMR OF 21-114, AND DISULFIDE BONDS. RX PubMed=16930619; DOI=10.1016/j.jmb.2006.07.029; RA Ghasriani H., Teilum K., Johnsson Y., Fernlund P., Drakenberg T.; RT "Solution structures of human and porcine beta-microseminoprotein."; RL J. Mol. Biol. 362:502-515(2006). RN [22] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 21-114, SUBUNIT, AND DISULFIDE RP BONDS. RX PubMed=20184897; DOI=10.1016/j.jmb.2010.02.035; RA Kumar A., Jagtap D.D., Mahale S.D., Kumar M.; RT "Crystal structure of prostate secretory protein PSP94 shows an edge-to- RT edge association of two monomers to form a homodimer."; RL J. Mol. Biol. 397:947-956(2010). CC -!- SUBUNIT: Homodimer; Interacts with PI16. {ECO:0000269|PubMed:15344909, CC ECO:0000269|PubMed:20184897}. CC -!- INTERACTION: CC P08118; O43765: SGTA; NbExp=3; IntAct=EBI-10195681, EBI-347996; CC -!- SUBCELLULAR LOCATION: Secreted. Note=Sperm surface. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=PSP94; CC IsoId=P08118-1; Sequence=Displayed; CC Name=PSP57; CC IsoId=P08118-2; Sequence=VSP_003275, VSP_003276; CC -!- TISSUE SPECIFICITY: Strongly expressed in prostate, liver, kidney, CC breast and penis. Also expressed in pancreas, esophagus, stomach, CC deodenum, colon, trachea, lung, salivary glands and fallopian tube. CC PSP94 is expressed in lung and breast, whereas PSP57 is found in kidney CC and bladder. {ECO:0000269|PubMed:7566962, ECO:0000269|PubMed:7671139}. CC -!- DISEASE: Prostate cancer, hereditary, 13 (HPC13) [MIM:611928]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Specific receptors for this protein are found on CC spermatozoa and in the prostate. CC -!- SIMILARITY: Belongs to the beta-microseminoprotein family. CC {ECO:0000305}. CC -!- CAUTION: Was originally thought to inhibit the secretion of FSH by CC pituitary cells. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M15885; AAA36635.1; -; mRNA. DR EMBL; M34376; AAA59871.1; -; Genomic_DNA. DR EMBL; M34373; AAA59871.1; JOINED; Genomic_DNA. DR EMBL; M34374; AAA59871.1; JOINED; Genomic_DNA. DR EMBL; M34375; AAA59871.1; JOINED; Genomic_DNA. DR EMBL; X57928; CAA41002.1; -; Genomic_DNA. DR EMBL; X57929; CAA41002.1; JOINED; Genomic_DNA. DR EMBL; X57930; CAA41002.1; JOINED; Genomic_DNA. DR EMBL; X57931; CAA41002.1; JOINED; Genomic_DNA. DR EMBL; S67815; AAB29732.1; -; mRNA. DR EMBL; U22178; AAA83556.1; -; mRNA. DR EMBL; U78976; AAB37355.1; -; mRNA. DR EMBL; BT006816; AAP35462.1; -; mRNA. DR EMBL; CR457015; CAG33296.1; -; mRNA. DR EMBL; AL450342; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC005257; AAH05257.1; -; mRNA. DR EMBL; AJ133356; CAB39325.1; -; Genomic_DNA. DR CCDS; CCDS73095.1; -. [P08118-2] DR CCDS; CCDS73096.1; -. [P08118-1] DR PIR; A34567; A34567. DR PIR; G01730; G01730. DR RefSeq; NP_002434.1; NM_002443.4. [P08118-1] DR RefSeq; NP_619540.1; NM_138634.3. [P08118-2] DR PDB; 2IZ3; NMR; -; A=21-114. DR PDB; 3IX0; X-ray; 2.30 A; A/B/C/D=21-114. DR PDBsum; 2IZ3; -. DR PDBsum; 3IX0; -. DR AlphaFoldDB; P08118; -. DR BMRB; P08118; -. DR SMR; P08118; -. DR BioGRID; 110583; 65. DR FunCoup; P08118; 65. DR IntAct; P08118; 36. DR MINT; P08118; -. DR STRING; 9606.ENSP00000463092; -. DR iPTMnet; P08118; -. DR PhosphoSitePlus; P08118; -. DR BioMuta; MSMB; -. DR DMDM; 131436; -. DR MassIVE; P08118; -. DR PaxDb; 9606-ENSP00000463092; -. DR PeptideAtlas; P08118; -. DR ProteomicsDB; 52068; -. [P08118-1] DR ProteomicsDB; 52069; -. [P08118-2] DR Antibodypedia; 72459; 774 antibodies from 31 providers. DR DNASU; 4477; -. DR Ensembl; ENST00000581478.5; ENSP00000462641.1; ENSG00000263639.7. [P08118-2] DR Ensembl; ENST00000582163.3; ENSP00000463092.1; ENSG00000263639.7. [P08118-1] DR GeneID; 4477; -. DR KEGG; hsa:4477; -. DR MANE-Select; ENST00000582163.3; ENSP00000463092.1; NM_002443.4; NP_002434.1. DR UCSC; uc001jiq.5; human. [P08118-1] DR AGR; HGNC:7372; -. DR ClinPGx; PA31177; -. DR CTD; 4477; -. DR DisGeNET; 4477; -. DR GeneCards; MSMB; -. DR HGNC; HGNC:7372; MSMB. DR HPA; ENSG00000263639; Tissue enriched (prostate). DR MalaCards; MSMB; -. DR MIM; 157145; gene. DR MIM; 611928; phenotype. DR OpenTargets; ENSG00000263639; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000263639; -. DR eggNOG; ENOG502SF48; Eukaryota. DR GeneTree; ENSGT00940000154371; -. DR HOGENOM; CLU_2637379_0_0_1; -. DR InParanoid; P08118; -. DR OMA; ETEIICC; -. DR OrthoDB; 6076852at2759; -. DR PAN-GO; P08118; 0 GO annotations based on evolutionary models. DR PhylomeDB; P08118; -. DR PathwayCommons; P08118; -. DR SignaLink; P08118; -. DR Agora; ENSG00000263639; -. DR BioGRID-ORCS; 4477; 20 hits in 1133 CRISPR screens. DR ChiTaRS; MSMB; human. DR EvolutionaryTrace; P08118; -. DR GeneWiki; MSMB; -. DR GenomeRNAi; 4477; -. DR Pharos; P08118; Tbio. DR PRO; PR:P08118; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P08118; protein. DR Bgee; ENSG00000263639; Expressed in trachea and 123 other cell types or tissues. DR ExpressionAtlas; P08118; baseline and differential. DR GO; GO:0005615; C:extracellular space; TAS:ProtInc. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR FunFam; 2.10.70.10:FF:000137; Beta-microseminoprotein; 1. DR FunFam; 2.20.25.590:FF:000001; Beta-microseminoprotein; 1. DR Gene3D; 2.20.25.590; -; 1. DR Gene3D; 2.10.70.10; Complement Module, domain 1; 1. DR InterPro; IPR008735; PSP94. DR PANTHER; PTHR10500; BETA-MICROSEMINOPROTEIN; 1. DR PANTHER; PTHR10500:SF8; BETA-MICROSEMINOPROTEIN; 1. DR Pfam; PF05825; PSP94; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Direct protein sequencing; KW Disulfide bond; Proteomics identification; Reference proteome; Secreted; KW Signal. FT SIGNAL 1..20 FT /evidence="ECO:0000269|PubMed:11788998, FT ECO:0000269|PubMed:1930232, ECO:0000269|PubMed:3995056, FT ECO:0000269|PubMed:6434350, ECO:0000269|PubMed:7671139" FT CHAIN 21..114 FT /note="Beta-microseminoprotein" FT /id="PRO_0000019268" FT DISULFID 22..70 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 38..62 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 57..93 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 60..69 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 84..107 FT VAR_SEQ 37..77 FT /note="KCMDLKGNKHPINSEWQTDNCETCTCYETEISCCTLVSTPV -> MFLHLWV FT MTKTTAKESSRRRTASISWWRRRTQKRPVLSVNG (in isoform PSP57)" FT /evidence="ECO:0000303|PubMed:7566962" FT /id="VSP_003275" FT VAR_SEQ 78..114 FT /note="Missing (in isoform PSP57)" FT /evidence="ECO:0000303|PubMed:7566962" FT /id="VSP_003276" FT VARIANT 17 FT /note="L -> S (in dbSNP:rs1804776)" FT /id="VAR_011935" FT VARIANT 25 FT /note="I -> M (in dbSNP:rs1804778)" FT /id="VAR_011936" FT VARIANT 52 FT /note="W -> R (in dbSNP:rs1804780)" FT /id="VAR_011937" FT VARIANT 53 FT /note="Q -> R (in dbSNP:rs1804468)" FT /id="VAR_011938" FT VARIANT 80 FT /note="D -> A (in dbSNP:rs1802774)" FT /id="VAR_011939" FT VARIANT 87 FT /note="I -> T (in dbSNP:rs1802771)" FT /id="VAR_011940" FT VARIANT 91 FT /note="E -> G (in dbSNP:rs1804469)" FT /id="VAR_011941" FT VARIANT 92 FT /note="D -> G (in dbSNP:rs1804461)" FT /id="VAR_011942" FT VARIANT 98 FT /note="V -> L (in dbSNP:rs1804464)" FT /id="VAR_011943" FT CONFLICT 113 FT /note="I -> G (in Ref. 14; AA sequence)" FT /evidence="ECO:0000305" FT STRAND 22..26 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 51..53 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 57..62 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 64..71 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 75..79 FT /evidence="ECO:0007829|PDB:3IX0" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 84..89 FT /evidence="ECO:0007829|PDB:3IX0" FT HELIX 90..92 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 110..113 FT /evidence="ECO:0007829|PDB:3IX0" SQ SEQUENCE 114 AA; 12865 MW; D0B13E436D70BB1D CRC64; MNVLLGSVVI FATFVTLCNA SCYFIPNEGV PGDSTRKCMD LKGNKHPINS EWQTDNCETC TCYETEISCC TLVSTPVGYD KDNCQRIFKK EDCKYIVVEK KDPKKTCSVS EWII // ID MUC1_HUMAN Reviewed; 1255 AA. AC P15941; A5YRV1; A6ZID9; A6ZIE0; B1AVQ8; B1AVR0; B6ECA1; E7ESE5; E7EUG9; AC P13931; P15942; P17626; Q0VAP5; Q0VAP6; Q14128; Q14876; Q16437; Q16442; AC Q16615; Q6S4Y3; Q7Z547; Q7Z548; Q7Z550; Q7Z552; Q9BXA4; Q9UE75; Q9UE76; AC Q9UQL1; Q9Y4J2; DT 01-APR-1990, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 3. DT 28-JAN-2026, entry version 249. DE RecName: Full=Mucin-1; DE Short=MUC-1; DE AltName: Full=Breast carcinoma-associated antigen DF3; DE AltName: Full=Cancer antigen 15-3; DE Short=CA 15-3; DE AltName: Full=Carcinoma-associated mucin; DE AltName: Full=Episialin; DE AltName: Full=H23AG; DE AltName: Full=Krebs von den Lungen-6; DE Short=KL-6; DE AltName: Full=PEMT; DE AltName: Full=Peanut-reactive urinary mucin; DE Short=PUM; DE AltName: Full=Polymorphic epithelial mucin; DE Short=PEM; DE AltName: Full=Tumor-associated epithelial membrane antigen; DE Short=EMA; DE AltName: Full=Tumor-associated mucin; DE AltName: CD_antigen=CD227; DE Contains: DE RecName: Full=Mucin-1 subunit alpha; DE Short=MUC1-NT; DE Short=MUC1-alpha; DE Contains: DE RecName: Full=Mucin-1 subunit beta; DE Short=MUC1-beta; DE AltName: Full=MUC1-CT; DE Flags: Precursor; GN Name=MUC1; Synonyms=PUM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreatic carcinoma; RX PubMed=2394722; DOI=10.1016/s0021-9258(18)77255-4; RA Lan M.S., Batra S.K., Qi W.-N., Metzgar R.S., Hollingsworth M.A.; RT "Cloning and sequencing of a human pancreatic tumor mucin cDNA."; RL J. Biol. Chem. 265:15294-15299(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=2318825; DOI=10.1016/s0021-9258(19)39399-8; RA Ligtenberg M.J.L., Vos H.L., Gennissen A.M.C., Hilkens J.; RT "Episialin, a carcinoma-associated mucin, is generated by a polymorphic RT gene encoding splice variants with alternative amino termini."; RL J. Biol. Chem. 265:5573-5578(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary carcinoma; RX PubMed=1697589; DOI=10.1016/s0021-9258(18)77254-2; RA Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., RA Burchell J., Pemberton L., Lalani E.-N., Wilson D.; RT "Molecular cloning and expression of human tumor-associated polymorphic RT epithelial mucin."; RL J. Biol. Chem. 265:15286-15293(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=2268309; DOI=10.1016/s0006-291x(05)80888-5; RA Lancaster C.A., Peat N., Duhig T., Wilson D., Taylor-Papadimitriou J., RA Gendler S.J.; RT "Structure and expression of the human polymorphic epithelial mucin gene: RT an expressed VNTR unit."; RL Biochem. Biophys. Res. Commun. 173:1019-1029(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RC TISSUE=Mammary carcinoma; RX PubMed=2351132; DOI=10.1111/j.1432-1033.1990.tb15511.x; RA Wreschner D.H., Hareuveni M., Tsarfaty I., Smorodinsky N., Horev J., RA Zaretsky J., Kotkes P., Weiss M., Lathe R., Dion A., Keydar I.; RT "Human epithelial tumor antigen cDNA sequences. Differential splicing may RT generate multiple protein forms."; RL Eur. J. Biochem. 189:463-473(1990). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Mammary carcinoma; RX PubMed=2112460; DOI=10.1111/j.1432-1033.1990.tb15512.x; RA Hareuveni M., Tsarfaty I., Zaretsky J., Kotkes P., Horev J., Zrihan S., RA Weiss M., Green S., Lathe R., Keydar I., Wreschner D.H.; RT "A transcribed gene, containing a variable number of tandem repeats, codes RT for a human epithelial tumor antigen. cDNA cloning, expression of the RT transfected gene and over-expression in breast cancer tissue."; RL Eur. J. Biochem. 189:475-486(1990). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=1688329; DOI=10.1016/0378-1119(90)90242-j; RA Tsarfaty I., Hareuveni M., Horev J., Zaretsky J., Weiss M., Jeltsch J.-M., RA Garnier J.-M., Lathe R., Keydar I., Wreschner D.H.; RT "Isolation and characterization of an expressed hypervariable gene coding RT for a breast-cancer-associated antigen."; RL Gene 93:313-318(1990). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM Y). RX PubMed=7925397; DOI=10.1111/j.1432-1033.1994.00787.x; RA Zrihan-Licht S., Vos H.L., Baruch A., Elroy-Stein O., Sagiv D., Keydar I., RA Hilkens J., Wreschner D.H.; RT "Characterization and molecular cloning of a novel MUC1 protein, devoid of RT tandem repeats, expressed in human breast cancer tissue."; RL Eur. J. Biochem. 224:787-795(1994). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; Y AND 8), AND TISSUE SPECIFICITY. RX PubMed=9212228; RX DOI=10.1002/(sici)1097-0215(19970703)72:1<87::aid-ijc13>3.0.co;2-7; RA Oosterkamp H.M., Scheiner L., Stefanova M.C., Lloyd K.O., Finstad C.L.; RT "Comparison of MUC-1 mucin expression in epithelial and non-epithelial RT cancer cell lines and demonstration of a new short variant form (MUC- RT 1/Z)."; RL Int. J. Cancer 72:87-94(1997). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZD). RX PubMed=15623537; DOI=10.1074/jbc.m406943200; RA Levitin F., Baruch A., Weiss M., Stiegman K., Hartmann M.L., RA Yoeli-Lerner M., Ziv R., Zrihan-Licht S., Shina S., Gat A., Lifschitz B., RA Simha M., Stadler Y., Cholostoy A., Gil B., Greaves D., Keydar I., RA Zaretsky J., Smorodinsky N., Wreschner D.H.; RT "A novel protein derived from the MUC1 gene by alternative splicing and RT frameshifting."; RL J. Biol. Chem. 280:10655-10663(2005). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; E2; J13; M6; S2; T10; Y-LSP AND RP ZD), ALTERNATIVE SPLICING, AND VARIANT MET-1117. RX PubMed=22941036; DOI=10.1007/s00262-012-1325-2; RA Zhang L., Vlad A., Milcarek C., Finn O.J.; RT "Human mucin MUC1 RNA undergoes different types of alternative splicing RT resulting in multiple isoforms."; RL Cancer Immunol. Immunother. 62:423-435(2013). RN [12] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 9). RC TISSUE=Carcinoma; RA Zhang L.X., Li C.H., Sun L.Y., Yue W.; RT "Cloning of a new potential secreted short variant form of MUC1 mucin in RT epithelial cancer cell line."; RL Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM Y), AND VARIANT MET-1117. RC TISSUE=Cervix carcinoma; RX PubMed=15969018; RA Zhang L.X., Li C.H., Sun L.Y., Wang M., Lu H.J.; RT "Soluble expression of peptide containing MUC1/Y-specific epitope in RT Escherichia coli and preparation of the antibody."; RL Sheng Wu Gong Cheng Xue Bao 19:337-342(2003). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM F). RA Zhang L.X., Lu H.J.; RT "Cloning of a new MUC1 short variant mRNA F from HeLa cells."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM S2). RA Zhang L.X., Lu H.J.; RT "Cloning of a new MUC1 short variant mRNA S2 from HeLa cells."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M6). RA Zhang L., Finn O.J.; RT "Isolation of MUC1 isoforms from MCF7 cells."; RL Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases. RN [17] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-1117 AND ASN-1142. RG NIEHS SNPs program; RL Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [19] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [20] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS Y AND Y-LSP). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [21] RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3417635; DOI=10.1016/s0021-9258(18)37632-4; RA Gendler S.J., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J.; RT "A highly immunogenic region of a human polymorphic epithelial mucin RT expressed by carcinomas is made up of tandem repeats."; RL J. Biol. Chem. 263:12820-12823(1988). RN [22] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-160 (ISOFORM 2). RX PubMed=2597151; DOI=10.1016/s0006-291x(89)80014-2; RA Abe M., Siddiqui J., Kufe D.; RT "Sequence analysis of the 5' region of the human DF3 breast carcinoma- RT associated antigen gene."; RL Biochem. Biophys. Res. Commun. 165:644-649(1989). RN [23] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-109 (ISOFORM 2). RC TISSUE=Thyroid; RX PubMed=8608966; RX DOI=10.1002/(sici)1097-0215(19960328)66:1<55::aid-ijc10>3.0.co;2-a; RA Weiss M., Baruch A., Keydar I., Wreschner D.H.; RT "Preoperative diagnosis of thyroid papillary carcinoma by reverse RT transcriptase polymerase chain reaction of the MUC1 gene."; RL Int. J. Cancer 66:55-59(1996). RN [24] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-89. RC TISSUE=Lung; RX PubMed=8604237; DOI=10.1159/000227547; RA Yu C.J., Yang P.C., Shew J.Y., Hong T.M., Yang S.C., Lee Y.C., Lee L.N., RA Luh K.T., Wu C.W.; RT "Mucin mRNA expression in lung adenocarcinoma cell lines and tissues."; RL Oncology 53:118-126(1996). RN [25] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-46 (ISOFORMS 3 AND 4). RC TISSUE=Mammary carcinoma; RA Buluwela L., Liu Q., Luqmani Y.A., Gomm J.J., Coombes R.C.; RL Submitted (OCT-1992) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 24-33; 28-37 AND 1098-1107, AND PROTEOLYTIC PROCESSING. RX PubMed=11341784; DOI=10.1006/bbrc.2001.4775; RA Parry S., Silverman H.S., McDermott K., Willis A., Hollingsworth M.A., RA Harris A.; RT "Identification of MUC1 proteolytic cleavage sites in vivo."; RL Biochem. Biophys. Res. Commun. 283:715-720(2001). RN [27] RP PROTEIN SEQUENCE OF 1098-1111, PROTEOLYTIC CLEAVAGE, AND MUTAGENESIS OF RP SER-1098. RX PubMed=15987679; DOI=10.1074/jbc.m506047200; RA Levitin F., Stern O., Weiss M., Gil-Henn C., Ziv R., Prokocimer Z., RA Smorodinsky N.I., Rubinstein D.B., Wreschner D.H.; RT "The MUC1 SEA module is a self-cleaving domain."; RL J. Biol. Chem. 280:33374-33386(2005). RN [28] RP PROTEIN SEQUENCE OF TANDEM REPEAT, IDENTIFICATION BY MASS SPECTROMETRY, AND RP GLYCOSYLATION. RX PubMed=10373415; DOI=10.1074/jbc.274.26.18165; RA Mueller S., Alving K., Peter-Katalinic J., Zachara N., Gooley A.A., RA Hanisch F.-G.; RT "High density O-glycosylation on tandem repeat peptide from secretory MUC1 RT of T47D breast cancer cells."; RL J. Biol. Chem. 274:18165-18172(1999). RN [29] RP PHOSPHORYLATION. RX PubMed=7988707; DOI=10.1016/0014-5793(94)01251-2; RA Zrihan-Licht S., Baruch A., Elroy-Stein O., Keydar I., Wreschner D.H.; RT "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. RT Cytokine receptor-like molecules."; RL FEBS Lett. 356:130-136(1994). RN [30] RP IDENTIFICATION IN A COMPLEX WITH SOS1 AND GRB2, INTERACTION WITH GRB2 AND RP SOS1, AND PHOSPHORYLATION. RX PubMed=7664271; RA Pandey P., Kharbanda S., Kufe D.; RT "Association of the DF3/MUC1 breast cancer antigen with Grb2 and the RT Sos/Ras exchange protein."; RL Cancer Res. 55:4000-4003(1995). RN [31] RP GLYCOSYLATION AT THR-131 AND THR-139, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=7744025; DOI=10.1111/j.1432-1033.1995.tb20448.x; RA Stadie T.R., Chai W., Lawson A.M., Byfield P.G., Hanisch F.G.; RT "Studies on the order and site specificity of GalNAc transfer to MUC1 RT tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase RT from milk or mammary carcinoma cells."; RL Eur. J. Biochem. 229:140-147(1995). RN [32] RP INTERACTION WITH CTNNB1 AND JUP, AND FUNCTION. RX PubMed=9139698; DOI=10.1074/jbc.272.19.12492; RA Yamamoto M., Bharti A., Li Y., Kufe D.; RT "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta- RT catenin in cell adhesion."; RL J. Biol. Chem. 272:12492-12494(1997). RN [33] RP GLYCOSYLATION. RX PubMed=9312074; DOI=10.1074/jbc.272.40.24780; RA Mueller S., Goletz S., Packer N.H., Gooley A.A., Lawson A.M., RA Hanisch F.-G.; RT "Localization of O-glycosylation sites on glycopeptide fragments from RT lactation-associated MUC1. All putative sites within the tandem repeat are RT glycosylation targets in vivo."; RL J. Biol. Chem. 272:24780-24793(1997). RN [34] RP DEVELOPMENTAL STAGE. RX PubMed=9536947; DOI=10.1136/gut.42.2.220; RA Reid C.J., Harris A.; RT "Developmental expression of mucin genes in the human gastrointestinal RT system."; RL Gut 42:220-226(1998). RN [35] RP GLYCOSYLATION AT THR-131 AND THR-139, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=9597769; RX DOI=10.1002/(sici)1096-9888(199804)33:4<358::aid-jms642>3.0.co;2-3; RA Hanisch F.G., Green B.N., Bateman R., Peter-Katalinic J.; RT "Localization of O-glycosylation sites of MUC1 tandem repeats by QTOF ESI RT mass spectrometry."; RL J. Mass Spectrom. 33:358-362(1998). RN [36] RP INTERACTION WITH GSK3B AND CTNNB1, PHOSPHORYLATION AT SER-1227, AND RP MUTAGENESIS OF SER-1223 AND SER-1227. RX PubMed=9819408; DOI=10.1128/mcb.18.12.7216; RA Li Y., Bharti A., Chen D., Gong J., Kufe D.; RT "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma- RT associated antigen and beta-catenin."; RL Mol. Cell. Biol. 18:7216-7224(1998). RN [37] RP CHARACTERIZATION (ISOFORM Y), AND MUTAGENESIS OF ASP-1116. RX PubMed=10197628; RA Baruch A., Hartmann M.-L., Yoeli M., Adereth Y., Greenstein S., Stadler Y., RA Skornik Y., Zaretsky J., Smorodinsky N.I., Keydar I., Wreschner D.H.; RT "The breast cancer-associated MUC1 gene generates both a receptor and its RT cognate binding protein."; RL Cancer Res. 59:1552-1561(1999). RN [38] RP INTERACTION WITH ICAM1. RX PubMed=11173916; DOI=10.1159/000051917; RA Hayashi T., Takahashi T., Motoya S., Ishida T., Itoh F., Adachi M., RA Hinoda Y., Imai K.; RT "MUC1 mucin core protein binds to the domain 1 of ICAM-1."; RL Digestion 63 Suppl. 1:87-92(2001). RN [39] RP SUBCELLULAR LOCATION. RX PubMed=11118479; DOI=10.1177/002215540104900107; RA Bennett R. Jr., Jaervelae T., Engelhardt P., Kostamovaara L., Sparks P., RA Carpen O., Turunen O., Vaheri A.; RT "Mucin MUC1 is seen in cell surface protrusions together with ezrin in RT immunoelectron tomography and is concentrated at tips of filopodial RT protrusions in MCF-7 breast carcinoma cells."; RL J. Histochem. Cytochem. 49:67-77(2001). RN [40] RP INTERACTION WITH SRC; GSK3B AND CTNNB1, PHOSPHORYLATION AT TYR-1229, AND RP MUTAGENESIS OF TYR-1229. RX PubMed=11152665; DOI=10.1074/jbc.c000754200; RA Li Y., Kuwahara H., Ren J., Wen G., Kufe D.; RT "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 RT carcinoma-associated antigen with GSK3 beta and beta-catenin."; RL J. Biol. Chem. 276:6061-6064(2001). RN [41] RP POLYMORPHISM WITHIN THE REPEAT. RX PubMed=11350974; DOI=10.1074/jbc.m103187200; RA Engelmann K., Baldus S.E., Hanisch F.-G.; RT "Identification and topology of variant sequences within individual repeat RT domains of the human epithelial tumor mucin MUC1."; RL J. Biol. Chem. 276:27764-27769(2001). RN [42] RP INTERACTION WITH EGFR, PHOSPHORYLATION AT TYR-1229 BY EGFR, AND MUTAGENESIS RP OF TYR-1191; TYR-1203; TYR-1209; TYR-1218 AND TYR-1229. RX PubMed=11483589; DOI=10.1074/jbc.c100359200; RA Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III, RA Kufe D.; RT "The epidermal growth factor receptor regulates interaction of the human RT DF3/MUC1 carcinoma antigen with c-Src and beta-catenin."; RL J. Biol. Chem. 276:35239-35242(2001). RN [43] RP PHOSPHORYLATION AT THR-1224, INTERACTION WITH PRKCD, FUNCTION, AND RP MUTAGENESIS OF SER-1223; THR-1224 AND SER-1227. RX PubMed=11877440; DOI=10.1074/jbc.m200436200; RA Ren J., Li Y., Kufe D.; RT "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma RT antigen in beta-catenin signaling."; RL J. Biol. Chem. 277:17616-17622(2002). RN [44] RP PHOSPHORYLATION AT TYR-1203; TYR-1212; TYR-1229 AND TYR-1243. RX PubMed=14521915; DOI=10.1016/j.bbrc.2003.09.030; RA Wang H., Lillehoj E.P., Kim K.C.; RT "Identification of four sites of stimulated tyrosine phosphorylation in the RT MUC1 cytoplasmic tail."; RL Biochem. Biophys. Res. Commun. 310:341-346(2003). RN [45] RP INTERACTION WITH LYN, AND PHOSPHORYLATION. RX PubMed=12750561; DOI=10.4161/cbt.2.2.282; RA Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.; RT "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin- RT 7."; RL Cancer Biol. Ther. 2:187-193(2003). RN [46] RP INTERACTION WITH CTNNB1, FUNCTION, AND MUTAGENESIS OF TYR-1229. RX PubMed=14688481; RA Huang L., Ren J., Chen D., Li Y., Kharbanda S., Kufe D.; RT "MUC1 cytoplasmic domain coactivates Wnt target gene transcription and RT confers transformation."; RL Cancer Biol. Ther. 2:702-706(2003). RN [47] RP INTERACTION WITH ADAM17, AND CLEAVAGE. RX PubMed=12441351; DOI=10.1074/jbc.m208326200; RA Thathiah A., Blobel C.P., Carson D.D.; RT "Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 RT shedding."; RL J. Biol. Chem. 278:3386-3394(2003). RN [48] RP INTERACTION WITH CTNNB1, AND SUBCELLULAR LOCATION. RX PubMed=12832415; DOI=10.1074/jbc.m304333200; RA Wen Y., Caffrey T.C., Wheelock M.J., Johnson K.R., Hollingsworth M.A.; RT "Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin."; RL J. Biol. Chem. 278:38029-38039(2003). RN [49] RP INTERACTION WITH ERBB2; ERBB3 AND ERBB4, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF 1187-ARG--LYS-1189. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [50] RP INTERACTION WITH AP1S2 AND GRB2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP TYR-1191; TYR-1203; TYR-1229 AND TYR-1243. RX PubMed=15471854; DOI=10.1074/jbc.m409360200; RA Kinlough C.L., Poland P.A., Bruns J.B., Harkleroad K.L., Hughey R.P.; RT "MUC1 membrane trafficking is modulated by multiple interactions."; RL J. Biol. Chem. 279:53071-53077(2004). RN [51] RP INTERACTION WITH TP53, AND FUNCTION. RX PubMed=15710329; DOI=10.1016/j.ccr.2005.01.008; RA Wei X., Xu H., Kufe D.; RT "Human MUC1 oncoprotein regulates p53-responsive gene transcription in the RT genotoxic stress response."; RL Cancer Cell 7:167-178(2005). RN [52] RP INTERACTION WITH GSK3B, PHOSPHORYLATION, AND FUNCTION. RX PubMed=16288032; DOI=10.1158/0008-5472.can-05-2474; RA Huang L., Chen D., Liu D., Yin L., Kharbanda S., Kufe D.; RT "MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated RT phosphorylation and degradation of beta-catenin."; RL Cancer Res. 65:10413-10422(2005). RN [53] RP ERRATUM OF PUBMED:16288032. RA Kinlough C.L., Poland P.A., Bruns J.B., Harkleroad K.L., Hughey R.P.; RL J. Biol. Chem. 280:28827-28827(2005). RN [54] RP STRUCTURE OF CARBOHYDRATES, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBCELLULAR LOCATION. RX PubMed=15972891; DOI=10.1093/glycob/cwi099; RA Engelmann K., Kinlough C.L., Muller S., Razawi H., Baldus S.E., RA Hughey R.P., Hanisch F.-G.; RT "Transmembrane and secreted MUC1 probes show trafficking-dependent changes RT in O-glycan core profiles."; RL Glycobiology 15:1111-1124(2005). RN [55] RP INTERACTION WITH LCK, PHOSPHORYLATION, FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=15513966; DOI=10.1189/jlb.0604333; RA Mukherjee P., Tinder T.L., Basu G.D., Gendler S.J.; RT "MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells RT and normal T cells."; RL J. Leukoc. Biol. 77:90-99(2005). RN [56] RP PALMITOYLATION AT CYS-1184 AND CYS-1186, SUBCELLULAR LOCATION, INTERACTION RP WITH AP1S1 AND AP1S2, AND MUTAGENESIS OF CYS-1184; CYS-1186; TYR-1203 AND RP 1187-ARG--LYS-1189. RX PubMed=16507569; DOI=10.1074/jbc.m512996200; RA Kinlough C.L., McMahan R.J., Poland P.A., Bruns J.B., Harkleroad K.L., RA Stremple R.J., Kashlan O.B., Weixel K.M., Weisz O.A., Hughey R.P.; RT "Recycling of MUC1 is dependent on its palmitoylation."; RL J. Biol. Chem. 281:12112-12122(2006). RN [57] RP INTERACTION WITH ESR1. RX PubMed=16427018; DOI=10.1016/j.molcel.2005.11.030; RA Wei X., Xu H., Kufe D.; RT "MUC1 oncoprotein stabilizes and activates estrogen receptor alpha."; RL Mol. Cell 21:295-305(2006). RN [58] RP INTERACTION WITH CTNNB1, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009; RA Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.; RT "MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism."; RL Biochim. Biophys. Acta 1773:1028-1038(2007). RN [59] RP INTERACTION WITH KLF4, AND FUNCTION. RX PubMed=17308127; DOI=10.1158/0008-5472.can-06-3063; RA Wei X., Xu H., Kufe D.; RT "Human mucin 1 oncoprotein represses transcription of the p53 tumor RT suppressor gene."; RL Cancer Res. 67:1853-1858(2007). RN [60] RP PHOSPHORYLATION AT TYR-1203; TYR-1218 AND TYR-1229, MUTAGENESIS OF TYR-1203 RP AND TYR-1218, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=17545600; DOI=10.1158/0008-5472.can-06-4647; RA Singh P.K., Wen Y., Swanson B.J., Shanmugam K., Kazlauskas A., Cerny R.L., RA Gendler S.J., Hollingsworth M.A.; RT "Platelet-derived growth factor receptor beta-mediated phosphorylation of RT MUC1 enhances invasiveness in pancreatic adenocarcinoma cells."; RL Cancer Res. 67:5201-5210(2007). RN [61] RP INTERACTION WITH EGFR, AND FUNCTION. RX PubMed=16983337; DOI=10.1038/sj.onc.1209976; RA Pochampalli M.R., el Bejjani R.M., Schroeder J.A.; RT "MUC1 is a novel regulator of ErbB1 receptor trafficking."; RL Oncogene 26:1693-1701(2007). RN [62] RP MARKER IN BREAST CANCER. RX PubMed=20816948; DOI=10.1016/j.cca.2010.08.039; RA Duffy M.J., Evoy D., McDermott E.W.; RT "CA 15-3: uses and limitation as a biomarker for breast cancer."; RL Clin. Chim. Acta 411:1869-1874(2010). RN [63] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1227, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP INVOLVEMENT IN ADTKD2. RX PubMed=23396133; DOI=10.1038/ng.2543; RA Kirby A., Gnirke A., Jaffe D.B., Baresova V., Pochet N., Blumenstiel B., RA Ye C., Aird D., Stevens C., Robinson J.T., Cabili M.N., Gat-Viks I., RA Kelliher E., Daza R., DeFelice M., Hulkova H., Sovova J., Vylet'al P., RA Antignac C., Guttman M., Handsaker R.E., Perrin D., Steelman S., RA Sigurdsson S., Scheinman S.J., Sougnez C., Cibulskis K., Parkin M., RA Green T., Rossin E., Zody M.C., Xavier R.J., Pollak M.R., Alper S.L., RA Lindblad-Toh K., Gabriel S., Hart P.S., Regev A., Nusbaum C., Kmoch S., RA Bleyer A.J., Lander E.S., Daly M.J.; RT "Mutations causing medullary cystic kidney disease type 1 lie in a large RT VNTR in MUC1 missed by massively parallel sequencing."; RL Nat. Genet. 45:299-303(2013). RN [65] RP STRUCTURE BY NMR OF 1041-1097 AND 1098-1152 OF WILD TYPE AND MUTANT RP ALA-1098, IDENTIFICATION BY MASS SPECTROMETRY, STRUCTURE OF CARBOHYDRATES, RP AND AUTOCATALYTIC CLEAVAGE. RX PubMed=16585136; DOI=10.1093/glycob/cwj110; RA Parry S., Hanisch F.G., Leir S.H., Sutton-Smith M., Morris H.R., Dell A., RA Harris A.; RT "N-glycosylation of the MUC1 mucin in epithelial cells and secretions."; RL Glycobiology 16:623-634(2006). RN [66] {ECO:0007744|PDB:7Q4I} RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 921-926 IN COMPLEX WITH RP DROSOPHILA C1GALTA; MN(2+) AND UDP. RX PubMed=35504880; DOI=10.1038/s41467-022-29833-0; RA Gonzalez-Ramirez A.M., Grosso A.S., Yang Z., Companon I., Coelho H., RA Narimatsu Y., Clausen H., Marcelo F., Corzana F., Hurtado-Guerrero R.; RT "Structural basis for the synthesis of the core 1 structure by C1GalT1."; RL Nat. Commun. 13:2398-2398(2022). CC -!- FUNCTION: The alpha subunit has cell adhesive properties. Can act both CC as an adhesion and an anti-adhesion protein. May provide a protective CC layer on epithelial cells against bacterial and enzyme attack. CC -!- FUNCTION: The beta subunit contains a C-terminal domain which is CC involved in cell signaling, through phosphorylations and protein- CC protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B CC pathways. In activated T-cells, influences directly or indirectly the CC Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated CC transcription and determines cell fate in the genotoxic stress CC response. Binds, together with KLF4, the PE21 promoter element of TP53 CC and represses TP53 activity. CC -!- SUBUNIT: The alpha subunit forms a tight, non-covalent heterodimeric CC complex with the proteolytically-released beta-subunit. Interaction, CC via the tandem repeat region, with domain 1 of ICAM1 is implicated in CC cell migration and metastases. Isoform 1 binds directly the SH2 domain CC of GRB2, and forms a MUC1/GRB2/SOS1 complex involved in RAS signaling. CC The cytoplasmic tail (MUC1CT) interacts with several proteins such as CC SRC, CTNNB1 and ERBs. Interaction with the SH2 domain of CSK decreases CC interaction with GSK3B. Interacts with CTNNB1/beta-catenin and CC JUP/gamma-catenin and promotes cell adhesion. Interaction with CC JUP/gamma-catenin is induced by heregulin. Binds PRKCD, ERBB2, ERBB3 CC and ERBB4. Heregulin (HRG) stimulates the interaction with ERBB2 and, CC to a much lesser extent, the interaction with ERBB3 and ERBB4. CC Interacts with P53 in response to DNA damage. Interacts with KLF4. CC Interacts with estrogen receptor alpha/ESR1, through its DNA-binding CC domain, and stimulates its transcription activity. Binds ADAM17. CC Isoform ZD forms disulfide-linked oligomers. CC {ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11173916, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11877440, CC ECO:0000269|PubMed:12441351, ECO:0000269|PubMed:12750561, CC ECO:0000269|PubMed:12832415, ECO:0000269|PubMed:12939402, CC ECO:0000269|PubMed:14688481, ECO:0000269|PubMed:15471854, CC ECO:0000269|PubMed:15513966, ECO:0000269|PubMed:15710329, CC ECO:0000269|PubMed:16288032, ECO:0000269|PubMed:16427018, CC ECO:0000269|PubMed:16507569, ECO:0000269|PubMed:16983337, CC ECO:0000269|PubMed:17308127, ECO:0000269|PubMed:17524503, CC ECO:0000269|PubMed:7664271, ECO:0000269|PubMed:9139698, CC ECO:0000269|PubMed:9819408}. CC -!- INTERACTION: CC P15941; P00519: ABL1; NbExp=4; IntAct=EBI-2804728, EBI-375543; CC P15941; P00533: EGFR; NbExp=6; IntAct=EBI-2804728, EBI-297353; CC P15941; P08581: MET; NbExp=2; IntAct=EBI-2804728, EBI-1039152; CC P15941; P15941-7: MUC1; NbExp=2; IntAct=EBI-2804728, EBI-4396776; CC P15941; P12931: SRC; NbExp=5; IntAct=EBI-2804728, EBI-621482; CC P15941-11; Q08AM2: ADAM33; NbExp=3; IntAct=EBI-17263240, EBI-10225815; CC P15941-11; O60242: ADGRB3; NbExp=3; IntAct=EBI-17263240, EBI-2682765; CC P15941-11; Q15848: ADIPOQ; NbExp=3; IntAct=EBI-17263240, EBI-10827839; CC P15941-11; Q86W74-2: ANKRD46; NbExp=3; IntAct=EBI-17263240, EBI-12109402; CC P15941-11; P02652: APOA2; NbExp=3; IntAct=EBI-17263240, EBI-1171525; CC P15941-11; P05067-2: APP; NbExp=3; IntAct=EBI-17263240, EBI-17264467; CC P15941-11; P29972: AQP1; NbExp=3; IntAct=EBI-17263240, EBI-745213; CC P15941-11; P41181: AQP2; NbExp=3; IntAct=EBI-17263240, EBI-12701138; CC P15941-11; Q92482: AQP3; NbExp=3; IntAct=EBI-17263240, EBI-2808854; CC P15941-11; Q9H2C2: ARV1; NbExp=3; IntAct=EBI-17263240, EBI-11724186; CC P15941-11; Q92843: BCL2L2; NbExp=3; IntAct=EBI-17263240, EBI-707714; CC P15941-11; Q6PL45-2: BRICD5; NbExp=3; IntAct=EBI-17263240, EBI-12244618; CC P15941-11; Q8WVV5: BTN2A2; NbExp=3; IntAct=EBI-17263240, EBI-8648738; CC P15941-11; P06681: C2; NbExp=3; IntAct=EBI-17263240, EBI-2835920; CC P15941-11; O14523: C2CD2L; NbExp=3; IntAct=EBI-17263240, EBI-12822627; CC P15941-11; Q06432: CACNG1; NbExp=3; IntAct=EBI-17263240, EBI-9686780; CC P15941-11; Q9P0B6: CCDC167; NbExp=3; IntAct=EBI-17263240, EBI-9083477; CC P15941-11; Q08722-3: CD47; NbExp=3; IntAct=EBI-17263240, EBI-17263290; CC P15941-11; P19397: CD53; NbExp=3; IntAct=EBI-17263240, EBI-6657396; CC P15941-11; P34810: CD68; NbExp=3; IntAct=EBI-17263240, EBI-2826276; CC P15941-11; Q8N6F1-2: CLDN19; NbExp=3; IntAct=EBI-17263240, EBI-12256978; CC P15941-11; P56747: CLDN6; NbExp=3; IntAct=EBI-17263240, EBI-12955011; CC P15941-11; Q8NHS1: CLDND2; NbExp=3; IntAct=EBI-17263240, EBI-11959453; CC P15941-11; Q96FZ5: CMTM7; NbExp=3; IntAct=EBI-17263240, EBI-2807956; CC P15941-11; Q4VAQ0: COL8A2; NbExp=3; IntAct=EBI-17263240, EBI-10241815; CC P15941-11; Q8N6G5: CSGALNACT2; NbExp=3; IntAct=EBI-17263240, EBI-10267100; CC P15941-11; Q07325: CXCL9; NbExp=3; IntAct=EBI-17263240, EBI-3911467; CC P15941-11; O43169: CYB5B; NbExp=3; IntAct=EBI-17263240, EBI-1058710; CC P15941-11; P78329: CYP4F2; NbExp=3; IntAct=EBI-17263240, EBI-1752413; CC P15941-11; P56851: EDDM3B; NbExp=3; IntAct=EBI-17263240, EBI-10215665; CC P15941-11; Q9BV81: EMC6; NbExp=3; IntAct=EBI-17263240, EBI-2820492; CC P15941-11; P54852: EMP3; NbExp=3; IntAct=EBI-17263240, EBI-3907816; CC P15941-11; O75355-2: ENTPD3; NbExp=3; IntAct=EBI-17263240, EBI-12279764; CC P15941-11; Q9UKR5: ERG28; NbExp=3; IntAct=EBI-17263240, EBI-711490; CC P15941-11; P01350: GAST; NbExp=3; IntAct=EBI-17263240, EBI-3436637; CC P15941-11; P39905-3: GDNF; NbExp=3; IntAct=EBI-17263240, EBI-12702062; CC P15941-11; Q9Y3E0: GOLT1B; NbExp=3; IntAct=EBI-17263240, EBI-4402607; CC P15941-11; Q9NPR9: GPR108; NbExp=3; IntAct=EBI-17263240, EBI-11343451; CC P15941-11; Q9HCP6: HHATL; NbExp=3; IntAct=EBI-17263240, EBI-5916693; CC P15941-11; O60725: ICMT; NbExp=3; IntAct=EBI-17263240, EBI-11721771; CC P15941-11; Q9Y5U4: INSIG2; NbExp=3; IntAct=EBI-17263240, EBI-8503746; CC P15941-11; P11215: ITGAM; NbExp=3; IntAct=EBI-17263240, EBI-2568251; CC P15941-11; Q969L2: MAL2; NbExp=3; IntAct=EBI-17263240, EBI-944295; CC P15941-11; Q13021: MALL; NbExp=3; IntAct=EBI-17263240, EBI-750078; CC P15941-11; Q9P0N8: MARCHF2; NbExp=3; IntAct=EBI-17263240, EBI-10317612; CC P15941-11; Q6N075: MFSD5; NbExp=3; IntAct=EBI-17263240, EBI-3920969; CC P15941-11; P30301: MIP; NbExp=3; IntAct=EBI-17263240, EBI-8449636; CC P15941-11; Q96S97: MYADM; NbExp=3; IntAct=EBI-17263240, EBI-13301517; CC P15941-11; O95167: NDUFA3; NbExp=3; IntAct=EBI-17263240, EBI-1246131; CC P15941-11; Q99519: NEU1; NbExp=3; IntAct=EBI-17263240, EBI-721517; CC P15941-11; Q92982: NINJ1; NbExp=3; IntAct=EBI-17263240, EBI-2802124; CC P15941-11; Q9NZG7: NINJ2; NbExp=3; IntAct=EBI-17263240, EBI-10317425; CC P15941-11; Q16617: NKG7; NbExp=3; IntAct=EBI-17263240, EBI-3919611; CC P15941-11; Q8N912: NRAC; NbExp=3; IntAct=EBI-17263240, EBI-12051377; CC P15941-11; Q8NH19: OR10AG1; NbExp=3; IntAct=EBI-17263240, EBI-13339917; CC P15941-11; Q6TCH4: PAQR6; NbExp=3; IntAct=EBI-17263240, EBI-17265310; CC P15941-11; P26678: PLN; NbExp=3; IntAct=EBI-17263240, EBI-692836; CC P15941-11; P60201-2: PLP1; NbExp=3; IntAct=EBI-17263240, EBI-12188331; CC P15941-11; Q8IY26: PLPP6; NbExp=3; IntAct=EBI-17263240, EBI-11721828; CC P15941-11; P54315: PNLIPRP1; NbExp=3; IntAct=EBI-17263240, EBI-8652812; CC P15941-11; Q59EV6: PPGB; NbExp=3; IntAct=EBI-17263240, EBI-14210385; CC P15941-11; P30405: PPIF; NbExp=3; IntAct=EBI-17263240, EBI-5544229; CC P15941-11; Q96AA3: RFT1; NbExp=3; IntAct=EBI-17263240, EBI-6269616; CC P15941-11; Q02161-2: RHD; NbExp=3; IntAct=EBI-17263240, EBI-17249212; CC P15941-11; Q8TAC9: SCAMP5; NbExp=3; IntAct=EBI-17263240, EBI-2695784; CC P15941-11; Q9Y6D0: SELENOK; NbExp=3; IntAct=EBI-17263240, EBI-9679163; CC P15941-11; Q8N6R1: SERP2; NbExp=3; IntAct=EBI-17263240, EBI-749270; CC P15941-11; P11686: SFTPC; NbExp=3; IntAct=EBI-17263240, EBI-10197617; CC P15941-11; Q8IWU4: SLC30A8; NbExp=3; IntAct=EBI-17263240, EBI-10262251; CC P15941-11; Q969S0: SLC35B4; NbExp=3; IntAct=EBI-17263240, EBI-10281213; CC P15941-11; Q6ICL7: SLC35E4; NbExp=3; IntAct=EBI-17263240, EBI-12867720; CC P15941-11; Q9NVC3: SLC38A7; NbExp=3; IntAct=EBI-17263240, EBI-10314552; CC P15941-11; Q9NRQ5: SMCO4; NbExp=3; IntAct=EBI-17263240, EBI-8640191; CC P15941-11; B2RUZ4: SMIM1; NbExp=3; IntAct=EBI-17263240, EBI-12188413; CC P15941-11; Q9NZ01: TECR; NbExp=3; IntAct=EBI-17263240, EBI-2877718; CC P15941-11; P07204: THBD; NbExp=3; IntAct=EBI-17263240, EBI-941422; CC P15941-11; Q9BZW4: TM6SF2; NbExp=3; IntAct=EBI-17263240, EBI-13082040; CC P15941-11; P17152: TMEM11; NbExp=3; IntAct=EBI-17263240, EBI-723946; CC P15941-11; A0PK00: TMEM120B; NbExp=3; IntAct=EBI-17263240, EBI-10171534; CC P15941-11; Q9BTD3: TMEM121; NbExp=3; IntAct=EBI-17263240, EBI-12155101; CC P15941-11; Q5BJH2-2: TMEM128; NbExp=3; IntAct=EBI-17263240, EBI-10694905; CC P15941-11; Q9BVK8: TMEM147; NbExp=3; IntAct=EBI-17263240, EBI-348587; CC P15941-11; Q9Y6G1: TMEM14A; NbExp=3; IntAct=EBI-17263240, EBI-2800360; CC P15941-11; Q9P0S9: TMEM14C; NbExp=3; IntAct=EBI-17263240, EBI-2339195; CC P15941-11; Q14656: TMEM187; NbExp=3; IntAct=EBI-17263240, EBI-13046724; CC P15941-11; Q8NBD8: TMEM229B; NbExp=3; IntAct=EBI-17263240, EBI-12195227; CC P15941-11; Q9BU79: TMEM243; NbExp=3; IntAct=EBI-17263240, EBI-12887458; CC P15941-11; Q8N2M4: TMEM86A; NbExp=3; IntAct=EBI-17263240, EBI-12015604; CC P15941-11; Q8N661: TMEM86B; NbExp=3; IntAct=EBI-17263240, EBI-2548832; CC P15941-11; Q5BJF2: TMEM97; NbExp=3; IntAct=EBI-17263240, EBI-12111910; CC P15941-11; Q9Y2Y6: TMEM98; NbExp=3; IntAct=EBI-17263240, EBI-7333781; CC P15941-11; O14763: TNFRSF10B; NbExp=3; IntAct=EBI-17263240, EBI-518882; CC P15941-11; Q8N609: TRAM1L1; NbExp=3; IntAct=EBI-17263240, EBI-11996766; CC P15941-11; Q5BVD1: TTMP; NbExp=3; IntAct=EBI-17263240, EBI-10243654; CC P15941-11; Q53HI1: UNC50; NbExp=3; IntAct=EBI-17263240, EBI-7601760; CC P15941-11; O95183: VAMP5; NbExp=3; IntAct=EBI-17263240, EBI-10191195; CC P15941-11; Q9BQB6: VKORC1; NbExp=3; IntAct=EBI-17263240, EBI-6256462; CC P15941-11; Q8IVQ6: ZDHHC21; NbExp=3; IntAct=EBI-17263240, EBI-2849773; CC P15941-12; P00519: ABL1; NbExp=4; IntAct=EBI-34603716, EBI-375543; CC PRO_0000317447; P17676: CEBPB; NbExp=8; IntAct=EBI-10053698, EBI-969696; CC -!- SUBCELLULAR LOCATION: Apical cell membrane CC {ECO:0000269|PubMed:11118479, ECO:0000269|PubMed:12832415, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15471854, CC ECO:0000269|PubMed:15972891, ECO:0000269|PubMed:16507569, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:17545600}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:11118479, CC ECO:0000269|PubMed:12832415, ECO:0000269|PubMed:12939402, CC ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:15972891, CC ECO:0000269|PubMed:16507569, ECO:0000269|PubMed:17524503, CC ECO:0000269|PubMed:17545600}. Note=Exclusively located in the apical CC domain of the plasma membrane of highly polarized epithelial cells. CC After endocytosis, internalized and recycled to the cell membrane. CC Located to microvilli and to the tips of long filopodial protusions. CC -!- SUBCELLULAR LOCATION: [Isoform 5]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform Y]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Secreted. CC -!- SUBCELLULAR LOCATION: [Mucin-1 subunit beta]: Cell membrane. Cytoplasm. CC Nucleus. Note=On EGF and PDGFRB stimulation, transported to the nucleus CC through interaction with CTNNB1, a process which is stimulated by CC phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin CC at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=17; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=A; CC IsoId=P15941-1; Sequence=Displayed; CC Name=2; Synonyms=B; CC IsoId=P15941-2; Sequence=VSP_003280; CC Name=3; Synonyms=C; CC IsoId=P15941-3; Sequence=VSP_003281; CC Name=4; Synonyms=D; CC IsoId=P15941-4; Sequence=VSP_003282; CC Name=5; Synonyms=SEC; CC IsoId=P15941-5; Sequence=VSP_003288, VSP_003289; CC Name=6; Synonyms=X; CC IsoId=P15941-6; Sequence=VSP_003283, VSP_003284; CC Name=Y; Synonyms=MUC1/Y; CC IsoId=P15941-7; Sequence=VSP_003285; CC Name=8; Synonyms=Z; CC IsoId=P15941-8; Sequence=VSP_003286; CC Name=9; Synonyms=S; CC IsoId=P15941-9; Sequence=VSP_003286, VSP_003287; CC Name=F; CC IsoId=P15941-10; Sequence=VSP_035046, VSP_035047; CC Name=Y-LSP; CC IsoId=P15941-11; Sequence=VSP_003280, VSP_003285; CC Name=S2; CC IsoId=P15941-12; Sequence=VSP_003280, VSP_003285, VSP_003287; CC Name=M6; CC IsoId=P15941-13; Sequence=VSP_003286, VSP_046962, VSP_046963; CC Name=ZD; Synonyms=J19; CC IsoId=P15941-14; Sequence=VSP_047575, VSP_047576; CC Name=T10; CC IsoId=P15941-15; Sequence=VSP_003280, VSP_047873; CC Name=E2; CC IsoId=P15941-16; Sequence=VSP_003280, VSP_047872; CC Name=J13; CC IsoId=P15941-17; Sequence=VSP_003280, VSP_003285, VSP_047874; CC -!- TISSUE SPECIFICITY: Expressed on the apical surface of epithelial CC cells, especially of airway passages, breast and uterus. Also expressed CC in activated and unactivated T-cells. Overexpressed in epithelial CC tumors, such as breast or ovarian cancer and also in non-epithelial CC tumor cells. Isoform Y is expressed in tumor cells only. CC {ECO:0000269|PubMed:15513966, ECO:0000269|PubMed:9212228}. CC -!- DEVELOPMENTAL STAGE: During fetal development, expressed at low levels CC in the colonic epithelium from 13 weeks of gestation. CC {ECO:0000269|PubMed:9536947}. CC -!- PTM: Highly glycosylated (N- and O-linked carbohydrates and sialic CC acid). O-glycosylated to a varying degree on serine and threonine CC residues within each tandem repeat, ranging from mono- to penta- CC glycosylation. The average density ranges from about 50% in human milk CC to over 90% in T47D breast cancer cells. Further sialylation occurs CC during recycling. Membrane-shed glycoproteins from kidney and breast CC cancer cells have preferentially sialyated core 1 structures, while CC secreted forms from the same tissues display mainly core 2 structures. CC The O-glycosylated content is overlapping in both these tissues with CC terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6- CC linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O- CC glycosylated in breast carcinomas with 3,4-linked GlcNAc. N- CC glycosylation consists of high-mannose, acidic complex-type and hybrid CC glycans in the secreted form MUC1/SEC, and neutral complex-type in the CC transmembrane form, MUC1/TM. {ECO:0000269|PubMed:10373415, CC ECO:0000269|PubMed:7744025, ECO:0000269|PubMed:9312074, CC ECO:0000269|PubMed:9597769}. CC -!- PTM: Proteolytic cleavage in the SEA domain occurs in the endoplasmic CC reticulum by an autoproteolytic mechanism and requires the full-length CC SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 CC site. Cleavage at this site also occurs on isoform MUC1/X but not on CC isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17. CC {ECO:0000269|PubMed:11341784, ECO:0000269|PubMed:12441351, CC ECO:0000269|PubMed:15987679}. CC -!- PTM: Dual palmitoylation on cysteine residues in the CQC motif is CC required for recycling from endosomes back to the plasma membrane. CC {ECO:0000269|PubMed:16507569}. CC -!- PTM: Phosphorylated on tyrosines and serine residues in the C-terminal. CC Phosphorylation on tyrosines in the C-terminal increases the nuclear CC location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces CC binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation CC of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation CC inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation CC on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3B-mediated CC phosphorylation on Ser-1227 decreases this interaction but restores the CC formation of the beta-cadherin/E-cadherin complex. On T-cell receptor CC activation, phosphorylated by LCK. PDGFR-mediated phosphorylation CC increases nuclear colocalization of MUC1CT and CTNNB1. CC {ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11483589, CC ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12750561, CC ECO:0000269|PubMed:14521915, ECO:0000269|PubMed:15513966, CC ECO:0000269|PubMed:16288032, ECO:0000269|PubMed:17545600, CC ECO:0000269|PubMed:7664271, ECO:0000269|PubMed:7988707, CC ECO:0000269|PubMed:9819408}. CC -!- PTM: The N-terminal sequence has been shown to begin at position 24 or CC 28. {ECO:0000269|PubMed:11341784}. CC -!- POLYMORPHISM: The number of repeats is highly polymorphic. It varies CC from 21 to 125 in the northern European population. The most frequent CC alleles contains 41 and 85 repeats. The tandemly repeated icosapeptide CC underlies polymorphism at three positions: CC PAPGSTAP[PAQT]AHGVTSAP[DT/ES]R, DT -> ES and the single replacements P CC -> A, P -> Q and P-> T. The most frequent replacement DT -> ES occurs CC in up to 50% of the repeats. CC -!- DISEASE: Note=MUC1/CA 15-3 is used as a serological clinical marker of CC breast cancer to monitor response to breast cancer treatment and CC disease recurrence (PubMed:20816948). Decreased levels over time may be CC indicative of a positive response to treatment. Conversely, increased CC levels may indicate disease progression. At an early stage disease, CC only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA CC 15-3 is not a useful screening test. Most antibodies target the highly CC immunodominant core peptide domain of 20 amino acid CC (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize CC glycosylated epitopes. {ECO:0000269|PubMed:20816948}. CC -!- DISEASE: Tubulointerstitial kidney disease, autosomal dominant 2 CC (ADTKD2) [MIM:174000]: A form of autosomal dominant tubulointerstitial CC kidney disease, a genetically heterogeneous disorder characterized by CC slowly progressive loss of kidney function, bland urinary sediment, CC hyperuricemia, absent or mildly increased albuminuria, lack of severe CC hypertension during the early stages, and normal or small kidneys on CC ultrasound. Renal histology shows variable abnormalities including CC interstitial fibrosis with tubular atrophy, microcystic dilatation of CC the tubules, thickening of tubular basement membranes, medullary cysts, CC and secondary glomerulosclerotic or glomerulocystic changes with CC abnormal glomerular tufting. There is significant variability, as well CC as incomplete penetrance. {ECO:0000269|PubMed:23396133}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: The name KL-6 was originally that of a murine monoclonal CC antibody reacting with pulmonary adenocarcinoma cell lines and CC pulmonary epithelial cells. This antibody recognizes a sialylated CC carbohydrate chain on MUC1. CC -!- MISCELLANEOUS: [Isoform Y-LSP]: Lacks the mucin repeats. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform ZD]: Lacks the mucin repeats. Exists as a CC disulfide-linked oligomer. {ECO:0000305}. CC -!- CAUTION: O-glycosylation sites are annotated in first sequence repeat CC only. Residues at similar position are probably glycosylated in all CC repeats. Experimental sites were determined in a synthetic peptide CC glycosylated in vitro (PubMed:7744025, PubMed:9597769). CC {ECO:0000305|PubMed:7744025, ECO:0000305|PubMed:9597769}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD14369.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAD14376.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Mucin database; CC URL="http://www.medkem.gu.se/mucinbiology/databases/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J05582; AAA60019.1; -; mRNA. DR EMBL; M32738; AAA35804.1; -; mRNA. DR EMBL; M32739; AAA35806.1; -; mRNA. DR EMBL; M34089; AAA35807.1; -; mRNA. DR EMBL; M34088; AAA35805.1; -; mRNA. DR EMBL; J05581; AAA59876.1; -; mRNA. DR EMBL; M61170; AAB53150.1; -; Genomic_DNA. DR EMBL; X52229; CAA36478.1; ALT_SEQ; mRNA. DR EMBL; X52228; CAA36477.1; ALT_SEQ; mRNA. DR EMBL; M35093; AAB59612.1; ALT_SEQ; Genomic_DNA. DR EMBL; X80761; CAA56734.1; -; mRNA. DR EMBL; U60259; AAD10856.1; -; mRNA. DR EMBL; U60260; AAD10857.1; -; mRNA. DR EMBL; U60261; AAD10858.1; -; mRNA. DR EMBL; AF125525; AAD27842.1; -; mRNA. DR EMBL; AY466157; AAR28764.1; -; mRNA. DR EMBL; AY327582; AAP97013.1; -; mRNA. DR EMBL; AY327584; AAP97015.1; -; mRNA. DR EMBL; AY327586; AAP97017.1; -; mRNA. DR EMBL; AY327587; AAP97018.1; -; mRNA. DR EMBL; EF583653; ABQ59628.1; -; mRNA. DR EMBL; EF670711; ABS01298.1; -; mRNA. DR EMBL; EF670712; ABS01299.1; -; mRNA. DR EMBL; FJ226040; ACI25172.1; -; mRNA. DR EMBL; FJ226047; ACI25179.1; -; mRNA. DR EMBL; AF348143; AAK30142.1; -; mRNA. DR EMBL; AY463543; AAR18816.1; -; Genomic_DNA. DR EMBL; AL713999; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW53116.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53117.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53118.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53119.1; -; Genomic_DNA. DR EMBL; BC120974; AAI20975.1; -; mRNA. DR EMBL; BC120975; AAI20976.1; -; mRNA. DR EMBL; Z17324; CAA78972.1; -; mRNA. DR EMBL; Z17325; CAA78973.1; -; mRNA. DR EMBL; M31823; AAA35757.1; -; mRNA. DR EMBL; S81781; AAD14376.1; ALT_INIT; mRNA. DR EMBL; S81736; AAD14369.1; ALT_INIT; mRNA. DR EMBL; M21868; AAA59874.1; ALT_SEQ; mRNA. DR CCDS; CCDS1098.1; -. [P15941-8] DR CCDS; CCDS30882.1; -. [P15941-11] DR CCDS; CCDS30883.1; -. [P15941-7] DR CCDS; CCDS41408.1; -. [P15941-12] DR CCDS; CCDS41409.1; -. [P15941-10] DR CCDS; CCDS55641.1; -. [P15941-6] DR CCDS; CCDS55642.1; -. [P15941-13] DR PIR; A35175; A35175. DR RefSeq; NP_001018016.1; NM_001018016.3. [P15941-11] DR RefSeq; NP_001018017.1; NM_001018017.3. [P15941-7] DR RefSeq; NP_001037855.1; NM_001044390.3. [P15941-10] DR RefSeq; NP_001037856.1; NM_001044391.2. DR RefSeq; NP_001037857.1; NM_001044392.3. [P15941-12] DR RefSeq; NP_001037858.1; NM_001044393.2. DR RefSeq; NP_001191214.1; NM_001204285.1. DR RefSeq; NP_001191215.1; NM_001204286.1. DR RefSeq; NP_001191216.1; NM_001204287.1. DR RefSeq; NP_001191217.1; NM_001204288.1. DR RefSeq; NP_001191218.1; NM_001204289.1. DR RefSeq; NP_001191219.1; NM_001204290.1. DR RefSeq; NP_001191220.1; NM_001204291.1. DR RefSeq; NP_001191221.1; NM_001204292.1. DR RefSeq; NP_001191222.1; NM_001204293.2. [P15941-13] DR RefSeq; NP_001191223.1; NM_001204294.2. [P15941-6] DR RefSeq; NP_001191224.1; NM_001204295.1. DR RefSeq; NP_001191225.1; NM_001204296.1. DR RefSeq; NP_001191226.1; NM_001204297.1. DR RefSeq; NP_002447.4; NM_002456.5. [P15941-8] DR PDB; 1SM3; X-ray; 1.95 A; P=919-931. DR PDB; 2ACM; NMR; -; A=1042-1097, B=1098-1152. DR PDB; 2FO4; X-ray; 2.70 A; P=140-146. DR PDB; 5T6P; X-ray; 1.97 A; E/F=921-928. DR PDB; 5T78; X-ray; 2.20 A; E/F=921-928. DR PDB; 6BSB; X-ray; 1.60 A; A=1041-1097, B=1098-1152. DR PDB; 6BSC; X-ray; 1.30 A; A=1041-1097, B=1098-1152. DR PDB; 6FZQ; X-ray; 1.70 A; P=921-926. DR PDB; 6FZR; X-ray; 1.80 A; P=921-926. DR PDB; 6KX1; X-ray; 1.77 A; C=918-932. DR PDB; 6TGG; X-ray; 2.00 A; P=921-926. DR PDB; 7Q4I; X-ray; 2.40 A; F/G=921-926. DR PDB; 7V4W; X-ray; 2.10 A; C=925-937. DR PDB; 7V64; X-ray; 1.56 A; C=925-937. DR PDB; 7V7K; X-ray; 2.20 A; C=925-937. DR PDB; 7V8Q; X-ray; 3.20 A; G/H/I=925-937. DR PDB; 7VAC; X-ray; 3.50 A; G/H/I=925-937. DR PDB; 7VAZ; X-ray; 2.73 A; E/G/I=925-937. DR PDB; 8AXH; X-ray; 1.85 A; A=921-926. DR PDB; 8P6I; X-ray; 2.50 A; A/a=921-929. DR PDB; 8S6K; X-ray; 1.75 A; M/N=927-933. DR PDB; 8S6T; X-ray; 1.85 A; C=926-938. DR PDB; 8S6V; X-ray; 1.95 A; M/N=927-935. DR PDBsum; 1SM3; -. DR PDBsum; 2ACM; -. DR PDBsum; 2FO4; -. DR PDBsum; 5T6P; -. DR PDBsum; 5T78; -. DR PDBsum; 6BSB; -. DR PDBsum; 6BSC; -. DR PDBsum; 6FZQ; -. DR PDBsum; 6FZR; -. DR PDBsum; 6KX1; -. DR PDBsum; 6TGG; -. DR PDBsum; 7Q4I; -. DR PDBsum; 7V4W; -. DR PDBsum; 7V64; -. DR PDBsum; 7V7K; -. DR PDBsum; 7V8Q; -. DR PDBsum; 7VAC; -. DR PDBsum; 7VAZ; -. DR PDBsum; 8AXH; -. DR PDBsum; 8P6I; -. DR PDBsum; 8S6K; -. DR PDBsum; 8S6T; -. DR PDBsum; 8S6V; -. DR AlphaFoldDB; P15941; -. DR SMR; P15941; -. DR BioGRID; 110669; 170. DR CORUM; P15941; -. DR DIP; DIP-41890N; -. DR FunCoup; P15941; 33. DR IntAct; P15941; 121. DR MINT; P15941; -. DR STRING; 9606.ENSP00000484824; -. DR ChEMBL; CHEMBL3580494; -. DR DrugBank; DB06373; ASI402. DR DrugBank; DB11090; Potassium nitrate. DR DrugBank; DB06584; TG4010. DR MEROPS; S71.001; -. DR GlyConnect; 372; 9 O-Linked glycans. DR GlyConnect; 373; 8 O-Linked glycans. DR GlyConnect; 374; 7 N-Linked glycans (3 sites), 8 O-Linked glycans. DR GlyConnect; 375; 10 O-Linked glycans. DR GlyConnect; 376; 10 O-Linked glycans. DR GlyConnect; 377; 7 O-Linked glycans. DR GlyConnect; 413; 5 N-Linked glycans (1 site), 14 O-Linked glycans. DR GlyCosmos; P15941; 17 sites, 54 glycans. DR GlyGen; P15941; 33 sites, 5 N-linked glycans (1 site), 37 O-linked glycans (21 sites). DR iPTMnet; P15941; -. DR PhosphoSitePlus; P15941; -. DR SwissPalm; P15941; -. DR BioMuta; MUC1; -. DR DMDM; 296439295; -. DR CPTAC; CPTAC-146; -. DR CPTAC; CPTAC-147; -. DR CPTAC; CPTAC-719; -. DR CPTAC; CPTAC-730; -. DR jPOST; P15941; -. DR MassIVE; P15941; -. DR PaxDb; 9606-ENSP00000484824; -. DR PeptideAtlas; P15941; -. DR ProteomicsDB; 1779; -. DR ProteomicsDB; 53249; -. [P15941-1] DR ProteomicsDB; 53250; -. [P15941-10] DR ProteomicsDB; 53251; -. [P15941-2] DR ProteomicsDB; 53252; -. [P15941-3] DR ProteomicsDB; 53253; -. [P15941-4] DR ProteomicsDB; 53254; -. [P15941-5] DR ProteomicsDB; 53255; -. [P15941-6] DR ProteomicsDB; 53256; -. [P15941-7] DR ProteomicsDB; 53257; -. [P15941-8] DR ProteomicsDB; 53258; -. [P15941-9] DR ProteomicsDB; 58806; -. DR ProteomicsDB; 6245; -. DR ProteomicsDB; 69255; -. DR ProteomicsDB; 69256; -. DR ProteomicsDB; 767; -. DR Pumba; P15941; -. DR ABCD; P15941; 33 sequenced antibodies. DR Antibodypedia; 1298; 4901 antibodies from 58 providers. DR CPTC; P15941; 2 antibodies. DR DNASU; 4582; -. DR Ensembl; ENST00000337604.6; ENSP00000338983.5; ENSG00000185499.17. [P15941-8] DR Ensembl; ENST00000342482.8; ENSP00000342814.4; ENSG00000185499.17. [P15941-16] DR Ensembl; ENST00000343256.9; ENSP00000339690.5; ENSG00000185499.17. [P15941-10] DR Ensembl; ENST00000368389.6; ENSP00000357374.2; ENSG00000185499.17. [P15941-9] DR Ensembl; ENST00000368390.7; ENSP00000357375.3; ENSG00000185499.17. [P15941-7] DR Ensembl; ENST00000368392.7; ENSP00000357377.3; ENSG00000185499.17. [P15941-11] DR Ensembl; ENST00000368393.7; ENSP00000357378.3; ENSG00000185499.17. [P15941-13] DR Ensembl; ENST00000368396.8; ENSP00000357381.4; ENSG00000185499.17. [P15941-12] DR Ensembl; ENST00000368398.7; ENSP00000357383.3; ENSG00000185499.17. [P15941-6] DR GeneID; 4582; -. DR KEGG; hsa:4582; -. DR UCSC; uc001fia.4; human. [P15941-1] DR AGR; HGNC:7508; -. DR ClinPGx; PA31309; -. DR CTD; 4582; -. DR DisGeNET; 4582; -. DR GeneCards; MUC1; -. DR GeneReviews; MUC1; -. DR HGNC; HGNC:7508; MUC1. DR HPA; ENSG00000185499; Tissue enhanced (kidney, stomach). DR MalaCards; MUC1; -. DR MIM; 113720; gene. DR MIM; 158340; gene. DR MIM; 174000; phenotype. DR OpenTargets; ENSG00000185499; -. DR Orphanet; 88949; MUC1-related autosomal dominant tubulointerstitial kidney disease. DR VEuPathDB; HostDB:ENSG00000185499; -. DR eggNOG; ENOG502QWCT; Eukaryota. DR GeneTree; ENSGT00710000106874; -. DR HOGENOM; CLU_1386987_0_0_1; -. DR InParanoid; P15941; -. DR OrthoDB; 9909831at2759; -. DR PAN-GO; P15941; 1 GO annotation based on evolutionary models. DR PhylomeDB; P15941; -. DR PathwayCommons; P15941; -. DR Reactome; R-HSA-5083625; Defective GALNT3 causes HFTC. DR Reactome; R-HSA-5083632; Defective C1GALT1C1 causes TNPS. DR Reactome; R-HSA-5083636; Defective GALNT12 causes CRCS1. DR Reactome; R-HSA-5621480; Dectin-2 family. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-913709; O-linked glycosylation of mucins. DR Reactome; R-HSA-977068; Termination of O-glycan biosynthesis. DR SignaLink; P15941; -. DR SIGNOR; P15941; -. DR Agora; ENSG00000185499; -. DR BioGRID-ORCS; 4582; 31 hits in 1174 CRISPR screens. DR ChiTaRS; MUC1; human. DR EvolutionaryTrace; P15941; -. DR GeneWiki; MUC1; -. DR GenomeRNAi; 4582; -. DR Pharos; P15941; Tchem. DR PRO; PR:P15941; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P15941; protein. DR Bgee; ENSG00000185499; Expressed in pylorus and 172 other cell types or tissues. DR ExpressionAtlas; P15941; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IBA:GO_Central. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031982; C:vesicle; HDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0003712; F:transcription coregulator activity; IDA:BHF-UCL. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IDA:BHF-UCL. DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:CACAO. DR GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR DisProt; DP01790; -. DR Gene3D; 6.10.140.600; -; 1. DR IDEAL; IID00195; -. DR InterPro; IPR000082; SEA_dom. DR InterPro; IPR036364; SEA_dom_sf. DR PANTHER; PTHR10006:SF19; MUCIN-1; 1. DR PANTHER; PTHR10006; MUCIN-1-RELATED; 1. DR Pfam; PF01390; SEA; 1. DR SMART; SM00200; SEA; 1. DR SUPFAM; SSF82671; SEA domain; 1. DR PROSITE; PS50024; SEA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Autocatalytic cleavage; Cell membrane; KW Cytoplasm; Direct protein sequencing; Disulfide bond; Glycoprotein; KW Lipoprotein; Membrane; Nucleus; Palmitate; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Secreted; Signal; KW Transmembrane; Transmembrane helix; Tumor suppressor. FT SIGNAL 1..23 FT /evidence="ECO:0000269|PubMed:10373415, FT ECO:0000269|PubMed:11341784" FT CHAIN 24..1255 FT /note="Mucin-1" FT /id="PRO_0000019277" FT CHAIN 24..1097 FT /note="Mucin-1 subunit alpha" FT /id="PRO_0000317446" FT CHAIN 1098..1255 FT /note="Mucin-1 subunit beta" FT /id="PRO_0000317447" FT TOPO_DOM 24..1158 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1159..1181 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1182..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 61..80 FT /note="1; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 81..100 FT /note="2; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 101..120 FT /note="3" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 121..140 FT /note="4" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 141..160 FT /note="5" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 161..180 FT /note="6" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 181..200 FT /note="7" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 201..220 FT /note="8" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 221..240 FT /note="9" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 241..260 FT /note="10" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 261..280 FT /note="11" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 281..300 FT /note="12" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 301..320 FT /note="13" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 321..340 FT /note="14" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 341..360 FT /note="15" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 361..380 FT /note="16" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 381..400 FT /note="17" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 401..420 FT /note="18" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 421..440 FT /note="19" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 441..460 FT /note="20" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 461..480 FT /note="21" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 481..500 FT /note="22" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 501..520 FT /note="23" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 521..540 FT /note="24" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 541..560 FT /note="25" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 561..580 FT /note="26" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 581..600 FT /note="27" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 601..620 FT /note="28" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 621..640 FT /note="29" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 641..660 FT /note="30" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 661..680 FT /note="31" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 681..700 FT /note="32" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 701..720 FT /note="33" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 721..740 FT /note="34" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 741..760 FT /note="35" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 761..780 FT /note="36" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 781..800 FT /note="37" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 801..820 FT /note="38" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 821..840 FT /note="39" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 841..860 FT /note="40" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 861..880 FT /note="41" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 881..900 FT /note="42" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 901..920 FT /note="43" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 921..940 FT /note="44" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 941..960 FT /note="45" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 961..980 FT /note="46; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 981..1000 FT /note="47; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 1001..1020 FT /note="48; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT DOMAIN 1039..1148 FT /note="SEA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00188" FT REGION 23..1033 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 126..965 FT /note="42 X 20 AA approximate tandem repeats of P-A-P-G-S- FT T-A-P-P-A-H-G-V-T-S-A-P-D-T-R" FT REGION 1192..1228 FT /note="Interaction with P53" FT REGION 1214..1237 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1223..1230 FT /note="Required for interaction with GSK3B" FT REGION 1233..1241 FT /note="Required for interaction with beta- and gamma- FT catenins" FT MOTIF 1203..1206 FT /note="Interaction with GRB2" FT MOTIF 1229..1232 FT /note="Interaction with SRC and ESR1" FT MOTIF 1243..1246 FT /note="Required for interaction with AP1S2" FT COMPBIAS 38..54 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 55..75 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 90..102 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 960..970 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 971..993 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1001..1033 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 1097..1098 FT /note="Cleavage; by autolysis" FT MOD_RES 1203 FT /note="Phosphotyrosine; by PDGFR" FT /evidence="ECO:0000269|PubMed:14521915, FT ECO:0000269|PubMed:17545600" FT MOD_RES 1212 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:14521915" FT MOD_RES 1218 FT /note="Phosphotyrosine; by PDGFR" FT /evidence="ECO:0000269|PubMed:17545600" FT MOD_RES 1224 FT /note="Phosphothreonine; by PKC/PRKCD" FT /evidence="ECO:0000269|PubMed:11877440" FT MOD_RES 1227 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:9819408, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1229 FT /note="Phosphotyrosine; by CSK, EGFR and SRC" FT /evidence="ECO:0000269|PubMed:11152665, FT ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:14521915, FT ECO:0000269|PubMed:17545600" FT MOD_RES 1243 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:14521915" FT LIPID 1184 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:16507569" FT LIPID 1186 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:16507569" FT CARBOHYD 131 FT /note="O-linked (GalNAc...) threonine" FT /evidence="ECO:0000305|PubMed:7744025, FT ECO:0000305|PubMed:9597769" FT CARBOHYD 139 FT /note="O-linked (GalNAc...) threonine" FT /evidence="ECO:0000305|PubMed:7744025, FT ECO:0000305|PubMed:9597769" FT CARBOHYD 140 FT /note="O-linked (GalNAc...) serine" FT /evidence="ECO:0000255" FT CARBOHYD 144 FT /note="O-linked (GalNAc...) threonine" FT /evidence="ECO:0000255" FT CARBOHYD 957 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 975 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1029 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1055 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1133 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 19..21 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.25" FT /id="VSP_003281" FT VAR_SEQ 19 FT /note="T -> TATTAPKPAT (in isoform 2, isoform Y-LSP, FT isoform E2, isoform J13, isoform S2 and isoform T10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:22941036, ECO:0000303|PubMed:2318825, FT ECO:0000303|PubMed:2597151, ECO:0000303|PubMed:8608966, FT ECO:0000303|Ref.15" FT /id="VSP_003280" FT VAR_SEQ 20..31 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.25" FT /id="VSP_003282" FT VAR_SEQ 54..1151 FT /note="Missing (in isoform E2)" FT /evidence="ECO:0000303|PubMed:22941036" FT /id="VSP_047872" FT VAR_SEQ 54..1093 FT /note="Missing (in isoform T10)" FT /evidence="ECO:0000303|PubMed:22941036" FT /id="VSP_047873" FT VAR_SEQ 54..1053 FT /note="Missing (in isoform J13, isoform Y, isoform Y-LSP FT and isoform S2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:15969018, ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:7925397, ECO:0000303|PubMed:9212228, FT ECO:0000303|Ref.15" FT /id="VSP_003285" FT VAR_SEQ 54..1035 FT /note="Missing (in isoform 8, isoform 9 and isoform M6)" FT /evidence="ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:9212228, ECO:0000303|Ref.12, FT ECO:0000303|Ref.16" FT /id="VSP_003286" FT VAR_SEQ 54..96 FT /note="VSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPASGSAATWGQ -> IPAPT FT TTKSCRETFLKCFCRFINKGVFWASPILSSGQDLWWYN (in isoform ZD)" FT /evidence="ECO:0000303|PubMed:15623537, FT ECO:0000303|PubMed:22941036" FT /id="VSP_047575" FT VAR_SEQ 54..87 FT /note="VSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPA -> IPAPTTTKSCRETF FT LKCFCRFINKGVFWASPILS (in isoform F)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_035046" FT VAR_SEQ 54..70 FT /note="VSMTSSVLSSHSPGSGS -> IPAPTTTKSCRETFLKW (in isoform FT 6)" FT /evidence="ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:9212228" FT /id="VSP_003283" FT VAR_SEQ 71..1095 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:9212228" FT /id="VSP_003284" FT VAR_SEQ 88..1139 FT /note="Missing (in isoform F)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_035047" FT VAR_SEQ 97..1255 FT /note="Missing (in isoform ZD)" FT /evidence="ECO:0000303|PubMed:15623537, FT ECO:0000303|PubMed:22941036" FT /id="VSP_047576" FT VAR_SEQ 1077..1181 FT /note="Missing (in isoform 9 and isoform S2)" FT /evidence="ECO:0000303|PubMed:22941036, ECO:0000303|Ref.12, FT ECO:0000303|Ref.15" FT /id="VSP_003287" FT VAR_SEQ 1077..1087 FT /note="FLQIYKQGGFL -> VSIGLSFPMLP (in isoform 5)" FT /evidence="ECO:0000303|PubMed:2351132" FT /id="VSP_003288" FT VAR_SEQ 1088..1255 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:2351132" FT /id="VSP_003289" FT VAR_SEQ 1141..1180 FT /note="VSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIA -> GCLSVPPK FT ELRAAGHLSSPGYLPSYERVPHLPHPWALCAP (in isoform M6)" FT /evidence="ECO:0000303|PubMed:22941036, ECO:0000303|Ref.16" FT /id="VSP_046962" FT VAR_SEQ 1181..1255 FT /note="Missing (in isoform M6)" FT /evidence="ECO:0000303|PubMed:22941036, ECO:0000303|Ref.16" FT /id="VSP_046963" FT VAR_SEQ 1232..1255 FT /note="VSAGNGGSSLSYTNPAVAATSANL -> RQNGWSTMPRGALPEESQG (in FT isoform J13)" FT /evidence="ECO:0000303|PubMed:22941036" FT /id="VSP_047874" FT VARIANT 1117 FT /note="V -> M (in dbSNP:rs1611770)" FT /evidence="ECO:0000269|PubMed:15969018, FT ECO:0000269|PubMed:22941036, ECO:0000269|Ref.17" FT /id="VAR_019390" FT VARIANT 1142 FT /note="S -> N (in dbSNP:rs11465207)" FT /evidence="ECO:0000269|Ref.17" FT /id="VAR_019391" FT MUTAGEN 1098 FT /note="S->A,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y: Completely FT abrogates cleavage." FT /evidence="ECO:0000269|PubMed:15987679" FT MUTAGEN 1098 FT /note="S->C,T: Almost complete cleavage." FT /evidence="ECO:0000269|PubMed:15987679" FT MUTAGEN 1116 FT /note="D->A: Greatly reduced formation of isoform 5/isoform FT Y complex." FT /evidence="ECO:0000269|PubMed:10197628" FT MUTAGEN 1116 FT /note="D->E: No effect on formation of isoform 5/isoform Y FT complex." FT /evidence="ECO:0000269|PubMed:10197628" FT MUTAGEN 1184 FT /note="C->A: S-palmitoylation reduced by 50%. Complete loss FT of palmitoylation, no effect on endocytosis, recycling FT inhibited and AP1S1 binding reduced by 30%; when associated FT with C-1186. Accumulates in intracellular compartments; FT when associated with C-1186 and N-1203." FT /evidence="ECO:0000269|PubMed:16507569" FT MUTAGEN 1186 FT /note="C->A: S-palmitoylation reduced by 50%. Complete loss FT of palmitoylation, no effect on endocytosis, recycling FT inhibited, and AP1S1 binding reduced by 30%; when FT associated with C-1184. Accumulates in intracellular FT compartments; when associated with C-1184 and N-1203." FT /evidence="ECO:0000269|PubMed:16507569" FT MUTAGEN 1187..1189 FT /note="RRK->AAA: No nuclear targeting of HRG-stimulated FT MUC1 C-terminal nor JUP/gamma-catenin. No effect on FT interaction with JUP/gamma-catenin." FT /evidence="ECO:0000269|PubMed:12939402, FT ECO:0000269|PubMed:16507569" FT MUTAGEN 1187..1189 FT /note="RRK->QQQ: No effect on palmitoylation." FT /evidence="ECO:0000269|PubMed:12939402, FT ECO:0000269|PubMed:16507569" FT MUTAGEN 1191 FT /note="Y->F: No effect on EGFR-mediated phosphorylation." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1191 FT /note="Y->N: No effect on endocytosis." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1203 FT /note="Y->E: No effect on nuclear colocalization of MUC1CT FT and CTNNB1. No effect on in vitro PDFGR-induced cell FT invasiveness." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:16507569, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1203 FT /note="Y->F: No effect on EGFR-mediated phosphorylation. No FT nuclear localization of MUC1CT. Reduced in vitro PDGFR- FT induced cell invasiveness." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:16507569, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1203 FT /note="Y->N: Reduced endocytosis by 30%. Greatly reduced FT binding to AP1S2 and GRB2. Binding AP1S1 reduced by 25%. FT Reduced endocytosis by 77%; when associated with N-1243. FT Accumulates in intracellular compartments; when associated FT with C-1184 and C-1186." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:16507569, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1209 FT /note="Y->F: Some reduction in EGFR-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:11483589" FT MUTAGEN 1218 FT /note="Y->F: No effect on EGFR-mediated phosphorylation. No FT nuclear colocalization of MUC1CT and CTNNB1." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1223 FT /note="S->A: No change in PRKCD- nor GSK3B-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:11877440, FT ECO:0000269|PubMed:9819408" FT MUTAGEN 1224 FT /note="T->A: Loss of PRKCD-mediated phosphorylation. FT Decreased PRKCD binding. No increased binding to CTNNB1 in FT the presence of autophosphorylated PRKCD. Increases FT formation of E-cadherin/beta-catenin complex." FT /evidence="ECO:0000269|PubMed:11877440" FT MUTAGEN 1227 FT /note="S->A: No change in PRKCD-mediated phosphorylation. FT Loss of GSK3B-mediated phosphorylation. CTNNB1." FT /evidence="ECO:0000269|PubMed:11877440, FT ECO:0000269|PubMed:9819408" FT MUTAGEN 1229 FT /note="Y->F: Greatly reduced EGFR- and Src-mediated FT phosphorylation. No nuclear localization of MUC1CT. Reduced FT in vitro PDGFR-mediated phosphorylation. Decreased Src- FT binding." FT /evidence="ECO:0000269|PubMed:11152665, FT ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:14688481, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1229 FT /note="Y->N: No effect on endocytosis." FT /evidence="ECO:0000269|PubMed:11152665, FT ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:14688481, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1243 FT /note="Y->N: Reduces binding to AP1S2 by 33%. Greatly FT reduced binding to GRB2. Reduced endocytosis by 50%. FT Reduced endocytosis by 77%; when associated with N-1203." FT /evidence="ECO:0000269|PubMed:15471854" FT CONFLICT 2 FT /note="T -> A (in Ref. 24; AAD14369)" FT /evidence="ECO:0000305" FT CONFLICT 134 FT /note="P -> Q (in Ref. 22; AAA35757)" FT /evidence="ECO:0000305" FT CONFLICT 154 FT /note="P -> Q (in Ref. 22; AAA35757)" FT /evidence="ECO:0000305" FT CONFLICT 1021 FT /note="S -> T (in Ref. 2; AAA35805/AAA35807 and 3; FT AAA59876)" FT /evidence="ECO:0000305" FT CONFLICT 1143 FT /note="D -> G (in Ref. 11; AAP97018)" FT /evidence="ECO:0000305" FT CONFLICT 1193 FT /note="Q -> L (in Ref. 13; AAK30142)" FT /evidence="ECO:0000305" FT CONFLICT 1231 FT /note="K -> T (in Ref. 9; AAD10858)" FT /evidence="ECO:0000305" FT CONFLICT 1251 FT /note="T -> A (in Ref. 1; AAA60019)" FT /evidence="ECO:0000305" FT STRAND 1042..1052 FT /evidence="ECO:0007829|PDB:2ACM" FT HELIX 1056..1059 FT /evidence="ECO:0007829|PDB:2ACM" FT HELIX 1064..1080 FT /evidence="ECO:0007829|PDB:2ACM" FT TURN 1082..1085 FT /evidence="ECO:0007829|PDB:2ACM" FT STRAND 1086..1096 FT /evidence="ECO:0007829|PDB:2ACM" FT STRAND 1099..1107 FT /evidence="ECO:0007829|PDB:2ACM" FT TURN 1109..1111 FT /evidence="ECO:0007829|PDB:2ACM" FT HELIX 1114..1132 FT /evidence="ECO:0007829|PDB:2ACM" FT STRAND 1136..1142 FT /evidence="ECO:0007829|PDB:2ACM" SQ SEQUENCE 1255 AA; 122102 MW; 5E28DFC4C20D9A82 CRC64; MTPGTQSPFF LLLLLTVLTV VTGSGHASST PGGEKETSAT QRSSVPSSTE KNAVSMTSSV LSSHSPGSGS STTQGQDVTL APATEPASGS AATWGQDVTS VPVTRPALGS TTPPAHDVTS APDNKPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDNRPALGS TAPPVHNVTS ASGSASGSAS TLVHNGTSAR ATTTPASKST PFSIPSHHSD TPTTLASHST KTDASSTHHS SVPPLTSSNH STSPQLSTGV SFFFLSFHIS NLQFNSSLED PSTDYYQELQ RDISEMFLQI YKQGGFLGLS NIKFRPGSVV VQLTLAFREG TINVHDVETQ FNQYKTEAAS RYNLTISDVS VSDVPFPFSA QSGAGVPGWG IALLVLVCVL VALAIVYLIA LAVCQCRRKN YGQLDIFPAR DTYHPMSEYP TYHTHGRYVP PSSTDRSPYE KVSAGNGGSS LSYTNPAVAA TSANL // ID NBEL1_HUMAN Reviewed; 2694 AA. AC Q6ZS30; A6NHD5; Q6Y876; Q6ZP36; Q6ZQY5; Q8N8R4; Q96Q30; Q96Q31; DT 24-JAN-2006, integrated into UniProtKB/Swiss-Prot. DT 15-JUN-2010, sequence version 3. DT 28-JAN-2026, entry version 171. DE RecName: Full=Neurobeachin-like protein 1; DE AltName: Full=Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 16 protein; DE AltName: Full=Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 17 protein; GN Name=NBEAL1; Synonyms=ALS2CR16, ALS2CR17; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-132 AND 2473-2694 (ISOFORM 2). RX PubMed=11586298; DOI=10.1038/ng1001-166; RA Hadano S., Hand C.K., Osuga H., Yanagisawa Y., Otomo A., Devon R.S., RA Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., Figlewicz D.A., RA Kwiatkowski T., Hosler B.A., Sagie T., Skaug J., Nasir J., Brown R.H. Jr., RA Scherer S.W., Rouleau G.A., Hayden M.R., Ikeda J.-E.; RT "A gene encoding a putative GTPase regulator is mutated in familial RT amyotrophic lateral sclerosis 2."; RL Nat. Genet. 29:166-173(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1268-2694 (ISOFORM 1), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 81-366 AND 1692-2694 (ISOFORM 2). RC TISSUE=Brain, Lung, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1588-2694 (ISOFORM 2), AND TISSUE RP SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=15193433; DOI=10.1016/j.molbrainres.2004.02.022; RA Chen J., Lu Y., Xu J., Huang Y., Cheng H., Hu G., Luo C., Lou M., Cao G., RA Xie Y., Ying K.; RT "Identification and characterization of NBEAL1, a novel human neurobeachin- RT like 1 protein gene from fetal brain, which is up regulated in glioma."; RL Brain Res. Mol. Brain Res. 125:147-155(2004). CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=2; CC IsoId=Q6ZS30-2; Sequence=Displayed; CC Name=1; CC IsoId=Q6ZS30-1; Sequence=VSP_039337, VSP_039338; CC -!- TISSUE SPECIFICITY: Highly expressed in brain, kidney, prostate and CC testis. Weakly expressed in ovary, small intestine, colon and CC peripheral blood leukocytes. May be correlative to several tumors, such CC as ovary serous adenocarcinoma and metastasis mammary gland carcinoma CC breast. {ECO:0000269|PubMed:15193433}. CC -!- SIMILARITY: Belongs to the WD repeat neurobeachin family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAO45288.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAB69027.1; Type=Erroneous termination; Note=Extended C-terminus.; Evidence={ECO:0000305}; CC Sequence=BAC85289.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAC87125.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAC87543.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AC011737; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AB053318; BAB69026.1; -; mRNA. DR EMBL; AB053319; BAB69027.1; ALT_SEQ; mRNA. DR EMBL; AK127772; BAC87125.1; ALT_INIT; mRNA. DR EMBL; AK128636; BAC87543.1; ALT_INIT; mRNA. DR EMBL; AK130065; BAC85289.1; ALT_INIT; mRNA. DR EMBL; AY172970; AAO45288.1; ALT_FRAME; mRNA. DR CCDS; CCDS46495.1; -. [Q6ZS30-2] DR RefSeq; NP_001107604.1; NM_001114132.2. [Q6ZS30-2] DR AlphaFoldDB; Q6ZS30; -. DR SMR; Q6ZS30; -. DR BioGRID; 122383; 32. DR FunCoup; Q6ZS30; 1382. DR IntAct; Q6ZS30; 27. DR STRING; 9606.ENSP00000399903; -. DR GlyGen; Q6ZS30; 6 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q6ZS30; -. DR PhosphoSitePlus; Q6ZS30; -. DR BioMuta; NBEAL1; -. DR DMDM; 298286908; -. DR jPOST; Q6ZS30; -. DR MassIVE; Q6ZS30; -. DR PaxDb; 9606-ENSP00000399903; -. DR PeptideAtlas; Q6ZS30; -. DR ProteomicsDB; 68187; -. [Q6ZS30-2] DR ProteomicsDB; 68188; -. [Q6ZS30-1] DR Pumba; Q6ZS30; -. DR Antibodypedia; 34160; 72 antibodies from 20 providers. DR DNASU; 65065; -. DR Ensembl; ENST00000449802.5; ENSP00000399903.1; ENSG00000144426.19. [Q6ZS30-2] DR GeneID; 65065; -. DR KEGG; hsa:65065; -. DR UCSC; uc002uzt.4; human. [Q6ZS30-2] DR AGR; HGNC:20681; -. DR ClinPGx; PA24740; -. DR CTD; 65065; -. DR DisGeNET; 65065; -. DR GeneCards; NBEAL1; -. DR HGNC; HGNC:20681; NBEAL1. DR HPA; ENSG00000144426; Low tissue specificity. DR MIM; 609816; gene. DR OpenTargets; ENSG00000144426; -. DR VEuPathDB; HostDB:ENSG00000144426; -. DR eggNOG; KOG1787; Eukaryota. DR GeneTree; ENSGT00940000155041; -. DR HOGENOM; CLU_000218_0_0_1; -. DR InParanoid; Q6ZS30; -. DR OMA; IVFKVME; -. DR OrthoDB; 26681at2759; -. DR PAN-GO; Q6ZS30; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZS30; -. DR PathwayCommons; Q6ZS30; -. DR SignaLink; Q6ZS30; -. DR Agora; ENSG00000144426; -. DR BioGRID-ORCS; 65065; 221 hits in 1153 CRISPR screens. DR ChiTaRS; NBEAL1; human. DR GenomeRNAi; 65065; -. DR Pharos; Q6ZS30; Tbio. DR PRO; PR:Q6ZS30; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q6ZS30; protein. DR Bgee; ENSG00000144426; Expressed in colonic epithelium and 176 other cell types or tissues. DR ExpressionAtlas; Q6ZS30; baseline and differential. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0019901; F:protein kinase binding; IBA:GO_Central. DR GO; GO:0008104; P:intracellular protein localization; IBA:GO_Central. DR CDD; cd06071; Beach; 1. DR CDD; cd01201; PH_BEACH; 1. DR FunFam; 1.10.1540.10:FF:000001; neurobeachin isoform X1; 1. DR Gene3D; 2.60.120.200; -; 1. DR Gene3D; 1.10.1540.10; BEACH domain; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000409; BEACH_dom. DR InterPro; IPR036372; BEACH_dom_sf. DR InterPro; IPR050865; BEACH_Domain. DR InterPro; IPR013320; ConA-like_dom_sf. DR InterPro; IPR046851; NBCH_WD40. DR InterPro; IPR031570; NBEA/BDCP_DUF4704. DR InterPro; IPR023362; PH-BEACH_dom. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR InterPro; IPR036322; WD40_repeat_dom_sf. DR InterPro; IPR001680; WD40_rpt. DR PANTHER; PTHR13743; BEIGE/BEACH-RELATED; 1. DR PANTHER; PTHR13743:SF115; NEUROBEACHIN-LIKE PROTEIN 1; 1. DR Pfam; PF02138; Beach; 1. DR Pfam; PF15787; DUF4704; 1. DR Pfam; PF16057; DUF4800; 1. DR Pfam; PF20426; NBCH_WD40; 1. DR Pfam; PF14844; PH_BEACH; 1. DR SMART; SM01026; Beach; 1. DR SMART; SM00320; WD40; 3. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF81837; BEACH domain; 1. DR SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF50978; WD40 repeat-like; 1. DR PROSITE; PS50197; BEACH; 1. DR PROSITE; PS51783; PH_BEACH; 1. DR PROSITE; PS50082; WD_REPEATS_2; 1. DR PROSITE; PS50294; WD_REPEATS_REGION; 1. PE 1: Evidence at protein level; KW Alternative splicing; Proteomics identification; Reference proteome; KW Repeat; WD repeat. FT CHAIN 1..2694 FT /note="Neurobeachin-like protein 1" FT /id="PRO_0000051094" FT DOMAIN 1883..1980 FT /note="BEACH-type PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01119" FT DOMAIN 1992..2284 FT /note="BEACH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00026" FT REPEAT 2439..2478 FT /note="WD 1" FT REPEAT 2490..2531 FT /note="WD 2" FT REGION 1289..1314 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1330..1350 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1381..1411 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1290..1314 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1383..1409 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 2279..2347 FT /note="Missing (in isoform 1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_039337" FT VAR_SEQ 2522..2542 FT /note="Missing (in isoform 1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_039338" FT CONFLICT 1763 FT /note="Q -> R (in Ref. 3; BAC87125)" FT /evidence="ECO:0000305" FT CONFLICT 2330 FT /note="I -> V (in Ref. 3; BAC87543 and 4; AAO45288)" FT /evidence="ECO:0000305" SQ SEQUENCE 2694 AA; 307237 MW; B62684F310239FA9 CRC64; MASRERLFEL WMLYCTKKDP DYLKLWLDTF VSSYEQFLDV DFEKLPTRVD DMPPGISLLP DNILQVLRIQ LLQCVQKMAD GLEEQQQALS ILLVKFFIIL CRNLSNVEEI GTCSYINYVI TMTTLYIQQL KSKKKEKEMA DQTCIEEFVI HALAFCESLY DPYRNWRHRI SGRILSTVEK SRQKYKPASL TVEFVPFFYQ CFQESEHLKE SLKCCLLHLF GAIVAGGQRN ALQAISPATM EVLMRVLADC DSWEDGDPEE VGRKAELTLK CLTEVVHILL SSNSDQRQVE TSTILENYFK LLNSDHSALP NQRRSRQWEN RFIALQIKML NTITAMLDCT DRPVLQAIFL NSNCFEHLIR LLQNCKVFQG QLDCLAISTI QALTAVMNKS PAAKEVFKER IGYTHMLEVL KSLGQPPLEL LKELMNMAVE GDHTSVGILG ISNVQPLLLL IQWLPELQSH DLQIFISDWL KRICCINRQS RTTCVNANMG IRIIETLDLH SSLHQTCAEN LIAIHGSLGS QSVSSEEIRR LLRLLRVDES ESVHPYVTPV TRAILTMARK LSLESALQYF NLSHSMAGIS VPPIQKWPGS AFSFSAWFCL DQDQLTLGIA NKGGKRKQLY SFFTGSGMGF EAFITHSGML VVAVCTKREY ATVMLPDHSF CDSLWHNITV VHMPGKRPFG QSFVYIYDNG QQKVSAPLRF PAMNEPFTSC CIGSAGQRTT TPPPSQIPDP PFSSPITPHR TSFGGILSSA SWGGTIEKSK LITKLISAGT QDSEWGCPTS LEGQLGSVII FYEPLQPPQV KALYLAGPNC LSPWKCQESD MADLPGNILL YYTAKACKNS ICLDLSTNCL HGRLTGNKVV NWDIKDIINC IGGLNVLFPL LEQISHFSEG QIPEEKNEST VPESVTPVEG DWLVWTSTKA SESRLERNLV ATFILIVKHF IQRHPINQGN LIHSHGVATL GALLQKVPST LMDVNVLMAV QLLIEQVSLE KNMQLLQQMY QYLLFDFRIW NRGDFPFRIG HIQYLSTIIK DSRRVFRKKY GVQFLLDTLR IYYGNGCKYN ELSLDDIRTI RTSLYGLIKY FLCKGGSHEE IQSIMGYIAA TNEEEQLFGI LDVLFSLLRT SPTRGQLFLL LFEPGNADIL YALLLNQKYS DRLREIIFKI MEQMLKCTNV YERSKQHIRL REVGYSGLGL LLNEALVNTS LIKNLTHQII NTDPVINFKD LLSVVYISHR AHINVRVAIC RKVLQILQFQ PDAAHQISQQ VGWQDTLVRL FLKAKFENGN TLHKHSRAVL MKDNDKNMST EDTKKNSDEK TDEEKITSFA SANVSSDQWS LEDRHSLDSN TPLFPEDSSV GELSFKSENQ EEFWHSNPSH LSLDLSGIDS CEMSDSGSQV PDSLPSTPSP VESTKSFSVH SDRESSITND MGFSDDFSLL ESQERCEEEL LQLLTHILNY VMCKGLEKSD DDTWIERGQV FSALSKPGIS SELLRPSDEI KLTLLQKMLE WAISENREAK TNPVTAENAF RLVLIIQDFL QSEGLVNSNM WTEKLLEDMM LLFDCLSVCY SESPVWVKLS QIQIQLLLGF IGRGNLQVCA MASAKLNTLL QTKVIENQDE ACYILGKLEH VLSQSIKEQT EIYSFLIPLV RTLVSKIYEL LFMNLHLPSL PFTNGSSSFF EDFQEYCNSN EWQVYIEKYI VPYMKQYEAH TFYDGHENMA LYWKDCYEAL MVNMHKRDRE GGESKLKFQE LFVEPFNRKA RQENLRYNNM LKQLSSQQLA TLRRWKAIQL YLTCERGPWA KRKQNPIHWK LANVENYSRM RLKLVPNYNF KTHEEASALR DNLGIQHSQP SSDTLLLEVV KQVKVSDMVE DKLDLPEEDI TARVNVDEKE EQDQKEKLVL MEDCELITII DVIPGRLEIT TQHIYFYDGS IEKEDGVGFD FKWPHSQIRE IHLRRYNLRR SALEIFHVDQ SNYFLNFKKE VRNKIYSRLL SLHSPNSYYG SRSPQELFKA SGLTQKWVNR EISNFDYLIQ INTMAGRTYN DLAQYPVFPW ILQDYTSEEL DLNNPAVFRD LSKPIGVVNE KNAKAMREKY ENFEDPMGTI DKFHYGTHYS NSAGVMHYLI RVEPFTTLHI QLQSGRFDCA DRQFHSIPAT WQALMDNPYD VKELIPEFFY FPEFLENQNQ FNLGRLQISK ELVNDVILPK WAKSAEDFIY KHRKALESEY VSAHLHEWID LIFGYKQRGP AAVEALNVFY YCSYEGAVDL DALTDEKERK ALEGMINNFG QTPCQLLKEP HPPRLSAEEA VQKPTKIDTS TLNLFQHLPE LKSFFIEGIS DGIPLLKATI PKNQYRSFMS QGSPELLITI SMNYVIGTHG WLPYDRNISN YFTFIKDQTV TNPKTQRSIN GSFAPGLEIT SKLFVVSHDA KLLFSAGYWD NSIQVMSLTK GKIISHIIRH MDIVTCLATD YCGIHLISGS RDTTCMIWQI TQQGGVPVGL ASKPFQILYG HTNEVLSVGI STELDMAVSG SRDGTVIIHT IQKGQYMRTL RPPCESSLFL TIPNLAISWE GHIVVYSSTE EKTTLKDKNA LHLFSINGKY LGSQILKEQV SDICIIGEHI VTGSIQGFLS IRDLHSLNLS INPLAMRLPI HCVCVTKEYS HILVGLEDGK LIVVGVGKPA EMRSGQLSRK FWGSSKRLSQ ISAGETEYNT QDSK // ID NEK8_HUMAN Reviewed; 692 AA. AC Q86SG6; A6NIC5; Q14CL7; Q2M1S6; Q8NDH1; DT 15-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 190. DE RecName: Full=Serine/threonine-protein kinase Nek8; DE EC=2.7.11.1; DE AltName: Full=Never in mitosis A-related kinase 8; DE Short=NimA-related protein kinase 8; DE AltName: Full=Nima-related protein kinase 12a; GN Name=NEK8; Synonyms=JCK, NEK12A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Huang C.Q., Wu S.L., Yu L.; RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Nedwidek M.N., Roig J., Lenz G., Avruch J.; RT "NIMA-family kinase Nek8 complete human coding region."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 445-692. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [7] RP TISSUE SPECIFICITY. RX PubMed=15019993; DOI=10.1016/j.gene.2003.12.002; RA Bowers A.J., Boylan J.F.; RT "Nek8, a NIMA family kinase member, is overexpressed in primary human RT breast tumors."; RL Gene 328:135-142(2004). RN [8] RP INVOLVEMENT IN RHPD2, FUNCTION, AND INTERACTION WITH NPHP3. RX PubMed=23418306; DOI=10.1093/hmg/ddt070; RA Frank V., Habbig S., Bartram M.P., Eisenberger T., Veenstra-Knol H.E., RA Decker C., Boorsma R.A., Goebel H., Nuernberg G., Griessmann A., Franke M., RA Borgal L., Kohli P., Voelker L.A., Doetsch J., Nuernberg P., Benzing T., RA Bolz H.J., Johnson C., Gerkes E.H., Schermer B., Bergmann C.; RT "Mutations in NEK8 link multiple organ dysplasia with altered Hippo RT signalling and increased c-MYC expression."; RL Hum. Mol. Genet. 22:2177-2185(2013). RN [9] RP INTERACTION WITH ANKS6; INVS AND NPHP3. RX PubMed=23793029; DOI=10.1038/ng.2681; RA Hoff S., Halbritter J., Epting D., Frank V., Nguyen T.M., van Reeuwijk J., RA Boehlke C., Schell C., Yasunaga T., Helmstadter M., Mergen M., Filhol E., RA Boldt K., Horn N., Ueffing M., Otto E.A., Eisenberger T., Elting M.W., RA van Wijk J.A., Bockenhauer D., Sebire N.J., Rittig S., Vyberg M., Ring T., RA Pohl M., Pape L., Neuhaus T.J., Elshakhs N.A., Koon S.J., Harris P.C., RA Grahammer F., Huber T.B., Kuehn E.W., Kramer-Zucker A., Bolz H.J., RA Roepman R., Saunier S., Walz G., Hildebrandt F., Bergmann C., RA Lienkamp S.S.; RT "ANKS6 is a central component of a nephronophthisis module linking NEK8 to RT INVS and NPHP3."; RL Nat. Genet. 45:951-956(2013). RN [10] RP INTERACTION WITH ANKS3. RX PubMed=26188091; DOI=10.1016/j.bbrc.2015.07.063; RA Ramachandran H., Engel C., Mueller B., Dengjel J., Walz G., Yakulov T.A.; RT "Anks3 alters the sub-cellular localization of the Nek7 kinase."; RL Biochem. Biophys. Res. Commun. 464:901-907(2015). RN [11] RP VARIANTS NPHP9 PHE-330; TYR-425 AND PRO-497, CHARACTERIZATION OF VARIANTS RP NPHP9 PHE-330; TYR-425 AND PRO-497, AND SUBCELLULAR LOCATION. RX PubMed=18199800; DOI=10.1681/asn.2007040490; RA Otto E.A., Trapp M.L., Schultheiss U.T., Helou J., Quarmby L.M., RA Hildebrandt F.; RT "NEK8 mutations affect ciliary and centrosomal localization and may cause RT nephronophthisis."; RL J. Am. Soc. Nephrol. 19:587-592(2008). RN [12] RP VARIANTS RHPD2 ALA-87; 127-ARG--PRO-692 DEL; SER-416; 462-ARG--PRO-692 DEL; RP SER-580 AND TRP-602, CHARACTERIZATION OF VARIANTS RHPD2 ALA-87; RP 127-ARG--PRO-692 DEL; 462-ARG--PRO-692 DEL; SER-580 AND TRP-602, RP CHARACTERIZATION OF VARIANT NPHP9 TYR-425, INTERACTION WITH ANKS6, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=26967905; DOI=10.1371/journal.pgen.1005894; RA Grampa V., Delous M., Zaidan M., Odye G., Thomas S., Elkhartoufi N., RA Filhol E., Niel O., Silbermann F., Lebreton C., Collardeau-Frachon S., RA Rouvet I., Alessandri J.L., Devisme L., Dieux-Coeslier A., Cordier M.P., RA Capri Y., Khung-Savatovsky S., Sigaudy S., Salomon R., Antignac C., RA Gubler M.C., Benmerah A., Terzi F., Attie-Bitach T., Jeanpierre C., RA Saunier S.; RT "Novel NEK8 Mutations Cause Severe Syndromic Renal Cystic Dysplasia through RT YAP Dysregulation."; RL PLoS Genet. 12:e1005894-e1005894(2016). RN [13] RP VARIANTS PKD8 TRP-45; MET-150 AND GLN-157, CHARACTERIZATION OF VARIANTS RP PKD8 TRP-45; MET-150 AND GLN-157, INVOLVEMENT IN PKD8, AND FUNCTION. RX PubMed=37598857; DOI=10.1016/j.kint.2023.07.021; RG Genomics England Research Consortium; RA Claus L.R., Chen C., Stallworth J., Turner J.L., Slaats G.G., Hawks A.L., RA Mabillard H., Senum S.R., Srikanth S., Flanagan-Steet H., Louie R.J., RA Silver J., Lerner-Ellis J., Morel C., Mighton C., Sleutels F., RA van Slegtenhorst M., van Ham T., Brooks A.S., Dorresteijn E.M., RA Barakat T.S., Dahan K., Demoulin N., Goffin E.J., Olinger E., Larsen M., RA Hertz J.M., Lilien M.R., Obeidova L., Seeman T., Stone H.K., Kerecuk L., RA Gurgu M., Yousef Yengej F.A., Ammerlaan C.M.E., Rookmaaker M.B., Hanna C., RA Rogers R.C., Duran K., Peters E., Sayer J.A., van Haaften G., Harris P.C., RA Ling K., Mason J.M., van Eerde A.M., Steet R.; RT "Certain heterozygous variants in the kinase domain of the serine/threonine RT kinase NEK8 can cause an autosomal dominant form of polycystic kidney RT disease."; RL Kidney Int. 104:995-1007(2023). RN [14] RP VARIANT PKD8 TRP-45, AND INVOLVEMENT IN PKD8. RX PubMed=36215968; DOI=10.1159/000526841; RA Mehawej C., Chouery E., Ghabril R., Tokajian S., Megarbane A.; RT "NEK8-Associated Nephropathies: Do Autosomal Dominant Forms Exist?"; RL Nephron 147:229-233(2023). CC -!- FUNCTION: Required for renal tubular integrity. May regulate local CC cytoskeletal structure in kidney tubule epithelial cells. May regulate CC ciliary biogenesis through targeting of proteins to the cilia CC (PubMed:37598857). Plays a role in organogenesis, and is involved in CC the regulation of the Hippo signaling pathway (PubMed:26967905). CC {ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:26967905, CC ECO:0000269|PubMed:37598857}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with PKD2; may regulate PKD2 targeting to the cilium CC (By similarity). Interacts with ANKS6 (PubMed:26967905). Component of a CC complex containing at least ANKS6, INVS, NEK8 and NPHP3 CC (PubMed:23418306, PubMed:23793029). ANKS6 may organize complex assembly CC by linking INVS and NPHP3 to NEK8 and INVS may target the complex to CC the proximal ciliary axoneme (PubMed:23418306, PubMed:23793029). CC Interacts with ANKS3 (PubMed:26188091). {ECO:0000250|UniProtKB:Q91ZR4, CC ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:23793029, CC ECO:0000269|PubMed:26188091}. CC -!- INTERACTION: CC Q86SG6; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-1752987, EBI-10173507; CC Q86SG6; Q6ZW76: ANKS3; NbExp=3; IntAct=EBI-1752987, EBI-949601; CC Q86SG6; Q68DC2: ANKS6; NbExp=5; IntAct=EBI-1752987, EBI-7054139; CC Q86SG6; P54253: ATXN1; NbExp=3; IntAct=EBI-1752987, EBI-930964; CC Q86SG6; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1752987, EBI-352572; CC Q86SG6; P42858: HTT; NbExp=3; IntAct=EBI-1752987, EBI-466029; CC Q86SG6; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-1752987, EBI-11953846; CC Q86SG6; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-1752987, EBI-1055945; CC Q86SG6; Q8WVJ2: NUDCD2; NbExp=3; IntAct=EBI-1752987, EBI-1052153; CC Q86SG6; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-1752987, EBI-12813389; CC Q86SG6; O76081-6: RGS20; NbExp=3; IntAct=EBI-1752987, EBI-10178530; CC Q86SG6; P15884: TCF4; NbExp=3; IntAct=EBI-1752987, EBI-533224; CC Q86SG6; Q8IWZ5: TRIM42; NbExp=3; IntAct=EBI-1752987, EBI-5235829; CC Q86SG6; Q86WT6: TRIM69; NbExp=3; IntAct=EBI-1752987, EBI-749955; CC Q86SG6; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-1752987, EBI-11525489; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18199800}. CC Cytoplasm, cytoskeleton {ECO:0000250|UniProtKB:Q91ZR4}. Cell CC projection, cilium {ECO:0000269|PubMed:18199800}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:18199800}. Cytoplasm, cytoskeleton, cilium axoneme CC {ECO:0000269|PubMed:26967905}. Note=Predominantly cytoplasmic. CC Localizes to the proximal region of the primary cilium and is not CC observed in dividing cells. {ECO:0000250|UniProtKB:Q91ZR4}. CC -!- TISSUE SPECIFICITY: Highest expression in thyroid, adrenal gland and CC skin. Low levels in spleen, colon and uterus. Overexpressed in breast CC tumors, with highest expression in infiltrating ductal carcinomas and CC moderate levels in mucinous adenocarcinoma. CC {ECO:0000269|PubMed:15019993}. CC -!- DISEASE: Nephronophthisis 9 (NPHP9) [MIM:613824]: An autosomal CC recessive disorder resulting in end-stage renal disease. It is a CC progressive tubulo-interstitial kidney disorder histologically CC characterized by modifications of the tubules with thickening of the CC basement membrane, interstitial fibrosis and, in the advanced stages, CC medullary cysts. {ECO:0000269|PubMed:18199800, CC ECO:0000269|PubMed:26967905}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Renal-hepatic-pancreatic dysplasia 2 (RHPD2) [MIM:615415]: A CC form of renal-hepatic-pancreatic dysplasia, a disease characterized by CC cystic malformations of the kidneys, liver, and pancreas. The CC pathological findings consist of multicystic dysplastic kidneys, CC dilated and dysgenetic bile ducts, a dysplastic pancreas with dilated CC ducts, cysts, fibrosis and inflammatory infiltrates. CC {ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:26967905}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Polycystic kidney disease 8 (PKD8) [MIM:620903]: A form of CC polycystic kidney disease, a disorder characterized by progressive CC formation and enlargement of cysts in both kidneys, typically leading CC to end-stage renal disease in adult life. Cysts may also occur in other CC organs, particularly the liver. PKD8 inheritance is autosomal dominant. CC {ECO:0000269|PubMed:36215968, ECO:0000269|PubMed:37598857}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY242354; AAO88243.1; -; mRNA. DR EMBL; AY267371; AAP04006.1; -; mRNA. DR EMBL; AC010761; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471159; EAW51136.1; -; Genomic_DNA. DR EMBL; BC112240; AAI12241.1; -; mRNA. DR EMBL; BC113705; AAI13706.1; -; mRNA. DR EMBL; AL833909; CAD38765.1; -; mRNA. DR CCDS; CCDS32597.1; -. DR RefSeq; NP_835464.1; NM_178170.3. DR AlphaFoldDB; Q86SG6; -. DR SMR; Q86SG6; -. DR BioGRID; 129755; 63. DR CORUM; Q86SG6; -. DR FunCoup; Q86SG6; 177. DR IntAct; Q86SG6; 64. DR STRING; 9606.ENSP00000268766; -. DR BindingDB; Q86SG6; -. DR ChEMBL; CHEMBL2417353; -. DR iPTMnet; Q86SG6; -. DR PhosphoSitePlus; Q86SG6; -. DR BioMuta; NEK8; -. DR DMDM; 34098463; -. DR jPOST; Q86SG6; -. DR MassIVE; Q86SG6; -. DR PaxDb; 9606-ENSP00000268766; -. DR PeptideAtlas; Q86SG6; -. DR ProteomicsDB; 69588; -. DR Pumba; Q86SG6; -. DR Antibodypedia; 26547; 285 antibodies from 26 providers. DR DNASU; 284086; -. DR Ensembl; ENST00000268766.11; ENSP00000268766.6; ENSG00000160602.15. DR GeneID; 284086; -. DR KEGG; hsa:284086; -. DR MANE-Select; ENST00000268766.11; ENSP00000268766.6; NM_178170.3; NP_835464.1. DR UCSC; uc002hcp.4; human. DR AGR; HGNC:13387; -. DR ClinPGx; PA38361; -. DR CTD; 284086; -. DR DisGeNET; 284086; -. DR GeneCards; NEK8; -. DR GeneReviews; NEK8; -. DR HGNC; HGNC:13387; NEK8. DR HPA; ENSG00000160602; Low tissue specificity. DR MalaCards; NEK8; -. DR MIM; 609799; gene. DR MIM; 613824; phenotype. DR MIM; 615415; phenotype. DR MIM; 620903; phenotype. DR OpenTargets; ENSG00000160602; -. DR Orphanet; 730; Autosomal dominant polycystic kidney disease. DR Orphanet; 93591; Infantile nephronophthisis. DR Orphanet; 294415; Renal-hepatic-pancreatic dysplasia. DR VEuPathDB; HostDB:ENSG00000160602; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000159297; -. DR HOGENOM; CLU_000288_123_1_1; -. DR InParanoid; Q86SG6; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q86SG6; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q86SG6; -. DR PathwayCommons; Q86SG6; -. DR SignaLink; Q86SG6; -. DR SIGNOR; Q86SG6; -. DR Agora; ENSG00000160602; -. DR BioGRID-ORCS; 284086; 18 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR GeneWiki; NEK8; -. DR GenomeRNAi; 284086; -. DR Pharos; Q86SG6; Tchem. DR PRO; PR:Q86SG6; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q86SG6; protein. DR Bgee; ENSG00000160602; Expressed in buccal mucosa cell and 133 other cell types or tissues. DR ExpressionAtlas; Q86SG6; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0097546; C:ciliary base; IEA:Ensembl. DR GO; GO:0097543; C:ciliary inversin compartment; IEA:Ensembl. DR GO; GO:0005929; C:cilium; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; IMP:UniProtKB. DR GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035330; P:regulation of hippo signaling; IDA:UniProtKB. DR CDD; cd08220; STKc_Nek8; 1. DR FunFam; 1.10.510.10:FF:000262; Serine/threonine-protein kinase Nek8; 1. DR FunFam; 2.130.10.30:FF:000017; Serine/threonine-protein kinase Nek8; 1. DR FunFam; 2.130.10.30:FF:000020; serine/threonine-protein kinase Nek8; 1. DR FunFam; 3.30.200.20:FF:000243; serine/threonine-protein kinase Nek8; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.130.10.30; Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR058923; RCC1-like_dom. DR InterPro; IPR009091; RCC1/BLIP-II. DR InterPro; IPR000408; Reg_chr_condens. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051997; STK_NEK. DR InterPro; IPR044120; STKc_Nek8. DR PANTHER; PTHR44535; PROTEIN CBG16200; 1. DR PANTHER; PTHR44535:SF4; SERINE_THREONINE-PROTEIN KINASE NEK8; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF25390; WD40_RLD; 1. DR PRINTS; PR00633; RCCNDNSATION. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50985; RCC1/BLIP-II; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50012; RCC1_3; 5. PE 1: Evidence at protein level; KW ATP-binding; Cell projection; Ciliopathy; Cilium; Cytoplasm; Cytoskeleton; KW Disease variant; Kinase; Magnesium; Metal-binding; Nephronophthisis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..692 FT /note="Serine/threonine-protein kinase Nek8" FT /id="PRO_0000086432" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 312..350 FT /note="RCC1 1" FT REPEAT 410..461 FT /note="RCC1 2" FT REPEAT 462..513 FT /note="RCC1 3" FT REPEAT 580..631 FT /note="RCC1 4" FT REPEAT 632..684 FT /note="RCC1 5" FT REGION 277..301 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..293 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT VARIANT 45 FT /note="R -> W (in PKD8; pathogenic; fails to rescue FT defective PKD2 targeting to cilia in NEK8-deficient FT epithelial renal cells; decreased autophosphorylation; FT dbSNP:rs1567759130)" FT /evidence="ECO:0000269|PubMed:36215968, FT ECO:0000269|PubMed:37598857" FT /id="VAR_089841" FT VARIANT 87 FT /note="T -> A (in RHPD2; likely pathogenic; contrary to the FT wild type, it fails to rescue body curvature defects in FT zebrafish morphants; decreased localization to cilia; FT decreased interaction with ANKS6; dbSNP:rs1555563787)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089842" FT VARIANT 127..692 FT /note="Missing (in RHPD2; likely pathogenic; loss of FT protein expression)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089843" FT VARIANT 150 FT /note="I -> M (in PKD8; uncertain significance; it rescues FT ciliary defects when transfected in NEK8-deficient FT epithelial renal cells)" FT /evidence="ECO:0000269|PubMed:37598857" FT /id="VAR_089844" FT VARIANT 157 FT /note="K -> Q (in PKD8; likely pathogenic; contrary to the FT wild type, it does not rescue ciliary defects when FT transfected in NEK8-deficient epithelial renal cells)" FT /evidence="ECO:0000269|PubMed:37598857" FT /id="VAR_089845" FT VARIANT 330 FT /note="L -> F (in NPHP9; a full-length mouse NEK8 construct FT containing the mutation shows a defect in ciliary FT localization with no apparent effect on ciliation, mitosis FT or centriole number; dbSNP:rs199962228)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065769" FT VARIANT 416 FT /note="G -> S (in RHPD2; uncertain significance; FT dbSNP:rs199823733)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089846" FT VARIANT 425 FT /note="H -> Y (in NPHP9; loss of ciliary localization; a FT full-length mouse NEK8 construct containing the mutation FT shows a defect in ciliary localization with no apparent FT effect on ciliation, mitosis or centriole number; no effect FT on interaction with ANKS6; dbSNP:rs118204032)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065770" FT VARIANT 462..692 FT /note="Missing (in RHPD2; likely pathogenic; loss of FT protein expression)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089847" FT VARIANT 497 FT /note="A -> P (in NPHP9; a full-length mouse NEK8 construct FT containing the mutation shows a defect in ciliary FT localization with no apparent effect on ciliation, mitosis FT or centriole number; dbSNP:rs146326420)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065771" FT VARIANT 580 FT /note="G -> S (in RHPD2; likely pathogenic; loss of ciliary FT localization; no effect on interaction with ANKS6; FT dbSNP:rs751440831)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089848" FT VARIANT 602 FT /note="R -> W (in RHPD2; likely pathogenic; contrary to the FT wild type, it fails to rescue body curvature defects in FT zebrafish morphants; loss of ciliary localization; no FT effect on interaction with ANKS6; dbSNP:rs773883764)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089849" SQ SEQUENCE 692 AA; 74806 MW; 9E09820DFB3D5CA1 CRC64; MEKYERIRVV GRGAFGIVHL CLRKADQKLV IIKQIPVEQM TKEERQAAQN ECQVLKLLNH PNVIEYYENF LEDKALMIAM EYAPGGTLAE FIQKRCNSLL EEETILHFFV QILLALHHVH THLILHRDLK TQNILLDKHR MVVKIGDFGI SKILSSKSKA YTVVGTPCYI SPELCEGKPY NQKSDIWALG CVLYELASLK RAFEAANLPA LVLKIMSGTF APISDRYSPE LRQLVLSLLS LEPAQRPPLS HIMAQPLCIR ALLNLHTDVG SVRMRRAEKS VAPSNTGSRT TSVRCRGIPR GPVRPAIPPP LSSVYAWGGG LGTPLRLPML NTEVVQVAAG RTQKAGVTRS GRLILWEAPP LGAGGGSLLP GAVEQPQPQF ISRFLEGQSG VTIKHVACGD FFTACLTDRG IIMTFGSGSN GCLGHGSLTD ISQPTIVEAL LGYEMVQVAC GASHVLALST ERELFAWGRG DSGRLGLGTR ESHSCPQQVP MPPGQEAQRV VCGIDSSMIL TVPGQALACG SNRFNKLGLD HLSLGEEPVP HQQVEEALSF TLLGSAPLDQ EPLLSIDLGT AHSAAVTASG DCYTFGSNQH GQLGTNTRRG SRAPCKVQGL EGIKMAMVAC GDAFTVAIGA ESEVYSWGKG ARGRLGRRDE DAGLPRPVQL DETHPYTVTS VSCCHGNTLL AVRSVTDEPV PP // ID NF1_HUMAN Reviewed; 2839 AA. AC P21359; O00662; Q14284; Q14930; Q14931; Q9UMK3; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 2. DT 28-JAN-2026, entry version 262. DE RecName: Full=Neurofibromin; DE AltName: Full=Neurofibromatosis-related protein NF-1; DE Contains: DE RecName: Full=Neurofibromin truncated; GN Name=NF1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS I AND II). RX PubMed=1457041; DOI=10.1089/dna.1992.11.727; RA Bernards A., Haase V.H., Murthy A.E., Menon A., Hannigan G.E., RA Gusella J.F.; RT "Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and RT absence of expression in a neuroblastoma line."; RL DNA Cell Biol. 11:727-734(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I). RX PubMed=2134734; DOI=10.1126/science.2134734; RA Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., RA Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., RA Brownstein B.H., Collins F.S.; RT "Type 1 neurofibromatosis gene: identification of a large transcript RT disrupted in three NF1 patients."; RL Science 249:181-186(1990). RN [3] RP ERRATUM OF PUBMED:2134734. RX PubMed=2125369; RA Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., RA Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., RA Brownstein B.H., Collins F.S.; RL Science 250:1749-1749(1990). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I). RX PubMed=1783401; DOI=10.1016/0888-7543(91)90017-9; RA Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R., RA Andersen L.B., Mitchell A.L., Gutmann D.H., Boguski M.S., Collins F.S.; RT "cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of RT the NF1 gene product."; RL Genomics 11:931-940(1991). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING. RC TISSUE=Placenta; RX PubMed=1339276; DOI=10.1016/0006-291x(92)91294-z; RA Suzuki H., Takahashi K., Kubota Y., Shibahara S.; RT "Molecular cloning of a cDNA coding for neurofibromatosis type 1 protein RT isoform lacking the domain related to ras GTPase-activating protein."; RL Biochem. Biophys. Res. Commun. 187:984-990(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RC TISSUE=Kidney; RX PubMed=7570581; DOI=10.1620/tjem.175.225; RA Suzuki H., Takahashi K., Shibahara S.; RT "Evidence for the presence of two amino-terminal isoforms of neurofibromin, RT a gene product responsible for neurofibromatosis type 1."; RL Tohoku J. Exp. Med. 175:225-233(1995). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-80; LEU-678; HIS-1422 RP AND LEU-2511. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 335-2839 (ISOFORM I), AND RP VARIANT NF1 PRO-1953. RX PubMed=2114220; DOI=10.1016/0092-8674(90)90253-b; RA Cawthon R.M., Weiss R., Xu G., Viskochil D., Culver M., Stevens J., RA Robertson M., Dunn D., Gesteland R., O'Connell P., White R.; RT "A major segment of the neurofibromatosis type 1 gene: cDNA sequence, RT genomic structure, and point mutations."; RL Cell 62:193-201(1990). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 335-2839 (ISOFORMS I AND 6). RX PubMed=2116237; DOI=10.1016/0092-8674(90)90024-9; RA Xu G., O'Connell P., Viskochil D., Cawthon R.M., Robertson M., Culver M., RA Dunn D., Stevens J., Gesteland R., White R., Weiss R.; RT "The neurofibromatosis type 1 gene encodes a protein related to GAP."; RL Cell 62:599-608(1990). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 707-782. RX PubMed=9002664; DOI=10.1093/hmg/6.1.9; RA Regnier V., Meddeb M., Lecointre G., Richard F., Duverger A., Nguyen V.C., RA Dutrillaux B., Bernheim A., Danglot G.; RT "Emergence and scattering of multiple neurofibromatosis (NF1)-related RT sequences during hominoid evolution suggest a process of pericentromeric RT interchromosomal transposition."; RL Hum. Mol. Genet. 6:9-16(1997). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 751-1611 (ISOFORMS I AND II). RX PubMed=7774960; DOI=10.1016/0888-7543(95)80104-t; RA Li Y., O'Connell P., Breidenbach H.H., Cawthon R.M., Stevens J., Xu G., RA Neil S., Robertson M., White R., Viskochil D.; RT "Genomic organization of the neurofibromatosis 1 gene (NF1)."; RL Genomics 25:9-18(1995). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1090-1598 (ISOFORM 4). RX PubMed=2121370; DOI=10.1016/0092-8674(90)90150-d; RA Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., RA Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., Innis M., RA McCormick F.; RT "The GAP-related domain of the neurofibromatosis type 1 gene product RT interacts with ras p21."; RL Cell 63:843-849(1990). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1168-1566 (ISOFORMS I AND II). RX PubMed=1923522; RA Nishi T., Lee P.S., Oka K., Levin V.A., Tanase S., Morino Y., Saya H.; RT "Differential expression of two types of the neurofibromatosis type 1 (NF1) RT gene transcripts related to neuronal differentiation."; RL Oncogene 6:1555-1559(1991). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=8417346; DOI=10.1128/mcb.13.1.487-495.1993; RA Andersen L.B., Ballester R., Marchuk D.A., Chang E., Gutmann D.H., RA Saulino A.M., Camonis J., Wigler M., Collins F.S.; RT "A conserved alternative splice in the von Recklinghausen neurofibromatosis RT (NF1) gene produces two neurofibromin isoforms, both of which have GTPase- RT activating protein activity."; RL Mol. Cell. Biol. 13:487-495(1993). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II). RX PubMed=1662505; DOI=10.1016/0006-291x(91)92029-j; RA Suzuki Y., Suzuki H., Kayama T., Yoshimoto T., Shibahara S.; RT "Brain tumors predominantly express the neurofibromatosis type 1 gene RT transcripts containing the 63 base insert in the region coding for GTPase RT activating protein-related domain."; RL Biochem. Biophys. Res. Commun. 181:955-961(1991). RN [18] RP FUNCTION. RX PubMed=2121371; DOI=10.1016/0092-8674(90)90151-4; RA Ballester R., Marchuk D.A., Boguski M.S., Saulino A.M., Letcher R., RA Wigler M., Collins F.S.; RT "The NF1 locus encodes a protein functionally related to mammalian GAP and RT yeast IRA proteins."; RL Cell 63:851-859(1990). RN [19] RP RNA EDITING. RX PubMed=8602361; DOI=10.1093/nar/24.3.478; RA Skuse G.R., Cappione A.J., Sowden M., Metheny L.J., Smith H.C.; RT "The neurofibromatosis type I messenger RNA undergoes base-modification RNA RT editing."; RL Nucleic Acids Res. 24:478-485(1996). RN [20] RP RNA EDITING. RX PubMed=11727199; DOI=10.1086/337952; RA Mukhopadhyay D., Anant S., Lee R.M., Kennedy S., Viskochil D., RA Davidson N.O.; RT "C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express RT both the type II transcript and apobec-1, the catalytic subunit of the RT apolipoprotein B mRNA-editing enzyme."; RL Am. J. Hum. Genet. 70:38-50(2002). RN [21] RP REVIEW ON VARIANTS. RX PubMed=7981724; DOI=10.1002/humu.1380040202; RA Upadhyaya M., Shaw D.J., Harper P.S.; RT "Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and RT polymorphisms in the NF1 gene."; RL Hum. Mutat. 4:83-101(1994). RN [22] RP REVIEW ON VARIANTS. RX PubMed=8825042; DOI=10.1136/jmg.33.1.2; RA Shen M.H., Harper P.S., Upadhyaya M.; RT "Molecular genetics of neurofibromatosis type 1 (NF1)."; RL J. Med. Genet. 33:2-17(1996). RN [23] RP SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL. RX PubMed=14988005; DOI=10.1016/s0014-5793(04)00078-x; RA Vandenbroucke I., Van Oostveldt P., Coene E., De Paepe A., Messiaen L.; RT "Neurofibromin is actively transported to the nucleus."; RL FEBS Lett. 560:98-102(2004). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-2188; SER-2515; RP SER-2521 AND SER-2543, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876 AND SER-2515, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [33] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876; SER-2188; RP SER-2515; SER-2521; SER-2523; SER-2543; THR-2565; SER-2597 AND SER-2802, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH SPRED2, AND SUBCELLULAR LOCATION. RX PubMed=34626534; DOI=10.1016/j.ajhg.2021.09.007; RA Motta M., Fasano G., Gredy S., Brinkmann J., Bonnard A.A., RA Simsek-Kiper P.O., Gulec E.Y., Essaddam L., Utine G.E., RA Guarnetti Prandi I., Venditti M., Pantaleoni F., Radio F.C., Ciolfi A., RA Petrini S., Consoli F., Vignal C., Hepbasli D., Ullrich M., de Boer E., RA Vissers L.E.L.M., Gritli S., Rossi C., De Luca A., Ben Becher S., RA Gelb B.D., Dallapiccola B., Lauri A., Chillemi G., Schuh K., Cave H., RA Zenker M., Tartaglia M.; RT "SPRED2 loss-of-function causes a recessive Noonan syndrome-like RT phenotype."; RL Am. J. Hum. Genet. 108:2112-2129(2021). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1198-1551. RX PubMed=9687500; DOI=10.1093/emboj/17.15.4313; RA Scheffzek K., Ahmadian M.R., Wiesmuller L., Kabsch W., Stege P., RA Schmitz F., Wittinghofer A.; RT "Structural analysis of the GAP-related domain from neurofibromin and its RT implications."; RL EMBO J. 17:4313-4327(1998). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1581-1837, LIPID-BINDING, DOMAIN, RP AND MUTAGENESIS OF LYS-1691; ARG-1695; ARG-1769 AND LYS-1771. RX PubMed=16397625; DOI=10.1038/sj.embor.7400602; RA D'Angelo I., Welti S., Bonneau F., Scheffzek K.; RT "A novel bipartite phospholipid-binding module in the neurofibromatosis RT type 1 protein."; RL EMBO Rep. 7:174-179(2006). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1566-1837 IN COMPLEX WITH RP PHOSPHOLIPID, LIPID-BINDING, AND DOMAIN. RX PubMed=17187824; DOI=10.1016/j.jmb.2006.11.055; RA Welti S., Fraterman S., D'Angelo I., Wilm M., Scheffzek K.; RT "The sec14 homology module of neurofibromin binds cellular RT glycerophospholipids: mass spectrometry and structure of a lipid complex."; RL J. Mol. Biol. 366:551-562(2007). RN [40] RP X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 1581-1837 OF VARIANT NF1 VAL-1605 RP AND MUTANT LYS-1771 DEL IN COMPLEX WITH LIPID, CHARACTERIZATION OF VARIANT RP NF1 VAL-1605, MUTAGENESIS OF LYS-1771, LIPID-BINDING, AND DOMAIN. RX PubMed=21089070; DOI=10.1002/humu.21405; RA Welti S., Kuhn S., D'Angelo I., Brugger B., Kaufmann D., Scheffzek K.; RT "Structural and biochemical consequences of NF1 associated nontruncating RT mutations in the Sec14-PH module of neurofibromin."; RL Hum. Mutat. 32:191-197(2011). RN [41] RP VARIANT GLU-1444. RX PubMed=1568247; DOI=10.1016/0092-8674(92)90408-5; RA Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D., Ward K., RA Friedman E., Samowitz W., Robertson M., Bradley P., McCormick F., White R., RA Cawthon R.M.; RT "Somatic mutations in the neurofibromatosis 1 gene in human tumors."; RL Cell 69:275-281(1992). RN [42] RP VARIANTS NF1 MET-2164 AND ASN-2192. RX PubMed=1302608; DOI=10.1093/hmg/1.9.735; RA Upadhyaya M., Shen M.H., Cherryson A., Farnham J., Maynard J., Huson S.M., RA Harper P.S.; RT "Analysis of mutations at the neurofibromatosis 1 (NF1) locus."; RL Hum. Mol. Genet. 1:735-740(1992). RN [43] RP VARIANT GLY-HIS-GLU-GLN-GLN-LYS-LEU-PRO-ALA-ALA-THR-LEU-ALA-LEU-1733 INS. RX PubMed=8317503; RA Tassabehji M., Strachan T., Sharland M., Colley A., Donnai D., Harris R., RA Thakker N.; RT "Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a RT family with features of Watson syndrome and Noonan syndrome."; RL Am. J. Hum. Genet. 53:90-95(1993). RN [44] RP VARIANT MET-991 DEL. RX PubMed=7904209; DOI=10.1093/hmg/2.11.1861; RA Shen M.H., Harper P.S., Upadhyaya M.; RT "Neurofibromatosis type 1 (NF1): the search for mutations by PCR- RT heteroduplex analysis on Hydrolink gels."; RL Hum. Mol. Genet. 2:1861-1864(1993). RN [45] RP VARIANTS NF1 ASP-1166 AND ARG-1440. RX PubMed=7981679; DOI=10.1093/hmg/3.7.1109; RA Purandare S.M., Lanyon W.G., Connor J.M.; RT "Characterisation of inherited and sporadic mutations in neurofibromatosis RT type-1."; RL Hum. Mol. Genet. 3:1109-1115(1994). RN [46] RP VARIANT NF1 2387-ASN-PHE-2388 DEL. RX PubMed=8081387; DOI=10.1002/humu.1380030404; RA Abernathy C.R., Colman S.D., Kousseff B.G., Wallace M.R.; RT "Two NF1 mutations: frameshift in the GAP-related domain, and loss of two RT codons toward the 3' end of the gene."; RL Hum. Mutat. 3:347-352(1994). RN [47] RP VARIANT NF1 ALA-2631. RX PubMed=8544190; DOI=10.1136/jmg.32.9.706; RA Upadhyaya M., Maynard J., Osborn M.J., Huson S.M., Ponder M., RA Ponder B.A.J., Harper P.S.; RT "Characterisation of germline mutations in the neurofibromatosis type 1 RT (NF1) gene."; RL J. Med. Genet. 32:706-710(1995). RN [48] RP VARIANT NF1 ARG-629. RX PubMed=8834249; DOI=10.1007/bf02267073; RA Gasparini P., D'Agruma L., de Cillis G.P., Balestrazzi P., Mingarelli R., RA Zelante L.; RT "Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: RT identification of three novel mutations and of two new polymorphisms."; RL Hum. Genet. 97:492-495(1996). RN [49] RP VARIANT NF1 ARG-1035. RX PubMed=8807336; RX DOI=10.1002/(sici)1098-1004(1996)8:1<51::aid-humu7>3.0.co;2-s; RA Wu R., Legius E., Robberecht W., Dumoulin M., Cassiman J.-J., Fryns J.-P.; RT "Neurofibromatosis type I gene mutation in a patient with features of RT LEOPARD syndrome."; RL Hum. Mutat. 8:51-56(1996). RN [50] RP VARIANTS NF1 SER-1412; GLN-1440; GLU-1444 AND GLY-1489. RX PubMed=9003501; DOI=10.1007/s004390050317; RA Upadhyaya M., Osborn M.J., Maynard J., Kim M.R., Tamanoi F., Cooper D.N.; RT "Mutational and functional analysis of the neurofibromatosis type 1 (NF1) RT gene."; RL Hum. Genet. 99:88-92(1997). RN [51] RP VARIANTS NF1 ARG-844 AND PRO-898. RX PubMed=9150739; DOI=10.1007/s004390050427; RA Maynard J., Krawczak M., Upadhyaya M.; RT "Characterization and significance of nine novel mutations in exon 16 of RT the neurofibromatosis type 1 (NF1) gene."; RL Hum. Genet. 99:674-676(1997). RN [52] RP VARIANT NF1 ARG-1952. RX PubMed=9101300; RX DOI=10.1002/(sici)1098-1004(1997)9:4<366::aid-humu12>3.0.co;2-0; RA Hudson J., Wu C.L., Tassabehji M., Summers E.M., Simon S., Super M., RA Donnai D., Thakker N.; RT "Novel and recurrent mutations in the neurofibromatosis type 1 (NF1) RT gene."; RL Hum. Mutat. 9:366-367(1997). RN [53] RP VARIANTS NF1 GLY-338 AND TRP-1611. RX PubMed=9298829; RX DOI=10.1002/(sici)1098-1004(1997)10:3<248::aid-humu14>3.0.co;2-#; RA Upadhyaya M., Maynard J., Osborn M.J., Harper P.S.; RT "Six novel mutations in the neurofibromatosis type 1 (NF1) gene."; RL Hum. Mutat. 10:248-250(1997). RN [54] RP VARIANT NF1 PRO-1276. RX PubMed=9668168; DOI=10.1093/hmg/7.8.1261; RA Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S., RA Gewies A., Schmitz F., Kaufmann D., Peters H., Wittinghofer A., RA Nuernberg P.; RT "Selective disactivation of neurofibromin GAP activity in neurofibromatosis RT type 1 (NF1)."; RL Hum. Mol. Genet. 7:1261-1268(1998). RN [55] RP VARIANTS NF1 HIS-765 AND GLY-1204. RX PubMed=10336779; RX DOI=10.1002/(sici)1098-1004(1998)11:5<411::aid-humu11>3.0.co;2-2; RA Krkljus S., Abernathy C.R., Johnson J.S., Williams C.A., Driscoll D.J., RA Zori R., Stalker H.J., Rasmussen S.A., Collins F.S., Kousseff B.G., RA Baumbach L., Wallace M.R.; RT "Analysis of CpG C-to-T mutations in neurofibromatosis type 1."; RL Hum. Mutat. 11:411-411(1998). RN [56] RP VARIANT NF1 PRO-508. RX PubMed=11258625; DOI=10.1097/00125817-199909000-00002; RA Messiaen L.M., Callens T., Roux K.J., Mortier G.R., De Paepe A., RA Abramowicz M., Pericak-Vance M.A., Vance J.M., Wallace M.R.; RT "Exon 10b of the NF1 gene represents a mutational hotspot and harbors a RT recurrent missense mutation Y489C associated with aberrant splicing."; RL Genet. Med. 1:248-253(1999). RN [57] RP VARIANT NF1 PRO-1446. RX PubMed=10220149; RX DOI=10.1002/(sici)1098-1004(1999)13:4<337::aid-humu12>3.0.co;2-f; RA Peters H., Hess D., Fahsold R., Schuelke M.; RT "A novel mutation L1425P in the GAP-region of the NF1 gene detected by RT temperature gradient gel electrophoresis (TGGE)."; RL Hum. Mutat. 13:337-337(1999). RN [58] RP VARIANTS NF1 PRO-216; PRO-357; CYS-491; PRO-549; THR-581; ARG-583; PHE-665; RP PRO-695; PRO-763; SER-777; LYS-780; PRO-781; PRO-847; SER-1156; PRO-1250; RP GLN-1276; PRO-1276; PRO-1446; VAL-1605 AND ILE-2507, AND VARIANT GLU-176. RX PubMed=10712197; DOI=10.1086/302809; RA Fahsold R., Hoffmeyer S., Mischung C., Gille C., Ehlers C., RA Kuecuekceylan N., Abdel-Nour M., Gewies A., Peters H., Kaufmann D., RA Buske A., Tinschert S., Nuernberg P.; RT "Minor lesion mutational spectrum of the entire NF1 gene does not explain RT its high mutability but points to a functional domain upstream of the GAP- RT related domain."; RL Am. J. Hum. Genet. 66:790-818(2000). RN [59] RP VARIANTS NF1 SER-117; TRP-1204; PRO-1446 AND 2387-ASN-PHE-2388 DEL. RX PubMed=10607834; DOI=10.1093/hmg/9.2.237; RA Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.; RT "Mutations affecting mRNA splicing are the most common molecular defects in RT patients with neurofibromatosis type 1."; RL Hum. Mol. Genet. 9:237-247(2000). RN [60] RP ERRATUM OF PUBMED:10607834. RA Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.; RL Hum. Mol. Genet. 9:659-659(2000). RN [61] RP VARIANT NF1 PHE-844. RX PubMed=10980545; RX DOI=10.1002/1098-1004(200009)16:3<274::aid-humu21>3.3.co;2-6; RA Boulandet E.G., Pantel J., Cazeneuve C., Van Gijn M., Vidaud D., Lemay S., RA Martin J., Zeller J., Revuz J., Goossens M., Amselem S., Wolkenstein P.; RT "NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients RT with neurofibromatosis type 1."; RL Hum. Mutat. 16:274-275(2000). RN [62] RP VARIANT SPINAL FSNF PRO-2088. RX PubMed=11704931; DOI=10.1086/324648; RA Kaufmann D., Mueller R., Bartelt B., Wolf M., Kunzi-Rapp K., Hanemann C.O., RA Fahsold R., Hein C., Vogel W., Assum G.; RT "Spinal neurofibromatosis without cafe-au-lait macules in two families with RT null mutations of the NF1 gene."; RL Am. J. Hum. Genet. 69:1395-1400(2001). RN [63] RP VARIANTS NF1 LYS-780; CYS-784; PRO-1147; CYS-1193; ARG-1444; SER-1785; RP ASN-2012 AND LYS-2357. RX PubMed=11735023; DOI=10.1007/s004390100594; RA Han S.S., Cooper D.N., Upadhyaya M.N.; RT "Evaluation of denaturing high performance liquid chromatography (DHPLC) RT for the mutational analysis of the neurofibromatosis type 1 (NF1) gene."; RL Hum. Genet. 109:487-497(2001). RN [64] RP VARIANTS NF1 PHE-82; ARG-784 AND GLU-1444. RX PubMed=11857752; DOI=10.1002/humu.9018; RA Kluwe L., Friedrich R.E., Korf B., Fahsold R., Mautner V.-F.; RT "NF1 mutations in neurofibromatosis 1 patients with plexiform RT neurofibromas."; RL Hum. Mutat. 19:309-309(2002). RN [65] RP VARIANT NFNS GLU-1459 DEL. RX PubMed=12707950; DOI=10.1002/ajmg.a.20023; RA Baralle D., Mattocks C., Kalidas K., Elmslie F., Whittaker J., Lees M., RA Ragge N., Patton M.A., Winter R.M., ffrench-Constant C.; RT "Different mutations in the NF1 gene are associated with neurofibromatosis- RT Noonan syndrome (NFNS)."; RL Am. J. Med. Genet. A 119:1-8(2003). RN [66] RP VARIANTS NF1 TYR-93; VAL-604; ARG-844 AND PRO-898, AND VARIANTS ASP-74; RP GLU-176; ARG-712 AND GLN-1276. RX PubMed=12522551; DOI=10.1007/s00439-002-0858-4; RA Wang Q., Montmain G., Ruano E., Upadhyaya M., Dudley S., Liskay R.M., RA Thibodeau S.N., Puisieux A.; RT "Neurofibromatosis type 1 gene as a mutational target in a mismatch repair- RT deficient cell type."; RL Hum. Genet. 112:117-123(2003). RN [67] RP VARIANTS NF1 LYS-780; PRO-847; GLU-848 AND ARG-968; ASN-1444; LEU-1953 DEL RP AND ARG-2001. RX PubMed=12552569; DOI=10.1002/humu.9111; RA De Luca A., Buccino A., Gianni D., Mangino M., Giustini S., Richetta A., RA Divona L., Calvieri S., Mingarelli R., Dallapiccola B.; RT "NF1 gene analysis based on DHPLC."; RL Hum. Mutat. 21:171-172(2003). RN [68] RP VARIANTS NF1 ARG-578; PRO-920 AND ALA-2221. RX PubMed=12746402; DOI=10.1136/jmg.40.5.368; RA Kluwe L., Tatagiba M., Fuensterer C., Mautner V.F.; RT "NF1 mutations and clinical spectrum in patients with spinal RT neurofibromas."; RL J. Med. Genet. 40:368-371(2003). RN [69] RP VARIANT NF1 VAL-186, AND CHARACTERIZATION OF VARIANT NF1 VAL-186. RX PubMed=15523642; DOI=10.1002/humu.20103; RA Zatkova A., Messiaen L., Vandenbroucke I., Wieser R., Fonatsch C., RA Krainer A.R., Wimmer K.; RT "Disruption of exonic splicing enhancer elements is the principal cause of RT exon skipping associated with seven nonsense or missense alleles of NF1."; RL Hum. Mutat. 24:491-501(2004). RN [70] RP VARIANTS NF1 ASN-157; ARG-629; SER-777; LYS-780; ARG-784; PRO-847; GLU-848; RP ARG-968; ASN-1444; LEU-1953 DEL AND ARG-2001, AND VARIANT GLU-176. RX PubMed=15146469; DOI=10.1002/humu.9245; RA De Luca A., Schirinzi A., Buccino A., Bottillo I., Sinibaldi L., RA Torrente I., Ciavarella A., Dottorini T., Porciello R., Giustini S., RA Calvieri S., Dallapiccola B.; RT "Novel and recurrent mutations in the NF1 gene in Italian patients with RT neurofibromatosis type 1."; RL Hum. Mutat. 23:629-629(2004). RN [71] RP VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532; ARG-574; RP ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073; ARG-1196; RP GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489, AND VARIANTS RP GLU-176 AND CYS-873. RX PubMed=15060124; DOI=10.1136/jmg.2003.011890; RA Mattocks C., Baralle D., Tarpey P., ffrench-Constant C., Bobrow M., RA Whittaker J.; RT "Automated comparative sequence analysis identifies mutations in 89% of NF1 RT patients and confirms a mutation cluster in exons 11-17 distinct from the RT GAP related domain."; RL J. Med. Genet. 41:E48-E48(2004). RN [72] RP VARIANT NF1 PRO-1243. RX PubMed=15520408; DOI=10.1136/jmg.2004.021683; RA Ferner R.E., Hughes R.A.C., Hall S.M., Upadhyaya M., Johnson M.R.; RT "Neurofibromatous neuropathy in neurofibromatosis 1 (NF1)."; RL J. Med. Genet. 41:837-841(2004). RN [73] RP VARIANT NF1 ARG-844. RX PubMed=15948193; DOI=10.1002/ajmg.a.30813; RA Bertola D.R., Pereira A.C., Passetti F., de Oliveira P.S.L., Messiaen L., RA Gelb B.D., Kim C.A., Krieger J.E.; RT "Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence RT of both disorders in a patient."; RL Am. J. Med. Genet. A 136:242-245(2005). RN [74] RP VARIANTS NFNS ARG-194; GLU-1444; THR-1451; LEU-1453 AND GLU-1459 DEL. RX PubMed=16380919; DOI=10.1086/498454; RA De Luca A., Bottillo I., Sarkozy A., Carta C., Neri C., Bellacchio E., RA Schirinzi A., Conti E., Zampino G., Battaglia A., Majore S., Rinaldi M.M., RA Carella M., Marino B., Pizzuti A., Digilio M.C., Tartaglia M., RA Dallapiccola B.; RT "NF1 gene mutations represent the major molecular event underlying RT neurofibromatosis-Noonan syndrome."; RL Am. J. Hum. Genet. 77:1092-1101(2005). RN [75] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-1187; LEU-1951 AND ARG-2745. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [76] RP VARIANT NF1 MET-991 DEL. RX PubMed=17160901; DOI=10.1086/510781; RA Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N., RA Giovannini S., Evans D.G., Howard E., Kerr B., Griffiths S., Consoli C., RA Side L., Adams D., Pierpont M., Hachen R., Barnicoat A., Li H., Wallace P., RA Van Biervliet J.P., Stevenson D., Viskochil D., Baralle D., Haan E., RA Riccardi V., Turnpenny P., Lazaro C., Messiaen L.; RT "An absence of cutaneous neurofibromas associated with a 3-bp inframe RT deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a RT clinically significant NF1 genotype-phenotype correlation."; RL Am. J. Hum. Genet. 80:140-151(2007). RN [77] RP VARIANT NFNS PHE-1411. RX PubMed=19845691; DOI=10.1111/j.1399-0004.2009.01233.x; RA Nystrom A.M., Ekvall S., Allanson J., Edeby C., Elinder M., Holmstrom G., RA Bondeson M.L., Anneren G.; RT "Noonan syndrome and neurofibromatosis type I in a family with a novel RT mutation in NF1."; RL Clin. Genet. 76:524-534(2009). RN [78] RP VARIANT NF1 THR-160. RX PubMed=21838856; DOI=10.1186/1897-4287-9-6; RA Ponti G., Losi L., Martorana D., Priola M., Boni E., Pollio A., Neri T.M., RA Seidenari S.; RT "Clinico-pathological and biomolecular findings in Italian patients with RT multiple cutaneous neurofibromas."; RL Hered. Cancer Clin. Pract. 9:6-6(2011). RN [79] RP VARIANTS GLU-176; THR-330; ASP-393; LEU-393; PRO-519; THR-776 AND PHE-1484. RX PubMed=22108604; DOI=10.1038/ejhg.2011.207; RA Thomas L., Spurlock G., Eudall C., Thomas N.S., Mort M., Hamby S.E., RA Chuzhanova N., Brems H., Legius E., Cooper D.N., Upadhyaya M.; RT "Exploring the somatic NF1 mutational spectrum associated with NF1 RT cutaneous neurofibromas."; RL Eur. J. Hum. Genet. 20:411-419(2012). RN [80] RP VARIANTS NF1 TRP-93; ARG-1048; ARG-1189; ARG-1661 (ISOFORM I) AND THR-1918 RP (ISOFORM I). RX PubMed=23758643; DOI=10.1111/ahg.12026; RA Nemethova M., Bolcekova A., Ilencikova D., Durovcikova D., Hlinkova K., RA Hlavata A., Kovacs L., Kadasi L., Zatkova A.; RT "Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in RT Slovak patients."; RL Ann. Hum. Genet. 77:364-379(2013). RN [81] RP VARIANT NF1 PRO-2125. RX PubMed=24413922; DOI=10.1007/s00381-013-2352-9; RA Ben-Salem S., Al-Shamsi A.M., Ali B.R., Al-Gazali L.; RT "The mutational spectrum of the NF1 gene in neurofibromatosis type I RT patients from UAE."; RL Childs Nerv. Syst. 30:1183-1189(2014). CC -!- FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater CC affinity for Ras GAP, but lower specific activity. May be a regulator CC of Ras activity. {ECO:0000269|PubMed:2121371, CC ECO:0000269|PubMed:8417346}. CC -!- SUBUNIT: Interacts with HTR6 (PubMed:23027611). Interacts with SPRED2 CC (PubMed:34626534). {ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:34626534}. CC -!- INTERACTION: CC P21359; P05067: APP; NbExp=3; IntAct=EBI-1172917, EBI-77613; CC P21359; P01112: HRAS; NbExp=3; IntAct=EBI-1172917, EBI-350145; CC P21359; P34741: SDC2; NbExp=4; IntAct=EBI-1172917, EBI-1172957; CC P21359; Q7Z699: SPRED1; NbExp=6; IntAct=EBI-1172917, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14988005}. Nucleus, CC nucleolus {ECO:0000269|PubMed:14988005}. Cell membrane CC {ECO:0000269|PubMed:34626534}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Experimental confirmation may be lacking for some isoforms.; CC Name=II {ECO:0000303|PubMed:1923522}; CC IsoId=P21359-1; Sequence=Displayed; CC Name=I {ECO:0000303|PubMed:1923522}; CC IsoId=P21359-2; Sequence=VSP_001628; CC Name=3; CC IsoId=P21359-3; Sequence=VSP_001629, VSP_001630; CC Name=4; CC IsoId=P21359-4; Sequence=VSP_001631, VSP_001632; CC Name=5; CC IsoId=P21359-5; Sequence=VSP_043467, VSP_043468; CC Name=6; CC IsoId=P21359-6; Sequence=VSP_001628, VSP_053587; CC -!- TISSUE SPECIFICITY: Detected in brain, peripheral nerve, lung, colon CC and muscle. {ECO:0000269|PubMed:8417346}. CC -!- DOMAIN: Binds phospholipids via its C-terminal CRAL-TRIO domain. Binds CC primarily glycerophospholipids with monounsaturated C18:1 and/or C16:1 CC fatty acid moieties and a phosphatidylethanolamine or CC phosphatidylcholine headgroup. Has lesser affinity for lipids CC containing phosphatidylserine and phosphatidylinositol. CC {ECO:0000269|PubMed:16397625, ECO:0000269|PubMed:17187824, CC ECO:0000269|PubMed:21089070}. CC -!- PTM: Ubiquitinated by RNF7/RBX2, leading to its degradation. CC {ECO:0000250|UniProtKB:Q04690}. CC -!- RNA EDITING: Modified_positions=1306 {ECO:0000269|PubMed:11727199, CC ECO:0000269|PubMed:8602361}; Note=The stop codon (UGA) at position 1306 CC is created by RNA editing. Various levels of RNA editing occurs in CC peripheral nerve-sheath tumor samples (PNSTs) from patients with NF1. CC Preferentially observed in transcripts containing exon 23A.; CC -!- DISEASE: Neurofibromatosis 1 (NF1) [MIM:162200]: A disease CC characterized by patches of skin pigmentation (cafe-au-lait spots), CC Lisch nodules of the iris, tumors in the peripheral nervous system and CC fibromatous skin tumors. Individuals with the disorder have increased CC susceptibility to the development of benign and malignant tumors. CC {ECO:0000269|PubMed:10220149, ECO:0000269|PubMed:10336779, CC ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197, CC ECO:0000269|PubMed:10980545, ECO:0000269|PubMed:11258625, CC ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:11857752, CC ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:12552569, CC ECO:0000269|PubMed:12746402, ECO:0000269|PubMed:1302608, CC ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:15146469, CC ECO:0000269|PubMed:15520408, ECO:0000269|PubMed:15523642, CC ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:17160901, CC ECO:0000269|PubMed:21089070, ECO:0000269|PubMed:2114220, CC ECO:0000269|PubMed:21838856, ECO:0000269|PubMed:23758643, CC ECO:0000269|PubMed:24413922, ECO:0000269|PubMed:7981679, CC ECO:0000269|PubMed:8081387, ECO:0000269|PubMed:8544190, CC ECO:0000269|PubMed:8807336, ECO:0000269|PubMed:8834249, CC ECO:0000269|PubMed:9003501, ECO:0000269|PubMed:9101300, CC ECO:0000269|PubMed:9150739, ECO:0000269|PubMed:9298829, CC ECO:0000269|PubMed:9668168}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Watson syndrome (WTSN) [MIM:193520]: A syndrome characterized CC by the presence of pulmonary stenosis, cafe-au-lait spots, and CC intellectual disability. It is considered as an atypical form of CC neurofibromatosis. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Familial spinal neurofibromatosis (FSNF) [MIM:162210]: CC Considered to be an alternative form of neurofibromatosis, showing CC multiple spinal tumors. {ECO:0000269|PubMed:11704931}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]: CC Characterized by manifestations of both NF1 and Noonan syndrome (NS). CC NS is a disorder characterized by dysmorphic facial features, short CC stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a CC bleeding diathesis. {ECO:0000269|PubMed:12707950, CC ECO:0000269|PubMed:16380919, ECO:0000269|PubMed:19845691}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- CAUTION: Was originally thought to be associated with LEOPARD (LS), an CC autosomal dominant syndrome. {ECO:0000305|PubMed:8807336}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA59923.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/134/NF1"; CC -!- WEB RESOURCE: Name=Mendelian genes neurofibromin 1 (NF1); Note=Leiden CC Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/NF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M89914; AAA59925.1; -; mRNA. DR EMBL; M82814; AAA59924.1; -; mRNA. DR EMBL; M60496; AAA59928.1; -; mRNA. DR EMBL; D12625; BAA02150.1; -; mRNA. DR EMBL; M38106; AAA74897.1; -; mRNA. DR EMBL; M38107; AAB59558.1; -; mRNA. DR EMBL; D42072; BAA07669.1; -; mRNA. DR EMBL; AY796305; AAV50004.1; -; Genomic_DNA. DR EMBL; AC004222; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC079915; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC134669; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC135724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138207; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC139072; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471147; EAW80272.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80275.1; -; Genomic_DNA. DR EMBL; AH000834; AAA18483.1; -; Genomic_DNA. DR EMBL; Y07853; CAA69179.1; -; Genomic_DNA. DR EMBL; U17690; AAB48380.1; -; Genomic_DNA. DR EMBL; U17680; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17681; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17682; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17683; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17684; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17685; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17686; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17687; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17688; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17689; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17690; AAB48379.1; -; Genomic_DNA. DR EMBL; U17680; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17681; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17682; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17683; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17684; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17685; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17687; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17688; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17689; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17656; AAB48373.1; -; Genomic_DNA. DR EMBL; U17659; AAB48374.1; -; Genomic_DNA. DR EMBL; U17662; AAB48375.1; -; Genomic_DNA. DR EMBL; U17668; AAB48376.1; -; Genomic_DNA. DR EMBL; U17667; AAB48376.1; JOINED; Genomic_DNA. DR EMBL; U17673; AAB48377.1; -; Genomic_DNA. DR EMBL; U17677; AAB48378.1; -; Genomic_DNA. DR EMBL; U17676; AAB48378.1; JOINED; Genomic_DNA. DR EMBL; M60915; AAA59921.1; -; mRNA. DR EMBL; M60915; AAA59922.1; -; mRNA. DR EMBL; M61213; AAA59923.1; ALT_INIT; mRNA. DR EMBL; S51751; AAB24636.1; -; mRNA. DR EMBL; D10490; BAA01371.1; -; mRNA. DR CCDS; CCDS11264.1; -. [P21359-2] DR CCDS; CCDS42292.1; -. [P21359-1] DR CCDS; CCDS45645.1; -. [P21359-5] DR PIR; B55282; B55282. DR PIR; I78852; I78852. DR RefSeq; NP_000258.1; NM_000267.4. [P21359-2] DR RefSeq; NP_001035957.1; NM_001042492.3. [P21359-1] DR RefSeq; NP_001121619.1; NM_001128147.3. [P21359-5] DR PDB; 1NF1; X-ray; 2.50 A; A=1198-1551. DR PDB; 2D4Q; X-ray; 2.30 A; A/B=1581-1837. DR PDB; 2E2X; X-ray; 2.50 A; A/B=1566-1837. DR PDB; 3P7Z; X-ray; 2.65 A; A/B=1566-1837. DR PDB; 3PEG; X-ray; 2.52 A; A=1566-1837. DR PDB; 3PG7; X-ray; 2.19 A; A/B=1581-1837. DR PDB; 6OB2; X-ray; 2.85 A; B/D=1209-1484. DR PDB; 6OB3; X-ray; 2.10 A; B/D=1209-1484. DR PDB; 6V65; X-ray; 2.76 A; B=1203-1551. DR PDB; 6V6F; X-ray; 2.54 A; B=1203-1551. DR PDB; 7MOC; EM; 4.56 A; A/B=2-2839. DR PDB; 7MP5; EM; 5.60 A; A/B=2-2839. DR PDB; 7MP6; EM; 6.25 A; A/B=2-2839. DR PDB; 7PGP; EM; 3.10 A; F/N=1-2839. DR PDB; 7PGQ; EM; 3.50 A; F/N=1-2839. DR PDB; 7PGR; EM; 4.00 A; F/N=1-2839. DR PDB; 7PGS; EM; 3.40 A; F/N=1-2839. DR PDB; 7PGT; EM; 4.80 A; F/N=1-2839. DR PDB; 7PGU; EM; 3.30 A; F/N=1-2839. DR PDB; 7R03; EM; 3.60 A; A/B=1-2839. DR PDB; 7R04; EM; 3.70 A; A/B=1-2839. DR PDB; 8E20; EM; 3.60 A; A/B=1-2839. DR PDB; 8EDL; EM; 3.70 A; A=1-2839. DR PDB; 8EDM; EM; 3.60 A; A/B=1-2839. DR PDB; 8EDN; EM; 3.80 A; A=1-2839. DR PDB; 8EDO; EM; 3.40 A; A/B=1039-2302. DR PDBsum; 1NF1; -. DR PDBsum; 2D4Q; -. DR PDBsum; 2E2X; -. DR PDBsum; 3P7Z; -. DR PDBsum; 3PEG; -. DR PDBsum; 3PG7; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 7MOC; -. DR PDBsum; 7MP5; -. DR PDBsum; 7MP6; -. DR PDBsum; 7PGP; -. DR PDBsum; 7PGQ; -. DR PDBsum; 7PGR; -. DR PDBsum; 7PGS; -. DR PDBsum; 7PGT; -. DR PDBsum; 7PGU; -. DR PDBsum; 7R03; -. DR PDBsum; 7R04; -. DR PDBsum; 8E20; -. DR PDBsum; 8EDL; -. DR PDBsum; 8EDM; -. DR PDBsum; 8EDN; -. DR PDBsum; 8EDO; -. DR EMDB; EMD-13391; -. DR EMDB; EMD-13392; -. DR EMDB; EMD-13393; -. DR EMDB; EMD-13394; -. DR EMDB; EMD-13395; -. DR EMDB; EMD-13396; -. DR EMDB; EMD-14218; -. DR EMDB; EMD-14219; -. DR EMDB; EMD-23924; -. DR EMDB; EMD-23929; -. DR EMDB; EMD-23930; -. DR EMDB; EMD-27826; -. DR EMDB; EMD-28035; -. DR EMDB; EMD-28036; -. DR EMDB; EMD-28037; -. DR EMDB; EMD-28038; -. DR SMR; P21359; -. DR BioGRID; 110836; 239. DR CORUM; P21359; -. DR FunCoup; P21359; 3476. DR IntAct; P21359; 149. DR MINT; P21359; -. DR STRING; 9606.ENSP00000351015; -. DR GlyGen; P21359; 5 sites, 1 O-linked glycan (3 sites). DR iPTMnet; P21359; -. DR PhosphoSitePlus; P21359; -. DR SwissPalm; P21359; -. DR BioMuta; NF1; -. DR DMDM; 548350; -. DR CPTAC; CPTAC-1622; -. DR jPOST; P21359; -. DR MassIVE; P21359; -. DR PaxDb; 9606-ENSP00000351015; -. DR PeptideAtlas; P21359; -. DR ProteomicsDB; 53861; -. [P21359-1] DR ProteomicsDB; 53862; -. [P21359-2] DR ProteomicsDB; 53863; -. [P21359-3] DR ProteomicsDB; 53864; -. [P21359-4] DR ProteomicsDB; 53865; -. [P21359-5] DR Pumba; P21359; -. DR Antibodypedia; 3471; 481 antibodies from 39 providers. DR CPTC; P21359; 3 antibodies. DR DNASU; 4763; -. DR Ensembl; ENST00000356175.7; ENSP00000348498.3; ENSG00000196712.20. [P21359-2] DR Ensembl; ENST00000358273.9; ENSP00000351015.4; ENSG00000196712.20. [P21359-1] DR Ensembl; ENST00000431387.8; ENSP00000412921.4; ENSG00000196712.20. [P21359-5] DR Ensembl; ENST00000487476.5; ENSP00000491589.1; ENSG00000196712.20. [P21359-3] DR GeneID; 4763; -. DR KEGG; hsa:4763; -. DR MANE-Select; ENST00000358273.9; ENSP00000351015.4; NM_001042492.3; NP_001035957.1. DR UCSC; uc002hgf.3; human. [P21359-1] DR AGR; HGNC:7765; -. DR CIViC; 4763; 58 evidence items across 51 molecular profiles. DR ClinPGx; PA31572; -. DR CTD; 4763; -. DR DisGeNET; 4763; -. DR GeneCards; NF1; -. DR GeneReviews; NF1; -. DR HGNC; HGNC:7765; NF1. DR HPA; ENSG00000196712; Low tissue specificity. DR MalaCards; NF1; -. DR MIM; 114500; phenotype. DR MIM; 162200; phenotype. DR MIM; 162210; phenotype. DR MIM; 193520; phenotype. DR MIM; 601321; phenotype. DR MIM; 607785; phenotype. DR MIM; 613113; gene. DR OpenTargets; ENSG00000196712; -. DR Orphanet; 97685; 17q11 microdeletion syndrome. DR Orphanet; 139474; 17q11.2 microduplication syndrome. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 363700; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion. DR Orphanet; 638; Neurofibromatosis-Noonan syndrome. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR VEuPathDB; HostDB:ENSG00000196712; -. DR eggNOG; KOG1826; Eukaryota. DR GeneTree; ENSGT00550000074797; -. DR HOGENOM; CLU_036305_0_0_1; -. DR InParanoid; P21359; -. DR OMA; TKEPYMF; -. DR OrthoDB; 28245at2759; -. DR PAN-GO; P21359; 0 GO annotations based on evolutionary models. DR PhylomeDB; P21359; -. DR PathwayCommons; P21359; -. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR SignaLink; P21359; -. DR SIGNOR; P21359; -. DR Agora; ENSG00000196712; -. DR BioGRID-ORCS; 4763; 62 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; NF1; human. DR EvolutionaryTrace; P21359; -. DR GeneWiki; Neurofibromin_1; -. DR GenomeRNAi; 4763; -. DR Pharos; P21359; Tbio. DR PRO; PR:P21359; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P21359; protein. DR Bgee; ENSG00000196712; Expressed in colonic epithelium and 202 other cell types or tissues. DR ExpressionAtlas; P21359; baseline and differential. DR GO; GO:0030424; C:axon; IDA:HGNC-UCL. DR GO; GO:0005737; C:cytoplasm; ISS:HGNC-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IDA:HGNC-UCL. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:HGNC-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB. DR GO; GO:0031210; F:phosphatidylcholine binding; IDA:UniProtKB. DR GO; GO:0008429; F:phosphatidylethanolamine binding; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:HGNC-UCL. DR GO; GO:0030325; P:adrenal gland development; ISS:HGNC-UCL. DR GO; GO:0021764; P:amygdala development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:Ensembl. DR GO; GO:0048844; P:artery morphogenesis; ISS:HGNC-UCL. DR GO; GO:0007420; P:brain development; ISS:HGNC-UCL. DR GO; GO:0048593; P:camera-type eye morphogenesis; ISS:HGNC-UCL. DR GO; GO:0007154; P:cell communication; ISS:HGNC-UCL. DR GO; GO:0034605; P:cellular response to heat; IEA:Ensembl. DR GO; GO:0021987; P:cerebral cortex development; ISS:HGNC-UCL. DR GO; GO:0050890; P:cognition; IMP:HGNC-UCL. DR GO; GO:0030199; P:collagen fibril organization; ISS:HGNC-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl. DR GO; GO:0030198; P:extracellular matrix organization; ISS:HGNC-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; ISS:HGNC-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:HGNC-UCL. DR GO; GO:0061534; P:gamma-aminobutyric acid secretion, neurotransmission; IEA:Ensembl. DR GO; GO:0061535; P:glutamate secretion, neurotransmission; IEA:Ensembl. DR GO; GO:0048820; P:hair follicle maturation; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:HGNC-UCL. DR GO; GO:0001889; P:liver development; ISS:HGNC-UCL. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; ISS:HGNC-UCL. DR GO; GO:0033024; P:mast cell apoptotic process; IEA:Ensembl. DR GO; GO:0070662; P:mast cell proliferation; IEA:Ensembl. DR GO; GO:0001656; P:metanephros development; ISS:HGNC-UCL. DR GO; GO:0022011; P:myelination in peripheral nervous system; ISS:HGNC-UCL. DR GO; GO:0097529; P:myeloid leukocyte migration; IEA:Ensembl. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:MGI. DR GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:MGI. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:UniProtKB. DR GO; GO:0002686; P:negative regulation of leukocyte migration; IEA:Ensembl. DR GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:MGI. DR GO; GO:0070667; P:negative regulation of mast cell proliferation; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; ISS:HGNC-UCL. DR GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:Ensembl. DR GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:HGNC-UCL. DR GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl. DR GO; GO:0042308; P:negative regulation of protein import into nucleus; IEA:Ensembl. DR GO; GO:0035021; P:negative regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IEA:Ensembl. DR GO; GO:1900148; P:negative regulation of Schwann cell migration; IEA:Ensembl. DR GO; GO:0010626; P:negative regulation of Schwann cell proliferation; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0098597; P:observational learning; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:HGNC-UCL. DR GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl. DR GO; GO:0007422; P:peripheral nervous system development; ISS:HGNC-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:HGNC-UCL. DR GO; GO:0043473; P:pigmentation; ISS:HGNC-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:HGNC-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:0033027; P:positive regulation of mast cell apoptotic process; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:HGNC-UCL. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; ISS:HGNC-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; IMP:HGNC-UCL. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; IMP:HGNC-UCL. DR GO; GO:0045124; P:regulation of bone resorption; ISS:HGNC-UCL. DR GO; GO:0001952; P:regulation of cell-matrix adhesion; ISS:HGNC-UCL. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IEA:Ensembl. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:0045685; P:regulation of glial cell differentiation; ISS:HGNC-UCL. DR GO; GO:1902531; P:regulation of intracellular signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:1900271; P:regulation of long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; ISS:HGNC-UCL. DR GO; GO:0014044; P:Schwann cell development; ISS:HGNC-UCL. DR GO; GO:0036135; P:Schwann cell migration; IEA:Ensembl. DR GO; GO:0014010; P:Schwann cell proliferation; IEA:Ensembl. DR GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:0048745; P:smooth muscle tissue development; ISS:HGNC-UCL. DR GO; GO:0021510; P:spinal cord development; ISS:HGNC-UCL. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0048485; P:sympathetic nervous system development; ISS:HGNC-UCL. DR GO; GO:1904738; P:vascular associated smooth muscle cell migration; IEA:Ensembl. DR GO; GO:1990874; P:vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; ISS:HGNC-UCL. DR GO; GO:0042060; P:wound healing; ISS:HGNC-UCL. DR CDD; cd13313; PH_NF1; 1. DR CDD; cd05130; RasGAP_Neurofibromin; 1. DR CDD; cd00170; SEC14; 1. DR FunFam; 2.30.29.30:FF:000070; Neurofibromin 1; 1. DR FunFam; 3.40.525.10:FF:000004; Neurofibromin 1; 1. DR FunFam; 1.10.506.10:FF:000015; Neurofibromin isoform 1; 1. DR FunFam; 1.10.506.10:FF:000023; Neurofibromin isoform 1; 1. DR Gene3D; 3.40.525.10; CRAL-TRIO lipid binding domain; 1. DR Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR001251; CRAL-TRIO_dom. DR InterPro; IPR036865; CRAL-TRIO_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR054071; PH_NF1. DR InterPro; IPR039360; Ras_GTPase. DR InterPro; IPR023152; RasGAP_CS. DR InterPro; IPR001936; RasGAP_dom. DR InterPro; IPR008936; Rho_GTPase_activation_prot. DR PANTHER; PTHR10194:SF142; NEUROFIBROMIN; 1. DR PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1. DR Pfam; PF13716; CRAL_TRIO_2; 1. DR Pfam; PF21877; PH_NF1; 1. DR Pfam; PF00616; RasGAP; 1. DR SMART; SM00323; RasGAP; 1. DR SMART; SM00516; SEC14; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF48350; GTPase activation domain, GAP; 1. DR PROSITE; PS50191; CRAL_TRIO; 1. DR PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1. DR PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Disease variant; GTPase activation; Lipid-binding; Membrane; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; RNA editing; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P97526" FT CHAIN 2..2839 FT /note="Neurofibromin" FT /id="PRO_0000010773" FT CHAIN 2..1305 FT /note="Neurofibromin truncated" FT /id="PRO_0000010774" FT DOMAIN 1251..1482 FT /note="Ras-GAP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00167" FT DOMAIN 1580..1738 FT /note="CRAL-TRIO" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00056" FT REGION 1580..1837 FT /note="Lipid binding" FT REGION 2787..2839 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 2555..2571 FT /note="Bipartite nuclear localization signal" FT COMPBIAS 2801..2827 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 1276 FT /note="Arginine finger; crucial for GTP hydrolysis by FT stabilizing the transition state" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00167" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P97526" FT MOD_RES 864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 876 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2188 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2467 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q04690" FT MOD_RES 2514 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q04690" FT MOD_RES 2515 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2523 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2543 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2565 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2597 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2802 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2817 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT VAR_SEQ 548..551 FT /note="ALLV -> VRGK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:1339276" FT /id="VSP_001629" FT VAR_SEQ 552..2839 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:1339276" FT /id="VSP_001630" FT VAR_SEQ 574..593 FT /note="SSQMLFYICKKLTSHQMLSS -> RYMYFYFLNSTFKFYFVFLS (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:7570581" FT /id="VSP_043467" FT VAR_SEQ 594..2839 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:7570581" FT /id="VSP_043468" FT VAR_SEQ 1371..1391 FT /note="Missing (in isoform I and isoform 6)" FT /evidence="ECO:0000303|PubMed:1457041, FT ECO:0000303|PubMed:1783401, ECO:0000303|PubMed:1923522, FT ECO:0000303|PubMed:2114220, ECO:0000303|PubMed:2116237, FT ECO:0000303|PubMed:2134734" FT /id="VSP_001628" FT VAR_SEQ 1591..1598 FT /note="SIFYQAGT -> TPPPEPET (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2121370" FT /id="VSP_001631" FT VAR_SEQ 1599..2839 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2121370" FT /id="VSP_001632" FT VAR_SEQ 2792 FT /note="P -> PASLPCSNSAVFMQLFPHQ (in isoform 6)" FT /evidence="ECO:0000303|PubMed:2116237" FT /id="VSP_053587" FT VARIANT 31 FT /note="H -> R (in NF1; dbSNP:rs199474725)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032459" FT VARIANT 74 FT /note="A -> D (in mismatch repair deficient cancer cells; FT dbSNP:rs199474726)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017550" FT VARIANT 80 FT /note="Y -> C (in dbSNP:rs4795581)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022254" FT VARIANT 80 FT /note="Y -> S (in dbSNP:rs4795581)" FT /id="VAR_049135" FT VARIANT 82 FT /note="S -> F (in NF1; dbSNP:rs199474729)" FT /evidence="ECO:0000269|PubMed:11857752" FT /id="VAR_021730" FT VARIANT 93 FT /note="C -> W (in NF1; dbSNP:rs1597629882)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071668" FT VARIANT 93 FT /note="C -> Y (in NF1; dbSNP:rs199474728)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017551" FT VARIANT 117 FT /note="I -> S (in NF1; dbSNP:rs199474731)" FT /evidence="ECO:0000269|PubMed:10607834" FT /id="VAR_010989" FT VARIANT 145 FT /note="L -> P (in NF1; dbSNP:rs199474734)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032460" FT VARIANT 157 FT /note="I -> N (in NF1; dbSNP:rs199474744)" FT /evidence="ECO:0000269|PubMed:15146469" FT /id="VAR_021731" FT VARIANT 160 FT /note="R -> T (in NF1; dbSNP:rs199474752)" FT /evidence="ECO:0000269|PubMed:21838856" FT /id="VAR_065888" FT VARIANT 176 FT /note="D -> E (found in mismatch repair deficient cancer FT cells; also found in a cutaneous neurofibroma from a FT patient with neurofibromatosis; somatic mutation; FT dbSNP:rs112306990)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:22108604" FT /id="VAR_017552" FT VARIANT 186 FT /note="D -> V (in NF1; reduced splicing enhancement; FT dbSNP:rs1567820771)" FT /evidence="ECO:0000269|PubMed:15523642" FT /id="VAR_032461" FT VARIANT 194 FT /note="L -> R (in NFNS; dbSNP:rs199474753)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032462" FT VARIANT 216 FT /note="L -> P (in NF1; dbSNP:rs199474756)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021732" FT VARIANT 324 FT /note="C -> R (in NF1; dbSNP:rs199474735)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032463" FT VARIANT 330 FT /note="A -> T (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474767)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067201" FT VARIANT 337 FT /note="E -> V (in NF1; dbSNP:rs199474736)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032464" FT VARIANT 338 FT /note="D -> G (in NF1; dbSNP:rs199474773)" FT /evidence="ECO:0000269|PubMed:9298829" FT /id="VAR_010990" FT VARIANT 357 FT /note="L -> P (in NF1; dbSNP:rs137854563)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021733" FT VARIANT 393 FT /note="H -> D (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474768)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067202" FT VARIANT 393 FT /note="H -> L (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474769)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067203" FT VARIANT 489 FT /note="Y -> C (in NF1; dbSNP:rs137854557)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032465" FT VARIANT 491 FT /note="Y -> C (in NF1; dbSNP:rs199474757)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021734" FT VARIANT 508 FT /note="L -> P (in NF1; dbSNP:rs137854558)" FT /evidence="ECO:0000269|PubMed:11258625" FT /id="VAR_010991" FT VARIANT 519 FT /note="Q -> P (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474770)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067204" FT VARIANT 532 FT /note="L -> P (in NF1; dbSNP:rs199474737)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032466" FT VARIANT 549 FT /note="L -> P (in NF1; dbSNP:rs199474758)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021735" FT VARIANT 574 FT /note="S -> R (in NF1; dbSNP:rs2144015494 and FT dbSNP:rs2066929440)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032467" FT VARIANT 578 FT /note="L -> R (in NF1; dbSNP:rs199474774)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021736" FT VARIANT 581 FT /note="I -> T (in NF1; dbSNP:rs199474759)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021737" FT VARIANT 583 FT /note="K -> R (in NF1; dbSNP:rs199474760)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021738" FT VARIANT 604 FT /note="L -> V (in NF1; dbSNP:rs142712751)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017553" FT VARIANT 629 FT /note="G -> R (in NF1; affects splicing by creating a novel FT splice acceptor site; dbSNP:rs199474738)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:8834249" FT /id="VAR_002653" FT VARIANT 665 FT /note="S -> F (in NF1; uncertain significance; FT dbSNP:rs145891889)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:15060124" FT /id="VAR_021739" FT VARIANT 678 FT /note="P -> L (in dbSNP:rs17881753)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022255" FT VARIANT 695 FT /note="L -> P (in NF1; dbSNP:rs199474761)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021740" FT VARIANT 712 FT /note="H -> R (in mismatch repair deficient cancer cells; FT dbSNP:rs199474727)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017554" FT VARIANT 763 FT /note="L -> P (in NF1; dbSNP:rs199474762)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021741" FT VARIANT 765 FT /note="R -> H (in NF1; uncertain significance; FT dbSNP:rs199474777)" FT /evidence="ECO:0000269|PubMed:10336779" FT /id="VAR_021742" FT VARIANT 776 FT /note="A -> T (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474771)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067205" FT VARIANT 777 FT /note="W -> S (in NF1; dbSNP:rs199474745)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021743" FT VARIANT 780 FT /note="T -> K (in NF1; dbSNP:rs199474746)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021744" FT VARIANT 781 FT /note="H -> P (in NF1; dbSNP:rs199474763)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021745" FT VARIANT 784 FT /note="W -> C (in NF1; dbSNP:rs199474778)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021746" FT VARIANT 784 FT /note="W -> R (in NF1; dbSNP:rs199474730)" FT /evidence="ECO:0000269|PubMed:11857752, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021747" FT VARIANT 844 FT /note="L -> F (in NF1; dbSNP:rs199474785)" FT /evidence="ECO:0000269|PubMed:10980545, FT ECO:0000269|PubMed:15060124" FT /id="VAR_010992" FT VARIANT 844 FT /note="L -> P (in NF1; dbSNP:rs137854566)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032468" FT VARIANT 844 FT /note="L -> R (in NF1; sporadic; dbSNP:rs137854566)" FT /evidence="ECO:0000269|PubMed:12522551, FT ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:9150739" FT /id="VAR_002654" FT VARIANT 847 FT /note="L -> P (in NF1; dbSNP:rs199474747)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12552569, ECO:0000269|PubMed:15146469" FT /id="VAR_021748" FT VARIANT 848 FT /note="G -> E (in NF1; dbSNP:rs199474748)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021749" FT VARIANT 873 FT /note="R -> C (in dbSNP:rs199474739)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032469" FT VARIANT 898 FT /note="L -> P (in NF1; sporadic; dbSNP:rs199474786)" FT /evidence="ECO:0000269|PubMed:12522551, FT ECO:0000269|PubMed:9150739" FT /id="VAR_002655" FT VARIANT 920 FT /note="L -> P (in NF1; patient with cafe-au-lait spots; may FT be a distinct form of NF1; dbSNP:rs199474775)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021750" FT VARIANT 968 FT /note="M -> R (in NF1; dbSNP:rs199474749)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021751" FT VARIANT 991 FT /note="Missing (in NF1; most patients carrying the mutation FT do not manifest cutaneous neurofibromas)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:17160901, ECO:0000269|PubMed:7904209" FT /id="VAR_002656" FT VARIANT 1035 FT /note="M -> R (in NF1; dbSNP:rs137854553)" FT /evidence="ECO:0000269|PubMed:8807336" FT /id="VAR_002657" FT VARIANT 1048 FT /note="W -> R (in NF1; dbSNP:rs1555614634)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071669" FT VARIANT 1073 FT /note="M -> V (in NF1; dbSNP:rs199474740)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032470" FT VARIANT 1147 FT /note="L -> P (in NF1; dbSNP:rs199474779)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021752" FT VARIANT 1156 FT /note="N -> S (in NF1; dbSNP:rs199474764)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021753" FT VARIANT 1166 FT /note="G -> D (in NF1; dbSNP:rs199474787)" FT /evidence="ECO:0000269|PubMed:7981679" FT /id="VAR_010993" FT VARIANT 1187 FT /note="L -> I (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2067142260)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035543" FT VARIANT 1189 FT /note="Q -> R (in NF1; dbSNP:rs752039618)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071670" FT VARIANT 1193 FT /note="F -> C (in NF1; dbSNP:rs199474780)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021754" FT VARIANT 1196 FT /note="L -> R (in NF1; dbSNP:rs199474741)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032471" FT VARIANT 1204 FT /note="R -> G (in NF1; dbSNP:rs199474732)" FT /evidence="ECO:0000269|PubMed:10336779" FT /id="VAR_021755" FT VARIANT 1204 FT /note="R -> W (in NF1; dbSNP:rs199474732)" FT /evidence="ECO:0000269|PubMed:10607834" FT /id="VAR_010994" FT VARIANT 1243 FT /note="L -> P (in NF1; with neurofibromatous neuropathy; FT dbSNP:rs137854564)" FT /evidence="ECO:0000269|PubMed:15520408" FT /id="VAR_032472" FT VARIANT 1250 FT /note="R -> P (in NF1; dbSNP:rs199474765)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021756" FT VARIANT 1276 FT /note="R -> G (in NF1; dbSNP:rs199474742)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032473" FT VARIANT 1276 FT /note="R -> P (in NF1; complete loss of GAP activity; FT dbSNP:rs137854556)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:9668168" FT /id="VAR_010995" FT VARIANT 1276 FT /note="R -> Q (in NF1 and mismatch repair deficient cancer FT cells; dbSNP:rs137854556)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124" FT /id="VAR_017555" FT VARIANT 1411 FT /note="L -> F (in NFNS; dbSNP:rs199474789)" FT /evidence="ECO:0000269|PubMed:19845691" FT /id="VAR_065236" FT VARIANT 1412 FT /note="R -> S (in NF1; significant reduction of GAP FT activity; dbSNP:rs137854554)" FT /evidence="ECO:0000269|PubMed:9003501" FT /id="VAR_010996" FT VARIANT 1422 FT /note="Y -> H (in dbSNP:rs17884349)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022256" FT VARIANT 1430 FT /note="K -> E (in NF1)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032474" FT VARIANT 1440 FT /note="K -> Q (in NF1; dbSNP:rs199474790)" FT /evidence="ECO:0000269|PubMed:9003501" FT /id="VAR_010997" FT VARIANT 1440 FT /note="K -> R (in NF1; dbSNP:rs199474788)" FT /evidence="ECO:0000269|PubMed:7981679" FT /id="VAR_002658" FT VARIANT 1444 FT /note="K -> E (in NF1 and NFNS; significant reduction of FT intrinsic GAP activity; dbSNP:rs137854550)" FT /evidence="ECO:0000269|PubMed:11857752, FT ECO:0000269|PubMed:1568247, ECO:0000269|PubMed:16380919, FT ECO:0000269|PubMed:9003501" FT /id="VAR_002659" FT VARIANT 1444 FT /note="K -> N (in NF1; dbSNP:rs199474750)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021757" FT VARIANT 1444 FT /note="K -> R (in NF1; dbSNP:rs199474781)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021758" FT VARIANT 1446 FT /note="L -> P (in NF1; dbSNP:rs199474733)" FT /evidence="ECO:0000269|PubMed:10220149, FT ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197" FT /id="VAR_008129" FT VARIANT 1451 FT /note="N -> T (in NFNS; dbSNP:rs199474754)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032475" FT VARIANT 1453 FT /note="V -> L (in NFNS; dbSNP:rs199474755)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032476" FT VARIANT 1459 FT /note="Missing (in NFNS; dbSNP:rs267606607)" FT /evidence="ECO:0000269|PubMed:12707950, FT ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:16380919" FT /id="VAR_032477" FT VARIANT 1484 FT /note="S -> F (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474772)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067206" FT VARIANT 1489 FT /note="S -> G (in NF1; dbSNP:rs199474743)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:9003501" FT /id="VAR_010998" FT VARIANT 1605 FT /note="I -> V (in NF1; reduces protein stability; FT dbSNP:rs199474766)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:21089070" FT /id="VAR_021759" FT VARIANT 1611 FT /note="R -> W (in NF1; dbSNP:rs1060500316)" FT /evidence="ECO:0000269|PubMed:9298829" FT /id="VAR_002660" FT VARIANT 1733 FT /note="L -> LGHEQQKLPAATLAL (in NF1)" FT /evidence="ECO:0000269|PubMed:8317503" FT /id="VAR_002661" FT VARIANT 1785 FT /note="A -> S (in NF1; dbSNP:rs199474782)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021760" FT VARIANT 1951 FT /note="P -> L (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2151550343)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035544" FT VARIANT 1952 FT /note="W -> R (in NF1; dbSNP:rs199474791)" FT /evidence="ECO:0000269|PubMed:9101300" FT /id="VAR_002662" FT VARIANT 1953 FT /note="L -> P (in NF1; dbSNP:rs199474792)" FT /evidence="ECO:0000269|PubMed:2114220" FT /id="VAR_002663" FT VARIANT 1953 FT /note="Missing (in NF1)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021761" FT VARIANT 2001 FT /note="G -> R (in NF1; dbSNP:rs199474751)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021762" FT VARIANT 2012 FT /note="D -> N (in NF1; dbSNP:rs199474783)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021763" FT VARIANT 2088 FT /note="L -> P (in FSNF; no cafe-au-lait macules; null FT mutation; 50% reduction of protein level; FT dbSNP:rs137854561)" FT /evidence="ECO:0000269|PubMed:11704931" FT /id="VAR_017669" FT VARIANT 2125 FT /note="L -> P (in NF1; dbSNP:rs1597843129)" FT /evidence="ECO:0000269|PubMed:24413922" FT /id="VAR_071671" FT VARIANT 2164 FT /note="L -> M (in NF1; dbSNP:rs137854551)" FT /evidence="ECO:0000269|PubMed:1302608" FT /id="VAR_002664" FT VARIANT 2192 FT /note="Y -> N (in NF1; dbSNP:rs267606598)" FT /evidence="ECO:0000269|PubMed:1302608" FT /id="VAR_002665" FT VARIANT 2221 FT /note="P -> A (in NF1; dbSNP:rs199474776)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021764" FT VARIANT 2357 FT /note="E -> K (in NF1; dbSNP:rs199474784)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021765" FT VARIANT 2387..2388 FT /note="Missing (in NF1)" FT /evidence="ECO:0000269|PubMed:10607834, FT ECO:0000269|PubMed:8081387" FT /id="VAR_002666" FT VARIANT 2507 FT /note="T -> I (in NF1; dbSNP:rs149055633)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021766" FT VARIANT 2511 FT /note="V -> L (in dbSNP:rs2230850)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022257" FT VARIANT 2631 FT /note="T -> A (in NF1; dbSNP:rs199474793)" FT /evidence="ECO:0000269|PubMed:8544190" FT /id="VAR_002667" FT VARIANT 2745 FT /note="G -> R (in a breast cancer sample; somatic mutation; FT dbSNP:rs2151587866)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035545" FT MUTAGEN 1691 FT /note="K->A: Reduces phospholipid binding; when associated FT with A-1695; A-1769 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1695 FT /note="R->A: Reduces phospholipid binding; when associated FT with A-1691; A-1769 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1769 FT /note="R->A: Reduces phospholipid binding; when associated FT with A-1691; A-1695 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1771 FT /note="K->A: Reduces phospholipid binding; when associated FT with A-1691; A-169 and A-1769." FT /evidence="ECO:0000269|PubMed:16397625, FT ECO:0000269|PubMed:21089070" FT MUTAGEN 1771 FT /note="Missing: Reduces protein stability." FT /evidence="ECO:0000269|PubMed:16397625, FT ECO:0000269|PubMed:21089070" FT CONFLICT 496 FT /note="M -> I (in Ref. 11; AAA74897/AAB59558)" FT /evidence="ECO:0000305" FT CONFLICT 1094..1095 FT /note="EL -> ST (in Ref. 14; AAA59923)" FT /evidence="ECO:0000305" FT CONFLICT 1576 FT /note="H -> HH (in Ref. 11; AAA74897/AAB59558)" FT /evidence="ECO:0000305" FT HELIX 5..18 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 34..46 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 51..66 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 73..96 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 106..111 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 114..121 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 130..146 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 150..166 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 174..181 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 187..201 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 206..226 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 228..236 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 240..256 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 260..276 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 278..285 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 294..307 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 314..331 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 341..357 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 360..362 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 367..371 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 373..386 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 387..389 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 394..398 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 399..402 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 404..419 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 429..435 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 436..454 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 483..502 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 505..508 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 516..518 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 522..530 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 531..534 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 539..551 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 559..561 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 566..568 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 569..587 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 593..617 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 678..691 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 693..696 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 700..708 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 711..720 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 724..727 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 728..730 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 735..745 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 752..762 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 771..793 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 832..846 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 849..851 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 890..899 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 900..903 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 907..909 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 910..923 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 927..929 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 930..942 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 947..949 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 955..973 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 979..983 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 989..1000 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1006..1021 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 1026..1028 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1034..1046 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 1049..1052 FT /evidence="ECO:0007829|PDB:8EDO" FT HELIX 1053..1056 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1060..1063 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1064..1080 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 1091..1093 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1095..1116 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1135..1155 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1157..1160 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1162..1167 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1173..1190 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1197..1200 FT /evidence="ECO:0007829|PDB:7PGU" FT TURN 1201..1204 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1208..1216 FT /evidence="ECO:0007829|PDB:1NF1" FT TURN 1217..1219 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1220..1228 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1233..1235 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1236..1249 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1253..1267 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1271..1273 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1277..1279 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1280..1309 FT /evidence="ECO:0007829|PDB:6OB3" FT TURN 1310..1312 FT /evidence="ECO:0007829|PDB:6V6F" FT HELIX 1315..1317 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1323..1325 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1328..1330 FT /evidence="ECO:0007829|PDB:6V65" FT HELIX 1332..1351 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1354..1356 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1359..1370 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1392..1394 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1398..1400 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1401..1411 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1414..1419 FT /evidence="ECO:0007829|PDB:6OB3" FT TURN 1421..1425 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1426..1429 FT /evidence="ECO:0007829|PDB:6V6F" FT HELIX 1433..1451 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1459..1464 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1465..1483 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1510..1514 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1517..1520 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1531..1533 FT /evidence="ECO:0007829|PDB:7PGS" FT HELIX 1535..1544 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1569..1578 FT /evidence="ECO:0007829|PDB:3P7Z" FT TURN 1582..1586 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1587..1590 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1592..1598 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1604..1609 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1610..1612 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1615..1617 FT /evidence="ECO:0007829|PDB:2D4Q" FT HELIX 1620..1631 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1632..1636 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1639..1644 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1650..1652 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1656..1661 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1662..1664 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1668..1672 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1674..1681 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1684..1692 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1694..1697 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1698..1702 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1706..1711 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1714..1717 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1721..1723 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1728..1732 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1738..1749 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1751..1757 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1759..1767 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1770..1772 FT /evidence="ECO:0007829|PDB:2D4Q" FT STRAND 1775..1777 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1780..1784 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1785..1787 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1788..1795 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1798..1803 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1810..1813 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1817..1833 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1847..1849 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1851..1861 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1867..1884 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1906..1918 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1920..1922 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1923..1936 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1939..1949 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1950..1952 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1957..1960 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 1961..1963 FT /evidence="ECO:0007829|PDB:8EDO" FT STRAND 1965..1967 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1968..1984 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1989..2000 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2004..2006 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2007..2021 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2026..2041 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2043..2057 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2058..2060 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2061..2063 FT /evidence="ECO:0007829|PDB:8EDO" FT HELIX 2069..2071 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2075..2089 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2090..2092 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2096..2108 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2109..2112 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2116..2134 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2143..2155 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2159..2165 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2173..2177 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2180..2184 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2199..2219 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2225..2237 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2242..2244 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2245..2250 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2252..2255 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2261..2280 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2285..2287 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2289..2301 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2302..2304 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2311..2314 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2317..2323 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2328..2347 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 2351..2354 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2356..2363 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2365..2367 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2368..2378 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2382..2384 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2386..2392 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2393..2395 FT /evidence="ECO:0007829|PDB:7PGS" FT HELIX 2396..2399 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2403..2424 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2427..2429 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2434..2436 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2437..2441 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2443..2445 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2447..2452 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2607..2609 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2613..2629 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2633..2649 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2651..2653 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2654..2657 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2658..2671 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2675..2690 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2700..2702 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2704..2706 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2709..2715 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2728..2742 FT /evidence="ECO:0007829|PDB:7PGP" FT VARIANT P21359-2:1661 FT /note="C -> R (in NF1; dbSNP:rs1597829901)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_082822" FT VARIANT P21359-2:1918 FT /note="I -> T (in NF1; dbSNP:rs1304057833)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_082823" SQ SEQUENCE 2839 AA; 319372 MW; C079475139DBD51E CRC64; MAAHRPVEWV QAVVSRFDEQ LPIKTGQQNT HTKVSTEHNK ECLINISKYK FSLVISGLTT ILKNVNNMRI FGEAAEKNLY LSQLIILDTL EKCLAGQPKD TMRLDETMLV KQLLPEICHF LHTCREGNQH AAELRNSASG VLFSLSCNNF NAVFSRISTR LQELTVCSED NVDVHDIELL QYINVDCAKL KRLLKETAFK FKALKKVAQL AVINSLEKAF WNWVENYPDE FTKLYQIPQT DMAECAEKLF DLVDGFAEST KRKAAVWPLQ IILLILCPEI IQDISKDVVD ENNMNKKLFL DSLRKALAGH GGSRQLTESA AIACVKLCKA STYINWEDNS VIFLLVQSMV VDLKNLLFNP SKPFSRGSQP ADVDLMIDCL VSCFRISPHN NQHFKICLAQ NSPSTFHYVL VNSLHRIITN SALDWWPKID AVYCHSVELR NMFGETLHKA VQGCGAHPAI RMAPSLTFKE KVTSLKFKEK PTDLETRSYK YLLLSMVKLI HADPKLLLCN PRKQGPETQG STAELITGLV QLVPQSHMPE IAQEAMEALL VLHQLDSIDL WNPDAPVETF WEISSQMLFY ICKKLTSHQM LSSTEILKWL REILICRNKF LLKNKQADRS SCHFLLFYGV GCDIPSSGNT SQMSMDHEEL LRTPGASLRK GKGNSSMDSA AGCSGTPPIC RQAQTKLEVA LYMFLWNPDT EAVLVAMSCF RHLCEEADIR CGVDEVSVHN LLPNYNTFME FASVSNMMST GRAALQKRVM ALLRRIEHPT AGNTEAWEDT HAKWEQATKL ILNYPKAKME DGQAAESLHK TIVKRRMSHV SGGGSIDLSD TDSLQEWINM TGFLCALGGV CLQQRSNSGL ATYSPPMGPV SERKGSMISV MSSEGNADTP VSKFMDRLLS LMVCNHEKVG LQIRTNVKDL VGLELSPALY PMLFNKLKNT ISKFFDSQGQ VLLTDTNTQF VEQTIAIMKN LLDNHTEGSS EHLGQASIET MMLNLVRYVR VLGNMVHAIQ IKTKLCQLVE VMMARRDDLS FCQEMKFRNK MVEYLTDWVM GTSNQAADDD VKCLTRDLDQ ASMEAVVSLL AGLPLQPEEG DGVELMEAKS QLFLKYFTLF MNLLNDCSEV EDESAQTGGR KRGMSRRLAS LRHCTVLAMS NLLNANVDSG LMHSIGLGYH KDLQTRATFM EVLTKILQQG TEFDTLAETV LADRFERLVE LVTMMGDQGE LPIAMALANV VPCSQWDELA RVLVTLFDSR HLLYQLLWNM FSKEVELADS MQTLFRGNSL ASKIMTFCFK VYGATYLQKL LDPLLRIVIT SSDWQHVSFE VDPTRLEPSE SLEENQRNLL QMTEKFFHAI ISSSSEFPPQ LRSVCHCLYQ ATCHSLLNKA TVKEKKENKK SVVSQRFPQN SIGAVGSAMF LRFINPAIVS PYEAGILDKK PPPRIERGLK LMSKILQSIA NHVLFTKEEH MRPFNDFVKS NFDAARRFFL DIASDCPTSD AVNHSLSFIS DGNVLALHRL LWNNQEKIGQ YLSSNRDHKA VGRRPFDKMA TLLAYLGPPE HKPVADTHWS SLNLTSSKFE EFMTRHQVHE KEEFKALKTL SIFYQAGTSK AGNPIFYYVA RRFKTGQING DLLIYHVLLT LKPYYAKPYE IVVDLTHTGP SNRFKTDFLS KWFVVFPGFA YDNVSAVYIY NCNSWVREYT KYHERLLTGL KGSKRLVFID CPGKLAEHIE HEQQKLPAAT LALEEDLKVF HNALKLAHKD TKVSIKVGST AVQVTSAERT KVLGQSVFLN DIYYASEIEE ICLVDENQFT LTIANQGTPL TFMHQECEAI VQSIIHIRTR WELSQPDSIP QHTKIRPKDV PGTLLNIALL NLGSSDPSLR SAAYNLLCAL TCTFNLKIEG QLLETSGLCI PANNTLFIVS ISKTLAANEP HLTLEFLEEC ISGFSKSSIE LKHLCLEYMT PWLSNLVRFC KHNDDAKRQR VTAILDKLIT MTINEKQMYP SIQAKIWGSL GQITDLLDVV LDSFIKTSAT GGLGSIKAEV MADTAVALAS GNVKLVSSKV IGRMCKIIDK TCLSPTPTLE QHLMWDDIAI LARYMLMLSF NNSLDVAAHL PYLFHVVTFL VATGPLSLRA STHGLVINII HSLCTCSQLH FSEETKQVLR LSLTEFSLPK FYLLFGISKV KSAAVIAFRS SYRDRSFSPG SYERETFALT SLETVTEALL EIMEACMRDI PTCKWLDQWT ELAQRFAFQY NPSLQPRALV VFGCISKRVS HGQIKQIIRI LSKALESCLK GPDTYNSQVL IEATVIALTK LQPLLNKDSP LHKALFWVAV AVLQLDEVNL YSAGTALLEQ NLHTLDSLRI FNDKSPEEVF MAIRNPLEWH CKQMDHFVGL NFNSNFNFAL VGHLLKGYRH PSPAIVARTV RILHTLLTLV NKHRNCDKFE VNTQSVAYLA ALLTVSEEVR SRCSLKHRKS LLLTDISMEN VPMDTYPIHH GDPSYRTLKE TQPWSSPKGS EGYLAATYPT VGQTSPRARK SMSLDMGQPS QANTKKLLGT RKSFDHLISD TKAPKRQEME SGITTPPKMR RVAETDYEME TQRISSSQQH PHLRKVSVSE SNVLLDEEVL TDPKIQALLL TVLATLVKYT TDEFDQRILY EYLAEASVVF PKVFPVVHNL LDSKINTLLS LCQDPNLLNP IHGIVQSVVY HEESPPQYQT SYLQSFGFNG LWRFAGPFSK QTQIPDYAEL IVKFLDALID TYLPGIDEET SEESLLTPTS PYPPALQSQL SITANLNLSN SMTSLATSQH SPGIDKENVE LSPTTGHCNS GRTRHGSASQ VQKQRSAGSF KRNSIKKIV // ID NRK_HUMAN Reviewed; 1582 AA. AC Q7Z2Y5; Q32ND6; Q5H9K2; Q6ZMP2; DT 03-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 03-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 167. DE RecName: Full=Nik-related protein kinase; DE EC=2.7.11.1; GN Name=NRK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Fetal kidney; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1291 (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-852; SER-855; SER-1027; RP SER-1031 AND SER-1034, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [6] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-355; MET-358; CYS-424; ALA-426; RP GLY-579; GLY-679; LEU-880; GLY-971; SER-1106; PRO-1121; LEU-1276; ALA-1471 RP AND LEU-1472. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May phosphorylate cofilin-1 and induce actin polymerization CC through this process, during the late stages of embryogenesis. Involved CC in the TNF-induced signaling pathway (By similarity). {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q7Z2Y5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q7Z2Y5-2; Sequence=VSP_020654, VSP_020657; CC Name=3; CC IsoId=Q7Z2Y5-3; Sequence=VSP_020655, VSP_020656; CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; BX538345; CAD98108.1; -; mRNA. DR EMBL; Z68339; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z69734; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z70274; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z83850; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC108702; AAI08703.1; -; mRNA. DR EMBL; AK131549; BAD18683.1; -; mRNA. DR CCDS; CCDS65305.1; -. [Q7Z2Y5-1] DR RefSeq; NP_940867.2; NM_198465.4. [Q7Z2Y5-1] DR AlphaFoldDB; Q7Z2Y5; -. DR SMR; Q7Z2Y5; -. DR BioGRID; 128472; 7. DR FunCoup; Q7Z2Y5; 21. DR IntAct; Q7Z2Y5; 2. DR MINT; Q7Z2Y5; -. DR STRING; 9606.ENSP00000434830; -. DR GlyCosmos; Q7Z2Y5; 2 sites, 1 glycan. DR GlyGen; Q7Z2Y5; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; Q7Z2Y5; -. DR PhosphoSitePlus; Q7Z2Y5; -. DR BioMuta; NRK; -. DR DMDM; 115502506; -. DR CPTAC; non-CPTAC-5656; -. DR jPOST; Q7Z2Y5; -. DR MassIVE; Q7Z2Y5; -. DR PaxDb; 9606-ENSP00000434830; -. DR PeptideAtlas; Q7Z2Y5; -. DR ProteomicsDB; 68985; -. [Q7Z2Y5-1] DR ProteomicsDB; 68986; -. [Q7Z2Y5-2] DR ProteomicsDB; 68987; -. [Q7Z2Y5-3] DR Antibodypedia; 2074; 67 antibodies from 20 providers. DR DNASU; 203447; -. DR Ensembl; ENST00000243300.14; ENSP00000434830.1; ENSG00000123572.18. [Q7Z2Y5-1] DR Ensembl; ENST00000536164.5; ENSP00000438785.1; ENSG00000123572.18. [Q7Z2Y5-3] DR GeneID; 203447; -. DR KEGG; hsa:203447; -. DR MANE-Select; ENST00000243300.14; ENSP00000434830.1; NM_198465.4; NP_940867.2. DR UCSC; uc065ans.1; human. [Q7Z2Y5-1] DR AGR; HGNC:25391; -. DR ClinPGx; PA134869113; -. DR CTD; 203447; -. DR DisGeNET; 203447; -. DR GeneCards; NRK; -. DR HGNC; HGNC:25391; NRK. DR HPA; ENSG00000123572; Tissue enhanced (adrenal gland, ovary, placenta). DR MIM; 300791; gene. DR OpenTargets; ENSG00000123572; -. DR VEuPathDB; HostDB:ENSG00000123572; -. DR eggNOG; KOG0587; Eukaryota. DR GeneTree; ENSGT00940000161533; -. DR HOGENOM; CLU_001831_2_0_1; -. DR InParanoid; Q7Z2Y5; -. DR OrthoDB; 8693905at2759; -. DR PAN-GO; Q7Z2Y5; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q7Z2Y5; -. DR PathwayCommons; Q7Z2Y5; -. DR SignaLink; Q7Z2Y5; -. DR SIGNOR; Q7Z2Y5; -. DR Agora; ENSG00000123572; -. DR BioGRID-ORCS; 203447; 25 hits in 788 CRISPR screens. DR ChiTaRS; NRK; human. DR GeneWiki; NRK_(gene); -. DR GenomeRNAi; 203447; -. DR Pharos; Q7Z2Y5; Tdark. DR PRO; PR:Q7Z2Y5; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q7Z2Y5; protein. DR Bgee; ENSG00000123572; Expressed in tibia and 123 other cell types or tissues. DR ExpressionAtlas; Q7Z2Y5; baseline and differential. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0046330; P:positive regulation of JNK cascade; IBA:GO_Central. DR FunFam; 3.30.200.20:FF:000355; Nik related kinase; 1. DR FunFam; 1.10.510.10:FF:000435; Nik-related protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001180; CNH_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051700; STE20_Ser-Thr_kinase. DR PANTHER; PTHR47096; MISSHAPEN LIKE KINASE 1; 1. DR PANTHER; PTHR47096:SF2; NIK-RELATED PROTEIN KINASE; 1. DR Pfam; PF00780; CNH; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00036; CNH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50219; CNH; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Coiled coil; Kinase; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1582 FT /note="Nik-related protein kinase" FT /id="PRO_0000250511" FT DOMAIN 25..313 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 1209..1552 FT /note="CNH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00795" FT REGION 492..579 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 783..859 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 926..1156 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 725..759 FT /evidence="ECO:0000255" FT COMPBIAS 492..507 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 527..538 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 551..572 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 803..814 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 825..834 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 850..859 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 926..944 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 965..978 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 999..1016 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1043..1061 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1125..1135 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1136..1154 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 177 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 31..39 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 54 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 852 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 855 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 1027 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 1031 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 1034 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT VAR_SEQ 1..332 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020654" FT VAR_SEQ 164..188 FT /note="GLAHLHAHRVIHRDIKGQNVLLTHN -> PKVIFLGTGCSDSSLKKELCLKH FT QN (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_020655" FT VAR_SEQ 189..1582 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_020656" FT VAR_SEQ 333..338 FT /note="IIKKRQ -> MFFSFV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020657" FT VARIANT 355 FT /note="Q -> H (in dbSNP:rs55862725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040951" FT VARIANT 358 FT /note="V -> M (in dbSNP:rs209373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_033908" FT VARIANT 424 FT /note="S -> C (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040952" FT VARIANT 426 FT /note="P -> A (in dbSNP:rs55635933)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040953" FT VARIANT 579 FT /note="E -> G (in dbSNP:rs56350428)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040954" FT VARIANT 679 FT /note="E -> G (in dbSNP:rs35115195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040955" FT VARIANT 727 FT /note="R -> H (in dbSNP:rs33936206)" FT /id="VAR_051653" FT VARIANT 880 FT /note="I -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs764355898)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040956" FT VARIANT 971 FT /note="D -> G (in dbSNP:rs35334892)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040957" FT VARIANT 993 FT /note="A -> E (in dbSNP:rs16984889)" FT /id="VAR_033909" FT VARIANT 1106 FT /note="P -> S (in dbSNP:rs35393519)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040958" FT VARIANT 1121 FT /note="A -> P (in dbSNP:rs35720774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040959" FT VARIANT 1276 FT /note="H -> L (in dbSNP:rs35942881)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040960" FT VARIANT 1471 FT /note="G -> A (in dbSNP:rs34232354)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040961" FT VARIANT 1472 FT /note="M -> L (in dbSNP:rs35609510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040962" FT CONFLICT 152 FT /note="D -> G (in Ref. 1; CAD98108)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="G -> S (in Ref. 1; CAD98108)" FT /evidence="ECO:0000305" FT CONFLICT 572 FT /note="E -> G (in Ref. 1; CAD98108)" FT /evidence="ECO:0000305" FT CONFLICT 705 FT /note="R -> G (in Ref. 1; CAD98108)" FT /evidence="ECO:0000305" FT CONFLICT 1138 FT /note="S -> P (in Ref. 1; CAD98108)" FT /evidence="ECO:0000305" SQ SEQUENCE 1582 AA; 178479 MW; C9C56860C8AEBFF3 CRC64; MAGPGGWRDR EVTDLGHLPD PTGIFSLDKT IGLGTYGRIY LGLHEKTGAF TAVKVMNARK TPLPEIGRRV RVNKYQKSVG WRYSDEEEDL RTELNLLRKY SFHKNIVSFY GAFFKLSPPG QRHQLWMVME LCAAGSVTDV VRMTSNQSLK EDWIAYICRE ILQGLAHLHA HRVIHRDIKG QNVLLTHNAE VKLVDFGVSA QVSRTNGRRN SFIGTPYWMA PEVIDCDEDP RRSYDYRSDV WSVGITAIEM AEGAPPLCNL QPLEALFVIL RESAPTVKSS GWSRKFHNFM EKCTIKNFLF RPTSANMLQH PFVRDIKNER HVVESLTRHL TGIIKKRQKK GIPLIFEREE AIKEQYTVRR FRGPSCTHEL LRLPTSSRCR PLRVLHGEPS QPRWLPDREE PQVQALQQLQ GAARVFMPLQ ALDSAPKPLK GQAQAPQRLQ GAARVFMPLQ AQVKAKASKP LQMQIKAPPR LRRAARVLMP LQAQVRAPRL LQVQSQVSKK QQAQTQTSEP QDLDQVPEEF QGQDQVPEQQ RQGQAPEQQQ RHNQVPEQEL EQNQAPEQPE VQEQAAEPAQ AETEAEEPES LRVNAQVFLP LLSQDHHVLL PLHLDTQVLI PVEGQTEGSP QAQAWTLEPP QAIGSVQALI EGLSRDLLRA PNSNNSKPLG PLQTLMENLS SNRFYSQPEQ AREKKSKVST LRQALAKRLS PKRFRAKSSW RPEKLELSDL EARRQRRQRR WEDIFNQHEE ELRQVDKDKE DESSDNDEVF HSIQAEVQIE PLKPYISNPK KIEVQERSPS VPNNQDHAHH VKFSSSVPQR SLLEQAQKPI DIRQRSSQNR QNWLAASESS SEEESPVTGR RSQSSPPYST IDQKLLVDIH VPDGFKVGKI SPPVYLTNEW VGYNALSEIF RNDWLTPAPV IQPPEEDGDY VELYDASADT DGDDDDESND TFEDTYDHAN GNDDLDNQVD QANDVCKDHD DDNNKFVDDV NNNYYEAPSC PRASYGRDGS CKQDGYDGSR GKEEAYRGYG SHTANRSHGG SAASEDNAAI GDQEEHAANI GSERRGSEGD GGKGVVRTSE ESGALGLNGE ENCSETDGPG LKRPASQDFE YLQEEPGGGN EASNAIDSGA APSAPDHESD NKDISESSTQ SDFSANHSSP SKGSGMSADA NFASAILYAG FVEVPEESPK QPSEVNVNPL YVSPACKKPL IHMYEKEFTS EICCGSLWGV NLLLGTRSNL YLMDRSGKAD ITKLIRRRPF RQIQVLEPLN LLITISGHKN RLRVYHLTWL RNKILNNDPE SKRRQEEMLK TEEACKAIDK LTGCEHFSVL QHEETTYIAI ALKSSIHLYA WAPKSFDEST AIKVCIDQSA DSEGDYMSYQ AYIRILAKIQ AADPVNRFKR PDELLHLLKL KVFPTLDHKP VTVDLAIGSE KRLKIFFSSA DGYHLIDAES EVMSDVTLPK NPLEIIIPQN IIILPDCLGI GMMLTFNAEA LSVEANEQLF KKILEMWKDI PSSIAFECTQ RTTGWGQKAI EVRSLQSRVL ESELKRRSIK KLRFLCTRGD KLFFTSTLRN HHSRVYFMTL GKLEELQSNY DV // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PGFRB_HUMAN Reviewed; 1106 AA. AC P09619; B5A957; Q8N5L4; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1989, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=Platelet-derived growth factor receptor beta; DE Short=PDGF-R-beta; DE Short=PDGFR-beta; DE EC=2.7.10.1; DE AltName: Full=Beta platelet-derived growth factor receptor; DE AltName: Full=Beta-type platelet-derived growth factor receptor; DE AltName: Full=CD140 antigen-like family member B; DE AltName: Full=Platelet-derived growth factor receptor 1; DE Short=PDGFR-1; DE AltName: CD_antigen=CD140b; DE Flags: Precursor; GN Name=PDGFRB; Synonyms=PDGFR, PDGFR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB. RX PubMed=2835772; DOI=10.1073/pnas.85.10.3435; RA Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J., RA Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.; RT "Cloning and expression of a cDNA coding for the human platelet-derived RT growth factor receptor: evidence for more than one receptor class."; RL Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH PDGFA AND PDGFB. RX PubMed=2850496; DOI=10.1128/mcb.8.8.3476-3486.1988; RA Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B., RA Oestman A., Betsholtz C., Heldin C.-H.; RT "cDNA cloning and expression of a human platelet-derived growth factor RT (PDGF) receptor specific for B-chain-containing PDGF molecules."; RL Mol. Cell. Biol. 8:3476-3486(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PHE-180. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569. RX PubMed=9285559; DOI=10.1038/sj.onc.1201267; RA Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P., Goustin A.S.; RT "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I- RT infected T-cells results in a novel tyrosine kinase product with RT transforming activity."; RL Oncogene 15:1051-1057(1997). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CEP85L. RX PubMed=21938754; DOI=10.1002/gcc.20930; RA Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J., Socci N.D., RA Hollis C.J., Dean R.S., Yenamandra A., Jagasia M., Kim A.S., Dave U.P., RA Thomas R.K., Pao W.; RT "Systematic screen for tyrosine kinase rearrangements identifies a novel RT C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated RT myeloproliferative neoplasm."; RL Genes Chromosomes Cancer 51:54-65(2012). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106. RX PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3; RA Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.; RT "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes."; RL Cell 55:655-661(1988). RN [9] RP PROTEIN SEQUENCE OF 33-47. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [10] RP PHOSPHORYLATION AT TYR-751 AND TYR-857. RX PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2; RA Kazlauskas A., Cooper J.A.; RT "Autophosphorylation of the PDGF receptor in the kinase insert region RT regulates interactions with cell proteins."; RL Cell 58:1121-1133(1989). RN [11] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND RP SUBCELLULAR LOCATION. RX PubMed=2554309; DOI=10.1073/pnas.86.21.8314; RA Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J., RA Ruggiero M., Aaronson S.A.; RT "Independent expression of human alpha or beta platelet-derived growth RT factor receptor cDNAs in a naive hematopoietic cell leads to functional RT coupling with mitogenic and chemotactic signaling pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989). RN [12] RP FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN PHOSPHORYLATION RP OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND TYR-857. RX PubMed=1653029; DOI=10.1091/mbc.2.6.413; RA Kazlauskas A., Durden D.L., Cooper J.A.; RT "Functions of the major tyrosine phosphorylation site of the PDGF receptor RT beta subunit."; RL Cell Regul. 2:413-425(1991). RN [13] RP INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR PDGFA RP AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751. RX PubMed=1709159; DOI=10.1016/s0021-9258(18)31541-2; RA Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A., RA Bowen-Pope D.F., Cooper J.A., Kazlauskas A.; RT "Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit RT dimerization and intersubunit trans-phosphorylation."; RL J. Biol. Chem. 266:8987-8992(1991). RN [14] RP FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION, CATALYTIC RP ACTIVITY, AND MUTAGENESIS OF LYS-634. RX PubMed=1846866; DOI=10.1083/jcb.112.3.469; RA Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.; RT "Effect of receptor kinase inactivation on the rate of internalization and RT degradation of PDGF and the PDGF beta-receptor."; RL J. Cell Biol. 112:469-478(1991). RN [15] RP FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY, RP INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740; TYR-751; RP TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716; TYR-740; TYR-751; RP TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857. RX PubMed=1314164; DOI=10.1002/j.1460-2075.1992.tb05182.x; RA Kashishian A., Kazlauskas A., Cooper J.A.; RT "Phosphorylation sites in the PDGF receptor with different specificities RT for binding GAP and PI3 kinase in vivo."; RL EMBO J. 11:1373-1382(1992). RN [16] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION OF RP PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND TYR-1021, RP AND MUTAGENESIS OF TYR-1009 AND TYR-1021. RX PubMed=1396585; DOI=10.1002/j.1460-2075.1992.tb05484.x; RA Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C., RA Hellman U., Claesson-Welsh L., Heldin C.H.; RT "Identification of two C-terminal autophosphorylation sites in the PDGF RT beta-receptor: involvement in the interaction with phospholipase C-gamma."; RL EMBO J. 11:3911-3919(1992). RN [17] RP UBIQUITINATION, AND DEGRADATION. RX PubMed=1313434; DOI=10.1016/s0021-9258(18)42714-7; RA Mori S., Heldin C.H., Claesson-Welsh L.; RT "Ligand-induced polyubiquitination of the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 267:6429-6434(1992). RN [18] RP INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751 AND RP TYR-771. RX PubMed=1375321; DOI=10.1128/mcb.12.6.2534-2544.1992; RA Kazlauskas A., Kashishian A., Cooper J.A., Valius M.; RT "GTPase-activating protein and phosphatidylinositol 3-kinase bind to RT distinct regions of the platelet-derived growth factor receptor beta RT subunit."; RL Mol. Cell. Biol. 12:2534-2544(1992). RN [19] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT RP TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF TYR-579 AND TYR-581. RX PubMed=7685273; DOI=10.1002/j.1460-2075.1993.tb05879.x; RA Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A., RA Claesson-Welsh L., Heldin C.H.; RT "Identification of two juxtamembrane autophosphorylation sites in the PDGF RT beta-receptor; involvement in the interaction with Src family tyrosine RT kinases."; RL EMBO J. 12:2257-2264(1993). RN [20] RP INTERACTION WITH DGFA AND PDGFB. RX PubMed=7679113; DOI=10.1016/s0021-9258(18)53739-x; RA Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L., RA LaRochelle W.J., Giese N.A.; RT "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding RT to alpha and beta PDGF receptor."; RL J. Biol. Chem. 268:3625-3631(1993). RN [21] RP FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH RP PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009. RX PubMed=7691811; DOI=10.1016/s0021-9258(20)80562-6; RA Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S., Cooper J.A., RA Shoelson S.E., Walsh C.T., Neel B.G.; RT "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by RT its binding site, phosphotyrosine 1009, on the human platelet-derived RT growth factor receptor."; RL J. Biol. Chem. 268:21478-21481(1993). RN [22] RP INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1, AND RP MUTAGENESIS OF TYR-751. RX PubMed=7692233; DOI=10.1128/mcb.13.11.6889-6896.1993; RA Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J., RA Schlessinger J.; RT "Two signaling molecules share a phosphotyrosine-containing binding site in RT the platelet-derived growth factor receptor."; RL Mol. Cell. Biol. 13:6889-6896(1993). RN [23] RP INTERACTION WITH SHB. RX PubMed=8302579; RA Welsh M., Mares J., Karlsson T., Lavergne C., Breant B., Claesson-Welsh L.; RT "Shb is a ubiquitously expressed Src homology 2 protein."; RL Oncogene 9:19-27(1994). RN [24] RP INTERACTION WITH GRB7. RX PubMed=8940081; DOI=10.1074/jbc.271.48.30942; RA Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.; RT "Grb7 is a downstream signaling component of platelet-derived growth factor RT alpha- and beta-receptors."; RL J. Biol. Chem. 271:30942-30949(1996). RN [25] RP CHROMOSOMAL TRANSLOCATION WITH TRIP11. RX PubMed=9373237; RA Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.; RT "Fusion of the platelet-derived growth factor receptor beta to a novel gene RT CEV14 in acute myelogenous leukemia after clonal evolution."; RL Blood 90:4271-4277(1997). RN [26] RP INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716; RP TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021. RX PubMed=10454568; DOI=10.1128/mcb.19.9.6217; RA Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A., RA Swamy O.R., Leone M.E., Riedel H.; RT "Grb10, a positive, stimulatory signaling adapter in platelet-derived RT growth factor BB-, insulin-like growth factor I-, and insulin-mediated RT mitogenesis."; RL Mol. Cell. Biol. 19:6217-6228(1999). RN [27] RP INTERACTION WITH SH2B2/APS. RX PubMed=9989826; DOI=10.1038/sj.onc.1202326; RA Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., RA Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.; RT "APS, an adaptor protein containing PH and SH2 domains, is associated with RT the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis."; RL Oncogene 18:759-767(1999). RN [28] RP PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778; RP TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT TYR-751; TYR-857; RP TYR-1009 AND TYR-1021 BY PTPRJ. RX PubMed=10821867; DOI=10.1074/jbc.275.21.16219; RA Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E., RA Vilella R., Bohmer F., Ostman A.; RT "Site-selective dephosphorylation of the platelet-derived growth factor RT beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1."; RL J. Biol. Chem. 275:16219-16226(2000). RN [29] RP INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [30] RP FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC. RX PubMed=11297552; DOI=10.1074/jbc.m101056200; RA Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., RA Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., RA Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.; RT "Platelet-derived growth factor C (PDGF-C), a novel growth factor that RT binds to PDGF alpha and beta receptor."; RL J. Biol. Chem. 276:27406-27414(2001). RN [31] RP FUNCTION AS A RECEPTOR FOR PDGFD. RX PubMed=11331881; DOI=10.1038/35074588; RA Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H., RA Alitalo K., Eriksson U.; RT "PDGF-D is a specific, protease-activated ligand for the PDGF beta- RT receptor."; RL Nat. Cell Biol. 3:512-516(2001). RN [32] RP CHROMOSOMAL TRANSLOCATION WITH ETV6. RX PubMed=12181402; DOI=10.1056/nejmoa020150; RA Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., RA Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., RA Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E., RA Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.; RT "Response to imatinib mesylate in patients with chronic myeloproliferative RT diseases with rearrangements of the platelet-derived growth factor receptor RT beta."; RL N. Engl. J. Med. 347:481-487(2002). RN [33] RP CHROMOSOMAL TRANSLOCATION WITH PDE4DIP. RX PubMed=12907457; DOI=10.1182/blood-2003-04-1150; RA Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C., Shipp M.A., RA Aguiar R.C.T.; RT "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated RT with eosinophilia: involvement of PDGFRB and response to imatinib."; RL Blood 102:4187-4190(2003). RN [34] RP CHROMOSOMAL TRANSLOCATION WITH SPECC1. RX PubMed=15087372; DOI=10.1158/0008-5472.can-03-4026; RA Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C., Locatelli F., RA Maserati E., Pasquali F., Panarello C.; RT "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic RT leukemia with t(5;17)(q33;p11.2)."; RL Cancer Res. 64:2649-2651(2004). RN [35] RP CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ACTIVITY REGULATION. RX PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005; RA Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J., RA Chase A.J., Cross N.C.; RT "p53-Binding protein 1 is fused to the platelet-derived growth factor RT receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib- RT responsive eosinophilic myeloproliferative disorder."; RL Cancer Res. 64:7216-7219(2004). RN [36] RP PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND RP DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2. RX PubMed=14966296; DOI=10.1128/mcb.24.5.2190-2201.2004; RA Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B., RA Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H., Roennstrand L., RA Ostman A., Hellberg C.; RT "Site-selective regulation of platelet-derived growth factor beta receptor RT tyrosine phosphorylation by T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 24:2190-2201(2004). RN [37] RP PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771; TYR-857; RP TYR-1009 AND TYR-1021. RX PubMed=15902258; DOI=10.1038/nature03587; RA Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., RA Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.; RT "Regulation of PDGF signalling and vascular remodelling by peroxiredoxin RT II."; RL Nature 435:347-353(2005). RN [38] RP INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021, AND RP UBIQUITINATION. RX PubMed=17620338; DOI=10.1074/jbc.m701797200; RA Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J., RA Naramura M., Band V., Band H.; RT "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived RT growth factor receptor beta provides a dual mechanism of negative RT regulation."; RL J. Biol. Chem. 282:29336-29347(2007). RN [39] RP FUNCTION AS PDGFD RECEPTOR. RX PubMed=21098708; DOI=10.1158/0008-5472.can-10-0511; RA Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M., Abrams J., RA Kim H.R.; RT "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate RT cancer."; RL Cancer Res. 70:9631-9640(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND PTPN11, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-634 AND TYR-857. RX PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004; RA Wardega P., Heldin C.H., Lennartsson J.; RT "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell RT proliferation but not migration."; RL Cell. Signal. 22:1363-1368(2010). RN [41] RP FUNCTION. RX PubMed=20529858; DOI=10.1074/jbc.m110.102566; RA Mendelson K., Swendeman S., Saftig P., Blobel C.P.; RT "Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) RT activates ADAM17 and promotes metalloproteinase-dependent cross-talk RT between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling RT pathways."; RL J. Biol. Chem. 285:25024-25032(2010). RN [42] RP FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION. RX PubMed=21733313; DOI=10.1017/s0007114511002571; RA Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.; RT "Glyceollins inhibit platelet-derived growth factor-mediated human arterial RT smooth muscle cell proliferation and migration."; RL Br. J. Nutr. 107:24-35(2012). RN [43] RP INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF SHC1. RX PubMed=8195171; DOI=10.1016/s0021-9258(17)36611-5; RA Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H., RA Claesson-Welsh L.; RT "Direct interaction between Shc and the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 269:15337-15343(1994). RN [44] RP FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER RP BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021. RX PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037; RA Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L., RA Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H., Tallquist M.D., RA Rosenkranz S.; RT "Disruption of platelet-derived growth factor-dependent RT phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity abolishes RT vascular smooth muscle cell proliferation and migration and attenuates RT neointima formation in vivo."; RL J. Am. Coll. Cardiol. 57:2527-2538(2011). RN [45] RP INVOLVEMENT IN PENTT, VARIANT PENTT ALA-665, AND CHARACTERIZATION OF RP VARIANT PENTT ALA-665. RX PubMed=26279204; DOI=10.1016/j.ajhg.2015.07.009; RA Johnston J.J., Sanchez-Contreras M.Y., Keppler-Noreuil K.M., Sapp J., RA Crenshaw M., Finch N.A., Cormier-Daire V., Rademakers R., Sybert V.P., RA Biesecker L.G.; RT "A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome."; RL Am. J. Hum. Genet. 97:465-474(2015). RN [46] RP INVOLVEMENT IN KOGS, AND VARIANT KOGS ARG-584. RX PubMed=25454926; DOI=10.1016/j.jpeds.2014.10.015; RA Takenouchi T., Yamaguchi Y., Tanikawa A., Kosaki R., Okano H., Kosaki K.; RT "Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB RT mutation."; RL J. Pediatr. 166:483-486(2015). RN [47] RP CHARACTERIZATION OF VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND RP FUNCTION. RX PubMed=26599395; DOI=10.1371/journal.pone.0143407; RA Vanlandewijck M., Lebouvier T., Andaloussi Maee M., Nahar K., Hornemann S., RA Kenkel D., Cunha S.I., Lennartsson J., Boss A., Heldin C.H., Keller A., RA Betsholtz C.; RT "Functional characterization of germline mutations in PDGFB and PDGFRB in RT primary familial brain calcification."; RL PLoS ONE 10:E0143407-E0143407(2015). RN [48] RP REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION. RX PubMed=9739761; DOI=10.1016/s0304-419x(98)00015-8; RA Heldin C.H., Ostman A., Ronnstrand L.; RT "Signal transduction via platelet-derived growth factor receptors."; RL Biochim. Biophys. Acta 1378:F79-113(1998). RN [49] RP REVIEW. RX PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002; RA Ostman A.; RT "PDGF receptors-mediators of autocrine tumor growth and regulators of tumor RT vasculature and stroma."; RL Cytokine Growth Factor Rev. 15:275-286(2004). RN [50] RP REVIEW. RX PubMed=17419949; DOI=10.1016/s0065-230x(06)97011-0; RA Ostman A., Heldin C.H.; RT "PDGF receptors as targets in tumor treatment."; RL Adv. Cancer Res. 97:247-274(2007). RN [51] RP REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND ACTIVATION RP OF SIGNALING PATHWAYS. RX PubMed=18483217; DOI=10.1101/gad.1653708; RA Andrae J., Gallini R., Betsholtz C.; RT "Role of platelet-derived growth factors in physiology and medicine."; RL Genes Dev. 22:1276-1312(2008). RN [52] RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH PIK3R1, RP AND COMPARISON WITH NMR ANALYSIS. RX PubMed=11567151; DOI=10.1107/s0907444901012434; RA Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A., RA Rowsell S., Murshudov G.N.; RT "NMR trial models: experiences with the colicin immunity protein Im7 and RT the p85alpha C-terminal SH2-peptide complex."; RL Acta Crystallogr. D 57:1397-1404(2001). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH NHERF1, RP AND INTERACTION WITH NHERF1. RX PubMed=11882663; DOI=10.1074/jbc.m201507200; RA Karthikeyan S., Leung T., Ladias J.A.A.; RT "Structural determinants of the Na+/H+ exchanger regulatory factor RT interaction with the beta 2 adrenergic and platelet-derived growth factor RT receptors."; RL J. Biol. Chem. 277:18973-18978(2002). RN [54] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB, RP SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230; RP ASN-292 AND ASN-307, AND DISULFIDE BONDS. RX PubMed=20534510; DOI=10.1073/pnas.1000806107; RA Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.; RT "Structures of a platelet-derived growth factor/propeptide complex and a RT platelet-derived growth factor/receptor complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010). RN [55] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589; TYR-718 RP AND ILE-882. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [56] RP VARIANT IMF1 THR-660, AND INVOLVEMENT IN IMF1. RX PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024; RA Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O., RA Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E., RA Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D., Fournet J.C., RA Papp E., McPherson E.W., Zabel C., Vaksmann G., Morisot C., Keating B., RA Sleiman P.M., Cleveland J.A., Everman D.B., Zackai E., Hakonarson H.; RT "Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:1001-1007(2013). RN [57] RP VARIANT IMF1 CYS-561, AND INVOLVEMENT IN IMF1. RX PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026; RA Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D., Nguyen V.H., RA Guo J., Qi M., Guan Y., Albrecht S., Moroz B., Eldin K.W., Lu J.T., RA Schwartzentruber J., Malkin D., Berghuis A.M., Emil S., Gibbs R.A., RA Burk D.L., Vanstone M., Lee B.H., Orchard D., Boycott K.M., Chung W.K., RA Jabado N.; RT "A recurrent PDGFRB mutation causes familial infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:996-1000(2013). RN [58] RP VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND INVOLVEMENT IN IBGC4. RX PubMed=24065723; DOI=10.1093/brain/awt255; RG French IBGC Study Group; RA Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I., RA Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D., RA Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B., RA Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P., RA Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O., RA Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T., RA Campion D., Hannequin D.; RT "Phenotypic spectrum of probable and genetically-confirmed idiopathic basal RT ganglia calcification."; RL Brain 136:3395-3407(2013). RN [59] RP VARIANTS IBGC4 PRO-658 AND TRP-987, AND INVOLVEMENT IN IBGC4. RX PubMed=23255827; DOI=10.1212/wnl.0b013e31827ccf34; RA Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A., RA Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L., Augustin J., RA Martinaud O., Defebvre L., Krystkowiak P., Pariente J., Clanet M., RA Labauge P., Ayrignac X., Lefaucheur R., Le Ber I., Frebourg T., RA Hannequin D., Campion D.; RT "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia RT calcification."; RL Neurology 80:181-187(2013). RN [60] RP VARIANT PENTT SER-666, CHARACTERIZATION OF VARIANT PENTT SER-666, AND RP INVOLVEMENT IN PENTT. RX PubMed=30573803; DOI=10.1038/s41431-018-0323-z; RA Bredrup C., Stokowy T., McGaughran J., Lee S., Sapkota D., Cristea I., RA Xu L., Tveit K.S., Hoevding G., Steen V.M., Roedahl E., Bruland O., RA Houge G.; RT "A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a RT progeria-like condition in the severe end of Penttinen syndrome."; RL Eur. J. Hum. Genet. 27:574-581(2019). RN [61] RP VARIANT OPDKD TYR-666, CHARACTERIZATION OF VARIANT OPDKD TYR-666, AND RP INVOLVEMENT IN OPDKD. RX PubMed=33450762; DOI=10.1093/hmg/ddab014; RA Bredrup C., Cristea I., Safieh L.A., Di Maria E., Gjertsen B.T., RA Tveit K.S., Thu F., Bull N., Edward D.P., Hennekam R.C.M., Hoevding G., RA Haugen O.H., Houge G., Roedahl E., Bruland O.; RT "Temperature-dependent autoactivation associated with clinical variability RT of PDGFRB Asn666 substitutions."; RL Hum. Mol. Genet. 30:72-77(2021). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA CC and PDGFB, and plays an essential role in the regulation of embryonic CC development, cell proliferation, survival, differentiation, chemotaxis CC and migration. Plays an essential role in blood vessel development by CC promoting proliferation, migration and recruitment of pericytes and CC smooth muscle cells to endothelial cells. Plays a role in the migration CC of vascular smooth muscle cells and the formation of neointima at CC vascular injury sites. Required for normal development of the CC cardiovascular system. Required for normal recruitment of pericytes CC (mesangial cells) in the kidney glomerulus, and for normal formation of CC a branched network of capillaries in kidney glomeruli. Promotes CC rearrangement of the actin cytoskeleton and the formation of membrane CC ruffles. Binding of its cognate ligands - homodimeric PDGFB, CC heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to CC the activation of several signaling cascades; the response depends on CC the nature of the bound ligand and is modulated by the formation of CC heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, CC PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the CC activation of protein kinase C. Phosphorylation of PIK3R1, the CC regulatory subunit of phosphatidylinositol 3-kinase, leads to the CC activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or CC of the C-terminus of PTPN11, creates a binding site for GRB2, resulting CC in the activation of HRAS, RAF1 and down-stream MAP kinases, including CC MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation CC of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and CC STAM. Receptor signaling is down-regulated by protein phosphatases that CC dephosphorylate the receptor and its down-stream effectors, and by CC rapid internalization of the activated receptor. CC {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, CC ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, CC ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, CC ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, CC ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, CC ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:7685273}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of PDGFB and/or PDGFD leads to dimerization CC and activation by autophosphorylation on tyrosine residues. Inhibited CC by imatinib. {ECO:0000269|PubMed:15492236}. CC -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with CC heterodimers formed by PDGFA and PDGFB. May also interact with CC homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction CC with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or CC homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA CC homodimers and heterodimers with PDGFRB are observed. Interacts with CC SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. CC Interacts (tyrosine phosphorylated) with PIK3R1 and RASA1. Interacts CC (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) CC with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) CC with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) CC with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by CC SHC1. Interacts (via C-terminus) with NHERF1. CC {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151, CC ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164, CC ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338, CC ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772, CC ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113, CC ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, CC ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579, CC ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}. CC -!- INTERACTION: CC P09619; P05067: APP; NbExp=3; IntAct=EBI-641237, EBI-77613; CC P09619; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-641237, EBI-742887; CC P09619; P06241: FYN; NbExp=3; IntAct=EBI-641237, EBI-515315; CC P09619; Q14451: GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191; CC P09619; P14778: IL1R1; NbExp=2; IntAct=EBI-641237, EBI-525905; CC P09619; P35968: KDR; NbExp=2; IntAct=EBI-641237, EBI-1005487; CC P09619; Q53G59: KLHL12; NbExp=6; IntAct=EBI-641237, EBI-740929; CC P09619; Q5T749: KPRP; NbExp=3; IntAct=EBI-641237, EBI-10981970; CC P09619; Q15323: KRT31; NbExp=3; IntAct=EBI-641237, EBI-948001; CC P09619; O76011: KRT34; NbExp=3; IntAct=EBI-641237, EBI-1047093; CC P09619; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-641237, EBI-10172052; CC P09619; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-641237, EBI-11953334; CC P09619; O94898: LRIG2; NbExp=3; IntAct=EBI-641237, EBI-2830372; CC P09619; O75581: LRP6; NbExp=3; IntAct=EBI-641237, EBI-910915; CC P09619; O14745: NHERF1; NbExp=5; IntAct=EBI-641237, EBI-349787; CC P09619; Q15599: NHERF2; NbExp=2; IntAct=EBI-641237, EBI-1149760; CC P09619; P01127: PDGFB; NbExp=16; IntAct=EBI-641237, EBI-1554925; CC P09619; P27986: PIK3R1; NbExp=21; IntAct=EBI-641237, EBI-79464; CC P09619; O00459: PIK3R2; NbExp=3; IntAct=EBI-641237, EBI-346930; CC P09619; P19174: PLCG1; NbExp=7; IntAct=EBI-641237, EBI-79387; CC P09619; P60484: PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162; CC P09619; P18031: PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788; CC P09619; Q06124: PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779; CC P09619; Q05209: PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035; CC P09619; P23470: PTPRG; NbExp=2; IntAct=EBI-641237, EBI-2258115; CC P09619; Q12913: PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500; CC P09619; P20936: RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476; CC P09619; Q13239: SLA; NbExp=4; IntAct=EBI-641237, EBI-726214; CC P09619; Q15654: TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327; CC P09619; P07947: YES1; NbExp=3; IntAct=EBI-641237, EBI-515331; CC P09619; P0CK45: E5; Xeno; NbExp=2; IntAct=EBI-641237, EBI-7015490; CC P09619; P35918: Kdr; Xeno; NbExp=4; IntAct=EBI-641237, EBI-1555005; CC P09619; Q28619: NHERF1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-7073613; CC P09619; P23727: PIK3R1; Xeno; NbExp=6; IntAct=EBI-641237, EBI-520244; CC P09619; P08487: PLCG1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-8013886; CC P09619; P41499: Ptpn11; Xeno; NbExp=4; IntAct=EBI-641237, EBI-7180604; CC P09619; P25020: V-SRC; Xeno; NbExp=4; IntAct=EBI-641237, EBI-8636140; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand CC binding, the autophosphorylated receptor is ubiquitinated and CC internalized, leading to its degradation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P09619-1; Sequence=Displayed; CC Name=2; CC IsoId=P09619-2; Sequence=VSP_056008, VSP_056009; CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-579, and to a lesser degree, at Tyr-581, is CC important for interaction with SRC family kinases. Phosphorylation at CC Tyr-740 and Tyr-751 is important for interaction with PIK3R1. CC Phosphorylation at Tyr-751 is important for interaction with NCK1. CC Phosphorylation at Tyr-771 and Tyr-857 is important for interaction CC with RASA1/GAP. Phosphorylation at Tyr-857 is important for efficient CC phosphorylation of PLCG1 and PTPN11, resulting in increased CC phosphorylation of AKT1, MAPK1/ERK2 and/or MAPK3/ERK1, PDCD6IP/ALIX and CC STAM, and in increased cell proliferation. Phosphorylation at Tyr-1009 CC is important for interaction with PTPN11. Phosphorylation at Tyr-1009 CC and Tyr-1021 is important for interaction with PLCG1. Phosphorylation CC at Tyr-1021 is important for interaction with CBL; PLCG1 and CBL CC compete for the same binding site. Dephosphorylated by PTPRJ at Tyr- CC 751, Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr- CC 579 and Tyr-1021. {ECO:0000269|PubMed:10821867, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144, CC ECO:0000269|PubMed:7685273}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510, CC ECO:0000269|PubMed:2850496}. CC -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is CC polyubiquitinated, leading to its degradation. CC {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}. CC -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a CC form of chronic myelomonocytic leukemia (CMML). Translocation CC t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal CC myeloid proliferation and by progression to acute myelogenous leukemia CC (AML). CC -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia (MPE) CC [MIM:131440]: A hematologic disorder characterized by malignant CC eosinophils proliferation. Note=The gene represented in this entry may CC be involved in disease pathogenesis. Chromosomal aberrations involving CC PDGFRB have been found in many instances of chronic myeloproliferative CC disorder with eosinophilia. Translocation t(5;12) with ETV6 on CC chromosome 12 creating an PDGFRB-ETV6 fusion protein (PubMed:12181402). CC Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 CC fusion protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that CC forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457). Translocation CC t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end of CEP85L (isoform CC 4) to the 3'-end of PDGFRB (PubMed:21938754). CC {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457, CC ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. A chromosomal aberration involving PDGFRB has been found CC in a patient with AML. Translocation t(5;14)(q33;q32) with TRIP11 CC (PubMed:9373237). {ECO:0000269|PubMed:9373237}. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The gene represented in this entry may be involved in CC disease pathogenesis. A chromosomal aberration involving PDGFRB has CC been found in a patient with JMML. Translocation t(5;17)(q33;p11.2) CC with SPECC1 (PubMed:15087372). {ECO:0000269|PubMed:15087372}. CC -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4) CC [MIM:615007]: A form of basal ganglia calcification, an autosomal CC dominant condition characterized by symmetric calcification in the CC basal ganglia and other brain regions. Affected individuals can either CC be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, CC including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, CC seizures, and chronic headache. Serum levels of calcium, phosphate, CC alkaline phosphatase and parathyroid hormone are normal. The CC neuropathological hallmark of the disease is vascular and pericapillary CC calcification, mainly of calcium phosphate, in the affected brain CC areas. {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, CC ECO:0000269|PubMed:26599395}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare CC mesenchymal disorder characterized by the development of benign tumors CC in the skin, striated muscles, bones, and, more rarely, visceral CC organs. Subcutaneous or soft tissue nodules commonly involve the skin CC of the head, neck, and trunk. Skeletal and muscular lesions occur in CC about half of the patients. Lesions may be solitary or multicentric, CC and they may be present at birth or become apparent in early infancy or CC occasionally in adult life. Visceral lesions are associated with high CC morbidity and mortality. {ECO:0000269|PubMed:23731537, CC ECO:0000269|PubMed:23731542}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A syndrome CC characterized by somatic overgrowth, distinctive facial features, CC hyperelastic and fragile skin, and progressive neurologic deterioration CC with white matter lesions on brain imaging. CC {ECO:0000269|PubMed:25454926}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Premature aging syndrome, Penttinen type (PENTT) [MIM:601812]: CC An autosomal dominant syndrome characterized by a prematurely aged CC appearance with lipoatrophy, epidermal and dermal atrophy along with CC hypertrophic lesions that resemble scars, thin hair, proptosis, CC underdeveloped cheekbones, and marked acro-osteolysis. CC {ECO:0000269|PubMed:26279204, ECO:0000269|PubMed:30573803}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Ocular pterygium-digital keloid dysplasia syndrome (OPDKD) CC [MIM:621091]: An autosomal dominant disorder that presents in childhood CC with aggressive ingrowth of vascularized connective tissue on the CC cornea, ultimately leading to loss of vision. Later, affected CC individuals develop keloids on digits after minor trauma, but are CC otherwise healthy. {ECO:0000269|PubMed:33450762}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/21/PDGFRB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J03278; AAA60049.1; -; mRNA. DR EMBL; M21616; AAA36427.1; -; mRNA. DR EMBL; EU826595; ACF47631.1; -; mRNA. DR EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032224; AAH32224.1; -; mRNA. DR EMBL; U33172; AAC51675.1; -; Genomic_DNA. DR CCDS; CCDS4303.1; -. [P09619-1] DR PIR; A28206; PFHUGB. DR RefSeq; NP_002600.1; NM_002609.4. [P09619-1] DR PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106. DR PDB; 1H9O; X-ray; 1.79 A; B=751-755. DR PDB; 1SHA; X-ray; 1.50 A; B=751-755. DR PDB; 2IUI; X-ray; 2.40 A; C/D=748-758. DR PDB; 2L6W; NMR; -; A/B=526-563. DR PDB; 2PLD; NMR; -; B=1018-1029. DR PDB; 2PLE; NMR; -; B=1018-1029. DR PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314. DR PDBsum; 1GQ5; -. DR PDBsum; 1H9O; -. DR PDBsum; 1SHA; -. DR PDBsum; 2IUI; -. DR PDBsum; 2L6W; -. DR PDBsum; 2PLD; -. DR PDBsum; 2PLE; -. DR PDBsum; 3MJG; -. DR AlphaFoldDB; P09619; -. DR BMRB; P09619; -. DR EMDB; EMD-6426; -. DR SMR; P09619; -. DR BioGRID; 111185; 211. DR ComplexPortal; CPX-2882; PDGF receptor beta - PDGF-BB complex. DR ComplexPortal; CPX-2883; PDGF receptor alpha-beta - PDGF-BB complex. DR ComplexPortal; CPX-2886; PDGF receptor beta - PDGF-AB complex. DR ComplexPortal; CPX-2888; PDGF receptor alpha-beta - PDGF-CC complex. DR ComplexPortal; CPX-2889; PDGF receptor beta - PDGF-DD complex. DR ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex. DR ComplexPortal; CPX-2891; PDGF receptor beta - PDGF-CC complex. DR ComplexPortal; CPX-2892; PDGF receptor alpha-beta - PDGF-AB complex. DR CORUM; P09619; -. DR DIP; DIP-558N; -. DR FunCoup; P09619; 1764. DR IntAct; P09619; 390. DR MINT; P09619; -. DR STRING; 9606.ENSP00000261799; -. DR BindingDB; P09619; -. DR ChEMBL; CHEMBL1913; -. DR DrugBank; DB00102; Becaplermin. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB17041; PD-173952. DR DrugBank; DB02567; PD173955. DR DrugBank; DB12978; Pexidartinib. DR DrugBank; DB09221; Polaprezinc. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB13093; TAK-593. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05146; XL820. DR DrugBank; DB05014; XL999. DR DrugCentral; P09619; -. DR GuidetoPHARMACOLOGY; 1804; -. DR TCDB; 8.A.23.1.37; the basigin (basigin) family. DR GlyConnect; 1967; 4 N-Linked glycans (3 sites). DR GlyCosmos; P09619; 11 sites, 4 glycans. DR GlyGen; P09619; 13 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P09619; -. DR PhosphoSitePlus; P09619; -. DR BioMuta; PDGFRB; -. DR DMDM; 129890; -. DR CPTAC; CPTAC-1630; -. DR CPTAC; CPTAC-3063; -. DR jPOST; P09619; -. DR MassIVE; P09619; -. DR PaxDb; 9606-ENSP00000261799; -. DR PeptideAtlas; P09619; -. DR ProteomicsDB; 52253; -. [P09619-1] DR Pumba; P09619; -. DR ABCD; P09619; 7 sequenced antibodies. DR Antibodypedia; 3424; 2244 antibodies from 49 providers. DR DNASU; 5159; -. DR Ensembl; ENST00000261799.9; ENSP00000261799.4; ENSG00000113721.15. [P09619-1] DR GeneID; 5159; -. DR KEGG; hsa:5159; -. DR MANE-Select; ENST00000261799.9; ENSP00000261799.4; NM_002609.4; NP_002600.1. DR UCSC; uc003lro.4; human. [P09619-1] DR AGR; HGNC:8804; -. DR CIViC; 5159; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA33148; -. DR CTD; 5159; -. DR DisGeNET; 5159; -. DR GeneCards; PDGFRB; -. DR GeneReviews; PDGFRB; -. DR HGNC; HGNC:8804; PDGFRB. DR HPA; ENSG00000113721; Low tissue specificity. DR MalaCards; PDGFRB; -. DR MIM; 131440; phenotype. DR MIM; 173410; gene. DR MIM; 228550; phenotype. DR MIM; 601626; phenotype. DR MIM; 601812; phenotype. DR MIM; 607785; phenotype. DR MIM; 615007; phenotype. DR MIM; 616592; phenotype. DR MIM; 621091; phenotype. DR OpenTargets; ENSG00000113721; -. DR Orphanet; 363665; Acroosteolysis-keloid-like lesions-premature aging syndrome. DR Orphanet; 1980; Bilateral striopallidodentate calcinosis. DR Orphanet; 86830; Chronic myeloproliferative disease, unclassifiable. DR Orphanet; 2591; Infantile myofibromatosis. DR Orphanet; 477831; Kosaki overgrowth syndrome. DR Orphanet; 168950; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement. DR Orphanet; 314950; Primary hypereosinophilic syndrome. DR VEuPathDB; HostDB:ENSG00000113721; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000157138; -. DR HOGENOM; CLU_000288_49_0_1; -. DR InParanoid; P09619; -. DR OMA; WPEDQEF; -. DR OrthoDB; 9936425at2759; -. DR PAN-GO; P09619; 10 GO annotations based on evolutionary models. DR PhylomeDB; P09619; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P09619; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-186797; Signaling by PDGF. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P09619; -. DR SIGNOR; P09619; -. DR Agora; ENSG00000113721; -. DR BioGRID-ORCS; 5159; 18 hits in 1194 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PDGFRB; human. DR EvolutionaryTrace; P09619; -. DR GeneWiki; PDGFRB; -. DR GenomeRNAi; 5159; -. DR Pharos; P09619; Tclin. DR PRO; PR:P09619; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P09619; protein. DR Bgee; ENSG00000113721; Expressed in stromal cell of endometrium and 182 other cell types or tissues. DR ExpressionAtlas; P09619; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0160185; F:phospholipase C activator activity; IMP:UniProtKB. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB. DR GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB. DR GO; GO:0005017; F:platelet-derived growth factor receptor activity; TAS:ProtInc. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB. DR GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB. DR GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB. DR GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB. DR GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB. DR GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB. DR GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0014805; P:smooth muscle adaptation; NAS:BHF-UCL. DR GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL. DR CDD; cd00096; Ig; 1. DR CDD; cd05859; Ig4_PDGFR; 1. DR CDD; cd05861; IgI_PDGFR-alphabeta; 1. DR CDD; cd05107; PTKc_PDGFR_beta; 1. DR FunFam; 3.30.200.20:FF:000025; Platelet-derived growth factor receptor alpha; 1. DR FunFam; 1.10.510.10:FF:000140; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000572; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000715; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000814; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000982; Platelet-derived growth factor receptor beta; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 5. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR027288; PGFRB. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR PANTHER; PTHR24416:SF53; PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF25305; Ig_PDGFR_d4; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF500948; Beta-PDGF_receptor; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Chemotaxis; KW Chromosomal rearrangement; Cytoplasmic vesicle; Developmental protein; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Lysosome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..32 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 33..1106 FT /note="Platelet-derived growth factor receptor beta" FT /id="PRO_0000016757" FT TOPO_DOM 33..532 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 533..553 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 554..1106 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 33..120 FT /note="Ig-like C2-type 1" FT DOMAIN 129..210 FT /note="Ig-like C2-type 2" FT DOMAIN 214..309 FT /note="Ig-like C2-type 3" FT DOMAIN 331..403 FT /note="Ig-like C2-type 4" FT DOMAIN 416..524 FT /note="Ig-like C2-type 5" FT DOMAIN 600..962 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1019..1106 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1043..1060 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1066..1088 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 826 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 606..614 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 634 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 527..528 FT /note="Breakpoint for insertion to form PDE4DIP-PDGFRB FT fusion protein" FT SITE 527..528 FT /note="Breakpoint for translocation to form TRIP11-PDGFRB" FT SITE 558..559 FT /note="Breakpoint for translocation to form the CEP85L- FT PDGFRB fusion protein" FT MOD_RES 562 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 579 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258, ECO:0000269|PubMed:7685273" FT MOD_RES 581 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:7685273" FT MOD_RES 686 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 716 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258" FT MOD_RES 740 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:15902258" FT MOD_RES 751 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 763 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 771 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT MOD_RES 775 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 778 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 857 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 934 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 970 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 1009 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:15902258" FT MOD_RES 1021 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT CARBOHYD 45 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 89 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 103 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 215 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 230 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 292 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 307 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 354 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 371 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 479 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 54..100 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 149..190 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 235..291 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 436..508 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..336 FT /note="VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERWAHYNLLSCIGA FT GHCR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056008" FT VAR_SEQ 337..1106 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056009" FT VARIANT 29 FT /note="I -> F (in dbSNP:rs17110944)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_034377" FT VARIANT 180 FT /note="S -> F (in dbSNP:rs17853027)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_035125" FT VARIANT 282 FT /note="E -> K (in dbSNP:rs34586048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042027" FT VARIANT 345 FT /note="P -> S (in dbSNP:rs2229558)" FT /id="VAR_049717" FT VARIANT 485 FT /note="E -> K (in dbSNP:rs41287110)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042028" FT VARIANT 561 FT /note="R -> C (in IMF1; dbSNP:rs367543286)" FT /evidence="ECO:0000269|PubMed:23731537" FT /id="VAR_069925" FT VARIANT 584 FT /note="P -> R (in KOGS; dbSNP:rs863224946)" FT /evidence="ECO:0000269|PubMed:25454926" FT /id="VAR_075865" FT VARIANT 589 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042029" FT VARIANT 658 FT /note="L -> P (in IBGC4; no effect on protein abundance; FT loss of PDGF beta receptor activity; dbSNP:rs397509381)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069320" FT VARIANT 660 FT /note="P -> T (in IMF1; dbSNP:rs144050370)" FT /evidence="ECO:0000269|PubMed:23731542" FT /id="VAR_069926" FT VARIANT 665 FT /note="V -> A (in PENTT; gain of function in protein FT tyrosine kinase activity; shows ligand-independent FT constitutive signaling; dbSNP:rs1554108211)" FT /evidence="ECO:0000269|PubMed:26279204" FT /id="VAR_075866" FT VARIANT 666 FT /note="N -> S (in PENTT; likely pathogenic; gain-of- FT function variant resulting in constitutive FT autophosphorylation and increased phosphorylation of FT downstream signaling proteins; levels of protein FT phosphorylation are similar at 32 and 37 degrees Celsius; FT dbSNP:rs2113894766)" FT /evidence="ECO:0000269|PubMed:30573803" FT /id="VAR_090402" FT VARIANT 666 FT /note="N -> Y (in OPDKD; likely pathogenic; gain-of- FT function variant resulting in temperature-dependent FT constitutive autophosphorylation and increased FT phosphorylation of downstream signaling proteins; levels of FT protein phosphorylation at 32 degrees Celsius are higher FT than at 37 degrees; dbSNP:rs797044887)" FT /evidence="ECO:0000269|PubMed:33450762" FT /id="VAR_090403" FT VARIANT 718 FT /note="N -> Y (in dbSNP:rs35322465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042030" FT VARIANT 882 FT /note="T -> I (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042031" FT VARIANT 987 FT /note="R -> W (in IBGC4; decreased protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway; dbSNP:rs397509382)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069321" FT VARIANT 1071 FT /note="E -> V (in IBGC4; no effect on protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway)" FT /evidence="ECO:0000269|PubMed:24065723, FT ECO:0000269|PubMed:26599395" FT /id="VAR_075395" FT MUTAGEN 579 FT /note="Y->F: Loss of kinase activity; when associated with FT F-581. Strongly reduces interaction with SRC family FT kinases. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 581 FT /note="Y->F: Loss of kinase activity; when associated with FT F-579. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 634 FT /note="K->A,R: Loss of kinase activity. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825" FT MUTAGEN 716 FT /note="Y->F: No effect neither on interaction with GRB10 FT and RASA1 nor on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164" FT MUTAGEN 740 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-751. Strongly FT decreases phosphatidylinositol 3-kinase activity. No effect FT on interaction with GRB10 and RASA1." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:21679854" FT MUTAGEN 751 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-740. Abolishes FT phosphatidylinositol 3-kinase activity and interaction with FT NCK1, and slightly reduces interaction with RASA1. No FT effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, FT ECO:0000269|PubMed:7692233" FT MUTAGEN 763 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 771 FT /note="Y->F: Loss of interaction with GRB10. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321" FT MUTAGEN 775 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 778 FT /note="Y->F: Strongly reduces expression levels." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 857 FT /note="Y->F: Reduces kinase activity. No effect on FT interaction with GRB10. Abolishes interaction with RASA1. FT No effect on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, FT ECO:0000269|PubMed:20494825" FT MUTAGEN 1009 FT /note="Y->F: No effect on interaction with GRB10. Abolishes FT interaction with PLCG1; when associated with F-1021." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811" FT MUTAGEN 1021 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation. Abolishes interaction with PLCG1; when FT associated with F-1009. No effect on interaction with FT GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, FT ECO:0000269|PubMed:21679854" FT CONFLICT 241 FT /note="E -> D (in Ref. 2; AAA36427)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 50..58 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 81..87 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 96..101 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 114..119 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 136..141 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 158..164 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 175..177 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 178..181 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 223..226 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 241..248 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 252..255 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 261..265 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 271..280 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 287..295 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 296..299 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 300..311 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 530..556 FT /evidence="ECO:0007829|PDB:2L6W" SQ SEQUENCE 1106 AA; 123968 MW; 038C15E531D6E89D CRC64; MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV EPEPELEQLP DSGCPAPRAE AEDSFL // ID PK3CA_HUMAN Reviewed; 1068 AA. AC P42336; Q14CW1; Q99762; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 2. DT 28-JAN-2026, entry version 242. DE RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; DE Short=PI3-kinase subunit alpha; DE Short=PI3K-alpha; DE Short=PI3Kalpha {ECO:0000303|PubMed:28676499}; DE Short=PtdIns-3-kinase subunit alpha; DE EC=2.7.1.137 {ECO:0000269|PubMed:23936502}; DE EC=2.7.1.153 {ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; DE AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; DE Short=PtdIns-3-kinase subunit p110-alpha; DE Short=p110alpha {ECO:0000303|PubMed:15135396}; DE AltName: Full=Phosphoinositide 3-kinase alpha {ECO:0000303|PubMed:28676499}; DE AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide; DE AltName: Full=Serine/threonine protein kinase PIK3CA; DE EC=2.7.11.1 {ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; GN Name=PIK3CA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332. RX PubMed=7713498; DOI=10.1006/geno.1994.1655; RA Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R., Rocchi M., RA Waterfield M.; RT "Molecular cloning, cDNA sequence, and chromosomal localization of the RT human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene."; RL Genomics 24:472-477(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9043658; DOI=10.1016/s0968-0896(96)00196-4; RA Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M., RA Oliff A., Heimbrook D.C.; RT "Cloning and mutagenesis of the p110 alpha subunit of human RT phosphoinositide 3'-hydroxykinase."; RL Bioorg. Med. Chem. 5:65-74(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH APPL1. RX PubMed=10490823; DOI=10.1038/sj.onc.1203080; RA Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A., Testa J.R.; RT "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor RT molecule that interacts with the oncoprotein-serine/threonine kinase RT AKT2."; RL Oncogene 18:4891-4898(1999). RN [5] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15135396; DOI=10.1016/j.pep.2003.12.010; RA Meier T.I., Cook J.A., Thomas J.E., Radding J.A., Horn C., Lingaraj T., RA Smith M.C.; RT "Cloning, expression, purification, and characterization of the human Class RT Ia phosphoinositide 3-kinase isoforms."; RL Protein Expr. Purif. 35:218-224(2004). RN [6] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23936502; DOI=10.1371/journal.pone.0071337; RA Buchanan C.M., Dickson J.M., Lee W.J., Guthridge M.A., Kendall J.D., RA Shepherd P.R.; RT "Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its RT protein kinase activity."; RL PLoS ONE 8:e71337-e71337(2013). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=28676499; DOI=10.1074/jbc.m116.772426; RA Maheshwari S., Miller M.S., O'Meally R., Cole R.N., Amzel L.M., RA Gabelli S.B.; RT "Kinetic and structural analyses reveal residues in phosphoinositide 3- RT kinase alpha that are critical for catalysis and substrate recognition."; RL J. Biol. Chem. 292:13541-13550(2017). RN [8] RP FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS LYS-545 RP AND ARG-1047. RX PubMed=21708979; DOI=10.1083/jcb.201009126; RA Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M., Kouchi Z., RA Nakamura Y., Sakai R., Fukami K.; RT "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} RT regulates invadopodia formation."; RL J. Cell Biol. 193:1275-1288(2011). RN [9] RP INVOLVEMENT IN MADAC, AND VARIANTS MADAC PRO-115; LYS-542; ARG-1047 AND RP LEU-1047. RX PubMed=23100325; DOI=10.1093/hmg/dds440; RA Rios J.J., Paria N., Burns D.K., Israel B.A., Cornelia R., Wise C.A., RA Ezaki M.; RT "Somatic gain-of-function mutations in PIK3CA in patients with RT macrodactyly."; RL Hum. Mol. Genet. 22:444-451(2013). RN [10] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [11] RP REVIEW ON CANCER. RX PubMed=18418043; DOI=10.4161/cc.7.9.5817; RA Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.; RT "Insights into the oncogenic effects of PIK3CA mutations from the structure RT of p110alpha/p85alpha."; RL Cell Cycle 7:1151-1156(2008). RN [12] RP REVIEW ON FUNCTION, AND REVIEW ON CANCER. RX PubMed=18794883; DOI=10.1038/onc.2008.244; RA Zhao L., Vogt P.K.; RT "Class I PI3K in oncogenic cellular transformation."; RL Oncogene 27:5486-5496(2008). RN [13] RP REVIEW ON FUNCTION. RX PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007; RA Jia S., Roberts T.M., Zhao J.J.; RT "Should individual PI3 kinase isoforms be targeted in cancer?"; RL Curr. Opin. Cell Biol. 21:199-208(2009). RN [14] RP INVOLVEMENT IN CLAPO, AND VARIANTS CLAPO SER-83; PRO-115; ARG-420; LYS-542 RP AND LEU-1047. RX PubMed=29446767; DOI=10.1038/gim.2017.200; RA Rodriguez-Laguna L., Ibanez K., Gordo G., Garcia-Minaur S., RA Santos-Simarro F., Agra N., Vallespin E., Fernandez-Montano V.E., RA Martin-Arenas R., Del Pozo A., Gonzalez-Pecellin H., Mena R., RA Rueda-Arenas I., Gomez M.V., Villaverde C., Bustamante A., Ayuso C., RA Ruiz-Perez V.L., Nevado J., Lapunzina P., Lopez-Gutierrez J.C., RA Martinez-Glez V.; RT "CLAPO syndrome: identification of somatic activating PIK3CA mutations and RT delineation of the natural history and phenotype."; RL Genet. Med. 20:882-889(2018). RN [15] RP INVOLVEMENT IN CCM4, AND VARIANTS CCM4 LYS-542; ARG-1047 AND LEU-1047. RX PubMed=34496175; DOI=10.1056/nejmoa2100440; RA Peyre M., Miyagishima D., Bielle F., Chapon F., Sierant M., Venot Q., RA Lerond J., Marijon P., Abi-Jaoude S., Le Van T., Labreche K., Houlston R., RA Faisant M., Clemenceau S., Boch A.L., Nouet A., Carpentier A., Boetto J., RA Louvi A., Kalamarides M.; RT "Somatic PIK3CA mutations in sporadic cerebral cavernous malformations."; RL N. Engl. J. Med. 385:996-996(2021). RN [16] RP INVOLVEMENT IN HFMH, VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047, AND RP CHARACTERIZATION OF VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047. RX PubMed=37712948; DOI=10.1084/jem.20230926; RA Bayard C., Segna E., Taverne M., Fraissenon A., Hennocq Q., Periou B., RA Zerbib L., Ladraa S., Chapelle C., Hoguin C., Kaltenbach S., Villarese P., RA Asnafi V., Broissand C., Nemazanyy I., Autret G., Goudin N., Legendre C., RA Authier F.J., Viel T., Tavitian B., Gitiaux C., Fraitag S., Duong J.P., RA Delcros C., Sergent B., Picard A., Dussiot M., Guibaud L., Khonsari R., RA Canaud G.; RT "Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of- RT function mutations and responds to pharmacological inhibition."; RL J. Exp. Med. 220:0-0(2023). RN [17] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND DOMAINS. RX PubMed=18079394; DOI=10.1126/science.1150799; RA Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., RA Kinzler K.W., Vogelstein B., Gabelli S.B., Amzel L.M.; RT "The structure of a human p110alpha/p85alpha complex elucidates the effects RT of oncogenic PI3Kalpha mutations."; RL Science 318:1744-1748(2007). RN [18] RP STRUCTURE BY NMR OF 331-481. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C2 domain from human PI3-kinase p110 subunit RT alpha."; RL Submitted (APR-2008) to the PDB data bank. RN [19] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH RP WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION OF VARIANT RP ARG-1047, AND DOMAINS. RX PubMed=19805105; DOI=10.1073/pnas.0908444106; RA Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., RA Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.; RT "A frequent kinase domain mutation that changes the interaction between RT PI3Kalpha and the membrane."; RL Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009). RN [20] RP VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND RP TYR-1065. RX PubMed=15289301; DOI=10.1158/0008-5472.can-04-1170; RA Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., RA McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.; RT "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade RT astrocytomas, and medulloblastomas."; RL Cancer Res. 64:5048-5050(2004). RN [21] RP INVOLVEMENT IN OC, AND VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; RP ARG-1047 AND LEU-1047. RX PubMed=15520168; DOI=10.1158/0008-5472.can-04-2933; RA Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., RA Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A.; RT "Mutation of the PIK3CA gene in ovarian and breast cancer."; RL Cancer Res. 64:7678-7681(2004). RN [22] RP VARIANT CANCER ARG-1047. RX PubMed=15016963; DOI=10.1126/science.1096502; RA Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., RA Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V., Markowitz S., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "High frequency of mutations of the PIK3CA gene in human cancers."; RL Science 304:554-554(2004). RN [23] RP VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025. RX PubMed=15924253; DOI=10.1007/s00401-005-1000-1; RA Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.; RT "PIK3CA mutations in glioblastoma multiforme."; RL Acta Neuropathol. 109:639-642(2005). RN [24] RP VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=15784156; DOI=10.1186/1471-2407-5-29; RA Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M., So S., RA Chen X., Yuen S.T., Leung S.Y.; RT "Mutations of PIK3CA in gastric adenocarcinoma."; RL BMC Cancer 5:29-29(2005). RN [25] RP INVOLVEMENT IN CRC, AND CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; RP ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047. RX PubMed=15930273; DOI=10.1158/0008-5472.can-04-4114; RA Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., RA Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M., Kawabe T., RA Omata M.; RT "Functional analysis of PIK3CA gene mutations in human colorectal cancer."; RL Cancer Res. 65:4562-4567(2005). RN [26] RP VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; RP CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND RP LEU-1065. RX PubMed=16322209; DOI=10.1158/0008-5472.can-05-2620; RA Oda K., Stokoe D., Taketani Y., McCormick F.; RT "High frequency of coexistent mutations of PIK3CA and PTEN genes in RT endometrial carcinoma."; RL Cancer Res. 65:10669-10673(2005). RN [27] RP INVOLVEMENT IN CRC, AND VARIANTS CANCER LYS-542; GLY-545; LYS-545; RP GLN-1023; ARG-1047 AND LEU-1047. RX PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022; RA Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., RA Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R., RA Seruca R.; RT "The prevalence of PIK3CA mutations in gastric and colon cancer."; RL Eur. J. Cancer 41:1649-1654(2005). RN [28] RP VARIANTS CANCER LYS-545 AND ARG-1047. RX PubMed=15712344; DOI=10.1002/humu.9316; RA Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.; RT "PIK3CA mutations in advanced ovarian carcinomas."; RL Hum. Mutat. 25:322-322(2005). RN [29] RP VARIANT HCC ALA-545. RX PubMed=15608678; DOI=10.1038/sj.onc.1208304; RA Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., RA Lee J.Y., Yoo N.J., Lee S.H.; RT "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular RT carcinomas."; RL Oncogene 24:1477-1480(2005). RN [30] RP VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT RP MET-391. RX PubMed=16533766; DOI=10.1158/1078-0432.ccr-05-2173; RA Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S., RA Bennett B.P., Su G.H.; RT "PIK3CA mutations in head and neck squamous cell carcinoma."; RL Clin. Cancer Res. 12:1441-1446(2006). RN [31] RP VARIANT CANCER ARG-1047. RX PubMed=16114017; DOI=10.1002/ijc.21444; RA Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.; RT "PIK3CA mutations in nasopharyngeal carcinoma."; RL Int. J. Cancer 118:1065-1067(2006). RN [32] RP VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047. RX PubMed=16353168; DOI=10.1002/path.1908; RA Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D., Fresu G., RA Salvatore S., Cuccurullo F., Mezzetti A., Campani D., Marchetti A.; RT "PIK3CA mutation and histological type in breast carcinoma: high frequency RT of mutations in lobular carcinoma."; RL J. Pathol. 208:350-355(2006). RN [33] RP CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=16432179; DOI=10.1073/pnas.0510857103; RA Bader A.G., Kang S., Vogt P.K.; RT "Cancer-specific mutations in PIK3CA are oncogenic in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006). RN [34] RP VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047. RX PubMed=17673550; DOI=10.1073/pnas.0705218104; RA Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E., RA Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R., RA Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A., Real F.X.; RT "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic RT keratoses with a characteristic mutation pattern."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007). RN [35] RP VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047. RX PubMed=22658544; DOI=10.1016/j.ajhg.2012.05.006; RA Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J., RA Spencer S.A., Mulliken J.B., Bowen M.E., Yamamoto G.L., Kozakewich H.P., RA Warman M.L.; RT "Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome."; RL Am. J. Hum. Genet. 90:1108-1115(2012). RN [36] RP VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; RP LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 RP AND SER-1049. RX PubMed=22729224; DOI=10.1038/ng.2331; RA Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., RA Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., RA Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., RA Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., RA Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., RA Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., RA Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E., RA O'Driscoll M., Shendure J., Graham J.M. Jr., Boycott K.M., Dobyns W.B.; RT "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA RT cause a spectrum of related megalencephaly syndromes."; RL Nat. Genet. 44:934-940(2012). RN [37] RP VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). RN [38] RP VARIANT MCAP ASN-112, CHARACTERIZATION OF VARIANT MCAP ASN-112, FUNCTION, RP AND SUBUNIT. RX PubMed=26593112; DOI=10.1002/humu.22933; RA Donato N.D., Rump A., Mirzaa G.M., Alcantara D., Oliver A., Schrock E., RA Dobyns W.B., O'Driscoll M.; RT "Identification and characterisation of a novel constitutional PIK3CA RT mutation in a child lacking the typical segmental overgrowth of 'PIK3CA- RT related overgrowth spectrum' (PROS)."; RL Hum. Mutat. 37:242-245(2016). CC -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates CC phosphatidylinositol (PI) and its phosphorylated derivatives at CC position 3 of the inositol ring to produce 3-phosphoinositides CC (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and CC PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate CC phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, CC PubMed:28676499). PIP3 plays a key role by recruiting PH domain- CC containing proteins to the membrane, including AKT1 and PDPK1, CC activating signaling cascades involved in cell growth, survival, CC proliferation, motility and morphology. Participates in cellular CC signaling in response to various growth factors. Involved in the CC activation of AKT1 upon stimulation by receptor tyrosine kinases CC ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in CC signaling via insulin-receptor substrate (IRS) proteins. Essential in CC endothelial cell migration during vascular development through VEGFA CC signaling, possibly by regulating RhoA activity. Required for lymphatic CC vasculature development, possibly by binding to RAS and by activation CC by EGF and FGF2, but not by PDGF. Regulates invadopodia formation CC through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in CC embryonic stem cells through a AKT1 pathway. Participates in CC vasculogenesis in embryonic stem cells through PDK1 and protein kinase CC C pathway. In addition to its lipid kinase activity, it displays a CC serine-protein kinase activity that results in the autophosphorylation CC of the p85alpha regulatory subunit as well as phosphorylation of other CC proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly CC others (PubMed:23936502, PubMed:28676499). Plays a role in the positive CC regulation of phagocytosis and pinocytosis (By similarity). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:15135396, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:23936502, CC ECO:0000269|PubMed:26593112, ECO:0000269|PubMed:28676499}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153; CC Evidence={ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293; CC Evidence={ECO:0000305|PubMed:15135396, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a CC 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP + CC H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216; CC EC=2.7.1.137; Evidence={ECO:0000269|PubMed:23936502}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710; CC Evidence={ECO:0000305|PubMed:23936502}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000305|PubMed:23936502, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:55632, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55633; CC Evidence={ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero- CC 3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2- CC (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo- CC inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137, CC ChEBI:CHEBI:83243, ChEBI:CHEBI:456216; CC Evidence={ECO:0000305|PubMed:15135396}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397; CC Evidence={ECO:0000305|PubMed:15135396}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=1.77 uM for PIP2 (1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate)) {ECO:0000269|PubMed:28676499}; CC KM=2.00 uM for ATP {ECO:0000269|PubMed:28676499}; CC Vmax=1.70 pmol/min/ng enzyme for the phosphorylation of PIP2 (1,2- CC dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)) CC {ECO:0000269|PubMed:28676499}; CC -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate CC biosynthesis. {ECO:0000305|PubMed:15135396, CC ECO:0000305|PubMed:28676499}. CC -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory CC subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112). Interacts with CC IRS1 in nuclear extracts (By similarity). Interacts with RUFY3 (By CC similarity). Interacts with RASD2 (By similarity). Interacts with CC APPL1. Interacts with HRAS and KRAS (By similarity). Interaction with CC HRAS/KRAS is required for PI3K pathway signaling and cell proliferation CC stimulated by EGF and FGF2 (By similarity). Interacts with FAM83B; CC activates the PI3K/AKT signaling cascade (PubMed:23676467). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:23676467, CC ECO:0000269|PubMed:26593112}. CC -!- INTERACTION: CC P42336; P54253: ATXN1; NbExp=3; IntAct=EBI-2116585, EBI-930964; CC P42336; P54252: ATXN3; NbExp=3; IntAct=EBI-2116585, EBI-946046; CC P42336; P21860: ERBB3; NbExp=18; IntAct=EBI-2116585, EBI-720706; CC P42336; P01100: FOS; NbExp=3; IntAct=EBI-2116585, EBI-852851; CC P42336; P62993: GRB2; NbExp=6; IntAct=EBI-2116585, EBI-401755; CC P42336; P42858: HTT; NbExp=3; IntAct=EBI-2116585, EBI-466029; CC P42336; P35568: IRS1; NbExp=42; IntAct=EBI-2116585, EBI-517592; CC P42336; P27986: PIK3R1; NbExp=63; IntAct=EBI-2116585, EBI-79464; CC P42336; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-2116585, EBI-9090282; CC P42336; O00459: PIK3R2; NbExp=49; IntAct=EBI-2116585, EBI-346930; CC P42336; Q92569: PIK3R3; NbExp=48; IntAct=EBI-2116585, EBI-79893; CC P42336; O43791: SPOP; NbExp=4; IntAct=EBI-2116585, EBI-743549; CC -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the CC PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the CC recruitment to the plasma membrane. The inhibitory interactions with CC PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain CC with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type CC domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with CC the nSH2 (N-terminal SH2) region of PIK3R1. CC {ECO:0000269|PubMed:18079394, ECO:0000269|PubMed:19805105}. CC -!- DISEASE: Note=PIK3CA mutations are involved in various type of cancer. CC Most of the cancer-associated mutations are missense mutations and map CC to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated CC isoforms participate in cellular transformation and tumorigenesis CC induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS/KRAS. CC Interaction with HRAS/KRAS is required for Ras-driven tumor formation. CC Mutations increasing the lipid kinase activity are required for CC oncogenic signaling. The protein kinase activity may not be required CC for tumorigenesis. {ECO:0000269|PubMed:15016963, CC ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, CC ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, CC ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16114017, CC ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, CC ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, CC ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:19805105, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22658544, CC ECO:0000269|PubMed:22729224}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:16353168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15520168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC {ECO:0000269|PubMed:15608678}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:17673550}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Megalencephaly-capillary malformation-polymicrogyria syndrome CC (MCAP) [MIM:602501]: A syndrome characterized by a spectrum of CC anomalies including primary megalencephaly, prenatal overgrowth, brain CC and body asymmetry, cutaneous vascular malformations, digital anomalies CC consisting of syndactyly with or without postaxial polydactyly, CC connective tissue dysplasia involving the skin, subcutaneous tissue, CC and joints, and cortical brain malformations, most distinctively CC polymicrogyria. {ECO:0000269|PubMed:22729224, CC ECO:0000269|PubMed:26593112}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital lipomatous overgrowth, vascular malformations, and CC epidermal nevi (CLOVE) [MIM:612918]: A sporadically occurring, non- CC hereditary disorder characterized by asymmetric somatic hypertrophy and CC anomalies in multiple organs. It is defined by four main clinical CC findings: congenital lipomatous overgrowth, vascular malformations, CC epidermal nevi, and skeletal/spinal abnormalities. The presence of CC truncal overgrowth and characteristic patterned macrodactyly at birth CC differentiates CLOVE from other syndromic forms of overgrowth. CC {ECO:0000269|PubMed:22658544}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 5 (CWS5) [MIM:615108]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:23246288}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: CLAPO syndrome (CLAPO) [MIM:613089]: A syndrome characterized CC by capillary malformation of the lower lip, lymphatic malformation of CC the face and neck, asymmetry of face and limbs and partial or CC generalised overgrowth. {ECO:0000269|PubMed:29446767}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC The tissue distribution of the clinical manifestations in CLAPO seems CC to follow a pattern of somatic mosaicism. CC {ECO:0000269|PubMed:29446767}. CC -!- DISEASE: Macrodactyly (MADAC) [MIM:155500]: A congenital anomaly CC characterized by fibrofatty tissue enlargement and bony overgrowth CC affecting the digits or the entire hand or foot. CC {ECO:0000269|PubMed:23100325}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. The tissue CC distribution of the clinical manifestations in MADAC seems to follow a CC pattern of somatic mosaicism. {ECO:0000269|PubMed:23100325}. CC -!- DISEASE: Cerebral cavernous malformations 4 (CCM4) [MIM:619538]: A form CC of cerebral cavernous malformations, a congenital vascular anomaly of CC the central nervous system that can result in hemorrhagic stroke, CC seizures, recurrent headaches, and focal neurologic deficits. The CC lesions are characterized by grossly enlarged blood vessels consisting CC of a single layer of endothelium and without any intervening neural CC tissue, ranging in diameter from a few millimeters to several CC centimeters. CCM4 cases occur sporadically. CC {ECO:0000269|PubMed:34496175}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hemifacial myohyperplasia (HFMH) [MIM:606773]: A rare disease CC characterized by facial asymmetry due to unilateral muscular CC hypertrophy mimicking spasm and orofacial dystonia. CC {ECO:0000269|PubMed:37712948}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an oncogene CC derived from PIK3CA. {ECO:0000305|PubMed:18418043}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE- CC ProRule:PRU00877, ECO:0000255|PROSITE-ProRule:PRU00879, CC ECO:0000255|PROSITE-ProRule:PRU00880}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/415/PIK3CA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z29090; CAA82333.1; -; mRNA. DR EMBL; U79143; AAB39753.1; -; mRNA. DR EMBL; BC113601; AAI13602.1; -; mRNA. DR EMBL; BC113603; AAI13604.1; -; mRNA. DR CCDS; CCDS43171.1; -. DR PIR; I38110; I38110. DR RefSeq; NP_006209.2; NM_006218.4. DR RefSeq; XP_006713721.1; XM_006713658.5. DR RefSeq; XP_054202817.1; XM_054346842.1. DR RefSeq; XP_054202818.1; XM_054346843.1. DR RefSeq; XP_054202819.1; XM_054346844.1. DR RefSeq; XP_054202820.1; XM_054346845.1. DR RefSeq; XP_054202821.1; XM_054346846.1. DR RefSeq; XP_054202822.1; XM_054346847.1. DR RefSeq; XP_054202823.1; XM_054346848.1. DR PDB; 2ENQ; NMR; -; A=331-481. DR PDB; 2RD0; X-ray; 3.05 A; A=1-1068. DR PDB; 3HHM; X-ray; 2.80 A; A=1-1068. DR PDB; 3HIZ; X-ray; 3.30 A; A=1-1068. DR PDB; 3ZIM; X-ray; 2.85 A; A=107-1046. DR PDB; 4JPS; X-ray; 2.20 A; A=1-1068. DR PDB; 4L1B; X-ray; 2.59 A; A=1-1068. DR PDB; 4L23; X-ray; 2.50 A; A=1-1068. DR PDB; 4L2Y; X-ray; 2.80 A; A=1-1068. DR PDB; 4OVU; X-ray; 2.96 A; A=1-1068. DR PDB; 4OVV; X-ray; 3.50 A; A=1-1068. DR PDB; 4TUU; X-ray; 2.64 A; A=105-1048. DR PDB; 4TV3; X-ray; 2.85 A; A=105-1048. DR PDB; 4WAF; X-ray; 2.39 A; A=2-1068. DR PDB; 4YKN; X-ray; 2.90 A; A=2-1068. DR PDB; 4ZOP; X-ray; 2.62 A; A=1-1068. DR PDB; 5DXH; X-ray; 3.00 A; A/D=2-1068. DR PDB; 5DXT; X-ray; 2.25 A; A=107-1068. DR PDB; 5FI4; X-ray; 2.50 A; A=1-1068. DR PDB; 5ITD; X-ray; 3.02 A; A=1-1068. DR PDB; 5SW8; X-ray; 3.30 A; A=1-1068. DR PDB; 5SWG; X-ray; 3.11 A; A=1-1068. DR PDB; 5SWO; X-ray; 3.50 A; A=1-1068. DR PDB; 5SWP; X-ray; 3.41 A; A=1-1068. DR PDB; 5SWR; X-ray; 3.31 A; A=1-1068. DR PDB; 5SWT; X-ray; 3.49 A; A=1-1068. DR PDB; 5SX8; X-ray; 3.47 A; A=1-1068. DR PDB; 5SX9; X-ray; 3.52 A; A=1-1068. DR PDB; 5SXA; X-ray; 3.35 A; A=1-1068. DR PDB; 5SXB; X-ray; 3.30 A; A=1-1068. DR PDB; 5SXC; X-ray; 3.55 A; A=1-1068. DR PDB; 5SXD; X-ray; 3.50 A; A=1-1068. DR PDB; 5SXE; X-ray; 3.51 A; A=1-1068. DR PDB; 5SXF; X-ray; 3.46 A; A=1-1068. DR PDB; 5SXI; X-ray; 3.40 A; A=1-1068. DR PDB; 5SXJ; X-ray; 3.42 A; A=1-1068. DR PDB; 5SXK; X-ray; 3.55 A; A=1-1068. DR PDB; 5UBR; X-ray; 2.40 A; A=107-1050. DR PDB; 5UK8; X-ray; 2.50 A; A=1-1068. DR PDB; 5UKJ; X-ray; 2.80 A; A=1-1068. DR PDB; 5UL1; X-ray; 3.00 A; A=1-1068. DR PDB; 5XGH; X-ray; 2.97 A; A=8-1055. DR PDB; 5XGI; X-ray; 2.56 A; A=8-1059. DR PDB; 5XGJ; X-ray; 2.97 A; A=8-1055. DR PDB; 6GVF; X-ray; 2.50 A; A=107-1051. DR PDB; 6GVG; X-ray; 3.00 A; A=107-1068. DR PDB; 6GVH; X-ray; 2.74 A; A=107-1068. DR PDB; 6GVI; X-ray; 2.90 A; A=107-1068. DR PDB; 6NCT; X-ray; 3.35 A; A=1-1068. DR PDB; 6OAC; X-ray; 3.15 A; A=105-1048. DR PDB; 6PYS; X-ray; 2.19 A; A=107-1051. DR PDB; 6VO7; X-ray; 2.31 A; A=157-300. DR PDB; 7JIU; X-ray; 2.12 A; A=107-1052. DR PDB; 7K6M; X-ray; 2.41 A; A=105-1048. DR PDB; 7K6N; X-ray; 2.77 A; A=105-1048. DR PDB; 7K6O; X-ray; 2.74 A; A=105-1048. DR PDB; 7K71; X-ray; 2.90 A; A=105-1048. DR PDB; 7L1B; X-ray; 2.04 A; C=1046-1054. DR PDB; 7L1C; X-ray; 1.96 A; C=1046-1054. DR PDB; 7L1D; X-ray; 3.11 A; C=1046-1054. DR PDB; 7MLK; X-ray; 2.91 A; A=105-1048. DR PDB; 7MYN; EM; 2.79 A; A=1-1068. DR PDB; 7MYO; EM; 2.92 A; A=1-1068. DR PDB; 7PG5; X-ray; 2.20 A; A=1-1068. DR PDB; 7PG6; X-ray; 2.50 A; A=1-1068. DR PDB; 7R9V; X-ray; 2.69 A; A=105-1048. DR PDB; 7R9Y; X-ray; 2.85 A; A=105-1048. DR PDB; 7RRG; X-ray; 2.12 A; C=1046-1054. DR PDB; 7TZ7; X-ray; 2.41 A; A=1-1068. DR PDB; 8AM0; X-ray; 2.82 A; A=1-1068. DR PDB; 8BFU; X-ray; 2.41 A; A=105-1048. DR PDB; 8DCP; EM; 2.41 A; A=1-1068. DR PDB; 8DCX; EM; 2.80 A; A=1-1068. DR PDB; 8DD4; EM; 3.10 A; A=1-1068. DR PDB; 8DD8; EM; 3.40 A; A=1-1068. DR PDB; 8EXL; X-ray; 1.99 A; A=7-1052. DR PDB; 8EXO; X-ray; 2.46 A; A=7-1052. DR PDB; 8EXU; X-ray; 2.68 A; A=7-1052. DR PDB; 8EXV; X-ray; 2.48 A; A=7-1052. DR PDB; 8GUA; EM; 2.77 A; A=1-1068. DR PDB; 8GUB; EM; 2.73 A; A=1-1068. DR PDB; 8GUD; EM; 2.62 A; A=1-1068. DR PDB; 8ILR; EM; 3.05 A; A=1-1068. DR PDB; 8ILS; EM; 3.10 A; A=1-1068. DR PDB; 8ILV; EM; 3.19 A; A=1-1068. DR PDB; 8OW2; X-ray; 2.57 A; A=105-1048. DR PDB; 8SBC; X-ray; 2.30 A; A=1-1068. DR PDB; 8SBJ; X-ray; 3.10 A; A=1-1068. DR PDB; 8TDU; X-ray; 3.11 A; A/C=1-1068. DR PDB; 8TGD; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8TS7; X-ray; 2.71 A; A=2-1053. DR PDB; 8TS8; X-ray; 2.72 A; A=2-1053. DR PDB; 8TS9; X-ray; 2.83 A; A=2-1050. DR PDB; 8TSA; X-ray; 2.51 A; A=2-1050. DR PDB; 8TSB; X-ray; 3.53 A; A=2-1053. DR PDB; 8TSC; X-ray; 3.62 A; A=2-1050. DR PDB; 8TSD; X-ray; 2.70 A; A=2-1053. DR PDB; 8TU6; EM; 3.12 A; A=2-1068. DR PDB; 8TWY; X-ray; 2.67 A; A=105-1048. DR PDB; 8V8H; X-ray; 3.58 A; A/C=1-1068. DR PDB; 8V8I; X-ray; 3.20 A; A/C=1-1068. DR PDB; 8V8J; X-ray; 3.35 A; A/C=1-1068. DR PDB; 8V8U; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8V8V; X-ray; 2.61 A; A/C=1-1068. DR PDB; 8VCL; X-ray; 2.40 A; C=1046-1054. DR PDB; 8W9A; EM; 2.70 A; A=1-1068. DR PDB; 8W9B; EM; 3.00 A; A=1-1068. DR PDB; 9ASF; X-ray; 1.77 A; C=1046-1054. DR PDB; 9ASG; X-ray; 2.03 A; C=1046-1054. DR PDB; 9B4S; X-ray; 3.10 A; A=105-1068. DR PDB; 9B4T; X-ray; 2.75 A; A=105-1068. DR PDB; 9B4U; X-ray; 2.21 A; A/B=157-300. DR PDB; 9C15; X-ray; 2.81 A; A=105-1068. DR PDB; 9CMK; X-ray; 1.75 A; A/B=160-300. DR PDB; 9CML; X-ray; 2.01 A; A/B=160-300. DR PDB; 9CMV; X-ray; 3.01 A; A=105-1068. DR PDB; 9E8M; X-ray; 2.83 A; A/B=157-300. DR PDBsum; 2ENQ; -. DR PDBsum; 2RD0; -. DR PDBsum; 3HHM; -. DR PDBsum; 3HIZ; -. DR PDBsum; 3ZIM; -. DR PDBsum; 4JPS; -. DR PDBsum; 4L1B; -. DR PDBsum; 4L23; -. DR PDBsum; 4L2Y; -. DR PDBsum; 4OVU; -. DR PDBsum; 4OVV; -. DR PDBsum; 4TUU; -. DR PDBsum; 4TV3; -. DR PDBsum; 4WAF; -. DR PDBsum; 4YKN; -. DR PDBsum; 4ZOP; -. DR PDBsum; 5DXH; -. DR PDBsum; 5DXT; -. DR PDBsum; 5FI4; -. DR PDBsum; 5ITD; -. DR PDBsum; 5SW8; -. DR PDBsum; 5SWG; -. DR PDBsum; 5SWO; -. DR PDBsum; 5SWP; -. DR PDBsum; 5SWR; -. DR PDBsum; 5SWT; -. DR PDBsum; 5SX8; -. DR PDBsum; 5SX9; -. DR PDBsum; 5SXA; -. DR PDBsum; 5SXB; -. DR PDBsum; 5SXC; -. DR PDBsum; 5SXD; -. DR PDBsum; 5SXE; -. DR PDBsum; 5SXF; -. DR PDBsum; 5SXI; -. DR PDBsum; 5SXJ; -. DR PDBsum; 5SXK; -. DR PDBsum; 5UBR; -. DR PDBsum; 5UK8; -. DR PDBsum; 5UKJ; -. DR PDBsum; 5UL1; -. DR PDBsum; 5XGH; -. DR PDBsum; 5XGI; -. DR PDBsum; 5XGJ; -. DR PDBsum; 6GVF; -. DR PDBsum; 6GVG; -. DR PDBsum; 6GVH; -. DR PDBsum; 6GVI; -. DR PDBsum; 6NCT; -. DR PDBsum; 6OAC; -. DR PDBsum; 6PYS; -. DR PDBsum; 6VO7; -. DR PDBsum; 7JIU; -. DR PDBsum; 7K6M; -. DR PDBsum; 7K6N; -. DR PDBsum; 7K6O; -. DR PDBsum; 7K71; -. DR PDBsum; 7L1B; -. DR PDBsum; 7L1C; -. DR PDBsum; 7L1D; -. DR PDBsum; 7MLK; -. DR PDBsum; 7MYN; -. DR PDBsum; 7MYO; -. DR PDBsum; 7PG5; -. DR PDBsum; 7PG6; -. DR PDBsum; 7R9V; -. DR PDBsum; 7R9Y; -. DR PDBsum; 7RRG; -. DR PDBsum; 7TZ7; -. DR PDBsum; 8AM0; -. DR PDBsum; 8BFU; -. DR PDBsum; 8DCP; -. DR PDBsum; 8DCX; -. DR PDBsum; 8DD4; -. DR PDBsum; 8DD8; -. DR PDBsum; 8EXL; -. DR PDBsum; 8EXO; -. DR PDBsum; 8EXU; -. DR PDBsum; 8EXV; -. DR PDBsum; 8GUA; -. DR PDBsum; 8GUB; -. DR PDBsum; 8GUD; -. DR PDBsum; 8ILR; -. DR PDBsum; 8ILS; -. DR PDBsum; 8ILV; -. DR PDBsum; 8OW2; -. DR PDBsum; 8SBC; -. DR PDBsum; 8SBJ; -. DR PDBsum; 8TDU; -. DR PDBsum; 8TGD; -. DR PDBsum; 8TS7; -. DR PDBsum; 8TS8; -. DR PDBsum; 8TS9; -. DR PDBsum; 8TSA; -. DR PDBsum; 8TSB; -. DR PDBsum; 8TSC; -. DR PDBsum; 8TSD; -. DR PDBsum; 8TU6; -. DR PDBsum; 8TWY; -. DR PDBsum; 8V8H; -. DR PDBsum; 8V8I; -. DR PDBsum; 8V8J; -. DR PDBsum; 8V8U; -. DR PDBsum; 8V8V; -. DR PDBsum; 8VCL; -. DR PDBsum; 8W9A; -. DR PDBsum; 8W9B; -. DR PDBsum; 9ASF; -. DR PDBsum; 9ASG; -. DR PDBsum; 9B4S; -. DR PDBsum; 9B4T; -. DR PDBsum; 9B4U; -. DR PDBsum; 9C15; -. DR PDBsum; 9CMK; -. DR PDBsum; 9CML; -. DR PDBsum; 9CMV; -. DR PDBsum; 9E8M; -. DR AlphaFoldDB; P42336; -. DR EMDB; EMD-24081; -. DR EMDB; EMD-24082; -. DR EMDB; EMD-27327; -. DR EMDB; EMD-27330; -. DR EMDB; EMD-27334; -. DR EMDB; EMD-27336; -. DR EMDB; EMD-34271; -. DR EMDB; EMD-34272; -. DR EMDB; EMD-34273; -. DR EMDB; EMD-35543; -. DR EMDB; EMD-35545; -. DR EMDB; EMD-35547; -. DR EMDB; EMD-37362; -. DR EMDB; EMD-37363; -. DR EMDB; EMD-41617; -. DR SMR; P42336; -. DR BioGRID; 111308; 178. DR ComplexPortal; CPX-1917; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85beta. DR ComplexPortal; CPX-1918; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55gamma. DR ComplexPortal; CPX-2384; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85alpha. DR ComplexPortal; CPX-5970; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55alpha. DR ComplexPortal; CPX-5971; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p50alpha. DR CORUM; P42336; -. DR DIP; DIP-42728N; -. DR FunCoup; P42336; 3134. DR IntAct; P42336; 216. DR MINT; P42336; -. DR STRING; 9606.ENSP00000263967; -. DR BindingDB; P42336; -. DR ChEMBL; CHEMBL4005; -. DR DrugBank; DB12015; Alpelisib. DR DrugBank; DB00171; ATP. DR DrugBank; DB11666; Buparlisib. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB13051; CH-5132799. DR DrugBank; DB12483; Copanlisib. DR DrugBank; DB15275; Inavolisib. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB11772; Pilaralisib. DR DrugBank; DB14935; Serabelisib. DR DrugBank; DB12108; Taselisib. DR DrugBank; DB08059; Wortmannin. DR DrugBank; DB05241; XL765. DR DrugCentral; P42336; -. DR GuidetoPHARMACOLOGY; 2153; -. DR iPTMnet; P42336; -. DR MetOSite; P42336; -. DR PhosphoSitePlus; P42336; -. DR BioMuta; PIK3CA; -. DR DMDM; 126302584; -. DR CPTAC; CPTAC-1631; -. DR CPTAC; CPTAC-3127; -. DR CPTAC; CPTAC-3128; -. DR CPTAC; CPTAC-3129; -. DR jPOST; P42336; -. DR MassIVE; P42336; -. DR PaxDb; 9606-ENSP00000263967; -. DR PeptideAtlas; P42336; -. DR ProteomicsDB; 55509; -. DR Pumba; P42336; -. DR Antibodypedia; 1374; 746 antibodies from 44 providers. DR CPTC; P42336; 1 antibody. DR DNASU; 5290; -. DR Ensembl; ENST00000263967.4; ENSP00000263967.3; ENSG00000121879.7. DR GeneID; 5290; -. DR KEGG; hsa:5290; -. DR MANE-Select; ENST00000263967.4; ENSP00000263967.3; NM_006218.4; NP_006209.2. DR UCSC; uc003fjk.4; human. DR AGR; HGNC:8975; -. DR CIViC; 5290; 319 evidence items across 211 molecular profiles. DR ClinPGx; PA33308; -. DR CTD; 5290; -. DR DisGeNET; 5290; -. DR GeneCards; PIK3CA; -. DR GeneReviews; PIK3CA; -. DR HGNC; HGNC:8975; PIK3CA. DR HPA; ENSG00000121879; Low tissue specificity. DR MalaCards; PIK3CA; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 114550; phenotype. DR MIM; 155500; phenotype. DR MIM; 167000; phenotype. DR MIM; 171834; gene. DR MIM; 182000; phenotype. DR MIM; 602501; phenotype. DR MIM; 606773; phenotype. DR MIM; 612918; phenotype. DR MIM; 613089; phenotype. DR MIM; 615108; phenotype. DR MIM; 619538; phenotype. DR OpenTargets; ENSG00000121879; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 90308; Capillary-lymphatic-venous malformation with segmental distribution. DR Orphanet; 168984; CLAPO syndrome. DR Orphanet; 140944; CLOVES syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 221061; Familial cerebral cavernous malformation. DR Orphanet; 276280; Hemihyperplasia-multiple lipomatosis syndrome. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 295239; Macrodactyly of fingers, unilateral. DR Orphanet; 295243; Macrodactyly of toes, unilateral. DR Orphanet; 60040; Megalencephaly-capillary malformation-polymicrogyria syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 314662; Segmental progressive overgrowth syndrome with fibroadipose hyperplasia. DR VEuPathDB; HostDB:ENSG00000121879; -. DR eggNOG; KOG0904; Eukaryota. DR GeneTree; ENSGT00940000155531; -. DR HOGENOM; CLU_002191_1_1_1; -. DR InParanoid; P42336; -. DR OMA; RWSEWLN; -. DR OrthoDB; 67688at2759; -. DR PAN-GO; P42336; 9 GO annotations based on evolutionary models. DR PhylomeDB; P42336; -. DR BioCyc; MetaCyc:HS04527-MONOMER; -. DR BRENDA; 2.7.1.137; 2681. DR BRENDA; 2.7.1.153; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P42336; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-112399; IRS-mediated signalling. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-198203; PI3K/AKT activation. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization. DR Reactome; R-HSA-373753; Nephrin family interactions. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-416476; G alpha (q) signalling events. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654689; PI-3K cascade:FGFR1. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K). DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-912631; Regulation of signaling by CBL. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9842640; Signaling by LTK in cancer. DR Reactome; R-HSA-9842663; Signaling by LTK. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9927354; Co-stimulation by ICOS. DR SABIO-RK; P42336; -. DR SignaLink; P42336; -. DR SIGNOR; P42336; -. DR UniPathway; UPA00220; -. DR Agora; ENSG00000121879; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5290; 275 hits in 1174 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PIK3CA; human. DR EvolutionaryTrace; P42336; -. DR GeneWiki; P110%CE%B1; -. DR GenomeRNAi; 5290; -. DR Pharos; P42336; Tclin. DR PRO; PR:P42336; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P42336; protein. DR Bgee; ENSG00000121879; Expressed in calcaneal tendon and 201 other cell types or tissues. DR ExpressionAtlas; P42336; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0014704; C:intercalated disc; ISS:BHF-UCL. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:BHF-UCL. DR GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL. DR GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IDA:UniProtKB. DR GO; GO:0005944; C:phosphatidylinositol 3-kinase complex, class IB; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB. DR GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IDA:UniProt. DR GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl. DR GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0141068; P:autosome genomic imprinting; IEA:Ensembl. DR GO; GO:0086003; P:cardiac muscle cell contraction; ISS:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071464; P:cellular response to hydrostatic pressure; ISS:BHF-UCL. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0030835; P:negative regulation of actin filament depolymerization; ISS:BHF-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; ISS:BHF-UCL. DR GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central. DR GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central. DR GO; GO:0030168; P:platelet activation; TAS:UniProtKB. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISS:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:1905477; P:positive regulation of protein localization to membrane; IDA:UniProt. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032008; P:positive regulation of TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0110053; P:regulation of actin filament organization; ISS:BHF-UCL. DR GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl. DR GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl. DR GO; GO:0055119; P:relaxation of cardiac muscle; ISS:BHF-UCL. DR GO; GO:0014823; P:response to activity; IEA:Ensembl. DR GO; GO:1903544; P:response to butyrate; IEA:Ensembl. DR GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl. DR GO; GO:0043201; P:response to L-leucine; IEA:Ensembl. DR GO; GO:0014870; P:response to muscle inactivity; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; ISS:BHF-UCL. DR GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome. DR GO; GO:0038203; P:TORC2 signaling; IMP:MGI. DR GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IGI:BHF-UCL. DR GO; GO:0001944; P:vasculature development; TAS:UniProtKB. DR CDD; cd08398; C2_PI3K_class_I_alpha; 1. DR CDD; cd00872; PI3Ka_I; 1. DR CDD; cd05175; PI3Kc_IA_alpha; 1. DR FunFam; 1.10.1070.11:FF:000006; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 1.25.40.70:FF:000001; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 2.60.40.150:FF:000041; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000055; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000074; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000007; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR037704; PI3-kinase_alpha_cat. DR InterPro; IPR015433; PI3/4_kinase. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR002420; PI3K-type_C2_dom. DR InterPro; IPR003113; PI3K_ABD. DR InterPro; IPR001263; PI3K_accessory_dom. DR InterPro; IPR042236; PI3K_accessory_sf. DR InterPro; IPR000341; PI3K_Ras-bd_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10048:SF107; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; 1. DR PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF00792; PI3K_C2; 1. DR Pfam; PF02192; PI3K_p85B; 1. DR Pfam; PF00794; PI3K_rbd; 1. DR Pfam; PF00613; PI3Ka; 1. DR SMART; SM00142; PI3K_C2; 1. DR SMART; SM00143; PI3K_p85B; 1. DR SMART; SM00144; PI3K_rbd; 1. DR SMART; SM00145; PI3Ka; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS51547; C2_PI3K; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. DR PROSITE; PS51544; PI3K_ABD; 1. DR PROSITE; PS51546; PI3K_RBD; 1. DR PROSITE; PS51545; PIK_HELICAL; 1. PE 1: Evidence at protein level; KW 3D-structure; Angiogenesis; ATP-binding; Disease variant; Kinase; KW Lipid metabolism; Nucleotide-binding; Phagocytosis; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1068 FT /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase FT catalytic subunit alpha isoform" FT /id="PRO_0000088785" FT DOMAIN 16..105 FT /note="PI3K-ABD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00877" FT DOMAIN 187..289 FT /note="PI3K-RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00879" FT DOMAIN 330..487 FT /note="C2 PI3K-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00880" FT DOMAIN 517..694 FT /note="PIK helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00878" FT DOMAIN 765..1051 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 771..777 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 912..920 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 931..957 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 776 FT /note="Implicated in the recognition of ATP as well as FT PIP2. Also crucial for autophosphorylation of the p85alpha FT subunit" FT /evidence="ECO:0000305|PubMed:23936502" FT VARIANT 38 FT /note="R -> H (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction between the PI3K-ABD domain and FT the N-terminal lobe of PI3K/PI4K kinase domain possibly FT affecting the conformation of the kinase domain; FT dbSNP:rs772110575)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026166" FT VARIANT 43 FT /note="I -> V (in dbSNP:rs1051399)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042942" FT VARIANT 81 FT /note="E -> K (in MCAP; dbSNP:rs1057519929)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069251" FT VARIANT 83 FT /note="F -> S (in CLAPO; uncertain significance; somatic FT mutation; dbSNP:rs1560137208)" FT /evidence="ECO:0000269|PubMed:29446767" FT /id="VAR_081475" FT VARIANT 88 FT /note="R -> Q (in MCAP; also found in a glioblastoma FT multiforme sample; dbSNP:rs121913287)" FT /evidence="ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026167" FT VARIANT 106 FT /note="G -> V (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT dbSNP:rs1057519930)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026168" FT VARIANT 112 FT /note="I -> N (in MCAP; increased phosphatidylinositol 3- FT kinase signaling; decreased interaction with p85 regulatory FT subunit; no effect on protein abundance; FT dbSNP:rs863225460)" FT /evidence="ECO:0000269|PubMed:26593112" FT /id="VAR_075634" FT VARIANT 115 FT /note="R -> P (in CLAPO and MADAC; uncertain significance; FT somatic mutation in CLAPO and MADAC patients; FT dbSNP:rs200018596)" FT /evidence="ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767" FT /id="VAR_081476" FT VARIANT 118 FT /note="G -> D (in CWS5; dbSNP:rs587777790)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069786" FT VARIANT 135 FT /note="E -> K (in CWS5; dbSNP:rs587777791)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069787" FT VARIANT 218 FT /note="E -> K (in CWS5; dbSNP:rs587777792)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069788" FT VARIANT 332 FT /note="S -> R (in dbSNP:rs1051407)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042943" FT VARIANT 343 FT /note="Y -> C (found in a cancer sample; uncertain FT significance; dbSNP:rs2108393253)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026169" FT VARIANT 356 FT /note="V -> I (in CWS5; dbSNP:rs587777793)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069789" FT VARIANT 364 FT /note="G -> R (in MCAP; dbSNP:rs1576935161)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069252" FT VARIANT 365 FT /note="E -> K (in MCAP; dbSNP:rs1064793732)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069253" FT VARIANT 378 FT /note="C -> Y (in MCAP; dbSNP:rs397514565)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069254" FT VARIANT 382 FT /note="R -> K (in CWS5; dbSNP:rs587777794)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069790" FT VARIANT 391 FT /note="I -> M (in dbSNP:rs2230461)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026170" FT VARIANT 420 FT /note="C -> R (in CLOVE, CRC and CLAPO; uncertain FT significance; somatic mutation in CLAPO patients; shows an FT increase in lipid kinase activity; may increase the FT affinity for lipid membranes; dbSNP:rs121913272)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:29446767" FT /id="VAR_026171" FT VARIANT 453 FT /note="E -> Q (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction of the C2 PI3K-type domain with FT the iSH2 region of the p85 regulatory subunit; FT dbSNP:rs1057519925)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026172" FT VARIANT 453 FT /note="Missing (in MCAP)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069255" FT VARIANT 542 FT /note="E -> K (in CLOVE, KERSEB, CRC, BC, CLAPO, MADAC, FT CCM4 and HFMH; somatic mutation; also found in glioblastoma FT multiforme and endometrial carcinoma; somatic mutation; FT shows an increase in lipid kinase activity; oncogenic in FT vivo; occurs in the interface between the PI3K helical FT domain and the nSH2 (N-terminal SH2) region of the p85 FT regulatory subunit and may reduce the inhibitory effect of FT p85; requires interaction with RAS to induce cellular FT transformation; increased AKT and RPS6 phosphorylation in FT HFMH patient's cells; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, FT ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, FT ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:22658544, FT ECO:0000269|PubMed:23100325, ECO:0000269|PubMed:29446767, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026173" FT VARIANT 542 FT /note="E -> Q (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026174" FT VARIANT 542 FT /note="E -> V (in BC; uncertain significance; FT dbSNP:rs1057519927)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026175" FT VARIANT 545 FT /note="E -> A (in CWS5 and HCC; also found in a FT glioblastoma multiforme sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15608678, FT ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:23246288" FT /id="VAR_026176" FT VARIANT 545 FT /note="E -> G (in KERSEB; also found in an endometrial FT carcinoma sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:17673550" FT /id="VAR_026177" FT VARIANT 545 FT /note="E -> K (in MCAP, KERSEB, CRC, BC and HFMH; somatic FT mutation; shows an increase in lipid kinase activity; FT oncogenic in vivo; occurs in the interface between the PI3K FT helical domain and the nSH2 (N-terminal SH2) region of the FT p85 regulatory subunit and may reduce the inhibitory effect FT of p85; requires interaction with RAS to induce cellular FT transformation; enhances invadopodia-mediated extracellular FT matrix degradation and invasion in breast cancer cells; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cells; dbSNP:rs104886003)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15712344, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22729224, FT ECO:0000269|PubMed:37712948" FT /id="VAR_026178" FT VARIANT 546 FT /note="Q -> E (in BC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026179" FT VARIANT 546 FT /note="Q -> K (in OC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026180" FT VARIANT 546 FT /note="Q -> P (found in an anaplastic astrocytoma sample; FT uncertain significance; dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026181" FT VARIANT 546 FT /note="Q -> R (in BC; uncertain significance; FT dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026182" FT VARIANT 726 FT /note="E -> K (in MCAP; dbSNP:rs867262025)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069256" FT VARIANT 914 FT /note="G -> R (in MCAP; dbSNP:rs587776932)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069257" FT VARIANT 1007 FT /note="G -> R (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1448660730)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026183" FT VARIANT 1021 FT /note="Y -> C (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913288)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026184" FT VARIANT 1021 FT /note="Y -> H (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026185" FT VARIANT 1021 FT /note="Y -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026186" FT VARIANT 1023 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs2108429549)" FT /evidence="ECO:0000269|PubMed:15994075" FT /id="VAR_026187" FT VARIANT 1025 FT /note="T -> A (in MCAP; dbSNP:rs397517202)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069258" FT VARIANT 1025 FT /note="T -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs1553826166)" FT /evidence="ECO:0000269|PubMed:15924253" FT /id="VAR_026188" FT VARIANT 1035 FT /note="A -> V (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs1242945375)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026189" FT VARIANT 1043 FT /note="M -> I (in MCAP and CRC; also found in an FT endometrial carcinoma sample; shows an increase in lipid FT kinase activity; dbSNP:rs121913283)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:22729224" FT /id="VAR_026190" FT VARIANT 1047 FT /note="H -> L (in BC, CLAPO, MADAC and CCM4; somatic FT mutation; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767, ECO:0000269|PubMed:34496175" FT /id="VAR_026191" FT VARIANT 1047 FT /note="H -> R (in CLOVE, KERSEB, CRC, BC, OC, MADAC, CCM4 FT and HFMH; also found in an endometrial carcinoma sample; FT somatic mutation; shows an increase in lipid kinase FT activity; oncogenic in vivo; requires binding to p85 FT regulatory subunit to induce cellular transformation but FT not interaction with RAS; may mimic the conformatitonal FT change triggered by the interaction with RAS; enhances FT invadopodia-mediated extracellular matrix degradation and FT invasion in breast cancer cells; may alter the interaction FT of the PI3K/PI4K kinase domain with the cell membrane; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cell; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15016963, FT ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16114017, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:21708979, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026192" FT VARIANT 1047 FT /note="H -> Y (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913281)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026193" FT VARIANT 1049 FT /note="G -> S (in MCAP; dbSNP:rs121913277)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069259" FT VARIANT 1050 FT /note="G -> D (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429937)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026194" FT VARIANT 1052 FT /note="T -> K (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429956)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026195" FT VARIANT 1065 FT /note="H -> L (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1560150596)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026196" FT VARIANT 1065 FT /note="H -> Y (found in brain tumors; uncertain FT significance; dbSNP:rs2108430115)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026197" FT CONFLICT 170 FT /note="N -> H (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 286..287 FT /note="ML -> KM (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="V -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 723 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 751 FT /note="F -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 767 FT /note="E -> K (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT STRAND 5..10 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 18..25 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 27..29 FT /evidence="ECO:0007829|PDB:8TSA" FT STRAND 31..37 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 42..52 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 59..61 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 69..74 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4OVU" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 89..91 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 94..102 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5SXA" FT HELIX 108..121 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 126..129 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 134..142 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 144..154 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 155..159 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 160..166 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 179..182 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 183..185 FT /evidence="ECO:0007829|PDB:3HHM" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:8BFU" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 199..202 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 204..212 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:8V8V" FT HELIX 236..246 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 247..249 FT /evidence="ECO:0007829|PDB:7JIU" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8W9A" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8W9B" FT STRAND 263..265 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 271..279 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 284..289 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 290..294 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:5SXA" FT STRAND 323..326 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 332..343 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 348..350 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 353..362 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 365..368 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 378..380 FT /evidence="ECO:0007829|PDB:6PYS" FT STRAND 382..392 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 393..395 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 400..408 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 413..415 FT /evidence="ECO:0007829|PDB:8SBC" FT STRAND 420..430 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 434..436 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 439..444 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8GUA" FT STRAND 454..456 FT /evidence="ECO:0007829|PDB:6GVF" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:8V8V" FT STRAND 468..470 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 481..485 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 489..504 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 508..511 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:4TUU" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 525..536 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 539..541 FT /evidence="ECO:0007829|PDB:4TUU" FT HELIX 545..553 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 562..564 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 565..569 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:8W9A" FT HELIX 577..588 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 595..598 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 599..602 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 603..605 FT /evidence="ECO:0007829|PDB:8GUD" FT HELIX 609..622 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 625..630 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 632..638 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 639..641 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 661..672 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 673..676 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 681..694 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 724..726 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 728..739 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 742..747 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 749..753 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 756..761 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 766..768 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 773..776 FT /evidence="ECO:0007829|PDB:8DCP" FT STRAND 779..784 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 786..789 FT /evidence="ECO:0007829|PDB:7MYN" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 795..805 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 808..826 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 838..842 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 845..849 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 852..856 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 857..860 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 863..865 FT /evidence="ECO:0007829|PDB:7K6N" FT STRAND 866..868 FT /evidence="ECO:0007829|PDB:8TSA" FT HELIX 869..871 FT /evidence="ECO:0007829|PDB:7K6N" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 876..884 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7JIU" FT HELIX 890..911 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 920..924 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 925..927 FT /evidence="ECO:0007829|PDB:8GUD" FT STRAND 929..931 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 935..937 FT /evidence="ECO:0007829|PDB:8W9B" FT TURN 938..941 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 948..950 FT /evidence="ECO:0007829|PDB:7K6M" FT STRAND 951..954 FT /evidence="ECO:0007829|PDB:7K6M" FT HELIX 958..964 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 965..967 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 971..973 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 975..993 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 995..1003 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1004..1007 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1013..1015 FT /evidence="ECO:0007829|PDB:8EXV" FT HELIX 1016..1025 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1026..1029 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 1032..1047 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1048..1050 FT /evidence="ECO:0007829|PDB:5SW8" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:3HHM" FT STRAND 1056..1058 FT /evidence="ECO:0007829|PDB:4JPS" SQ SEQUENCE 1068 AA; 124284 MW; 041487231A9A1207 CRC64; MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN // ID PKN1_HUMAN Reviewed; 942 AA. AC Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Serine/threonine-protein kinase N1; DE EC=2.7.11.13 {ECO:0000269|PubMed:18066052}; DE AltName: Full=Protease-activated kinase 1; DE Short=PAK-1; DE AltName: Full=Protein kinase C-like 1; DE AltName: Full=Protein kinase C-like PKN; DE AltName: Full=Protein kinase PKN-alpha; DE AltName: Full=Protein-kinase C-related kinase 1; DE AltName: Full=Serine-threonine protein kinase N; GN Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644. RC TISSUE=Hippocampus; RX PubMed=8135837; DOI=10.1006/bbrc.1994.1313; RA Mukai H., Ono Y.; RT "A novel protein kinase with leucine zipper-like sequences: its catalytic RT domain is highly homologous to that of protein kinase C."; RL Biochem. Biophys. Res. Commun. 199:897-904(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x; RA Palmer R.H., Ridden J., Parker P.J.; RT "Cloning and expression patterns of two members of a novel protein-kinase- RT C-related kinase family."; RL Eur. J. Biochem. 227:344-351(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS RP ILE-555 AND ILE-901. RC TISSUE=Kidney, Synovium, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP ILE-901. RC TISSUE=Brain, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718. RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [7] RP FUNCTION. RX PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3; RA Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T., RA Parker P.J.; RT "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and RT serine 163."; RL FEBS Lett. 378:281-285(1996). RN [8] RP FUNCTION. RX PubMed=8621664; DOI=10.1074/jbc.271.16.9816; RA Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., RA Sunakawa H., Ono Y.; RT "PKN associates and phosphorylates the head-rod domain of neurofilament RT protein."; RL J. Biol. Chem. 271:9816-9822(1996). RN [9] RP ACTIVITY REGULATION, AND INTERACTION WITH RHOA. RX PubMed=8571126; DOI=10.1126/science.271.5249.645; RA Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N., RA Mukai H., Ono Y., Kakizuka A., Narumiya S.; RT "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of RT small GTPase Rho."; RL Science 271:645-648(1996). RN [10] RP FUNCTION. RX PubMed=9175763; DOI=10.1006/bbrc.1997.6669; RA Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y., RA Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.; RT "Domain-specific phosphorylation of vimentin and glial fibrillary acidic RT protein by PKN."; RL Biochem. Biophys. Res. Commun. 234:621-625(1997). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB. RX PubMed=9478917; DOI=10.1074/jbc.273.9.4811; RA Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.; RT "PRK1 is targeted to endosomes by the small GTPase, RhoB."; RL J. Biol. Chem. 273:4811-4814(1998). RN [12] RP ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108; RP ASP-451; ASP-454; ASP-558 AND ASP-560. RX PubMed=9751706; DOI=10.1073/pnas.95.20.11566; RA Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.; RT "Proteolytic activation of PKN by caspase-3 or related protease during RT apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998). RN [13] RP PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=10792047; DOI=10.1073/pnas.090491897; RA Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.; RT "Phosphorylation of protein kinase N by phosphoinositide-dependent protein RT kinase-1 mediates insulin signals to the actin cytoskeleton."; RL Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000). RN [14] RP FUNCTION. RX PubMed=11104762; DOI=10.1074/jbc.m007427200; RA Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., RA Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.; RT "Phosphorylation of tau is regulated by PKN."; RL J. Biol. Chem. 276:10025-10031(2001). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR. RX PubMed=12514133; DOI=10.1093/emboj/cdg023; RA Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.; RT "A novel inducible transactivation domain in the androgen receptor: RT implications for PRK in prostate cancer."; RL EMBO J. 22:270-280(2003). RN [16] RP INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION). RX PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x; RA Haraga A., Miller S.I.; RT "A Salmonella type III secretion effector interacts with the mammalian RT serine/threonine protein kinase PKN1."; RL Cell. Microbiol. 8:837-846(2006). RN [17] RP INTERACTION WITH CCNT2. RX PubMed=16331689; DOI=10.1002/jcp.20566; RA Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G., RA De Luca A.; RT "Pkn is a novel partner of cyclin T2a in muscle differentiation."; RL J. Cell. Physiol. 207:232-237(2006). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [19] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=17332740; DOI=10.1038/sj.emboj.7601637; RA Schmidt A., Durgan J., Magalhaes A., Hall A.; RT "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from RT cytokinesis."; RL EMBO J. 26:1624-1636(2007). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644. RX PubMed=18066052; DOI=10.1038/ncb1668; RA Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N., RA Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R., RA Schule R.; RT "Phosphorylation of histone H3 at threonine 11 establishes a novel RT chromatin mark for transcriptional regulation."; RL Nat. Cell Biol. 10:53-60(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559; RP SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [24] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537; RP SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [27] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057; RA Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B., RA McKinsey T.A.; RT "Protein kinase C-related kinase targets nuclear localization signals in a RT subset of class IIa histone deacetylases."; RL FEBS Lett. 584:1103-1110(2010). RN [28] RP INTERACTION WITH PRKCB. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND RP MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [32] RP FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY. RX PubMed=21754995; DOI=10.1371/journal.pone.0021732; RA Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., RA Collazos A., Parker P.J.; RT "Regulatory domain selectivity in the cell-type specific PKN-dependence of RT cell migration."; RL PLoS ONE 6:E21732-E21732(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537; RP SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA. RX PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5; RA Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.; RT "The structural basis of Rho effector recognition revealed by the crystal RT structure of human RhoA complexed with the effector domain of PKN/PRK1."; RL Mol. Cell 4:793-803(1999). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98. RX PubMed=10388627; DOI=10.1006/jsbi.1999.4114; RA Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.; RT "Biochemical and crystallographic characterization of a Rho effector domain RT of the protein serine/threonine kinase N in a complex with RhoA."; RL J. Struct. Biol. 126:166-170(1999). RN [39] RP STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1. RX PubMed=14514689; DOI=10.1074/jbc.m304313200; RA Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y., RA Parker P.J., Blundell T.L., Mott H.R.; RT "Molecular dissection of the interaction between the small G proteins Rac1 RT and RhoA and protein kinase C-related kinase 1 (PRK1)."; RL J. Biol. Chem. 278:50578-50587(2003). RN [40] RP STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1. RX PubMed=18006505; DOI=10.1074/jbc.m706760200; RA Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.; RT "The Rac1 polybasic region is required for interaction with its effector RT PRK1."; RL J. Biol. Chem. 283:1492-1500(2008). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH RP SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF RP ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND RP INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION). RX PubMed=24248594; DOI=10.1128/mcb.01360-13; RA Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., RA Sicheri F.; RT "Structure of an SspH1-PKN1 complex reveals the basis for host substrate RT recognition and mechanism of activation for a bacterial E3 ubiquitin RT ligase."; RL Mol. Cell. Biol. 34:362-373(2014). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520; RP ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in CC various processes such as regulation of the intermediate filaments of CC the actin cytoskeleton, cell migration, tumor cell invasion and CC transcription regulation. Part of a signaling cascade that begins with CC the activation of the adrenergic receptor ADRA1B and leads to the CC activation of MAPK14. Regulates the cytoskeletal network by CC phosphorylating proteins such as VIM and neurofilament proteins NEFH, CC NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates CC 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to CC bind to microtubules, resulting in disruption of tubulin assembly. Acts CC as a key coactivator of androgen receptor (AR)-dependent transcription, CC by being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for CC epigenetic transcriptional activation that promotes demethylation of CC histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, CC HDAC7 and HDAC9, leading to impair their import in the nucleus. CC Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' CC of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. CC {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, CC ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, CC ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, CC ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, CC ECO:0000269|PubMed:9175763}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho CC proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly CC cardiolipin and to a lesser extent by other acidic phospholipids. CC Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific CC sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn CC motif), need to be phosphorylated for its full activation. CC {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095}; CC -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR CC (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts CC (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689, CC PubMed:18006505). Interacts (via REM 1 repeat) with RHOA CC (PubMed:10619026, PubMed:8571126). Interacts with RHOB CC (PubMed:9478917). Interacts (via C-terminus) with PDPK1 CC (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent CC transcription (PubMed:16331689). Component of a signaling complex CC containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this CC complex, AKAP13 interacts directly with PKN1, which in turn recruits CC MAPK14, MAP2K3 and ZAK (PubMed:21224381). CC {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026, CC ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689, CC ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126, CC ECO:0000269|PubMed:9478917}. CC -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat) CC with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine- CC rich repeat region) (PubMed:16611232, PubMed:24248594). CC {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}. CC -!- INTERACTION: CC Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507; CC Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530; CC Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576; CC Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613; CC Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357; CC Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378; CC Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012; CC Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676; CC Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887; CC Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674; CC Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062; CC Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367; CC Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486; CC Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988; CC Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624; CC Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333; CC Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027; CC Q16512; Q8IW40: DNAAF19; NbExp=3; IntAct=EBI-602382, EBI-10261970; CC Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680; CC Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467; CC Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990; CC Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189; CC Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309; CC Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454; CC Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814; CC Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791; CC Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420; CC Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203; CC Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204; CC Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258; CC Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960; CC Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878; CC Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566; CC Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410; CC Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756; CC Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001; CC Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093; CC Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674; CC Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506; CC Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716; CC Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424; CC Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346; CC Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406; CC Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316; CC Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526; CC Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642; CC Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751; CC Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269; CC Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433; CC Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646; CC Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165; CC Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345; CC Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004; CC Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350; CC Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839; CC Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621; CC Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919; CC Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317; CC Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028; CC Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557; CC Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135; CC Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466; CC Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286; CC Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224; CC Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744; CC Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493; CC Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794; CC Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957; CC Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895; CC Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844; CC Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867; CC Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023; CC Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733; CC Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520; CC Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853; CC Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740, CC ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}. CC Endosome {ECO:0000269|PubMed:9478917}. Cell membrane CC {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow CC {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}. CC Note=Associates with chromatin in a ligand-dependent manner. CC Localization to endosomes is mediated via its interaction with RHOB. CC Association to the cell membrane is dependent on Ser-377 CC phosphorylation. Accumulates during telophase at the cleavage furrow CC and finally concentrates around the midbody in cytokinesis. CC {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q16512-1; Sequence=Displayed; CC Name=2; CC IsoId=Q16512-2; Sequence=VSP_038143; CC Name=3; CC IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214; CC -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain, CC placenta, lung, skeletal muscle, kidney and pancreas. Expressed in CC numerous tumor cell lines, especially in breast tumor cells. CC {ECO:0000269|PubMed:21754995}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during CC mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}. CC -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}. CC -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by CC the bacterial E3 ubiquitin-protein ligase SspH1, leading to its CC proteasomal degradation. {ECO:0000269|PubMed:24248594}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26181; BAA05169.1; -; mRNA. DR EMBL; S75546; AAB33345.1; -; mRNA. DR EMBL; U33053; AAC50209.1; -; mRNA. DR EMBL; AK123007; BAG53845.1; -; mRNA. DR EMBL; AK292130; BAF84819.1; -; mRNA. DR EMBL; AK313886; BAG36611.1; -; mRNA. DR EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040061; AAH40061.1; -; mRNA. DR EMBL; BC094766; AAH94766.1; -; mRNA. DR CCDS; CCDS42513.1; -. [Q16512-1] DR CCDS; CCDS42514.1; -. [Q16512-2] DR PIR; JC2129; JC2129. DR PIR; S51162; S51162. DR RefSeq; NP_002732.3; NM_002741.3. [Q16512-1] DR RefSeq; NP_998725.1; NM_213560.3. [Q16512-2] DR PDB; 1CXZ; X-ray; 2.20 A; B=13-98. DR PDB; 1URF; NMR; -; A=122-199. DR PDB; 2RMK; NMR; -; B=122-199. DR PDB; 4NKG; X-ray; 2.90 A; B/D=122-199. DR PDB; 4OTD; X-ray; 2.00 A; A=605-942. DR PDB; 4OTG; X-ray; 2.60 A; A=605-942. DR PDB; 4OTH; X-ray; 1.80 A; A=605-942. DR PDB; 4OTI; X-ray; 1.93 A; A=605-942. DR PDBsum; 1CXZ; -. DR PDBsum; 1URF; -. DR PDBsum; 2RMK; -. DR PDBsum; 4NKG; -. DR PDBsum; 4OTD; -. DR PDBsum; 4OTG; -. DR PDBsum; 4OTH; -. DR PDBsum; 4OTI; -. DR AlphaFoldDB; Q16512; -. DR SMR; Q16512; -. DR BioGRID; 111571; 147. DR CORUM; Q16512; -. DR DIP; DIP-34240N; -. DR ELM; Q16512; -. DR FunCoup; Q16512; 2793. DR IntAct; Q16512; 116. DR MINT; Q16512; -. DR STRING; 9606.ENSP00000343325; -. DR BindingDB; Q16512; -. DR ChEMBL; CHEMBL3384; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q16512; -. DR GuidetoPHARMACOLOGY; 1520; -. DR GlyConnect; 1737; 1 N-Linked glycan (1 site). DR GlyCosmos; Q16512; 3 sites, 2 glycans. DR GlyGen; Q16512; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q16512; -. DR MetOSite; Q16512; -. DR PhosphoSitePlus; Q16512; -. DR BioMuta; PKN1; -. DR DMDM; 259016304; -. DR CPTAC; CPTAC-3003; -. DR jPOST; Q16512; -. DR MassIVE; Q16512; -. DR PaxDb; 9606-ENSP00000343325; -. DR PeptideAtlas; Q16512; -. DR ProteomicsDB; 60877; -. [Q16512-1] DR ProteomicsDB; 60878; -. [Q16512-2] DR ProteomicsDB; 60879; -. [Q16512-3] DR Pumba; Q16512; -. DR Antibodypedia; 1296; 250 antibodies from 36 providers. DR DNASU; 5585; -. DR Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.14. [Q16512-1] DR Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.14. [Q16512-2] DR GeneID; 5585; -. DR KEGG; hsa:5585; -. DR MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3. DR UCSC; uc002myp.4; human. [Q16512-1] DR AGR; HGNC:9405; -. DR ClinPGx; PA33769; -. DR CTD; 5585; -. DR DisGeNET; 5585; -. DR GeneCards; PKN1; -. DR HGNC; HGNC:9405; PKN1. DR HPA; ENSG00000123143; Low tissue specificity. DR MalaCards; PKN1; -. DR MIM; 601032; gene. DR OpenTargets; ENSG00000123143; -. DR VEuPathDB; HostDB:ENSG00000123143; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000154990; -. DR HOGENOM; CLU_000288_132_1_1; -. DR InParanoid; Q16512; -. DR OMA; CTELRIE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q16512; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q16512; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q16512; -. DR Reactome; R-HSA-5625740; RHO GTPases activate PKNs. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SABIO-RK; Q16512; -. DR SignaLink; Q16512; -. DR SIGNOR; Q16512; -. DR Agora; ENSG00000123143; -. DR BioGRID-ORCS; 5585; 15 hits in 1195 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PKN1; human. DR EvolutionaryTrace; Q16512; -. DR GeneWiki; Protein_kinase_N1; -. DR GenomeRNAi; 5585; -. DR Pharos; Q16512; Tchem. DR PRO; PR:Q16512; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q16512; protein. DR Bgee; ENSG00000123143; Expressed in apex of heart and 142 other cell types or tissues. DR ExpressionAtlas; Q16512; baseline and differential. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB. DR GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB. DR GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl. DR GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome. DR GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB. DR GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl. DR GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR CDD; cd08687; C2_PKN-like; 1. DR CDD; cd11630; HR1_PKN1_2; 1. DR CDD; cd11636; HR1_PKN1_3; 1. DR CDD; cd11622; HR1_PKN_1; 1. DR CDD; cd05589; STKc_PKN; 1. DR FunFam; 1.10.287.160:FF:000001; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000002; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000003; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 3.30.200.20:FF:000058; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.510.10:FF:000038; serine/threonine-protein kinase N2 isoform X1; 1. DR Gene3D; 1.10.287.160; HR1 repeat; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00416; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037784; C2_PKN. DR InterPro; IPR011072; HR1_rho-bd. DR InterPro; IPR036274; HR1_rpt_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR037317; PKN1_HR1_2. DR InterPro; IPR037313; PKN_HR1_1. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF02185; HR1; 3. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00742; Hr1; 3. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF46585; HR1 repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS51860; REM_1; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome; KW Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..942 FT /note="Serine/threonine-protein kinase N1" FT /id="PRO_0000055719" FT DOMAIN 25..100 FT /note="REM-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 112..193 FT /note="REM-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 201..280 FT /note="REM-1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 307..470 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 615..874 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..942 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 102..121 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 181..185 FT /note="Important for interaction with bacterial SspH1 and FT SspH1-mediated polyubiquitination" FT /evidence="ECO:0000269|PubMed:24248594" FT REGION 341..363 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 581..596 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 644 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 108..109 FT /note="Cleavage; by caspase-3" FT SITE 454..455 FT /note="Cleavage; by caspase-3" FT SITE 558..559 FT /note="Cleavage; by caspase-3" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332" FT MOD_RES 374 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63433" FT MOD_RES 448 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 540 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 559 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 562 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 774 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10792047" FT MOD_RES 778 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 914 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 916 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..7 FT /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038143" FT VAR_SEQ 603 FT /note="S -> R (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039213" FT VAR_SEQ 604..942 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039214" FT VARIANT 185 FT /note="R -> C (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267605306)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042337" FT VARIANT 197 FT /note="A -> E (in dbSNP:rs1287763348)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042338" FT VARIANT 436 FT /note="R -> W (in dbSNP:rs35132656)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042339" FT VARIANT 520 FT /note="R -> Q (in dbSNP:rs56273055)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042340" FT VARIANT 555 FT /note="L -> I (in dbSNP:rs34309238)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042341" FT VARIANT 635 FT /note="R -> Q (in dbSNP:rs35416389)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042342" FT VARIANT 718 FT /note="I -> V (in dbSNP:rs2230539)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7988719" FT /id="VAR_042343" FT VARIANT 873 FT /note="F -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042344" FT VARIANT 901 FT /note="V -> I (in dbSNP:rs10846)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_014937" FT VARIANT 921 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042345" FT MUTAGEN 108 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF1 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 181 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 181 FT /note="R->K: Decreases interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 185 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 451 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 454 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 558 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 560 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 644 FT /note="K->E: Abolishes Serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT MUTAGEN 644 FT /note="K->R: Substantial reduction of autophosphorylation." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT CONFLICT 191 FT /note="G -> D (in Ref. 2; AAB33345/AAC50209)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="S -> P (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 736 FT /note="I -> T (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="T -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 800 FT /note="G -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="E -> G (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="L -> P (in Ref. 3; BAG53845)" FT /evidence="ECO:0000305" FT HELIX 15..18 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 29..66 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 71..95 FT /evidence="ECO:0007829|PDB:1CXZ" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:1URF" FT HELIX 126..151 FT /evidence="ECO:0007829|PDB:4NKG" FT TURN 157..159 FT /evidence="ECO:0007829|PDB:4NKG" FT HELIX 160..187 FT /evidence="ECO:0007829|PDB:4NKG" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:2RMK" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 615..624 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 627..634 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 640..647 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 657..671 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 672..674 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 688..696 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 700..702 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 703..706 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 763..765 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 779..781 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 784..788 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 794..810 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 820..829 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 840..849 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 854..856 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 862..864 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 865..869 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 879..883 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 906..909 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 926..930 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 931..934 FT /evidence="ECO:0007829|PDB:4OTH" SQ SEQUENCE 942 AA; 103932 MW; 61360295EC70BB8E CRC64; MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID PTK6_HUMAN Reviewed; 451 AA. AC Q13882; B2RCR3; B4DW46; Q58F01; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Protein-tyrosine kinase 6; DE EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}; DE AltName: Full=Breast tumor kinase; DE AltName: Full=Tyrosine-protein kinase BRK; GN Name=PTK6; Synonyms=BRK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary tumor; RX PubMed=8036022; RA Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., RA Page M.J., Gusterson B.A., Crompton M.R.; RT "Cloning and characterisation of cDNAs encoding a novel non-receptor RT tyrosine kinase, brk, expressed in human breast tumours."; RL Oncogene 9:2383-2390(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=9333026; DOI=10.1038/sj.onc.1201292; RA Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.; RT "Characterisation and chromosome mapping of the human non receptor tyrosine RT kinase gene, brk."; RL Oncogene 15:1497-1502(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Melanocyte; RX PubMed=9749526; RA Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.; RT "Exon-intron structure of the human PTK6 gene demonstrates that PTK6 RT constitutes a distinct family of non-receptor tyrosine kinase."; RL Mol. Cells 8:401-407(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND RP TYR-447. RX PubMed=8940083; DOI=10.1074/jbc.271.48.30956; RA Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., RA Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.; RT "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, RT sensitizes mammary epithelial cells to epidermal growth factor."; RL J. Biol. Chem. 271:30956-30963(1996). RN [8] RP TISSUE SPECIFICITY. RX PubMed=9185712; RX DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f; RA Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A., RA Bennett D.C.; RT "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK RT in metastatic melanoma."; RL Int. J. Cancer 71:1061-1065(1997). RN [9] RP FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66; RP ARG-105 AND LYS-219. RX PubMed=10980601; DOI=10.1038/sj.onc.1203775; RA Mitchell P.J., Sara E.A., Crompton M.R.; RT "A novel adaptor-like protein which is a substrate for the non-receptor RT tyrosine kinase, BRK."; RL Oncogene 19:4273-4282(2000). RN [10] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH RP KHDRBS1. RX PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000; RA Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., RA Cochrane A.W., Chen T., Tyner A.L.; RT "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RT RNA binding ability."; RL Mol. Cell. Biol. 20:6114-6126(2000). RN [11] RP PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351, RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342 RP AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12121988; DOI=10.1074/jbc.m203877200; RA Qiu H., Miller W.T.; RT "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation RT and by autoinhibition."; RL J. Biol. Chem. 277:34634-34641(2002). RN [12] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12833144; DOI=10.1038/sj.onc.1206465; RA Derry J.J., Prins G.S., Ray V., Tyner A.L.; RT "Altered localization and activity of the intracellular tyrosine kinase RT BRK/Sik in prostate tumor cells."; RL Oncogene 22:4212-4220(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND RP PHOSPHORYLATION. RX PubMed=15471878; DOI=10.1074/jbc.m409579200; RA Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.; RT "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA- RT binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2."; RL J. Biol. Chem. 279:54398-54404(2004). RN [14] RP FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR RP LOCATION, AND INTERACTION WITH PXN. RX PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004; RA Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.; RT "Brk activates rac1 and promotes cell migration and invasion by RT phosphorylating paxillin."; RL Mol. Cell. Biol. 24:10558-10572(2004). RN [15] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010; RA Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.; RT "Differential expression of the non-receptor tyrosine kinase BRK in oral RT squamous cell carcinoma and normal oral epithelium."; RL Oral Oncol. 40:1040-1047(2004). RN [16] RP FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK. RX PubMed=15539407; DOI=10.1074/jbc.m412038200; RA Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., RA Lange C.A.; RT "Regulated association of protein kinase B/Akt with breast tumor kinase."; RL J. Biol. Chem. 280:1982-1991(2005). RN [17] RP MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION. RX PubMed=15961400; DOI=10.1074/jbc.m504568200; RA Kim H.I.E., Lee S.T.; RT "An intramolecular interaction between SH2-kinase linker and kinase domain RT is essential for the catalytic activity of protein-tyrosine kinase-6."; RL J. Biol. Chem. 280:28973-28980(2005). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KHDRBS1. RX PubMed=16179349; DOI=10.1074/jbc.m505802200; RA Lukong K.E., Larocque D., Tyner A.L., Richard S.; RT "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates RT intranuclear localization and cell cycle progression."; RL J. Biol. Chem. 280:38639-38647(2005). RN [19] RP INTERACTION WITH IRS4, AND ACTIVITY REGULATION. RX PubMed=15870689; DOI=10.1038/sj.onc.1208721; RA Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.; RT "Interaction between Brk kinase and insulin receptor substrate-4."; RL Oncogene 24:5656-5664(2005). RN [20] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16651629; DOI=10.2353/ajpath.2006.050521; RA Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., RA Marzec M., Gimotty P., Crompton M.R., Wasik M.A.; RT "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in RT lymphocytes."; RL Am. J. Pathol. 168:1631-1641(2006). RN [21] RP FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION. RX PubMed=16568091; DOI=10.1038/sj.onc.1209501; RA Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.; RT "Identification of STAT3 as a specific substrate of breast tumor kinase."; RL Oncogene 25:4904-4912(2006). RN [22] RP ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44. RX PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055; RA Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.; RT "Molecular dissection of the interaction between the SH3 domain and the RT SH2-Kinase Linker region in PTK6."; RL Biochem. Biophys. Res. Commun. 362:829-834(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF STAT5B. RX PubMed=17997837; DOI=10.1186/bcr1794; RA Weaver A.M., Silva C.M.; RT "Signal transducer and activator of transcription 5b: a new target of RT breast tumor kinase/protein tyrosine kinase 6."; RL Breast Cancer Res. 9:R79-R79(2007). RN [24] RP FUNCTION IN PHOSPHORYLATION OF ARHGAP35. RX PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997; RA Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., RA Settleman J., Chen R.H.; RT "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and RT promote breast carcinoma growth, migration, and invasion."; RL Cancer Res. 68:7779-7787(2008). RN [25] RP INTERACTION WITH ADAM15. RX PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028; RA Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., RA Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., RA Edwards D.R.; RT "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human RT mammary carcinoma."; RL Mol. Cancer Res. 6:383-394(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [27] RP INTERACTION WITH ERBB2. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [28] RP INTERACTION WITH SFPQ. RX PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008; RA Lukong K.E., Huot M.E., Richard S.; RT "BRK phosphorylates PSF promoting its cytoplasmic localization and cell RT cycle arrest."; RL Cell. Signal. 21:1415-1422(2009). RN [29] RP REVIEW ON FUNCTION. RX PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003; RA Brauer P.M., Tyner A.L.; RT "Building a better understanding of the intracellular tyrosine kinase PTK6 RT - BRK by BRK."; RL Biochim. Biophys. Acta 1806:66-73(2010). RN [30] RP FUNCTION, AND MUTAGENESIS OF ARG-105 AND LYS-219. RX PubMed=20554524; DOI=10.1074/jbc.m109.088971; RA Kang S.A., Lee E.S., Yoon H.Y., Randazzo P.A., Lee S.T.; RT "PTK6 inhibits down-regulation of EGF receptor through phosphorylation of RT ARAP1."; RL J. Biol. Chem. 285:26013-26021(2010). RN [31] RP PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [32] RP FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1. RX PubMed=21479203; DOI=10.1371/journal.pone.0014789; RA Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M., RA Tyner A.L.; RT "The alternative splice variant of protein tyrosine kinase 6 negatively RT regulates growth and enhances PTK6-mediated inhibition of beta-catenin."; RL PLoS ONE 6:E14789-E14789(2011). RN [33] RP STRUCTURE BY NMR OF 75-174. RX PubMed=15056653; DOI=10.1074/jbc.m313185200; RA Hong E., Shin J., Kim H.I., Lee S.T., Lee W.; RT "Solution structure and backbone dynamics of the non-receptor protein- RT tyrosine kinase-6 Src homology 2 domain."; RL J. Biol. Chem. 279:29700-29708(2004). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF LYS-219. RX PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121; RA Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.; RT "Crystal structure of the kinase domain of human protein tyrosine kinase 6 RT (PTK6) at 2.33 A resolution."; RL Biochem. Biophys. Res. Commun. 478:637-642(2016). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH RP INHIBITORS, AND CATALYTIC ACTIVITY. RX PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030; RA Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S., RA Tyagi R., Gosu R.; RT "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel RT imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution."; RL Biochem. Biophys. Res. Commun. 482:1289-1295(2017). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the CC regulation of a variety of signaling pathways that control the CC differentiation and maintenance of normal epithelia, as well as tumor CC growth. Function seems to be context dependent and differ depending on CC cell type, as well as its intracellular localization. A number of CC potential nuclear and cytoplasmic substrates have been identified. CC These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, CC KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B CC and a variety of signaling molecules: ARHGAP35/p190RhoGAP, CC PXN/paxillin, BTK/ATK, STAP2/BKS. Phosphorylates the GTPase-activating CC protein ARAP1 following EGF stimulation which enhances EGFR signaling CC by delaying EGFR down-regulation (PubMed:20554524). Also associates CC with a variety of proteins that are likely upstream of PTK6 in various CC signaling pathways, or for which PTK6 may play an adapter-like role. CC These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal CC or non-tumorigenic tissues, PTK6 promotes cellular differentiation and CC apoptosis. In tumors PTK6 contributes to cancer progression by CC sensitizing cells to mitogenic signals and enhancing proliferation, CC anchorage-independent survival and migration/invasion. Association with CC EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and CC growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 CC kinase. Contributes to migration and proliferation by contributing to CC EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes CC association with RASA1/p120RasGAP, inactivating RhoA while activating CC RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by CC PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration CC and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. CC Nuclear PTK6 may be important for regulating growth in normal CC epithelia, while cytoplasmic PTK6 might activate oncogenic signaling CC pathways. {ECO:0000269|PubMed:20554524}. CC -!- FUNCTION: [Isoform 2]: Inhibits PTK6 phosphorylation and PTK6 CC association with other tyrosine-phosphorylated proteins. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, CC ECO:0000269|PubMed:27993680}; CC -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by CC SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an CC association between the SH3 domain and the SH2-TK linker region. CC Interaction between Trp-184 within SH2-TK linker region and the CC catalytic domain appears essential for positive regulation of kinase CC activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091, CC ECO:0000269|PubMed:17822667}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=83 uM for ATP {ECO:0000269|PubMed:12121988}; CC Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988}; CC -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3 CC and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with CC phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) CC with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2. CC Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK. CC Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193, CC ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407, CC ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:8940083}. CC -!- INTERACTION: CC Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652; CC Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093; CC Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027; CC Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634; CC Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012; CC Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258; CC Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927; CC Q13882; P00533: EGFR; NbExp=2; IntAct=EBI-1383632, EBI-297353; CC Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062; CC Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824; CC Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823; CC Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684; CC Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572; CC Q13882; P42858: HTT; NbExp=4; IntAct=EBI-1383632, EBI-466029; CC Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204; CC Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808; CC Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326; CC Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503; CC Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850; CC Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269; CC Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487; CC Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265; CC Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284; CC Q13882; Q13882: PTK6; NbExp=3; IntAct=EBI-1383632, EBI-1383632; CC Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352; CC Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453; CC Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587; CC Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615; CC Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle. CC Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or CC KHDRBS3, within the nucleus. Nuclear localization in epithelial cells CC of normal prostate but cytoplasmic localization in cancer prostate. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13882-1; Sequence=Displayed; CC Name=2; Synonyms=ALT-PTK6, LambdaM5; CC IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067; CC -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and CC high levels in small intestine and prostate, and low levels in some CC fetal tissues. Not expressed in breast or ovarian tissue but expressed CC in high percentage of breast and ovarian cancers. Also overexpressed in CC some metastatic melanomas, lymphomas, colon cancers, squamous cell CC carcinomas and prostate cancers. Also found in melanocytes. Not CC expressed in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas. Isoform 2 is present in prostate epithelial cell CC lines derived from normal prostate and prostate adenocarcinomas, as CC well as in a variety of cell lines. {ECO:0000269|PubMed:12833144, CC ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629, CC ECO:0000269|PubMed:9185712}. CC -!- DOMAIN: The SH3 domain plays a major role in substrate interactions. CC The SH2 domain of PTK6 plays a role in protein-protein interactions, CC but is likely more important for the regulation of catalytic activity. CC -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an CC increase of kinase activity. Tyr-447 binds to the SH2 domain when CC phosphorylated and negatively regulates kinase activity. CC {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988, CC ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}. CC -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket. CC {ECO:0000269|PubMed:27993680}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X78549; CAA55295.1; -; mRNA. DR EMBL; U61412; AAC34935.1; -; Genomic_DNA. DR EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; AK315232; BAG37660.1; -; mRNA. DR EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA. DR EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC035843; AAH35843.1; -; mRNA. DR CCDS; CCDS13524.1; -. [Q13882-1] DR CCDS; CCDS74750.1; -. [Q13882-2] DR PIR; S49016; S49016. DR RefSeq; NP_001243287.1; NM_001256358.2. [Q13882-2] DR RefSeq; NP_005966.1; NM_005975.4. [Q13882-1] DR PDB; 1RJA; NMR; -; A=75-174. DR PDB; 2KGT; NMR; -; A=1-72. DR PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446. DR PDB; 5DA3; X-ray; 1.70 A; A=185-446. DR PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446. DR PDB; 6CZ2; X-ray; 2.50 A; A=182-443. DR PDB; 6CZ3; X-ray; 1.80 A; A=182-443. DR PDB; 6CZ4; X-ray; 1.50 A; A=182-443. DR PDB; 8S1C; X-ray; 1.75 A; A/B=11-72. DR PDBsum; 1RJA; -. DR PDBsum; 2KGT; -. DR PDBsum; 5D7V; -. DR PDBsum; 5DA3; -. DR PDBsum; 5H2U; -. DR PDBsum; 6CZ2; -. DR PDBsum; 6CZ3; -. DR PDBsum; 6CZ4; -. DR PDBsum; 8S1C; -. DR AlphaFoldDB; Q13882; -. DR BMRB; Q13882; -. DR SMR; Q13882; -. DR BioGRID; 111720; 103. DR DIP; DIP-39785N; -. DR FunCoup; Q13882; 312. DR IntAct; Q13882; 83. DR MINT; Q13882; -. DR STRING; 9606.ENSP00000442460; -. DR BindingDB; Q13882; -. DR ChEMBL; CHEMBL4601; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q13882; -. DR GuidetoPHARMACOLOGY; 2182; -. DR GlyGen; Q13882; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13882; -. DR PhosphoSitePlus; Q13882; -. DR BioMuta; PTK6; -. DR DMDM; 8928302; -. DR CPTAC; CPTAC-2842; -. DR CPTAC; CPTAC-2880; -. DR jPOST; Q13882; -. DR MassIVE; Q13882; -. DR PaxDb; 9606-ENSP00000442460; -. DR PeptideAtlas; Q13882; -. DR ProteomicsDB; 59709; -. [Q13882-1] DR ProteomicsDB; 59710; -. [Q13882-2] DR Antibodypedia; 29774; 545 antibodies from 39 providers. DR DNASU; 5753; -. DR Ensembl; ENST00000217185.3; ENSP00000217185.3; ENSG00000101213.8. [Q13882-2] DR Ensembl; ENST00000542869.3; ENSP00000442460.2; ENSG00000101213.8. [Q13882-1] DR GeneID; 5753; -. DR KEGG; hsa:5753; -. DR MANE-Select; ENST00000542869.3; ENSP00000442460.2; NM_005975.4; NP_005966.1. DR UCSC; uc002yfg.5; human. [Q13882-1] DR AGR; HGNC:9617; -. DR ClinPGx; PA33960; -. DR CTD; 5753; -. DR DisGeNET; 5753; -. DR GeneCards; PTK6; -. DR HGNC; HGNC:9617; PTK6. DR HPA; ENSG00000101213; Tissue enhanced (esophagus, skin, vagina). DR MIM; 602004; gene. DR OpenTargets; ENSG00000101213; -. DR VEuPathDB; HostDB:ENSG00000101213; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161218; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q13882; -. DR OMA; LWKGQVR; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q13882; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q13882; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13882; -. DR Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8849472; PTK6 Down-Regulation. DR Reactome; R-HSA-8849473; PTK6 Expression. DR Reactome; R-HSA-8849474; PTK6 Activates STAT3. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-9707564; Cytoprotection by HMOX1. DR SABIO-RK; Q13882; -. DR SignaLink; Q13882; -. DR SIGNOR; Q13882; -. DR Agora; ENSG00000101213; -. DR BioGRID-ORCS; 5753; 17 hits in 1179 CRISPR screens. DR EvolutionaryTrace; Q13882; -. DR GeneWiki; PTK6; -. DR GenomeRNAi; 5753; -. DR Pharos; Q13882; Tchem. DR PRO; PR:Q13882; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13882; protein. DR Bgee; ENSG00000101213; Expressed in esophagus squamous epithelium and 125 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0001726; C:ruffle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome. DR GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl. DR GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome. DR GO; GO:0045740; P:positive regulation of DNA replication; TAS:Reactome. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; TAS:Reactome. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB. DR CDD; cd05148; PTKc_Srm_Brk; 1. DR CDD; cd10358; SH2_PTK6_Brk; 1. DR CDD; cd11847; SH3_Brk; 1. DR FunFam; 1.10.510.10:FF:000399; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000229; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000074; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR035846; PTK6_SH2. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase. FT CHAIN 1..451 FT /note="Protein-tyrosine kinase 6" FT /id="PRO_0000088133" FT DOMAIN 8..72 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 78..170 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 191..445 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 171..190 FT /note="Linker" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 197..205 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 219 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680" FT MOD_RES 13 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 61 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 66 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 114 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0007744|PubMed:18691976" FT MOD_RES 342 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 351 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 447 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:10913193" FT VAR_SEQ 78..134 FT /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI FT WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR FT ALPEARA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042066" FT VAR_SEQ 135..451 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042067" FT VARIANT 16 FT /note="L -> F (in a renal papillary sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041760" FT VARIANT 436 FT /note="A -> T (in dbSNP:rs56145017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041761" FT MUTAGEN 44 FT /note="W->A: Strong decrease in STAP2 phosphorylation. FT Markedly decreased interaction between SH3 domain the FT linker region." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:17822667" FT MUTAGEN 66 FT /note="Y->A: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 105 FT /note="R->A: Abolishes interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:20554524" FT MUTAGEN 105 FT /note="R->L: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 184 FT /note="W->A: Abrogates interaction between PTK6-domain FT kinase and PTK6-linker. Abrogates autophosphorylation and FT phosphorylation of KHDRBS1." FT /evidence="ECO:0000269|PubMed:15961400" FT MUTAGEN 219 FT /note="K->M: Abolishes kinase activity and cell FT transformation, and phosphorylation of STAP2. Reduces FT interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20554524, FT ECO:0000269|PubMed:8940083" FT MUTAGEN 219 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:27480927" FT MUTAGEN 342 FT /note="Y->A: 3-fold lower specific kinase activity. FT Decreased, but still significant, autophosphorylation. FT Decreased, but still significant, autophosphorylation; when FT associated with A-447." FT /evidence="ECO:0000269|PubMed:12121988" FT MUTAGEN 447 FT /note="Y->F: Decrease in transforming potential and FT increase in the kinase activity level. Decreased, but still FT significant, autophosphorylation; when associated with A- FT 342." FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 45..50 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2KGT" FT TURN 64..66 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 67..70 FT /evidence="ECO:0007829|PDB:2KGT" FT HELIX 85..92 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 102..106 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 114..118 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 125..131 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 137..140 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 143..147 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 148..157 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 162..164 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 188..190 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 191..200 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 214..221 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 229..240 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 256..264 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:6CZ2" FT HELIX 272..278 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:5DA3" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 339..342 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 356..361 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 366..380 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 381..384 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 434..441 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 442..444 FT /evidence="ECO:0007829|PDB:5D7V" SQ SEQUENCE 451 AA; 51834 MW; CDCAC0EE242E1BD7 CRC64; MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM LTCWCRDPEQ RPCFKALRER LSSFTSYENP T // ID RABL3_HUMAN Reviewed; 236 AA. AC Q5HYI8; Q8WUD3; DT 04-DEC-2007, integrated into UniProtKB/Swiss-Prot. DT 15-FEB-2005, sequence version 1. DT 28-JAN-2026, entry version 169. DE RecName: Full=Rab-like protein 3; DE EC=3.6.5.2 {ECO:0000250|UniProtKB:Q9D4V7}; GN Name=RABL3 {ECO:0000312|HGNC:HGNC:18072}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Bone marrow, Fetal skin, and Heart; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [8] RP FUNCTION, INTERACTION WITH RAB11, MUTAGENESIS OF SER-20, AND SUBCELLULAR RP LOCATION. RX PubMed=36052645; DOI=10.1242/jcs.260021; RA Kobayashi T., Ikeda T., Ota R., Yasukawa T., Itoh H.; RT "The atypical small GTPase RABL3 interacts with RAB11 to regulate early RT ciliogenesis in human cells."; RL J. Cell Sci. 135:0-0(2022). RN [9] RP FUNCTION, INTERACTION WITH RAP1GDS1, INVOLVEMENT IN PNCA5, VARIANTS PNCA5 RP 36-SER--ASP-236 DEL AND GLN-184, AND CHARACTERIZATION OF VARIANT PNCA5 RP 36-SER--ASP-236 DEL. RX PubMed=31406347; DOI=10.1038/s41588-019-0475-y; RA Nissim S., Leshchiner I., Mancias J.D., Greenblatt M.B., Maertens O., RA Cassa C.A., Rosenfeld J.A., Cox A.G., Hedgepeth J., Wucherpfennig J.I., RA Kim A.J., Henderson J.E., Gonyo P., Brandt A., Lorimer E., Unger B., RA Prokop J.W., Heidel J.R., Wang X.X., Ukaegbu C.I., Jennings B.C., RA Paulo J.A., Gableske S., Fierke C.A., Getz G., Sunyaev S.R., RA Wade Harper J., Cichowski K., Kimmelman A.C., Houvras Y., Syngal S., RA Williams C., Goessling W.; RT "Mutations in RABL3 alter KRAS prenylation and are associated with RT hereditary pancreatic cancer."; RL Nat. Genet. 51:1308-1314(2019). CC -!- FUNCTION: Small GTPase required for KRAS signaling regulation and CC modulation of cell proliferation (PubMed:31406347). Regulator of KRAS CC prenylation, and probably prenylation of other small GTPases CC (PubMed:31406347). Required for lymphocyte development and function (By CC similarity). Not required for myeloid cell development (By similarity). CC Interacts with Rab11 to promote ciliary vesicle formation at the mother CC centriole, thereby regulating early ciliogenesis. The GTP-binding CC capacity of RABL3 is essential for ciliogenesis (PubMed:36052645). CC {ECO:0000250|UniProtKB:Q9D4V7, ECO:0000269|PubMed:31406347, CC ECO:0000269|PubMed:36052645}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000250|UniProtKB:P62493}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670; CC Evidence={ECO:0000250|UniProtKB:P62493}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9D4V7}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with GPR89; the CC interaction stabilizes GPR89 (By similarity). Interacts with RAP1GDS1 CC (PubMed:31406347). Interacts (GDP-bound) with RAB11A (GTP-bound); the CC interaction stabilizes RABL3 and regulates ciliary vesicle formation CC during early ciliogenesis (PubMed:36052645). CC {ECO:0000250|UniProtKB:Q9D4V7, ECO:0000269|PubMed:31406347, CC ECO:0000269|PubMed:36052645}. CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:36052645}. Golgi apparatus CC {ECO:0000269|PubMed:36052645}. Note=Accumulates around the centrosome CC during early ciliogenesis. {ECO:0000269|PubMed:36052645}. CC -!- DOMAIN: Switch I, switch II and the interswitch regions are CC characteristic of Rab GTPases and mediate the interactions with Rab CC downstream effectors. The switch regions undergo conformational changes CC upon nucleotide binding which drive interaction with specific sets of CC effector proteins, with most effectors only binding to GTP-bound Rab. CC {ECO:0000250|UniProtKB:P62820}. CC -!- DISEASE: Pancreatic cancer 5 (PNCA5) [MIM:618680]: A malignant neoplasm CC of the pancreas. Tumors can arise from both the exocrine and endocrine CC portions of the pancreas, but 95% of them develop from the exocrine CC portion, including the ductal epithelium, acinar cells, connective CC tissue, and lymphatic tissue. {ECO:0000269|PubMed:31406347}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. RABL3 variants have been found in CC families with a history of pancreatic ductal adenocarcinoma and CC multiple other occurrences of cancer, including melanoma, breast CC cancer, prostate cancer, and colon cancer. CC {ECO:0000269|PubMed:31406347}. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Rab family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK293085; BAF85774.1; -; mRNA. DR EMBL; BX647664; CAI46059.1; -; mRNA. DR EMBL; BX647593; CAI46064.1; -; mRNA. DR EMBL; BX647559; CAI46095.1; -; mRNA. DR EMBL; CH471052; EAW79521.1; -; Genomic_DNA. DR EMBL; BC020832; AAH20832.1; -; mRNA. DR CCDS; CCDS3001.1; -. DR RefSeq; NP_776186.2; NM_173825.5. DR AlphaFoldDB; Q5HYI8; -. DR SMR; Q5HYI8; -. DR BioGRID; 130066; 248. DR FunCoup; Q5HYI8; 2126. DR IntAct; Q5HYI8; 118. DR MINT; Q5HYI8; -. DR STRING; 9606.ENSP00000273375; -. DR ChEMBL; CHEMBL4105853; -. DR DrugCentral; Q5HYI8; -. DR iPTMnet; Q5HYI8; -. DR PhosphoSitePlus; Q5HYI8; -. DR SwissPalm; Q5HYI8; -. DR BioMuta; RABL3; -. DR DMDM; 74762186; -. DR jPOST; Q5HYI8; -. DR MassIVE; Q5HYI8; -. DR PaxDb; 9606-ENSP00000273375; -. DR PeptideAtlas; Q5HYI8; -. DR ProteomicsDB; 62938; -. DR Pumba; Q5HYI8; -. DR TopDownProteomics; Q5HYI8; -. DR Antibodypedia; 32810; 46 antibodies from 20 providers. DR DNASU; 285282; -. DR Ensembl; ENST00000273375.8; ENSP00000273375.4; ENSG00000144840.11. DR GeneID; 285282; -. DR KEGG; hsa:285282; -. DR MANE-Select; ENST00000273375.8; ENSP00000273375.4; NM_173825.5; NP_776186.2. DR UCSC; uc003edx.3; human. DR AGR; HGNC:18072; -. DR ClinPGx; PA34161; -. DR CTD; 285282; -. DR DisGeNET; 285282; -. DR GeneCards; RABL3; -. DR HGNC; HGNC:18072; RABL3. DR HPA; ENSG00000144840; Low tissue specificity. DR MalaCards; RABL3; -. DR MIM; 618542; gene. DR MIM; 618680; phenotype. DR OpenTargets; ENSG00000144840; -. DR Orphanet; 1333; Familial pancreatic carcinoma. DR VEuPathDB; HostDB:ENSG00000144840; -. DR eggNOG; ENOG502QT3S; Eukaryota. DR GeneTree; ENSGT00390000007467; -. DR HOGENOM; CLU_084875_1_0_1; -. DR InParanoid; Q5HYI8; -. DR OMA; HIRFDME; -. DR OrthoDB; 5914890at2759; -. DR PAN-GO; Q5HYI8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q5HYI8; -. DR PathwayCommons; Q5HYI8; -. DR SignaLink; Q5HYI8; -. DR Agora; ENSG00000144840; -. DR BioGRID-ORCS; 285282; 34 hits in 1157 CRISPR screens. DR GenomeRNAi; 285282; -. DR Pharos; Q5HYI8; Tbio. DR PRO; PR:Q5HYI8; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q5HYI8; protein. DR Bgee; ENSG00000144840; Expressed in adrenal tissue and 198 other cell types or tissues. DR ExpressionAtlas; Q5HYI8; baseline and differential. DR GO; GO:0012505; C:endomembrane system; IBA:GO_Central. DR GO; GO:0003925; F:G protein activity; IMP:UniProtKB. DR GO; GO:0005525; F:GTP binding; ISS:UniProtKB. DR GO; GO:0003924; F:GTPase activity; IBA:GO_Central. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB. DR GO; GO:0006886; P:intracellular protein transport; IBA:GO_Central. DR GO; GO:0001779; P:natural killer cell differentiation; ISS:UniProtKB. DR GO; GO:0045724; P:positive regulation of cilium assembly; IMP:UniProtKB. DR GO; GO:0050821; P:protein stabilization; ISS:UniProtKB. DR GO; GO:1903059; P:regulation of protein lipidation; IMP:UniProtKB. DR GO; GO:0046578; P:regulation of Ras protein signal transduction; IMP:UniProtKB. DR GO; GO:0033077; P:T cell differentiation in thymus; ISS:UniProtKB. DR CDD; cd04102; RabL3; 1. DR FunFam; 3.40.50.300:FF:000525; rab-like protein 3 isoform X1; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR24073; DRAB5-RELATED; 1. DR Pfam; PF08477; Roc; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51419; RAB; 1. PE 1: Evidence at protein level; KW Cytoplasm; Cytoskeleton; Disease variant; Golgi apparatus; GTP-binding; KW Hydrolase; Magnesium; Metal-binding; Nucleotide-binding; KW Proteomics identification; Reference proteome. FT CHAIN 1..236 FT /note="Rab-like protein 3" FT /id="PRO_0000312166" FT REGION 1..236 FT /note="Small GTPase-like" FT REGION 33..41 FT /note="Switch-I" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00753" FT REGION 69..89 FT /note="Switch-II" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00753" FT BINDING 15 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 16 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 19 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 20 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 20 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 21 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 38 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 38 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 66 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 148 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 150 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 179 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 180 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT VARIANT 36..236 FT /note="Missing (in PNCA5; associated with disease FT susceptibility; increased KRAS signaling and cell FT proliferation; increased interaction with RAP1GDS1; FT increased KRAS prenylation)" FT /evidence="ECO:0000269|PubMed:31406347" FT /id="VAR_083453" FT VARIANT 184 FT /note="R -> Q (in PNCA5; associated with disease FT susceptibility; dbSNP:rs61756477)" FT /evidence="ECO:0000269|PubMed:31406347" FT /id="VAR_083454" FT MUTAGEN 20 FT /note="S->N: Dominant-negative mutant (GDP-bound form). FT Increased interaction with GTP-bound RAB11A. Increased FT recruitment to the centrosome. Impaired positive regulation FT of ciliary vesicle formation." FT /evidence="ECO:0000269|PubMed:36052645" FT CONFLICT 60 FT /note="Y -> C (in Ref. 4; AAH20832)" FT /evidence="ECO:0000305" FT CONFLICT 163 FT /note="R -> T (in Ref. 4; AAH20832)" FT /evidence="ECO:0000305" SQ SEQUENCE 236 AA; 26423 MW; B80898B1293C88C6 CRC64; MASLDRVKVL VLGDSGVGKS SLVHLLCQNQ VLGNPSWTVG CSVDVRVHDY KEGTPEEKTY YIELWDVGGS VGSASSVKST RAVFYNSVNG IIFVHDLTNK KSSQNLRRWS LEALNRDLVP TGVLVTNGDY DQEQFADNQI PLLVIGTKLD QIHETKRHEV LTRTAFLAED FNPEEINLDC TNPRYLAAGS SNAVKLSRFF DKVIEKRYFL REGNQIPGFP DRKRFGAGTL KSLHYD // ID RAD54_HUMAN Reviewed; 747 AA. AC Q92698; Q5TE31; Q6IUY3; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 16-AUG-2004, sequence version 2. DT 28-JAN-2026, entry version 187. DE RecName: Full=DNA repair and recombination protein RAD54-like {ECO:0000305|PubMed:9774452}; DE EC=3.6.4.- {ECO:0000269|PubMed:11884632, ECO:0000269|PubMed:9774452}; DE AltName: Full=RAD54 homolog; DE Short=hHR54; DE Short=hRAD54; GN Name=RAD54L {ECO:0000312|HGNC:HGNC:9826}; Synonyms=RAD54A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, CELL CYCLE REGULATION, RP AND MUTAGENESIS OF LYS-189. RC TISSUE=Testis; RX PubMed=8805304; DOI=10.1016/s0960-9822(02)00606-1; RA Kanaar R., Troelstra C., Swagemakers S.M.A., Essers J., Smit B., RA Franssen J.-H., Pastink A., Bezzubova O.Y., Buerstedde J.-M., Clever B., RA Heyer W.-D., Hoeijmakers J.H.J.; RT "Human and mouse homologs of the Saccharomyces cerevisiae RAD54 DNA repair RT gene: evidence for functional conservation."; RL Curr. Biol. 6:828-838(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-21; MET-74; CYS-202; RP GLN-380; CYS-534 AND THR-583. RG NIEHS SNPs program; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP CHARACTERIZATION. RX PubMed=9192813; RA Rasio D., Murakumo Y., Robbins D., Roth T., Silver A., Negrini M., RA Schmidt C., Burczak J., Fishel R., Croce C.M.; RT "Characterization of the human homologue of RAD54: a gene located on RT chromosome 1p32 at a region of high loss of heterozygosity in breast RT tumors."; RL Cancer Res. 57:2378-2383(1997). RN [6] RP INTERACTION WITH RAD51. RX PubMed=9321665; DOI=10.1093/nar/25.20.4106; RA Golub E.I., Kovalenko O.V., Gupta R.C., Ward D.C., Radding C.M.; RT "Interaction of human recombination proteins Rad51 and Rad54."; RL Nucleic Acids Res. 25:4106-4110(1997). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=9774452; DOI=10.1074/jbc.273.43.28292; RA Swagemakers S.M.A., Essers J., de Wit J., Hoeijmakers J.H.J., Kanaar R.; RT "The human RAD54 recombinational DNA repair protein is a double-stranded RT DNA-dependent ATPase."; RL J. Biol. Chem. 273:28292-28297(1998). RN [8] RP LACK OF INVOLVEMENT IN PARATHYROID ADENOMAS. RX PubMed=10449612; RX DOI=10.1002/(sici)1097-0215(19990924)83:1<80::aid-ijc15>3.0.co;2-e; RA Carling T., Imanishi Y., Gaz R.D., Arnold A.; RT "Analysis of the RAD54 gene on chromosome 1p as a potential tumor- RT suppressor gene in parathyroid adenomas."; RL Int. J. Cancer 83:80-82(1999). RN [9] RP FUNCTION. RX PubMed=11459989; DOI=10.1073/pnas.151056798; RA Ristic D., Wyman C., Paulusma C., Kanaar R.; RT "The architecture of the human Rad54-DNA complex provides evidence for RT protein translocation along DNA."; RL Proc. Natl. Acad. Sci. U.S.A. 98:8454-8460(2001). RN [10] RP FUNCTION. RX PubMed=12205100; DOI=10.1074/jbc.m208004200; RA Sigurdsson S., Van Komen S., Petukhova G., Sung P.; RT "Homologous DNA pairing by human recombination factors Rad51 and Rad54."; RL J. Biol. Chem. 277:42790-42794(2002). RN [11] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH RAD51, RP AND MUTAGENESIS OF LYS-189. RX PubMed=11884632; DOI=10.1093/nar/30.6.1346; RA Tanaka K., Kagawa W., Kinebuchi T., Kurumizaka H., Miyagawa K.; RT "Human Rad54B is a double-stranded DNA-dependent ATPase and has biochemical RT properties different from its structural homolog in yeast, Tid1/Rdh54."; RL Nucleic Acids Res. 30:1346-1353(2002). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-38, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP FUNCTION, AND INTERACTION WITH NAP1L1. RX PubMed=24798879; DOI=10.1038/srep04863; RA Machida S., Takaku M., Ikura M., Sun J., Suzuki H., Kobayashi W., RA Kinomura A., Osakabe A., Tachiwana H., Horikoshi Y., Fukuto A., Matsuda R., RA Ura K., Tashiro S., Ikura T., Kurumizaka H.; RT "Nap1 stimulates homologous recombination by RAD51 and RAD54 in higher- RT ordered chromatin containing histone H1."; RL Sci. Rep. 4:4863-4863(2014). RN [14] RP PHOSPHORYLATION AT SER-572, MUTAGENESIS OF SER-572, AND FUNCTION. RX PubMed=27264870; DOI=10.1016/j.molcel.2016.04.032; RA Spies J., Waizenegger A., Barton O., Suerder M., Wright W.D., Heyer W.D., RA Loebrich M.; RT "Nek1 Regulates Rad54 to Orchestrate Homologous Recombination and RT Replication Fork Stability."; RL Mol. Cell 62:903-917(2016). RN [15] RP ACETYLATION AT LYS-515, INTERACTION WITH BRD9, FUNCTION, AND MUTAGENESIS OF RP LYS-515. RX PubMed=32457312; DOI=10.1038/s41467-020-16443-x; RA Zhou Q., Huang J., Zhang C., Zhao F., Kim W., Tu X., Zhang Y., Nowsheen S., RA Zhu Q., Deng M., Chen Y., Qin B., Luo K., Liu B., Lou Z., Mutter R.W., RA Yuan J.; RT "The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex RT formation and regulates homologous recombination-mediated repair."; RL Nat. Commun. 11:2639-2639(2020). RN [16] RP VARIANTS HIS-63; GLU-151; ARG-325 AND GLU-444. RX PubMed=10362365; DOI=10.1038/sj.onc.1202692; RA Matsuda M., Miyagawa K., Takahashi M., Fukuda T., Kataoka T., Asahara T., RA Inui H., Watatani M., Yasutomi M., Kamada N., Dohi K., Kamiya K.; RT "Mutations in the RAD54 recombination gene in primary cancers."; RL Oncogene 18:3427-3430(1999). CC -!- FUNCTION: Multifunctional ATPase that plays a role in homologous CC recombination (HR) which is a major pathway for repairing DNA double- CC strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or CC collapsed replication forks (PubMed:11459989, PubMed:12205100, CC PubMed:24798879, PubMed:27264870, PubMed:32457312, PubMed:9774452). CC Acts as a molecular motor during the homology search and guides RAD51 CC ssDNA along a donor dsDNA thereby changing the homology search from the CC diffusion-based mechanism to a motor-guided mechanism. Also plays an CC essential role in RAD51-mediated synaptic complex formation which CC consists of three strands encased in a protein filament formed once CC homology is recognized. Once DNA strand exchange occured, dissociates CC RAD51 from nucleoprotein filaments formed on dsDNA (By similarity). CC {ECO:0000250|UniProtKB:P32863, ECO:0000269|PubMed:11459989, CC ECO:0000269|PubMed:12205100, ECO:0000269|PubMed:24798879, CC ECO:0000269|PubMed:27264870, ECO:0000269|PubMed:32457312, CC ECO:0000269|PubMed:9774452}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:11884632, ECO:0000269|PubMed:9774452}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066; CC Evidence={ECO:0000305|PubMed:9774452}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=410 uM for ATP {ECO:0000269|PubMed:11884632}; CC -!- SUBUNIT: Homohexamer (By similarity). Interacts (via N-terminus) with CC RAD51; RAD51 nucleoprotein filament stimulate RAD54L ATPase activity CC (PubMed:9321665, PubMed:11884632). Interacts with NAP1L1 CC (PubMed:24798879). Interacts with BRD9; this interaction orchestrates CC RAD51-RAD54 complex formation (PubMed:32457312). CC {ECO:0000250|UniProtKB:F1Q8K0, ECO:0000269|PubMed:11884632, CC ECO:0000269|PubMed:24798879, ECO:0000269|PubMed:32457312, CC ECO:0000269|PubMed:9321665}. CC -!- INTERACTION: CC Q92698; Q96HA8: NTAQ1; NbExp=6; IntAct=EBI-5333483, EBI-741158; CC Q92698; Q9H2K2: TNKS2; NbExp=3; IntAct=EBI-5333483, EBI-4398527; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:8805304}. CC -!- INDUCTION: Expression increases approximately 3-fold in late G1 phase CC compared to other phases of the cell cycle. CC -!- PTM: Acetylated. Acetylation promotes interaction with BRD9, and CC subsequently with RAD54, which is essential for homologous CC recombination (HR). {ECO:0000269|PubMed:32457312}. CC -!- PTM: Phosphorylated. Phosphorylation at Ser-572 by NEK1 specifically in CC G2 phase allows efficient removal of RAD51 filaments from DNA. CC {ECO:0000269|PubMed:27264870}. CC -!- SIMILARITY: Belongs to the SNF2/RAD54 helicase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X97795; CAA66379.1; -; mRNA. DR EMBL; AY623117; AAT38113.1; -; Genomic_DNA. DR EMBL; AL121602; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC121059; AAI21060.1; -; mRNA. DR EMBL; BC121060; AAI21061.1; -; mRNA. DR CCDS; CCDS532.1; -. DR RefSeq; NP_001136020.1; NM_001142548.2. DR RefSeq; NP_003570.2; NM_003579.4. DR AlphaFoldDB; Q92698; -. DR SMR; Q92698; -. DR BioGRID; 114018; 18. DR DIP; DIP-48628N; -. DR ELM; Q92698; -. DR FunCoup; Q92698; 1350. DR IntAct; Q92698; 10. DR STRING; 9606.ENSP00000361043; -. DR BindingDB; Q92698; -. DR ChEMBL; CHEMBL2146297; -. DR iPTMnet; Q92698; -. DR PhosphoSitePlus; Q92698; -. DR BioMuta; RAD54L; -. DR DMDM; 51316508; -. DR jPOST; Q92698; -. DR MassIVE; Q92698; -. DR PaxDb; 9606-ENSP00000361043; -. DR PeptideAtlas; Q92698; -. DR ProteomicsDB; 75414; -. DR Pumba; Q92698; -. DR Antibodypedia; 18708; 262 antibodies from 31 providers. DR DNASU; 8438; -. DR Ensembl; ENST00000371975.9; ENSP00000361043.4; ENSG00000085999.14. DR Ensembl; ENST00000442598.5; ENSP00000396113.1; ENSG00000085999.14. DR Ensembl; ENST00000671528.1; ENSP00000499652.1; ENSG00000085999.14. DR GeneID; 8438; -. DR KEGG; hsa:8438; -. DR MANE-Select; ENST00000371975.9; ENSP00000361043.4; NM_003579.4; NP_003570.2. DR UCSC; uc001cpl.3; human. DR AGR; HGNC:9826; -. DR CIViC; 8438; 1 evidence item across 1 molecular profile. DR ClinPGx; PA34181; -. DR CTD; 8438; -. DR DisGeNET; 8438; -. DR GeneCards; RAD54L; -. DR HGNC; HGNC:9826; RAD54L. DR HPA; ENSG00000085999; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; RAD54L; -. DR MIM; 603615; gene. DR OpenTargets; ENSG00000085999; -. DR Orphanet; 227535; Hereditary breast cancer. DR VEuPathDB; HostDB:ENSG00000085999; -. DR eggNOG; KOG0390; Eukaryota. DR GeneTree; ENSGT00940000156897; -. DR HOGENOM; CLU_000315_10_5_1; -. DR InParanoid; Q92698; -. DR OMA; YTEHERM; -. DR OrthoDB; 413460at2759; -. DR PAN-GO; Q92698; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q92698; -. DR BRENDA; 3.6.4.B9; 2681. DR PathwayCommons; Q92698; -. DR SignaLink; Q92698; -. DR SIGNOR; Q92698; -. DR Agora; ENSG00000085999; -. DR BioGRID-ORCS; 8438; 55 hits in 1167 CRISPR screens. DR ChiTaRS; RAD54L; human. DR GeneWiki; DNA_repair_and_recombination_protein_RAD54-like; -. DR GenomeRNAi; 8438; -. DR Pharos; Q92698; Tbio. DR PRO; PR:Q92698; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q92698; protein. DR Bgee; ENSG00000085999; Expressed in left testis and 102 other cell types or tissues. DR ExpressionAtlas; Q92698; baseline and differential. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0032991; C:protein-containing complex; IMP:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProt. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:UniProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003678; F:DNA helicase activity; IEA:UniProtKB-EC. DR GO; GO:0015616; F:DNA translocase activity; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006310; P:DNA recombination; TAS:ProtInc. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0045003; P:double-strand break repair via synthesis-dependent strand annealing; IBA:GO_Central. DR GO; GO:0051321; P:meiotic cell cycle; TAS:ProtInc. DR GO; GO:0007131; P:reciprocal meiotic recombination; IBA:GO_Central. DR GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR CDD; cd18067; DEXHc_RAD54A; 1. DR CDD; cd18793; SF2_C_SNF; 1. DR FunFam; 1.20.120.850:FF:000002; DNA repair and recombination protein RAD54-like; 1. DR FunFam; 3.40.50.10810:FF:000010; DNA repair and recombination protein RAD54-like; 1. DR FunFam; 3.40.50.300:FF:000332; DNA repair and recombination protein RAD54-like; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR Gene3D; 1.20.120.850; SWI2/SNF2 ATPases, N-terminal domain; 1. DR Gene3D; 3.40.50.10810; Tandem AAA-ATPase domain; 1. DR InterPro; IPR014001; Helicase_ATP-bd. DR InterPro; IPR001650; Helicase_C-like. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR038718; SNF2-like_sf. DR InterPro; IPR049730; SNF2/RAD54-like_C. DR InterPro; IPR000330; SNF2_N. DR InterPro; IPR050496; SNF2_RAD54_helicase_repair. DR PANTHER; PTHR45629:SF7; DNA EXCISION REPAIR PROTEIN ERCC-6-RELATED; 1. DR PANTHER; PTHR45629; SNF2/RAD54 FAMILY MEMBER; 1. DR Pfam; PF00271; Helicase_C; 1. DR Pfam; PF00176; SNF2-rel_dom; 1. DR SMART; SM00487; DEXDc; 1. DR SMART; SM00490; HELICc; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2. DR PROSITE; PS51192; HELICASE_ATP_BIND_1; 1. DR PROSITE; PS51194; HELICASE_CTER; 1. PE 1: Evidence at protein level; KW Acetylation; DNA damage; DNA repair; DNA-binding; Hydrolase; Metal-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Zinc. FT CHAIN 1..747 FT /note="DNA repair and recombination protein RAD54-like" FT /id="PRO_0000074337" FT DOMAIN 170..345 FT /note="Helicase ATP-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT DOMAIN 500..653 FT /note="Helicase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00542" FT REGION 1..41 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2..9 FT /note="Required for chromatin remodeling, strand pairing FT activities and coupling of ATPase activity" FT /evidence="ECO:0000250" FT MOTIF 296..299 FT /note="DEAH box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT BINDING 183..190 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT MOD_RES 38 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 515 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:32457312" FT MOD_RES 572 FT /note="Phosphoserine; by NEK1" FT /evidence="ECO:0000269|PubMed:27264870" FT VARIANT 21 FT /note="D -> G (in dbSNP:rs28363192)" FT /evidence="ECO:0000269|Ref.2" FT /id="VAR_055363" FT VARIANT 63 FT /note="P -> H (in a colon adenocarcinoma sample; FT dbSNP:rs121908688)" FT /evidence="ECO:0000269|PubMed:10362365" FT /id="VAR_019559" FT VARIANT 74 FT /note="I -> M (in dbSNP:rs28363209)" FT /evidence="ECO:0000269|Ref.2" FT /id="VAR_055364" FT VARIANT 151 FT /note="K -> E (in dbSNP:rs2295466)" FT /evidence="ECO:0000269|PubMed:10362365" FT /id="VAR_019560" FT VARIANT 202 FT /note="R -> C (in dbSNP:rs28363218)" FT /evidence="ECO:0000269|Ref.2" FT /id="VAR_055365" FT VARIANT 325 FT /note="G -> R (in a breast cancer sample; invasive ductal; FT dbSNP:rs121908690)" FT /evidence="ECO:0000269|PubMed:10362365" FT /id="VAR_019561" FT VARIANT 380 FT /note="R -> Q (in dbSNP:rs28363234)" FT /evidence="ECO:0000269|Ref.2" FT /id="VAR_055366" FT VARIANT 444 FT /note="V -> E (in a non-Hodgkin lymphoma sample; FT dbSNP:rs121908689)" FT /evidence="ECO:0000269|PubMed:10362365" FT /id="VAR_019562" FT VARIANT 534 FT /note="R -> C (in dbSNP:rs28363240)" FT /evidence="ECO:0000269|Ref.2" FT /id="VAR_055367" FT VARIANT 583 FT /note="I -> T (in dbSNP:rs28363243)" FT /evidence="ECO:0000269|Ref.2" FT /id="VAR_055368" FT MUTAGEN 189 FT /note="K->R: Loss of dsDNA-dependent ATPase activity. Loss FT of function in double-strand break repair based on FT complementation assays in yeast." FT /evidence="ECO:0000269|PubMed:11884632, FT ECO:0000269|PubMed:8805304" FT MUTAGEN 515 FT /note="K->R: Loss of acetylation." FT /evidence="ECO:0000269|PubMed:32457312" FT MUTAGEN 572 FT /note="S->A: Defect in homologous recombination (HR)." FT /evidence="ECO:0000269|PubMed:27264870" FT MUTAGEN 572 FT /note="S->E: Promotes homologous recombination (HR), but FT causes RAD51 removal from chromatin." FT /evidence="ECO:0000269|PubMed:27264870" FT CONFLICT 738 FT /note="R -> H (in Ref. 1; CAA66379)" FT /evidence="ECO:0000305" SQ SEQUENCE 747 AA; 84352 MW; 718100974CA6687B CRC64; MRRSLAPSQL AKRKPEGRSC DDEDWQPGLV TPRKRKSSSE TQIQECFLSP FRKPLSQLTN QPPCLDSSQH EAFIRSILSK PFKVPIPNYQ GPLGSRALGL KRAGVRRALH DPLEKDALVL YEPPPLSAHD QLKLDKEKLP VHVVVDPILS KVLRPHQREG VKFLWECVTS RRIPGSHGCI MADEMGLGKT LQCITLMWTL LRQSPECKPE IDKAVVVSPS SLVKNWYNEV GKWLGGRIQP LAIDGGSKDE IDQKLEGFMN QRGARVSSPI LIISYETFRL HVGVLQKGSV GLVICDEGHR LKNSENQTYQ ALDSLNTSRR VLISGTPIQN DLLEYFSLVH FVNSGILGTA HEFKKHFELP ILKGRDAAAS EADRQLGEER LRELTSIVNR CLIRRTSDIL SKYLPVKIEQ VVCCRLTPLQ TELYKRFLRQ AKPAEELLEG KMSVSSLSSI TSLKKLCNHP ALIYDKCVEE EDGFVGALDL FPPGYSSKAL EPQLSGKMLV LDYILAVTRS RSSDKVVLVS NYTQTLDLFE KLCRARRYLY VRLDGTMSIK KRAKVVERFN SPSSPDFVFM LSSKAGGCGL NLIGANRLVM FDPDWNPAND EQAMARVWRD GQKKTCYIYR LLSAGTIEEK IFQRQSHKKA LSSCVVDEEQ DVERHFSLGE LKELFILDEA SLSDTHDRLH CRRCVNSRQI RPPPDGSDCT SDLAGWNHCT DKWGLRDEVL QAAWDAASTA ITFVFHQRSH EEQRGLR // ID RASK_HUMAN Reviewed; 189 AA. AC P01116; A8K8Z5; B0LPF9; P01118; Q96D10; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 268. DE RecName: Full=GTPase KRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; DE AltName: Full=K-Ras 2; DE AltName: Full=Ki-Ras; DE AltName: Full=c-K-ras; DE AltName: Full=c-Ki-ras; DE Contains: DE RecName: Full=GTPase KRas, N-terminally processed; DE Flags: Precursor; GN Name=KRAS; Synonyms=KRAS2, RASK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RX PubMed=6308466; DOI=10.1038/304501a0; RA McGrath J.P., Capon D.J., Smith D.H., Chen E.Y., Seeburg P.H., RA Goeddel D.V., Levinson A.D.; RT "Structure and organization of the human Ki-ras proto-oncogene and a RT related processed pseudogene."; RL Nature 304:501-506(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Lung carcinoma; RX PubMed=6308465; DOI=10.1038/304497a0; RA Shimizu K., Birnbaum D., Ruley M.A., Fasano O., Suard Y., Edlund L., RA Taparowsky E., Goldfarb M., Wigler M.; RT "Structure of the Ki-ras gene of the human lung carcinoma cell line Calu- RT 1."; RL Nature 304:497-500(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Colon carcinoma, and Lung; RX PubMed=6308467; DOI=10.1038/304507a0; RA Capon D.J., Seeburg P.H., McGrath J.P., Hayflick J.S., Edman U., RA Levinson A.D., Goeddel D.V.; RT "Activation of Ki-ras2 gene in human colon and lung carcinomas by two RT different point mutations."; RL Nature 304:507-513(1983). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B), AND VARIANT COLON RP CANCER VAL-12. RC TISSUE=Colon carcinoma; RX PubMed=6092920; DOI=10.1128/mcb.4.8.1577-1582.1984; RA McCoy M.S., Bargmann C.I., Weinberg R.A.; RT "Human colon carcinoma Ki-ras2 oncogene and its corresponding proto- RT oncogene."; RL Mol. Cell. Biol. 4:1577-1582(1984). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2B). RX PubMed=3310850; RA Kahn S., Yamamoto F., Almoguera C., Winter E., Forrester K., Jordano J., RA Perucho M.; RT "The c-K-ras gene and human cancer (review)."; RL Anticancer Res. 7:639-652(1987). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG SeattleSNPs variation discovery resource; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT LUNG CARCINOMA RP CYS-12. RC TISSUE=Lung carcinoma; RX PubMed=6320174; DOI=10.1073/pnas.81.1.71; RA Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M.; RT "Isolation of transforming sequences of two human lung carcinomas: RT structural and functional analysis of the activated c-K-ras oncogenes."; RL Proc. Natl. Acad. Sci. U.S.A. 81:71-75(1984). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96. RC TISSUE=Pancreatic carcinoma; RX PubMed=3855240; DOI=10.1016/s0006-291x(85)80140-6; RA Hirai H., Okabe T., Anraku Y., Fujisawa M., Urabe A., Takaku F.; RT "Activation of the c-K-ras oncogene in a human pancreas carcinoma."; RL Biochem. Biophys. Res. Commun. 127:168-174(1985). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT GASC VAL-12. RX PubMed=3034404; RA Deng G., Lu Y., Chen S., Miao J., Lu G., Li H., Cai H., Xu X., Zheng E., RA Liu P.; RT "Activated c-Ha-ras oncogene with a guanine to thymine transversion at the RT twelfth codon in a human stomach cancer cell line."; RL Cancer Res. 47:3195-3198(1987). RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36, AND VARIANT BLADDER/LUNG CANCER RP ARG-12. RC TISSUE=Lung carcinoma; RX PubMed=6695174; DOI=10.1126/science.6695174; RA Santos E., Martin-Zanca D., Reddy P.E., Pierotti M.A., Porta G., RA Barbacid M.; RT "Malignant activation of a K-ras oncogene in lung carcinoma but not in RT normal tissue of the same patient."; RL Science 223:661-664(1984). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=3932274; RA Sekiya T., Tokunaga A., Fushimi M.; RT "Essential region for transforming activity of human c-Ha-ras-1."; RL Jpn. J. Cancer Res. 76:787-791(1985). RN [17] RP PROTEIN SEQUENCE OF 1-41; 43-147 AND 150-161, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96. RC TISSUE=Lung carcinoma; RX PubMed=6096811; DOI=10.1093/nar/12.23.8873; RA Yamamoto F., Perucho M.; RT "Activation of a human c-K-ras oncogene."; RL Nucleic Acids Res. 12:8873-8885(1984). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [20] RP INTERACTION WITH RAP1GDS1. RX PubMed=20709748; DOI=10.1074/jbc.m110.129916; RA Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R., RA Fields A.P., Williams C.L.; RT "Splice variants of SmgGDS control small GTPase prenylation and membrane RT localization."; RL J. Biol. Chem. 285:35255-35266(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP ACETYLATION AT LYS-104, VARIANT VAL-12, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=22711838; DOI=10.1073/pnas.1201487109; RA Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R., RA Philips M.R., Shan Y., Shaw D.E., Bar-Sagi D., Haigis M.C., Haigis K.M.; RT "Regulation of RAS oncogenicity by acetylation."; RL Proc. Natl. Acad. Sci. U.S.A. 109:10843-10848(2012). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDE6D. RX PubMed=23698361; DOI=10.1038/nature12205; RA Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., RA Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H.; RT "Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic RT KRAS signalling."; RL Nature 497:638-642(2013). RN [24] RP FUNCTION, AND CHARACTERIZATION OF VARIANT COLON CANCER VAL-12. RX PubMed=24623306; DOI=10.7554/elife.02313; RA Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.; RT "A KRAS-directed transcriptional silencing pathway that mediates the CpG RT island methylator phenotype."; RL Elife 3:E02313-E02313(2014). RN [25] RP INTERACTION WITH RAP1GDS1, AND ISOPRENYLATION AT CYS-186. RX PubMed=24415755; DOI=10.1074/jbc.m113.527192; RA Schuld N.J., Vervacke J.S., Lorimer E.L., Simon N.C., Hauser A.D., RA Barbieri J.T., Distefano M.D., Williams C.L.; RT "The chaperone protein SmgGDS interacts with small GTPases entering the RT prenylation pathway by recognizing the last amino acid in the CAAX motif."; RL J. Biol. Chem. 289:6862-6876(2014). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [27] RP PALMITOYLATION AT CYS-180; LYS-182; LYS-184 AND LYS-185, DEPALMITOYLATION RP BY SIRT2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-180 AND RP 182-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [28] RP INTERACTION WITH GPR31. RX PubMed=28619714; DOI=10.1083/jcb.201609096; RA Fehrenbacher N., Tojal da Silva I., Ramirez C., Zhou Y., Cho K.J., RA Kuchay S., Shi J., Thomas S., Pagano M., Hancock J.F., Bar-Sagi D., RA Philips M.R.; RT "The G protein-coupled receptor GPR31 promotes membrane association of RT KRAS."; RL J. Cell Biol. 216:2329-2338(2017). RN [29] RP UBIQUITINATION AT LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [30] RP UBIQUITINATION. RX PubMed=30442766; DOI=10.1126/science.aap8210; RA Bigenzahn J.W., Collu G.M., Kartnig F., Pieraks M., Vladimer G.I., RA Heinz L.X., Sedlyarov V., Schischlik F., Fauster A., Rebsamen M., RA Parapatics K., Blomen V.A., Mueller A.C., Winter G.E., Kralovics R., RA Brummelkamp T.R., Mlodzik M., Superti-Furga G.; RT "LZTR1 is a regulator of RAS ubiquitination and signaling."; RL Science 362:1171-1177(2018). RN [31] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [32] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [33] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND CHARACTERIZATION OF RP VARIANT GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [34] RP INTERACTION WITH PPP1CA AND SHOC2, AND CHARACTERIZATION OF VARIANT GLN-61. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1-164 IN COMPLEX WITH THE GTP RP ANALOG GUANOSINE-5'-DIPHOSPHATE, AND ACTIVITY REGULATION. RX PubMed=22566140; DOI=10.1002/anie.201201358; RA Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., RA Lee T., Rossanese O.W., Fesik S.W.; RT "Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated RT activation."; RL Angew. Chem. Int. Ed. Engl. 51:6140-6143(2012). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 2-164 IN COMPLEX WITH GTP ANALOGS RP AND MAGNESIUM, FUNCTION, ACTIVITY REGULATION, INTERACTION WITH SOS1, AND RP SUBCELLULAR LOCATION. RX PubMed=22431598; DOI=10.1073/pnas.1116510109; RA Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., RA Fauber B.P., Pan B., Malek S., Stokoe D., Ludlam M.J., Bowman K.K., Wu J., RA Giannetti A.M., Starovasnik M.A., Mellman I., Jackson P.K., Rudolph J., RA Wang W., Fang G.; RT "Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS- RT mediated nucleotide exchange activity."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5299-5304(2012). RN [37] {ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-164, ISOPRENYLATION AT CYS-186, RP AND METHYLATION AT CYS-186. RX PubMed=27791178; DOI=10.1073/pnas.1615316113; RA Dharmaiah S., Bindu L., Tran T.H., Gillette W.K., Frank P.H., Ghirlando R., RA Nissley D.V., Esposito D., McCormick F., Stephen A.G., Simanshu D.K.; RT "Structural basis of recognition of farnesylated and methylated KRAS4b by RT PDEdelta."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E6766-E6775(2016). RN [38] {ECO:0007744|PDB:7LC1, ECO:0007744|PDB:7LC2} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH MAPKAP1, INTERACTION RP WITH MAPKAP1, AND MUTAGENESIS OF ASP-38 AND TYR-40. RX PubMed=34380736; DOI=10.1073/pnas.2103261118; RA Castel P., Dharmaiah S., Sale M.J., Messing S., Rizzuto G., RA Cuevas-Navarro A., Cheng A., Trnka M.J., Urisman A., Esposito D., RA Simanshu D.K., McCormick F.; RT "RAS interaction with Sin1 is dispensable for mTORC2 assembly and RT activity."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [39] {ECO:0007744|PDB:7VVB} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH MAPKAP1, AND RP INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [40] RP VARIANT BREAST CANCER ASP-13. RX PubMed=3627975; DOI=10.1093/nar/15.15.5963; RA Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., RA Hynes N.E.; RT "The human c-Kirsten ras gene is activated by a novel mutation in codon 13 RT in the breast carcinoma cell line MDA-MB231."; RL Nucleic Acids Res. 15:5963-5971(1987). RN [41] RP VARIANT BLADDER CANCER THR-59. RX PubMed=1553789; DOI=10.1007/bf00296523; RA Grimmond S.M., Raghavan D., Russell P.J.; RT "Detection of a rare point mutation in Ki-ras of a human bladder cancer RT xenograft by polymerase chain reaction and direct sequencing."; RL Urol. Res. 20:121-126(1992). RN [42] RP VARIANTS PANCREATIC CARCINOMA ASP-12 AND VAL-12. RX PubMed=8439212; DOI=10.1097/00000658-199302000-00007; RA Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T., Kanematsu T.; RT "Detection of point mutations in the Kirsten-ras oncogene provides evidence RT for the multicentricity of pancreatic carcinoma."; RL Ann. Surg. 217:138-143(1993). RN [43] RP VARIANTS GASC SER-12 AND ASP-12. RX PubMed=7773929; RX DOI=10.1002/1097-0142(19950615)75:12<2794::aid-cncr2820751203>3.0.co;2-f; RA Lee K.H., Lee J.S., Suh C., Kim S.W., Kim S.B., Lee J.H., Lee M.S., RA Park M.Y., Sun H.S., Kim S.H.; RT "Clinicopathologic significance of the K-ras gene codon 12 point mutation RT in stomach cancer. An analysis of 140 cases."; RL Cancer 75:2794-2801(1995). RN [44] RP INVOLVEMENT IN AML, VARIANT GLY-10 INS, AND CHARACTERIZATION OF VARIANT RP GLY-10 INS. RX PubMed=8955068; DOI=10.1074/jbc.271.51.32491; RA Bollag G., Adler F., elMasry N., McCabe P.C., Conner E. Jr., Thompson P., RA McCormick F., Shannon K.; RT "Biochemical characterization of a novel KRAS insertion mutation from a RT human leukemia."; RL J. Biol. Chem. 271:32491-32494(1996). RN [45] RP VARIANTS GASC ASN-5; VAL-12; ASP-13 AND THR-59. RX PubMed=14534542; DOI=10.1038/sj.onc.1206749; RA Lee S.H., Lee J.W., Soung Y.H., Kim H.S., Park W.S., Kim S.Y., Lee J.H., RA Park J.Y., Cho Y.G., Kim C.J., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J.; RT "BRAF and KRAS mutations in stomach cancer."; RL Oncogene 22:6942-6945(2003). RN [46] RP VARIANT PYLOCYTIC ASTROCYTOMA ARG-13. RX PubMed=16247081; DOI=10.1212/01.wnl.0000180409.78098.d7; RA Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H.; RT "RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic RT astrocytoma."; RL Neurology 65:1335-1336(2005). RN [47] RP VARIANTS NS3 GLY-152 AND VAL-153 (ISOFORM 2). RX PubMed=16773572; DOI=10.1086/504394; RA Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., RA Digilio C., Palleschi A., Pizzuti A., Grammatico P., Zampino G., RA Dallapiccola B., Gelb B.D., Tartaglia M.; RT "Germline missense mutations affecting KRAS Isoform B are associated with a RT severe Noonan syndrome phenotype."; RL Am. J. Hum. Genet. 79:129-135(2006). RN [48] RP VARIANTS LUNG CARCINOMA CYS-12; ASP-12; SER-12; VAL-12 AND HIS-61. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [49] RP VARIANT CFC2 ARG-60. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [50] RP VARIANTS NS3 ILE-14 AND ILE-58, VARIANT CFC2 ARG-34, AND CHARACTERIZATION RP OF VARIANTS NS3 ILE-14 AND ILE-58. RX PubMed=16474405; DOI=10.1038/ng1748; RA Schubbert S., Zenker M., Rowe S.L., Boell S., Klein C., Bollag G., RA van der Burgt I., Musante L., Kalscheuer V., Wehner L.-E., Nguyen H., RA West B., Zhang K.Y.J., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., RA Kratz C.P.; RT "Germline KRAS mutations cause Noonan syndrome."; RL Nat. Genet. 38:331-336(2006). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-12; ASP-12; SER-12; VAL-12; ASP-13; RP ARG-61; ASN-117 AND THR-146. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS JMML ASP-12; SER-12 AND ASP-13. RX PubMed=17332249; DOI=10.1182/blood-2006-09-046649; RA Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S., RA Iizuka S., Koike K., Yanai F., Kawasaki K., Yanagimachi M., Kikuchi A., RA Ohtsuka Y., Hidaka E., Yamauchi K., Tanaka M., Yanagisawa R., Nakazawa Y., RA Shiohara M., Manabe A., Kojima S., Koike K.; RT "Spontaneous improvement of hematologic abnormalities in patients having RT juvenile myelomonocytic leukemia with specific RAS mutations."; RL Blood 109:5477-5480(2007). RN [53] RP VARIANT NS3 GLU-5. RX PubMed=17468812; DOI=10.1007/s10038-007-0146-1; RA Bertola D.R., Pereira A.C., Brasil A.S., Albano L.M., Kim C.A., RA Krieger J.E.; RT "Further evidence of genetic heterogeneity in Costello syndrome: RT involvement of the KRAS gene."; RL J. Hum. Genet. 52:521-526(2007). RN [54] RP VARIANTS NS3 ILE-14; ARG-22; LEU-34; GLN-34; MET-36; VAL-153 AND ILE-156 RP (ISOFORM 2), VARIANT CFC2 GLU-22, AND VARIANTS ASN-5 AND LEU-156 (ISOFORM RP 2). RX PubMed=17056636; DOI=10.1136/jmg.2006.046300; RA Zenker M., Lehmann K., Schulz A.L., Barth H., Hansmann D., Koenig R., RA Korinthenberg R., Kreiss-Nachtsheim M., Meinecke P., Morlot S., Mundlos S., RA Quante A.S., Raskin S., Schnabel D., Wehner L.E., Kratz C.P., Horn D., RA Kutsche K.; RT "Expansion of the genotypic and phenotypic spectrum in patients with KRAS RT germline mutations."; RL J. Med. Genet. 44:131-135(2007). RN [55] RP VARIANTS NS3 ILE-58 AND SER-60. RX PubMed=19396835; DOI=10.1002/ajmg.a.32786; RA Kratz C.P., Zampino G., Kriek M., Kant S.G., Leoni C., Pantaleoni F., RA Oudesluys-Murphy A.M., Di Rocco C., Kloska S.P., Tartaglia M., Zenker M.; RT "Craniosynostosis in patients with Noonan syndrome caused by germline KRAS RT mutations."; RL Am. J. Med. Genet. A 149:1036-1040(2009). RN [56] RP CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND VAL-153 RP (ISOFORM 2), CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34 AND ARG-60, RP CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156 (ISOFORM 2), FUNCTION, AND RP CATALYTIC ACTIVITY. RX PubMed=20949621; DOI=10.1002/humu.21377; RA Gremer L., Merbitz-Zahradnik T., Dvorsky R., Cirstea I.C., Kratz C.P., RA Zenker M., Wittinghofer A., Ahmadian M.R.; RT "Germline KRAS mutations cause aberrant biochemical and physical properties RT leading to developmental disorders."; RL Hum. Mutat. 32:33-43(2011). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, CHARACTERIZATION OF RP VARIANT VAL-12, AND MUTAGENESIS OF GLN-61. RX PubMed=39809765; DOI=10.1038/s41467-025-55967-y; RA Bernal Astrain G., Strakhova R., Jo C.H., Teszner E., Killoran R.C., RA Smith M.J.; RT "The small GTPase MRAS is a broken switch."; RL Nat. Commun. 16:647-647(2025). RN [58] RP VARIANTS CFC2 HIS-71 AND GLU-147. RX PubMed=21797849; DOI=10.1111/j.1399-0004.2011.01754.x; RA Stark Z., Gillessen-Kaesbach G., Ryan M.M., Cirstea I.C., Gremer L., RA Ahmadian M.R., Savarirayan R., Zenker M.; RT "Two novel germline KRAS mutations: expanding the molecular and clinical RT phenotype."; RL Clin. Genet. 81:590-594(2012). RN [59] RP VARIANTS OES ASP-13 AND PHE-19, AND INVOLVEMENT IN OES. RX PubMed=25808193; DOI=10.1002/ajmg.a.37048; RA Peacock J.D., Dykema K.J., Toriello H.V., Mooney M.R., Scholten D.J. II, RA Winn M.E., Borgman A., Duesbery N.S., Hiemenga J.A., Liu C., Campbell S., RA Nickoloff B.P., Williams B.O., Steensma M.; RT "Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS RT alterations."; RL Am. J. Med. Genet. A 167:1429-1435(2015). RN [60] RP VARIANTS OES THR-146 AND VAL-146, AND INVOLVEMENT IN OES. RX PubMed=26970110; DOI=10.1111/cge.12775; RA Boppudi S., Boegershausen N., Hove H.B., Percin E.F., Aslan D., Dvorsky R., RA Kayhan G., Li Y., Cursiefen C., Tantcheva-Poor I., Toft P.B., Bartsch O., RA Lissewski C., Wieland I., Jakubiczka S., Wollnik B., Ahmadian M.R., RA Heindl L.M., Zenker M.; RT "Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal RT syndrome and encephalocraniocutaneous lipomatosis."; RL Clin. Genet. 90:334-342(2016). RN [61] RP VARIANT SFM ASP-12, VARIANTS OES THR-146 AND VAL-146, INVOLVEMENT IN SFM, RP AND INVOLVEMENT IN OES. RX PubMed=30891959; DOI=10.1002/mgg3.625; RA Chacon-Camacho O.F., Lopez-Moreno D., Morales-Sanchez M.A., Hofmann E., RA Pacheco-Quito M., Wieland I., Cortes-Gonzalez V., Villanueva-Mendoza C., RA Zenker M., Zenteno J.C.; RT "Expansion of the phenotypic spectrum and description of molecular findings RT in a cohort of patients with oculocutaneous mosaic RASopathies."; RL Mol. Genet. Genomic Med. 7:E625-E625(2019). RN [62] RP VARIANTS ALA-12; ASP-12; CYS-12; VAL-12; ASN-117 AND THR-146. RX PubMed=34820593; DOI=10.1200/po.21.00223; RA van 't Erve I., Wesdorp N.J., Medina J.E., Ferreira L., Leal A., RA Huiskens J., Bolhuis K., van Waesberghe J.T.M., Swijnenburg R.J., RA van den Broek D., Velculescu V.E., Kazemier G., Punt C.J.A., Meijer G.A., RA Fijneman R.J.A.; RT "KRAS A146 mutations are associated with distinct clinical behavior in RT patients with colorectal liver metastases."; RL JCO Precis. Oncol. 5:0-0(2021). CC -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase CC activity (PubMed:20949621, PubMed:39809765). Plays an important role in CC the regulation of cell proliferation (PubMed:22711838, CC PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation CC and ultimately degradation of GJA1 (By similarity). Plays a role in CC promoting oncogenic events by inducing transcriptional silencing of CC tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a CC ZNF304-dependent manner (PubMed:24623306). CC {ECO:0000250|UniProtKB:P08644, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, CC ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:39809765}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP (PubMed:22566140, PubMed:22431598, CC PubMed:39809765). Activated by a guanine nucleotide-exchange factor CC (GEF) and inactivated by a GTPase-activating protein (GAP) CC (PubMed:22711838). Interaction with SOS1 promotes exchange of bound GDP CC to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765). CC {ECO:0000269|PubMed:22431598, ECO:0000269|PubMed:22566140, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:39809765}. CC -!- SUBUNIT: Interacts with PHLPP (By similarity). Interacts (active GTP- CC bound form preferentially) with RGS14 (By similarity). Interacts (when CC farnesylated) with PDE6D; this promotes dissociation from the cell CC membrane (PubMed:23698361). Interacts with SOS1 (PubMed:22431598). CC Interacts (when farnesylated) with GPR31 (PubMed:28619714). Interacts CC with RAP1GDS1 (PubMed:20709748, PubMed:24415755). Interacts (active CC GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a CC tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they CC also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:35768504, CC PubMed:35830882, PubMed:35831509, PubMed:36175670). Interacts (GTP- CC bound form) with MAPKAP1/SIN1; inhibiting K-Ras/KRAS activity CC (PubMed:34380736, PubMed:35522713). {ECO:0000250|UniProtKB:P08644, CC ECO:0000269|PubMed:20709748, ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24415755, CC ECO:0000269|PubMed:28619714, ECO:0000269|PubMed:34380736, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:36175670}. CC -!- SUBUNIT: [Isoform 2B]: Interacts with GPR31; in a farnelysation- CC dependent manner. {ECO:0000269|PubMed:28619714}. CC -!- INTERACTION: CC P01116; Q96II5: ARAF; NbExp=3; IntAct=EBI-367415, EBI-9383168; CC P01116; Q99755: PIP5K1A; NbExp=9; IntAct=EBI-367415, EBI-726414; CC P01116; P04049: RAF1; NbExp=6; IntAct=EBI-367415, EBI-365996; CC P01116; P50749: RASSF2; NbExp=2; IntAct=EBI-367415, EBI-960081; CC P01116-2; P05067: APP; NbExp=3; IntAct=EBI-367427, EBI-77613; CC P01116-2; P49354: FNTA; NbExp=2; IntAct=EBI-367427, EBI-602336; CC P01116-2; O00270: GPR31; NbExp=4; IntAct=EBI-367427, EBI-34583813; CC P01116-2; P01116-2: KRAS; NbExp=6; IntAct=EBI-367427, EBI-367427; CC P01116-2; P04049: RAF1; NbExp=3; IntAct=EBI-367427, EBI-365996; CC P01116-2; Q04631: Fnta; Xeno; NbExp=3; IntAct=EBI-367427, EBI-602447; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:29239724}; Lipid-anchor CC {ECO:0000269|PubMed:29239724, ECO:0000305|PubMed:23698361}; Cytoplasmic CC side {ECO:0000305|PubMed:23698361}. Endomembrane system CC {ECO:0000269|PubMed:29239724}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:23698361}. CC -!- SUBCELLULAR LOCATION: [Isoform 2B]: Cell membrane CC {ECO:0000269|PubMed:28619714}; Lipid-anchor CC {ECO:0000305|PubMed:28619714}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Isoforms differ in the C-terminal region which is encoded by CC two alternative exons (IVA and IVB).; CC Name=2A; Synonyms=K-Ras4A {ECO:0000303|PubMed:29239724}; CC IsoId=P01116-1; Sequence=Displayed; CC Name=2B; Synonyms=K-Ras4B; CC IsoId=P01116-2, P01118-1; CC Sequence=VSP_011140, VSP_011141; CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000269|PubMed:22711838, CC ECO:0000269|Ref.17}. CC -!- PTM: Palmitoylated at Lys-182, Lys-184 and Lys-185 (PubMed:29239724). CC Palmitoylation on lysine residues is promoted by palmitoylation at Cys- CC 180 (PubMed:29239724). Lysine-depalmitoylation by SIRT2 promotes its CC localization to endomembranes in endocytic pathways (PubMed:29239724). CC {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000305|PubMed:30442762, ECO:0000305|PubMed:30442766}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL. {ECO:0000269|PubMed:19744486}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC {ECO:0000269|PubMed:8955068}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, CC ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835, CC ECO:0000269|PubMed:20949621}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:14534542, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma CC (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord CC derived from glial cells which vary from histologically benign forms to CC highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}. CC -!- DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of CC cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder CC characterized by a distinctive facial appearance, heart defects and CC intellectual disability. Heart defects include pulmonic stenosis, CC atrial septal defects and hypertrophic cardiomyopathy. Some affected CC individuals present with ectodermal abnormalities such as sparse, CC friable hair, hyperkeratotic skin lesions and a generalized ichthyosis- CC like condition. Typical facial features are similar to Noonan syndrome. CC They include high forehead with bitemporal constriction, hypoplastic CC supraorbital ridges, downslanting palpebral fissures, a depressed nasal CC bridge, and posteriorly angulated ears with prominent helices. CFC2 CC patients often do not have the skin abnormalities, such as ichthyosis, CC hyperkeratosis, and hemangioma observed in CFC1. CC {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:21797849}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=KRAS mutations are involved in cancer development. CC {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, CC ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:24623306, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, CC ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, CC ECO:0000269|PubMed:7773929}. CC -!- DISEASE: Oculoectodermal syndrome (OES) [MIM:600268]: A syndrome CC characterized by the association of epibulbar dermoids and aplasia CC cutis congenita. Affected individuals show multiple, asymmetric, CC atrophic, non-scarring and hairless regions that may be associated with CC hamartomas. Ectodermal changes include linear hyperpigmentation that CC may follow the lines of Blaschko and rarely epidermal nevus-like CC lesions. Epibulbar dermoids may be uni-or bilateral. Additional ocular CC anomalies such as skin tags of the upper eyelid, rarely optic nerve or CC retinal changes, and microphthalmia can be present. The phenotypic CC expression is highly variable, and various other abnormalities have CC occasionally been reported including growth failure, lymphedema, CC cardiovascular defects, as well as neurodevelopmental symptoms like CC developmental delay, epilepsy, learning difficulties, and behavioral CC abnormalities. Benign tumor-like lesions such as nonossifying fibromas CC of the long bones and giant cell granulomas of the jaws have repeatedly CC been observed and appear to be age-dependent, becoming a common CC manifestation in individuals aged 5 years or older. CC {ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:26970110, CC ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/91/KRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L00049; AAB59444.1; -; Genomic_DNA. DR EMBL; L00045; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00048; AAB59445.1; -; Genomic_DNA. DR EMBL; L00045; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; M54968; AAB41942.1; -; mRNA. DR EMBL; AF493917; AAM12631.1; -; mRNA. DR EMBL; BT007153; AAP35817.1; -; mRNA. DR EMBL; AK292510; BAF85199.1; -; mRNA. DR EMBL; CH471094; EAW96511.1; -; Genomic_DNA. DR EMBL; CH471094; EAW96512.1; -; Genomic_DNA. DR EMBL; EU332849; ABY87538.1; -; Genomic_DNA. DR EMBL; BC013572; AAH13572.1; -; mRNA. DR EMBL; K01519; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; K01520; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M25876; AAA35683.1; -; Genomic_DNA. DR EMBL; M34904; AAA36149.1; -; Genomic_DNA. DR EMBL; M30539; AAA36557.1; -; Genomic_DNA. DR EMBL; X01669; CAA25828.1; -; Genomic_DNA. DR EMBL; X02825; CAA26593.1; -; Genomic_DNA. DR EMBL; K03210; AAA36554.1; -; Genomic_DNA. DR EMBL; K03209; AAA36554.1; JOINED; Genomic_DNA. DR CCDS; CCDS8702.1; -. [P01116-2] DR CCDS; CCDS8703.1; -. [P01116-1] DR PIR; A93311; TVHUK. DR PIR; B93311; TVHU2K. DR RefSeq; NP_001356715.1; NM_001369786.1. [P01116-1] DR RefSeq; NP_001356716.1; NM_001369787.1. [P01116-2] DR RefSeq; NP_004976.2; NM_004985.4. [P01116-2] DR RefSeq; NP_203524.1; NM_033360.4. [P01116-1] DR PDB; 1D8D; X-ray; 2.00 A; P=178-188. DR PDB; 1D8E; X-ray; 3.00 A; P=178-188. DR PDB; 1KZO; X-ray; 2.20 A; C=169-173. DR PDB; 1KZP; X-ray; 2.10 A; C=169-173. DR PDB; 1N4P; X-ray; 2.65 A; M/N=185-189. DR PDB; 1N4Q; X-ray; 2.40 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4R; X-ray; 2.80 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4S; X-ray; 2.60 A; M/N/O/P/Q/R=185-189. DR PDB; 2MSC; NMR; -; B=1-186. DR PDB; 2MSD; NMR; -; B=1-186. DR PDB; 2MSE; NMR; -; B=1-186. DR PDB; 3GFT; X-ray; 2.27 A; A/B/C/D/E/F=1-164. DR PDB; 4DSN; X-ray; 2.03 A; A=2-164. DR PDB; 4DSO; X-ray; 1.85 A; A=2-164. DR PDB; 4EPR; X-ray; 2.00 A; A=1-164. DR PDB; 4EPT; X-ray; 2.00 A; A=1-164. DR PDB; 4EPV; X-ray; 1.35 A; A=1-164. DR PDB; 4EPW; X-ray; 1.70 A; A=1-164. DR PDB; 4EPX; X-ray; 1.76 A; A=1-164. DR PDB; 4EPY; X-ray; 1.80 A; A=1-164. DR PDB; 4L8G; X-ray; 1.52 A; A=1-169. DR PDB; 4LDJ; X-ray; 1.15 A; A=1-164. DR PDB; 4LPK; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LRW; X-ray; 2.15 A; A/B=1-169. DR PDB; 4LUC; X-ray; 1.29 A; A/B=1-169. DR PDB; 4LV6; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LYF; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4LYH; X-ray; 1.37 A; A/B/C=1-169. DR PDB; 4LYJ; X-ray; 1.93 A; A=1-169. DR PDB; 4M1O; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4M1S; X-ray; 1.55 A; A/B/C=1-169. DR PDB; 4M1T; X-ray; 1.70 A; A/B/C=1-169. DR PDB; 4M1W; X-ray; 1.58 A; A/B/C=1-169. DR PDB; 4M1Y; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 4M21; X-ray; 1.94 A; A/B/C=1-169. DR PDB; 4M22; X-ray; 2.09 A; A/B/C=1-169. DR PDB; 4NMM; X-ray; 1.89 A; A=1-164. DR PDB; 4OBE; X-ray; 1.24 A; A/B=1-164. DR PDB; 4PZY; X-ray; 1.88 A; A/B=1-164. DR PDB; 4PZZ; X-ray; 1.40 A; A=1-164. DR PDB; 4Q01; X-ray; 1.29 A; A/B=1-164. DR PDB; 4Q02; X-ray; 1.70 A; A=1-164. DR PDB; 4Q03; X-ray; 1.20 A; A=1-164. DR PDB; 4QL3; X-ray; 1.04 A; A=1-11, A=13-164. DR PDB; 4TQ9; X-ray; 1.49 A; A/B=1-164. DR PDB; 4TQA; X-ray; 1.13 A; A/B=1-164. DR PDB; 4WA7; X-ray; 1.99 A; A=1-164. DR PDB; 5F2E; X-ray; 1.40 A; A=1-169. DR PDB; 5KYK; X-ray; 2.70 A; A/B/C=1-167. DR PDB; 5MLA; X-ray; 2.19 A; A=1-166. DR PDB; 5MLB; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2S; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2T; X-ray; 2.19 A; A=1-166. DR PDB; 5OCG; X-ray; 1.48 A; A=2-189. DR PDB; 5OCO; X-ray; 1.66 A; A/B/C/D/E/F=1-169. DR PDB; 5OCT; X-ray; 2.07 A; A/B/C/D/E/F=1-169. DR PDB; 5TAR; X-ray; 1.90 A; A=2-164. DR PDB; 5TB5; X-ray; 2.00 A; A/C=2-164. DR PDB; 5UFE; X-ray; 2.30 A; A=1-166. DR PDB; 5UFQ; X-ray; 2.20 A; A/B=1-166. DR PDB; 5UK9; X-ray; 1.89 A; A/B=1-166. DR PDB; 5UQW; X-ray; 1.50 A; A/B=1-164. DR PDB; 5US4; X-ray; 1.83 A; A/B=1-164. DR PDB; 5USJ; X-ray; 1.94 A; A/B/C/D/E/F=1-164. DR PDB; 5V6S; X-ray; 1.70 A; A=1-169. DR PDB; 5V6V; X-ray; 1.72 A; A/B=1-169. DR PDB; 5V71; X-ray; 2.23 A; A/B/C/D/E/F=1-167. DR PDB; 5V9L; X-ray; 1.98 A; A/B/C=1-167. DR PDB; 5V9O; X-ray; 1.56 A; A=1-167. DR PDB; 5V9U; X-ray; 1.38 A; A/B=1-169. DR PDB; 5VBM; X-ray; 1.49 A; A=1-169. DR PDB; 5VP7; X-ray; 1.70 A; A/F=1-169. DR PDB; 5VPI; X-ray; 1.62 A; A/B=1-169. DR PDB; 5VPY; X-ray; 2.00 A; A/B=1-169. DR PDB; 5VPZ; X-ray; 1.85 A; A/B=1-169. DR PDB; 5VQ0; X-ray; 2.30 A; A/B=1-169. DR PDB; 5VQ1; X-ray; 1.78 A; A/B=1-169. DR PDB; 5VQ2; X-ray; 1.96 A; A/B=1-169. DR PDB; 5VQ6; X-ray; 1.99 A; A/B=1-169. DR PDB; 5VQ8; X-ray; 2.30 A; A/B=1-169. DR PDB; 5W22; X-ray; 1.76 A; A/B=1-169. DR PDB; 5WHA; X-ray; 2.04 A; A/D/G/J=1-166. DR PDB; 5WHB; X-ray; 2.18 A; A/D/G/J=1-166. DR PDB; 5WHD; X-ray; 1.64 A; A/B/C/D=1-166. DR PDB; 5WHE; X-ray; 1.91 A; A/D/G/J=1-166. DR PDB; 5WLB; X-ray; 1.72 A; A/D=1-166. DR PDB; 5WPM; X-ray; 1.72 A; A=1-166. DR PDB; 5XCO; X-ray; 1.25 A; A=1-169. DR PDB; 5YXZ; X-ray; 1.70 A; A=1-169. DR PDB; 5YY1; X-ray; 1.69 A; A=1-169. DR PDB; 6ARK; X-ray; 1.75 A; A=1-169. DR PDB; 6ASA; X-ray; 2.54 A; A=1-167. DR PDB; 6ASE; X-ray; 1.55 A; A=1-169. DR PDB; 6B0V; X-ray; 1.29 A; A/B=1-169. DR PDB; 6B0Y; X-ray; 1.43 A; A/B=1-169. DR PDB; 6BOF; X-ray; 1.40 A; A/B=2-169. DR PDB; 6BP1; X-ray; 2.00 A; A=1-169. DR PDB; 6CC9; NMR; -; B=1-186. DR PDB; 6CCH; NMR; -; B=1-186. DR PDB; 6CCX; NMR; -; B=1-186. DR PDB; 6CU6; X-ray; 1.50 A; A/B/C=1-169. DR PDB; 6E6F; X-ray; 3.40 A; A/B=1-166. DR PDB; 6E6G; X-ray; 1.93 A; A=1-166. DR PDB; 6EPL; X-ray; 2.55 A; R=1-169. DR PDB; 6EPM; X-ray; 2.50 A; R=1-169. DR PDB; 6EPN; X-ray; 2.50 A; R=1-169. DR PDB; 6EPO; X-ray; 2.40 A; R=1-169. DR PDB; 6EPP; X-ray; 2.40 A; R=1-169. DR PDB; 6F76; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6FA1; X-ray; 1.97 A; A/C/D/F=1-167, B/E=1-169. DR PDB; 6FA2; X-ray; 2.60 A; A/B/C/D/E/F=1-167. DR PDB; 6FA3; X-ray; 1.82 A; A/B/C/D/E/F=1-167. DR PDB; 6FA4; X-ray; 2.02 A; A/B/C/D/E/F=1-169. DR PDB; 6GJ5; X-ray; 1.50 A; A/B=1-169. DR PDB; 6GJ6; X-ray; 1.76 A; A=1-169. DR PDB; 6GJ7; X-ray; 1.67 A; A=1-169. DR PDB; 6GJ8; X-ray; 1.65 A; A=1-167. DR PDB; 6GOD; X-ray; 1.71 A; A=2-173. DR PDB; 6GOE; X-ray; 1.60 A; A=2-169. DR PDB; 6GOF; X-ray; 1.98 A; A=2-173. DR PDB; 6GOG; X-ray; 2.05 A; A/B/C/D/E/F=1-169. DR PDB; 6GOM; X-ray; 1.63 A; A/B/C/D/E/F=1-167. DR PDB; 6GQT; X-ray; 1.69 A; A/B/C/D/E/F=1-167. DR PDB; 6GQW; X-ray; 2.80 A; A/B/C/D/E/F=1-167. DR PDB; 6GQX; X-ray; 2.20 A; A/B/C/D/E/F=1-167. DR PDB; 6GQY; X-ray; 2.75 A; A/B/C/D/E/F=1-167. DR PDB; 6H46; X-ray; 2.22 A; A=1-166. DR PDB; 6H47; X-ray; 1.70 A; A=1-166. DR PDB; 6JTN; X-ray; 1.90 A; C=10-19. DR PDB; 6JTO; X-ray; 1.70 A; C=10-19. DR PDB; 6JTP; X-ray; 1.90 A; C=10-18. DR PDB; 6M9W; X-ray; 1.50 A; A=2-169. DR PDB; 6MBQ; X-ray; 1.35 A; A=2-166. DR PDB; 6MBT; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MBU; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MNX; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6MQG; X-ray; 1.50 A; A=3-169. DR PDB; 6MQN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6MS9; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 6MTA; X-ray; 2.15 A; A/B/C=1-169. DR PDB; 6N2J; X-ray; 1.80 A; A=1-169. DR PDB; 6N2K; X-ray; 1.72 A; A=1-169. DR PDB; 6O36; X-ray; 2.00 A; A/B/C=1-167. DR PDB; 6O46; X-ray; 1.90 A; A/B/C=1-167. DR PDB; 6O4Y; X-ray; 1.58 A; C=7-14. DR PDB; 6O4Z; X-ray; 1.50 A; C=5-12. DR PDB; 6O51; X-ray; 1.55 A; C=6-14. DR PDB; 6O53; X-ray; 1.40 A; C=5-14. DR PDB; 6OB2; X-ray; 2.85 A; A/C=1-169. DR PDB; 6OB3; X-ray; 2.10 A; A/C=1-169. DR PDB; 6OIM; X-ray; 1.65 A; A=1-169. DR PDB; 6P0Z; X-ray; 1.01 A; A/B=2-169. DR PDB; 6P8W; X-ray; 2.10 A; A/B=1-169. DR PDB; 6P8X; X-ray; 2.11 A; A/B/C/D=1-169. DR PDB; 6P8Y; X-ray; 2.31 A; A/B=1-169. DR PDB; 6P8Z; X-ray; 1.65 A; A/B=1-169. DR PDB; 6PGO; X-ray; 1.60 A; A/B=1-169. DR PDB; 6PGP; X-ray; 1.50 A; A/B=1-169. DR PDB; 6PQ3; X-ray; 1.75 A; A=1-169. DR PDB; 6PTS; NMR; -; B=1-186. DR PDB; 6PTW; NMR; -; B=1-186. DR PDB; 6QUU; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUV; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUW; X-ray; 1.24 A; A/B=1-169. DR PDB; 6QUX; X-ray; 1.62 A; A/B=1-169. DR PDB; 6T5B; X-ray; 1.37 A; A=1-169. DR PDB; 6T5U; X-ray; 1.72 A; B=1-166. DR PDB; 6T5V; X-ray; 1.31 A; A=1-169. DR PDB; 6TAM; X-ray; 1.64 A; A=1-169. DR PDB; 6TAN; X-ray; 1.16 A; A=1-169. DR PDB; 6USX; X-ray; 2.27 A; A/B=1-169. DR PDB; 6USZ; X-ray; 2.03 A; A=1-169. DR PDB; 6UT0; X-ray; 1.94 A; A/B/C/D=1-169. DR PDB; 6V5L; NMR; -; A=1-169. DR PDB; 6V65; X-ray; 2.76 A; C=1-169. DR PDB; 6V6F; X-ray; 2.54 A; C=1-169. DR PDB; 6VC8; X-ray; 2.50 A; A/B/C=1-169. DR PDB; 6VJJ; X-ray; 1.40 A; A=1-169. DR PDB; 6W4E; NMR; -; B/C=2-186. DR PDB; 6W4F; NMR; -; B/C=2-186. DR PDB; 6WGN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6WS2; X-ray; 1.59 A; A/B/C/D=1-169. DR PDB; 6WS4; X-ray; 1.84 A; A/B/C/D=1-169. DR PDB; 6XGU; X-ray; 2.70 A; A=1-169. DR PDB; 6XGV; X-ray; 2.11 A; A=1-169. DR PDB; 6XHA; X-ray; 2.87 A; A=1-169. DR PDB; 6XHB; X-ray; 2.50 A; A=1-169. DR PDB; 6YR8; X-ray; 1.90 A; A=1-166. DR PDB; 6YXW; X-ray; 2.06 A; A/C=1-167. DR PDB; 6ZL5; X-ray; 1.65 A; A=1-169. DR PDB; 6ZLI; X-ray; 1.73 A; A/B=1-169. DR PDB; 7A1W; X-ray; 1.76 A; A=1-169. DR PDB; 7A1X; X-ray; 1.32 A; A=1-164. DR PDB; 7A1Y; X-ray; 2.00 A; A=1-164. DR PDB; 7A47; X-ray; 2.16 A; A/C/E=1-169. DR PDB; 7ACA; X-ray; 1.57 A; A/B/C/D=1-169. DR PDB; 7ACF; X-ray; 1.91 A; A/B/C/D=1-169. DR PDB; 7ACH; X-ray; 1.90 A; A/B=1-169. DR PDB; 7ACQ; X-ray; 1.86 A; A/B/C=1-169. DR PDB; 7C40; X-ray; 2.52 A; A=1-167. DR PDB; 7C41; X-ray; 2.28 A; A/G/J/M=1-167. DR PDB; 7EW9; X-ray; 2.13 A; A/B/C=1-169. DR PDB; 7EWA; X-ray; 2.25 A; A/B/C=1-169. DR PDB; 7EWB; X-ray; 1.99 A; A/B/C=1-169. DR PDB; 7EYX; X-ray; 1.82 A; A=2-169. DR PDB; 7F0W; X-ray; 1.39 A; A=2-169. DR PDB; 7KFZ; EM; 3.47 A; A/C=1-169. DR PDB; 7KMR; X-ray; 1.51 A; A=1-186. DR PDB; 7KYZ; NMR; -; A=1-189. DR PDB; 7LC1; X-ray; 2.35 A; A/C=1-169. DR PDB; 7LC2; X-ray; 2.70 A; A/B=1-169. DR PDB; 7LGI; NMR; -; A=1-169. DR PDB; 7LZ5; X-ray; 1.50 A; A=1-164. DR PDB; 7MDP; X-ray; 1.96 A; A=1-169. DR PDB; 7MQU; NMR; -; A=1-169. DR PDB; 7NY8; X-ray; 1.80 A; A/B=1-167. DR PDB; 7O70; X-ray; 1.18 A; A/D=1-169. DR PDB; 7OK3; X-ray; 1.60 A; A=1-169. DR PDB; 7OK4; X-ray; 1.70 A; A=1-169. DR PDB; 7OO7; X-ray; 1.48 A; A/D=1-164. DR PDB; 7Q9U; X-ray; 2.24 A; AAA/BBB=1-176. DR PDB; 7R0M; X-ray; 1.61 A; A/B=1-169. DR PDB; 7R0N; X-ray; 1.20 A; A=1-169. DR PDB; 7R0Q; X-ray; 1.95 A; A/B=1-169. DR PDB; 7ROV; X-ray; 1.32 A; A/B=1-189. DR PDB; 7RP2; X-ray; 2.20 A; A=1-169. DR PDB; 7RP3; X-ray; 2.00 A; A=2-169. DR PDB; 7RP4; X-ray; 2.15 A; A/B=2-169. DR PDB; 7RPZ; X-ray; 1.30 A; A=1-169. DR PDB; 7RSC; NMR; -; A/B=2-186. DR PDB; 7RSE; NMR; -; A/B=2-186. DR PDB; 7RT1; X-ray; 1.27 A; A=1-169. DR PDB; 7RT2; X-ray; 1.59 A; A=1-169. DR PDB; 7RT3; X-ray; 1.56 A; A=1-169. DR PDB; 7RT4; X-ray; 2.10 A; A=1-169. DR PDB; 7RT5; X-ray; 1.29 A; A=1-169. DR PDB; 7SCW; X-ray; 1.98 A; A=1-189. DR PDB; 7SCX; X-ray; 1.96 A; A=1-189. DR PDB; 7STF; EM; 3.14 A; C=7-16. DR PDB; 7T1F; X-ray; 2.20 A; A/B/C=1-169. DR PDB; 7T47; X-ray; 1.27 A; A=1-164. DR PDB; 7TLE; X-ray; 1.99 A; A=1-164. DR PDB; 7TLG; X-ray; 1.80 A; A/B=1-164. DR PDB; 7TLK; X-ray; 1.71 A; A/B=1-164. DR PDB; 7U8H; X-ray; 1.70 A; A/B/C/D=1-169. DR PDB; 7VVB; X-ray; 1.70 A; A=1-189. DR PDB; 7W5R; X-ray; 3.87 A; A/E/I/M/Q/U=1-167. DR PDB; 7YCC; X-ray; 1.79 A; A/B/C=1-169. DR PDB; 7YCE; X-ray; 1.80 A; A=1-169. DR PDB; 7YUZ; X-ray; 1.88 A; A=2-174. DR PDB; 7YV1; X-ray; 1.45 A; A=2-174. DR PDB; 8AFB; X-ray; 1.12 A; A=1-164. DR PDB; 8AFC; X-ray; 2.41 A; A/B=1-164. DR PDB; 8AFD; X-ray; 1.63 A; A/B/C/D=1-164. DR PDB; 8AQ5; X-ray; 1.80 A; A=1-169. DR PDB; 8AQ7; X-ray; 1.65 A; A/B=1-169. DR PDB; 8AZR; X-ray; 1.60 A; A=1-164. DR PDB; 8AZV; X-ray; 1.05 A; A=1-164. DR PDB; 8AZX; X-ray; 1.04 A; A=1-164. DR PDB; 8AZY; X-ray; 1.09 A; A=1-169. DR PDB; 8AZZ; X-ray; 1.02 A; A=1-164. DR PDB; 8B00; X-ray; 1.04 A; A=1-164. DR PDB; 8B69; X-ray; 3.07 A; B/D=1-169. DR PDB; 8B6I; X-ray; 1.70 A; A/B=1-169. DR PDB; 8B78; X-ray; 1.11 A; A=1-164. DR PDB; 8BE3; X-ray; 1.85 A; A/R=1-169. DR PDB; 8BE4; X-ray; 1.90 A; R=1-169. DR PDB; 8BE5; X-ray; 3.13 A; R=1-169. DR PDB; 8BLR; X-ray; 1.40 A; A=2-169. DR PDB; 8CPR; X-ray; 2.00 A; A=2-169. DR PDB; 8CX5; X-ray; 1.72 A; A/B=1-169. DR PDB; 8DGS; EM; 4.30 A; E=1-169. DR PDB; 8DGT; EM; 3.90 A; F=1-169. DR PDB; 8DNI; X-ray; 1.50 A; A=1-169. DR PDB; 8DNJ; X-ray; 1.81 A; A/B/C=1-169. DR PDB; 8DNK; X-ray; 2.23 A; A=1-169. DR PDB; 8DVG; X-ray; 2.59 A; C=7-16. DR PDB; 8EBZ; X-ray; 1.20 A; A=1-169. DR PDB; 8ECR; X-ray; 1.42 A; A/B=1-186. DR PDB; 8EDY; X-ray; 1.18 A; A=1-186. DR PDB; 8EER; X-ray; 1.18 A; A=1-186. DR PDB; 8EIE; X-ray; 1.41 A; A=1-186. DR PDB; 8EPW; X-ray; 2.00 A; A=1-169. DR PDB; 8EZG; X-ray; 2.52 A; A=1-167. DR PDB; 8F0M; X-ray; 2.44 A; A/C=1-169. DR PDB; 8FMI; X-ray; 1.12 A; A=1-169. DR PDB; 8FMJ; X-ray; 1.33 A; A=1-169. DR PDB; 8FMK; X-ray; 1.48 A; A=1-169. DR PDB; 8G42; EM; 3.02 A; B=1-169. DR PDB; 8G47; EM; 3.19 A; B=1-169. DR PDB; 8G4F; EM; 2.91 A; B=1-166. DR PDB; 8G4H; EM; 2.87 A; B=1-169. DR PDB; 8G9P; X-ray; 1.50 A; A/B=1-169. DR PDB; 8G9Q; X-ray; 1.40 A; A=1-169. DR PDB; 8I5C; X-ray; 3.34 A; C/H/M/R/W/b/g/l/q/v=8-16. DR PDB; 8I5D; X-ray; 3.30 A; P=8-16. DR PDB; 8I5E; X-ray; 2.20 A; P=8-16. DR PDB; 8JGD; X-ray; 1.60 A; A=1-169. DR PDB; 8JHL; X-ray; 2.10 A; A=1-169. DR PDB; 8JJS; X-ray; 1.53 A; A=2-174. DR PDB; 8K4T; X-ray; 2.30 A; C/F=7-16. DR PDB; 8K4V; X-ray; 3.10 A; C/F/I/L=7-16. DR PDB; 8K50; X-ray; 2.80 A; C/F/I/L=7-16. DR PDB; 8ONV; X-ray; 1.01 A; A=1-164. DR PDB; 8PI0; NMR; -; A=1-167. DR PDB; 8PIY; NMR; -; A=1-169. DR PDB; 8QU8; EM; 3.50 A; F=1-164. DR PDB; 8QUG; X-ray; 1.56 A; A=1-164. DR PDB; 8QVU; X-ray; 2.24 A; A/E=1-189. DR PDB; 8QW6; X-ray; 2.20 A; A/E=1-169. DR PDB; 8QW7; X-ray; 2.36 A; A/E=1-169. DR PDB; 8R7W; X-ray; 1.16 A; A/B=1-169. DR PDB; 8R7X; X-ray; 1.31 A; A/B=1-169. DR PDB; 8RNI; X-ray; 2.49 A; C=7-16. DR PDB; 8RRO; X-ray; 3.50 A; E/J/O/T/Y/d/i/n=7-16. DR PDB; 8S8C; X-ray; 1.90 A; A=1-169. DR PDB; 8STM; X-ray; 2.00 A; A/B/C/D=1-169. DR PDB; 8STN; X-ray; 2.03 A; A/B=1-169. DR PDB; 8T4V; X-ray; 1.47 A; A/B=1-169. DR PDB; 8T71; X-ray; 1.80 A; A/B=1-177. DR PDB; 8T72; X-ray; 1.60 A; A/B/C=1-177. DR PDB; 8T73; X-ray; 1.50 A; A/B=1-169. DR PDB; 8T74; X-ray; 1.65 A; A=1-177. DR PDB; 8T75; X-ray; 2.65 A; A/C/E/G=1-177. DR PDB; 8TBF; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBH; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBJ; X-ray; 1.45 A; A/B=1-169. DR PDB; 8TBK; X-ray; 1.26 A; A/B=1-169. DR PDB; 8TBL; X-ray; 1.88 A; A/B=1-169. DR PDB; 8TBM; X-ray; 1.57 A; A/B=1-169. DR PDB; 8TBN; X-ray; 1.46 A; A/B=1-169. DR PDB; 8TVK; X-ray; 1.04 A; A=1-169. DR PDB; 8TXE; X-ray; 1.35 A; A/B=1-169. DR PDB; 8TXG; X-ray; 1.50 A; A=1-169. DR PDB; 8TXH; X-ray; 1.20 A; A/B=1-169. DR PDB; 8TXJ; X-ray; 1.40 A; A=1-169. DR PDB; 8TXK; X-ray; 1.38 A; A=1-169. DR PDB; 8TY2; X-ray; 1.41 A; A=1-169. DR PDB; 8TY8; X-ray; 1.40 A; A=1-169. DR PDB; 8TY9; X-ray; 1.43 A; A=1-169. DR PDB; 8UDR; EM; 3.10 A; C=7-16. DR PDB; 8UN3; X-ray; 2.07 A; A/B/C/D=2-167. DR PDB; 8UN4; X-ray; 1.57 A; A=2-169. DR PDB; 8UN5; X-ray; 1.31 A; A/B=2-167. DR PDB; 8V39; X-ray; 2.10 A; A/B/C=1-169. DR PDB; 8V3A; X-ray; 1.67 A; A/B=1-169. DR PDB; 8VGQ; EM; 2.80 A; A=1-169. DR PDB; 8VJZ; X-ray; 1.90 A; C=7-16. DR PDB; 8VR9; EM; 3.06 A; C=8-16. DR PDB; 8VRA; EM; 3.12 A; C=7-16. DR PDB; 8VRB; EM; 3.25 A; C=7-16. DR PDB; 8WTE; X-ray; 2.17 A; G/J=8-16. DR PDB; 8WUL; X-ray; 2.36 A; K/N/Q/T=8-16. DR PDB; 8X6R; X-ray; 1.85 A; A/B/C/D/E/F=1-169. DR PDB; 8YIV; X-ray; 2.10 A; C=55-64. DR PDB; 8YJ2; X-ray; 2.26 A; C=55-64. DR PDB; 9AX6; X-ray; 1.65 A; A/B=1-169. DR PDB; 9BAI; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAJ; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAK; X-ray; 1.67 A; A/B/C/D=1-169. DR PDB; 9BFV; X-ray; 1.20 A; A/B=1-169. DR PDB; 9BFW; X-ray; 1.20 A; A=1-169. DR PDB; 9BFX; X-ray; 1.40 A; A/B=1-169. DR PDB; 9BFY; X-ray; 1.26 A; A/B=1-169. DR PDB; 9BFZ; X-ray; 1.80 A; A/B=1-169. DR PDB; 9BG1; X-ray; 1.51 A; A/B=1-169. DR PDB; 9BG2; X-ray; 1.64 A; A/B=1-169. DR PDB; 9BG4; X-ray; 1.14 A; A/B=1-169. DR PDB; 9BG5; X-ray; 1.67 A; A/B=1-164. DR PDB; 9BG6; X-ray; 1.66 A; A/B=1-169. DR PDB; 9BG7; X-ray; 1.60 A; A/B=1-169. DR PDB; 9BG9; X-ray; 1.58 A; A/B=1-164. DR PDB; 9BGA; X-ray; 1.41 A; A/B=1-169. DR PDB; 9BGB; X-ray; 1.68 A; A/B=1-164. DR PDB; 9BGC; X-ray; 1.87 A; A/B=1-169. DR PDB; 9BHO; X-ray; 1.89 A; A/C=1-169. DR PDB; 9BHP; X-ray; 2.10 A; A/C=1-169. DR PDB; 9BHQ; X-ray; 1.90 A; A/C=1-169. DR PDB; 9BI1; X-ray; 1.65 A; A/C=1-169. DR PDB; 9BI2; X-ray; 2.15 A; A/C=1-169. DR PDB; 9BL0; X-ray; 1.66 A; A/B=1-169. DR PDB; 9C15; X-ray; 2.81 A; B=1-169. DR PDB; 9DMM; X-ray; 1.90 A; A=1-169. DR PDB; 9E5D; X-ray; 1.36 A; A=1-169. DR PDB; 9E5F; X-ray; 1.35 A; A=1-169. DR PDB; 9E9H; X-ray; 1.65 A; A=1-169. DR PDB; 9E9I; X-ray; 1.18 A; A=1-169. DR PDB; 9G0Y; X-ray; 1.31 A; A=1-169. DR PDB; 9G4B; X-ray; 1.14 A; A=1-169. DR PDB; 9GBJ; X-ray; 1.71 A; A=1-169. DR PDB; 9GGT; X-ray; 1.71 A; A=1-169. DR PDB; 9GGU; X-ray; 1.60 A; A=1-169. DR PDB; 9GGV; X-ray; 1.19 A; A=1-169. DR PDB; 9GGW; X-ray; 1.82 A; A/B=1-169. DR PDB; 9GGX; X-ray; 1.30 A; A=1-169. DR PDB; 9GGY; X-ray; 1.27 A; A=1-169. DR PDB; 9GGZ; X-ray; 1.37 A; A=1-169. DR PDB; 9GH0; X-ray; 1.57 A; A=1-169. DR PDB; 9GH1; X-ray; 1.33 A; A=1-169. DR PDB; 9GH2; X-ray; 1.35 A; A=1-169. DR PDB; 9KPM; X-ray; 1.41 A; A=1-169. DR PDB; 9KPN; X-ray; 1.29 A; A/B=1-169. DR PDBsum; 1D8D; -. DR PDBsum; 1D8E; -. DR PDBsum; 1KZO; -. DR PDBsum; 1KZP; -. DR PDBsum; 1N4P; -. DR PDBsum; 1N4Q; -. DR PDBsum; 1N4R; -. DR PDBsum; 1N4S; -. DR PDBsum; 2MSC; -. DR PDBsum; 2MSD; -. DR PDBsum; 2MSE; -. DR PDBsum; 3GFT; -. DR PDBsum; 4DSN; -. DR PDBsum; 4DSO; -. DR PDBsum; 4EPR; -. DR PDBsum; 4EPT; -. DR PDBsum; 4EPV; -. DR PDBsum; 4EPW; -. DR PDBsum; 4EPX; -. DR PDBsum; 4EPY; -. DR PDBsum; 4L8G; -. DR PDBsum; 4LDJ; -. DR PDBsum; 4LPK; -. DR PDBsum; 4LRW; -. DR PDBsum; 4LUC; -. DR PDBsum; 4LV6; -. DR PDBsum; 4LYF; -. DR PDBsum; 4LYH; -. DR PDBsum; 4LYJ; -. DR PDBsum; 4M1O; -. DR PDBsum; 4M1S; -. DR PDBsum; 4M1T; -. DR PDBsum; 4M1W; -. DR PDBsum; 4M1Y; -. DR PDBsum; 4M21; -. DR PDBsum; 4M22; -. DR PDBsum; 4NMM; -. DR PDBsum; 4OBE; -. DR PDBsum; 4PZY; -. DR PDBsum; 4PZZ; -. DR PDBsum; 4Q01; -. DR PDBsum; 4Q02; -. DR PDBsum; 4Q03; -. DR PDBsum; 4QL3; -. DR PDBsum; 4TQ9; -. DR PDBsum; 4TQA; -. DR PDBsum; 4WA7; -. DR PDBsum; 5F2E; -. DR PDBsum; 5KYK; -. DR PDBsum; 5MLA; -. DR PDBsum; 5MLB; -. DR PDBsum; 5O2S; -. DR PDBsum; 5O2T; -. DR PDBsum; 5OCG; -. DR PDBsum; 5OCO; -. DR PDBsum; 5OCT; -. DR PDBsum; 5TAR; -. DR PDBsum; 5TB5; -. DR PDBsum; 5UFE; -. DR PDBsum; 5UFQ; -. DR PDBsum; 5UK9; -. DR PDBsum; 5UQW; -. DR PDBsum; 5US4; -. DR PDBsum; 5USJ; -. DR PDBsum; 5V6S; -. DR PDBsum; 5V6V; -. DR PDBsum; 5V71; -. DR PDBsum; 5V9L; -. DR PDBsum; 5V9O; -. DR PDBsum; 5V9U; -. DR PDBsum; 5VBM; -. DR PDBsum; 5VP7; -. DR PDBsum; 5VPI; -. DR PDBsum; 5VPY; -. DR PDBsum; 5VPZ; -. DR PDBsum; 5VQ0; -. DR PDBsum; 5VQ1; -. DR PDBsum; 5VQ2; -. DR PDBsum; 5VQ6; -. DR PDBsum; 5VQ8; -. DR PDBsum; 5W22; -. DR PDBsum; 5WHA; -. DR PDBsum; 5WHB; -. DR PDBsum; 5WHD; -. DR PDBsum; 5WHE; -. DR PDBsum; 5WLB; -. DR PDBsum; 5WPM; -. DR PDBsum; 5XCO; -. DR PDBsum; 5YXZ; -. DR PDBsum; 5YY1; -. DR PDBsum; 6ARK; -. DR PDBsum; 6ASA; -. DR PDBsum; 6ASE; -. DR PDBsum; 6B0V; -. DR PDBsum; 6B0Y; -. DR PDBsum; 6BOF; -. DR PDBsum; 6BP1; -. DR PDBsum; 6CC9; -. DR PDBsum; 6CCH; -. DR PDBsum; 6CCX; -. DR PDBsum; 6CU6; -. DR PDBsum; 6E6F; -. DR PDBsum; 6E6G; -. DR PDBsum; 6EPL; -. DR PDBsum; 6EPM; -. DR PDBsum; 6EPN; -. DR PDBsum; 6EPO; -. DR PDBsum; 6EPP; -. DR PDBsum; 6F76; -. DR PDBsum; 6FA1; -. DR PDBsum; 6FA2; -. DR PDBsum; 6FA3; -. DR PDBsum; 6FA4; -. DR PDBsum; 6GJ5; -. DR PDBsum; 6GJ6; -. DR PDBsum; 6GJ7; -. DR PDBsum; 6GJ8; -. DR PDBsum; 6GOD; -. DR PDBsum; 6GOE; -. DR PDBsum; 6GOF; -. DR PDBsum; 6GOG; -. DR PDBsum; 6GOM; -. DR PDBsum; 6GQT; -. DR PDBsum; 6GQW; -. DR PDBsum; 6GQX; -. DR PDBsum; 6GQY; -. DR PDBsum; 6H46; -. DR PDBsum; 6H47; -. DR PDBsum; 6JTN; -. DR PDBsum; 6JTO; -. DR PDBsum; 6JTP; -. DR PDBsum; 6M9W; -. DR PDBsum; 6MBQ; -. DR PDBsum; 6MBT; -. DR PDBsum; 6MBU; -. DR PDBsum; 6MNX; -. DR PDBsum; 6MQG; -. DR PDBsum; 6MQN; -. DR PDBsum; 6MS9; -. DR PDBsum; 6MTA; -. DR PDBsum; 6N2J; -. DR PDBsum; 6N2K; -. DR PDBsum; 6O36; -. DR PDBsum; 6O46; -. DR PDBsum; 6O4Y; -. DR PDBsum; 6O4Z; -. DR PDBsum; 6O51; -. DR PDBsum; 6O53; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6OIM; -. DR PDBsum; 6P0Z; -. DR PDBsum; 6P8W; -. DR PDBsum; 6P8X; -. DR PDBsum; 6P8Y; -. DR PDBsum; 6P8Z; -. DR PDBsum; 6PGO; -. DR PDBsum; 6PGP; -. DR PDBsum; 6PQ3; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6QUU; -. DR PDBsum; 6QUV; -. DR PDBsum; 6QUW; -. DR PDBsum; 6QUX; -. DR PDBsum; 6T5B; -. DR PDBsum; 6T5U; -. DR PDBsum; 6T5V; -. DR PDBsum; 6TAM; -. DR PDBsum; 6TAN; -. DR PDBsum; 6USX; -. DR PDBsum; 6USZ; -. DR PDBsum; 6UT0; -. DR PDBsum; 6V5L; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 6VC8; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6W4E; -. DR PDBsum; 6W4F; -. DR PDBsum; 6WGN; -. DR PDBsum; 6WS2; -. DR PDBsum; 6WS4; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6YR8; -. DR PDBsum; 6YXW; -. DR PDBsum; 6ZL5; -. DR PDBsum; 6ZLI; -. DR PDBsum; 7A1W; -. DR PDBsum; 7A1X; -. DR PDBsum; 7A1Y; -. DR PDBsum; 7A47; -. DR PDBsum; 7ACA; -. DR PDBsum; 7ACF; -. DR PDBsum; 7ACH; -. DR PDBsum; 7ACQ; -. DR PDBsum; 7C40; -. DR PDBsum; 7C41; -. DR PDBsum; 7EW9; -. DR PDBsum; 7EWA; -. DR PDBsum; 7EWB; -. DR PDBsum; 7EYX; -. DR PDBsum; 7F0W; -. DR PDBsum; 7KFZ; -. DR PDBsum; 7KMR; -. DR PDBsum; 7KYZ; -. DR PDBsum; 7LC1; -. DR PDBsum; 7LC2; -. DR PDBsum; 7LGI; -. DR PDBsum; 7LZ5; -. DR PDBsum; 7MDP; -. DR PDBsum; 7MQU; -. DR PDBsum; 7NY8; -. DR PDBsum; 7O70; -. DR PDBsum; 7OK3; -. DR PDBsum; 7OK4; -. DR PDBsum; 7OO7; -. DR PDBsum; 7Q9U; -. DR PDBsum; 7R0M; -. DR PDBsum; 7R0N; -. DR PDBsum; 7R0Q; -. DR PDBsum; 7ROV; -. DR PDBsum; 7RP2; -. DR PDBsum; 7RP3; -. DR PDBsum; 7RP4; -. DR PDBsum; 7RPZ; -. DR PDBsum; 7RSC; -. DR PDBsum; 7RSE; -. DR PDBsum; 7RT1; -. DR PDBsum; 7RT2; -. DR PDBsum; 7RT3; -. DR PDBsum; 7RT4; -. DR PDBsum; 7RT5; -. DR PDBsum; 7SCW; -. DR PDBsum; 7SCX; -. DR PDBsum; 7STF; -. DR PDBsum; 7T1F; -. DR PDBsum; 7T47; -. DR PDBsum; 7TLE; -. DR PDBsum; 7TLG; -. DR PDBsum; 7TLK; -. DR PDBsum; 7U8H; -. DR PDBsum; 7VVB; -. DR PDBsum; 7W5R; -. DR PDBsum; 7YCC; -. DR PDBsum; 7YCE; -. DR PDBsum; 7YUZ; -. DR PDBsum; 7YV1; -. DR PDBsum; 8AFB; -. DR PDBsum; 8AFC; -. DR PDBsum; 8AFD; -. DR PDBsum; 8AQ5; -. DR PDBsum; 8AQ7; -. DR PDBsum; 8AZR; -. DR PDBsum; 8AZV; -. DR PDBsum; 8AZX; -. DR PDBsum; 8AZY; -. DR PDBsum; 8AZZ; -. DR PDBsum; 8B00; -. DR PDBsum; 8B69; -. DR PDBsum; 8B6I; -. DR PDBsum; 8B78; -. DR PDBsum; 8BE3; -. DR PDBsum; 8BE4; -. DR PDBsum; 8BE5; -. DR PDBsum; 8BLR; -. DR PDBsum; 8CPR; -. DR PDBsum; 8CX5; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8DNI; -. DR PDBsum; 8DNJ; -. DR PDBsum; 8DNK; -. DR PDBsum; 8DVG; -. DR PDBsum; 8EBZ; -. DR PDBsum; 8ECR; -. DR PDBsum; 8EDY; -. DR PDBsum; 8EER; -. DR PDBsum; 8EIE; -. DR PDBsum; 8EPW; -. DR PDBsum; 8EZG; -. DR PDBsum; 8F0M; -. DR PDBsum; 8FMI; -. DR PDBsum; 8FMJ; -. DR PDBsum; 8FMK; -. DR PDBsum; 8G42; -. DR PDBsum; 8G47; -. DR PDBsum; 8G4F; -. DR PDBsum; 8G4H; -. DR PDBsum; 8G9P; -. DR PDBsum; 8G9Q; -. DR PDBsum; 8I5C; -. DR PDBsum; 8I5D; -. DR PDBsum; 8I5E; -. DR PDBsum; 8JGD; -. DR PDBsum; 8JHL; -. DR PDBsum; 8JJS; -. DR PDBsum; 8K4T; -. DR PDBsum; 8K4V; -. DR PDBsum; 8K50; -. DR PDBsum; 8ONV; -. DR PDBsum; 8PI0; -. DR PDBsum; 8PIY; -. DR PDBsum; 8QU8; -. DR PDBsum; 8QUG; -. DR PDBsum; 8QVU; -. DR PDBsum; 8QW6; -. DR PDBsum; 8QW7; -. DR PDBsum; 8R7W; -. DR PDBsum; 8R7X; -. DR PDBsum; 8RNI; -. DR PDBsum; 8RRO; -. DR PDBsum; 8S8C; -. DR PDBsum; 8STM; -. DR PDBsum; 8STN; -. DR PDBsum; 8T4V; -. DR PDBsum; 8T71; -. DR PDBsum; 8T72; -. DR PDBsum; 8T73; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8TBF; -. DR PDBsum; 8TBH; -. DR PDBsum; 8TBJ; -. DR PDBsum; 8TBK; -. DR PDBsum; 8TBL; -. DR PDBsum; 8TBM; -. DR PDBsum; 8TBN; -. DR PDBsum; 8TVK; -. DR PDBsum; 8TXE; -. DR PDBsum; 8TXG; -. DR PDBsum; 8TXH; -. DR PDBsum; 8TXJ; -. DR PDBsum; 8TXK; -. DR PDBsum; 8TY2; -. DR PDBsum; 8TY8; -. DR PDBsum; 8TY9; -. DR PDBsum; 8UDR; -. DR PDBsum; 8UN3; -. DR PDBsum; 8UN4; -. DR PDBsum; 8UN5; -. DR PDBsum; 8V39; -. DR PDBsum; 8V3A; -. DR PDBsum; 8VGQ; -. DR PDBsum; 8VJZ; -. DR PDBsum; 8VR9; -. DR PDBsum; 8VRA; -. DR PDBsum; 8VRB; -. DR PDBsum; 8WTE; -. DR PDBsum; 8WUL; -. DR PDBsum; 8X6R; -. DR PDBsum; 8YIV; -. DR PDBsum; 8YJ2; -. DR PDBsum; 9AX6; -. DR PDBsum; 9BAI; -. DR PDBsum; 9BAJ; -. DR PDBsum; 9BAK; -. DR PDBsum; 9BFV; -. DR PDBsum; 9BFW; -. DR PDBsum; 9BFX; -. DR PDBsum; 9BFY; -. DR PDBsum; 9BFZ; -. DR PDBsum; 9BG1; -. DR PDBsum; 9BG2; -. DR PDBsum; 9BG4; -. DR PDBsum; 9BG5; -. DR PDBsum; 9BG6; -. DR PDBsum; 9BG7; -. DR PDBsum; 9BG9; -. DR PDBsum; 9BGA; -. DR PDBsum; 9BGB; -. DR PDBsum; 9BGC; -. DR PDBsum; 9BHO; -. DR PDBsum; 9BHP; -. DR PDBsum; 9BHQ; -. DR PDBsum; 9BI1; -. DR PDBsum; 9BI2; -. DR PDBsum; 9BL0; -. DR PDBsum; 9C15; -. DR PDBsum; 9DMM; -. DR PDBsum; 9E5D; -. DR PDBsum; 9E5F; -. DR PDBsum; 9E9H; -. DR PDBsum; 9E9I; -. DR PDBsum; 9G0Y; -. DR PDBsum; 9G4B; -. DR PDBsum; 9GBJ; -. DR PDBsum; 9GGT; -. DR PDBsum; 9GGU; -. DR PDBsum; 9GGV; -. DR PDBsum; 9GGW; -. DR PDBsum; 9GGX; -. DR PDBsum; 9GGY; -. DR PDBsum; 9GGZ; -. DR PDBsum; 9GH0; -. DR PDBsum; 9GH1; -. DR PDBsum; 9GH2; -. DR PDBsum; 9KPM; -. DR PDBsum; 9KPN; -. DR AlphaFoldDB; P01116; -. DR BMRB; P01116; -. DR EMDB; EMD-18657; -. DR EMDB; EMD-22857; -. DR EMDB; EMD-29713; -. DR EMDB; EMD-29715; -. DR EMDB; EMD-29719; -. DR EMDB; EMD-29720; -. DR EMDB; EMD-42151; -. DR EMDB; EMD-43221; -. DR EMDB; EMD-43478; -. DR EMDB; EMD-43479; -. DR EMDB; EMD-43480; -. DR EMDB; EMD-70124; -. DR SASBDB; P01116; -. DR SMR; P01116; -. DR BioGRID; 110043; 3005. DR ComplexPortal; CPX-26355; SHOC2-KRAS-PPP1CA complex. DR CORUM; P01116; -. DR DIP; DIP-33951N; -. DR FunCoup; P01116; 3194. DR IntAct; P01116; 549. DR MINT; P01116; -. DR STRING; 9606.ENSP00000256078; -. DR BindingDB; P01116; -. DR ChEMBL; CHEMBL2189121; -. DR DrugBank; DB07771; [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID. DR DrugBank; DB15568; Adagrasib. DR DrugBank; DB07780; Farnesyl diphosphate. DR DrugBank; DB15569; Sotorasib. DR DrugCentral; P01116; -. DR GuidetoPHARMACOLOGY; 2824; -. DR GlyCosmos; P01116; 1 site, No reported glycans. DR GlyGen; P01116; 1 site. DR iPTMnet; P01116; -. DR PhosphoSitePlus; P01116; -. DR SwissPalm; P01116; -. DR BioMuta; KRAS; -. DR DMDM; 131875; -. DR CPTAC; CPTAC-1550; -. DR jPOST; P01116; -. DR MassIVE; P01116; -. DR PaxDb; 9606-ENSP00000256078; -. DR PeptideAtlas; P01116; -. DR ProteomicsDB; 51323; -. [P01116-1] DR ProteomicsDB; 51324; -. [P01116-2] DR Pumba; P01116; -. DR TopDownProteomics; P01116-2; -. [P01116-2] DR ABCD; P01116; 18 sequenced antibodies. DR Antibodypedia; 24248; 916 antibodies from 40 providers. DR CPTC; P01116; 6 antibodies. DR DNASU; 3845; -. DR Ensembl; ENST00000256078.10; ENSP00000256078.5; ENSG00000133703.15. [P01116-1] DR Ensembl; ENST00000311936.8; ENSP00000308495.3; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000685328.1; ENSP00000508921.1; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000688940.1; ENSP00000509238.1; ENSG00000133703.15. [P01116-2] DR GeneID; 3845; -. DR KEGG; hsa:3845; -. DR MANE-Select; ENST00000311936.8; ENSP00000308495.3; NM_004985.5; NP_004976.2. [P01116-2] DR UCSC; uc001rgp.3; human. [P01116-1] DR AGR; HGNC:6407; -. DR CIViC; 3845; 1 clinical assertion and 480 evidence items across 102 molecular profiles. DR ClinPGx; PA30196; -. DR CTD; 3845; -. DR DisGeNET; 3845; -. DR GeneCards; KRAS; -. DR GeneReviews; KRAS; -. DR HGNC; HGNC:6407; KRAS. DR HPA; ENSG00000133703; Low tissue specificity. DR MalaCards; KRAS; -. DR MIM; 163200; phenotype. DR MIM; 190070; gene. DR MIM; 600268; phenotype. DR MIM; 601626; phenotype. DR MIM; 607785; phenotype. DR MIM; 609942; phenotype. DR MIM; 613659; phenotype. DR MIM; 615278; phenotype. DR OpenTargets; ENSG00000133703; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2396; Encephalocraniocutaneous lipomatosis. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 3339; Oculoectodermal syndrome. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 268114; RAS-associated autoimmune leukoproliferative disease. DR VEuPathDB; HostDB:ENSG00000133703; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155871; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01116; -. DR OMA; CCGGCVI; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01116; 5 GO annotations based on evolutionary models. DR PhylomeDB; P01116; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01116; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-4086398; Ca2+ pathway. [P01116-2] DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF). DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SignaLink; P01116; -. DR SIGNOR; P01116; -. DR Agora; ENSG00000133703; -. DR BioGRID-ORCS; 3845; 259 hits in 1133 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; KRAS; human. DR EvolutionaryTrace; P01116; -. DR GeneWiki; KRAS; -. DR GenomeRNAi; 3845; -. DR Pharos; P01116; Tclin. DR PRO; PR:P01116; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P01116; protein. DR Bgee; ENSG00000133703; Expressed in trigeminal ganglion and 218 other cell types or tissues. DR ExpressionAtlas; P01116; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IBA:GO_Central. DR GO; GO:0019002; F:GMP binding; IEA:Ensembl. DR GO; GO:0005525; F:GTP binding; IBA:GO_Central. DR GO; GO:0003924; F:GTPase activity; IMP:DisProt. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:MGI. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl. DR GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0007565; P:female pregnancy; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:0035022; P:positive regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl. DR GO; GO:0009629; P:response to gravity; IEA:Ensembl. DR GO; GO:0035900; P:response to isolation stress; IEA:Ensembl. DR GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060509; P:type I pneumocyte differentiation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP03860; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00176; RAN; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Ectodermal dysplasia; Glycoprotein; GTP-binding; KW Hydrolase; Intellectual disability; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase KRas" FT /id="PRO_0000082641" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.17" FT CHAIN 2..186 FT /note="GTPase KRas, N-terminally processed" FT /id="PRO_0000326480" FT PROPEP 187..189 FT /note="Removed in mature form" FT /evidence="ECO:0000305|PubMed:27791178" FT /id="PRO_0000281291" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 10..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase KRas; alternate" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase KRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 104 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22711838" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5" FT LIPID 180 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 182 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000269|PubMed:29239724" FT LIPID 184 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 185 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0000305|PubMed:24415755, ECO:0007744|PDB:5TAR, FT ECO:0007744|PDB:5TB5" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:30442762" FT VAR_SEQ 151..153 FT /note="RVE -> GVD (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011140" FT VAR_SEQ 165..189 FT /note="QYRLKKISKEEKTPGCVKIKKCIIM -> KHKEKMSKDGKKKKKKSKTKCVI FT M (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011141" FT VARIANT 5 FT /note="K -> E (in NS3; dbSNP:rs193929331)" FT /evidence="ECO:0000269|PubMed:17468812" FT /id="VAR_065144" FT VARIANT 5 FT /note="K -> N (in GASC; found also in a patient with FT Costello syndrome; exhibits only minor alterations in its FT in vitro biochemical behavior compared to wild-type FT protein; dbSNP:rs104894361)" FT /evidence="ECO:0000269|PubMed:14534542" FT /id="VAR_064849" FT VARIANT 10 FT /note="G -> GG (in AML; expression in 3T3 cell causes FT cellular transformation; expression in COS cells activates FT the Ras-MAPK signaling pathway; lower GTPase activity; FT faster GDP dissociation rate)" FT /evidence="ECO:0000269|PubMed:8955068" FT /id="VAR_034601" FT VARIANT 12 FT /note="G -> A (in colorectal cancer samples; somatic FT mutation; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036305" FT VARIANT 12 FT /note="G -> C (in lung carcinoma; somatic mutation; also FT found in metastatic colorectal cancer; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:34820593, ECO:0000269|PubMed:6320174" FT /id="VAR_006839" FT VARIANT 12 FT /note="G -> D (in GASC, JMML and SFM; somatic mutation; FT also found in pancreatic carcinoma and lung carcinoma; also FT found in metastatic colorectal cancer; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:30891959, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:7773929, ECO:0000269|PubMed:8439212" FT /id="VAR_016026" FT VARIANT 12 FT /note="G -> R (in lung cancer and bladder cancer; somatic FT mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:6695174" FT /id="VAR_016027" FT VARIANT 12 FT /note="G -> S (in GASC and JMML; also found in lung FT carcinoma; somatic mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:7773929" FT /id="VAR_016028" FT VARIANT 12 FT /note="G -> V (in GASC; also found in lung carcinoma, FT pancreatic carcinoma and colon cancer; also found in FT metastatic colorectal cancer; somatic mutation; it is FT constitutively activated and stimulates transcription FT activation of tumor suppressor genes in non-transformed FT fibroblasts; promotes GTP binding; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:24623306, FT ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:39809765, ECO:0000269|PubMed:6092920, FT ECO:0000269|PubMed:8439212" FT /id="VAR_006840" FT VARIANT 13 FT /note="G -> D (in GASC, JMML and OES; also found in a FT breast carcinoma cell line; somatic mutation; FT dbSNP:rs112445441)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:3627975" FT /id="VAR_016029" FT VARIANT 13 FT /note="G -> R (in pylocytic astrocytoma; somatic mutation; FT increase activation of the Ras pathway; dbSNP:rs121913535)" FT /evidence="ECO:0000269|PubMed:16247081" FT /id="VAR_065145" FT VARIANT 14 FT /note="V -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; characterized FT by a strong increase of both intrinsic and guanine FT nucleotide exchanged factor-catalyzed nucleotide exchange FT leading to an increased level of the activated state; FT dbSNP:rs104894365)" FT /evidence="ECO:0000269|PubMed:16474405" FT /id="VAR_026109" FT VARIANT 19 FT /note="L -> F (in OES; somatic mutation; FT dbSNP:rs121913538)" FT /evidence="ECO:0000269|PubMed:25808193" FT /id="VAR_083261" FT VARIANT 22 FT /note="Q -> E (in CFC2; exhibits an increase in intrinsic FT and guanine nucleotide exchange factor catalyzed nucleotide FT exchange in combination with an impaired GTPase-activating FT protein-stimulated GTP hydrolysis but functional in FT interaction with effectors; dbSNP:rs121913236)" FT /evidence="ECO:0000269|PubMed:17056636, FT ECO:0000269|PubMed:20949621" FT /id="VAR_064850" FT VARIANT 22 FT /note="Q -> R (in NS3; impairs GTPase-activating protein FT stimulated GTP hydrolysis with unaffected intrinsic FT functions and a virtually functional effector interaction; FT dbSNP:rs727503110)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064851" FT VARIANT 34 FT /note="P -> L (in NS3; characterized by a defective GTPase- FT activating protein sensitivity and a strongly reduced FT interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064852" FT VARIANT 34 FT /note="P -> Q (in NS3; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064853" FT VARIANT 34 FT /note="P -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026110" FT VARIANT 36 FT /note="I -> M (in NS3; dbSNP:rs727503109)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064854" FT VARIANT 58 FT /note="T -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; exhibits only FT minor alterations in its in vitro biochemical behavior FT compared to wild-type protein; dbSNP:rs104894364)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:19396835" FT /id="VAR_026111" FT VARIANT 59 FT /note="A -> T (in GASC; also found in bladder cancer; FT somatic mutation; dbSNP:rs121913528)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:1553789" FT /id="VAR_016030" FT VARIANT 60 FT /note="G -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026112" FT VARIANT 60 FT /note="G -> S (in NS3; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:19396835" FT /id="VAR_065146" FT VARIANT 61 FT /note="Q -> H (in lung carcinoma; dbSNP:rs17851045)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:16533793, ECO:0000269|Ref.7" FT /id="VAR_006841" FT VARIANT 61 FT /note="Q -> R (in a colorectal cancer sample; somatic FT mutation; promotes interaction with SHOC2 and PP1C; FT dbSNP:rs121913240)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509" FT /id="VAR_036306" FT VARIANT 71 FT /note="Y -> H (in CFC2; dbSNP:rs387907205)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069784" FT VARIANT 117 FT /note="K -> N (in colorectal cancer samples; somatic FT mutation; dbSNP:rs770248150)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036307" FT VARIANT 146 FT /note="A -> T (in OES; somatic mutation; also found in FT colorectal cancer samples; dbSNP:rs121913527)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:26970110, ECO:0000269|PubMed:30891959, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036308" FT VARIANT 146 FT /note="A -> V (in OES; somatic mutation; FT dbSNP:rs1057519725)" FT /evidence="ECO:0000269|PubMed:26970110, FT ECO:0000269|PubMed:30891959" FT /id="VAR_083262" FT VARIANT 147 FT /note="K -> E (in CFC2; dbSNP:rs387907206)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069785" FT MUTAGEN 38 FT /note="D->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 40 FT /note="Y->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 61 FT /note="Q->L: Promotes GTP binding." FT /evidence="ECO:0000269|PubMed:39809765" FT MUTAGEN 180 FT /note="C->S: Abolished palmitoylation on Cys; reduced FT palmitoylation on Lys residues." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 182..185 FT /note="KIKK->RIRR: In K-Ras-3KR; abolished lysine- FT palmitoylation." FT /evidence="ECO:0000269|PubMed:29239724" FT STRAND 3..9 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:6EPO" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 28..32 FT /evidence="ECO:0007829|PDB:7F0W" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:6H46" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 60..62 FT /evidence="ECO:0007829|PDB:4Q01" FT HELIX 66..73 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 87..91 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 93..104 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5VBM" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:4OBE" FT HELIX 127..137 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 141..143 FT /evidence="ECO:0007829|PDB:8ONV" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 169..172 FT /evidence="ECO:0007829|PDB:5OCG" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:4DSN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:5TB5" FT VARIANT P01116-2:152 FT /note="V -> G (in NS3; dbSNP:rs104894367)" FT /evidence="ECO:0000305" FT /id="VAR_082908" FT VARIANT P01116-2:153 FT /note="D -> V (in CFC2 and NS3; exhibits only minor FT alterations in its in vitro biochemical behavior compared FT to wild-type protein; dbSNP:rs104894360)" FT /evidence="ECO:0000305" FT /id="VAR_082909" FT VARIANT P01116-2:156 FT /note="F -> I (in NS3; the patient also has features of FT cardiofaciocutaneous syndrome; dbSNP:rs397517042)" FT /evidence="ECO:0000305" FT /id="VAR_082910" FT VARIANT P01116-2:156 FT /note="F -> L (found in a patient with Costello syndrome; FT exhibits an increase in intrinsic and guanine nucleotide FT exchange factor catalyzed nucleotide exchange in FT combination with an impaired GTPase-activating protein- FT stimulated GTP hydrolysis but functional in interaction FT with effectors; dbSNP:rs104894362)" FT /evidence="ECO:0000305" FT /id="VAR_082911" FT MUTAGEN P01116-2:185 FT /note="C->S: Abolished interaction with GPR131." FT /evidence="ECO:0000269|PubMed:28619714" SQ SEQUENCE 189 AA; 21656 MW; 973547B2E11C2C81 CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKCIIM // ID RCAS1_HUMAN Reviewed; 213 AA. AC O00559; A8K3N6; Q5Y8C7; Q6IB20; Q9BS76; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1997, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Receptor-binding cancer antigen expressed on SiSo cells; DE AltName: Full=Cancer-associated surface antigen RCAS1; DE AltName: Full=Estrogen receptor-binding fragment-associated gene 9 protein; GN Name=EBAG9; Synonyms=RCAS1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Uterine adenocarcinoma; RX PubMed=10426319; DOI=10.1038/11383; RA Nakashima M., Sonoda K., Watanabe T.; RT "Inhibition of cell growth and induction of apoptotic cell death by the RT human tumor-associated antigen RCAS1."; RL Nat. Med. 5:938-942(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary cancer; RX PubMed=9418891; DOI=10.1128/mcb.18.1.442; RA Watanabe T., Inoue S., Hiroi H., Orimo A., Kawashima H., Muramatsu M.; RT "Isolation of estrogen-responsive genes with a CpG island library."; RL Mol. Cell. Biol. 18:442-449(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Lo W.Y., Hsieh S.L.; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, Lung, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP ROLE IN CANCER. RX PubMed=12054692; DOI=10.1016/s0006-291x(02)00401-1; RA Rousseau J., Tetu B., Caron D., Malenfant P., Cattaruzzi P., Audette M., RA Doillon C., Tremblay J.P., Guerette B.; RT "RCAS1 is associated with ductal breast cancer progression."; RL Biochem. Biophys. Res. Commun. 293:1544-1549(2002). RN [9] RP ROLE IN CANCER. RX PubMed=12138241; DOI=10.1159/000065065; RA Oizumi S., Yamazaki K., Nakashima M., Watanabe T., Hommura F., Ogura S., RA Nishimura M., Dosaka-Akita H.; RT "RCAS1 expression: a potential prognostic marker for adenocarcinomas of the RT lung."; RL Oncology 62:333-339(2002). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=12672804; DOI=10.1074/jbc.m301361200; RA Engelsberg A., Hermosilla R., Karsten U., Schuelein R., Doerken B., RA Rehm A.; RT "The Golgi protein RCAS1 controls cell surface expression of tumor- RT associated O-linked glycan antigens."; RL J. Biol. Chem. 278:22998-23007(2003). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND THR-41, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-94, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: May participate in suppression of cell proliferation and CC induces apoptotic cell death through activation of interleukin-1-beta CC converting enzyme (ICE)-like proteases. {ECO:0000269|PubMed:12054692, CC ECO:0000269|PubMed:12138241, ECO:0000269|PubMed:12672804}. CC -!- SUBUNIT: Homodimer. CC -!- INTERACTION: CC O00559; Q9ULC5: ACSL5; NbExp=3; IntAct=EBI-8787095, EBI-2876927; CC O00559; Q9BQE5: APOL2; NbExp=3; IntAct=EBI-8787095, EBI-4290634; CC O00559; Q12983: BNIP3; NbExp=3; IntAct=EBI-8787095, EBI-749464; CC O00559; Q9BXR6: CFHR5; NbExp=3; IntAct=EBI-8787095, EBI-11579371; CC O00559; Q9H5X1: CIAO2A; NbExp=3; IntAct=EBI-8787095, EBI-752069; CC O00559; Q6UXB4: CLEC4G; NbExp=3; IntAct=EBI-8787095, EBI-2114729; CC O00559; Q9NWW5: CLN6; NbExp=3; IntAct=EBI-8787095, EBI-6165897; CC O00559; A0A0C4DFN3: MGLL; NbExp=3; IntAct=EBI-8787095, EBI-12866138; CC O00559; Q8N912: NRAC; NbExp=3; IntAct=EBI-8787095, EBI-12051377; CC O00559; Q8NH19: OR10AG1; NbExp=3; IntAct=EBI-8787095, EBI-13339917; CC O00559; Q9P0S3: ORMDL1; NbExp=3; IntAct=EBI-8787095, EBI-1054848; CC O00559; Q9Y5Y5: PEX16; NbExp=3; IntAct=EBI-8787095, EBI-981985; CC O00559; O60831: PRAF2; NbExp=3; IntAct=EBI-8787095, EBI-2506064; CC O00559; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-8787095, EBI-14065960; CC O00559; Q9BRI3: SLC30A2; NbExp=3; IntAct=EBI-8787095, EBI-8644112; CC O00559; P78382: SLC35A1; NbExp=3; IntAct=EBI-8787095, EBI-12870360; CC O00559; Q96G79: SLC35A4; NbExp=3; IntAct=EBI-8787095, EBI-12363689; CC O00559; Q969S0: SLC35B4; NbExp=3; IntAct=EBI-8787095, EBI-10281213; CC O00559; Q16623: STX1A; NbExp=3; IntAct=EBI-8787095, EBI-712466; CC O00559; P32856-2: STX2; NbExp=3; IntAct=EBI-8787095, EBI-11956649; CC O00559; Q13277: STX3; NbExp=3; IntAct=EBI-8787095, EBI-1394295; CC O00559; Q6UX40: TMEM107; NbExp=3; IntAct=EBI-8787095, EBI-12845616; CC O00559; Q6ZUI0: TPRG1; NbExp=3; IntAct=EBI-8787095, EBI-17249488; CC O00559; Q9Y228: TRAF3IP3; NbExp=3; IntAct=EBI-8787095, EBI-765817; CC O00559; Q9P0L0: VAPA; NbExp=3; IntAct=EBI-8787095, EBI-1059156; CC O00559; O95292: VAPB; NbExp=3; IntAct=EBI-8787095, EBI-1188298; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane CC {ECO:0000269|PubMed:12672804}; Single-pass type III membrane protein CC {ECO:0000269|PubMed:12672804}. Note=According to PubMed:10426319, it CC also exists as a soluble form which has the same biological activities. CC The existence of such soluble form is however uncertain. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O00559-1; Sequence=Displayed; CC Name=2; CC IsoId=O00559-2; Sequence=VSP_055503; CC -!- TISSUE SPECIFICITY: Widely expressed. Expressed in ovary, testis, CC prostate, thymus, muscle and heart, but not in small intestine, colon, CC lymph nodes, or peripherical blood lymphocytes. The protein is not CC detected in any of the above organs. CC -!- INDUCTION: By estrogen. CC -!- DOMAIN: The coiled coil domain is necessary for the homodimerization. CC -!- MISCELLANEOUS: May serve as a prognostic marker for cancers such as CC adenocarcinomas of the lung and breast cancers. It is present and CC overexpressed in many patients suffering from breast carcinomas, its CC level of expression correlates with tumor grade, suggesting that it may CC be involved in cancer immune escape. According to PubMed:12672804, it CC is however not directly a tumor-associated antigen, but it rather CC modulates surface expression of tumor-associated O-linked glycan Tn CC when it is overexpressed, suggesting that it contributes indirectly to CC the antigenicity of tumor cells. CC -!- CAUTION: It was initially reported to be a ligand for some putative CC receptor present on T-, B-, natural killer (NK) cells and various human CC cell lines. However, PubMed:12672804 showed that it does not bind any CC receptor. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40393/EBAG9"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF006265; AAB61617.1; -; mRNA. DR EMBL; AB007619; BAA22572.1; -; mRNA. DR EMBL; AY653072; AAU85838.1; -; mRNA. DR EMBL; AK290651; BAF83340.1; -; mRNA. DR EMBL; CR456984; CAG33265.1; -; mRNA. DR EMBL; AC079061; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP000427; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC005249; AAH05249.1; -; mRNA. DR EMBL; BC017729; AAH17729.1; -; mRNA. DR EMBL; BC022506; AAH22506.1; -; mRNA. DR CCDS; CCDS6313.1; -. [O00559-1] DR RefSeq; NP_001265867.1; NM_001278938.2. [O00559-1] DR RefSeq; NP_004206.1; NM_004215.5. [O00559-1] DR RefSeq; NP_936056.1; NM_198120.3. [O00559-1] DR RefSeq; XP_016869449.1; XM_017013960.2. [O00559-1] DR RefSeq; XP_047278368.1; XM_047422412.1. [O00559-1] DR RefSeq; XP_047278369.1; XM_047422413.1. [O00559-1] DR RefSeq; XP_054217468.1; XM_054361493.1. [O00559-1] DR RefSeq; XP_054217469.1; XM_054361494.1. [O00559-1] DR AlphaFoldDB; O00559; -. DR SMR; O00559; -. DR BioGRID; 114607; 313. DR FunCoup; O00559; 1234. DR IntAct; O00559; 33. DR STRING; 9606.ENSP00000337675; -. DR iPTMnet; O00559; -. DR PhosphoSitePlus; O00559; -. DR SwissPalm; O00559; -. DR BioMuta; EBAG9; -. DR jPOST; O00559; -. DR MassIVE; O00559; -. DR PaxDb; 9606-ENSP00000337675; -. DR PeptideAtlas; O00559; -. DR ProteomicsDB; 47973; -. [O00559-1] DR ProteomicsDB; 65861; -. DR Pumba; O00559; -. DR Antibodypedia; 13458; 429 antibodies from 38 providers. DR CPTC; O00559; 3 antibodies. DR DNASU; 9166; -. DR Ensembl; ENST00000337573.10; ENSP00000337675.5; ENSG00000147654.17. [O00559-1] DR Ensembl; ENST00000395785.7; ENSP00000379131.2; ENSG00000147654.17. [O00559-1] DR Ensembl; ENST00000531677.5; ENSP00000432082.1; ENSG00000147654.17. [O00559-2] DR Ensembl; ENST00000614147.1; ENSP00000477734.1; ENSG00000147654.17. [O00559-2] DR Ensembl; ENST00000620557.4; ENSP00000477645.1; ENSG00000147654.17. [O00559-1] DR Ensembl; ENST00000699338.1; ENSP00000514313.1; ENSG00000147654.17. [O00559-1] DR GeneID; 9166; -. DR KEGG; hsa:9166; -. DR MANE-Select; ENST00000337573.10; ENSP00000337675.5; NM_004215.5; NP_004206.1. DR UCSC; uc003ynf.5; human. [O00559-1] DR AGR; HGNC:3123; -. DR ClinPGx; PA27581; -. DR CTD; 9166; -. DR DisGeNET; 9166; -. DR GeneCards; EBAG9; -. DR HGNC; HGNC:3123; EBAG9. DR HPA; ENSG00000147654; Low tissue specificity. DR MIM; 605772; gene. DR OpenTargets; ENSG00000147654; -. DR VEuPathDB; HostDB:ENSG00000147654; -. DR eggNOG; ENOG502QSN4; Eukaryota. DR GeneTree; ENSGT00390000004040; -. DR HOGENOM; CLU_094995_0_0_1; -. DR InParanoid; O00559; -. DR OMA; LGEMENW; -. DR OrthoDB; 10017216at2759; -. DR PAN-GO; O00559; 1 GO annotation based on evolutionary models. DR PhylomeDB; O00559; -. DR PathwayCommons; O00559; -. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR SignaLink; O00559; -. DR Agora; ENSG00000147654; -. DR BioGRID-ORCS; 9166; 19 hits in 1151 CRISPR screens. DR ChiTaRS; EBAG9; human. DR GeneWiki; EBAG9; -. DR GenomeRNAi; 9166; -. DR Pharos; O00559; Tbio. DR PRO; PR:O00559; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O00559; protein. DR Bgee; ENSG00000147654; Expressed in parotid gland and 212 other cell types or tissues. DR ExpressionAtlas; O00559; baseline and differential. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030141; C:secretory granule; IBA:GO_Central. DR GO; GO:0016505; F:peptidase activator activity involved in apoptotic process; NAS:UniProtKB. DR GO; GO:0090717; P:adaptive immune memory response involving T cells and B cells; IEA:Ensembl. DR GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB. DR GO; GO:0001913; P:T cell mediated cytotoxicity; IEA:Ensembl. DR InterPro; IPR017025; Cancer-assoc_antigen_RCAS1. DR PANTHER; PTHR15208:SF2; RECEPTOR-BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS; 1. DR PANTHER; PTHR15208; RECEPTOR-BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS CANCER ASSOCIATED SURFACE ANTIGEN RCAS1 ESTROGEN RECEPTOR-BINDING FRAGMENT- ASSOCIATED GENE 9 PROTEIN; 1. DR PIRSF; PIRSF034247; RCAS1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; Coiled coil; Golgi apparatus; Membrane; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Signal-anchor; Transmembrane; Transmembrane helix. FT CHAIN 1..213 FT /note="Receptor-binding cancer antigen expressed on SiSo FT cells" FT /id="PRO_0000097195" FT TOPO_DOM 1..6 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 7..27 FT /note="Helical; Signal-anchor for type III membrane FT protein" FT /evidence="ECO:0000255" FT TOPO_DOM 28..213 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REGION 178..213 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 163..211 FT /evidence="ECO:0000255" FT COMPBIAS 178..206 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 36 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:15144186, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18088087, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 41 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:15144186" FT MOD_RES 94 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:15592455" FT VAR_SEQ 174 FT /note="R -> RSRTNVCLLCSLLFHHPTPTSTPYINQSVKIERVSLGQWSYGKSKE FT (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_055503" FT CONFLICT 183 FT /note="K -> E (in Ref. 7; AAH05249)" FT /evidence="ECO:0000305" FT CONFLICT 199 FT /note="R -> Q (in Ref. 4; BAF83340)" FT /evidence="ECO:0000305" SQ SEQUENCE 213 AA; 24377 MW; B115E741E23891C5 CRC64; MAITQFRLFK FCTCLATVFS FLKRLICRSG RGRKLSGDQI TLPTTVDYSS VPKQTDVEEW TSWDEDAPTS VKIEGGNGNV ATQQNSLEQL EPDYFKDMTP TIRKTQKIVI KKREPLNFGI PDGSTGFSSR LAATQDLPFI HQSSELGDLD TWQENTNAWE EEEDAAWQAE EVLRQQKLAD REKRAAEQQR KKMEKEAQRL MKKEQNKIGV KLS // ID RHXF1_HUMAN Reviewed; 184 AA. AC Q8NHV9; O95030; Q3SYE0; DT 03-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 170. DE RecName: Full=Rhox homeobox family member 1 {ECO:0000305}; DE AltName: Full=Ovary-, testis- and epididymis-expressed gene protein; DE AltName: Full=Paired-like homeobox protein PEPP-1; GN Name=RHOXF1 {ECO:0000312|HGNC:HGNC:29993}; Synonyms=OTEX, PEPP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND MUTAGENESIS OF THE RP NUCLEAR LOCALIZATION SIGNAL. RC TISSUE=Ovary, and Testis; RX PubMed=11980563; DOI=10.1042/bj20020399; RA Geserick C., Weiss B., Schleuning W.-D., Haendler B.; RT "OTEX, an androgen-regulated human member of the paired-like class of RT homeobox genes."; RL Biochem. J. 366:367-375(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP TISSUE SPECIFICITY. RX PubMed=12490318; DOI=10.1016/s0378-1119(02)01087-9; RA Wayne C.M., MacLean J.A. II, Cornwall G., Wilkinson M.F.; RT "Two novel human X-linked homeobox genes, hPEPP1 and hPEPP2, selectively RT expressed in the testis."; RL Gene 301:1-11(2002). RN [5] RP VARIANT HIS-177. RX PubMed=26506222; DOI=10.1002/ana.24550; RA Park H.J., Hong Y.B., Choi Y.C., Lee J., Kim E.J., Lee J.S., Mo W.M., RA Ki S.M., Kim H.I., Kim H.J., Hyun Y.S., Hong H.D., Nam K., Jung S.C., RA Kim S.B., Kim S.H., Kim D.H., Oh K.W., Kim S.H., Yoo J.H., Lee J.E., RA Chung K.W., Choi B.O.; RT "ADSSL1 mutation relevant to autosomal recessive adolescent onset distal RT myopathy."; RL Ann. Neurol. 79:231-243(2016). RN [6] RP FUNCTION, TISSUE SPECIFICITY, VARIANT HIS-172, AND CHARACTERIZATION OF RP VARIANT HIS-172. RX PubMed=28171660; DOI=10.1093/hmg/ddw313; RA Borgmann J., Tuettelmann F., Dworniczak B., Roepke A., Song H.W., RA Kliesch S., Wilkinson M.F., Laurentino S., Gromoll J.; RT "The human RHOX gene cluster: target genes and functional analysis of gene RT variants in infertile men."; RL Hum. Mol. Genet. 25:4898-4910(2016). RN [7] RP VARIANTS VAL-91; MET-130; VAL-156 AND 160-ARG--ASP-184 DEL. RX PubMed=38258527; DOI=10.1093/molehr/gaae002; RA Yi S., Wang W., Su L., Meng L., Li Y., Tan C., Liu Q., Zhang H., Fan L., RA Lu G., Hu L., Du J., Lin G., Tan Y.Q., Tu C., Zhang Q.; RT "Deleterious variants in X-linked RHOXF1 cause male infertility with RT oligo- and azoospermia."; RL Mol. Hum. Reprod. 30:0-0(2024). CC -!- FUNCTION: Transcription factor maybe involved in reproductive CC processes. Modulates expression of target genes encoding proteins CC involved in processes relevant to spermatogenesis. CC {ECO:0000269|PubMed:28171660}. CC -!- SUBUNIT: Does not interact with itself. CC -!- INTERACTION: CC Q8NHV9; Q9BXW4: MAP1LC3C; NbExp=3; IntAct=EBI-3923409, EBI-2603996; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00108, CC ECO:0000269|PubMed:11980563}. CC -!- TISSUE SPECIFICITY: Ovary, testis and epididymis. Also detected in the CC prostate and the mammary gland. Expressed in many tumor cell lines CC derived from acute lymphocytic leukemia, prostate, endometrial CC adenocarcinoma, melanoma, bladder carcinoma, colon carcinoma, CC erythroleukemia and breast carcinoma. Not expressed in placenta. In CC testis, mainly expressed in germ cells, but also detected in somatic CC cells such as Sertoli cells, Leydig cells and peritubular cells CC (PubMed:28171660). {ECO:0000269|PubMed:12490318, CC ECO:0000269|PubMed:28171660}. CC -!- DEVELOPMENTAL STAGE: Predominantly expressed in late stage germ cells, CC pachytene spermatocytes and round spermatides. CC {ECO:0000269|PubMed:28171660}. CC -!- INDUCTION: By androgen. CC -!- DOMAIN: Mutagenesis of amino acids 147 to 164 and 155 to 164 lead to a CC major cytoplasmic localization, with only minor localization in the CC nucleus. CC -!- SIMILARITY: Belongs to the paired-like homeobox family. PEPP subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC78617.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY099086; AAM22794.1; -; mRNA. DR EMBL; AC005023; AAC78617.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC069324; AAH69324.1; -; mRNA. DR EMBL; BC069529; AAH69529.1; -; mRNA. DR EMBL; BC103857; AAI03858.1; -; mRNA. DR EMBL; BC103858; AAI03859.1; -; mRNA. DR CCDS; CCDS14593.1; -. DR RefSeq; NP_644811.1; NM_139282.3. DR AlphaFoldDB; Q8NHV9; -. DR SMR; Q8NHV9; -. DR BioGRID; 127708; 4. DR FunCoup; Q8NHV9; 31. DR IntAct; Q8NHV9; 3. DR STRING; 9606.ENSP00000217999; -. DR GlyGen; Q8NHV9; 1 site. DR BioMuta; RHOXF1; -. DR DMDM; 37537960; -. DR MassIVE; Q8NHV9; -. DR PaxDb; 9606-ENSP00000217999; -. DR PeptideAtlas; Q8NHV9; -. DR ProteomicsDB; 73767; -. DR Antibodypedia; 29868; 138 antibodies from 25 providers. DR DNASU; 158800; -. DR Ensembl; ENST00000217999.3; ENSP00000217999.1; ENSG00000101883.7. DR Ensembl; ENST00000703667.1; ENSP00000515423.1; ENSG00000101883.7. DR GeneID; 158800; -. DR KEGG; hsa:158800; -. DR MANE-Select; ENST00000217999.3; ENSP00000217999.1; NM_139282.3; NP_644811.1. DR UCSC; uc004esk.2; human. DR AGR; HGNC:29993; -. DR ClinPGx; PA162401287; -. DR CTD; 158800; -. DR DisGeNET; 158800; -. DR GeneCards; RHOXF1; -. DR HGNC; HGNC:29993; RHOXF1. DR HPA; ENSG00000101883; Tissue enhanced (brain, testis). DR MIM; 300446; gene. DR OpenTargets; ENSG00000101883; -. DR VEuPathDB; HostDB:ENSG00000101883; -. DR eggNOG; KOG0490; Eukaryota. DR GeneTree; ENSGT00940000163385; -. DR HOGENOM; CLU_118646_0_0_1; -. DR InParanoid; Q8NHV9; -. DR OMA; DDCVYIV; -. DR OrthoDB; 9634605at2759; -. DR PAN-GO; Q8NHV9; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q8NHV9; -. DR PathwayCommons; Q8NHV9; -. DR SignaLink; Q8NHV9; -. DR SIGNOR; Q8NHV9; -. DR Agora; ENSG00000101883; -. DR BioGRID-ORCS; 158800; 14 hits in 796 CRISPR screens. DR GeneWiki; RHOXF1; -. DR GenomeRNAi; 158800; -. DR Pharos; Q8NHV9; Tbio. DR PRO; PR:Q8NHV9; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q8NHV9; protein. DR Bgee; ENSG00000101883; Expressed in primordial germ cell in gonad and 94 other cell types or tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; NAS:UniProtKB. DR GO; GO:0003700; F:DNA-binding transcription factor activity; NAS:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0030521; P:androgen receptor signaling pathway; IEP:UniProtKB. DR GO; GO:0048666; P:neuron development; IBA:GO_Central. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd00086; homeodomain; 1. DR FunFam; 1.10.10.60:FF:000485; Rhox homeobox family member 1; 1. DR Gene3D; 1.10.10.60; Homeodomain-like; 1. DR InterPro; IPR001356; HD. DR InterPro; IPR017970; Homeobox_CS. DR InterPro; IPR009057; Homeodomain-like_sf. DR InterPro; IPR000047; HTH_motif. DR InterPro; IPR050649; Paired_Homeobox_TFs. DR PANTHER; PTHR24329; HOMEOBOX PROTEIN ARISTALESS; 1. DR PANTHER; PTHR24329:SF549; RHOX HOMEOBOX FAMILY MEMBER 1; 1. DR Pfam; PF00046; Homeodomain; 1. DR PRINTS; PR00031; HTHREPRESSR. DR SMART; SM00389; HOX; 1. DR SUPFAM; SSF46689; Homeodomain-like; 1. DR PROSITE; PS00027; HOMEOBOX_1; 1. DR PROSITE; PS50071; HOMEOBOX_2; 1. PE 1: Evidence at protein level; KW DNA-binding; Homeobox; Nucleus; Proteomics identification; KW Reference proteome; Transcription; Transcription regulation. FT CHAIN 1..184 FT /note="Rhox homeobox family member 1" FT /id="PRO_0000049245" FT DNA_BIND 103..162 FT /note="Homeobox" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108" FT REGION 26..104 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 155..164 FT /note="Nuclear localization signal" FT COMPBIAS 88..99 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VARIANT 91 FT /note="A -> V (found in a man with non-obstructive FT azoospermia; uncertain significance; dbSNP:rs1246288348)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089313" FT VARIANT 130 FT /note="V -> M (found in a man with non-obstructive FT azoospermia; uncertain significance)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089314" FT VARIANT 156 FT /note="A -> V (found in a man with severe oligozoospermia; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089315" FT VARIANT 160..184 FT /note="Missing (found in a man with severe oligozoospermia; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089316" FT VARIANT 172 FT /note="R -> H (in dbSNP:rs2301977)" FT /evidence="ECO:0000269|PubMed:28171660" FT /id="VAR_049587" FT VARIANT 177 FT /note="D -> H (in dbSNP:rs138060880)" FT /evidence="ECO:0000269|PubMed:26506222" FT /id="VAR_077002" SQ SEQUENCE 184 AA; 20542 MW; 90C67C7ACA2B292B CRC64; MARSLVHDTV FYCLSVYQVK ISPTPQLGAA SSAEGHVGQG APGLMGNMNP EGGVNHENGM NRDGGMIPEG GGGNQEPRQQ PQPPPEEPAQ AAMEGPQPEN MQPRTRRTKF TLLQVEELES VFRHTQYPDV PTRRELAENL GVTEDKVRVW FKNKRARCRR HQRELMLANE LRADPDDCVY IVVD // ID ROR1_HUMAN Reviewed; 937 AA. AC Q01973; Q5VVX6; Q66K77; Q92776; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 28-NOV-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Inactive tyrosine-protein kinase transmembrane receptor ROR1 {ECO:0000305}; DE AltName: Full=Neurotrophic tyrosine kinase, receptor-related 1; DE Flags: Precursor; GN Name=ROR1; Synonyms=NTRKR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT MET-518. RX PubMed=1334494; DOI=10.1016/s0021-9258(18)35733-8; RA Masiakowski P., Carroll R.D.; RT "A novel family of cell surface receptors with tyrosine kinase-like RT domain."; RL J. Biol. Chem. 267:26181-26190(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT). RX PubMed=8875995; RA Reddy U.R., Phatak S., Pleasure D.; RT "Human neural tissues express a truncated Ror1 receptor tyrosine kinase, RT lacking both extracellular and transmembrane domains."; RL Oncogene 13:1555-1559(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP LACK OF CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-482. RX PubMed=25029443; DOI=10.1371/journal.pone.0102695; RA Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C., Pan B., RA Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R., Sandoval W., RA Costa M., Polakis P., Arnott D., Rubinfeld B., Ernst J.A.; RT "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and RT ROR2 kinase domains."; RL PLoS ONE 9:E102695-E102695(2014). RN [7] RP FUNCTION, AND INTERACTION WITH IGFBP5 AND ERBB2. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [8] RP VARIANT [LARGE SCALE ANALYSIS] ASP-562. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-144; LEU-150; VAL-301; MET-518; RP ILE-567; ARG-624; CYS-646 AND ASN-776. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP INVOLVEMENT IN DFNB108, VARIANT DFNB108 THR-736, CHARACTERIZATION OF RP VARIANT DFNB108 THR-736, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=27162350; DOI=10.1073/pnas.1522512113; RA Diaz-Horta O., Abad C., Sennaroglu L., Foster J. II, DeSmidt A., RA Bademci G., Tokgoz-Yilmaz S., Duman D., Cengiz F.B., Grati M., Fitoz S., RA Liu X.Z., Farooq A., Imtiaz F., Currall B.B., Morton C.C., Nishita M., RA Minami Y., Lu Z., Walz K., Tekin M.; RT "ROR1 is essential for proper innervation of auditory hair cells and RT hearing in humans and mice."; RL Proc. Natl. Acad. Sci. U.S.A. 113:5993-5998(2016). CC -!- FUNCTION: Has very low kinase activity in vitro and is unlikely to CC function as a tyrosine kinase in vivo (PubMed:25029443). Receptor for CC ligand WNT5A which activate downstream NFkB signaling pathway and may CC result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, CC PubMed:27162350). In inner ear, crucial for spiral ganglion neurons to CC innervate auditory hair cells (PubMed:27162350). Via IGFBP5 ligand, CC forms a complex with ERBB2 to enhance CREB oncogenic signaling CC (PubMed:36949068). {ECO:0000269|PubMed:25029443, CC ECO:0000269|PubMed:27162350, ECO:0000269|PubMed:36949068}. CC -!- SUBUNIT: Interacts with ERBB2 and IGFBP5. CC {ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC Q01973; P00533: EGFR; NbExp=8; IntAct=EBI-6082337, EBI-297353; CC Q01973; P12931: SRC; NbExp=9; IntAct=EBI-6082337, EBI-621482; CC Q01973; P05480: Src; Xeno; NbExp=2; IntAct=EBI-6082337, EBI-298680; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:27162350}; Single- CC pass type I membrane protein. Cell projection, axon CC {ECO:0000250|UniProtKB:Q9Z139}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=Long; CC IsoId=Q01973-1; Sequence=Displayed; CC Name=Short; Synonyms=T-ROR1; CC IsoId=Q01973-2; Sequence=VSP_005008; CC Name=3; CC IsoId=Q01973-3; Sequence=VSP_043663, VSP_043664; CC -!- TISSUE SPECIFICITY: Expressed strongly in human heart, lung and kidney, CC but weakly in the CNS. Isoform Short is strongly expressed in fetal and CC adult CNS and in a variety of human cancers, including those CC originating from CNS or PNS neuroectoderm. CC -!- DEVELOPMENTAL STAGE: Expressed at high levels during early embryonic CC development. The expression levels drop strongly around day 16 and CC there are only very low levels in adult tissues. CC -!- DISEASE: Deafness, autosomal recessive, 108 (DFNB108) [MIM:617654]: A CC form of non-syndromic sensorineural hearing loss. Sensorineural CC deafness results from damage to the neural receptors of the inner ear, CC the nerve pathways to the brain, or the area of the brain that receives CC sound information. {ECO:0000269|PubMed:27162350}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. ROR subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: The kinase domain has very low catalytic activity in vitro. CC {ECO:0000269|PubMed:25029443}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M97675; AAA60275.1; -; mRNA. DR EMBL; U38894; AAC50714.1; -; mRNA. DR EMBL; AL137859; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL161742; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445205; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138793; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353713; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808029; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808030; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06556.1; -; Genomic_DNA. DR EMBL; BC080541; AAH80541.1; -; mRNA. DR CCDS; CCDS41344.1; -. [Q01973-3] DR CCDS; CCDS626.1; -. [Q01973-1] DR PIR; A45082; A45082. DR RefSeq; NP_001077061.1; NM_001083592.2. [Q01973-3] DR RefSeq; NP_005003.2; NM_005012.4. [Q01973-1] DR PDB; 5Z55; NMR; -; A=312-394. DR PDB; 6BA5; X-ray; 1.62 A; M/N/O/P=311-391. DR PDB; 6BAN; X-ray; 1.95 A; M/N/O/P=311-391. DR PDB; 6TU9; X-ray; 1.94 A; A/B=453-752. DR PDB; 7TNG; X-ray; 1.40 A; A=312-393. DR PDBsum; 5Z55; -. DR PDBsum; 6BA5; -. DR PDBsum; 6BAN; -. DR PDBsum; 6TU9; -. DR PDBsum; 7TNG; -. DR AlphaFoldDB; Q01973; -. DR SMR; Q01973; -. DR BioGRID; 110973; 124. DR DIP; DIP-29734N; -. DR FunCoup; Q01973; 357. DR IntAct; Q01973; 107. DR MINT; Q01973; -. DR STRING; 9606.ENSP00000360120; -. DR BindingDB; Q01973; -. DR ChEMBL; CHEMBL4665585; -. DR TCDB; 8.A.23.1.60; the basigin (basigin) family. DR GlyCosmos; Q01973; 4 sites, No reported glycans. DR GlyGen; Q01973; 5 sites, 5 N-linked glycans (2 sites). DR iPTMnet; Q01973; -. DR PhosphoSitePlus; Q01973; -. DR SwissPalm; Q01973; -. DR BioMuta; ROR1; -. DR DMDM; 118572711; -. DR jPOST; Q01973; -. DR MassIVE; Q01973; -. DR PaxDb; 9606-ENSP00000360120; -. DR PeptideAtlas; Q01973; -. DR ProteomicsDB; 58025; -. [Q01973-1] DR ProteomicsDB; 58026; -. [Q01973-2] DR ProteomicsDB; 58027; -. [Q01973-3] DR Pumba; Q01973; -. DR ABCD; Q01973; 29 sequenced antibodies. DR Antibodypedia; 33360; 927 antibodies from 43 providers. DR DNASU; 4919; -. DR Ensembl; ENST00000371079.6; ENSP00000360120.1; ENSG00000185483.13. [Q01973-1] DR Ensembl; ENST00000371080.5; ENSP00000360121.1; ENSG00000185483.13. [Q01973-3] DR GeneID; 4919; -. DR KEGG; hsa:4919; -. DR MANE-Select; ENST00000371079.6; ENSP00000360120.1; NM_005012.4; NP_005003.2. DR UCSC; uc001dbi.5; human. [Q01973-1] DR AGR; HGNC:10256; -. DR ClinPGx; PA34628; -. DR CTD; 4919; -. DR DisGeNET; 4919; -. DR GeneCards; ROR1; -. DR HGNC; HGNC:10256; ROR1. DR HPA; ENSG00000185483; Tissue enhanced (parathyroid). DR MalaCards; ROR1; -. DR MIM; 602336; gene. DR MIM; 617654; phenotype. DR OpenTargets; ENSG00000185483; -. DR Orphanet; 90636; Rare autosomal recessive non-syndromic sensorineural deafness type DFNB. DR VEuPathDB; HostDB:ENSG00000185483; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000153947; -. DR HOGENOM; CLU_701993_0_0_1; -. DR InParanoid; Q01973; -. DR OMA; IQNDECP; -. DR OrthoDB; 2431000at2759; -. DR PAN-GO; Q01973; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q01973; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q01973; -. DR Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2. DR SignaLink; Q01973; -. DR SIGNOR; Q01973; -. DR Agora; ENSG00000185483; -. DR BioGRID-ORCS; 4919; 17 hits in 1190 CRISPR screens. DR ChiTaRS; ROR1; human. DR GeneWiki; ROR1; -. DR GenomeRNAi; 4919; -. DR Pharos; Q01973; Tbio. DR PRO; PR:Q01973; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q01973; protein. DR Bgee; ENSG00000185483; Expressed in germinal epithelium of ovary and 154 other cell types or tissues. DR ExpressionAtlas; Q01973; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001725; C:stress fiber; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; TAS:ParkinsonsUK-UCL. DR GO; GO:0038023; F:signaling receptor activity; IDA:UniProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0042813; F:Wnt receptor activity; IMP:UniProtKB. DR GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB. DR GO; GO:0014002; P:astrocyte development; IEA:Ensembl. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; TAS:ProtInc. DR GO; GO:0048839; P:inner ear development; ISS:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd07467; CRD_TK_ROR1; 1. DR CDD; cd00108; KR; 1. DR CDD; cd05090; PTKc_Ror1; 1. DR FunFam; 1.10.2000.10:FF:000002; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.40.20.10:FF:000003; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.60.40.10:FF:000242; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 1.10.510.10:FF:000116; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 3.30.200.20:FF:000139; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR Gene3D; 1.10.2000.10; Frizzled cysteine-rich domain; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.40.20.10; Plasminogen Kringle 4; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR020067; Frizzled_dom. DR InterPro; IPR036790; Frizzled_dom_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000001; Kringle. DR InterPro; IPR013806; Kringle-like. DR InterPro; IPR018056; Kringle_CS. DR InterPro; IPR038178; Kringle_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR016247; Tyr_kinase_rcpt_ROR. DR PANTHER; PTHR24416:SF134; INACTIVE TYROSINE-PROTEIN KINASE TRANSMEMBRANE RECEPTOR ROR1; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF01392; Fz; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00051; Kringle; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000624; TyrPK_TMrec_ROR; 1. DR PRINTS; PR00018; KRINGLE. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00130; KR; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF57440; Kringle-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50038; FZ; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00021; KRINGLE_1; 1. DR PROSITE; PS50070; KRINGLE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; Deafness; KW Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain; KW Kinase; Kringle; Membrane; Non-syndromic deafness; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Signal; Transferase; Transmembrane; Transmembrane helix; KW Wnt signaling pathway. FT SIGNAL 1..29 FT /evidence="ECO:0000255" FT CHAIN 30..937 FT /note="Inactive tyrosine-protein kinase transmembrane FT receptor ROR1" FT /id="PRO_0000024458" FT TOPO_DOM 30..406 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 407..427 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 428..937 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 42..147 FT /note="Ig-like C2-type" FT DOMAIN 165..299 FT /note="FZ" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00090" FT DOMAIN 312..391 FT /note="Kringle" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00121" FT DOMAIN 473..746 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 753..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 833..890 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 753..762 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 763..779 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..864 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..880 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 479..487 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 506 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 645 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 47 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 315 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 79..131 FT /evidence="ECO:0000250" FT DISULFID 170..235 FT /evidence="ECO:0000250" FT DISULFID 178..228 FT /evidence="ECO:0000250" FT DISULFID 219..260 FT /evidence="ECO:0000250" FT DISULFID 248..296 FT /evidence="ECO:0000250" FT DISULFID 252..282 FT /evidence="ECO:0000250" FT DISULFID 313..391 FT /evidence="ECO:0000250" FT DISULFID 334..374 FT /evidence="ECO:0000250" FT DISULFID 362..386 FT /evidence="ECO:0000250" FT VAR_SEQ 1..549 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:8875995" FT /id="VSP_005008" FT VAR_SEQ 392..393 FT /note="DS -> GK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043663" FT VAR_SEQ 394..937 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043664" FT VARIANT 144 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041779" FT VARIANT 150 FT /note="F -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041780" FT VARIANT 301 FT /note="I -> V (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041781" FT VARIANT 518 FT /note="T -> M (in dbSNP:rs7527017)" FT /evidence="ECO:0000269|PubMed:1334494, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041782" FT VARIANT 562 FT /note="E -> D (in a breast cancer sample; somatic mutation; FT dbSNP:rs760789417)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035713" FT VARIANT 567 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041783" FT VARIANT 624 FT /note="G -> R (in dbSNP:rs55832740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041784" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34109134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041785" FT VARIANT 736 FT /note="R -> T (in DFNB108; impairs plasma membrane FT location; abolishes downstream NFkB activation; FT dbSNP:rs1553163562)" FT /evidence="ECO:0000269|PubMed:27162350" FT /id="VAR_079530" FT VARIANT 776 FT /note="S -> N (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041786" FT MUTAGEN 482 FT /note="C->G: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:25029443" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:7TNG" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 365..367 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 373..377 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 383..387 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 470..472 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 473..481 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 486..492 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 501..507 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 514..527 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 538..542 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 544..547 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 549..553 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 560..566 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 589..608 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 621..623 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 625..627 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 636..640 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 642..644 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 656..658 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 661..666 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 671..686 FT /evidence="ECO:0007829|PDB:6TU9" FT TURN 692..695 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 698..706 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 719..728 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 739..748 FT /evidence="ECO:0007829|PDB:6TU9" SQ SEQUENCE 937 AA; 104283 MW; 0EC0E4762A90C6C7 CRC64; MHRPRRRGTR PPLLALLAAL LLAARGAAAQ ETELSVSAEL VPTSSWNISS ELNKDSYLTL DEPMNNITTS LGQTAELHCK VSGNPPPTIR WFKNDAPVVQ EPRRLSFRST IYGSRLRIRN LDTTDTGYFQ CVATNGKEVV SSTGVLFVKF GPPPTASPGY SDEYEEDGFC QPYRGIACAR FIGNRTVYME SLHMQGEIEN QITAAFTMIG TSSHLSDKCS QFAIPSLCHY AFPYCDETSS VPKPRDLCRD ECEILENVLC QTEYIFARSN PMILMRLKLP NCEDLPQPES PEAANCIRIG IPMADPINKN HKCYNSTGVD YRGTVSVTKS GRQCQPWNSQ YPHTHTFTAL RFPELNGGHS YCRNPGNQKE APWCFTLDEN FKSDLCDIPA CDSKDSKEKN KMEILYILVP SVAIPLAIAL LFFFICVCRN NQKSSSAPVQ RQPKHVRGQN VEMSMLNAYK PKSKAKELPL SAVRFMEELG ECAFGKIYKG HLYLPGMDHA QLVAIKTLKD YNNPQQWTEF QQEASLMAEL HHPNIVCLLG AVTQEQPVCM LFEYINQGDL HEFLIMRSPH SDVGCSSDED GTVKSSLDHG DFLHIAIQIA AGMEYLSSHF FVHKDLAARN ILIGEQLHVK ISDLGLSREI YSADYYRVQS KSLLPIRWMP PEAIMYGKFS SDSDIWSFGV VLWEIFSFGL QPYYGFSNQE VIEMVRKRQL LPCSEDCPPR MYSLMTECWN EIPSRRPRFK DIHVRLRSWE GLSSHTSSTT PSGGNATTQT TSLSASPVSN LSNPRYPNYM FPSQGITPQG QIAGFIGPPI PQNQRFIPIN GYPIPPGYAA FPAAHYQPTG PPRVIQHCPP PKSRSPSSAS GSTSTGHVTS LPSSGSNQEA NIPLLPHMSI PNHPGGMGIT VFGNKSQKPY KIDSKQASLL GDANIHGHTE SMISAEL // ID S39A6_HUMAN Reviewed; 755 AA. AC Q13433; B4DR49; B4E224; Q8IXR3; Q96HP5; DT 05-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 23-MAR-2010, sequence version 3. DT 28-JAN-2026, entry version 187. DE RecName: Full=Zinc transporter ZIP6 {ECO:0000305}; DE AltName: Full=Estrogen-regulated protein LIV-1; DE AltName: Full=Solute carrier family 39 member 6; DE AltName: Full=Zrt- and Irt-like protein 6; DE Short=ZIP-6; DE Flags: Precursor; GN Name=SLC39A6 {ECO:0000312|HGNC:HGNC:18607}; Synonyms=LIV1, ZIP6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-119. RA Green C., Morgan H.E.; RL Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASP-119. RC TISSUE=Teratocarcinoma, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16177791; DOI=10.1038/nature03983; RA Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D., RA Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., RA Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J., RA Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L., RA Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., RA Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., RA Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K., RA Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R., RA Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.; RT "DNA sequence and analysis of human chromosome 18."; RL Nature 437:551-555(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-119. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 382-755 (ISOFORM 1). RC TISSUE=Eye, and Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 29-43. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [7] RP INDUCTION. RX PubMed=2903103; DOI=10.1016/0303-7207(88)90105-0; RA Manning D.L., Daly R.J., Lord P.G., Kelly K.F., Green C.D.; RT "Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 RT human breast cancer cell line."; RL Mol. Cell. Endocrinol. 59:205-212(1988). RN [8] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, TOPOLOGY, TISSUE RP SPECIFICITY, AND GLYCOSYLATION. RX PubMed=12839489; DOI=10.1042/bj20030478; RA Taylor K.M., Morgan H.E., Johnson A., Hadley L.J., Nicholson R.I.; RT "Structure-function analysis of LIV-1, the breast cancer-associated protein RT that belongs to a new subfamily of zinc transporters."; RL Biochem. J. 375:51-59(2003). RN [9] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=18272141; DOI=10.1016/j.brainres.2008.01.015; RA Chowanadisai W., Loennerdal B., Kelleher S.L.; RT "Zip6 (LIV-1) regulates zinc uptake in neuroblastoma cells under resting RT but not depolarizing conditions."; RL Brain Res. 1199:10-19(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67 AND ASN-241. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [13] RP FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=21422171; DOI=10.1084/jem.20100031; RA Yu M., Lee W.W., Tomar D., Pryshchep S., Czesnikiewicz-Guzik M., RA Lamar D.L., Li G., Singh K., Tian L., Weyand C.M., Goronzy J.J.; RT "Regulation of T cell receptor signaling by activation-induced zinc RT influx."; RL J. Exp. Med. 208:775-785(2011). RN [14] RP FUNCTION, PROTEOLYTIC CLEAVAGE, GLYCOSYLATION, AND INDUCTION. RX PubMed=23919497; DOI=10.1042/bj20130483; RA Hogstrand C., Kille P., Ackland M.L., Hiscox S., Taylor K.M.; RT "A mechanism for epithelial-mesenchymal transition and anoikis resistance RT in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal RT transducer and activator of transcription 3)."; RL Biochem. J. 455:229-237(2013). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-471 AND SER-478, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=25143461; DOI=10.1093/molehr/gau066; RA Kong B.Y., Duncan F.E., Que E.L., Kim A.M., O'Halloran T.V., Woodruff T.K.; RT "Maternally-derived zinc transporters ZIP6 and ZIP10 drive the mammalian RT oocyte-to-egg transition."; RL Mol. Hum. Reprod. 20:1077-1089(2014). RN [17] RP INTERACTION WITH SLC39A10, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=27274087; DOI=10.1042/bcj20160388; RA Taylor K.M., Muraina I.A., Brethour D., Schmitt-Ulms G., Nimmanon T., RA Ziliotto S., Kille P., Hogstrand C.; RT "Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates RT embryonic development and cell migration."; RL Biochem. J. 473:2531-2544(2016). RN [18] RP INDUCTION, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=30552163; DOI=10.4049/jimmunol.1800689; RA Colomar-Carando N., Meseguer A., Company-Garrido I., Jutz S., RA Herrera-Fernandez V., Olvera A., Kiefer K., Brander C., Steinberger P., RA Vicente R.; RT "Zip6 Transporter Is an Essential Component of the Lymphocyte Activation RT Machinery."; RL J. Immunol. 202:441-450(2019). RN [19] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH SLC39A10 AND STAT3. RX PubMed=32797246; DOI=10.1007/s00018-020-03616-6; RA Nimmanon T., Ziliotto S., Ogle O., Burt A., Gee J.M.W., Andrews G.K., RA Kille P., Hogstrand C., Maret W., Taylor K.M.; RT "The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of RT mitosis."; RL Cell. Mol. Life Sci. 78:1781-1798(2021). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=34394081; DOI=10.3389/fimmu.2021.687367; RA Kim B., Kim H.Y., Lee W.W.; RT "Zap70 Regulates TCR-Mediated Zip6 Activation at the Immunological RT Synapse."; RL Front. Immunol. 12:687367-687367(2021). CC -!- FUNCTION: Zinc-influx transporter which plays a role in zinc CC homeostasis and in the induction of epithelial-to-mesenchymal CC transition (EMT) (PubMed:12839489, PubMed:18272141, PubMed:21422171, CC PubMed:23919497, PubMed:27274087, PubMed:34394081). When associated CC with SLC39A10, the heterodimer formed by SLC39A10 and SLC39A6 mediates CC cellular zinc uptake to trigger cells to undergo epithelial- to- CC mesenchymal transition (EMT) (PubMed:27274087). The SLC39A10-SLC39A6 CC heterodimer also controls NCAM1 phosphorylation and its integration CC into focal adhesion complexes during EMT (By similarity). Zinc influx CC inactivates GSK3B, enabling unphosphorylated SNAI1 in the nucleus to CC down-regulate adherence genes such as CDH1, causing loss of cell CC adherence (PubMed:23919497). In addition, the SLC39A10-SLC39A6 CC heterodimer plays an essentiel role in initiating mitosis by importing CC zinc into cells to initiate a pathway resulting in the onset of mitosis CC (PubMed:32797246). Participates in the T-cell receptor signaling CC regulation by mediating cellular zinc uptake into activated lymphocytes CC (PubMed:21422171, PubMed:30552163, PubMed:34394081). Regulates the zinc CC influx necessary for proper meiotic progression to metaphase II (MII) CC that allows the oocyte-to-egg transition (PubMed:25143461). CC {ECO:0000250|UniProtKB:Q8C145, ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:21422171, CC ECO:0000269|PubMed:23919497, ECO:0000269|PubMed:25143461, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:30552163, CC ECO:0000269|PubMed:32797246, ECO:0000269|PubMed:34394081}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:21422171, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:30552163, CC ECO:0000269|PubMed:34394081}; CC -!- SUBUNIT: Interacts with SLC39A10; which triggers cells to undergo EMT CC and mitosis (PubMed:27274087). Found in a complex with SLC39A6, CC SLC39A10 and with the 'Ser-727' phosphorylated form of STAT3 throughout CC mitosis (PubMed:32797246). Found in a complex with SLC39A6, SLC39A10 CC and with NCAM1; this complex controls NCAM1 phosphorylation and CC integration into focal adhesion complexes during epithelial-to- CC mesenchymal transition (EMT) (By similarity). Found in a complex with CC SLC39A6, SLC39A10 and with GSK3B that controls NCAM1 phosphorylation CC (By similarity). {ECO:0000250|UniProtKB:Q8C145, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:32797246}. CC -!- INTERACTION: CC Q13433-2; Q92843: BCL2L2; NbExp=3; IntAct=EBI-12956703, EBI-707714; CC Q13433-2; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-12956703, EBI-10192441; CC Q13433-2; Q3KNW5: SLC10A6; NbExp=3; IntAct=EBI-12956703, EBI-18159983; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18272141}; CC Multi-pass membrane protein {ECO:0000255}. Cell projection, CC lamellipodium membrane {ECO:0000269|PubMed:12839489}; Multi-pass CC membrane protein {ECO:0000269|PubMed:12839489}. Membrane raft CC {ECO:0000269|PubMed:34394081}; Multi-pass membrane protein CC {ECO:0000255}. Apical cell membrane {ECO:0000250|UniProtKB:Q4V887}. CC Note=Localizes to lipid rafts in T cells and is recruited into the CC immunological synapse in response to TCR stimulation (PubMed:34394081). CC In the choroid plexus is limited to the apical membrane in epithelial CC cells (By similarity). {ECO:0000250|UniProtKB:Q4V887, CC ECO:0000269|PubMed:34394081}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13433-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13433-2; Sequence=VSP_014309, VSP_014310, VSP_014311; CC -!- TISSUE SPECIFICITY: Highly expressed in the breast, prostate, placenta, CC kidney, pituitary and corpus callosum (PubMed:12839489). Weakly CC expressed in heart and intestine. Also highly expressed in cells CC derived from an adenocarcinoma of the cervix and lung carcinoma CC (PubMed:12839489). {ECO:0000269|PubMed:12839489}. CC -!- INDUCTION: Up-regulated by estrogen in breast cancer cells lines CC (PubMed:23919497, PubMed:2903103). Decreased protein level in response CC to zinc treatment (PubMed:18272141). Increased upon T cell activation CC (PubMed:30552163). Induced by STAT3 (PubMed:23919497). CC {ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:23919497, CC ECO:0000269|PubMed:2903103, ECO:0000269|PubMed:30552163}. CC -!- PTM: Cleaved on the N-terminus before locating to the plasma membrane. CC {ECO:0000269|PubMed:23919497}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:23919497}. CC -!- PTM: Phosphorylated by ZAP70 in response to TCR stimulation leading to CC its activation. {ECO:0000269|PubMed:34394081}. CC -!- SIMILARITY: Belongs to the ZIP transporter (TC 2.A.5) family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG61161.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44189/SLC39A6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U41060; AAA96258.2; -; mRNA. DR EMBL; AK299102; BAG61161.1; ALT_INIT; mRNA. DR EMBL; AK304079; BAG64986.1; -; mRNA. DR EMBL; AC091060; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471088; EAX01372.1; -; Genomic_DNA. DR EMBL; BC008317; AAH08317.2; -; mRNA. DR EMBL; BC039498; AAH39498.1; -; mRNA. DR CCDS; CCDS42428.1; -. [Q13433-1] DR CCDS; CCDS45854.1; -. [Q13433-2] DR PIR; G02273; G02273. DR RefSeq; NP_001092876.1; NM_001099406.2. [Q13433-2] DR AlphaFoldDB; Q13433; -. DR BioGRID; 117332; 184. DR FunCoup; Q13433; 1178. DR IntAct; Q13433; 82. DR MINT; Q13433; -. DR STRING; 9606.ENSP00000269187; -. DR ChEMBL; CHEMBL4523581; -. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MEROPS; X40.001; -. DR TCDB; 2.A.5.4.13; the zinc (zn(2+))-iron (fe(2+)) permease (zip) family. DR GlyConnect; 1908; 8 N-Linked glycans (3 sites). DR GlyCosmos; Q13433; 7 sites, 10 glycans. DR GlyGen; Q13433; 22 sites, 15 N-linked glycans (4 sites), 4 O-linked glycans (15 sites). DR iPTMnet; Q13433; -. DR PhosphoSitePlus; Q13433; -. DR SwissPalm; Q13433; -. DR BioMuta; SLC39A6; -. DR DMDM; 292495066; -. DR jPOST; Q13433; -. DR MassIVE; Q13433; -. DR PaxDb; 9606-ENSP00000269187; -. DR PeptideAtlas; Q13433; -. DR ProteomicsDB; 59428; -. [Q13433-1] DR ProteomicsDB; 59429; -. [Q13433-2] DR Pumba; Q13433; -. DR ABCD; Q13433; 1 sequenced antibody. DR Antibodypedia; 5245; 295 antibodies from 38 providers. DR DNASU; 25800; -. DR Ensembl; ENST00000269187.10; ENSP00000269187.4; ENSG00000141424.13. [Q13433-1] DR Ensembl; ENST00000440549.6; ENSP00000401139.1; ENSG00000141424.13. [Q13433-2] DR Ensembl; ENST00000590986.5; ENSP00000465915.1; ENSG00000141424.13. [Q13433-1] DR GeneID; 25800; -. DR KEGG; hsa:25800; -. DR MANE-Select; ENST00000269187.10; ENSP00000269187.4; NM_012319.4; NP_036451.4. DR UCSC; uc002kzj.3; human. [Q13433-1] DR AGR; HGNC:18607; -. DR ClinPGx; PA134905551; -. DR CTD; 25800; -. DR DisGeNET; 25800; -. DR GeneCards; SLC39A6; -. DR HGNC; HGNC:18607; SLC39A6. DR HPA; ENSG00000141424; Low tissue specificity. DR MIM; 608731; gene. DR OpenTargets; ENSG00000141424; -. DR VEuPathDB; HostDB:ENSG00000141424; -. DR eggNOG; KOG2693; Eukaryota. DR GeneTree; ENSGT00940000156387; -. DR HOGENOM; CLU_015114_13_2_1; -. DR InParanoid; Q13433; -. DR OMA; LLMSHGM; -. DR OrthoDB; 200954at2759; -. DR PAN-GO; Q13433; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q13433; -. DR PathwayCommons; Q13433; -. DR Reactome; R-HSA-442380; Zinc influx into cells by the SLC39 gene family. DR SignaLink; Q13433; -. DR Agora; ENSG00000141424; -. DR BioGRID-ORCS; 25800; 15 hits in 1165 CRISPR screens. DR ChiTaRS; SLC39A6; human. DR GeneWiki; SLC39A6; -. DR GenomeRNAi; 25800; -. DR Pharos; Q13433; Tbio. DR PRO; PR:Q13433; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q13433; protein. DR Bgee; ENSG00000141424; Expressed in secondary oocyte and 210 other cell types or tissues. DR ExpressionAtlas; Q13433; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl. DR GO; GO:0031258; C:lamellipodium membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0140410; F:monoatomic cation:bicarbonate symporter activity; IBA:GO_Central. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB. DR GO; GO:0030003; P:intracellular monoatomic cation homeostasis; IBA:GO_Central. DR GO; GO:0006882; P:intracellular zinc ion homeostasis; IDA:BHF-UCL. DR GO; GO:0046649; P:lymphocyte activation; IMP:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0071578; P:zinc ion import across plasma membrane; IDA:UniProtKB. DR GO; GO:0071577; P:zinc ion transmembrane transport; IMP:UniProtKB. DR InterPro; IPR003689; ZIP. DR InterPro; IPR050799; ZIP_Transporter. DR PANTHER; PTHR12191; SOLUTE CARRIER FAMILY 39; 1. DR PANTHER; PTHR12191:SF22; ZINC TRANSPORTER ZIP6; 1. DR Pfam; PF02535; Zip; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cell projection; Coiled coil; KW Direct protein sequencing; Glycoprotein; Ion transport; Membrane; KW Phosphoprotein; Proteomics identification; Reference proteome; Signal; KW Transmembrane; Transmembrane helix; Transport; Zinc; Zinc transport. FT SIGNAL 1..28 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 29..755 FT /note="Zinc transporter ZIP6" FT /id="PRO_0000041650" FT TOPO_DOM 29..325 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:12839489" FT TRANSMEM 326..346 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 347..355 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 356..376 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 377..423 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 424..444 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 445..657 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 658..678 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 679..686 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 687..707 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 708..724 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 725..745 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 746..755 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:12839489" FT REGION 95..186 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 202..246 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 464..480 FT /evidence="ECO:0000255" FT COMPBIAS 95..128 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 129..144 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 145..159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 167..179 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 219..234 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 266 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 684 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..275 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014309" FT VAR_SEQ 707..708 FT /note="PE -> SF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014310" FT VAR_SEQ 709..755 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014311" FT VARIANT 119 FT /note="E -> D (in dbSNP:rs1789528)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.1, FT ECO:0000269|Ref.4" FT /id="VAR_059964" FT CONFLICT 127..132 FT /note="Missing (in Ref. 1; AAA96258)" FT /evidence="ECO:0000305" SQ SEQUENCE 755 AA; 85047 MW; 8BC1D02CA116DD25 CRC64; MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSEH EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC HSHFHDTLGQ SDDLIHHHHD YHHILHHHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF // ID STK36_HUMAN Reviewed; 1315 AA. AC Q9NRP7; B7WPM3; Q8TC32; Q9H9N9; Q9UF35; Q9ULE2; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Serine/threonine-protein kinase 36; DE EC=2.7.11.1; DE AltName: Full=Fused homolog; GN Name=STK36 {ECO:0000312|EMBL:AAH26158.1}; GN Synonyms=KIAA1278 {ECO:0000312|EMBL:BAA86592.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAF97028.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH GLI1; RP GLI2; GLI3 AND SUFU, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-33. RX PubMed=10806483; DOI=10.1038/35010610; RA Murone M., Luoh S.-L., Stone D., Li W., Gurney A., Armanini M., Grey C., RA Rosenthal A., de Sauvage F.J.; RT "Gli regulation by the opposing activities of fused and suppressor of RT fused."; RL Nat. Cell Biol. 2:310-312(2000). RN [2] {ECO:0000305, ECO:0000312|EMBL:BAA86592.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain {ECO:0000312|EMBL:BAA86592.1}; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] {ECO:0000305, ECO:0000312|EMBL:AAH26158.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ASN-463 RP AND THR-767. RC TISSUE=Testis {ECO:0000312|EMBL:AAH26158.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 823-1315 (ISOFORM 1). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] {ECO:0000305, ECO:0000312|EMBL:BAB14184.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 839-1315 (ISOFORM 1), AND VARIANT RP ASP-1003. RC TISSUE=Teratocarcinoma {ECO:0000312|EMBL:BAB14184.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] MET-90; TRP-240; ARG-295; ASN-329; VAL-462; RP SER-476; TRP-477; GLN-583; CYS-660; PRO-672; TYR-767; ALA-816; GLN-839; RP VAL-840; ASP-1003; CYS-1111; GLN-1112; LYS-1138; SER-1185 AND PRO-1313. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [8] RP INVOLVEMENT IN CILD46, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=28543983; DOI=10.1002/humu.23261; RA Edelbusch C., Cindric S., Dougherty G.W., Loges N.T., Olbrich H., RA Rivlin J., Wallmeier J., Pennekamp P., Amirav I., Omran H.; RT "Mutation of serine/threonine protein kinase 36 (STK36) causes primary RT ciliary dyskinesia with a central pair defect."; RL Hum. Mutat. 38:964-969(2017). CC -!- FUNCTION: Serine/threonine protein kinase which plays an important role CC in the sonic hedgehog (Shh) pathway by regulating the activity of GLI CC transcription factors (PubMed:10806483). Controls the activity of the CC transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect CC of SUFU and promoting their nuclear localization (PubMed:10806483). CC GLI2 requires an additional function of STK36 to become CC transcriptionally active, but the enzyme does not need to possess an CC active kinase catalytic site for this to occur (PubMed:10806483). CC Required for postnatal development, possibly by regulating the CC homeostasis of cerebral spinal fluid or ciliary function. Essential for CC construction of the central pair apparatus of motile cilia. CC {ECO:0000269|PubMed:10806483, ECO:0000269|PubMed:28543983}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:P23647}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:P23647}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305}; CC -!- SUBUNIT: Interacts with GLI1, GLI2 and GLI3 (PubMed:10806483). CC Interacts with SPAG16 and KIF27. {ECO:0000250|UniProtKB:Q69ZM6, CC ECO:0000269|PubMed:10806483}. CC -!- INTERACTION: CC Q9NRP7; P54252: ATXN3; NbExp=3; IntAct=EBI-863797, EBI-946046; CC Q9NRP7; G5E9A7: DMWD; NbExp=3; IntAct=EBI-863797, EBI-10976677; CC Q9NRP7; P14136: GFAP; NbExp=3; IntAct=EBI-863797, EBI-744302; CC Q9NRP7; O14901: KLF11; NbExp=3; IntAct=EBI-863797, EBI-948266; CC Q9NRP7; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-863797, EBI-5235340; CC Q9NRP7; Q9UMX1: SUFU; NbExp=3; IntAct=EBI-863797, EBI-740595; CC Q9NRP7; Q96C45: ULK4; NbExp=4; IntAct=EBI-863797, EBI-3922541; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10806483}. Nucleus CC {ECO:0000269|PubMed:10806483}. Cytoplasm, cytoskeleton, cilium axoneme CC {ECO:0000269|PubMed:28543983}. Note=Low levels also present in the CC nucleus. {ECO:0000269|PubMed:10806483}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:10806483, ECO:0000269|PubMed:14702039, CC ECO:0000269|PubMed:15489334}; CC IsoId=Q9NRP7-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:10574462}; CC IsoId=Q9NRP7-2; Sequence=VSP_051983; CC -!- TISSUE SPECIFICITY: Expressed at low levels in most fetal tissues, CC adult ovaries and at high levels in adult testis, where it is localized CC in germ cells (PubMed:10806483). Expressed in respiratory epithelial CC cells of the lung (PubMed:28543983). {ECO:0000269|PubMed:10806483, CC ECO:0000269|PubMed:28543983}. CC -!- DISEASE: Ciliary dyskinesia, primary, 46 (CILD46) [MIM:619436]: A form CC of primary ciliary dyskinesia, a disorder characterized by CC abnormalities of motile cilia. Respiratory infections leading to CC chronic inflammation and bronchiectasis are recurrent, due to defects CC in the respiratory cilia. CILD46 is an autosomal recessive form. No CC situs abnormalities have been observed. {ECO:0000269|PubMed:28543983}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA86592.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB14184.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF200815; AAF97028.1; -; mRNA. DR EMBL; AB033104; BAA86592.1; ALT_INIT; mRNA. DR EMBL; AC009974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC026158; AAH26158.1; -; mRNA. DR EMBL; AL133630; CAB63754.1; -; mRNA. DR EMBL; AK022692; BAB14184.1; ALT_FRAME; mRNA. DR CCDS; CCDS2421.1; -. [Q9NRP7-1] DR CCDS; CCDS58750.1; -. [Q9NRP7-2] DR PIR; T43465; T43465. DR RefSeq; NP_001230242.1; NM_001243313.2. [Q9NRP7-2] DR RefSeq; NP_001356352.1; NM_001369423.1. [Q9NRP7-1] DR RefSeq; NP_056505.2; NM_015690.5. [Q9NRP7-1] DR AlphaFoldDB; Q9NRP7; -. DR SMR; Q9NRP7; -. DR BioGRID; 118032; 44. DR FunCoup; Q9NRP7; 1539. DR IntAct; Q9NRP7; 40. DR STRING; 9606.ENSP00000295709; -. DR BindingDB; Q9NRP7; -. DR ChEMBL; CHEMBL4312; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9NRP7; -. DR iPTMnet; Q9NRP7; -. DR PhosphoSitePlus; Q9NRP7; -. DR BioMuta; STK36; -. DR DMDM; 90101761; -. DR jPOST; Q9NRP7; -. DR MassIVE; Q9NRP7; -. DR PaxDb; 9606-ENSP00000295709; -. DR PeptideAtlas; Q9NRP7; -. DR ProteomicsDB; 82401; -. [Q9NRP7-1] DR ProteomicsDB; 82402; -. [Q9NRP7-2] DR Antibodypedia; 34284; 179 antibodies from 29 providers. DR DNASU; 27148; -. DR Ensembl; ENST00000295709.8; ENSP00000295709.3; ENSG00000163482.13. [Q9NRP7-1] DR Ensembl; ENST00000392105.7; ENSP00000375954.3; ENSG00000163482.13. [Q9NRP7-2] DR Ensembl; ENST00000440309.5; ENSP00000394095.1; ENSG00000163482.13. [Q9NRP7-1] DR GeneID; 27148; -. DR KEGG; hsa:27148; -. DR MANE-Select; ENST00000295709.8; ENSP00000295709.3; NM_015690.5; NP_056505.2. DR UCSC; uc002viu.4; human. [Q9NRP7-1] DR AGR; HGNC:17209; -. DR ClinPGx; PA38212; -. DR CTD; 27148; -. DR DisGeNET; 27148; -. DR GeneCards; STK36; -. DR HGNC; HGNC:17209; STK36. DR HPA; ENSG00000163482; Low tissue specificity. DR MalaCards; STK36; -. DR MIM; 607652; gene. DR MIM; 619436; phenotype. DR OpenTargets; ENSG00000163482; -. DR Orphanet; 244; Primary ciliary dyskinesia. DR VEuPathDB; HostDB:ENSG00000163482; -. DR eggNOG; KOG0597; Eukaryota. DR GeneTree; ENSGT00940000158375; -. DR HOGENOM; CLU_002453_2_0_1; -. DR InParanoid; Q9NRP7; -. DR OMA; LCPSFLH; -. DR OrthoDB; 266718at2759; -. DR PAN-GO; Q9NRP7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9NRP7; -. DR PathwayCommons; Q9NRP7; -. DR SignaLink; Q9NRP7; -. DR SIGNOR; Q9NRP7; -. DR Agora; ENSG00000163482; -. DR BioGRID-ORCS; 27148; 6 hits in 1185 CRISPR screens. DR ChiTaRS; STK36; human. DR GeneWiki; STK36; -. DR GenomeRNAi; 27148; -. DR Pharos; Q9NRP7; Tbio. DR PRO; PR:Q9NRP7; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q9NRP7; protein. DR Bgee; ENSG00000163482; Expressed in right uterine tube and 146 other cell types or tissues. DR ExpressionAtlas; Q9NRP7; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005576; C:extracellular region; IEA:GOC. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; TAS:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:FlyBase. DR GO; GO:0001222; F:transcription corepressor binding; IDA:UniProtKB. DR GO; GO:0035082; P:axoneme assembly; IMP:UniProtKB. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0003351; P:epithelial cilium movement involved in extracellular fluid movement; IEA:Ensembl. DR GO; GO:0045880; P:positive regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:UniProtKB. DR GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0007224; P:smoothened signaling pathway; IMP:FlyBase. DR CDD; cd14002; STKc_STK36; 1. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000292; Serine/threonine-protein kinase 36; 1. DR FunFam; 1.25.10.10:FF:000325; Serine/threonine-protein kinase 36; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22983; PROTEIN KINASE RELATED; 1. DR PANTHER; PTHR22983:SF6; SERINE_THREONINE-PROTEIN KINASE 36; 1. DR Pfam; PF13646; HEAT_2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell projection; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; KW Developmental protein; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Primary ciliary dyskinesia; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1315 FT /note="Serine/threonine-protein kinase 36" FT /id="PRO_0000229020" FT DOMAIN 4..254 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 312..346 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 365..387 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 125 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P23647, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P23647, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT VAR_SEQ 838..858 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10574462" FT /id="VSP_051983" FT VARIANT 90 FT /note="I -> M (in dbSNP:rs55706732)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041177" FT VARIANT 240 FT /note="R -> W (in dbSNP:rs35038757)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041178" FT VARIANT 295 FT /note="K -> R (in dbSNP:rs1863703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041179" FT VARIANT 329 FT /note="D -> N (in dbSNP:rs34027859)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041180" FT VARIANT 462 FT /note="L -> V (in dbSNP:rs45586733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041181" FT VARIANT 463 FT /note="K -> N (in dbSNP:rs17856747)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_025727" FT VARIANT 476 FT /note="F -> S (in dbSNP:rs34128793)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041182" FT VARIANT 477 FT /note="R -> W (in dbSNP:rs16859180)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041183" FT VARIANT 583 FT /note="R -> Q (in dbSNP:rs1344642)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041184" FT VARIANT 638 FT /note="Q -> P (in dbSNP:rs6709303)" FT /id="VAR_057112" FT VARIANT 660 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs1244829273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041185" FT VARIANT 672 FT /note="L -> P (in dbSNP:rs35448374)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041186" FT VARIANT 767 FT /note="S -> T (in dbSNP:rs17856748)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_025728" FT VARIANT 767 FT /note="S -> Y (in an ovarian papillary serous FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041187" FT VARIANT 816 FT /note="T -> A (in dbSNP:rs34271431)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041188" FT VARIANT 839 FT /note="R -> Q (in dbSNP:rs13023540)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041189" FT VARIANT 840 FT /note="L -> V (in dbSNP:rs36099639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041190" FT VARIANT 1003 FT /note="G -> D (in dbSNP:rs1863704)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_025729" FT VARIANT 1004 FT /note="V -> I (in dbSNP:rs55633575)" FT /id="VAR_061747" FT VARIANT 1111 FT /note="Y -> C (in dbSNP:rs56278660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041191" FT VARIANT 1112 FT /note="R -> Q (in dbSNP:rs12993599)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041192" FT VARIANT 1138 FT /note="Q -> K (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041193" FT VARIANT 1185 FT /note="P -> S (in an ovarian endometrioid sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041194" FT VARIANT 1313 FT /note="H -> P" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041195" FT MUTAGEN 33 FT /note="K->R: No effect on nuclear localization of GLI1 or FT GLI2 or on GLI-mediated transcription." FT /evidence="ECO:0000269|PubMed:10806483" FT CONFLICT 229 FT /note="N -> D (in Ref. 4; AAH26158)" FT /evidence="ECO:0000305" FT CONFLICT 971..986 FT /note="Missing (in Ref. 6)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="G -> V (in Ref. 1; AAF97028)" FT /evidence="ECO:0000305" SQ SEQUENCE 1315 AA; 143995 MW; 793F4638F1871C01 CRC64; MEKYHVLEMI GEGSFGRVYK GRRKYSAQVV ALKFIPKLGR SEKELRNLQR EIEIMRGLRH PNIVHMLDSF ETDKEVVVVT DYAEGELFQI LEDDGKLPED QVQAIAAQLV SALYYLHSHR ILHRDMKPQN ILLAKGGGIK LCDFGFARAM STNTMVLTSI KGTPLYMSPE LVEERPYDHT ADLWSVGCIL YELAVGTPPF YATSIFQLVS LILKDPVRWP STISPCFKNF LQGLLTKDPR QRLSWPDLLY HPFIAGHVTI ITEPAGPDLG TPFTSRLPPE LQVLKDEQAH RLAPKGNQSR ILTQAYKRMA EEAMQKKHQN TGPALEQEDK TSKVAPGTAP LPRLGATPQE SSLLAGILAS ELKSSWAKSG TGEVPSAPRE NRTTPDCERA FPEERPEVLG QRSTDVVDLE NEEPDSDNEW QHLLETTEPV PIQLKAPLTL LCNPDFCQRI QSQLHEAGGQ ILKGILEGAS HILPAFRVLS SLLSSCSDSV ALYSFCREAG LPGLLLSLLR HSQESNSLQQ QSWYGTFLQD LMAVIQAYFA CTFNLERSQT SDSLQVFQEA ANLFLDLLGK LLAQPDDSEQ TLRRDSLMCF TVLCEAMDGN SRAISKAFYS SLLTTQQVVL DGLLHGLTVP QLPVHTPQGA PQVSQPLREQ SEDIPGAISS ALAAICTAPV GLPDCWDAKE QVCWHLANQL TEDSSQLRPS LISGLQHPIL CLHLLKVLYS CCLVSEGLCR LLGQEPLALE SLFMLIQGKV KVVDWEESTE VTLYFLSLLV FRLQNLPCGM EKLGSDVATL FTHSHVVSLV SAAACLLGQL GQQGVTFDLQ PMEWMAAATH ALSAPAEVRL TPPGSCGFYD GLLILLLQLL TEQGKASLIR DMSSSEMWTV LWHRFSMVLR LPEEASAQEG ELSLSSPPSP EPDWTLISPQ GMAALLSLAM ATFTQEPQLC LSCLSQHGSI LMSILKHLLC PSFLNQLRQA PHGSEFLPVV VLSVCQLLCF PFALDMDADL LIGVLADLRD SEVAAHLLQV CCYHLPLMQV ELPISLLTRL ALMDPTSLNQ FVNTVSASPR TIVSFLSVAL LSDQPLLTSD LLSLLAHTAR VLSPSHLSFI QELLAGSDES YRPLRSLLGH PENSVRAHTY RLLGHLLQHS MALRGALQSQ SGLLSLLLLG LGDKDPVVRC SASFAVGNAA YQAGPLGPAL AAAVPSMTQL LGDPQAGIRR NVASALGNLG PEGLGEELLQ CEVPQRLLEM ACGDPQPNVK EAALIALRSL QQEPGIHQVL VSLGASEKLS LLSLGNQSLP HSSPRPASAK HCRKLIHLLR PAHSM // ID TBK1_HUMAN Reviewed; 729 AA. AC Q9UHD2; A8K4S4; Q8IYV3; Q9NUJ5; DT 20-DEC-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 215. DE RecName: Full=Serine/threonine-protein kinase TBK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:25636800}; DE AltName: Full=NF-kappa-B-activating kinase {ECO:0000303|PubMed:10783893}; DE AltName: Full=T2K; DE AltName: Full=TANK-binding kinase 1 {ECO:0000303|PubMed:10581243}; GN Name=TBK1 {ECO:0000303|PubMed:10581243, ECO:0000312|HGNC:HGNC:11584}; GN Synonyms=NAK {ECO:0000303|PubMed:10783893}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH TANK AND TRAF2, AND RP MUTAGENESIS OF LYS-38. RC TISSUE=Spleen; RX PubMed=10581243; DOI=10.1093/emboj/18.23.6694; RA Pomerantz J.L., Baltimore D.; RT "NF-kB activation by a signaling complex containing TRAF2, TANK, and TBK1, RT a novel IKK-related kinase."; RL EMBO J. 18:6694-6704(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN PHOSPHORYLATION OF NFKBIA AND RP IKBKB, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY. RX PubMed=10783893; DOI=10.1038/35008109; RA Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S., Nakayama K., RA Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M., Nakanishi M.; RT "NAK is an IkappaB kinase-activating kinase."; RL Nature 404:778-782(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-388 AND GLN-570. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, MUTAGENESIS OF SER-172, AND PHOSPHORYLATION AT SER-172. RX PubMed=11839743; DOI=10.1074/jbc.m110474200; RA Kishore N., Huynh Q.K., Mathialagan S., Hall T., Rouw S., Creely D., RA Lange G., Caroll J., Reitz B., Donnelly A., Boddupalli H., Combs R.G., RA Kretzmer K., Tripp C.S.; RT "IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK- RT 2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2."; RL J. Biol. Chem. 277:13840-13847(2002). RN [7] RP INTERACTION WITH TIRAP AND TICAM1. RX PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304; RA Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., RA Akira S.; RT "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF) RT associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, RT and activates two distinct transcription factors, NF-kappa B and IFN- RT regulatory factor-3, in the Toll-like receptor signaling."; RL J. Immunol. 171:4304-4310(2003). RN [8] RP FUNCTION. RX PubMed=12692549; DOI=10.1038/ni921; RA Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., RA Golenbock D.T., Coyle A.J., Liao S.-M., Maniatis T.; RT "IKKepsilon and TBK1 are essential components of the IRF3 signaling RT pathway."; RL Nat. Immunol. 4:491-496(2003). RN [9] RP FUNCTION. RX PubMed=12702806; DOI=10.1126/science.1081315; RA Sharma S., tenOever B.R., Grandvaux N., Zhou G.-P., Lin R., Hiscott J.; RT "Triggering the interferon antiviral response through an IKK-related RT pathway."; RL Science 300:1148-1151(2003). RN [10] RP INTERACTION WITH AZI2. RX PubMed=14560022; DOI=10.1128/mcb.23.21.7780-7793.2003; RA Fujita F., Taniguchi Y., Kato T., Narita Y., Furuya A., Ogawa T., RA Sakurai H., Joh T., Itoh M., Delhase M., Karin M., Nakanishi M.; RT "Identification of NAP1, a regulatory subunit of IkappaB kinase-related RT kinases that potentiates NF-kappaB signaling."; RL Mol. Cell. Biol. 23:7780-7793(2003). RN [11] RP FUNCTION IN PHOSPHORYLATION OF IRF3, AND CATALYTIC ACTIVITY. RX PubMed=14703513; DOI=10.1074/jbc.m310616200; RA Mori M., Yoneyama M., Ito T., Takahashi K., Inagaki F., Fujita T.; RT "Identification of Ser-386 of interferon regulatory factor 3 as critical RT target for inducible phosphorylation that determines activation."; RL J. Biol. Chem. 279:9698-9702(2004). RN [12] RP INTERACTION WITH TICAM1. RX PubMed=14739303; DOI=10.1074/jbc.m311629200; RA Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.; RT "Mechanisms of the TRIF-induced interferon-stimulated response element and RT NF-kappaB activation and apoptosis pathways."; RL J. Biol. Chem. 279:15652-15661(2004). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15485837; DOI=10.1074/jbc.m411037200; RA Kuai J., Wooters J., Hall J.P., Rao V.R., Nickbarg E., Li B., RA Chatterjee-Kishore M., Qiu Y., Lin L.-L.; RT "NAK is recruited to the TNFR1 complex in a TNFalpha-dependent manner and RT mediates the production of RANTES: identification of endogenous TNFR- RT interacting proteins by a proteomic approach."; RL J. Biol. Chem. 279:53266-53271(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RELA, AND CATALYTIC ACTIVITY. RX PubMed=15489227; DOI=10.1074/jbc.m409825200; RA Buss H., Dorrie A., Schmitz M.L., Hoffmann E., Resch K., Kracht M.; RT "Constitutive and interleukin-1-inducible phosphorylation of p65 RT NF-{kappa}B at serine 536 is mediated by multiple protein kinases including RT I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family RT member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and RT couples p65 to TATA-binding protein-associated factor II31-mediated RT interleukin-8 transcription."; RL J. Biol. Chem. 279:55633-55643(2004). RN [15] RP FUNCTION IN PHOSPHORYLATION OF IRF7, AND CATALYTIC ACTIVITY. RX PubMed=15367631; DOI=10.1128/jvi.78.19.10636-10649.2004; RA tenOever B.R., Sharma S., Zou W., Sun Q., Grandvaux N., Julkunen I., RA Hemmi H., Yamamoto M., Akira S., Yeh W.C., Lin R., Hiscott J.; RT "Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus RT infection and the role of viral ribonucleoprotein in the development of RT interferon antiviral immunity."; RL J. Virol. 78:10636-10649(2004). RN [16] RP INTERACTION WITH SIKE1; IRF3; TICAM1 AND RIGI. RX PubMed=16281057; DOI=10.1038/sj.emboj.7600863; RA Huang J., Liu T., Xu L.-G., Chen D., Zhai Z., Shu H.-B.; RT "SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus- RT triggered IRF-3 activation pathways."; RL EMBO J. 24:4018-4028(2005). RN [17] RP INTERACTION WITH HCV NS3 (MICROBIAL INFECTION). RX PubMed=15841462; DOI=10.1002/hep.20666; RA Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N., RA Kawabe T., Omata M.; RT "Interaction between the HCV NS3 protein and the host TBK1 protein leads to RT inhibition of cellular antiviral responses."; RL Hepatology 41:1004-1012(2005). RN [18] RP FUNCTION, AND INTERACTION WITH BORNA DISEASE VIRUS P PROTEIN. RX PubMed=16155125; DOI=10.1073/pnas.0502883102; RA Unterstab G., Ludwig S., Anton A., Planz O., Dauber B., Krappmann D., RA Heins G., Ehrhardt C., Wolff T.; RT "Viral targeting of the interferon-beta-inducing Traf family member- RT associated NF-kappa-B activator (TANK)-binding kinase-1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13640-13645(2005). RN [19] RP INTERACTION WITH EXOC2, AND SUBCELLULAR LOCATION. RX PubMed=17018283; DOI=10.1016/j.cell.2006.08.034; RA Chien Y., Kim S., Bumeister R., Loo Y.M., Kwon S.W., Johnson C.L., RA Balakireva M.G., Romeo Y., Kopelovich L., Gale M. Jr., Yeaman C., RA Camonis J.H., Zhao Y., White M.A.; RT "RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples RT innate immune signaling to tumor cell survival."; RL Cell 127:157-170(2006). RN [20] RP DOMAIN. RX PubMed=17599067; DOI=10.1038/sj.emboj.7601773; RA Ikeda F., Hecker C.M., Rozenknop A., Nordmeier R.D., Rogov V., Hofmann K., RA Akira S., Dotsch V., Dikic I.; RT "Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in RT regulation of IFN-inducible genes."; RL EMBO J. 26:3451-3462(2007). RN [21] RP FUNCTION IN PHOSPHORYLATION OF DDX3X, AND CATALYTIC ACTIVITY. RX PubMed=18583960; DOI=10.1038/emboj.2008.126; RA Soulat D., Burckstummer T., Westermayer S., Goncalves A., Bauch A., RA Stefanovic A., Hantschel O., Bennett K.L., Decker T., Superti-Furga G.; RT "The DEAD-box helicase DDX3X is a critical component of the TANK-binding RT kinase 1-dependent innate immune response."; RL EMBO J. 27:2135-2146(2008). RN [22] RP INTERACTION WITH CYLD. RX PubMed=18636086; DOI=10.1038/embor.2008.136; RA Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A., Cardenas W.B., RA Yount J.S., Moran T.M., Basler C.F., Komuro A., Horvath C.M., Xavier R., RA Ting A.T.; RT "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated RT antiviral response."; RL EMBO Rep. 9:930-936(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP INTERACTION WITH SRC. RX PubMed=19419966; DOI=10.1074/jbc.m808233200; RA Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A., Anthonsen M.W.; RT "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)- RT elicited antiviral signaling."; RL J. Biol. Chem. 284:19122-19131(2009). RN [25] RP INTERACTION WITH EBOLAVIRUS PROTEIN VP35, AND AUTOPHOSPHORYLATION. RX PubMed=19153231; DOI=10.1128/jvi.01875-08; RA Prins K.C., Cardenas W.B., Basler C.F.; RT "Ebola virus protein VP35 impairs the function of interferon regulatory RT factor-activating kinases IKKepsilon and TBK-1."; RL J. Virol. 83:3069-3077(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [27] RP UBIQUITINATION BY NRDP1. RX PubMed=19483718; DOI=10.1038/ni.1742; RA Wang C., Chen T., Zhang J., Yang M., Li N., Xu X., Cao X.; RT "The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated RT production of type I interferon."; RL Nat. Immunol. 10:744-752(2009). RN [28] RP INTERACTION WITH STING1. RX PubMed=19416887; DOI=10.1073/pnas.0900818106; RA Li Y., Li C., Xue P., Zhong B., Mao A.P., Ran Y., Chen H., Wang Y.Y., RA Yang F., Shu H.B.; RT "ISG56 is a negative-feedback regulator of virus-triggered signaling and RT cellular antiviral response."; RL Proc. Natl. Acad. Sci. U.S.A. 106:7945-7950(2009). RN [29] RP INTERACTION WITH HSP90AA1. RX PubMed=20628368; DOI=10.1038/cr.2010.103; RA Liu X.Y., Wei B., Shi H.X., Shan Y.F., Wang C.; RT "Tom70 mediates activation of interferon regulatory factor 3 on RT mitochondria."; RL Cell Res. 20:994-1011(2010). RN [30] RP AUTOPHOSPHORYLATION, SUBUNIT, AND INTERACTION WITH GSK3B. RX PubMed=21145761; DOI=10.1016/j.immuni.2010.11.021; RA Lei C.Q., Zhong B., Zhang Y., Zhang J., Wang S., Shu H.B.; RT "Glycogen synthase kinase 3beta regulates IRF3 transcription factor- RT mediated antiviral response via activation of the kinase TBK1."; RL Immunity 33:878-889(2010). RN [31] RP INTERACTION WITH DDX3X. RX PubMed=20375222; DOI=10.1099/vir.0.020552-0; RA Yu S., Chen J., Wu M., Chen H., Kato N., Yuan Z.; RT "Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3- RT mediated beta interferon induction in human hepatocytes through RT interference with interferon regulatory factor 3 activation and dampening RT of the interaction between TBK1/IKKepsilon and DDX3."; RL J. Gen. Virol. 91:2080-2090(2010). RN [32] RP INTERACTION WITH OPTN AND TRAF3. RX PubMed=20174559; DOI=10.1371/journal.ppat.1000778; RA Mankouri J., Fragkoudis R., Richards K.H., Wetherill L.F., Harris M., RA Kohl A., Elliott R.M., Macdonald A.; RT "Optineurin negatively regulates the induction of IFNbeta in response to RT RNA virus infection."; RL PLoS Pathog. 6:E1000778-E1000778(2010). RN [33] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [34] RP INVOLVEMENT IN GLC1P, TISSUE SPECIFICITY, AND VARIANTS PHE-151; ILE-306 AND RP ALA-464. RX PubMed=21447600; DOI=10.1093/hmg/ddr123; RA Fingert J.H., Robin A.L., Stone J.L., Roos B.R., Davis L.K., Scheetz T.E., RA Bennett S.R., Wassink T.H., Kwon Y.H., Alward W.L., Mullins R.F., RA Sheffield V.C., Stone E.M.; RT "Copy number variations on chromosome 12q14 in patients with normal tension RT glaucoma."; RL Hum. Mol. Genet. 20:2482-2494(2011). RN [35] RP UBIQUITINATION BY MIB1. RX PubMed=21903422; DOI=10.1016/j.immuni.2011.06.014; RA Li S., Wang L., Berman M., Kong Y.Y., Dorf M.E.; RT "Mapping a dynamic innate immunity protein interaction network regulating RT type I interferon production."; RL Immunity 35:426-440(2011). RN [36] RP SUBCELLULAR LOCATION, AND INTERACTION WITH IFIT3 AND MAVS. RX PubMed=21813773; DOI=10.4049/jimmunol.1100963; RA Liu X.Y., Chen W., Wei B., Shan Y.F., Wang C.; RT "IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging RT MAVS and TBK1."; RL J. Immunol. 187:2559-2568(2011). RN [37] RP FUNCTION IN PHOSPHORYLATION OF VPS37C, AND CATALYTIC ACTIVITY. RX PubMed=21270402; DOI=10.4049/jimmunol.1000262; RA Da Q., Yang X., Xu Y., Gao G., Cheng G., Tang H.; RT "TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through RT targeting endosomal sorting complex required for transport-I."; RL J. Immunol. 186:3023-3030(2011). RN [38] RP FUNCTION, INTERACTION WITH AZI2; TANK AND TBKBP1, AND MUTAGENESIS OF RP ASP-135; MET-690; LEU-693; LYS-694; LEU-704; ASN-708 AND LEU-711. RX PubMed=21931631; DOI=10.1371/journal.pone.0023971; RA Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W., RA Karayel E., Sugar C., Stukalov A., Berg T., Kralovics R., Planyavsky M., RA Bennett K.L., Colinge J., Superti-Furga G.; RT "Functional dissection of the TBK1 molecular network."; RL PLoS ONE 6:E23971-E23971(2011). RN [39] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [40] RP FUNCTION IN PHOSPHORYLATION OF OPTN, AND CATALYTIC ACTIVITY. RX PubMed=21617041; DOI=10.1126/science.1205405; RA Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R., RA Richter B., Korac J., Waidmann O., Choudhary C., Dotsch V., Bumann D., RA Dikic I.; RT "Phosphorylation of the autophagy receptor optineurin restricts Salmonella RT growth."; RL Science 333:228-233(2011). RN [41] RP REVIEW ON FUNCTION, AND DOMAIN. RX PubMed=21042276; DOI=10.1038/onc.2010.493; RA Shen R.R., Hahn W.C.; RT "Emerging roles for the non-canonical IKKs in cancer."; RL Oncogene 30:631-641(2011). RN [42] RP FUNCTION, AND PHOSPHORYLATION BY IKBKB/IKKB. RX PubMed=21138416; DOI=10.1042/bj20101701; RA Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B., RA Hough J., McIver E.G., Cohen P.; RT "Novel cross-talk within the IKK family controls innate immunity."; RL Biochem. J. 434:93-104(2011). RN [43] RP INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP34.5 (MICROBIAL INFECTION). RX PubMed=19010780; DOI=10.1074/jbc.m805905200; RA Verpooten D., Ma Y., Hou S., Yan Z., He B.; RT "Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 RT protein of herpes simplex virus 1."; RL J. Biol. Chem. 284:1097-1105(2009). RN [44] RP DEPHOSPHORYLATION AT SER-172. RX PubMed=22750291; DOI=10.1016/j.cellsig.2012.06.017; RA Zhao Y., Liang L., Fan Y., Sun S., An L., Shi Z., Cheng J., Jia W., Sun W., RA Mori-Akiyama Y., Zhang H., Fu S., Yang J.; RT "PPM1B negatively regulates antiviral response via dephosphorylating RT TBK1."; RL Cell. Signal. 24:2197-2204(2012). RN [45] RP INVOLVEMENT IN GLC1P. RX PubMed=22306015; DOI=10.1016/j.exer.2011.12.021; RA Kawase K., Allingham R.R., Meguro A., Mizuki N., Roos B., RA Solivan-Timpe F.M., Robin A.L., Ritch R., Fingert J.H.; RT "Confirmation of TBK1 duplication in normal tension glaucoma."; RL Exp. Eye Res. 96:178-180(2012). RN [46] RP INVOLVEMENT IN IIAE8, VARIANTS IIAE8 ALA-50 AND ALA-159, CHARACTERIZATION RP OF VARIANTS IIAE8 ALA-50 AND ALA-159, MUTAGENESIS OF LYS-38, RP PHOSPHORYLATION AT SER-172, AND FUNCTION. RX PubMed=22851595; DOI=10.1084/jem.20111316; RA Herman M., Ciancanelli M., Ou Y.H., Lorenzo L., Klaudel-Dreszler M., RA Pauwels E., Sancho-Shimizu V., Perez de Diego R., Abhyankar A., RA Israelsson E., Guo Y., Cardon A., Rozenberg F., Lebon P., Tardieu M., RA Heropolitanska-Pliszka E., Chaussabel D., White M.A., Abel L., Zhang S.Y., RA Casanova J.L.; RT "Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes RT simplex encephalitis of childhood."; RL J. Exp. Med. 209:1567-1582(2012). RN [47] RP UBIQUITINATION BY TRAIP. RX PubMed=22945920; DOI=10.1084/jem.20120024; RA Zhang M., Wang L., Zhao X., Zhao K., Meng H., Zhao W., Gao C.; RT "TRAF-interacting protein (TRIP) negatively regulates IFN-beta production RT and antiviral response by promoting proteasomal degradation of TANK-binding RT kinase 1."; RL J. Exp. Med. 209:1703-1711(2012). RN [48] RP UBIQUITINATION AT LYS-670 BY DTX4. RX PubMed=22388039; DOI=10.1038/ni.2239; RA Cui J., Li Y., Zhu L., Liu D., Songyang Z., Wang H.Y., Wang R.F.; RT "NLRP4 negatively regulates type I interferon signaling by targeting the RT kinase TBK1 for degradation via the ubiquitin ligase DTX4."; RL Nat. Immunol. 13:387-395(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-716, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=24478431; DOI=10.1128/jvi.03021-13; RA Santiago F.W., Covaleda L.M., Sanchez-Aparicio M.T., Silvas J.A., RA Diaz-Vizarreta A.C., Patel J.R., Popov V., Yu X.J., Garcia-Sastre A., RA Aguilar P.V.; RT "Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic RT structures correlates with the inhibition of type I interferon responses."; RL J. Virol. 88:4572-4585(2014). RN [51] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=24706939; DOI=10.1093/jmcb/mju015; RA Ning Y.J., Wang M., Deng M., Shen S., Liu W., Cao W.C., Deng F., Wang Y.Y., RA Hu Z., Wang H.; RT "Viral suppression of innate immunity via spatial isolation of RT TBK1/IKKepsilon from mitochondrial antiviral platform."; RL J. Mol. Cell Biol. 6:324-337(2014). RN [52] RP INVOLVEMENT IN FTDALS4, AND VARIANTS FTDALS4 ILE-306; GLU-401 AND LYS-696. RX PubMed=25943890; DOI=10.1007/s00401-015-1436-x; RA Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M., RA Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M., RA Nicholson A.M., DeTure M., Knopman D.S., Josephs K.A., Parisi J.E., RA Petersen R.C., Boylan K.B., Boeve B.F., Graff-Radford N.R., Veltman J.A., RA Gilissen C., Murray M.E., Dickson D.W., Rademakers R.; RT "Whole-genome sequencing reveals important role for TBK1 and OPTN mutations RT in frontotemporal lobar degeneration without motor neuron disease."; RL Acta Neuropathol. 130:77-92(2015). RN [53] RP INTERACTION WITH TICAM1. RX PubMed=25736436; DOI=10.15252/embr.201439637; RA Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., RA Liu Y.; RT "WDFY1 mediates TLR3/4 signaling by recruiting TRIF."; RL EMBO Rep. 16:447-455(2015). RN [54] RP INVOLVEMENT IN IIAE8, AND VARIANT IIAE8 VAL-207. RX PubMed=26513235; DOI=10.1038/gene.2015.46; RA Moerk N., Kofod-Olsen E., Soerensen K.B., Bach E., Oerntoft T.F., RA Oestergaard L., Paludan S.R., Christiansen M., Mogensen T.H.; RT "Mutations in the TLR3 signaling pathway and beyond in adult patients with RT herpes simplex encephalitis."; RL Genes Immun. 16:552-566(2015). RN [55] RP INVOLVEMENT IN FTDALS4, VARIANTS FTDALS4 HIS-47; CYS-105; THR-305; GLN-308; RP GLN-357; ARG-559; VAL-571; VAL-598; GLU-643 DEL AND LYS-696, AND RP CHARACTERIZATION OF VARIANTS FTDALS4 HIS-47; GLN-308; GLN-357; ARG-559 AND RP LYS-696. RX PubMed=25803835; DOI=10.1038/nn.4000; RA Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Mueller K., RA Marroquin N., Nordin F., Huebers A., Weydt P., Pinto S., Press R., RA Millecamps S., Molko N., Bernard E., Desnuelle C., Soriani M.H., Dorst J., RA Graf E., Nordstroem U., Feiler M.S., Putz S., Boeckers T.M., Meyer T., RA Winkler A.S., Winkelman J., de Carvalho M., Thal D.R., Otto M., RA Braennstroem T., Volk A.E., Kursula P., Danzer K.M., Lichtner P., Dikic I., RA Meitinger T., Ludolph A.C., Strom T.M., Andersen P.M., Weishaupt J.H.; RT "Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal RT dementia."; RL Nat. Neurosci. 18:631-636(2015). RN [56] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25636800; DOI=10.1126/science.aaa2630; RA Liu S., Cai X., Wu J., Cong Q., Chen X., Li T., Du F., Ren J., Wu Y.T., RA Grishin N.V., Chen Z.J.; RT "Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF RT induces IRF3 activation."; RL Science 347:AAA2630-AAA2630(2015). RN [57] RP FUNCTION, AND INTERACTION WITH ICOS. RX PubMed=27135603; DOI=10.1038/ni.3463; RA Pedros C., Zhang Y., Hu J.K., Choi Y.S., Canonigo-Balancio A.J., RA Yates J.R. III, Altman A., Crotty S., Kong K.F.; RT "A TRAF-like motif of the inducible costimulator ICOS controls development RT of germinal center TFH cells via the kinase TBK1."; RL Nat. Immunol. 17:825-833(2016). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-670, AND MUTAGENESIS RP OF SER-172 AND LYS-670. RX PubMed=27692986; DOI=10.1016/j.molcel.2016.08.029; RA Lin M., Zhao Z., Yang Z., Meng Q., Tan P., Xie W., Qin Y., Wang R.F., RA Cui J.; RT "USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination RT through NLRP4 Signalosome."; RL Mol. Cell 64:267-281(2016). RN [59] RP FUNCTION. RX PubMed=27103069; DOI=10.15252/embj.201593350; RA Sellier C., Campanari M.L., Julie Corbier C., Gaucherot A., RA Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S., RA Kabashi E., Charlet-Berguerand N.; RT "Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to RT induce motor neuron dysfunction and cell death."; RL EMBO J. 35:1276-1297(2016). RN [60] RP INTERACTION WITH TRIM26, AND FUNCTION. RX PubMed=26611359; DOI=10.1093/jmcb/mjv068; RA Ran Y., Zhang J., Liu L.L., Pan Z.Y., Nie Y., Zhang H.Y., Wang Y.Y.; RT "Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate RT antiviral immune response."; RL J. Mol. Cell Biol. 8:31-43(2016). RN [61] RP UBIQUITINATION BY RNF128. RX PubMed=27776110; DOI=10.1038/ni.3588; RA Song G., Liu B., Li Z., Wu H., Wang P., Zhao K., Jiang G., Zhang L., RA Gao C.; RT "E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63- RT linked ubiquitination of TBK1."; RL Nat. Immunol. 17:1342-1351(2016). RN [62] RP INTERACTION WITH TTLL12 AND MAVS. RX PubMed=28011935; DOI=10.4049/jimmunol.1601194; RA Ju L.G., Zhu Y., Lei P.J., Yan D., Zhu K., Wang X., Li Q.L., Li X.J., RA Chen J.W., Li L.Y., Wu M.; RT "TTLL12 Inhibits the Activation of Cellular Antiviral Signaling through RT Interaction with VISA/MAVS."; RL J. Immunol. 198:1274-1284(2017). RN [63] RP INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION). RX PubMed=28848048; DOI=10.1074/jbc.m117.805127; RA Ning Y.J., Feng K., Min Y.Q., Deng F., Hu Z., Wang H.; RT "Heartland virus NSs protein disrupts host defenses by blocking the TBK1 RT kinase-IRF3 transcription factor interaction and signaling required for RT interferon induction."; RL J. Biol. Chem. 292:16722-16733(2017). RN [64] RP INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION), INTERACTION RP WITH SFTSV NSS (MICROBIAL INFECTION), AND PHOSPHORYLATION AT SER-172. RX PubMed=28680969; DOI=10.1128/msphere.00234-17; RA Rezelj V.V., Li P., Chaudhary V., Elliott R.M., Jin D.Y., Brennan B.; RT "Differential Antagonism of Human Innate Immune Responses by Tick-Borne RT Phlebovirus Nonstructural Proteins."; RL MSphere 2:0-0(2017). RN [65] RP INTERACTION WITH TRIM23. RX PubMed=28871090; DOI=10.1038/s41564-017-0017-2; RA Sparrer K.M.J., Gableske S., Zurenski M.A., Parker Z.M., Full F., RA Baumgart G.J., Kato J., Pacheco-Rodriguez G., Liang C., Pornillos O., RA Moss J., Vaughan M., Gack M.U.; RT "TRIM23 mediates virus-induced autophagy via activation of TBK1."; RL Nat. Microbiol. 2:1543-1557(2017). RN [66] RP INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP34.5 (MICROBIAL INFECTION). RX PubMed=28904192; DOI=10.1128/jvi.01156-17; RA Manivanh R., Mehrbach J., Knipe D.M., Leib D.A.; RT "Role of Herpes Simplex Virus 1 gamma34.5 in the Regulation of IRF3 RT Signaling."; RL J. Virol. 91:0-0(2017). RN [67] RP INTERACTION WITH ZIKA VIRUS NON-STRUCTURAL PROTEIN 1 AND NON-STRUCTURAL RP PROTEIN 4B (MICROBIAL INFECTION). RX PubMed=28373913; DOI=10.1038/celldisc.2017.6; RA Wu Y., Liu Q., Zhou J., Xie W., Chen C., Wang Z., Yang H., Cui J.; RT "Zika virus evades interferon-mediated antiviral response through the co- RT operation of multiple nonstructural proteins in vitro."; RL Cell Discov. 3:17006-17006(2017). RN [68] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [69] RP INTERACTION WITH CEP170. RX PubMed=30354798; DOI=10.1091/mbc.e18-02-0115; RA Baerenz F., Kschonsak Y.T., Meyer A., Jafarpour A., Lorenz H., Hoffmann I.; RT "Ccdc61 controls centrosomal localization of Cep170 and is required for RT spindle assembly and symmetry."; RL Mol. Biol. Cell 29:3105-3118(2018). RN [70] RP INTERACTION WITH TTC4; IKBKE; AZI2 AND TANK, AND SUBCELLULAR LOCATION. RX PubMed=29251827; DOI=10.1002/pmic.201700403; RA Shang J., Xia T., Han Q.Q., Zhao X., Hu M.M., Shu H.B., Guo L.; RT "Quantitative Proteomics Identified TTC4 as a TBK1 Interactor and a RT Positive Regulator of SeV-Induced Innate Immunity."; RL Proteomics 18:0-0(2018). RN [71] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=30021900; DOI=10.1128/jvi.00706-18; RA Moriyama M., Igarashi M., Koshiba T., Irie T., Takada A., Ichinohe T.; RT "Two Conserved Amino Acids within the NSs of Severe Fever with RT Thrombocytopenia Syndrome Phlebovirus Are Essential for Anti-interferon RT Activity."; RL J. Virol. 92:0-0(2018). RN [72] RP INTERACTION WITH HNRNPA2B1. RX PubMed=31320558; DOI=10.1126/science.aav0758; RA Wang L., Wen M., Cao X.; RT "Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to RT DNA viruses."; RL Science 0:0-0(2019). RN [73] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=31530866; DOI=10.1038/s41598-019-49707-8; RA Antonia R.J., Castillo J., Herring L.E., Serafin D.S., Liu P., Graves L.M., RA Baldwin A.S., Hagan R.S.; RT "TBK1 limits mTORC1 by promoting phosphorylation of Raptor Ser877."; RL Sci. Rep. 9:13470-13470(2019). RN [74] RP INTERACTION WITH RNF144B. RX PubMed=31509299; DOI=10.1002/jlb.2a0819-055r; RA Zhang Z., Zhang L., Wang B., Zhu X., Zhao L., Chu C., Guo Q., Wei R., RA Yin X., Zhang Y., Li X.; RT "RNF144B inhibits LPS-induced inflammatory responses via binding TBK1."; RL J. Leukoc. Biol. 106:1303-1311(2019). RN [75] RP INTERACTION WITH CYLD. RX PubMed=32185393; DOI=10.1093/brain/awaa039; RA Dobson-Stone C., Hallupp M., Shahheydari H., Ragagnin A.M.G., RA Chatterton Z., Carew-Jones F., Shepherd C.E., Stefen H., Paric E., Fath T., RA Thompson E.M., Blumbergs P., Short C.L., Field C.D., Panegyres P.K., RA Hecker J., Nicholson G., Shaw A.D., Fullerton J.M., Luty A.A., RA Schofield P.R., Brooks W.S., Rajan N., Bennett M.F., Bahlo M., RA Landers J.E., Piguet O., Hodges J.R., Halliday G.M., Topp S.D., Smith B.N., RA Shaw C.E., McCann E., Fifita J.A., Williams K.L., Atkin J.D., Blair I.P., RA Kwok J.B.; RT "CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral RT sclerosis."; RL Brain 143:783-799(2020). RN [76] RP INTERACTION WITH SARS-COV-2 NON-STRUCTURAL PROTEIN 6 (MICROBIAL INFECTION), RP AND INTERACTION WITH SARS-COV-2 HELICASE (MICROBIAL INFECTION). RX PubMed=32979938; DOI=10.1016/j.celrep.2020.108234; RA Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D., RA Rajsbaum R., Shi P.Y.; RT "Evasion of Type I Interferon by SARS-CoV-2."; RL Cell Rep. 33:108234-108234(2020). RN [77] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=31709703; DOI=10.15252/embr.201948317; RA Herhaus L., Bhaskara R.M., Lystad A.H., Gestal-Mato U., RA Covarrubias-Pinto A., Bonn F., Simonsen A., Hummer G., Dikic I.; RT "TBK1-mediated phosphorylation of LC3C and GABARAP-L2 controls RT autophagosome shedding by ATG4 protease."; RL EMBO Rep. 21:e48317-e48317(2020). RN [78] RP INTERACTION WITH TRIM14, AND FUNCTION. RX PubMed=32404352; DOI=10.4049/jimmunol.1901511; RA Hoffpauir C.T., Bell S.L., West K.O., Jing T., Wagner A.R., Torres-Odio S., RA Cox J.S., West A.P., Li P., Patrick K.L., Watson R.O.; RT "TRIM14 Is a Key Regulator of the Type I IFN Response during Mycobacterium RT tuberculosis Infection."; RL J. Immunol. 205:153-167(2020). RN [79] RP INTERACTION WITH TAX1BP1. RX PubMed=33226137; DOI=10.15252/embj.2020104948; RA Ohnstad A.E., Delgado J.M., North B.J., Nasa I., Kettenbach A.N., RA Schultz S.W., Shoemaker C.J.; RT "Receptor-mediated clustering of FIP200 bypasses the role of LC3 lipidation RT in autophagy."; RL EMBO J. 39:e104948-e104948(2020). RN [80] RP INTERACTION WITH TRAF3IP3, AND UBIQUITINATION. RX PubMed=32366851; DOI=10.1038/s41467-020-16014-0; RA Deng M., Tam J.W., Wang L., Liang K., Li S., Zhang L., Guo H., Luo X., RA Zhang Y., Petrucelli A., Davis B.K., Conti B.J., June Brickey W., Ko C.C., RA Lei Y.L., Sun S., Ting J.P.; RT "TRAF3IP3 negatively regulates cytosolic RNA induced anti-viral signaling RT by promoting TBK1 K48 ubiquitination."; RL Nat. Commun. 11:2193-2193(2020). RN [81] RP INTERACTION WITH IKBKB. RX PubMed=32209697; DOI=10.1126/scisignal.aay0574; RA Metwally H., Tanaka T., Li S., Parajuli G., Kang S., Hanieh H., RA Hashimoto S., Chalise J.P., Gemechu Y., Standley D.M., Kishimoto T.; RT "Noncanonical STAT1 phosphorylation expands its transcriptional activity RT into promoting LPS-induced IL-6 and IL-12p40 production."; RL Sci. Signal. 13:0-0(2020). RN [82] RP INTERACTION WITH SARS-COV-2 M PROTEIN (MICROBIAL INFECTION), FUNCTION, AND RP UBIQUITINATION. RX PubMed=34084167; DOI=10.3389/fimmu.2021.662989; RA Sui L., Zhao Y., Wang W., Wu P., Wang Z., Yu Y., Hou Z., Tan G., Liu Q.; RT "SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through RT Ubiquitin-Mediated Degradation of TBK1."; RL Front. Immunol. 12:662989-662989(2021). RN [83] RP INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL35 (MICROBIAL INFECTION). RX PubMed=32466380; DOI=10.3390/microorganisms8060790; RA Fabits M., Goncalves Magalhaes V., Chan B., Girault V., Elbasani E., RA Rossetti E., Saeland E., Messerle M., Pichlmair A., Lisnic V.J., RA Brinkmann M.M.; RT "The Cytomegalovirus Tegument Protein UL35 Antagonizes Pattern Recognition RT Receptor-Mediated Type I IFN Transcription."; RL Microorganisms 8:0-0(2020). RN [84] RP FUNCTION, INTERACTION WITH ASB8, AND SUBCELLULAR LOCATION. RX PubMed=32298923; DOI=10.1016/j.molimm.2020.03.011; RA Guo Y., Li R., Tan Z., Shi J., Fu Y., Song Y., Zhu M., Zhang L., Huang J.; RT "E3 ubiquitin ligase ASB8 negatively regulates interferon via regulating RT TBK1/IKKi homeostasis."; RL Mol. Immunol. 121:195-203(2020). RN [85] RP UBIQUITINATION BY TRAF7. RX PubMed=37086853; DOI=10.1016/j.virs.2023.04.005; RA Huang J.P., Yang Y.X., Chen T., Wang D.D., Li J., Xu L.G.; RT "TRAF7 negatively regulates the RLR signaling pathway by facilitating the RT K48-linked ubiquitination of TBK1."; RL Virol. Sin. 38:419-428(2023). RN [86] RP DEUBIQUITINATION BY EPSTEIN-BARR VIRUS PROTEIN BPLF1 (MICROBIAL INFECTION). RX PubMed=36802409; DOI=10.1371/journal.ppat.1011186; RA Lui W.Y., Bharti A., Wong N.M., Jangra S., Botelho M.G., Yuen K.S., RA Jin D.Y.; RT "Suppression of cGAS- and RIG-I-mediated innate immune signaling by RT Epstein-Barr virus deubiquitinase BPLF1."; RL PLoS Pathog. 19:e1011186-e1011186(2023). RN [87] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, ACTIVE SITE, HOMODIMER, UBIQUITINATION AT LYS-30 AND LYS-401, AND RP MUTAGENESIS OF LYS-30; ASP-33; LYS-38; ASP-135; GLU-355; ARG-357; LYS-401; RP ARG-547; TYR-577; GLU-580; ILE-582 AND LYS-589. RX PubMed=23453971; DOI=10.1016/j.celrep.2013.01.034; RA Larabi A., Devos J.M., Ng S.L., Nanao M.H., Round A., Maniatis T., RA Panne D.; RT "Crystal structure and mechanism of activation of TANK-binding kinase 1."; RL Cell Rep. 3:734-746(2013). RN [88] RP X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, ACTIVE SITE, AUTOPHOSPHORYLATION, HOMODIMER, INTERACTION WITH RP AZI2, AND MUTAGENESIS OF LYS-38; ASP-135; SER-172; LEU-316; TYR-325; RP GLU-355; GLU-448; HIS-459; ILE-466 AND PHE-470. RX PubMed=23453972; DOI=10.1016/j.celrep.2013.01.033; RA Tu D., Zhu Z., Zhou A.Y., Yun C.H., Lee K.E., Toms A.V., Li Y., Dunn G.P., RA Chan E., Thai T., Yang S., Ficarro S.B., Marto J.A., Jeon H., Hahn W.C., RA Barbie D.A., Eck M.J.; RT "Structure and ubiquitination-dependent activation of TANK-binding kinase RT 1."; RL Cell Rep. 3:747-758(2013). RN [89] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, AND PHOSPHORYLATION AT SER-172. RX PubMed=23746807; DOI=10.1016/j.str.2013.04.025; RA Shu C., Sankaran B., Chaton C.T., Herr A.B., Mishra A., Peng J., Li P.; RT "Structural insights into the functions of TBK1 in innate antimicrobial RT immunity."; RL Structure 21:1137-1148(2013). RN [90] RP STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF 1-729 OF MUTANT ASN-135 RP IN COMPLEX WITH STING1, FUNCTION, INTERACTION WITH STING1, ACTIVE SITE, AND RP MUTAGENESIS OF TYR-577; ASN-578 AND GLN-581. RX PubMed=30842653; DOI=10.1038/s41586-019-1000-2; RA Zhang C., Shang G., Gui X., Zhang X., Bai X.C., Chen Z.J.; RT "Structural basis of STING binding with and phosphorylation by TBK1."; RL Nature 567:394-398(2019). RN [91] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-271; GLU-291; HIS-296; ARG-410 AND RP ALA-464. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [92] RP VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; SER-388; RP THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, CHARACTERIZATION RP OF VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; RP SER-388; THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, AND RP FUNCTION. RX PubMed=32972995; DOI=10.1126/science.abd4570; RG COVID-STORM Clinicians; RG COVID Clinicians; RG Imagine COVID Group; RG French COVID Cohort Study Group; RG CoV-Contact Cohort; RG Amsterdam UMC Covid-19 Biobank; RG COVID Human Genetic Effort; RG NIAID-USUHS/TAGC COVID Immunity Group; RA Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., RA Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Rosain J., Bilguvar K., RA Ye J., Bolze A., Bigio B., Yang R., Arias A.A., Zhou Q., Zhang Y., RA Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L., RA Dorgham K., Smith N., Schneider W.M., Razooky B.S., Hoffmann H.H., RA Michailidis E., Moens L., Han J.E., Lorenzo L., Bizien L., Meade P., RA Neehus A.L., Ugurbil A.C., Corneau A., Kerner G., Zhang P., Rapaport F., RA Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlueter A., Le Voyer T., RA Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M.F., RA Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S.Z., RA Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A., RA Bettini L.R., D'Angio' M., Bonfanti P., Imberti L., Sottini A., Paghera S., RA Quiros-Roldan E., Rossi C., Oler A.J., Tompkins M.F., Alba C., RA Vandernoot I., Goffard J.C., Smits G., Migeotte I., Haerynck F., RA Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.E., Keles S., RA Coelkesen F., Ozcelik T., Yasar K.K., Senoglu S., Karabela S.N., RA Rodriguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y., RA Duval X., Laouenan C., Snow A.L., Dalgard C.L., Milner J.D., Vinh D.C., RA Mogensen T.H., Marr N., Spaan A.N., Boisson B., Boisson-Dupuis S., RA Bustamante J., Puel A., Ciancanelli M.J., Meyts I., Maniatis T., RA Soumelis V., Amara A., Nussenzweig M., Garcia-Sastre A., Krammer F., RA Pujol A., Duffy D., Lifton R.P., Zhang S.Y., Gorochov G., Beziat V., RA Jouanguy E., Sancho-Shimizu V., Rice C.M., Abel L., Notarangelo L.D., RA Cobat A., Su H.C., Casanova J.L.; RT "Inborn errors of type I IFN immunity in patients with life-threatening RT COVID-19."; RL Science 370:0-0(2020). RN [93] RP VARIANTS AIARV ASP-212; 440-ARG--LEU-729 DEL AND 619-TRP--LEU-729 DEL, RP CHARACTERIZATION OF VARIANTS AIARV ASP-212 AND 619-TRP--LEU-729 DEL, RP INVOLVEMENT IN AIARV, AND FUNCTION. RX PubMed=34363755; DOI=10.1016/j.cell.2021.07.026; RA Taft J., Markson M., Legarda D., Patel R., Chan M., Malle L., RA Richardson A., Gruber C., Martin-Fernandez M., Mancini G.M.S., RA van Laar J.A.M., van Pelt P., Buta S., Wokke B.H.A., Sabli I.K.D., RA Sancho-Shimizu V., Chavan P.P., Schnappauf O., Khubchandani R., RA Cueceoglu M.K., Oezen S., Kastner D.L., Ting A.T., Aksentijevich I., RA Hollink I.H.I.M., Bogunovic D.; RT "Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell RT death."; RL Cell 184:4447-4463.e20(2021). RN [94] RP VARIANT AIARV 440-ARG--LEU-729 DEL. RX PubMed=32447396; DOI=10.1093/rheumatology/keaa165; RA Kosukcu C., Taskiran E.Z., Batu E.D., Sag E., Bilginer Y., Alikasifoglu M., RA Ozen S.; RT "Whole exome sequencing in unclassified autoinflammatory diseases: more RT monogenic diseases in the pipeline?"; RL Rheumatology 60:607-616(2021). RN [95] RP FUNCTION, HOMODIMERIZATION, INTERACTION WITH IRF3; MAVS AND ZNF268, RP METHYLATION AT LYS-607, AND MUTAGENESIS OF LYS-584 AND LYS-607. RX PubMed=37926288; DOI=10.1016/j.jbc.2023.105428; RA Liu Y., Yin W., Zeng X., Fan J., Liu C., Gao M., Huang Z., Sun G., Guo M.; RT "TBK1-stabilized ZNF268a recruits SETD4 to methylate TBK1 for efficient RT interferon signaling."; RL J. Biol. Chem. 299:105428-105428(2023). CC -!- FUNCTION: Serine/threonine kinase that plays an essential role in CC regulating inflammatory responses to foreign agents (PubMed:10581243, CC PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, CC PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, CC PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, CC PubMed:26611359, PubMed:32404352, PubMed:34363755, PubMed:32298923). CC Following activation of toll-like receptors by viral or bacterial CC components, associates with TRAF3 and TANK and phosphorylates CC interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X CC (PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, CC PubMed:18583960, PubMed:25636800). This activity allows subsequent CC homodimerization and nuclear translocation of the IRFs leading to CC transcriptional activation of pro-inflammatory and antiviral genes CC including IFNA and IFNB (PubMed:12702806, PubMed:15367631, CC PubMed:25636800, PubMed:32972995). In order to establish such an CC antiviral state, TBK1 form several different complexes whose CC composition depends on the type of cell and cellular stimuli CC (PubMed:23453971, PubMed:23453972, PubMed:23746807). Plays a key role CC in IRF3 activation: acts by first phosphorylating innate adapter CC proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to CC recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1 CC (PubMed:25636800, PubMed:30842653, PubMed:37926288). Phosphorylated CC IRF3 dissociates from the adapter proteins, dimerizes, and then enters CC the nucleus to induce expression of interferons (PubMed:25636800). CC Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, CC TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing- CC complexes (PubMed:21931631). Under particular conditions, functions as CC a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor CC alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus CC (PubMed:10783893, PubMed:15489227). Restricts bacterial proliferation CC by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', CC thus enhancing LC3 binding affinity and antibacterial autophagy CC (PubMed:21617041). Phosphorylates SMCR8 component of the C9orf72-SMCR8 CC complex, promoting autophagosome maturation (PubMed:27103069). CC Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing CC their delipidation and premature removal from nascent autophagosomes CC (PubMed:31709703). Seems to play a role in energy balance regulation by CC sustaining a state of chronic, low-grade inflammation in obesity, which CC leads to a negative impact on insulin sensitivity (By similarity). CC Attenuates retroviral budding by phosphorylating the endosomal sorting CC complex required for transport-I (ESCRT-I) subunit VPS37C CC (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P protein CC (PubMed:16155125). Plays an essential role in the TLR3- and IFN- CC dependent control of herpes virus HSV-1 and HSV-2 infections in the CC central nervous system (PubMed:22851595). Acts both as a positive and CC negative regulator of the mTORC1 complex, depending on the context: CC activates mTORC1 in response to growth factors by catalyzing CC phosphorylation of MTOR, while it limits the mTORC1 complex by CC promoting phosphorylation of RPTOR (PubMed:29150432, PubMed:31530866). CC Acts as a positive regulator of the mTORC2 complex by mediating CC phosphorylation of MTOR, leading to increased phosphorylation and CC activation of AKT1 (By similarity). Phosphorylates and activates AKT1 CC (PubMed:21464307). Involved in the regulation of TNF-induced RIPK1- CC mediated cell death, probably acting via CYLD phosphorylation that in CC turn controls RIPK1 ubiquitination status (PubMed:34363755). Also CC participates in the differentiation of T follicular regulatory cells CC together with the receptor ICOS (PubMed:27135603). CC {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243, CC ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743, CC ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806, CC ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631, CC ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227, CC ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595, CC ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, CC ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800, CC ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069, CC ECO:0000269|PubMed:27135603, ECO:0000269|PubMed:29150432, CC ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31530866, CC ECO:0000269|PubMed:31709703, ECO:0000269|PubMed:32298923, CC ECO:0000269|PubMed:32972995, ECO:0000269|PubMed:34363755, CC ECO:0000269|PubMed:37926288}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513, CC ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:29150432, CC ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513, CC ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:25636800}; CC -!- SUBUNIT: Homodimer (PubMed:21145761, PubMed:37926288). Interacts with CC DDX3X, TIRAP and TRAF2 (PubMed:10581243, PubMed:14530355). Part of a CC ternary complex consisting of TANK, TRAF2 and TBK1 (PubMed:10581243). CC Interacts with AZI2, TANK and TBKBP1; these interactions are mutually CC exclusive and mediate TBK1 activation (PubMed:10581243, CC PubMed:14560022, PubMed:21931631, PubMed:23453972, PubMed:29251827). CC Interacts with GSK3B; this interaction promotes TBK1 self-association CC and autophosphorylation (PubMed:21145761). Interacts with SIKE1; SIKE1 CC is associated with TBK1 under physiological condition and dissociated CC from TBK1 upon viral infection or TLR3 stimulation (PubMed:16281057). CC Interacts with IRF3, leading to IRF3 phosphorylation (PubMed:14703513, CC PubMed:25636800, PubMed:37926288). Interacts with RIGI CC (PubMed:16281057). Interacts with CYLD (PubMed:18636086, CC PubMed:32185393). Interacts with OPTN and TRAF3 (PubMed:20174559). CC Interacts with SRC (PubMed:19419966). Interacts with the exocyst CC complex subunit SEC5/EXOC2; this interaction is sufficient to trigger CC TBK1 activity (PubMed:17018283). Interacts with STING1, leading to CC STING1 phosphorylation (PubMed:19416887, PubMed:25636800, CC PubMed:30842653). Interacts with IFIT3 (via N-terminus) CC (PubMed:21813773). Interacts with MAVS; interaction only takes place in CC the presence of IFIT3 and leads to MAVS phosphorylation CC (PubMed:21813773, PubMed:25636800, PubMed:28011935, PubMed:37926288). CC Interacts (via protein kinase domain) with TTLL12 (via TTL domain); the CC interaction prevents MAVS binding to TBK1 (PubMed:28011935). Interacts CC with TICAM1; this interaction is enhanced in the presence of WDFY1 and CC leads to TICAM1 phosphorylation (PubMed:14530355, PubMed:14739303, CC PubMed:25636800, PubMed:25736436). Interacts with TRIM26 CC (PubMed:26611359). Interacts with TRIM23 (PubMed:28871090). Interacts CC with TTC4 and IKBKE (PubMed:29251827). Interacts with HNRNPA2B1 CC (PubMed:31320558). Interacts with DDX3X (PubMed:20375222). Interacts CC with TRIM14 (PubMed:32404352). Interacts with CEP170; efficient complex CC formation may be dependent on the presence of CCDC61 (PubMed:30354798). CC Interacts with TRAF3IP3 (PubMed:32366851). Interacts with HSP90AA1; the CC interaction mediates TBK1 association with TOMM70 (PubMed:20628368). CC Interacts with TAX1BP1 (PubMed:33226137). Interacts with kinase IKBKB; CC the complex interacts with STAT1, leading to phosphorylation of STAT1 CC on 'Thr-749' by IKBKB (PubMed:32209697). Interacts with ICOS; this CC interaction is critical for the maturation of T follicular regulatory CC cells (PubMed:27135603). Interacts with RNF144B; this interaction CC prevents TBK1 phosphorylation and subsequent activation CC (PubMed:31509299). Interacts with ASB8; this interaction promotes TBK1 CC proteasomal degradation (PubMed:32298923). Forms a ternary complex with CC ZNF268 and SETD4; the interaction with SETD4 is ZNF268-dependent and CC leads to TBK1 monomethylation, which enhances its interaction with IRF3 CC and MAVS (PubMed:37926288). {ECO:0000269|PubMed:10581243, CC ECO:0000269|PubMed:14530355, ECO:0000269|PubMed:14560022, CC ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:14739303, CC ECO:0000269|PubMed:16281057, ECO:0000269|PubMed:17018283, CC ECO:0000269|PubMed:18636086, ECO:0000269|PubMed:19416887, CC ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:20174559, CC ECO:0000269|PubMed:20375222, ECO:0000269|PubMed:20628368, CC ECO:0000269|PubMed:21145761, ECO:0000269|PubMed:21813773, CC ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:23453972, CC ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:25736436, CC ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27135603, CC ECO:0000269|PubMed:28011935, ECO:0000269|PubMed:28871090, CC ECO:0000269|PubMed:29251827, ECO:0000269|PubMed:30354798, CC ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31320558, CC ECO:0000269|PubMed:31509299, ECO:0000269|PubMed:32185393, CC ECO:0000269|PubMed:32209697, ECO:0000269|PubMed:32298923, CC ECO:0000269|PubMed:32366851, ECO:0000269|PubMed:32404352, CC ECO:0000269|PubMed:33226137, ECO:0000269|PubMed:37926288}. CC -!- SUBUNIT: (Microbial infection) Interacts with Borna disease virus (BDV) CC P protein leading to its phosphorylation. CC {ECO:0000269|PubMed:16155125}. CC -!- SUBUNIT: (Microbial infection) Interacts with Ebola virus protein VP35. CC {ECO:0000269|PubMed:19153231}. CC -!- SUBUNIT: (Microbial infection) Interacts with HCV NS3; this interaction CC leads to inhibition of cellular antiviral response by blocking CC necessary interactions between the TBK1 and its substrates IRF3 and CC IRF7. {ECO:0000269|PubMed:15841462}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 1 CC protein ICP34.5. {ECO:0000269|PubMed:19010780, CC ECO:0000269|PubMed:28904192}. CC -!- SUBUNIT: (Microbial infection) Interacts with Zika virus non-structural CC protein 1/NS1 and non-structural protein 4B/NS4B. CC {ECO:0000269|PubMed:28373913}. CC -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV-2 non-structural CC protein 6; this interaction decreases IRF3 phosphorylation by 57%, CC which leads to reduced IFN-beta (IFNB) production (PubMed:32979938). CC Interacts with SARS-CoV-2 helicase; this interaction inhibits TBK1 CC phosphorylation and decreases IRF3 phosphorylation by 75%, which leads CC to reduced IFN-beta production (PubMed:32979938). Interacts with SARS- CC CoV-2 M protein; the interaction promotes TBK1 degradation via 'Lys- CC 48'-linked ubiquitination (PubMed:34084167). CC {ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:34084167}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC protein UL35; this interaction inhibits type I interferon production. CC {ECO:0000269|PubMed:32466380}. CC -!- SUBUNIT: (Microbial infection) Interacts with heartland virus NSs; this CC interaction antagonizes TBK1 phosphorylation and inhibits TBK1-IRF3 CC interaction and thus the establishment of an antiviral state. CC {ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:28848048}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with Severe CC fever with thrombocytopenia virus (SFTSV) NSs; this interaction CC antagonizes TBK1 phosphorylation and sequesters TBK1 in NSs-induced CC cytoplasmic inclusion bodies thereby inhibiting the IFN responses. CC {ECO:0000269|PubMed:24478431, ECO:0000269|PubMed:24706939, CC ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:30021900}. CC -!- INTERACTION: CC Q9UHD2; Q9UKV8: AGO2; NbExp=2; IntAct=EBI-356402, EBI-528269; CC Q9UHD2; Q7Z3C6: ATG9A; NbExp=2; IntAct=EBI-356402, EBI-727146; CC Q9UHD2; Q9H6S1: AZI2; NbExp=7; IntAct=EBI-356402, EBI-359973; CC Q9UHD2; Q13137: CALCOCO2; NbExp=10; IntAct=EBI-356402, EBI-739580; CC Q9UHD2; Q6DT37: CDC42BPG; NbExp=3; IntAct=EBI-356402, EBI-689124; CC Q9UHD2; P08238: HSP90AB1; NbExp=3; IntAct=EBI-356402, EBI-352572; CC Q9UHD2; Q9Y6W8: ICOS; NbExp=5; IntAct=EBI-356402, EBI-3922712; CC Q9UHD2; Q14164: IKBKE; NbExp=5; IntAct=EBI-356402, EBI-307369; CC Q9UHD2; Q9Y6K9: IKBKG; NbExp=6; IntAct=EBI-356402, EBI-81279; CC Q9UHD2; Q14653: IRF3; NbExp=10; IntAct=EBI-356402, EBI-2650369; CC Q9UHD2; Q92985: IRF7; NbExp=2; IntAct=EBI-356402, EBI-968267; CC Q9UHD2; Q9H492: MAP1LC3A; NbExp=2; IntAct=EBI-356402, EBI-720768; CC Q9UHD2; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-356402, EBI-373144; CC Q9UHD2; Q7Z434: MAVS; NbExp=6; IntAct=EBI-356402, EBI-995373; CC Q9UHD2; Q86YT6: MIB1; NbExp=2; IntAct=EBI-356402, EBI-2129148; CC Q9UHD2; Q96AX9: MIB2; NbExp=2; IntAct=EBI-356402, EBI-2130249; CC Q9UHD2; Q9NVV4: MTPAP; NbExp=2; IntAct=EBI-356402, EBI-2556166; CC Q9UHD2; Q96CV9: OPTN; NbExp=17; IntAct=EBI-356402, EBI-748974; CC Q9UHD2; O14730: RIOK3; NbExp=3; IntAct=EBI-356402, EBI-1047061; CC Q9UHD2; P42226: STAT6; NbExp=7; IntAct=EBI-356402, EBI-1186478; CC Q9UHD2; Q86WV6: STING1; NbExp=9; IntAct=EBI-356402, EBI-2800345; CC Q9UHD2; O75558: STX11; NbExp=5; IntAct=EBI-356402, EBI-714135; CC Q9UHD2; Q92844: TANK; NbExp=15; IntAct=EBI-356402, EBI-356349; CC Q9UHD2; Q9UHD2: TBK1; NbExp=2; IntAct=EBI-356402, EBI-356402; CC Q9UHD2; A7MCY6: TBKBP1; NbExp=9; IntAct=EBI-356402, EBI-359969; CC Q9UHD2; Q8IUC6: TICAM1; NbExp=3; IntAct=EBI-356402, EBI-525995; CC Q9UHD2; Q12933: TRAF2; NbExp=9; IntAct=EBI-356402, EBI-355744; CC Q9UHD2; Q13114: TRAF3; NbExp=4; IntAct=EBI-356402, EBI-357631; CC Q9UHD2; O95801: TTC4; NbExp=5; IntAct=EBI-356402, EBI-1050890; CC Q9UHD2; P40222: TXLNA; NbExp=8; IntAct=EBI-356402, EBI-359793; CC Q9UHD2; Q62167: Ddx3x; Xeno; NbExp=8; IntAct=EBI-356402, EBI-773173; CC Q9UHD2; O41932: GAMMAHV.ORF11; Xeno; NbExp=4; IntAct=EBI-356402, EBI-9544132; CC Q9UHD2; P0DTC5: M; Xeno; NbExp=10; IntAct=EBI-356402, EBI-25475853; CC Q9UHD2; P59596: M; Xeno; NbExp=5; IntAct=EBI-356402, EBI-25487824; CC Q9UHD2; W5VXH5: NSs; Xeno; NbExp=3; IntAct=EBI-356402, EBI-9543922; CC Q9UHD2; PRO_0000449630 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-356402, EBI-25475888; CC Q9UHD2; Q60803: Traf3; Xeno; NbExp=2; IntAct=EBI-356402, EBI-520135; CC Q9UHD2; Q8BHN1: Txlng; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6116854; CC Q9UHD2; Q05127: VP35; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6148294; CC Q9UHD2; I6W9F2; Xeno; NbExp=6; IntAct=EBI-356402, EBI-9518472; CC Q9UHD2; K7Y1A2; Xeno; NbExp=2; IntAct=EBI-356402, EBI-8788634; CC Q9UHD2; PRO_0000037572 [P27958]; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6919131; CC Q9UHD2; PRO_0000037573 [P27958]; Xeno; NbExp=4; IntAct=EBI-356402, EBI-3649474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15485837, CC ECO:0000269|PubMed:21813773, ECO:0000269|PubMed:29251827, CC ECO:0000269|PubMed:32298923}. Note=Upon mitogen stimulation or CC triggering of the immune system, TBK1 is recruited to the exocyst by CC EXOC2. {ECO:0000269|PubMed:17018283}. CC -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in testis. CC Expressed in the ganglion cells, nerve fiber layer and microvasculature CC of the retina. {ECO:0000269|PubMed:10783893, CC ECO:0000269|PubMed:21447600}. CC -!- DOMAIN: Comprises A N-terminal kinase domain, a ubiquitin-like domain CC and a C-terminal coiled-coil region mediating homodimerization. CC {ECO:0000269|PubMed:17599067, ECO:0000269|PubMed:21042276}. CC -!- PTM: Autophosphorylation at Ser-172 activates the kinase, and is an CC essential step for virus-triggered signaling. Phosphorylated by CC IKBKB/IKKB at Ser-172. Phosphorylation requires homodimerization and CC ubiquitination at Lys-30 and Lys-401. Dephosphorylated at Ser-172 by CC PPM1B and this negatively regulates its role in mediating antiviral CC response. {ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:21138416, CC ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23746807}. CC -!- PTM: 'Lys-63'-linked polyubiquitination by MIB1 after RNA virus CC infection, or by NRDP1 after LPS stimulation at Lys-30 and Lys-401, CC participates in kinase activation. 'Lys-48'-linked polyubiquitination CC at Lys-670 by DTX4 leads to proteasomal degradation. 'Lys-48'-linked CC polyubiquitination by TRAIP also leads to proteasomal degradation. CC 'Lys-48'-linked polyubiquitination by TRAF7; leading to proteasomal CC degradation (PubMed:37086853). 'Lys-63'-linked polyubiquitination by CC RNF128 at Lys-30 and Lys-401 leads to the activation of antiviral CC responses. 'Lys-48'-linked polyubiquitination after 'lys-33'-linked CC deubiquitination by USP38 promotes TBK1 degradation (PubMed:27692986). CC {ECO:0000269|PubMed:22388039, ECO:0000269|PubMed:23453971, CC ECO:0000269|PubMed:27692986, ECO:0000269|PubMed:27776110, CC ECO:0000269|PubMed:32366851, ECO:0000269|PubMed:37086853}. CC -!- PTM: (Microbial infection) Interaction with SARS-CoV-2 M protein CC induces 'Lys-48'-linked ubiquitination which leads to proteasomal CC degradation. {ECO:0000269|PubMed:34084167}. CC -!- PTM: (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1 CC on both 'Lys-48' and 'Lys-63'-linked ubiquitin chains; leading to CC inhibition of type I interfewron production. CC {ECO:0000269|PubMed:36802409}. CC -!- PTM: Monomethylation at Lys-607 by SETD4 maximizes TBK1 activation and CC promotes efficient interferon signaling. {ECO:0000269|PubMed:37926288}. CC -!- DISEASE: Glaucoma 1, open angle, P (GLC1P) [MIM:177700]: A form of CC primary open angle glaucoma (POAG). POAG is characterized by a specific CC pattern of optic nerve and visual field defects. The angle of the CC anterior chamber of the eye is open, and usually the intraocular CC pressure is increased. However, glaucoma can occur at any intraocular CC pressure. The disease is generally asymptomatic until the late stages, CC by which time significant and irreversible optic nerve damage has CC already taken place. GLC1P is characterized by early onset, thin CC central corneas and low intraocular pressure. CC {ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:22306015}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. A copy number variation on chromosome 12q14 consisting of a CC 300 kb duplication that includes TBK1, XPOT, RASSF3 and GNS has been CC found in individuals affected by glaucoma. TBK1 is the most likely CC candidate for the disorder (PubMed:21447600). CC {ECO:0000269|PubMed:21447600}. CC -!- DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 CC (FTDALS4) [MIM:616439]: A neurodegenerative disorder characterized by CC frontotemporal dementia and/or amyotrophic lateral sclerosis in CC affected individuals. There is high intrafamilial variation. CC Frontotemporal dementia is characterized by frontal and temporal lobe CC atrophy associated with neuronal loss, gliosis, and dementia. Patients CC exhibit progressive changes in social, behavioral, and/or language CC function. Amyotrophic lateral sclerosis is characterized by the death CC of motor neurons in the brain, brainstem, and spinal cord, resulting in CC fatal paralysis. {ECO:0000269|PubMed:25803835, CC ECO:0000269|PubMed:25943890}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Encephalopathy, acute, infection-induced, 8, herpes-specific CC (IIAE8) [MIM:617900]: A rare, often fatal complication of herpes CC simplex infection, caused by virus spreading in the central nervous CC system. Disease manifestations include low-grade fever, severe CC headache, nausea, vomiting, and lethargy. Neurological features include CC confusion, acute memory disturbances, disorientation, behavioral CC changes, hemiparesis and seizures. {ECO:0000269|PubMed:22851595, CC ECO:0000269|PubMed:26513235}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Autoinflammation with arthritis and vasculitis (AIARV) CC [MIM:620880]: An autosomal recessive disorder characterized by onset of CC chronic and systemic autoinflammation in infancy or early childhood. CC Affected individuals have recurrent fever, erythematous skin rashes, CC vasculitis, oral aphthous lesions, and polyarthritis. Additional CC variable features are poor overall growth, microcytic anemia, mild CC intellectual disability, and seizures. {ECO:0000269|PubMed:32447396, CC ECO:0000269|PubMed:34363755}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In cancer cells, pathological TBK1 activation promotes CC oncogenic transformation by suppressing programmed cell death. CC Mechanistically, the RALB-SEC5/EXOC2-TBK1 signaling cascade seems to CC participate in both innate immune signaling and cell transformation. CC Additionally, TBK1 supports oncogenesis by directly phosphorylating and CC activating AKT1 at the exocyst (PubMed:21042276). CC {ECO:0000305|PubMed:21042276}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. I-kappa-B kinase subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA92129.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF191838; AAF05989.1; -; mRNA. DR EMBL; AF174536; AAF69106.1; -; mRNA. DR EMBL; AK002192; BAA92129.1; ALT_INIT; mRNA. DR EMBL; AK291039; BAF83728.1; -; mRNA. DR EMBL; CH471054; EAW97133.1; -; Genomic_DNA. DR EMBL; BC034950; AAH34950.1; -; mRNA. DR CCDS; CCDS8968.1; -. DR RefSeq; NP_037386.1; NM_013254.4. DR RefSeq; XP_005268866.1; XM_005268809.2. DR RefSeq; XP_005268867.1; XM_005268810.2. DR RefSeq; XP_054227832.1; XM_054371857.1. DR RefSeq; XP_054227833.1; XM_054371858.1. DR PDB; 4EFO; X-ray; 1.77 A; A/B=302-383. DR PDB; 4EUT; X-ray; 2.60 A; A/B=2-385. DR PDB; 4EUU; X-ray; 1.80 A; A/B=2-308. DR PDB; 4IM0; X-ray; 2.40 A; A=1-657. DR PDB; 4IM2; X-ray; 2.50 A; A=1-657. DR PDB; 4IM3; X-ray; 3.34 A; A=1-657. DR PDB; 4IW0; X-ray; 4.00 A; A=2-657. DR PDB; 4IWO; X-ray; 2.61 A; A=2-657. DR PDB; 4IWP; X-ray; 3.06 A; A=2-657. DR PDB; 4IWQ; X-ray; 3.00 A; A=2-657. DR PDB; 5EOA; X-ray; 2.50 A; C/D=677-729. DR PDB; 5EOF; X-ray; 2.05 A; C/D=677-729. DR PDB; 5EP6; X-ray; 1.45 A; B/D=677-729. DR PDB; 5W5V; X-ray; 3.65 A; A=1-657. DR PDB; 6BNY; X-ray; 3.34 A; A=1-657. DR PDB; 6BOD; X-ray; 3.20 A; A=1-657. DR PDB; 6BOE; X-ray; 3.60 A; A=1-657. DR PDB; 6CQ0; X-ray; 3.19 A; A=1-657. DR PDB; 6CQ4; X-ray; 3.20 A; A=1-657. DR PDB; 6CQ5; X-ray; 3.35 A; A=1-657. DR PDB; 6NT9; EM; 3.30 A; A/B=1-729. DR PDB; 6O8B; X-ray; 3.40 A; A/B=2-657. DR PDB; 6RSR; X-ray; 3.15 A; A=2-657. DR PDB; 6RST; X-ray; 3.29 A; A=2-657. DR PDB; 6RSU; X-ray; 2.75 A; A=2-657. DR PDBsum; 4EFO; -. DR PDBsum; 4EUT; -. DR PDBsum; 4EUU; -. DR PDBsum; 4IM0; -. DR PDBsum; 4IM2; -. DR PDBsum; 4IM3; -. DR PDBsum; 4IW0; -. DR PDBsum; 4IWO; -. DR PDBsum; 4IWP; -. DR PDBsum; 4IWQ; -. DR PDBsum; 5EOA; -. DR PDBsum; 5EOF; -. DR PDBsum; 5EP6; -. DR PDBsum; 5W5V; -. DR PDBsum; 6BNY; -. DR PDBsum; 6BOD; -. DR PDBsum; 6BOE; -. DR PDBsum; 6CQ0; -. DR PDBsum; 6CQ4; -. DR PDBsum; 6CQ5; -. DR PDBsum; 6NT9; -. DR PDBsum; 6O8B; -. DR PDBsum; 6RSR; -. DR PDBsum; 6RST; -. DR PDBsum; 6RSU; -. DR AlphaFoldDB; Q9UHD2; -. DR EMDB; EMD-0506; -. DR SMR; Q9UHD2; -. DR BioGRID; 118878; 435. DR ComplexPortal; CPX-6018; STING-TRAF3-TBK1 complex. DR ComplexPortal; CPX-6038; TBK1-IKKepsilon-NAP1 complex. DR ComplexPortal; CPX-6089; TBK1-IKKepsilon-TANK complex. DR ComplexPortal; CPX-6090; TBK1-IKKepsilon-SINTBAD complex. DR CORUM; Q9UHD2; -. DR DIP; DIP-27529N; -. DR FunCoup; Q9UHD2; 4748. DR IntAct; Q9UHD2; 197. DR MINT; Q9UHD2; -. DR STRING; 9606.ENSP00000329967; -. DR BindingDB; Q9UHD2; -. DR ChEMBL; CHEMBL5408; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9UHD2; -. DR GuidetoPHARMACOLOGY; 2237; -. DR GlyGen; Q9UHD2; 1 site, 1 N-linked glycan (1 site). DR iPTMnet; Q9UHD2; -. DR MetOSite; Q9UHD2; -. DR PhosphoSitePlus; Q9UHD2; -. DR BioMuta; TBK1; -. DR DMDM; 74761953; -. DR CPTAC; CPTAC-2972; -. DR CPTAC; CPTAC-2973; -. DR CPTAC; CPTAC-910; -. DR CPTAC; CPTAC-911; -. DR jPOST; Q9UHD2; -. DR MassIVE; Q9UHD2; -. DR PaxDb; 9606-ENSP00000329967; -. DR PeptideAtlas; Q9UHD2; -. DR ProteomicsDB; 84323; -. DR Pumba; Q9UHD2; -. DR Antibodypedia; 16584; 631 antibodies from 46 providers. DR DNASU; 29110; -. DR YCharOS; Q9UHD2; Tested 11 antibodies from 6 manufacturers. DR Ensembl; ENST00000331710.10; ENSP00000329967.5; ENSG00000183735.12. DR Ensembl; ENST00000650790.1; ENSP00000498995.1; ENSG00000183735.12. DR GeneID; 29110; -. DR KEGG; hsa:29110; -. DR MANE-Select; ENST00000331710.10; ENSP00000329967.5; NM_013254.4; NP_037386.1. DR UCSC; uc001ssc.3; human. DR AGR; HGNC:11584; -. DR CIViC; 29110; 1 evidence item across 1 molecular profile. DR ClinPGx; PA36348; -. DR CTD; 29110; -. DR DisGeNET; 29110; -. DR GeneCards; TBK1; -. DR HGNC; HGNC:11584; TBK1. DR HPA; ENSG00000183735; Low tissue specificity. DR MalaCards; TBK1; -. DR MIM; 177700; phenotype. DR MIM; 604834; gene. DR MIM; 616439; phenotype. DR MIM; 617900; phenotype. DR MIM; 620880; phenotype. DR OpenTargets; ENSG00000183735; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 275872; Frontotemporal dementia with motor neuron disease. DR Orphanet; 1930; Herpes simplex virus encephalitis. DR VEuPathDB; HostDB:ENSG00000183735; -. DR eggNOG; KOG4250; Eukaryota. DR GeneTree; ENSGT00950000182937; -. DR HOGENOM; CLU_000288_101_1_1; -. DR InParanoid; Q9UHD2; -. DR OMA; WSADMPV; -. DR OrthoDB; 10013850at2759; -. DR PAN-GO; Q9UHD2; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHD2; -. DR PathwayCommons; Q9UHD2; -. DR Reactome; R-HSA-1606341; IRF3 mediated activation of type 1 IFN. DR Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta. DR Reactome; R-HSA-3134975; Regulation of innate immune responses to cytosolic DNA. DR Reactome; R-HSA-3249367; STAT6-mediated induction of chemokines. DR Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN. DR Reactome; R-HSA-5205685; PINK1-PRKN Mediated Mitophagy. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-9008059; Interleukin-37 signaling. DR Reactome; R-HSA-9013973; TICAM1-dependent activation of IRF3/IRF7. DR Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway. DR Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation. DR Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling. DR Reactome; R-HSA-936964; Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE). DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-9824878; Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF7. DR Reactome; R-HSA-9828211; Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligation. DR SABIO-RK; Q9UHD2; -. DR SignaLink; Q9UHD2; -. DR SIGNOR; Q9UHD2; -. DR Agora; ENSG00000183735; -. DR BioGRID-ORCS; 29110; 34 hits in 1203 CRISPR screens. DR CD-CODE; 7F558BCC; STING phase-separator. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; TBK1; human. DR EvolutionaryTrace; Q9UHD2; -. DR GeneWiki; TANK-binding_kinase_1; -. DR GenomeRNAi; 29110; -. DR Pharos; Q9UHD2; Tchem. DR PRO; PR:Q9UHD2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9UHD2; protein. DR Bgee; ENSG00000183735; Expressed in colonic epithelium and 198 other cell types or tissues. DR ExpressionAtlas; Q9UHD2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:1902554; C:serine/threonine protein kinase complex; NAS:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0003676; F:nucleic acid binding; IEA:Ensembl. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; NAS:ProtInc. DR GO; GO:0019903; F:protein phosphatase binding; ISS:ARUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IDA:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0002218; P:activation of innate immune response; IDA:UniProt. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; TAS:UniProtKB. DR GO; GO:0140896; P:cGAS/STING signaling pathway; TAS:FlyBase. DR GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; IDA:UniProt. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0051607; P:defense response to virus; NAS:ComplexPortal. DR GO; GO:0044565; P:dendritic cell proliferation; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; TAS:UniProtKB. DR GO; GO:0045087; P:innate immune response; IDA:UniProtKB. DR GO; GO:0016236; P:macroautophagy; TAS:Reactome. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProt. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEP:UniProtKB. DR GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:BHF-UCL. DR GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL. DR GO; GO:0016239; P:positive regulation of macroautophagy; IDA:HGNC. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0032481; P:positive regulation of type I interferon production; IDA:UniProt. DR GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032479; P:regulation of type I interferon production; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; TAS:UniProtKB. DR GO; GO:0061470; P:T follicular helper cell differentiation; IDA:UniProt. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IDA:UniProt. DR GO; GO:0060337; P:type I interferon-mediated signaling pathway; NAS:ComplexPortal. DR CDD; cd13988; STKc_TBK1; 1. DR CDD; cd21954; TBK1_C; 1. DR CDD; cd17127; Ubl_TBK1; 1. DR FunFam; 1.10.510.10:FF:000100; inhibitor of nuclear factor kappa-B kinase subunit epsilon; 1. DR FunFam; 1.20.1270.420:FF:000001; Serine/threonine-protein kinase TBK1; 1. DR FunFam; 3.30.200.20:FF:000106; serine/threonine-protein kinase TBK1 isoform X1; 1. DR FunFam; 3.10.20.90:FF:000112; TANK binding kinase TBK1; 1. DR Gene3D; 1.20.1270.420; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR051180; IKK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041309; TBK1_CC1. DR InterPro; IPR041087; TBK1_ULD. DR PANTHER; PTHR22969; IKB KINASE; 1. DR PANTHER; PTHR22969:SF14; SERINE_THREONINE-PROTEIN KINASE TBK1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF18394; TBK1_CCD1; 1. DR Pfam; PF18396; TBK1_ULD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Amyotrophic lateral sclerosis; Antiviral defense; KW ATP-binding; Coiled coil; Cytoplasm; Disease variant; Glaucoma; KW Host-virus interaction; Immunity; Innate immunity; Isopeptide bond; Kinase; KW Methylation; Neurodegeneration; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..729 FT /note="Serine/threonine-protein kinase TBK1" FT /id="PRO_0000086743" FT DOMAIN 9..310 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 309..385 FT /note="Ubiquitin-like" FT REGION 621..729 FT /note="Interaction with AZI2, TANK and TBKBP1" FT /evidence="ECO:0000269|PubMed:21931631" FT COILED 407..657 FT /evidence="ECO:0000250|UniProtKB:Q9WUN2" FT COILED 658..713 FT /evidence="ECO:0000255" FT ACT_SITE 135 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:23453971, FT ECO:0000305|PubMed:23453972, ECO:0000305|PubMed:30842653" FT BINDING 15..23 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 172 FT /note="Phosphoserine; by autocatalysis and IKKB" FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23746807" FT MOD_RES 607 FT /note="N6-methyllysine; by SETD4" FT /evidence="ECO:0000269|PubMed:37926288" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 30 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23453971" FT CROSSLNK 401 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23453971" FT CROSSLNK 670 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22388039, FT ECO:0000269|PubMed:27692986" FT VARIANT 24 FT /note="F -> S (loss of IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084111" FT VARIANT 47 FT /note="R -> H (in FTDALS4; loss of kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073938" FT VARIANT 50 FT /note="D -> A (in IIAE8; decreased expression levels; FT dbSNP:rs1010930015)" FT /evidence="ECO:0000269|PubMed:22851595" FT /id="VAR_080517" FT VARIANT 105 FT /note="Y -> C (in FTDALS4; dbSNP:rs1366668789)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073939" FT VARIANT 151 FT /note="S -> F (in dbSNP:rs55824172)" FT /evidence="ECO:0000269|PubMed:21447600" FT /id="VAR_069754" FT VARIANT 152 FT /note="V -> L (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084112" FT VARIANT 159 FT /note="G -> A (in IIAE8; loss of kinase activity; loss of FT autophosphorylation at S-172; loss of IFNB induction; FT dbSNP:rs1555202947)" FT /evidence="ECO:0000269|PubMed:22851595, FT ECO:0000269|PubMed:32972995" FT /id="VAR_080518" FT VARIANT 207 FT /note="I -> V (in IIAE8; uncertain significance; FT dbSNP:rs1555203557)" FT /evidence="ECO:0000269|PubMed:26513235" FT /id="VAR_080519" FT VARIANT 212 FT /note="Y -> D (in AIARV; likely pathogenic; severely FT decreased function in IRF3 phosphorylation and in positive FT regulation of type I interferon-mediated signaling pathway; FT does not rescue defective IRF3 phosphorylation on S-386 and FT IFN-1 stimulated gene expression in TBK1-deficient patient FT cells)" FT /evidence="ECO:0000269|PubMed:34363755" FT /id="VAR_089908" FT VARIANT 271 FT /note="R -> Q (in dbSNP:rs56196591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041208" FT VARIANT 291 FT /note="K -> E (in dbSNP:rs34774243)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041209" FT VARIANT 296 FT /note="D -> H (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041210" FT VARIANT 305 FT /note="I -> T (in FTDALS4; dbSNP:rs770942184)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073940" FT VARIANT 306 FT /note="L -> I (in FTDALS4; uncertain significance; FT dbSNP:rs201970436)" FT /evidence="ECO:0000269|PubMed:21447600, FT ECO:0000269|PubMed:25943890" FT /id="VAR_069755" FT VARIANT 308..729 FT /note="Missing (loss of IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084113" FT VARIANT 308 FT /note="R -> Q (in FTDALS4; reduced kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073941" FT VARIANT 357 FT /note="R -> Q (in FTDALS4; reduced kinase activity; FT dbSNP:rs758357594)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073942" FT VARIANT 384 FT /note="R -> Q (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084114" FT VARIANT 388 FT /note="N -> D (in dbSNP:rs17857028)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_024746" FT VARIANT 388 FT /note="N -> S (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084115" FT VARIANT 397 FT /note="I -> T (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084116" FT VARIANT 401 FT /note="K -> E (in FTDALS4; dbSNP:rs756751089)" FT /evidence="ECO:0000269|PubMed:25943890" FT /id="VAR_073943" FT VARIANT 410 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1262765773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041211" FT VARIANT 440..729 FT /note="Missing (in AIARV; pathogenic)" FT /evidence="ECO:0000269|PubMed:32447396, FT ECO:0000269|PubMed:34363755" FT /id="VAR_089909" FT VARIANT 464 FT /note="V -> A (in dbSNP:rs35635889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21447600" FT /id="VAR_041212" FT VARIANT 508 FT /note="L -> I (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084117" FT VARIANT 522 FT /note="I -> M (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084118" FT VARIANT 533 FT /note="A -> T (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084119" FT VARIANT 559 FT /note="M -> R (in FTDALS4; loss of kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073944" FT VARIANT 570 FT /note="K -> Q (in dbSNP:rs17853341)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_024747" FT VARIANT 571 FT /note="A -> V (in FTDALS4; dbSNP:rs765035140)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073945" FT VARIANT 598 FT /note="M -> V (in FTDALS4; dbSNP:rs899858451)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073946" FT VARIANT 619..729 FT /note="Missing (in AIARV; pathogenic; homozygous patient- FT derived cells show high rates of cell death; loss of FT protein expression in homozygous patient cells)" FT /evidence="ECO:0000269|PubMed:34363755" FT /id="VAR_089910" FT VARIANT 643 FT /note="Missing (in FTDALS4)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073947" FT VARIANT 653 FT /note="E -> Q (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084120" FT VARIANT 659 FT /note="P -> S (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084121" FT VARIANT 696 FT /note="E -> K (in FTDALS4; loss of kinase activity; impairs FT binding to OPTN; dbSNP:rs748112833)" FT /evidence="ECO:0000269|PubMed:25803835, FT ECO:0000269|PubMed:25943890" FT /id="VAR_073948" FT MUTAGEN 30 FT /note="K->R: Decreases ubiquitination. Abolishes FT ubiquitination, phosphorylation and kinase activity; when FT associated with R-401." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 33 FT /note="D->A: Decreases phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 38 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10581243, FT ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:29150432, FT ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703" FT MUTAGEN 135 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:21931631, FT ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, FT ECO:0000269|PubMed:30842653" FT MUTAGEN 172 FT /note="S->A: Loss of kinase activity. No effect on FT dimerization. Loss of USP38-mediated degradation." FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:27692986" FT MUTAGEN 172 FT /note="S->E: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:23453972" FT MUTAGEN 316 FT /note="L->E: Decreases kinase activity. No effect on FT phosphorylation." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 325 FT /note="Y->E: Abolishes phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 355 FT /note="E->R: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with A-357 or R- FT 448." FT /evidence="ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:23453972" FT MUTAGEN 357 FT /note="R->A: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with R-355." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 401 FT /note="K->R: Decreases ubiquitination. Abolishes FT ubiquitination, phosphorylation and kinase activity; when FT associated with R-30." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 448 FT /note="E->R: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with R-355." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 459 FT /note="H->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-466 and E-470." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 466 FT /note="I->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-459 and E-470." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 470 FT /note="F->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-459 and E-466." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 547 FT /note="R->D: Decreases phosphorylation and kinase activity. FT Abolishes dimerization." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 577 FT /note="Y->A: Decreases kinase activity. Reduced FT phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:30842653" FT MUTAGEN 578 FT /note="N->A: Reduced phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:30842653" FT MUTAGEN 580 FT /note="E->A: Decreases kinase activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 581 FT /note="Q->A: Reduced phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:30842653" FT MUTAGEN 582 FT /note="I->A: Decreases kinase activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 584 FT /note="K->A: Decreased IFNB1 promoter activation." FT /evidence="ECO:0000269|PubMed:37926288" FT MUTAGEN 589 FT /note="K->D: Decreases phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 607 FT /note="K->A,R: Attenuated homodimerization during Sendai FT virus infection; decreased interaction with IRF3 or MAVS; FT decreased IFNB1 promoter activation." FT /evidence="ECO:0000269|PubMed:37926288" FT MUTAGEN 670 FT /note="K->R: Abrogates both 'Lys-48'-linked and 'Lys-33'- FT linked ubiquitination." FT /evidence="ECO:0000269|PubMed:27692986" FT MUTAGEN 690 FT /note="M->A: Decreases interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 693 FT /note="L->A: Almost abolishes interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 694 FT /note="K->E: Strongly decreases interaction with TANK and FT TBKBP1. No effect on phosphorylation." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 704 FT /note="L->A: Strongly decreases interaction with AZI2, TANK FT and TBKBP1. No effect on phosphorylation." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 708 FT /note="N->A: Decreases interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 711 FT /note="L->A: Almost abolishes interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT STRAND 1..3 FT /evidence="ECO:0007829|PDB:6CQ0" FT STRAND 5..17 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 19..28 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 29..31 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 34..40 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 42..46 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 49..61 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 65..67 FT /evidence="ECO:0007829|PDB:4IWO" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 82..87 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 94..99 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 109..128 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 138..140 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 151..155 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 161..163 FT /evidence="ECO:0007829|PDB:4IWQ" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:4EUT" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:4EUT" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 182..188 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 202..216 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 227..229 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 231..240 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 247..250 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6NT9" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 271..284 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 285..287 FT /evidence="ECO:0007829|PDB:4IWP" FT TURN 289..291 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 305..307 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 308..315 FT /evidence="ECO:0007829|PDB:4EFO" FT TURN 316..319 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 320..327 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 332..343 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 347..349 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 350..354 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 367..369 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 375..377 FT /evidence="ECO:0007829|PDB:4IM0" FT STRAND 379..383 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 408..480 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 498..526 FT /evidence="ECO:0007829|PDB:4IM0" FT TURN 527..529 FT /evidence="ECO:0007829|PDB:6RSU" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:4IWO" FT HELIX 535..539 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 544..546 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 548..571 FT /evidence="ECO:0007829|PDB:4IM0" FT STRAND 572..574 FT /evidence="ECO:0007829|PDB:6O8B" FT HELIX 577..603 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 605..647 FT /evidence="ECO:0007829|PDB:4IM0" FT TURN 648..651 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 680..714 FT /evidence="ECO:0007829|PDB:5EP6" FT STRAND 715..717 FT /evidence="ECO:0007829|PDB:5EP6" SQ SEQUENCE 729 AA; 83642 MW; B58E4FE1B502276D CRC64; MQSTSNHLWL LSDILGQGAT ANVFRGRHKK TGDLFAIKVF NNISFLRPVD VQMREFEVLK KLNHKNIVKL FAIEEETTTR HKVLIMEFCP CGSLYTVLEE PSNAYGLPES EFLIVLRDVV GGMNHLRENG IVHRDIKPGN IMRVIGEDGQ SVYKLTDFGA ARELEDDEQF VSLYGTEEYL HPDMYERAVL RKDHQKKYGA TVDLWSIGVT FYHAATGSLP FRPFEGPRRN KEVMYKIITG KPSGAISGVQ KAENGPIDWS GDMPVSCSLS RGLQVLLTPV LANILEADQE KCWGFDQFFA ETSDILHRMV IHVFSLQQMT AHKIYIHSYN TATIFHELVY KQTKIISSNQ ELIYEGRRLV LEPGRLAQHF PKTTEENPIF VVSREPLNTI GLIYEKISLP KVHPRYDLDG DASMAKAITG VVCYACRIAS TLLLYQELMR KGIRWLIELI KDDYNETVHK KTEVVITLDF CIRNIEKTVK VYEKLMKINL EAAELGEISD IHTKLLRLSS SQGTIETSLQ DIDSRLSPGG SLADAWAHQE GTHPKDRNVE KLQVLLNCMT EIYYQFKKDK AERRLAYNEE QIHKFDKQKL YYHATKAMTH FTDECVKKYE AFLNKSEEWI RKMLHLRKQL LSLTNQCFDI EEEVSKYQEY TNELQETLPQ KMFTASSGIK HTMTPIYPSS NTLVEMTLGM KKLKEEMEGV VKELAENNHI LERFGSLTMD GGLRNVDCL // ID TGFR2_HUMAN Reviewed; 567 AA. AC P37173; B4DTV5; Q15580; Q6DKT6; Q99474; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 258. DE RecName: Full=TGF-beta receptor type-2; DE Short=TGFR-2; DE EC=2.7.11.30; DE AltName: Full=TGF-beta type II receptor; DE AltName: Full=Transforming growth factor-beta receptor type II; DE Short=TGF-beta receptor type II; DE Short=TbetaR-II; DE Flags: Precursor; GN Name=TGFBR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-439, AND SUBCELLULAR RP LOCATION. RC TISSUE=Liver; RX PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RT "Expression cloning of the TGF-beta type II receptor, a functional RT transmembrane serine/threonine kinase."; RL Cell 68:775-785(1992). RN [2] RP ERRATUM OF PUBMED:1310899. RX PubMed=1525823; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RL Cell 70:1069-1069(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Glial cell; RX PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3; RA Nikawa J.; RT "A cDNA encoding the human transforming growth factor beta receptor RT suppresses the growth defect of a yeast mutant."; RL Gene 149:367-372(1994). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8812462; DOI=10.1006/geno.1996.0471; RA Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P., RA Harris C.C.; RT "The genomic structure of the gene encoding the human transforming growth RT factor beta type II receptor (TGF-beta RII)."; RL Genomics 36:341-344(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8840968; RA Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.; RT "Genomic structure of the transforming growth factor beta type II receptor RT gene and its mutations in hereditary nonpolyposis colorectal cancers."; RL Cancer Res. 56:4595-4598(1996). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439. RC TISSUE=Liver; RX PubMed=8973329; DOI=10.1016/s0378-1119(96)00501-x; RA Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.; RT "Cloning of a cDNA encoding the human transforming growth factor-beta type RT II receptor: heterogeneity of the mRNA."; RL Gene 181:185-190(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION (ISOFORM 3), SUBUNIT RP (ISOFORM 3), AND SUBCELLULAR LOCATION (ISOFORM 3). RC TISSUE=Peripheral blood T-cell {ECO:0000303|PubMed:34568316}; RX PubMed=34568316; DOI=10.3389/fcell.2021.690397; RA Bertolio M.S., La Colla A., Carrea A., Romo A., Canziani G., Echarte S.M., RA Campisano S., Barletta G.P., Monzon A.M., Rodriguez T.M., Chisari A.N., RA Dewey R.A.; RT "A Novel Splice Variant of Human TGF-beta Type II Receptor Encodes a RT Soluble Protein and Its Fc-Tagged Version Prevents Liver Fibrosis in RT vivo."; RL Front. Cell Dev. Biol. 9:690397-690397(2021). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36. RG NIEHS SNPs program; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 23-37. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [12] RP FUNCTION IN PHOSPHORYLATION OF TGFBR1. RX PubMed=7774578; DOI=10.1002/j.1460-2075.1995.tb07214.x; RA Wieser R., Wrana J.L., Massague J.; RT "GS domain mutations that constitutively activate T beta R-I, the RT downstream signaling component in the TGF-beta receptor complex."; RL EMBO J. 14:2199-2208(1995). RN [13] RP INTERACTION WITH CLU. RX PubMed=8555189; DOI=10.1021/bi951880a; RA Reddy K.B., Karode M.C., Harmony A.K., Howe P.H.; RT "Interaction of transforming growth factor beta receptors with RT apolipoprotein J/clusterin."; RL Biochemistry 35:309-314(1996). RN [14] RP ALTERNATIVE SPLICING (ISOFORM 2), AND FUNCTION (ISOFORMS 1 AND 2). RX PubMed=8635485; DOI=10.1006/excr.1996.0066; RA Hirai R., Fijita T.; RT "A human transforming growth factor-beta type II receptor that contains an RT insertion in the extracellular domain."; RL Exp. Cell Res. 223:135-141(1996). RN [15] RP INTERACTION WITH ZFYVE9. RX PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8; RA Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.; RT "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."; RL Cell 95:779-791(1998). RN [16] RP HOMODIMERIZATION. RX PubMed=9472030; DOI=10.1083/jcb.140.4.767; RA Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.; RT "Oligomeric structure of type I and type II transforming growth factor beta RT receptors: homodimers form in the ER and persist at the plasma membrane."; RL J. Cell Biol. 140:767-777(1998). RN [17] RP INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277. RX PubMed=11483955; DOI=10.1038/35087019; RA Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.; RT "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that RT facilitates JNK activation."; RL Nat. Cell Biol. 3:708-714(2001). RN [18] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [19] RP INTERACTION WITH DYNLT4. RX PubMed=16982625; DOI=10.1074/jbc.m608614200; RA Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T., RA McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.; RT "Identification of Tctex2beta, a novel dynein light chain family member RT that interacts with different transforming growth factor-beta receptors."; RL J. Biol. Chem. 281:37069-37080(2006). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP IDENTIFICATION IN A COMPLEX WITH TSC22D1 AND TGFBR1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [23] RP INTERACTION WITH SCUBE3. RX PubMed=21441952; DOI=10.1038/onc.2011.85; RA Wu Y.Y., Peck K., Chang Y.L., Pan S.H., Cheng Y.F., Lin J.C., Yang R.B., RA Hong T.M., Yang P.C.; RT "SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the RT epithelial-mesenchymal transition in lung cancer."; RL Oncogene 30:3682-3693(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUBCELLULAR LOCATION. RX PubMed=25893292; DOI=10.1038/onc.2015.100; RA Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.; RT "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial- RT to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I RT receptor internalization."; RL Oncogene 35:389-401(2016). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH TGF-BETA3, RP AND DISULFIDE BONDS. RX PubMed=11850637; DOI=10.1038/nsb766; RA Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.; RT "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex."; RL Nat. Struct. Biol. 9:203-208(2002). RN [28] RP X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159, AND DISULFIDE BONDS. RX PubMed=12121646; DOI=10.1016/s0969-2126(02)00780-3; RA Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.; RT "The 1.1 A crystal structure of human TGF-beta type II receptor ligand RT binding domain."; RL Structure 10:913-919(2002). RN [29] RP STRUCTURE BY NMR OF 38-159, AND DISULFIDE BONDS. RX PubMed=12939140; DOI=10.1021/bi034366a; RA Deep S., Walker K.P. III, Shu Z., Hinck A.P.; RT "Solution structure and backbone dynamics of the TGFbeta type II receptor RT extracellular domain."; RL Biochemistry 42:10126-10139(2003). RN [30] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 43-149 IN COMPLEX WITH TGFBR1 AND RP TGFB3, AND DISULFIDE BONDS. RX PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039; RA Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., RA Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.; RT "Cooperative assembly of TGF-beta superfamily signaling complexes is RT mediated by two disparate mechanisms and distinct modes of receptor RT binding."; RL Mol. Cell 29:157-168(2008). RN [31] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 38-153 IN COMPLEX WITH TGFBR1 AND RP TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS. RX PubMed=20207738; DOI=10.1074/jbc.m109.079921; RA Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.; RT "Ternary complex of transforming growth factor-beta1 reveals isoform- RT specific ligand recognition and receptor recruitment in the superfamily."; RL J. Biol. Chem. 285:14806-14814(2010). RN [32] RP VARIANT HNPCC6 MET-315. RX PubMed=9590282; DOI=10.1038/ng0598-17; RA Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K., RA Yuasa Y.; RT "HNPCC associated with germline mutation in the TGF-beta type II receptor RT gene."; RL Nat. Genet. 19:17-18(1998). RN [33] RP VARIANT ESOPHAGEAL CANCER GLN-526. RX PubMed=10789724; DOI=10.1054/bjoc.1999.1178; RA Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.; RT "A dominant negative mutation of transforming growth factor-beta receptor RT type II gene in microsatellite stable oesophageal carcinoma."; RL Br. J. Cancer 82:1557-1560(2000). RN [34] RP VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND RP CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND MET-452. RX PubMed=11212236; RA Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M., Hughes-Davies L., RA Kemp P.R., Hesketh R.; RT "Inhibiting mutations in the transforming growth factor beta type 2 RT receptor in recurrent human breast cancer."; RL Cancer Res. 61:482-485(2001). RN [35] RP VARIANT ILE-191. RX PubMed=12202987; DOI=10.1007/s100380200069; RA Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T., Matsumoto N., RA Ishikawa M., Niikawa N., Yoshiura K.; RT "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types RT of variations in genes for transforming growth factor-beta1 (TGF-beta1) and RT its signaling pathway."; RL J. Hum. Genet. 47:478-483(2002). RN [36] RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537. RX PubMed=15235604; DOI=10.1038/ng1392; RA Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N., RA Morisaki T., Allard D., Varret M., Claustres M., Morisaki H., Ihara M., RA Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G., Ohta T., RA Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C., Matsumoto N.; RT "Heterozygous TGFBR2 mutations in Marfan syndrome."; RL Nat. Genet. 36:855-860(2004). RN [37] RP VARIANTS LDS2 CYS-460 AND HIS-460. RX PubMed=16027248; DOI=10.1161/circulationaha.105.537340; RA Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E., RA Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S., RA Willing M.C., Raman C.S., Milewicz D.M.; RT "Mutations in transforming growth factor-beta receptor type II cause RT familial thoracic aortic aneurysms and dissections."; RL Circulation 112:513-520(2005). RN [38] RP VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528. RX PubMed=15731757; DOI=10.1038/ng1511; RA Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., RA Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., RA Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y., RA Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B., De Paepe A.M., RA Dietz H.C.; RT "A syndrome of altered cardiovascular, craniofacial, neurocognitive and RT skeletal development caused by mutations in TGFBR1 or TGFBR2."; RL Nat. Genet. 37:275-281(2005). RN [39] RP VARIANT LDS2 ASN-446. RX PubMed=16251899; DOI=10.1038/sj.ejhg.5201502; RA Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C., Porcu E., RA Tagliani M., Pilotto A., Diegoli M., Lanzarini L., Malattia C., RA Pelliccia A., Ficcadenti A., Gabrielli O., Arbustini E.; RT "Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not RT associated with FBN1 gene defects."; RL Eur. J. Hum. Genet. 14:34-38(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328; ILE-373; RP MET-387 AND SER-490. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [42] RP VARIANTS LDS2 HIS-190; VAL-247; PRO-325; ARG-357 AND ILE-530. RX PubMed=19533785; DOI=10.1002/ajmg.a.32918; RA Chung B.H., Lam S.T., Tong T.M., Li S.Y., Lun K.S., Chan D.H., Fok S.F., RA Or J.S., Smith D.K., Yang W., Lau Y.L.; RT "Identification of novel FBN1 and TGFBR2 mutations in 65 probands with RT Marfan syndrome or Marfan-like phenotypes."; RL Am. J. Med. Genet. A 149A:1452-1459(2009). RN [43] RP VARIANT LDS2 SER-510. RX PubMed=19883511; DOI=10.1186/1750-1172-4-24; RA Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R., RA Calzavara-Pinton P.G., Barlati S., Colombi M.; RT "Loeys-Dietz syndrome type I and type II: clinical findings and novel RT mutations in two Italian patients."; RL Orphanet J. Rare Dis. 4:24-24(2009). RN [44] RP VARIANT LDS2 LYS-457. RX PubMed=20101701; DOI=10.1002/ajmg.a.33263; RA Muramatsu Y., Kosho T., Magota M., Yokotsuka T., Ito M., Yasuda A., RA Kito O., Suzuki C., Nagata Y., Kawai S., Ikoma M., Hatano T., Nakayama M., RA Kawamura R., Wakui K., Morisaki H., Morisaki T., Fukushima Y.; RT "Progressive aortic root and pulmonary artery aneurysms in a neonate with RT Loeys-Dietz syndrome type 1B."; RL Am. J. Med. Genet. A 152:417-421(2010). RN [45] RP VARIANTS LDS2 PRO-308 AND ARG-521. RX PubMed=20358619; DOI=10.1002/ajmg.a.33356; RA Kirmani S., Tebben P.J., Lteif A.N., Gordon D., Clarke B.L., Hefferan T.E., RA Yaszemski M.J., McGrann P.S., Lindor N.M., Ellison J.W.; RT "Germline TGF-beta receptor mutations and skeletal fragility: a report on RT two patients with Loeys-Dietz syndrome."; RL Am. J. Med. Genet. A 152:1016-1019(2010). RN [46] RP VARIANTS LDS2 GLN-306 DELINS HIS-GLU; ARG-377; PHE-449 AND ARG-514. RX PubMed=22113417; DOI=10.1038/jhg.2011.130; RA Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K., RA Lee H.J., Kim D.K.; RT "Clinical features and genetic analysis of Korean patients with Loeys-Dietz RT syndrome."; RL J. Hum. Genet. 57:52-56(2012). RN [47] RP VARIANTS LDS2 VAL-509 AND PHE-510. RX PubMed=21949523; DOI=10.3345/kjp.2011.54.6.272; RA Ha J.S., Kim Y.H.; RT "A sporadic case of Loeys-Dietz syndrome type I with two novel mutations of RT the TGFBR2 gene."; RL Korean J. Pediatr. 54:272-275(2011). CC -!- FUNCTION: Transmembrane serine/threonine kinase forming with the TGF- CC beta type I serine/threonine kinase receptor, TGFBR1, the non- CC promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. CC Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to CC the cytoplasm and thus regulates a plethora of physiological and CC pathological processes including cell cycle arrest in epithelial and CC hematopoietic cells, control of mesenchymal cell proliferation and CC differentiation, wound healing, extracellular matrix production, CC immunosuppression and carcinogenesis. The formation of the receptor CC complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound CC to the cytokine dimer results in the phosphorylation and activation of CC TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 CC phosphorylates SMAD2 which dissociates from the receptor and interacts CC with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the CC nucleus where it modulates the transcription of the TGF-beta-regulated CC genes. This constitutes the canonical SMAD-dependent TGF-beta signaling CC cascade. Also involved in non-canonical, SMAD-independent TGF-beta CC signaling pathways. {ECO:0000269|PubMed:7774578}. CC -!- FUNCTION: [Isoform 1]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar CC affinity range without the participation of additional receptors. CC Blocks activation of SMAD2 and SMAD3 by TGFB1. CC {ECO:0000269|PubMed:34568316}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric CC ligands assemble a functional receptor composed of two TGFBR1 and CC TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The CC respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate CC the kinetics of assembly of the receptor and may explain the different CC biological activities of TGFB1, TGFB2 and TGFB3. Component of a complex CC composed of TSC22D1 (via N-terminus), TGFBR1 and TGFBR2; the CC interaction between TSC22D1 and TGFBR1 is inhibited by SMAD7 and CC promoted by TGFB1 (PubMed:21791611). Interacts with DAXX. Interacts CC with DYNLT4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to CC the TGF-beta receptor. Interacts with and is activated by SCUBE3; this CC interaction does not affect TGFB1-binding to TGFBR2. Interacts with CC VPS39; this interaction is independent of the receptor kinase activity CC and of the presence of TGF-beta. Interacts with CLU (PubMed:8555189). CC {ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11850637, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:16982625, CC ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738, CC ECO:0000269|PubMed:21441952, ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:8555189, ECO:0000269|PubMed:9865696}. CC -!- SUBUNIT: [Isoform 3]: Homodimer; disulfide-linked. CC {ECO:0000269|PubMed:34568316}. CC -!- INTERACTION: CC P37173; P54819: AK2; NbExp=3; IntAct=EBI-296151, EBI-1056291; CC P37173; P61966-2: AP1S1; NbExp=3; IntAct=EBI-296151, EBI-12067760; CC P37173; Q9NP61: ARFGAP3; NbExp=3; IntAct=EBI-296151, EBI-2875816; CC P37173; O75143-2: ATG13; NbExp=3; IntAct=EBI-296151, EBI-20151086; CC P37173; Q93084-2: ATP2A3; NbExp=3; IntAct=EBI-296151, EBI-21505448; CC P37173; P54253: ATXN1; NbExp=3; IntAct=EBI-296151, EBI-930964; CC P37173; P54252: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-946046; CC P37173; Q4VBR4: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-12928880; CC P37173; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-296151, EBI-742750; CC P37173; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-296151, EBI-747505; CC P37173; P40227: CCT6A; NbExp=3; IntAct=EBI-296151, EBI-356687; CC P37173; P12830: CDH1; NbExp=3; IntAct=EBI-296151, EBI-727477; CC P37173; Q8NE08: COL25A1; NbExp=3; IntAct=EBI-296151, EBI-25836642; CC P37173; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-296151, EBI-9087876; CC P37173; Q9UER7: DAXX; NbExp=2; IntAct=EBI-296151, EBI-77321; CC P37173; Q9UMR2: DDX19B; NbExp=3; IntAct=EBI-296151, EBI-719232; CC P37173; P49184: DNASE1L1; NbExp=3; IntAct=EBI-296151, EBI-20894690; CC P37173; O14531: DPYSL4; NbExp=3; IntAct=EBI-296151, EBI-719542; CC P37173; P26378-2: ELAVL4; NbExp=3; IntAct=EBI-296151, EBI-21603100; CC P37173; P15036: ETS2; NbExp=3; IntAct=EBI-296151, EBI-1646991; CC P37173; P09471: GNAO1; NbExp=3; IntAct=EBI-296151, EBI-715087; CC P37173; P51674: GPM6A; NbExp=3; IntAct=EBI-296151, EBI-7187133; CC P37173; P42858: HTT; NbExp=3; IntAct=EBI-296151, EBI-466029; CC P37173; O75874: IDH1; NbExp=3; IntAct=EBI-296151, EBI-715695; CC P37173; Q6PI98: INO80C; NbExp=3; IntAct=EBI-296151, EBI-722540; CC P37173; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-296151, EBI-2557660; CC P37173; P06756: ITGAV; NbExp=3; IntAct=EBI-296151, EBI-298282; CC P37173; P23276: KEL; NbExp=3; IntAct=EBI-296151, EBI-746662; CC P37173; O60259: KLK8; NbExp=3; IntAct=EBI-296151, EBI-3915857; CC P37173; Q96E93: KLRG1; NbExp=3; IntAct=EBI-296151, EBI-750770; CC P37173; Q8N448: LNX2; NbExp=3; IntAct=EBI-296151, EBI-2340947; CC P37173; Q7Z434: MAVS; NbExp=3; IntAct=EBI-296151, EBI-995373; CC P37173; Q93074: MED12; NbExp=3; IntAct=EBI-296151, EBI-394357; CC P37173; Q14728: MFSD10; NbExp=3; IntAct=EBI-296151, EBI-11337904; CC P37173; P01106: MYC; NbExp=3; IntAct=EBI-296151, EBI-447544; CC P37173; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-296151, EBI-3446748; CC P37173; Q99435-2: NELL2; NbExp=3; IntAct=EBI-296151, EBI-17754404; CC P37173; Q8TAT6: NPLOC4; NbExp=3; IntAct=EBI-296151, EBI-1994109; CC P37173; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-296151, EBI-22002759; CC P37173; Q96IY1: NSL1; NbExp=3; IntAct=EBI-296151, EBI-2554690; CC P37173; Q16549: PCSK7; NbExp=3; IntAct=EBI-296151, EBI-8059854; CC P37173; Q9NUD9: PIGV; NbExp=3; IntAct=EBI-296151, EBI-25836582; CC P37173; Q8TBJ4: PLPPR1; NbExp=3; IntAct=EBI-296151, EBI-18063495; CC P37173; Q07869: PPARA; NbExp=3; IntAct=EBI-296151, EBI-78615; CC P37173; Q13200: PSMD2; NbExp=3; IntAct=EBI-296151, EBI-357648; CC P37173; P21246: PTN; NbExp=3; IntAct=EBI-296151, EBI-473725; CC P37173; Q13702-2: RAPSN; NbExp=3; IntAct=EBI-296151, EBI-22012855; CC P37173; P52756: RBM5; NbExp=3; IntAct=EBI-296151, EBI-714003; CC P37173; Q6NTF9-3: RHBDD2; NbExp=3; IntAct=EBI-296151, EBI-17589229; CC P37173; Q96NA2: RILP; NbExp=3; IntAct=EBI-296151, EBI-2856119; CC P37173; P61513: RPL37A; NbExp=3; IntAct=EBI-296151, EBI-356793; CC P37173; Q8IX30: SCUBE3; NbExp=6; IntAct=EBI-296151, EBI-4479975; CC P37173; Q8NC51: SERBP1; NbExp=3; IntAct=EBI-296151, EBI-523558; CC P37173; Q16586: SGCA; NbExp=3; IntAct=EBI-296151, EBI-5663553; CC P37173; Q99720-4: SIGMAR1; NbExp=3; IntAct=EBI-296151, EBI-25831036; CC P37173; Q8NCS7: SLC44A5; NbExp=3; IntAct=EBI-296151, EBI-21504521; CC P37173; Q16560-2: SNRNP35; NbExp=3; IntAct=EBI-296151, EBI-12938570; CC P37173; Q7Z614-3: SNX20; NbExp=3; IntAct=EBI-296151, EBI-12336127; CC P37173; Q3SY56: SP6; NbExp=3; IntAct=EBI-296151, EBI-11175533; CC P37173; P46977: STT3A; NbExp=3; IntAct=EBI-296151, EBI-719212; CC P37173; O43463: SUV39H1; NbExp=3; IntAct=EBI-296151, EBI-349968; CC P37173; Q13428-5: TCOF1; NbExp=3; IntAct=EBI-296151, EBI-25832010; CC P37173; P01137: TGFB1; NbExp=11; IntAct=EBI-296151, EBI-779636; CC P37173; P10600: TGFB3; NbExp=8; IntAct=EBI-296151, EBI-1033020; CC P37173; Q9Y228: TRAF3IP3; NbExp=3; IntAct=EBI-296151, EBI-765817; CC P37173; Q96BQ3: TRIM43; NbExp=3; IntAct=EBI-296151, EBI-2129899; CC P37173; Q9UHP3: USP25; NbExp=3; IntAct=EBI-296151, EBI-2513462; CC P37173; Q969W3: VCF1; NbExp=3; IntAct=EBI-296151, EBI-10281506; CC P37173; P19544-6: WT1; NbExp=3; IntAct=EBI-296151, EBI-11745701; CC P37173; P25490: YY1; NbExp=3; IntAct=EBI-296151, EBI-765538; CC P37173; A2AGH6: Med12; Xeno; NbExp=3; IntAct=EBI-296151, EBI-5744969; CC P37173; P07200: TGFB1; Xeno; NbExp=2; IntAct=EBI-296151, EBI-907660; CC P37173-2; P02750: LRG1; NbExp=3; IntAct=EBI-16065370, EBI-9083443; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1310899, CC ECO:0000269|PubMed:25893292}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:1310899}. Membrane raft CC {ECO:0000269|PubMed:25893292}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted CC {ECO:0000269|PubMed:34568316}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=betaR-II {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-1; Sequence=Displayed; CC Name=2; Synonyms=betaR-IIB {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-2; Sequence=VSP_012157; CC Name=3; Synonyms=TbetaRII-SE {ECO:0000303|PubMed:34568316}; CC IsoId=P37173-3; Sequence=VSP_061513, VSP_061514; CC -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic domain. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 6 (HNPCC6) CC [MIM:614331]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:9590282}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10789724}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic aneurysm CC syndrome with widespread systemic involvement, characterized by CC arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or CC cleft palate. Physical findings include prominent joint laxity, easy CC bruising, wide and atrophic scars, velvety and translucent skin with CC easily visible veins, spontaneous rupture of the spleen or bowel, and CC catastrophic complications of pregnancy, including rupture of the CC gravid uterus and the arteries, either during pregnancy or in the CC immediate postpartum period. Some patients have craniosynostosis, CC exotropy, micrognathia and retrognathia, structural brain CC abnormalities, and intellectual deficit. {ECO:0000269|PubMed:15235604, CC ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16027248, CC ECO:0000269|PubMed:16251899, ECO:0000269|PubMed:19533785, CC ECO:0000269|PubMed:19883511, ECO:0000269|PubMed:20101701, CC ECO:0000269|PubMed:20358619, ECO:0000269|PubMed:21949523, CC ECO:0000269|PubMed:22113417}. Note=The disease is caused by variants CC affecting the gene represented in this entry. TGFBR2 mutations Cys-460 CC and His-460 have been reported to be associated with thoracic aortic CC aneurysms and dissection (TAAD). This phenotype, also known as thoracic CC aortic aneurysms type 3 (AAT3), is distinguised from LDS2 by having CC aneurysms restricted to thoracic aorta. As individuals carrying these CC mutations also exhibit descending aortic disease and aneurysms of other CC arteries (PubMed:16027248), they have been considered as LDS2 by the CC OMIM resource. {ECO:0000269|PubMed:16027248}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M85079; AAA61164.1; -; mRNA. DR EMBL; D28131; BAA05673.1; -; mRNA. DR EMBL; U52246; AAB17553.1; -; Genomic_DNA. DR EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U69152; AAB40916.1; -; Genomic_DNA. DR EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; D50683; BAA09332.1; -; mRNA. DR EMBL; MW881156; UDE22710.1; -; mRNA. DR EMBL; AY675319; AAT70724.1; -; Genomic_DNA. DR EMBL; AK300383; BAG62117.1; -; mRNA. DR EMBL; CH471055; EAW64412.1; -; Genomic_DNA. DR CCDS; CCDS2648.1; -. [P37173-1] DR CCDS; CCDS33727.1; -. [P37173-2] DR PIR; A42100; A42100. DR RefSeq; NP_001020018.1; NM_001024847.3. [P37173-2] DR RefSeq; NP_003233.4; NM_003242.5. [P37173-1] DR PDB; 1KTZ; X-ray; 2.15 A; B=38-159. DR PDB; 1M9Z; X-ray; 1.05 A; A=49-159. DR PDB; 1PLO; NMR; -; A=38-159. DR PDB; 2PJY; X-ray; 3.00 A; B=42-149. DR PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153. DR PDB; 4P7U; X-ray; 1.50 A; A=49-159. DR PDB; 4XJJ; X-ray; 1.40 A; A=50-159. DR PDB; 5E8V; X-ray; 1.69 A; A=237-549. DR PDB; 5E8Y; X-ray; 2.05 A; A=237-549. DR PDB; 5E91; X-ray; 2.42 A; A=237-549. DR PDB; 5E92; X-ray; 2.08 A; A=237-549. DR PDB; 5QIN; X-ray; 1.57 A; A=237-549. DR PDB; 5TX4; X-ray; 1.88 A; A=38-153. DR PDB; 5TY4; EM; 2.90 A; A=47-149. DR PDB; 7DV6; X-ray; 2.39 A; A=237-549. DR PDB; 8G4K; X-ray; 1.24 A; B=45-155. DR PDB; 8YGZ; X-ray; 2.10 A; A=237-549. DR PDB; 9B9F; X-ray; 3.00 A; D/I=42-153. DR PDB; 9E9G; X-ray; 1.40 A; A=38-154. DR PDB; 9FDY; EM; 3.40 A; D/E=42-153. DR PDB; 9FK5; EM; 4.10 A; D=42-153. DR PDB; 9FKP; EM; 3.72 A; D/E=42-153. DR PDBsum; 1KTZ; -. DR PDBsum; 1M9Z; -. DR PDBsum; 1PLO; -. DR PDBsum; 2PJY; -. DR PDBsum; 3KFD; -. DR PDBsum; 4P7U; -. DR PDBsum; 4XJJ; -. DR PDBsum; 5E8V; -. DR PDBsum; 5E8Y; -. DR PDBsum; 5E91; -. DR PDBsum; 5E92; -. DR PDBsum; 5QIN; -. DR PDBsum; 5TX4; -. DR PDBsum; 5TY4; -. DR PDBsum; 7DV6; -. DR PDBsum; 8G4K; -. DR PDBsum; 8YGZ; -. DR PDBsum; 9B9F; -. DR PDBsum; 9E9G; -. DR PDBsum; 9FDY; -. DR PDBsum; 9FK5; -. DR PDBsum; 9FKP; -. DR AlphaFoldDB; P37173; -. DR BMRB; P37173; -. DR EMDB; EMD-50333; -. DR EMDB; EMD-50519; -. DR EMDB; EMD-50524; -. DR EMDB; EMD-8472; -. DR SMR; P37173; -. DR BioGRID; 112906; 202. DR ComplexPortal; CPX-2544; TGF-beta-3-TGFR complex. DR ComplexPortal; CPX-529; TGF-beta-1-TGFR complex. DR ComplexPortal; CPX-834; TGF-beta-2-TGFR complex. DR CORUM; P37173; -. DR DIP; DIP-5939N; -. DR FunCoup; P37173; 1304. DR IntAct; P37173; 185. DR MINT; P37173; -. DR STRING; 9606.ENSP00000351905; -. DR BindingDB; P37173; -. DR ChEMBL; CHEMBL4267; -. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P37173; -. DR GuidetoPHARMACOLOGY; 1795; -. DR GlyConnect; 1979; 9 N-Linked glycans (3 sites). DR GlyCosmos; P37173; 5 sites, 9 glycans. DR GlyGen; P37173; 7 sites, 11 N-linked glycans (3 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P37173; -. DR PhosphoSitePlus; P37173; -. DR SwissPalm; P37173; -. DR BioMuta; TGFBR2; -. DR DMDM; 116242818; -. DR jPOST; P37173; -. DR MassIVE; P37173; -. DR PaxDb; 9606-ENSP00000351905; -. DR PeptideAtlas; P37173; -. DR ProteomicsDB; 55264; -. [P37173-1] DR ProteomicsDB; 55265; -. [P37173-2] DR Pumba; P37173; -. DR Antibodypedia; 11570; 809 antibodies from 42 providers. DR DNASU; 7048; -. DR Ensembl; ENST00000295754.10; ENSP00000295754.5; ENSG00000163513.21. [P37173-1] DR Ensembl; ENST00000359013.4; ENSP00000351905.4; ENSG00000163513.21. [P37173-2] DR GeneID; 7048; -. DR KEGG; hsa:7048; -. DR MANE-Select; ENST00000295754.10; ENSP00000295754.5; NM_003242.6; NP_003233.4. DR UCSC; uc003cen.4; human. [P37173-1] DR AGR; HGNC:11773; -. DR ClinPGx; PA36486; -. DR CTD; 7048; -. DR DisGeNET; 7048; -. DR GeneCards; TGFBR2; -. DR GeneReviews; TGFBR2; -. DR HGNC; HGNC:11773; TGFBR2. DR HPA; ENSG00000163513; Low tissue specificity. DR MalaCards; TGFBR2; -. DR MIM; 133239; phenotype. DR MIM; 190182; gene. DR MIM; 610168; phenotype. DR MIM; 614331; phenotype. DR OpenTargets; ENSG00000163513; -. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 60030; Loeys-Dietz syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 284973; Marfan syndrome type 2. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000163513; -. DR eggNOG; KOG3653; Eukaryota. DR GeneTree; ENSGT00940000157527; -. DR HOGENOM; CLU_000288_8_3_1; -. DR InParanoid; P37173; -. DR OMA; QMPNLCK; -. DR OrthoDB; 547665at2759; -. DR PAN-GO; P37173; 12 GO annotations based on evolutionary models. DR PhylomeDB; P37173; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P37173; -. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer. DR Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer. DR Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer. DR Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer. DR Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-9839389; TGFBR3 regulates TGF-beta signaling. DR SignaLink; P37173; -. DR SIGNOR; P37173; -. DR Agora; ENSG00000163513; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 7048; 45 hits in 1213 CRISPR screens. DR ChiTaRS; TGFBR2; human. DR EvolutionaryTrace; P37173; -. DR GeneWiki; TGF_beta_receptor_2; -. DR GenomeRNAi; 7048; -. DR Pharos; P37173; Tchem. DR PRO; PR:P37173; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P37173; protein. DR Bgee; ENSG00000163513; Expressed in pericardium and 211 other cell types or tissues. DR ExpressionAtlas; P37173; baseline and differential. DR GO; GO:0048179; C:activin receptor complex; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0070021; C:transforming growth factor beta ligand-receptor complex; IPI:ComplexPortal. DR GO; GO:0048185; F:activin binding; IBA:GO_Central. DR GO; GO:0016361; F:activin receptor activity, type I; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL. DR GO; GO:0019209; F:kinase activator activity; IEA:Ensembl. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL. DR GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL. DR GO; GO:0005024; F:transforming growth factor beta receptor activity; IDA:BHF-UCL. DR GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IDA:UniProt. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; IMP:BHF-UCL. DR GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0048844; P:artery morphogenesis; IMP:BHF-UCL. DR GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001568; P:blood vessel development; TAS:BHF-UCL. DR GO; GO:0007420; P:brain development; ISS:BHF-UCL. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; ISS:BHF-UCL. DR GO; GO:0060434; P:bronchus morphogenesis; IEA:Ensembl. DR GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL. DR GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL. DR GO; GO:0003274; P:endocardial cushion fusion; ISS:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:BHF-UCL. DR GO; GO:0001947; P:heart looping; ISS:BHF-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:1905317; P:inferior endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0061520; P:Langerhans cell differentiation; IEA:Ensembl. DR GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl. DR GO; GO:1990086; P:lens fiber cell apoptotic process; IEA:Ensembl. DR GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl. DR GO; GO:0060443; P:mammary gland morphogenesis; IEA:Ensembl. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:BHF-UCL. DR GO; GO:1990428; P:miRNA transport; ISS:BHF-UCL. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0002663; P:positive regulation of B cell tolerance induction; ISS:BHF-UCL. DR GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL. DR GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL. DR GO; GO:0051138; P:positive regulation of NK T cell differentiation; ISS:BHF-UCL. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0002666; P:positive regulation of T cell tolerance induction; ISS:BHF-UCL. DR GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; ISS:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:2000736; P:regulation of stem cell differentiation; IMP:BHF-UCL. DR GO; GO:0072091; P:regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IDA:BHF-UCL. DR GO; GO:0060021; P:roof of mouth development; IMP:BHF-UCL. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0060395; P:SMAD protein signal transduction; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd14055; STKc_TGFbR2_like; 1. DR CDD; cd23538; TFP_LU_ECD_TGFR2; 1. DR DisProt; DP01760; -. DR FunFam; 1.10.510.10:FF:000260; TGF-beta receptor type-2; 1. DR FunFam; 2.10.60.10:FF:000009; TGF-beta receptor type-2; 1. DR FunFam; 3.30.200.20:FF:000213; TGF-beta receptor type-2; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00414; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR InterPro; IPR017194; Transform_growth_fac-b_typ-2. DR InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto. DR PANTHER; PTHR23255:SF55; TGF-BETA RECEPTOR TYPE-2; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF08917; ecTbetaR2; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF037393; TGFRII; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis; KW ATP-binding; Cell membrane; Craniosynostosis; Differentiation; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Growth regulation; Hereditary nonpolyposis colorectal cancer; Kinase; KW Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Secreted; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 23..567 FT /note="TGF-beta receptor type-2" FT /id="PRO_0000024426" FT TOPO_DOM 23..166 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 167..187 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 188..567 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 244..544 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 439..567 FT /note="Sufficient for interaction with CLU" FT /evidence="ECO:0000269|PubMed:8555189" FT ACT_SITE 379 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 250..258 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 277 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 409 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT MOD_RES 548 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 553 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT CARBOHYD 70 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 94 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 154 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 51..84 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 54..71 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 61..67 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 77..101 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 121..136 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 138..143 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT VAR_SEQ 31..32 FT /note="SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7959019" FT /id="VSP_012157" FT VAR_SEQ 68..80 FT /note="MSNCSITSICEKP -> FSKVHYEGKKKAW (in isoform 3)" FT /id="VSP_061513" FT VAR_SEQ 81..567 FT /note="Missing (in isoform 3)" FT /id="VSP_061514" FT VARIANT 36 FT /note="M -> V (in dbSNP:rs17025864)" FT /evidence="ECO:0000269|Ref.8" FT /id="VAR_020510" FT VARIANT 61 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041414" FT VARIANT 73 FT /note="I -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036070" FT VARIANT 190 FT /note="R -> H (in LDS2; dbSNP:rs780542125)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076167" FT VARIANT 191 FT /note="V -> I (in dbSNP:rs56105708)" FT /evidence="ECO:0000269|PubMed:12202987, FT ECO:0000269|PubMed:17344846" FT /id="VAR_017606" FT VARIANT 247 FT /note="D -> V (in LDS2; dbSNP:rs761231369)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076168" FT VARIANT 306 FT /note="Q -> HE (in LDS2)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066723" FT VARIANT 308 FT /note="L -> P (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs28934568)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:20358619" FT /id="VAR_022351" FT VARIANT 315 FT /note="T -> M (in HNPCC6; dbSNP:rs34833812)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9590282" FT /id="VAR_008156" FT VARIANT 325 FT /note="T -> P (in LDS2; dbSNP:rs2125435431)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076169" FT VARIANT 328 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs2125435491)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041415" FT VARIANT 336 FT /note="Y -> N (in LDS2; dbSNP:rs104893812)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022352" FT VARIANT 355 FT /note="A -> P (in LDS2; dbSNP:rs104893813)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022353" FT VARIANT 357 FT /note="G -> R (in LDS2)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076170" FT VARIANT 357 FT /note="G -> W (in LDS2; dbSNP:rs104893814)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022354" FT VARIANT 373 FT /note="M -> I (in dbSNP:rs35719192)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041416" FT VARIANT 377 FT /note="H -> R (in LDS2; dbSNP:rs1553630274)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066724" FT VARIANT 387 FT /note="V -> M (in a breast tumor; dbSNP:rs35766612)" FT /evidence="ECO:0000269|PubMed:11212236, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022355" FT VARIANT 435 FT /note="N -> S (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022356" FT VARIANT 439 FT /note="V -> A (in dbSNP:rs1050833)" FT /evidence="ECO:0000269|PubMed:1310899, FT ECO:0000269|PubMed:8812462, ECO:0000269|PubMed:8840968, FT ECO:0000269|PubMed:8973329" FT /id="VAR_028063" FT VARIANT 446 FT /note="D -> N (in LDS2; dbSNP:rs886039551)" FT /evidence="ECO:0000269|PubMed:16251899" FT /id="VAR_066725" FT VARIANT 447 FT /note="V -> A (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022357" FT VARIANT 449 FT /note="S -> F (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893807)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:22113417" FT /id="VAR_022358" FT VARIANT 452 FT /note="L -> M (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022359" FT VARIANT 457 FT /note="M -> K (in LDS2)" FT /evidence="ECO:0000269|PubMed:20101701" FT /id="VAR_066726" FT VARIANT 460 FT /note="R -> C (in LDS2; dbSNP:rs104893811)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029760" FT VARIANT 460 FT /note="R -> H (in LDS2; dbSNP:rs104893816)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029761" FT VARIANT 490 FT /note="N -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1699660823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041417" FT VARIANT 509 FT /note="G -> V (in LDS2; dbSNP:rs863223853)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066727" FT VARIANT 510 FT /note="I -> F (in LDS2; dbSNP:rs2125455070)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066728" FT VARIANT 510 FT /note="I -> S (in LDS2)" FT /evidence="ECO:0000269|PubMed:19883511" FT /id="VAR_066729" FT VARIANT 514 FT /note="C -> R (in LDS2; dbSNP:rs193922664)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066730" FT VARIANT 521 FT /note="W -> R (in LDS2; dbSNP:rs1575166666)" FT /evidence="ECO:0000269|PubMed:20358619" FT /id="VAR_066731" FT VARIANT 526 FT /note="E -> Q (in esophageal cancer; dbSNP:rs121918714)" FT /evidence="ECO:0000269|PubMed:10789724" FT /id="VAR_015816" FT VARIANT 528 FT /note="R -> C (in LDS2; dbSNP:rs104893810)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022360" FT VARIANT 528 FT /note="R -> H (in LDS2; dbSNP:rs104893815)" FT /evidence="ECO:0000269|PubMed:15731757, FT ECO:0000269|PubMed:16959974" FT /id="VAR_022361" FT VARIANT 530 FT /note="T -> I (in LDS2; dbSNP:rs1699708963)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076171" FT VARIANT 537 FT /note="R -> C (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893809)" FT /evidence="ECO:0000269|PubMed:15235604" FT /id="VAR_022362" FT MUTAGEN 277 FT /note="K->R: Abolishes kinase activity, TGF-beta signaling FT and interaction with DAXX." FT /evidence="ECO:0000269|PubMed:11483955" FT CONFLICT 381 FT /note="K -> N (in Ref. 6; BAA09332)" FT /evidence="ECO:0000305" FT STRAND 40..45 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 50..52 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 55..58 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 65..68 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 74..76 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 78..81 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 83..90 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 95..102 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 104..106 FT /evidence="ECO:0007829|PDB:5TY4" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:2PJY" FT TURN 114..117 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 119..122 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 124..126 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 131..138 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:1PLO" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 146..148 FT /evidence="ECO:0007829|PDB:1M9Z" FT HELIX 151..153 FT /evidence="ECO:0007829|PDB:9E9G" FT STRAND 244..252 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 257..263 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 267..269 FT /evidence="ECO:0007829|PDB:7DV6" FT STRAND 272..280 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 281..283 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 284..294 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 297..299 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 307..315 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 333..339 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 344..362 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 382..384 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 385..387 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 393..395 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 410..413 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 422..424 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 427..430 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 440..459 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 473..477 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 484..491 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 492..494 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 502..506 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 508..520 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 531..539 FT /evidence="ECO:0007829|PDB:5QIN" SQ SEQUENCE 567 AA; 64568 MW; C541DA751FFBDBEB CRC64; MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE LEHLDRLSGR SCSEEKIPED GSLNTTK // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML // ID UB2V1_HUMAN Reviewed; 147 AA. AC Q13404; E1P629; Q13403; Q13532; Q5TGE0; Q5TGE3; Q96H34; Q9GZT0; Q9GZW1; AC Q9H4J3; Q9H4J4; Q9UKL1; Q9UM48; Q9UM49; Q9UM50; DT 31-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Ubiquitin-conjugating enzyme E2 variant 1; DE Short=UEV-1; DE AltName: Full=CROC-1; DE AltName: Full=TRAF6-regulated IKK activator 1 beta Uev1A; GN Name=UBE2V1; Synonyms=CROC1, UBE2V, UEV1; ORFNames=P/OKcl.19; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND SUBCELLULAR RP LOCATION. RC TISSUE=Brain; RX PubMed=9305758; DOI=10.1016/s0378-1119(97)00097-8; RA Rothofsky M.L., Lin S.L.; RT "CROC-1 encodes a protein which mediates transcriptional activation of the RT human FOS promoter."; RL Gene 195:141-149(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4), FUNCTION, INDUCTION, AND RP TISSUE SPECIFICITY. RC TISSUE=Colon adenocarcinoma; RX PubMed=9418904; DOI=10.1128/mcb.18.1.576; RA Sancho E., Vila M.R., Sanchez-Pulido L., Lozano J.J., Paciucci R., RA Nadal M., Fox M., Harvey C., Bercovich B., Loukili N., Ciechanover A., RA Lin S.L., Sanz F., Estivill X., Valencia A., Thomson T.M.; RT "Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating RT enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 RT intestinal mucosecretory cells."; RL Mol. Cell. Biol. 18:576-589(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), FUNCTION, INTERACTION WITH TRAF6 RP AND UBE2N, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11057907; DOI=10.1016/s0092-8674(00)00126-4; RA Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., RA Pickart C., Chen Z.J.; RT "Activation of the IkappaB kinase complex by TRAF6 requires a dimeric RT ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain."; RL Cell 103:351-361(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6). RC TISSUE=Lung; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-13 (ISOFORM 3), CLEAVAGE OF INITIATOR METHIONINE, RP ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Lung fibroblast; RA Bienvenut W.V., Pchelintsev N., Adams P.D.; RL Submitted (JUL-2009) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-147 (ISOFORMS 1 AND 3). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP FUNCTION. RX PubMed=9580084; DOI=10.1016/s0014-5793(98)00060-x; RA Thomson T.M., Khalid H., Lozano J.J., Sancho E., Arino J.; RT "Role of UEV-1A, a homologue of the tumor suppressor protein TSG101, in RT protection from DNA damage."; RL FEBS Lett. 423:49-52(1998). RN [11] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=9705497; DOI=10.1093/nar/26.17.3908; RA Xiao W., Lin S.L., Broomfield S., Chow B.L., Wei Y.-F.; RT "The products of the yeast MMS2 and two human homologs (hMMS2 and CROC-1) RT define a structurally and functionally conserved Ubc-like protein family."; RL Nucleic Acids Res. 26:3908-3914(1998). RN [12] RP SUBCELLULAR LOCATION, AND IDENTIFICATION OF PESD1-UBE2V1 FUSION PROTEIN. RC TISSUE=Colon cancer; RX PubMed=11076860; DOI=10.1101/gr.gr-1405r; RA Thomson T.M., Lozano J.J., Loukili N., Carrio R., Serras F., Cormand B., RA Valeri M., Diaz V.M., Abril J., Burset M., Merino J., Macaya A., RA Corominas M., Guigo R.; RT "Fusion of the human gene for the polyubiquitination coeffector UEV1 with RT Kua, a newly identified gene."; RL Genome Res. 10:1743-1756(2000). RN [13] RP FUNCTION. RX PubMed=19825828; DOI=10.1126/scisignal.2000382; RA Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., Misra S., RA Deng L., Chen Z.J., Li X.; RT "Act1, a U-box E3 ubiquitin ligase for IL-17 signaling."; RL Sci. Signal. 2:ra63-ra63(2009). RN [14] RP FUNCTION. RX PubMed=20061386; DOI=10.1074/jbc.m109.089003; RA David Y., Ziv T., Admon A., Navon A.; RT "The E2 ubiquitin-conjugating enzymes direct polyubiquitination to RT preferred lysines."; RL J. Biol. Chem. 285:8595-8604(2010). RN [15] RP FUNCTION. RX PubMed=21512573; DOI=10.1038/nature09976; RA Pertel T., Hausmann S., Morger D., Zueger S., Guerra J., Lascano J., RA Reinhard C., Santoni F.A., Uchil P.D., Chatel L., Bisiaux A., Albert M.L., RA Strambio-De-Castillia C., Mothes W., Pizzato M., Gruetter M.G., Luban J.; RT "TRIM5 is an innate immune sensor for the retrovirus capsid lattice."; RL Nature 472:361-365(2011). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [18] RP FUNCTION. RX PubMed=31006531; DOI=10.1016/j.cell.2019.03.017; RA Cadena C., Ahmad S., Xavier A., Willemsen J., Park S., Park J.W., Oh S.W., RA Fujita T., Hou F., Binder M., Hur S.; RT "Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate RT Immunity."; RL Cell 177:1187-1200(2019). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 8-147 IN COMPLEX WITH STUB1 AND RP UBE2N. RX PubMed=16307917; DOI=10.1016/j.molcel.2005.09.023; RA Zhang M., Windheim M., Roe S.M., Peggie M., Cohen P., Prodromou C., RA Pearl L.H.; RT "Chaperoned ubiquitylation -- crystal structures of the CHIP U box E3 RT ubiquitin ligase and a CHIP-Ubc13-Uev1a complex."; RL Mol. Cell 20:525-538(2005). RN [20] {ECO:0007744|PDB:2HLW} RP STRUCTURE BY NMR OF 7-147, AND INTERACTION WITH UBE2N. RX PubMed=16893187; DOI=10.1021/bi060631r; RA Hau D.D., Lewis M.J., Saltibus L.F., Pastushok L., Xiao W., RA Spyracopoulos L.; RT "Structure and interactions of the ubiquitin-conjugating enzyme variant RT human Uev1a: implications for enzymatic synthesis of polyubiquitin RT chains."; RL Biochemistry 45:9866-9877(2006). RN [21] {ECO:0007744|PDB:2A4D} RP X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 7-147. RX PubMed=22496338; DOI=10.1074/mcp.o111.013706; RA Sheng Y., Hong J.H., Doherty R., Srikumar T., Shloush J., Avvakumov G.V., RA Walker J.R., Xue S., Neculai D., Wan J.W., Kim S.K., Arrowsmith C.H., RA Raught B., Dhe-Paganon S.; RT "A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure- RT function screen."; RL Mol. Cell. Proteomics 11:329-341(2012). CC -!- FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N CC heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin CC chains that are linked through Lys-63. This type of poly-ubiquitination CC activates IKK and does not seem to involve protein degradation by the CC proteasome. Plays a role in the activation of NF-kappa-B mediated by CC IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of CC target genes. Plays a role in the control of progress through the cell CC cycle and differentiation. Plays a role in the error-free DNA repair CC pathway and contributes to the survival of cells after DNA damage. CC Promotes TRIM5 capsid-specific restriction activity and the UBE2V1- CC UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'- CC linked polyubiquitin chains which activate the MAP3K7/TAK1 complex CC which in turn results in the induction and expression of NF-kappa-B and CC MAPK-responsive inflammatory genes. Together with RNF135 and UBE2N, CC catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of CC RIGI to activate the downstream signaling pathway that leads to CC interferon beta production (PubMed:31006531). UBE2V1-UBE2N together CC with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked CC polyubiquitination of TRAF6, a component of IL17A-mediated signaling CC pathway. {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:19825828, CC ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:21512573, CC ECO:0000269|PubMed:31006531, ECO:0000269|PubMed:9305758, CC ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9580084, CC ECO:0000269|PubMed:9705497}. CC -!- SUBUNIT: Heterodimer with UBE2N (PubMed:11057907, PubMed:16307917, CC PubMed:16893187). Interacts (UBE2V2-UBE2N heterodimer) with the E3 CC ligase STUB1 (via the U-box domain); the complex has a specific 'Lys- CC 63'-linked polyubiquitination activity (PubMed:16307917). Interacts CC with TRAF6 (PubMed:11057907, PubMed:16307917). CC {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:16307917, CC ECO:0000269|PubMed:16893187}. CC -!- INTERACTION: CC Q13404; Q92870-2: APBB2; NbExp=3; IntAct=EBI-1050671, EBI-21535880; CC Q13404; P54253: ATXN1; NbExp=6; IntAct=EBI-1050671, EBI-930964; CC Q13404; P02489: CRYAA; NbExp=3; IntAct=EBI-1050671, EBI-6875961; CC Q13404; P78358: CTAG1B; NbExp=3; IntAct=EBI-1050671, EBI-1188472; CC Q13404; Q15038: DAZAP2; NbExp=3; IntAct=EBI-1050671, EBI-724310; CC Q13404; G5E9A7: DMWD; NbExp=3; IntAct=EBI-1050671, EBI-10976677; CC Q13404; Q92567: FAM168A; NbExp=4; IntAct=EBI-1050671, EBI-7957930; CC Q13404; P22607: FGFR3; NbExp=3; IntAct=EBI-1050671, EBI-348399; CC Q13404; Q14957: GRIN2C; NbExp=3; IntAct=EBI-1050671, EBI-8285963; CC Q13404; P06396: GSN; NbExp=3; IntAct=EBI-1050671, EBI-351506; CC Q13404; P11021: HSPA5; NbExp=3; IntAct=EBI-1050671, EBI-354921; CC Q13404; O60333-2: KIF1B; NbExp=3; IntAct=EBI-1050671, EBI-10975473; CC Q13404; Q92876: KLK6; NbExp=3; IntAct=EBI-1050671, EBI-2432309; CC Q13404; O60260-5: PRKN; NbExp=3; IntAct=EBI-1050671, EBI-21251460; CC Q13404; Q9Y3C5: RNF11; NbExp=4; IntAct=EBI-1050671, EBI-396669; CC Q13404; Q6ZNA4: RNF111; NbExp=2; IntAct=EBI-1050671, EBI-2129175; CC Q13404; Q96DD7: SHISA4; NbExp=3; IntAct=EBI-1050671, EBI-18035902; CC Q13404; Q13148: TARDBP; NbExp=3; IntAct=EBI-1050671, EBI-372899; CC Q13404; Q13049: TRIM32; NbExp=4; IntAct=EBI-1050671, EBI-742790; CC Q13404; P61088: UBE2N; NbExp=22; IntAct=EBI-1050671, EBI-1052908; CC Q13404; Q9UMX0: UBQLN1; NbExp=9; IntAct=EBI-1050671, EBI-741480; CC Q13404; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-1050671, EBI-10173939; CC Q13404; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-1050671, EBI-947187; CC Q13404; P17861: XBP1; NbExp=3; IntAct=EBI-1050671, EBI-6942961; CC Q13404; P98170: XIAP; NbExp=3; IntAct=EBI-1050671, EBI-517127; CC Q13404; Q8ND25: ZNRF1; NbExp=2; IntAct=EBI-1050671, EBI-2129250; CC Q13404-2; P61088: UBE2N; NbExp=2; IntAct=EBI-15972179, EBI-1052908; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11076860, CC ECO:0000269|PubMed:9305758}. Note=Excluded from the nucleolus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Additional isoforms seem to exist.; CC Name=3; Synonyms=Isoform 2; CC IsoId=Q13404-4; Sequence=Displayed; CC Name=1; Synonyms=CROC-1B, UEV-1B, Isoform 4; CC IsoId=Q13404-1; Sequence=VSP_038034; CC Name=2; Synonyms=CROC-1A, UEV-1A; CC IsoId=Q13404-2; Sequence=VSP_038033; CC Name=4; Synonyms=UEV-1As; CC IsoId=Q13404-6; Sequence=VSP_038032, VSP_038036; CC Name=5; Synonyms=Isoform 3; CC IsoId=Q13404-7; Sequence=VSP_038035; CC Name=6; CC IsoId=Q13404-8; Sequence=VSP_044818; CC -!- TISSUE SPECIFICITY: Highly expressed in thyroid, pancreas, spinal cord, CC lymph node, trachea, adrenal gland, bone marrow and pancreas. Detected CC at low levels in heart, breast, placenta, brain, liver, kidney, stomach CC and lung. {ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9705497}. CC -!- INDUCTION: Down-regulated during differentiation of cultured colon CC adenocarcinoma cells. {ECO:0000269|PubMed:9418904}. CC -!- MISCELLANEOUS: In human, PESD1/KUA and UBE2V1/UEV1 are adjacent genes CC which can produce independent proteins and can also be fused to form a CC PESD1-UBE2V1 hybrid protein. CC -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family. CC {ECO:0000255|PROSITE-ProRule:PRU00388}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08944.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39360; AAB72015.1; -; mRNA. DR EMBL; U39361; AAB72016.1; -; mRNA. DR EMBL; U49278; AAC02757.1; -; mRNA. DR EMBL; U97279; AAC02780.1; -; mRNA. DR EMBL; U97280; AAC02755.1; -; mRNA. DR EMBL; U97281; AAC02756.1; -; mRNA. DR EMBL; AY008273; AAG24229.1; -; mRNA. DR EMBL; BT007382; AAP36046.1; -; mRNA. DR EMBL; DA580976; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL034423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75635.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75634.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75636.1; -; Genomic_DNA. DR EMBL; BC000468; AAH00468.1; -; mRNA. DR EMBL; BC008944; AAH08944.2; ALT_INIT; mRNA. DR CCDS; CCDS13426.1; -. [Q13404-7] DR CCDS; CCDS13427.1; -. [Q13404-6] DR CCDS; CCDS33483.1; -. [Q13404-4] DR CCDS; CCDS58775.1; -. [Q13404-8] DR RefSeq; NP_001027459.1; NM_001032288.3. [Q13404-4] DR RefSeq; NP_001244322.1; NM_001257393.2. [Q13404-7] DR RefSeq; NP_001244323.1; NM_001257394.2. [Q13404-6] DR RefSeq; NP_001244325.1; NM_001257396.2. [Q13404-8] DR RefSeq; NP_068823.2; NM_021988.5. [Q13404-7] DR RefSeq; NP_071887.1; NM_022442.6. [Q13404-6] DR RefSeq; NP_954595.1; NM_199144.3. [Q13404-7] DR RefSeq; NP_954673.2; NM_199203.3. DR PDB; 2A4D; X-ray; 1.69 A; A=8-147. DR PDB; 2C2V; X-ray; 2.90 A; C/F/I/L=8-147. DR PDB; 2HLW; NMR; -; A=8-147. DR PDB; 6D6I; X-ray; 2.55 A; A/D=8-147. DR PDBsum; 2A4D; -. DR PDBsum; 2C2V; -. DR PDBsum; 2HLW; -. DR PDBsum; 6D6I; -. DR AlphaFoldDB; Q13404; -. DR BMRB; Q13404; -. DR SMR; Q13404; -. DR BioGRID; 113183; 125. DR BioGRID; 132321; 42. DR ComplexPortal; CPX-485; UBC13-UEV1A ubiquitin-conjugating enzyme E2 complex. DR CORUM; Q13404; -. DR DIP; DIP-41911N; -. DR FunCoup; Q13404; 3253. DR IntAct; Q13404; 144. DR MINT; Q13404; -. DR MoonDB; Q13404; Predicted. DR GlyGen; Q13404; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13404; -. DR PhosphoSitePlus; Q13404; -. DR SwissPalm; Q13404; -. DR BioMuta; UBE2V1; -. DR DMDM; 259016163; -. DR jPOST; Q13404; -. DR MassIVE; Q13404; -. DR PeptideAtlas; Q13404; -. DR ProteomicsDB; 59382; -. [Q13404-4] DR ProteomicsDB; 59383; -. [Q13404-1] DR ProteomicsDB; 59384; -. [Q13404-2] DR ProteomicsDB; 59385; -. [Q13404-6] DR ProteomicsDB; 59386; -. [Q13404-7] DR ProteomicsDB; 65114; -. DR Pumba; Q13404; -. DR TopDownProteomics; Q13404-4; -. [Q13404-4] DR Antibodypedia; 35021; 274 antibodies from 33 providers. DR DNASU; 7335; -. DR Ensembl; ENST00000340309.7; ENSP00000340305.3; ENSG00000244687.14. [Q13404-7] DR Ensembl; ENST00000371657.9; ENSP00000360720.5; ENSG00000244687.14. [Q13404-8] DR Ensembl; ENST00000371674.8; ENSP00000360739.4; ENSG00000244687.14. [Q13404-4] DR Ensembl; ENST00000371677.7; ENSP00000360742.3; ENSG00000244687.14. [Q13404-7] DR Ensembl; ENST00000415862.6; ENSP00000407770.2; ENSG00000244687.14. [Q13404-6] DR GeneID; 7335; -. DR KEGG; hsa:387522; -. DR KEGG; hsa:7335; -. DR MANE-Select; ENST00000371674.8; ENSP00000360739.4; NM_001032288.3; NP_001027459.1. DR UCSC; uc002xva.5; human. [Q13404-4] DR AGR; HGNC:12494; -. DR AGR; HGNC:33521; -. DR ClinPGx; PA37142; -. DR CTD; 7335; -. DR DisGeNET; 387522; -. DR DisGeNET; 7335; -. DR GeneCards; UBE2V1; -. DR HGNC; HGNC:12494; UBE2V1. DR HPA; ENSG00000244687; Low tissue specificity. DR MIM; 602995; gene. DR OpenTargets; ENSG00000244687; -. DR VEuPathDB; HostDB:ENSG00000244687; -. DR eggNOG; KOG0896; Eukaryota. DR GeneTree; ENSGT00940000158854; -. DR HOGENOM; CLU_063065_1_2_1; -. DR InParanoid; Q13404; -. DR OMA; GPESCSY; -. DR OrthoDB; 6508832at2759; -. DR PAN-GO; Q13404; 3 GO annotations based on evolutionary models. DR BRENDA; 2.3.2.23; 2681. DR BRENDA; 2.3.2.24; 2681. DR PathwayCommons; Q13404; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2871837; FCERI mediated NF-kB activation. DR Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5205685; PINK1-PRKN Mediated Mitophagy. DR Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling. DR Reactome; R-HSA-9020702; Interleukin-1 signaling. DR Reactome; R-HSA-937039; IRAK1 recruits IKK complex. DR Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1. DR Reactome; R-HSA-9646399; Aggrephagy. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling. DR Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q13404; -. DR SIGNOR; Q13404; -. DR Agora; ENSG00000244687; -. DR BioGRID-ORCS; 387522; 76 hits in 964 CRISPR screens. DR BioGRID-ORCS; 7335; 228 hits in 1089 CRISPR screens. DR ChiTaRS; UBE2V1; human. DR EvolutionaryTrace; Q13404; -. DR GeneWiki; UBE2V1; -. DR Pharos; Q13404; Tbio. DR PRO; PR:Q13404; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13404; protein. DR Bgee; ENSG00000244687; Expressed in colonic epithelium and 104 other cell types or tissues. DR ExpressionAtlas; Q13404; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL. DR GO; GO:0005829; C:cytosol; IDA:ComplexPortal. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0031372; C:UBC13-MMS2 complex; IDA:UniProtKB. DR GO; GO:0031371; C:ubiquitin conjugating enzyme complex; IDA:HGNC-UCL. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IEA:Ensembl. DR GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; NAS:UniProtKB. DR GO; GO:0006301; P:DNA damage tolerance; IBA:GO_Central. DR GO; GO:0042275; P:error-free postreplication DNA repair; IEA:Ensembl. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:HGNC-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IDA:ComplexPortal. DR GO; GO:1902523; P:positive regulation of protein K63-linked ubiquitination; IDA:ComplexPortal. DR GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0000209; P:protein polyubiquitination; TAS:ProtInc. DR GO; GO:0006282; P:regulation of DNA repair; TAS:ProtInc. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR CDD; cd23807; UEV_UBE2V; 1. DR FunFam; 3.10.110.10:FF:000012; Ubiquitin-conjugating enzyme E2 variant 2; 1. DR Gene3D; 3.10.110.10; Ubiquitin Conjugating Enzyme; 1. DR InterPro; IPR000608; UBC. DR InterPro; IPR016135; UBQ-conjugating_enzyme/RWD. DR PANTHER; PTHR24068; UBIQUITIN-CONJUGATING ENZYME E2; 1. DR Pfam; PF00179; UQ_con; 1. DR SMART; SM00212; UBCc; 1. DR SUPFAM; SSF54495; UBC-like; 1. DR PROSITE; PS50127; UBC_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Direct protein sequencing; KW Nucleus; Proteomics identification; Reference proteome; KW Ubl conjugation pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22814378, FT ECO:0007744|PubMed:25944712" FT CHAIN 2..147 FT /note="Ubiquitin-conjugating enzyme E2 variant 1" FT /id="PRO_0000082600" FT DOMAIN 12..147 FT /note="UBC core" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00388" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22814378, FT ECO:0007744|PubMed:25944712" FT VAR_SEQ 1..44 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:9418904" FT /id="VSP_038032" FT VAR_SEQ 1..14 FT /note="MAATTGSGVKVPRN -> MPGEVQASYLKSQSKLSDEGRLEPRKFHCKGSKS FT PSQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9305758, FT ECO:0000303|PubMed:9418904" FT /id="VSP_038033" FT VAR_SEQ 1..7 FT /note="MAATTGS -> MAYKFRTHSPEALEQLYPWECFVFCLIIFGTFTNQIHKWSH FT TYFGLPRWVTLLQDWHVILPRKHHRIHHVSPHETYFCITT (in isoform 1)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9305758, ECO:0000303|PubMed:9418904" FT /id="VSP_038034" FT VAR_SEQ 1..7 FT /note="MAATTGS -> MPGEVQASYLKSQSKLSDEGRLEPRKFHCK (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11057907" FT /id="VSP_038035" FT VAR_SEQ 45..57 FT /note="LTRWTGMIIGPPR -> MKEDLNLENFTAK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:9418904" FT /id="VSP_038036" FT VAR_SEQ 58..99 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044818" FT HELIX 11..25 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 31..39 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 47..53 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:2HLW" FT TURN 59..62 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:2A4D" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 81..86 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 91..93 FT /evidence="ECO:0007829|PDB:2HLW" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 106..109 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 117..128 FT /evidence="ECO:0007829|PDB:2A4D" FT TURN 131..135 FT /evidence="ECO:0007829|PDB:2A4D" FT CONFLICT Q13404-1:71..81 FT /note="SPHETYFCITT -> WPTSSAQCYSP (in Ref. 2; AAC02755)" FT /evidence="ECO:0000305" SQ SEQUENCE 147 AA; 16495 MW; BA53837F21977B3F CRC64; MAATTGSGVK VPRNFRLLEE LEEGQKGVGD GTVSWGLEDD EDMTLTRWTG MIIGPPRTIY ENRIYSLKIE CGPKYPEAPP FVRFVTKINM NGVNSSNGVV DPRAISVLAK WQNSYSIKVV LQELRRLMMS KENMKLPQPP EGQCYSN // ID UFO_HUMAN Reviewed; 894 AA. AC P30530; Q8N5L2; Q9UD27; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 4. DT 28-JAN-2026, entry version 241. DE RecName: Full=Tyrosine-protein kinase receptor UFO; DE EC=2.7.10.1 {ECO:0000269|PubMed:28076778}; DE AltName: Full=AXL oncogene; DE Flags: Precursor; GN Name=AXL; Synonyms=UFO; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ROLE IN MYELOID LEUKEMIA. RC TISSUE=Fibroblast; RX PubMed=1656220; DOI=10.1128/mcb.11.10.5016-5031.1991; RA O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., RA Espinosa R., le Beau M.M., Earp H., Liu E.T.; RT "AXL, a transforming gene isolated from primary human myeloid leukemia RT cells, encodes a novel receptor tyrosine kinase."; RL Mol. Cell. Biol. 11:5016-5031(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG). RX PubMed=1834974; RA Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M., RA Strehl S., Ambros P., Bartram C.R.; RT "A novel putative tyrosine kinase receptor with oncogenic potential."; RL Oncogene 6:2113-2120(1991). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 674-730. RX PubMed=8247543; RA Lee S.-T., Strunk K.M., Spritz R.A.; RT "A survey of protein tyrosine kinase mRNAs expressed in normal human RT melanocytes."; RL Oncogene 8:3403-3410(1993). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Colon tumor; RX PubMed=7896447; DOI=10.1002/ijc.2910600611; RA Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S., RA Varnum B., Liu E.T., Cance W.G.; RT "Receptor tyrosine kinases expressed in metastatic colon cancer."; RL Int. J. Cancer 60:791-797(1995). RN [8] RP INTERACTION WITH LIGAND GAS6. RX PubMed=7854420; DOI=10.1038/373623a0; RA Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W., RA Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L., RA Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.; RT "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein RT encoded by growth-arrest-specific gene 6."; RL Nature 373:623-626(1995). RN [9] RP INTERACTION WITH GAS6, AND ACTIVITY REGULATION. RX PubMed=8621659; DOI=10.1074/jbc.271.16.9785; RA Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.; RT "Characterization of Gas6, a member of the superfamily of G domain- RT containing proteins, as a ligand for Rse and Axl."; RL J. Biol. Chem. 271:9785-9789(1996). RN [10] RP PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH GRB2; RP LCK; PIK3R1; PIK3R2 AND PLCG1. RX PubMed=9178760; DOI=10.1038/sj.onc.1201123; RA Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R., RA Ullrich A., Bartram C.R., Janssen J.W.; RT "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is RT mediated mainly by a multi-substrate docking-site."; RL Oncogene 14:2619-2631(1997). RN [11] RP ROLE IN PROSTATIC CARCINOMA. RX PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x; RA Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N., RA Prashar Y., Kandpal R.P.; RT "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a RT modified differential display PCR are overexpressed in metastatic prostatic RT carcinoma cell line DU145."; RL Cancer Detect. Prev. 23:325-332(1999). RN [12] RP ROLE IN BREAST CANCER. RX PubMed=11484958; DOI=10.1023/a:1011126330233; RA Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E., RA Andres A.C.; RT "Estrogen dependent expression of the receptor tyrosine kinase axl in RT normal and malignant human breast."; RL Ann. Oncol. 12:819-824(2001). RN [13] RP INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2. RX PubMed=12470648; DOI=10.1016/s0006-291x(02)02718-3; RA Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.; RT "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 RT domain-containing protein with homology to tensin."; RL Biochem. Biophys. Res. Commun. 299:793-800(2002). RN [14] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9; RA D'Arcangelo D., Gaetano C., Capogrossi M.C.; RT "Acidification prevents endothelial cell apoptosis by Axl activation."; RL Circ. Res. 91:E4-12(2002). RN [15] RP ROLE IN THYROID CARCINOMAS. RX PubMed=12490074; DOI=10.1089/105072502320908303; RA Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y., Takamura N., RA Demedchik E.P., Sekine I., Yamashita S.; RT "Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in RT pediatric thyroid carcinomas around Chernobyl."; RL Thyroid 12:971-975(2002). RN [16] RP INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION. RX PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086; RA Valverde P.; RT "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and RT downregulation."; RL Biochem. Biophys. Res. Commun. 333:180-185(2005). RN [17] RP ACTIVITY REGULATION, AND FUNCTION. RX PubMed=15507525; DOI=10.1182/blood-2004-04-1469; RA Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B., RA Avanzi G.C., Bussolino F.; RT "Inhibition of vascular endothelial growth factor receptor 2-mediated RT endothelial cell activation by Axl tyrosine kinase receptor."; RL Blood 105:1970-1976(2005). RN [18] RP FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION. RX PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x; RA Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J., RA Peterson J.T., Perrin L.A.; RT "Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate RT thrombotic responses."; RL J. Thromb. Haemost. 3:733-741(2005). RN [19] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=17005688; DOI=10.1128/jvi.01157-06; RA Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T., RA Jones S., Feldmann H., Kawaoka Y.; RT "Tyro3 family-mediated cell entry of Ebola and Marburg viruses."; RL J. Virol. 80:10109-10116(2006). RN [20] RP INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT TYR-779; RP TYR-821 AND TYR-866. RX PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x; RA Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B., Shafit-Zagardo B.; RT "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; RT in vitro mutagenesis defines the requisite binding sites for downstream Akt RT activation."; RL J. Neurochem. 106:134-146(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=18840707; DOI=10.1182/blood-2008-05-157073; RA Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.; RT "The Axl/Gas6 pathway is required for optimal cytokine signaling during RT human natural killer cell development."; RL Blood 113:2470-2477(2009). RN [23] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [24] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21501828; DOI=10.1016/j.chom.2011.03.012; RA Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.; RT "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine RT to the TAM receptor tyrosine kinase Axl to mediate viral entry."; RL Cell Host Microbe 9:286-298(2011). RN [25] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22156524; DOI=10.1128/jvi.06451-11; RA Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.; RT "Identification of cell surface molecules involved in dystroglycan- RT independent Lassa virus cell entry."; RL J. Virol. 86:2067-2078(2012). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22673088; DOI=10.1292/jvms.12-0176; RA Shimojima M., Kawaoka Y.; RT "Cell surface molecules involved in infection mediated by lymphocytic RT choriomeningitis virus glycoprotein."; RL J. Vet. Med. Sci. 74:1363-1366(2012). RN [27] RP FUNCTION (MICROBIAL INFECTION), AND REVIEW. RX PubMed=25277499; DOI=10.1016/j.virol.2014.09.009; RA Moller-Tank S., Maury W.; RT "Phosphatidylserine receptors: enhancers of enveloped virus entry and RT infection."; RL Virology 468:565-580(2014). RN [28] RP FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF LYS-567, CATALYTIC ACTIVITY, RP AND SUBCELLULAR LOCATION. RX PubMed=28076778; DOI=10.1016/j.celrep.2016.12.045; RA Meertens L., Labeau A., Dejarnac O., Cipriani S., Sinigaglia L., RA Bonnet-Madin L., Le Charpentier T., Hafirassou M.L., Zamborlini A., RA Cao-Lormeau V.M., Coulpier M., Misse D., Jouvenet N., Tabibiazar R., RA Gressens P., Schwartz O., Amara A.; RT "Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate RT Immune Responses."; RL Cell Rep. 18:324-333(2017). RN [29] RP INDUCTION BY MOSQUITO LYMPHOTOXIN BETA RECEPTOR INHIBITOR DURING ZIKA VIRUS RP INFECTION (MICROBIAL INFECTION). RX PubMed=29507355; DOI=10.1038/s41590-018-0063-9; RA Jin L., Guo X., Shen C., Hao X., Sun P., Li P., Xu T., Hu C., Rose O., RA Zhou H., Yang M., Qin C.F., Guo J., Peng H., Zhu M., Cheng G., Qi X., RA Lai R.; RT "Salivary factor LTRIN from Aedes aegypti facilitates the transmission of RT Zika virus by interfering with the lymphotoxin-beta receptor."; RL Nat. Immunol. 19:342-353(2018). RN [30] RP FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=29379210; DOI=10.1038/s41564-017-0092-4; RA Chen J., Yang Y.F., Yang Y., Zou P., Chen J., He Y., Shui S.L., Cui Y.R., RA Bai R., Liang Y.J., Hu Y., Jiang B., Lu L., Zhang X., Liu J., Xu J.; RT "AXL promotes Zika virus infection in astrocytes by antagonizing type I RT interferon signalling."; RL Nat. Microbiol. 3:302-309(2018). RN [31] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=31311882; DOI=10.1128/mbio.01372-19; RA Strange D.P., Jiyarom B., Pourhabibi Zarandi N., Xie X., Baker C., RA Sadri-Ardekani H., Shi P.Y., Verma S.; RT "Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human RT Sertoli Cells."; RL MBio 10:0-0(2019). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6, RP MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT. RX PubMed=16362042; DOI=10.1038/sj.emboj.7600912; RA Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A., RA Timpl R., Hohenester E.; RT "Structural basis for Gas6-Axl signalling."; RL EMBO J. 25:80-87(2006). RN [33] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the CC extracellular matrix into the cytoplasm by binding growth factor GAS6 CC and which is thus regulating many physiological processes including CC cell survival, cell proliferation, migration and differentiation. CC Ligand binding at the cell surface induces dimerization and CC autophosphorylation of AXL. Following activation by ligand, AXL binds CC and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, CC PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other CC downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. CC Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory CC subunits by AXL leads to the downstream activation of the AKT kinase. CC GAS6/AXL signaling plays a role in various processes such as CC endothelial cell survival during acidification by preventing apoptosis, CC optimal cytokine signaling during human natural killer cell CC development, hepatic regeneration, gonadotropin-releasing hormone CC neuron survival and migration, platelet activation, or regulation of CC thrombotic responses. Also plays an important role in inhibition of CC Toll-like receptors (TLRs)-mediated innate immune response. CC {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, CC ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, CC ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, CC ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and CC lymphocytic choriomeningitis virus, possibly through GAS6 binding to CC phosphatidyl-serine at the surface of virion envelope. CC {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, CC ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, CC possibly through GAS6 binding to phosphatidyl-serine at the surface of CC virion envelope. {ECO:0000269|PubMed:22673088}. CC -!- FUNCTION: (Microbial infection) Promotes Zika virus entry in glial CC cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, CC PubMed:31311882). Additionally, Zika virus potentiates AXL kinase CC activity to antagonize type I interferon signaling and thereby promotes CC infection (PubMed:28076778). Interferon signaling inhibition occurs via CC an SOCS1-dependent mechanism (PubMed:29379210). CC {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, CC ECO:0000269|PubMed:31311882}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:28076778}; CC -!- ACTIVITY REGULATION: Activated by GAS6-binding and subsequent CC autophosphorylation. {ECO:0000269|PubMed:15507525, CC ECO:0000269|PubMed:8621659}. CC -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6. Interacts CC with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3, PLCG1, SOCS1 and CC TNS2. Part of a complex including AXL, TNK2 and GRB2, in which GRB2 CC promotes AXL recruitment by TNK2. {ECO:0000269|PubMed:12470648, CC ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:16362042, CC ECO:0000269|PubMed:18346204, ECO:0000269|PubMed:19815557, CC ECO:0000269|PubMed:7854420, ECO:0000269|PubMed:8621659, CC ECO:0000269|PubMed:9178760}. CC -!- INTERACTION: CC P30530; P00533: EGFR; NbExp=5; IntAct=EBI-2850927, EBI-297353; CC P30530; P29317: EPHA2; NbExp=2; IntAct=EBI-2850927, EBI-702104; CC P30530; Q14393-2: GAS6; NbExp=8; IntAct=EBI-2850927, EBI-21517417; CC P30530; P62993: GRB2; NbExp=4; IntAct=EBI-2850927, EBI-401755; CC P30530; P08238: HSP90AB1; NbExp=3; IntAct=EBI-2850927, EBI-352572; CC P30530; Q01638: IL1RL1; NbExp=2; IntAct=EBI-2850927, EBI-993762; CC P30530; P27986: PIK3R1; NbExp=3; IntAct=EBI-2850927, EBI-79464; CC P30530; O43791: SPOP; NbExp=5; IntAct=EBI-2850927, EBI-743549; CC P30530; P0DTC2: S; Xeno; NbExp=9; IntAct=EBI-2850927, EBI-25474821; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28076778, CC ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:7896447}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:7896447}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; CC IsoId=P30530-1; Sequence=Displayed; CC Name=Short; CC IsoId=P30530-2; Sequence=VSP_005017; CC -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors. CC Expressed in primary colon tumors. Weakly expressed in normal colon CC tissue. {ECO:0000269|PubMed:7896447}. CC -!- INDUCTION: (Microbial infection) Up-regulated by Aedes aegypti CC lymphotoxin beta receptor inhibitor during Zika virus infection. CC {ECO:0000269|PubMed:29507355}. CC -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion of CC the receptor could be subjected to polyubiquitination in a very CC transient fashion. {ECO:0000269|PubMed:15958209}. CC -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which CC activates kinase activity. {ECO:0000269|PubMed:18346204, CC ECO:0000269|PubMed:9178760}. CC -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in thyroid CC carcinoma tissues, and might thus be involved in thyroid tumorigenesis. CC Overexpression of AXL and its ligand was also detected in many other CC cancers such as myeloproliferative disorders, prostatic carcinoma CC cells, or breast cancer. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/733/AXL"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M76125; AAA61243.1; -; mRNA. DR EMBL; S65125; AAB20305.1; -; mRNA. DR EMBL; X57019; CAA40338.1; -; mRNA. DR EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032229; AAH32229.1; -; mRNA. DR CCDS; CCDS12574.1; -. [P30530-2] DR CCDS; CCDS12575.1; -. [P30530-1] DR PIR; A41527; A41527. DR RefSeq; NP_001690.2; NM_001699.5. [P30530-2] DR RefSeq; NP_068713.2; NM_021913.4. [P30530-1] DR PDB; 2C5D; X-ray; 3.30 A; C/D=33-227. DR PDB; 4RA0; X-ray; 3.07 A; C/D=33-227. DR PDB; 5U6B; X-ray; 2.84 A; A/B/C/D=514-818. DR PDB; 5VXZ; X-ray; 2.30 A; C/D=34-135. DR PDBsum; 2C5D; -. DR PDBsum; 4RA0; -. DR PDBsum; 5U6B; -. DR PDBsum; 5VXZ; -. DR AlphaFoldDB; P30530; -. DR SMR; P30530; -. DR BioGRID; 107036; 404. DR CORUM; P30530; -. DR FunCoup; P30530; 354. DR IntAct; P30530; 298. DR MINT; P30530; -. DR STRING; 9606.ENSP00000301178; -. DR BindingDB; P30530; -. DR ChEMBL; CHEMBL4895; -. DR DrugBank; DB12411; Bemcentinib. DR DrugBank; DB15187; Dubermatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12141; Gilteritinib. DR DrugBank; DB19201; Tamnorzatinib. DR DrugCentral; P30530; -. DR GuidetoPHARMACOLOGY; 1835; -. DR GlyConnect; 1983; 12 N-Linked glycans (4 sites). DR GlyCosmos; P30530; 8 sites, 12 glycans. DR GlyGen; P30530; 10 sites, 13 N-linked glycans (4 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P30530; -. DR PhosphoSitePlus; P30530; -. DR BioMuta; AXL; -. DR DMDM; 239938818; -. DR CPTAC; CPTAC-1766; -. DR CPTAC; CPTAC-2791; -. DR jPOST; P30530; -. DR MassIVE; P30530; -. DR PaxDb; 9606-ENSP00000301178; -. DR PeptideAtlas; P30530; -. DR ProteomicsDB; 54712; -. [P30530-1] DR ProteomicsDB; 54713; -. [P30530-2] DR Pumba; P30530; -. DR ABCD; P30530; 23 sequenced antibodies. DR Antibodypedia; 30709; 1302 antibodies from 46 providers. DR CPTC; P30530; 2 antibodies. DR DNASU; 558; -. DR Ensembl; ENST00000301178.9; ENSP00000301178.3; ENSG00000167601.13. [P30530-1] DR Ensembl; ENST00000359092.7; ENSP00000351995.2; ENSG00000167601.13. [P30530-2] DR GeneID; 558; -. DR KEGG; hsa:558; -. DR MANE-Select; ENST00000301178.9; ENSP00000301178.3; NM_021913.5; NP_068713.2. DR UCSC; uc010ehj.5; human. [P30530-1] DR AGR; HGNC:905; -. DR CIViC; 558; 1 evidence item across 1 molecular profile. DR ClinPGx; PA25197; -. DR CTD; 558; -. DR DisGeNET; 558; -. DR GeneCards; AXL; -. DR GeneReviews; AXL; -. DR HGNC; HGNC:905; AXL. DR HPA; ENSG00000167601; Low tissue specificity. DR MalaCards; AXL; -. DR MIM; 109135; gene. DR OpenTargets; ENSG00000167601; -. DR VEuPathDB; HostDB:ENSG00000167601; -. DR eggNOG; ENOG502QQQ3; Eukaryota. DR GeneTree; ENSGT00940000160232; -. DR InParanoid; P30530; -. DR OMA; WTIMSTL; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P30530; 13 GO annotations based on evolutionary models. DR PhylomeDB; P30530; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P30530; -. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR SignaLink; P30530; -. DR SIGNOR; P30530; -. DR Agora; ENSG00000167601; -. DR BioGRID-ORCS; 558; 17 hits in 1198 CRISPR screens. DR ChiTaRS; AXL; human. DR EvolutionaryTrace; P30530; -. DR GeneWiki; AXL_receptor_tyrosine_kinase; -. DR GenomeRNAi; 558; -. DR Pharos; P30530; Tchem. DR PRO; PR:P30530; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P30530; protein. DR Bgee; ENSG00000167601; Expressed in synovial joint and 206 other cell types or tissues. DR ExpressionAtlas; P30530; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IDA:FlyBase. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEP:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB. DR GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB. DR GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0001779; P:natural killer cell differentiation; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB. DR GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl. DR GO; GO:0010936; P:negative regulation of macrophage cytokine production; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl. DR GO; GO:0032689; P:negative regulation of type II interferon production; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl. DR GO; GO:0042698; P:ovulation cycle; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IDA:UniProtKB. DR GO; GO:0030168; P:platelet activation; IBA:GO_Central. DR GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO. DR GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase. DR GO; GO:0032940; P:secretion by cell; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:CACAO. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome. DR CDD; cd00063; FN3; 2. DR CDD; cd20966; IgI_1_Axl_like; 1. DR CDD; cd05749; IgI_2_Axl_Tyro3_like; 1. DR CDD; cd05075; PTKc_Axl; 1. DR FunFam; 2.60.40.10:FF:000865; AXL receptor tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:000089; Tyrosine-protein kinase receptor TYRO3; 1. DR FunFam; 2.60.40.10:FF:000662; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000810; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 3.30.200.20:FF:000509; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000696; tyrosine-protein kinase receptor UFO isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF323; TYROSINE-PROTEIN KINASE RECEPTOR UFO; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Differentiation; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Immunity; KW Immunoglobulin domain; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Oncogene; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..894 FT /note="Tyrosine-protein kinase receptor UFO" FT /id="PRO_0000024481" FT TOPO_DOM 26..451 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 452..472 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 473..894 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..128 FT /note="Ig-like C2-type 1" FT DOMAIN 139..222 FT /note="Ig-like C2-type 2" FT DOMAIN 227..331 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 336..428 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 536..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 26..92 FT /note="Interaction with GAS6" FT REGION 823..853 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..894 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 672 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 542..550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 703 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 821 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 866 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 884 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 157 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 339 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 401 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 56..117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 160..205 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 429..437 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:1656220" FT /id="VSP_005017" FT VARIANT 112 FT /note="T -> M (in dbSNP:rs35202236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045596" FT VARIANT 266 FT /note="D -> N (in dbSNP:rs7249222)" FT /id="VAR_057990" FT VARIANT 295 FT /note="R -> W (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs751738506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045597" FT VARIANT 499 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs747576071)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041877" FT VARIANT 515 FT /note="S -> G (in dbSNP:rs1240393707)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041878" FT MUTAGEN 63 FT /note="E->R: Slightly reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 66 FT /note="E->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 84 FT /note="T->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 567 FT /note="K->M: Catalytically inactive mutant." FT /evidence="ECO:0000269|PubMed:28076778" FT CONFLICT 303 FT /note="T -> P (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 338 FT /note="E -> K (in Ref. 2; AAA61243)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="Q -> E (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 696 FT /note="K -> I (in Ref. 7; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 764 FT /note="Q -> R (in Ref. 5; AAH32229)" FT /evidence="ECO:0000305" FT STRAND 37..39 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 44..46 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 52..63 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 68..71 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 80..87 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 89..91 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 94..106 FT /evidence="ECO:0007829|PDB:5VXZ" FT HELIX 109..111 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 113..121 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 131..134 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 140..143 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 156..159 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 170..175 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 178..187 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 190..194 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 201..209 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 219..223 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 536..544 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 546..556 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 558..571 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 576..590 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 602..605 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 628..637 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 638..640 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 646..665 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 678..680 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 686..688 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 698..700 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 713..715 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 718..723 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 728..743 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 755..763 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 796..809 FT /evidence="ECO:0007829|PDB:5U6B" SQ SEQUENCE 894 AA; 98337 MW; 262D3659218E3202 CRC64; MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE LEVAWTPGLS GIYPLTHCTL QAVLSDDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA // ID UHRF1_HUMAN Reviewed; 793 AA. AC Q96T88; A0JBR2; A8K024; B2RBA9; Q2HIX7; Q8J022; Q9H6S6; Q9P115; Q9P1U7; DT 07-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 210. DE RecName: Full=E3 ubiquitin-protein ligase UHRF1; DE EC=2.3.2.27 {ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, ECO:0000269|PubMed:37728657}; DE AltName: Full=Inverted CCAAT box-binding protein of 90 kDa {ECO:0000303|PubMed:17967883}; DE AltName: Full=Nuclear zinc finger protein Np95 {ECO:0000303|PubMed:17067204}; DE Short=HuNp95 {ECO:0000303|PubMed:17067204}; DE Short=Nuclear protein 95 {ECO:0000303|PubMed:17067204}; DE Short=hNp95 {ECO:0000303|PubMed:17067204}; DE AltName: Full=RING finger protein 106; DE AltName: Full=Transcription factor ICBP90 {ECO:0000303|PubMed:17967883}; DE AltName: Full=Ubiquitin-like PHD and RING finger domain-containing protein 1 {ECO:0000303|PubMed:17673620}; DE Short=hUHRF1 {ECO:0000303|PubMed:17673620}; GN Name=UHRF1 {ECO:0000303|PubMed:17673620, ECO:0000312|HGNC:HGNC:12556}; GN Synonyms=ICBP90 {ECO:0000303|PubMed:17967883}, GN NP95 {ECO:0000303|PubMed:17067204}, RNF106; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, DEVELOPMENTAL RP STAGE, SUBCELLULAR LOCATION, DNA-BINDING, INDUCTION, AND FUNCTION. RC TISSUE=Thymus; RX PubMed=10646863; RA Hopfner R., Mousli M., Jeltsch J.-M., Voulgaris A., Lutz Y., Marin C., RA Bellocq J.-P., Oudet P., Bronner C.; RT "ICBP90, a novel human CCAAT binding protein, involved in the regulation of RT topoisomerase IIa expression."; RL Cancer Res. 60:121-128(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=17067204; DOI=10.1667/rr0459.1; RA Muto M., Fujimori A., Nenoi M., Daino K., Matsuda Y., Kuroiwa A., Kubo E., RA Kanari Y., Utsuno M., Tsuji H., Ukai H., Mita K., Takahagi M., Tatsumi K.; RT "Isolation and characterization of a novel human radiosusceptibility gene, RT NP95."; RL Radiat. Res. 166:723-733(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Davenport J.W., Fernandes E.R., Neale G.A.M., Goorha R.M.; RT "LMO2-induced T cell leukemias overexpress Np95, a gene containing RING and RT PHD zinc fingers and an ubiquitin-like domain."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS LYS-379 RP AND THR-638. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-240; LYS-379; THR-638; RP MET-642 AND PHE-713. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=12838312; DOI=10.1038/sj.bjc.6601068; RA Mousli M., Hopfner R., Abbady A.-Q., Monte D., Jeanblanc M., Oudet P., RA Louis B., Bronner C.; RT "ICBP90 belongs to a new family of proteins with an expression that is RT deregulated in cancer cells."; RL Br. J. Cancer 89:120-127(2003). RN [11] RP PHOSPHORYLATION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS OF SER-298; RP SER-651 AND SER-666. RX PubMed=15178447; DOI=10.1016/j.bbrc.2004.05.028; RA Trotzier M.-A., Bronner C., Bathami K., Mathieu E., Abbady A.-Q., RA Jeanblanc M., Muller C.D., Rochette-Egly C., Mousli M.; RT "Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase RT IIalpha expression."; RL Biochem. Biophys. Res. Commun. 319:590-595(2004). RN [12] RP INDUCTION, UBIQUITINATION, AND FUNCTION. RX PubMed=15009091; DOI=10.1111/j.1356-9597.2004.00710.x; RA Arima Y., Hirota T., Bronner C., Mousli M., Fujiwara T., Niwa S., RA Ishikawa H., Saya H.; RT "Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent RT DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S RT transition."; RL Genes Cells 9:131-142(2004). RN [13] RP FUNCTION, INDUCTION, TISSUE SPECIFICITY, DNA-BINDING, AND INTERACTION WITH RP HDAC1 AND BLTP3A. RX PubMed=15361834; DOI=10.1038/sj.onc.1208053; RA Unoki M., Nishidate T., Nakamura Y.; RT "ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through RT its SRA domain."; RL Oncogene 23:7601-7610(2004). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-639, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-639, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [16] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DNMT1. RX PubMed=17673620; DOI=10.1126/science.1147939; RA Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S., Jacobsen S.E.; RT "UHRF1 plays a role in maintaining DNA methylation in mammalian cells."; RL Science 317:1760-1764(2007). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [18] RP FUNCTION, SUBCELLULAR LOCATION, AND AUTOUBIQUITINATION. RX PubMed=17967883; DOI=10.1128/mcb.01598-07; RA Karagianni P., Amazit L., Qin J., Wong J.; RT "ICBP90, a novel methyl K9 H3 binding protein linking protein RT ubiquitination with heterochromatin formation."; RL Mol. Cell. Biol. 28:705-717(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91 AND SER-707, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [20] RP INVOLVEMENT IN CANCER. RX PubMed=19491893; DOI=10.1038/sj.bjc.6605123; RA Unoki M., Kelly J.D., Neal D.E., Ponder B.A., Nakamura Y., Hamamoto R.; RT "UHRF1 is a novel molecular marker for diagnosis and the prognosis of RT bladder cancer."; RL Br. J. Cancer 101:98-105(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EHMT2. RX PubMed=19056828; DOI=10.1093/nar/gkn961; RA Kim J.K., Esteve P.O., Jacobsen S.E., Pradhan S.; RT "UHRF1 binds G9a and participates in p21 transcriptional regulation in RT mammalian cells."; RL Nucleic Acids Res. 37:493-505(2009). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [23] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-399 AND LYS-546, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [24] RP MUTAGENESIS OF TYR-188 AND TYR-191. RX PubMed=20026581; DOI=10.1093/nar/gkp1152; RA Rottach A., Frauer C., Pichler G., Bonapace I.M., Spada F., Leonhardt H.; RT "The multi-domain protein Np95 connects DNA methylation and histone RT modification."; RL Nucleic Acids Res. 38:1796-1804(2010). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-287; SER-639 AND RP SER-707, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [27] RP FUNCTION, AUTOUBIQUITINATION, AND INTERACTION WITH DNMT1. RX PubMed=21745816; DOI=10.1093/nar/gkr528; RA Felle M., Joppien S., Nemeth A., Diermeier S., Thalhammer V., Dobner T., RA Kremmer E., Kappler R., Langst G.; RT "The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 RT and regulates the stability of UHRF1."; RL Nucleic Acids Res. 39:8355-8365(2011). RN [28] RP HYDROXYMETHYLCYTOSINE-BINDING. RX PubMed=21731699; DOI=10.1371/journal.pone.0021306; RA Frauer C., Hoffmann T., Bultmann S., Casa V., Cardoso M.C., Antes I., RA Leonhardt H.; RT "Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain."; RL PLoS ONE 6:E21306-E21306(2011). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [30] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-147 AND TYR-188. RX PubMed=23022729; DOI=10.1038/nsmb.2391; RA Rothbart S.B., Krajewski K., Nady N., Tempel W., Xue S., Badeaux A.I., RA Barsyte-Lovejoy D., Martinez J.Y., Bedford M.T., Fuchs S.M., RA Arrowsmith C.H., Strahl B.D.; RT "Association of UHRF1 with methylated H3K9 directs the maintenance of DNA RT methylation."; RL Nat. Struct. Mol. Biol. 19:1155-1160(2012). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91; SER-287; SER-368; RP SER-639; SER-707 AND SER-709, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF 724-CYS--CYS-727. RX PubMed=24013172; DOI=10.1038/nature12488; RA Nishiyama A., Yamaguchi L., Sharif J., Johmura Y., Kawamura T., RA Nakanishi K., Shimamura S., Arita K., Kodama T., Ishikawa F., Koseki H., RA Nakanishi M.; RT "Uhrf1-dependent H3K23 ubiquitylation couples maintenance DNA methylation RT and replication."; RL Nature 502:249-253(2013). RN [33] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF HIS-741. RX PubMed=22945642; DOI=10.1038/onc.2012.406; RA Guan D., Factor D., Liu Y., Wang Z., Kao H.Y.; RT "The epigenetic regulator UHRF1 promotes ubiquitination-mediated RT degradation of the tumor-suppressor protein promyelocytic leukemia RT protein."; RL Oncogene 32:3819-3828(2013). RN [34] RP INVOLVEMENT IN CANCER. RX PubMed=22286757; DOI=10.1038/onc.2012.3; RA Sabatino L., Fucci A., Pancione M., Carafa V., Nebbioso A., Pistore C., RA Babbio F., Votino C., Laudanna C., Ceccarelli M., Altucci L., RA Bonapace I.M., Colantuoni V.; RT "UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) RT epigenetic silencing and mediates colorectal cancer progression."; RL Oncogene 31:5061-5072(2012). RN [35] RP INVOLVEMENT IN CANCER. RX PubMed=22330138; DOI=10.1038/onc.2011.641; RA Babbio F., Pistore C., Curti L., Castiglioni I., Kunderfranco P., Brino L., RA Oudet P., Seiler R., Thalman G.N., Roggero E., Sarti M., Pinton S., RA Mello-Grand M., Chiorino G., Catapano C.V., Carbone G.M., Bonapace I.M.; RT "The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in RT prostate cancer progression."; RL Oncogene 31:4878-4887(2012). RN [36] RP AUTOUBIQUITINATION, DEUBIQUITINATION BY USP7, PHOSPHORYLATION AT SER-639, RP AND MUTAGENESIS OF SER-639. RX PubMed=22411829; DOI=10.1073/pnas.1116349109; RA Ma H., Chen H., Guo X., Wang Z., Sowa M.E., Zheng L., Hu S., Zeng P., RA Guo R., Diao J., Lan F., Harper J.W., Shi Y.G., Xu Y., Shi Y.; RT "M phase phosphorylation of the epigenetic regulator UHRF1 regulates its RT physical association with the deubiquitylase USP7 and stability."; RL Proc. Natl. Acad. Sci. U.S.A. 109:4828-4833(2012). RN [37] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-385; LYS-546 AND LYS-670, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [38] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF GLY-448; ASP-469 AND HIS-741. RX PubMed=27595565; DOI=10.7554/elife.17101; RA Harrison J.S., Cornett E.M., Goldfarb D., DaRosa P.A., Li Z.M., Yan F., RA Dickson B.M., Guo A.H., Cantu D.V., Kaustov L., Brown P.J., RA Arrowsmith C.H., Erie D.A., Major M.B., Klevit R.E., Krajewski K., RA Kuhlman B., Strahl B.D., Rothbart S.B.; RT "Hemi-methylated DNA regulates DNA methylation inheritance through RT allosteric activation of H3 ubiquitylation by UHRF1."; RL Elife 5:0-0(2016). RN [39] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-279 AND LYS-670, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND DOMAIN. RX PubMed=30392929; DOI=10.1016/j.molcel.2018.09.028; RA Foster B.M., Stolz P., Mulholland C.B., Montoya A., Kramer H., Bultmann S., RA Bartke T.; RT "Critical role of the UBL domain in stimulating the E3 ubiquitin ligase RT activity of UHRF1 toward chromatin."; RL Mol. Cell 72:739-752(2018). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, DOMAIN, AND MUTAGENESIS OF TRP-2; RP ARG-6; MET-8; PHE-46; ARG-48; LYS-50; HIS-56; PHE-59; GLU-62; ARG-64; RP LEU-65; GLN-70 AND LEU-72. RX PubMed=30392931; DOI=10.1016/j.molcel.2018.09.029; RA DaRosa P.A., Harrison J.S., Zelter A., Davis T.N., Brzovic P., Kuhlman B., RA Klevit R.E.; RT "A bifunctional role for the UHRF1 UBL domain in the control of hemi- RT methylated DNA-dependent histone ubiquitylation."; RL Mol. Cell 72:753-765(2018). RN [42] RP FUNCTION, INTERACTION WITH UHRF2 AND FANCD2, AND SUBCELLULAR LOCATION. RX PubMed=30335751; DOI=10.1371/journal.pgen.1007643; RA Motnenko A., Liang C.C., Yang D., Lopez-Martinez D., Yoshikawa Y., Zhan B., RA Ward K.E., Tian J., Haas W., Spingardi P., Kessler B.M., Kriaucionis S., RA Gygi S.P., Cohn M.A.; RT "Identification of UHRF2 as a novel DNA interstrand crosslink sensor RT protein."; RL PLoS Genet. 14:e1007643-e1007643(2018). RN [43] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 334-ASP-GLU-335 AND RP GLY-448. RX PubMed=30104358; DOI=10.1073/pnas.1806373115; RA Vaughan R.M., Dickson B.M., Whelihan M.F., Johnstone A.L., Cornett E.M., RA Cheek M.A., Ausherman C.A., Cowles M.W., Sun Z.W., Rothbart S.B.; RT "Chromatin structure and its chemical modifications regulate the ubiquitin RT ligase substrate selectivity of UHRF1."; RL Proc. Natl. Acad. Sci. U.S.A. 115:8775-8780(2018). RN [44] RP INTERACTION WITH ZNF263. RX PubMed=32051553; DOI=10.1038/s41388-020-1206-7; RA Yu Z., Feng J., Wang W., Deng Z., Zhang Y., Xiao L., Wang Z., Liu C., RA Liu Q., Chen S., Wu M.; RT "The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma RT epigenetically."; RL Oncogene 39:3163-3178(2020). RN [45] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=37728657; DOI=10.1083/jcb.202210093; RA Qi X., Liu Y., Peng Y., Fu Y., Fu Y., Yin L., Li X.; RT "UHRF1 promotes spindle assembly and chromosome congression by catalyzing RT EG5 polyubiquitination."; RL J. Cell Biol. 222:0-0(2023). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF PHE-59; GLY-448 RP AND HIS-741. RX PubMed=39607687; DOI=10.1093/nar/gkae1105; RA Tiedemann R.L., Hrit J., Du Q., Wiseman A.K., Eden H.E., Dickson B.M., RA Kong X., Chomiak A.A., Vaughan R.M., Tibben B.M., Hebert J.M., David Y., RA Zhou W., Baylin S.B., Jones P.A., Clark S.J., Rothbart S.B.; RT "UHRF1 ubiquitin ligase activity supports the maintenance of low-density RT CpG methylation."; RL Nucleic Acids Res. 52:13733-13756(2024). RN [47] RP FUNCTION, AND MUTAGENESIS OF TYR-188. RX PubMed=39631394; DOI=10.1016/j.molcel.2024.11.009; RA Liu Y., Hrit J.A., Chomiak A.A., Stransky S., Hoffman J.R., Tiedemann R.L., RA Wiseman A.K., Kariapper L.S., Dickson B.M., Worden E.J., Fry C.J., RA Sidoli S., Rothbart S.B.; RT "DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk RT between H3K18ub and H3K9me3 to reinforce heterochromatin states."; RL Mol. Cell 85:394-412(2025). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-76. RG Structural genomics consortium (SGC); RT "Ubiquitin-like domain of human nuclear zinc finger protein NP95."; RL Submitted (JAN-2006) to the PDB data bank. RN [49] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 408-643. RX PubMed=18931436; DOI=10.1107/s1744309108027462; RA Delagoutte B., Lallous N., Birck C., Oudet P., Samama J.P.; RT "Expression, purification, crystallization and preliminary crystallographic RT study of the SRA domain of the human UHRF1 protein."; RL Acta Crystallogr. F 64:922-925(2008). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 414-617, AND MUTAGENESIS OF RP ARG-433; ARG-443; TYR-466 AND ARG-491. RX PubMed=18945682; DOI=10.1074/jbc.c800169200; RA Qian C., Li S., Jakoncic J., Zeng L., Walsh M.J., Zhou M.M.; RT "Structure and hemimethylated CpG binding of the SRA domain from human RT UHRF1."; RL J. Biol. Chem. 283:34490-34494(2008). RN [51] {ECO:0007744|PDB:3BI7, ECO:0007744|PDB:3CLZ} RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 414-617 IN COMPLEX WITH RP HEMIMETHYLATED DNA, FUNCTION, AND MUTAGENESIS OF GLY-448; ASP-469; ASN-489 RP AND ARG-491. RX PubMed=18772889; DOI=10.1038/nature07273; RA Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C., RA Arrowsmith C.H., Dhe-Paganon S.; RT "Structural basis for recognition of hemi-methylated DNA by the SRA domain RT of human UHRF1."; RL Nature 455:822-825(2008). RN [52] {ECO:0007744|PDB:3FL2} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 672-793 IN COMPLEX WITH ZN(2+). RA Walker J.R., Avvakumov G.V., Xue S., Li Y., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.; RT "Structure of the Ring domain of the E3 ubiquitin-protein ligase Uhrf1."; RL Submitted (DEC-2008) to the PDB data bank. RN [53] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 298-366 IN COMPLEX WITH ZINC, AND RP MUTAGENESIS OF ASP-334 AND ASP-337. RX PubMed=21808300; DOI=10.1038/cr.2011.124; RA Hu L., Li Z., Wang P., Lin Y., Xu Y.; RT "Crystal structure of PHD domain of UHRF1 and insights into recognition of RT unmodified histone H3 arginine residue 2."; RL Cell Res. 21:1374-1378(2011). RN [54] RP STRUCTURE BY NMR OF 298-366, AND MUTAGENESIS OF ASP-334 AND ASP-337. RX PubMed=21808299; DOI=10.1038/cr.2011.123; RA Wang C., Shen J., Yang Z., Chen P., Zhao B., Hu W., Lan W., Tong X., Wu H., RA Li G., Cao C.; RT "Structural basis for site-specific reading of unmodified R2 of histone H3 RT tail by UHRF1 PHD finger."; RL Cell Res. 21:1379-1382(2011). RN [55] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 126-285, STRUCTURE BY NMR OF RP 126-285, AND MUTAGENESIS OF ASP-142; ASP-145; PHE-152; GLU-153; TYR-188 AND RP ASP-190. RX PubMed=21489993; DOI=10.1074/jbc.m111.234104; RA Nady N., Lemak A., Walker J.R., Avvakumov G.V., Kareta M.S., Achour M., RA Xue S., Duan S., Allali-Hassani A., Zuo X., Wang Y.X., Bronner C., RA Chedin F., Arrowsmith C.H., Dhe-Paganon S.; RT "Recognition of multivalent histone states associated with heterochromatin RT by UHRF1 protein."; RL J. Biol. Chem. 286:24300-24311(2011). RN [56] {ECO:0007744|PDB:3SOU, ECO:0007744|PDB:3SOW, ECO:0007744|PDB:3SOX} RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 298-367 IN COMPLEX WITH ZINC AND RP HISTONE H3 PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 334-ASP-GLU-335. RX PubMed=21777816; DOI=10.1016/j.molcel.2011.07.006; RA Rajakumara E., Wang Z., Ma H., Hu L., Chen H., Lin Y., Guo R., Wu F., RA Li H., Lan F., Shi Y.G., Xu Y., Patel D.J., Shi Y.; RT "PHD finger recognition of unmodified histone H3R2 links UHRF1 to RT regulation of euchromatic gene expression."; RL Mol. Cell 43:275-284(2011). RN [57] RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 314-367, AND MUTAGENESIS OF RP GLN-330; ASP-334 AND ASP-337. RX PubMed=22096602; DOI=10.1371/journal.pone.0027599; RA Lallous N., Legrand P., McEwen A.G., Ramon-Maiques S., Samama J.P., RA Birck C.; RT "The PHD finger of human UHRF1 reveals a new subgroup of unmethylated RT histone H3 tail readers."; RL PLoS ONE 6:E27599-E27599(2011). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 299-364 IN COMPLEX WITH HISTONE RP H3 PEPTIDE, AND FUNCTION. RX PubMed=22100450; DOI=10.1016/j.jmb.2011.11.012; RA Xie S., Jakoncic J., Qian C.; RT "UHRF1 double tudor domain and the adjacent PHD finger act together to RT recognize K9me3-containing histone H3 tail."; RL J. Mol. Biol. 415:318-328(2012). RN [59] {ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL} RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 134-367 IN COMPLEX WITH ZINC AND RP HISTONE H3 PEPTIDE, FUNCTION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS RP OF 295-ARG-ARG-296. RX PubMed=22837395; DOI=10.1073/pnas.1203701109; RA Arita K., Isogai S., Oda T., Unoki M., Sugita K., Sekiyama N., Kuwata K., RA Hamamoto R., Tochio H., Sato M., Ariyoshi M., Shirakawa M.; RT "Recognition of modification status on a histone H3 tail by linked histone RT reader modules of the epigenetic regulator UHRF1."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12950-12955(2012). CC -!- FUNCTION: E3 ubiquitin-protein ligase that acts as a key epigenetic CC regulator by bridging DNA methylation and chromatin modification CC (PubMed:10646863, PubMed:15009091, PubMed:19056828, PubMed:23022729, CC PubMed:24013172, PubMed:27595565, PubMed:30104358, PubMed:30392929, CC PubMed:30392931, PubMed:39607687). Plays a key role in DNA methylation CC inheritance by promoting recruitment of DNMT1 to hemimethylated DNA and CC ensure faithful propagation of the DNA methylation patterns through DNA CC replication (PubMed:23022729, PubMed:24013172, PubMed:27595565, CC PubMed:30104358, PubMed:30392929, PubMed:30392931, PubMed:39607687). CC Acts both as a histone reader and writer: specifically recognizes and CC binds (1) hemimethylated DNA at replication forks and (2) histone H3 CC trimethylated at 'Lys-9' and unmethylated at 'Arg-2' (H3K9me3 and CC H3R2me0, respectively), thereby activating its E3 ubiquitin-protein CC ligase activity (PubMed:15361834, PubMed:17673620, PubMed:17967883, CC PubMed:18772889, PubMed:21745816, PubMed:21777816, PubMed:22100450, CC PubMed:22837395, PubMed:23022729, PubMed:27595565, PubMed:30104358). CC UHRF1 then mediates histone H3 'Lys-18' monoubiquitination (H3K18ub), a CC docking site for DNMT1, leading to DNMT1 recruitment and replication- CC coupled DNA methylation maintenance (PubMed:27595565). Also mediates CC histone H3 'Lys-14' and 'Lys-23' ubiquitination (H3K14ub and H3K23ub) CC at lower level (PubMed:24013172, PubMed:27595565). Histone ubiquitin CC ligase activity also stimulates the methyltransferase activity of CC SUV39H1 and/or SUV39H2, promoting accumulation of H3K9me3 histone mark CC to reinformce heterochromatin state (PubMed:39631394). Enriched in CC pericentric heterochromatin where it recruits different chromatin CC modifiers required for this chromatin replication. Also localizes to CC euchromatic regions where it negatively regulates transcription CC possibly by impacting DNA methylation and histone modifications CC (PubMed:21777816). Plays a role in DNA repair by cooperating with UHRF2 CC to ensure recruitment of FANCD2 to interstrand cross-links (ICLs) CC leading to FANCD2 activation (PubMed:30335751). Also ubiquitinates non- CC histone proteins, such as histone H3, KIF11 and PML (PubMed:22945642, CC PubMed:37728657). Acts as a critical player of proper spindle CC architecture by catalyzing the 'Lys-63'-linked ubiquitination of KIF11, CC thereby controlling KIF11 localization on the spindle CC (PubMed:37728657). {ECO:0000269|PubMed:10646863, CC ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834, CC ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, CC ECO:0000269|PubMed:18772889, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:21777816, CC ECO:0000269|PubMed:22100450, ECO:0000269|PubMed:22837395, CC ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:23022729, CC ECO:0000269|PubMed:24013172, ECO:0000269|PubMed:27595565, CC ECO:0000269|PubMed:30104358, ECO:0000269|PubMed:30335751, CC ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, CC ECO:0000269|PubMed:37728657, ECO:0000269|PubMed:39607687, CC ECO:0000269|PubMed:39631394}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:22945642, CC ECO:0000269|PubMed:24013172, ECO:0000269|PubMed:27595565, CC ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, CC ECO:0000269|PubMed:37728657, ECO:0000269|PubMed:39607687}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:24013172, CC ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30392929, CC ECO:0000269|PubMed:30392931, ECO:0000269|PubMed:37728657, CC ECO:0000269|PubMed:39607687}. CC -!- SUBUNIT: Interacts with DNMT1; the interaction is direct CC (PubMed:17673620, PubMed:21745816). Interacts with DNMT3A and DNMT3B CC (By similarity). Interacts with HDAC1, but not with HDAC2 CC (PubMed:15361834). Interacts with BLTP3A (PubMed:15361834). Interacts CC with EHMT2 (PubMed:19056828). Interacts with ZNF263; recruited to the CC SIX3 promoter along with other proteins involved in chromatin CC modification and transcriptional corepression where it contributes to CC transcriptional repression (PubMed:32051553). Interacts with UHRF2 CC (PubMed:30335751). Interacts with FANCD2 (PubMed:30335751). Interacts CC with TET1 isoform 2; this interaction induces the recruitment of TET1 CC isoform 2 to replicating heterochromatin (By similarity). CC {ECO:0000250|UniProtKB:Q8VDF2, ECO:0000269|PubMed:15361834, CC ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:30335751, CC ECO:0000269|PubMed:32051553}. CC -!- INTERACTION: CC Q96T88; P26358: DNMT1; NbExp=12; IntAct=EBI-1548946, EBI-719459; CC Q96T88; Q9Y6K1: DNMT3A; NbExp=7; IntAct=EBI-1548946, EBI-923653; CC Q96T88; Q9UBC3: DNMT3B; NbExp=7; IntAct=EBI-1548946, EBI-80125; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00358, CC ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:17673620, CC ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:30335751}. Chromosome CC {ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:23022729, CC ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30104358}. CC Note=Associated with replicating DNA from early to late S phase, CC including at replicating pericentric heterochromatin (PubMed:17673620). CC Also localizes to euchromatic regions (PubMed:21777816). In non-S-phase CC cells, homogenously distributed through the nucleus (By similarity). CC {ECO:0000250|UniProtKB:Q8VDF2, ECO:0000269|PubMed:17673620, CC ECO:0000269|PubMed:21777816}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96T88-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96T88-2; Sequence=VSP_044394; CC -!- TISSUE SPECIFICITY: Expressed in thymus, bone marrow, testis, lung and CC heart. Overexpressed in breast cancer. {ECO:0000269|PubMed:10646863, CC ECO:0000269|PubMed:12838312, ECO:0000269|PubMed:15361834}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal thymus, liver and kidney. CC {ECO:0000269|PubMed:10646863}. CC -!- INDUCTION: Up-regulated in proliferating cells, and down-regulated in CC quiescent cells. Down-regulated upon adriamycin-induced DNA damage, in CC a p53/TP53 and CDKN1A-dependent way. Induced by E2F1 transcription CC factor. {ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:12838312, CC ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834}. CC -!- DOMAIN: The UBL domain is required for the E3 histone H3 ubiquitin- CC protein ligase activity: it binds the backside of UBE2D E2 ubiquitin- CC conjugating enzymes (UBE2D1, UBE2D2, UBE2D3 or UBE2D4) and coordinates CC with other domains that recognize epigenetic marks on DNA and histone CC H3 to direct ubiquitin to H3. {ECO:0000269|PubMed:30392929, CC ECO:0000269|PubMed:30392931}. CC -!- DOMAIN: The PHD-type zinc finger specifically recognizes and binds CC histone H3 unmethylated at 'Arg-2' (H3R2me0), while the tudor-like CC regions specifically recognize and bind histone H3 trimethylated at CC 'Lys-9' (H3K9me3) (PubMed:21489993, PubMed:21777816, PubMed:22100450). CC The tudor-like regions simultaneously recognizes H3K9me3 through a CC conserved aromatic cage in the first tudor-like subdomain and CC unmodified H3K4 (H3K4me0) within a groove between the tandem subdomains CC (PubMed:21489993, PubMed:21777816, PubMed:22100450). The linker region CC plays a role in the formation of a histone H3-binding hole between the CC reader modules formed by the tudor-like regions and the PHD-type zinc CC finger by making extended contacts with the tandem tudor-like regions CC (PubMed:22837395). {ECO:0000269|PubMed:21489993, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:22100450, CC ECO:0000269|PubMed:22837395}. CC -!- DOMAIN: The YDG domain (also named SRA domain) specifically recognizes CC and binds hemimethylated DNA at replication forks (DNA that is only CC methylated on the mother strand of replicating DNA) (PubMed:17673620). CC It contains a binding pocket that accommodates the 5-methylcytosine CC that is flipped out of the duplex DNA. 2 specialized loops reach CC through the resulting gap in the DNA from both the major and the minor CC grooves to read the other 3 bases of the CpG duplex. The major groove CC loop confers both specificity for the CpG dinucleotide and CC discrimination against methylation of deoxycytidine of the CC complementary strand (PubMed:18772889). The YDG domain also recognizes CC and binds 5-hydroxymethylcytosine (5hmC) (PubMed:21731699). CC {ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:18772889, CC ECO:0000269|PubMed:21731699}. CC -!- PTM: Phosphorylation at Ser-298 of the linker region by PKA decreases CC the binding to H3K9me3 (PubMed:15178447, PubMed:22837395). CC Phosphorylation at Ser-639 by CDK1 during M phase impairs interaction CC with USP7, preventing deubiquitination and leading to degradation by CC the proteasome (PubMed:22411829). {ECO:0000269|PubMed:15178447, CC ECO:0000269|PubMed:22411829, ECO:0000269|PubMed:22837395}. CC -!- PTM: Ubiquitinated; which leads to proteasomal degradation CC (PubMed:15009091). Autoubiquitinated; interaction with USP7 leads to CC deubiquitination and prevents degradation (PubMed:17967883, CC PubMed:21745816, PubMed:22411829). Ubiquitination and degradation takes CC place during M phase, when phosphorylation at Ser-639 prevents CC interaction with USP7 and subsequent deubiquitination CC (PubMed:22411829). Polyubiquitination may be stimulated by DNA damage CC (PubMed:15009091). {ECO:0000269|PubMed:15009091, CC ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:21745816, CC ECO:0000269|PubMed:22411829}. CC -!- DISEASE: Note=Defects in UHRF1 may be a cause of cancers. Overexpressed CC in many different forms of human cancers, including bladder, breast, CC cervical, colorectal and prostate cancers, as well as pancreatic CC adenocarcinomas, rhabdomyosarcomas and gliomas. Plays an important role CC in the correlation of histone modification and gene silencing in cancer CC progression. Expression is associated with a poor prognosis in patients CC with various cancers, suggesting that it participates in cancer CC progression. {ECO:0000269|PubMed:19491893, ECO:0000269|PubMed:22286757, CC ECO:0000269|PubMed:22330138}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15177.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF129507; AAF28469.1; -; mRNA. DR EMBL; AB177623; BAF36719.1; -; mRNA. DR EMBL; AB177624; BAF36720.1; -; mRNA. DR EMBL; AB075601; BAC20576.1; -; mRNA. DR EMBL; AF274048; AAK55744.1; -; mRNA. DR EMBL; EF560733; ABQ59043.1; -; mRNA. DR EMBL; AK025578; BAB15177.1; ALT_INIT; mRNA. DR EMBL; AK289389; BAF82078.1; -; mRNA. DR EMBL; AK314579; BAG37156.1; -; mRNA. DR EMBL; AY787925; AAV40831.1; -; Genomic_DNA. DR EMBL; AC027319; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC053467; AAF64067.1; -; Genomic_DNA. DR EMBL; CH471139; EAW69187.1; -; Genomic_DNA. DR EMBL; BC113875; AAI13876.2; -; mRNA. DR CCDS; CCDS74262.1; -. [Q96T88-2] DR CCDS; CCDS74263.1; -. [Q96T88-1] DR RefSeq; NP_001041666.1; NM_001048201.3. [Q96T88-1] DR RefSeq; NP_001276979.1; NM_001290050.2. [Q96T88-1] DR RefSeq; NP_001276980.1; NM_001290051.2. [Q96T88-1] DR RefSeq; NP_001276981.1; NM_001290052.2. [Q96T88-1] DR RefSeq; NP_037414.3; NM_013282.4. DR PDB; 2FAZ; X-ray; 2.00 A; A/B=1-76. DR PDB; 2L3R; NMR; -; A=126-285. DR PDB; 2LGG; NMR; -; A=298-366. DR PDB; 2LGK; NMR; -; A=298-366. DR PDB; 2LGL; NMR; -; A=298-366. DR PDB; 2PB7; X-ray; 1.90 A; A=408-643. DR PDB; 3ASK; X-ray; 2.90 A; A/B/C/D=134-367. DR PDB; 3ASL; X-ray; 1.41 A; A=298-367. DR PDB; 3BI7; X-ray; 1.70 A; A=414-617. DR PDB; 3CLZ; X-ray; 2.20 A; A/B/C/D=414-617. DR PDB; 3DB3; X-ray; 2.40 A; A=126-285. DR PDB; 3DB4; X-ray; 2.40 A; A=126-285. DR PDB; 3DWH; X-ray; 1.95 A; A=414-617. DR PDB; 3FL2; X-ray; 1.75 A; A=672-793. DR PDB; 3SHB; X-ray; 1.80 A; A=298-366. DR PDB; 3SOU; X-ray; 1.80 A; A/B=298-367. DR PDB; 3SOW; X-ray; 1.95 A; A/B=298-367. DR PDB; 3SOX; X-ray; 2.65 A; A/B=298-367. DR PDB; 3T6R; X-ray; 1.95 A; A/B=299-364. DR PDB; 3ZVY; X-ray; 1.95 A; A/B=296-367. DR PDB; 3ZVZ; X-ray; 1.45 A; B=314-367. DR PDB; 4GY5; X-ray; 2.96 A; A/B/C/D=134-366. DR PDB; 4QQD; X-ray; 2.28 A; A/B=126-285. DR PDB; 5C6D; X-ray; 2.29 A; C/D=634-665. DR PDB; 5IAY; NMR; -; A=134-285, B=642-657. DR PDB; 5XPI; X-ray; 2.20 A; A=127-283. DR PDB; 5YY9; X-ray; 2.65 A; A/B=123-285. DR PDB; 5YYA; X-ray; 1.70 A; A=123-285. DR PDB; 6B9M; X-ray; 1.68 A; D=638-678. DR PDB; 6IIW; X-ray; 1.70 A; A=299-366. DR PDB; 6VCS; X-ray; 1.70 A; A/B/E=414-617. DR PDB; 6VED; NMR; -; A=133-300. DR PDB; 6VYJ; X-ray; 1.39 A; A=122-283. DR PDB; 6W92; X-ray; 1.30 A; A=122-283. DR PDB; 7FB7; X-ray; 1.45 A; A/B=123-285. DR PDB; 8JIG; X-ray; 2.40 A; A/B=413-617. DR PDB; 8WMS; X-ray; 2.40 A; A=299-366. DR PDB; 8XV4; X-ray; 3.20 A; A/B=134-366. DR PDB; 8XV6; X-ray; 1.60 A; A/C=298-367. DR PDB; 8XV7; X-ray; 2.25 A; A/C/E/G=134-366. DR PDB; 8XV8; X-ray; 2.05 A; A/C/E/G=298-367. DR PDBsum; 2FAZ; -. DR PDBsum; 2L3R; -. DR PDBsum; 2LGG; -. DR PDBsum; 2LGK; -. DR PDBsum; 2LGL; -. DR PDBsum; 2PB7; -. DR PDBsum; 3ASK; -. DR PDBsum; 3ASL; -. DR PDBsum; 3BI7; -. DR PDBsum; 3CLZ; -. DR PDBsum; 3DB3; -. DR PDBsum; 3DB4; -. DR PDBsum; 3DWH; -. DR PDBsum; 3FL2; -. DR PDBsum; 3SHB; -. DR PDBsum; 3SOU; -. DR PDBsum; 3SOW; -. DR PDBsum; 3SOX; -. DR PDBsum; 3T6R; -. DR PDBsum; 3ZVY; -. DR PDBsum; 3ZVZ; -. DR PDBsum; 4GY5; -. DR PDBsum; 4QQD; -. DR PDBsum; 5C6D; -. DR PDBsum; 5IAY; -. DR PDBsum; 5XPI; -. DR PDBsum; 5YY9; -. DR PDBsum; 5YYA; -. DR PDBsum; 6B9M; -. DR PDBsum; 6IIW; -. DR PDBsum; 6VCS; -. DR PDBsum; 6VED; -. DR PDBsum; 6VYJ; -. DR PDBsum; 6W92; -. DR PDBsum; 7FB7; -. DR PDBsum; 8JIG; -. DR PDBsum; 8WMS; -. DR PDBsum; 8XV4; -. DR PDBsum; 8XV6; -. DR PDBsum; 8XV7; -. DR PDBsum; 8XV8; -. DR AlphaFoldDB; Q96T88; -. DR BMRB; Q96T88; -. DR SASBDB; Q96T88; -. DR SMR; Q96T88; -. DR BioGRID; 118893; 235. DR CORUM; Q96T88; -. DR FunCoup; Q96T88; 1543. DR IntAct; Q96T88; 82. DR MINT; Q96T88; -. DR STRING; 9606.ENSP00000479617; -. DR BindingDB; Q96T88; -. DR ChEMBL; CHEMBL2424510; -. DR GlyGen; Q96T88; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96T88; -. DR PhosphoSitePlus; Q96T88; -. DR SwissPalm; Q96T88; -. DR BioMuta; UHRF1; -. DR DMDM; 67462077; -. DR jPOST; Q96T88; -. DR MassIVE; Q96T88; -. DR PaxDb; 9606-ENSP00000479617; -. DR PeptideAtlas; Q96T88; -. DR ProteomicsDB; 78215; -. [Q96T88-1] DR Pumba; Q96T88; -. DR Antibodypedia; 72541; 412 antibodies from 35 providers. DR DNASU; 29128; -. DR Ensembl; ENST00000612630.4; ENSP00000484739.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000615884.4; ENSP00000478601.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000616255.1; ENSP00000478348.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000624301.3; ENSP00000485604.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000650932.1; ENSP00000498698.1; ENSG00000276043.6. [Q96T88-1] DR GeneID; 29128; -. DR KEGG; hsa:29128; -. DR MANE-Select; ENST00000650932.1; ENSP00000498698.1; NM_001048201.3; NP_001041666.1. DR UCSC; uc032hkj.2; human. [Q96T88-1] DR AGR; HGNC:12556; -. DR ClinPGx; PA37196; -. DR CTD; 29128; -. DR DisGeNET; 29128; -. DR GeneCards; UHRF1; -. DR HGNC; HGNC:12556; UHRF1. DR HPA; ENSG00000276043; Group enriched (bone marrow, lymphoid tissue). DR MalaCards; UHRF1; -. DR MIM; 607990; gene. DR OpenTargets; ENSG00000276043; -. DR Orphanet; 2268; ICF syndrome. DR VEuPathDB; HostDB:ENSG00000276043; -. DR eggNOG; ENOG502QRDQ; Eukaryota. DR GeneTree; ENSGT00390000008296; -. DR HOGENOM; CLU_022357_0_0_1; -. DR InParanoid; Q96T88; -. DR OrthoDB; 2270193at2759; -. DR PAN-GO; Q96T88; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q96T88; -. DR PathwayCommons; Q96T88; -. DR Reactome; R-HSA-5334118; DNA methylation. DR Reactome; R-HSA-9821002; Chromatin modifications during the maternal to zygotic transition (MZT). DR SignaLink; Q96T88; -. DR SIGNOR; Q96T88; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000276043; -. DR BioGRID-ORCS; 29128; 65 hits in 331 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; UHRF1; human. DR EvolutionaryTrace; Q96T88; -. DR GeneWiki; UHRF1; -. DR GenomeRNAi; 29128; -. DR Pharos; Q96T88; Tbio. DR PRO; PR:Q96T88; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q96T88; protein. DR Bgee; ENSG00000276043; Expressed in oocyte and 139 other cell types or tissues. DR ExpressionAtlas; Q96T88; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProtKB. DR GO; GO:0000791; C:euchromatin; IDA:UniProtKB. DR GO; GO:0000792; C:heterochromatin; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005657; C:replication fork; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IC:UniProt. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0140612; F:DNA damage sensor activity; TAS:BHF-UCL. DR GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0141055; F:histone H3 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140851; F:histone H3K14 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140248; F:histone H3K18 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140234; F:histone H3K23 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0062072; F:histone H3K9me2/3 reader activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL. DR GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB. DR GO; GO:0003676; F:nucleic acid binding; EXP:DisProt. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProt. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0141119; P:chromosomal DNA methylation maintenance following DNA replication; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; TAS:BHF-UCL. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:BHF-UCL. DR GO; GO:0040029; P:epigenetic regulation of gene expression; TAS:BHF-UCL. DR GO; GO:0031507; P:heterochromatin formation; IDA:UniProtKB. DR GO; GO:0035825; P:homologous recombination; TAS:BHF-UCL. DR GO; GO:0090307; P:mitotic spindle assembly; IDA:UniProt. DR GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IMP:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051247; P:positive regulation of protein metabolic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProt. DR GO; GO:0016567; P:protein ubiquitination; IBA:GO_Central. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR CDD; cd15616; PHD_UHRF1; 1. DR CDD; cd16769; RING-HC_UHRF1; 1. DR CDD; cd20455; Tudor_UHRF1_rpt1; 1. DR CDD; cd20457; Tudor_UHRF1_rpt2; 1. DR CDD; cd17122; Ubl_UHRF1; 1. DR DisProt; DP01651; -. DR FunFam; 2.30.280.10:FF:000001; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 2.30.30.140:FF:000068; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 3.10.20.90:FF:000143; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 2.30.30.1150:FF:000001; E3 ubiquitin-protein ligase UHRF2 isoform X1; 1. DR FunFam; 3.30.40.10:FF:000066; E3 ubiquitin-protein ligase UHRF2 isoform X1; 1. DR Gene3D; 2.30.30.1150; -; 1. DR Gene3D; 2.30.30.140; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 2.30.280.10; SRA-YDG; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR IDEAL; IID00327; -. DR InterPro; IPR015947; PUA-like_sf. DR InterPro; IPR036987; SRA-YDG_sf. DR InterPro; IPR003105; SRA_YDG. DR InterPro; IPR021991; TTD_dom. DR InterPro; IPR000626; Ubiquitin-like_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR InterPro; IPR047406; Ubl_UHRF1. DR InterPro; IPR045134; UHRF1/2-like. DR InterPro; IPR011011; Znf_FYVE_PHD. DR InterPro; IPR001965; Znf_PHD. DR InterPro; IPR019787; Znf_PHD-finger. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR14140; E3 UBIQUITIN-PROTEIN LIGASE UHRF-RELATED; 1. DR PANTHER; PTHR14140:SF2; E3 UBIQUITIN-PROTEIN LIGASE UHRF1; 1. DR Pfam; PF00628; PHD; 1. DR Pfam; PF02182; SAD_SRA; 1. DR Pfam; PF12148; TTD; 1. DR Pfam; PF00240; ubiquitin; 1. DR SMART; SM00249; PHD; 1. DR SMART; SM00184; RING; 2. DR SMART; SM00466; SRA; 1. DR SMART; SM00213; UBQ; 1. DR SUPFAM; SSF57903; FYVE/PHD zinc finger; 1. DR SUPFAM; SSF88697; PUA domain-like; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS50053; UBIQUITIN_2; 1. DR PROSITE; PS51015; YDG; 1. DR PROSITE; PS01359; ZF_PHD_1; 1. DR PROSITE; PS50016; ZF_PHD_2; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; KW Chromatin regulator; Chromosome; DNA damage; DNA repair; DNA-binding; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW Transcription; Transcription regulation; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..793 FT /note="E3 ubiquitin-protein ligase UHRF1" FT /id="PRO_0000056144" FT DOMAIN 1..78 FT /note="Ubiquitin-like" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT DOMAIN 419..582 FT /note="YDG" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00358" FT ZN_FING 310..366 FT /note="PHD-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00146" FT ZN_FING 724..763 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 82..124 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 133..209 FT /note="Tudor-like 1" FT /evidence="ECO:0000269|PubMed:21489993" FT REGION 216..283 FT /note="Tudor-like 2" FT /evidence="ECO:0000269|PubMed:21489993" FT REGION 296..301 FT /note="Linker" FT /evidence="ECO:0000269|PubMed:22837395" FT REGION 333..337 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT REGION 353..355 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT REGION 445..446 FT /note="Required to promote base flipping" FT /evidence="ECO:0000250|UniProtKB:Q8VDF2" FT REGION 466..469 FT /note="Required for formation of a 5-methylcytosine-binding FT pocket" FT /evidence="ECO:0000269|PubMed:18772889" FT REGION 478..481 FT /note="Required for formation of a 5-methylcytosine-binding FT pocket" FT /evidence="ECO:0000269|PubMed:18772889" FT REGION 618..673 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 618..629 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 302 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 305 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 313 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 316 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 318 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 319 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASL, FT ECO:0007744|PDB:3SOU" FT BINDING 321 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASL, FT ECO:0007744|PDB:3SOU" FT BINDING 333 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 336 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 341 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 344 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 360 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 362 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 363 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 463..464 FT /ligand="DNA" FT /ligand_id="ChEBI:CHEBI:16991" FT /ligand_part="5-methylcytosine group" FT /ligand_part_id="ChEBI:CHEBI:65274" FT /evidence="ECO:0000269|PubMed:18772889" FT BINDING 469 FT /ligand="DNA" FT /ligand_id="ChEBI:CHEBI:16991" FT /ligand_part="5-methylcytosine group" FT /ligand_part_id="ChEBI:CHEBI:65274" FT /evidence="ECO:0000269|PubMed:18772889" FT BINDING 724 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 727 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 739 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 741 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 744 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 747 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 759 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 762 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT SITE 316 FT /note="Histone H3K4me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 327 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 330 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 479 FT /note="Required to confer preferential recognition of FT cytosine over thymine" FT /evidence="ECO:0000269|PubMed:18772889" FT SITE 489 FT /note="Required to discriminate between hemimethylated DNA FT versus symmetrically methylated DNA" FT /evidence="ECO:0000269|PubMed:18772889" FT SITE 491 FT /note="Required for affinity and specificity for 5-mCpG FT sequence" FT /evidence="ECO:0000269|PubMed:18772889" FT MOD_RES 76 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 95 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7TPK1" FT MOD_RES 165 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VDF2" FT MOD_RES 287 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 298 FT /note="Phosphoserine; by PKA" FT /evidence="ECO:0000269|PubMed:15178447, FT ECO:0000269|PubMed:22837395" FT MOD_RES 368 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 399 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 546 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 639 FT /note="Phosphoserine; by CDK1" FT /evidence="ECO:0000269|PubMed:22411829, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 707 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 709 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 279 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 385 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 546 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 670 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1 FT /note="M -> MGVFAVPPLSSDTM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_044394" FT VARIANT 240 FT /note="D -> H (in dbSNP:rs17886098)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022554" FT VARIANT 379 FT /note="E -> K (in dbSNP:rs17885791)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_022555" FT VARIANT 638 FT /note="A -> T (in dbSNP:rs2307209)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_022556" FT VARIANT 642 FT /note="T -> M (in dbSNP:rs17884843)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022557" FT VARIANT 713 FT /note="L -> F (in dbSNP:rs17883563)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022558" FT MUTAGEN 2 FT /note="W->V: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 6 FT /note="R->D: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 8 FT /note="M->R: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 46 FT /note="F->V: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 48 FT /note="R->E: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 50 FT /note="K->R: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 56 FT /note="H->A: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 59 FT /note="F->V: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931, FT ECO:0000269|PubMed:39607687" FT MUTAGEN 62 FT /note="E->K: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 64 FT /note="R->E: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 65 FT /note="L->A: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 70 FT /note="Q->E: Abolished binding to UBE2D E2 ubiquitin FT conjugating enzymes, leading to strongly decreased histone FT H3 ubiquitin ligase activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 72 FT /note="L->A: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 142 FT /note="D->A: Impaired binding to histone H3 without FT affecting the protein folding; when associated with A-153." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 145 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 147 FT /note="N->D,E: Reduced binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:23022729" FT MUTAGEN 152 FT /note="F->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 153 FT /note="E->A: Impaired binding to histone H3 without FT affecting the protein folding; when associated with A-142." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 188 FT /note="Y->A: Abolished binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:20026581, FT ECO:0000269|PubMed:21489993, ECO:0000269|PubMed:23022729, FT ECO:0000269|PubMed:39631394" FT MUTAGEN 190 FT /note="D->A: Slightly impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 191 FT /note="Y->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:20026581" FT MUTAGEN 295..296 FT /note="RR->AA: Disrupts the simultaneous binding to H3R2me0 FT and H3K9me3." FT /evidence="ECO:0000269|PubMed:22837395" FT MUTAGEN 298 FT /note="S->A: Diminishes phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 330 FT /note="Q->A,K: Does not affect ability to bind histone H3 FT peptide." FT /evidence="ECO:0000269|PubMed:22096602" FT MUTAGEN 334..335 FT /note="DE->AA: Abolishes binding to histone H3. Abolished FT binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:30104358" FT MUTAGEN 334 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21808299, FT ECO:0000269|PubMed:21808300, ECO:0000269|PubMed:22096602" FT MUTAGEN 337 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21808299, FT ECO:0000269|PubMed:21808300, ECO:0000269|PubMed:22096602" FT MUTAGEN 433 FT /note="R->A: Does not affect ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 443 FT /note="R->A: Decreased ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 448 FT /note="G->D: Decreased affinity for DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30104358, FT ECO:0000269|PubMed:39607687" FT MUTAGEN 466 FT /note="Y->G: Decreased ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 469 FT /note="D->G: Abolishes ability to bind hemimethylated DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:27595565" FT MUTAGEN 489 FT /note="N->A: Abolishes specificity to hemimethylated DNA." FT /evidence="ECO:0000269|PubMed:18772889" FT MUTAGEN 491 FT /note="R->A: Decreased binding to methylated DNA but does FT not affect ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:18945682" FT MUTAGEN 639 FT /note="S->A: Prevents phosphorylation by CDK1 during M FT phase, leading to increased stability." FT /evidence="ECO:0000269|PubMed:22411829" FT MUTAGEN 639 FT /note="S->D: Mimics phosphorylation; impaired interaction FT with USP7, leading to decreased stability." FT /evidence="ECO:0000269|PubMed:22411829" FT MUTAGEN 651 FT /note="S->A: No effect on in vitro phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 666 FT /note="S->A: No effect on in vitro phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 724..727 FT /note="CICC->AIAA: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:24013172" FT MUTAGEN 741 FT /note="H->A: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:22945642, FT ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:39607687" FT CONFLICT 383 FT /note="K -> E (in Ref. 5; BAF82078)" FT /evidence="ECO:0000305" FT CONFLICT 383 FT /note="K -> N (in Ref. 1; AAF28469)" FT /evidence="ECO:0000305" FT CONFLICT 457 FT /note="A -> S (in Ref. 1; AAF28469)" FT /evidence="ECO:0000305" FT CONFLICT 675 FT /note="S -> N (in Ref. 5; BAF82078)" FT /evidence="ECO:0000305" FT STRAND 1..7 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 13..19 FT /evidence="ECO:0007829|PDB:2FAZ" FT HELIX 25..36 FT /evidence="ECO:0007829|PDB:2FAZ" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 43..47 FT /evidence="ECO:0007829|PDB:2FAZ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 68..73 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 126..128 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:7FB7" FT STRAND 140..144 FT /evidence="ECO:0007829|PDB:6W92" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 151..162 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 164..167 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 183..190 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 196..200 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:7FB7" FT STRAND 210..212 FT /evidence="ECO:0007829|PDB:2L3R" FT HELIX 214..216 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 229..231 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 237..248 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 253..260 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:8XV4" FT STRAND 266..270 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 274..276 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 277..279 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 283..286 FT /evidence="ECO:0007829|PDB:3ASK" FT TURN 303..307 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:2LGG" FT TURN 314..316 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 319..321 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:2LGL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 339..341 FT /evidence="ECO:0007829|PDB:3ASL" FT HELIX 342..344 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 354..356 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 361..363 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 417..419 FT /evidence="ECO:0007829|PDB:3DWH" FT STRAND 429..432 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 433..438 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 439..442 FT /evidence="ECO:0007829|PDB:3DWH" FT STRAND 448..452 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 453..455 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 456..462 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 473..479 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 487..489 FT /evidence="ECO:0007829|PDB:3CLZ" FT HELIX 503..511 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 512..514 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 518..520 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 533..538 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 539..544 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:3CLZ" FT STRAND 550..568 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 572..582 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 592..601 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 611..617 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 678..686 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 691..699 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 710..721 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 725..727 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 728..730 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 732..736 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 742..744 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 745..753 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 760..762 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 787..792 FT /evidence="ECO:0007829|PDB:3FL2" SQ SEQUENCE 793 AA; 89814 MW; E65B15657525C89F CRC64; MWIQVRTMDG RQTHTVDSLS RLTKVEELRR KIQELFHVEP GLQRLFYRGK QMEDGHTLFD YEVRLNDTIQ LLVRQSLVLP HSTKERDSEL SDTDSGCCLG QSESDKSSTH GEAAAETDSR PADEDMWDET ELGLYKVNEY VDARDTNMGA WFEAQVVRVT RKAPSRDEPC SSTSRPALEE DVIYHVKYDD YPENGVVQMN SRDVRARART IIKWQDLEVG QVVMLNYNPD NPKERGFWYD AEISRKRETR TARELYANVV LGDDSLNDCR IIFVDEVFKI ERPGEGSPMV DNPMRRKSGP SCKHCKDDVN RLCRVCACHL CGGRQDPDKQ LMCDECDMAF HIYCLDPPLS SVPSEDEWYC PECRNDASEV VLAGERLRES KKKAKMASAT SSSQRDWGKG MACVGRTKEC TIVPSNHYGP IPGIPVGTMW RFRVQVSESG VHRPHVAGIH GRSNDGAYSL VLAGGYEDDV DHGNFFTYTG SGGRDLSGNK RTAEQSCDQK LTNTNRALAL NCFAPINDQE GAEAKDWRSG KPVRVVRNVK GGKNSKYAPA EGNRYDGIYK VVKYWPEKGK SGFLVWRYLL RRDDDEPGPW TKEGKDRIKK LGLTMQYPEG YLEALANRER EKENSKREEE EQQEGGFASP RTGKGKWKRK SAGGGPSRAG SPRRTSKKTK VEPYSLTAQQ SSLIREDKSN AKLWNEVLAS LKDRPASGSP FQLFLSKVEE TFQCICCQEL VFRPITTVCQ HNVCKDCLDR SFRAQVFSCP ACRYDLGRSY AMQVNQPLQT VLNQLFPGYG NGR // ID WNK1_HUMAN Reviewed; 2382 AA. AC Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9; AC Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9; DT 02-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913}; DE AltName: Full=Erythrocyte 65 kDa protein; DE Short=p65; DE AltName: Full=Kinase deficient protein; DE AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|HGNC:HGNC:14540}; DE AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:11571656}; DE Short=hWNK1; GN Name=WNK1 {ECO:0000303|PubMed:11571656, ECO:0000312|HGNC:HGNC:14540}; GN Synonyms=HSN2 {ECO:0000303|PubMed:15060842}, KDP, GN KIAA0344 {ECO:0000312|EMBL:BAA20802.2}, GN PRKWNK1 {ECO:0000312|HGNC:HGNC:14540}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC15059.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CHROMOSOMAL RP LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808. RC TISSUE=Heart {ECO:0000312|EMBL:CAC15059.1}; RX PubMed=11571656; DOI=10.1038/sj.onc.1204726; RA Verissimo F., Jordan P.; RT "WNK kinases, a novel protein kinase subfamily in multi-cellular RT organisms."; RL Oncogene 20:5562-5569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Neuron; RX PubMed=22701532; DOI=10.1371/journal.pone.0037751; RA Vidal-Petiot E., Cheval L., Faugeroux J., Malard T., Doucet A., RA Jeunemaitre X., Hadchouel J.; RT "A new methodology for quantification of alternatively spliced exons RT reveals a highly tissue-specific expression pattern of WNK1 isoforms."; RL PLoS ONE 7:E37751-E37751(2012). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND RP ILE-1808. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=10660600; DOI=10.1074/jbc.275.6.4311; RA Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J., Morris J.D.H.; RT "PSK, a novel STE20-like kinase derived from prostatic carcinoma that RT activates the JNK MAPK pathway and regulates actin cytoskeletal RT organisation."; RL J. Biol. Chem. 275:4311-4322(2000). RN [6] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND VARIANTS RP PRO-1056 AND SER-1506. RC TISSUE=Brain {ECO:0000312|EMBL:BAA20802.2}; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [7] {ECO:0000305} RP SEQUENCE REVISION TO N-TERMINUS. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [8] RP PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION. RX PubMed=2507249; DOI=10.1002/9780470513828.ch7; RA Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.; RT "Nucleoplasmic and cytoplasmic glycoproteins."; RL Ciba Found. Symp. 145:102-118(1989). RN [9] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE RP PROMOTER USAGE, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY. RC TISSUE=Kidney {ECO:0000269|PubMed:14645531}; RX PubMed=14645531; DOI=10.1128/mcb.23.24.9208-9221.2003; RA Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M., Corvol P., RA Jeunemaitre X.; RT "Multiple promoters in the WNK1 gene: one controls expression of a kidney- RT specific kinase-defective isoform."; RL Mol. Cell. Biol. 23:9208-9221(2003). RN [10] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1/4/5). RC TISSUE=Placenta {ECO:0000269|PubMed:15489334}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP IDENTIFICATION (ISOFORMS 4/5), AND INVOLVEMENT IN HSAN2A. RX PubMed=15060842; DOI=10.1086/420795; RA Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J., RA O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T., RA Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M., RA Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W., RA Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R., RA Rouleau G.A., Samuels M.E.; RT "Identification of a novel gene (HSN2) causing hereditary sensory and RT autonomic neuropathy type II through the study of Canadian genetic RT isolates."; RL Am. J. Hum. Genet. 74:1064-1073(2004). RN [12] {ECO:0000305} RP INVOLVEMENT IN PHA2C. RX PubMed=11498583; DOI=10.1126/science.1062844; RA Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., RA Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., RA Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., RA Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.; RT "Human hypertension caused by mutations in WNK kinases."; RL Science 293:1107-1112(2001). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-382. RX PubMed=15883153; DOI=10.1074/jbc.m502598200; RA Lenertz L.Y., Lee B.H., Min X., Xu B.E., Wedin K., Earnest S., RA Goldsmith E.J., Cobb M.H.; RT "Properties of WNK1 and implications for other family members."; RL J. Biol. Chem. 280:26653-26658(2005). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, ACTIVITY REGULATION, DOMAIN, RP PHOSPHORYLATION AT SER-382, AND MUTAGENESIS OF LYS-233; ASP-368; SER-382; RP PHE-1258; PHE-1860; PHE-1946 AND PHE-1958. RX PubMed=16263722; DOI=10.1074/jbc.m510042200; RA Moriguchi T., Urushiyama S., Hisamoto N., Iemura S., Uchida S., Natsume T., RA Matsumoto K., Shibuya H.; RT "WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters RT via the STE20-related kinases, SPAK and OSR1."; RL J. Biol. Chem. 280:42685-42693(2005). RN [15] RP INVOLVEMENT IN HSAN2A. RX PubMed=15911806; DOI=10.1212/01.wnl.0000161849.29944.43; RA Roddier K., Thomas T., Marleau G., Gagnon A.M., Dicaire M.J., St Denis A., RA Gosselin I., Sarrazin A.M., Larbrisseau A., Lambert M., Vanasse M., RA Gaudet D., Rouleau G.A., Brais B.; RT "Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in RT French Canadians."; RL Neurology 64:1762-1767(2005). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002 AND SER-2032, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [18] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT RP SER-382, AND MUTAGENESIS OF SER-382. RX PubMed=16832045; DOI=10.1073/pnas.0604607103; RA Anselmo A.N., Earnest S., Chen W., Juang Y.C., Kim S.C., Zhao Y., RA Cobb M.H.; RT "WNK1 and OSR1 regulate the Na+, K+, 2Cl- cotransporter in HeLa cells."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10883-10888(2006). RN [19] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT SER-15; SER-167; SER-382; THR-1848; SER-1261; SER-2012; RP SER-2029; SER-2032 AND SER-2372, AND MUTAGENESIS OF ASP-368 AND SER-382. RX PubMed=17190791; DOI=10.1083/jcb.200605093; RA Zagorska A., Pozo-Guisado E., Boudeau J., Vitari A.C., Rafiqi F.H., RA Thastrup J., Deak M., Campbell D.G., Morrice N.A., Prescott A.R., RA Alessi D.R.; RT "Regulation of activity and localization of the WNK1 protein kinase by RT hyperosmotic stress."; RL J. Cell Biol. 176:89-100(2007). RN [20] RP ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND INVOLVEMENT IN HSAN2A. RX PubMed=18521183; DOI=10.1172/jci34088; RA Shekarabi M., Girard N., Riviere J.B., Dion P., Houle M., Toulouse A., RA Lafreniere R.G., Vercauteren F., Hince P., Laganiere J., Rochefort D., RA Faivre L., Samuels M., Rouleau G.A.; RT "Mutations in the nervous system--specific HSN2 exon of WNK1 cause RT hereditary sensory neuropathy type II."; RL J. Clin. Invest. 118:2496-2505(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-2011; RP SER-2012; SER-2027; SER-2029 AND SER-2032, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY RP REGULATION. RX PubMed=19739668; DOI=10.1021/bi900666n; RA Yagi Y.I., Abe K., Ikebukuro K., Sode K.; RT "Kinetic mechanism and inhibitor characterization of WNK1 kinase."; RL Biochemistry 48:10255-10266(2009). RN [25] RP FUNCTION. RX PubMed=19665974; DOI=10.1016/j.cell.2009.05.031; RA Rinehart J., Maksimova Y.D., Tanis J.E., Stone K.L., Hodson C.A., Zhang J., RA Risinger M., Pan W., Wu D., Colangelo C.M., Forbush B., Joiner C.H., RA Gulcicek E.E., Gallagher P.G., Lifton R.P.; RT "Sites of regulated phosphorylation that control K-Cl cotransporter RT activity."; RL Cell 138:525-536(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978; RP SER-2032 AND SER-2121, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21321328; DOI=10.1242/jcs.077230; RA Richardson C., Sakamoto K., de los Heros P., Deak M., Campbell D.G., RA Prescott A.R., Alessi D.R.; RT "Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and RT -independent pathways."; RL J. Cell Sci. 124:789-800(2011). RN [30] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21220314; DOI=10.1073/pnas.1018567108; RA Tu S.W., Bugde A., Luby-Phelps K., Cobb M.H.; RT "WNK1 is required for mitosis and abscission."; RL Proc. Natl. Acad. Sci. U.S.A. 108:1385-1390(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2027; SER-2029 AND SER-2032, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF VAL-318. RX PubMed=22989884; DOI=10.1074/jbc.m112.398750; RA Sengupta S., Tu S.W., Wedin K., Earnest S., Stippec S., Luby-Phelps K., RA Cobb M.H.; RT "Interactions with WNK (with no lysine) family members regulate oxidative RT stress response 1 and ion co-transporter activity."; RL J. Biol. Chem. 287:37868-37879(2012). RN [33] RP UBIQUITINATION BY KLHL2. RX PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104; RA Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M., RA Sohara E., Rai T., Sasaki S., Uchida S.; RT "KLHL2 interacts with and ubiquitinates WNK kinases."; RL Biochem. Biophys. Res. Commun. 437:457-462(2013). RN [34] RP UBIQUITINATION. RX PubMed=23387299; DOI=10.1042/bj20121903; RA Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A., RA Macartney T.J., Wood N.T., Alessi D.R., Kurz T.; RT "The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome RT interacts with and ubiquitylates WNK isoforms: disease-causing mutations in RT KLHL3 and WNK4 disrupt interaction."; RL Biochem. J. 451:111-122(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-167; SER-174; RP SER-1261; SER-2029; SER-2032; SER-2370 AND SER-2372, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP UBIQUITINATION. RX PubMed=23576762; DOI=10.1073/pnas.1304592110; RA Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P.; RT "Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via RT ubiquitination and degradation of WNK4."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7838-7843(2013). RN [37] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167; SER-174; SER-1978 AND RP SER-2027, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [38] RP FUNCTION. RX PubMed=25362046; DOI=10.1073/pnas.1419057111; RA Dbouk H.A., Weil L.M., Perera G.K., Dellinger M.T., Pearson G., RA Brekken R.A., Cobb M.H.; RT "Actions of the protein kinase WNK1 on endothelial cells are differentially RT mediated by its substrate kinases OSR1 and SPAK."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15999-16004(2014). RN [39] RP FUNCTION. RX PubMed=25477473; DOI=10.1152/ajprenal.00612.2014; RA Roy A., Goodman J.H., Begum G., Donnelly B.F., Pittman G., Weinman E.J., RA Sun D., Subramanya A.R.; RT "Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome RT editing."; RL Am. J. Physiol. 308:F366-F376(2015). RN [40] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UVRAG. RX PubMed=27911840; DOI=10.1073/pnas.1617649113; RA Gallolu Kankanamalage S., Lee A.Y., Wichaidit C., Lorente-Rodriguez A., RA Shah A.M., Stippec S., Whitehurst A.W., Cobb M.H.; RT "Multistep regulation of autophagy by WNK1."; RL Proc. Natl. Acad. Sci. U.S.A. 113:14342-14347(2016). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=29196535; DOI=10.1101/gad.303677.117; RA Volanakis A., Kamieniarz-Gdula K., Schlackow M., Proudfoot N.J.; RT "WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export RT with transcription."; RL Genes Dev. 31:2175-2185(2017). RN [42] RP MUTAGENESIS OF GLY-1255 AND ARG-1257. RX PubMed=29581290; DOI=10.1073/pnas.1802339115; RA Taylor C.A. IV, An S.W., Kankanamalage S.G., Stippec S., Earnest S., RA Trivedi A.T., Yang J.Z., Mirzaei H., Huang C.L., Cobb M.H.; RT "OSR1 regulates a subset of inward rectifier potassium channels via a RT binding motif variant."; RL Proc. Natl. Acad. Sci. U.S.A. 115:3840-3845(2018). RN [43] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-378 AND SER-382. RX PubMed=31656913; DOI=10.1021/acsomega.9b02187; RA Jonniya N.A., Sk M.F., Kar P.; RT "Investigating phosphorylation-induced conformational changes in WNK1 RT kinase by molecular dynamics simulations."; RL ACS Omega 4:17404-17416(2019). RN [44] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-382. RX PubMed=34289367; DOI=10.1016/j.celrep.2021.109416; RA Schiapparelli P., Pirman N.L., Mohler K., Miranda-Herrera P.A., Zarco N., RA Kilic O., Miller C., Shah S.R., Rogulina S., Hungerford W., Abriola L., RA Hoyer D., Turk B.E., Guerrero-Cazares H., Isaacs F.J., RA Quinones-Hinojosa A., Levchenko A., Rinehart J.; RT "Phosphorylated WNK kinase networks in recoded bacteria recapitulate RT physiological function."; RL Cell Rep. 36:109416-109416(2021). RN [45] RP FUNCTION, INTERACTION WITH EMC2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP PHE-2246; ASP-2248; ASP-2249; LEU-2250; HIS-2251; LEU-2253; TRP-2257 AND RP ASP-2260. RX PubMed=33964204; DOI=10.1016/j.molcel.2021.04.013; RA Pleiner T., Hazu M., Tomaleri G.P., Januszyk K., Oania R.S., RA Sweredoski M.J., Moradian A., Guna A., Voorhees R.M.; RT "WNK1 is an assembly factor for the human ER membrane protein complex."; RL Mol. Cell 81:2693-2704(2021). RN [46] RP FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND DOMAIN. RX PubMed=36318922; DOI=10.1016/j.cell.2022.09.042; RA Boyd-Shiwarski C.R., Shiwarski D.J., Griffiths S.E., Beacham R.T., RA Norrell L., Morrison D.E., Wang J., Mann J., Tennant W., Anderson E.N., RA Franks J., Calderon M., Connolly K.A., Cheema M.U., Weaver C.J., RA Nkashama L.J., Weckerly C.C., Querry K.E., Pandey U.B., Donnelly C.J., RA Sun D., Rodan A.R., Subramanya A.R.; RT "WNK kinases sense molecular crowding and rescue cell volume via phase RT separation."; RL Cell 185:4488-4506(2022). RN [47] RP FUNCTION, INTERACTION WITH SGK1, INTERACTION WITH THE MTORC2 COMPLEX, AND RP MUTAGENESIS OF LYS-233. RX PubMed=36373794; DOI=10.1242/jcs.260313; RA Saha B., Leite-Dellova D.C.A., Demko J., Soerensen M.V., Takagi E., RA Gleason C.E., Shabbir W., Pearce D.; RT "WNK1 is a chloride-stimulated scaffold that regulates mTORC2 activity and RT ion transport."; RL J. Cell Sci. 135:0-0(2022). RN [48] {ECO:0007744|PDB:4PWN} RP X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 210-482. RX PubMed=24803536; DOI=10.1126/scisignal.2005050; RA Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.; RT "Chloride sensing by WNK1 involves inhibition of autophosphorylation."; RL Sci. Signal. 7:RA41-RA41(2014). RN [49] {ECO:0007744|PDB:5TF9} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP AND RP ALLOSTERIC INHIBITOR. RX PubMed=27712055; DOI=10.1021/acschembio.6b00511; RA Yamada K., Zhang J.H., Xie X., Reinhardt J., Xie A.Q., LaSala D., Kohls D., RA Yowe D., Burdick D., Yoshisue H., Wakai H., Schmidt I., Gunawan J., RA Yasoshima K., Yue Q.K., Kato M., Mogi M., Idamakanti N., Kreder N., RA Drueckes P., Pandey P., Kawanami T., Huang W., Yagi Y.I., Deng Z., RA Park H.M.; RT "Discovery and characterization of allosteric WNK kinase inhibitors."; RL ACS Chem. Biol. 11:3338-3346(2016). RN [50] {ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP RP ANALOG AND ALLOSTERIC INHIBITOR. RX PubMed=28771350; DOI=10.1021/acs.jmedchem.7b00708; RA Yamada K., Levell J., Yoon T., Kohls D., Yowe D., Rigel D.F., Imase H., RA Yuan J., Yasoshima K., DiPetrillo K., Monovich L., Xu L., Zhu M., Kato M., RA Jain M., Idamakanti N., Taslimi P., Kawanami T., Argikar U.A., RA Kunjathoor V., Xie X., Yagi Y.I., Iwaki Y., Robinson Z., Park H.M.; RT "Optimization of allosteric With-No-Lysine (WNK) kinase inhibitors and RT efficacy in rodent hypertension models."; RL J. Med. Chem. 60:7099-7107(2017). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509; RP GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808; LEU-1823; RP HIS-1957; CYS-2190; LEU-2362 AND TRP-2380. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the WNK1- CC SPAK/OSR1 kinase cascade, which acts as a key regulator of blood CC pressure and regulatory volume increase by promoting ion influx CC (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, CC PubMed:36318922). WNK1 mediates regulatory volume increase in response CC to hyperosmotic stress by acting as a molecular crowding sensor, which CC senses cell shrinkage and mediates formation of a membraneless CC compartment by undergoing liquid-liquid phase separation CC (PubMed:36318922). The membraneless compartment concentrates WNK1 with CC its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent CC phosphorylation and activation of downstream kinases OXSR1/OSR1 and CC STK39/SPAK (PubMed:15883153, PubMed:16263722, PubMed:17190791, CC PubMed:19739668, PubMed:21321328, PubMed:22989884, PubMed:25477473, CC PubMed:34289367, PubMed:36318922). Following activation, OXSR1/OSR1 and CC STK39/SPAK catalyze phosphorylation of ion cotransporters CC SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and SLC12A6/KCC3, regulating CC their activity (PubMed:16263722, PubMed:21321328). Phosphorylation of CC Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their CC activation and ion influx; simultaneously, phosphorylation of K-Cl CC cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, CC blocking ion efflux (PubMed:19665974, PubMed:21321328). Also acts as a CC regulator of angiogenesis in endothelial cells via activation of CC OXSR1/OSR1 and STK39/SPAK: activation of OXSR1/OSR1 regulates CC chemotaxis and invasion, while STK39/SPAK regulates endothelial cell CC proliferation (PubMed:25362046). Also acts independently of the WNK1- CC SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other CC substrates, such as SYT2, PCF11 and NEDD4L (PubMed:29196535). Mediates CC phosphorylation of SYT2, regulating SYT2 association with phospholipids CC and membrane-binding (By similarity). Regulates mRNA export in the CC nucleus by mediating phosphorylation of PCF11, thereby decreasing the CC association between PCF11 and POLR2A/RNA polymerase II and promoting CC mRNA export to the cytoplasm (PubMed:29196535). Acts as a negative CC regulator of autophagy (PubMed:27911840). Required for the abscission CC step during mitosis, independently of the WNK1-SPAK/OSR1 kinase cascade CC (PubMed:21220314). May also play a role in actin cytoskeletal CC reorganization (PubMed:10660600). Also acts as a scaffold protein CC independently of its protein kinase activity: negatively regulates cell CC membrane localization of various transporters and channels, such as CC SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR (By similarity). Involved in CC the regulation of epithelial Na(+) channel (ENaC) by promoting CC activation of SGK1 in a kinase-independent manner: probably acts as a CC scaffold protein that promotes the recruitment of SGK1 to the mTORC2 CC complex in response to chloride, leading to mTORC2-dependent CC phosphorylation and activation of SGK1 (PubMed:36373794). Acts as an CC assembly factor for the ER membrane protein complex independently of CC its protein kinase activity: associates with EMC2 in the cytoplasm via CC its amphipathic alpha-helix, and prevents EMC2 ubiquitination and CC subsequent degradation, thereby promoting EMC2 stabilization CC (PubMed:33964204). {ECO:0000250|UniProtKB:P83741, CC ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19665974, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:22989884, CC ECO:0000269|PubMed:25362046, ECO:0000269|PubMed:25477473, CC ECO:0000269|PubMed:27911840, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913, ECO:0000269|PubMed:33964204, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922, CC ECO:0000269|PubMed:36373794}. CC -!- FUNCTION: [Isoform 3]: Kinase-defective isoform specifically expressed CC in kidney, which acts as a dominant-negative regulator of the longer CC isoform 1 (PubMed:14645531). Does not directly inhibit WNK4 and has no CC direct effect on sodium and chloride ion transport (By similarity). CC Down-regulates sodium-chloride cotransporter activity indirectly by CC inhibiting isoform 1, it associates with isoform 1 and attenuates its CC kinase activity (By similarity). In kidney, may play an important role CC regulating sodium and potassium balance (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:14645531}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:19739668, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:29196535}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10660600}; CC -!- ACTIVITY REGULATION: Activated in response to hyperosmotic stress: cell CC shrinkage promotes formation of a membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK CC (PubMed:36318922). Activation requires autophosphorylation of Ser-382 CC and, to a lower extent, Ser-378 (PubMed:15883153, PubMed:16263722, CC PubMed:16832045, PubMed:17190791, PubMed:31656913, PubMed:34289367). CC Autophosphorylation and subsequent activation is inhibited by increases CC in intracellular ionic strength: Cl(-) potently inhibits WNK1 kinase CC activity via direct binding (By similarity). Also inhibited by K(+) CC ions (By similarity). Inhibited by small compounds staurosporine, CC tyrphostin 47, as well as Src tyrosine kinase inhibitors PP1 and PP2 CC (PubMed:19739668). {ECO:0000250|UniProtKB:Q9JIH7, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.0 uM for ATP {ECO:0000269|PubMed:19739668}; CC KM=68.4 uM for a OXSR1/OSR1 peptide {ECO:0000269|PubMed:19739668}; CC -!- SUBUNIT: Interacts with WNK3 (By similarity). Interacts with WNK4; CC inhibiting the activity of WNK4 (By similarity). Interacts with SGK1; CC promoting its activation (PubMed:36373794). Associates with the mTORC2 CC complex (PubMed:36373794). Interacts with UVRAG (PubMed:27911840). CC Interacts (via amphipathic alpha-helix region) with EMC2; promoting the CC ER membrane protein complex assembly (PubMed:33964204). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36373794}. CC -!- SUBUNIT: [Isoform 3]: Interacts with isoform 1; inhibiting isoform 1 CC activity. {ECO:0000250|UniProtKB:Q9JIH7}. CC -!- INTERACTION: CC Q9H4A3; O95747: OXSR1; NbExp=9; IntAct=EBI-457907, EBI-620853; CC Q9H4A3; P62136: PPP1CA; NbExp=2; IntAct=EBI-457907, EBI-357253; CC Q9H4A3; P31947: SFN; NbExp=4; IntAct=EBI-457907, EBI-476295; CC Q9H4A3; P62258: YWHAE; NbExp=7; IntAct=EBI-457907, EBI-356498; CC Q9H4A3; P61981: YWHAG; NbExp=7; IntAct=EBI-457907, EBI-359832; CC Q9H4A3; P63104: YWHAZ; NbExp=3; IntAct=EBI-457907, EBI-347088; CC Q9H4A3; P29101: Syt2; Xeno; NbExp=2; IntAct=EBI-457907, EBI-458017; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:22989884, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36318922}. Nucleus CC {ECO:0000269|PubMed:29196535}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:21220314}. Note=Mediates formation and localizes to CC cytoplasmic membraneless compartment in response to hyperosmotic stress CC (PubMed:36318922). Also localizes to the nucleus (PubMed:29196535). CC Localizes to the mitotic spindle during mitosis (PubMed:21220314). CC {ECO:0000269|PubMed:21220314, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:36318922}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=6; CC Comment=WNK1 is a complex 33-exons gene, in total 9 WNK1 exons are CC alternatively spliced, some expressed in a tissue-specific manner. CC Additional isoforms seems to exist.; CC Name=1; Synonyms=L-WNK1 {ECO:0000303|PubMed:22701532}; CC IsoId=Q9H4A3-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:9205841}; CC IsoId=Q9H4A3-2; Sequence=VSP_040269, VSP_050638; CC Name=3; Synonyms=KS-WNK1, Kidney-Specific; CC IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637; CC Name=4; Synonyms=Brain and spinal cord variant; CC IsoId=Q9H4A3-5; Sequence=VSP_040268; CC Name=5; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and CC sciatic nerve variant; CC IsoId=Q9H4A3-6; Sequence=VSP_040267, VSP_040270; CC Name=6; CC IsoId=Q9H4A3-7; Sequence=VSP_040267, VSP_053767; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed in CC the testis, heart, kidney and skeletal muscle. CC {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11571656, CC ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Strong expression in dorsal root CC ganglia and spinal cord. {ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: This isoform is kidney-specific and CC specifically expressed in the distal convoluted tubule (DCT) and CC connecting tubule (CNT) of the nephron. {ECO:0000269|PubMed:14645531}. CC -!- DOMAIN: Disordered regions undergo liquid-liquid phase separation CC (LLPS) for the formation of a cytoplasmic membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK. CC {ECO:0000269|PubMed:36318922}. CC -!- DOMAIN: The RFXV motifs mediate recognition with downstream kinases CC OXSR1/OSR1 and STK39/SPAK. {ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:22989884}. CC -!- PTM: Autophosphorylated at Ser-378 and Ser-382, promoting its activity CC (PubMed:15883153, PubMed:16263722, PubMed:16832045, PubMed:17190791, CC PubMed:31656913, PubMed:34289367). Autophosphorylation at Ser-382 is CC inhibited by intracellular calcium (By similarity). Phosphorylation at CC Thr-60 increases ability to activate SGK1 (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367}. CC -!- PTM: Ubiquitinated by the BCR(KLHL3) complex, leading to its CC degradation (PubMed:23387299, PubMed:23576762). Also ubiquitinated by CC the BCR(KLHL2) complex (PubMed:23838290). {ECO:0000269|PubMed:23387299, CC ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23838290}. CC -!- PTM: May be O-glycosylated. {ECO:0000269|PubMed:2507249}. CC -!- DISEASE: Pseudohypoaldosteronism 2C (PHA2C) [MIM:614492]: An autosomal CC dominant disorder characterized by severe hypertension, hyperkalemia, CC hyperchloremia, mild hyperchloremic metabolic acidosis in some cases, CC and correction of physiologic abnormalities by thiazide diuretics. CC {ECO:0000269|PubMed:11498583}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 2A (HSAN2A) CC [MIM:201300]: A form of hereditary sensory and autonomic neuropathy, a CC genetically and clinically heterogeneous group of disorders CC characterized by degeneration of dorsal root and autonomic ganglion CC cells, and by sensory and/or autonomic abnormalities. HSAN2A is an CC autosomal recessive disorder characterized by impairment of pain, CC temperature and touch sensation, onset of symptoms in infancy or early CC childhood, occurrence of distal extremity pathologies (paronychia, CC whitlows, ulcers, and Charcot joints), frequent amputations, sensory CC loss that affects all modalities of sensation (lower and upper limbs CC and perhaps the trunk as well), absence or diminution of tendon CC reflexes (usually in all limbs), minimal autonomic dysfunction, absence CC of sensory nerve action potentials, and virtual absence of myelinated CC fibers with decreased numbers of unmyelinated fibers in sural nerves. CC {ECO:0000269|PubMed:15060842, ECO:0000269|PubMed:15911806, CC ECO:0000269|PubMed:18521183}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 4]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for CC catalysis, including the lysine involved in ATP binding, are either not CC conserved or differ compared to the residues described in other kinase CC family proteins. {ECO:0000305|PubMed:27712055}. CC -!- CAUTION: HSN2 was originally thought to be an intronless gene lying CC within a WNK1 gene intron. It has been shown to be a nervous system- CC specific exon of WNK1 included in isoform 4 and isoform 5 CC (PubMed:18521183). {ECO:0000305|PubMed:18521183}. CC -!- CAUTION: It is uncertain whether Met-1 or Met-214 is the initiator in CC isoform 4 and isoform 5. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305}; CC Sequence=AAI30468.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI30470.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=DAA04494.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ296290; CAC15059.1; -; mRNA. DR EMBL; JQ358908; AEY99342.1; -; mRNA. DR EMBL; FJ515833; ACS13726.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13727.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13728.1; -; Genomic_DNA. DR EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA. DR EMBL; AB002342; BAA20802.2; -; mRNA. DR EMBL; AY231477; AAO46160.1; -; mRNA. DR EMBL; BC013629; AAH13629.2; -; mRNA. DR EMBL; BC130467; AAI30468.1; ALT_SEQ; mRNA. DR EMBL; BC130469; AAI30470.1; ALT_SEQ; mRNA. DR EMBL; BK004108; DAA04494.1; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS73419.1; -. [Q9H4A3-5] DR CCDS; CCDS8506.1; -. [Q9H4A3-1] DR RefSeq; NP_001171914.1; NM_001184985.2. [Q9H4A3-6] DR RefSeq; NP_055638.2; NM_014823.2. DR RefSeq; NP_061852.3; NM_018979.4. [Q9H4A3-1] DR RefSeq; NP_998820.3; NM_213655.5. [Q9H4A3-5] DR RefSeq; XP_016875326.1; XM_017019837.1. DR RefSeq; XP_016875327.1; XM_017019838.2. [Q9H4A3-2] DR PDB; 4PWN; X-ray; 1.84 A; A=210-482. DR PDB; 5TF9; X-ray; 2.50 A; A/B=206-483. DR PDB; 5WDY; X-ray; 2.46 A; A/B=206-483. DR PDB; 5WE8; X-ray; 2.01 A; A/B=206-483. DR PDB; 6FBK; X-ray; 1.74 A; P=1247-1269. DR PDBsum; 4PWN; -. DR PDBsum; 5TF9; -. DR PDBsum; 5WDY; -. DR PDBsum; 5WE8; -. DR PDBsum; 6FBK; -. DR AlphaFoldDB; Q9H4A3; -. DR BMRB; Q9H4A3; -. DR SMR; Q9H4A3; -. DR BioGRID; 122403; 141. DR CORUM; Q9H4A3; -. DR DIP; DIP-32648N; -. DR ELM; Q9H4A3; -. DR FunCoup; Q9H4A3; 2655. DR IntAct; Q9H4A3; 121. DR MINT; Q9H4A3; -. DR STRING; 9606.ENSP00000341292; -. DR BindingDB; Q9H4A3; -. DR ChEMBL; CHEMBL1075173; -. DR GuidetoPHARMACOLOGY; 2280; -. DR MoonDB; Q9H4A3; Predicted. DR TCDB; 8.A.23.1.69; the basigin (basigin) family. DR GlyConnect; 484; 1 O-GlcNAc glycan. DR GlyCosmos; Q9H4A3; 38 sites, 2 glycans. DR GlyGen; Q9H4A3; 67 sites, 2 O-linked glycans (64 sites). DR iPTMnet; Q9H4A3; -. DR MetOSite; Q9H4A3; -. DR PhosphoSitePlus; Q9H4A3; -. DR BioMuta; WNK1; -. DR DMDM; 296453029; -. DR jPOST; Q9H4A3; -. DR MassIVE; Q9H4A3; -. DR PeptideAtlas; Q9H4A3; -. DR ProteomicsDB; 80804; -. [Q9H4A3-1] DR ProteomicsDB; 80805; -. [Q9H4A3-2] DR ProteomicsDB; 80806; -. [Q9H4A3-4] DR ProteomicsDB; 80807; -. [Q9H4A3-5] DR ProteomicsDB; 80808; -. [Q9H4A3-6] DR Pumba; Q9H4A3; -. DR Antibodypedia; 22083; 602 antibodies from 42 providers. DR DNASU; 65125; -. DR Ensembl; ENST00000315939.11; ENSP00000313059.6; ENSG00000060237.20. [Q9H4A3-1] DR Ensembl; ENST00000340908.9; ENSP00000341292.5; ENSG00000060237.20. [Q9H4A3-5] DR Ensembl; ENST00000530271.6; ENSP00000433548.3; ENSG00000060237.20. [Q9H4A3-7] DR Ensembl; ENST00000537687.5; ENSP00000444465.1; ENSG00000060237.20. [Q9H4A3-6] DR Ensembl; ENST00000675631.1; ENSP00000502415.1; ENSG00000060237.20. [Q9H4A3-4] DR GeneID; 65125; -. DR KEGG; hsa:65125; -. DR MANE-Select; ENST00000315939.11; ENSP00000313059.6; NM_018979.4; NP_061852.3. DR UCSC; uc001qio.4; human. [Q9H4A3-1] DR AGR; HGNC:14540; -. DR CIViC; 65125; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33782; -. DR CTD; 65125; -. DR DisGeNET; 65125; -. DR GeneCards; WNK1; -. DR GeneReviews; WNK1; -. DR HGNC; HGNC:14540; WNK1. DR HPA; ENSG00000060237; Low tissue specificity. DR MalaCards; WNK1; -. DR MIM; 201300; phenotype. DR MIM; 605232; gene. DR MIM; 614492; phenotype. DR OpenTargets; ENSG00000060237; -. DR Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2. DR Orphanet; 88940; Pseudohypoaldosteronism type 2C. DR VEuPathDB; HostDB:ENSG00000060237; -. DR eggNOG; KOG0584; Eukaryota. DR GeneTree; ENSGT00940000155474; -. DR InParanoid; Q9H4A3; -. DR OMA; PEPNGMT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q9H4A3; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9H4A3; -. DR PathwayCommons; Q9H4A3; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR SignaLink; Q9H4A3; -. DR SIGNOR; Q9H4A3; -. DR Agora; ENSG00000060237; -. DR BioGRID-ORCS; 65125; 582 hits in 1210 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; WNK1; human. DR EvolutionaryTrace; Q9H4A3; -. DR GeneWiki; WNK1; -. DR GenomeRNAi; 65125; -. DR Pharos; Q9H4A3; Tchem. DR PRO; PR:Q9H4A3; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9H4A3; protein. DR Bgee; ENSG00000060237; Expressed in medial globus pallidus and 204 other cell types or tissues. DR ExpressionAtlas; Q9H4A3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043232; C:intracellular membraneless organelle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:ParkinsonsUK-UCL. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006884; P:cell volume homeostasis; IDA:UniProtKB. DR GO; GO:0071474; P:cellular hyperosmotic response; IDA:UniProtKB. DR GO; GO:1990869; P:cellular response to chemokine; IMP:BHF-UCL. DR GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IBA:GO_Central. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0030644; P:intracellular chloride ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0097022; P:lymphocyte migration into lymph node; ISS:BHF-UCL. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:UniProtKB. DR GO; GO:0055080; P:monoatomic cation homeostasis; ISS:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; ISS:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB. DR GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; IMP:BHF-UCL. DR GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0090188; P:negative regulation of pancreatic juice secretion; IEA:Ensembl. DR GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; ISS:UniProtKB. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IMP:BHF-UCL. DR GO; GO:0010766; P:negative regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0048666; P:neuron development; NAS:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:FlyBase. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; IDA:UniProtKB. DR GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL. DR GO; GO:1904595; P:positive regulation of termination of RNA polymerase II transcription; IDA:UniProtKB. DR GO; GO:0055075; P:potassium ion homeostasis; IEA:Ensembl. DR GO; GO:0045050; P:protein insertion into ER membrane by stop-transfer membrane-anchor sequence; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; IMP:ARUK-UCL. DR GO; GO:0010793; P:regulation of mRNA export from nucleus; IDA:UniProtKB. DR GO; GO:1902305; P:regulation of sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:ParkinsonsUK-UCL. DR GO; GO:0035725; P:sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:BHF-UCL. DR CDD; cd14030; STKc_WNK1; 1. DR FunFam; 3.10.20.90:FF:000007; Serine/threonine-protein kinase WNK1 isoform 1; 1. DR FunFam; 1.10.510.10:FF:000006; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.10.20.90:FF:000012; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000494; serine/threonine-protein kinase WNK2 isoform X2; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR056865; CCTL2_WNK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024678; Kinase_OSR1/WNK_CCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050588; WNK_Ser-Thr_kinase. DR PANTHER; PTHR13902; SERINE/THREONINE-PROTEIN KINASE WNK WITH NO LYSINE -RELATED; 1. DR Pfam; PF24889; CCTL2_WNK; 1. DR Pfam; PF12202; OSR1_C; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Chloride; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Glycoprotein; Kinase; Neurodegeneration; Neuropathy; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..2382 FT /note="Serine/threonine-protein kinase WNK1" FT /id="PRO_0000086819" FT DOMAIN 221..479 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..81 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 95..203 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..555 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT REGION 573..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..638 FT /note="Interaction with KLHL3" FT /evidence="ECO:0000250|UniProtKB:Q96J92" FT REGION 1018..1041 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1053..1119 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1457..1476 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1733..1790 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1948 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1994..2069 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2101..2196 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2241..2261 FT /note="Amphipathic alpha-helix" FT /evidence="ECO:0000269|PubMed:33964204" FT REGION 2332..2352 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1257..1260 FT /note="RFXV motif 1" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1859..1862 FT /note="RFXV motif 2" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1945..1948 FT /note="RFXV motif 3" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1957..1960 FT /note="RFXV motif 4" FT /evidence="ECO:0000269|PubMed:16263722" FT COMPBIAS 50..66 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 95..108 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..153 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 573..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..614 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 615..625 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..689 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 709..779 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1041 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1053..1077 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1080..1090 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1098..1119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1457..1467 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1733..1745 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1869..1884 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1887..1905 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1927..1940 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1994..2003 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2035..2062 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2122..2134 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2135..2145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2146..2167 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2175..2196 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 368 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:16263722" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 283 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 299 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 351 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 369 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 371 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 15 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 19 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 60 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 167 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 174 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 378 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:31656913" FT MOD_RES 382 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15883153, FT ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, FT ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, FT ECO:0000269|PubMed:34289367" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 1848 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 1978 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 2002 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983" FT MOD_RES 2011 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2012 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2027 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 2029 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2032 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2121 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2286 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2372 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..407 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050634" FT VAR_SEQ 408..437 FT /note="FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKDFCSVFVIINSH FT CCCCPQKDCINE (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050637" FT VAR_SEQ 713 FT /note="V -> VPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR FT RKSTSFLEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQV FT HPMFEPSQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSS FT PMKQIPEQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTD FT ATRLKFHPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQV FT AVDLNQEELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSS FT QITSSDPSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLT FT ASFSSGGSALHPQ (in isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_040267" FT VAR_SEQ 714..1037 FT /note="AQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHF FT LPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTA FT AIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVL FT YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVES FT NLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLE -> PRRGRSMSVCVPIFLLLPL FT CPASLPVLFHPTASTVCTSFSFPPPDCPEETFAEKLSKALESVLPMHSASQRKHRRSSL FT PSLFVSTPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQRRKSTSF FT LEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQVHPMFEP FT SQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSSPMKQIP FT EQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTDATRLKF FT HPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQVAVDLNQ FT EELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSSQITSSD FT PSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLTASFSSG FT GSALHPQAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQ (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_040268" FT VAR_SEQ 740 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_040269" FT VAR_SEQ 792..1037 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_050638" FT VAR_SEQ 792..944 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_040270" FT VAR_SEQ 2215 FT /note="G -> GCAKFNCASEQVTFKPGGRRTRFLRKMVKKVCPCNQLCR (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_053767" FT VARIANT 141 FT /note="A -> T (in dbSNP:rs11554421)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041309" FT VARIANT 149 FT /note="A -> V (in dbSNP:rs34880640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041310" FT VARIANT 419 FT /note="E -> Q (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041311" FT VARIANT 509 FT /note="I -> T (in dbSNP:rs34728563)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041312" FT VARIANT 527 FT /note="D -> G (in dbSNP:rs34408667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041313" FT VARIANT 665 FT /note="T -> I (in dbSNP:rs2286007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019992" FT VARIANT 674 FT /note="T -> A (in dbSNP:rs11833299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041314" FT VARIANT 823 FT /note="H -> R (in dbSNP:rs56015776)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041315" FT VARIANT 1056 FT /note="T -> P (in dbSNP:rs956868)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059033" FT VARIANT 1199 FT /note="E -> G (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035640" FT VARIANT 1506 FT /note="C -> S (in dbSNP:rs7955371)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059034" FT VARIANT 1546 FT /note="A -> V (in dbSNP:rs56351358)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041316" FT VARIANT 1799 FT /note="Q -> E (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035641" FT VARIANT 1808 FT /note="M -> I (in dbSNP:rs12828016)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_041317" FT VARIANT 1823 FT /note="P -> L (in dbSNP:rs17755373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041318" FT VARIANT 1957 FT /note="R -> H (in dbSNP:rs36083875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041319" FT VARIANT 2190 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041320" FT VARIANT 2362 FT /note="F -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041321" FT VARIANT 2380 FT /note="R -> W (in dbSNP:rs56262445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041322" FT MUTAGEN 233 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity. Does not affect ability to activate SGK1." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:36373794" FT MUTAGEN 318 FT /note="V->E: Does not affect ability to phosphorylate FT OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:22989884" FT MUTAGEN 368 FT /note="D->A: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:17190791" FT MUTAGEN 382 FT /note="S->A: Decreased autophosphorylation, preventing FT activation of the serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791" FT MUTAGEN 1255 FT /note="G->R,N,D,C,Q,H,I,L,K,M,F,P,S,T,W,Y,V: Does not FT affect binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1257 FT /note="R->A,N,C,E,Q,H,I,L,K,M,F,S,T,W,Y,V: Does not affect FT binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1258 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1860. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1860 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1258. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1946 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1958. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1257, FT A-1860 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1958 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1946. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1860 and A-1946." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 2246 FT /note="F->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2248 FT /note="D->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2249 FT /note="D->A,K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2250 FT /note="Missing: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2251 FT /note="H->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2253 FT /note="L->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2257 FT /note="W->K,L,A: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2260 FT /note="D->A,K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT CONFLICT 164 FT /note="R -> S (in Ref. 8; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1836 FT /note="Missing (in Ref. 6; BAA20802)" FT /evidence="ECO:0000305" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 231..240 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 241..244 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 245..252 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 266..273 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 291..295 FT /evidence="ECO:0007829|PDB:5WDY" FT STRAND 297..302 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 309..316 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 355..358 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 359..362 FT /evidence="ECO:0007829|PDB:5WE8" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 377..380 FT /evidence="ECO:0007829|PDB:5WE8" FT HELIX 392..396 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 421..424 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 442..446 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 450..459 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 470..474 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 1248..1251 FT /evidence="ECO:0007829|PDB:6FBK" FT STRAND 1257..1261 FT /evidence="ECO:0007829|PDB:6FBK" SQ SEQUENCE 2382 AA; 250794 MW; 426785F98A452A0A CRC64; MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT // ID XAGE1_HUMAN Reviewed; 81 AA. AC Q9HD64; A6NJ94; Q5JPN8; Q5JPP0; Q5JPP3; Q8WWG5; Q8WWG6; Q969J6; DT 26-SEP-2001, integrated into UniProtKB/Swiss-Prot. DT 31-MAY-2011, sequence version 3. DT 28-JAN-2026, entry version 180. DE RecName: Full=X antigen family member 1; DE Short=XAGE-1; DE AltName: Full=Cancer/testis antigen 12.1; DE Short=CT12.1; DE AltName: Full=G antigen family D member 2; GN Name=XAGE1A {ECO:0000312|HGNC:HGNC:4111}; GN Synonyms=GAGED2 {ECO:0000312|HGNC:HGNC:4111}, GN XAGE1 {ECO:0000312|HGNC:HGNC:4111}; GN and GN Name=XAGE1B {ECO:0000312|HGNC:HGNC:25400}; GN Synonyms=XAGE1C {ECO:0000312|HGNC:HGNC:25400}, GN XAGE1D {ECO:0000312|HGNC:HGNC:25400}, XAGE1E {ECO:0000312|HGNC:HGNC:25400}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B). RC TISSUE=Testis; RX PubMed=10987281; RA Liu X.F., Helman L.J., Yeung C., Bera T.K., Lee B., Pastan I.; RT "XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma."; RL Cancer Res. 60:4752-4755(2000). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS B AND D). RX PubMed=11992404; DOI=10.1002/ijc.10371; RA Zendman A.J.W., van Kraats A.A., Weidle U.H., Ruiter D.J., RA van Muijen G.N.P.; RT "The XAGE family of cancer/testis-associated genes: alignment and RT expression profile in normal tissues, melanoma lesions and Ewing's RT sarcoma."; RL Int. J. Cancer 99:361-369(2002). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY, AND IDENTIFICATION OF INITIATOR METHIONINE (ISOFORM B). RX PubMed=12479262; RA Egland K.A., Kumar V., Duray P., Pastan I.; RT "Characterization of overlapping XAGE-1 transcripts encoding a cancer RT testis antigen expressed in lung, breast, and other types of cancers."; RL Mol. Cancer Ther. 1:441-450(2002). RN [7] RP TISSUE SPECIFICITY, ALTERNATIVE SPLICING (ISOFORMS B AND D), AND RP IDENTIFICATION OF INITIATOR METHIONINE (ISOFORM B). RX PubMed=17335148; RA Sato S., Noguchi Y., Ohara N., Uenaka A., Shimono M., Nakagawa K., RA Koizumi F., Ishida T., Yoshino T., Shiratori Y., Nakayama E.; RT "Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in RT testis and tumors."; RL Cancer Immun. 7:5-5(2007). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [9] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-12; LYS-61 AND LYS-65, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- INTERACTION: CC Q9HD64; Q8N9N5: BANP; NbExp=3; IntAct=EBI-2340004, EBI-744695; CC Q9HD64; Q8N488: RYBP; NbExp=3; IntAct=EBI-2340004, EBI-752324; CC Q9HD64; Q9Y6X0: SETBP1; NbExp=3; IntAct=EBI-2340004, EBI-2548259; CC Q9HD64; Q9H2G4: TSPYL2; NbExp=3; IntAct=EBI-2340004, EBI-947459; CC Q9HD64; Q8IY57: YAF2; NbExp=4; IntAct=EBI-2340004, EBI-2842031; CC Q9HD64; P25490: YY1; NbExp=3; IntAct=EBI-2340004, EBI-765538; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=B; Synonyms=XAGE-1a, XAGE-1b; CC IsoId=Q9HD64-2; Sequence=Displayed; CC Name=D; Synonyms=XAGE-1d; CC IsoId=Q9HD64-4; Sequence=VSP_001596; CC -!- TISSUE SPECIFICITY: In normal tissues, highly expressed in testis. CC Expressed also in many different types of cancers: highly expressed in CC breast cancer, prostate cancer and many types of lung cancers, CC including squamous cell carcinoma, small cell carcinoma, non-small cell CC carcinoma, and adenocarcinoma, as well as in Ewing's cell lines, in CC some Ewing's sarcoma patient samples, and in one of one alveolar CC rhabdomyosarcoma patient sample. {ECO:0000269|PubMed:12479262, CC ECO:0000269|PubMed:17335148}. CC -!- MISCELLANEOUS: According to PubMed:11992404, the transcription of CC XAGE1A is regulated by methylation of the CpG island in the promoter, CC and four alternative RNA splicing variants, XAGE-1a, b, c have been CC identified. CC -!- MISCELLANEOUS: [Isoform B]: XAGE-1a and XAGE-1b mRNAs are produced by CC alternative promoter usage. However, for both isoforms, the translation CC initiator codon remains the same, generating an identical protein. CC XAGE-1b is the predominant transcript, compared to XAGE-1a. CC -!- SIMILARITY: Belongs to the GAGE family. {ECO:0000305}. CC -!- CAUTION: PubMed:17335148, examines the translation products of theses CC four XAGE1A transcripts, and finds that the XAGE-1c transcript is CC possibly translated to 9- and 17-aa polypeptides and not to a protein CC consisting of 160 amino acids as shown in PubMed:11992404. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG01401.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAH09538.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC82986.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAI41526.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI41531.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI41534.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF251237; AAG01401.1; ALT_INIT; mRNA. DR EMBL; AJ290447; CAC38107.1; -; mRNA. DR EMBL; AJ400997; CAC38108.1; -; Genomic_DNA. DR EMBL; AJ318878; CAC82986.1; ALT_INIT; mRNA. DR EMBL; AJ318879; CAC82987.1; -; mRNA. DR EMBL; BT007099; AAP35763.1; -; mRNA. DR EMBL; AL772246; CAI41526.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL772246; CAI41527.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41528.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41530.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41531.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL772246; CAI41532.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41533.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41534.1; ALT_SEQ; Genomic_DNA. DR EMBL; BX088602; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC009538; AAH09538.2; ALT_INIT; mRNA. DR CCDS; CCDS48126.2; -. [Q9HD64-2] DR CCDS; CCDS48128.1; -. [Q9HD64-4] DR CCDS; CCDS75982.1; -. [Q9HD64-2] DR CCDS; CCDS75983.1; -. [Q9HD64-4] DR RefSeq; NP_001091063.2; NM_001097594.3. [Q9HD64-2] DR RefSeq; NP_001091065.1; NM_001097596.3. [Q9HD64-4] DR RefSeq; NP_001091073.2; NM_001097604.2. [Q9HD64-2] DR RefSeq; NP_001091074.1; NM_001097605.2. [Q9HD64-4] DR AlphaFoldDB; Q9HD64; -. DR BioGRID; 575500; 13. DR BioGRID; 575617; 45. DR FunCoup; Q9HD64; 88. DR IntAct; Q9HD64; 51. DR STRING; 9606.ENSP00000364752; -. DR ChEMBL; CHEMBL4295952; -. DR iPTMnet; Q9HD64; -. DR PhosphoSitePlus; Q9HD64; -. DR BioMuta; HGNC:18372; -. DR DMDM; 334302901; -. DR jPOST; Q9HD64; -. DR MassIVE; Q9HD64; -. DR PaxDb; 9606-ENSP00000364752; -. DR PeptideAtlas; Q9HD64; -. DR ProteomicsDB; 81838; -. [Q9HD64-2] DR ProteomicsDB; 81839; -. [Q9HD64-4] DR Pumba; Q9HD64; -. DR Antibodypedia; 26426; 75 antibodies from 20 providers. DR Antibodypedia; 54311; 17 antibodies from 4 providers. DR DNASU; 9503; -. DR Ensembl; ENST00000375600.5; ENSP00000364750.1; ENSG00000204379.11. [Q9HD64-4] DR Ensembl; ENST00000375602.2; ENSP00000364752.1; ENSG00000204379.11. [Q9HD64-2] DR Ensembl; ENST00000375613.7; ENSP00000364763.3; ENSG00000204382.13. [Q9HD64-4] DR Ensembl; ENST00000375616.6; ENSP00000364766.1; ENSG00000204382.13. [Q9HD64-2] DR Ensembl; ENST00000518075.1; ENSP00000430130.1; ENSG00000204382.13. [Q9HD64-2] DR GeneID; 653067; -. DR GeneID; 653220; -. DR KEGG; hsa:653067; -. DR KEGG; hsa:653220; -. DR MANE-Select; ENST00000375602.2; ENSP00000364752.1; NM_001097594.3; NP_001091063.2. DR MANE-Select; ENST00000375616.6; ENSP00000364766.1; NM_001097604.3; NP_001091073.2. DR UCSC; uc004dqf.4; human. [Q9HD64-2] DR AGR; HGNC:25400; -. DR AGR; HGNC:4111; -. DR CTD; 653067; -. DR CTD; 653220; -. DR DisGeNET; 653067; -. DR DisGeNET; 653220; -. DR GeneCards; XAGE1A; -. DR GeneCards; XAGE1B; -. DR HGNC; HGNC:4111; XAGE1A. DR HGNC; HGNC:25400; XAGE1B. DR HPA; ENSG00000204379; Tissue enriched (testis). DR HPA; ENSG00000204382; Tissue enriched (testis). DR MIM; 300289; gene. DR MIM; 300742; gene. DR OpenTargets; ENSG00000204382; -. DR VEuPathDB; HostDB:ENSG00000204379; -. DR VEuPathDB; HostDB:ENSG00000204382; -. DR eggNOG; ENOG502SZKH; Eukaryota. DR GeneTree; ENSGT00940000153097; -. DR HOGENOM; CLU_2573264_0_0_1; -. DR InParanoid; Q9HD64; -. DR OMA; GEHYKMP; -. DR OrthoDB; 9536099at2759; -. DR PAN-GO; Q9HD64; 0 GO annotations based on evolutionary models. DR PathwayCommons; Q9HD64; -. DR SignaLink; Q9HD64; -. DR BioGRID-ORCS; 653067; 8 hits in 237 CRISPR screens. DR BioGRID-ORCS; 653220; 15 hits in 251 CRISPR screens. DR Pharos; Q9HD64; Tbio. DR PRO; PR:Q9HD64; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q9HD64; protein. DR Bgee; ENSG00000204379; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 72 other cell types or tissues. PE 1: Evidence at protein level; KW Alternative splicing; Isopeptide bond; Phosphoprotein; KW Proteomics identification; Reference proteome; Ubl conjugation. FT CHAIN 1..81 FT /note="X antigen family member 1" FT /id="PRO_0000148349" FT MOD_RES 20 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 12 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 61 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 65 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 33..81 FT /note="CATWKVICKSCISQTPGINLDLGSGVKVKIIPKEEHCKMPEAGEEQPQV -> FT VLGREMRDMEGDLQELHQSNTGDKSGFGFRRQGEDNT (in isoform D)" FT /evidence="ECO:0000303|PubMed:11992404" FT /id="VSP_001596" SQ SEQUENCE 81 AA; 9078 MW; C73337C4C94C01D1 CRC64; MESPKKKNQQ LKVGILHLGS RQKKIRIQLR SQCATWKVIC KSCISQTPGI NLDLGSGVKV KIIPKEEHCK MPEAGEEQPQ V //